{
 "cells": [
  {
   "cell_type": "markdown",
   "id": "9ceffe3a",
   "metadata": {},
   "source": [
    "## Importing the Data"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 1,
   "id": "429a5a68",
   "metadata": {},
   "outputs": [],
   "source": [
    "import pandas as pd\n",
    "import numpy as np"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "a32a9ea8",
   "metadata": {},
   "source": [
    "# Variation Implementation Function"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "c4e5e07c",
   "metadata": {},
   "source": [
    "Credit: Elizabeth Iskander"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "id": "71054b50",
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "C:\\Users\\Power\\AppData\\Local\\Temp\\ipykernel_1776\\2774933809.py:1: FutureWarning: The error_bad_lines argument has been deprecated and will be removed in a future version. Use on_bad_lines in the future.\n",
      "\n",
      "\n",
      "  data2 = pd.read_csv(\"Full data.csv\", engine='python', encoding='utf-8', error_bad_lines=False).dropna(subset=['FAU','AU']).reset_index(drop=True)\n",
      "Skipping line 50805: field larger than field limit (131072)\n",
      "Skipping line 58745: field larger than field limit (131072)\n",
      "Skipping line 68065: field larger than field limit (131072)\n",
      "Skipping line 93350: field larger than field limit (131072)\n",
      "Skipping line 108675: field larger than field limit (131072)\n",
      "Skipping line 138891: field larger than field limit (131072)\n",
      "Skipping line 166424: field larger than field limit (131072)\n",
      "Skipping line 220645: field larger than field limit (131072)\n",
      "Skipping line 222178: field larger than field limit (131072)\n",
      "Skipping line 227730: field larger than field limit (131072)\n"
     ]
    }
   ],
   "source": [
    "data2 = pd.read_csv(\"Full data.csv\", engine='python', encoding='utf-8', error_bad_lines=False).dropna(subset=['FAU','AU']).reset_index(drop=True)\n",
    "AU = data2[\"AU\"]\n",
    "FAU = data2[\"FAU\"]\n",
    "AU_names = AU.str.split(\";\")\n",
    "FAU_names = FAU.str.split(\";\")\n",
    "\n",
    "cumulativeNames = []\n",
    "for cell in FAU_names:\n",
    "    cells = []\n",
    "    for person in cell:\n",
    "        personNames = []\n",
    "        splitted = person.split(\", \")\n",
    "        if len(splitted) == 1:\n",
    "            first_name = full_name[0]\n",
    "            first_initial =first_name[0]\n",
    "\n",
    "            personNames.append(first_name) #Elizabeth\n",
    "            personNames.append(first_initial) #E\n",
    "            personNames.append(first_initial + \".\") #E.\n",
    "            continue\n",
    "        fname = splitted[1].split(\" \")\n",
    "        lname = splitted[0].split(\" \")\n",
    "        if \" , \" in person: #bug where the name was Iskander , Elizabeth\n",
    "            splitted = person.split(\" , \")\n",
    "            fname = splitted[1].split(\" \")\n",
    "            lname = splitted[0].split(\" \")\n",
    "        full_name = fname + lname\n",
    "        \n",
    "        if len(full_name) == 2:\n",
    "            first_name = full_name[0]\n",
    "            last_name = full_name[1]\n",
    "        \n",
    "            first_initials = first_name[0]\n",
    "            last_initials = last_name[0]\n",
    "            if (\"-\" in first_name) & (not full_name[-1]): #there was a bug where the name was \"Iskander, Elizabeth-\"\n",
    "                first_initials = first_name[0]+first_name[first_name.find(\"-\") + 1]\n",
    "            if (\"-\" in last_name) & (not full_name[-1]):\n",
    "                last_initials = last_name[0]+last_name[last_name.find(\"-\") + 1]\n",
    "            \n",
    "            personNames.append(first_name + \" \" + last_name) #Elizabeth Iskander\n",
    "            personNames.append(first_name + \" \" + last_initials) #Elizabeth I\n",
    "            personNames.append(first_name + \" \" + last_initials + \".\") #Elizabeth I.\n",
    "            personNames.append(first_initials + last_initials) #EI\n",
    "            personNames.append(first_initials + \".\" + last_initials + \".\") #E.I.\n",
    "            personNames.append(first_initials + \" \" + last_name) #E Iskander\n",
    "            personNames.append(first_initials + \". \" + last_name) #E. Iskander \n",
    "            personNames.append(last_name + \" \" + first_initials) #Iskander E (same format as AU column )\n",
    "            personNames.append(last_name + \" \" + first_initials + \".\") #Iskander E.\n",
    "            personNames.append(last_name + \", \" + first_name) #Iskander, Elizabeth \n",
    "            personNames.append(last_name) #Iskander\n",
    "        if len(full_name) == 3:\n",
    "            first_name = full_name[0]\n",
    "            middle_name = full_name[1]\n",
    "            last_name = full_name[2]\n",
    "\n",
    "            first_initials = first_name[0]\n",
    "            middle_initials = middle_name[0]\n",
    "            last_initials = last_name[0]\n",
    "            \n",
    "            if (\"-\" in first_name) & (not first_name[-1]):\n",
    "                first_initials = first_name[0]+first_name[first_name.find(\"-\") + 1]\n",
    "            if (\"-\" in middle_name) & (not middle_name[-1]):\n",
    "                middle_initials = middle_name[0]+middle_name[middle_name.find(\"-\") + 1]\n",
    "            if (\"-\" in last_name) & (not last_name[-1]):\n",
    "                last_initials = last_name[0]+last_name[last_name.find(\"-\") + 1]\n",
    "            \n",
    "            \n",
    "            personNames.append(first_name + \" \" + last_name) #Elizabeth Iskander\n",
    "            personNames.append(first_name + \" \" + last_initials) #Elizabeth I\n",
    "            personNames.append(first_name + \" \" + last_initials + \".\") #Elizabeth I.\n",
    "            personNames.append(first_name + \" \" + middle_name + \" \" + last_name) #Elizabeth Rafik Iskander \n",
    "            personNames.append(first_name + \" \" + middle_initials + last_initials) #Elizabeth RI\n",
    "            personNames.append(first_name + \" \" + middle_initials + \".\" + last_initials + \".\") #Elizabeth R.I.\n",
    "            personNames.append(first_name + \" \" + middle_initials + \" \" + last_name) #Elizabeth R Iskander\n",
    "            personNames.append(first_name + \" \" + middle_initials + \". \" + last_name) #Elizabeth R. Iskander\n",
    "            personNames.append(first_initials + last_initials) #EI\n",
    "            personNames.append(first_initials + \".\" + last_initials + \".\") #E.I.\n",
    "            personNames.append(first_initials + middle_initials + last_initials) #ERI\n",
    "            personNames.append(first_initials + \".\" + middle_initials + \".\" + last_initials + \".\") #E.R.I.  \n",
    "            personNames.append(middle_name + \" \" + last_name + \", \" + first_name) #Rafik Iskander, Elizabeth\n",
    "            personNames.append(middle_name + \" \" + last_name + \", \" + first_initials) #Rafik Iskander, E\n",
    "            personNames.append(middle_name + \" \" + last_name + \", \" + first_initials + \".\") #Rafik Iskander, E.\n",
    "            personNames.append(last_name + \", \" + first_name + \" \" + middle_name) #Iskander, Elizabeth Rafik \n",
    "            personNames.append(last_name + \", \" + first_name + \" \" + middle_initials) #Iskander, Elizabeth R\n",
    "            personNames.append(last_name + \", \" + first_name + \" \" + middle_initials + \".\") #Iskander, Elizabeth R.\n",
    "            personNames.append(last_name + \" \" + first_initials + middle_initials) #Iskander ER (same format as AU column )\n",
    "            personNames.append(last_name + \" \" + first_initials + \".\" + middle_initials + \".\") #Iskander E.R. \n",
    "            personNames.append(last_name) #Iskander\n",
    "        if len(full_name) == 4:\n",
    "            first_name = full_name[0]\n",
    "            middle1_name = full_name[1]\n",
    "            middle2_name = full_name[2]\n",
    "            last_name = full_name[3]\n",
    "\n",
    "            first_initials = first_name[0]\n",
    "            middle1_initials = middle1_name[0]\n",
    "            middle2_initials = middle2_name[0]\n",
    "            last_initials = last_name[0]\n",
    "            \n",
    "            if (\"-\" in first_name) & (not first_name[-1]):\n",
    "                first_initials = first_name[0]+first_name[first_name.find(\"-\") + 1]\n",
    "            if (\"-\" in middle1_name) & (not middle1_name[-1]):\n",
    "                middle1_initials = middle1_name[0]+middle1_name[middle1_name.find(\"-\") + 1]\n",
    "            if (\"-\" in middle2_name) & (not middle2_name[-1]):\n",
    "                middle2_initials = middle2_name[0]+middle2_name[middle2_name.find(\"-\") + 1]\n",
    "            if (\"-\" in last_name) & (not last_name[-1]):\n",
    "                last_initials = last_name[0]+last_name[last_name.find(\"-\") + 1]\n",
    "            personNames.append(first_name + \" \" + last_name) #Elizabeth Iskander\n",
    "            personNames.append(first_name + \" \" + last_initials) #Elizabeth I\n",
    "            personNames.append(first_name + \" \" + last_initials + \".\") #Elizabeth I.\n",
    "            personNames.append(first_name + \" \" + middle1_name + \" \" + last_name) #Elizabeth Rafik Iskander \n",
    "            personNames.append(first_name + \" \" + middle1_name + \" \" + middle2_name + \" \" + last_name) #Elizabeth Rafik Sami Iskander\n",
    "            personNames.append(first_name + \" \" + middle1_name + \" \" + middle2_initials + \" \" + last_name) #Elizabeth Rafik S Iskander\n",
    "            personNames.append(first_name + \" \" + middle1_name + \" \" + middle2_initials + \". \" + last_name) #Elizabeth Rafik S. Iskander\n",
    "            personNames.append(first_name + \" \" + middle1_initials + last_initials) #Elizabeth RI\n",
    "            personNames.append(first_name + \" \" + middle1_initials + \".\" + last_initials + \".\") #Elizabeth R.I.\n",
    "            personNames.append(first_name + \" \" + middle1_initials + middle2_initials + last_initials) #Elizabeth RSI\n",
    "            personNames.append(first_name + \" \" + middle1_initials + \".\" + middle2_initials + \".\" + last_initials + \".\") #Elizabeth R.S.I.\n",
    "            personNames.append(first_name + \" \" + middle1_initials + \" \" + last_name) #Elizabeth R Iskander\n",
    "            personNames.append(first_name + \" \" + middle1_initials + \". \" + last_name) #Elizabeth R. Iskander\n",
    "            personNames.append(first_name + \" \" + middle1_initials + middle2_initials + \" \" + last_name) #Elizabeth RS Iskander\n",
    "            personNames.append(first_name + \" \" + middle1_initials + \".\" + middle2_initials + \". \" + last_name) #Elizabeth R.S. Iskander\n",
    "            personNames.append(first_initials + last_initials) #EI\n",
    "            personNames.append(first_initials + \".\" + last_initials + \".\") #E.I.\n",
    "            personNames.append(first_initials + middle1_initials + last_initials) #ERI\n",
    "            personNames.append(first_initials + \".\" + middle1_initials + \".\" + last_initials + \".\") #E.R.I\n",
    "            personNames.append(first_initials + middle1_initials + middle2_initials + last_initials) #ERSI\n",
    "            personNames.append(first_initials + \".\" + middle1_initials + \".\" + middle2_initials + \".\" + last_initials + \".\") #E.R.S.I.\n",
    "            personNames.append(middle1_name + \" \" + last_name + \", \" + first_name) #Rafik Iskander, Elizabeth\n",
    "            personNames.append(middle1_name + \" \" + last_name + \", \" + first_initials) #Rafik Iskander, E\n",
    "            personNames.append(middle1_name + \" \" + last_name + \", \" + first_initials + \".\") #Rafik Iskander, E.\n",
    "            personNames.append(middle1_name + \" \" + middle2_name + \" \" + last_name + \", \" + first_name) #Rafik Sami Iskander, Elizabeth\n",
    "            personNames.append(middle1_name + \" \" + middle2_name + \" \" + last_name + \", \" + first_initials) #Rafik Sami Iskander, E\n",
    "            personNames.append(middle1_name + \" \" + middle2_name + \" \" + last_name + \", \" + first_initials + \".\") #Rafik Sami Iskander, E.\n",
    "            personNames.append(last_name + \", \" + first_name + \" \" + middle1_name) #Iskander, Elizabeth Rafik \n",
    "            personNames.append(last_name + \", \" + first_name + \" \" + middle1_name + \" \" + middle2_name) #Iskander, Elizabeth Rafik Sami\n",
    "            personNames.append(last_name + \", \" + first_name + \" \" + middle1_initials) #Iskander, Elizabeth R\n",
    "            personNames.append(last_name + \", \" + first_name + \" \" + middle1_initials + \".\") #Iskander, Elizabeth R.\n",
    "            personNames.append(last_name + \", \" + first_name + \" \" + middle1_initials + middle2_initials) #Iskander, Elizabeth RS\n",
    "            personNames.append(last_name + \", \" + first_name + \" \" + middle1_initials + \".\" + middle2_initials + \".\") #Iskander, Elizabeth R.S.\n",
    "            personNames.append(last_name + \", \" + first_initials) #Iskander, E\n",
    "            personNames.append(last_name + \", \" + first_initials + \".\") #Iskander, E.\n",
    "            personNames.append(last_name + \" \" + first_initials + middle1_initials) #Iskander ER \n",
    "            personNames.append(last_name + \" \" + first_initials + \".\" + middle1_initials + \".\") #Iskander E.R. \n",
    "            personNames.append(last_name + \" \" + first_initials + middle1_initials + middle2_initials) #Iskander ERS (same format as AU column )\n",
    "            personNames.append(last_name + \" \" + first_initials + \".\" + middle1_initials + \".\" + middle2_initials + \".\") #Iskander E.R.S.\n",
    "            personNames.append(last_name) #Iskander\n",
    "        if len(full_name) == 5:\n",
    "            first_name = full_name[0]\n",
    "            middle1_name = full_name[1]\n",
    "            middle2_name = full_name[2]\n",
    "            middle3_name = full_name[3]\n",
    "            last_name = full_name[4]\n",
    "\n",
    "            first_initials = first_name[0]\n",
    "            middle1_initials = middle1_name[0]\n",
    "            middle2_initials = middle2_name[0]\n",
    "            middle3_initials = middle3_name[0]\n",
    "            last_initials = last_name[0]\n",
    "            \n",
    "            if (\"-\" in first_name) & (not first_name[-1]):\n",
    "                first_initials = first_name[0]+first_name[first_name.find(\"-\") + 1]\n",
    "            if (\"-\" in middle1_name) & (not middle1_name[-1]):\n",
    "                middle1_initials = middle1_name[0]+middle1_name[middle1_name.find(\"-\") + 1]\n",
    "            if (\"-\" in middle2_name) & (not middle2_name[-1]):\n",
    "                middle2_initials = middle2_name[0]+middle2_name[middle2_name.find(\"-\") + 1]\n",
    "            if (\"-\" in middle3_name) & (not middle3_name[-1]):\n",
    "                middle3_initials = middle3_name[0]+middle3_name[middle3_name.find(\"-\") + 1]\n",
    "            if (\"-\" in last_name) & (not last_name[-1]):\n",
    "                last_initials = last_name[0]+last_name[last_name.find(\"-\") + 1]\n",
    "            personNames.append(first_name + \" \" + last_name) #Elizabeth Iskander\n",
    "            personNames.append(first_name + \" \" + last_initials) #Elizabeth I\n",
    "            personNames.append(first_name + \" \" + last_initials + \".\") #Elizabeth I.\n",
    "            personNames.append(first_name + \" \" + middle1_name + \" \" + last_name) #Elizabeth Rafik Iskander \n",
    "            personNames.append(first_name + \" \" + middle1_name + \" \" + middle2_name + \" \" + last_name) #Elizabeth Rafik Sami Iskander\n",
    "            personNames.append(first_name + \" \" + middle1_name + \" \" + middle2_name + \" \" + middle3_name + \" \" + last_name) #Elizabeth Rafik Sami Mary Iskander\n",
    "            personNames.append(first_name + \" \" + middle1_name + \" \" + middle2_initials + \" \" + last_name) #Elizabeth Rafik S Iskander\n",
    "            personNames.append(first_name + \" \" + middle1_name + \" \" + middle2_initials + middle3_initials + \" \" + last_name) #Elizabeth Rafik SM Iskander\n",
    "            personNames.append(first_name + \" \" + middle1_name + \" \" + middle2_initials + \". \" + last_name) #Elizabeth Rafik S. Iskander\n",
    "            personNames.append(first_name + \" \" + middle1_name + \" \" + middle2_initials + \".\" + middle3_initials + \". \" + last_name) #Elizabeth Rafik S.M. Iskander\n",
    "            personNames.append(first_name + \" \" + middle1_initials + last_initials) #Elizabeth RI\n",
    "            personNames.append(first_name + \" \" + middle1_initials + \".\" + last_initials + \".\") #Elizabeth R.I.\n",
    "            personNames.append(first_name + \" \" + middle1_initials + middle2_initials + last_initials) #Elizabeth RSI\n",
    "            personNames.append(first_name + \" \" + middle1_initials + middle2_initials + middle3_initials +last_initials) #Elizabeth RSMI\n",
    "            personNames.append(first_name + \" \" + middle1_initials + \".\" + middle2_initials + \".\" + last_initials + \".\") #Elizabeth R.S.I.\n",
    "            personNames.append(first_name + \" \" + middle1_initials + \".\" + middle2_initials + \".\" + middle3_initials + \".\" +last_initials + \".\") #Elizabeth R.S.M.I.\n",
    "            personNames.append(first_name + \" \" + middle1_initials + \" \" + last_name) #Elizabeth R Iskander\n",
    "            personNames.append(first_name + \" \" + middle1_initials + \". \" + last_name) #Elizabeth R. Iskander\n",
    "            personNames.append(first_name + \" \" + middle1_initials + middle2_initials + \" \" + last_name) #Elizabeth RS Iskander\n",
    "            personNames.append(first_name + \" \" + middle1_initials + middle2_initials + middle3_initials + \" \" + last_name) #Elizabeth RSM Iskander\n",
    "            personNames.append(first_name + \" \" + middle1_initials + \".\" + middle2_initials + \". \" + last_name) #Elizabeth R.S. Iskander\n",
    "            personNames.append(first_name + \" \" + middle1_initials + \".\" + middle2_initials + \".\" + middle3_initials +\". \" + last_name) #Elizabeth R.S.M. Iskander\n",
    "            personNames.append(middle1_name + \" \" + last_name + \", \" + first_name) #Rafik Iskander, Elizabeth\n",
    "            personNames.append(middle1_name + \" \" + last_name + \", \" + first_initials) #Rafik Iskander, E\n",
    "            personNames.append(middle1_name + \" \" + last_name + \", \" + first_initials + \".\") #Rafik Iskander, E.\n",
    "            personNames.append(middle1_name + \" \" + middle2_name + \" \" + last_name + \", \" + first_name) #Rafik Sami Iskander, Elizabeth\n",
    "            personNames.append(middle1_name + \" \" + middle2_name + \" \" + last_name + \", \" + first_initials) #Rafik Sami Iskander, E\n",
    "            personNames.append(middle1_name + \" \" + middle2_name + \" \" + last_name + \", \" + first_initials + \".\") #Rafik Sami Iskander, E.\n",
    "            personNames.append(middle1_name + \" \" + middle2_name + \" \" + middle3_name + \" \" + last_name + \", \" + first_name) #Rafik Sami Mary Iskander, Elizabeth\n",
    "            personNames.append(middle1_name + \" \" + middle2_name + \" \" + middle3_name + \" \" + last_name + \", \" + first_initials) #Rafik Sami Mary Iskander, E\n",
    "            personNames.append(middle1_name + \" \" + middle2_name + \" \" + middle3_name + \" \" + last_name + \", \" + first_initials + \".\") #Rafik Sami Iskander, E.\n",
    "            personNames.append(first_initials + last_initials) #EI\n",
    "            personNames.append(first_initials + \".\" + last_initials + \".\") #E.I.\n",
    "            personNames.append(first_initials + middle1_initials + last_initials) #ERI\n",
    "            personNames.append(first_initials + \".\" + middle1_initials + \".\" + last_initials) #E.R.I\n",
    "            personNames.append(first_initials + middle1_initials + middle2_initials + last_initials) #ERSI\n",
    "            personNames.append(first_initials + \".\" + middle1_initials + \".\" + middle2_initials + \".\" + last_initials) #E.R.S.I.\n",
    "            personNames.append(first_initials + middle1_initials + middle2_initials + middle3_initials +last_initials) #ERSMI\n",
    "            personNames.append(first_initials + \".\" + middle1_initials + \".\" + middle2_initials + \".\" + middle3_initials + \".\" + last_initials + \".\") #E.R.S.M.I.\n",
    "            personNames.append(last_name + \", \" + first_name + \" \" + middle1_name) #Iskander, Elizabeth Rafik \n",
    "            personNames.append(last_name + \", \" + first_name + \" \" + middle1_name + \" \" + middle2_name) #Iskander, Elizabeth Rafik Sami\n",
    "            personNames.append(last_name + \", \" + first_name + \" \" + middle1_name + \" \" + middle2_name + \" \" + middle3_name) #Iskander, Elizabeth Rafik Sami\n",
    "            personNames.append(last_name + \", \" + first_name + \" \" + middle1_initials) #Iskander, Elizabeth R\n",
    "            personNames.append(last_name + \", \" + first_name + \" \" + middle1_initials + \".\") #Iskander, Elizabeth R.\n",
    "            personNames.append(last_name + \", \" + first_name + \" \" + middle1_initials + middle2_initials) #Iskander, Elizabeth RS\n",
    "            personNames.append(last_name + \", \" + first_name + \" \" + middle1_initials + \".\" + middle2_initials + \".\") #Iskander, Elizabeth R.S.\n",
    "            personNames.append(last_name + \", \" + first_name + \" \" + middle1_initials + middle2_initials + middle3_initials) #Iskander, Elizabeth RSM\n",
    "            personNames.append(last_name + \", \" + first_name + \" \" + middle1_initials + \".\" + middle2_initials + \".\" + middle3_initials + \".\") #Iskander, Elizabeth R.S.\n",
    "            personNames.append(last_name + \", \" + first_initials) #Iskander, E\n",
    "            personNames.append(last_name + \", \" + first_initials + \".\") #Iskander, E.\n",
    "            personNames.append(last_name + \" \" + first_initials + middle1_initials) #Iskander ER \n",
    "            personNames.append(last_name + \" \" + first_initials + \".\" + middle1_initials + \".\") #Iskander E.R. \n",
    "            personNames.append(last_name + \" \" + first_initials + middle1_initials + middle2_initials) #Iskander ERS\n",
    "            personNames.append(last_name + \" \" + first_initials + \".\" + middle1_initials + \".\" + middle2_initials + \".\") #Iskander E.R.S.\n",
    "            personNames.append(last_name + \" \" + first_initials + middle1_initials + middle2_initials + middle3_initials) #Iskander ERSM (same format as AU column )\n",
    "            personNames.append(last_name + \" \" + first_initials + \".\" + middle1_initials + \".\" + middle2_initials + \".\" + middle3_initials + \".\") #Iskander E.R.S.M.\n",
    "            personNames.append(last_name) #Iskander\n",
    "\n",
    "        cells.append(personNames)\n",
    "\n",
    "    cumulativeNames.append(cells)"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "668a67fa",
   "metadata": {},
   "source": [
    "## Supporting Functions"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 34,
   "id": "9bc91752",
   "metadata": {},
   "outputs": [],
   "source": [
    "def getName(name):\n",
    "    stack = []\n",
    "    test = []\n",
    "    test = name.split(\", \")\n",
    "    if(len(test))<2:\n",
    "        return test[-1]\n",
    "    lname, fname = name.split(\", \")\n",
    "    lname = [lname]\n",
    "    for n in fname.split(\" \"):\n",
    "        stack.append(n)\n",
    "    return stack+lname"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 32,
   "id": "98a0a1a2",
   "metadata": {},
   "outputs": [],
   "source": [
    "def getLName(name):\n",
    "    lname, fname = name.split(\", \")\n",
    "    return lname"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 30,
   "id": "a0a02c0d",
   "metadata": {},
   "outputs": [],
   "source": [
    "def getInitials(name):\n",
    "    name = getName(name)\n",
    "    if len(name)==0:\n",
    "        return None\n",
    "    name = [n[0] for n in name]\n",
    "    \n",
    "    def combinations(l):\n",
    "        if l:\n",
    "          result = combinations(l[:-1])\n",
    "          return result + [c + [l[-1]] for c in result]\n",
    "        else:\n",
    "          return [[]]\n",
    "\n",
    "    res = [n for n in combinations(name) if name[0] in n and name[-1] in n]\n",
    "    for i,r in enumerate(res):\n",
    "        temp = res.pop(i)\n",
    "        if r not in res:\n",
    "            res.insert(i,r)\n",
    "    final = []\n",
    "    for r in res:\n",
    "        final.append(\"\".join(r))\n",
    "    return final  \n",
    "    "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "id": "cba96c87",
   "metadata": {},
   "outputs": [],
   "source": [
    "def sort(arr):\n",
    "    n = len(arr)\n",
    "    for i in range(1, n):\n",
    "        temp = arr[i]\n",
    "        j = i - 1\n",
    "        while j >= 0 and len(temp) > len(arr[j]):\n",
    "            arr[j + 1] = arr[j]\n",
    "            j -= 1\n",
    " \n",
    "        arr[j + 1] = temp"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "id": "5432ce95",
   "metadata": {},
   "outputs": [],
   "source": [
    "def revsort(arr):\n",
    "    n = len(arr)\n",
    "    for i in range(1, n):\n",
    "        temp = arr[i]\n",
    "        j = i - 1\n",
    "        while j >= 0 and len(temp) < len(arr[j]):\n",
    "            arr[j + 1] = arr[j]\n",
    "            j -= 1\n",
    " \n",
    "        arr[j + 1] = temp"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 8,
   "id": "9256db4e",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "['AJ', 'AIJ', 'AOJ', 'AIOJ']"
      ]
     },
     "execution_count": 8,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "getInitials(\"Jideani, Afam I O\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 9,
   "id": "71d552b4",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Unnamed: 0</th>\n",
       "      <th>PMID</th>\n",
       "      <th>TI</th>\n",
       "      <th>AB</th>\n",
       "      <th>AD</th>\n",
       "      <th>AID</th>\n",
       "      <th>AU</th>\n",
       "      <th>AUID</th>\n",
       "      <th>FAU</th>\n",
       "      <th>COIS</th>\n",
       "      <th>DEP</th>\n",
       "      <th>DP</th>\n",
       "      <th>JT</th>\n",
       "      <th>PMC</th>\n",
       "      <th>NER</th>\n",
       "      <th>Ent</th>\n",
       "      <th>Tokenized Sentence</th>\n",
       "      <th>is_entity</th>\n",
       "      <th>check_entity</th>\n",
       "      <th>LAU</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>6</td>\n",
       "      <td>36057537</td>\n",
       "      <td>Anticoagulation and Subclinical Valve Thrombos...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Zena and Michael A. Wiener Cardiovascular Inst...</td>\n",
       "      <td>S1936-8798(22)01545-X [pii];10.1016/j.jcin.202...</td>\n",
       "      <td>Dangas G;Nicolas J</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Dangas, George;Nicolas, Johny</td>\n",
       "      <td>Funding Support and Author Disclosures Dr Dang...</td>\n",
       "      <td>20220822.0</td>\n",
       "      <td>2022 Aug 22</td>\n",
       "      <td>JACC. Cardiovascular interventions</td>\n",
       "      <td>NaN</td>\n",
       "      <td>['ORG', 'PERSON']</td>\n",
       "      <td>Entity Exists</td>\n",
       "      <td>['Funding Support and Author Disclosures Dr Da...</td>\n",
       "      <td>[['ORG'], ['PERSON']]</td>\n",
       "      <td>Not empty</td>\n",
       "      <td>[[George Dangas, George D, George D., GD, G.D....</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>8</td>\n",
       "      <td>36057535</td>\n",
       "      <td>Five-Year Follow-Up Images of a Balloon Expand...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Department of Cardiology, New Tokyo Hospital, ...</td>\n",
       "      <td>S1936-8798(22)01544-8 [pii];10.1016/j.jcin.202...</td>\n",
       "      <td>Naganuma T;Panoulas VF;Onishi H;Kawamoto H;Nak...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Naganuma, Toru;Panoulas, Vasileios F;Onishi, H...</td>\n",
       "      <td>Funding Support and Author Disclosures Dr. Nag...</td>\n",
       "      <td>20220824.0</td>\n",
       "      <td>2022 Aug 24</td>\n",
       "      <td>JACC. Cardiovascular interventions</td>\n",
       "      <td>NaN</td>\n",
       "      <td>['PERSON', 'ORG']</td>\n",
       "      <td>Entity Exists</td>\n",
       "      <td>['Funding Support and Author Disclosures Dr. N...</td>\n",
       "      <td>[['PERSON', 'ORG'], []]</td>\n",
       "      <td>Not empty</td>\n",
       "      <td>[[Toru Naganuma, Toru N, Toru N., TN, T.N., T ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>13</td>\n",
       "      <td>36057529</td>\n",
       "      <td>Survivors of Sudden Cardiac Arrest Presenting ...</td>\n",
       "      <td>BACKGROUND: The proportion of sudden cardiac a...</td>\n",
       "      <td>Center for Cardiac Arrest Prevention, Departme...</td>\n",
       "      <td>S2405-500X(22)00583-7 [pii];10.1016/j.jacep.20...</td>\n",
       "      <td>Holmstrom L;Salmasi S;Chugh H;Uy-Evanado A;Sor...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Holmstrom, Lauri;Salmasi, Shiva;Chugh, Harpriy...</td>\n",
       "      <td>Funding Support and Author Disclosures This wo...</td>\n",
       "      <td>20220829.0</td>\n",
       "      <td>2022 Aug 29</td>\n",
       "      <td>JACC. Clinical electrophysiology</td>\n",
       "      <td>NaN</td>\n",
       "      <td>['ORG', 'ORG', 'NORP', 'PERSON', 'ORG', 'ORG',...</td>\n",
       "      <td>Entity Exists</td>\n",
       "      <td>['Funding Support and Author Disclosures This ...</td>\n",
       "      <td>[['ORG', 'ORG', 'NORP'], [], ['ORG', 'ORG', 'O...</td>\n",
       "      <td>Not empty</td>\n",
       "      <td>[[Lauri Holmstrom, Lauri H, Lauri H., LH, L.H....</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>15</td>\n",
       "      <td>36057526</td>\n",
       "      <td>Predictive performance and clinical applicatio...</td>\n",
       "      <td>BACKGROUND: The SARS-CoV-2 pandemic is a world...</td>\n",
       "      <td>Non-Profit Research Institute Alliance for the...</td>\n",
       "      <td>S2589-7500(22)00150-9 [pii];10.1016/S2589-7500...</td>\n",
       "      <td>Staessen JA;Wendt R;Yu YL;Kalbitz S;Thijs L;Si...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Staessen, Jan A;Wendt, Ralph;Yu, Yu-Ling;Kalbi...</td>\n",
       "      <td>Declaration of interests HM is the co-founder ...</td>\n",
       "      <td>20220831.0</td>\n",
       "      <td>2022 Aug 31</td>\n",
       "      <td>The Lancet. Digital health</td>\n",
       "      <td>NaN</td>\n",
       "      <td>['ORG', 'GPE', 'GPE', 'PERSON', 'ORG', 'ORG', ...</td>\n",
       "      <td>Entity Exists</td>\n",
       "      <td>['Declaration of interests HM is the co-founde...</td>\n",
       "      <td>[['ORG', 'GPE', 'GPE'], ['PERSON', 'ORG'], ['O...</td>\n",
       "      <td>Not empty</td>\n",
       "      <td>[[Jan Staessen, Jan S, Jan S., Jan A Staessen,...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>16</td>\n",
       "      <td>36057525</td>\n",
       "      <td>Telomere biology disorders: time for moving to...</td>\n",
       "      <td>Telomere biology disorders (TBDs) are a group ...</td>\n",
       "      <td>Department of Medicine, Washington University ...</td>\n",
       "      <td>S1471-4914(22)00202-7 [pii];10.1016/j.molmed.2...</td>\n",
       "      <td>Batista LFZ;Dokal I;Parker R</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Batista, Luis F Z;Dokal, Inderjeet;Parker, Roy</td>\n",
       "      <td>Declaration of interests R.P. is a founder and...</td>\n",
       "      <td>20220831.0</td>\n",
       "      <td>2022 Aug 31</td>\n",
       "      <td>Trends in molecular medicine</td>\n",
       "      <td>NaN</td>\n",
       "      <td>['ORG', 'ORG']</td>\n",
       "      <td>Entity Exists</td>\n",
       "      <td>['Declaration of interests R.P.', 'is a founde...</td>\n",
       "      <td>[['ORG'], ['ORG'], []]</td>\n",
       "      <td>Not empty</td>\n",
       "      <td>[[Luis Batista, Luis B, Luis B., Luis F Batist...</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "   Unnamed: 0      PMID                                                 TI  \\\n",
       "0           6  36057537  Anticoagulation and Subclinical Valve Thrombos...   \n",
       "1           8  36057535  Five-Year Follow-Up Images of a Balloon Expand...   \n",
       "2          13  36057529  Survivors of Sudden Cardiac Arrest Presenting ...   \n",
       "3          15  36057526  Predictive performance and clinical applicatio...   \n",
       "4          16  36057525  Telomere biology disorders: time for moving to...   \n",
       "\n",
       "                                                  AB  \\\n",
       "0                                                NaN   \n",
       "1                                                NaN   \n",
       "2  BACKGROUND: The proportion of sudden cardiac a...   \n",
       "3  BACKGROUND: The SARS-CoV-2 pandemic is a world...   \n",
       "4  Telomere biology disorders (TBDs) are a group ...   \n",
       "\n",
       "                                                  AD  \\\n",
       "0  Zena and Michael A. Wiener Cardiovascular Inst...   \n",
       "1  Department of Cardiology, New Tokyo Hospital, ...   \n",
       "2  Center for Cardiac Arrest Prevention, Departme...   \n",
       "3  Non-Profit Research Institute Alliance for the...   \n",
       "4  Department of Medicine, Washington University ...   \n",
       "\n",
       "                                                 AID  \\\n",
       "0  S1936-8798(22)01545-X [pii];10.1016/j.jcin.202...   \n",
       "1  S1936-8798(22)01544-8 [pii];10.1016/j.jcin.202...   \n",
       "2  S2405-500X(22)00583-7 [pii];10.1016/j.jacep.20...   \n",
       "3  S2589-7500(22)00150-9 [pii];10.1016/S2589-7500...   \n",
       "4  S1471-4914(22)00202-7 [pii];10.1016/j.molmed.2...   \n",
       "\n",
       "                                                  AU AUID  \\\n",
       "0                                 Dangas G;Nicolas J  NaN   \n",
       "1  Naganuma T;Panoulas VF;Onishi H;Kawamoto H;Nak...  NaN   \n",
       "2  Holmstrom L;Salmasi S;Chugh H;Uy-Evanado A;Sor...  NaN   \n",
       "3  Staessen JA;Wendt R;Yu YL;Kalbitz S;Thijs L;Si...  NaN   \n",
       "4                       Batista LFZ;Dokal I;Parker R  NaN   \n",
       "\n",
       "                                                 FAU  \\\n",
       "0                      Dangas, George;Nicolas, Johny   \n",
       "1  Naganuma, Toru;Panoulas, Vasileios F;Onishi, H...   \n",
       "2  Holmstrom, Lauri;Salmasi, Shiva;Chugh, Harpriy...   \n",
       "3  Staessen, Jan A;Wendt, Ralph;Yu, Yu-Ling;Kalbi...   \n",
       "4     Batista, Luis F Z;Dokal, Inderjeet;Parker, Roy   \n",
       "\n",
       "                                                COIS         DEP           DP  \\\n",
       "0  Funding Support and Author Disclosures Dr Dang...  20220822.0  2022 Aug 22   \n",
       "1  Funding Support and Author Disclosures Dr. Nag...  20220824.0  2022 Aug 24   \n",
       "2  Funding Support and Author Disclosures This wo...  20220829.0  2022 Aug 29   \n",
       "3  Declaration of interests HM is the co-founder ...  20220831.0  2022 Aug 31   \n",
       "4  Declaration of interests R.P. is a founder and...  20220831.0  2022 Aug 31   \n",
       "\n",
       "                                   JT  PMC  \\\n",
       "0  JACC. Cardiovascular interventions  NaN   \n",
       "1  JACC. Cardiovascular interventions  NaN   \n",
       "2    JACC. Clinical electrophysiology  NaN   \n",
       "3          The Lancet. Digital health  NaN   \n",
       "4        Trends in molecular medicine  NaN   \n",
       "\n",
       "                                                 NER            Ent  \\\n",
       "0                                  ['ORG', 'PERSON']  Entity Exists   \n",
       "1                                  ['PERSON', 'ORG']  Entity Exists   \n",
       "2  ['ORG', 'ORG', 'NORP', 'PERSON', 'ORG', 'ORG',...  Entity Exists   \n",
       "3  ['ORG', 'GPE', 'GPE', 'PERSON', 'ORG', 'ORG', ...  Entity Exists   \n",
       "4                                     ['ORG', 'ORG']  Entity Exists   \n",
       "\n",
       "                                  Tokenized Sentence  \\\n",
       "0  ['Funding Support and Author Disclosures Dr Da...   \n",
       "1  ['Funding Support and Author Disclosures Dr. N...   \n",
       "2  ['Funding Support and Author Disclosures This ...   \n",
       "3  ['Declaration of interests HM is the co-founde...   \n",
       "4  ['Declaration of interests R.P.', 'is a founde...   \n",
       "\n",
       "                                           is_entity check_entity  \\\n",
       "0                              [['ORG'], ['PERSON']]    Not empty   \n",
       "1                            [['PERSON', 'ORG'], []]    Not empty   \n",
       "2  [['ORG', 'ORG', 'NORP'], [], ['ORG', 'ORG', 'O...    Not empty   \n",
       "3  [['ORG', 'GPE', 'GPE'], ['PERSON', 'ORG'], ['O...    Not empty   \n",
       "4                             [['ORG'], ['ORG'], []]    Not empty   \n",
       "\n",
       "                                                 LAU  \n",
       "0  [[George Dangas, George D, George D., GD, G.D....  \n",
       "1  [[Toru Naganuma, Toru N, Toru N., TN, T.N., T ...  \n",
       "2  [[Lauri Holmstrom, Lauri H, Lauri H., LH, L.H....  \n",
       "3  [[Jan Staessen, Jan S, Jan S., Jan A Staessen,...  \n",
       "4  [[Luis Batista, Luis B, Luis B., Luis F Batist...  "
      ]
     },
     "execution_count": 9,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "variations=pd.DataFrame(cumulativeNames)\n",
    "data2['LAU'] = variations.values.tolist()\n",
    "data2.head(5)"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "94f903eb",
   "metadata": {},
   "source": [
    "## Function Definition"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 10,
   "id": "b9a432d1",
   "metadata": {},
   "outputs": [],
   "source": [
    "def replacementFunction(string, name, allnames):\n",
    "    initials = getInitials(name)\n",
    "    \n",
    "    sort(initials)\n",
    "    \n",
    "    for initial in initials:\n",
    "        if initial in string:\n",
    "            fname = \" \".join(getName(name))\n",
    "            return string.replace(initial, fname)\n",
    "    return string\n",
    "    "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 25,
   "id": "18f2878e",
   "metadata": {},
   "outputs": [],
   "source": [
    "def check_all(index, all_names, string):\n",
    "    all_names.append(getLName(all_names[0]))\n",
    "    for name in all_names:\n",
    "        if name in string:\n",
    "            print(all_names[0])\n",
    "            temp = \" \".join(getName(all_names[0]))\n",
    "            return string.replace(name, temp)\n",
    "    return string"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "7dac7121",
   "metadata": {},
   "source": [
    "## Accessing the PMIDs of the Rows where there is a COIS"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "0879e923",
   "metadata": {},
   "source": [
    "## 11/2/2022"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 12,
   "id": "8a6eb030",
   "metadata": {},
   "outputs": [],
   "source": [
    "df = pd.read_csv('Full data.csv')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 13,
   "id": "30ec4c53",
   "metadata": {},
   "outputs": [],
   "source": [
    "pd.set_option('display.max_colwidth', None)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 37,
   "id": "4866cfa2",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Dangas, George\n",
      "Funding Support and Author Disclosures Dr George Dangas has received institutional research grants from Daiichi Sankyo. Dr Nicolas has reported that he has no relationships relevant to the contents of this paper to disclose.\n",
      "\n",
      "Nicolas, Johny\n",
      "Funding Support and Author Disclosures Dr George Dangas has received institutional research grants from Daiichi Sankyo. Dr Johny Nicolas has reported that he has no relationships relevant to the contents of this paper to disclose.\n",
      "\n",
      "Naganuma, Toru\n",
      "Funding Support and Author Disclosures Dr. Toru Naganuma is a clinical proctor of transcatheter aortic valve replacement for Edwards Lifesciences. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.\n",
      "\n",
      "Funding Support and Author Disclosures Dr. Toru Naganuma is a clinical proctor of transcatheter aortic valve replacement for Edwards Lifesciences. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.\n",
      "\n",
      "Funding Support and Author Disclosures Dr. Toru Naganuma is a clinical proctor of transcatheter aortic valve replacement for Edwards Lifesciences. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.\n",
      "\n",
      "Funding Support and Author Disclosures Dr. Toru Naganuma is a clinical proctor of transcatheter aortic valve replacement for Edwards Lifesciences. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.\n",
      "\n",
      "Funding Support and Author Disclosures Dr. Toru Naganuma is a clinical proctor of transcatheter aortic valve replacement for Edwards Lifesciences. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.\n",
      "\n",
      "Holmstrom, Lauri\n",
      "Funding Support and Author Disclosures This work was funded, in part, by National Institutes of Health, National Heart Lung and Blood Institute grants R01HL145675  and R01HL147358 to Dr Chugh. Dr Chugh holds the Pauline and Harold Price Chair in Cardiac Electrophysiology at Cedars-Sinai. Dr Lauri Holmstrom was supported by the Sigrid Juselius Foundation, Finnish Cultural Foundation, Instrumentarium Science  Foundation, Orion Research Foundation, and Paavo Nurmi Foundation. The funding sources had no involvement in the preparation of this work or the decision to submit for publication. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.\n",
      "\n",
      "Funding Support and Author Disclosures This work was funded, in part, by National Institutes of Health, National Heart Lung and Blood Institute grants R01HL145675  and R01HL147358 to Dr Chugh. Dr Chugh holds the Pauline and Harold Price Chair in Cardiac Electrophysiology at Cedars-Sinai. Dr Lauri Holmstrom was supported by the Sigrid Juselius Foundation, Finnish Cultural Foundation, Instrumentarium Science  Foundation, Orion Research Foundation, and Paavo Nurmi Foundation. The funding sources had no involvement in the preparation of this work or the decision to submit for publication. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.\n",
      "\n",
      "Chugh, Harpriya\n",
      "Funding Support and Author Disclosures This work was funded, in part, by National Institutes of Health, National Heart Lung and Blood Institute grants R01HL145675  and R01HL147358 to Dr Harpriya Chugh. Dr Harpriya Chugh holds the Pauline and Harold Price Chair in Cardiac Electrophysiology at Cedars-Sinai. Dr Lauri Holmstrom was supported by the Sigrid Juselius Foundation, Finnish Cultural Foundation, Instrumentarium Science  Foundation, Orion Research Foundation, and Paavo Nurmi Foundation. The funding sources had no involvement in the preparation of this work or the decision to submit for publication. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.\n",
      "\n",
      "Funding Support and Author Disclosures This work was funded, in part, by National Institutes of Health, National Heart Lung and Blood Institute grants R01HL145675  and R01HL147358 to Dr Harpriya Chugh. Dr Harpriya Chugh holds the Pauline and Harold Price Chair in Cardiac Electrophysiology at Cedars-Sinai. Dr Lauri Holmstrom was supported by the Sigrid Juselius Foundation, Finnish Cultural Foundation, Instrumentarium Science  Foundation, Orion Research Foundation, and Paavo Nurmi Foundation. The funding sources had no involvement in the preparation of this work or the decision to submit for publication. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.\n",
      "\n",
      "Funding Support and Author Disclosures This work was funded, in part, by National Institutes of Health, National Heart Lung and Blood Institute grants R01HL145675  and R01HL147358 to Dr Harpriya Chugh. Dr Harpriya Chugh holds the Pauline and Harold Price Chair in Cardiac Electrophysiology at Cedars-Sinai. Dr Lauri Holmstrom was supported by the Sigrid Juselius Foundation, Finnish Cultural Foundation, Instrumentarium Science  Foundation, Orion Research Foundation, and Paavo Nurmi Foundation. The funding sources had no involvement in the preparation of this work or the decision to submit for publication. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.\n",
      "\n",
      "Funding Support and Author Disclosures This work was funded, in part, by National Institutes of Health, National Heart Lung and Blood Institute grants R01HL145675  and R01HL147358 to Dr Harpriya Chugh. Dr Harpriya Chugh holds the Pauline and Harold Price Chair in Cardiac Electrophysiology at Cedars-Sinai. Dr Lauri Holmstrom was supported by the Sigrid Juselius Foundation, Finnish Cultural Foundation, Instrumentarium Science  Foundation, Orion Research Foundation, and Paavo Nurmi Foundation. The funding sources had no involvement in the preparation of this work or the decision to submit for publication. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.\n",
      "\n",
      "Funding Support and Author Disclosures This work was funded, in part, by National Institutes of Health, National Heart Lung and Blood Institute grants R01HL145675  and R01HL147358 to Dr Harpriya Chugh. Dr Harpriya Chugh holds the Pauline and Harold Price Chair in Cardiac Electrophysiology at Cedars-Sinai. Dr Lauri Holmstrom was supported by the Sigrid Juselius Foundation, Finnish Cultural Foundation, Instrumentarium Science  Foundation, Orion Research Foundation, and Paavo Nurmi Foundation. The funding sources had no involvement in the preparation of this work or the decision to submit for publication. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.\n",
      "\n",
      "Funding Support and Author Disclosures This work was funded, in part, by National Institutes of Health, National Heart Lung and Blood Institute grants R01HL145675  and R01HL147358 to Dr Harpriya Chugh. Dr Harpriya Chugh holds the Pauline and Harold Price Chair in Cardiac Electrophysiology at Cedars-Sinai. Dr Lauri Holmstrom was supported by the Sigrid Juselius Foundation, Finnish Cultural Foundation, Instrumentarium Science  Foundation, Orion Research Foundation, and Paavo Nurmi Foundation. The funding sources had no involvement in the preparation of this work or the decision to submit for publication. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.\n",
      "\n",
      "Funding Support and Author Disclosures This work was funded, in part, by National Institutes of Health, National Heart Lung and Blood Institute grants R01HL145675  and R01HL147358 to Dr Harpriya Chugh. Dr Harpriya Chugh holds the Pauline and Harold Price Chair in Cardiac Electrophysiology at Cedars-Sinai. Dr Lauri Holmstrom was supported by the Sigrid Juselius Foundation, Finnish Cultural Foundation, Instrumentarium Science  Foundation, Orion Research Foundation, and Paavo Nurmi Foundation. The funding sources had no involvement in the preparation of this work or the decision to submit for publication. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.\n",
      "\n",
      "Funding Support and Author Disclosures This work was funded, in part, by National Institutes of Health, National Heart Lung and Blood Institute grants R01HL145675  and R01HL147358 to Dr Harpriya Chugh. Dr Harpriya Chugh holds the Pauline and Harold Price Chair in Cardiac Electrophysiology at Cedars-Sinai. Dr Lauri Holmstrom was supported by the Sigrid Juselius Foundation, Finnish Cultural Foundation, Instrumentarium Science  Foundation, Orion Research Foundation, and Paavo Nurmi Foundation. The funding sources had no involvement in the preparation of this work or the decision to submit for publication. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.\n",
      "\n",
      "Funding Support and Author Disclosures This work was funded, in part, by National Institutes of Health, National Heart Lung and Blood Institute grants R01HL145675  and R01HL147358 to Dr Harpriya Chugh. Dr Harpriya Chugh holds the Pauline and Harold Price Chair in Cardiac Electrophysiology at Cedars-Sinai. Dr Lauri Holmstrom was supported by the Sigrid Juselius Foundation, Finnish Cultural Foundation, Instrumentarium Science  Foundation, Orion Research Foundation, and Paavo Nurmi Foundation. The funding sources had no involvement in the preparation of this work or the decision to submit for publication. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.\n",
      "\n",
      "Chugh, Sumeet S.\n",
      "Funding Support and Author Disclosures This work was funded, in part, by National Institutes of Health, National Heart Lung and Blood Institute grants R01HL145675  and R01HL147358 to Dr Harpriya Sumeet S. Chugh. Dr Harpriya Sumeet S. Chugh holds the Pauline and Harold Price Chair in Cardiac Electrophysiology at Cedars-Sinai. Dr Lauri Holmstrom was supported by the Sigrid Juselius Foundation, Finnish Cultural Foundation, Instrumentarium Science  Foundation, Orion Research Foundation, and Paavo Nurmi Foundation. The funding sources had no involvement in the preparation of this work or the decision to submit for publication. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.\n",
      "\n",
      "Staessen, Jan A.\n",
      "Declaration of interests HM is the co-founder and co-owner of Mosaiques-Diagnostiques (Hannover, Germany). Jan A. Staessen and JR are employees of Mosaiques-Diagnostics. HDR received consulting fees and honoraria for presentations from Alexion, AstraZeneca, and Bristol-Myers-Squibb. All other authors declare no competing interests.\n",
      "\n",
      "Declaration of interests HM is the co-founder and co-owner of Mosaiques-Diagnostiques (Hannover, Germany). Jan A. Staessen and JR are employees of Mosaiques-Diagnostics. HDR received consulting fees and honoraria for presentations from Alexion, AstraZeneca, and Bristol-Myers-Squibb. All other authors declare no competing interests.\n",
      "\n",
      "Declaration of interests HM is the co-founder and co-owner of Mosaiques-Diagnostiques (Hannover, Germany). Jan A. Staessen and JR are employees of Mosaiques-Diagnostics. HDR received consulting fees and honoraria for presentations from Alexion, AstraZeneca, and Bristol-Myers-Squibb. All other authors declare no competing interests.\n",
      "\n",
      "Declaration of interests HM is the co-founder and co-owner of Mosaiques-Diagnostiques (Hannover, Germany). Jan A. Staessen and JR are employees of Mosaiques-Diagnostics. HDR received consulting fees and honoraria for presentations from Alexion, AstraZeneca, and Bristol-Myers-Squibb. All other authors declare no competing interests.\n",
      "\n",
      "Declaration of interests HM is the co-founder and co-owner of Mosaiques-Diagnostiques (Hannover, Germany). Jan A. Staessen and JR are employees of Mosaiques-Diagnostics. HDR received consulting fees and honoraria for presentations from Alexion, AstraZeneca, and Bristol-Myers-Squibb. All other authors declare no competing interests.\n",
      "\n",
      "Declaration of interests HM is the co-founder and co-owner of Mosaiques-Diagnostiques (Hannover, Germany). Jan A. Staessen and JR are employees of Mosaiques-Diagnostics. HDR received consulting fees and honoraria for presentations from Alexion, AstraZeneca, and Bristol-Myers-Squibb. All other authors declare no competing interests.\n",
      "\n",
      "Raad, Julia\n",
      "Declaration of interests HM is the co-founder and co-owner of Mosaiques-Diagnostiques (Hannover, Germany). Jan A. Staessen and Julia Raad are employees of Mosaiques-Diagnostics. HDR received consulting fees and honoraria for presentations from Alexion, AstraZeneca, and Bristol-Myers-Squibb. All other authors declare no competing interests.\n",
      "\n",
      "Declaration of interests HM is the co-founder and co-owner of Mosaiques-Diagnostiques (Hannover, Germany). Jan A. Staessen and Julia Raad are employees of Mosaiques-Diagnostics. HDR received consulting fees and honoraria for presentations from Alexion, AstraZeneca, and Bristol-Myers-Squibb. All other authors declare no competing interests.\n",
      "\n",
      "Declaration of interests HM is the co-founder and co-owner of Mosaiques-Diagnostiques (Hannover, Germany). Jan A. Staessen and Julia Raad are employees of Mosaiques-Diagnostics. HDR received consulting fees and honoraria for presentations from Alexion, AstraZeneca, and Bristol-Myers-Squibb. All other authors declare no competing interests.\n",
      "\n",
      "Declaration of interests HM is the co-founder and co-owner of Mosaiques-Diagnostiques (Hannover, Germany). Jan A. Staessen and Julia Raad are employees of Mosaiques-Diagnostics. HDR received consulting fees and honoraria for presentations from Alexion, AstraZeneca, and Bristol-Myers-Squibb. All other authors declare no competing interests.\n",
      "\n",
      "Declaration of interests HM is the co-founder and co-owner of Mosaiques-Diagnostiques (Hannover, Germany). Jan A. Staessen and Julia Raad are employees of Mosaiques-Diagnostics. HDR received consulting fees and honoraria for presentations from Alexion, AstraZeneca, and Bristol-Myers-Squibb. All other authors declare no competing interests.\n",
      "\n",
      "Declaration of interests HM is the co-founder and co-owner of Mosaiques-Diagnostiques (Hannover, Germany). Jan A. Staessen and Julia Raad are employees of Mosaiques-Diagnostics. HDR received consulting fees and honoraria for presentations from Alexion, AstraZeneca, and Bristol-Myers-Squibb. All other authors declare no competing interests.\n",
      "\n",
      "Declaration of interests HM is the co-founder and co-owner of Mosaiques-Diagnostiques (Hannover, Germany). Jan A. Staessen and Julia Raad are employees of Mosaiques-Diagnostics. HDR received consulting fees and honoraria for presentations from Alexion, AstraZeneca, and Bristol-Myers-Squibb. All other authors declare no competing interests.\n",
      "\n",
      "Declaration of interests HM is the co-founder and co-owner of Mosaiques-Diagnostiques (Hannover, Germany). Jan A. Staessen and Julia Raad are employees of Mosaiques-Diagnostics. HDR received consulting fees and honoraria for presentations from Alexion, AstraZeneca, and Bristol-Myers-Squibb. All other authors declare no competing interests.\n",
      "\n",
      "Declaration of interests HM is the co-founder and co-owner of Mosaiques-Diagnostiques (Hannover, Germany). Jan A. Staessen and Julia Raad are employees of Mosaiques-Diagnostics. HDR received consulting fees and honoraria for presentations from Alexion, AstraZeneca, and Bristol-Myers-Squibb. All other authors declare no competing interests.\n",
      "\n",
      "Declaration of interests HM is the co-founder and co-owner of Mosaiques-Diagnostiques (Hannover, Germany). Jan A. Staessen and Julia Raad are employees of Mosaiques-Diagnostics. HDR received consulting fees and honoraria for presentations from Alexion, AstraZeneca, and Bristol-Myers-Squibb. All other authors declare no competing interests.\n",
      "\n",
      "Declaration of interests HM is the co-founder and co-owner of Mosaiques-Diagnostiques (Hannover, Germany). Jan A. Staessen and Julia Raad are employees of Mosaiques-Diagnostics. HDR received consulting fees and honoraria for presentations from Alexion, AstraZeneca, and Bristol-Myers-Squibb. All other authors declare no competing interests.\n",
      "\n",
      "Declaration of interests HM is the co-founder and co-owner of Mosaiques-Diagnostiques (Hannover, Germany). Jan A. Staessen and Julia Raad are employees of Mosaiques-Diagnostics. HDR received consulting fees and honoraria for presentations from Alexion, AstraZeneca, and Bristol-Myers-Squibb. All other authors declare no competing interests.\n",
      "\n",
      "Declaration of interests HM is the co-founder and co-owner of Mosaiques-Diagnostiques (Hannover, Germany). Jan A. Staessen and Julia Raad are employees of Mosaiques-Diagnostics. HDR received consulting fees and honoraria for presentations from Alexion, AstraZeneca, and Bristol-Myers-Squibb. All other authors declare no competing interests.\n",
      "\n",
      "Declaration of interests HM is the co-founder and co-owner of Mosaiques-Diagnostiques (Hannover, Germany). Jan A. Staessen and Julia Raad are employees of Mosaiques-Diagnostics. HDR received consulting fees and honoraria for presentations from Alexion, AstraZeneca, and Bristol-Myers-Squibb. All other authors declare no competing interests.\n",
      "\n",
      "Declaration of interests HM is the co-founder and co-owner of Mosaiques-Diagnostiques (Hannover, Germany). Jan A. Staessen and Julia Raad are employees of Mosaiques-Diagnostics. HDR received consulting fees and honoraria for presentations from Alexion, AstraZeneca, and Bristol-Myers-Squibb. All other authors declare no competing interests.\n",
      "\n",
      "Declaration of interests HM is the co-founder and co-owner of Mosaiques-Diagnostiques (Hannover, Germany). Jan A. Staessen and Julia Raad are employees of Mosaiques-Diagnostics. HDR received consulting fees and honoraria for presentations from Alexion, AstraZeneca, and Bristol-Myers-Squibb. All other authors declare no competing interests.\n",
      "\n",
      "Declaration of interests HM is the co-founder and co-owner of Mosaiques-Diagnostiques (Hannover, Germany). Jan A. Staessen and Julia Raad are employees of Mosaiques-Diagnostics. HDR received consulting fees and honoraria for presentations from Alexion, AstraZeneca, and Bristol-Myers-Squibb. All other authors declare no competing interests.\n",
      "\n",
      "Declaration of interests HM is the co-founder and co-owner of Mosaiques-Diagnostiques (Hannover, Germany). Jan A. Staessen and Julia Raad are employees of Mosaiques-Diagnostics. HDR received consulting fees and honoraria for presentations from Alexion, AstraZeneca, and Bristol-Myers-Squibb. All other authors declare no competing interests.\n",
      "\n",
      "Declaration of interests HM is the co-founder and co-owner of Mosaiques-Diagnostiques (Hannover, Germany). Jan A. Staessen and Julia Raad are employees of Mosaiques-Diagnostics. HDR received consulting fees and honoraria for presentations from Alexion, AstraZeneca, and Bristol-Myers-Squibb. All other authors declare no competing interests.\n",
      "\n",
      "Declaration of interests HM is the co-founder and co-owner of Mosaiques-Diagnostiques (Hannover, Germany). Jan A. Staessen and Julia Raad are employees of Mosaiques-Diagnostics. HDR received consulting fees and honoraria for presentations from Alexion, AstraZeneca, and Bristol-Myers-Squibb. All other authors declare no competing interests.\n",
      "\n",
      "Declaration of interests HM is the co-founder and co-owner of Mosaiques-Diagnostiques (Hannover, Germany). Jan A. Staessen and Julia Raad are employees of Mosaiques-Diagnostics. HDR received consulting fees and honoraria for presentations from Alexion, AstraZeneca, and Bristol-Myers-Squibb. All other authors declare no competing interests.\n",
      "\n",
      "Declaration of interests HM is the co-founder and co-owner of Mosaiques-Diagnostiques (Hannover, Germany). Jan A. Staessen and Julia Raad are employees of Mosaiques-Diagnostics. HDR received consulting fees and honoraria for presentations from Alexion, AstraZeneca, and Bristol-Myers-Squibb. All other authors declare no competing interests.\n",
      "\n",
      "Declaration of interests HM is the co-founder and co-owner of Mosaiques-Diagnostiques (Hannover, Germany). Jan A. Staessen and Julia Raad are employees of Mosaiques-Diagnostics. HDR received consulting fees and honoraria for presentations from Alexion, AstraZeneca, and Bristol-Myers-Squibb. All other authors declare no competing interests.\n",
      "\n",
      "Declaration of interests HM is the co-founder and co-owner of Mosaiques-Diagnostiques (Hannover, Germany). Jan A. Staessen and Julia Raad are employees of Mosaiques-Diagnostics. HDR received consulting fees and honoraria for presentations from Alexion, AstraZeneca, and Bristol-Myers-Squibb. All other authors declare no competing interests.\n",
      "\n",
      "Declaration of interests HM is the co-founder and co-owner of Mosaiques-Diagnostiques (Hannover, Germany). Jan A. Staessen and Julia Raad are employees of Mosaiques-Diagnostics. HDR received consulting fees and honoraria for presentations from Alexion, AstraZeneca, and Bristol-Myers-Squibb. All other authors declare no competing interests.\n",
      "\n",
      "Declaration of interests HM is the co-founder and co-owner of Mosaiques-Diagnostiques (Hannover, Germany). Jan A. Staessen and Julia Raad are employees of Mosaiques-Diagnostics. HDR received consulting fees and honoraria for presentations from Alexion, AstraZeneca, and Bristol-Myers-Squibb. All other authors declare no competing interests.\n",
      "\n",
      "Rupprecht, Harald D.\n",
      "Declaration of interests HM is the co-founder and co-owner of Mosaiques-Diagnostiques (Hannover, Germany). Jan A. Staessen and Julia Raad are employees of Mosaiques-Diagnostics. Harald D. Rupprecht received consulting fees and honoraria for presentations from Alexion, AstraZeneca, and Bristol-Myers-Squibb. All other authors declare no competing interests.\n",
      "\n",
      "Declaration of interests HM is the co-founder and co-owner of Mosaiques-Diagnostiques (Hannover, Germany). Jan A. Staessen and Julia Raad are employees of Mosaiques-Diagnostics. Harald D. Rupprecht received consulting fees and honoraria for presentations from Alexion, AstraZeneca, and Bristol-Myers-Squibb. All other authors declare no competing interests.\n",
      "\n",
      "Declaration of interests HM is the co-founder and co-owner of Mosaiques-Diagnostiques (Hannover, Germany). Jan A. Staessen and Julia Raad are employees of Mosaiques-Diagnostics. Harald D. Rupprecht received consulting fees and honoraria for presentations from Alexion, AstraZeneca, and Bristol-Myers-Squibb. All other authors declare no competing interests.\n",
      "\n",
      "Declaration of interests HM is the co-founder and co-owner of Mosaiques-Diagnostiques (Hannover, Germany). Jan A. Staessen and Julia Raad are employees of Mosaiques-Diagnostics. Harald D. Rupprecht received consulting fees and honoraria for presentations from Alexion, AstraZeneca, and Bristol-Myers-Squibb. All other authors declare no competing interests.\n",
      "\n",
      "Declaration of interests HM is the co-founder and co-owner of Mosaiques-Diagnostiques (Hannover, Germany). Jan A. Staessen and Julia Raad are employees of Mosaiques-Diagnostics. Harald D. Rupprecht received consulting fees and honoraria for presentations from Alexion, AstraZeneca, and Bristol-Myers-Squibb. All other authors declare no competing interests.\n",
      "\n",
      "Declaration of interests HM is the co-founder and co-owner of Mosaiques-Diagnostiques (Hannover, Germany). Jan A. Staessen and Julia Raad are employees of Mosaiques-Diagnostics. Harald D. Rupprecht received consulting fees and honoraria for presentations from Alexion, AstraZeneca, and Bristol-Myers-Squibb. All other authors declare no competing interests.\n",
      "\n",
      "Mischak, Harald\n",
      "Declaration of interests Harald Mischak is the co-founder and co-owner of Mosaiques-Diagnostiques (Hannover, Germany). Jan A. Staessen and Julia Raad are employees of Mosaiques-Diagnostics. Harald D. Rupprecht received consulting fees and honoraria for presentations from Alexion, AstraZeneca, and Bristol-Myers-Squibb. All other authors declare no competing interests.\n",
      "\n",
      "Declaration of interests Harald Mischak is the co-founder and co-owner of Mosaiques-Diagnostiques (Hannover, Germany). Jan A. Staessen and Julia Raad are employees of Mosaiques-Diagnostics. Harald D. Rupprecht received consulting fees and honoraria for presentations from Alexion, AstraZeneca, and Bristol-Myers-Squibb. All other authors declare no competing interests.\n",
      "\n",
      "Declaration of interests R.P. is a founder and consultant for Faze Medicines. The other authors declare no conflicts of interest.\n",
      "\n",
      "Declaration of interests R.P. is a founder and consultant for Faze Medicines. The other authors declare no conflicts of interest.\n",
      "\n",
      "Parker, Roy\n",
      "Declaration of interests Roy Parker is a founder and consultant for Faze Medicines. The other authors declare no conflicts of interest.\n",
      "\n",
      "Declaration of competing interest Dr. Hemetsberger received a speaker's honoraria from Boston Scientific. Dr. Abdel-Wahab reports that his hospital receives speaker's honoraria and/or consultancy fees on his behalf from Medtronic and Boston Scientific. Dr. Richardt received an institutional research grant from Boston Scientific. Dr. Allali is a proctor for Boston Scientific. The other authors have no conflicts of interest to declare.\n",
      "\n",
      "Hemetsberger, Rayyan\n",
      "Declaration of competing interest Dr. Rayyan Hemetsberger received a speaker's honoraria from Boston Scientific. Dr. Abdel-Wahab reports that his hospital receives speaker's honoraria and/or consultancy fees on his behalf from Medtronic and Boston Scientific. Dr. Richardt received an institutional research grant from Boston Scientific. Dr. Allali is a proctor for Boston Scientific. The other authors have no conflicts of interest to declare.\n",
      "\n",
      "Declaration of competing interest Dr. Rayyan Hemetsberger received a speaker's honoraria from Boston Scientific. Dr. Abdel-Wahab reports that his hospital receives speaker's honoraria and/or consultancy fees on his behalf from Medtronic and Boston Scientific. Dr. Richardt received an institutional research grant from Boston Scientific. Dr. Allali is a proctor for Boston Scientific. The other authors have no conflicts of interest to declare.\n",
      "\n",
      "Declaration of competing interest Dr. Rayyan Hemetsberger received a speaker's honoraria from Boston Scientific. Dr. Abdel-Wahab reports that his hospital receives speaker's honoraria and/or consultancy fees on his behalf from Medtronic and Boston Scientific. Dr. Richardt received an institutional research grant from Boston Scientific. Dr. Allali is a proctor for Boston Scientific. The other authors have no conflicts of interest to declare.\n",
      "\n",
      "Declaration of competing interest Dr. Rayyan Hemetsberger received a speaker's honoraria from Boston Scientific. Dr. Abdel-Wahab reports that his hospital receives speaker's honoraria and/or consultancy fees on his behalf from Medtronic and Boston Scientific. Dr. Richardt received an institutional research grant from Boston Scientific. Dr. Allali is a proctor for Boston Scientific. The other authors have no conflicts of interest to declare.\n",
      "\n",
      "Declaration of competing interest Dr. Rayyan Hemetsberger received a speaker's honoraria from Boston Scientific. Dr. Abdel-Wahab reports that his hospital receives speaker's honoraria and/or consultancy fees on his behalf from Medtronic and Boston Scientific. Dr. Richardt received an institutional research grant from Boston Scientific. Dr. Allali is a proctor for Boston Scientific. The other authors have no conflicts of interest to declare.\n",
      "\n",
      "Declaration of competing interest Dr. Rayyan Hemetsberger received a speaker's honoraria from Boston Scientific. Dr. Abdel-Wahab reports that his hospital receives speaker's honoraria and/or consultancy fees on his behalf from Medtronic and Boston Scientific. Dr. Richardt received an institutional research grant from Boston Scientific. Dr. Allali is a proctor for Boston Scientific. The other authors have no conflicts of interest to declare.\n",
      "\n",
      "Abdel-Wahab, Mohamed\n",
      "Declaration of competing interest Dr. Rayyan Hemetsberger received a speaker's honoraria from Boston Scientific. Dr. Mohamed Abdel-Wahab reports that his hospital receives speaker's honoraria and/or consultancy fees on his behalf from Medtronic and Boston Scientific. Dr. Richardt received an institutional research grant from Boston Scientific. Dr. Allali is a proctor for Boston Scientific. The other authors have no conflicts of interest to declare.\n",
      "\n",
      "Richardt, Gert\n",
      "Declaration of competing interest Dr. Rayyan Hemetsberger received a speaker's honoraria from Boston Scientific. Dr. Mohamed Abdel-Wahab reports that his hospital receives speaker's honoraria and/or consultancy fees on his behalf from Medtronic and Boston Scientific. Dr. Gert Richardt received an institutional research grant from Boston Scientific. Dr. Allali is a proctor for Boston Scientific. The other authors have no conflicts of interest to declare.\n",
      "\n",
      "Allali, Abdelhakim\n",
      "Declaration of competing interest Dr. Rayyan Hemetsberger received a speaker's honoraria from Boston Scientific. Dr. Mohamed Abdel-Wahab reports that his hospital receives speaker's honoraria and/or consultancy fees on his behalf from Medtronic and Boston Scientific. Dr. Gert Richardt received an institutional research grant from Boston Scientific. Dr. Abdelhakim Allali is a proctor for Boston Scientific. The other authors have no conflicts of interest to declare.\n",
      "\n",
      "Declaration of Competing Interest Michael D. McKee is a consultant for Implants for Trauma Surgery (ITS). Implants for Trauma Surgery (ITS) provided the funding  for the cadaveric humerus specimens that were used in this study.\n",
      "\n",
      "Declaration of Competing Interest Michael D. McKee is a consultant for Implants for Trauma Surgery (ITS). Implants for Trauma Surgery (ITS) provided the funding  for the cadaveric humerus specimens that were used in this study.\n",
      "\n",
      "Declaration of Competing Interest Michael D. McKee is a consultant for Implants for Trauma Surgery (ITS). Implants for Trauma Surgery (ITS) provided the funding  for the cadaveric humerus specimens that were used in this study.\n",
      "\n",
      "McKee, Michael D.\n",
      "Declaration of Competing Interest Michael D. McKee is a consultant for Implants for Trauma Surgery (ITS). Implants for Trauma Surgery (ITS) provided the funding  for the cadaveric humerus specimens that were used in this study.\n",
      "\n",
      "Declarations of interest VS and DGE are senior clinical researchers of the Research Foundation Flanders/Fonds Wetenschappelijk Onderzoek (FWO: 1804518N and  1800614N, respectively). The Department of Immunology-Allergology-Rheumatology is a centre of excellence of the World Allergy Organization.\n",
      "\n",
      "Declarations of interest VS and DGE are senior clinical researchers of the Research Foundation Flanders/Fonds Wetenschappelijk Onderzoek (FWO: 1804518N and  1800614N, respectively). The Department of Immunology-Allergology-Rheumatology is a centre of excellence of the World Allergy Organization.\n",
      "\n",
      "Declarations of interest VS and DGE are senior clinical researchers of the Research Foundation Flanders/Fonds Wetenschappelijk Onderzoek (FWO: 1804518N and  1800614N, respectively). The Department of Immunology-Allergology-Rheumatology is a centre of excellence of the World Allergy Organization.\n",
      "\n",
      "Declarations of interest VS and DGE are senior clinical researchers of the Research Foundation Flanders/Fonds Wetenschappelijk Onderzoek (FWO: 1804518N and  1800614N, respectively). The Department of Immunology-Allergology-Rheumatology is a centre of excellence of the World Allergy Organization.\n",
      "\n",
      "Declarations of interest VS and DGE are senior clinical researchers of the Research Foundation Flanders/Fonds Wetenschappelijk Onderzoek (FWO: 1804518N and  1800614N, respectively). The Department of Immunology-Allergology-Rheumatology is a centre of excellence of the World Allergy Organization.\n",
      "\n",
      "Declarations of interest VS and DGE are senior clinical researchers of the Research Foundation Flanders/Fonds Wetenschappelijk Onderzoek (FWO: 1804518N and  1800614N, respectively). The Department of Immunology-Allergology-Rheumatology is a centre of excellence of the World Allergy Organization.\n",
      "\n",
      "Declarations of interest VS and DGE are senior clinical researchers of the Research Foundation Flanders/Fonds Wetenschappelijk Onderzoek (FWO: 1804518N and  1800614N, respectively). The Department of Immunology-Allergology-Rheumatology is a centre of excellence of the World Allergy Organization.\n",
      "\n",
      "Declarations of interest VS and DGE are senior clinical researchers of the Research Foundation Flanders/Fonds Wetenschappelijk Onderzoek (FWO: 1804518N and  1800614N, respectively). The Department of Immunology-Allergology-Rheumatology is a centre of excellence of the World Allergy Organization.\n",
      "\n",
      "Declarations of interest VS and DGE are senior clinical researchers of the Research Foundation Flanders/Fonds Wetenschappelijk Onderzoek (FWO: 1804518N and  1800614N, respectively). The Department of Immunology-Allergology-Rheumatology is a centre of excellence of the World Allergy Organization.\n",
      "\n",
      "Declarations of interest VS and DGE are senior clinical researchers of the Research Foundation Flanders/Fonds Wetenschappelijk Onderzoek (FWO: 1804518N and  1800614N, respectively). The Department of Immunology-Allergology-Rheumatology is a centre of excellence of the World Allergy Organization.\n",
      "\n",
      "Declarations of interest VS and DGE are senior clinical researchers of the Research Foundation Flanders/Fonds Wetenschappelijk Onderzoek (FWO: 1804518N and  1800614N, respectively). The Department of Immunology-Allergology-Rheumatology is a centre of excellence of the World Allergy Organization.\n",
      "\n",
      "Declarations of interest VS and DGE are senior clinical researchers of the Research Foundation Flanders/Fonds Wetenschappelijk Onderzoek (FWO: 1804518N and  1800614N, respectively). The Department of Immunology-Allergology-Rheumatology is a centre of excellence of the World Allergy Organization.\n",
      "\n",
      "Declarations of interest VS and DGE are senior clinical researchers of the Research Foundation Flanders/Fonds Wetenschappelijk Onderzoek (FWO: 1804518N and  1800614N, respectively). The Department of Immunology-Allergology-Rheumatology is a centre of excellence of the World Allergy Organization.\n",
      "\n",
      "Sabato, Vito\n",
      "Declarations of interest Vito Sabato and DGE are senior clinical researchers of the Research Foundation Flanders/Fonds Wetenschappelijk Onderzoek (FWO: 1804518N and  1800614N, respectively). The Department of Immunology-Allergology-Rheumatology is a centre of excellence of the World Allergy Organization.\n",
      "\n",
      "Ebo, Didier G.\n",
      "Declarations of interest Vito Sabato and Didier G. Ebo are senior clinical researchers of the Research Foundation Flanders/Fonds Wetenschappelijk Onderzoek (FWO: 1804518N and  1800614N, respectively). The Department of Immunology-Allergology-Rheumatology is a centre of excellence of the World Allergy Organization.\n",
      "\n",
      "Pozzar, Rachel A.\n",
      "Declaration of Competing Interest Authors Rachel A. Pozzar, NX, FH, AAW, BAG, MLU, JAT, MJH, and DLB have nothing to disclose.\n",
      "\n",
      "Xiong, Niya\n",
      "Declaration of Competing Interest Authors Rachel A. Pozzar, Niya Xiong, FH, AAW, BAG, MLU, JAT, MJH, and DLB have nothing to disclose.\n",
      "\n",
      "Hong, Fangxin\n",
      "Declaration of Competing Interest Authors Rachel A. Pozzar, Niya Xiong, Fangxin Hong, AAW, BAG, MLU, JAT, MJH, and DLB have nothing to disclose.\n",
      "\n",
      "Wright, Alexi A.\n",
      "Declaration of Competing Interest Authors Rachel A. Pozzar, Niya Xiong, Fangxin Hong, Alexi A. Wright, BAG, MLU, JAT, MJH, and DLB have nothing to disclose.\n",
      "\n",
      "Goff, Barbara A.\n",
      "Declaration of Competing Interest Authors Rachel A. Pozzar, Niya Xiong, Fangxin Hong, Alexi A. Wright, Barbara A. Goff, MLU, JAT, MJH, and DLB have nothing to disclose.\n",
      "\n",
      "Underhill-Blazey, Meghan L.\n",
      "Declaration of Competing Interest Authors Rachel A. Pozzar, Niya Xiong, Fangxin Hong, Alexi A. Wright, Barbara A. Goff, Meghan L. Underhill-Blazey, JAT, MJH, and DLB have nothing to disclose.\n",
      "\n",
      "Tulsky, James A.\n",
      "Declaration of Competing Interest Authors Rachel A. Pozzar, Niya Xiong, Fangxin Hong, Alexi A. Wright, Barbara A. Goff, Meghan L. Underhill-Blazey, James A. Tulsky, MJH, and DLB have nothing to disclose.\n",
      "\n",
      "Hammer, Marilyn J.\n",
      "Declaration of Competing Interest Authors Rachel A. Pozzar, Niya Xiong, Fangxin Hong, Alexi A. Wright, Barbara A. Goff, Meghan L. Underhill-Blazey, James A. Tulsky, Marilyn J. Hammer, and DLB have nothing to disclose.\n",
      "\n",
      "Berry, Donna L.\n",
      "Declaration of Competing Interest Authors Rachel A. Pozzar, Niya Xiong, Fangxin Hong, Alexi A. Wright, Barbara A. Goff, Meghan L. Underhill-Blazey, James A. Tulsky, Marilyn J. Hammer, and Donna L. Berry have nothing to disclose.\n",
      "\n",
      "Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Ivan Rusyn reports financial support was provided by National Center for Advancing Translational Sciences. This work was performed through the TEX-VAL Consortium collaboration funded by equitable monetary contributions from member organizations (American Chemistry Council, Bristol-Myers Squibb, Merck Healthcare KGaA, National Institute of Environmental Health Sciences, Sanofi, Unilever, and  United States Environmental Protection Agency).\n",
      "\n",
      "Lim, Alicia Y.\n",
      "Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Ivan Rusyn reports financial support was provided by National Center for Advancing Translational Sciences. This work was performed through the TEX-VAlicia Y. Lim Consortium collaboration funded by equitable monetary contributions from member organizations (American Chemistry Council, Bristol-Myers Squibb, Merck Healthcare KGaA, National Institute of Environmental Health Sciences, Sanofi, Unilever, and  United States Environmental Protection Agency).\n",
      "\n",
      "Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Ivan Rusyn reports financial support was provided by National Center for Advancing Translational Sciences. This work was performed through the TEX-VAlicia Y. Lim Consortium collaboration funded by equitable monetary contributions from member organizations (American Chemistry Council, Bristol-Myers Squibb, Merck Healthcare KGaA, National Institute of Environmental Health Sciences, Sanofi, Unilever, and  United States Environmental Protection Agency).\n",
      "\n",
      "Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Ivan Rusyn reports financial support was provided by National Center for Advancing Translational Sciences. This work was performed through the TEX-VAlicia Y. Lim Consortium collaboration funded by equitable monetary contributions from member organizations (American Chemistry Council, Bristol-Myers Squibb, Merck Healthcare KGaA, National Institute of Environmental Health Sciences, Sanofi, Unilever, and  United States Environmental Protection Agency).\n",
      "\n",
      "Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Ivan Rusyn reports financial support was provided by National Center for Advancing Translational Sciences. This work was performed through the TEX-VAlicia Y. Lim Consortium collaboration funded by equitable monetary contributions from member organizations (American Chemistry Council, Bristol-Myers Squibb, Merck Healthcare KGaA, National Institute of Environmental Health Sciences, Sanofi, Unilever, and  United States Environmental Protection Agency).\n",
      "\n",
      "Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Ivan Rusyn reports financial support was provided by National Center for Advancing Translational Sciences. This work was performed through the TEX-VAlicia Y. Lim Consortium collaboration funded by equitable monetary contributions from member organizations (American Chemistry Council, Bristol-Myers Squibb, Merck Healthcare KGaA, National Institute of Environmental Health Sciences, Sanofi, Unilever, and  United States Environmental Protection Agency).\n",
      "\n",
      "Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Ivan Rusyn reports financial support was provided by National Center for Advancing Translational Sciences. This work was performed through the TEX-VAlicia Y. Lim Consortium collaboration funded by equitable monetary contributions from member organizations (American Chemistry Council, Bristol-Myers Squibb, Merck Healthcare KGaA, National Institute of Environmental Health Sciences, Sanofi, Unilever, and  United States Environmental Protection Agency).\n",
      "\n",
      "Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Ivan Rusyn reports financial support was provided by National Center for Advancing Translational Sciences. This work was performed through the TEX-VAlicia Y. Lim Consortium collaboration funded by equitable monetary contributions from member organizations (American Chemistry Council, Bristol-Myers Squibb, Merck Healthcare KGaA, National Institute of Environmental Health Sciences, Sanofi, Unilever, and  United States Environmental Protection Agency).\n",
      "\n",
      "Rusyn, Ivan\n",
      "Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Ivan Rusyn reports financial support was provided by National Center for Advancing Translational Sciences. This work was performed through the TEX-VAlicia Y. Lim Consortium collaboration funded by equitable monetary contributions from member organizations (American Chemistry Council, Bristol-Myers Squibb, Merck Healthcare KGaA, National Institute of Environmental Health Sciences, Sanofi, Unilever, and  United States Environmental Protection Agency).\n",
      "\n",
      "Tetereva, Alina\n",
      "Conflict of interest statement The authors declare no competing interests. Acknowledgements Data were provided by the Human Connectome Project, WU-Minn Consortium (Principal Investigators: David Van Essen and Kamil Ugurbil; 1U54MH091657) funded by the 16 NIH Institutes and Centers that support the NIH Blueprint for Neuroscience Research; and by the McDonnell Center for Systems Neuroscience at Washington University. The author(s) wish to acknowledge the use  of New Zealand eScience Infrastructure (NeSI) high performance computing facilities, consulting support and/or training services as part of this research. New Zealand's national facilities are provided by NeSI and funded jointly by NeSI's collaborator institutions and through the Ministry of Business, Innovation & Employment's Research Infrastructure programme. URL https://www.nesi.org.nz. The authors also thank Sam Harrison and Javier Rasero for their input on data analyses. Alina Tetereva and N.P. were supported by Health Research Council Funding (21/618) and by the University of Otago. N.P. and A.S. were supported by the Intramural Research Program of the National Institute of Mental Health, National  Institutes of Health, Baltimore, MD, USA (award number: ZIA-MH002957).\n",
      "\n",
      "Conflict of interest statement The authors declare no competing interests. Acknowledgements Data were provided by the Human Connectome Project, WU-Minn Consortium (Principal Investigators: David Van Essen and Kamil Ugurbil; 1U54MH091657) funded by the 16 NIH Institutes and Centers that support the NIH Blueprint for Neuroscience Research; and by the McDonnell Center for Systems Neuroscience at Washington University. The author(s) wish to acknowledge the use  of New Zealand eScience Infrastructure (NeSI) high performance computing facilities, consulting support and/or training services as part of this research. New Zealand's national facilities are provided by NeSI and funded jointly by NeSI's collaborator institutions and through the Ministry of Business, Innovation & Employment's Research Infrastructure programme. URL https://www.nesi.org.nz. The authors also thank Sam Harrison and Javier Rasero for their input on data analyses. Alina Tetereva and N.P. were supported by Health Research Council Funding (21/618) and by the University of Otago. N.P. and A.S. were supported by the Intramural Research Program of the National Institute of Mental Health, National  Institutes of Health, Baltimore, MD, USA (award number: ZIA-MH002957).\n",
      "\n",
      "Conflict of interest statement The authors declare no competing interests. Acknowledgements Data were provided by the Human Connectome Project, WU-Minn Consortium (Principal Investigators: David Van Essen and Kamil Ugurbil; 1U54MH091657) funded by the 16 NIH Institutes and Centers that support the NIH Blueprint for Neuroscience Research; and by the McDonnell Center for Systems Neuroscience at Washington University. The author(s) wish to acknowledge the use  of New Zealand eScience Infrastructure (NeSI) high performance computing facilities, consulting support and/or training services as part of this research. New Zealand's national facilities are provided by NeSI and funded jointly by NeSI's collaborator institutions and through the Ministry of Business, Innovation & Employment's Research Infrastructure programme. URL https://www.nesi.org.nz. The authors also thank Sam Harrison and Javier Rasero for their input on data analyses. Alina Tetereva and N.P. were supported by Health Research Council Funding (21/618) and by the University of Otago. N.P. and A.S. were supported by the Intramural Research Program of the National Institute of Mental Health, National  Institutes of Health, Baltimore, MD, USA (award number: ZIA-MH002957).\n",
      "\n",
      "Stringaris, Argyris\n",
      "Conflict of interest statement The authors declare no competing interests. Acknowledgements Data were provided by the Human Connectome Project, WU-Minn Consortium (Principal Investigators: David Van Essen and Kamil Ugurbil; 1U54MH091657) funded by the 16 NIH Institutes and Centers that support the NIH Blueprint for Neuroscience Research; and by the McDonnell Center for Systems Neuroscience at Washington University. The author(s) wish to acknowledge the use  of New Zealand eScience Infrastructure (NeSI) high performance computing facilities, consulting support and/or training services as part of this research. New Zealand's national facilities are provided by NeSI and funded jointly by NeSI's collaborator institutions and through the Ministry of Business, Innovation & Employment's Research Infrastructure programme. URL https://www.nesi.org.nz. The authors also thank Sam Harrison and Javier Rasero for their input on data analyses. Alina Tetereva and N.P. were supported by Health Research Council Funding (21/618) and by the University of Otago. N.P. and Argyris Stringaris were supported by the Intramural Research Program of the National Institute of Mental Health, National  Institutes of Health, Baltimore, MD, USA (award number: ZIA-MH002957).\n",
      "\n",
      "Pat, Narun\n",
      "Conflict of interest statement The authors declare no competing interests. Acknowledgements Data were provided by the Human Connectome Project, WU-Minn Consortium (Principal Investigators: David Van Essen and Kamil Ugurbil; 1U54MH091657) funded by the 16 NIH Institutes and Centers that support the NIH Blueprint for Neuroscience Research; and by the McDonnell Center for Systems Neuroscience at Washington University. The author(s) wish to acknowledge the use  of New Zealand eScience Infrastructure (NeSI) high performance computing facilities, consulting support and/or training services as part of this research. New Zealand's national facilities are provided by NeSI and funded jointly by NeSI's collaborator institutions and through the Ministry of Business, Innovation & Employment's Research Infrastructure programme. URL https://www.nesi.org.nz. The authors also thank Sam Harrison and Javier Rasero for their input on data analyses. Alina Tetereva and Narun Pat were supported by Health Research Council Funding (21/618) and by the University of Otago. Narun Pat and Argyris Stringaris were supported by the Intramural Research Program of the National Institute of Mental Health, National  Institutes of Health, Baltimore, MD, USA (award number: ZIA-MH002957).\n",
      "\n",
      "Naganuma, Yuuki\n",
      "Declaration of Competing Interest Yuuki Naganuma, MM, KN, HF, HS, RM, KH, YH, HK, TM were employees of Astellas Pharma Inc. and Astellas Research Technologies Co., Ltd. during the conduct of the study.\n",
      "\n",
      "Maeda, Masashi\n",
      "Declaration of Competing Interest Yuuki Naganuma, Masashi Maeda, KN, HF, HS, RM, KH, YH, HK, TM were employees of Astellas Pharma Inc. and Astellas Research Technologies Co., Ltd. during the conduct of the study.\n",
      "\n",
      "Nakamura, Koji\n",
      "Declaration of Competing Interest Yuuki Naganuma, Masashi Maeda, Koji Nakamura, HF, HS, RM, KH, YH, HK, TM were employees of Astellas Pharma Inc. and Astellas Research Technologies Co., Ltd. during the conduct of the study.\n",
      "\n",
      "Fukahori, Hidehiko\n",
      "Declaration of Competing Interest Yuuki Naganuma, Masashi Maeda, Koji Nakamura, Hidehiko Fukahori, HS, RM, KH, YH, HK, TM were employees of Astellas Pharma Inc. and Astellas Research Technologies Co., Ltd. during the conduct of the study.\n",
      "\n",
      "Satake, Hiroyuki\n",
      "Declaration of Competing Interest Yuuki Naganuma, Masashi Maeda, Koji Nakamura, Hidehiko Fukahori, Hiroyuki Satake, RM, KH, YH, HK, TM were employees of Astellas Pharma Inc. and Astellas Research Technologies Co., Ltd. during the conduct of the study.\n",
      "\n",
      "Murakami, Ryuji\n",
      "Declaration of Competing Interest Yuuki Naganuma, Masashi Maeda, Koji Nakamura, Hidehiko Fukahori, Hiroyuki Satake, Ryuji Murakami, KH, YH, HK, TM were employees of Astellas Pharma Inc. and Astellas Research Technologies Co., Ltd. during the conduct of the study.\n",
      "\n",
      "Hanaoka, Kaori\n",
      "Declaration of Competing Interest Yuuki Naganuma, Masashi Maeda, Koji Nakamura, Hidehiko Fukahori, Hiroyuki Satake, Ryuji Murakami, Kaori Hanaoka, YH, HK, TM were employees of Astellas Pharma Inc. and Astellas Research Technologies Co., Ltd. during the conduct of the study.\n",
      "\n",
      "Higashi, Yasuyuki\n",
      "Declaration of Competing Interest Yuuki Naganuma, Masashi Maeda, Koji Nakamura, Hidehiko Fukahori, Hiroyuki Satake, Ryuji Murakami, Kaori Hanaoka, Yasuyuki Higashi, HK, TM were employees of Astellas Pharma Inc. and Astellas Research Technologies Co., Ltd. during the conduct of the study.\n",
      "\n",
      "Koyama, Hironari\n",
      "Declaration of Competing Interest Yuuki Naganuma, Masashi Maeda, Koji Nakamura, Hidehiko Fukahori, Hiroyuki Satake, Ryuji Murakami, Kaori Hanaoka, Yasuyuki Higashi, Hironari Koyama, TM were employees of Astellas Pharma Inc. and Astellas Research Technologies Co., Ltd. during the conduct of the study.\n",
      "\n",
      "Morokata, Tatsuaki\n",
      "Declaration of Competing Interest Yuuki Naganuma, Masashi Maeda, Koji Nakamura, Hidehiko Fukahori, Hiroyuki Satake, Ryuji Murakami, Kaori Hanaoka, Yasuyuki Higashi, Hironari Koyama, Tatsuaki Morokata were employees of Astellas Pharma Inc. and Astellas Research Technologies Co., Ltd. during the conduct of the study.\n",
      "\n",
      "Declaration of competing interest Salary support to SPC from Pfizer, Inc., all remaining authors declare no competing interests.\n",
      "\n",
      "Declaration of competing interest Salary support to SPC from Pfizer, Inc., all remaining authors declare no competing interests.\n",
      "\n",
      "Chelko, Stephen P.\n",
      "Declaration of competing interest Salary support to Stephen P. Chelko from Pfizer, Inc., all remaining authors declare no competing interests.\n",
      "\n",
      "Declaration of competing interest Salary support to Stephen P. Chelko from Pfizer, Inc., all remaining authors declare no competing interests.\n",
      "\n",
      "Harada, Tasuku\n",
      "Declaration of Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Tasuku Harada received personal fees from Bayer Yakuhin Ltd. as a member of the Proper Use Advisory Committee for Mirena. Ikuko Ota received personal fees from Bayer Yakuhin Ltd., and personal fees from Mochida Pharmaceutical Co., Ltd, and ASKA Pharmaceutical Co., Ltd., unrelated to the submitted work. Jo Kitawaki received personal fees from Bayer Yakuhin Ltd., Mochida Pharmaceutical Co., Ltd, and ASKA Pharmaceutical Co., Ltd; a grant from Nichimo Biotics Co., Ltd, and has a patent of materials related to the treatment  of endometriosis. Mikio Momoeda received personal fees from Bayer Yakuhin Ltd. as a member of the Proper Use Advisory Committee for Mirena. Nagamasa Maeda received personal fees from Bayer Yakuhin Ltd. as a member of the Proper Use Advisory Committee for Mirena. Shigeo Akira received personal fees from Bayer Yakuhin Ltd. as a member of the Proper Use Advisory Committee for Mirena. Mikiko Umeyama, Toshiyuki Sunaya, and Kazufumi Hirano are employees of Bayer Yakuhin Ltd.\n",
      "\n",
      "Ota, Ikuko\n",
      "Declaration of Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Tasuku Harada received personal fees from Bayer Yakuhin Ltd. as a member of the Proper Use Advisory Committee for Mirena. Ikuko Ota received personal fees from Bayer Yakuhin Ltd., and personal fees from Mochida Pharmaceutical Co., Ltd, and ASKA Pharmaceutical Co., Ltd., unrelated to the submitted work. Jo Kitawaki received personal fees from Bayer Yakuhin Ltd., Mochida Pharmaceutical Co., Ltd, and ASKA Pharmaceutical Co., Ltd; a grant from Nichimo Biotics Co., Ltd, and has a patent of materials related to the treatment  of endometriosis. Mikio Momoeda received personal fees from Bayer Yakuhin Ltd. as a member of the Proper Use Advisory Committee for Mirena. Nagamasa Maeda received personal fees from Bayer Yakuhin Ltd. as a member of the Proper Use Advisory Committee for Mirena. Shigeo Akira received personal fees from Bayer Yakuhin Ltd. as a member of the Proper Use Advisory Committee for Mirena. Mikiko Umeyama, Toshiyuki Sunaya, and Kazufumi Hirano are employees of Bayer Yakuhin Ltd.\n",
      "\n",
      "Kitawaki, Jo\n",
      "Declaration of Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Tasuku Harada received personal fees from Bayer Yakuhin Ltd. as a member of the Proper Use Advisory Committee for Mirena. Ikuko Ota received personal fees from Bayer Yakuhin Ltd., and personal fees from Mochida Pharmaceutical Co., Ltd, and ASKA Pharmaceutical Co., Ltd., unrelated to the submitted work. Jo Kitawaki received personal fees from Bayer Yakuhin Ltd., Mochida Pharmaceutical Co., Ltd, and ASKA Pharmaceutical Co., Ltd; a grant from Nichimo Biotics Co., Ltd, and has a patent of materials related to the treatment  of endometriosis. Mikio Momoeda received personal fees from Bayer Yakuhin Ltd. as a member of the Proper Use Advisory Committee for Mirena. Nagamasa Maeda received personal fees from Bayer Yakuhin Ltd. as a member of the Proper Use Advisory Committee for Mirena. Shigeo Akira received personal fees from Bayer Yakuhin Ltd. as a member of the Proper Use Advisory Committee for Mirena. Mikiko Umeyama, Toshiyuki Sunaya, and Kazufumi Hirano are employees of Bayer Yakuhin Ltd.\n",
      "\n",
      "Momoeda, Mikio\n",
      "Declaration of Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Tasuku Harada received personal fees from Bayer Yakuhin Ltd. as a member of the Proper Use Advisory Committee for Mirena. Ikuko Ota received personal fees from Bayer Yakuhin Ltd., and personal fees from Mochida Pharmaceutical Co., Ltd, and ASKA Pharmaceutical Co., Ltd., unrelated to the submitted work. Jo Kitawaki received personal fees from Bayer Yakuhin Ltd., Mochida Pharmaceutical Co., Ltd, and ASKA Pharmaceutical Co., Ltd; a grant from Nichimo Biotics Co., Ltd, and has a patent of materials related to the treatment  of endometriosis. Mikio Momoeda received personal fees from Bayer Yakuhin Ltd. as a member of the Proper Use Advisory Committee for Mirena. Nagamasa Maeda received personal fees from Bayer Yakuhin Ltd. as a member of the Proper Use Advisory Committee for Mirena. Shigeo Akira received personal fees from Bayer Yakuhin Ltd. as a member of the Proper Use Advisory Committee for Mirena. Mikiko Umeyama, Toshiyuki Sunaya, and Kazufumi Hirano are employees of Bayer Yakuhin Ltd.\n",
      "\n",
      "Maeda, Nagamasa\n",
      "Declaration of Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Tasuku Harada received personal fees from Bayer Yakuhin Ltd. as a member of the Proper Use Advisory Committee for Mirena. Ikuko Ota received personal fees from Bayer Yakuhin Ltd., and personal fees from Mochida Pharmaceutical Co., Ltd, and ASKA Pharmaceutical Co., Ltd., unrelated to the submitted work. Jo Kitawaki received personal fees from Bayer Yakuhin Ltd., Mochida Pharmaceutical Co., Ltd, and ASKA Pharmaceutical Co., Ltd; a grant from Nichimo Biotics Co., Ltd, and has a patent of materials related to the treatment  of endometriosis. Mikio Momoeda received personal fees from Bayer Yakuhin Ltd. as a member of the Proper Use Advisory Committee for Mirena. Nagamasa Maeda received personal fees from Bayer Yakuhin Ltd. as a member of the Proper Use Advisory Committee for Mirena. Shigeo Akira received personal fees from Bayer Yakuhin Ltd. as a member of the Proper Use Advisory Committee for Mirena. Mikiko Umeyama, Toshiyuki Sunaya, and Kazufumi Hirano are employees of Bayer Yakuhin Ltd.\n",
      "\n",
      "Akira, Shigeo\n",
      "Declaration of Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Tasuku Harada received personal fees from Bayer Yakuhin Ltd. as a member of the Proper Use Advisory Committee for Mirena. Ikuko Ota received personal fees from Bayer Yakuhin Ltd., and personal fees from Mochida Pharmaceutical Co., Ltd, and ASKA Pharmaceutical Co., Ltd., unrelated to the submitted work. Jo Kitawaki received personal fees from Bayer Yakuhin Ltd., Mochida Pharmaceutical Co., Ltd, and ASKA Pharmaceutical Co., Ltd; a grant from Nichimo Biotics Co., Ltd, and has a patent of materials related to the treatment  of endometriosis. Mikio Momoeda received personal fees from Bayer Yakuhin Ltd. as a member of the Proper Use Advisory Committee for Mirena. Nagamasa Maeda received personal fees from Bayer Yakuhin Ltd. as a member of the Proper Use Advisory Committee for Mirena. Shigeo Akira received personal fees from Bayer Yakuhin Ltd. as a member of the Proper Use Advisory Committee for Mirena. Mikiko Umeyama, Toshiyuki Sunaya, and Kazufumi Hirano are employees of Bayer Yakuhin Ltd.\n",
      "\n",
      "Umeyama, Mikiko\n",
      "Declaration of Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Tasuku Harada received personal fees from Bayer Yakuhin Ltd. as a member of the Proper Use Advisory Committee for Mirena. Ikuko Ota received personal fees from Bayer Yakuhin Ltd., and personal fees from Mochida Pharmaceutical Co., Ltd, and ASKA Pharmaceutical Co., Ltd., unrelated to the submitted work. Jo Kitawaki received personal fees from Bayer Yakuhin Ltd., Mochida Pharmaceutical Co., Ltd, and ASKA Pharmaceutical Co., Ltd; a grant from Nichimo Biotics Co., Ltd, and has a patent of materials related to the treatment  of endometriosis. Mikio Momoeda received personal fees from Bayer Yakuhin Ltd. as a member of the Proper Use Advisory Committee for Mirena. Nagamasa Maeda received personal fees from Bayer Yakuhin Ltd. as a member of the Proper Use Advisory Committee for Mirena. Shigeo Akira received personal fees from Bayer Yakuhin Ltd. as a member of the Proper Use Advisory Committee for Mirena. Mikiko Umeyama, Toshiyuki Sunaya, and Kazufumi Hirano are employees of Bayer Yakuhin Ltd.\n",
      "\n",
      "Sunaya, Toshiyuki\n",
      "Declaration of Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Tasuku Harada received personal fees from Bayer Yakuhin Ltd. as a member of the Proper Use Advisory Committee for Mirena. Ikuko Ota received personal fees from Bayer Yakuhin Ltd., and personal fees from Mochida Pharmaceutical Co., Ltd, and ASKA Pharmaceutical Co., Ltd., unrelated to the submitted work. Jo Kitawaki received personal fees from Bayer Yakuhin Ltd., Mochida Pharmaceutical Co., Ltd, and ASKA Pharmaceutical Co., Ltd; a grant from Nichimo Biotics Co., Ltd, and has a patent of materials related to the treatment  of endometriosis. Mikio Momoeda received personal fees from Bayer Yakuhin Ltd. as a member of the Proper Use Advisory Committee for Mirena. Nagamasa Maeda received personal fees from Bayer Yakuhin Ltd. as a member of the Proper Use Advisory Committee for Mirena. Shigeo Akira received personal fees from Bayer Yakuhin Ltd. as a member of the Proper Use Advisory Committee for Mirena. Mikiko Umeyama, Toshiyuki Sunaya, and Kazufumi Hirano are employees of Bayer Yakuhin Ltd.\n",
      "\n",
      "Hirano, Kazufumi\n",
      "Declaration of Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Tasuku Harada received personal fees from Bayer Yakuhin Ltd. as a member of the Proper Use Advisory Committee for Mirena. Ikuko Ota received personal fees from Bayer Yakuhin Ltd., and personal fees from Mochida Pharmaceutical Co., Ltd, and ASKA Pharmaceutical Co., Ltd., unrelated to the submitted work. Jo Kitawaki received personal fees from Bayer Yakuhin Ltd., Mochida Pharmaceutical Co., Ltd, and ASKA Pharmaceutical Co., Ltd; a grant from Nichimo Biotics Co., Ltd, and has a patent of materials related to the treatment  of endometriosis. Mikio Momoeda received personal fees from Bayer Yakuhin Ltd. as a member of the Proper Use Advisory Committee for Mirena. Nagamasa Maeda received personal fees from Bayer Yakuhin Ltd. as a member of the Proper Use Advisory Committee for Mirena. Shigeo Akira received personal fees from Bayer Yakuhin Ltd. as a member of the Proper Use Advisory Committee for Mirena. Mikiko Umeyama, Toshiyuki Sunaya, and Kazufumi Hirano are employees of Bayer Yakuhin Ltd.\n",
      "\n",
      "Parfianowicz, Dominic\n",
      "Conflict of Interest 1) All authors have participated in the work and have reviewed and agree with the content of the article; 2) None of the article contents are under consideration for publication in any other journal or have been published in any journal; 3) No portion of the text has been copied from other material in the literature; 4) I am aware that it is the authors responsibility to obtain permission for any figures or tables reproduced from any prior publications, and to cover fully any costs involved. Every author listed contributed to our work in a substantial manner. Each author's contribution is listed. 1) Conception and design: Rahul Gupta and Theresa Maitz; 2) Drafting of the manuscript and revising it critically for important intellectual content: Dominic Parfianowicz, Swara Shah, Catherine Nguyen, Theresa Maitz, Adrija Hajra,  Akshay Goel, Jayakumar Sreenivasan, Wilbert S. Aronow, Apurva Vyas and Rahul Gupta; 3) Final approval of the manuscript submitted: Apurva Vyas, Rahul Gupta.\n",
      "\n",
      "Shah, Swara\n",
      "Conflict of Interest 1) All authors have participated in the work and have reviewed and agree with the content of the article; 2) None of the article contents are under consideration for publication in any other journal or have been published in any journal; 3) No portion of the text has been copied from other material in the literature; 4) I am aware that it is the authors responsibility to obtain permission for any figures or tables reproduced from any prior publications, and to cover fully any costs involved. Every author listed contributed to our work in a substantial manner. Each author's contribution is listed. 1) Conception and design: Rahul Gupta and Theresa Maitz; 2) Drafting of the manuscript and revising it critically for important intellectual content: Dominic Parfianowicz, Swara Shah, Catherine Nguyen, Theresa Maitz, Adrija Hajra,  Akshay Goel, Jayakumar Sreenivasan, Wilbert S. Aronow, Apurva Vyas and Rahul Gupta; 3) Final approval of the manuscript submitted: Apurva Vyas, Rahul Gupta.\n",
      "\n",
      "Nguyen, Catherine\n",
      "Conflict of Interest 1) All authors have participated in the work and have reviewed and agree with the content of the article; 2) None of the article contents are under consideration for publication in any other journal or have been published in any journal; 3) No portion of the text has been copied from other material in the literature; 4) I am aware that it is the authors responsibility to obtain permission for any figures or tables reproduced from any prior publications, and to cover fully any costs involved. Every author listed contributed to our work in a substantial manner. Each author's contribution is listed. 1) Conception and design: Rahul Gupta and Theresa Maitz; 2) Drafting of the manuscript and revising it critically for important intellectual content: Dominic Parfianowicz, Swara Shah, Catherine Nguyen, Theresa Maitz, Adrija Hajra,  Akshay Goel, Jayakumar Sreenivasan, Wilbert S. Aronow, Apurva Vyas and Rahul Gupta; 3) Final approval of the manuscript submitted: Apurva Vyas, Rahul Gupta.\n",
      "\n",
      "Maitz, Theresa N.\n",
      "Conflict of Interest 1) All authors have participated in the work and have reviewed and agree with the content of the article; 2) None of the article contents are under consideration for publication in any other journal or have been published in any journal; 3) No portion of the text has been copied from other material in the literature; 4) I am aware that it is the authors responsibility to obtain permission for any figures or tables reproduced from any prior publications, and to cover fully any costs involved. Every author listed contributed to our work in a substantial manner. Each author's contribution is listed. 1) Conception and design: Rahul Gupta and Theresa N. Maitz; 2) Drafting of the manuscript and revising it critically for important intellectual content: Dominic Parfianowicz, Swara Shah, Catherine Nguyen, Theresa N. Maitz, Adrija Hajra,  Akshay Goel, Jayakumar Sreenivasan, Wilbert S. Aronow, Apurva Vyas and Rahul Gupta; 3) Final approval of the manuscript submitted: Apurva Vyas, Rahul Gupta.\n",
      "\n",
      "Hajra, Adrija\n",
      "Conflict of Interest 1) All authors have participated in the work and have reviewed and agree with the content of the article; 2) None of the article contents are under consideration for publication in any other journal or have been published in any journal; 3) No portion of the text has been copied from other material in the literature; 4) I am aware that it is the authors responsibility to obtain permission for any figures or tables reproduced from any prior publications, and to cover fully any costs involved. Every author listed contributed to our work in a substantial manner. Each author's contribution is listed. 1) Conception and design: Rahul Gupta and Theresa N. Maitz; 2) Drafting of the manuscript and revising it critically for important intellectual content: Dominic Parfianowicz, Swara Shah, Catherine Nguyen, Theresa N. Maitz, Adrija Hajra,  Akshay Goel, Jayakumar Sreenivasan, Wilbert S. Aronow, Apurva Vyas and Rahul Gupta; 3) Final approval of the manuscript submitted: Apurva Vyas, Rahul Gupta.\n",
      "\n",
      "Goel, Akshay\n",
      "Conflict of Interest 1) All authors have participated in the work and have reviewed and agree with the content of the article; 2) None of the article contents are under consideration for publication in any other journal or have been published in any journal; 3) No portion of the text has been copied from other material in the literature; 4) I am aware that it is the authors responsibility to obtain permission for any figures or tables reproduced from any prior publications, and to cover fully any costs involved. Every author listed contributed to our work in a substantial manner. Each author's contribution is listed. 1) Conception and design: Rahul Gupta and Theresa N. Maitz; 2) Drafting of the manuscript and revising it critically for important intellectual content: Dominic Parfianowicz, Swara Shah, Catherine Nguyen, Theresa N. Maitz, Adrija Hajra,  Akshay Goel, Jayakumar Sreenivasan, Wilbert S. Aronow, Apurva Vyas and Rahul Gupta; 3) Final approval of the manuscript submitted: Apurva Vyas, Rahul Gupta.\n",
      "\n",
      "Sreenivasan, Jayakumar\n",
      "Conflict of Interest 1) All authors have participated in the work and have reviewed and agree with the content of the article; 2) None of the article contents are under consideration for publication in any other journal or have been published in any journal; 3) No portion of the text has been copied from other material in the literature; 4) I am aware that it is the authors responsibility to obtain permission for any figures or tables reproduced from any prior publications, and to cover fully any costs involved. Every author listed contributed to our work in a substantial manner. Each author's contribution is listed. 1) Conception and design: Rahul Gupta and Theresa N. Maitz; 2) Drafting of the manuscript and revising it critically for important intellectual content: Dominic Parfianowicz, Swara Shah, Catherine Nguyen, Theresa N. Maitz, Adrija Hajra,  Akshay Goel, Jayakumar Sreenivasan, Wilbert S. Aronow, Apurva Vyas and Rahul Gupta; 3) Final approval of the manuscript submitted: Apurva Vyas, Rahul Gupta.\n",
      "\n",
      "Aronow, Wilbert S.\n",
      "Conflict of Interest 1) All authors have participated in the work and have reviewed and agree with the content of the article; 2) None of the article contents are under consideration for publication in any other journal or have been published in any journal; 3) No portion of the text has been copied from other material in the literature; 4) I am aware that it is the authors responsibility to obtain permission for any figures or tables reproduced from any prior publications, and to cover fully any costs involved. Every author listed contributed to our work in a substantial manner. Each author's contribution is listed. 1) Conception and design: Rahul Gupta and Theresa N. Maitz; 2) Drafting of the manuscript and revising it critically for important intellectual content: Dominic Parfianowicz, Swara Shah, Catherine Nguyen, Theresa N. Maitz, Adrija Hajra,  Akshay Goel, Jayakumar Sreenivasan, Wilbert S. Aronow, Apurva Vyas and Rahul Gupta; 3) Final approval of the manuscript submitted: Apurva Vyas, Rahul Gupta.\n",
      "\n",
      "Vyas, Apurva\n",
      "Conflict of Interest 1) All authors have participated in the work and have reviewed and agree with the content of the article; 2) None of the article contents are under consideration for publication in any other journal or have been published in any journal; 3) No portion of the text has been copied from other material in the literature; 4) I am aware that it is the authors responsibility to obtain permission for any figures or tables reproduced from any prior publications, and to cover fully any costs involved. Every author listed contributed to our work in a substantial manner. Each author's contribution is listed. 1) Conception and design: Rahul Gupta and Theresa N. Maitz; 2) Drafting of the manuscript and revising it critically for important intellectual content: Dominic Parfianowicz, Swara Shah, Catherine Nguyen, Theresa N. Maitz, Adrija Hajra,  Akshay Goel, Jayakumar Sreenivasan, Wilbert S. Aronow, Apurva Vyas and Rahul Gupta; 3) Final approval of the manuscript submitted: Apurva Vyas, Rahul Gupta.\n",
      "\n",
      "Gupta, Rahul\n",
      "Conflict of Interest 1) All authors have participated in the work and have reviewed and agree with the content of the article; 2) None of the article contents are under consideration for publication in any other journal or have been published in any journal; 3) No portion of the text has been copied from other material in the literature; 4) I am aware that it is the authors responsibility to obtain permission for any figures or tables reproduced from any prior publications, and to cover fully any costs involved. Every author listed contributed to our work in a substantial manner. Each author's contribution is listed. 1) Conception and design: Rahul Gupta and Theresa N. Maitz; 2) Drafting of the manuscript and revising it critically for important intellectual content: Dominic Parfianowicz, Swara Shah, Catherine Nguyen, Theresa N. Maitz, Adrija Hajra,  Akshay Goel, Jayakumar Sreenivasan, Wilbert S. Aronow, Apurva Vyas and Rahul Gupta; 3) Final approval of the manuscript submitted: Apurva Vyas, Rahul Gupta.\n",
      "\n",
      "Declaration of interests SJ receives consulting fees from Drager, Fisher-Paykel,  Medtronic, Mindray, and Baxter. NL receives grant funding from Guerbet. GL receives consulting fees from Abbott, Abiomed, and Baxter; and speaking fees from LivaNova. AM receives grants from 4TEEN4, Abbott, Roche, and Sphyngotec; and consulting fees from Orion, Roche, Adrenomed, and Fire1. AM participates on the data and safety monitoring board for Roche. LBW declares grants from Genentech, Boehringer Ingelheim, and CSL Behring, outside the submitted work; and consulting fees from Foresee, Merck, Citius Pharmaceuticals, Quark, and Boehringer Ingelheim. MAM declares grant support from Roche-Genentech for ARDS observational studies; and consulting income from Citius Pharmaceuticals, Johnson & Johnson, Gilead Pharmaceuticals, Plant Therapeutics, and Novartis Pharmaceuticals, outside the submitted work. All other authors declare no competing interests.\n",
      "\n",
      "Declaration of interests SJ receives consulting fees from Drager, Fisher-Paykel,  Medtronic, Mindray, and Baxter. NL receives grant funding from Guerbet. GL receives consulting fees from Abbott, Abiomed, and Baxter; and speaking fees from LivaNova. AM receives grants from 4TEEN4, Abbott, Roche, and Sphyngotec; and consulting fees from Orion, Roche, Adrenomed, and Fire1. AM participates on the data and safety monitoring board for Roche. LBW declares grants from Genentech, Boehringer Ingelheim, and CSL Behring, outside the submitted work; and consulting fees from Foresee, Merck, Citius Pharmaceuticals, Quark, and Boehringer Ingelheim. MAM declares grant support from Roche-Genentech for ARDS observational studies; and consulting income from Citius Pharmaceuticals, Johnson & Johnson, Gilead Pharmaceuticals, Plant Therapeutics, and Novartis Pharmaceuticals, outside the submitted work. All other authors declare no competing interests.\n",
      "\n",
      "Declaration of interests SJ receives consulting fees from Drager, Fisher-Paykel,  Medtronic, Mindray, and Baxter. NL receives grant funding from Guerbet. GL receives consulting fees from Abbott, Abiomed, and Baxter; and speaking fees from LivaNova. AM receives grants from 4TEEN4, Abbott, Roche, and Sphyngotec; and consulting fees from Orion, Roche, Adrenomed, and Fire1. AM participates on the data and safety monitoring board for Roche. LBW declares grants from Genentech, Boehringer Ingelheim, and CSL Behring, outside the submitted work; and consulting fees from Foresee, Merck, Citius Pharmaceuticals, Quark, and Boehringer Ingelheim. MAM declares grant support from Roche-Genentech for ARDS observational studies; and consulting income from Citius Pharmaceuticals, Johnson & Johnson, Gilead Pharmaceuticals, Plant Therapeutics, and Novartis Pharmaceuticals, outside the submitted work. All other authors declare no competing interests.\n",
      "\n",
      "Declaration of interests SJ receives consulting fees from Drager, Fisher-Paykel,  Medtronic, Mindray, and Baxter. NL receives grant funding from Guerbet. GL receives consulting fees from Abbott, Abiomed, and Baxter; and speaking fees from LivaNova. AM receives grants from 4TEEN4, Abbott, Roche, and Sphyngotec; and consulting fees from Orion, Roche, Adrenomed, and Fire1. AM participates on the data and safety monitoring board for Roche. LBW declares grants from Genentech, Boehringer Ingelheim, and CSL Behring, outside the submitted work; and consulting fees from Foresee, Merck, Citius Pharmaceuticals, Quark, and Boehringer Ingelheim. MAM declares grant support from Roche-Genentech for ARDS observational studies; and consulting income from Citius Pharmaceuticals, Johnson & Johnson, Gilead Pharmaceuticals, Plant Therapeutics, and Novartis Pharmaceuticals, outside the submitted work. All other authors declare no competing interests.\n",
      "\n",
      "Jaber, Samir\n",
      "Declaration of interests Samir Jaber receives consulting fees from Drager, Fisher-Paykel,  Medtronic, Mindray, and Baxter. NL receives grant funding from Guerbet. GL receives consulting fees from Abbott, Abiomed, and Baxter; and speaking fees from LivaNova. AM receives grants from 4TEEN4, Abbott, Roche, and Sphyngotec; and consulting fees from Orion, Roche, Adrenomed, and Fire1. AM participates on the data and safety monitoring board for Roche. LBW declares grants from Genentech, Boehringer Ingelheim, and CSL Behring, outside the submitted work; and consulting fees from Foresee, Merck, Citius Pharmaceuticals, Quark, and Boehringer Ingelheim. MAM declares grant support from Roche-Genentech for ARDS observational studies; and consulting income from Citius Pharmaceuticals, Johnson & Johnson, Gilead Pharmaceuticals, Plant Therapeutics, and Novartis Pharmaceuticals, outside the submitted work. All other authors declare no competing interests.\n",
      "\n",
      "Declaration of interests Samir Jaber receives consulting fees from Drager, Fisher-Paykel,  Medtronic, Mindray, and Baxter. NL receives grant funding from Guerbet. GL receives consulting fees from Abbott, Abiomed, and Baxter; and speaking fees from LivaNova. AM receives grants from 4TEEN4, Abbott, Roche, and Sphyngotec; and consulting fees from Orion, Roche, Adrenomed, and Fire1. AM participates on the data and safety monitoring board for Roche. LBW declares grants from Genentech, Boehringer Ingelheim, and CSL Behring, outside the submitted work; and consulting fees from Foresee, Merck, Citius Pharmaceuticals, Quark, and Boehringer Ingelheim. MAM declares grant support from Roche-Genentech for ARDS observational studies; and consulting income from Citius Pharmaceuticals, Johnson & Johnson, Gilead Pharmaceuticals, Plant Therapeutics, and Novartis Pharmaceuticals, outside the submitted work. All other authors declare no competing interests.\n",
      "\n",
      "Lassau, Nathalie\n",
      "Declaration of interests Samir Jaber receives consulting fees from Drager, Fisher-Paykel,  Medtronic, Mindray, and Baxter. Nathalie Lassau receives grant funding from Guerbet. GL receives consulting fees from Abbott, Abiomed, and Baxter; and speaking fees from LivaNova. AM receives grants from 4TEEN4, Abbott, Roche, and Sphyngotec; and consulting fees from Orion, Roche, Adrenomed, and Fire1. AM participates on the data and safety monitoring board for Roche. LBW declares grants from Genentech, Boehringer Ingelheim, and CSL Behring, outside the submitted work; and consulting fees from Foresee, Merck, Citius Pharmaceuticals, Quark, and Boehringer Ingelheim. MAM declares grant support from Roche-Genentech for ARDS observational studies; and consulting income from Citius Pharmaceuticals, Johnson & Johnson, Gilead Pharmaceuticals, Plant Therapeutics, and Novartis Pharmaceuticals, outside the submitted work. All other authors declare no competing interests.\n",
      "\n",
      "Declaration of interests Samir Jaber receives consulting fees from Drager, Fisher-Paykel,  Medtronic, Mindray, and Baxter. Nathalie Lassau receives grant funding from Guerbet. GL receives consulting fees from Abbott, Abiomed, and Baxter; and speaking fees from LivaNova. AM receives grants from 4TEEN4, Abbott, Roche, and Sphyngotec; and consulting fees from Orion, Roche, Adrenomed, and Fire1. AM participates on the data and safety monitoring board for Roche. LBW declares grants from Genentech, Boehringer Ingelheim, and CSL Behring, outside the submitted work; and consulting fees from Foresee, Merck, Citius Pharmaceuticals, Quark, and Boehringer Ingelheim. MAM declares grant support from Roche-Genentech for ARDS observational studies; and consulting income from Citius Pharmaceuticals, Johnson & Johnson, Gilead Pharmaceuticals, Plant Therapeutics, and Novartis Pharmaceuticals, outside the submitted work. All other authors declare no competing interests.\n",
      "\n",
      "Lebreton, Guillaume\n",
      "Declaration of interests Samir Jaber receives consulting fees from Drager, Fisher-Paykel,  Medtronic, Mindray, and Baxter. Nathalie Lassau receives grant funding from Guerbet. Guillaume Lebreton receives consulting fees from Abbott, Abiomed, and Baxter; and speaking fees from LivaNova. AM receives grants from 4TEEN4, Abbott, Roche, and Sphyngotec; and consulting fees from Orion, Roche, Adrenomed, and Fire1. AM participates on the data and safety monitoring board for Roche. LBW declares grants from Genentech, Boehringer Ingelheim, and CSL Behring, outside the submitted work; and consulting fees from Foresee, Merck, Citius Pharmaceuticals, Quark, and Boehringer Ingelheim. MAM declares grant support from Roche-Genentech for ARDS observational studies; and consulting income from Citius Pharmaceuticals, Johnson & Johnson, Gilead Pharmaceuticals, Plant Therapeutics, and Novartis Pharmaceuticals, outside the submitted work. All other authors declare no competing interests.\n",
      "\n",
      "Declaration of interests Samir Jaber receives consulting fees from Drager, Fisher-Paykel,  Medtronic, Mindray, and Baxter. Nathalie Lassau receives grant funding from Guerbet. Guillaume Lebreton receives consulting fees from Abbott, Abiomed, and Baxter; and speaking fees from LivaNova. AM receives grants from 4TEEN4, Abbott, Roche, and Sphyngotec; and consulting fees from Orion, Roche, Adrenomed, and Fire1. AM participates on the data and safety monitoring board for Roche. LBW declares grants from Genentech, Boehringer Ingelheim, and CSL Behring, outside the submitted work; and consulting fees from Foresee, Merck, Citius Pharmaceuticals, Quark, and Boehringer Ingelheim. MAM declares grant support from Roche-Genentech for ARDS observational studies; and consulting income from Citius Pharmaceuticals, Johnson & Johnson, Gilead Pharmaceuticals, Plant Therapeutics, and Novartis Pharmaceuticals, outside the submitted work. All other authors declare no competing interests.\n",
      "\n",
      "Mebazaa, Alexandre\n",
      "Declaration of interests Samir Jaber receives consulting fees from Drager, Fisher-Paykel,  Medtronic, Mindray, and Baxter. Nathalie Lassau receives grant funding from Guerbet. Guillaume Lebreton receives consulting fees from Abbott, Abiomed, and Baxter; and speaking fees from LivaNova. Alexandre Mebazaa receives grants from 4TEEN4, Abbott, Roche, and Sphyngotec; and consulting fees from Orion, Roche, Adrenomed, and Fire1. Alexandre Mebazaa participates on the data and safety monitoring board for Roche. LBW declares grants from Genentech, Boehringer Ingelheim, and CSL Behring, outside the submitted work; and consulting fees from Foresee, Merck, Citius Pharmaceuticals, Quark, and Boehringer Ingelheim. MAlexandre Mebazaa declares grant support from Roche-Genentech for ARDS observational studies; and consulting income from Citius Pharmaceuticals, Johnson & Johnson, Gilead Pharmaceuticals, Plant Therapeutics, and Novartis Pharmaceuticals, outside the submitted work. All other authors declare no competing interests.\n",
      "\n",
      "Declaration of interests Samir Jaber receives consulting fees from Drager, Fisher-Paykel,  Medtronic, Mindray, and Baxter. Nathalie Lassau receives grant funding from Guerbet. Guillaume Lebreton receives consulting fees from Abbott, Abiomed, and Baxter; and speaking fees from LivaNova. Alexandre Mebazaa receives grants from 4TEEN4, Abbott, Roche, and Sphyngotec; and consulting fees from Orion, Roche, Adrenomed, and Fire1. Alexandre Mebazaa participates on the data and safety monitoring board for Roche. LBW declares grants from Genentech, Boehringer Ingelheim, and CSL Behring, outside the submitted work; and consulting fees from Foresee, Merck, Citius Pharmaceuticals, Quark, and Boehringer Ingelheim. MAlexandre Mebazaa declares grant support from Roche-Genentech for ARDS observational studies; and consulting income from Citius Pharmaceuticals, Johnson & Johnson, Gilead Pharmaceuticals, Plant Therapeutics, and Novartis Pharmaceuticals, outside the submitted work. All other authors declare no competing interests.\n",
      "\n",
      "Declaration of interests Samir Jaber receives consulting fees from Drager, Fisher-Paykel,  Medtronic, Mindray, and Baxter. Nathalie Lassau receives grant funding from Guerbet. Guillaume Lebreton receives consulting fees from Abbott, Abiomed, and Baxter; and speaking fees from LivaNova. Alexandre Mebazaa receives grants from 4TEEN4, Abbott, Roche, and Sphyngotec; and consulting fees from Orion, Roche, Adrenomed, and Fire1. Alexandre Mebazaa participates on the data and safety monitoring board for Roche. LBW declares grants from Genentech, Boehringer Ingelheim, and CSL Behring, outside the submitted work; and consulting fees from Foresee, Merck, Citius Pharmaceuticals, Quark, and Boehringer Ingelheim. MAlexandre Mebazaa declares grant support from Roche-Genentech for ARDS observational studies; and consulting income from Citius Pharmaceuticals, Johnson & Johnson, Gilead Pharmaceuticals, Plant Therapeutics, and Novartis Pharmaceuticals, outside the submitted work. All other authors declare no competing interests.\n",
      "\n",
      "Ware, Lorraine B.\n",
      "Declaration of interests Samir Jaber receives consulting fees from Drager, Fisher-Paykel,  Medtronic, Mindray, and Baxter. Nathalie Lassau receives grant funding from Guerbet. Guillaume Lebreton receives consulting fees from Abbott, Abiomed, and Baxter; and speaking fees from LivaNova. Alexandre Mebazaa receives grants from 4TEEN4, Abbott, Roche, and Sphyngotec; and consulting fees from Orion, Roche, Adrenomed, and Fire1. Alexandre Mebazaa participates on the data and safety monitoring board for Roche. Lorraine B. Ware declares grants from Genentech, Boehringer Ingelheim, and CSL Behring, outside the submitted work; and consulting fees from Foresee, Merck, Citius Pharmaceuticals, Quark, and Boehringer Ingelheim. MAlexandre Mebazaa declares grant support from Roche-Genentech for ARDS observational studies; and consulting income from Citius Pharmaceuticals, Johnson & Johnson, Gilead Pharmaceuticals, Plant Therapeutics, and Novartis Pharmaceuticals, outside the submitted work. All other authors declare no competing interests.\n",
      "\n",
      "Declaration of interests Samir Jaber receives consulting fees from Drager, Fisher-Paykel,  Medtronic, Mindray, and Baxter. Nathalie Lassau receives grant funding from Guerbet. Guillaume Lebreton receives consulting fees from Abbott, Abiomed, and Baxter; and speaking fees from LivaNova. Alexandre Mebazaa receives grants from 4TEEN4, Abbott, Roche, and Sphyngotec; and consulting fees from Orion, Roche, Adrenomed, and Fire1. Alexandre Mebazaa participates on the data and safety monitoring board for Roche. Lorraine B. Ware declares grants from Genentech, Boehringer Ingelheim, and CSL Behring, outside the submitted work; and consulting fees from Foresee, Merck, Citius Pharmaceuticals, Quark, and Boehringer Ingelheim. MAlexandre Mebazaa declares grant support from Roche-Genentech for ARDS observational studies; and consulting income from Citius Pharmaceuticals, Johnson & Johnson, Gilead Pharmaceuticals, Plant Therapeutics, and Novartis Pharmaceuticals, outside the submitted work. All other authors declare no competing interests.\n",
      "\n",
      "Ervin, Jennifer\n",
      "Declaration of interests Jennifer Ervin receives a yearly stipend (University of Melbourne Research Training Scholarship) while undertaking their PhD. All other authors declare no competing interests.\n",
      "\n",
      "Declaration of interests Jennifer Ervin receives a yearly stipend (University of Melbourne Research Training Scholarship) while undertaking their PhD. All other authors declare no competing interests.\n",
      "\n",
      "Declaration of interests Jennifer Ervin receives a yearly stipend (University of Melbourne Research Training Scholarship) while undertaking their PhD. All other authors declare no competing interests.\n",
      "\n",
      "Declaration of interests Jennifer Ervin receives a yearly stipend (University of Melbourne Research Training Scholarship) while undertaking their PhD. All other authors declare no competing interests.\n",
      "\n",
      "Declaration of interests Jennifer Ervin receives a yearly stipend (University of Melbourne Research Training Scholarship) while undertaking their PhD. All other authors declare no competing interests.\n",
      "\n",
      "Declaration of interests DAC, TL, and JKV were involved in formulating the studied policies as the commissioner of the NYC Department of Health and Mental Hygiene (DAC), the senior vice president for Ambulatory Care and Population Health at NYC Health and Hospitals (TL), and the New York City's Mayor's senior advisor for public health (JKV). All other authors declare no competing interests.\n",
      "\n",
      "Declaration of interests DAC, TL, and JKV were involved in formulating the studied policies as the commissioner of the NYC Department of Health and Mental Hygiene (DAC), the senior vice president for Ambulatory Care and Population Health at NYC Health and Hospitals (TL), and the New York City's Mayor's senior advisor for public health (JKV). All other authors declare no competing interests.\n",
      "\n",
      "Long, Theodore\n",
      "Declaration of interests DAC, Theodore Long, and JKV were involved in formulating the studied policies as the commissioner of the NYC Department of Health and Mental Hygiene (DAC), the senior vice president for Ambulatory Care and Population Health at NYC Health and Hospitals (Theodore Long), and the New York City's Mayor's senior advisor for public health (JKV). All other authors declare no competing interests.\n",
      "\n",
      "Varma, Jay K.\n",
      "Declaration of interests DAC, Theodore Long, and Jay K. Varma were involved in formulating the studied policies as the commissioner of the NYC Department of Health and Mental Hygiene (DAC), the senior vice president for Ambulatory Care and Population Health at NYC Health and Hospitals (Theodore Long), and the New York City's Mayor's senior advisor for public health (Jay K. Varma). All other authors declare no competing interests.\n",
      "\n",
      "Chokshi, Dave A.\n",
      "Declaration of interests Dave A. Chokshi, Theodore Long, and Jay K. Varma were involved in formulating the studied policies as the commissioner of the NYC Department of Health and Mental Hygiene (Dave A. Chokshi), the senior vice president for Ambulatory Care and Population Health at NYC Health and Hospitals (Theodore Long), and the New York City's Mayor's senior advisor for public health (Jay K. Varma). All other authors declare no competing interests.\n",
      "\n",
      "McMurray, John J.V.\n",
      "John J.V. McMurraycM reports consulting or lecture fees from Abbott, Alkem Metabolics, Alnylam, AstraZeneca, Boehringer Ingelheim, Cardurion, Cytokinetics, Eris Lifesciences, GlaxoSmithKline, Hikma, Ionis, KBP Biosciences, Lupin, Novartis, Sun Pharmaceuticals, Medscape/Heart.org, ProAdWise Communications, Radcliffe Cardiology, and the Corpus; John J.V. McMurraycM is a director of Global Clinical Trial Partners. NS has consulted for Abbott Laboratories, Afimmune, Amgen, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Hanmi Pharmaceuticals, Merck Sharp & Dohme, Novartis, Novo Nordisk, Pfizer, and Sanofi; and received grant support paid to his University from AstraZeneca, Boehringer Ingelheim, Novartis, and Roche Diagnostics.\n",
      "\n",
      "Sattar, Naveed\n",
      "John J.V. McMurraycM reports consulting or lecture fees from Abbott, Alkem Metabolics, Alnylam, AstraZeneca, Boehringer Ingelheim, Cardurion, Cytokinetics, Eris Lifesciences, GlaxoSmithKline, Hikma, Ionis, KBP Biosciences, Lupin, Novartis, Sun Pharmaceuticals, Medscape/Heart.org, ProAdWise Communications, Radcliffe Cardiology, and the Corpus; John J.V. McMurraycM is a director of Global Clinical Trial Partners. Naveed Sattar has consulted for Abbott Laboratories, Afimmune, Amgen, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Hanmi Pharmaceuticals, Merck Sharp & Dohme, Novartis, Novo Nordisk, Pfizer, and Sanofi; and received grant support paid to his University from AstraZeneca, Boehringer Ingelheim, Novartis, and Roche Diagnostics.\n",
      "\n",
      "Tison, Geoffrey H.\n",
      "PK and BB are employees of Azumio. There are no competing interests for the remaining authors. Azumio provided no financial support for this study and only provided access to the step count data and did not have any role in the decision  to publish the manuscript. Data analysis and interpretation were performed independently from Azumio. Geoffrey H. Tison received support from the National Institutes of Health NHLBI K23HL135274. RA received support from the Fonds de Recherche du Quebec en Sante (FRQS, grant number 312758). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the  manuscript.\n",
      "\n",
      "PK and BB are employees of Azumio. There are no competing interests for the remaining authors. Azumio provided no financial support for this study and only provided access to the step count data and did not have any role in the decision  to publish the manuscript. Data analysis and interpretation were performed independently from Azumio. Geoffrey H. Tison received support from the National Institutes of Health NHLBI K23HL135274. RA received support from the Fonds de Recherche du Quebec en Sante (FRQS, grant number 312758). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the  manuscript.\n",
      "\n",
      "Avram, Robert\n",
      "PK and BB are employees of Azumio. There are no competing interests for the remaining authors. Azumio provided no financial support for this study and only provided access to the step count data and did not have any role in the decision  to publish the manuscript. Data analysis and interpretation were performed independently from Azumio. Geoffrey H. Tison received support from the National Institutes of Health NHLBI K23HL135274. Robert Avram received support from the Fonds de Recherche du Quebec en Sante (FRQS, grant number 312758). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the  manuscript.\n",
      "\n",
      "Kuhar, Peter\n",
      "Peter Kuhar and BB are employees of Azumio. There are no competing interests for the remaining authors. Azumio provided no financial support for this study and only provided access to the step count data and did not have any role in the decision  to publish the manuscript. Data analysis and interpretation were performed independently from Azumio. Geoffrey H. Tison received support from the National Institutes of Health NHLBI K23HL135274. Robert Avram received support from the Fonds de Recherche du Quebec en Sante (FRQS, grant number 312758). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the  manuscript.\n",
      "\n",
      "Bostjancic, Bojan\n",
      "Peter Kuhar and Bojan Bostjancic are employees of Azumio. There are no competing interests for the remaining authors. Azumio provided no financial support for this study and only provided access to the step count data and did not have any role in the decision  to publish the manuscript. Data analysis and interpretation were performed independently from Azumio. Geoffrey H. Tison received support from the National Institutes of Health NHLBI K23HL135274. Robert Avram received support from the Fonds de Recherche du Quebec en Sante (FRQS, grant number 312758). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the  manuscript.\n",
      "\n",
      "Peter Kuhar and Bojan Bostjancic are employees of Azumio. There are no competing interests for the remaining authors. Azumio provided no financial support for this study and only provided access to the step count data and did not have any role in the decision  to publish the manuscript. Data analysis and interpretation were performed independently from Azumio. Geoffrey H. Tison received support from the National Institutes of Health NHLBI K23HL135274. Robert Avram received support from the Fonds de Recherche du Quebec en Sante (FRQS, grant number 312758). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the  manuscript.\n",
      "\n",
      "Peter Kuhar and Bojan Bostjancic are employees of Azumio. There are no competing interests for the remaining authors. Azumio provided no financial support for this study and only provided access to the step count data and did not have any role in the decision  to publish the manuscript. Data analysis and interpretation were performed independently from Azumio. Geoffrey H. Tison received support from the National Institutes of Health NHLBI K23HL135274. Robert Avram received support from the Fonds de Recherche du Quebec en Sante (FRQS, grant number 312758). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the  manuscript.\n",
      "\n",
      "Peter Kuhar and Bojan Bostjancic are employees of Azumio. There are no competing interests for the remaining authors. Azumio provided no financial support for this study and only provided access to the step count data and did not have any role in the decision  to publish the manuscript. Data analysis and interpretation were performed independently from Azumio. Geoffrey H. Tison received support from the National Institutes of Health NHLBI K23HL135274. Robert Avram received support from the Fonds de Recherche du Quebec en Sante (FRQS, grant number 312758). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the  manuscript.\n",
      "\n",
      "Declaration of interests WH reports his position as a member of Biobot Analytics' scientific advisory board and has received stock options in Biobot Analytics, as  well as payment for expert witness testimony on the expected course of the COVID-19 pandemic. DS reports previous employment at Pfizer before the initiation of this analysis and stock in Pfizer. DS also reports compensation for occasional 1 h blinded consultancies for several consulting companies over the past 36 months. MS reports receipt of institutional research funds from the Johnson and Johnson Foundation and from Pfizer; neither funder had a role in the design or content of the current manuscript. CC reports grant funding from the Wellcome Trust, South African Medical Research Council, US Centers for Disease Control and Prevention, and Sanofi Pasteur to institute COVID-19 research in the past 36 months, as well as a role on the scientific advisory committee for \"BCHW: Burden  of COVID-19 among health care workers, assessing infection, risk factors, vaccine effectiveness, working experiences and one-health implications: a mixed methodology, multisite international study\". RW reports shareholding stock in the following health or pharmaceutical companies in South Africa, none related to this work: Adcock Ingram Holdings, Dischem Pharmacies, Discovery, Netcare, and Aspen Pharmacare Holdings. All interests listed are outside the current work. All other authors declare no competing interests.\n",
      "\n",
      "Declaration of interests WH reports his position as a member of Biobot Analytics' scientific advisory board and has received stock options in Biobot Analytics, as  well as payment for expert witness testimony on the expected course of the COVID-19 pandemic. DS reports previous employment at Pfizer before the initiation of this analysis and stock in Pfizer. DS also reports compensation for occasional 1 h blinded consultancies for several consulting companies over the past 36 months. MS reports receipt of institutional research funds from the Johnson and Johnson Foundation and from Pfizer; neither funder had a role in the design or content of the current manuscript. CC reports grant funding from the Wellcome Trust, South African Medical Research Council, US Centers for Disease Control and Prevention, and Sanofi Pasteur to institute COVID-19 research in the past 36 months, as well as a role on the scientific advisory committee for \"BCHW: Burden  of COVID-19 among health care workers, assessing infection, risk factors, vaccine effectiveness, working experiences and one-health implications: a mixed methodology, multisite international study\". RW reports shareholding stock in the following health or pharmaceutical companies in South Africa, none related to this work: Adcock Ingram Holdings, Dischem Pharmacies, Discovery, Netcare, and Aspen Pharmacare Holdings. All interests listed are outside the current work. All other authors declare no competing interests.\n",
      "\n",
      "Declaration of interests WH reports his position as a member of Biobot Analytics' scientific advisory board and has received stock options in Biobot Analytics, as  well as payment for expert witness testimony on the expected course of the COVID-19 pandemic. DS reports previous employment at Pfizer before the initiation of this analysis and stock in Pfizer. DS also reports compensation for occasional 1 h blinded consultancies for several consulting companies over the past 36 months. MS reports receipt of institutional research funds from the Johnson and Johnson Foundation and from Pfizer; neither funder had a role in the design or content of the current manuscript. CC reports grant funding from the Wellcome Trust, South African Medical Research Council, US Centers for Disease Control and Prevention, and Sanofi Pasteur to institute COVID-19 research in the past 36 months, as well as a role on the scientific advisory committee for \"BCHW: Burden  of COVID-19 among health care workers, assessing infection, risk factors, vaccine effectiveness, working experiences and one-health implications: a mixed methodology, multisite international study\". RW reports shareholding stock in the following health or pharmaceutical companies in South Africa, none related to this work: Adcock Ingram Holdings, Dischem Pharmacies, Discovery, Netcare, and Aspen Pharmacare Holdings. All interests listed are outside the current work. All other authors declare no competing interests.\n",
      "\n",
      "Declaration of interests WH reports his position as a member of Biobot Analytics' scientific advisory board and has received stock options in Biobot Analytics, as  well as payment for expert witness testimony on the expected course of the COVID-19 pandemic. DS reports previous employment at Pfizer before the initiation of this analysis and stock in Pfizer. DS also reports compensation for occasional 1 h blinded consultancies for several consulting companies over the past 36 months. MS reports receipt of institutional research funds from the Johnson and Johnson Foundation and from Pfizer; neither funder had a role in the design or content of the current manuscript. CC reports grant funding from the Wellcome Trust, South African Medical Research Council, US Centers for Disease Control and Prevention, and Sanofi Pasteur to institute COVID-19 research in the past 36 months, as well as a role on the scientific advisory committee for \"BCHW: Burden  of COVID-19 among health care workers, assessing infection, risk factors, vaccine effectiveness, working experiences and one-health implications: a mixed methodology, multisite international study\". RW reports shareholding stock in the following health or pharmaceutical companies in South Africa, none related to this work: Adcock Ingram Holdings, Dischem Pharmacies, Discovery, Netcare, and Aspen Pharmacare Holdings. All interests listed are outside the current work. All other authors declare no competing interests.\n",
      "\n",
      "Declaration of interests WH reports his position as a member of Biobot Analytics' scientific advisory board and has received stock options in Biobot Analytics, as  well as payment for expert witness testimony on the expected course of the COVID-19 pandemic. DS reports previous employment at Pfizer before the initiation of this analysis and stock in Pfizer. DS also reports compensation for occasional 1 h blinded consultancies for several consulting companies over the past 36 months. MS reports receipt of institutional research funds from the Johnson and Johnson Foundation and from Pfizer; neither funder had a role in the design or content of the current manuscript. CC reports grant funding from the Wellcome Trust, South African Medical Research Council, US Centers for Disease Control and Prevention, and Sanofi Pasteur to institute COVID-19 research in the past 36 months, as well as a role on the scientific advisory committee for \"BCHW: Burden  of COVID-19 among health care workers, assessing infection, risk factors, vaccine effectiveness, working experiences and one-health implications: a mixed methodology, multisite international study\". RW reports shareholding stock in the following health or pharmaceutical companies in South Africa, none related to this work: Adcock Ingram Holdings, Dischem Pharmacies, Discovery, Netcare, and Aspen Pharmacare Holdings. All interests listed are outside the current work. All other authors declare no competing interests.\n",
      "\n",
      "Welch, Richard\n",
      "Declaration of interests WH reports his position as a member of Biobot Analytics' scientific advisory board and has received stock options in Biobot Analytics, as  well as payment for expert witness testimony on the expected course of the COVID-19 pandemic. DS reports previous employment at Pfizer before the initiation of this analysis and stock in Pfizer. DS also reports compensation for occasional 1 h blinded consultancies for several consulting companies over the past 36 months. MS reports receipt of institutional research funds from the Johnson and Johnson Foundation and from Pfizer; neither funder had a role in the design or content of the current manuscript. CC reports grant funding from the Wellcome Trust, South African Medical Research Council, US Centers for Disease Control and Prevention, and Sanofi Pasteur to institute COVID-19 research in the past 36 months, as well as a role on the scientific advisory committee for \"BCHW: Burden  of COVID-19 among health care workers, assessing infection, risk factors, vaccine effectiveness, working experiences and one-health implications: a mixed methodology, multisite international study\". Richard Welch reports shareholding stock in the following health or pharmaceutical companies in South Africa, none related to this work: Adcock Ingram Holdings, Dischem Pharmacies, Discovery, Netcare, and Aspen Pharmacare Holdings. All interests listed are outside the current work. All other authors declare no competing interests.\n",
      "\n",
      "Declaration of interests WH reports his position as a member of Biobot Analytics' scientific advisory board and has received stock options in Biobot Analytics, as  well as payment for expert witness testimony on the expected course of the COVID-19 pandemic. DS reports previous employment at Pfizer before the initiation of this analysis and stock in Pfizer. DS also reports compensation for occasional 1 h blinded consultancies for several consulting companies over the past 36 months. MS reports receipt of institutional research funds from the Johnson and Johnson Foundation and from Pfizer; neither funder had a role in the design or content of the current manuscript. CC reports grant funding from the Wellcome Trust, South African Medical Research Council, US Centers for Disease Control and Prevention, and Sanofi Pasteur to institute COVID-19 research in the past 36 months, as well as a role on the scientific advisory committee for \"BCHW: Burden  of COVID-19 among health care workers, assessing infection, risk factors, vaccine effectiveness, working experiences and one-health implications: a mixed methodology, multisite international study\". Richard Welch reports shareholding stock in the following health or pharmaceutical companies in South Africa, none related to this work: Adcock Ingram Holdings, Dischem Pharmacies, Discovery, Netcare, and Aspen Pharmacare Holdings. All interests listed are outside the current work. All other authors declare no competing interests.\n",
      "\n",
      "Declaration of interests WH reports his position as a member of Biobot Analytics' scientific advisory board and has received stock options in Biobot Analytics, as  well as payment for expert witness testimony on the expected course of the COVID-19 pandemic. DS reports previous employment at Pfizer before the initiation of this analysis and stock in Pfizer. DS also reports compensation for occasional 1 h blinded consultancies for several consulting companies over the past 36 months. MS reports receipt of institutional research funds from the Johnson and Johnson Foundation and from Pfizer; neither funder had a role in the design or content of the current manuscript. CC reports grant funding from the Wellcome Trust, South African Medical Research Council, US Centers for Disease Control and Prevention, and Sanofi Pasteur to institute COVID-19 research in the past 36 months, as well as a role on the scientific advisory committee for \"BCHW: Burden  of COVID-19 among health care workers, assessing infection, risk factors, vaccine effectiveness, working experiences and one-health implications: a mixed methodology, multisite international study\". Richard Welch reports shareholding stock in the following health or pharmaceutical companies in South Africa, none related to this work: Adcock Ingram Holdings, Dischem Pharmacies, Discovery, Netcare, and Aspen Pharmacare Holdings. All interests listed are outside the current work. All other authors declare no competing interests.\n",
      "\n",
      "Declaration of interests WH reports his position as a member of Biobot Analytics' scientific advisory board and has received stock options in Biobot Analytics, as  well as payment for expert witness testimony on the expected course of the COVID-19 pandemic. DS reports previous employment at Pfizer before the initiation of this analysis and stock in Pfizer. DS also reports compensation for occasional 1 h blinded consultancies for several consulting companies over the past 36 months. MS reports receipt of institutional research funds from the Johnson and Johnson Foundation and from Pfizer; neither funder had a role in the design or content of the current manuscript. CC reports grant funding from the Wellcome Trust, South African Medical Research Council, US Centers for Disease Control and Prevention, and Sanofi Pasteur to institute COVID-19 research in the past 36 months, as well as a role on the scientific advisory committee for \"BCHW: Burden  of COVID-19 among health care workers, assessing infection, risk factors, vaccine effectiveness, working experiences and one-health implications: a mixed methodology, multisite international study\". Richard Welch reports shareholding stock in the following health or pharmaceutical companies in South Africa, none related to this work: Adcock Ingram Holdings, Dischem Pharmacies, Discovery, Netcare, and Aspen Pharmacare Holdings. All interests listed are outside the current work. All other authors declare no competing interests.\n",
      "\n",
      "Declaration of interests WH reports his position as a member of Biobot Analytics' scientific advisory board and has received stock options in Biobot Analytics, as  well as payment for expert witness testimony on the expected course of the COVID-19 pandemic. DS reports previous employment at Pfizer before the initiation of this analysis and stock in Pfizer. DS also reports compensation for occasional 1 h blinded consultancies for several consulting companies over the past 36 months. MS reports receipt of institutional research funds from the Johnson and Johnson Foundation and from Pfizer; neither funder had a role in the design or content of the current manuscript. CC reports grant funding from the Wellcome Trust, South African Medical Research Council, US Centers for Disease Control and Prevention, and Sanofi Pasteur to institute COVID-19 research in the past 36 months, as well as a role on the scientific advisory committee for \"BCHW: Burden  of COVID-19 among health care workers, assessing infection, risk factors, vaccine effectiveness, working experiences and one-health implications: a mixed methodology, multisite international study\". Richard Welch reports shareholding stock in the following health or pharmaceutical companies in South Africa, none related to this work: Adcock Ingram Holdings, Dischem Pharmacies, Discovery, Netcare, and Aspen Pharmacare Holdings. All interests listed are outside the current work. All other authors declare no competing interests.\n",
      "\n",
      "Declaration of interests WH reports his position as a member of Biobot Analytics' scientific advisory board and has received stock options in Biobot Analytics, as  well as payment for expert witness testimony on the expected course of the COVID-19 pandemic. DS reports previous employment at Pfizer before the initiation of this analysis and stock in Pfizer. DS also reports compensation for occasional 1 h blinded consultancies for several consulting companies over the past 36 months. MS reports receipt of institutional research funds from the Johnson and Johnson Foundation and from Pfizer; neither funder had a role in the design or content of the current manuscript. CC reports grant funding from the Wellcome Trust, South African Medical Research Council, US Centers for Disease Control and Prevention, and Sanofi Pasteur to institute COVID-19 research in the past 36 months, as well as a role on the scientific advisory committee for \"BCHW: Burden  of COVID-19 among health care workers, assessing infection, risk factors, vaccine effectiveness, working experiences and one-health implications: a mixed methodology, multisite international study\". Richard Welch reports shareholding stock in the following health or pharmaceutical companies in South Africa, none related to this work: Adcock Ingram Holdings, Dischem Pharmacies, Discovery, Netcare, and Aspen Pharmacare Holdings. All interests listed are outside the current work. All other authors declare no competing interests.\n",
      "\n",
      "Hanage, William\n",
      "Declaration of interests William Hanage reports his position as a member of Biobot Analytics' scientific advisory board and has received stock options in Biobot Analytics, as  well as payment for expert witness testimony on the expected course of the COVID-19 pandemic. DS reports previous employment at Pfizer before the initiation of this analysis and stock in Pfizer. DS also reports compensation for occasional 1 h blinded consultancies for several consulting companies over the past 36 months. MS reports receipt of institutional research funds from the Johnson and Johnson Foundation and from Pfizer; neither funder had a role in the design or content of the current manuscript. CC reports grant funding from the Wellcome Trust, South African Medical Research Council, US Centers for Disease Control and Prevention, and Sanofi Pasteur to institute COVID-19 research in the past 36 months, as well as a role on the scientific advisory committee for \"BCHW: Burden  of COVID-19 among health care workers, assessing infection, risk factors, vaccine effectiveness, working experiences and one-health implications: a mixed methodology, multisite international study\". Richard Welch reports shareholding stock in the following health or pharmaceutical companies in South Africa, none related to this work: Adcock Ingram Holdings, Dischem Pharmacies, Discovery, Netcare, and Aspen Pharmacare Holdings. All interests listed are outside the current work. All other authors declare no competing interests.\n",
      "\n",
      "Santillana, Mauricio\n",
      "Declaration of interests William Hanage reports his position as a member of Biobot Analytics' scientific advisory board and has received stock options in Biobot Analytics, as  well as payment for expert witness testimony on the expected course of the COVID-19 pandemic. DS reports previous employment at Pfizer before the initiation of this analysis and stock in Pfizer. DS also reports compensation for occasional 1 h blinded consultancies for several consulting companies over the past 36 months. Mauricio Santillana reports receipt of institutional research funds from the Johnson and Johnson Foundation and from Pfizer; neither funder had a role in the design or content of the current manuscript. CC reports grant funding from the Wellcome Trust, South African Medical Research Council, US Centers for Disease Control and Prevention, and Sanofi Pasteur to institute COVID-19 research in the past 36 months, as well as a role on the scientific advisory committee for \"BCHW: Burden  of COVID-19 among health care workers, assessing infection, risk factors, vaccine effectiveness, working experiences and one-health implications: a mixed methodology, multisite international study\". Richard Welch reports shareholding stock in the following health or pharmaceutical companies in South Africa, none related to this work: Adcock Ingram Holdings, Dischem Pharmacies, Discovery, Netcare, and Aspen Pharmacare Holdings. All interests listed are outside the current work. All other authors declare no competing interests.\n",
      "\n",
      "Declaration of interests William Hanage reports his position as a member of Biobot Analytics' scientific advisory board and has received stock options in Biobot Analytics, as  well as payment for expert witness testimony on the expected course of the COVID-19 pandemic. DS reports previous employment at Pfizer before the initiation of this analysis and stock in Pfizer. DS also reports compensation for occasional 1 h blinded consultancies for several consulting companies over the past 36 months. Mauricio Santillana reports receipt of institutional research funds from the Johnson and Johnson Foundation and from Pfizer; neither funder had a role in the design or content of the current manuscript. CC reports grant funding from the Wellcome Trust, South African Medical Research Council, US Centers for Disease Control and Prevention, and Sanofi Pasteur to institute COVID-19 research in the past 36 months, as well as a role on the scientific advisory committee for \"BCHW: Burden  of COVID-19 among health care workers, assessing infection, risk factors, vaccine effectiveness, working experiences and one-health implications: a mixed methodology, multisite international study\". Richard Welch reports shareholding stock in the following health or pharmaceutical companies in South Africa, none related to this work: Adcock Ingram Holdings, Dischem Pharmacies, Discovery, Netcare, and Aspen Pharmacare Holdings. All interests listed are outside the current work. All other authors declare no competing interests.\n",
      "\n",
      "Cohen, Cheryl\n",
      "Declaration of interests William Hanage reports his position as a member of Biobot Analytics' scientific advisory board and has received stock options in Biobot Analytics, as  well as payment for expert witness testimony on the expected course of the COVID-19 pandemic. DS reports previous employment at Pfizer before the initiation of this analysis and stock in Pfizer. DS also reports compensation for occasional 1 h blinded consultancies for several consulting companies over the past 36 months. Mauricio Santillana reports receipt of institutional research funds from the Johnson and Johnson Foundation and from Pfizer; neither funder had a role in the design or content of the current manuscript. Cheryl Cohen reports grant funding from the Wellcome Trust, South African Medical Research Council, US Centers for Disease Control and Prevention, and Sanofi Pasteur to institute COVID-19 research in the past 36 months, as well as a role on the scientific advisory committee for \"BCHW: Burden  of COVID-19 among health care workers, assessing infection, risk factors, vaccine effectiveness, working experiences and one-health implications: a mixed methodology, multisite international study\". Richard Welch reports shareholding stock in the following health or pharmaceutical companies in South Africa, none related to this work: Adcock Ingram Holdings, Dischem Pharmacies, Discovery, Netcare, and Aspen Pharmacare Holdings. All interests listed are outside the current work. All other authors declare no competing interests.\n",
      "\n",
      "Swerdlow, David\n",
      "Declaration of interests William Hanage reports his position as a member of Biobot Analytics' scientific advisory board and has received stock options in Biobot Analytics, as  well as payment for expert witness testimony on the expected course of the COVID-19 pandemic. David Swerdlow reports previous employment at Pfizer before the initiation of this analysis and stock in Pfizer. David Swerdlow also reports compensation for occasional 1 h blinded consultancies for several consulting companies over the past 36 months. Mauricio Santillana reports receipt of institutional research funds from the Johnson and Johnson Foundation and from Pfizer; neither funder had a role in the design or content of the current manuscript. Cheryl Cohen reports grant funding from the Wellcome Trust, South African Medical Research Council, US Centers for Disease Control and Prevention, and Sanofi Pasteur to institute COVID-19 research in the past 36 months, as well as a role on the scientific advisory committee for \"BCHW: Burden  of COVID-19 among health care workers, assessing infection, risk factors, vaccine effectiveness, working experiences and one-health implications: a mixed methodology, multisite international study\". Richard Welch reports shareholding stock in the following health or pharmaceutical companies in South Africa, none related to this work: Adcock Ingram Holdings, Dischem Pharmacies, Discovery, Netcare, and Aspen Pharmacare Holdings. All interests listed are outside the current work. All other authors declare no competing interests.\n",
      "\n",
      "Declaration of interests The Department of General and Pancreatic Surgery at the  University of Verona received funding from the Italian Ministry of Health (Grant  FIMP-CUP J38D19000690001). GP reports funding from Associazione Italiana Ricerca  sul Cancro (IG 2021-26201). RH is under a license agreement between Thrive Earlier Detection, a subsidiary of Exact Sciences, and the Johns Hopkins University. AVM's research in tumour immunology is funded through the National Institutes of Health Method To Extend Research in Time award (R37CA238435), and AVM is an inventor who has the following pending or issued patents: WO2018183603A1 (PCT/US2018/025027) and US9757457B2.\n",
      "\n",
      "Declaration of interests The Department of General and Pancreatic Surgery at the  University of Verona received funding from the Italian Ministry of Health (Grant  FIMP-CUP J38D19000690001). GP reports funding from Associazione Italiana Ricerca  sul Cancro (IG 2021-26201). RH is under a license agreement between Thrive Earlier Detection, a subsidiary of Exact Sciences, and the Johns Hopkins University. AVM's research in tumour immunology is funded through the National Institutes of Health Method To Extend Research in Time award (R37CA238435), and AVM is an inventor who has the following pending or issued patents: WO2018183603A1 (PCT/US2018/025027) and US9757457B2.\n",
      "\n",
      "Declaration of interests The Department of General and Pancreatic Surgery at the  University of Verona received funding from the Italian Ministry of Health (Grant  FIMP-CUP J38D19000690001). GP reports funding from Associazione Italiana Ricerca  sul Cancro (IG 2021-26201). RH is under a license agreement between Thrive Earlier Detection, a subsidiary of Exact Sciences, and the Johns Hopkins University. AVM's research in tumour immunology is funded through the National Institutes of Health Method To Extend Research in Time award (R37CA238435), and AVM is an inventor who has the following pending or issued patents: WO2018183603A1 (PCT/US2018/025027) and US9757457B2.\n",
      "\n",
      "Declaration of interests The Department of General and Pancreatic Surgery at the  University of Verona received funding from the Italian Ministry of Health (Grant  FIMP-CUP J38D19000690001). GP reports funding from Associazione Italiana Ricerca  sul Cancro (IG 2021-26201). RH is under a license agreement between Thrive Earlier Detection, a subsidiary of Exact Sciences, and the Johns Hopkins University. AVM's research in tumour immunology is funded through the National Institutes of Health Method To Extend Research in Time award (R37CA238435), and AVM is an inventor who has the following pending or issued patents: WO2018183603A1 (PCT/US2018/025027) and US9757457B2.\n",
      "\n",
      "Declaration of interests The Department of General and Pancreatic Surgery at the  University of Verona received funding from the Italian Ministry of Health (Grant  FIMP-CUP J38D19000690001). GP reports funding from Associazione Italiana Ricerca  sul Cancro (IG 2021-26201). RH is under a license agreement between Thrive Earlier Detection, a subsidiary of Exact Sciences, and the Johns Hopkins University. AVM's research in tumour immunology is funded through the National Institutes of Health Method To Extend Research in Time award (R37CA238435), and AVM is an inventor who has the following pending or issued patents: WO2018183603A1 (PCT/US2018/025027) and US9757457B2.\n",
      "\n",
      "Hruban, Ralph\n",
      "Declaration of interests The Department of General and Pancreatic Surgery at the  University of Verona received funding from the Italian Ministry of Health (Grant  FIMP-CUP J38D19000690001). GP reports funding from Associazione Italiana Ricerca  sul Cancro (IG 2021-26201). Ralph Hruban is under a license agreement between Thrive Earlier Detection, a subsidiary of Exact Sciences, and the Johns Hopkins University. AVM's research in tumour immunology is funded through the National Institutes of Health Method To Extend Research in Time award (R37CA238435), and AVM is an inventor who has the following pending or issued patents: WO2018183603A1 (PCT/US2018/025027) and US9757457B2.\n",
      "\n",
      "Declaration of interests The Department of General and Pancreatic Surgery at the  University of Verona received funding from the Italian Ministry of Health (Grant  FIMP-CUP J38D19000690001). GP reports funding from Associazione Italiana Ricerca  sul Cancro (IG 2021-26201). Ralph Hruban is under a license agreement between Thrive Earlier Detection, a subsidiary of Exact Sciences, and the Johns Hopkins University. AVM's research in tumour immunology is funded through the National Institutes of Health Method To Extend Research in Time award (R37CA238435), and AVM is an inventor who has the following pending or issued patents: WO2018183603A1 (PCT/US2018/025027) and US9757457B2.\n",
      "\n",
      "Declaration of interests The Department of General and Pancreatic Surgery at the  University of Verona received funding from the Italian Ministry of Health (Grant  FIMP-CUP J38D19000690001). GP reports funding from Associazione Italiana Ricerca  sul Cancro (IG 2021-26201). Ralph Hruban is under a license agreement between Thrive Earlier Detection, a subsidiary of Exact Sciences, and the Johns Hopkins University. AVM's research in tumour immunology is funded through the National Institutes of Health Method To Extend Research in Time award (R37CA238435), and AVM is an inventor who has the following pending or issued patents: WO2018183603A1 (PCT/US2018/025027) and US9757457B2.\n",
      "\n",
      "Declaration of interests The Department of General and Pancreatic Surgery at the  University of Verona received funding from the Italian Ministry of Health (Grant  FIMP-CUP J38D19000690001). GP reports funding from Associazione Italiana Ricerca  sul Cancro (IG 2021-26201). Ralph Hruban is under a license agreement between Thrive Earlier Detection, a subsidiary of Exact Sciences, and the Johns Hopkins University. AVM's research in tumour immunology is funded through the National Institutes of Health Method To Extend Research in Time award (R37CA238435), and AVM is an inventor who has the following pending or issued patents: WO2018183603A1 (PCT/US2018/025027) and US9757457B2.\n",
      "\n",
      "Declaration of interests The Department of General and Pancreatic Surgery at the  University of Verona received funding from the Italian Ministry of Health (Grant  FIMP-CUP J38D19000690001). GP reports funding from Associazione Italiana Ricerca  sul Cancro (IG 2021-26201). Ralph Hruban is under a license agreement between Thrive Earlier Detection, a subsidiary of Exact Sciences, and the Johns Hopkins University. AVM's research in tumour immunology is funded through the National Institutes of Health Method To Extend Research in Time award (R37CA238435), and AVM is an inventor who has the following pending or issued patents: WO2018183603A1 (PCT/US2018/025027) and US9757457B2.\n",
      "\n",
      "Declaration of interests The Department of General and Pancreatic Surgery at the  University of Verona received funding from the Italian Ministry of Health (Grant  FIMP-CUP J38D19000690001). GP reports funding from Associazione Italiana Ricerca  sul Cancro (IG 2021-26201). Ralph Hruban is under a license agreement between Thrive Earlier Detection, a subsidiary of Exact Sciences, and the Johns Hopkins University. AVM's research in tumour immunology is funded through the National Institutes of Health Method To Extend Research in Time award (R37CA238435), and AVM is an inventor who has the following pending or issued patents: WO2018183603A1 (PCT/US2018/025027) and US9757457B2.\n",
      "\n",
      "Declaration of interests The Department of General and Pancreatic Surgery at the  University of Verona received funding from the Italian Ministry of Health (Grant  FIMP-CUP J38D19000690001). GP reports funding from Associazione Italiana Ricerca  sul Cancro (IG 2021-26201). Ralph Hruban is under a license agreement between Thrive Earlier Detection, a subsidiary of Exact Sciences, and the Johns Hopkins University. AVM's research in tumour immunology is funded through the National Institutes of Health Method To Extend Research in Time award (R37CA238435), and AVM is an inventor who has the following pending or issued patents: WO2018183603A1 (PCT/US2018/025027) and US9757457B2.\n",
      "\n",
      "Declaration of interests The Department of General and Pancreatic Surgery at the  University of Verona received funding from the Italian Ministry of Health (Grant  FIMP-CUP J38D19000690001). GP reports funding from Associazione Italiana Ricerca  sul Cancro (IG 2021-26201). Ralph Hruban is under a license agreement between Thrive Earlier Detection, a subsidiary of Exact Sciences, and the Johns Hopkins University. AVM's research in tumour immunology is funded through the National Institutes of Health Method To Extend Research in Time award (R37CA238435), and AVM is an inventor who has the following pending or issued patents: WO2018183603A1 (PCT/US2018/025027) and US9757457B2.\n",
      "\n",
      "Declaration of interests The Department of General and Pancreatic Surgery at the  University of Verona received funding from the Italian Ministry of Health (Grant  FIMP-CUP J38D19000690001). GP reports funding from Associazione Italiana Ricerca  sul Cancro (IG 2021-26201). Ralph Hruban is under a license agreement between Thrive Earlier Detection, a subsidiary of Exact Sciences, and the Johns Hopkins University. AVM's research in tumour immunology is funded through the National Institutes of Health Method To Extend Research in Time award (R37CA238435), and AVM is an inventor who has the following pending or issued patents: WO2018183603A1 (PCT/US2018/025027) and US9757457B2.\n",
      "\n",
      "Declaration of interests The Department of General and Pancreatic Surgery at the  University of Verona received funding from the Italian Ministry of Health (Grant  FIMP-CUP J38D19000690001). GP reports funding from Associazione Italiana Ricerca  sul Cancro (IG 2021-26201). Ralph Hruban is under a license agreement between Thrive Earlier Detection, a subsidiary of Exact Sciences, and the Johns Hopkins University. AVM's research in tumour immunology is funded through the National Institutes of Health Method To Extend Research in Time award (R37CA238435), and AVM is an inventor who has the following pending or issued patents: WO2018183603A1 (PCT/US2018/025027) and US9757457B2.\n",
      "\n",
      "Maker, Ajay V.\n",
      "Declaration of interests The Department of General and Pancreatic Surgery at the  University of Verona received funding from the Italian Ministry of Health (Grant  FIMP-CUP J38D19000690001). GP reports funding from Associazione Italiana Ricerca  sul Cancro (IG 2021-26201). Ralph Hruban is under a license agreement between Thrive Earlier Detection, a subsidiary of Exact Sciences, and the Johns Hopkins University. Ajay V. Maker's research in tumour immunology is funded through the National Institutes of Health Method To Extend Research in Time award (R37CA238435), and Ajay V. Maker is an inventor who has the following pending or issued patents: WO2018183603A1 (PCT/US2018/025027) and US9757457B2.\n",
      "\n",
      "Declaration of interests B.O. declares that he is a consultant specialist at Volastra Therapeutics.\n",
      "\n",
      "Orr, Bernardo\n",
      "Declaration of interests Bernardo Orr declares that he is a consultant specialist at Volastra Therapeutics.\n",
      "\n",
      "Declaration of interests Bernardo Orr declares that he is a consultant specialist at Volastra Therapeutics.\n",
      "\n",
      "Declaration of interests Bernardo Orr declares that he is a consultant specialist at Volastra Therapeutics.\n",
      "\n",
      "Declaration of interests Bernardo Orr declares that he is a consultant specialist at Volastra Therapeutics.\n",
      "\n",
      "Declaration of interests Bernardo Orr declares that he is a consultant specialist at Volastra Therapeutics.\n",
      "\n",
      "Declaration of interests Bernardo Orr declares that he is a consultant specialist at Volastra Therapeutics.\n",
      "\n",
      "Declaration of interests Bernardo Orr declares that he is a consultant specialist at Volastra Therapeutics.\n",
      "\n",
      "Declaration of interests The Broad Institute and the University of Pennsylvania have filed a patent on the described compounds related to YAP1 overexpression. A.E.C. reports receiving research funding from pharmaceutical companies in the JUMP-Cell Painting Consortium and Calico Life Sciences. A.E.C. has ownership interest and serves on the scientific advisory board for Recursion, a publicly traded biotech company using images for drug discovery. J.T.G. reports receiving  a commercial research grant from Bayer AG. S.M.C. reports receiving research funding from Bayer and Calico Life Sciences.\n",
      "\n",
      "Declaration of interests The Broad Institute and the University of Pennsylvania have filed a patent on the described compounds related to YAP1 overexpression. A.E.C. reports receiving research funding from pharmaceutical companies in the JUMP-Cell Painting Consortium and Calico Life Sciences. A.E.C. has ownership interest and serves on the scientific advisory board for Recursion, a publicly traded biotech company using images for drug discovery. J.T.G. reports receiving  a commercial research grant from Bayer AG. S.M.C. reports receiving research funding from Bayer and Calico Life Sciences.\n",
      "\n",
      "Declaration of interests The Broad Institute and the University of Pennsylvania have filed a patent on the described compounds related to YAP1 overexpression. A.E.C. reports receiving research funding from pharmaceutical companies in the JUMP-Cell Painting Consortium and Calico Life Sciences. A.E.C. has ownership interest and serves on the scientific advisory board for Recursion, a publicly traded biotech company using images for drug discovery. J.T.G. reports receiving  a commercial research grant from Bayer AG. S.M.C. reports receiving research funding from Bayer and Calico Life Sciences.\n",
      "\n",
      "Goldstein, Jonathan T.\n",
      "Declaration of interests The Broad Institute and the University of Pennsylvania have filed a patent on the described compounds related to YAP1 overexpression. A.E.C. reports receiving research funding from pharmaceutical companies in the JUMP-Cell Painting Consortium and Calico Life Sciences. A.E.C. has ownership interest and serves on the scientific advisory board for Recursion, a publicly traded biotech company using images for drug discovery. Jonathan T. Goldstein reports receiving  a commercial research grant from Bayer AG. S.M.C. reports receiving research funding from Bayer and Calico Life Sciences.\n",
      "\n",
      "Declaration of interests The Broad Institute and the University of Pennsylvania have filed a patent on the described compounds related to YAP1 overexpression. A.E.C. reports receiving research funding from pharmaceutical companies in the JUMP-Cell Painting Consortium and Calico Life Sciences. A.E.C. has ownership interest and serves on the scientific advisory board for Recursion, a publicly traded biotech company using images for drug discovery. Jonathan T. Goldstein reports receiving  a commercial research grant from Bayer AG. S.M.C. reports receiving research funding from Bayer and Calico Life Sciences.\n",
      "\n",
      "Gutnick, Amos\n",
      "Declaration of interests The Broad Institute and the University of Pennsylvania have filed a patent on the described compounds related to YAP1 overexpression. A.E.C. reports receiving research funding from pharmaceutical companies in the JUMP-Cell Painting Consortium and Calico Life Sciences. A.E.C. has ownership interest and serves on the scientific advisory board for Recursion, a publicly traded biotech company using images for drug discovery. Jonathan T. Goldstein reports receiving  a commercial research grant from Bayer Amos Gutnick. S.M.C. reports receiving research funding from Bayer and Calico Life Sciences.\n",
      "\n",
      "Declaration of interests The Broad Institute and the University of Pennsylvania have filed a patent on the described compounds related to YAP1 overexpression. A.E.C. reports receiving research funding from pharmaceutical companies in the JUMP-Cell Painting Consortium and Calico Life Sciences. A.E.C. has ownership interest and serves on the scientific advisory board for Recursion, a publicly traded biotech company using images for drug discovery. Jonathan T. Goldstein reports receiving  a commercial research grant from Bayer Amos Gutnick. S.M.C. reports receiving research funding from Bayer and Calico Life Sciences.\n",
      "\n",
      "Declaration of interests The Broad Institute and the University of Pennsylvania have filed a patent on the described compounds related to YAP1 overexpression. A.E.C. reports receiving research funding from pharmaceutical companies in the JUMP-Cell Painting Consortium and Calico Life Sciences. A.E.C. has ownership interest and serves on the scientific advisory board for Recursion, a publicly traded biotech company using images for drug discovery. Jonathan T. Goldstein reports receiving  a commercial research grant from Bayer Amos Gutnick. S.M.C. reports receiving research funding from Bayer and Calico Life Sciences.\n",
      "\n",
      "Declaration of interests The Broad Institute and the University of Pennsylvania have filed a patent on the described compounds related to YAP1 overexpression. A.E.C. reports receiving research funding from pharmaceutical companies in the JUMP-Cell Painting Consortium and Calico Life Sciences. A.E.C. has ownership interest and serves on the scientific advisory board for Recursion, a publicly traded biotech company using images for drug discovery. Jonathan T. Goldstein reports receiving  a commercial research grant from Bayer Amos Gutnick. S.M.C. reports receiving research funding from Bayer and Calico Life Sciences.\n",
      "\n",
      "Declaration of interests The Broad Institute and the University of Pennsylvania have filed a patent on the described compounds related to YAP1 overexpression. A.E.C. reports receiving research funding from pharmaceutical companies in the JUMP-Cell Painting Consortium and Calico Life Sciences. A.E.C. has ownership interest and serves on the scientific advisory board for Recursion, a publicly traded biotech company using images for drug discovery. Jonathan T. Goldstein reports receiving  a commercial research grant from Bayer Amos Gutnick. S.M.C. reports receiving research funding from Bayer and Calico Life Sciences.\n",
      "\n",
      "Corsello, Steven M.\n",
      "Declaration of interests The Broad Institute and the University of Pennsylvania have filed a patent on the described compounds related to YAP1 overexpression. A.E.C. reports receiving research funding from pharmaceutical companies in the JUMP-Cell Painting Consortium and Calico Life Sciences. A.E.C. has ownership interest and serves on the scientific advisory board for Recursion, a publicly traded biotech company using images for drug discovery. Jonathan T. Goldstein reports receiving  a commercial research grant from Bayer Amos Gutnick. Steven M. Corsello reports receiving research funding from Bayer and Calico Life Sciences.\n",
      "\n",
      "Declaration of interests The Broad Institute and the University of Pennsylvania have filed a patent on the described compounds related to YAP1 overexpression. A.E.C. reports receiving research funding from pharmaceutical companies in the JUMP-Cell Painting Consortium and Calico Life Sciences. A.E.C. has ownership interest and serves on the scientific advisory board for Recursion, a publicly traded biotech company using images for drug discovery. Jonathan T. Goldstein reports receiving  a commercial research grant from Bayer Amos Gutnick. Steven M. Corsello reports receiving research funding from Bayer and Calico Life Sciences.\n",
      "\n",
      "Declaration of interests The Broad Institute and the University of Pennsylvania have filed a patent on the described compounds related to YAP1 overexpression. A.E.C. reports receiving research funding from pharmaceutical companies in the JUMP-Cell Painting Consortium and Calico Life Sciences. A.E.C. has ownership interest and serves on the scientific advisory board for Recursion, a publicly traded biotech company using images for drug discovery. Jonathan T. Goldstein reports receiving  a commercial research grant from Bayer Amos Gutnick. Steven M. Corsello reports receiving research funding from Bayer and Calico Life Sciences.\n",
      "\n",
      "Declaration of interests The Broad Institute and the University of Pennsylvania have filed a patent on the described compounds related to YAP1 overexpression. A.E.C. reports receiving research funding from pharmaceutical companies in the JUMP-Cell Painting Consortium and Calico Life Sciences. A.E.C. has ownership interest and serves on the scientific advisory board for Recursion, a publicly traded biotech company using images for drug discovery. Jonathan T. Goldstein reports receiving  a commercial research grant from Bayer Amos Gutnick. Steven M. Corsello reports receiving research funding from Bayer and Calico Life Sciences.\n",
      "\n",
      "Declaration of interests The Broad Institute and the University of Pennsylvania have filed a patent on the described compounds related to YAP1 overexpression. A.E.C. reports receiving research funding from pharmaceutical companies in the JUMP-Cell Painting Consortium and Calico Life Sciences. A.E.C. has ownership interest and serves on the scientific advisory board for Recursion, a publicly traded biotech company using images for drug discovery. Jonathan T. Goldstein reports receiving  a commercial research grant from Bayer Amos Gutnick. Steven M. Corsello reports receiving research funding from Bayer and Calico Life Sciences.\n",
      "\n",
      "Declaration of interests The Broad Institute and the University of Pennsylvania have filed a patent on the described compounds related to YAP1 overexpression. A.E.C. reports receiving research funding from pharmaceutical companies in the JUMP-Cell Painting Consortium and Calico Life Sciences. A.E.C. has ownership interest and serves on the scientific advisory board for Recursion, a publicly traded biotech company using images for drug discovery. Jonathan T. Goldstein reports receiving  a commercial research grant from Bayer Amos Gutnick. Steven M. Corsello reports receiving research funding from Bayer and Calico Life Sciences.\n",
      "\n",
      "Declaration of interests The Broad Institute and the University of Pennsylvania have filed a patent on the described compounds related to YAP1 overexpression. A.E.C. reports receiving research funding from pharmaceutical companies in the JUMP-Cell Painting Consortium and Calico Life Sciences. A.E.C. has ownership interest and serves on the scientific advisory board for Recursion, a publicly traded biotech company using images for drug discovery. Jonathan T. Goldstein reports receiving  a commercial research grant from Bayer Amos Gutnick. Steven M. Corsello reports receiving research funding from Bayer and Calico Life Sciences.\n",
      "\n",
      "Declaration of interests The Broad Institute and the University of Pennsylvania have filed a patent on the described compounds related to YAP1 overexpression. A.E.C. reports receiving research funding from pharmaceutical companies in the JUMP-Cell Painting Consortium and Calico Life Sciences. A.E.C. has ownership interest and serves on the scientific advisory board for Recursion, a publicly traded biotech company using images for drug discovery. Jonathan T. Goldstein reports receiving  a commercial research grant from Bayer Amos Gutnick. Steven M. Corsello reports receiving research funding from Bayer and Calico Life Sciences.\n",
      "\n",
      "Declaration of interests The Broad Institute and the University of Pennsylvania have filed a patent on the described compounds related to YAP1 overexpression. A.E.C. reports receiving research funding from pharmaceutical companies in the JUMP-Cell Painting Consortium and Calico Life Sciences. A.E.C. has ownership interest and serves on the scientific advisory board for Recursion, a publicly traded biotech company using images for drug discovery. Jonathan T. Goldstein reports receiving  a commercial research grant from Bayer Amos Gutnick. Steven M. Corsello reports receiving research funding from Bayer and Calico Life Sciences.\n",
      "\n",
      "Declaration of interests The Broad Institute and the University of Pennsylvania have filed a patent on the described compounds related to YAP1 overexpression. A.E.C. reports receiving research funding from pharmaceutical companies in the JUMP-Cell Painting Consortium and Calico Life Sciences. A.E.C. has ownership interest and serves on the scientific advisory board for Recursion, a publicly traded biotech company using images for drug discovery. Jonathan T. Goldstein reports receiving  a commercial research grant from Bayer Amos Gutnick. Steven M. Corsello reports receiving research funding from Bayer and Calico Life Sciences.\n",
      "\n",
      "Declaration of interests The Broad Institute and the University of Pennsylvania have filed a patent on the described compounds related to YAP1 overexpression. A.E.C. reports receiving research funding from pharmaceutical companies in the JUMP-Cell Painting Consortium and Calico Life Sciences. A.E.C. has ownership interest and serves on the scientific advisory board for Recursion, a publicly traded biotech company using images for drug discovery. Jonathan T. Goldstein reports receiving  a commercial research grant from Bayer Amos Gutnick. Steven M. Corsello reports receiving research funding from Bayer and Calico Life Sciences.\n",
      "\n",
      "Declaration of interests The Broad Institute and the University of Pennsylvania have filed a patent on the described compounds related to YAP1 overexpression. A.E.C. reports receiving research funding from pharmaceutical companies in the JUMP-Cell Painting Consortium and Calico Life Sciences. A.E.C. has ownership interest and serves on the scientific advisory board for Recursion, a publicly traded biotech company using images for drug discovery. Jonathan T. Goldstein reports receiving  a commercial research grant from Bayer Amos Gutnick. Steven M. Corsello reports receiving research funding from Bayer and Calico Life Sciences.\n",
      "\n",
      "Declaration of interests The Broad Institute and the University of Pennsylvania have filed a patent on the described compounds related to YAP1 overexpression. A.E.C. reports receiving research funding from pharmaceutical companies in the JUMP-Cell Painting Consortium and Calico Life Sciences. A.E.C. has ownership interest and serves on the scientific advisory board for Recursion, a publicly traded biotech company using images for drug discovery. Jonathan T. Goldstein reports receiving  a commercial research grant from Bayer Amos Gutnick. Steven M. Corsello reports receiving research funding from Bayer and Calico Life Sciences.\n",
      "\n",
      "Declaration of interests The Broad Institute and the University of Pennsylvania have filed a patent on the described compounds related to YAP1 overexpression. A.E.C. reports receiving research funding from pharmaceutical companies in the JUMP-Cell Painting Consortium and Calico Life Sciences. A.E.C. has ownership interest and serves on the scientific advisory board for Recursion, a publicly traded biotech company using images for drug discovery. Jonathan T. Goldstein reports receiving  a commercial research grant from Bayer Amos Gutnick. Steven M. Corsello reports receiving research funding from Bayer and Calico Life Sciences.\n",
      "\n",
      "Declaration of interests The Broad Institute and the University of Pennsylvania have filed a patent on the described compounds related to YAP1 overexpression. A.E.C. reports receiving research funding from pharmaceutical companies in the JUMP-Cell Painting Consortium and Calico Life Sciences. A.E.C. has ownership interest and serves on the scientific advisory board for Recursion, a publicly traded biotech company using images for drug discovery. Jonathan T. Goldstein reports receiving  a commercial research grant from Bayer Amos Gutnick. Steven M. Corsello reports receiving research funding from Bayer and Calico Life Sciences.\n",
      "\n",
      "Declaration of interests The Broad Institute and the University of Pennsylvania have filed a patent on the described compounds related to YAP1 overexpression. A.E.C. reports receiving research funding from pharmaceutical companies in the JUMP-Cell Painting Consortium and Calico Life Sciences. A.E.C. has ownership interest and serves on the scientific advisory board for Recursion, a publicly traded biotech company using images for drug discovery. Jonathan T. Goldstein reports receiving  a commercial research grant from Bayer Amos Gutnick. Steven M. Corsello reports receiving research funding from Bayer and Calico Life Sciences.\n",
      "\n",
      "Declaration of interests The Broad Institute and the University of Pennsylvania have filed a patent on the described compounds related to YAP1 overexpression. A.E.C. reports receiving research funding from pharmaceutical companies in the JUMP-Cell Painting Consortium and Calico Life Sciences. A.E.C. has ownership interest and serves on the scientific advisory board for Recursion, a publicly traded biotech company using images for drug discovery. Jonathan T. Goldstein reports receiving  a commercial research grant from Bayer Amos Gutnick. Steven M. Corsello reports receiving research funding from Bayer and Calico Life Sciences.\n",
      "\n",
      "Declaration of interests The Broad Institute and the University of Pennsylvania have filed a patent on the described compounds related to YAP1 overexpression. A.E.C. reports receiving research funding from pharmaceutical companies in the JUMP-Cell Painting Consortium and Calico Life Sciences. A.E.C. has ownership interest and serves on the scientific advisory board for Recursion, a publicly traded biotech company using images for drug discovery. Jonathan T. Goldstein reports receiving  a commercial research grant from Bayer Amos Gutnick. Steven M. Corsello reports receiving research funding from Bayer and Calico Life Sciences.\n",
      "\n",
      "S Karin Eisinger-Mathason, T.\n",
      "Declaration of interests The Broad Institute and the University of Pennsylvania have filed a patent on the described compounds related to YAP1 overexpression. A.E.C. reports receiving research funding from pharmaceutical companies in the JUMP-Cell Painting Consortium and Calico Life Sciences. A.E.C. has ownership interest and serves on the scientific advisory board for Recursion, a publicly traded biotech company using images for drug discovery. Jonathan T. S Karin Eisinger-Mathason Goldstein reports receiving  a commercial research grant from Bayer Amos Gutnick. Steven M. Corsello reports receiving research funding from Bayer and Calico Life Sciences.\n",
      "\n",
      "Carpenter, Anne E.\n",
      "Declaration of interests The Broad Institute and the University of Pennsylvania have filed a patent on the described compounds related to YAP1 overexpression. Anne E. Carpenter reports receiving research funding from pharmaceutical companies in the JUMP-Cell Painting Consortium and Calico Life Sciences. Anne E. Carpenter has ownership interest and serves on the scientific advisory board for Recursion, a publicly traded biotech company using images for drug discovery. Jonathan T. S Karin Eisinger-Mathason Goldstein reports receiving  a commercial research grant from Bayer Amos Gutnick. Steven M. Corsello reports receiving research funding from Bayer and Calico Life Sciences.\n",
      "\n",
      "Declaration of Competing Interest The author has served on an advisory board for  Merck, and Roche has supported a student fellowship in the division.\n",
      "\n",
      "Wastler, Heather M.\n",
      "Declaration of competing interest Dr. Heather M. Wastler received funding from the American Foundation for Suicide Prevention during the conduct of this study. The  content of this manuscript is solely the responsibility of the authors and does not necessarily represent the official views of the American Foundation for Suicide Prevention.\n",
      "\n",
      "Declaration of competing interest Dr. Heather M. Wastler received funding from the American Foundation for Suicide Prevention during the conduct of this study. The  content of this manuscript is solely the responsibility of the authors and does not necessarily represent the official views of the American Foundation for Suicide Prevention.\n",
      "\n",
      "Declaration of competing interest Dr. Heather M. Wastler received funding from the American Foundation for Suicide Prevention during the conduct of this study. The  content of this manuscript is solely the responsibility of the authors and does not necessarily represent the official views of the American Foundation for Suicide Prevention.\n",
      "\n",
      "Teppo, Konsta\n",
      "Declaration of Competing Interest Konsta Teppo: none. Jussi Jaakkola: none. Fausto Biancari: none Olli Halminen: none. Jukka Putaala: Dr. Putaala reports personal fees from Boehringer-Ingelheim, personal fees and other from Bayer, grants and personal fees from BMS-Pfizer, personal fees from Portola, other from  Amgen, personal fees from Herantis Pharma, personal fees from Terve Media, other  from Vital Signum, personal fees from Abbott, outside the submitted work. Pirjo Mustonen: Consultant: Roche, BMS-Pfizer-alliance, Novartis Finland, Boehringer Ingelheim, MSD Finland. Miika Linna: Speaker: BMSPfizer-alliance, Bayer, Boehringer-Ingelheim. Juha Hartikainen: Research grants: The Finnish Foundation for Cardiovascular Research, EU Horizon 2020, EU FP7. Advisory Board Member: BMS-Pfizer-alliance, Novo Nordisk, Amgen. Speaker: Cardiome, Bayer. K.E. Juhani Airaksinen: Research grants: The Finnish Foundation for Cardiovascular Research;  Speaker: Bayer, Pfizer and Boehringer-Ingelheim. Member in the advisory boards: Bayer, Pfizer and AstraZeneca. Mika Lehto: Consultant: BMS-Pfizer-alliance, Bayer, Boehringer-Ingelheim, and MSD; Speaker: BMS-Pfizer-alliance, Bayer, Boehringer Ingelheim, MSD, Terve Media and Orion Pharma. Research grants: Aarne Koskelo Foundation, The Finnish Foundation for Cardiovascular Research, and Helsinki and Uusimaa Hospital District research fund, Boehringer-Ingelheim.\n",
      "\n",
      "Jaakkola, Jussi\n",
      "Declaration of Competing Interest Konsta Teppo: none. Jussi Jaakkola: none. Fausto Biancari: none Olli Halminen: none. Jukka Putaala: Dr. Putaala reports personal fees from Boehringer-Ingelheim, personal fees and other from Bayer, grants and personal fees from BMS-Pfizer, personal fees from Portola, other from  Amgen, personal fees from Herantis Pharma, personal fees from Terve Media, other  from Vital Signum, personal fees from Abbott, outside the submitted work. Pirjo Mustonen: Consultant: Roche, BMS-Pfizer-alliance, Novartis Finland, Boehringer Ingelheim, MSD Finland. Miika Linna: Speaker: BMSPfizer-alliance, Bayer, Boehringer-Ingelheim. Juha Hartikainen: Research grants: The Finnish Foundation for Cardiovascular Research, EU Horizon 2020, EU FP7. Advisory Board Member: BMS-Pfizer-alliance, Novo Nordisk, Amgen. Speaker: Cardiome, Bayer. K.E. Juhani Airaksinen: Research grants: The Finnish Foundation for Cardiovascular Research;  Speaker: Bayer, Pfizer and Boehringer-Ingelheim. Member in the advisory boards: Bayer, Pfizer and AstraZeneca. Mika Lehto: Consultant: BMS-Pfizer-alliance, Bayer, Boehringer-Ingelheim, and MSD; Speaker: BMS-Pfizer-alliance, Bayer, Boehringer Ingelheim, MSD, Terve Media and Orion Pharma. Research grants: Aarne Koskelo Foundation, The Finnish Foundation for Cardiovascular Research, and Helsinki and Uusimaa Hospital District research fund, Boehringer-Ingelheim.\n",
      "\n",
      "Biancari, Fausto\n",
      "Declaration of Competing Interest Konsta Teppo: none. Jussi Jaakkola: none. Fausto Biancari: none Olli Halminen: none. Jukka Putaala: Dr. Putaala reports personal fees from Boehringer-Ingelheim, personal fees and other from Bayer, grants and personal fees from BMS-Pfizer, personal fees from Portola, other from  Amgen, personal fees from Herantis Pharma, personal fees from Terve Media, other  from Vital Signum, personal fees from Abbott, outside the submitted work. Pirjo Mustonen: Consultant: Roche, BMS-Pfizer-alliance, Novartis Finland, Boehringer Ingelheim, MSD Finland. Miika Linna: Speaker: BMSPfizer-alliance, Bayer, Boehringer-Ingelheim. Juha Hartikainen: Research grants: The Finnish Foundation for Cardiovascular Research, EU Horizon 2020, EU FP7. Advisory Board Member: BMS-Pfizer-alliance, Novo Nordisk, Amgen. Speaker: Cardiome, Bayer. K.E. Juhani Airaksinen: Research grants: The Finnish Foundation for Cardiovascular Research;  Speaker: Bayer, Pfizer and Boehringer-Ingelheim. Member in the advisory boards: Bayer, Pfizer and AstraZeneca. Mika Lehto: Consultant: BMS-Pfizer-alliance, Bayer, Boehringer-Ingelheim, and MSD; Speaker: BMS-Pfizer-alliance, Bayer, Boehringer Ingelheim, MSD, Terve Media and Orion Pharma. Research grants: Aarne Koskelo Foundation, The Finnish Foundation for Cardiovascular Research, and Helsinki and Uusimaa Hospital District research fund, Boehringer-Ingelheim.\n",
      "\n",
      "Halminen, Olli\n",
      "Declaration of Competing Interest Konsta Teppo: none. Jussi Jaakkola: none. Fausto Biancari: none Olli Halminen: none. Jukka Putaala: Dr. Putaala reports personal fees from Boehringer-Ingelheim, personal fees and other from Bayer, grants and personal fees from BMS-Pfizer, personal fees from Portola, other from  Amgen, personal fees from Herantis Pharma, personal fees from Terve Media, other  from Vital Signum, personal fees from Abbott, outside the submitted work. Pirjo Mustonen: Consultant: Roche, BMS-Pfizer-alliance, Novartis Finland, Boehringer Ingelheim, MSD Finland. Miika Linna: Speaker: BMSPfizer-alliance, Bayer, Boehringer-Ingelheim. Juha Hartikainen: Research grants: The Finnish Foundation for Cardiovascular Research, EU Horizon 2020, EU FP7. Advisory Board Member: BMS-Pfizer-alliance, Novo Nordisk, Amgen. Speaker: Cardiome, Bayer. K.E. Juhani Airaksinen: Research grants: The Finnish Foundation for Cardiovascular Research;  Speaker: Bayer, Pfizer and Boehringer-Ingelheim. Member in the advisory boards: Bayer, Pfizer and AstraZeneca. Mika Lehto: Consultant: BMS-Pfizer-alliance, Bayer, Boehringer-Ingelheim, and MSD; Speaker: BMS-Pfizer-alliance, Bayer, Boehringer Ingelheim, MSD, Terve Media and Orion Pharma. Research grants: Aarne Koskelo Foundation, The Finnish Foundation for Cardiovascular Research, and Helsinki and Uusimaa Hospital District research fund, Boehringer-Ingelheim.\n",
      "\n",
      "Linna, Miika\n",
      "Declaration of Competing Interest Konsta Teppo: none. Jussi Jaakkola: none. Fausto Biancari: none Olli Halminen: none. Jukka Putaala: Dr. Putaala reports personal fees from Boehringer-Ingelheim, personal fees and other from Bayer, grants and personal fees from BMS-Pfizer, personal fees from Portola, other from  Amgen, personal fees from Herantis Pharma, personal fees from Terve Media, other  from Vital Signum, personal fees from Abbott, outside the submitted work. Pirjo Mustonen: Consultant: Roche, BMS-Pfizer-alliance, Novartis Finland, Boehringer Ingelheim, MSD Finland. Miika Linna: Speaker: BMSPfizer-alliance, Bayer, Boehringer-Ingelheim. Juha Hartikainen: Research grants: The Finnish Foundation for Cardiovascular Research, EU Horizon 2020, EU FP7. Advisory Board Member: BMS-Pfizer-alliance, Novo Nordisk, Amgen. Speaker: Cardiome, Bayer. K.E. Juhani Airaksinen: Research grants: The Finnish Foundation for Cardiovascular Research;  Speaker: Bayer, Pfizer and Boehringer-Ingelheim. Member in the advisory boards: Bayer, Pfizer and AstraZeneca. Mika Lehto: Consultant: BMS-Pfizer-alliance, Bayer, Boehringer-Ingelheim, and MSD; Speaker: BMS-Pfizer-alliance, Bayer, Boehringer Ingelheim, MSD, Terve Media and Orion Pharma. Research grants: Aarne Koskelo Foundation, The Finnish Foundation for Cardiovascular Research, and Helsinki and Uusimaa Hospital District research fund, Boehringer-Ingelheim.\n",
      "\n",
      "Putaala, Jukka\n",
      "Declaration of Competing Interest Konsta Teppo: none. Jussi Jaakkola: none. Fausto Biancari: none Olli Halminen: none. Jukka Putaala: Dr. Putaala reports personal fees from Boehringer-Ingelheim, personal fees and other from Bayer, grants and personal fees from BMS-Pfizer, personal fees from Portola, other from  Amgen, personal fees from Herantis Pharma, personal fees from Terve Media, other  from Vital Signum, personal fees from Abbott, outside the submitted work. Pirjo Mustonen: Consultant: Roche, BMS-Pfizer-alliance, Novartis Finland, Boehringer Ingelheim, MSD Finland. Miika Linna: Speaker: BMSPfizer-alliance, Bayer, Boehringer-Ingelheim. Juha Hartikainen: Research grants: The Finnish Foundation for Cardiovascular Research, EU Horizon 2020, EU FP7. Advisory Board Member: BMS-Pfizer-alliance, Novo Nordisk, Amgen. Speaker: Cardiome, Bayer. K.E. Juhani Airaksinen: Research grants: The Finnish Foundation for Cardiovascular Research;  Speaker: Bayer, Pfizer and Boehringer-Ingelheim. Member in the advisory boards: Bayer, Pfizer and AstraZeneca. Mika Lehto: Consultant: BMS-Pfizer-alliance, Bayer, Boehringer-Ingelheim, and MSD; Speaker: BMS-Pfizer-alliance, Bayer, Boehringer Ingelheim, MSD, Terve Media and Orion Pharma. Research grants: Aarne Koskelo Foundation, The Finnish Foundation for Cardiovascular Research, and Helsinki and Uusimaa Hospital District research fund, Boehringer-Ingelheim.\n",
      "\n",
      "Mustonen, Pirjo\n",
      "Declaration of Competing Interest Konsta Teppo: none. Jussi Jaakkola: none. Fausto Biancari: none Olli Halminen: none. Jukka Putaala: Dr. Putaala reports personal fees from Boehringer-Ingelheim, personal fees and other from Bayer, grants and personal fees from BMS-Pfizer, personal fees from Portola, other from  Amgen, personal fees from Herantis Pharma, personal fees from Terve Media, other  from Vital Signum, personal fees from Abbott, outside the submitted work. Pirjo Mustonen: Consultant: Roche, BMS-Pfizer-alliance, Novartis Finland, Boehringer Ingelheim, MSD Finland. Miika Linna: Speaker: BMSPfizer-alliance, Bayer, Boehringer-Ingelheim. Juha Hartikainen: Research grants: The Finnish Foundation for Cardiovascular Research, EU Horizon 2020, EU FP7. Advisory Board Member: BMS-Pfizer-alliance, Novo Nordisk, Amgen. Speaker: Cardiome, Bayer. K.E. Juhani Airaksinen: Research grants: The Finnish Foundation for Cardiovascular Research;  Speaker: Bayer, Pfizer and Boehringer-Ingelheim. Member in the advisory boards: Bayer, Pfizer and AstraZeneca. Mika Lehto: Consultant: BMS-Pfizer-alliance, Bayer, Boehringer-Ingelheim, and MSD; Speaker: BMS-Pfizer-alliance, Bayer, Boehringer Ingelheim, MSD, Terve Media and Orion Pharma. Research grants: Aarne Koskelo Foundation, The Finnish Foundation for Cardiovascular Research, and Helsinki and Uusimaa Hospital District research fund, Boehringer-Ingelheim.\n",
      "\n",
      "Declaration of Competing Interest Konsta Teppo: none. Jussi Jaakkola: none. Fausto Biancari: none Olli Halminen: none. Jukka Putaala: Dr. Putaala reports personal fees from Boehringer-Ingelheim, personal fees and other from Bayer, grants and personal fees from BMS-Pfizer, personal fees from Portola, other from  Amgen, personal fees from Herantis Pharma, personal fees from Terve Media, other  from Vital Signum, personal fees from Abbott, outside the submitted work. Pirjo Mustonen: Consultant: Roche, BMS-Pfizer-alliance, Novartis Finland, Boehringer Ingelheim, MSD Finland. Miika Linna: Speaker: BMSPfizer-alliance, Bayer, Boehringer-Ingelheim. Juha Hartikainen: Research grants: The Finnish Foundation for Cardiovascular Research, EU Horizon 2020, EU FP7. Advisory Board Member: BMS-Pfizer-alliance, Novo Nordisk, Amgen. Speaker: Cardiome, Bayer. K.E. Juhani Airaksinen: Research grants: The Finnish Foundation for Cardiovascular Research;  Speaker: Bayer, Pfizer and Boehringer-Ingelheim. Member in the advisory boards: Bayer, Pfizer and AstraZeneca. Mika Lehto: Consultant: BMS-Pfizer-alliance, Bayer, Boehringer-Ingelheim, and MSD; Speaker: BMS-Pfizer-alliance, Bayer, Boehringer Ingelheim, MSD, Terve Media and Orion Pharma. Research grants: Aarne Koskelo Foundation, The Finnish Foundation for Cardiovascular Research, and Helsinki and Uusimaa Hospital District research fund, Boehringer-Ingelheim.\n",
      "\n",
      "Declaration of Competing Interest Konsta Teppo: none. Jussi Jaakkola: none. Fausto Biancari: none Olli Halminen: none. Jukka Putaala: Dr. Putaala reports personal fees from Boehringer-Ingelheim, personal fees and other from Bayer, grants and personal fees from BMS-Pfizer, personal fees from Portola, other from  Amgen, personal fees from Herantis Pharma, personal fees from Terve Media, other  from Vital Signum, personal fees from Abbott, outside the submitted work. Pirjo Mustonen: Consultant: Roche, BMS-Pfizer-alliance, Novartis Finland, Boehringer Ingelheim, MSD Finland. Miika Linna: Speaker: BMSPfizer-alliance, Bayer, Boehringer-Ingelheim. Juha Hartikainen: Research grants: The Finnish Foundation for Cardiovascular Research, EU Horizon 2020, EU FP7. Advisory Board Member: BMS-Pfizer-alliance, Novo Nordisk, Amgen. Speaker: Cardiome, Bayer. K.E. Juhani Airaksinen: Research grants: The Finnish Foundation for Cardiovascular Research;  Speaker: Bayer, Pfizer and Boehringer-Ingelheim. Member in the advisory boards: Bayer, Pfizer and AstraZeneca. Mika Lehto: Consultant: BMS-Pfizer-alliance, Bayer, Boehringer-Ingelheim, and MSD; Speaker: BMS-Pfizer-alliance, Bayer, Boehringer Ingelheim, MSD, Terve Media and Orion Pharma. Research grants: Aarne Koskelo Foundation, The Finnish Foundation for Cardiovascular Research, and Helsinki and Uusimaa Hospital District research fund, Boehringer-Ingelheim.\n",
      "\n",
      "Declaration of Competing Interest Konsta Teppo: none. Jussi Jaakkola: none. Fausto Biancari: none Olli Halminen: none. Jukka Putaala: Dr. Putaala reports personal fees from Boehringer-Ingelheim, personal fees and other from Bayer, grants and personal fees from BMS-Pfizer, personal fees from Portola, other from  Amgen, personal fees from Herantis Pharma, personal fees from Terve Media, other  from Vital Signum, personal fees from Abbott, outside the submitted work. Pirjo Mustonen: Consultant: Roche, BMS-Pfizer-alliance, Novartis Finland, Boehringer Ingelheim, MSD Finland. Miika Linna: Speaker: BMSPfizer-alliance, Bayer, Boehringer-Ingelheim. Juha Hartikainen: Research grants: The Finnish Foundation for Cardiovascular Research, EU Horizon 2020, EU FP7. Advisory Board Member: BMS-Pfizer-alliance, Novo Nordisk, Amgen. Speaker: Cardiome, Bayer. K.E. Juhani Airaksinen: Research grants: The Finnish Foundation for Cardiovascular Research;  Speaker: Bayer, Pfizer and Boehringer-Ingelheim. Member in the advisory boards: Bayer, Pfizer and AstraZeneca. Mika Lehto: Consultant: BMS-Pfizer-alliance, Bayer, Boehringer-Ingelheim, and MSD; Speaker: BMS-Pfizer-alliance, Bayer, Boehringer Ingelheim, MSD, Terve Media and Orion Pharma. Research grants: Aarne Koskelo Foundation, The Finnish Foundation for Cardiovascular Research, and Helsinki and Uusimaa Hospital District research fund, Boehringer-Ingelheim.\n",
      "\n",
      "Hartikainen, Juha\n",
      "Declaration of Competing Interest Konsta Teppo: none. Jussi Jaakkola: none. Fausto Biancari: none Olli Halminen: none. Jukka Putaala: Dr. Putaala reports personal fees from Boehringer-Ingelheim, personal fees and other from Bayer, grants and personal fees from BMS-Pfizer, personal fees from Portola, other from  Amgen, personal fees from Herantis Pharma, personal fees from Terve Media, other  from Vital Signum, personal fees from Abbott, outside the submitted work. Pirjo Mustonen: Consultant: Roche, BMS-Pfizer-alliance, Novartis Finland, Boehringer Ingelheim, MSD Finland. Miika Linna: Speaker: BMSPfizer-alliance, Bayer, Boehringer-Ingelheim. Juha Hartikainen: Research grants: The Finnish Foundation for Cardiovascular Research, EU Horizon 2020, EU FP7. Advisory Board Member: BMS-Pfizer-alliance, Novo Nordisk, Amgen. Speaker: Cardiome, Bayer. K.E. Juhani Airaksinen: Research grants: The Finnish Foundation for Cardiovascular Research;  Speaker: Bayer, Pfizer and Boehringer-Ingelheim. Member in the advisory boards: Bayer, Pfizer and AstraZeneca. Mika Lehto: Consultant: BMS-Pfizer-alliance, Bayer, Boehringer-Ingelheim, and MSD; Speaker: BMS-Pfizer-alliance, Bayer, Boehringer Ingelheim, MSD, Terve Media and Orion Pharma. Research grants: Aarne Koskelo Foundation, The Finnish Foundation for Cardiovascular Research, and Helsinki and Uusimaa Hospital District research fund, Boehringer-Ingelheim.\n",
      "\n",
      "E Juhani Airaksinen, K.\n",
      "Declaration of Competing Interest Konsta Teppo: none. Jussi Jaakkola: none. Fausto Biancari: none Olli Halminen: none. Jukka Putaala: Dr. Putaala reports personal fees from Boehringer-Ingelheim, personal fees and other from Bayer, grants and personal fees from BMS-Pfizer, personal fees from Portola, other from  Amgen, personal fees from Herantis Pharma, personal fees from Terve Media, other  from Vital Signum, personal fees from Abbott, outside the submitted work. Pirjo Mustonen: Consultant: Roche, BMS-Pfizer-alliance, Novartis Finland, Boehringer Ingelheim, MSD Finland. Miika Linna: Speaker: BMSPfizer-alliance, Bayer, Boehringer-Ingelheim. Juha Hartikainen: Research grants: The Finnish Foundation for Cardiovascular Research, EU Horizon 2020, EU FP7. Advisory Board Member: BMS-Pfizer-alliance, Novo Nordisk, Amgen. Speaker: Cardiome, Bayer. K.E. Juhani K. E Juhani Airaksinen: Research grants: The Finnish Foundation for Cardiovascular Research;  Speaker: Bayer, Pfizer and Boehringer-Ingelheim. Member in the advisory boards: Bayer, Pfizer and AstraZeneca. Mika Lehto: Consultant: BMS-Pfizer-alliance, Bayer, Boehringer-Ingelheim, and MSD; Speaker: BMS-Pfizer-alliance, Bayer, Boehringer Ingelheim, MSD, Terve Media and Orion Pharma. Research grants: Aarne Koskelo Foundation, The Finnish Foundation for Cardiovascular Research, and Helsinki and Uusimaa Hospital District research fund, Boehringer-Ingelheim.\n",
      "\n",
      "Lehto, Mika\n",
      "Declaration of Competing Interest Konsta Teppo: none. Jussi Jaakkola: none. Fausto Biancari: none Olli Halminen: none. Jukka Putaala: Dr. Putaala reports personal fees from Boehringer-Ingelheim, personal fees and other from Bayer, grants and personal fees from BMS-Pfizer, personal fees from Portola, other from  Amgen, personal fees from Herantis Pharma, personal fees from Terve Media, other  from Vital Signum, personal fees from Abbott, outside the submitted work. Pirjo Mustonen: Consultant: Roche, BMS-Pfizer-alliance, Novartis Finland, Boehringer Ingelheim, MSD Finland. Miika Linna: Speaker: BMSPfizer-alliance, Bayer, Boehringer-Ingelheim. Juha Hartikainen: Research grants: The Finnish Foundation for Cardiovascular Research, EU Horizon 2020, EU FP7. Advisory Board Member: BMS-Pfizer-alliance, Novo Nordisk, Amgen. Speaker: Cardiome, Bayer. K.E. Juhani K. E Juhani Airaksinen: Research grants: The Finnish Foundation for Cardiovascular Research;  Speaker: Bayer, Pfizer and Boehringer-Ingelheim. Member in the advisory boards: Bayer, Pfizer and AstraZeneca. Mika Lehto: Consultant: BMS-Pfizer-alliance, Bayer, Boehringer-Ingelheim, and MSD; Speaker: BMS-Pfizer-alliance, Bayer, Boehringer Ingelheim, MSD, Terve Media and Orion Pharma. Research grants: Aarne Koskelo Foundation, The Finnish Foundation for Cardiovascular Research, and Helsinki and Uusimaa Hospital District research fund, Boehringer-Ingelheim.\n",
      "\n",
      "Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Adyati Pradini Yudison and Emenda Sembiring report financial support was provided by Bandung Institute of Technology.\n",
      "\n",
      "Pradini Yudison, Adyati\n",
      "Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Adyati Pradini Yudison and Emenda Sembiring report financial support was provided by Bandung Institute of Technology.\n",
      "\n",
      "Sembiring, Emenda\n",
      "Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Adyati Pradini Yudison and Emenda Sembiring report financial support was provided by Bandung Institute of Technology.\n",
      "\n",
      "Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Adyati Pradini Yudison and Emenda Sembiring report financial support was provided by Bandung Institute of Technology.\n",
      "\n",
      "Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Adyati Pradini Yudison and Emenda Sembiring report financial support was provided by Bandung Institute of Technology.\n",
      "\n",
      "Declaration of competing interest Authors Declare no conflict of interest.\n",
      "\n",
      "Declaration of competing interest Authors Declare no conflict of interest.\n",
      "\n",
      "Declaration of competing interest Authors Declare no conflict of interest.\n",
      "\n",
      "Declaration of competing interest Authors Declare no conflict of interest.\n",
      "\n",
      "Declaration of competing interest Authors Declare no conflict of interest.\n",
      "\n",
      "Declaration of competing interest Authors Declare no conflict of interest.\n",
      "\n",
      "Declaration of competing interest Authors Declare no conflict of interest.\n",
      "\n",
      "Declaration of competing interest Authors Declare no conflict of interest.\n",
      "\n",
      "Declaration of competing interest Authors Declare no conflict of interest.\n",
      "\n",
      "Sheen, Jack Z.\n",
      "Conflict of interest Jack Z. Sheen, FM, KD, TR, RZ, MH, LF, HV do not report any conflict of interest. DMB receives research support from CIHR, NIH, Brain Canada and the Temerty Family through the CAMH Foundation and the Campbell Research Institute. He received research support and in-kind equipment support for an investigator-initiated study from Brainsway Ltd. and he has been the site principal investigator for sponsor-initiated studies for Brainsway Ltd. He also receives in-kind equipment support from Magventure for investigator-initiated studies. He received medication supplies for an investigator-initiated trial from Indivior. ZJD has received research and equipment in-kind support for an investigator-initiated study through Brainsway Inc. and Magventure Inc. His work  has been supported by the Canadian Institutes of Health Research (CIHR), the National Institutes of Mental Health (NIMH), Brain Canada and the Temerty Family  and Grant Family and through the Centre for Addiction and Mental Health (CAMH) Foundation and the Campbell Institute. JD has received research support from the  Arrell Family Foundation, the Buchan Family Foundation, Brain Canada, the Canadian Biomarker Integration Network in Depression, the Canadian Institutes of  Health Research (CIHR), the Klarman Family Foundation, NIH, the Ontario Brain Institute, the Toronto General and Western Hospital Foundation, and the Weston Family Foundation; he has received travel stipends from Lundbeck and ANT Neuro; he has served as an advisor for BrainCheck, Restorative Brain Clinics, and TMS Neuro Solutions. JPM reports research grants from the Brain & Behavior Research Foundation (BBRF) Young Investigator Award and the Reseau Quebecois sur le Suicide, les troubles de l'Humeur et les troubles Associes (RQSHA) as well as salary support for his graduate studies from the Branch Out Neurological Foundation. JDG has received research support from the Labatt Family Network, the CAMH Discovery Fund, the University of Toronto EMHSeed program, and the Tri-Council Canada-UK AI Initiative.\n",
      "\n",
      "Conflict of interest Jack Z. Sheen, FM, KD, TR, RZ, MH, LF, HV do not report any conflict of interest. DMB receives research support from CIHR, NIH, Brain Canada and the Temerty Family through the CAMH Foundation and the Campbell Research Institute. He received research support and in-kind equipment support for an investigator-initiated study from Brainsway Ltd. and he has been the site principal investigator for sponsor-initiated studies for Brainsway Ltd. He also receives in-kind equipment support from Magventure for investigator-initiated studies. He received medication supplies for an investigator-initiated trial from Indivior. ZJD has received research and equipment in-kind support for an investigator-initiated study through Brainsway Inc. and Magventure Inc. His work  has been supported by the Canadian Institutes of Health Research (CIHR), the National Institutes of Mental Health (NIMH), Brain Canada and the Temerty Family  and Grant Family and through the Centre for Addiction and Mental Health (CAMH) Foundation and the Campbell Institute. JD has received research support from the  Arrell Family Foundation, the Buchan Family Foundation, Brain Canada, the Canadian Biomarker Integration Network in Depression, the Canadian Institutes of  Health Research (CIHR), the Klarman Family Foundation, NIH, the Ontario Brain Institute, the Toronto General and Western Hospital Foundation, and the Weston Family Foundation; he has received travel stipends from Lundbeck and ANT Neuro; he has served as an advisor for BrainCheck, Restorative Brain Clinics, and TMS Neuro Solutions. JPM reports research grants from the Brain & Behavior Research Foundation (BBRF) Young Investigator Award and the Reseau Quebecois sur le Suicide, les troubles de l'Humeur et les troubles Associes (RQSHA) as well as salary support for his graduate studies from the Branch Out Neurological Foundation. JDG has received research support from the Labatt Family Network, the CAMH Discovery Fund, the University of Toronto EMHSeed program, and the Tri-Council Canada-UK AI Initiative.\n",
      "\n",
      "Mansouri, Farrokh\n",
      "Conflict of interest Jack Z. Sheen, Farrokh Mansouri, KD, TR, RZ, MH, LF, HV do not report any conflict of interest. DMB receives research support from CIHR, NIH, Brain Canada and the Temerty Family through the CAMH Foundation and the Campbell Research Institute. He received research support and in-kind equipment support for an investigator-initiated study from Brainsway Ltd. and he has been the site principal investigator for sponsor-initiated studies for Brainsway Ltd. He also receives in-kind equipment support from Magventure for investigator-initiated studies. He received medication supplies for an investigator-initiated trial from Indivior. ZJD has received research and equipment in-kind support for an investigator-initiated study through Brainsway Inc. and Magventure Inc. His work  has been supported by the Canadian Institutes of Health Research (CIHR), the National Institutes of Mental Health (NIMH), Brain Canada and the Temerty Family  and Grant Family and through the Centre for Addiction and Mental Health (CAMH) Foundation and the Campbell Institute. JD has received research support from the  Arrell Family Foundation, the Buchan Family Foundation, Brain Canada, the Canadian Biomarker Integration Network in Depression, the Canadian Institutes of  Health Research (CIHR), the Klarman Family Foundation, NIH, the Ontario Brain Institute, the Toronto General and Western Hospital Foundation, and the Weston Family Foundation; he has received travel stipends from Lundbeck and ANT Neuro; he has served as an advisor for BrainCheck, Restorative Brain Clinics, and TMS Neuro Solutions. JPM reports research grants from the Brain & Behavior Research Foundation (BBRF) Young Investigator Award and the Reseau Quebecois sur le Suicide, les troubles de l'Humeur et les troubles Associes (RQSHA) as well as salary support for his graduate studies from the Branch Out Neurological Foundation. JDG has received research support from the Labatt Family Network, the CAMH Discovery Fund, the University of Toronto EMHSeed program, and the Tri-Council Canada-UK AI Initiative.\n",
      "\n",
      "Dunlop, Katherine\n",
      "Conflict of interest Jack Z. Sheen, Farrokh Mansouri, Katherine Dunlop, TR, RZ, MH, LF, HV do not report any conflict of interest. DMB receives research support from CIHR, NIH, Brain Canada and the Temerty Family through the CAMH Foundation and the Campbell Research Institute. He received research support and in-kind equipment support for an investigator-initiated study from Brainsway Ltd. and he has been the site principal investigator for sponsor-initiated studies for Brainsway Ltd. He also receives in-kind equipment support from Magventure for investigator-initiated studies. He received medication supplies for an investigator-initiated trial from Indivior. ZJD has received research and equipment in-kind support for an investigator-initiated study through Brainsway Inc. and Magventure Inc. His work  has been supported by the Canadian Institutes of Health Research (CIHR), the National Institutes of Mental Health (NIMH), Brain Canada and the Temerty Family  and Grant Family and through the Centre for Addiction and Mental Health (CAMH) Foundation and the Campbell Institute. JD has received research support from the  Arrell Family Foundation, the Buchan Family Foundation, Brain Canada, the Canadian Biomarker Integration Network in Depression, the Canadian Institutes of  Health Research (CIHR), the Klarman Family Foundation, NIH, the Ontario Brain Institute, the Toronto General and Western Hospital Foundation, and the Weston Family Foundation; he has received travel stipends from Lundbeck and ANT Neuro; he has served as an advisor for BrainCheck, Restorative Brain Clinics, and TMS Neuro Solutions. JPM reports research grants from the Brain & Behavior Research Foundation (BBRF) Young Investigator Award and the Reseau Quebecois sur le Suicide, les troubles de l'Humeur et les troubles Associes (RQSHA) as well as salary support for his graduate studies from the Branch Out Neurological Foundation. JDG has received research support from the Labatt Family Network, the CAMH Discovery Fund, the University of Toronto EMHSeed program, and the Tri-Council Canada-UK AI Initiative.\n",
      "\n",
      "Russell, Thomas\n",
      "Conflict of interest Jack Z. Sheen, Farrokh Mansouri, Katherine Dunlop, Thomas Russell, RZ, MH, LF, HV do not report any conflict of interest. DMB receives research support from CIHR, NIH, Brain Canada and the Temerty Family through the CAMH Foundation and the Campbell Research Institute. He received research support and in-kind equipment support for an investigator-initiated study from Brainsway Ltd. and he has been the site principal investigator for sponsor-initiated studies for Brainsway Ltd. He also receives in-kind equipment support from Magventure for investigator-initiated studies. He received medication supplies for an investigator-initiated trial from Indivior. ZJD has received research and equipment in-kind support for an investigator-initiated study through Brainsway Inc. and Magventure Inc. His work  has been supported by the Canadian Institutes of Health Research (CIHR), the National Institutes of Mental Health (NIMH), Brain Canada and the Temerty Family  and Grant Family and through the Centre for Addiction and Mental Health (CAMH) Foundation and the Campbell Institute. JD has received research support from the  Arrell Family Foundation, the Buchan Family Foundation, Brain Canada, the Canadian Biomarker Integration Network in Depression, the Canadian Institutes of  Health Research (CIHR), the Klarman Family Foundation, NIH, the Ontario Brain Institute, the Toronto General and Western Hospital Foundation, and the Weston Family Foundation; he has received travel stipends from Lundbeck and ANT Neuro; he has served as an advisor for BrainCheck, Restorative Brain Clinics, and TMS Neuro Solutions. JPM reports research grants from the Brain & Behavior Research Foundation (BBRF) Young Investigator Award and the Reseau Quebecois sur le Suicide, les troubles de l'Humeur et les troubles Associes (RQSHA) as well as salary support for his graduate studies from the Branch Out Neurological Foundation. JDG has received research support from the Labatt Family Network, the CAMH Discovery Fund, the University of Toronto EMHSeed program, and the Tri-Council Canada-UK AI Initiative.\n",
      "\n",
      "Zhou, Ryan\n",
      "Conflict of interest Jack Z. Sheen, Farrokh Mansouri, Katherine Dunlop, Thomas Russell, Ryan Zhou, MH, LF, HV do not report any conflict of interest. DMB receives research support from CIHR, NIH, Brain Canada and the Temerty Family through the CAMH Foundation and the Campbell Research Institute. He received research support and in-kind equipment support for an investigator-initiated study from Brainsway Ltd. and he has been the site principal investigator for sponsor-initiated studies for Brainsway Ltd. He also receives in-kind equipment support from Magventure for investigator-initiated studies. He received medication supplies for an investigator-initiated trial from Indivior. ZJD has received research and equipment in-kind support for an investigator-initiated study through Brainsway Inc. and Magventure Inc. His work  has been supported by the Canadian Institutes of Health Research (CIHR), the National Institutes of Mental Health (NIMH), Brain Canada and the Temerty Family  and Grant Family and through the Centre for Addiction and Mental Health (CAMH) Foundation and the Campbell Institute. JD has received research support from the  Arrell Family Foundation, the Buchan Family Foundation, Brain Canada, the Canadian Biomarker Integration Network in Depression, the Canadian Institutes of  Health Research (CIHR), the Klarman Family Foundation, NIH, the Ontario Brain Institute, the Toronto General and Western Hospital Foundation, and the Weston Family Foundation; he has received travel stipends from Lundbeck and ANT Neuro; he has served as an advisor for BrainCheck, Restorative Brain Clinics, and TMS Neuro Solutions. JPM reports research grants from the Brain & Behavior Research Foundation (BBRF) Young Investigator Award and the Reseau Quebecois sur le Suicide, les troubles de l'Humeur et les troubles Associes (RQSHA) as well as salary support for his graduate studies from the Branch Out Neurological Foundation. JDG has received research support from the Labatt Family Network, the CAMH Discovery Fund, the University of Toronto EMHSeed program, and the Tri-Council Canada-UK AI Initiative.\n",
      "\n",
      "Hyde, Molly\n",
      "Conflict of interest Jack Z. Sheen, Farrokh Mansouri, Katherine Dunlop, Thomas Russell, Ryan Zhou, Molly Hyde, LF, HV do not report any conflict of interest. DMB receives research support from CIHR, NIH, Brain Canada and the Temerty Family through the CAMolly Hyde Foundation and the Campbell Research Institute. He received research support and in-kind equipment support for an investigator-initiated study from Brainsway Ltd. and he has been the site principal investigator for sponsor-initiated studies for Brainsway Ltd. He also receives in-kind equipment support from Magventure for investigator-initiated studies. He received medication supplies for an investigator-initiated trial from Indivior. ZJD has received research and equipment in-kind support for an investigator-initiated study through Brainsway Inc. and Magventure Inc. His work  has been supported by the Canadian Institutes of Health Research (CIHR), the National Institutes of Mental Health (NIMolly Hyde), Brain Canada and the Temerty Family  and Grant Family and through the Centre for Addiction and Mental Health (CAMolly Hyde) Foundation and the Campbell Institute. JD has received research support from the  Arrell Family Foundation, the Buchan Family Foundation, Brain Canada, the Canadian Biomarker Integration Network in Depression, the Canadian Institutes of  Health Research (CIHR), the Klarman Family Foundation, NIH, the Ontario Brain Institute, the Toronto General and Western Hospital Foundation, and the Weston Family Foundation; he has received travel stipends from Lundbeck and ANT Neuro; he has served as an advisor for BrainCheck, Restorative Brain Clinics, and TMS Neuro Solutions. JPM reports research grants from the Brain & Behavior Research Foundation (BBRF) Young Investigator Award and the Reseau Quebecois sur le Suicide, les troubles de l'Humeur et les troubles Associes (RQSHA) as well as salary support for his graduate studies from the Branch Out Neurological Foundation. JDG has received research support from the Labatt Family Network, the CAMolly Hyde Discovery Fund, the University of Toronto EMolly HydeSeed program, and the Tri-Council Canada-UK AI Initiative.\n",
      "\n",
      "Fox, Linsay\n",
      "Conflict of interest Jack Z. Sheen, Farrokh Mansouri, Katherine Dunlop, Thomas Russell, Ryan Zhou, Molly Hyde, Linsay Fox, HV do not report any conflict of interest. DMB receives research support from CIHR, NIH, Brain Canada and the Temerty Family through the CAMolly Hyde Foundation and the Campbell Research Institute. He received research support and in-kind equipment support for an investigator-initiated study from Brainsway Ltd. and he has been the site principal investigator for sponsor-initiated studies for Brainsway Ltd. He also receives in-kind equipment support from Magventure for investigator-initiated studies. He received medication supplies for an investigator-initiated trial from Indivior. ZJD has received research and equipment in-kind support for an investigator-initiated study through Brainsway Inc. and Magventure Inc. His work  has been supported by the Canadian Institutes of Health Research (CIHR), the National Institutes of Mental Health (NIMolly Hyde), Brain Canada and the Temerty Family  and Grant Family and through the Centre for Addiction and Mental Health (CAMolly Hyde) Foundation and the Campbell Institute. JD has received research support from the  Arrell Family Foundation, the Buchan Family Foundation, Brain Canada, the Canadian Biomarker Integration Network in Depression, the Canadian Institutes of  Health Research (CIHR), the Klarman Family Foundation, NIH, the Ontario Brain Institute, the Toronto General and Western Hospital Foundation, and the Weston Family Foundation; he has received travel stipends from Lundbeck and ANT Neuro; he has served as an advisor for BrainCheck, Restorative Brain Clinics, and TMS Neuro Solutions. JPM reports research grants from the Brain & Behavior Research Foundation (BBRF) Young Investigator Award and the Reseau Quebecois sur le Suicide, les troubles de l'Humeur et les troubles Associes (RQSHA) as well as salary support for his graduate studies from the Branch Out Neurological Foundation. JDG has received research support from the Labatt Family Network, the CAMolly Hyde Discovery Fund, the University of Toronto EMolly HydeSeed program, and the Tri-Council Canada-UK AI Initiative.\n",
      "\n",
      "Votterl, Helena\n",
      "Conflict of interest Jack Z. Sheen, Farrokh Mansouri, Katherine Dunlop, Thomas Russell, Ryan Zhou, Molly Hyde, Linsay Fox, Helena Votterl do not report any conflict of interest. DMB receives research support from CIHR, NIH, Brain Canada and the Temerty Family through the CAMolly Hyde Foundation and the Campbell Research Institute. He received research support and in-kind equipment support for an investigator-initiated study from Brainsway Ltd. and he has been the site principal investigator for sponsor-initiated studies for Brainsway Ltd. He also receives in-kind equipment support from Magventure for investigator-initiated studies. He received medication supplies for an investigator-initiated trial from Indivior. ZJD has received research and equipment in-kind support for an investigator-initiated study through Brainsway Inc. and Magventure Inc. His work  has been supported by the Canadian Institutes of Health Research (CIHR), the National Institutes of Mental Health (NIMolly Hyde), Brain Canada and the Temerty Family  and Grant Family and through the Centre for Addiction and Mental Health (CAMolly Hyde) Foundation and the Campbell Institute. JD has received research support from the  Arrell Family Foundation, the Buchan Family Foundation, Brain Canada, the Canadian Biomarker Integration Network in Depression, the Canadian Institutes of  Health Research (CIHR), the Klarman Family Foundation, NIH, the Ontario Brain Institute, the Toronto General and Western Hospital Foundation, and the Weston Family Foundation; he has received travel stipends from Lundbeck and ANT Neuro; he has served as an advisor for BrainCheck, Restorative Brain Clinics, and TMS Neuro Solutions. JPM reports research grants from the Brain & Behavior Research Foundation (BBRF) Young Investigator Award and the Reseau Quebecois sur le Suicide, les troubles de l'Humeur et les troubles Associes (RQSHA) as well as salary support for his graduate studies from the Branch Out Neurological Foundation. JDG has received research support from the Labatt Family Network, the CAMolly Hyde Discovery Fund, the University of Toronto EMolly HydeSeed program, and the Tri-Council Canada-UK AI Initiative.\n",
      "\n",
      "Daskalakis, Zafiris J.\n",
      "Conflict of interest Jack Z. Sheen, Farrokh Mansouri, Katherine Dunlop, Thomas Russell, Ryan Zhou, Molly Hyde, Linsay Fox, Helena Votterl do not report any conflict of interest. DMB receives research support from CIHR, NIH, Brain Canada and the Temerty Family through the CAMolly Hyde Foundation and the Campbell Research Institute. He received research support and in-kind equipment support for an investigator-initiated study from Brainsway Ltd. and he has been the site principal investigator for sponsor-initiated studies for Brainsway Ltd. He also receives in-kind equipment support from Magventure for investigator-initiated studies. He received medication supplies for an investigator-initiated trial from Indivior. Zafiris J. Daskalakis has received research and equipment in-kind support for an investigator-initiated study through Brainsway Inc. and Magventure Inc. His work  has been supported by the Canadian Institutes of Health Research (CIHR), the National Institutes of Mental Health (NIMolly Hyde), Brain Canada and the Temerty Family  and Grant Family and through the Centre for Addiction and Mental Health (CAMolly Hyde) Foundation and the Campbell Institute. JD has received research support from the  Arrell Family Foundation, the Buchan Family Foundation, Brain Canada, the Canadian Biomarker Integration Network in Depression, the Canadian Institutes of  Health Research (CIHR), the Klarman Family Foundation, NIH, the Ontario Brain Institute, the Toronto General and Western Hospital Foundation, and the Weston Family Foundation; he has received travel stipends from Lundbeck and ANT Neuro; he has served as an advisor for BrainCheck, Restorative Brain Clinics, and TMS Neuro Solutions. JPM reports research grants from the Brain & Behavior Research Foundation (BBRF) Young Investigator Award and the Reseau Quebecois sur le Suicide, les troubles de l'Humeur et les troubles Associes (RQSHA) as well as salary support for his graduate studies from the Branch Out Neurological Foundation. JDG has received research support from the Labatt Family Network, the CAMolly Hyde Discovery Fund, the University of Toronto EMolly HydeSeed program, and the Tri-Council Canada-UK AI Initiative.\n",
      "\n",
      "Griffiths, John D.\n",
      "Conflict of interest Jack Z. Sheen, Farrokh Mansouri, Katherine Dunlop, Thomas Russell, Ryan Zhou, Molly Hyde, Linsay Fox, Helena Votterl do not report any conflict of interest. DMB receives research support from CIHR, NIH, Brain Canada and the Temerty Family through the CAMolly Hyde Foundation and the Campbell Research Institute. He received research support and in-kind equipment support for an investigator-initiated study from Brainsway Ltd. and he has been the site principal investigator for sponsor-initiated studies for Brainsway Ltd. He also receives in-kind equipment support from Magventure for investigator-initiated studies. He received medication supplies for an investigator-initiated trial from Indivior. Zafiris J. Daskalakis has received research and equipment in-kind support for an investigator-initiated study through Brainsway Inc. and Magventure Inc. His work  has been supported by the Canadian Institutes of Health Research (CIHR), the National Institutes of Mental Health (NIMolly Hyde), Brain Canada and the Temerty Family  and Grant Family and through the Centre for Addiction and Mental Health (CAMolly Hyde) Foundation and the Campbell Institute. JD has received research support from the  Arrell Family Foundation, the Buchan Family Foundation, Brain Canada, the Canadian Biomarker Integration Network in Depression, the Canadian Institutes of  Health Research (CIHR), the Klarman Family Foundation, NIH, the Ontario Brain Institute, the Toronto General and Western Hospital Foundation, and the Weston Family Foundation; he has received travel stipends from Lundbeck and ANT Neuro; he has served as an advisor for BrainCheck, Restorative Brain Clinics, and TMS Neuro Solutions. JPM reports research grants from the Brain & Behavior Research Foundation (BBRF) Young Investigator Award and the Reseau Quebecois sur le Suicide, les troubles de l'Humeur et les troubles Associes (RQSHA) as well as salary support for his graduate studies from the Branch Out Neurological Foundation. John D. Griffiths has received research support from the Labatt Family Network, the CAMolly Hyde Discovery Fund, the University of Toronto EMolly HydeSeed program, and the Tri-Council Canada-UK AI Initiative.\n",
      "\n",
      "Blumberger, Daniel M.\n",
      "Conflict of interest Jack Z. Sheen, Farrokh Mansouri, Katherine Dunlop, Thomas Russell, Ryan Zhou, Molly Hyde, Linsay Fox, Helena Votterl do not report any conflict of interest. Daniel M. Blumberger receives research support from CIHR, NIH, Brain Canada and the Temerty Family through the CAMolly Hyde Foundation and the Campbell Research Institute. He received research support and in-kind equipment support for an investigator-initiated study from Brainsway Ltd. and he has been the site principal investigator for sponsor-initiated studies for Brainsway Ltd. He also receives in-kind equipment support from Magventure for investigator-initiated studies. He received medication supplies for an investigator-initiated trial from Indivior. Zafiris J. Daskalakis has received research and equipment in-kind support for an investigator-initiated study through Brainsway Inc. and Magventure Inc. His work  has been supported by the Canadian Institutes of Health Research (CIHR), the National Institutes of Mental Health (NIMolly Hyde), Brain Canada and the Temerty Family  and Grant Family and through the Centre for Addiction and Mental Health (CAMolly Hyde) Foundation and the Campbell Institute. JD has received research support from the  Arrell Family Foundation, the Buchan Family Foundation, Brain Canada, the Canadian Biomarker Integration Network in Depression, the Canadian Institutes of  Health Research (CIHR), the Klarman Family Foundation, NIH, the Ontario Brain Institute, the Toronto General and Western Hospital Foundation, and the Weston Family Foundation; he has received travel stipends from Lundbeck and ANT Neuro; he has served as an advisor for BrainCheck, Restorative Brain Clinics, and TMS Neuro Solutions. JPM reports research grants from the Brain & Behavior Research Foundation (BBRF) Young Investigator Award and the Reseau Quebecois sur le Suicide, les troubles de l'Humeur et les troubles Associes (RQSHA) as well as salary support for his graduate studies from the Branch Out Neurological Foundation. John D. Griffiths has received research support from the Labatt Family Network, the CAMolly Hyde Discovery Fund, the University of Toronto EMolly HydeSeed program, and the Tri-Council Canada-UK AI Initiative.\n",
      "\n",
      "Downar, Jonathan\n",
      "Conflict of interest Jack Z. Sheen, Farrokh Mansouri, Katherine Dunlop, Thomas Russell, Ryan Zhou, Molly Hyde, Linsay Fox, Helena Votterl do not report any conflict of interest. Daniel M. Blumberger receives research support from CIHR, NIH, Brain Canada and the Temerty Family through the CAMolly Hyde Foundation and the Campbell Research Institute. He received research support and in-kind equipment support for an investigator-initiated study from Brainsway Ltd. and he has been the site principal investigator for sponsor-initiated studies for Brainsway Ltd. He also receives in-kind equipment support from Magventure for investigator-initiated studies. He received medication supplies for an investigator-initiated trial from Indivior. Zafiris J. Daskalakis has received research and equipment in-kind support for an investigator-initiated study through Brainsway Inc. and Magventure Inc. His work  has been supported by the Canadian Institutes of Health Research (CIHR), the National Institutes of Mental Health (NIMolly Hyde), Brain Canada and the Temerty Family  and Grant Family and through the Centre for Addiction and Mental Health (CAMolly Hyde) Foundation and the Campbell Institute. Jonathan Downar has received research support from the  Arrell Family Foundation, the Buchan Family Foundation, Brain Canada, the Canadian Biomarker Integration Network in Depression, the Canadian Institutes of  Health Research (CIHR), the Klarman Family Foundation, NIH, the Ontario Brain Institute, the Toronto General and Western Hospital Foundation, and the Weston Family Foundation; he has received travel stipends from Lundbeck and ANT Neuro; he has served as an advisor for BrainCheck, Restorative Brain Clinics, and TMS Neuro Solutions. JPM reports research grants from the Brain & Behavior Research Foundation (BBRF) Young Investigator Award and the Reseau Quebecois sur le Suicide, les troubles de l'Humeur et les troubles Associes (RQSHA) as well as salary support for his graduate studies from the Branch Out Neurological Foundation. John D. Griffiths has received research support from the Labatt Family Network, the CAMolly Hyde Discovery Fund, the University of Toronto EMolly HydeSeed program, and the Tri-Council Canada-UK AI Initiative.\n",
      "\n",
      "Conflict of interest KH declare grants from the National Institute for Health Research and the Department of Health and Social Care. He is a member of the National Suicide Prevention Strategy for England Advisory Group. KH is a National Institute for Health Research (NIHR) Senior Investigator (Emeritus). NK is a member of the Department of Health's National Suicide Prevention Advisory Group.  NK chaired the NICE guideline development group for the longer-term management of self-harm and is currently Topic Advisor for the new NICE self-harm guideline. He also chairs the NICE guideline committee for depression in adults. All other authors declare no competing interests. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR, or the Department of Health and Social Care.\n",
      "\n",
      "Conflict of interest KH declare grants from the National Institute for Health Research and the Department of Health and Social Care. He is a member of the National Suicide Prevention Strategy for England Advisory Group. KH is a National Institute for Health Research (NIHR) Senior Investigator (Emeritus). NK is a member of the Department of Health's National Suicide Prevention Advisory Group.  NK chaired the NICE guideline development group for the longer-term management of self-harm and is currently Topic Advisor for the new NICE self-harm guideline. He also chairs the NICE guideline committee for depression in adults. All other authors declare no competing interests. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR, or the Department of Health and Social Care.\n",
      "\n",
      "Conflict of interest KH declare grants from the National Institute for Health Research and the Department of Health and Social Care. He is a member of the National Suicide Prevention Strategy for England Advisory Group. KH is a National Institute for Health Research (NIHR) Senior Investigator (Emeritus). NK is a member of the Department of Health's National Suicide Prevention Advisory Group.  NK chaired the NICE guideline development group for the longer-term management of self-harm and is currently Topic Advisor for the new NICE self-harm guideline. He also chairs the NICE guideline committee for depression in adults. All other authors declare no competing interests. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR, or the Department of Health and Social Care.\n",
      "\n",
      "Conflict of interest KH declare grants from the National Institute for Health Research and the Department of Health and Social Care. He is a member of the National Suicide Prevention Strategy for England Advisory Group. KH is a National Institute for Health Research (NIHR) Senior Investigator (Emeritus). NK is a member of the Department of Health's National Suicide Prevention Advisory Group.  NK chaired the NICE guideline development group for the longer-term management of self-harm and is currently Topic Advisor for the new NICE self-harm guideline. He also chairs the NICE guideline committee for depression in adults. All other authors declare no competing interests. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR, or the Department of Health and Social Care.\n",
      "\n",
      "Conflict of interest KH declare grants from the National Institute for Health Research and the Department of Health and Social Care. He is a member of the National Suicide Prevention Strategy for England Advisory Group. KH is a National Institute for Health Research (NIHR) Senior Investigator (Emeritus). NK is a member of the Department of Health's National Suicide Prevention Advisory Group.  NK chaired the NICE guideline development group for the longer-term management of self-harm and is currently Topic Advisor for the new NICE self-harm guideline. He also chairs the NICE guideline committee for depression in adults. All other authors declare no competing interests. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR, or the Department of Health and Social Care.\n",
      "\n",
      "Conflict of interest KH declare grants from the National Institute for Health Research and the Department of Health and Social Care. He is a member of the National Suicide Prevention Strategy for England Advisory Group. KH is a National Institute for Health Research (NIHR) Senior Investigator (Emeritus). NK is a member of the Department of Health's National Suicide Prevention Advisory Group.  NK chaired the NICE guideline development group for the longer-term management of self-harm and is currently Topic Advisor for the new NICE self-harm guideline. He also chairs the NICE guideline committee for depression in adults. All other authors declare no competing interests. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR, or the Department of Health and Social Care.\n",
      "\n",
      "Kapur, Nav\n",
      "Conflict of interest KH declare grants from the National Institute for Health Research and the Department of Health and Social Care. He is a member of the National Suicide Prevention Strategy for England Advisory Group. KH is a National Institute for Health Research (NIHR) Senior Investigator (Emeritus). Nav Kapur is a member of the Department of Health's National Suicide Prevention Advisory Group.  Nav Kapur chaired the NICE guideline development group for the longer-term management of self-harm and is currently Topic Advisor for the new NICE self-harm guideline. He also chairs the NICE guideline committee for depression in adults. All other authors declare no competing interests. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR, or the Department of Health and Social Care.\n",
      "\n",
      "Conflict of interest KH declare grants from the National Institute for Health Research and the Department of Health and Social Care. He is a member of the National Suicide Prevention Strategy for England Advisory Group. KH is a National Institute for Health Research (NIHR) Senior Investigator (Emeritus). Nav Kapur is a member of the Department of Health's National Suicide Prevention Advisory Group.  Nav Kapur chaired the NICE guideline development group for the longer-term management of self-harm and is currently Topic Advisor for the new NICE self-harm guideline. He also chairs the NICE guideline committee for depression in adults. All other authors declare no competing interests. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR, or the Department of Health and Social Care.\n",
      "\n",
      "Conflict of interest KH declare grants from the National Institute for Health Research and the Department of Health and Social Care. He is a member of the National Suicide Prevention Strategy for England Advisory Group. KH is a National Institute for Health Research (NIHR) Senior Investigator (Emeritus). Nav Kapur is a member of the Department of Health's National Suicide Prevention Advisory Group.  Nav Kapur chaired the NICE guideline development group for the longer-term management of self-harm and is currently Topic Advisor for the new NICE self-harm guideline. He also chairs the NICE guideline committee for depression in adults. All other authors declare no competing interests. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR, or the Department of Health and Social Care.\n",
      "\n",
      "Conflict of interest KH declare grants from the National Institute for Health Research and the Department of Health and Social Care. He is a member of the National Suicide Prevention Strategy for England Advisory Group. KH is a National Institute for Health Research (NIHR) Senior Investigator (Emeritus). Nav Kapur is a member of the Department of Health's National Suicide Prevention Advisory Group.  Nav Kapur chaired the NICE guideline development group for the longer-term management of self-harm and is currently Topic Advisor for the new NICE self-harm guideline. He also chairs the NICE guideline committee for depression in adults. All other authors declare no competing interests. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR, or the Department of Health and Social Care.\n",
      "\n",
      "Hawton, Keith\n",
      "Conflict of interest Keith Hawton declare grants from the National Institute for Health Research and the Department of Health and Social Care. He is a member of the National Suicide Prevention Strategy for England Advisory Group. Keith Hawton is a National Institute for Health Research (NIHR) Senior Investigator (Emeritus). Nav Kapur is a member of the Department of Health's National Suicide Prevention Advisory Group.  Nav Kapur chaired the NICE guideline development group for the longer-term management of self-harm and is currently Topic Advisor for the new NICE self-harm guideline. He also chairs the NICE guideline committee for depression in adults. All other authors declare no competing interests. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR, or the Department of Health and Social Care.\n",
      "\n",
      "Groves, Samantha J.\n",
      "Declaration of competing interest KD, Samantha J. Groves, CB, and RP use software provided free-of-charge by Scientific Brain Training Pro for Cognitive Remediation trials. RP has received support for travel to educational meetings from Servier and Lundbeck. CB has grant support from Lundbeck, Takeda, and Pfizer and has received consulting fees from Boehringer Ingelheim, Pfizer, and Lundbeck.\n",
      "\n",
      "Douglas, Katie M.\n",
      "Declaration of competing interest Katie M. Douglas, Samantha J. Groves, CB, and RP use software provided free-of-charge by Scientific Brain Training Pro for Cognitive Remediation trials. RP has received support for travel to educational meetings from Servier and Lundbeck. CB has grant support from Lundbeck, Takeda, and Pfizer and has received consulting fees from Boehringer Ingelheim, Pfizer, and Lundbeck.\n",
      "\n",
      "Declaration of competing interest Katie M. Douglas, Samantha J. Groves, CB, and RP use software provided free-of-charge by Scientific Brain Training Pro for Cognitive Remediation trials. RP has received support for travel to educational meetings from Servier and Lundbeck. CB has grant support from Lundbeck, Takeda, and Pfizer and has received consulting fees from Boehringer Ingelheim, Pfizer, and Lundbeck.\n",
      "\n",
      "Declaration of competing interest Katie M. Douglas, Samantha J. Groves, CB, and RP use software provided free-of-charge by Scientific Brain Training Pro for Cognitive Remediation trials. RP has received support for travel to educational meetings from Servier and Lundbeck. CB has grant support from Lundbeck, Takeda, and Pfizer and has received consulting fees from Boehringer Ingelheim, Pfizer, and Lundbeck.\n",
      "\n",
      "Declaration of competing interest Katie M. Douglas, Samantha J. Groves, CB, and RP use software provided free-of-charge by Scientific Brain Training Pro for Cognitive Remediation trials. RP has received support for travel to educational meetings from Servier and Lundbeck. CB has grant support from Lundbeck, Takeda, and Pfizer and has received consulting fees from Boehringer Ingelheim, Pfizer, and Lundbeck.\n",
      "\n",
      "Declaration of competing interest Katie M. Douglas, Samantha J. Groves, CB, and RP use software provided free-of-charge by Scientific Brain Training Pro for Cognitive Remediation trials. RP has received support for travel to educational meetings from Servier and Lundbeck. CB has grant support from Lundbeck, Takeda, and Pfizer and has received consulting fees from Boehringer Ingelheim, Pfizer, and Lundbeck.\n",
      "\n",
      "Declaration of competing interest Katie M. Douglas, Samantha J. Groves, CB, and RP use software provided free-of-charge by Scientific Brain Training Pro for Cognitive Remediation trials. RP has received support for travel to educational meetings from Servier and Lundbeck. CB has grant support from Lundbeck, Takeda, and Pfizer and has received consulting fees from Boehringer Ingelheim, Pfizer, and Lundbeck.\n",
      "\n",
      "Declaration of competing interest Katie M. Douglas, Samantha J. Groves, CB, and RP use software provided free-of-charge by Scientific Brain Training Pro for Cognitive Remediation trials. RP has received support for travel to educational meetings from Servier and Lundbeck. CB has grant support from Lundbeck, Takeda, and Pfizer and has received consulting fees from Boehringer Ingelheim, Pfizer, and Lundbeck.\n",
      "\n",
      "Porter, Richard J.\n",
      "Declaration of competing interest Katie M. Douglas, Samantha J. Groves, CB, and Richard J. Porter use software provided free-of-charge by Scientific Brain Training Pro for Cognitive Remediation trials. Richard J. Porter has received support for travel to educational meetings from Servier and Lundbeck. CB has grant support from Lundbeck, Takeda, and Pfizer and has received consulting fees from Boehringer Ingelheim, Pfizer, and Lundbeck.\n",
      "\n",
      "Conflict of interest Dr. Ressler has received consulting fees or sponsored research support from Alkermes, BrainsWay, and Genomind, and he serves on scientific advisory boards for Janssen, Takeda, and Verily. The other authors report no financial relationships with commercial interests.\n",
      "\n",
      "Conflict of interest Dr. Ressler has received consulting fees or sponsored research support from Alkermes, BrainsWay, and Genomind, and he serves on scientific advisory boards for Janssen, Takeda, and Verily. The other authors report no financial relationships with commercial interests.\n",
      "\n",
      "Conflict of interest Dr. Ressler has received consulting fees or sponsored research support from Alkermes, BrainsWay, and Genomind, and he serves on scientific advisory boards for Janssen, Takeda, and Verily. The other authors report no financial relationships with commercial interests.\n",
      "\n",
      "Conflict of interest Dr. Ressler has received consulting fees or sponsored research support from Alkermes, BrainsWay, and Genomind, and he serves on scientific advisory boards for Janssen, Takeda, and Verily. The other authors report no financial relationships with commercial interests.\n",
      "\n",
      "Conflict of interest Dr. Ressler has received consulting fees or sponsored research support from Alkermes, BrainsWay, and Genomind, and he serves on scientific advisory boards for Janssen, Takeda, and Verily. The other authors report no financial relationships with commercial interests.\n",
      "\n",
      "Conflict of interest Dr. Ressler has received consulting fees or sponsored research support from Alkermes, BrainsWay, and Genomind, and he serves on scientific advisory boards for Janssen, Takeda, and Verily. The other authors report no financial relationships with commercial interests.\n",
      "\n",
      "Ressler, Kerry J.\n",
      "Conflict of interest Dr. Kerry J. Ressler has received consulting fees or sponsored research support from Alkermes, BrainsWay, and Genomind, and he serves on scientific advisory boards for Janssen, Takeda, and Verily. The other authors report no financial relationships with commercial interests.\n",
      "\n",
      "Conflict of interest Dr. Kerry J. Ressler has received consulting fees or sponsored research support from Alkermes, BrainsWay, and Genomind, and he serves on scientific advisory boards for Janssen, Takeda, and Verily. The other authors report no financial relationships with commercial interests.\n",
      "\n",
      "Conflict of interest Dr. Kerry J. Ressler has received consulting fees or sponsored research support from Alkermes, BrainsWay, and Genomind, and he serves on scientific advisory boards for Janssen, Takeda, and Verily. The other authors report no financial relationships with commercial interests.\n",
      "\n",
      "Declaration of Competing Interest This report contains work supported by UKHSA Grant-in-Aid. The contents of this paper, including any opinions and/or conclusions expressed, are those of the authors alone and do not necessarily reflect UK Health Security Agency policy.\n",
      "\n",
      "Declaration of Competing Interest This report contains work supported by UKHSA Grant-in-Aid. The contents of this paper, including any opinions and/or conclusions expressed, are those of the authors alone and do not necessarily reflect UK Health Security Agency policy.\n",
      "\n",
      "Declaration of Competing Interest This report contains work supported by UKHSA Grant-in-Aid. The contents of this paper, including any opinions and/or conclusions expressed, are those of the authors alone and do not necessarily reflect UK Health Security Agency policy.\n",
      "\n",
      "Declaration of Competing Interest This report contains work supported by UKHSA Grant-in-Aid. The contents of this paper, including any opinions and/or conclusions expressed, are those of the authors alone and do not necessarily reflect UK Health Security Agency policy.\n",
      "\n",
      "Declaration of Competing Interest This report contains work supported by UKHSA Grant-in-Aid. The contents of this paper, including any opinions and/or conclusions expressed, are those of the authors alone and do not necessarily reflect UK Health Security Agency policy.\n",
      "\n",
      "Declaration of Competing Interest This report contains work supported by UKHSA Grant-in-Aid. The contents of this paper, including any opinions and/or conclusions expressed, are those of the authors alone and do not necessarily reflect UK Health Security Agency policy.\n",
      "\n",
      "Declaration of Competing Interest This report contains work supported by UKHSA Grant-in-Aid. The contents of this paper, including any opinions and/or conclusions expressed, are those of the authors alone and do not necessarily reflect UK Health Security Agency policy.\n",
      "\n",
      "Declaration of Competing Interest This report contains work supported by UKHSA Grant-in-Aid. The contents of this paper, including any opinions and/or conclusions expressed, are those of the authors alone and do not necessarily reflect UK Health Security Agency policy.\n",
      "\n",
      "Declaration of Competing Interest This report contains work supported by UKHSA Grant-in-Aid. The contents of this paper, including any opinions and/or conclusions expressed, are those of the authors alone and do not necessarily reflect UK Health Security Agency policy.\n",
      "\n",
      "Declaration of Competing Interest This report contains work supported by UKHSA Grant-in-Aid. The contents of this paper, including any opinions and/or conclusions expressed, are those of the authors alone and do not necessarily reflect UK Health Security Agency policy.\n",
      "\n",
      "Declaration of Competing Interest This report contains work supported by UKHSA Grant-in-Aid. The contents of this paper, including any opinions and/or conclusions expressed, are those of the authors alone and do not necessarily reflect UK Health Security Agency policy.\n",
      "\n",
      "Conflict of Interest None\n",
      "\n",
      "Conflict of Interest None\n",
      "\n",
      "Conflict of Interest None\n",
      "\n",
      "Conflict of Interest None\n",
      "\n",
      "Conflict of Interest None\n",
      "\n",
      "Conflict of Interest None\n",
      "\n",
      "Conflict of Interest None\n",
      "\n",
      "Ma, Junpeng\n",
      "Declarations of Interest The author Weikang Junpeng Mao is employed by the LC-BIO TECHNOLOGIES (HANGZHOU) CO., LTD., China. The remaining authors declare that the  research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.\n",
      "\n",
      "Declarations of Interest The author Weikang Junpeng Mao is employed by the LC-BIO TECHNOLOGIES (HANGZHOU) CO., LTD., China. The remaining authors declare that the  research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.\n",
      "\n",
      "Declarations of Interest The author Weikang Junpeng Mao is employed by the LC-BIO TECHNOLOGIES (HANGZHOU) CO., LTD., China. The remaining authors declare that the  research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.\n",
      "\n",
      "Mao, Weikang\n",
      "Declarations of Interest The author Weikang Junpeng Weikang Mao is employed by the LC-BIO TECHNOLOGIES (HANGZHOU) CO., LTD., China. The remaining authors declare that the  research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.\n",
      "\n",
      "Declarations of Interest The author Weikang Junpeng Weikang Mao is employed by the LC-BIO TECHNOLOGIES (HANGZHOU) CO., LTD., China. The remaining authors declare that the  research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.\n",
      "\n",
      "Declarations of Interest The author Weikang Junpeng Weikang Mao is employed by the LC-BIO TECHNOLOGIES (HANGZHOU) CO., LTD., China. The remaining authors declare that the  research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.\n",
      "\n",
      "Declarations of Interest The author Weikang Junpeng Weikang Mao is employed by the LC-BIO TECHNOLOGIES (HANGZHOU) CO., LTD., China. The remaining authors declare that the  research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.\n",
      "\n",
      "Declarations of Interest The author Weikang Junpeng Weikang Mao is employed by the LC-BIO TECHNOLOGIES (HANGZHOU) CO., LTD., China. The remaining authors declare that the  research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.\n",
      "\n",
      "Declarations of Interest The author Weikang Junpeng Weikang Mao is employed by the LC-BIO TECHNOLOGIES (HANGZHOU) CO., LTD., China. The remaining authors declare that the  research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.\n",
      "\n",
      "Declarations of Interest The author Weikang Junpeng Weikang Mao is employed by the LC-BIO TECHNOLOGIES (HANGZHOU) CO., LTD., China. The remaining authors declare that the  research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.\n",
      "\n",
      "Declarations of Interest The author Weikang Junpeng Weikang Mao is employed by the LC-BIO TECHNOLOGIES (HANGZHOU) CO., LTD., China. The remaining authors declare that the  research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.\n",
      "\n",
      "Declarations of Interest The author Weikang Junpeng Weikang Mao is employed by the LC-BIO TECHNOLOGIES (HANGZHOU) CO., LTD., China. The remaining authors declare that the  research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.\n",
      "\n",
      "Declarations of Interest The author Weikang Junpeng Weikang Mao is employed by the LC-BIO TECHNOLOGIES (HANGZHOU) CO., LTD., China. The remaining authors declare that the  research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.\n",
      "\n",
      "Declarations of Interest The author Weikang Junpeng Weikang Mao is employed by the LC-BIO TECHNOLOGIES (HANGZHOU) CO., LTD., China. The remaining authors declare that the  research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.\n",
      "\n",
      "Kari Kvernebo, Anne\n",
      "Declaration of competing interest The ODIN concept is patented in Japan and USA and is pending Europe. Kvernebo K is founder, shareholder and CMO of ODI Medical  AS. ODI Medical AS has provided the analysis algorithms used in this study. Anne Kari Kvernebo is related to Kvernebo K. Luigino Capone is currently employed by ODI Medical. Remaining authors have no financial conflicts of interest.\n",
      "\n",
      "Declaration of competing interest The ODIN concept is patented in Japan and USA and is pending Europe. Kvernebo K is founder, shareholder and CMO of ODI Medical  AS. ODI Medical AS has provided the analysis algorithms used in this study. Anne Kari Kvernebo is related to Kvernebo K. Luigino Capone is currently employed by ODI Medical. Remaining authors have no financial conflicts of interest.\n",
      "\n",
      "Declaration of competing interest The ODIN concept is patented in Japan and USA and is pending Europe. Kvernebo K is founder, shareholder and CMO of ODI Medical  AS. ODI Medical AS has provided the analysis algorithms used in this study. Anne Kari Kvernebo is related to Kvernebo K. Luigino Capone is currently employed by ODI Medical. Remaining authors have no financial conflicts of interest.\n",
      "\n",
      "Capone, Luigino\n",
      "Declaration of competing interest The ODIN concept is patented in Japan and USA and is pending Europe. Kvernebo K is founder, shareholder and CMO of ODI Medical  AS. ODI Medical AS has provided the analysis algorithms used in this study. Anne Kari Kvernebo is related to Kvernebo K. Luigino Capone is currently employed by ODI Medical. Remaining authors have no financial conflicts of interest.\n",
      "\n",
      "Declaration of competing interest The ODIN concept is patented in Japan and USA and is pending Europe. Kvernebo K is founder, shareholder and CMO of ODI Medical  AS. ODI Medical AS has provided the analysis algorithms used in this study. Anne Kari Kvernebo is related to Kvernebo K. Luigino Capone is currently employed by ODI Medical. Remaining authors have no financial conflicts of interest.\n",
      "\n",
      "Kvernebo, Knut\n",
      "Declaration of competing interest The ODIN concept is patented in Japan and USA and is pending Europe. Kvernebo K is founder, shareholder and CMO of ODI Medical  AS. ODI Medical AS has provided the analysis algorithms used in this study. Anne Kari Kvernebo is related to Knut Kvernebo Luigino Capone is currently employed by ODI Medical. Remaining authors have no financial conflicts of interest.\n",
      "\n",
      "Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Raj Kumar reports financial support and administrative support were provided by Central University of Punjab. Raj Kumar reports a relationship with Central University of Punjab that includes: employment. Raj Kumar has patent No with royalties paid to Pending. Authors do not have any conflict of interest.\n",
      "\n",
      "Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Raj Kumar reports financial support and administrative support were provided by Central University of Punjab. Raj Kumar reports a relationship with Central University of Punjab that includes: employment. Raj Kumar has patent No with royalties paid to Pending. Authors do not have any conflict of interest.\n",
      "\n",
      "Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Raj Kumar reports financial support and administrative support were provided by Central University of Punjab. Raj Kumar reports a relationship with Central University of Punjab that includes: employment. Raj Kumar has patent No with royalties paid to Pending. Authors do not have any conflict of interest.\n",
      "\n",
      "Kumar, Raj\n",
      "Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Raj Kumar reports financial support and administrative support were provided by Central University of Punjab. Raj Kumar reports a relationship with Central University of Punjab that includes: employment. Raj Kumar has patent No with royalties paid to Pending. Authors do not have any conflict of interest.\n",
      "\n",
      "N. Balakrishna\n",
      "Declaration of interests The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. No conflict of interest. Contribution: All the authors were involved in the conception and design of study. Meshram II has written manuscript, Meshram II, N .   B a l a k r i s h n a & Naveen Kumar carried out analysis and others have critically reviewed the manuscript.\n",
      "\n",
      "Declaration of interests The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. No conflict of interest. Contribution: All the authors were involved in the conception and design of study. Meshram II has written manuscript, Meshram II, N .   B a l a k r i s h n a & Naveen Kumar carried out analysis and others have critically reviewed the manuscript.\n",
      "\n",
      "Declaration of interests The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. No conflict of interest. Contribution: All the authors were involved in the conception and design of study. Meshram II has written manuscript, Meshram II, N .   B a l a k r i s h n a & Naveen Kumar carried out analysis and others have critically reviewed the manuscript.\n",
      "\n",
      "Declaration of interests The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. No conflict of interest. Contribution: All the authors were involved in the conception and design of study. Meshram II has written manuscript, Meshram II, N .   B a l a k r i s h n a & Naveen Kumar carried out analysis and others have critically reviewed the manuscript.\n",
      "\n",
      "Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Nobuaki Matsumori and Masanao Kinoshita has patent licensed to WO2016/148125.\n",
      "\n",
      "Kinoshita, Masanao\n",
      "Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Nobuaki Matsumori and Masanao Kinoshita has patent licensed to WO2016/148125.\n",
      "\n",
      "Matsumori, Nobuaki\n",
      "Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Nobuaki Matsumori and Masanao Kinoshita has patent licensed to WO2016/148125.\n",
      "\n",
      "Erklarung zu finanziellen Interessen Forschungsforderung erhalten: nein; Honorar/geldwerten Vorteil fur Referententatigkeit erhalten: ja, von einer anderen Institution (Pharma- oder Medizintechnikfirma usw.); Bezahlter Berater/interner Schulungsreferent/Gehaltsempfanger: ja, von einer anderen Institution (Pharma- oder Medizintechnikfirma usw.); Patent/Geschaftsanteile/Aktien (Autor/Partner, Ehepartner, Kinder) an im Bereich  der Medizin aktiven Firma: nein; Patent/Geschaftsanteile/Aktien (Autor/Partner, Ehepartner, Kinder) an zu Sponsoren dieser Fortbildung bzw. durch die Fortbildung in ihren Geschaftsinteressen beruhrten Firma: nein Erklarung zu nichtfinanziellen Interessen Die Autorinnen/Autoren geben an, dass kein Interessenkonflikt besteht.\n",
      "\n",
      "Erklarung zu finanziellen Interessen Forschungsforderung erhalten: nein; Honorar/geldwerten Vorteil fur Referententatigkeit erhalten: ja, von einer anderen Institution (Pharma- oder Medizintechnikfirma usw.); Bezahlter Berater/interner Schulungsreferent/Gehaltsempfanger: ja, von einer anderen Institution (Pharma- oder Medizintechnikfirma usw.); Patent/Geschaftsanteile/Aktien (Autor/Partner, Ehepartner, Kinder) an im Bereich  der Medizin aktiven Firma: nein; Patent/Geschaftsanteile/Aktien (Autor/Partner, Ehepartner, Kinder) an zu Sponsoren dieser Fortbildung bzw. durch die Fortbildung in ihren Geschaftsinteressen beruhrten Firma: nein Erklarung zu nichtfinanziellen Interessen Die Autorinnen/Autoren geben an, dass kein Interessenkonflikt besteht.\n",
      "\n",
      "Die Autorinnen/Autoren geben an, dass kein Interessenkonflikt besteht.\n",
      "\n",
      "Gwozdz, Adam M.\n",
      "Declaration of interests AAH reports research grants from The Danish Heart Foundation and The Novo Nordisk Foundation, consulting fees from Bayer and The Bristol-Myers Squibb-Pfizer Alliance, speaker bureaus from Bayer, The Bristol-Myers Squibb-Pfizer Alliance, and Merck Sharp & Dohme, and role as vice chair of special interest group venous thromboembolism of Danish Nurses' Council. JIA reports honoraria from Sanofi and Rovi for educational activities, and research funding from Sanofi and Bayer Adam M. Gwozdz. WRA reports payment or honoraria from  Bayer Pharmaceuticals, support for attending meeting from Bayer Pharmaceuticals,  and participation as Clinical Advisor for Janssen. CA received personal fees for  lectures and participation in advisory boards from Bayer, Bristol Myers Squibb, Daiichi-Sankyo, Pfizer, and Sanofi. SB reports unrestricted scientific grants from Bayer, INARI, Boston Scientific, Medtronic, Bard, SANOFI, and Concept Medical; consulting fees from INARI, Bayer, Boston Scientific, and Concept Medical; and travel financial support for attending meetings from Bayer and Daiichi Sankyo. LB reports personal fees and non-financial support from Aspen, personal fees and non-financial support from Bayer, Bristol Myers Squibb-Pfizer,  Leo Pharma, and Johnson and Johnson; grants, personal fees and non-financial support from Merck Sharp & Dohme, outside the submitted work. ATC reports grants  from Alexion Pharmaceuticals, Bayer Pharma Adam M. Gwozdz, and Bristol Myers Squibb-Pfizer, consulting fees from Alexion Pharmaceuticals, Bayer Pharma Adam M. Gwozdz, and Bristol Myers  Squibb-Pfizer, and payments from Alexion Pharmaceuticals, Bayer Pharma Adam M. Gwozdz, and Bristol Myers Squibb-Pfizer, all fees paid to his company. HR-E reports speaker's honoraria from Bayer and Daichi-Sankyo, and support for attending meetings and travel from Bayer. RPR reports consulting fees from Bristol Myers Squibb, Janssen, Inari, Penumbra, Abbott, and research grants paid to her institution from Bristol Myers Squibb and Janssen, all outside the scope of this paper. CT reports honoraria from Riche Bayer, Astra Zeneca, Actelion, and Janssen. K-LW reports honoraria from Bayer, Boehringer Ingelheim, Daiichi-Sankyo, and Pfizer for Continuing Medical Education lectures. SAB reports consulting fees from Boston Scientific, Gore, Becton Dickinson, Cook, Phillips, Vesper, Veryan, Vetex, and Medtronic; honoraria from Boston Scientific, Gore, Becton Dickinson, Cook, Philips, Vesper, Veryan, Vetex, and Medtronic; research grants from Boston Scientific and Medtronic that are paid to his institution; is on the advisory board for Philips, Medtronic, Gore, and Boston Scientific. FAK reports research grants from Bayer, Bristol-Myers Squibb, Boehringer-Ingelheim, Merck Sharp & Dohme, Leo Pharma, Daiichi-Sankyo, Actelion, The Netherlands Organisation for Health Research and Development, The Dutch Thrombosis Association, The Dutch Heart Foundation, and the Horizon Europe Program, all outside the submitted work  and paid to his institution. All other authors declare no competing interests.\n",
      "\n",
      "Declaration of interests AAH reports research grants from The Danish Heart Foundation and The Novo Nordisk Foundation, consulting fees from Bayer and The Bristol-Myers Squibb-Pfizer Alliance, speaker bureaus from Bayer, The Bristol-Myers Squibb-Pfizer Alliance, and Merck Sharp & Dohme, and role as vice chair of special interest group venous thromboembolism of Danish Nurses' Council. JIA reports honoraria from Sanofi and Rovi for educational activities, and research funding from Sanofi and Bayer Adam M. Gwozdz. WRA reports payment or honoraria from  Bayer Pharmaceuticals, support for attending meeting from Bayer Pharmaceuticals,  and participation as Clinical Advisor for Janssen. CA received personal fees for  lectures and participation in advisory boards from Bayer, Bristol Myers Squibb, Daiichi-Sankyo, Pfizer, and Sanofi. SB reports unrestricted scientific grants from Bayer, INARI, Boston Scientific, Medtronic, Bard, SANOFI, and Concept Medical; consulting fees from INARI, Bayer, Boston Scientific, and Concept Medical; and travel financial support for attending meetings from Bayer and Daiichi Sankyo. LB reports personal fees and non-financial support from Aspen, personal fees and non-financial support from Bayer, Bristol Myers Squibb-Pfizer,  Leo Pharma, and Johnson and Johnson; grants, personal fees and non-financial support from Merck Sharp & Dohme, outside the submitted work. ATC reports grants  from Alexion Pharmaceuticals, Bayer Pharma Adam M. Gwozdz, and Bristol Myers Squibb-Pfizer, consulting fees from Alexion Pharmaceuticals, Bayer Pharma Adam M. Gwozdz, and Bristol Myers  Squibb-Pfizer, and payments from Alexion Pharmaceuticals, Bayer Pharma Adam M. Gwozdz, and Bristol Myers Squibb-Pfizer, all fees paid to his company. HR-E reports speaker's honoraria from Bayer and Daichi-Sankyo, and support for attending meetings and travel from Bayer. RPR reports consulting fees from Bristol Myers Squibb, Janssen, Inari, Penumbra, Abbott, and research grants paid to her institution from Bristol Myers Squibb and Janssen, all outside the scope of this paper. CT reports honoraria from Riche Bayer, Astra Zeneca, Actelion, and Janssen. K-LW reports honoraria from Bayer, Boehringer Ingelheim, Daiichi-Sankyo, and Pfizer for Continuing Medical Education lectures. SAB reports consulting fees from Boston Scientific, Gore, Becton Dickinson, Cook, Phillips, Vesper, Veryan, Vetex, and Medtronic; honoraria from Boston Scientific, Gore, Becton Dickinson, Cook, Philips, Vesper, Veryan, Vetex, and Medtronic; research grants from Boston Scientific and Medtronic that are paid to his institution; is on the advisory board for Philips, Medtronic, Gore, and Boston Scientific. FAK reports research grants from Bayer, Bristol-Myers Squibb, Boehringer-Ingelheim, Merck Sharp & Dohme, Leo Pharma, Daiichi-Sankyo, Actelion, The Netherlands Organisation for Health Research and Development, The Dutch Thrombosis Association, The Dutch Heart Foundation, and the Horizon Europe Program, all outside the submitted work  and paid to his institution. All other authors declare no competing interests.\n",
      "\n",
      "Declaration of interests AAH reports research grants from The Danish Heart Foundation and The Novo Nordisk Foundation, consulting fees from Bayer and The Bristol-Myers Squibb-Pfizer Alliance, speaker bureaus from Bayer, The Bristol-Myers Squibb-Pfizer Alliance, and Merck Sharp & Dohme, and role as vice chair of special interest group venous thromboembolism of Danish Nurses' Council. JIA reports honoraria from Sanofi and Rovi for educational activities, and research funding from Sanofi and Bayer Adam M. Gwozdz. WRA reports payment or honoraria from  Bayer Pharmaceuticals, support for attending meeting from Bayer Pharmaceuticals,  and participation as Clinical Advisor for Janssen. CA received personal fees for  lectures and participation in advisory boards from Bayer, Bristol Myers Squibb, Daiichi-Sankyo, Pfizer, and Sanofi. SB reports unrestricted scientific grants from Bayer, INARI, Boston Scientific, Medtronic, Bard, SANOFI, and Concept Medical; consulting fees from INARI, Bayer, Boston Scientific, and Concept Medical; and travel financial support for attending meetings from Bayer and Daiichi Sankyo. LB reports personal fees and non-financial support from Aspen, personal fees and non-financial support from Bayer, Bristol Myers Squibb-Pfizer,  Leo Pharma, and Johnson and Johnson; grants, personal fees and non-financial support from Merck Sharp & Dohme, outside the submitted work. ATC reports grants  from Alexion Pharmaceuticals, Bayer Pharma Adam M. Gwozdz, and Bristol Myers Squibb-Pfizer, consulting fees from Alexion Pharmaceuticals, Bayer Pharma Adam M. Gwozdz, and Bristol Myers  Squibb-Pfizer, and payments from Alexion Pharmaceuticals, Bayer Pharma Adam M. Gwozdz, and Bristol Myers Squibb-Pfizer, all fees paid to his company. HR-E reports speaker's honoraria from Bayer and Daichi-Sankyo, and support for attending meetings and travel from Bayer. RPR reports consulting fees from Bristol Myers Squibb, Janssen, Inari, Penumbra, Abbott, and research grants paid to her institution from Bristol Myers Squibb and Janssen, all outside the scope of this paper. CT reports honoraria from Riche Bayer, Astra Zeneca, Actelion, and Janssen. K-LW reports honoraria from Bayer, Boehringer Ingelheim, Daiichi-Sankyo, and Pfizer for Continuing Medical Education lectures. SAB reports consulting fees from Boston Scientific, Gore, Becton Dickinson, Cook, Phillips, Vesper, Veryan, Vetex, and Medtronic; honoraria from Boston Scientific, Gore, Becton Dickinson, Cook, Philips, Vesper, Veryan, Vetex, and Medtronic; research grants from Boston Scientific and Medtronic that are paid to his institution; is on the advisory board for Philips, Medtronic, Gore, and Boston Scientific. FAK reports research grants from Bayer, Bristol-Myers Squibb, Boehringer-Ingelheim, Merck Sharp & Dohme, Leo Pharma, Daiichi-Sankyo, Actelion, The Netherlands Organisation for Health Research and Development, The Dutch Thrombosis Association, The Dutch Heart Foundation, and the Horizon Europe Program, all outside the submitted work  and paid to his institution. All other authors declare no competing interests.\n",
      "\n",
      "Declaration of interests AAH reports research grants from The Danish Heart Foundation and The Novo Nordisk Foundation, consulting fees from Bayer and The Bristol-Myers Squibb-Pfizer Alliance, speaker bureaus from Bayer, The Bristol-Myers Squibb-Pfizer Alliance, and Merck Sharp & Dohme, and role as vice chair of special interest group venous thromboembolism of Danish Nurses' Council. JIA reports honoraria from Sanofi and Rovi for educational activities, and research funding from Sanofi and Bayer Adam M. Gwozdz. WRA reports payment or honoraria from  Bayer Pharmaceuticals, support for attending meeting from Bayer Pharmaceuticals,  and participation as Clinical Advisor for Janssen. CA received personal fees for  lectures and participation in advisory boards from Bayer, Bristol Myers Squibb, Daiichi-Sankyo, Pfizer, and Sanofi. SB reports unrestricted scientific grants from Bayer, INARI, Boston Scientific, Medtronic, Bard, SANOFI, and Concept Medical; consulting fees from INARI, Bayer, Boston Scientific, and Concept Medical; and travel financial support for attending meetings from Bayer and Daiichi Sankyo. LB reports personal fees and non-financial support from Aspen, personal fees and non-financial support from Bayer, Bristol Myers Squibb-Pfizer,  Leo Pharma, and Johnson and Johnson; grants, personal fees and non-financial support from Merck Sharp & Dohme, outside the submitted work. ATC reports grants  from Alexion Pharmaceuticals, Bayer Pharma Adam M. Gwozdz, and Bristol Myers Squibb-Pfizer, consulting fees from Alexion Pharmaceuticals, Bayer Pharma Adam M. Gwozdz, and Bristol Myers  Squibb-Pfizer, and payments from Alexion Pharmaceuticals, Bayer Pharma Adam M. Gwozdz, and Bristol Myers Squibb-Pfizer, all fees paid to his company. HR-E reports speaker's honoraria from Bayer and Daichi-Sankyo, and support for attending meetings and travel from Bayer. RPR reports consulting fees from Bristol Myers Squibb, Janssen, Inari, Penumbra, Abbott, and research grants paid to her institution from Bristol Myers Squibb and Janssen, all outside the scope of this paper. CT reports honoraria from Riche Bayer, Astra Zeneca, Actelion, and Janssen. K-LW reports honoraria from Bayer, Boehringer Ingelheim, Daiichi-Sankyo, and Pfizer for Continuing Medical Education lectures. SAB reports consulting fees from Boston Scientific, Gore, Becton Dickinson, Cook, Phillips, Vesper, Veryan, Vetex, and Medtronic; honoraria from Boston Scientific, Gore, Becton Dickinson, Cook, Philips, Vesper, Veryan, Vetex, and Medtronic; research grants from Boston Scientific and Medtronic that are paid to his institution; is on the advisory board for Philips, Medtronic, Gore, and Boston Scientific. FAK reports research grants from Bayer, Bristol-Myers Squibb, Boehringer-Ingelheim, Merck Sharp & Dohme, Leo Pharma, Daiichi-Sankyo, Actelion, The Netherlands Organisation for Health Research and Development, The Dutch Thrombosis Association, The Dutch Heart Foundation, and the Horizon Europe Program, all outside the submitted work  and paid to his institution. All other authors declare no competing interests.\n",
      "\n",
      "Declaration of interests AAH reports research grants from The Danish Heart Foundation and The Novo Nordisk Foundation, consulting fees from Bayer and The Bristol-Myers Squibb-Pfizer Alliance, speaker bureaus from Bayer, The Bristol-Myers Squibb-Pfizer Alliance, and Merck Sharp & Dohme, and role as vice chair of special interest group venous thromboembolism of Danish Nurses' Council. JIA reports honoraria from Sanofi and Rovi for educational activities, and research funding from Sanofi and Bayer Adam M. Gwozdz. WRA reports payment or honoraria from  Bayer Pharmaceuticals, support for attending meeting from Bayer Pharmaceuticals,  and participation as Clinical Advisor for Janssen. CA received personal fees for  lectures and participation in advisory boards from Bayer, Bristol Myers Squibb, Daiichi-Sankyo, Pfizer, and Sanofi. SB reports unrestricted scientific grants from Bayer, INARI, Boston Scientific, Medtronic, Bard, SANOFI, and Concept Medical; consulting fees from INARI, Bayer, Boston Scientific, and Concept Medical; and travel financial support for attending meetings from Bayer and Daiichi Sankyo. LB reports personal fees and non-financial support from Aspen, personal fees and non-financial support from Bayer, Bristol Myers Squibb-Pfizer,  Leo Pharma, and Johnson and Johnson; grants, personal fees and non-financial support from Merck Sharp & Dohme, outside the submitted work. ATC reports grants  from Alexion Pharmaceuticals, Bayer Pharma Adam M. Gwozdz, and Bristol Myers Squibb-Pfizer, consulting fees from Alexion Pharmaceuticals, Bayer Pharma Adam M. Gwozdz, and Bristol Myers  Squibb-Pfizer, and payments from Alexion Pharmaceuticals, Bayer Pharma Adam M. Gwozdz, and Bristol Myers Squibb-Pfizer, all fees paid to his company. HR-E reports speaker's honoraria from Bayer and Daichi-Sankyo, and support for attending meetings and travel from Bayer. RPR reports consulting fees from Bristol Myers Squibb, Janssen, Inari, Penumbra, Abbott, and research grants paid to her institution from Bristol Myers Squibb and Janssen, all outside the scope of this paper. CT reports honoraria from Riche Bayer, Astra Zeneca, Actelion, and Janssen. K-LW reports honoraria from Bayer, Boehringer Ingelheim, Daiichi-Sankyo, and Pfizer for Continuing Medical Education lectures. SAB reports consulting fees from Boston Scientific, Gore, Becton Dickinson, Cook, Phillips, Vesper, Veryan, Vetex, and Medtronic; honoraria from Boston Scientific, Gore, Becton Dickinson, Cook, Philips, Vesper, Veryan, Vetex, and Medtronic; research grants from Boston Scientific and Medtronic that are paid to his institution; is on the advisory board for Philips, Medtronic, Gore, and Boston Scientific. FAK reports research grants from Bayer, Bristol-Myers Squibb, Boehringer-Ingelheim, Merck Sharp & Dohme, Leo Pharma, Daiichi-Sankyo, Actelion, The Netherlands Organisation for Health Research and Development, The Dutch Thrombosis Association, The Dutch Heart Foundation, and the Horizon Europe Program, all outside the submitted work  and paid to his institution. All other authors declare no competing interests.\n",
      "\n",
      "Declaration of interests AAH reports research grants from The Danish Heart Foundation and The Novo Nordisk Foundation, consulting fees from Bayer and The Bristol-Myers Squibb-Pfizer Alliance, speaker bureaus from Bayer, The Bristol-Myers Squibb-Pfizer Alliance, and Merck Sharp & Dohme, and role as vice chair of special interest group venous thromboembolism of Danish Nurses' Council. JIA reports honoraria from Sanofi and Rovi for educational activities, and research funding from Sanofi and Bayer Adam M. Gwozdz. WRA reports payment or honoraria from  Bayer Pharmaceuticals, support for attending meeting from Bayer Pharmaceuticals,  and participation as Clinical Advisor for Janssen. CA received personal fees for  lectures and participation in advisory boards from Bayer, Bristol Myers Squibb, Daiichi-Sankyo, Pfizer, and Sanofi. SB reports unrestricted scientific grants from Bayer, INARI, Boston Scientific, Medtronic, Bard, SANOFI, and Concept Medical; consulting fees from INARI, Bayer, Boston Scientific, and Concept Medical; and travel financial support for attending meetings from Bayer and Daiichi Sankyo. LB reports personal fees and non-financial support from Aspen, personal fees and non-financial support from Bayer, Bristol Myers Squibb-Pfizer,  Leo Pharma, and Johnson and Johnson; grants, personal fees and non-financial support from Merck Sharp & Dohme, outside the submitted work. ATC reports grants  from Alexion Pharmaceuticals, Bayer Pharma Adam M. Gwozdz, and Bristol Myers Squibb-Pfizer, consulting fees from Alexion Pharmaceuticals, Bayer Pharma Adam M. Gwozdz, and Bristol Myers  Squibb-Pfizer, and payments from Alexion Pharmaceuticals, Bayer Pharma Adam M. Gwozdz, and Bristol Myers Squibb-Pfizer, all fees paid to his company. HR-E reports speaker's honoraria from Bayer and Daichi-Sankyo, and support for attending meetings and travel from Bayer. RPR reports consulting fees from Bristol Myers Squibb, Janssen, Inari, Penumbra, Abbott, and research grants paid to her institution from Bristol Myers Squibb and Janssen, all outside the scope of this paper. CT reports honoraria from Riche Bayer, Astra Zeneca, Actelion, and Janssen. K-LW reports honoraria from Bayer, Boehringer Ingelheim, Daiichi-Sankyo, and Pfizer for Continuing Medical Education lectures. SAB reports consulting fees from Boston Scientific, Gore, Becton Dickinson, Cook, Phillips, Vesper, Veryan, Vetex, and Medtronic; honoraria from Boston Scientific, Gore, Becton Dickinson, Cook, Philips, Vesper, Veryan, Vetex, and Medtronic; research grants from Boston Scientific and Medtronic that are paid to his institution; is on the advisory board for Philips, Medtronic, Gore, and Boston Scientific. FAK reports research grants from Bayer, Bristol-Myers Squibb, Boehringer-Ingelheim, Merck Sharp & Dohme, Leo Pharma, Daiichi-Sankyo, Actelion, The Netherlands Organisation for Health Research and Development, The Dutch Thrombosis Association, The Dutch Heart Foundation, and the Horizon Europe Program, all outside the submitted work  and paid to his institution. All other authors declare no competing interests.\n",
      "\n",
      "Arbjerg Hojen, Anette\n",
      "Declaration of interests Anette Arbjerg Hojen reports research grants from The Danish Heart Foundation and The Novo Nordisk Foundation, consulting fees from Bayer and The Bristol-Myers Squibb-Pfizer Alliance, speaker bureaus from Bayer, The Bristol-Myers Squibb-Pfizer Alliance, and Merck Sharp & Dohme, and role as vice chair of special interest group venous thromboembolism of Danish Nurses' Council. JIA reports honoraria from Sanofi and Rovi for educational activities, and research funding from Sanofi and Bayer Adam M. Gwozdz. WRA reports payment or honoraria from  Bayer Pharmaceuticals, support for attending meeting from Bayer Pharmaceuticals,  and participation as Clinical Advisor for Janssen. CA received personal fees for  lectures and participation in advisory boards from Bayer, Bristol Myers Squibb, Daiichi-Sankyo, Pfizer, and Sanofi. SB reports unrestricted scientific grants from Bayer, INARI, Boston Scientific, Medtronic, Bard, SANOFI, and Concept Medical; consulting fees from INARI, Bayer, Boston Scientific, and Concept Medical; and travel financial support for attending meetings from Bayer and Daiichi Sankyo. LB reports personal fees and non-financial support from Aspen, personal fees and non-financial support from Bayer, Bristol Myers Squibb-Pfizer,  Leo Pharma, and Johnson and Johnson; grants, personal fees and non-financial support from Merck Sharp & Dohme, outside the submitted work. ATC reports grants  from Alexion Pharmaceuticals, Bayer Pharma Adam M. Gwozdz, and Bristol Myers Squibb-Pfizer, consulting fees from Alexion Pharmaceuticals, Bayer Pharma Adam M. Gwozdz, and Bristol Myers  Squibb-Pfizer, and payments from Alexion Pharmaceuticals, Bayer Pharma Adam M. Gwozdz, and Bristol Myers Squibb-Pfizer, all fees paid to his company. HR-E reports speaker's honoraria from Bayer and Daichi-Sankyo, and support for attending meetings and travel from Bayer. RPR reports consulting fees from Bristol Myers Squibb, Janssen, Inari, Penumbra, Abbott, and research grants paid to her institution from Bristol Myers Squibb and Janssen, all outside the scope of this paper. CT reports honoraria from Riche Bayer, Astra Zeneca, Actelion, and Janssen. K-LW reports honoraria from Bayer, Boehringer Ingelheim, Daiichi-Sankyo, and Pfizer for Continuing Medical Education lectures. SAB reports consulting fees from Boston Scientific, Gore, Becton Dickinson, Cook, Phillips, Vesper, Veryan, Vetex, and Medtronic; honoraria from Boston Scientific, Gore, Becton Dickinson, Cook, Philips, Vesper, Veryan, Vetex, and Medtronic; research grants from Boston Scientific and Medtronic that are paid to his institution; is on the advisory board for Philips, Medtronic, Gore, and Boston Scientific. FAK reports research grants from Bayer, Bristol-Myers Squibb, Boehringer-Ingelheim, Merck Sharp & Dohme, Leo Pharma, Daiichi-Sankyo, Actelion, The Netherlands Organisation for Health Research and Development, The Dutch Thrombosis Association, The Dutch Heart Foundation, and the Horizon Europe Program, all outside the submitted work  and paid to his institution. All other authors declare no competing interests.\n",
      "\n",
      "Arcelus, Juan I.\n",
      "Declaration of interests Anette Arbjerg Hojen reports research grants from The Danish Heart Foundation and The Novo Nordisk Foundation, consulting fees from Bayer and The Bristol-Myers Squibb-Pfizer Alliance, speaker bureaus from Bayer, The Bristol-Myers Squibb-Pfizer Alliance, and Merck Sharp & Dohme, and role as vice chair of special interest group venous thromboembolism of Danish Nurses' Council. Juan I. Arcelus reports honoraria from Sanofi and Rovi for educational activities, and research funding from Sanofi and Bayer Adam M. Gwozdz. WRA reports payment or honoraria from  Bayer Pharmaceuticals, support for attending meeting from Bayer Pharmaceuticals,  and participation as Clinical Advisor for Janssen. CA received personal fees for  lectures and participation in advisory boards from Bayer, Bristol Myers Squibb, Daiichi-Sankyo, Pfizer, and Sanofi. SB reports unrestricted scientific grants from Bayer, INARI, Boston Scientific, Medtronic, Bard, SANOFI, and Concept Medical; consulting fees from INARI, Bayer, Boston Scientific, and Concept Medical; and travel financial support for attending meetings from Bayer and Daiichi Sankyo. LB reports personal fees and non-financial support from Aspen, personal fees and non-financial support from Bayer, Bristol Myers Squibb-Pfizer,  Leo Pharma, and Johnson and Johnson; grants, personal fees and non-financial support from Merck Sharp & Dohme, outside the submitted work. ATC reports grants  from Alexion Pharmaceuticals, Bayer Pharma Adam M. Gwozdz, and Bristol Myers Squibb-Pfizer, consulting fees from Alexion Pharmaceuticals, Bayer Pharma Adam M. Gwozdz, and Bristol Myers  Squibb-Pfizer, and payments from Alexion Pharmaceuticals, Bayer Pharma Adam M. Gwozdz, and Bristol Myers Squibb-Pfizer, all fees paid to his company. HR-E reports speaker's honoraria from Bayer and Daichi-Sankyo, and support for attending meetings and travel from Bayer. RPR reports consulting fees from Bristol Myers Squibb, Janssen, Inari, Penumbra, Abbott, and research grants paid to her institution from Bristol Myers Squibb and Janssen, all outside the scope of this paper. CT reports honoraria from Riche Bayer, Astra Zeneca, Actelion, and Janssen. K-LW reports honoraria from Bayer, Boehringer Ingelheim, Daiichi-Sankyo, and Pfizer for Continuing Medical Education lectures. SAB reports consulting fees from Boston Scientific, Gore, Becton Dickinson, Cook, Phillips, Vesper, Veryan, Vetex, and Medtronic; honoraria from Boston Scientific, Gore, Becton Dickinson, Cook, Philips, Vesper, Veryan, Vetex, and Medtronic; research grants from Boston Scientific and Medtronic that are paid to his institution; is on the advisory board for Philips, Medtronic, Gore, and Boston Scientific. FAK reports research grants from Bayer, Bristol-Myers Squibb, Boehringer-Ingelheim, Merck Sharp & Dohme, Leo Pharma, Daiichi-Sankyo, Actelion, The Netherlands Organisation for Health Research and Development, The Dutch Thrombosis Association, The Dutch Heart Foundation, and the Horizon Europe Program, all outside the submitted work  and paid to his institution. All other authors declare no competing interests.\n",
      "\n",
      "Auger, William R.\n",
      "Declaration of interests Anette Arbjerg Hojen reports research grants from The Danish Heart Foundation and The Novo Nordisk Foundation, consulting fees from Bayer and The Bristol-Myers Squibb-Pfizer Alliance, speaker bureaus from Bayer, The Bristol-Myers Squibb-Pfizer Alliance, and Merck Sharp & Dohme, and role as vice chair of special interest group venous thromboembolism of Danish Nurses' Council. Juan I. Arcelus reports honoraria from Sanofi and Rovi for educational activities, and research funding from Sanofi and Bayer Adam M. Gwozdz. William R. Auger reports payment or honoraria from  Bayer Pharmaceuticals, support for attending meeting from Bayer Pharmaceuticals,  and participation as Clinical Advisor for Janssen. CA received personal fees for  lectures and participation in advisory boards from Bayer, Bristol Myers Squibb, Daiichi-Sankyo, Pfizer, and Sanofi. SB reports unrestricted scientific grants from Bayer, INARI, Boston Scientific, Medtronic, Bard, SANOFI, and Concept Medical; consulting fees from INARI, Bayer, Boston Scientific, and Concept Medical; and travel financial support for attending meetings from Bayer and Daiichi Sankyo. LB reports personal fees and non-financial support from Aspen, personal fees and non-financial support from Bayer, Bristol Myers Squibb-Pfizer,  Leo Pharma, and Johnson and Johnson; grants, personal fees and non-financial support from Merck Sharp & Dohme, outside the submitted work. ATC reports grants  from Alexion Pharmaceuticals, Bayer Pharma Adam M. Gwozdz, and Bristol Myers Squibb-Pfizer, consulting fees from Alexion Pharmaceuticals, Bayer Pharma Adam M. Gwozdz, and Bristol Myers  Squibb-Pfizer, and payments from Alexion Pharmaceuticals, Bayer Pharma Adam M. Gwozdz, and Bristol Myers Squibb-Pfizer, all fees paid to his company. HR-E reports speaker's honoraria from Bayer and Daichi-Sankyo, and support for attending meetings and travel from Bayer. RPR reports consulting fees from Bristol Myers Squibb, Janssen, Inari, Penumbra, Abbott, and research grants paid to her institution from Bristol Myers Squibb and Janssen, all outside the scope of this paper. CT reports honoraria from Riche Bayer, Astra Zeneca, Actelion, and Janssen. K-LW reports honoraria from Bayer, Boehringer Ingelheim, Daiichi-Sankyo, and Pfizer for Continuing Medical Education lectures. SAB reports consulting fees from Boston Scientific, Gore, Becton Dickinson, Cook, Phillips, Vesper, Veryan, Vetex, and Medtronic; honoraria from Boston Scientific, Gore, Becton Dickinson, Cook, Philips, Vesper, Veryan, Vetex, and Medtronic; research grants from Boston Scientific and Medtronic that are paid to his institution; is on the advisory board for Philips, Medtronic, Gore, and Boston Scientific. FAK reports research grants from Bayer, Bristol-Myers Squibb, Boehringer-Ingelheim, Merck Sharp & Dohme, Leo Pharma, Daiichi-Sankyo, Actelion, The Netherlands Organisation for Health Research and Development, The Dutch Thrombosis Association, The Dutch Heart Foundation, and the Horizon Europe Program, all outside the submitted work  and paid to his institution. All other authors declare no competing interests.\n",
      "\n",
      "Ay, Cihan\n",
      "Declaration of interests Anette Arbjerg Hojen reports research grants from The Danish Heart Foundation and The Novo Nordisk Foundation, consulting fees from Bayer and The Bristol-Myers Squibb-Pfizer Alliance, speaker bureaus from Bayer, The Bristol-Myers Squibb-Pfizer Alliance, and Merck Sharp & Dohme, and role as vice chair of special interest group venous thromboembolism of Danish Nurses' Council. Juan I. Arcelus reports honoraria from Sanofi and Rovi for educational activities, and research funding from Sanofi and Bayer Adam M. Gwozdz. William R. Auger reports payment or honoraria from  Bayer Pharmaceuticals, support for attending meeting from Bayer Pharmaceuticals,  and participation as Clinical Advisor for Janssen. Cihan Ay received personal fees for  lectures and participation in advisory boards from Bayer, Bristol Myers Squibb, Daiichi-Sankyo, Pfizer, and Sanofi. SB reports unrestricted scientific grants from Bayer, INARI, Boston Scientific, Medtronic, Bard, SANOFI, and Concept Medical; consulting fees from INARI, Bayer, Boston Scientific, and Concept Medical; and travel financial support for attending meetings from Bayer and Daiichi Sankyo. LB reports personal fees and non-financial support from Aspen, personal fees and non-financial support from Bayer, Bristol Myers Squibb-Pfizer,  Leo Pharma, and Johnson and Johnson; grants, personal fees and non-financial support from Merck Sharp & Dohme, outside the submitted work. ATC reports grants  from Alexion Pharmaceuticals, Bayer Pharma Adam M. Gwozdz, and Bristol Myers Squibb-Pfizer, consulting fees from Alexion Pharmaceuticals, Bayer Pharma Adam M. Gwozdz, and Bristol Myers  Squibb-Pfizer, and payments from Alexion Pharmaceuticals, Bayer Pharma Adam M. Gwozdz, and Bristol Myers Squibb-Pfizer, all fees paid to his company. HR-E reports speaker's honoraria from Bayer and Daichi-Sankyo, and support for attending meetings and travel from Bayer. RPR reports consulting fees from Bristol Myers Squibb, Janssen, Inari, Penumbra, Abbott, and research grants paid to her institution from Bristol Myers Squibb and Janssen, all outside the scope of this paper. CT reports honoraria from Riche Bayer, Astra Zeneca, Actelion, and Janssen. K-LW reports honoraria from Bayer, Boehringer Ingelheim, Daiichi-Sankyo, and Pfizer for Continuing Medical Education lectures. SAB reports consulting fees from Boston Scientific, Gore, Becton Dickinson, Cook, Phillips, Vesper, Veryan, Vetex, and Medtronic; honoraria from Boston Scientific, Gore, Becton Dickinson, Cook, Philips, Vesper, Veryan, Vetex, and Medtronic; research grants from Boston Scientific and Medtronic that are paid to his institution; is on the advisory board for Philips, Medtronic, Gore, and Boston Scientific. FAK reports research grants from Bayer, Bristol-Myers Squibb, Boehringer-Ingelheim, Merck Sharp & Dohme, Leo Pharma, Daiichi-Sankyo, Actelion, The Netherlands Organisation for Health Research and Development, The Dutch Thrombosis Association, The Dutch Heart Foundation, and the Horizon Europe Program, all outside the submitted work  and paid to his institution. All other authors declare no competing interests.\n",
      "\n",
      "Barco, Stefano\n",
      "Declaration of interests Anette Arbjerg Hojen reports research grants from The Danish Heart Foundation and The Novo Nordisk Foundation, consulting fees from Bayer and The Bristol-Myers Squibb-Pfizer Alliance, speaker bureaus from Bayer, The Bristol-Myers Squibb-Pfizer Alliance, and Merck Sharp & Dohme, and role as vice chair of special interest group venous thromboembolism of Danish Nurses' Council. Juan I. Arcelus reports honoraria from Sanofi and Rovi for educational activities, and research funding from Sanofi and Bayer Adam M. Gwozdz. William R. Auger reports payment or honoraria from  Bayer Pharmaceuticals, support for attending meeting from Bayer Pharmaceuticals,  and participation as Clinical Advisor for Janssen. Cihan Ay received personal fees for  lectures and participation in advisory boards from Bayer, Bristol Myers Squibb, Daiichi-Sankyo, Pfizer, and Sanofi. Stefano Barco reports unrestricted scientific grants from Bayer, INARI, Boston Scientific, Medtronic, Bard, SANOFI, and Concept Medical; consulting fees from INARI, Bayer, Boston Scientific, and Concept Medical; and travel financial support for attending meetings from Bayer and Daiichi Sankyo. LB reports personal fees and non-financial support from Aspen, personal fees and non-financial support from Bayer, Bristol Myers Squibb-Pfizer,  Leo Pharma, and Johnson and Johnson; grants, personal fees and non-financial support from Merck Sharp & Dohme, outside the submitted work. ATC reports grants  from Alexion Pharmaceuticals, Bayer Pharma Adam M. Gwozdz, and Bristol Myers Squibb-Pfizer, consulting fees from Alexion Pharmaceuticals, Bayer Pharma Adam M. Gwozdz, and Bristol Myers  Squibb-Pfizer, and payments from Alexion Pharmaceuticals, Bayer Pharma Adam M. Gwozdz, and Bristol Myers Squibb-Pfizer, all fees paid to his company. HR-E reports speaker's honoraria from Bayer and Daichi-Sankyo, and support for attending meetings and travel from Bayer. RPR reports consulting fees from Bristol Myers Squibb, Janssen, Inari, Penumbra, Abbott, and research grants paid to her institution from Bristol Myers Squibb and Janssen, all outside the scope of this paper. CT reports honoraria from Riche Bayer, Astra Zeneca, Actelion, and Janssen. K-LW reports honoraria from Bayer, Boehringer Ingelheim, Daiichi-Sankyo, and Pfizer for Continuing Medical Education lectures. SAB reports consulting fees from Boston Scientific, Gore, Becton Dickinson, Cook, Phillips, Vesper, Veryan, Vetex, and Medtronic; honoraria from Boston Scientific, Gore, Becton Dickinson, Cook, Philips, Vesper, Veryan, Vetex, and Medtronic; research grants from Boston Scientific and Medtronic that are paid to his institution; is on the advisory board for Philips, Medtronic, Gore, and Boston Scientific. FAK reports research grants from Bayer, Bristol-Myers Squibb, Boehringer-Ingelheim, Merck Sharp & Dohme, Leo Pharma, Daiichi-Sankyo, Actelion, The Netherlands Organisation for Health Research and Development, The Dutch Thrombosis Association, The Dutch Heart Foundation, and the Horizon Europe Program, all outside the submitted work  and paid to his institution. All other authors declare no competing interests.\n",
      "\n",
      "Declaration of interests Anette Arbjerg Hojen reports research grants from The Danish Heart Foundation and The Novo Nordisk Foundation, consulting fees from Bayer and The Bristol-Myers Squibb-Pfizer Alliance, speaker bureaus from Bayer, The Bristol-Myers Squibb-Pfizer Alliance, and Merck Sharp & Dohme, and role as vice chair of special interest group venous thromboembolism of Danish Nurses' Council. Juan I. Arcelus reports honoraria from Sanofi and Rovi for educational activities, and research funding from Sanofi and Bayer Adam M. Gwozdz. William R. Auger reports payment or honoraria from  Bayer Pharmaceuticals, support for attending meeting from Bayer Pharmaceuticals,  and participation as Clinical Advisor for Janssen. Cihan Ay received personal fees for  lectures and participation in advisory boards from Bayer, Bristol Myers Squibb, Daiichi-Sankyo, Pfizer, and Sanofi. Stefano Barco reports unrestricted scientific grants from Bayer, INARI, Boston Scientific, Medtronic, Bard, SANOFI, and Concept Medical; consulting fees from INARI, Bayer, Boston Scientific, and Concept Medical; and travel financial support for attending meetings from Bayer and Daiichi Sankyo. LB reports personal fees and non-financial support from Aspen, personal fees and non-financial support from Bayer, Bristol Myers Squibb-Pfizer,  Leo Pharma, and Johnson and Johnson; grants, personal fees and non-financial support from Merck Sharp & Dohme, outside the submitted work. ATC reports grants  from Alexion Pharmaceuticals, Bayer Pharma Adam M. Gwozdz, and Bristol Myers Squibb-Pfizer, consulting fees from Alexion Pharmaceuticals, Bayer Pharma Adam M. Gwozdz, and Bristol Myers  Squibb-Pfizer, and payments from Alexion Pharmaceuticals, Bayer Pharma Adam M. Gwozdz, and Bristol Myers Squibb-Pfizer, all fees paid to his company. HR-E reports speaker's honoraria from Bayer and Daichi-Sankyo, and support for attending meetings and travel from Bayer. RPR reports consulting fees from Bristol Myers Squibb, Janssen, Inari, Penumbra, Abbott, and research grants paid to her institution from Bristol Myers Squibb and Janssen, all outside the scope of this paper. CT reports honoraria from Riche Bayer, Astra Zeneca, Actelion, and Janssen. K-LW reports honoraria from Bayer, Boehringer Ingelheim, Daiichi-Sankyo, and Pfizer for Continuing Medical Education lectures. SAB reports consulting fees from Boston Scientific, Gore, Becton Dickinson, Cook, Phillips, Vesper, Veryan, Vetex, and Medtronic; honoraria from Boston Scientific, Gore, Becton Dickinson, Cook, Philips, Vesper, Veryan, Vetex, and Medtronic; research grants from Boston Scientific and Medtronic that are paid to his institution; is on the advisory board for Philips, Medtronic, Gore, and Boston Scientific. FAK reports research grants from Bayer, Bristol-Myers Squibb, Boehringer-Ingelheim, Merck Sharp & Dohme, Leo Pharma, Daiichi-Sankyo, Actelion, The Netherlands Organisation for Health Research and Development, The Dutch Thrombosis Association, The Dutch Heart Foundation, and the Horizon Europe Program, all outside the submitted work  and paid to his institution. All other authors declare no competing interests.\n",
      "\n",
      "Declaration of interests Anette Arbjerg Hojen reports research grants from The Danish Heart Foundation and The Novo Nordisk Foundation, consulting fees from Bayer and The Bristol-Myers Squibb-Pfizer Alliance, speaker bureaus from Bayer, The Bristol-Myers Squibb-Pfizer Alliance, and Merck Sharp & Dohme, and role as vice chair of special interest group venous thromboembolism of Danish Nurses' Council. Juan I. Arcelus reports honoraria from Sanofi and Rovi for educational activities, and research funding from Sanofi and Bayer Adam M. Gwozdz. William R. Auger reports payment or honoraria from  Bayer Pharmaceuticals, support for attending meeting from Bayer Pharmaceuticals,  and participation as Clinical Advisor for Janssen. Cihan Ay received personal fees for  lectures and participation in advisory boards from Bayer, Bristol Myers Squibb, Daiichi-Sankyo, Pfizer, and Sanofi. Stefano Barco reports unrestricted scientific grants from Bayer, INARI, Boston Scientific, Medtronic, Bard, SANOFI, and Concept Medical; consulting fees from INARI, Bayer, Boston Scientific, and Concept Medical; and travel financial support for attending meetings from Bayer and Daiichi Sankyo. LB reports personal fees and non-financial support from Aspen, personal fees and non-financial support from Bayer, Bristol Myers Squibb-Pfizer,  Leo Pharma, and Johnson and Johnson; grants, personal fees and non-financial support from Merck Sharp & Dohme, outside the submitted work. ATC reports grants  from Alexion Pharmaceuticals, Bayer Pharma Adam M. Gwozdz, and Bristol Myers Squibb-Pfizer, consulting fees from Alexion Pharmaceuticals, Bayer Pharma Adam M. Gwozdz, and Bristol Myers  Squibb-Pfizer, and payments from Alexion Pharmaceuticals, Bayer Pharma Adam M. Gwozdz, and Bristol Myers Squibb-Pfizer, all fees paid to his company. HR-E reports speaker's honoraria from Bayer and Daichi-Sankyo, and support for attending meetings and travel from Bayer. RPR reports consulting fees from Bristol Myers Squibb, Janssen, Inari, Penumbra, Abbott, and research grants paid to her institution from Bristol Myers Squibb and Janssen, all outside the scope of this paper. CT reports honoraria from Riche Bayer, Astra Zeneca, Actelion, and Janssen. K-LW reports honoraria from Bayer, Boehringer Ingelheim, Daiichi-Sankyo, and Pfizer for Continuing Medical Education lectures. SAB reports consulting fees from Boston Scientific, Gore, Becton Dickinson, Cook, Phillips, Vesper, Veryan, Vetex, and Medtronic; honoraria from Boston Scientific, Gore, Becton Dickinson, Cook, Philips, Vesper, Veryan, Vetex, and Medtronic; research grants from Boston Scientific and Medtronic that are paid to his institution; is on the advisory board for Philips, Medtronic, Gore, and Boston Scientific. FAK reports research grants from Bayer, Bristol-Myers Squibb, Boehringer-Ingelheim, Merck Sharp & Dohme, Leo Pharma, Daiichi-Sankyo, Actelion, The Netherlands Organisation for Health Research and Development, The Dutch Thrombosis Association, The Dutch Heart Foundation, and the Horizon Europe Program, all outside the submitted work  and paid to his institution. All other authors declare no competing interests.\n",
      "\n",
      "Bertoletti, Laurent\n",
      "Declaration of interests Anette Arbjerg Hojen reports research grants from The Danish Heart Foundation and The Novo Nordisk Foundation, consulting fees from Bayer and The Bristol-Myers Squibb-Pfizer Alliance, speaker bureaus from Bayer, The Bristol-Myers Squibb-Pfizer Alliance, and Merck Sharp & Dohme, and role as vice chair of special interest group venous thromboembolism of Danish Nurses' Council. Juan I. Arcelus reports honoraria from Sanofi and Rovi for educational activities, and research funding from Sanofi and Bayer Adam M. Gwozdz. William R. Auger reports payment or honoraria from  Bayer Pharmaceuticals, support for attending meeting from Bayer Pharmaceuticals,  and participation as Clinical Advisor for Janssen. Cihan Ay received personal fees for  lectures and participation in advisory boards from Bayer, Bristol Myers Squibb, Daiichi-Sankyo, Pfizer, and Sanofi. Stefano Barco reports unrestricted scientific grants from Bayer, INARI, Boston Scientific, Medtronic, Bard, SANOFI, and Concept Medical; consulting fees from INARI, Bayer, Boston Scientific, and Concept Medical; and travel financial support for attending meetings from Bayer and Daiichi Sankyo. Laurent Bertoletti reports personal fees and non-financial support from Aspen, personal fees and non-financial support from Bayer, Bristol Myers Squibb-Pfizer,  Leo Pharma, and Johnson and Johnson; grants, personal fees and non-financial support from Merck Sharp & Dohme, outside the submitted work. ATC reports grants  from Alexion Pharmaceuticals, Bayer Pharma Adam M. Gwozdz, and Bristol Myers Squibb-Pfizer, consulting fees from Alexion Pharmaceuticals, Bayer Pharma Adam M. Gwozdz, and Bristol Myers  Squibb-Pfizer, and payments from Alexion Pharmaceuticals, Bayer Pharma Adam M. Gwozdz, and Bristol Myers Squibb-Pfizer, all fees paid to his company. HR-E reports speaker's honoraria from Bayer and Daichi-Sankyo, and support for attending meetings and travel from Bayer. RPR reports consulting fees from Bristol Myers Squibb, Janssen, Inari, Penumbra, Abbott, and research grants paid to her institution from Bristol Myers Squibb and Janssen, all outside the scope of this paper. CT reports honoraria from Riche Bayer, Astra Zeneca, Actelion, and Janssen. K-LW reports honoraria from Bayer, Boehringer Ingelheim, Daiichi-Sankyo, and Pfizer for Continuing Medical Education lectures. SAB reports consulting fees from Boston Scientific, Gore, Becton Dickinson, Cook, Phillips, Vesper, Veryan, Vetex, and Medtronic; honoraria from Boston Scientific, Gore, Becton Dickinson, Cook, Philips, Vesper, Veryan, Vetex, and Medtronic; research grants from Boston Scientific and Medtronic that are paid to his institution; is on the advisory board for Philips, Medtronic, Gore, and Boston Scientific. FAK reports research grants from Bayer, Bristol-Myers Squibb, Boehringer-Ingelheim, Merck Sharp & Dohme, Leo Pharma, Daiichi-Sankyo, Actelion, The Netherlands Organisation for Health Research and Development, The Dutch Thrombosis Association, The Dutch Heart Foundation, and the Horizon Europe Program, all outside the submitted work  and paid to his institution. All other authors declare no competing interests.\n",
      "\n",
      "Ten Cate-Hoek, Arina\n",
      "Declaration of interests Anette Arbjerg Hojen reports research grants from The Danish Heart Foundation and The Novo Nordisk Foundation, consulting fees from Bayer and The Bristol-Myers Squibb-Pfizer Alliance, speaker bureaus from Bayer, The Bristol-Myers Squibb-Pfizer Alliance, and Merck Sharp & Dohme, and role as vice chair of special interest group venous thromboembolism of Danish Nurses' Council. Juan I. Arcelus reports honoraria from Sanofi and Rovi for educational activities, and research funding from Sanofi and Bayer Adam M. Gwozdz. William R. Auger reports payment or honoraria from  Bayer Pharmaceuticals, support for attending meeting from Bayer Pharmaceuticals,  and participation as Clinical Advisor for Janssen. Cihan Ay received personal fees for  lectures and participation in advisory boards from Bayer, Bristol Myers Squibb, Daiichi-Sankyo, Pfizer, and Sanofi. Stefano Barco reports unrestricted scientific grants from Bayer, INARI, Boston Scientific, Medtronic, Bard, SANOFI, and Concept Medical; consulting fees from INARI, Bayer, Boston Scientific, and Concept Medical; and travel financial support for attending meetings from Bayer and Daiichi Sankyo. Laurent Bertoletti reports personal fees and non-financial support from Aspen, personal fees and non-financial support from Bayer, Bristol Myers Squibb-Pfizer,  Leo Pharma, and Johnson and Johnson; grants, personal fees and non-financial support from Merck Sharp & Dohme, outside the submitted work. Arina Ten Cate-Hoek reports grants  from Alexion Pharmaceuticals, Bayer Pharma Adam M. Gwozdz, and Bristol Myers Squibb-Pfizer, consulting fees from Alexion Pharmaceuticals, Bayer Pharma Adam M. Gwozdz, and Bristol Myers  Squibb-Pfizer, and payments from Alexion Pharmaceuticals, Bayer Pharma Adam M. Gwozdz, and Bristol Myers Squibb-Pfizer, all fees paid to his company. HR-E reports speaker's honoraria from Bayer and Daichi-Sankyo, and support for attending meetings and travel from Bayer. RPR reports consulting fees from Bristol Myers Squibb, Janssen, Inari, Penumbra, Abbott, and research grants paid to her institution from Bristol Myers Squibb and Janssen, all outside the scope of this paper. CT reports honoraria from Riche Bayer, Astra Zeneca, Actelion, and Janssen. K-LW reports honoraria from Bayer, Boehringer Ingelheim, Daiichi-Sankyo, and Pfizer for Continuing Medical Education lectures. SAB reports consulting fees from Boston Scientific, Gore, Becton Dickinson, Cook, Phillips, Vesper, Veryan, Vetex, and Medtronic; honoraria from Boston Scientific, Gore, Becton Dickinson, Cook, Philips, Vesper, Veryan, Vetex, and Medtronic; research grants from Boston Scientific and Medtronic that are paid to his institution; is on the advisory board for Philips, Medtronic, Gore, and Boston Scientific. FAK reports research grants from Bayer, Bristol-Myers Squibb, Boehringer-Ingelheim, Merck Sharp & Dohme, Leo Pharma, Daiichi-Sankyo, Actelion, The Netherlands Organisation for Health Research and Development, The Dutch Thrombosis Association, The Dutch Heart Foundation, and the Horizon Europe Program, all outside the submitted work  and paid to his institution. All other authors declare no competing interests.\n",
      "\n",
      "Declaration of interests Anette Arbjerg Hojen reports research grants from The Danish Heart Foundation and The Novo Nordisk Foundation, consulting fees from Bayer and The Bristol-Myers Squibb-Pfizer Alliance, speaker bureaus from Bayer, The Bristol-Myers Squibb-Pfizer Alliance, and Merck Sharp & Dohme, and role as vice chair of special interest group venous thromboembolism of Danish Nurses' Council. Juan I. Arcelus reports honoraria from Sanofi and Rovi for educational activities, and research funding from Sanofi and Bayer Adam M. Gwozdz. William R. Auger reports payment or honoraria from  Bayer Pharmaceuticals, support for attending meeting from Bayer Pharmaceuticals,  and participation as Clinical Advisor for Janssen. Cihan Ay received personal fees for  lectures and participation in advisory boards from Bayer, Bristol Myers Squibb, Daiichi-Sankyo, Pfizer, and Sanofi. Stefano Barco reports unrestricted scientific grants from Bayer, INARI, Boston Scientific, Medtronic, Bard, SANOFI, and Concept Medical; consulting fees from INARI, Bayer, Boston Scientific, and Concept Medical; and travel financial support for attending meetings from Bayer and Daiichi Sankyo. Laurent Bertoletti reports personal fees and non-financial support from Aspen, personal fees and non-financial support from Bayer, Bristol Myers Squibb-Pfizer,  Leo Pharma, and Johnson and Johnson; grants, personal fees and non-financial support from Merck Sharp & Dohme, outside the submitted work. Arina Ten Cate-Hoek reports grants  from Alexion Pharmaceuticals, Bayer Pharma Adam M. Gwozdz, and Bristol Myers Squibb-Pfizer, consulting fees from Alexion Pharmaceuticals, Bayer Pharma Adam M. Gwozdz, and Bristol Myers  Squibb-Pfizer, and payments from Alexion Pharmaceuticals, Bayer Pharma Adam M. Gwozdz, and Bristol Myers Squibb-Pfizer, all fees paid to his company. HR-E reports speaker's honoraria from Bayer and Daichi-Sankyo, and support for attending meetings and travel from Bayer. RPR reports consulting fees from Bristol Myers Squibb, Janssen, Inari, Penumbra, Abbott, and research grants paid to her institution from Bristol Myers Squibb and Janssen, all outside the scope of this paper. CT reports honoraria from Riche Bayer, Astra Zeneca, Actelion, and Janssen. K-LW reports honoraria from Bayer, Boehringer Ingelheim, Daiichi-Sankyo, and Pfizer for Continuing Medical Education lectures. SAB reports consulting fees from Boston Scientific, Gore, Becton Dickinson, Cook, Phillips, Vesper, Veryan, Vetex, and Medtronic; honoraria from Boston Scientific, Gore, Becton Dickinson, Cook, Philips, Vesper, Veryan, Vetex, and Medtronic; research grants from Boston Scientific and Medtronic that are paid to his institution; is on the advisory board for Philips, Medtronic, Gore, and Boston Scientific. FAK reports research grants from Bayer, Bristol-Myers Squibb, Boehringer-Ingelheim, Merck Sharp & Dohme, Leo Pharma, Daiichi-Sankyo, Actelion, The Netherlands Organisation for Health Research and Development, The Dutch Thrombosis Association, The Dutch Heart Foundation, and the Horizon Europe Program, all outside the submitted work  and paid to his institution. All other authors declare no competing interests.\n",
      "\n",
      "Declaration of interests Anette Arbjerg Hojen reports research grants from The Danish Heart Foundation and The Novo Nordisk Foundation, consulting fees from Bayer and The Bristol-Myers Squibb-Pfizer Alliance, speaker bureaus from Bayer, The Bristol-Myers Squibb-Pfizer Alliance, and Merck Sharp & Dohme, and role as vice chair of special interest group venous thromboembolism of Danish Nurses' Council. Juan I. Arcelus reports honoraria from Sanofi and Rovi for educational activities, and research funding from Sanofi and Bayer Adam M. Gwozdz. William R. Auger reports payment or honoraria from  Bayer Pharmaceuticals, support for attending meeting from Bayer Pharmaceuticals,  and participation as Clinical Advisor for Janssen. Cihan Ay received personal fees for  lectures and participation in advisory boards from Bayer, Bristol Myers Squibb, Daiichi-Sankyo, Pfizer, and Sanofi. Stefano Barco reports unrestricted scientific grants from Bayer, INARI, Boston Scientific, Medtronic, Bard, SANOFI, and Concept Medical; consulting fees from INARI, Bayer, Boston Scientific, and Concept Medical; and travel financial support for attending meetings from Bayer and Daiichi Sankyo. Laurent Bertoletti reports personal fees and non-financial support from Aspen, personal fees and non-financial support from Bayer, Bristol Myers Squibb-Pfizer,  Leo Pharma, and Johnson and Johnson; grants, personal fees and non-financial support from Merck Sharp & Dohme, outside the submitted work. Arina Ten Cate-Hoek reports grants  from Alexion Pharmaceuticals, Bayer Pharma Adam M. Gwozdz, and Bristol Myers Squibb-Pfizer, consulting fees from Alexion Pharmaceuticals, Bayer Pharma Adam M. Gwozdz, and Bristol Myers  Squibb-Pfizer, and payments from Alexion Pharmaceuticals, Bayer Pharma Adam M. Gwozdz, and Bristol Myers Squibb-Pfizer, all fees paid to his company. HR-E reports speaker's honoraria from Bayer and Daichi-Sankyo, and support for attending meetings and travel from Bayer. RPR reports consulting fees from Bristol Myers Squibb, Janssen, Inari, Penumbra, Abbott, and research grants paid to her institution from Bristol Myers Squibb and Janssen, all outside the scope of this paper. CT reports honoraria from Riche Bayer, Astra Zeneca, Actelion, and Janssen. K-LW reports honoraria from Bayer, Boehringer Ingelheim, Daiichi-Sankyo, and Pfizer for Continuing Medical Education lectures. SAB reports consulting fees from Boston Scientific, Gore, Becton Dickinson, Cook, Phillips, Vesper, Veryan, Vetex, and Medtronic; honoraria from Boston Scientific, Gore, Becton Dickinson, Cook, Philips, Vesper, Veryan, Vetex, and Medtronic; research grants from Boston Scientific and Medtronic that are paid to his institution; is on the advisory board for Philips, Medtronic, Gore, and Boston Scientific. FAK reports research grants from Bayer, Bristol-Myers Squibb, Boehringer-Ingelheim, Merck Sharp & Dohme, Leo Pharma, Daiichi-Sankyo, Actelion, The Netherlands Organisation for Health Research and Development, The Dutch Thrombosis Association, The Dutch Heart Foundation, and the Horizon Europe Program, all outside the submitted work  and paid to his institution. All other authors declare no competing interests.\n",
      "\n",
      "Declaration of interests Anette Arbjerg Hojen reports research grants from The Danish Heart Foundation and The Novo Nordisk Foundation, consulting fees from Bayer and The Bristol-Myers Squibb-Pfizer Alliance, speaker bureaus from Bayer, The Bristol-Myers Squibb-Pfizer Alliance, and Merck Sharp & Dohme, and role as vice chair of special interest group venous thromboembolism of Danish Nurses' Council. Juan I. Arcelus reports honoraria from Sanofi and Rovi for educational activities, and research funding from Sanofi and Bayer Adam M. Gwozdz. William R. Auger reports payment or honoraria from  Bayer Pharmaceuticals, support for attending meeting from Bayer Pharmaceuticals,  and participation as Clinical Advisor for Janssen. Cihan Ay received personal fees for  lectures and participation in advisory boards from Bayer, Bristol Myers Squibb, Daiichi-Sankyo, Pfizer, and Sanofi. Stefano Barco reports unrestricted scientific grants from Bayer, INARI, Boston Scientific, Medtronic, Bard, SANOFI, and Concept Medical; consulting fees from INARI, Bayer, Boston Scientific, and Concept Medical; and travel financial support for attending meetings from Bayer and Daiichi Sankyo. Laurent Bertoletti reports personal fees and non-financial support from Aspen, personal fees and non-financial support from Bayer, Bristol Myers Squibb-Pfizer,  Leo Pharma, and Johnson and Johnson; grants, personal fees and non-financial support from Merck Sharp & Dohme, outside the submitted work. Arina Ten Cate-Hoek reports grants  from Alexion Pharmaceuticals, Bayer Pharma Adam M. Gwozdz, and Bristol Myers Squibb-Pfizer, consulting fees from Alexion Pharmaceuticals, Bayer Pharma Adam M. Gwozdz, and Bristol Myers  Squibb-Pfizer, and payments from Alexion Pharmaceuticals, Bayer Pharma Adam M. Gwozdz, and Bristol Myers Squibb-Pfizer, all fees paid to his company. HR-E reports speaker's honoraria from Bayer and Daichi-Sankyo, and support for attending meetings and travel from Bayer. RPR reports consulting fees from Bristol Myers Squibb, Janssen, Inari, Penumbra, Abbott, and research grants paid to her institution from Bristol Myers Squibb and Janssen, all outside the scope of this paper. CT reports honoraria from Riche Bayer, Astra Zeneca, Actelion, and Janssen. K-LW reports honoraria from Bayer, Boehringer Ingelheim, Daiichi-Sankyo, and Pfizer for Continuing Medical Education lectures. SAB reports consulting fees from Boston Scientific, Gore, Becton Dickinson, Cook, Phillips, Vesper, Veryan, Vetex, and Medtronic; honoraria from Boston Scientific, Gore, Becton Dickinson, Cook, Philips, Vesper, Veryan, Vetex, and Medtronic; research grants from Boston Scientific and Medtronic that are paid to his institution; is on the advisory board for Philips, Medtronic, Gore, and Boston Scientific. FAK reports research grants from Bayer, Bristol-Myers Squibb, Boehringer-Ingelheim, Merck Sharp & Dohme, Leo Pharma, Daiichi-Sankyo, Actelion, The Netherlands Organisation for Health Research and Development, The Dutch Thrombosis Association, The Dutch Heart Foundation, and the Horizon Europe Program, all outside the submitted work  and paid to his institution. All other authors declare no competing interests.\n",
      "\n",
      "Declaration of interests Anette Arbjerg Hojen reports research grants from The Danish Heart Foundation and The Novo Nordisk Foundation, consulting fees from Bayer and The Bristol-Myers Squibb-Pfizer Alliance, speaker bureaus from Bayer, The Bristol-Myers Squibb-Pfizer Alliance, and Merck Sharp & Dohme, and role as vice chair of special interest group venous thromboembolism of Danish Nurses' Council. Juan I. Arcelus reports honoraria from Sanofi and Rovi for educational activities, and research funding from Sanofi and Bayer Adam M. Gwozdz. William R. Auger reports payment or honoraria from  Bayer Pharmaceuticals, support for attending meeting from Bayer Pharmaceuticals,  and participation as Clinical Advisor for Janssen. Cihan Ay received personal fees for  lectures and participation in advisory boards from Bayer, Bristol Myers Squibb, Daiichi-Sankyo, Pfizer, and Sanofi. Stefano Barco reports unrestricted scientific grants from Bayer, INARI, Boston Scientific, Medtronic, Bard, SANOFI, and Concept Medical; consulting fees from INARI, Bayer, Boston Scientific, and Concept Medical; and travel financial support for attending meetings from Bayer and Daiichi Sankyo. Laurent Bertoletti reports personal fees and non-financial support from Aspen, personal fees and non-financial support from Bayer, Bristol Myers Squibb-Pfizer,  Leo Pharma, and Johnson and Johnson; grants, personal fees and non-financial support from Merck Sharp & Dohme, outside the submitted work. Arina Ten Cate-Hoek reports grants  from Alexion Pharmaceuticals, Bayer Pharma Adam M. Gwozdz, and Bristol Myers Squibb-Pfizer, consulting fees from Alexion Pharmaceuticals, Bayer Pharma Adam M. Gwozdz, and Bristol Myers  Squibb-Pfizer, and payments from Alexion Pharmaceuticals, Bayer Pharma Adam M. Gwozdz, and Bristol Myers Squibb-Pfizer, all fees paid to his company. HR-E reports speaker's honoraria from Bayer and Daichi-Sankyo, and support for attending meetings and travel from Bayer. RPR reports consulting fees from Bristol Myers Squibb, Janssen, Inari, Penumbra, Abbott, and research grants paid to her institution from Bristol Myers Squibb and Janssen, all outside the scope of this paper. CT reports honoraria from Riche Bayer, Astra Zeneca, Actelion, and Janssen. K-LW reports honoraria from Bayer, Boehringer Ingelheim, Daiichi-Sankyo, and Pfizer for Continuing Medical Education lectures. SAB reports consulting fees from Boston Scientific, Gore, Becton Dickinson, Cook, Phillips, Vesper, Veryan, Vetex, and Medtronic; honoraria from Boston Scientific, Gore, Becton Dickinson, Cook, Philips, Vesper, Veryan, Vetex, and Medtronic; research grants from Boston Scientific and Medtronic that are paid to his institution; is on the advisory board for Philips, Medtronic, Gore, and Boston Scientific. FAK reports research grants from Bayer, Bristol-Myers Squibb, Boehringer-Ingelheim, Merck Sharp & Dohme, Leo Pharma, Daiichi-Sankyo, Actelion, The Netherlands Organisation for Health Research and Development, The Dutch Thrombosis Association, The Dutch Heart Foundation, and the Horizon Europe Program, all outside the submitted work  and paid to his institution. All other authors declare no competing interests.\n",
      "\n",
      "Declaration of interests Anette Arbjerg Hojen reports research grants from The Danish Heart Foundation and The Novo Nordisk Foundation, consulting fees from Bayer and The Bristol-Myers Squibb-Pfizer Alliance, speaker bureaus from Bayer, The Bristol-Myers Squibb-Pfizer Alliance, and Merck Sharp & Dohme, and role as vice chair of special interest group venous thromboembolism of Danish Nurses' Council. Juan I. Arcelus reports honoraria from Sanofi and Rovi for educational activities, and research funding from Sanofi and Bayer Adam M. Gwozdz. William R. Auger reports payment or honoraria from  Bayer Pharmaceuticals, support for attending meeting from Bayer Pharmaceuticals,  and participation as Clinical Advisor for Janssen. Cihan Ay received personal fees for  lectures and participation in advisory boards from Bayer, Bristol Myers Squibb, Daiichi-Sankyo, Pfizer, and Sanofi. Stefano Barco reports unrestricted scientific grants from Bayer, INARI, Boston Scientific, Medtronic, Bard, SANOFI, and Concept Medical; consulting fees from INARI, Bayer, Boston Scientific, and Concept Medical; and travel financial support for attending meetings from Bayer and Daiichi Sankyo. Laurent Bertoletti reports personal fees and non-financial support from Aspen, personal fees and non-financial support from Bayer, Bristol Myers Squibb-Pfizer,  Leo Pharma, and Johnson and Johnson; grants, personal fees and non-financial support from Merck Sharp & Dohme, outside the submitted work. Arina Ten Cate-Hoek reports grants  from Alexion Pharmaceuticals, Bayer Pharma Adam M. Gwozdz, and Bristol Myers Squibb-Pfizer, consulting fees from Alexion Pharmaceuticals, Bayer Pharma Adam M. Gwozdz, and Bristol Myers  Squibb-Pfizer, and payments from Alexion Pharmaceuticals, Bayer Pharma Adam M. Gwozdz, and Bristol Myers Squibb-Pfizer, all fees paid to his company. HR-E reports speaker's honoraria from Bayer and Daichi-Sankyo, and support for attending meetings and travel from Bayer. RPR reports consulting fees from Bristol Myers Squibb, Janssen, Inari, Penumbra, Abbott, and research grants paid to her institution from Bristol Myers Squibb and Janssen, all outside the scope of this paper. CT reports honoraria from Riche Bayer, Astra Zeneca, Actelion, and Janssen. K-LW reports honoraria from Bayer, Boehringer Ingelheim, Daiichi-Sankyo, and Pfizer for Continuing Medical Education lectures. SAB reports consulting fees from Boston Scientific, Gore, Becton Dickinson, Cook, Phillips, Vesper, Veryan, Vetex, and Medtronic; honoraria from Boston Scientific, Gore, Becton Dickinson, Cook, Philips, Vesper, Veryan, Vetex, and Medtronic; research grants from Boston Scientific and Medtronic that are paid to his institution; is on the advisory board for Philips, Medtronic, Gore, and Boston Scientific. FAK reports research grants from Bayer, Bristol-Myers Squibb, Boehringer-Ingelheim, Merck Sharp & Dohme, Leo Pharma, Daiichi-Sankyo, Actelion, The Netherlands Organisation for Health Research and Development, The Dutch Thrombosis Association, The Dutch Heart Foundation, and the Horizon Europe Program, all outside the submitted work  and paid to his institution. All other authors declare no competing interests.\n",
      "\n",
      "Declaration of interests Anette Arbjerg Hojen reports research grants from The Danish Heart Foundation and The Novo Nordisk Foundation, consulting fees from Bayer and The Bristol-Myers Squibb-Pfizer Alliance, speaker bureaus from Bayer, The Bristol-Myers Squibb-Pfizer Alliance, and Merck Sharp & Dohme, and role as vice chair of special interest group venous thromboembolism of Danish Nurses' Council. Juan I. Arcelus reports honoraria from Sanofi and Rovi for educational activities, and research funding from Sanofi and Bayer Adam M. Gwozdz. William R. Auger reports payment or honoraria from  Bayer Pharmaceuticals, support for attending meeting from Bayer Pharmaceuticals,  and participation as Clinical Advisor for Janssen. Cihan Ay received personal fees for  lectures and participation in advisory boards from Bayer, Bristol Myers Squibb, Daiichi-Sankyo, Pfizer, and Sanofi. Stefano Barco reports unrestricted scientific grants from Bayer, INARI, Boston Scientific, Medtronic, Bard, SANOFI, and Concept Medical; consulting fees from INARI, Bayer, Boston Scientific, and Concept Medical; and travel financial support for attending meetings from Bayer and Daiichi Sankyo. Laurent Bertoletti reports personal fees and non-financial support from Aspen, personal fees and non-financial support from Bayer, Bristol Myers Squibb-Pfizer,  Leo Pharma, and Johnson and Johnson; grants, personal fees and non-financial support from Merck Sharp & Dohme, outside the submitted work. Arina Ten Cate-Hoek reports grants  from Alexion Pharmaceuticals, Bayer Pharma Adam M. Gwozdz, and Bristol Myers Squibb-Pfizer, consulting fees from Alexion Pharmaceuticals, Bayer Pharma Adam M. Gwozdz, and Bristol Myers  Squibb-Pfizer, and payments from Alexion Pharmaceuticals, Bayer Pharma Adam M. Gwozdz, and Bristol Myers Squibb-Pfizer, all fees paid to his company. HR-E reports speaker's honoraria from Bayer and Daichi-Sankyo, and support for attending meetings and travel from Bayer. RPR reports consulting fees from Bristol Myers Squibb, Janssen, Inari, Penumbra, Abbott, and research grants paid to her institution from Bristol Myers Squibb and Janssen, all outside the scope of this paper. CT reports honoraria from Riche Bayer, Astra Zeneca, Actelion, and Janssen. K-LW reports honoraria from Bayer, Boehringer Ingelheim, Daiichi-Sankyo, and Pfizer for Continuing Medical Education lectures. SAB reports consulting fees from Boston Scientific, Gore, Becton Dickinson, Cook, Phillips, Vesper, Veryan, Vetex, and Medtronic; honoraria from Boston Scientific, Gore, Becton Dickinson, Cook, Philips, Vesper, Veryan, Vetex, and Medtronic; research grants from Boston Scientific and Medtronic that are paid to his institution; is on the advisory board for Philips, Medtronic, Gore, and Boston Scientific. FAK reports research grants from Bayer, Bristol-Myers Squibb, Boehringer-Ingelheim, Merck Sharp & Dohme, Leo Pharma, Daiichi-Sankyo, Actelion, The Netherlands Organisation for Health Research and Development, The Dutch Thrombosis Association, The Dutch Heart Foundation, and the Horizon Europe Program, all outside the submitted work  and paid to his institution. All other authors declare no competing interests.\n",
      "\n",
      "Declaration of interests Anette Arbjerg Hojen reports research grants from The Danish Heart Foundation and The Novo Nordisk Foundation, consulting fees from Bayer and The Bristol-Myers Squibb-Pfizer Alliance, speaker bureaus from Bayer, The Bristol-Myers Squibb-Pfizer Alliance, and Merck Sharp & Dohme, and role as vice chair of special interest group venous thromboembolism of Danish Nurses' Council. Juan I. Arcelus reports honoraria from Sanofi and Rovi for educational activities, and research funding from Sanofi and Bayer Adam M. Gwozdz. William R. Auger reports payment or honoraria from  Bayer Pharmaceuticals, support for attending meeting from Bayer Pharmaceuticals,  and participation as Clinical Advisor for Janssen. Cihan Ay received personal fees for  lectures and participation in advisory boards from Bayer, Bristol Myers Squibb, Daiichi-Sankyo, Pfizer, and Sanofi. Stefano Barco reports unrestricted scientific grants from Bayer, INARI, Boston Scientific, Medtronic, Bard, SANOFI, and Concept Medical; consulting fees from INARI, Bayer, Boston Scientific, and Concept Medical; and travel financial support for attending meetings from Bayer and Daiichi Sankyo. Laurent Bertoletti reports personal fees and non-financial support from Aspen, personal fees and non-financial support from Bayer, Bristol Myers Squibb-Pfizer,  Leo Pharma, and Johnson and Johnson; grants, personal fees and non-financial support from Merck Sharp & Dohme, outside the submitted work. Arina Ten Cate-Hoek reports grants  from Alexion Pharmaceuticals, Bayer Pharma Adam M. Gwozdz, and Bristol Myers Squibb-Pfizer, consulting fees from Alexion Pharmaceuticals, Bayer Pharma Adam M. Gwozdz, and Bristol Myers  Squibb-Pfizer, and payments from Alexion Pharmaceuticals, Bayer Pharma Adam M. Gwozdz, and Bristol Myers Squibb-Pfizer, all fees paid to his company. HR-E reports speaker's honoraria from Bayer and Daichi-Sankyo, and support for attending meetings and travel from Bayer. RPR reports consulting fees from Bristol Myers Squibb, Janssen, Inari, Penumbra, Abbott, and research grants paid to her institution from Bristol Myers Squibb and Janssen, all outside the scope of this paper. CT reports honoraria from Riche Bayer, Astra Zeneca, Actelion, and Janssen. K-LW reports honoraria from Bayer, Boehringer Ingelheim, Daiichi-Sankyo, and Pfizer for Continuing Medical Education lectures. SAB reports consulting fees from Boston Scientific, Gore, Becton Dickinson, Cook, Phillips, Vesper, Veryan, Vetex, and Medtronic; honoraria from Boston Scientific, Gore, Becton Dickinson, Cook, Philips, Vesper, Veryan, Vetex, and Medtronic; research grants from Boston Scientific and Medtronic that are paid to his institution; is on the advisory board for Philips, Medtronic, Gore, and Boston Scientific. FAK reports research grants from Bayer, Bristol-Myers Squibb, Boehringer-Ingelheim, Merck Sharp & Dohme, Leo Pharma, Daiichi-Sankyo, Actelion, The Netherlands Organisation for Health Research and Development, The Dutch Thrombosis Association, The Dutch Heart Foundation, and the Horizon Europe Program, all outside the submitted work  and paid to his institution. All other authors declare no competing interests.\n",
      "\n",
      "Declaration of interests Anette Arbjerg Hojen reports research grants from The Danish Heart Foundation and The Novo Nordisk Foundation, consulting fees from Bayer and The Bristol-Myers Squibb-Pfizer Alliance, speaker bureaus from Bayer, The Bristol-Myers Squibb-Pfizer Alliance, and Merck Sharp & Dohme, and role as vice chair of special interest group venous thromboembolism of Danish Nurses' Council. Juan I. Arcelus reports honoraria from Sanofi and Rovi for educational activities, and research funding from Sanofi and Bayer Adam M. Gwozdz. William R. Auger reports payment or honoraria from  Bayer Pharmaceuticals, support for attending meeting from Bayer Pharmaceuticals,  and participation as Clinical Advisor for Janssen. Cihan Ay received personal fees for  lectures and participation in advisory boards from Bayer, Bristol Myers Squibb, Daiichi-Sankyo, Pfizer, and Sanofi. Stefano Barco reports unrestricted scientific grants from Bayer, INARI, Boston Scientific, Medtronic, Bard, SANOFI, and Concept Medical; consulting fees from INARI, Bayer, Boston Scientific, and Concept Medical; and travel financial support for attending meetings from Bayer and Daiichi Sankyo. Laurent Bertoletti reports personal fees and non-financial support from Aspen, personal fees and non-financial support from Bayer, Bristol Myers Squibb-Pfizer,  Leo Pharma, and Johnson and Johnson; grants, personal fees and non-financial support from Merck Sharp & Dohme, outside the submitted work. Arina Ten Cate-Hoek reports grants  from Alexion Pharmaceuticals, Bayer Pharma Adam M. Gwozdz, and Bristol Myers Squibb-Pfizer, consulting fees from Alexion Pharmaceuticals, Bayer Pharma Adam M. Gwozdz, and Bristol Myers  Squibb-Pfizer, and payments from Alexion Pharmaceuticals, Bayer Pharma Adam M. Gwozdz, and Bristol Myers Squibb-Pfizer, all fees paid to his company. HR-E reports speaker's honoraria from Bayer and Daichi-Sankyo, and support for attending meetings and travel from Bayer. RPR reports consulting fees from Bristol Myers Squibb, Janssen, Inari, Penumbra, Abbott, and research grants paid to her institution from Bristol Myers Squibb and Janssen, all outside the scope of this paper. CT reports honoraria from Riche Bayer, Astra Zeneca, Actelion, and Janssen. K-LW reports honoraria from Bayer, Boehringer Ingelheim, Daiichi-Sankyo, and Pfizer for Continuing Medical Education lectures. SAB reports consulting fees from Boston Scientific, Gore, Becton Dickinson, Cook, Phillips, Vesper, Veryan, Vetex, and Medtronic; honoraria from Boston Scientific, Gore, Becton Dickinson, Cook, Philips, Vesper, Veryan, Vetex, and Medtronic; research grants from Boston Scientific and Medtronic that are paid to his institution; is on the advisory board for Philips, Medtronic, Gore, and Boston Scientific. FAK reports research grants from Bayer, Bristol-Myers Squibb, Boehringer-Ingelheim, Merck Sharp & Dohme, Leo Pharma, Daiichi-Sankyo, Actelion, The Netherlands Organisation for Health Research and Development, The Dutch Thrombosis Association, The Dutch Heart Foundation, and the Horizon Europe Program, all outside the submitted work  and paid to his institution. All other authors declare no competing interests.\n",
      "\n",
      "Declaration of interests Anette Arbjerg Hojen reports research grants from The Danish Heart Foundation and The Novo Nordisk Foundation, consulting fees from Bayer and The Bristol-Myers Squibb-Pfizer Alliance, speaker bureaus from Bayer, The Bristol-Myers Squibb-Pfizer Alliance, and Merck Sharp & Dohme, and role as vice chair of special interest group venous thromboembolism of Danish Nurses' Council. Juan I. Arcelus reports honoraria from Sanofi and Rovi for educational activities, and research funding from Sanofi and Bayer Adam M. Gwozdz. William R. Auger reports payment or honoraria from  Bayer Pharmaceuticals, support for attending meeting from Bayer Pharmaceuticals,  and participation as Clinical Advisor for Janssen. Cihan Ay received personal fees for  lectures and participation in advisory boards from Bayer, Bristol Myers Squibb, Daiichi-Sankyo, Pfizer, and Sanofi. Stefano Barco reports unrestricted scientific grants from Bayer, INARI, Boston Scientific, Medtronic, Bard, SANOFI, and Concept Medical; consulting fees from INARI, Bayer, Boston Scientific, and Concept Medical; and travel financial support for attending meetings from Bayer and Daiichi Sankyo. Laurent Bertoletti reports personal fees and non-financial support from Aspen, personal fees and non-financial support from Bayer, Bristol Myers Squibb-Pfizer,  Leo Pharma, and Johnson and Johnson; grants, personal fees and non-financial support from Merck Sharp & Dohme, outside the submitted work. Arina Ten Cate-Hoek reports grants  from Alexion Pharmaceuticals, Bayer Pharma Adam M. Gwozdz, and Bristol Myers Squibb-Pfizer, consulting fees from Alexion Pharmaceuticals, Bayer Pharma Adam M. Gwozdz, and Bristol Myers  Squibb-Pfizer, and payments from Alexion Pharmaceuticals, Bayer Pharma Adam M. Gwozdz, and Bristol Myers Squibb-Pfizer, all fees paid to his company. HR-E reports speaker's honoraria from Bayer and Daichi-Sankyo, and support for attending meetings and travel from Bayer. RPR reports consulting fees from Bristol Myers Squibb, Janssen, Inari, Penumbra, Abbott, and research grants paid to her institution from Bristol Myers Squibb and Janssen, all outside the scope of this paper. CT reports honoraria from Riche Bayer, Astra Zeneca, Actelion, and Janssen. K-LW reports honoraria from Bayer, Boehringer Ingelheim, Daiichi-Sankyo, and Pfizer for Continuing Medical Education lectures. SAB reports consulting fees from Boston Scientific, Gore, Becton Dickinson, Cook, Phillips, Vesper, Veryan, Vetex, and Medtronic; honoraria from Boston Scientific, Gore, Becton Dickinson, Cook, Philips, Vesper, Veryan, Vetex, and Medtronic; research grants from Boston Scientific and Medtronic that are paid to his institution; is on the advisory board for Philips, Medtronic, Gore, and Boston Scientific. FAK reports research grants from Bayer, Bristol-Myers Squibb, Boehringer-Ingelheim, Merck Sharp & Dohme, Leo Pharma, Daiichi-Sankyo, Actelion, The Netherlands Organisation for Health Research and Development, The Dutch Thrombosis Association, The Dutch Heart Foundation, and the Horizon Europe Program, all outside the submitted work  and paid to his institution. All other authors declare no competing interests.\n",
      "\n",
      "Robert-Ebadi, Helia\n",
      "Declaration of interests Anette Arbjerg Hojen reports research grants from The Danish Heart Foundation and The Novo Nordisk Foundation, consulting fees from Bayer and The Bristol-Myers Squibb-Pfizer Alliance, speaker bureaus from Bayer, The Bristol-Myers Squibb-Pfizer Alliance, and Merck Sharp & Dohme, and role as vice chair of special interest group venous thromboembolism of Danish Nurses' Council. Juan I. Arcelus reports honoraria from Sanofi and Rovi for educational activities, and research funding from Sanofi and Bayer Adam M. Gwozdz. William R. Auger reports payment or honoraria from  Bayer Pharmaceuticals, support for attending meeting from Bayer Pharmaceuticals,  and participation as Clinical Advisor for Janssen. Cihan Ay received personal fees for  lectures and participation in advisory boards from Bayer, Bristol Myers Squibb, Daiichi-Sankyo, Pfizer, and Sanofi. Stefano Barco reports unrestricted scientific grants from Bayer, INARI, Boston Scientific, Medtronic, Bard, SANOFI, and Concept Medical; consulting fees from INARI, Bayer, Boston Scientific, and Concept Medical; and travel financial support for attending meetings from Bayer and Daiichi Sankyo. Laurent Bertoletti reports personal fees and non-financial support from Aspen, personal fees and non-financial support from Bayer, Bristol Myers Squibb-Pfizer,  Leo Pharma, and Johnson and Johnson; grants, personal fees and non-financial support from Merck Sharp & Dohme, outside the submitted work. Arina Ten Cate-Hoek reports grants  from Alexion Pharmaceuticals, Bayer Pharma Adam M. Gwozdz, and Bristol Myers Squibb-Pfizer, consulting fees from Alexion Pharmaceuticals, Bayer Pharma Adam M. Gwozdz, and Bristol Myers  Squibb-Pfizer, and payments from Alexion Pharmaceuticals, Bayer Pharma Adam M. Gwozdz, and Bristol Myers Squibb-Pfizer, all fees paid to his company. Helia Robert-Ebadi-E reports speaker's honoraria from Bayer and Daichi-Sankyo, and support for attending meetings and travel from Bayer. RPR reports consulting fees from Bristol Myers Squibb, Janssen, Inari, Penumbra, Abbott, and research grants paid to her institution from Bristol Myers Squibb and Janssen, all outside the scope of this paper. CT reports honoraria from Riche Bayer, Astra Zeneca, Actelion, and Janssen. K-LW reports honoraria from Bayer, Boehringer Ingelheim, Daiichi-Sankyo, and Pfizer for Continuing Medical Education lectures. SAB reports consulting fees from Boston Scientific, Gore, Becton Dickinson, Cook, Phillips, Vesper, Veryan, Vetex, and Medtronic; honoraria from Boston Scientific, Gore, Becton Dickinson, Cook, Philips, Vesper, Veryan, Vetex, and Medtronic; research grants from Boston Scientific and Medtronic that are paid to his institution; is on the advisory board for Philips, Medtronic, Gore, and Boston Scientific. FAK reports research grants from Bayer, Bristol-Myers Squibb, Boehringer-Ingelheim, Merck Sharp & Dohme, Leo Pharma, Daiichi-Sankyo, Actelion, The Netherlands Organisation for Health Research and Development, The Dutch Thrombosis Association, The Dutch Heart Foundation, and the Horizon Europe Program, all outside the submitted work  and paid to his institution. All other authors declare no competing interests.\n",
      "\n",
      "Rosovsky, Rachel P.\n",
      "Declaration of interests Anette Arbjerg Hojen reports research grants from The Danish Heart Foundation and The Novo Nordisk Foundation, consulting fees from Bayer and The Bristol-Myers Squibb-Pfizer Alliance, speaker bureaus from Bayer, The Bristol-Myers Squibb-Pfizer Alliance, and Merck Sharp & Dohme, and role as vice chair of special interest group venous thromboembolism of Danish Nurses' Council. Juan I. Arcelus reports honoraria from Sanofi and Rovi for educational activities, and research funding from Sanofi and Bayer Adam M. Gwozdz. William R. Auger reports payment or honoraria from  Bayer Pharmaceuticals, support for attending meeting from Bayer Pharmaceuticals,  and participation as Clinical Advisor for Janssen. Cihan Ay received personal fees for  lectures and participation in advisory boards from Bayer, Bristol Myers Squibb, Daiichi-Sankyo, Pfizer, and Sanofi. Stefano Barco reports unrestricted scientific grants from Bayer, INARI, Boston Scientific, Medtronic, Bard, SANOFI, and Concept Medical; consulting fees from INARI, Bayer, Boston Scientific, and Concept Medical; and travel financial support for attending meetings from Bayer and Daiichi Sankyo. Laurent Bertoletti reports personal fees and non-financial support from Aspen, personal fees and non-financial support from Bayer, Bristol Myers Squibb-Pfizer,  Leo Pharma, and Johnson and Johnson; grants, personal fees and non-financial support from Merck Sharp & Dohme, outside the submitted work. Arina Ten Cate-Hoek reports grants  from Alexion Pharmaceuticals, Bayer Pharma Adam M. Gwozdz, and Bristol Myers Squibb-Pfizer, consulting fees from Alexion Pharmaceuticals, Bayer Pharma Adam M. Gwozdz, and Bristol Myers  Squibb-Pfizer, and payments from Alexion Pharmaceuticals, Bayer Pharma Adam M. Gwozdz, and Bristol Myers Squibb-Pfizer, all fees paid to his company. Helia Robert-Ebadi-E reports speaker's honoraria from Bayer and Daichi-Sankyo, and support for attending meetings and travel from Bayer. Rachel P. Rosovsky reports consulting fees from Bristol Myers Squibb, Janssen, Inari, Penumbra, Abbott, and research grants paid to her institution from Bristol Myers Squibb and Janssen, all outside the scope of this paper. CT reports honoraria from Riche Bayer, Astra Zeneca, Actelion, and Janssen. K-LW reports honoraria from Bayer, Boehringer Ingelheim, Daiichi-Sankyo, and Pfizer for Continuing Medical Education lectures. SAB reports consulting fees from Boston Scientific, Gore, Becton Dickinson, Cook, Phillips, Vesper, Veryan, Vetex, and Medtronic; honoraria from Boston Scientific, Gore, Becton Dickinson, Cook, Philips, Vesper, Veryan, Vetex, and Medtronic; research grants from Boston Scientific and Medtronic that are paid to his institution; is on the advisory board for Philips, Medtronic, Gore, and Boston Scientific. FAK reports research grants from Bayer, Bristol-Myers Squibb, Boehringer-Ingelheim, Merck Sharp & Dohme, Leo Pharma, Daiichi-Sankyo, Actelion, The Netherlands Organisation for Health Research and Development, The Dutch Thrombosis Association, The Dutch Heart Foundation, and the Horizon Europe Program, all outside the submitted work  and paid to his institution. All other authors declare no competing interests.\n",
      "\n",
      "Declaration of interests Anette Arbjerg Hojen reports research grants from The Danish Heart Foundation and The Novo Nordisk Foundation, consulting fees from Bayer and The Bristol-Myers Squibb-Pfizer Alliance, speaker bureaus from Bayer, The Bristol-Myers Squibb-Pfizer Alliance, and Merck Sharp & Dohme, and role as vice chair of special interest group venous thromboembolism of Danish Nurses' Council. Juan I. Arcelus reports honoraria from Sanofi and Rovi for educational activities, and research funding from Sanofi and Bayer Adam M. Gwozdz. William R. Auger reports payment or honoraria from  Bayer Pharmaceuticals, support for attending meeting from Bayer Pharmaceuticals,  and participation as Clinical Advisor for Janssen. Cihan Ay received personal fees for  lectures and participation in advisory boards from Bayer, Bristol Myers Squibb, Daiichi-Sankyo, Pfizer, and Sanofi. Stefano Barco reports unrestricted scientific grants from Bayer, INARI, Boston Scientific, Medtronic, Bard, SANOFI, and Concept Medical; consulting fees from INARI, Bayer, Boston Scientific, and Concept Medical; and travel financial support for attending meetings from Bayer and Daiichi Sankyo. Laurent Bertoletti reports personal fees and non-financial support from Aspen, personal fees and non-financial support from Bayer, Bristol Myers Squibb-Pfizer,  Leo Pharma, and Johnson and Johnson; grants, personal fees and non-financial support from Merck Sharp & Dohme, outside the submitted work. Arina Ten Cate-Hoek reports grants  from Alexion Pharmaceuticals, Bayer Pharma Adam M. Gwozdz, and Bristol Myers Squibb-Pfizer, consulting fees from Alexion Pharmaceuticals, Bayer Pharma Adam M. Gwozdz, and Bristol Myers  Squibb-Pfizer, and payments from Alexion Pharmaceuticals, Bayer Pharma Adam M. Gwozdz, and Bristol Myers Squibb-Pfizer, all fees paid to his company. Helia Robert-Ebadi-E reports speaker's honoraria from Bayer and Daichi-Sankyo, and support for attending meetings and travel from Bayer. Rachel P. Rosovsky reports consulting fees from Bristol Myers Squibb, Janssen, Inari, Penumbra, Abbott, and research grants paid to her institution from Bristol Myers Squibb and Janssen, all outside the scope of this paper. CT reports honoraria from Riche Bayer, Astra Zeneca, Actelion, and Janssen. K-LW reports honoraria from Bayer, Boehringer Ingelheim, Daiichi-Sankyo, and Pfizer for Continuing Medical Education lectures. SAB reports consulting fees from Boston Scientific, Gore, Becton Dickinson, Cook, Phillips, Vesper, Veryan, Vetex, and Medtronic; honoraria from Boston Scientific, Gore, Becton Dickinson, Cook, Philips, Vesper, Veryan, Vetex, and Medtronic; research grants from Boston Scientific and Medtronic that are paid to his institution; is on the advisory board for Philips, Medtronic, Gore, and Boston Scientific. FAK reports research grants from Bayer, Bristol-Myers Squibb, Boehringer-Ingelheim, Merck Sharp & Dohme, Leo Pharma, Daiichi-Sankyo, Actelion, The Netherlands Organisation for Health Research and Development, The Dutch Thrombosis Association, The Dutch Heart Foundation, and the Horizon Europe Program, all outside the submitted work  and paid to his institution. All other authors declare no competing interests.\n",
      "\n",
      "Declaration of interests Anette Arbjerg Hojen reports research grants from The Danish Heart Foundation and The Novo Nordisk Foundation, consulting fees from Bayer and The Bristol-Myers Squibb-Pfizer Alliance, speaker bureaus from Bayer, The Bristol-Myers Squibb-Pfizer Alliance, and Merck Sharp & Dohme, and role as vice chair of special interest group venous thromboembolism of Danish Nurses' Council. Juan I. Arcelus reports honoraria from Sanofi and Rovi for educational activities, and research funding from Sanofi and Bayer Adam M. Gwozdz. William R. Auger reports payment or honoraria from  Bayer Pharmaceuticals, support for attending meeting from Bayer Pharmaceuticals,  and participation as Clinical Advisor for Janssen. Cihan Ay received personal fees for  lectures and participation in advisory boards from Bayer, Bristol Myers Squibb, Daiichi-Sankyo, Pfizer, and Sanofi. Stefano Barco reports unrestricted scientific grants from Bayer, INARI, Boston Scientific, Medtronic, Bard, SANOFI, and Concept Medical; consulting fees from INARI, Bayer, Boston Scientific, and Concept Medical; and travel financial support for attending meetings from Bayer and Daiichi Sankyo. Laurent Bertoletti reports personal fees and non-financial support from Aspen, personal fees and non-financial support from Bayer, Bristol Myers Squibb-Pfizer,  Leo Pharma, and Johnson and Johnson; grants, personal fees and non-financial support from Merck Sharp & Dohme, outside the submitted work. Arina Ten Cate-Hoek reports grants  from Alexion Pharmaceuticals, Bayer Pharma Adam M. Gwozdz, and Bristol Myers Squibb-Pfizer, consulting fees from Alexion Pharmaceuticals, Bayer Pharma Adam M. Gwozdz, and Bristol Myers  Squibb-Pfizer, and payments from Alexion Pharmaceuticals, Bayer Pharma Adam M. Gwozdz, and Bristol Myers Squibb-Pfizer, all fees paid to his company. Helia Robert-Ebadi-E reports speaker's honoraria from Bayer and Daichi-Sankyo, and support for attending meetings and travel from Bayer. Rachel P. Rosovsky reports consulting fees from Bristol Myers Squibb, Janssen, Inari, Penumbra, Abbott, and research grants paid to her institution from Bristol Myers Squibb and Janssen, all outside the scope of this paper. CT reports honoraria from Riche Bayer, Astra Zeneca, Actelion, and Janssen. K-LW reports honoraria from Bayer, Boehringer Ingelheim, Daiichi-Sankyo, and Pfizer for Continuing Medical Education lectures. SAB reports consulting fees from Boston Scientific, Gore, Becton Dickinson, Cook, Phillips, Vesper, Veryan, Vetex, and Medtronic; honoraria from Boston Scientific, Gore, Becton Dickinson, Cook, Philips, Vesper, Veryan, Vetex, and Medtronic; research grants from Boston Scientific and Medtronic that are paid to his institution; is on the advisory board for Philips, Medtronic, Gore, and Boston Scientific. FAK reports research grants from Bayer, Bristol-Myers Squibb, Boehringer-Ingelheim, Merck Sharp & Dohme, Leo Pharma, Daiichi-Sankyo, Actelion, The Netherlands Organisation for Health Research and Development, The Dutch Thrombosis Association, The Dutch Heart Foundation, and the Horizon Europe Program, all outside the submitted work  and paid to his institution. All other authors declare no competing interests.\n",
      "\n",
      "Tromeur, Cecile\n",
      "Declaration of interests Anette Arbjerg Hojen reports research grants from The Danish Heart Foundation and The Novo Nordisk Foundation, consulting fees from Bayer and The Bristol-Myers Squibb-Pfizer Alliance, speaker bureaus from Bayer, The Bristol-Myers Squibb-Pfizer Alliance, and Merck Sharp & Dohme, and role as vice chair of special interest group venous thromboembolism of Danish Nurses' Council. Juan I. Arcelus reports honoraria from Sanofi and Rovi for educational activities, and research funding from Sanofi and Bayer Adam M. Gwozdz. William R. Auger reports payment or honoraria from  Bayer Pharmaceuticals, support for attending meeting from Bayer Pharmaceuticals,  and participation as Clinical Advisor for Janssen. Cihan Ay received personal fees for  lectures and participation in advisory boards from Bayer, Bristol Myers Squibb, Daiichi-Sankyo, Pfizer, and Sanofi. Stefano Barco reports unrestricted scientific grants from Bayer, INARI, Boston Scientific, Medtronic, Bard, SANOFI, and Concept Medical; consulting fees from INARI, Bayer, Boston Scientific, and Concept Medical; and travel financial support for attending meetings from Bayer and Daiichi Sankyo. Laurent Bertoletti reports personal fees and non-financial support from Aspen, personal fees and non-financial support from Bayer, Bristol Myers Squibb-Pfizer,  Leo Pharma, and Johnson and Johnson; grants, personal fees and non-financial support from Merck Sharp & Dohme, outside the submitted work. Arina Ten Cate-Hoek reports grants  from Alexion Pharmaceuticals, Bayer Pharma Adam M. Gwozdz, and Bristol Myers Squibb-Pfizer, consulting fees from Alexion Pharmaceuticals, Bayer Pharma Adam M. Gwozdz, and Bristol Myers  Squibb-Pfizer, and payments from Alexion Pharmaceuticals, Bayer Pharma Adam M. Gwozdz, and Bristol Myers Squibb-Pfizer, all fees paid to his company. Helia Robert-Ebadi-E reports speaker's honoraria from Bayer and Daichi-Sankyo, and support for attending meetings and travel from Bayer. Rachel P. Rosovsky reports consulting fees from Bristol Myers Squibb, Janssen, Inari, Penumbra, Abbott, and research grants paid to her institution from Bristol Myers Squibb and Janssen, all outside the scope of this paper. Cecile Tromeur reports honoraria from Riche Bayer, Astra Zeneca, Actelion, and Janssen. K-LW reports honoraria from Bayer, Boehringer Ingelheim, Daiichi-Sankyo, and Pfizer for Continuing Medical Education lectures. SAB reports consulting fees from Boston Scientific, Gore, Becton Dickinson, Cook, Phillips, Vesper, Veryan, Vetex, and Medtronic; honoraria from Boston Scientific, Gore, Becton Dickinson, Cook, Philips, Vesper, Veryan, Vetex, and Medtronic; research grants from Boston Scientific and Medtronic that are paid to his institution; is on the advisory board for Philips, Medtronic, Gore, and Boston Scientific. FAK reports research grants from Bayer, Bristol-Myers Squibb, Boehringer-Ingelheim, Merck Sharp & Dohme, Leo Pharma, Daiichi-Sankyo, Actelion, The Netherlands Organisation for Health Research and Development, The Dutch Thrombosis Association, The Dutch Heart Foundation, and the Horizon Europe Program, all outside the submitted work  and paid to his institution. All other authors declare no competing interests.\n",
      "\n",
      "Declaration of interests Anette Arbjerg Hojen reports research grants from The Danish Heart Foundation and The Novo Nordisk Foundation, consulting fees from Bayer and The Bristol-Myers Squibb-Pfizer Alliance, speaker bureaus from Bayer, The Bristol-Myers Squibb-Pfizer Alliance, and Merck Sharp & Dohme, and role as vice chair of special interest group venous thromboembolism of Danish Nurses' Council. Juan I. Arcelus reports honoraria from Sanofi and Rovi for educational activities, and research funding from Sanofi and Bayer Adam M. Gwozdz. William R. Auger reports payment or honoraria from  Bayer Pharmaceuticals, support for attending meeting from Bayer Pharmaceuticals,  and participation as Clinical Advisor for Janssen. Cihan Ay received personal fees for  lectures and participation in advisory boards from Bayer, Bristol Myers Squibb, Daiichi-Sankyo, Pfizer, and Sanofi. Stefano Barco reports unrestricted scientific grants from Bayer, INARI, Boston Scientific, Medtronic, Bard, SANOFI, and Concept Medical; consulting fees from INARI, Bayer, Boston Scientific, and Concept Medical; and travel financial support for attending meetings from Bayer and Daiichi Sankyo. Laurent Bertoletti reports personal fees and non-financial support from Aspen, personal fees and non-financial support from Bayer, Bristol Myers Squibb-Pfizer,  Leo Pharma, and Johnson and Johnson; grants, personal fees and non-financial support from Merck Sharp & Dohme, outside the submitted work. Arina Ten Cate-Hoek reports grants  from Alexion Pharmaceuticals, Bayer Pharma Adam M. Gwozdz, and Bristol Myers Squibb-Pfizer, consulting fees from Alexion Pharmaceuticals, Bayer Pharma Adam M. Gwozdz, and Bristol Myers  Squibb-Pfizer, and payments from Alexion Pharmaceuticals, Bayer Pharma Adam M. Gwozdz, and Bristol Myers Squibb-Pfizer, all fees paid to his company. Helia Robert-Ebadi-E reports speaker's honoraria from Bayer and Daichi-Sankyo, and support for attending meetings and travel from Bayer. Rachel P. Rosovsky reports consulting fees from Bristol Myers Squibb, Janssen, Inari, Penumbra, Abbott, and research grants paid to her institution from Bristol Myers Squibb and Janssen, all outside the scope of this paper. Cecile Tromeur reports honoraria from Riche Bayer, Astra Zeneca, Actelion, and Janssen. K-LW reports honoraria from Bayer, Boehringer Ingelheim, Daiichi-Sankyo, and Pfizer for Continuing Medical Education lectures. SAB reports consulting fees from Boston Scientific, Gore, Becton Dickinson, Cook, Phillips, Vesper, Veryan, Vetex, and Medtronic; honoraria from Boston Scientific, Gore, Becton Dickinson, Cook, Philips, Vesper, Veryan, Vetex, and Medtronic; research grants from Boston Scientific and Medtronic that are paid to his institution; is on the advisory board for Philips, Medtronic, Gore, and Boston Scientific. FAK reports research grants from Bayer, Bristol-Myers Squibb, Boehringer-Ingelheim, Merck Sharp & Dohme, Leo Pharma, Daiichi-Sankyo, Actelion, The Netherlands Organisation for Health Research and Development, The Dutch Thrombosis Association, The Dutch Heart Foundation, and the Horizon Europe Program, all outside the submitted work  and paid to his institution. All other authors declare no competing interests.\n",
      "\n",
      "Declaration of interests Anette Arbjerg Hojen reports research grants from The Danish Heart Foundation and The Novo Nordisk Foundation, consulting fees from Bayer and The Bristol-Myers Squibb-Pfizer Alliance, speaker bureaus from Bayer, The Bristol-Myers Squibb-Pfizer Alliance, and Merck Sharp & Dohme, and role as vice chair of special interest group venous thromboembolism of Danish Nurses' Council. Juan I. Arcelus reports honoraria from Sanofi and Rovi for educational activities, and research funding from Sanofi and Bayer Adam M. Gwozdz. William R. Auger reports payment or honoraria from  Bayer Pharmaceuticals, support for attending meeting from Bayer Pharmaceuticals,  and participation as Clinical Advisor for Janssen. Cihan Ay received personal fees for  lectures and participation in advisory boards from Bayer, Bristol Myers Squibb, Daiichi-Sankyo, Pfizer, and Sanofi. Stefano Barco reports unrestricted scientific grants from Bayer, INARI, Boston Scientific, Medtronic, Bard, SANOFI, and Concept Medical; consulting fees from INARI, Bayer, Boston Scientific, and Concept Medical; and travel financial support for attending meetings from Bayer and Daiichi Sankyo. Laurent Bertoletti reports personal fees and non-financial support from Aspen, personal fees and non-financial support from Bayer, Bristol Myers Squibb-Pfizer,  Leo Pharma, and Johnson and Johnson; grants, personal fees and non-financial support from Merck Sharp & Dohme, outside the submitted work. Arina Ten Cate-Hoek reports grants  from Alexion Pharmaceuticals, Bayer Pharma Adam M. Gwozdz, and Bristol Myers Squibb-Pfizer, consulting fees from Alexion Pharmaceuticals, Bayer Pharma Adam M. Gwozdz, and Bristol Myers  Squibb-Pfizer, and payments from Alexion Pharmaceuticals, Bayer Pharma Adam M. Gwozdz, and Bristol Myers Squibb-Pfizer, all fees paid to his company. Helia Robert-Ebadi-E reports speaker's honoraria from Bayer and Daichi-Sankyo, and support for attending meetings and travel from Bayer. Rachel P. Rosovsky reports consulting fees from Bristol Myers Squibb, Janssen, Inari, Penumbra, Abbott, and research grants paid to her institution from Bristol Myers Squibb and Janssen, all outside the scope of this paper. Cecile Tromeur reports honoraria from Riche Bayer, Astra Zeneca, Actelion, and Janssen. K-LW reports honoraria from Bayer, Boehringer Ingelheim, Daiichi-Sankyo, and Pfizer for Continuing Medical Education lectures. SAB reports consulting fees from Boston Scientific, Gore, Becton Dickinson, Cook, Phillips, Vesper, Veryan, Vetex, and Medtronic; honoraria from Boston Scientific, Gore, Becton Dickinson, Cook, Philips, Vesper, Veryan, Vetex, and Medtronic; research grants from Boston Scientific and Medtronic that are paid to his institution; is on the advisory board for Philips, Medtronic, Gore, and Boston Scientific. FAK reports research grants from Bayer, Bristol-Myers Squibb, Boehringer-Ingelheim, Merck Sharp & Dohme, Leo Pharma, Daiichi-Sankyo, Actelion, The Netherlands Organisation for Health Research and Development, The Dutch Thrombosis Association, The Dutch Heart Foundation, and the Horizon Europe Program, all outside the submitted work  and paid to his institution. All other authors declare no competing interests.\n",
      "\n",
      "Declaration of interests Anette Arbjerg Hojen reports research grants from The Danish Heart Foundation and The Novo Nordisk Foundation, consulting fees from Bayer and The Bristol-Myers Squibb-Pfizer Alliance, speaker bureaus from Bayer, The Bristol-Myers Squibb-Pfizer Alliance, and Merck Sharp & Dohme, and role as vice chair of special interest group venous thromboembolism of Danish Nurses' Council. Juan I. Arcelus reports honoraria from Sanofi and Rovi for educational activities, and research funding from Sanofi and Bayer Adam M. Gwozdz. William R. Auger reports payment or honoraria from  Bayer Pharmaceuticals, support for attending meeting from Bayer Pharmaceuticals,  and participation as Clinical Advisor for Janssen. Cihan Ay received personal fees for  lectures and participation in advisory boards from Bayer, Bristol Myers Squibb, Daiichi-Sankyo, Pfizer, and Sanofi. Stefano Barco reports unrestricted scientific grants from Bayer, INARI, Boston Scientific, Medtronic, Bard, SANOFI, and Concept Medical; consulting fees from INARI, Bayer, Boston Scientific, and Concept Medical; and travel financial support for attending meetings from Bayer and Daiichi Sankyo. Laurent Bertoletti reports personal fees and non-financial support from Aspen, personal fees and non-financial support from Bayer, Bristol Myers Squibb-Pfizer,  Leo Pharma, and Johnson and Johnson; grants, personal fees and non-financial support from Merck Sharp & Dohme, outside the submitted work. Arina Ten Cate-Hoek reports grants  from Alexion Pharmaceuticals, Bayer Pharma Adam M. Gwozdz, and Bristol Myers Squibb-Pfizer, consulting fees from Alexion Pharmaceuticals, Bayer Pharma Adam M. Gwozdz, and Bristol Myers  Squibb-Pfizer, and payments from Alexion Pharmaceuticals, Bayer Pharma Adam M. Gwozdz, and Bristol Myers Squibb-Pfizer, all fees paid to his company. Helia Robert-Ebadi-E reports speaker's honoraria from Bayer and Daichi-Sankyo, and support for attending meetings and travel from Bayer. Rachel P. Rosovsky reports consulting fees from Bristol Myers Squibb, Janssen, Inari, Penumbra, Abbott, and research grants paid to her institution from Bristol Myers Squibb and Janssen, all outside the scope of this paper. Cecile Tromeur reports honoraria from Riche Bayer, Astra Zeneca, Actelion, and Janssen. K-LW reports honoraria from Bayer, Boehringer Ingelheim, Daiichi-Sankyo, and Pfizer for Continuing Medical Education lectures. SAB reports consulting fees from Boston Scientific, Gore, Becton Dickinson, Cook, Phillips, Vesper, Veryan, Vetex, and Medtronic; honoraria from Boston Scientific, Gore, Becton Dickinson, Cook, Philips, Vesper, Veryan, Vetex, and Medtronic; research grants from Boston Scientific and Medtronic that are paid to his institution; is on the advisory board for Philips, Medtronic, Gore, and Boston Scientific. FAK reports research grants from Bayer, Bristol-Myers Squibb, Boehringer-Ingelheim, Merck Sharp & Dohme, Leo Pharma, Daiichi-Sankyo, Actelion, The Netherlands Organisation for Health Research and Development, The Dutch Thrombosis Association, The Dutch Heart Foundation, and the Horizon Europe Program, all outside the submitted work  and paid to his institution. All other authors declare no competing interests.\n",
      "\n",
      "Black, Stephen A.\n",
      "Declaration of interests Anette Arbjerg Hojen reports research grants from The Danish Heart Foundation and The Novo Nordisk Foundation, consulting fees from Bayer and The Bristol-Myers Squibb-Pfizer Alliance, speaker bureaus from Bayer, The Bristol-Myers Squibb-Pfizer Alliance, and Merck Sharp & Dohme, and role as vice chair of special interest group venous thromboembolism of Danish Nurses' Council. Juan I. Arcelus reports honoraria from Sanofi and Rovi for educational activities, and research funding from Sanofi and Bayer Adam M. Gwozdz. William R. Auger reports payment or honoraria from  Bayer Pharmaceuticals, support for attending meeting from Bayer Pharmaceuticals,  and participation as Clinical Advisor for Janssen. Cihan Ay received personal fees for  lectures and participation in advisory boards from Bayer, Bristol Myers Squibb, Daiichi-Sankyo, Pfizer, and Sanofi. Stefano Barco reports unrestricted scientific grants from Bayer, INARI, Boston Scientific, Medtronic, Bard, SANOFI, and Concept Medical; consulting fees from INARI, Bayer, Boston Scientific, and Concept Medical; and travel financial support for attending meetings from Bayer and Daiichi Sankyo. Laurent Bertoletti reports personal fees and non-financial support from Aspen, personal fees and non-financial support from Bayer, Bristol Myers Squibb-Pfizer,  Leo Pharma, and Johnson and Johnson; grants, personal fees and non-financial support from Merck Sharp & Dohme, outside the submitted work. Arina Ten Cate-Hoek reports grants  from Alexion Pharmaceuticals, Bayer Pharma Adam M. Gwozdz, and Bristol Myers Squibb-Pfizer, consulting fees from Alexion Pharmaceuticals, Bayer Pharma Adam M. Gwozdz, and Bristol Myers  Squibb-Pfizer, and payments from Alexion Pharmaceuticals, Bayer Pharma Adam M. Gwozdz, and Bristol Myers Squibb-Pfizer, all fees paid to his company. Helia Robert-Ebadi-E reports speaker's honoraria from Bayer and Daichi-Sankyo, and support for attending meetings and travel from Bayer. Rachel P. Rosovsky reports consulting fees from Bristol Myers Squibb, Janssen, Inari, Penumbra, Abbott, and research grants paid to her institution from Bristol Myers Squibb and Janssen, all outside the scope of this paper. Cecile Tromeur reports honoraria from Riche Bayer, Astra Zeneca, Actelion, and Janssen. K-LW reports honoraria from Bayer, Boehringer Ingelheim, Daiichi-Sankyo, and Pfizer for Continuing Medical Education lectures. Stephen A. Black reports consulting fees from Boston Scientific, Gore, Becton Dickinson, Cook, Phillips, Vesper, Veryan, Vetex, and Medtronic; honoraria from Boston Scientific, Gore, Becton Dickinson, Cook, Philips, Vesper, Veryan, Vetex, and Medtronic; research grants from Boston Scientific and Medtronic that are paid to his institution; is on the advisory board for Philips, Medtronic, Gore, and Boston Scientific. FAK reports research grants from Bayer, Bristol-Myers Squibb, Boehringer-Ingelheim, Merck Sharp & Dohme, Leo Pharma, Daiichi-Sankyo, Actelion, The Netherlands Organisation for Health Research and Development, The Dutch Thrombosis Association, The Dutch Heart Foundation, and the Horizon Europe Program, all outside the submitted work  and paid to his institution. All other authors declare no competing interests.\n",
      "\n",
      "Klok, Frederikus A.\n",
      "Declaration of interests Anette Arbjerg Hojen reports research grants from The Danish Heart Foundation and The Novo Nordisk Foundation, consulting fees from Bayer and The Bristol-Myers Squibb-Pfizer Alliance, speaker bureaus from Bayer, The Bristol-Myers Squibb-Pfizer Alliance, and Merck Sharp & Dohme, and role as vice chair of special interest group venous thromboembolism of Danish Nurses' Council. Juan I. Arcelus reports honoraria from Sanofi and Rovi for educational activities, and research funding from Sanofi and Bayer Adam M. Gwozdz. William R. Auger reports payment or honoraria from  Bayer Pharmaceuticals, support for attending meeting from Bayer Pharmaceuticals,  and participation as Clinical Advisor for Janssen. Cihan Ay received personal fees for  lectures and participation in advisory boards from Bayer, Bristol Myers Squibb, Daiichi-Sankyo, Pfizer, and Sanofi. Stefano Barco reports unrestricted scientific grants from Bayer, INARI, Boston Scientific, Medtronic, Bard, SANOFI, and Concept Medical; consulting fees from INARI, Bayer, Boston Scientific, and Concept Medical; and travel financial support for attending meetings from Bayer and Daiichi Sankyo. Laurent Bertoletti reports personal fees and non-financial support from Aspen, personal fees and non-financial support from Bayer, Bristol Myers Squibb-Pfizer,  Leo Pharma, and Johnson and Johnson; grants, personal fees and non-financial support from Merck Sharp & Dohme, outside the submitted work. Arina Ten Cate-Hoek reports grants  from Alexion Pharmaceuticals, Bayer Pharma Adam M. Gwozdz, and Bristol Myers Squibb-Pfizer, consulting fees from Alexion Pharmaceuticals, Bayer Pharma Adam M. Gwozdz, and Bristol Myers  Squibb-Pfizer, and payments from Alexion Pharmaceuticals, Bayer Pharma Adam M. Gwozdz, and Bristol Myers Squibb-Pfizer, all fees paid to his company. Helia Robert-Ebadi-E reports speaker's honoraria from Bayer and Daichi-Sankyo, and support for attending meetings and travel from Bayer. Rachel P. Rosovsky reports consulting fees from Bristol Myers Squibb, Janssen, Inari, Penumbra, Abbott, and research grants paid to her institution from Bristol Myers Squibb and Janssen, all outside the scope of this paper. Cecile Tromeur reports honoraria from Riche Bayer, Astra Zeneca, Actelion, and Janssen. K-LW reports honoraria from Bayer, Boehringer Ingelheim, Daiichi-Sankyo, and Pfizer for Continuing Medical Education lectures. Stephen A. Black reports consulting fees from Boston Scientific, Gore, Becton Dickinson, Cook, Phillips, Vesper, Veryan, Vetex, and Medtronic; honoraria from Boston Scientific, Gore, Becton Dickinson, Cook, Philips, Vesper, Veryan, Vetex, and Medtronic; research grants from Boston Scientific and Medtronic that are paid to his institution; is on the advisory board for Philips, Medtronic, Gore, and Boston Scientific. Frederikus A. Klok reports research grants from Bayer, Bristol-Myers Squibb, Boehringer-Ingelheim, Merck Sharp & Dohme, Leo Pharma, Daiichi-Sankyo, Actelion, The Netherlands Organisation for Health Research and Development, The Dutch Thrombosis Association, The Dutch Heart Foundation, and the Horizon Europe Program, all outside the submitted work  and paid to his institution. All other authors declare no competing interests.\n",
      "\n",
      "Pierce, Glenn F.\n",
      "Declaration of interests RK has received research funding paid to his institution from the Bayer Hemophilia Awards Program. Glenn F. Pierce is the Vice President Medical of the WFH and a member of the medical and scientific advisory board for the National Hemophilia Foundation (NHF). SWP has received consulting fees paid to himself or his institution (University of Michigan, Michigan, MI, USA) from ApcinteX, ASC Therapeutics, Bayer, BioMarin Pharmaceutical, Catalyst Biosciences, CSL Behring, GenVentiv Therapeutics, HEMA Biologics, Freeline, LFB, Novo Nordisk, Pfizer, Regeneron and Intellia (jointly), Roche and Genentech (jointly), Sangamo  Therapeutics, Sanofi, Takeda Pharmaceutical, Spark Therapeutics, and uniQure. FR  has received consulting fees from Roche, European Haemophilia Consortium, NHF, WFH, and the American Thrombosis and Hemostasis Network. All other authors declare no competing interests.\n",
      "\n",
      "Adediran, Megan\n",
      "Declaration of interests RK has received research funding paid to his institution from the Bayer Hemophilia Awards Program. Glenn F. Pierce is the Vice President Medical of the WFH and a member of the medical and scientific advisory board for the National Hemophilia Foundation (NHF). SWP has received consulting fees paid to himself or his institution (University of Michigan, Michigan, MI, USA) from ApcinteX, ASC Therapeutics, Bayer, BioMarin Pharmaceutical, Catalyst Biosciences, CSL Behring, GenVentiv Therapeutics, HEMegan Adediran Biologics, Freeline, LFB, Novo Nordisk, Pfizer, Regeneron and Intellia (jointly), Roche and Genentech (jointly), Sangamo  Therapeutics, Sanofi, Takeda Pharmaceutical, Spark Therapeutics, and uniQure. FR  has received consulting fees from Roche, European Haemophilia Consortium, NHF, WFH, and the American Thrombosis and Hemostasis Network. All other authors declare no competing interests.\n",
      "\n",
      "Declaration of interests RK has received research funding paid to his institution from the Bayer Hemophilia Awards Program. Glenn F. Pierce is the Vice President Medical of the WFH and a member of the medical and scientific advisory board for the National Hemophilia Foundation (NHF). SWP has received consulting fees paid to himself or his institution (University of Michigan, Michigan, MI, USA) from ApcinteX, ASC Therapeutics, Bayer, BioMarin Pharmaceutical, Catalyst Biosciences, CSL Behring, GenVentiv Therapeutics, HEMegan Adediran Biologics, Freeline, LFB, Novo Nordisk, Pfizer, Regeneron and Intellia (jointly), Roche and Genentech (jointly), Sangamo  Therapeutics, Sanofi, Takeda Pharmaceutical, Spark Therapeutics, and uniQure. FR  has received consulting fees from Roche, European Haemophilia Consortium, NHF, WFH, and the American Thrombosis and Hemostasis Network. All other authors declare no competing interests.\n",
      "\n",
      "Declaration of interests RK has received research funding paid to his institution from the Bayer Hemophilia Awards Program. Glenn F. Pierce is the Vice President Medical of the WFH and a member of the medical and scientific advisory board for the National Hemophilia Foundation (NHF). SWP has received consulting fees paid to himself or his institution (University of Michigan, Michigan, MI, USA) from ApcinteX, ASC Therapeutics, Bayer, BioMarin Pharmaceutical, Catalyst Biosciences, CSL Behring, GenVentiv Therapeutics, HEMegan Adediran Biologics, Freeline, LFB, Novo Nordisk, Pfizer, Regeneron and Intellia (jointly), Roche and Genentech (jointly), Sangamo  Therapeutics, Sanofi, Takeda Pharmaceutical, Spark Therapeutics, and uniQure. FR  has received consulting fees from Roche, European Haemophilia Consortium, NHF, WFH, and the American Thrombosis and Hemostasis Network. All other authors declare no competing interests.\n",
      "\n",
      "Declaration of interests RK has received research funding paid to his institution from the Bayer Hemophilia Awards Program. Glenn F. Pierce is the Vice President Medical of the WFH and a member of the medical and scientific advisory board for the National Hemophilia Foundation (NHF). SWP has received consulting fees paid to himself or his institution (University of Michigan, Michigan, MI, USA) from ApcinteX, ASC Therapeutics, Bayer, BioMarin Pharmaceutical, Catalyst Biosciences, CSL Behring, GenVentiv Therapeutics, HEMegan Adediran Biologics, Freeline, LFB, Novo Nordisk, Pfizer, Regeneron and Intellia (jointly), Roche and Genentech (jointly), Sangamo  Therapeutics, Sanofi, Takeda Pharmaceutical, Spark Therapeutics, and uniQure. FR  has received consulting fees from Roche, European Haemophilia Consortium, NHF, WFH, and the American Thrombosis and Hemostasis Network. All other authors declare no competing interests.\n",
      "\n",
      "Kaczmarek, Radoslaw\n",
      "Declaration of interests Radoslaw Kaczmarek has received research funding paid to his institution from the Bayer Hemophilia Awards Program. Glenn F. Pierce is the Vice President Medical of the WFH and a member of the medical and scientific advisory board for the National Hemophilia Foundation (NHF). SWP has received consulting fees paid to himself or his institution (University of Michigan, Michigan, MI, USA) from ApcinteX, ASC Therapeutics, Bayer, BioMarin Pharmaceutical, Catalyst Biosciences, CSL Behring, GenVentiv Therapeutics, HEMegan Adediran Biologics, Freeline, LFB, Novo Nordisk, Pfizer, Regeneron and Intellia (jointly), Roche and Genentech (jointly), Sangamo  Therapeutics, Sanofi, Takeda Pharmaceutical, Spark Therapeutics, and uniQure. FR  has received consulting fees from Roche, European Haemophilia Consortium, NHF, WFH, and the American Thrombosis and Hemostasis Network. All other authors declare no competing interests.\n",
      "\n",
      "Declaration of interests Radoslaw Kaczmarek has received research funding paid to his institution from the Bayer Hemophilia Awards Program. Glenn F. Pierce is the Vice President Medical of the WFH and a member of the medical and scientific advisory board for the National Hemophilia Foundation (NHF). SWP has received consulting fees paid to himself or his institution (University of Michigan, Michigan, MI, USA) from ApcinteX, ASC Therapeutics, Bayer, BioMarin Pharmaceutical, Catalyst Biosciences, CSL Behring, GenVentiv Therapeutics, HEMegan Adediran Biologics, Freeline, LFB, Novo Nordisk, Pfizer, Regeneron and Intellia (jointly), Roche and Genentech (jointly), Sangamo  Therapeutics, Sanofi, Takeda Pharmaceutical, Spark Therapeutics, and uniQure. FR  has received consulting fees from Roche, European Haemophilia Consortium, NHF, WFH, and the American Thrombosis and Hemostasis Network. All other authors declare no competing interests.\n",
      "\n",
      "Pipe, Steven W.\n",
      "Declaration of interests Radoslaw Kaczmarek has received research funding paid to his institution from the Bayer Hemophilia Awards Program. Glenn F. Pierce is the Vice President Medical of the WFH and a member of the medical and scientific advisory board for the National Hemophilia Foundation (NHF). Steven W. Pipe has received consulting fees paid to himself or his institution (University of Michigan, Michigan, MI, USA) from ApcinteX, ASC Therapeutics, Bayer, BioMarin Pharmaceutical, Catalyst Biosciences, CSL Behring, GenVentiv Therapeutics, HEMegan Adediran Biologics, Freeline, LFB, Novo Nordisk, Pfizer, Regeneron and Intellia (jointly), Roche and Genentech (jointly), Sangamo  Therapeutics, Sanofi, Takeda Pharmaceutical, Spark Therapeutics, and uniQure. FR  has received consulting fees from Roche, European Haemophilia Consortium, NHF, WFH, and the American Thrombosis and Hemostasis Network. All other authors declare no competing interests.\n",
      "\n",
      "Declaration of interests Radoslaw Kaczmarek has received research funding paid to his institution from the Bayer Hemophilia Awards Program. Glenn F. Pierce is the Vice President Medical of the WFH and a member of the medical and scientific advisory board for the National Hemophilia Foundation (NHF). Steven W. Pipe has received consulting fees paid to himself or his institution (University of Michigan, Michigan, MI, USA) from ApcinteX, ASC Therapeutics, Bayer, BioMarin Pharmaceutical, Catalyst Biosciences, CSL Behring, GenVentiv Therapeutics, HEMegan Adediran Biologics, Freeline, LFB, Novo Nordisk, Pfizer, Regeneron and Intellia (jointly), Roche and Genentech (jointly), Sangamo  Therapeutics, Sanofi, Takeda Pharmaceutical, Spark Therapeutics, and uniQure. FR  has received consulting fees from Roche, European Haemophilia Consortium, NHF, WFH, and the American Thrombosis and Hemostasis Network. All other authors declare no competing interests.\n",
      "\n",
      "Declaration of interests Radoslaw Kaczmarek has received research funding paid to his institution from the Bayer Hemophilia Awards Program. Glenn F. Pierce is the Vice President Medical of the WFH and a member of the medical and scientific advisory board for the National Hemophilia Foundation (NHF). Steven W. Pipe has received consulting fees paid to himself or his institution (University of Michigan, Michigan, MI, USA) from ApcinteX, ASC Therapeutics, Bayer, BioMarin Pharmaceutical, Catalyst Biosciences, CSL Behring, GenVentiv Therapeutics, HEMegan Adediran Biologics, Freeline, LFB, Novo Nordisk, Pfizer, Regeneron and Intellia (jointly), Roche and Genentech (jointly), Sangamo  Therapeutics, Sanofi, Takeda Pharmaceutical, Spark Therapeutics, and uniQure. FR  has received consulting fees from Roche, European Haemophilia Consortium, NHF, WFH, and the American Thrombosis and Hemostasis Network. All other authors declare no competing interests.\n",
      "\n",
      "Robinson, Fiona\n",
      "Declaration of interests Radoslaw Kaczmarek has received research funding paid to his institution from the Bayer Hemophilia Awards Program. Glenn F. Pierce is the Vice President Medical of the WFH and a member of the medical and scientific advisory board for the National Hemophilia Foundation (NHF). Steven W. Pipe has received consulting fees paid to himself or his institution (University of Michigan, Michigan, MI, USA) from ApcinteX, ASC Therapeutics, Bayer, BioMarin Pharmaceutical, Catalyst Biosciences, CSL Behring, GenVentiv Therapeutics, HEMegan Adediran Biologics, Freeline, LFB, Novo Nordisk, Pfizer, Regeneron and Intellia (jointly), Roche and Genentech (jointly), Sangamo  Therapeutics, Sanofi, Takeda Pharmaceutical, Spark Therapeutics, and uniQure. Fiona Robinson  has received consulting fees from Roche, European Haemophilia Consortium, NHF, WFH, and the American Thrombosis and Hemostasis Network. All other authors declare no competing interests.\n",
      "\n",
      "Declaration of interests Radoslaw Kaczmarek has received research funding paid to his institution from the Bayer Hemophilia Awards Program. Glenn F. Pierce is the Vice President Medical of the WFH and a member of the medical and scientific advisory board for the National Hemophilia Foundation (NHF). Steven W. Pipe has received consulting fees paid to himself or his institution (University of Michigan, Michigan, MI, USA) from ApcinteX, ASC Therapeutics, Bayer, BioMarin Pharmaceutical, Catalyst Biosciences, CSL Behring, GenVentiv Therapeutics, HEMegan Adediran Biologics, Freeline, LFB, Novo Nordisk, Pfizer, Regeneron and Intellia (jointly), Roche and Genentech (jointly), Sangamo  Therapeutics, Sanofi, Takeda Pharmaceutical, Spark Therapeutics, and uniQure. Fiona Robinson  has received consulting fees from Roche, European Haemophilia Consortium, NHF, WFH, and the American Thrombosis and Hemostasis Network. All other authors declare no competing interests.\n",
      "\n",
      "Declaration of interests Radoslaw Kaczmarek has received research funding paid to his institution from the Bayer Hemophilia Awards Program. Glenn F. Pierce is the Vice President Medical of the WFH and a member of the medical and scientific advisory board for the National Hemophilia Foundation (NHF). Steven W. Pipe has received consulting fees paid to himself or his institution (University of Michigan, Michigan, MI, USA) from ApcinteX, ASC Therapeutics, Bayer, BioMarin Pharmaceutical, Catalyst Biosciences, CSL Behring, GenVentiv Therapeutics, HEMegan Adediran Biologics, Freeline, LFB, Novo Nordisk, Pfizer, Regeneron and Intellia (jointly), Roche and Genentech (jointly), Sangamo  Therapeutics, Sanofi, Takeda Pharmaceutical, Spark Therapeutics, and uniQure. Fiona Robinson  has received consulting fees from Roche, European Haemophilia Consortium, NHF, WFH, and the American Thrombosis and Hemostasis Network. All other authors declare no competing interests.\n",
      "\n",
      "Declaration of interests Radoslaw Kaczmarek has received research funding paid to his institution from the Bayer Hemophilia Awards Program. Glenn F. Pierce is the Vice President Medical of the WFH and a member of the medical and scientific advisory board for the National Hemophilia Foundation (NHF). Steven W. Pipe has received consulting fees paid to himself or his institution (University of Michigan, Michigan, MI, USA) from ApcinteX, ASC Therapeutics, Bayer, BioMarin Pharmaceutical, Catalyst Biosciences, CSL Behring, GenVentiv Therapeutics, HEMegan Adediran Biologics, Freeline, LFB, Novo Nordisk, Pfizer, Regeneron and Intellia (jointly), Roche and Genentech (jointly), Sangamo  Therapeutics, Sanofi, Takeda Pharmaceutical, Spark Therapeutics, and uniQure. Fiona Robinson  has received consulting fees from Roche, European Haemophilia Consortium, NHF, WFH, and the American Thrombosis and Hemostasis Network. All other authors declare no competing interests.\n",
      "\n",
      "Peffault de Latour, Regis\n",
      "Declaration of interests Regis Peffault de Latour reports consultancy at Novartis, Pfizer, Amgen, Alexion Pharmaceuticals, Apellis Pharmaceuticals, and Swedish Orphan Biovitrum; honoraria from Novartis, Pfizer, Amgen, Alexion Pharmaceuticals, Apellis Pharmaceuticals, and Swedish Orphan Biovitrum; research funding from Novartis, Pfizer, Amgen, and Alexion Pharmaceuticals; and grants from Alexion Pharmaceuticals, Amgen, Novartis, and Pfizer. JS reports consultancy at Novartis, Alexion Pharmaceuticals, and Apellis Pharmaceuticals; honoraria from Takeda, Pfizer, Novartis, Prevail Therapeutics, and Alexion Pharmaceuticals; speakers' bureau at Takeda, Pfizer, Novartis, and Alexion Pharmaceuticals; and membership on an entity's board of directors or advisory committees at Prevail Therapeutics  and Alexion Pharmaceuticals. ICW reports consultancy at Alexion Pharmaceuticals,  Apellis Pharmaceuticals, Biocryst, Novartis, and Sanofi Genxyme; honoraria from Alexion Pharmaceuticals, Apellis Pharmaceuticals, Biocryst, Novartis, and Sanofi  Genxyme; and speakers' bureau at Alexion Pharmaceuticals. AR reports personal fees from Alexion Pharmaceuticals, Apellis Pharmaceuticals, Kira, Novartis, Roche, Swedish Orphan Biovitrum, Sanofi, Bioverativ, and Grifols; and grants from Roche. BH reports honoraria and advisory board member at Novartis, Roche, Alexion Pharmaceuticals, and Apellis Pharmaceuticals. JP reports consultancy and honoraria at Blueprint Medicines, Amgen, F Hoffmann-La Roche, MSD, Bristol Myers  Squibb, Alexion Pharmaceuticals, Novartis, Pfizer, Gilead, Boehringer Ingelheim,  Swedish Orphan Biovitrum, and Apellis Pharmaceuticals; and honoraria from SwixxBiopharma. KU reports grants from Alexion Pharmaceuticals, Apellis Pharmaceuticals, Chugai, and Novartis; and personal fees from Novartis, Chugai, and Alexion Pharmaceuticals. MG reports consultancy at Biocryst and Regeneron Pharmaceuticals; honoraria from Alexion Pharmaceuticals and Swedish Orphan Biovitrum; advisory board member at Novartis, Biocryst, Alexion Pharmaceuticals,  and Swedish Orphan Biovitrum; and educational work sponsored by Apellis with unrestricted grant paid to Medscape. J-JK reports membership on an entity's board of directors or advisory committees at AbbVie, Novartis, Bristol Myers Squibb, and AOP Orphan. CMdC reports consultancy at Apellis Pharmaceuticals; honoraria from Novartis, Alexion Pharmaceuticals, Biocryst, and Apellis Pharmaceuticals; and research funding from Alexion Pharmaceuticals, and Apellis Pharmaceuticals. TA reports current employment and current equity holder at Apellis Pharmaceuticals. MA-A reports current employment at Apellis Pharmaceuticals. PD reports being a founder, Chief Scientific Officer, and current equity holder at Apellis Pharmaceuticals. CF and FG report current employment and current equity holder at Apellis Pharmaceuticals. AMR reports consultancy at Novartis and Amyndas; membership on an entity's board of directors or advisory committees at Novartis, Alexion Pharmaceuticals, Samsung, Biocryst, Achillion, Roche, Sanofi, and Apellis Pharmaceuticals; and grants from Alexion Pharmaceuticals, Novartis, Alnylam, and Rapharma. PH reports consultancy at Alexion Pharmaceuticals, Apellis Pharmaceuticals, AbbVie, AstraZeneca, Janssen, and Roche; research funding from Alexion Pharmaceuticals, Apellis Pharmaceuticals, AbbVie, Gilead, Janssen, Pharmacyclics, and Roche; and speakers bureau at Alexion Pharmaceuticals, Apellis Pharmaceuticals, AbbVie, AstraZeneca, Janssen, and Roche. HN declares no competing interests.\n",
      "\n",
      "Szer, Jeff\n",
      "Declaration of interests Regis Peffault de Latour reports consultancy at Novartis, Pfizer, Amgen, Alexion Pharmaceuticals, Apellis Pharmaceuticals, and Swedish Orphan Biovitrum; honoraria from Novartis, Pfizer, Amgen, Alexion Pharmaceuticals, Apellis Pharmaceuticals, and Swedish Orphan Biovitrum; research funding from Novartis, Pfizer, Amgen, and Alexion Pharmaceuticals; and grants from Alexion Pharmaceuticals, Amgen, Novartis, and Pfizer. Jeff Szer reports consultancy at Novartis, Alexion Pharmaceuticals, and Apellis Pharmaceuticals; honoraria from Takeda, Pfizer, Novartis, Prevail Therapeutics, and Alexion Pharmaceuticals; speakers' bureau at Takeda, Pfizer, Novartis, and Alexion Pharmaceuticals; and membership on an entity's board of directors or advisory committees at Prevail Therapeutics  and Alexion Pharmaceuticals. ICW reports consultancy at Alexion Pharmaceuticals,  Apellis Pharmaceuticals, Biocryst, Novartis, and Sanofi Genxyme; honoraria from Alexion Pharmaceuticals, Apellis Pharmaceuticals, Biocryst, Novartis, and Sanofi  Genxyme; and speakers' bureau at Alexion Pharmaceuticals. AR reports personal fees from Alexion Pharmaceuticals, Apellis Pharmaceuticals, Kira, Novartis, Roche, Swedish Orphan Biovitrum, Sanofi, Bioverativ, and Grifols; and grants from Roche. BH reports honoraria and advisory board member at Novartis, Roche, Alexion Pharmaceuticals, and Apellis Pharmaceuticals. JP reports consultancy and honoraria at Blueprint Medicines, Amgen, F Hoffmann-La Roche, MSD, Bristol Myers  Squibb, Alexion Pharmaceuticals, Novartis, Pfizer, Gilead, Boehringer Ingelheim,  Swedish Orphan Biovitrum, and Apellis Pharmaceuticals; and honoraria from SwixxBiopharma. KU reports grants from Alexion Pharmaceuticals, Apellis Pharmaceuticals, Chugai, and Novartis; and personal fees from Novartis, Chugai, and Alexion Pharmaceuticals. MG reports consultancy at Biocryst and Regeneron Pharmaceuticals; honoraria from Alexion Pharmaceuticals and Swedish Orphan Biovitrum; advisory board member at Novartis, Biocryst, Alexion Pharmaceuticals,  and Swedish Orphan Biovitrum; and educational work sponsored by Apellis with unrestricted grant paid to Medscape. J-JK reports membership on an entity's board of directors or advisory committees at AbbVie, Novartis, Bristol Myers Squibb, and AOP Orphan. CMdC reports consultancy at Apellis Pharmaceuticals; honoraria from Novartis, Alexion Pharmaceuticals, Biocryst, and Apellis Pharmaceuticals; and research funding from Alexion Pharmaceuticals, and Apellis Pharmaceuticals. TA reports current employment and current equity holder at Apellis Pharmaceuticals. MA-A reports current employment at Apellis Pharmaceuticals. PD reports being a founder, Chief Scientific Officer, and current equity holder at Apellis Pharmaceuticals. CF and FG report current employment and current equity holder at Apellis Pharmaceuticals. AMR reports consultancy at Novartis and Amyndas; membership on an entity's board of directors or advisory committees at Novartis, Alexion Pharmaceuticals, Samsung, Biocryst, Achillion, Roche, Sanofi, and Apellis Pharmaceuticals; and grants from Alexion Pharmaceuticals, Novartis, Alnylam, and Rapharma. PH reports consultancy at Alexion Pharmaceuticals, Apellis Pharmaceuticals, AbbVie, AstraZeneca, Janssen, and Roche; research funding from Alexion Pharmaceuticals, Apellis Pharmaceuticals, AbbVie, Gilead, Janssen, Pharmacyclics, and Roche; and speakers bureau at Alexion Pharmaceuticals, Apellis Pharmaceuticals, AbbVie, AstraZeneca, Janssen, and Roche. HN declares no competing interests.\n",
      "\n",
      "Weitz, Ilene C.\n",
      "Declaration of interests Regis Peffault de Latour reports consultancy at Novartis, Pfizer, Amgen, Alexion Pharmaceuticals, Apellis Pharmaceuticals, and Swedish Orphan Biovitrum; honoraria from Novartis, Pfizer, Amgen, Alexion Pharmaceuticals, Apellis Pharmaceuticals, and Swedish Orphan Biovitrum; research funding from Novartis, Pfizer, Amgen, and Alexion Pharmaceuticals; and grants from Alexion Pharmaceuticals, Amgen, Novartis, and Pfizer. Jeff Szer reports consultancy at Novartis, Alexion Pharmaceuticals, and Apellis Pharmaceuticals; honoraria from Takeda, Pfizer, Novartis, Prevail Therapeutics, and Alexion Pharmaceuticals; speakers' bureau at Takeda, Pfizer, Novartis, and Alexion Pharmaceuticals; and membership on an entity's board of directors or advisory committees at Prevail Therapeutics  and Alexion Pharmaceuticals. Ilene C. Weitz reports consultancy at Alexion Pharmaceuticals,  Apellis Pharmaceuticals, Biocryst, Novartis, and Sanofi Genxyme; honoraria from Alexion Pharmaceuticals, Apellis Pharmaceuticals, Biocryst, Novartis, and Sanofi  Genxyme; and speakers' bureau at Alexion Pharmaceuticals. AR reports personal fees from Alexion Pharmaceuticals, Apellis Pharmaceuticals, Kira, Novartis, Roche, Swedish Orphan Biovitrum, Sanofi, Bioverativ, and Grifols; and grants from Roche. BH reports honoraria and advisory board member at Novartis, Roche, Alexion Pharmaceuticals, and Apellis Pharmaceuticals. JP reports consultancy and honoraria at Blueprint Medicines, Amgen, F Hoffmann-La Roche, MSD, Bristol Myers  Squibb, Alexion Pharmaceuticals, Novartis, Pfizer, Gilead, Boehringer Ingelheim,  Swedish Orphan Biovitrum, and Apellis Pharmaceuticals; and honoraria from SwixxBiopharma. KU reports grants from Alexion Pharmaceuticals, Apellis Pharmaceuticals, Chugai, and Novartis; and personal fees from Novartis, Chugai, and Alexion Pharmaceuticals. MG reports consultancy at Biocryst and Regeneron Pharmaceuticals; honoraria from Alexion Pharmaceuticals and Swedish Orphan Biovitrum; advisory board member at Novartis, Biocryst, Alexion Pharmaceuticals,  and Swedish Orphan Biovitrum; and educational work sponsored by Apellis with unrestricted grant paid to Medscape. J-JK reports membership on an entity's board of directors or advisory committees at AbbVie, Novartis, Bristol Myers Squibb, and AOP Orphan. CMdC reports consultancy at Apellis Pharmaceuticals; honoraria from Novartis, Alexion Pharmaceuticals, Biocryst, and Apellis Pharmaceuticals; and research funding from Alexion Pharmaceuticals, and Apellis Pharmaceuticals. TA reports current employment and current equity holder at Apellis Pharmaceuticals. MA-A reports current employment at Apellis Pharmaceuticals. PD reports being a founder, Chief Scientific Officer, and current equity holder at Apellis Pharmaceuticals. CF and FG report current employment and current equity holder at Apellis Pharmaceuticals. AMR reports consultancy at Novartis and Amyndas; membership on an entity's board of directors or advisory committees at Novartis, Alexion Pharmaceuticals, Samsung, Biocryst, Achillion, Roche, Sanofi, and Apellis Pharmaceuticals; and grants from Alexion Pharmaceuticals, Novartis, Alnylam, and Rapharma. PH reports consultancy at Alexion Pharmaceuticals, Apellis Pharmaceuticals, AbbVie, AstraZeneca, Janssen, and Roche; research funding from Alexion Pharmaceuticals, Apellis Pharmaceuticals, AbbVie, Gilead, Janssen, Pharmacyclics, and Roche; and speakers bureau at Alexion Pharmaceuticals, Apellis Pharmaceuticals, AbbVie, AstraZeneca, Janssen, and Roche. HN declares no competing interests.\n",
      "\n",
      "Roth, Alexander\n",
      "Declaration of interests Regis Peffault de Latour reports consultancy at Novartis, Pfizer, Amgen, Alexion Pharmaceuticals, Apellis Pharmaceuticals, and Swedish Orphan Biovitrum; honoraria from Novartis, Pfizer, Amgen, Alexion Pharmaceuticals, Apellis Pharmaceuticals, and Swedish Orphan Biovitrum; research funding from Novartis, Pfizer, Amgen, and Alexion Pharmaceuticals; and grants from Alexion Pharmaceuticals, Amgen, Novartis, and Pfizer. Jeff Szer reports consultancy at Novartis, Alexion Pharmaceuticals, and Apellis Pharmaceuticals; honoraria from Takeda, Pfizer, Novartis, Prevail Therapeutics, and Alexion Pharmaceuticals; speakers' bureau at Takeda, Pfizer, Novartis, and Alexion Pharmaceuticals; and membership on an entity's board of directors or advisory committees at Prevail Therapeutics  and Alexion Pharmaceuticals. Ilene C. Weitz reports consultancy at Alexion Pharmaceuticals,  Apellis Pharmaceuticals, Biocryst, Novartis, and Sanofi Genxyme; honoraria from Alexion Pharmaceuticals, Apellis Pharmaceuticals, Biocryst, Novartis, and Sanofi  Genxyme; and speakers' bureau at Alexion Pharmaceuticals. Alexander Roth reports personal fees from Alexion Pharmaceuticals, Apellis Pharmaceuticals, Kira, Novartis, Roche, Swedish Orphan Biovitrum, Sanofi, Bioverativ, and Grifols; and grants from Roche. BH reports honoraria and advisory board member at Novartis, Roche, Alexion Pharmaceuticals, and Apellis Pharmaceuticals. JP reports consultancy and honoraria at Blueprint Medicines, Amgen, F Hoffmann-La Roche, MSD, Bristol Myers  Squibb, Alexion Pharmaceuticals, Novartis, Pfizer, Gilead, Boehringer Ingelheim,  Swedish Orphan Biovitrum, and Apellis Pharmaceuticals; and honoraria from SwixxBiopharma. KU reports grants from Alexion Pharmaceuticals, Apellis Pharmaceuticals, Chugai, and Novartis; and personal fees from Novartis, Chugai, and Alexion Pharmaceuticals. MG reports consultancy at Biocryst and Regeneron Pharmaceuticals; honoraria from Alexion Pharmaceuticals and Swedish Orphan Biovitrum; advisory board member at Novartis, Biocryst, Alexion Pharmaceuticals,  and Swedish Orphan Biovitrum; and educational work sponsored by Apellis with unrestricted grant paid to Medscape. J-JK reports membership on an entity's board of directors or advisory committees at AbbVie, Novartis, Bristol Myers Squibb, and AOP Orphan. CMdC reports consultancy at Apellis Pharmaceuticals; honoraria from Novartis, Alexion Pharmaceuticals, Biocryst, and Apellis Pharmaceuticals; and research funding from Alexion Pharmaceuticals, and Apellis Pharmaceuticals. TA reports current employment and current equity holder at Apellis Pharmaceuticals. MA-A reports current employment at Apellis Pharmaceuticals. PD reports being a founder, Chief Scientific Officer, and current equity holder at Apellis Pharmaceuticals. CF and FG report current employment and current equity holder at Apellis Pharmaceuticals. AMR reports consultancy at Novartis and Amyndas; membership on an entity's board of directors or advisory committees at Novartis, Alexion Pharmaceuticals, Samsung, Biocryst, Achillion, Roche, Sanofi, and Apellis Pharmaceuticals; and grants from Alexion Pharmaceuticals, Novartis, Alnylam, and Rapharma. PH reports consultancy at Alexion Pharmaceuticals, Apellis Pharmaceuticals, AbbVie, AstraZeneca, Janssen, and Roche; research funding from Alexion Pharmaceuticals, Apellis Pharmaceuticals, AbbVie, Gilead, Janssen, Pharmacyclics, and Roche; and speakers bureau at Alexion Pharmaceuticals, Apellis Pharmaceuticals, AbbVie, AstraZeneca, Janssen, and Roche. HN declares no competing interests.\n",
      "\n",
      "Hochsmann, Britta\n",
      "Declaration of interests Regis Peffault de Latour reports consultancy at Novartis, Pfizer, Amgen, Alexion Pharmaceuticals, Apellis Pharmaceuticals, and Swedish Orphan Biovitrum; honoraria from Novartis, Pfizer, Amgen, Alexion Pharmaceuticals, Apellis Pharmaceuticals, and Swedish Orphan Biovitrum; research funding from Novartis, Pfizer, Amgen, and Alexion Pharmaceuticals; and grants from Alexion Pharmaceuticals, Amgen, Novartis, and Pfizer. Jeff Szer reports consultancy at Novartis, Alexion Pharmaceuticals, and Apellis Pharmaceuticals; honoraria from Takeda, Pfizer, Novartis, Prevail Therapeutics, and Alexion Pharmaceuticals; speakers' bureau at Takeda, Pfizer, Novartis, and Alexion Pharmaceuticals; and membership on an entity's board of directors or advisory committees at Prevail Therapeutics  and Alexion Pharmaceuticals. Ilene C. Weitz reports consultancy at Alexion Pharmaceuticals,  Apellis Pharmaceuticals, Biocryst, Novartis, and Sanofi Genxyme; honoraria from Alexion Pharmaceuticals, Apellis Pharmaceuticals, Biocryst, Novartis, and Sanofi  Genxyme; and speakers' bureau at Alexion Pharmaceuticals. Alexander Roth reports personal fees from Alexion Pharmaceuticals, Apellis Pharmaceuticals, Kira, Novartis, Roche, Swedish Orphan Biovitrum, Sanofi, Bioverativ, and Grifols; and grants from Roche. Britta Hochsmann reports honoraria and advisory board member at Novartis, Roche, Alexion Pharmaceuticals, and Apellis Pharmaceuticals. JP reports consultancy and honoraria at Blueprint Medicines, Amgen, F Hoffmann-La Roche, MSD, Bristol Myers  Squibb, Alexion Pharmaceuticals, Novartis, Pfizer, Gilead, Boehringer Ingelheim,  Swedish Orphan Biovitrum, and Apellis Pharmaceuticals; and honoraria from SwixxBiopharma. KU reports grants from Alexion Pharmaceuticals, Apellis Pharmaceuticals, Chugai, and Novartis; and personal fees from Novartis, Chugai, and Alexion Pharmaceuticals. MG reports consultancy at Biocryst and Regeneron Pharmaceuticals; honoraria from Alexion Pharmaceuticals and Swedish Orphan Biovitrum; advisory board member at Novartis, Biocryst, Alexion Pharmaceuticals,  and Swedish Orphan Biovitrum; and educational work sponsored by Apellis with unrestricted grant paid to Medscape. J-JK reports membership on an entity's board of directors or advisory committees at AbbVie, Novartis, Bristol Myers Squibb, and AOP Orphan. CMdC reports consultancy at Apellis Pharmaceuticals; honoraria from Novartis, Alexion Pharmaceuticals, Biocryst, and Apellis Pharmaceuticals; and research funding from Alexion Pharmaceuticals, and Apellis Pharmaceuticals. TA reports current employment and current equity holder at Apellis Pharmaceuticals. MA-A reports current employment at Apellis Pharmaceuticals. PD reports being a founder, Chief Scientific Officer, and current equity holder at Apellis Pharmaceuticals. CF and FG report current employment and current equity holder at Apellis Pharmaceuticals. AMR reports consultancy at Novartis and Amyndas; membership on an entity's board of directors or advisory committees at Novartis, Alexion Pharmaceuticals, Samsung, Biocryst, Achillion, Roche, Sanofi, and Apellis Pharmaceuticals; and grants from Alexion Pharmaceuticals, Novartis, Alnylam, and Rapharma. PH reports consultancy at Alexion Pharmaceuticals, Apellis Pharmaceuticals, AbbVie, AstraZeneca, Janssen, and Roche; research funding from Alexion Pharmaceuticals, Apellis Pharmaceuticals, AbbVie, Gilead, Janssen, Pharmacyclics, and Roche; and speakers bureau at Alexion Pharmaceuticals, Apellis Pharmaceuticals, AbbVie, AstraZeneca, Janssen, and Roche. HN declares no competing interests.\n",
      "\n",
      "Panse, Jens\n",
      "Declaration of interests Regis Peffault de Latour reports consultancy at Novartis, Pfizer, Amgen, Alexion Pharmaceuticals, Apellis Pharmaceuticals, and Swedish Orphan Biovitrum; honoraria from Novartis, Pfizer, Amgen, Alexion Pharmaceuticals, Apellis Pharmaceuticals, and Swedish Orphan Biovitrum; research funding from Novartis, Pfizer, Amgen, and Alexion Pharmaceuticals; and grants from Alexion Pharmaceuticals, Amgen, Novartis, and Pfizer. Jeff Szer reports consultancy at Novartis, Alexion Pharmaceuticals, and Apellis Pharmaceuticals; honoraria from Takeda, Pfizer, Novartis, Prevail Therapeutics, and Alexion Pharmaceuticals; speakers' bureau at Takeda, Pfizer, Novartis, and Alexion Pharmaceuticals; and membership on an entity's board of directors or advisory committees at Prevail Therapeutics  and Alexion Pharmaceuticals. Ilene C. Weitz reports consultancy at Alexion Pharmaceuticals,  Apellis Pharmaceuticals, Biocryst, Novartis, and Sanofi Genxyme; honoraria from Alexion Pharmaceuticals, Apellis Pharmaceuticals, Biocryst, Novartis, and Sanofi  Genxyme; and speakers' bureau at Alexion Pharmaceuticals. Alexander Roth reports personal fees from Alexion Pharmaceuticals, Apellis Pharmaceuticals, Kira, Novartis, Roche, Swedish Orphan Biovitrum, Sanofi, Bioverativ, and Grifols; and grants from Roche. Britta Hochsmann reports honoraria and advisory board member at Novartis, Roche, Alexion Pharmaceuticals, and Apellis Pharmaceuticals. Jens Panse reports consultancy and honoraria at Blueprint Medicines, Amgen, F Hoffmann-La Roche, MSD, Bristol Myers  Squibb, Alexion Pharmaceuticals, Novartis, Pfizer, Gilead, Boehringer Ingelheim,  Swedish Orphan Biovitrum, and Apellis Pharmaceuticals; and honoraria from SwixxBiopharma. KU reports grants from Alexion Pharmaceuticals, Apellis Pharmaceuticals, Chugai, and Novartis; and personal fees from Novartis, Chugai, and Alexion Pharmaceuticals. MG reports consultancy at Biocryst and Regeneron Pharmaceuticals; honoraria from Alexion Pharmaceuticals and Swedish Orphan Biovitrum; advisory board member at Novartis, Biocryst, Alexion Pharmaceuticals,  and Swedish Orphan Biovitrum; and educational work sponsored by Apellis with unrestricted grant paid to Medscape. J-JK reports membership on an entity's board of directors or advisory committees at AbbVie, Novartis, Bristol Myers Squibb, and AOP Orphan. CMdC reports consultancy at Apellis Pharmaceuticals; honoraria from Novartis, Alexion Pharmaceuticals, Biocryst, and Apellis Pharmaceuticals; and research funding from Alexion Pharmaceuticals, and Apellis Pharmaceuticals. TA reports current employment and current equity holder at Apellis Pharmaceuticals. MA-A reports current employment at Apellis Pharmaceuticals. PD reports being a founder, Chief Scientific Officer, and current equity holder at Apellis Pharmaceuticals. CF and FG report current employment and current equity holder at Apellis Pharmaceuticals. AMR reports consultancy at Novartis and Amyndas; membership on an entity's board of directors or advisory committees at Novartis, Alexion Pharmaceuticals, Samsung, Biocryst, Achillion, Roche, Sanofi, and Apellis Pharmaceuticals; and grants from Alexion Pharmaceuticals, Novartis, Alnylam, and Rapharma. PH reports consultancy at Alexion Pharmaceuticals, Apellis Pharmaceuticals, AbbVie, AstraZeneca, Janssen, and Roche; research funding from Alexion Pharmaceuticals, Apellis Pharmaceuticals, AbbVie, Gilead, Janssen, Pharmacyclics, and Roche; and speakers bureau at Alexion Pharmaceuticals, Apellis Pharmaceuticals, AbbVie, AstraZeneca, Janssen, and Roche. HN declares no competing interests.\n",
      "\n",
      "Usuki, Kensuke\n",
      "Declaration of interests Regis Peffault de Latour reports consultancy at Novartis, Pfizer, Amgen, Alexion Pharmaceuticals, Apellis Pharmaceuticals, and Swedish Orphan Biovitrum; honoraria from Novartis, Pfizer, Amgen, Alexion Pharmaceuticals, Apellis Pharmaceuticals, and Swedish Orphan Biovitrum; research funding from Novartis, Pfizer, Amgen, and Alexion Pharmaceuticals; and grants from Alexion Pharmaceuticals, Amgen, Novartis, and Pfizer. Jeff Szer reports consultancy at Novartis, Alexion Pharmaceuticals, and Apellis Pharmaceuticals; honoraria from Takeda, Pfizer, Novartis, Prevail Therapeutics, and Alexion Pharmaceuticals; speakers' bureau at Takeda, Pfizer, Novartis, and Alexion Pharmaceuticals; and membership on an entity's board of directors or advisory committees at Prevail Therapeutics  and Alexion Pharmaceuticals. Ilene C. Weitz reports consultancy at Alexion Pharmaceuticals,  Apellis Pharmaceuticals, Biocryst, Novartis, and Sanofi Genxyme; honoraria from Alexion Pharmaceuticals, Apellis Pharmaceuticals, Biocryst, Novartis, and Sanofi  Genxyme; and speakers' bureau at Alexion Pharmaceuticals. Alexander Roth reports personal fees from Alexion Pharmaceuticals, Apellis Pharmaceuticals, Kira, Novartis, Roche, Swedish Orphan Biovitrum, Sanofi, Bioverativ, and Grifols; and grants from Roche. Britta Hochsmann reports honoraria and advisory board member at Novartis, Roche, Alexion Pharmaceuticals, and Apellis Pharmaceuticals. Jens Panse reports consultancy and honoraria at Blueprint Medicines, Amgen, F Hoffmann-La Roche, MSD, Bristol Myers  Squibb, Alexion Pharmaceuticals, Novartis, Pfizer, Gilead, Boehringer Ingelheim,  Swedish Orphan Biovitrum, and Apellis Pharmaceuticals; and honoraria from SwixxBiopharma. Kensuke Usuki reports grants from Alexion Pharmaceuticals, Apellis Pharmaceuticals, Chugai, and Novartis; and personal fees from Novartis, Chugai, and Alexion Pharmaceuticals. MG reports consultancy at Biocryst and Regeneron Pharmaceuticals; honoraria from Alexion Pharmaceuticals and Swedish Orphan Biovitrum; advisory board member at Novartis, Biocryst, Alexion Pharmaceuticals,  and Swedish Orphan Biovitrum; and educational work sponsored by Apellis with unrestricted grant paid to Medscape. J-JK reports membership on an entity's board of directors or advisory committees at AbbVie, Novartis, Bristol Myers Squibb, and AOP Orphan. CMdC reports consultancy at Apellis Pharmaceuticals; honoraria from Novartis, Alexion Pharmaceuticals, Biocryst, and Apellis Pharmaceuticals; and research funding from Alexion Pharmaceuticals, and Apellis Pharmaceuticals. TA reports current employment and current equity holder at Apellis Pharmaceuticals. MA-A reports current employment at Apellis Pharmaceuticals. PD reports being a founder, Chief Scientific Officer, and current equity holder at Apellis Pharmaceuticals. CF and FG report current employment and current equity holder at Apellis Pharmaceuticals. AMR reports consultancy at Novartis and Amyndas; membership on an entity's board of directors or advisory committees at Novartis, Alexion Pharmaceuticals, Samsung, Biocryst, Achillion, Roche, Sanofi, and Apellis Pharmaceuticals; and grants from Alexion Pharmaceuticals, Novartis, Alnylam, and Rapharma. PH reports consultancy at Alexion Pharmaceuticals, Apellis Pharmaceuticals, AbbVie, AstraZeneca, Janssen, and Roche; research funding from Alexion Pharmaceuticals, Apellis Pharmaceuticals, AbbVie, Gilead, Janssen, Pharmacyclics, and Roche; and speakers bureau at Alexion Pharmaceuticals, Apellis Pharmaceuticals, AbbVie, AstraZeneca, Janssen, and Roche. HN declares no competing interests.\n",
      "\n",
      "Griffin, Morag\n",
      "Declaration of interests Regis Peffault de Latour reports consultancy at Novartis, Pfizer, Amgen, Alexion Pharmaceuticals, Apellis Pharmaceuticals, and Swedish Orphan Biovitrum; honoraria from Novartis, Pfizer, Amgen, Alexion Pharmaceuticals, Apellis Pharmaceuticals, and Swedish Orphan Biovitrum; research funding from Novartis, Pfizer, Amgen, and Alexion Pharmaceuticals; and grants from Alexion Pharmaceuticals, Amgen, Novartis, and Pfizer. Jeff Szer reports consultancy at Novartis, Alexion Pharmaceuticals, and Apellis Pharmaceuticals; honoraria from Takeda, Pfizer, Novartis, Prevail Therapeutics, and Alexion Pharmaceuticals; speakers' bureau at Takeda, Pfizer, Novartis, and Alexion Pharmaceuticals; and membership on an entity's board of directors or advisory committees at Prevail Therapeutics  and Alexion Pharmaceuticals. Ilene C. Weitz reports consultancy at Alexion Pharmaceuticals,  Apellis Pharmaceuticals, Biocryst, Novartis, and Sanofi Genxyme; honoraria from Alexion Pharmaceuticals, Apellis Pharmaceuticals, Biocryst, Novartis, and Sanofi  Genxyme; and speakers' bureau at Alexion Pharmaceuticals. Alexander Roth reports personal fees from Alexion Pharmaceuticals, Apellis Pharmaceuticals, Kira, Novartis, Roche, Swedish Orphan Biovitrum, Sanofi, Bioverativ, and Grifols; and grants from Roche. Britta Hochsmann reports honoraria and advisory board member at Novartis, Roche, Alexion Pharmaceuticals, and Apellis Pharmaceuticals. Jens Panse reports consultancy and honoraria at Blueprint Medicines, Amgen, F Hoffmann-La Roche, MSD, Bristol Myers  Squibb, Alexion Pharmaceuticals, Novartis, Pfizer, Gilead, Boehringer Ingelheim,  Swedish Orphan Biovitrum, and Apellis Pharmaceuticals; and honoraria from SwixxBiopharma. Kensuke Usuki reports grants from Alexion Pharmaceuticals, Apellis Pharmaceuticals, Chugai, and Novartis; and personal fees from Novartis, Chugai, and Alexion Pharmaceuticals. Morag Griffin reports consultancy at Biocryst and Regeneron Pharmaceuticals; honoraria from Alexion Pharmaceuticals and Swedish Orphan Biovitrum; advisory board member at Novartis, Biocryst, Alexion Pharmaceuticals,  and Swedish Orphan Biovitrum; and educational work sponsored by Apellis with unrestricted grant paid to Medscape. J-JK reports membership on an entity's board of directors or advisory committees at AbbVie, Novartis, Bristol Myers Squibb, and AOP Orphan. CMdC reports consultancy at Apellis Pharmaceuticals; honoraria from Novartis, Alexion Pharmaceuticals, Biocryst, and Apellis Pharmaceuticals; and research funding from Alexion Pharmaceuticals, and Apellis Pharmaceuticals. TA reports current employment and current equity holder at Apellis Pharmaceuticals. MA-A reports current employment at Apellis Pharmaceuticals. PD reports being a founder, Chief Scientific Officer, and current equity holder at Apellis Pharmaceuticals. CF and FG report current employment and current equity holder at Apellis Pharmaceuticals. AMR reports consultancy at Novartis and Amyndas; membership on an entity's board of directors or advisory committees at Novartis, Alexion Pharmaceuticals, Samsung, Biocryst, Achillion, Roche, Sanofi, and Apellis Pharmaceuticals; and grants from Alexion Pharmaceuticals, Novartis, Alnylam, and Rapharma. PH reports consultancy at Alexion Pharmaceuticals, Apellis Pharmaceuticals, AbbVie, AstraZeneca, Janssen, and Roche; research funding from Alexion Pharmaceuticals, Apellis Pharmaceuticals, AbbVie, Gilead, Janssen, Pharmacyclics, and Roche; and speakers bureau at Alexion Pharmaceuticals, Apellis Pharmaceuticals, AbbVie, AstraZeneca, Janssen, and Roche. HN declares no competing interests.\n",
      "\n",
      "Kiladjian, Jean-Jacques\n",
      "Declaration of interests Regis Peffault de Latour reports consultancy at Novartis, Pfizer, Amgen, Alexion Pharmaceuticals, Apellis Pharmaceuticals, and Swedish Orphan Biovitrum; honoraria from Novartis, Pfizer, Amgen, Alexion Pharmaceuticals, Apellis Pharmaceuticals, and Swedish Orphan Biovitrum; research funding from Novartis, Pfizer, Amgen, and Alexion Pharmaceuticals; and grants from Alexion Pharmaceuticals, Amgen, Novartis, and Pfizer. Jeff Szer reports consultancy at Novartis, Alexion Pharmaceuticals, and Apellis Pharmaceuticals; honoraria from Takeda, Pfizer, Novartis, Prevail Therapeutics, and Alexion Pharmaceuticals; speakers' bureau at Takeda, Pfizer, Novartis, and Alexion Pharmaceuticals; and membership on an entity's board of directors or advisory committees at Prevail Therapeutics  and Alexion Pharmaceuticals. Ilene C. Weitz reports consultancy at Alexion Pharmaceuticals,  Apellis Pharmaceuticals, Biocryst, Novartis, and Sanofi Genxyme; honoraria from Alexion Pharmaceuticals, Apellis Pharmaceuticals, Biocryst, Novartis, and Sanofi  Genxyme; and speakers' bureau at Alexion Pharmaceuticals. Alexander Roth reports personal fees from Alexion Pharmaceuticals, Apellis Pharmaceuticals, Kira, Novartis, Roche, Swedish Orphan Biovitrum, Sanofi, Bioverativ, and Grifols; and grants from Roche. Britta Hochsmann reports honoraria and advisory board member at Novartis, Roche, Alexion Pharmaceuticals, and Apellis Pharmaceuticals. Jens Panse reports consultancy and honoraria at Blueprint Medicines, Amgen, F Hoffmann-La Roche, MSD, Bristol Myers  Squibb, Alexion Pharmaceuticals, Novartis, Pfizer, Gilead, Boehringer Ingelheim,  Swedish Orphan Biovitrum, and Apellis Pharmaceuticals; and honoraria from SwixxBiopharma. Kensuke Usuki reports grants from Alexion Pharmaceuticals, Apellis Pharmaceuticals, Chugai, and Novartis; and personal fees from Novartis, Chugai, and Alexion Pharmaceuticals. Morag Griffin reports consultancy at Biocryst and Regeneron Pharmaceuticals; honoraria from Alexion Pharmaceuticals and Swedish Orphan Biovitrum; advisory board member at Novartis, Biocryst, Alexion Pharmaceuticals,  and Swedish Orphan Biovitrum; and educational work sponsored by Apellis with unrestricted grant paid to Medscape. J-Jean-Jacques Kiladjian reports membership on an entity's board of directors or advisory committees at AbbVie, Novartis, Bristol Myers Squibb, and AOP Orphan. CMdC reports consultancy at Apellis Pharmaceuticals; honoraria from Novartis, Alexion Pharmaceuticals, Biocryst, and Apellis Pharmaceuticals; and research funding from Alexion Pharmaceuticals, and Apellis Pharmaceuticals. TA reports current employment and current equity holder at Apellis Pharmaceuticals. MA-A reports current employment at Apellis Pharmaceuticals. PD reports being a founder, Chief Scientific Officer, and current equity holder at Apellis Pharmaceuticals. CF and FG report current employment and current equity holder at Apellis Pharmaceuticals. AMR reports consultancy at Novartis and Amyndas; membership on an entity's board of directors or advisory committees at Novartis, Alexion Pharmaceuticals, Samsung, Biocryst, Achillion, Roche, Sanofi, and Apellis Pharmaceuticals; and grants from Alexion Pharmaceuticals, Novartis, Alnylam, and Rapharma. PH reports consultancy at Alexion Pharmaceuticals, Apellis Pharmaceuticals, AbbVie, AstraZeneca, Janssen, and Roche; research funding from Alexion Pharmaceuticals, Apellis Pharmaceuticals, AbbVie, Gilead, Janssen, Pharmacyclics, and Roche; and speakers bureau at Alexion Pharmaceuticals, Apellis Pharmaceuticals, AbbVie, AstraZeneca, Janssen, and Roche. HN declares no competing interests.\n",
      "\n",
      "M de Castro, Carlos\n",
      "Declaration of interests Regis Peffault de Latour reports consultancy at Novartis, Pfizer, Amgen, Alexion Pharmaceuticals, Apellis Pharmaceuticals, and Swedish Orphan Biovitrum; honoraria from Novartis, Pfizer, Amgen, Alexion Pharmaceuticals, Apellis Pharmaceuticals, and Swedish Orphan Biovitrum; research funding from Novartis, Pfizer, Amgen, and Alexion Pharmaceuticals; and grants from Alexion Pharmaceuticals, Amgen, Novartis, and Pfizer. Jeff Szer reports consultancy at Novartis, Alexion Pharmaceuticals, and Apellis Pharmaceuticals; honoraria from Takeda, Pfizer, Novartis, Prevail Therapeutics, and Alexion Pharmaceuticals; speakers' bureau at Takeda, Pfizer, Novartis, and Alexion Pharmaceuticals; and membership on an entity's board of directors or advisory committees at Prevail Therapeutics  and Alexion Pharmaceuticals. Ilene C. Weitz reports consultancy at Alexion Pharmaceuticals,  Apellis Pharmaceuticals, Biocryst, Novartis, and Sanofi Genxyme; honoraria from Alexion Pharmaceuticals, Apellis Pharmaceuticals, Biocryst, Novartis, and Sanofi  Genxyme; and speakers' bureau at Alexion Pharmaceuticals. Alexander Roth reports personal fees from Alexion Pharmaceuticals, Apellis Pharmaceuticals, Kira, Novartis, Roche, Swedish Orphan Biovitrum, Sanofi, Bioverativ, and Grifols; and grants from Roche. Britta Hochsmann reports honoraria and advisory board member at Novartis, Roche, Alexion Pharmaceuticals, and Apellis Pharmaceuticals. Jens Panse reports consultancy and honoraria at Blueprint Medicines, Amgen, F Hoffmann-La Roche, MSD, Bristol Myers  Squibb, Alexion Pharmaceuticals, Novartis, Pfizer, Gilead, Boehringer Ingelheim,  Swedish Orphan Biovitrum, and Apellis Pharmaceuticals; and honoraria from SwixxBiopharma. Kensuke Usuki reports grants from Alexion Pharmaceuticals, Apellis Pharmaceuticals, Chugai, and Novartis; and personal fees from Novartis, Chugai, and Alexion Pharmaceuticals. Morag Griffin reports consultancy at Biocryst and Regeneron Pharmaceuticals; honoraria from Alexion Pharmaceuticals and Swedish Orphan Biovitrum; advisory board member at Novartis, Biocryst, Alexion Pharmaceuticals,  and Swedish Orphan Biovitrum; and educational work sponsored by Apellis with unrestricted grant paid to Medscape. J-Jean-Jacques Kiladjian reports membership on an entity's board of directors or advisory committees at AbbVie, Novartis, Bristol Myers Squibb, and AOP Orphan. Carlos M de Castro reports consultancy at Apellis Pharmaceuticals; honoraria from Novartis, Alexion Pharmaceuticals, Biocryst, and Apellis Pharmaceuticals; and research funding from Alexion Pharmaceuticals, and Apellis Pharmaceuticals. TA reports current employment and current equity holder at Apellis Pharmaceuticals. MA-A reports current employment at Apellis Pharmaceuticals. PD reports being a founder, Chief Scientific Officer, and current equity holder at Apellis Pharmaceuticals. CF and FG report current employment and current equity holder at Apellis Pharmaceuticals. AMR reports consultancy at Novartis and Amyndas; membership on an entity's board of directors or advisory committees at Novartis, Alexion Pharmaceuticals, Samsung, Biocryst, Achillion, Roche, Sanofi, and Apellis Pharmaceuticals; and grants from Alexion Pharmaceuticals, Novartis, Alnylam, and Rapharma. PH reports consultancy at Alexion Pharmaceuticals, Apellis Pharmaceuticals, AbbVie, AstraZeneca, Janssen, and Roche; research funding from Alexion Pharmaceuticals, Apellis Pharmaceuticals, AbbVie, Gilead, Janssen, Pharmacyclics, and Roche; and speakers bureau at Alexion Pharmaceuticals, Apellis Pharmaceuticals, AbbVie, AstraZeneca, Janssen, and Roche. HN declares no competing interests.\n",
      "\n",
      "Nishimori, Hisakazu\n",
      "Declaration of interests Regis Peffault de Latour reports consultancy at Novartis, Pfizer, Amgen, Alexion Pharmaceuticals, Apellis Pharmaceuticals, and Swedish Orphan Biovitrum; honoraria from Novartis, Pfizer, Amgen, Alexion Pharmaceuticals, Apellis Pharmaceuticals, and Swedish Orphan Biovitrum; research funding from Novartis, Pfizer, Amgen, and Alexion Pharmaceuticals; and grants from Alexion Pharmaceuticals, Amgen, Novartis, and Pfizer. Jeff Szer reports consultancy at Novartis, Alexion Pharmaceuticals, and Apellis Pharmaceuticals; honoraria from Takeda, Pfizer, Novartis, Prevail Therapeutics, and Alexion Pharmaceuticals; speakers' bureau at Takeda, Pfizer, Novartis, and Alexion Pharmaceuticals; and membership on an entity's board of directors or advisory committees at Prevail Therapeutics  and Alexion Pharmaceuticals. Ilene C. Weitz reports consultancy at Alexion Pharmaceuticals,  Apellis Pharmaceuticals, Biocryst, Novartis, and Sanofi Genxyme; honoraria from Alexion Pharmaceuticals, Apellis Pharmaceuticals, Biocryst, Novartis, and Sanofi  Genxyme; and speakers' bureau at Alexion Pharmaceuticals. Alexander Roth reports personal fees from Alexion Pharmaceuticals, Apellis Pharmaceuticals, Kira, Novartis, Roche, Swedish Orphan Biovitrum, Sanofi, Bioverativ, and Grifols; and grants from Roche. Britta Hochsmann reports honoraria and advisory board member at Novartis, Roche, Alexion Pharmaceuticals, and Apellis Pharmaceuticals. Jens Panse reports consultancy and honoraria at Blueprint Medicines, Amgen, F Hoffmann-La Roche, MSD, Bristol Myers  Squibb, Alexion Pharmaceuticals, Novartis, Pfizer, Gilead, Boehringer Ingelheim,  Swedish Orphan Biovitrum, and Apellis Pharmaceuticals; and honoraria from SwixxBiopharma. Kensuke Usuki reports grants from Alexion Pharmaceuticals, Apellis Pharmaceuticals, Chugai, and Novartis; and personal fees from Novartis, Chugai, and Alexion Pharmaceuticals. Morag Griffin reports consultancy at Biocryst and Regeneron Pharmaceuticals; honoraria from Alexion Pharmaceuticals and Swedish Orphan Biovitrum; advisory board member at Novartis, Biocryst, Alexion Pharmaceuticals,  and Swedish Orphan Biovitrum; and educational work sponsored by Apellis with unrestricted grant paid to Medscape. J-Jean-Jacques Kiladjian reports membership on an entity's board of directors or advisory committees at AbbVie, Novartis, Bristol Myers Squibb, and AOP Orphan. Carlos M de Castro reports consultancy at Apellis Pharmaceuticals; honoraria from Novartis, Alexion Pharmaceuticals, Biocryst, and Apellis Pharmaceuticals; and research funding from Alexion Pharmaceuticals, and Apellis Pharmaceuticals. TA reports current employment and current equity holder at Apellis Pharmaceuticals. MA-A reports current employment at Apellis Pharmaceuticals. PD reports being a founder, Chief Scientific Officer, and current equity holder at Apellis Pharmaceuticals. CF and FG report current employment and current equity holder at Apellis Pharmaceuticals. AMR reports consultancy at Novartis and Amyndas; membership on an entity's board of directors or advisory committees at Novartis, Alexion Pharmaceuticals, Samsung, Biocryst, Achillion, Roche, Sanofi, and Apellis Pharmaceuticals; and grants from Alexion Pharmaceuticals, Novartis, Alnylam, and Rapharma. PH reports consultancy at Alexion Pharmaceuticals, Apellis Pharmaceuticals, AbbVie, AstraZeneca, Janssen, and Roche; research funding from Alexion Pharmaceuticals, Apellis Pharmaceuticals, AbbVie, Gilead, Janssen, Pharmacyclics, and Roche; and speakers bureau at Alexion Pharmaceuticals, Apellis Pharmaceuticals, AbbVie, AstraZeneca, Janssen, and Roche. Hisakazu Nishimori declares no competing interests.\n",
      "\n",
      "Ajayi, Temitayo\n",
      "Declaration of interests Regis Peffault de Latour reports consultancy at Novartis, Pfizer, Amgen, Alexion Pharmaceuticals, Apellis Pharmaceuticals, and Swedish Orphan Biovitrum; honoraria from Novartis, Pfizer, Amgen, Alexion Pharmaceuticals, Apellis Pharmaceuticals, and Swedish Orphan Biovitrum; research funding from Novartis, Pfizer, Amgen, and Alexion Pharmaceuticals; and grants from Alexion Pharmaceuticals, Amgen, Novartis, and Pfizer. Jeff Szer reports consultancy at Novartis, Alexion Pharmaceuticals, and Apellis Pharmaceuticals; honoraria from Takeda, Pfizer, Novartis, Prevail Therapeutics, and Alexion Pharmaceuticals; speakers' bureau at Takeda, Pfizer, Novartis, and Alexion Pharmaceuticals; and membership on an entity's board of directors or advisory committees at Prevail Therapeutics  and Alexion Pharmaceuticals. Ilene C. Weitz reports consultancy at Alexion Pharmaceuticals,  Apellis Pharmaceuticals, Biocryst, Novartis, and Sanofi Genxyme; honoraria from Alexion Pharmaceuticals, Apellis Pharmaceuticals, Biocryst, Novartis, and Sanofi  Genxyme; and speakers' bureau at Alexion Pharmaceuticals. Alexander Roth reports personal fees from Alexion Pharmaceuticals, Apellis Pharmaceuticals, Kira, Novartis, Roche, Swedish Orphan Biovitrum, Sanofi, Bioverativ, and Grifols; and grants from Roche. Britta Hochsmann reports honoraria and advisory board member at Novartis, Roche, Alexion Pharmaceuticals, and Apellis Pharmaceuticals. Jens Panse reports consultancy and honoraria at Blueprint Medicines, Amgen, F Hoffmann-La Roche, MSD, Bristol Myers  Squibb, Alexion Pharmaceuticals, Novartis, Pfizer, Gilead, Boehringer Ingelheim,  Swedish Orphan Biovitrum, and Apellis Pharmaceuticals; and honoraria from SwixxBiopharma. Kensuke Usuki reports grants from Alexion Pharmaceuticals, Apellis Pharmaceuticals, Chugai, and Novartis; and personal fees from Novartis, Chugai, and Alexion Pharmaceuticals. Morag Griffin reports consultancy at Biocryst and Regeneron Pharmaceuticals; honoraria from Alexion Pharmaceuticals and Swedish Orphan Biovitrum; advisory board member at Novartis, Biocryst, Alexion Pharmaceuticals,  and Swedish Orphan Biovitrum; and educational work sponsored by Apellis with unrestricted grant paid to Medscape. J-Jean-Jacques Kiladjian reports membership on an entity's board of directors or advisory committees at AbbVie, Novartis, Bristol Myers Squibb, and AOP Orphan. Carlos M de Castro reports consultancy at Apellis Pharmaceuticals; honoraria from Novartis, Alexion Pharmaceuticals, Biocryst, and Apellis Pharmaceuticals; and research funding from Alexion Pharmaceuticals, and Apellis Pharmaceuticals. Temitayo Ajayi reports current employment and current equity holder at Apellis Pharmaceuticals. MA-A reports current employment at Apellis Pharmaceuticals. PD reports being a founder, Chief Scientific Officer, and current equity holder at Apellis Pharmaceuticals. CF and FG report current employment and current equity holder at Apellis Pharmaceuticals. AMR reports consultancy at Novartis and Amyndas; membership on an entity's board of directors or advisory committees at Novartis, Alexion Pharmaceuticals, Samsung, Biocryst, Achillion, Roche, Sanofi, and Apellis Pharmaceuticals; and grants from Alexion Pharmaceuticals, Novartis, Alnylam, and Rapharma. PH reports consultancy at Alexion Pharmaceuticals, Apellis Pharmaceuticals, AbbVie, AstraZeneca, Janssen, and Roche; research funding from Alexion Pharmaceuticals, Apellis Pharmaceuticals, AbbVie, Gilead, Janssen, Pharmacyclics, and Roche; and speakers bureau at Alexion Pharmaceuticals, Apellis Pharmaceuticals, AbbVie, AstraZeneca, Janssen, and Roche. Hisakazu Nishimori declares no competing interests.\n",
      "\n",
      "Al-Adhami, Mohammed\n",
      "Declaration of interests Regis Peffault de Latour reports consultancy at Novartis, Pfizer, Amgen, Alexion Pharmaceuticals, Apellis Pharmaceuticals, and Swedish Orphan Biovitrum; honoraria from Novartis, Pfizer, Amgen, Alexion Pharmaceuticals, Apellis Pharmaceuticals, and Swedish Orphan Biovitrum; research funding from Novartis, Pfizer, Amgen, and Alexion Pharmaceuticals; and grants from Alexion Pharmaceuticals, Amgen, Novartis, and Pfizer. Jeff Szer reports consultancy at Novartis, Alexion Pharmaceuticals, and Apellis Pharmaceuticals; honoraria from Takeda, Pfizer, Novartis, Prevail Therapeutics, and Alexion Pharmaceuticals; speakers' bureau at Takeda, Pfizer, Novartis, and Alexion Pharmaceuticals; and membership on an entity's board of directors or advisory committees at Prevail Therapeutics  and Alexion Pharmaceuticals. Ilene C. Weitz reports consultancy at Alexion Pharmaceuticals,  Apellis Pharmaceuticals, Biocryst, Novartis, and Sanofi Genxyme; honoraria from Alexion Pharmaceuticals, Apellis Pharmaceuticals, Biocryst, Novartis, and Sanofi  Genxyme; and speakers' bureau at Alexion Pharmaceuticals. Alexander Roth reports personal fees from Alexion Pharmaceuticals, Apellis Pharmaceuticals, Kira, Novartis, Roche, Swedish Orphan Biovitrum, Sanofi, Bioverativ, and Grifols; and grants from Roche. Britta Hochsmann reports honoraria and advisory board member at Novartis, Roche, Alexion Pharmaceuticals, and Apellis Pharmaceuticals. Jens Panse reports consultancy and honoraria at Blueprint Medicines, Amgen, F Hoffmann-La Roche, MSD, Bristol Myers  Squibb, Alexion Pharmaceuticals, Novartis, Pfizer, Gilead, Boehringer Ingelheim,  Swedish Orphan Biovitrum, and Apellis Pharmaceuticals; and honoraria from SwixxBiopharma. Kensuke Usuki reports grants from Alexion Pharmaceuticals, Apellis Pharmaceuticals, Chugai, and Novartis; and personal fees from Novartis, Chugai, and Alexion Pharmaceuticals. Morag Griffin reports consultancy at Biocryst and Regeneron Pharmaceuticals; honoraria from Alexion Pharmaceuticals and Swedish Orphan Biovitrum; advisory board member at Novartis, Biocryst, Alexion Pharmaceuticals,  and Swedish Orphan Biovitrum; and educational work sponsored by Apellis with unrestricted grant paid to Medscape. J-Jean-Jacques Kiladjian reports membership on an entity's board of directors or advisory committees at AbbVie, Novartis, Bristol Myers Squibb, and AOP Orphan. Carlos M de Castro reports consultancy at Apellis Pharmaceuticals; honoraria from Novartis, Alexion Pharmaceuticals, Biocryst, and Apellis Pharmaceuticals; and research funding from Alexion Pharmaceuticals, and Apellis Pharmaceuticals. Temitayo Ajayi reports current employment and current equity holder at Apellis Pharmaceuticals. Mohammed Al-Adhami-A reports current employment at Apellis Pharmaceuticals. PD reports being a founder, Chief Scientific Officer, and current equity holder at Apellis Pharmaceuticals. CF and FG report current employment and current equity holder at Apellis Pharmaceuticals. AMR reports consultancy at Novartis and Amyndas; membership on an entity's board of directors or advisory committees at Novartis, Alexion Pharmaceuticals, Samsung, Biocryst, Achillion, Roche, Sanofi, and Apellis Pharmaceuticals; and grants from Alexion Pharmaceuticals, Novartis, Alnylam, and Rapharma. PH reports consultancy at Alexion Pharmaceuticals, Apellis Pharmaceuticals, AbbVie, AstraZeneca, Janssen, and Roche; research funding from Alexion Pharmaceuticals, Apellis Pharmaceuticals, AbbVie, Gilead, Janssen, Pharmacyclics, and Roche; and speakers bureau at Alexion Pharmaceuticals, Apellis Pharmaceuticals, AbbVie, AstraZeneca, Janssen, and Roche. Hisakazu Nishimori declares no competing interests.\n",
      "\n",
      "Deschatelets, Pascal\n",
      "Declaration of interests Regis Peffault de Latour reports consultancy at Novartis, Pfizer, Amgen, Alexion Pharmaceuticals, Apellis Pharmaceuticals, and Swedish Orphan Biovitrum; honoraria from Novartis, Pfizer, Amgen, Alexion Pharmaceuticals, Apellis Pharmaceuticals, and Swedish Orphan Biovitrum; research funding from Novartis, Pfizer, Amgen, and Alexion Pharmaceuticals; and grants from Alexion Pharmaceuticals, Amgen, Novartis, and Pfizer. Jeff Szer reports consultancy at Novartis, Alexion Pharmaceuticals, and Apellis Pharmaceuticals; honoraria from Takeda, Pfizer, Novartis, Prevail Therapeutics, and Alexion Pharmaceuticals; speakers' bureau at Takeda, Pfizer, Novartis, and Alexion Pharmaceuticals; and membership on an entity's board of directors or advisory committees at Prevail Therapeutics  and Alexion Pharmaceuticals. Ilene C. Weitz reports consultancy at Alexion Pharmaceuticals,  Apellis Pharmaceuticals, Biocryst, Novartis, and Sanofi Genxyme; honoraria from Alexion Pharmaceuticals, Apellis Pharmaceuticals, Biocryst, Novartis, and Sanofi  Genxyme; and speakers' bureau at Alexion Pharmaceuticals. Alexander Roth reports personal fees from Alexion Pharmaceuticals, Apellis Pharmaceuticals, Kira, Novartis, Roche, Swedish Orphan Biovitrum, Sanofi, Bioverativ, and Grifols; and grants from Roche. Britta Hochsmann reports honoraria and advisory board member at Novartis, Roche, Alexion Pharmaceuticals, and Apellis Pharmaceuticals. Jens Panse reports consultancy and honoraria at Blueprint Medicines, Amgen, F Hoffmann-La Roche, MSD, Bristol Myers  Squibb, Alexion Pharmaceuticals, Novartis, Pfizer, Gilead, Boehringer Ingelheim,  Swedish Orphan Biovitrum, and Apellis Pharmaceuticals; and honoraria from SwixxBiopharma. Kensuke Usuki reports grants from Alexion Pharmaceuticals, Apellis Pharmaceuticals, Chugai, and Novartis; and personal fees from Novartis, Chugai, and Alexion Pharmaceuticals. Morag Griffin reports consultancy at Biocryst and Regeneron Pharmaceuticals; honoraria from Alexion Pharmaceuticals and Swedish Orphan Biovitrum; advisory board member at Novartis, Biocryst, Alexion Pharmaceuticals,  and Swedish Orphan Biovitrum; and educational work sponsored by Apellis with unrestricted grant paid to Medscape. J-Jean-Jacques Kiladjian reports membership on an entity's board of directors or advisory committees at AbbVie, Novartis, Bristol Myers Squibb, and AOP Orphan. Carlos M de Castro reports consultancy at Apellis Pharmaceuticals; honoraria from Novartis, Alexion Pharmaceuticals, Biocryst, and Apellis Pharmaceuticals; and research funding from Alexion Pharmaceuticals, and Apellis Pharmaceuticals. Temitayo Ajayi reports current employment and current equity holder at Apellis Pharmaceuticals. Mohammed Al-Adhami-A reports current employment at Apellis Pharmaceuticals. Pascal Deschatelets reports being a founder, Chief Scientific Officer, and current equity holder at Apellis Pharmaceuticals. CF and FG report current employment and current equity holder at Apellis Pharmaceuticals. AMR reports consultancy at Novartis and Amyndas; membership on an entity's board of directors or advisory committees at Novartis, Alexion Pharmaceuticals, Samsung, Biocryst, Achillion, Roche, Sanofi, and Apellis Pharmaceuticals; and grants from Alexion Pharmaceuticals, Novartis, Alnylam, and Rapharma. PH reports consultancy at Alexion Pharmaceuticals, Apellis Pharmaceuticals, AbbVie, AstraZeneca, Janssen, and Roche; research funding from Alexion Pharmaceuticals, Apellis Pharmaceuticals, AbbVie, Gilead, Janssen, Pharmacyclics, and Roche; and speakers bureau at Alexion Pharmaceuticals, Apellis Pharmaceuticals, AbbVie, AstraZeneca, Janssen, and Roche. Hisakazu Nishimori declares no competing interests.\n",
      "\n",
      "Francois, Cedric\n",
      "Declaration of interests Regis Peffault de Latour reports consultancy at Novartis, Pfizer, Amgen, Alexion Pharmaceuticals, Apellis Pharmaceuticals, and Swedish Orphan Biovitrum; honoraria from Novartis, Pfizer, Amgen, Alexion Pharmaceuticals, Apellis Pharmaceuticals, and Swedish Orphan Biovitrum; research funding from Novartis, Pfizer, Amgen, and Alexion Pharmaceuticals; and grants from Alexion Pharmaceuticals, Amgen, Novartis, and Pfizer. Jeff Szer reports consultancy at Novartis, Alexion Pharmaceuticals, and Apellis Pharmaceuticals; honoraria from Takeda, Pfizer, Novartis, Prevail Therapeutics, and Alexion Pharmaceuticals; speakers' bureau at Takeda, Pfizer, Novartis, and Alexion Pharmaceuticals; and membership on an entity's board of directors or advisory committees at Prevail Therapeutics  and Alexion Pharmaceuticals. Ilene C. Weitz reports consultancy at Alexion Pharmaceuticals,  Apellis Pharmaceuticals, Biocryst, Novartis, and Sanofi Genxyme; honoraria from Alexion Pharmaceuticals, Apellis Pharmaceuticals, Biocryst, Novartis, and Sanofi  Genxyme; and speakers' bureau at Alexion Pharmaceuticals. Alexander Roth reports personal fees from Alexion Pharmaceuticals, Apellis Pharmaceuticals, Kira, Novartis, Roche, Swedish Orphan Biovitrum, Sanofi, Bioverativ, and Grifols; and grants from Roche. Britta Hochsmann reports honoraria and advisory board member at Novartis, Roche, Alexion Pharmaceuticals, and Apellis Pharmaceuticals. Jens Panse reports consultancy and honoraria at Blueprint Medicines, Amgen, F Hoffmann-La Roche, MSD, Bristol Myers  Squibb, Alexion Pharmaceuticals, Novartis, Pfizer, Gilead, Boehringer Ingelheim,  Swedish Orphan Biovitrum, and Apellis Pharmaceuticals; and honoraria from SwixxBiopharma. Kensuke Usuki reports grants from Alexion Pharmaceuticals, Apellis Pharmaceuticals, Chugai, and Novartis; and personal fees from Novartis, Chugai, and Alexion Pharmaceuticals. Morag Griffin reports consultancy at Biocryst and Regeneron Pharmaceuticals; honoraria from Alexion Pharmaceuticals and Swedish Orphan Biovitrum; advisory board member at Novartis, Biocryst, Alexion Pharmaceuticals,  and Swedish Orphan Biovitrum; and educational work sponsored by Apellis with unrestricted grant paid to Medscape. J-Jean-Jacques Kiladjian reports membership on an entity's board of directors or advisory committees at AbbVie, Novartis, Bristol Myers Squibb, and AOP Orphan. Carlos M de Castro reports consultancy at Apellis Pharmaceuticals; honoraria from Novartis, Alexion Pharmaceuticals, Biocryst, and Apellis Pharmaceuticals; and research funding from Alexion Pharmaceuticals, and Apellis Pharmaceuticals. Temitayo Ajayi reports current employment and current equity holder at Apellis Pharmaceuticals. Mohammed Al-Adhami-A reports current employment at Apellis Pharmaceuticals. Pascal Deschatelets reports being a founder, Chief Scientific Officer, and current equity holder at Apellis Pharmaceuticals. Cedric Francois and FG report current employment and current equity holder at Apellis Pharmaceuticals. AMR reports consultancy at Novartis and Amyndas; membership on an entity's board of directors or advisory committees at Novartis, Alexion Pharmaceuticals, Samsung, Biocryst, Achillion, Roche, Sanofi, and Apellis Pharmaceuticals; and grants from Alexion Pharmaceuticals, Novartis, Alnylam, and Rapharma. PH reports consultancy at Alexion Pharmaceuticals, Apellis Pharmaceuticals, AbbVie, AstraZeneca, Janssen, and Roche; research funding from Alexion Pharmaceuticals, Apellis Pharmaceuticals, AbbVie, Gilead, Janssen, Pharmacyclics, and Roche; and speakers bureau at Alexion Pharmaceuticals, Apellis Pharmaceuticals, AbbVie, AstraZeneca, Janssen, and Roche. Hisakazu Nishimori declares no competing interests.\n",
      "\n",
      "Grossi, Federico\n",
      "Declaration of interests Regis Peffault de Latour reports consultancy at Novartis, Pfizer, Amgen, Alexion Pharmaceuticals, Apellis Pharmaceuticals, and Swedish Orphan Biovitrum; honoraria from Novartis, Pfizer, Amgen, Alexion Pharmaceuticals, Apellis Pharmaceuticals, and Swedish Orphan Biovitrum; research funding from Novartis, Pfizer, Amgen, and Alexion Pharmaceuticals; and grants from Alexion Pharmaceuticals, Amgen, Novartis, and Pfizer. Jeff Szer reports consultancy at Novartis, Alexion Pharmaceuticals, and Apellis Pharmaceuticals; honoraria from Takeda, Pfizer, Novartis, Prevail Therapeutics, and Alexion Pharmaceuticals; speakers' bureau at Takeda, Pfizer, Novartis, and Alexion Pharmaceuticals; and membership on an entity's board of directors or advisory committees at Prevail Therapeutics  and Alexion Pharmaceuticals. Ilene C. Weitz reports consultancy at Alexion Pharmaceuticals,  Apellis Pharmaceuticals, Biocryst, Novartis, and Sanofi Genxyme; honoraria from Alexion Pharmaceuticals, Apellis Pharmaceuticals, Biocryst, Novartis, and Sanofi  Genxyme; and speakers' bureau at Alexion Pharmaceuticals. Alexander Roth reports personal fees from Alexion Pharmaceuticals, Apellis Pharmaceuticals, Kira, Novartis, Roche, Swedish Orphan Biovitrum, Sanofi, Bioverativ, and Grifols; and grants from Roche. Britta Hochsmann reports honoraria and advisory board member at Novartis, Roche, Alexion Pharmaceuticals, and Apellis Pharmaceuticals. Jens Panse reports consultancy and honoraria at Blueprint Medicines, Amgen, F Hoffmann-La Roche, MSD, Bristol Myers  Squibb, Alexion Pharmaceuticals, Novartis, Pfizer, Gilead, Boehringer Ingelheim,  Swedish Orphan Biovitrum, and Apellis Pharmaceuticals; and honoraria from SwixxBiopharma. Kensuke Usuki reports grants from Alexion Pharmaceuticals, Apellis Pharmaceuticals, Chugai, and Novartis; and personal fees from Novartis, Chugai, and Alexion Pharmaceuticals. Morag Griffin reports consultancy at Biocryst and Regeneron Pharmaceuticals; honoraria from Alexion Pharmaceuticals and Swedish Orphan Biovitrum; advisory board member at Novartis, Biocryst, Alexion Pharmaceuticals,  and Swedish Orphan Biovitrum; and educational work sponsored by Apellis with unrestricted grant paid to Medscape. J-Jean-Jacques Kiladjian reports membership on an entity's board of directors or advisory committees at AbbVie, Novartis, Bristol Myers Squibb, and AOP Orphan. Carlos M de Castro reports consultancy at Apellis Pharmaceuticals; honoraria from Novartis, Alexion Pharmaceuticals, Biocryst, and Apellis Pharmaceuticals; and research funding from Alexion Pharmaceuticals, and Apellis Pharmaceuticals. Temitayo Ajayi reports current employment and current equity holder at Apellis Pharmaceuticals. Mohammed Al-Adhami-A reports current employment at Apellis Pharmaceuticals. Pascal Deschatelets reports being a founder, Chief Scientific Officer, and current equity holder at Apellis Pharmaceuticals. Cedric Francois and Federico Grossi report current employment and current equity holder at Apellis Pharmaceuticals. AMR reports consultancy at Novartis and Amyndas; membership on an entity's board of directors or advisory committees at Novartis, Alexion Pharmaceuticals, Samsung, Biocryst, Achillion, Roche, Sanofi, and Apellis Pharmaceuticals; and grants from Alexion Pharmaceuticals, Novartis, Alnylam, and Rapharma. PH reports consultancy at Alexion Pharmaceuticals, Apellis Pharmaceuticals, AbbVie, AstraZeneca, Janssen, and Roche; research funding from Alexion Pharmaceuticals, Apellis Pharmaceuticals, AbbVie, Gilead, Janssen, Pharmacyclics, and Roche; and speakers bureau at Alexion Pharmaceuticals, Apellis Pharmaceuticals, AbbVie, AstraZeneca, Janssen, and Roche. Hisakazu Nishimori declares no competing interests.\n",
      "\n",
      "Risitano, Antonio M.\n",
      "Declaration of interests Regis Peffault de Latour reports consultancy at Novartis, Pfizer, Amgen, Alexion Pharmaceuticals, Apellis Pharmaceuticals, and Swedish Orphan Biovitrum; honoraria from Novartis, Pfizer, Amgen, Alexion Pharmaceuticals, Apellis Pharmaceuticals, and Swedish Orphan Biovitrum; research funding from Novartis, Pfizer, Amgen, and Alexion Pharmaceuticals; and grants from Alexion Pharmaceuticals, Amgen, Novartis, and Pfizer. Jeff Szer reports consultancy at Novartis, Alexion Pharmaceuticals, and Apellis Pharmaceuticals; honoraria from Takeda, Pfizer, Novartis, Prevail Therapeutics, and Alexion Pharmaceuticals; speakers' bureau at Takeda, Pfizer, Novartis, and Alexion Pharmaceuticals; and membership on an entity's board of directors or advisory committees at Prevail Therapeutics  and Alexion Pharmaceuticals. Ilene C. Weitz reports consultancy at Alexion Pharmaceuticals,  Apellis Pharmaceuticals, Biocryst, Novartis, and Sanofi Genxyme; honoraria from Alexion Pharmaceuticals, Apellis Pharmaceuticals, Biocryst, Novartis, and Sanofi  Genxyme; and speakers' bureau at Alexion Pharmaceuticals. Alexander Roth reports personal fees from Alexion Pharmaceuticals, Apellis Pharmaceuticals, Kira, Novartis, Roche, Swedish Orphan Biovitrum, Sanofi, Bioverativ, and Grifols; and grants from Roche. Britta Hochsmann reports honoraria and advisory board member at Novartis, Roche, Alexion Pharmaceuticals, and Apellis Pharmaceuticals. Jens Panse reports consultancy and honoraria at Blueprint Medicines, Amgen, F Hoffmann-La Roche, MSD, Bristol Myers  Squibb, Alexion Pharmaceuticals, Novartis, Pfizer, Gilead, Boehringer Ingelheim,  Swedish Orphan Biovitrum, and Apellis Pharmaceuticals; and honoraria from SwixxBiopharma. Kensuke Usuki reports grants from Alexion Pharmaceuticals, Apellis Pharmaceuticals, Chugai, and Novartis; and personal fees from Novartis, Chugai, and Alexion Pharmaceuticals. Morag Griffin reports consultancy at Biocryst and Regeneron Pharmaceuticals; honoraria from Alexion Pharmaceuticals and Swedish Orphan Biovitrum; advisory board member at Novartis, Biocryst, Alexion Pharmaceuticals,  and Swedish Orphan Biovitrum; and educational work sponsored by Apellis with unrestricted grant paid to Medscape. J-Jean-Jacques Kiladjian reports membership on an entity's board of directors or advisory committees at AbbVie, Novartis, Bristol Myers Squibb, and AOP Orphan. Carlos M de Castro reports consultancy at Apellis Pharmaceuticals; honoraria from Novartis, Alexion Pharmaceuticals, Biocryst, and Apellis Pharmaceuticals; and research funding from Alexion Pharmaceuticals, and Apellis Pharmaceuticals. Temitayo Ajayi reports current employment and current equity holder at Apellis Pharmaceuticals. Mohammed Al-Adhami-A reports current employment at Apellis Pharmaceuticals. Pascal Deschatelets reports being a founder, Chief Scientific Officer, and current equity holder at Apellis Pharmaceuticals. Cedric Francois and Federico Grossi report current employment and current equity holder at Apellis Pharmaceuticals. Antonio M. Risitano reports consultancy at Novartis and Amyndas; membership on an entity's board of directors or advisory committees at Novartis, Alexion Pharmaceuticals, Samsung, Biocryst, Achillion, Roche, Sanofi, and Apellis Pharmaceuticals; and grants from Alexion Pharmaceuticals, Novartis, Alnylam, and Rapharma. PH reports consultancy at Alexion Pharmaceuticals, Apellis Pharmaceuticals, AbbVie, AstraZeneca, Janssen, and Roche; research funding from Alexion Pharmaceuticals, Apellis Pharmaceuticals, AbbVie, Gilead, Janssen, Pharmacyclics, and Roche; and speakers bureau at Alexion Pharmaceuticals, Apellis Pharmaceuticals, AbbVie, AstraZeneca, Janssen, and Roche. Hisakazu Nishimori declares no competing interests.\n",
      "\n",
      "Hillmen, Peter\n",
      "Declaration of interests Regis Peffault de Latour reports consultancy at Novartis, Pfizer, Amgen, Alexion Pharmaceuticals, Apellis Pharmaceuticals, and Swedish Orphan Biovitrum; honoraria from Novartis, Pfizer, Amgen, Alexion Pharmaceuticals, Apellis Pharmaceuticals, and Swedish Orphan Biovitrum; research funding from Novartis, Pfizer, Amgen, and Alexion Pharmaceuticals; and grants from Alexion Pharmaceuticals, Amgen, Novartis, and Pfizer. Jeff Szer reports consultancy at Novartis, Alexion Pharmaceuticals, and Apellis Pharmaceuticals; honoraria from Takeda, Pfizer, Novartis, Prevail Therapeutics, and Alexion Pharmaceuticals; speakers' bureau at Takeda, Pfizer, Novartis, and Alexion Pharmaceuticals; and membership on an entity's board of directors or advisory committees at Prevail Therapeutics  and Alexion Pharmaceuticals. Ilene C. Weitz reports consultancy at Alexion Pharmaceuticals,  Apellis Pharmaceuticals, Biocryst, Novartis, and Sanofi Genxyme; honoraria from Alexion Pharmaceuticals, Apellis Pharmaceuticals, Biocryst, Novartis, and Sanofi  Genxyme; and speakers' bureau at Alexion Pharmaceuticals. Alexander Roth reports personal fees from Alexion Pharmaceuticals, Apellis Pharmaceuticals, Kira, Novartis, Roche, Swedish Orphan Biovitrum, Sanofi, Bioverativ, and Grifols; and grants from Roche. Britta Hochsmann reports honoraria and advisory board member at Novartis, Roche, Alexion Pharmaceuticals, and Apellis Pharmaceuticals. Jens Panse reports consultancy and honoraria at Blueprint Medicines, Amgen, F Hoffmann-La Roche, MSD, Bristol Myers  Squibb, Alexion Pharmaceuticals, Novartis, Pfizer, Gilead, Boehringer Ingelheim,  Swedish Orphan Biovitrum, and Apellis Pharmaceuticals; and honoraria from SwixxBiopharma. Kensuke Usuki reports grants from Alexion Pharmaceuticals, Apellis Pharmaceuticals, Chugai, and Novartis; and personal fees from Novartis, Chugai, and Alexion Pharmaceuticals. Morag Griffin reports consultancy at Biocryst and Regeneron Pharmaceuticals; honoraria from Alexion Pharmaceuticals and Swedish Orphan Biovitrum; advisory board member at Novartis, Biocryst, Alexion Pharmaceuticals,  and Swedish Orphan Biovitrum; and educational work sponsored by Apellis with unrestricted grant paid to Medscape. J-Jean-Jacques Kiladjian reports membership on an entity's board of directors or advisory committees at AbbVie, Novartis, Bristol Myers Squibb, and AOP Orphan. Carlos M de Castro reports consultancy at Apellis Pharmaceuticals; honoraria from Novartis, Alexion Pharmaceuticals, Biocryst, and Apellis Pharmaceuticals; and research funding from Alexion Pharmaceuticals, and Apellis Pharmaceuticals. Temitayo Ajayi reports current employment and current equity holder at Apellis Pharmaceuticals. Mohammed Al-Adhami-A reports current employment at Apellis Pharmaceuticals. Pascal Deschatelets reports being a founder, Chief Scientific Officer, and current equity holder at Apellis Pharmaceuticals. Cedric Francois and Federico Grossi report current employment and current equity holder at Apellis Pharmaceuticals. Antonio M. Risitano reports consultancy at Novartis and Amyndas; membership on an entity's board of directors or advisory committees at Novartis, Alexion Pharmaceuticals, Samsung, Biocryst, Achillion, Roche, Sanofi, and Apellis Pharmaceuticals; and grants from Alexion Pharmaceuticals, Novartis, Alnylam, and Rapharma. Peter Hillmen reports consultancy at Alexion Pharmaceuticals, Apellis Pharmaceuticals, AbbVie, AstraZeneca, Janssen, and Roche; research funding from Alexion Pharmaceuticals, Apellis Pharmaceuticals, AbbVie, Gilead, Janssen, Pharmacyclics, and Roche; and speakers bureau at Alexion Pharmaceuticals, Apellis Pharmaceuticals, AbbVie, AstraZeneca, Janssen, and Roche. Hisakazu Nishimori declares no competing interests.\n",
      "\n",
      "Miles, Lachlan F.\n",
      "Another study for which Lachlan F. Miles and KLB are Principal Investigators has received a grant from Vifor Pharma as part of a matched funding arrangement with the Victorian Department of Health. The institution for which Lachlan F. Miles works has received  funds and non-financial support from Edwards Lifesciences. TR or his institution  have received grants, personal fees, and non-financial support from Pharmocosmos  and Vifor Pharma, outside the submitted work.\n",
      "\n",
      "Burbury, Kate L.\n",
      "Another study for which Lachlan F. Miles and Kate L. Burbury are Principal Investigators has received a grant from Vifor Pharma as part of a matched funding arrangement with the Victorian Department of Health. The institution for which Lachlan F. Miles works has received  funds and non-financial support from Edwards Lifesciences. TR or his institution  have received grants, personal fees, and non-financial support from Pharmocosmos  and Vifor Pharma, outside the submitted work.\n",
      "\n",
      "Richards, Toby\n",
      "Another study for which Lachlan F. Miles and Kate L. Burbury are Principal Investigators has received a grant from Vifor Pharma as part of a matched funding arrangement with the Victorian Department of Health. The institution for which Lachlan F. Miles works has received  funds and non-financial support from Edwards Lifesciences. Toby Richards or his institution  have received grants, personal fees, and non-financial support from Pharmocosmos  and Vifor Pharma, outside the submitted work.\n",
      "\n",
      "Joanna Sophia J. Vinke\n",
      "J o a n n a   S o p h i a   J .   V i n k e reports speakers bureaus from Vifor Pharma. MFE reports consultant fees from Vifor Pharma; served on the Advisory Board for Cablon Medical; and speakers bureaus from Vifor Pharma, Cablon Medical, and Astellas.\n",
      "\n",
      "Eisenga, Michele F.\n",
      "J o a n n a   S o p h i a   J .   V i n k e reports speakers bureaus from Vifor Pharma. Michele F. Eisenga reports consultant fees from Vifor Pharma; served on the Advisory Board for Cablon Medical; and speakers bureaus from Vifor Pharma, Cablon Medical, and Astellas.\n",
      "\n",
      "TS and KK report joint research funding from the Japanese Red Cross Society. All  other authors declare no competing interests.\n",
      "\n",
      "Sato, Tomohiko\n",
      "Tomohiko Sato and KK report joint research funding from the Japanese Red Cross Society. All  other authors declare no competing interests.\n",
      "\n",
      "Tomohiko Sato and KK report joint research funding from the Japanese Red Cross Society. All  other authors declare no competing interests.\n",
      "\n",
      "Tomohiko Sato and KK report joint research funding from the Japanese Red Cross Society. All  other authors declare no competing interests.\n",
      "\n",
      "Kida, Kotaro\n",
      "Tomohiko Sato and Kotaro Kida report joint research funding from the Japanese Red Cross Society. All  other authors declare no competing interests.\n",
      "\n",
      "Clarke, Lisa\n",
      "Lisa Clarke has provided education sponsored by Vifor Pharma and Pfizer. KK declares no competing interests.\n",
      "\n",
      "King, Kylie\n",
      "Lisa Clarke has provided education sponsored by Vifor Pharma and Pfizer. Kylie King declares no competing interests.\n",
      "\n",
      "I have received honoraria and research funding from Alexion Pharmaceuticals, Novartis, and Sobi and research funding from Alnylam and BioCryst.\n",
      "\n",
      "Declaration of interests This manuscript was prepared by staff members of the Te  Aho o Te Kahu Cancer Control Agency (an agency of the New Zealand Government), as well as other researchers and clinicians from around New Zealand. All editorial decisions regarding the content of the manuscript were made by the research team. We declare no competing interests.\n",
      "\n",
      "Declaration of interests This manuscript was prepared by staff members of the Te  Aho o Te Kahu Cancer Control Agency (an agency of the New Zealand Government), as well as other researchers and clinicians from around New Zealand. All editorial decisions regarding the content of the manuscript were made by the research team. We declare no competing interests.\n",
      "\n",
      "Declaration of interests This manuscript was prepared by staff members of the Te  Aho o Te Kahu Cancer Control Agency (an agency of the New Zealand Government), as well as other researchers and clinicians from around New Zealand. All editorial decisions regarding the content of the manuscript were made by the research team. We declare no competing interests.\n",
      "\n",
      "Declaration of interests This manuscript was prepared by staff members of the Te  Aho o Te Kahu Cancer Control Agency (an agency of the New Zealand Government), as well as other researchers and clinicians from around New Zealand. All editorial decisions regarding the content of the manuscript were made by the research team. We declare no competing interests.\n",
      "\n",
      "Declaration of interests This manuscript was prepared by staff members of the Te  Aho o Te Kahu Cancer Control Agency (an agency of the New Zealand Government), as well as other researchers and clinicians from around New Zealand. All editorial decisions regarding the content of the manuscript were made by the research team. We declare no competing interests.\n",
      "\n",
      "Declaration of interests This manuscript was prepared by staff members of the Te  Aho o Te Kahu Cancer Control Agency (an agency of the New Zealand Government), as well as other researchers and clinicians from around New Zealand. All editorial decisions regarding the content of the manuscript were made by the research team. We declare no competing interests.\n",
      "\n",
      "Declaration of interests This manuscript was prepared by staff members of the Te  Aho o Te Kahu Cancer Control Agency (an agency of the New Zealand Government), as well as other researchers and clinicians from around New Zealand. All editorial decisions regarding the content of the manuscript were made by the research team. We declare no competing interests.\n",
      "\n",
      "Eyre, Toby A.\n",
      "Declaration of interests TCE-G is partly funded from a grant from the Danish Cancer Society. AJMF declares research funding from ADC Therapeutics, Bayer HealthCare Pharmaceuticals, Beigene, Bristol Myers Squibb (BMS), Genmab, Gilead,  Hutchison Medipharma, Incyte, Janssen Research & Development, MEI Pharma, Novartis, PletixaPharm, Pharmacyclics, Protherics, Roche, and Takeda; consulting  fees from Gilead, Juno, Novartis, PletixaPharm, and Roche; speaker fees from Gilead and Roche; and advisory work for Gilead, Juno, Novartis, PletixaPharm, and Roche. PM declares speaker fees from Janssen. Toby A. Eyre declares advisory work from Janssen, Kite Pharma, Roche, AbbVie, AstraZeneca, Loxo Oncology, Beigene, Incyte, and Secura Bio; speaker bureau fees from Janssen, Kite Pharma, Roche, AbbVie, AstraZeneca, Loxo Oncology, Beigene, and Incyte; and travel support from Roche and AbbVie. MJM recognises the National Cancer Institute: University of Iowa Mayo Clinic Lymphoma SPORE (P50-CA097274) grant; declares advisory work from Adaptive  Biotechnologies, Pfizer, Kite Pharma, and Genmab; and research support from BMS,  Genentech, Genmab, and Morphosys to his institution. KLL declares speaker bureau  from Janssen, AstraZeneca, and Roche; travel support from Novartis and Janssen; and advisory work from IQVIA and Loxo at Lilly. KC declares consulting fees from  Roche, BMS, KITE Pharma, and Janssen; speaker bureau from Roche, KITE Pharma, and BMS; and travel support from Roche, KITE Pharma, and BMS. CYC declares speaker bureau from Beigene, Janssen, and Gilead; and advisory work from TG Therapeutics, Roche, Novartis, Janssen, Beigene, AstraZeneca, Eli Lilly, BMS, Gilead, and BMS.  KJS declares advisory work from BMS, Seattle Genetics, Merck, Janssen, Novartis,  and Kyowa; and DSMC Regeneron, Steering Committee Beigene, research funding from  BMS. TCE-G declares previous employment with Roche (March, 2019 until February, 2021) and an honorarium from AbbVie. All other authors declare no competing interests.\n",
      "\n",
      "Savage, Kerry J.\n",
      "Declaration of interests TCE-G is partly funded from a grant from the Danish Cancer Society. AJMF declares research funding from ADC Therapeutics, Bayer HealthCare Pharmaceuticals, Beigene, Bristol Myers Squibb (BMS), Genmab, Gilead,  Hutchison Medipharma, Incyte, Janssen Research & Development, MEI Pharma, Novartis, PletixaPharm, Pharmacyclics, Protherics, Roche, and Takeda; consulting  fees from Gilead, Juno, Novartis, PletixaPharm, and Roche; speaker fees from Gilead and Roche; and advisory work for Gilead, Juno, Novartis, PletixaPharm, and Roche. PM declares speaker fees from Janssen. Toby A. Eyre declares advisory work from Janssen, Kite Pharma, Roche, AbbVie, AstraZeneca, Loxo Oncology, Beigene, Incyte, and Secura Bio; speaker bureau fees from Janssen, Kite Pharma, Roche, AbbVie, AstraZeneca, Loxo Oncology, Beigene, and Incyte; and travel support from Roche and AbbVie. MJM recognises the National Cancer Institute: University of Iowa Mayo Clinic Lymphoma SPORE (P50-CA097274) grant; declares advisory work from Adaptive  Biotechnologies, Pfizer, Kite Pharma, and Genmab; and research support from BMS,  Genentech, Genmab, and Morphosys to his institution. KLL declares speaker bureau  from Janssen, AstraZeneca, and Roche; travel support from Novartis and Janssen; and advisory work from IQVIA and Loxo at Lilly. KC declares consulting fees from  Roche, BMS, KITE Pharma, and Janssen; speaker bureau from Roche, KITE Pharma, and BMS; and travel support from Roche, KITE Pharma, and BMS. CYC declares speaker bureau from Beigene, Janssen, and Gilead; and advisory work from TG Therapeutics, Roche, Novartis, Janssen, Beigene, AstraZeneca, Eli Lilly, BMS, Gilead, and BMS.  Kerry J. Savage declares advisory work from BMS, Seattle Genetics, Merck, Janssen, Novartis,  and Kyowa; and DSMC Regeneron, Steering Committee Beigene, research funding from  BMS. TCE-G declares previous employment with Roche (March, 2019 until February, 2021) and an honorarium from AbbVie. All other authors declare no competing interests.\n",
      "\n",
      "Cheah, Chan Y.\n",
      "Declaration of interests TCE-G is partly funded from a grant from the Danish Cancer Society. AJMF declares research funding from ADC Therapeutics, Bayer HealthCare Pharmaceuticals, Beigene, Bristol Myers Squibb (BMS), Genmab, Gilead,  Hutchison Medipharma, Incyte, Janssen Research & Development, MEI Pharma, Novartis, PletixaPharm, Pharmacyclics, Protherics, Roche, and Takeda; consulting  fees from Gilead, Juno, Novartis, PletixaPharm, and Roche; speaker fees from Gilead and Roche; and advisory work for Gilead, Juno, Novartis, PletixaPharm, and Roche. PM declares speaker fees from Janssen. Toby A. Eyre declares advisory work from Janssen, Kite Pharma, Roche, AbbVie, AstraZeneca, Loxo Oncology, Beigene, Incyte, and Secura Bio; speaker bureau fees from Janssen, Kite Pharma, Roche, AbbVie, AstraZeneca, Loxo Oncology, Beigene, and Incyte; and travel support from Roche and AbbVie. MJM recognises the National Cancer Institute: University of Iowa Mayo Clinic Lymphoma SPORE (P50-CA097274) grant; declares advisory work from Adaptive  Biotechnologies, Pfizer, Kite Pharma, and Genmab; and research support from BMS,  Genentech, Genmab, and Morphosys to his institution. KLL declares speaker bureau  from Janssen, AstraZeneca, and Roche; travel support from Novartis and Janssen; and advisory work from IQVIA and Loxo at Lilly. KC declares consulting fees from  Roche, BMS, KITE Pharma, and Janssen; speaker bureau from Roche, KITE Pharma, and BMS; and travel support from Roche, KITE Pharma, and BMS. Chan Y. Cheah declares speaker bureau from Beigene, Janssen, and Gilead; and advisory work from TG Therapeutics, Roche, Novartis, Janssen, Beigene, AstraZeneca, Eli Lilly, BMS, Gilead, and BMS.  Kerry J. Savage declares advisory work from BMS, Seattle Genetics, Merck, Janssen, Novartis,  and Kyowa; and DSMC Regeneron, Steering Committee Beigene, research funding from  BMS. TCE-G declares previous employment with Roche (March, 2019 until February, 2021) and an honorarium from AbbVie. All other authors declare no competing interests.\n",
      "\n",
      "El-Galaly, Tarec C.\n",
      "Declaration of interests Tarec C. El-Galaly-G is partly funded from a grant from the Danish Cancer Society. AJMF declares research funding from ADC Therapeutics, Bayer HealthCare Pharmaceuticals, Beigene, Bristol Myers Squibb (BMS), Genmab, Gilead,  Hutchison Medipharma, Incyte, Janssen Research & Development, MEI Pharma, Novartis, PletixaPharm, Pharmacyclics, Protherics, Roche, and Takeda; consulting  fees from Gilead, Juno, Novartis, PletixaPharm, and Roche; speaker fees from Gilead and Roche; and advisory work for Gilead, Juno, Novartis, PletixaPharm, and Roche. PM declares speaker fees from Janssen. Toby A. Eyre declares advisory work from Janssen, Kite Pharma, Roche, AbbVie, AstraZeneca, Loxo Oncology, Beigene, Incyte, and Secura Bio; speaker bureau fees from Janssen, Kite Pharma, Roche, AbbVie, AstraZeneca, Loxo Oncology, Beigene, and Incyte; and travel support from Roche and AbbVie. MJM recognises the National Cancer Institute: University of Iowa Mayo Clinic Lymphoma SPORE (P50-CA097274) grant; declares advisory work from Adaptive  Biotechnologies, Pfizer, Kite Pharma, and Genmab; and research support from BMS,  Genentech, Genmab, and Morphosys to his institution. KLL declares speaker bureau  from Janssen, AstraZeneca, and Roche; travel support from Novartis and Janssen; and advisory work from IQVIA and Loxo at Lilly. KC declares consulting fees from  Roche, BMS, KITE Pharma, and Janssen; speaker bureau from Roche, KITE Pharma, and BMS; and travel support from Roche, KITE Pharma, and BMS. Chan Y. Cheah declares speaker bureau from Beigene, Janssen, and Gilead; and advisory work from TG Therapeutics, Roche, Novartis, Janssen, Beigene, AstraZeneca, Eli Lilly, BMS, Gilead, and BMS.  Kerry J. Savage declares advisory work from BMS, Seattle Genetics, Merck, Janssen, Novartis,  and Kyowa; and DSMC Regeneron, Steering Committee Beigene, research funding from  BMS. Tarec C. El-Galaly-G declares previous employment with Roche (March, 2019 until February, 2021) and an honorarium from AbbVie. All other authors declare no competing interests.\n",
      "\n",
      "Lewis, Katharine L.\n",
      "Declaration of interests Tarec C. El-Galaly-G is partly funded from a grant from the Danish Cancer Society. AJMF declares research funding from ADC Therapeutics, Bayer HealthCare Pharmaceuticals, Beigene, Bristol Myers Squibb (BMS), Genmab, Gilead,  Hutchison Medipharma, Incyte, Janssen Research & Development, MEI Pharma, Novartis, PletixaPharm, Pharmacyclics, Protherics, Roche, and Takeda; consulting  fees from Gilead, Juno, Novartis, PletixaPharm, and Roche; speaker fees from Gilead and Roche; and advisory work for Gilead, Juno, Novartis, PletixaPharm, and Roche. PM declares speaker fees from Janssen. Toby A. Eyre declares advisory work from Janssen, Kite Pharma, Roche, AbbVie, AstraZeneca, Loxo Oncology, Beigene, Incyte, and Secura Bio; speaker bureau fees from Janssen, Kite Pharma, Roche, AbbVie, AstraZeneca, Loxo Oncology, Beigene, and Incyte; and travel support from Roche and AbbVie. MJM recognises the National Cancer Institute: University of Iowa Mayo Clinic Lymphoma SPORE (P50-CA097274) grant; declares advisory work from Adaptive  Biotechnologies, Pfizer, Kite Pharma, and Genmab; and research support from BMS,  Genentech, Genmab, and Morphosys to his institution. Katharine L. Lewis declares speaker bureau  from Janssen, AstraZeneca, and Roche; travel support from Novartis and Janssen; and advisory work from IQVIA and Loxo at Lilly. KC declares consulting fees from  Roche, BMS, KITE Pharma, and Janssen; speaker bureau from Roche, KITE Pharma, and BMS; and travel support from Roche, KITE Pharma, and BMS. Chan Y. Cheah declares speaker bureau from Beigene, Janssen, and Gilead; and advisory work from TG Therapeutics, Roche, Novartis, Janssen, Beigene, AstraZeneca, Eli Lilly, BMS, Gilead, and BMS.  Kerry J. Savage declares advisory work from BMS, Seattle Genetics, Merck, Janssen, Novartis,  and Kyowa; and DSMC Regeneron, Steering Committee Beigene, research funding from  BMS. Tarec C. El-Galaly-G declares previous employment with Roche (March, 2019 until February, 2021) and an honorarium from AbbVie. All other authors declare no competing interests.\n",
      "\n",
      "McKay, Pamela\n",
      "Declaration of interests Tarec C. El-Galaly-G is partly funded from a grant from the Danish Cancer Society. AJMF declares research funding from ADC Therapeutics, Bayer HealthCare Pharmaceuticals, Beigene, Bristol Myers Squibb (BMS), Genmab, Gilead,  Hutchison Medipharma, Incyte, Janssen Research & Development, MEI Pharma, Novartis, PletixaPharm, Pharmacyclics, Protherics, Roche, and Takeda; consulting  fees from Gilead, Juno, Novartis, PletixaPharm, and Roche; speaker fees from Gilead and Roche; and advisory work for Gilead, Juno, Novartis, PletixaPharm, and Roche. Pamela McKay declares speaker fees from Janssen. Toby A. Eyre declares advisory work from Janssen, Kite Pharma, Roche, AbbVie, AstraZeneca, Loxo Oncology, Beigene, Incyte, and Secura Bio; speaker bureau fees from Janssen, Kite Pharma, Roche, AbbVie, AstraZeneca, Loxo Oncology, Beigene, and Incyte; and travel support from Roche and AbbVie. MJM recognises the National Cancer Institute: University of Iowa Mayo Clinic Lymphoma SPORE (P50-CA097274) grant; declares advisory work from Adaptive  Biotechnologies, Pfizer, Kite Pharma, and Genmab; and research support from BMS,  Genentech, Genmab, and Morphosys to his institution. Katharine L. Lewis declares speaker bureau  from Janssen, AstraZeneca, and Roche; travel support from Novartis and Janssen; and advisory work from IQVIA and Loxo at Lilly. KC declares consulting fees from  Roche, BMS, KITE Pharma, and Janssen; speaker bureau from Roche, KITE Pharma, and BMS; and travel support from Roche, KITE Pharma, and BMS. Chan Y. Cheah declares speaker bureau from Beigene, Janssen, and Gilead; and advisory work from TG Therapeutics, Roche, Novartis, Janssen, Beigene, AstraZeneca, Eli Lilly, BMS, Gilead, and BMS.  Kerry J. Savage declares advisory work from BMS, Seattle Genetics, Merck, Janssen, Novartis,  and Kyowa; and DSMC Regeneron, Steering Committee Beigene, research funding from  BMS. Tarec C. El-Galaly-G declares previous employment with Roche (March, 2019 until February, 2021) and an honorarium from AbbVie. All other authors declare no competing interests.\n",
      "\n",
      "Declaration of interests Tarec C. El-Galaly-G is partly funded from a grant from the Danish Cancer Society. AJMF declares research funding from ADC Therapeutics, Bayer HealthCare Pharmaceuticals, Beigene, Bristol Myers Squibb (BMS), Genmab, Gilead,  Hutchison Medipharma, Incyte, Janssen Research & Development, MEI Pharma, Novartis, PletixaPharm, Pharmacyclics, Protherics, Roche, and Takeda; consulting  fees from Gilead, Juno, Novartis, PletixaPharm, and Roche; speaker fees from Gilead and Roche; and advisory work for Gilead, Juno, Novartis, PletixaPharm, and Roche. Pamela McKay declares speaker fees from Janssen. Toby A. Eyre declares advisory work from Janssen, Kite Pharma, Roche, AbbVie, AstraZeneca, Loxo Oncology, Beigene, Incyte, and Secura Bio; speaker bureau fees from Janssen, Kite Pharma, Roche, AbbVie, AstraZeneca, Loxo Oncology, Beigene, and Incyte; and travel support from Roche and AbbVie. MJM recognises the National Cancer Institute: University of Iowa Mayo Clinic Lymphoma SPORE (P50-CA097274) grant; declares advisory work from Adaptive  Biotechnologies, Pfizer, Kite Pharma, and Genmab; and research support from BMS,  Genentech, Genmab, and Morphosys to his institution. Katharine L. Lewis declares speaker bureau  from Janssen, AstraZeneca, and Roche; travel support from Novartis and Janssen; and advisory work from IQVIA and Loxo at Lilly. KC declares consulting fees from  Roche, BMS, KITE Pharma, and Janssen; speaker bureau from Roche, KITE Pharma, and BMS; and travel support from Roche, KITE Pharma, and BMS. Chan Y. Cheah declares speaker bureau from Beigene, Janssen, and Gilead; and advisory work from TG Therapeutics, Roche, Novartis, Janssen, Beigene, AstraZeneca, Eli Lilly, BMS, Gilead, and BMS.  Kerry J. Savage declares advisory work from BMS, Seattle Genetics, Merck, Janssen, Novartis,  and Kyowa; and DSMC Regeneron, Steering Committee Beigene, research funding from  BMS. Tarec C. El-Galaly-G declares previous employment with Roche (March, 2019 until February, 2021) and an honorarium from AbbVie. All other authors declare no competing interests.\n",
      "\n",
      "Declaration of interests Tarec C. El-Galaly-G is partly funded from a grant from the Danish Cancer Society. AJMF declares research funding from ADC Therapeutics, Bayer HealthCare Pharmaceuticals, Beigene, Bristol Myers Squibb (BMS), Genmab, Gilead,  Hutchison Medipharma, Incyte, Janssen Research & Development, MEI Pharma, Novartis, PletixaPharm, Pharmacyclics, Protherics, Roche, and Takeda; consulting  fees from Gilead, Juno, Novartis, PletixaPharm, and Roche; speaker fees from Gilead and Roche; and advisory work for Gilead, Juno, Novartis, PletixaPharm, and Roche. Pamela McKay declares speaker fees from Janssen. Toby A. Eyre declares advisory work from Janssen, Kite Pharma, Roche, AbbVie, AstraZeneca, Loxo Oncology, Beigene, Incyte, and Secura Bio; speaker bureau fees from Janssen, Kite Pharma, Roche, AbbVie, AstraZeneca, Loxo Oncology, Beigene, and Incyte; and travel support from Roche and AbbVie. MJM recognises the National Cancer Institute: University of Iowa Mayo Clinic Lymphoma SPORE (P50-CA097274) grant; declares advisory work from Adaptive  Biotechnologies, Pfizer, Kite Pharma, and Genmab; and research support from BMS,  Genentech, Genmab, and Morphosys to his institution. Katharine L. Lewis declares speaker bureau  from Janssen, AstraZeneca, and Roche; travel support from Novartis and Janssen; and advisory work from IQVIA and Loxo at Lilly. KC declares consulting fees from  Roche, BMS, KITE Pharma, and Janssen; speaker bureau from Roche, KITE Pharma, and BMS; and travel support from Roche, KITE Pharma, and BMS. Chan Y. Cheah declares speaker bureau from Beigene, Janssen, and Gilead; and advisory work from TG Therapeutics, Roche, Novartis, Janssen, Beigene, AstraZeneca, Eli Lilly, BMS, Gilead, and BMS.  Kerry J. Savage declares advisory work from BMS, Seattle Genetics, Merck, Janssen, Novartis,  and Kyowa; and DSMC Regeneron, Steering Committee Beigene, research funding from  BMS. Tarec C. El-Galaly-G declares previous employment with Roche (March, 2019 until February, 2021) and an honorarium from AbbVie. All other authors declare no competing interests.\n",
      "\n",
      "Declaration of interests Tarec C. El-Galaly-G is partly funded from a grant from the Danish Cancer Society. AJMF declares research funding from ADC Therapeutics, Bayer HealthCare Pharmaceuticals, Beigene, Bristol Myers Squibb (BMS), Genmab, Gilead,  Hutchison Medipharma, Incyte, Janssen Research & Development, MEI Pharma, Novartis, PletixaPharm, Pharmacyclics, Protherics, Roche, and Takeda; consulting  fees from Gilead, Juno, Novartis, PletixaPharm, and Roche; speaker fees from Gilead and Roche; and advisory work for Gilead, Juno, Novartis, PletixaPharm, and Roche. Pamela McKay declares speaker fees from Janssen. Toby A. Eyre declares advisory work from Janssen, Kite Pharma, Roche, AbbVie, AstraZeneca, Loxo Oncology, Beigene, Incyte, and Secura Bio; speaker bureau fees from Janssen, Kite Pharma, Roche, AbbVie, AstraZeneca, Loxo Oncology, Beigene, and Incyte; and travel support from Roche and AbbVie. MJM recognises the National Cancer Institute: University of Iowa Mayo Clinic Lymphoma SPORE (P50-CA097274) grant; declares advisory work from Adaptive  Biotechnologies, Pfizer, Kite Pharma, and Genmab; and research support from BMS,  Genentech, Genmab, and Morphosys to his institution. Katharine L. Lewis declares speaker bureau  from Janssen, AstraZeneca, and Roche; travel support from Novartis and Janssen; and advisory work from IQVIA and Loxo at Lilly. KC declares consulting fees from  Roche, BMS, KITE Pharma, and Janssen; speaker bureau from Roche, KITE Pharma, and BMS; and travel support from Roche, KITE Pharma, and BMS. Chan Y. Cheah declares speaker bureau from Beigene, Janssen, and Gilead; and advisory work from TG Therapeutics, Roche, Novartis, Janssen, Beigene, AstraZeneca, Eli Lilly, BMS, Gilead, and BMS.  Kerry J. Savage declares advisory work from BMS, Seattle Genetics, Merck, Janssen, Novartis,  and Kyowa; and DSMC Regeneron, Steering Committee Beigene, research funding from  BMS. Tarec C. El-Galaly-G declares previous employment with Roche (March, 2019 until February, 2021) and an honorarium from AbbVie. All other authors declare no competing interests.\n",
      "\n",
      "Declaration of interests Tarec C. El-Galaly-G is partly funded from a grant from the Danish Cancer Society. AJMF declares research funding from ADC Therapeutics, Bayer HealthCare Pharmaceuticals, Beigene, Bristol Myers Squibb (BMS), Genmab, Gilead,  Hutchison Medipharma, Incyte, Janssen Research & Development, MEI Pharma, Novartis, PletixaPharm, Pharmacyclics, Protherics, Roche, and Takeda; consulting  fees from Gilead, Juno, Novartis, PletixaPharm, and Roche; speaker fees from Gilead and Roche; and advisory work for Gilead, Juno, Novartis, PletixaPharm, and Roche. Pamela McKay declares speaker fees from Janssen. Toby A. Eyre declares advisory work from Janssen, Kite Pharma, Roche, AbbVie, AstraZeneca, Loxo Oncology, Beigene, Incyte, and Secura Bio; speaker bureau fees from Janssen, Kite Pharma, Roche, AbbVie, AstraZeneca, Loxo Oncology, Beigene, and Incyte; and travel support from Roche and AbbVie. MJM recognises the National Cancer Institute: University of Iowa Mayo Clinic Lymphoma SPORE (P50-CA097274) grant; declares advisory work from Adaptive  Biotechnologies, Pfizer, Kite Pharma, and Genmab; and research support from BMS,  Genentech, Genmab, and Morphosys to his institution. Katharine L. Lewis declares speaker bureau  from Janssen, AstraZeneca, and Roche; travel support from Novartis and Janssen; and advisory work from IQVIA and Loxo at Lilly. KC declares consulting fees from  Roche, BMS, KITE Pharma, and Janssen; speaker bureau from Roche, KITE Pharma, and BMS; and travel support from Roche, KITE Pharma, and BMS. Chan Y. Cheah declares speaker bureau from Beigene, Janssen, and Gilead; and advisory work from TG Therapeutics, Roche, Novartis, Janssen, Beigene, AstraZeneca, Eli Lilly, BMS, Gilead, and BMS.  Kerry J. Savage declares advisory work from BMS, Seattle Genetics, Merck, Janssen, Novartis,  and Kyowa; and DSMC Regeneron, Steering Committee Beigene, research funding from  BMS. Tarec C. El-Galaly-G declares previous employment with Roche (March, 2019 until February, 2021) and an honorarium from AbbVie. All other authors declare no competing interests.\n",
      "\n",
      "Maurer, Matthew J.\n",
      "Declaration of interests Tarec C. El-Galaly-G is partly funded from a grant from the Danish Cancer Society. AJMF declares research funding from ADC Therapeutics, Bayer HealthCare Pharmaceuticals, Beigene, Bristol Myers Squibb (BMS), Genmab, Gilead,  Hutchison Medipharma, Incyte, Janssen Research & Development, MEI Pharma, Novartis, PletixaPharm, Pharmacyclics, Protherics, Roche, and Takeda; consulting  fees from Gilead, Juno, Novartis, PletixaPharm, and Roche; speaker fees from Gilead and Roche; and advisory work for Gilead, Juno, Novartis, PletixaPharm, and Roche. Pamela McKay declares speaker fees from Janssen. Toby A. Eyre declares advisory work from Janssen, Kite Pharma, Roche, AbbVie, AstraZeneca, Loxo Oncology, Beigene, Incyte, and Secura Bio; speaker bureau fees from Janssen, Kite Pharma, Roche, AbbVie, AstraZeneca, Loxo Oncology, Beigene, and Incyte; and travel support from Roche and AbbVie. Matthew J. Maurer recognises the National Cancer Institute: University of Iowa Mayo Clinic Lymphoma SPORE (P50-CA097274) grant; declares advisory work from Adaptive  Biotechnologies, Pfizer, Kite Pharma, and Genmab; and research support from BMS,  Genentech, Genmab, and Morphosys to his institution. Katharine L. Lewis declares speaker bureau  from Janssen, AstraZeneca, and Roche; travel support from Novartis and Janssen; and advisory work from IQVIA and Loxo at Lilly. KC declares consulting fees from  Roche, BMS, KITE Pharma, and Janssen; speaker bureau from Roche, KITE Pharma, and BMS; and travel support from Roche, KITE Pharma, and BMS. Chan Y. Cheah declares speaker bureau from Beigene, Janssen, and Gilead; and advisory work from TG Therapeutics, Roche, Novartis, Janssen, Beigene, AstraZeneca, Eli Lilly, BMS, Gilead, and BMS.  Kerry J. Savage declares advisory work from BMS, Seattle Genetics, Merck, Janssen, Novartis,  and Kyowa; and DSMC Regeneron, Steering Committee Beigene, research funding from  BMS. Tarec C. El-Galaly-G declares previous employment with Roche (March, 2019 until February, 2021) and an honorarium from AbbVie. All other authors declare no competing interests.\n",
      "\n",
      "Cwynarski, Kate\n",
      "Declaration of interests Tarec C. El-Galaly-G is partly funded from a grant from the Danish Cancer Society. AJMF declares research funding from ADC Therapeutics, Bayer HealthCare Pharmaceuticals, Beigene, Bristol Myers Squibb (BMS), Genmab, Gilead,  Hutchison Medipharma, Incyte, Janssen Research & Development, MEI Pharma, Novartis, PletixaPharm, Pharmacyclics, Protherics, Roche, and Takeda; consulting  fees from Gilead, Juno, Novartis, PletixaPharm, and Roche; speaker fees from Gilead and Roche; and advisory work for Gilead, Juno, Novartis, PletixaPharm, and Roche. Pamela McKay declares speaker fees from Janssen. Toby A. Eyre declares advisory work from Janssen, Kite Pharma, Roche, AbbVie, AstraZeneca, Loxo Oncology, Beigene, Incyte, and Secura Bio; speaker bureau fees from Janssen, Kite Pharma, Roche, AbbVie, AstraZeneca, Loxo Oncology, Beigene, and Incyte; and travel support from Roche and AbbVie. Matthew J. Maurer recognises the National Cancer Institute: University of Iowa Mayo Clinic Lymphoma SPORE (P50-CA097274) grant; declares advisory work from Adaptive  Biotechnologies, Pfizer, Kite Pharma, and Genmab; and research support from BMS,  Genentech, Genmab, and Morphosys to his institution. Katharine L. Lewis declares speaker bureau  from Janssen, AstraZeneca, and Roche; travel support from Novartis and Janssen; and advisory work from IQVIA and Loxo at Lilly. Kate Cwynarski declares consulting fees from  Roche, BMS, KITE Pharma, and Janssen; speaker bureau from Roche, KITE Pharma, and BMS; and travel support from Roche, KITE Pharma, and BMS. Chan Y. Cheah declares speaker bureau from Beigene, Janssen, and Gilead; and advisory work from TG Therapeutics, Roche, Novartis, Janssen, Beigene, AstraZeneca, Eli Lilly, BMS, Gilead, and BMS.  Kerry J. Savage declares advisory work from BMS, Seattle Genetics, Merck, Janssen, Novartis,  and Kyowa; and DSMC Regeneron, Steering Committee Beigene, research funding from  BMS. Tarec C. El-Galaly-G declares previous employment with Roche (March, 2019 until February, 2021) and an honorarium from AbbVie. All other authors declare no competing interests.\n",
      "\n",
      "Ferreri, Andres J.M.\n",
      "Declaration of interests Tarec C. El-Galaly-G is partly funded from a grant from the Danish Cancer Society. Andres J.M. Ferreri declares research funding from ADC Therapeutics, Bayer HealthCare Pharmaceuticals, Beigene, Bristol Myers Squibb (BMS), Genmab, Gilead,  Hutchison Medipharma, Incyte, Janssen Research & Development, MEI Pharma, Novartis, PletixaPharm, Pharmacyclics, Protherics, Roche, and Takeda; consulting  fees from Gilead, Juno, Novartis, PletixaPharm, and Roche; speaker fees from Gilead and Roche; and advisory work for Gilead, Juno, Novartis, PletixaPharm, and Roche. Pamela McKay declares speaker fees from Janssen. Toby A. Eyre declares advisory work from Janssen, Kite Pharma, Roche, AbbVie, AstraZeneca, Loxo Oncology, Beigene, Incyte, and Secura Bio; speaker bureau fees from Janssen, Kite Pharma, Roche, AbbVie, AstraZeneca, Loxo Oncology, Beigene, and Incyte; and travel support from Roche and AbbVie. Matthew J. Maurer recognises the National Cancer Institute: University of Iowa Mayo Clinic Lymphoma SPORE (P50-CA097274) grant; declares advisory work from Adaptive  Biotechnologies, Pfizer, Kite Pharma, and Genmab; and research support from BMS,  Genentech, Genmab, and Morphosys to his institution. Katharine L. Lewis declares speaker bureau  from Janssen, AstraZeneca, and Roche; travel support from Novartis and Janssen; and advisory work from IQVIA and Loxo at Lilly. Kate Cwynarski declares consulting fees from  Roche, BMS, KITE Pharma, and Janssen; speaker bureau from Roche, KITE Pharma, and BMS; and travel support from Roche, KITE Pharma, and BMS. Chan Y. Cheah declares speaker bureau from Beigene, Janssen, and Gilead; and advisory work from TG Therapeutics, Roche, Novartis, Janssen, Beigene, AstraZeneca, Eli Lilly, BMS, Gilead, and BMS.  Kerry J. Savage declares advisory work from BMS, Seattle Genetics, Merck, Janssen, Novartis,  and Kyowa; and DSMC Regeneron, Steering Committee Beigene, research funding from  BMS. Tarec C. El-Galaly-G declares previous employment with Roche (March, 2019 until February, 2021) and an honorarium from AbbVie. All other authors declare no competing interests.\n",
      "\n",
      "Giraud, Eline L.\n",
      "Declaration of interests NS has received research grants for the Antoni van Leeuwenhoek Ziekenhuis from AB Science, AbbVie, Actuate Therapeutics, ADC Therapeutics, Amgen, Array, Ascendis Pharma, Astex Pharmaceuticals, AstraZeneca,  Bayer, Blueprint Medicines, Boehringer Ingelheim, BridgeBio, Bristol-Myers Squibb, Cantargia, Celgene, CellCentric, Crescendo Biologics, Cytovation, Deciphera, Eli Lilly, Exelixis, Genentech, Genmab, Gilead Sciences, GlaxoSmithKline, Incyte, InteRNA Technologies, Janssen/Johnson & Johnson, Kinnate Biopharma, Merck, Merck Sharp & Dohme, Merus, Molecular Partners, Novartis, Numab, Pfizer, Laboratoires Pierre Fabre, Regeneron, Roche, Sanofi, Seattle Genetics, Servier, Taiho Pharmaceutical, and Takeda, outside of the submitted work. NS also attended advisory boards for Boehringer Ingelheim and Ellipses Pharma. NPvE has received research grants for Radboudumc from Astellas Pharma, Janssen-Cilag, Ipsen, KWF, and ZonMW, and has received payments for Radboudumc from Sanofi, Bayer, and Pfizer. IMED has received a research grant for Radboudumc from EORTC-QLG and has received honoraria for the institute from Zorginstituut Nederland. NAGL has received honoraria from Roche Nederland. KRMF, Eline L. Giraud, EJS, and  RJB declare no competing interests.\n",
      "\n",
      "Ferrier, Kaylee R.M.\n",
      "Declaration of interests NS has received research grants for the Antoni van Leeuwenhoek Ziekenhuis from AB Science, AbbVie, Actuate Therapeutics, ADC Therapeutics, Amgen, Array, Ascendis Pharma, Astex Pharmaceuticals, AstraZeneca,  Bayer, Blueprint Medicines, Boehringer Ingelheim, BridgeBio, Bristol-Myers Squibb, Cantargia, Celgene, CellCentric, Crescendo Biologics, Cytovation, Deciphera, Eli Lilly, Exelixis, Genentech, Genmab, Gilead Sciences, GlaxoSmithKline, Incyte, InteRNA Technologies, Janssen/Johnson & Johnson, Kinnate Biopharma, Merck, Merck Sharp & Dohme, Merus, Molecular Partners, Novartis, Numab, Pfizer, Laboratoires Pierre Fabre, Regeneron, Roche, Sanofi, Seattle Genetics, Servier, Taiho Pharmaceutical, and Takeda, outside of the submitted work. NS also attended advisory boards for Boehringer Ingelheim and Ellipses Pharma. NPvE has received research grants for Radboudumc from Astellas Pharma, Janssen-Cilag, Ipsen, KWF, and ZonMW, and has received payments for Radboudumc from Sanofi, Bayer, and Pfizer. IMED has received a research grant for Radboudumc from EORTC-QLG and has received honoraria for the institute from Zorginstituut Nederland. NAGL has received honoraria from Roche Nederland. Kaylee R.M. Ferrier, Eline L. Giraud, EJS, and  RJB declare no competing interests.\n",
      "\n",
      "Lankheet, Nienke A.G.\n",
      "Declaration of interests NS has received research grants for the Antoni van Leeuwenhoek Ziekenhuis from AB Science, AbbVie, Actuate Therapeutics, ADC Therapeutics, Amgen, Array, Ascendis Pharma, Astex Pharmaceuticals, AstraZeneca,  Bayer, Blueprint Medicines, Boehringer Ingelheim, BridgeBio, Bristol-Myers Squibb, Cantargia, Celgene, CellCentric, Crescendo Biologics, Cytovation, Deciphera, Eli Lilly, Exelixis, Genentech, Genmab, Gilead Sciences, GlaxoSmithKline, Incyte, InteRNA Technologies, Janssen/Johnson & Johnson, Kinnate Biopharma, Merck, Merck Sharp & Dohme, Merus, Molecular Partners, Novartis, Numab, Pfizer, Laboratoires Pierre Fabre, Regeneron, Roche, Sanofi, Seattle Genetics, Servier, Taiho Pharmaceutical, and Takeda, outside of the submitted work. NS also attended advisory boards for Boehringer Ingelheim and Ellipses Pharma. NPvE has received research grants for Radboudumc from Astellas Pharma, Janssen-Cilag, Ipsen, KWF, and ZonMW, and has received payments for Radboudumc from Sanofi, Bayer, and Pfizer. IMED has received a research grant for Radboudumc from EORTC-QLG and has received honoraria for the institute from Zorginstituut Nederland. Nienke A.G. Lankheet has received honoraria from Roche Nederland. Kaylee R.M. Ferrier, Eline L. Giraud, EJS, and  RJB declare no competing interests.\n",
      "\n",
      "Desar, Ingrid M.E.\n",
      "Declaration of interests NS has received research grants for the Antoni van Leeuwenhoek Ziekenhuis from AB Science, AbbVie, Actuate Therapeutics, ADC Therapeutics, Amgen, Array, Ascendis Pharma, Astex Pharmaceuticals, AstraZeneca,  Bayer, Blueprint Medicines, Boehringer Ingelheim, BridgeBio, Bristol-Myers Squibb, Cantargia, Celgene, CellCentric, Crescendo Biologics, Cytovation, Deciphera, Eli Lilly, Exelixis, Genentech, Genmab, Gilead Sciences, GlaxoSmithKline, Incyte, InteRNA Technologies, Janssen/Johnson & Johnson, Kinnate Biopharma, Merck, Merck Sharp & Dohme, Merus, Molecular Partners, Novartis, Numab, Pfizer, Laboratoires Pierre Fabre, Regeneron, Roche, Sanofi, Seattle Genetics, Servier, Taiho Pharmaceutical, and Takeda, outside of the submitted work. NS also attended advisory boards for Boehringer Ingelheim and Ellipses Pharma. NPvE has received research grants for Radboudumc from Astellas Pharma, Janssen-Cilag, Ipsen, KWF, and ZonMW, and has received payments for Radboudumc from Sanofi, Bayer, and Pfizer. Ingrid M.E. Desar has received a research grant for Radboudumc from EORTC-QLG and has received honoraria for the institute from Zorginstituut Nederland. Nienke A.G. Lankheet has received honoraria from Roche Nederland. Kaylee R.M. Ferrier, Eline L. Giraud, EJS, and  RJB declare no competing interests.\n",
      "\n",
      "Steeghs, Neeltje\n",
      "Declaration of interests Neeltje Steeghs has received research grants for the Antoni van Leeuwenhoek Ziekenhuis from AB Science, AbbVie, Actuate Therapeutics, ADC Therapeutics, Amgen, Array, Ascendis Pharma, Astex Pharmaceuticals, AstraZeneca,  Bayer, Blueprint Medicines, Boehringer Ingelheim, BridgeBio, Bristol-Myers Squibb, Cantargia, Celgene, CellCentric, Crescendo Biologics, Cytovation, Deciphera, Eli Lilly, Exelixis, Genentech, Genmab, Gilead Sciences, GlaxoSmithKline, Incyte, InteRNA Technologies, Janssen/Johnson & Johnson, Kinnate Biopharma, Merck, Merck Sharp & Dohme, Merus, Molecular Partners, Novartis, Numab, Pfizer, Laboratoires Pierre Fabre, Regeneron, Roche, Sanofi, Seattle Genetics, Servier, Taiho Pharmaceutical, and Takeda, outside of the submitted work. Neeltje Steeghs also attended advisory boards for Boehringer Ingelheim and Ellipses Pharma. NPvE has received research grants for Radboudumc from Astellas Pharma, Janssen-Cilag, Ipsen, KWF, and ZonMW, and has received payments for Radboudumc from Sanofi, Bayer, and Pfizer. Ingrid M.E. Desar has received a research grant for Radboudumc from EORTC-QLG and has received honoraria for the institute from Zorginstituut Nederland. Nienke A.G. Lankheet has received honoraria from Roche Nederland. Kaylee R.M. Ferrier, Eline L. Giraud, EJS, and  RJB declare no competing interests.\n",
      "\n",
      "Beukema, Rypko J.\n",
      "Declaration of interests Neeltje Steeghs has received research grants for the Antoni van Leeuwenhoek Ziekenhuis from AB Science, AbbVie, Actuate Therapeutics, ADC Therapeutics, Amgen, Array, Ascendis Pharma, Astex Pharmaceuticals, AstraZeneca,  Bayer, Blueprint Medicines, Boehringer Ingelheim, BridgeBio, Bristol-Myers Squibb, Cantargia, Celgene, CellCentric, Crescendo Biologics, Cytovation, Deciphera, Eli Lilly, Exelixis, Genentech, Genmab, Gilead Sciences, GlaxoSmithKline, Incyte, InteRNA Technologies, Janssen/Johnson & Johnson, Kinnate Biopharma, Merck, Merck Sharp & Dohme, Merus, Molecular Partners, Novartis, Numab, Pfizer, Laboratoires Pierre Fabre, Regeneron, Roche, Sanofi, Seattle Genetics, Servier, Taiho Pharmaceutical, and Takeda, outside of the submitted work. Neeltje Steeghs also attended advisory boards for Boehringer Ingelheim and Ellipses Pharma. NPvE has received research grants for Radboudumc from Astellas Pharma, Janssen-Cilag, Ipsen, KWF, and ZonMW, and has received payments for Radboudumc from Sanofi, Bayer, and Pfizer. Ingrid M.E. Desar has received a research grant for Radboudumc from EORTC-QLG and has received honoraria for the institute from Zorginstituut Nederland. Nienke A.G. Lankheet has received honoraria from Roche Nederland. Kaylee R.M. Ferrier, Eline L. Giraud, EJS, and  Rypko J. Beukema declare no competing interests.\n",
      "\n",
      "P van Erp, Nielka\n",
      "Declaration of interests Neeltje Steeghs has received research grants for the Antoni van Leeuwenhoek Ziekenhuis from AB Science, AbbVie, Actuate Therapeutics, ADC Therapeutics, Amgen, Array, Ascendis Pharma, Astex Pharmaceuticals, AstraZeneca,  Bayer, Blueprint Medicines, Boehringer Ingelheim, BridgeBio, Bristol-Myers Squibb, Cantargia, Celgene, CellCentric, Crescendo Biologics, Cytovation, Deciphera, Eli Lilly, Exelixis, Genentech, Genmab, Gilead Sciences, GlaxoSmithKline, Incyte, InteRNA Technologies, Janssen/Johnson & Johnson, Kinnate Biopharma, Merck, Merck Sharp & Dohme, Merus, Molecular Partners, Novartis, Numab, Pfizer, Laboratoires Pierre Fabre, Regeneron, Roche, Sanofi, Seattle Genetics, Servier, Taiho Pharmaceutical, and Takeda, outside of the submitted work. Neeltje Steeghs also attended advisory boards for Boehringer Ingelheim and Ellipses Pharma. Nielka P van Erp has received research grants for Radboudumc from Astellas Pharma, Janssen-Cilag, Ipsen, KWF, and ZonMW, and has received payments for Radboudumc from Sanofi, Bayer, and Pfizer. Ingrid M.E. Desar has received a research grant for Radboudumc from EORTC-QLG and has received honoraria for the institute from Zorginstituut Nederland. Nienke A.G. Lankheet has received honoraria from Roche Nederland. Kaylee R.M. Ferrier, Eline L. Giraud, EJS, and  Rypko J. Beukema declare no competing interests.\n",
      "\n",
      "Smolders, Elise J.\n",
      "Declaration of interests Neeltje Steeghs has received research grants for the Antoni van Leeuwenhoek Ziekenhuis from AB Science, AbbVie, Actuate Therapeutics, ADC Therapeutics, Amgen, Array, Ascendis Pharma, Astex Pharmaceuticals, AstraZeneca,  Bayer, Blueprint Medicines, Boehringer Ingelheim, BridgeBio, Bristol-Myers Squibb, Cantargia, Celgene, CellCentric, Crescendo Biologics, Cytovation, Deciphera, Eli Lilly, Exelixis, Genentech, Genmab, Gilead Sciences, GlaxoSmithKline, Incyte, InteRNA Technologies, Janssen/Johnson & Johnson, Kinnate Biopharma, Merck, Merck Sharp & Dohme, Merus, Molecular Partners, Novartis, Numab, Pfizer, Laboratoires Pierre Fabre, Regeneron, Roche, Sanofi, Seattle Genetics, Servier, Taiho Pharmaceutical, and Takeda, outside of the submitted work. Neeltje Steeghs also attended advisory boards for Boehringer Ingelheim and Ellipses Pharma. Nielka P van Erp has received research grants for Radboudumc from Astellas Pharma, Janssen-Cilag, Ipsen, KWF, and ZonMW, and has received payments for Radboudumc from Sanofi, Bayer, and Pfizer. Ingrid M.E. Desar has received a research grant for Radboudumc from EORTC-QLG and has received honoraria for the institute from Zorginstituut Nederland. Nienke A.G. Lankheet has received honoraria from Roche Nederland. Kaylee R.M. Ferrier, Eline L. Giraud, Elise J. Smolders, and  Rypko J. Beukema declare no competing interests.\n",
      "\n",
      "Powles, Thomas\n",
      "Declaration of interests Thomas Powles reports having served as a consultant or adviser for  Astellas Pharma, AstraZeneca, Bristol Myers Squibb, Eisai, Exelixis, Incyte, Ipsen, Johnson & Johnson, Merck, Merck Serono, MSD, Novartis, Pfizer, Roche, and  Seattle Genetics; honoraria from Astellas Pharma, AstraZeneca, Bristol Myers Squibb, Eisai, Exelixis, Incyte, Ipsen, Johnson & Johnson, Merck, Merck Serono, MSD, Novartis, Pfizer, Roche, and Seattle Genetics; research funding paid to institution from Astellas Pharma, AstraZeneca, Bristol Myers Squibb, Eisai, Exelixis, Ipsen, Johnson & Johnson, Merck, Merck Serono, MSD, Novartis, Pfizer, Roche, and Seattle Genetics; and travel, accommodations, and expenses from AstraZeneca, Ipsen, MSD, Pfizer, and Roche. PT reports research funding from MSD. SHP reports having served as a consultant or adviser for Janssen Oncology and Lilly; and research funding from Ono Pharmaceutical. Bxports having served as a consultant or adviser for Bristol Myers Squibb, MSD Oncology, and Pfizer/EMD Serono; honoraria from Bristol Myers Squibb, Eisai, EUSA Pharma, Ipsen, Merck, MSD Oncology, and Pfizer; research funding paid to institution from Calithera Biosciences, Ipsen, MSD Oncology, and Pfizer/EMD Serono; serving as a speaker for Eisai, MSD Oncology, and Pfizer; and travel, accommodations, and expenses from EUSA Pharma and Ipsen. TF reports research funding paid to institution from AstraZeneca, Janssen, and MSD; and travel, accommodations, and expenses from Bristol Myers Squibb, MSD, and Roche. SNS reports having served as a consultant or adviser for Bicycle Therapeutics, Bristol Myers Squibb, Boxer Capital, Duke Street Bio, Eisai, Ellipses Pharma, EMD Serono, EUSA Pharma, MedAnnex, MSD, Pfizer, and Vaccitech; having served as a speaker for Bristol Myers Squibb, EUSA  Pharma, and Ipsen; research funding paid to institution from BiolineRx, BioNTech, Boston Pharmaceuticals, Incyte, MSD, Nouscom, Nucana, Roche, Sapience Therapeutics, Scancell, Sierra Oncology, and Verastem; and travel, accommodations, and expenses from Bristol Myers Squibb, EUSA Pharma, and Ipsen. HG reports personal speaker fees from MSD; and personal advisory fees from MSD, Roche, Merck, Bristol Myers Squibb, Pfizer, and Ipsen. JLL reports honoraria from Astellas Pharma, AstraZeneca, Bristol Myers Squibb, MSD, and Pfizer; having served as an advisr or consultant for Alteogen, AstraZeneca, BMS Korea, GI Innovation, Merck, MSD, Pfizer, and Sanofi/Aventis; research funding paid to institution from AstraZeneca/MedImmune, Bayer Schering Pharma, Bristol Myers Squibb, Janssen, MSD, Novartis, Pfizer, Roche/Genentech, and Seattle Genetics; and owns stock in Amgen, BeiGene, Black Diamond Therapeutics, Innovent Biologics, Johnson & Johnson/Janssen, Karyopharm Therapeutics, Merck, Myovant Sciences, and  Zymeworks. NS reports having served as a consultant or adviser for Bristol Myers  Squibb, Eisai, EUSA Pharma, MSD, and Roche; having served as a speaker for Pfizer; and research funding from MSD. AT-V reports honoraria from Astellas Pharma, AstraZeneca, Bristol Myers Squibb, Ipsen, Janssen, MSD, Novartis, Pfizer, Roche/Genentech, and Sanofi; having served as a consultant for Astellas Pharma, AstraZeneca, Bristol Myers Squibb, Ipsen, Janssen, MSD, Novartis, Pfizer, Roche,  and Sanofi; research funding paid to institution from Pfizer; and travel, accommodations, and expenses from Astellas Pharma, AstraZeneca, Bristol Myers Squibb, Ipsen, Janssen, MSD, Pfizer, and Roche. MG-G reports having served as a consultant or adviser for Amgen, Astellas Medivation, AstraZeneca, Bayer/Onyx, Bristol Myers Squibb, Ipsen, Janssen-Cilag, MSD Oncology, Pfizer, Roche, and Sanofi; research funding paid to institution from AstraZeneca, Ipsen, Janssen-Cilag, Merck, MSD Oncology, Pfizer, and Roche; and travel, accommodations, and expenses from Astellas Pharma, AstraZeneca, AstraZeneca, Ipsen, Janssen-Cilag, Pfizer, and Roche. MM reports research funding from MSD. NBH reports having served as a consultant or adviser for AVEO, Calithera Biosciences, Eisai, Exelixis, MSD, Pfizer, and Roche/Genentech; and has provided  expert testimony for Lilly. PS reports honoraria from Bristol Myers Squibb and Novartis; research funding paid to institution from Boehringer Ingelheim, Chiltern, G1 Therapeutics, Gilead Sciences, Merrimack, MSD, Parexel, PAREXEL/Puma Biotechnology, PPD Global, Regeneron, and Tesaro; and travel, accommodations, and expenses from Pierre Fabre and Roche. JEB and LX are employees of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co, Inc, Rahway, NJ, USA. KI is an employee of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co, Inc, and owns stock in Merck & Co, Inc, Rahway, NJ, USA. DIQ reports having served as a consultant or adviser  for Astellas Pharma, AstraZeneca, Bayer, Bristol Myers Squibb, Eisai, Exelixis, Genentech/Roche, Janssen Oncology, MSD, Myovant Sciences, Novartis, Pfizer, Seattle Genetics, and US Biotest; honoraria from Astellas Pharma, AstraZeneca, Bayer, Bristol Myers Squibb, Exelixis, Genentech/Roche, MSD, Myovant Sciences, Novartis, Pfizer, and Seattle Genetics; research funding paid to institution from Genentech/Roche, Merck, and Pfizer; and travel, accommodations, and expenses from Astellas Pharma, Bayer, Bristol Myers Squibb Japan, Exelexis, Merck, and Roche. TKC reports institutional and personal support, paid and unpaid support for research, participating in advisory boards, consultancy, and honoraria from AstraZeneca, Aravive, Aveo, Bayer, Bristol Myers Squibb, Calithera, Circle Pharma, Eisai, EMD Serono, Exelixis, GlaxoSmithKline, IQVA, Infinity, Ipsen, Jansen, Kanaph, Lilly, Merck, Nikang, Nuscan, Novartis, Pfizer, Roche, Sanofi/Aventis, Surface Oncology, Takeda, Tempest, UpToDate, and CME events (Peerview, OncLive, and MJH), outside the submitted work; institutional patents filed on molecular mutations, immunotherapy response and toxicity, and ctDNA; equity in Tempest, Pionyr, Osel, Precede Bio; being part of committees in the National Comprehensive Cancer Network, GU Steering Committee, American Society of Clinical Oncology, European Society for Medical Oncology, Academic and Community  Cancer Research United, and KidneyCAN; having mentored several non-US citizens on research projects partly funded by non-US sources; and additional independent funding from drug companies or royalties for research around the subject matter paid to institution. All other authors declare no competing interests.\n",
      "\n",
      "Tomczak, Piotr\n",
      "Declaration of interests Thomas Powles reports having served as a consultant or adviser for  Astellas Pharma, AstraZeneca, Bristol Myers Squibb, Eisai, Exelixis, Incyte, Ipsen, Johnson & Johnson, Merck, Merck Serono, MSD, Novartis, Pfizer, Roche, and  Seattle Genetics; honoraria from Astellas Pharma, AstraZeneca, Bristol Myers Squibb, Eisai, Exelixis, Incyte, Ipsen, Johnson & Johnson, Merck, Merck Serono, MSD, Novartis, Pfizer, Roche, and Seattle Genetics; research funding paid to institution from Astellas Pharma, AstraZeneca, Bristol Myers Squibb, Eisai, Exelixis, Ipsen, Johnson & Johnson, Merck, Merck Serono, MSD, Novartis, Pfizer, Roche, and Seattle Genetics; and travel, accommodations, and expenses from AstraZeneca, Ipsen, MSD, Pfizer, and Roche. Piotr Tomczak reports research funding from MSD. SHP reports having served as a consultant or adviser for Janssen Oncology and Lilly; and research funding from Ono Pharmaceutical. Bxports having served as a consultant or adviser for Bristol Myers Squibb, MSD Oncology, and Pfizer/EMD Serono; honoraria from Bristol Myers Squibb, Eisai, EUSA Pharma, Ipsen, Merck, MSD Oncology, and Pfizer; research funding paid to institution from Calithera Biosciences, Ipsen, MSD Oncology, and Pfizer/EMD Serono; serving as a speaker for Eisai, MSD Oncology, and Pfizer; and travel, accommodations, and expenses from EUSA Pharma and Ipsen. TF reports research funding paid to institution from AstraZeneca, Janssen, and MSD; and travel, accommodations, and expenses from Bristol Myers Squibb, MSD, and Roche. SNS reports having served as a consultant or adviser for Bicycle Therapeutics, Bristol Myers Squibb, Boxer Capital, Duke Street Bio, Eisai, Ellipses Pharma, EMD Serono, EUSA Pharma, MedAnnex, MSD, Pfizer, and Vaccitech; having served as a speaker for Bristol Myers Squibb, EUSA  Pharma, and Ipsen; research funding paid to institution from BiolineRx, BioNTech, Boston Pharmaceuticals, Incyte, MSD, Nouscom, Nucana, Roche, Sapience Therapeutics, Scancell, Sierra Oncology, and Verastem; and travel, accommodations, and expenses from Bristol Myers Squibb, EUSA Pharma, and Ipsen. HG reports personal speaker fees from MSD; and personal advisory fees from MSD, Roche, Merck, Bristol Myers Squibb, Pfizer, and Ipsen. JLL reports honoraria from Astellas Pharma, AstraZeneca, Bristol Myers Squibb, MSD, and Pfizer; having served as an advisr or consultant for Alteogen, AstraZeneca, BMS Korea, GI Innovation, Merck, MSD, Pfizer, and Sanofi/Aventis; research funding paid to institution from AstraZeneca/MedImmune, Bayer Schering Pharma, Bristol Myers Squibb, Janssen, MSD, Novartis, Pfizer, Roche/Genentech, and Seattle Genetics; and owns stock in Amgen, BeiGene, Black Diamond Therapeutics, Innovent Biologics, Johnson & Johnson/Janssen, Karyopharm Therapeutics, Merck, Myovant Sciences, and  Zymeworks. NS reports having served as a consultant or adviser for Bristol Myers  Squibb, Eisai, EUSA Pharma, MSD, and Roche; having served as a speaker for Pfizer; and research funding from MSD. AT-V reports honoraria from Astellas Pharma, AstraZeneca, Bristol Myers Squibb, Ipsen, Janssen, MSD, Novartis, Pfizer, Roche/Genentech, and Sanofi; having served as a consultant for Astellas Pharma, AstraZeneca, Bristol Myers Squibb, Ipsen, Janssen, MSD, Novartis, Pfizer, Roche,  and Sanofi; research funding paid to institution from Pfizer; and travel, accommodations, and expenses from Astellas Pharma, AstraZeneca, Bristol Myers Squibb, Ipsen, Janssen, MSD, Pfizer, and Roche. MG-G reports having served as a consultant or adviser for Amgen, Astellas Medivation, AstraZeneca, Bayer/Onyx, Bristol Myers Squibb, Ipsen, Janssen-Cilag, MSD Oncology, Pfizer, Roche, and Sanofi; research funding paid to institution from AstraZeneca, Ipsen, Janssen-Cilag, Merck, MSD Oncology, Pfizer, and Roche; and travel, accommodations, and expenses from Astellas Pharma, AstraZeneca, AstraZeneca, Ipsen, Janssen-Cilag, Pfizer, and Roche. MM reports research funding from MSD. NBH reports having served as a consultant or adviser for AVEO, Calithera Biosciences, Eisai, Exelixis, MSD, Pfizer, and Roche/Genentech; and has provided  expert testimony for Lilly. PS reports honoraria from Bristol Myers Squibb and Novartis; research funding paid to institution from Boehringer Ingelheim, Chiltern, G1 Therapeutics, Gilead Sciences, Merrimack, MSD, Parexel, PAREXEL/Puma Biotechnology, PPD Global, Regeneron, and Tesaro; and travel, accommodations, and expenses from Pierre Fabre and Roche. JEB and LX are employees of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co, Inc, Rahway, NJ, USA. KI is an employee of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co, Inc, and owns stock in Merck & Co, Inc, Rahway, NJ, USA. DIQ reports having served as a consultant or adviser  for Astellas Pharma, AstraZeneca, Bayer, Bristol Myers Squibb, Eisai, Exelixis, Genentech/Roche, Janssen Oncology, MSD, Myovant Sciences, Novartis, Pfizer, Seattle Genetics, and US Biotest; honoraria from Astellas Pharma, AstraZeneca, Bayer, Bristol Myers Squibb, Exelixis, Genentech/Roche, MSD, Myovant Sciences, Novartis, Pfizer, and Seattle Genetics; research funding paid to institution from Genentech/Roche, Merck, and Pfizer; and travel, accommodations, and expenses from Astellas Pharma, Bayer, Bristol Myers Squibb Japan, Exelexis, Merck, and Roche. TKC reports institutional and personal support, paid and unpaid support for research, participating in advisory boards, consultancy, and honoraria from AstraZeneca, Aravive, Aveo, Bayer, Bristol Myers Squibb, Calithera, Circle Pharma, Eisai, EMD Serono, Exelixis, GlaxoSmithKline, IQVA, Infinity, Ipsen, Jansen, Kanaph, Lilly, Merck, Nikang, Nuscan, Novartis, Pfizer, Roche, Sanofi/Aventis, Surface Oncology, Takeda, Tempest, UpToDate, and CME events (Peerview, OncLive, and MJH), outside the submitted work; institutional patents filed on molecular mutations, immunotherapy response and toxicity, and ctDNA; equity in Tempest, Pionyr, Osel, Precede Bio; being part of committees in the National Comprehensive Cancer Network, GU Steering Committee, American Society of Clinical Oncology, European Society for Medical Oncology, Academic and Community  Cancer Research United, and KidneyCAN; having mentored several non-US citizens on research projects partly funded by non-US sources; and additional independent funding from drug companies or royalties for research around the subject matter paid to institution. All other authors declare no competing interests.\n",
      "\n",
      "Hoon Park, Se\n",
      "Declaration of interests Thomas Powles reports having served as a consultant or adviser for  Astellas Pharma, AstraZeneca, Bristol Myers Squibb, Eisai, Exelixis, Incyte, Ipsen, Johnson & Johnson, Merck, Merck Serono, MSD, Novartis, Pfizer, Roche, and  Seattle Genetics; honoraria from Astellas Pharma, AstraZeneca, Bristol Myers Squibb, Eisai, Exelixis, Incyte, Ipsen, Johnson & Johnson, Merck, Merck Serono, MSD, Novartis, Pfizer, Roche, and Seattle Genetics; research funding paid to institution from Astellas Pharma, AstraZeneca, Bristol Myers Squibb, Eisai, Exelixis, Ipsen, Johnson & Johnson, Merck, Merck Serono, MSD, Novartis, Pfizer, Roche, and Seattle Genetics; and travel, accommodations, and expenses from AstraZeneca, Ipsen, MSD, Pfizer, and Roche. Piotr Tomczak reports research funding from MSD. Se Hoon Park reports having served as a consultant or adviser for Janssen Oncology and Lilly; and research funding from Ono Pharmaceutical. Bxports having served as a consultant or adviser for Bristol Myers Squibb, MSD Oncology, and Pfizer/EMD Serono; honoraria from Bristol Myers Squibb, Eisai, EUSA Pharma, Ipsen, Merck, MSD Oncology, and Pfizer; research funding paid to institution from Calithera Biosciences, Ipsen, MSD Oncology, and Pfizer/EMD Serono; serving as a speaker for Eisai, MSD Oncology, and Pfizer; and travel, accommodations, and expenses from EUSA Pharma and Ipsen. TF reports research funding paid to institution from AstraZeneca, Janssen, and MSD; and travel, accommodations, and expenses from Bristol Myers Squibb, MSD, and Roche. SNS reports having served as a consultant or adviser for Bicycle Therapeutics, Bristol Myers Squibb, Boxer Capital, Duke Street Bio, Eisai, Ellipses Pharma, EMD Serono, EUSA Pharma, MedAnnex, MSD, Pfizer, and Vaccitech; having served as a speaker for Bristol Myers Squibb, EUSA  Pharma, and Ipsen; research funding paid to institution from BiolineRx, BioNTech, Boston Pharmaceuticals, Incyte, MSD, Nouscom, Nucana, Roche, Sapience Therapeutics, Scancell, Sierra Oncology, and Verastem; and travel, accommodations, and expenses from Bristol Myers Squibb, EUSA Pharma, and Ipsen. HG reports personal speaker fees from MSD; and personal advisory fees from MSD, Roche, Merck, Bristol Myers Squibb, Pfizer, and Ipsen. JLL reports honoraria from Astellas Pharma, AstraZeneca, Bristol Myers Squibb, MSD, and Pfizer; having served as an advisr or consultant for Alteogen, AstraZeneca, BMS Korea, GI Innovation, Merck, MSD, Pfizer, and Sanofi/Aventis; research funding paid to institution from AstraZeneca/MedImmune, Bayer Schering Pharma, Bristol Myers Squibb, Janssen, MSD, Novartis, Pfizer, Roche/Genentech, and Seattle Genetics; and owns stock in Amgen, BeiGene, Black Diamond Therapeutics, Innovent Biologics, Johnson & Johnson/Janssen, Karyopharm Therapeutics, Merck, Myovant Sciences, and  Zymeworks. NS reports having served as a consultant or adviser for Bristol Myers  Squibb, Eisai, EUSA Pharma, MSD, and Roche; having served as a speaker for Pfizer; and research funding from MSD. AT-V reports honoraria from Astellas Pharma, AstraZeneca, Bristol Myers Squibb, Ipsen, Janssen, MSD, Novartis, Pfizer, Roche/Genentech, and Sanofi; having served as a consultant for Astellas Pharma, AstraZeneca, Bristol Myers Squibb, Ipsen, Janssen, MSD, Novartis, Pfizer, Roche,  and Sanofi; research funding paid to institution from Pfizer; and travel, accommodations, and expenses from Astellas Pharma, AstraZeneca, Bristol Myers Squibb, Ipsen, Janssen, MSD, Pfizer, and Roche. MG-G reports having served as a consultant or adviser for Amgen, Astellas Medivation, AstraZeneca, Bayer/Onyx, Bristol Myers Squibb, Ipsen, Janssen-Cilag, MSD Oncology, Pfizer, Roche, and Sanofi; research funding paid to institution from AstraZeneca, Ipsen, Janssen-Cilag, Merck, MSD Oncology, Pfizer, and Roche; and travel, accommodations, and expenses from Astellas Pharma, AstraZeneca, AstraZeneca, Ipsen, Janssen-Cilag, Pfizer, and Roche. MM reports research funding from MSD. NBH reports having served as a consultant or adviser for AVEO, Calithera Biosciences, Eisai, Exelixis, MSD, Pfizer, and Roche/Genentech; and has provided  expert testimony for Lilly. PS reports honoraria from Bristol Myers Squibb and Novartis; research funding paid to institution from Boehringer Ingelheim, Chiltern, G1 Therapeutics, Gilead Sciences, Merrimack, MSD, Parexel, PAREXEL/Puma Biotechnology, PPD Global, Regeneron, and Tesaro; and travel, accommodations, and expenses from Pierre Fabre and Roche. JEB and LX are employees of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co, Inc, Rahway, NJ, USA. KI is an employee of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co, Inc, and owns stock in Merck & Co, Inc, Rahway, NJ, USA. DIQ reports having served as a consultant or adviser  for Astellas Pharma, AstraZeneca, Bayer, Bristol Myers Squibb, Eisai, Exelixis, Genentech/Roche, Janssen Oncology, MSD, Myovant Sciences, Novartis, Pfizer, Seattle Genetics, and US Biotest; honoraria from Astellas Pharma, AstraZeneca, Bayer, Bristol Myers Squibb, Exelixis, Genentech/Roche, MSD, Myovant Sciences, Novartis, Pfizer, and Seattle Genetics; research funding paid to institution from Genentech/Roche, Merck, and Pfizer; and travel, accommodations, and expenses from Astellas Pharma, Bayer, Bristol Myers Squibb Japan, Exelexis, Merck, and Roche. TKC reports institutional and personal support, paid and unpaid support for research, participating in advisory boards, consultancy, and honoraria from AstraZeneca, Aravive, Aveo, Bayer, Bristol Myers Squibb, Calithera, Circle Pharma, Eisai, EMD Serono, Exelixis, GlaxoSmithKline, IQVA, Infinity, Ipsen, Jansen, Kanaph, Lilly, Merck, Nikang, Nuscan, Novartis, Pfizer, Roche, Sanofi/Aventis, Surface Oncology, Takeda, Tempest, UpToDate, and CME events (Peerview, OncLive, and MJH), outside the submitted work; institutional patents filed on molecular mutations, immunotherapy response and toxicity, and ctDNA; equity in Tempest, Pionyr, Osel, Precede Bio; being part of committees in the National Comprehensive Cancer Network, GU Steering Committee, American Society of Clinical Oncology, European Society for Medical Oncology, Academic and Community  Cancer Research United, and KidneyCAN; having mentored several non-US citizens on research projects partly funded by non-US sources; and additional independent funding from drug companies or royalties for research around the subject matter paid to institution. All other authors declare no competing interests.\n",
      "\n",
      "Declaration of interests Thomas Powles reports having served as a consultant or adviser for  Astellas Pharma, AstraZeneca, Bristol Myers Squibb, Eisai, Exelixis, Incyte, Ipsen, Johnson & Johnson, Merck, Merck Serono, MSD, Novartis, Pfizer, Roche, and  Seattle Genetics; honoraria from Astellas Pharma, AstraZeneca, Bristol Myers Squibb, Eisai, Exelixis, Incyte, Ipsen, Johnson & Johnson, Merck, Merck Serono, MSD, Novartis, Pfizer, Roche, and Seattle Genetics; research funding paid to institution from Astellas Pharma, AstraZeneca, Bristol Myers Squibb, Eisai, Exelixis, Ipsen, Johnson & Johnson, Merck, Merck Serono, MSD, Novartis, Pfizer, Roche, and Seattle Genetics; and travel, accommodations, and expenses from AstraZeneca, Ipsen, MSD, Pfizer, and Roche. Piotr Tomczak reports research funding from MSD. Se Hoon Park reports having served as a consultant or adviser for Janssen Oncology and Lilly; and research funding from Ono Pharmaceutical. Bxports having served as a consultant or adviser for Bristol Myers Squibb, MSD Oncology, and Pfizer/EMD Serono; honoraria from Bristol Myers Squibb, Eisai, EUSA Pharma, Ipsen, Merck, MSD Oncology, and Pfizer; research funding paid to institution from Calithera Biosciences, Ipsen, MSD Oncology, and Pfizer/EMD Serono; serving as a speaker for Eisai, MSD Oncology, and Pfizer; and travel, accommodations, and expenses from EUSA Pharma and Ipsen. TF reports research funding paid to institution from AstraZeneca, Janssen, and MSD; and travel, accommodations, and expenses from Bristol Myers Squibb, MSD, and Roche. SNS reports having served as a consultant or adviser for Bicycle Therapeutics, Bristol Myers Squibb, Boxer Capital, Duke Street Bio, Eisai, Ellipses Pharma, EMD Serono, EUSA Pharma, MedAnnex, MSD, Pfizer, and Vaccitech; having served as a speaker for Bristol Myers Squibb, EUSA  Pharma, and Ipsen; research funding paid to institution from BiolineRx, BioNTech, Boston Pharmaceuticals, Incyte, MSD, Nouscom, Nucana, Roche, Sapience Therapeutics, Scancell, Sierra Oncology, and Verastem; and travel, accommodations, and expenses from Bristol Myers Squibb, EUSA Pharma, and Ipsen. HG reports personal speaker fees from MSD; and personal advisory fees from MSD, Roche, Merck, Bristol Myers Squibb, Pfizer, and Ipsen. JLL reports honoraria from Astellas Pharma, AstraZeneca, Bristol Myers Squibb, MSD, and Pfizer; having served as an advisr or consultant for Alteogen, AstraZeneca, BMS Korea, GI Innovation, Merck, MSD, Pfizer, and Sanofi/Aventis; research funding paid to institution from AstraZeneca/MedImmune, Bayer Schering Pharma, Bristol Myers Squibb, Janssen, MSD, Novartis, Pfizer, Roche/Genentech, and Seattle Genetics; and owns stock in Amgen, BeiGene, Black Diamond Therapeutics, Innovent Biologics, Johnson & Johnson/Janssen, Karyopharm Therapeutics, Merck, Myovant Sciences, and  Zymeworks. NS reports having served as a consultant or adviser for Bristol Myers  Squibb, Eisai, EUSA Pharma, MSD, and Roche; having served as a speaker for Pfizer; and research funding from MSD. AT-V reports honoraria from Astellas Pharma, AstraZeneca, Bristol Myers Squibb, Ipsen, Janssen, MSD, Novartis, Pfizer, Roche/Genentech, and Sanofi; having served as a consultant for Astellas Pharma, AstraZeneca, Bristol Myers Squibb, Ipsen, Janssen, MSD, Novartis, Pfizer, Roche,  and Sanofi; research funding paid to institution from Pfizer; and travel, accommodations, and expenses from Astellas Pharma, AstraZeneca, Bristol Myers Squibb, Ipsen, Janssen, MSD, Pfizer, and Roche. MG-G reports having served as a consultant or adviser for Amgen, Astellas Medivation, AstraZeneca, Bayer/Onyx, Bristol Myers Squibb, Ipsen, Janssen-Cilag, MSD Oncology, Pfizer, Roche, and Sanofi; research funding paid to institution from AstraZeneca, Ipsen, Janssen-Cilag, Merck, MSD Oncology, Pfizer, and Roche; and travel, accommodations, and expenses from Astellas Pharma, AstraZeneca, AstraZeneca, Ipsen, Janssen-Cilag, Pfizer, and Roche. MM reports research funding from MSD. NBH reports having served as a consultant or adviser for AVEO, Calithera Biosciences, Eisai, Exelixis, MSD, Pfizer, and Roche/Genentech; and has provided  expert testimony for Lilly. PS reports honoraria from Bristol Myers Squibb and Novartis; research funding paid to institution from Boehringer Ingelheim, Chiltern, G1 Therapeutics, Gilead Sciences, Merrimack, MSD, Parexel, PAREXEL/Puma Biotechnology, PPD Global, Regeneron, and Tesaro; and travel, accommodations, and expenses from Pierre Fabre and Roche. JEB and LX are employees of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co, Inc, Rahway, NJ, USA. KI is an employee of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co, Inc, and owns stock in Merck & Co, Inc, Rahway, NJ, USA. DIQ reports having served as a consultant or adviser  for Astellas Pharma, AstraZeneca, Bayer, Bristol Myers Squibb, Eisai, Exelixis, Genentech/Roche, Janssen Oncology, MSD, Myovant Sciences, Novartis, Pfizer, Seattle Genetics, and US Biotest; honoraria from Astellas Pharma, AstraZeneca, Bayer, Bristol Myers Squibb, Exelixis, Genentech/Roche, MSD, Myovant Sciences, Novartis, Pfizer, and Seattle Genetics; research funding paid to institution from Genentech/Roche, Merck, and Pfizer; and travel, accommodations, and expenses from Astellas Pharma, Bayer, Bristol Myers Squibb Japan, Exelexis, Merck, and Roche. TKC reports institutional and personal support, paid and unpaid support for research, participating in advisory boards, consultancy, and honoraria from AstraZeneca, Aravive, Aveo, Bayer, Bristol Myers Squibb, Calithera, Circle Pharma, Eisai, EMD Serono, Exelixis, GlaxoSmithKline, IQVA, Infinity, Ipsen, Jansen, Kanaph, Lilly, Merck, Nikang, Nuscan, Novartis, Pfizer, Roche, Sanofi/Aventis, Surface Oncology, Takeda, Tempest, UpToDate, and CME events (Peerview, OncLive, and MJH), outside the submitted work; institutional patents filed on molecular mutations, immunotherapy response and toxicity, and ctDNA; equity in Tempest, Pionyr, Osel, Precede Bio; being part of committees in the National Comprehensive Cancer Network, GU Steering Committee, American Society of Clinical Oncology, European Society for Medical Oncology, Academic and Community  Cancer Research United, and KidneyCAN; having mentored several non-US citizens on research projects partly funded by non-US sources; and additional independent funding from drug companies or royalties for research around the subject matter paid to institution. All other authors declare no competing interests.\n",
      "\n",
      "Ferguson, Thomas\n",
      "Declaration of interests Thomas Powles reports having served as a consultant or adviser for  Astellas Pharma, AstraZeneca, Bristol Myers Squibb, Eisai, Exelixis, Incyte, Ipsen, Johnson & Johnson, Merck, Merck Serono, MSD, Novartis, Pfizer, Roche, and  Seattle Genetics; honoraria from Astellas Pharma, AstraZeneca, Bristol Myers Squibb, Eisai, Exelixis, Incyte, Ipsen, Johnson & Johnson, Merck, Merck Serono, MSD, Novartis, Pfizer, Roche, and Seattle Genetics; research funding paid to institution from Astellas Pharma, AstraZeneca, Bristol Myers Squibb, Eisai, Exelixis, Ipsen, Johnson & Johnson, Merck, Merck Serono, MSD, Novartis, Pfizer, Roche, and Seattle Genetics; and travel, accommodations, and expenses from AstraZeneca, Ipsen, MSD, Pfizer, and Roche. Piotr Tomczak reports research funding from MSD. Se Hoon Park reports having served as a consultant or adviser for Janssen Oncology and Lilly; and research funding from Ono Pharmaceutical. Bxports having served as a consultant or adviser for Bristol Myers Squibb, MSD Oncology, and Pfizer/EMD Serono; honoraria from Bristol Myers Squibb, Eisai, EUSA Pharma, Ipsen, Merck, MSD Oncology, and Pfizer; research funding paid to institution from Calithera Biosciences, Ipsen, MSD Oncology, and Pfizer/EMD Serono; serving as a speaker for Eisai, MSD Oncology, and Pfizer; and travel, accommodations, and expenses from EUSA Pharma and Ipsen. Thomas Ferguson reports research funding paid to institution from AstraZeneca, Janssen, and MSD; and travel, accommodations, and expenses from Bristol Myers Squibb, MSD, and Roche. SNS reports having served as a consultant or adviser for Bicycle Therapeutics, Bristol Myers Squibb, Boxer Capital, Duke Street Bio, Eisai, Ellipses Pharma, EMD Serono, EUSA Pharma, MedAnnex, MSD, Pfizer, and Vaccitech; having served as a speaker for Bristol Myers Squibb, EUSA  Pharma, and Ipsen; research funding paid to institution from BiolineRx, BioNTech, Boston Pharmaceuticals, Incyte, MSD, Nouscom, Nucana, Roche, Sapience Therapeutics, Scancell, Sierra Oncology, and Verastem; and travel, accommodations, and expenses from Bristol Myers Squibb, EUSA Pharma, and Ipsen. HG reports personal speaker fees from MSD; and personal advisory fees from MSD, Roche, Merck, Bristol Myers Squibb, Pfizer, and Ipsen. JLL reports honoraria from Astellas Pharma, AstraZeneca, Bristol Myers Squibb, MSD, and Pfizer; having served as an advisr or consultant for Alteogen, AstraZeneca, BMS Korea, GI Innovation, Merck, MSD, Pfizer, and Sanofi/Aventis; research funding paid to institution from AstraZeneca/MedImmune, Bayer Schering Pharma, Bristol Myers Squibb, Janssen, MSD, Novartis, Pfizer, Roche/Genentech, and Seattle Genetics; and owns stock in Amgen, BeiGene, Black Diamond Therapeutics, Innovent Biologics, Johnson & Johnson/Janssen, Karyopharm Therapeutics, Merck, Myovant Sciences, and  Zymeworks. NS reports having served as a consultant or adviser for Bristol Myers  Squibb, Eisai, EUSA Pharma, MSD, and Roche; having served as a speaker for Pfizer; and research funding from MSD. AT-V reports honoraria from Astellas Pharma, AstraZeneca, Bristol Myers Squibb, Ipsen, Janssen, MSD, Novartis, Pfizer, Roche/Genentech, and Sanofi; having served as a consultant for Astellas Pharma, AstraZeneca, Bristol Myers Squibb, Ipsen, Janssen, MSD, Novartis, Pfizer, Roche,  and Sanofi; research funding paid to institution from Pfizer; and travel, accommodations, and expenses from Astellas Pharma, AstraZeneca, Bristol Myers Squibb, Ipsen, Janssen, MSD, Pfizer, and Roche. MG-G reports having served as a consultant or adviser for Amgen, Astellas Medivation, AstraZeneca, Bayer/Onyx, Bristol Myers Squibb, Ipsen, Janssen-Cilag, MSD Oncology, Pfizer, Roche, and Sanofi; research funding paid to institution from AstraZeneca, Ipsen, Janssen-Cilag, Merck, MSD Oncology, Pfizer, and Roche; and travel, accommodations, and expenses from Astellas Pharma, AstraZeneca, AstraZeneca, Ipsen, Janssen-Cilag, Pfizer, and Roche. MM reports research funding from MSD. NBH reports having served as a consultant or adviser for AVEO, Calithera Biosciences, Eisai, Exelixis, MSD, Pfizer, and Roche/Genentech; and has provided  expert testimony for Lilly. PS reports honoraria from Bristol Myers Squibb and Novartis; research funding paid to institution from Boehringer Ingelheim, Chiltern, G1 Therapeutics, Gilead Sciences, Merrimack, MSD, Parexel, PAREXEL/Puma Biotechnology, PPD Global, Regeneron, and Tesaro; and travel, accommodations, and expenses from Pierre Fabre and Roche. JEB and LX are employees of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co, Inc, Rahway, NJ, USA. KI is an employee of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co, Inc, and owns stock in Merck & Co, Inc, Rahway, NJ, USA. DIQ reports having served as a consultant or adviser  for Astellas Pharma, AstraZeneca, Bayer, Bristol Myers Squibb, Eisai, Exelixis, Genentech/Roche, Janssen Oncology, MSD, Myovant Sciences, Novartis, Pfizer, Seattle Genetics, and US Biotest; honoraria from Astellas Pharma, AstraZeneca, Bayer, Bristol Myers Squibb, Exelixis, Genentech/Roche, MSD, Myovant Sciences, Novartis, Pfizer, and Seattle Genetics; research funding paid to institution from Genentech/Roche, Merck, and Pfizer; and travel, accommodations, and expenses from Astellas Pharma, Bayer, Bristol Myers Squibb Japan, Exelexis, Merck, and Roche. TKC reports institutional and personal support, paid and unpaid support for research, participating in advisory boards, consultancy, and honoraria from AstraZeneca, Aravive, Aveo, Bayer, Bristol Myers Squibb, Calithera, Circle Pharma, Eisai, EMD Serono, Exelixis, GlaxoSmithKline, IQVA, Infinity, Ipsen, Jansen, Kanaph, Lilly, Merck, Nikang, Nuscan, Novartis, Pfizer, Roche, Sanofi/Aventis, Surface Oncology, Takeda, Tempest, UpToDate, and CME events (Peerview, OncLive, and MJH), outside the submitted work; institutional patents filed on molecular mutations, immunotherapy response and toxicity, and ctDNA; equity in Tempest, Pionyr, Osel, Precede Bio; being part of committees in the National Comprehensive Cancer Network, GU Steering Committee, American Society of Clinical Oncology, European Society for Medical Oncology, Academic and Community  Cancer Research United, and KidneyCAN; having mentored several non-US citizens on research projects partly funded by non-US sources; and additional independent funding from drug companies or royalties for research around the subject matter paid to institution. All other authors declare no competing interests.\n",
      "\n",
      "Symeonides, Stefan N.\n",
      "Declaration of interests Thomas Powles reports having served as a consultant or adviser for  Astellas Pharma, AstraZeneca, Bristol Myers Squibb, Eisai, Exelixis, Incyte, Ipsen, Johnson & Johnson, Merck, Merck Serono, MSD, Novartis, Pfizer, Roche, and  Seattle Genetics; honoraria from Astellas Pharma, AstraZeneca, Bristol Myers Squibb, Eisai, Exelixis, Incyte, Ipsen, Johnson & Johnson, Merck, Merck Serono, MSD, Novartis, Pfizer, Roche, and Seattle Genetics; research funding paid to institution from Astellas Pharma, AstraZeneca, Bristol Myers Squibb, Eisai, Exelixis, Ipsen, Johnson & Johnson, Merck, Merck Serono, MSD, Novartis, Pfizer, Roche, and Seattle Genetics; and travel, accommodations, and expenses from AstraZeneca, Ipsen, MSD, Pfizer, and Roche. Piotr Tomczak reports research funding from MSD. Se Hoon Park reports having served as a consultant or adviser for Janssen Oncology and Lilly; and research funding from Ono Pharmaceutical. Bxports having served as a consultant or adviser for Bristol Myers Squibb, MSD Oncology, and Pfizer/EMD Serono; honoraria from Bristol Myers Squibb, Eisai, EUSA Pharma, Ipsen, Merck, MSD Oncology, and Pfizer; research funding paid to institution from Calithera Biosciences, Ipsen, MSD Oncology, and Pfizer/EMD Serono; serving as a speaker for Eisai, MSD Oncology, and Pfizer; and travel, accommodations, and expenses from EUSA Pharma and Ipsen. Thomas Ferguson reports research funding paid to institution from AstraZeneca, Janssen, and MSD; and travel, accommodations, and expenses from Bristol Myers Squibb, MSD, and Roche. Stefan N. Symeonides reports having served as a consultant or adviser for Bicycle Therapeutics, Bristol Myers Squibb, Boxer Capital, Duke Street Bio, Eisai, Ellipses Pharma, EMD Serono, EUSA Pharma, MedAnnex, MSD, Pfizer, and Vaccitech; having served as a speaker for Bristol Myers Squibb, EUSA  Pharma, and Ipsen; research funding paid to institution from BiolineRx, BioNTech, Boston Pharmaceuticals, Incyte, MSD, Nouscom, Nucana, Roche, Sapience Therapeutics, Scancell, Sierra Oncology, and Verastem; and travel, accommodations, and expenses from Bristol Myers Squibb, EUSA Pharma, and Ipsen. HG reports personal speaker fees from MSD; and personal advisory fees from MSD, Roche, Merck, Bristol Myers Squibb, Pfizer, and Ipsen. JLL reports honoraria from Astellas Pharma, AstraZeneca, Bristol Myers Squibb, MSD, and Pfizer; having served as an advisr or consultant for Alteogen, AstraZeneca, BMS Korea, GI Innovation, Merck, MSD, Pfizer, and Sanofi/Aventis; research funding paid to institution from AstraZeneca/MedImmune, Bayer Schering Pharma, Bristol Myers Squibb, Janssen, MSD, Novartis, Pfizer, Roche/Genentech, and Seattle Genetics; and owns stock in Amgen, BeiGene, Black Diamond Therapeutics, Innovent Biologics, Johnson & Johnson/Janssen, Karyopharm Therapeutics, Merck, Myovant Sciences, and  Zymeworks. NS reports having served as a consultant or adviser for Bristol Myers  Squibb, Eisai, EUSA Pharma, MSD, and Roche; having served as a speaker for Pfizer; and research funding from MSD. AT-V reports honoraria from Astellas Pharma, AstraZeneca, Bristol Myers Squibb, Ipsen, Janssen, MSD, Novartis, Pfizer, Roche/Genentech, and Sanofi; having served as a consultant for Astellas Pharma, AstraZeneca, Bristol Myers Squibb, Ipsen, Janssen, MSD, Novartis, Pfizer, Roche,  and Sanofi; research funding paid to institution from Pfizer; and travel, accommodations, and expenses from Astellas Pharma, AstraZeneca, Bristol Myers Squibb, Ipsen, Janssen, MSD, Pfizer, and Roche. MG-G reports having served as a consultant or adviser for Amgen, Astellas Medivation, AstraZeneca, Bayer/Onyx, Bristol Myers Squibb, Ipsen, Janssen-Cilag, MSD Oncology, Pfizer, Roche, and Sanofi; research funding paid to institution from AstraZeneca, Ipsen, Janssen-Cilag, Merck, MSD Oncology, Pfizer, and Roche; and travel, accommodations, and expenses from Astellas Pharma, AstraZeneca, AstraZeneca, Ipsen, Janssen-Cilag, Pfizer, and Roche. MM reports research funding from MSD. NBH reports having served as a consultant or adviser for AVEO, Calithera Biosciences, Eisai, Exelixis, MSD, Pfizer, and Roche/Genentech; and has provided  expert testimony for Lilly. PS reports honoraria from Bristol Myers Squibb and Novartis; research funding paid to institution from Boehringer Ingelheim, Chiltern, G1 Therapeutics, Gilead Sciences, Merrimack, MSD, Parexel, PAREXEL/Puma Biotechnology, PPD Global, Regeneron, and Tesaro; and travel, accommodations, and expenses from Pierre Fabre and Roche. JEB and LX are employees of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co, Inc, Rahway, NJ, USA. KI is an employee of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co, Inc, and owns stock in Merck & Co, Inc, Rahway, NJ, USA. DIQ reports having served as a consultant or adviser  for Astellas Pharma, AstraZeneca, Bayer, Bristol Myers Squibb, Eisai, Exelixis, Genentech/Roche, Janssen Oncology, MSD, Myovant Sciences, Novartis, Pfizer, Seattle Genetics, and US Biotest; honoraria from Astellas Pharma, AstraZeneca, Bayer, Bristol Myers Squibb, Exelixis, Genentech/Roche, MSD, Myovant Sciences, Novartis, Pfizer, and Seattle Genetics; research funding paid to institution from Genentech/Roche, Merck, and Pfizer; and travel, accommodations, and expenses from Astellas Pharma, Bayer, Bristol Myers Squibb Japan, Exelexis, Merck, and Roche. TKC reports institutional and personal support, paid and unpaid support for research, participating in advisory boards, consultancy, and honoraria from AstraZeneca, Aravive, Aveo, Bayer, Bristol Myers Squibb, Calithera, Circle Pharma, Eisai, EMD Serono, Exelixis, GlaxoSmithKline, IQVA, Infinity, Ipsen, Jansen, Kanaph, Lilly, Merck, Nikang, Nuscan, Novartis, Pfizer, Roche, Sanofi/Aventis, Surface Oncology, Takeda, Tempest, UpToDate, and CME events (Peerview, OncLive, and MJH), outside the submitted work; institutional patents filed on molecular mutations, immunotherapy response and toxicity, and ctDNA; equity in Tempest, Pionyr, Osel, Precede Bio; being part of committees in the National Comprehensive Cancer Network, GU Steering Committee, American Society of Clinical Oncology, European Society for Medical Oncology, Academic and Community  Cancer Research United, and KidneyCAN; having mentored several non-US citizens on research projects partly funded by non-US sources; and additional independent funding from drug companies or royalties for research around the subject matter paid to institution. All other authors declare no competing interests.\n",
      "\n",
      "Hajek, Jaroslav\n",
      "Declaration of interests Thomas Powles reports having served as a consultant or adviser for  Astellas Pharma, AstraZeneca, Bristol Myers Squibb, Eisai, Exelixis, Incyte, Ipsen, Johnson & Johnson, Merck, Merck Serono, MSD, Novartis, Pfizer, Roche, and  Seattle Genetics; honoraria from Astellas Pharma, AstraZeneca, Bristol Myers Squibb, Eisai, Exelixis, Incyte, Ipsen, Johnson & Johnson, Merck, Merck Serono, MSD, Novartis, Pfizer, Roche, and Seattle Genetics; research funding paid to institution from Astellas Pharma, AstraZeneca, Bristol Myers Squibb, Eisai, Exelixis, Ipsen, Johnson & Johnson, Merck, Merck Serono, MSD, Novartis, Pfizer, Roche, and Seattle Genetics; and travel, accommodations, and expenses from AstraZeneca, Ipsen, MSD, Pfizer, and Roche. Piotr Tomczak reports research funding from MSD. Se Hoon Park reports having served as a consultant or adviser for Janssen Oncology and Lilly; and research funding from Ono Pharmaceutical. Bxports having served as a consultant or adviser for Bristol Myers Squibb, MSD Oncology, and Pfizer/EMD Serono; honoraria from Bristol Myers Squibb, Eisai, EUSA Pharma, Ipsen, Merck, MSD Oncology, and Pfizer; research funding paid to institution from Calithera Biosciences, Ipsen, MSD Oncology, and Pfizer/EMD Serono; serving as a speaker for Eisai, MSD Oncology, and Pfizer; and travel, accommodations, and expenses from EUSA Pharma and Ipsen. Thomas Ferguson reports research funding paid to institution from AstraZeneca, Janssen, and MSD; and travel, accommodations, and expenses from Bristol Myers Squibb, MSD, and Roche. Stefan N. Symeonides reports having served as a consultant or adviser for Bicycle Therapeutics, Bristol Myers Squibb, Boxer Capital, Duke Street Bio, Eisai, Ellipses Pharma, EMD Serono, EUSA Pharma, MedAnnex, MSD, Pfizer, and Vaccitech; having served as a speaker for Bristol Myers Squibb, EUSA  Pharma, and Ipsen; research funding paid to institution from BiolineRx, BioNTech, Boston Pharmaceuticals, Incyte, MSD, Nouscom, Nucana, Roche, Sapience Therapeutics, Scancell, Sierra Oncology, and Verastem; and travel, accommodations, and expenses from Bristol Myers Squibb, EUSA Pharma, and Ipsen. HG reports personal speaker fees from MSD; and personal advisory fees from MSD, Roche, Merck, Bristol Myers Squibb, Pfizer, and Ipsen. JLL reports honoraria from Astellas Pharma, AstraZeneca, Bristol Myers Squibb, MSD, and Pfizer; having served as an advisr or consultant for Alteogen, AstraZeneca, BMS Korea, GI Innovation, Merck, MSD, Pfizer, and Sanofi/Aventis; research funding paid to institution from AstraZeneca/MedImmune, Bayer Schering Pharma, Bristol Myers Squibb, Janssen, MSD, Novartis, Pfizer, Roche/Genentech, and Seattle Genetics; and owns stock in Amgen, BeiGene, Black Diamond Therapeutics, Innovent Biologics, Johnson & Johnson/Janssen, Karyopharm Therapeutics, Merck, Myovant Sciences, and  Zymeworks. NS reports having served as a consultant or adviser for Bristol Myers  Squibb, Eisai, EUSA Pharma, MSD, and Roche; having served as a speaker for Pfizer; and research funding from MSD. AT-V reports honoraria from Astellas Pharma, AstraZeneca, Bristol Myers Squibb, Ipsen, Janssen, MSD, Novartis, Pfizer, Roche/Genentech, and Sanofi; having served as a consultant for Astellas Pharma, AstraZeneca, Bristol Myers Squibb, Ipsen, Janssen, MSD, Novartis, Pfizer, Roche,  and Sanofi; research funding paid to institution from Pfizer; and travel, accommodations, and expenses from Astellas Pharma, AstraZeneca, Bristol Myers Squibb, Ipsen, Janssen, MSD, Pfizer, and Roche. MG-G reports having served as a consultant or adviser for Amgen, Astellas Medivation, AstraZeneca, Bayer/Onyx, Bristol Myers Squibb, Ipsen, Janssen-Cilag, MSD Oncology, Pfizer, Roche, and Sanofi; research funding paid to institution from AstraZeneca, Ipsen, Janssen-Cilag, Merck, MSD Oncology, Pfizer, and Roche; and travel, accommodations, and expenses from Astellas Pharma, AstraZeneca, AstraZeneca, Ipsen, Janssen-Cilag, Pfizer, and Roche. MM reports research funding from MSD. NBH reports having served as a consultant or adviser for AVEO, Calithera Biosciences, Eisai, Exelixis, MSD, Pfizer, and Roche/Genentech; and has provided  expert testimony for Lilly. PS reports honoraria from Bristol Myers Squibb and Novartis; research funding paid to institution from Boehringer Ingelheim, Chiltern, G1 Therapeutics, Gilead Sciences, Merrimack, MSD, Parexel, PAREXEL/Puma Biotechnology, PPD Global, Regeneron, and Tesaro; and travel, accommodations, and expenses from Pierre Fabre and Roche. JEB and LX are employees of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co, Inc, Rahway, NJ, USA. KI is an employee of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co, Inc, and owns stock in Merck & Co, Inc, Rahway, NJ, USA. DIQ reports having served as a consultant or adviser  for Astellas Pharma, AstraZeneca, Bayer, Bristol Myers Squibb, Eisai, Exelixis, Genentech/Roche, Janssen Oncology, MSD, Myovant Sciences, Novartis, Pfizer, Seattle Genetics, and US Biotest; honoraria from Astellas Pharma, AstraZeneca, Bayer, Bristol Myers Squibb, Exelixis, Genentech/Roche, MSD, Myovant Sciences, Novartis, Pfizer, and Seattle Genetics; research funding paid to institution from Genentech/Roche, Merck, and Pfizer; and travel, accommodations, and expenses from Astellas Pharma, Bayer, Bristol Myers Squibb Japan, Exelexis, Merck, and Roche. TKC reports institutional and personal support, paid and unpaid support for research, participating in advisory boards, consultancy, and honoraria from AstraZeneca, Aravive, Aveo, Bayer, Bristol Myers Squibb, Calithera, Circle Pharma, Eisai, EMD Serono, Exelixis, GlaxoSmithKline, IQVA, Infinity, Ipsen, Jansen, Kanaph, Lilly, Merck, Nikang, Nuscan, Novartis, Pfizer, Roche, Sanofi/Aventis, Surface Oncology, Takeda, Tempest, UpToDate, and CME events (Peerview, OncLive, and MJaroslav Hajek), outside the submitted work; institutional patents filed on molecular mutations, immunotherapy response and toxicity, and ctDNA; equity in Tempest, Pionyr, Osel, Precede Bio; being part of committees in the National Comprehensive Cancer Network, GU Steering Committee, American Society of Clinical Oncology, European Society for Medical Oncology, Academic and Community  Cancer Research United, and KidneyCAN; having mentored several non-US citizens on research projects partly funded by non-US sources; and additional independent funding from drug companies or royalties for research around the subject matter paid to institution. All other authors declare no competing interests.\n",
      "\n",
      "Gurney, Howard\n",
      "Declaration of interests Thomas Powles reports having served as a consultant or adviser for  Astellas Pharma, AstraZeneca, Bristol Myers Squibb, Eisai, Exelixis, Incyte, Ipsen, Johnson & Johnson, Merck, Merck Serono, MSD, Novartis, Pfizer, Roche, and  Seattle Genetics; honoraria from Astellas Pharma, AstraZeneca, Bristol Myers Squibb, Eisai, Exelixis, Incyte, Ipsen, Johnson & Johnson, Merck, Merck Serono, MSD, Novartis, Pfizer, Roche, and Seattle Genetics; research funding paid to institution from Astellas Pharma, AstraZeneca, Bristol Myers Squibb, Eisai, Exelixis, Ipsen, Johnson & Johnson, Merck, Merck Serono, MSD, Novartis, Pfizer, Roche, and Seattle Genetics; and travel, accommodations, and expenses from AstraZeneca, Ipsen, MSD, Pfizer, and Roche. Piotr Tomczak reports research funding from MSD. Se Hoon Park reports having served as a consultant or adviser for Janssen Oncology and Lilly; and research funding from Ono Pharmaceutical. Bxports having served as a consultant or adviser for Bristol Myers Squibb, MSD Oncology, and Pfizer/EMD Serono; honoraria from Bristol Myers Squibb, Eisai, EUSA Pharma, Ipsen, Merck, MSD Oncology, and Pfizer; research funding paid to institution from Calithera Biosciences, Ipsen, MSD Oncology, and Pfizer/EMD Serono; serving as a speaker for Eisai, MSD Oncology, and Pfizer; and travel, accommodations, and expenses from EUSA Pharma and Ipsen. Thomas Ferguson reports research funding paid to institution from AstraZeneca, Janssen, and MSD; and travel, accommodations, and expenses from Bristol Myers Squibb, MSD, and Roche. Stefan N. Symeonides reports having served as a consultant or adviser for Bicycle Therapeutics, Bristol Myers Squibb, Boxer Capital, Duke Street Bio, Eisai, Ellipses Pharma, EMD Serono, EUSA Pharma, MedAnnex, MSD, Pfizer, and Vaccitech; having served as a speaker for Bristol Myers Squibb, EUSA  Pharma, and Ipsen; research funding paid to institution from BiolineRx, BioNTech, Boston Pharmaceuticals, Incyte, MSD, Nouscom, Nucana, Roche, Sapience Therapeutics, Scancell, Sierra Oncology, and Verastem; and travel, accommodations, and expenses from Bristol Myers Squibb, EUSA Pharma, and Ipsen. Howard Gurney reports personal speaker fees from MSD; and personal advisory fees from MSD, Roche, Merck, Bristol Myers Squibb, Pfizer, and Ipsen. JLL reports honoraria from Astellas Pharma, AstraZeneca, Bristol Myers Squibb, MSD, and Pfizer; having served as an advisr or consultant for Alteogen, AstraZeneca, BMS Korea, GI Innovation, Merck, MSD, Pfizer, and Sanofi/Aventis; research funding paid to institution from AstraZeneca/MedImmune, Bayer Schering Pharma, Bristol Myers Squibb, Janssen, MSD, Novartis, Pfizer, Roche/Genentech, and Seattle Genetics; and owns stock in Amgen, BeiGene, Black Diamond Therapeutics, Innovent Biologics, Johnson & Johnson/Janssen, Karyopharm Therapeutics, Merck, Myovant Sciences, and  Zymeworks. NS reports having served as a consultant or adviser for Bristol Myers  Squibb, Eisai, EUSA Pharma, MSD, and Roche; having served as a speaker for Pfizer; and research funding from MSD. AT-V reports honoraria from Astellas Pharma, AstraZeneca, Bristol Myers Squibb, Ipsen, Janssen, MSD, Novartis, Pfizer, Roche/Genentech, and Sanofi; having served as a consultant for Astellas Pharma, AstraZeneca, Bristol Myers Squibb, Ipsen, Janssen, MSD, Novartis, Pfizer, Roche,  and Sanofi; research funding paid to institution from Pfizer; and travel, accommodations, and expenses from Astellas Pharma, AstraZeneca, Bristol Myers Squibb, Ipsen, Janssen, MSD, Pfizer, and Roche. MG-G reports having served as a consultant or adviser for Amgen, Astellas Medivation, AstraZeneca, Bayer/Onyx, Bristol Myers Squibb, Ipsen, Janssen-Cilag, MSD Oncology, Pfizer, Roche, and Sanofi; research funding paid to institution from AstraZeneca, Ipsen, Janssen-Cilag, Merck, MSD Oncology, Pfizer, and Roche; and travel, accommodations, and expenses from Astellas Pharma, AstraZeneca, AstraZeneca, Ipsen, Janssen-Cilag, Pfizer, and Roche. MM reports research funding from MSD. NBH reports having served as a consultant or adviser for AVEO, Calithera Biosciences, Eisai, Exelixis, MSD, Pfizer, and Roche/Genentech; and has provided  expert testimony for Lilly. PS reports honoraria from Bristol Myers Squibb and Novartis; research funding paid to institution from Boehringer Ingelheim, Chiltern, G1 Therapeutics, Gilead Sciences, Merrimack, MSD, Parexel, PAREXEL/Puma Biotechnology, PPD Global, Regeneron, and Tesaro; and travel, accommodations, and expenses from Pierre Fabre and Roche. JEB and LX are employees of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co, Inc, Rahway, NJ, USA. KI is an employee of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co, Inc, and owns stock in Merck & Co, Inc, Rahway, NJ, USA. DIQ reports having served as a consultant or adviser  for Astellas Pharma, AstraZeneca, Bayer, Bristol Myers Squibb, Eisai, Exelixis, Genentech/Roche, Janssen Oncology, MSD, Myovant Sciences, Novartis, Pfizer, Seattle Genetics, and US Biotest; honoraria from Astellas Pharma, AstraZeneca, Bayer, Bristol Myers Squibb, Exelixis, Genentech/Roche, MSD, Myovant Sciences, Novartis, Pfizer, and Seattle Genetics; research funding paid to institution from Genentech/Roche, Merck, and Pfizer; and travel, accommodations, and expenses from Astellas Pharma, Bayer, Bristol Myers Squibb Japan, Exelexis, Merck, and Roche. TKC reports institutional and personal support, paid and unpaid support for research, participating in advisory boards, consultancy, and honoraria from AstraZeneca, Aravive, Aveo, Bayer, Bristol Myers Squibb, Calithera, Circle Pharma, Eisai, EMD Serono, Exelixis, GlaxoSmithKline, IQVA, Infinity, Ipsen, Jansen, Kanaph, Lilly, Merck, Nikang, Nuscan, Novartis, Pfizer, Roche, Sanofi/Aventis, Surface Oncology, Takeda, Tempest, UpToDate, and CME events (Peerview, OncLive, and MJaroslav Hajek), outside the submitted work; institutional patents filed on molecular mutations, immunotherapy response and toxicity, and ctDNA; equity in Tempest, Pionyr, Osel, Precede Bio; being part of committees in the National Comprehensive Cancer Network, GU Steering Committee, American Society of Clinical Oncology, European Society for Medical Oncology, Academic and Community  Cancer Research United, and KidneyCAN; having mentored several non-US citizens on research projects partly funded by non-US sources; and additional independent funding from drug companies or royalties for research around the subject matter paid to institution. All other authors declare no competing interests.\n",
      "\n",
      "Declaration of interests Thomas Powles reports having served as a consultant or adviser for  Astellas Pharma, AstraZeneca, Bristol Myers Squibb, Eisai, Exelixis, Incyte, Ipsen, Johnson & Johnson, Merck, Merck Serono, MSD, Novartis, Pfizer, Roche, and  Seattle Genetics; honoraria from Astellas Pharma, AstraZeneca, Bristol Myers Squibb, Eisai, Exelixis, Incyte, Ipsen, Johnson & Johnson, Merck, Merck Serono, MSD, Novartis, Pfizer, Roche, and Seattle Genetics; research funding paid to institution from Astellas Pharma, AstraZeneca, Bristol Myers Squibb, Eisai, Exelixis, Ipsen, Johnson & Johnson, Merck, Merck Serono, MSD, Novartis, Pfizer, Roche, and Seattle Genetics; and travel, accommodations, and expenses from AstraZeneca, Ipsen, MSD, Pfizer, and Roche. Piotr Tomczak reports research funding from MSD. Se Hoon Park reports having served as a consultant or adviser for Janssen Oncology and Lilly; and research funding from Ono Pharmaceutical. Bxports having served as a consultant or adviser for Bristol Myers Squibb, MSD Oncology, and Pfizer/EMD Serono; honoraria from Bristol Myers Squibb, Eisai, EUSA Pharma, Ipsen, Merck, MSD Oncology, and Pfizer; research funding paid to institution from Calithera Biosciences, Ipsen, MSD Oncology, and Pfizer/EMD Serono; serving as a speaker for Eisai, MSD Oncology, and Pfizer; and travel, accommodations, and expenses from EUSA Pharma and Ipsen. Thomas Ferguson reports research funding paid to institution from AstraZeneca, Janssen, and MSD; and travel, accommodations, and expenses from Bristol Myers Squibb, MSD, and Roche. Stefan N. Symeonides reports having served as a consultant or adviser for Bicycle Therapeutics, Bristol Myers Squibb, Boxer Capital, Duke Street Bio, Eisai, Ellipses Pharma, EMD Serono, EUSA Pharma, MedAnnex, MSD, Pfizer, and Vaccitech; having served as a speaker for Bristol Myers Squibb, EUSA  Pharma, and Ipsen; research funding paid to institution from BiolineRx, BioNTech, Boston Pharmaceuticals, Incyte, MSD, Nouscom, Nucana, Roche, Sapience Therapeutics, Scancell, Sierra Oncology, and Verastem; and travel, accommodations, and expenses from Bristol Myers Squibb, EUSA Pharma, and Ipsen. Howard Gurney reports personal speaker fees from MSD; and personal advisory fees from MSD, Roche, Merck, Bristol Myers Squibb, Pfizer, and Ipsen. JLL reports honoraria from Astellas Pharma, AstraZeneca, Bristol Myers Squibb, MSD, and Pfizer; having served as an advisr or consultant for Alteogen, AstraZeneca, BMS Korea, GI Innovation, Merck, MSD, Pfizer, and Sanofi/Aventis; research funding paid to institution from AstraZeneca/MedImmune, Bayer Schering Pharma, Bristol Myers Squibb, Janssen, MSD, Novartis, Pfizer, Roche/Genentech, and Seattle Genetics; and owns stock in Amgen, BeiGene, Black Diamond Therapeutics, Innovent Biologics, Johnson & Johnson/Janssen, Karyopharm Therapeutics, Merck, Myovant Sciences, and  Zymeworks. NS reports having served as a consultant or adviser for Bristol Myers  Squibb, Eisai, EUSA Pharma, MSD, and Roche; having served as a speaker for Pfizer; and research funding from MSD. AT-V reports honoraria from Astellas Pharma, AstraZeneca, Bristol Myers Squibb, Ipsen, Janssen, MSD, Novartis, Pfizer, Roche/Genentech, and Sanofi; having served as a consultant for Astellas Pharma, AstraZeneca, Bristol Myers Squibb, Ipsen, Janssen, MSD, Novartis, Pfizer, Roche,  and Sanofi; research funding paid to institution from Pfizer; and travel, accommodations, and expenses from Astellas Pharma, AstraZeneca, Bristol Myers Squibb, Ipsen, Janssen, MSD, Pfizer, and Roche. MG-G reports having served as a consultant or adviser for Amgen, Astellas Medivation, AstraZeneca, Bayer/Onyx, Bristol Myers Squibb, Ipsen, Janssen-Cilag, MSD Oncology, Pfizer, Roche, and Sanofi; research funding paid to institution from AstraZeneca, Ipsen, Janssen-Cilag, Merck, MSD Oncology, Pfizer, and Roche; and travel, accommodations, and expenses from Astellas Pharma, AstraZeneca, AstraZeneca, Ipsen, Janssen-Cilag, Pfizer, and Roche. MM reports research funding from MSD. NBH reports having served as a consultant or adviser for AVEO, Calithera Biosciences, Eisai, Exelixis, MSD, Pfizer, and Roche/Genentech; and has provided  expert testimony for Lilly. PS reports honoraria from Bristol Myers Squibb and Novartis; research funding paid to institution from Boehringer Ingelheim, Chiltern, G1 Therapeutics, Gilead Sciences, Merrimack, MSD, Parexel, PAREXEL/Puma Biotechnology, PPD Global, Regeneron, and Tesaro; and travel, accommodations, and expenses from Pierre Fabre and Roche. JEB and LX are employees of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co, Inc, Rahway, NJ, USA. KI is an employee of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co, Inc, and owns stock in Merck & Co, Inc, Rahway, NJ, USA. DIQ reports having served as a consultant or adviser  for Astellas Pharma, AstraZeneca, Bayer, Bristol Myers Squibb, Eisai, Exelixis, Genentech/Roche, Janssen Oncology, MSD, Myovant Sciences, Novartis, Pfizer, Seattle Genetics, and US Biotest; honoraria from Astellas Pharma, AstraZeneca, Bayer, Bristol Myers Squibb, Exelixis, Genentech/Roche, MSD, Myovant Sciences, Novartis, Pfizer, and Seattle Genetics; research funding paid to institution from Genentech/Roche, Merck, and Pfizer; and travel, accommodations, and expenses from Astellas Pharma, Bayer, Bristol Myers Squibb Japan, Exelexis, Merck, and Roche. TKC reports institutional and personal support, paid and unpaid support for research, participating in advisory boards, consultancy, and honoraria from AstraZeneca, Aravive, Aveo, Bayer, Bristol Myers Squibb, Calithera, Circle Pharma, Eisai, EMD Serono, Exelixis, GlaxoSmithKline, IQVA, Infinity, Ipsen, Jansen, Kanaph, Lilly, Merck, Nikang, Nuscan, Novartis, Pfizer, Roche, Sanofi/Aventis, Surface Oncology, Takeda, Tempest, UpToDate, and CME events (Peerview, OncLive, and MJaroslav Hajek), outside the submitted work; institutional patents filed on molecular mutations, immunotherapy response and toxicity, and ctDNA; equity in Tempest, Pionyr, Osel, Precede Bio; being part of committees in the National Comprehensive Cancer Network, GU Steering Committee, American Society of Clinical Oncology, European Society for Medical Oncology, Academic and Community  Cancer Research United, and KidneyCAN; having mentored several non-US citizens on research projects partly funded by non-US sources; and additional independent funding from drug companies or royalties for research around the subject matter paid to institution. All other authors declare no competing interests.\n",
      "\n",
      "Lyun Lee, Jae\n",
      "Declaration of interests Thomas Powles reports having served as a consultant or adviser for  Astellas Pharma, AstraZeneca, Bristol Myers Squibb, Eisai, Exelixis, Incyte, Ipsen, Johnson & Johnson, Merck, Merck Serono, MSD, Novartis, Pfizer, Roche, and  Seattle Genetics; honoraria from Astellas Pharma, AstraZeneca, Bristol Myers Squibb, Eisai, Exelixis, Incyte, Ipsen, Johnson & Johnson, Merck, Merck Serono, MSD, Novartis, Pfizer, Roche, and Seattle Genetics; research funding paid to institution from Astellas Pharma, AstraZeneca, Bristol Myers Squibb, Eisai, Exelixis, Ipsen, Johnson & Johnson, Merck, Merck Serono, MSD, Novartis, Pfizer, Roche, and Seattle Genetics; and travel, accommodations, and expenses from AstraZeneca, Ipsen, MSD, Pfizer, and Roche. Piotr Tomczak reports research funding from MSD. Se Hoon Park reports having served as a consultant or adviser for Janssen Oncology and Lilly; and research funding from Ono Pharmaceutical. Bxports having served as a consultant or adviser for Bristol Myers Squibb, MSD Oncology, and Pfizer/EMD Serono; honoraria from Bristol Myers Squibb, Eisai, EUSA Pharma, Ipsen, Merck, MSD Oncology, and Pfizer; research funding paid to institution from Calithera Biosciences, Ipsen, MSD Oncology, and Pfizer/EMD Serono; serving as a speaker for Eisai, MSD Oncology, and Pfizer; and travel, accommodations, and expenses from EUSA Pharma and Ipsen. Thomas Ferguson reports research funding paid to institution from AstraZeneca, Janssen, and MSD; and travel, accommodations, and expenses from Bristol Myers Squibb, MSD, and Roche. Stefan N. Symeonides reports having served as a consultant or adviser for Bicycle Therapeutics, Bristol Myers Squibb, Boxer Capital, Duke Street Bio, Eisai, Ellipses Pharma, EMD Serono, EUSA Pharma, MedAnnex, MSD, Pfizer, and Vaccitech; having served as a speaker for Bristol Myers Squibb, EUSA  Pharma, and Ipsen; research funding paid to institution from BiolineRx, BioNTech, Boston Pharmaceuticals, Incyte, MSD, Nouscom, Nucana, Roche, Sapience Therapeutics, Scancell, Sierra Oncology, and Verastem; and travel, accommodations, and expenses from Bristol Myers Squibb, EUSA Pharma, and Ipsen. Howard Gurney reports personal speaker fees from MSD; and personal advisory fees from MSD, Roche, Merck, Bristol Myers Squibb, Pfizer, and Ipsen. Jae Lyun Lee reports honoraria from Astellas Pharma, AstraZeneca, Bristol Myers Squibb, MSD, and Pfizer; having served as an advisr or consultant for Alteogen, AstraZeneca, BMS Korea, GI Innovation, Merck, MSD, Pfizer, and Sanofi/Aventis; research funding paid to institution from AstraZeneca/MedImmune, Bayer Schering Pharma, Bristol Myers Squibb, Janssen, MSD, Novartis, Pfizer, Roche/Genentech, and Seattle Genetics; and owns stock in Amgen, BeiGene, Black Diamond Therapeutics, Innovent Biologics, Johnson & Johnson/Janssen, Karyopharm Therapeutics, Merck, Myovant Sciences, and  Zymeworks. NS reports having served as a consultant or adviser for Bristol Myers  Squibb, Eisai, EUSA Pharma, MSD, and Roche; having served as a speaker for Pfizer; and research funding from MSD. AT-V reports honoraria from Astellas Pharma, AstraZeneca, Bristol Myers Squibb, Ipsen, Janssen, MSD, Novartis, Pfizer, Roche/Genentech, and Sanofi; having served as a consultant for Astellas Pharma, AstraZeneca, Bristol Myers Squibb, Ipsen, Janssen, MSD, Novartis, Pfizer, Roche,  and Sanofi; research funding paid to institution from Pfizer; and travel, accommodations, and expenses from Astellas Pharma, AstraZeneca, Bristol Myers Squibb, Ipsen, Janssen, MSD, Pfizer, and Roche. MG-G reports having served as a consultant or adviser for Amgen, Astellas Medivation, AstraZeneca, Bayer/Onyx, Bristol Myers Squibb, Ipsen, Janssen-Cilag, MSD Oncology, Pfizer, Roche, and Sanofi; research funding paid to institution from AstraZeneca, Ipsen, Janssen-Cilag, Merck, MSD Oncology, Pfizer, and Roche; and travel, accommodations, and expenses from Astellas Pharma, AstraZeneca, AstraZeneca, Ipsen, Janssen-Cilag, Pfizer, and Roche. MM reports research funding from MSD. NBH reports having served as a consultant or adviser for AVEO, Calithera Biosciences, Eisai, Exelixis, MSD, Pfizer, and Roche/Genentech; and has provided  expert testimony for Lilly. PS reports honoraria from Bristol Myers Squibb and Novartis; research funding paid to institution from Boehringer Ingelheim, Chiltern, G1 Therapeutics, Gilead Sciences, Merrimack, MSD, Parexel, PAREXEL/Puma Biotechnology, PPD Global, Regeneron, and Tesaro; and travel, accommodations, and expenses from Pierre Fabre and Roche. JEB and LX are employees of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co, Inc, Rahway, NJ, USA. KI is an employee of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co, Inc, and owns stock in Merck & Co, Inc, Rahway, NJ, USA. DIQ reports having served as a consultant or adviser  for Astellas Pharma, AstraZeneca, Bayer, Bristol Myers Squibb, Eisai, Exelixis, Genentech/Roche, Janssen Oncology, MSD, Myovant Sciences, Novartis, Pfizer, Seattle Genetics, and US Biotest; honoraria from Astellas Pharma, AstraZeneca, Bayer, Bristol Myers Squibb, Exelixis, Genentech/Roche, MSD, Myovant Sciences, Novartis, Pfizer, and Seattle Genetics; research funding paid to institution from Genentech/Roche, Merck, and Pfizer; and travel, accommodations, and expenses from Astellas Pharma, Bayer, Bristol Myers Squibb Japan, Exelexis, Merck, and Roche. TKC reports institutional and personal support, paid and unpaid support for research, participating in advisory boards, consultancy, and honoraria from AstraZeneca, Aravive, Aveo, Bayer, Bristol Myers Squibb, Calithera, Circle Pharma, Eisai, EMD Serono, Exelixis, GlaxoSmithKline, IQVA, Infinity, Ipsen, Jansen, Kanaph, Lilly, Merck, Nikang, Nuscan, Novartis, Pfizer, Roche, Sanofi/Aventis, Surface Oncology, Takeda, Tempest, UpToDate, and CME events (Peerview, OncLive, and MJaroslav Hajek), outside the submitted work; institutional patents filed on molecular mutations, immunotherapy response and toxicity, and ctDNA; equity in Tempest, Pionyr, Osel, Precede Bio; being part of committees in the National Comprehensive Cancer Network, GU Steering Committee, American Society of Clinical Oncology, European Society for Medical Oncology, Academic and Community  Cancer Research United, and KidneyCAN; having mentored several non-US citizens on research projects partly funded by non-US sources; and additional independent funding from drug companies or royalties for research around the subject matter paid to institution. All other authors declare no competing interests.\n",
      "\n",
      "Sarwar, Naveed\n",
      "Declaration of interests Thomas Powles reports having served as a consultant or adviser for  Astellas Pharma, AstraZeneca, Bristol Myers Squibb, Eisai, Exelixis, Incyte, Ipsen, Johnson & Johnson, Merck, Merck Serono, MSD, Novartis, Pfizer, Roche, and  Seattle Genetics; honoraria from Astellas Pharma, AstraZeneca, Bristol Myers Squibb, Eisai, Exelixis, Incyte, Ipsen, Johnson & Johnson, Merck, Merck Serono, MSD, Novartis, Pfizer, Roche, and Seattle Genetics; research funding paid to institution from Astellas Pharma, AstraZeneca, Bristol Myers Squibb, Eisai, Exelixis, Ipsen, Johnson & Johnson, Merck, Merck Serono, MSD, Novartis, Pfizer, Roche, and Seattle Genetics; and travel, accommodations, and expenses from AstraZeneca, Ipsen, MSD, Pfizer, and Roche. Piotr Tomczak reports research funding from MSD. Se Hoon Park reports having served as a consultant or adviser for Janssen Oncology and Lilly; and research funding from Ono Pharmaceutical. Bxports having served as a consultant or adviser for Bristol Myers Squibb, MSD Oncology, and Pfizer/EMD Serono; honoraria from Bristol Myers Squibb, Eisai, EUSA Pharma, Ipsen, Merck, MSD Oncology, and Pfizer; research funding paid to institution from Calithera Biosciences, Ipsen, MSD Oncology, and Pfizer/EMD Serono; serving as a speaker for Eisai, MSD Oncology, and Pfizer; and travel, accommodations, and expenses from EUSA Pharma and Ipsen. Thomas Ferguson reports research funding paid to institution from AstraZeneca, Janssen, and MSD; and travel, accommodations, and expenses from Bristol Myers Squibb, MSD, and Roche. Stefan N. Symeonides reports having served as a consultant or adviser for Bicycle Therapeutics, Bristol Myers Squibb, Boxer Capital, Duke Street Bio, Eisai, Ellipses Pharma, EMD Serono, EUSA Pharma, MedAnnex, MSD, Pfizer, and Vaccitech; having served as a speaker for Bristol Myers Squibb, EUSA  Pharma, and Ipsen; research funding paid to institution from BiolineRx, BioNTech, Boston Pharmaceuticals, Incyte, MSD, Nouscom, Nucana, Roche, Sapience Therapeutics, Scancell, Sierra Oncology, and Verastem; and travel, accommodations, and expenses from Bristol Myers Squibb, EUSA Pharma, and Ipsen. Howard Gurney reports personal speaker fees from MSD; and personal advisory fees from MSD, Roche, Merck, Bristol Myers Squibb, Pfizer, and Ipsen. Jae Lyun Lee reports honoraria from Astellas Pharma, AstraZeneca, Bristol Myers Squibb, MSD, and Pfizer; having served as an advisr or consultant for Alteogen, AstraZeneca, BMS Korea, GI Innovation, Merck, MSD, Pfizer, and Sanofi/Aventis; research funding paid to institution from AstraZeneca/MedImmune, Bayer Schering Pharma, Bristol Myers Squibb, Janssen, MSD, Novartis, Pfizer, Roche/Genentech, and Seattle Genetics; and owns stock in Amgen, BeiGene, Black Diamond Therapeutics, Innovent Biologics, Johnson & Johnson/Janssen, Karyopharm Therapeutics, Merck, Myovant Sciences, and  Zymeworks. Naveed Sarwar reports having served as a consultant or adviser for Bristol Myers  Squibb, Eisai, EUSA Pharma, MSD, and Roche; having served as a speaker for Pfizer; and research funding from MSD. AT-V reports honoraria from Astellas Pharma, AstraZeneca, Bristol Myers Squibb, Ipsen, Janssen, MSD, Novartis, Pfizer, Roche/Genentech, and Sanofi; having served as a consultant for Astellas Pharma, AstraZeneca, Bristol Myers Squibb, Ipsen, Janssen, MSD, Novartis, Pfizer, Roche,  and Sanofi; research funding paid to institution from Pfizer; and travel, accommodations, and expenses from Astellas Pharma, AstraZeneca, Bristol Myers Squibb, Ipsen, Janssen, MSD, Pfizer, and Roche. MG-G reports having served as a consultant or adviser for Amgen, Astellas Medivation, AstraZeneca, Bayer/Onyx, Bristol Myers Squibb, Ipsen, Janssen-Cilag, MSD Oncology, Pfizer, Roche, and Sanofi; research funding paid to institution from AstraZeneca, Ipsen, Janssen-Cilag, Merck, MSD Oncology, Pfizer, and Roche; and travel, accommodations, and expenses from Astellas Pharma, AstraZeneca, AstraZeneca, Ipsen, Janssen-Cilag, Pfizer, and Roche. MM reports research funding from MSD. NBH reports having served as a consultant or adviser for AVEO, Calithera Biosciences, Eisai, Exelixis, MSD, Pfizer, and Roche/Genentech; and has provided  expert testimony for Lilly. PS reports honoraria from Bristol Myers Squibb and Novartis; research funding paid to institution from Boehringer Ingelheim, Chiltern, G1 Therapeutics, Gilead Sciences, Merrimack, MSD, Parexel, PAREXEL/Puma Biotechnology, PPD Global, Regeneron, and Tesaro; and travel, accommodations, and expenses from Pierre Fabre and Roche. JEB and LX are employees of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co, Inc, Rahway, NJ, USA. KI is an employee of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co, Inc, and owns stock in Merck & Co, Inc, Rahway, NJ, USA. DIQ reports having served as a consultant or adviser  for Astellas Pharma, AstraZeneca, Bayer, Bristol Myers Squibb, Eisai, Exelixis, Genentech/Roche, Janssen Oncology, MSD, Myovant Sciences, Novartis, Pfizer, Seattle Genetics, and US Biotest; honoraria from Astellas Pharma, AstraZeneca, Bayer, Bristol Myers Squibb, Exelixis, Genentech/Roche, MSD, Myovant Sciences, Novartis, Pfizer, and Seattle Genetics; research funding paid to institution from Genentech/Roche, Merck, and Pfizer; and travel, accommodations, and expenses from Astellas Pharma, Bayer, Bristol Myers Squibb Japan, Exelexis, Merck, and Roche. TKC reports institutional and personal support, paid and unpaid support for research, participating in advisory boards, consultancy, and honoraria from AstraZeneca, Aravive, Aveo, Bayer, Bristol Myers Squibb, Calithera, Circle Pharma, Eisai, EMD Serono, Exelixis, GlaxoSmithKline, IQVA, Infinity, Ipsen, Jansen, Kanaph, Lilly, Merck, Nikang, Nuscan, Novartis, Pfizer, Roche, Sanofi/Aventis, Surface Oncology, Takeda, Tempest, UpToDate, and CME events (Peerview, OncLive, and MJaroslav Hajek), outside the submitted work; institutional patents filed on molecular mutations, immunotherapy response and toxicity, and ctDNA; equity in Tempest, Pionyr, Osel, Precede Bio; being part of committees in the National Comprehensive Cancer Network, GU Steering Committee, American Society of Clinical Oncology, European Society for Medical Oncology, Academic and Community  Cancer Research United, and KidneyCAN; having mentored several non-US citizens on research projects partly funded by non-US sources; and additional independent funding from drug companies or royalties for research around the subject matter paid to institution. All other authors declare no competing interests.\n",
      "\n",
      "Thiery-Vuillemin, Antoine\n",
      "Declaration of interests Thomas Powles reports having served as a consultant or adviser for  Astellas Pharma, AstraZeneca, Bristol Myers Squibb, Eisai, Exelixis, Incyte, Ipsen, Johnson & Johnson, Merck, Merck Serono, MSD, Novartis, Pfizer, Roche, and  Seattle Genetics; honoraria from Astellas Pharma, AstraZeneca, Bristol Myers Squibb, Eisai, Exelixis, Incyte, Ipsen, Johnson & Johnson, Merck, Merck Serono, MSD, Novartis, Pfizer, Roche, and Seattle Genetics; research funding paid to institution from Astellas Pharma, AstraZeneca, Bristol Myers Squibb, Eisai, Exelixis, Ipsen, Johnson & Johnson, Merck, Merck Serono, MSD, Novartis, Pfizer, Roche, and Seattle Genetics; and travel, accommodations, and expenses from AstraZeneca, Ipsen, MSD, Pfizer, and Roche. Piotr Tomczak reports research funding from MSD. Se Hoon Park reports having served as a consultant or adviser for Janssen Oncology and Lilly; and research funding from Ono Pharmaceutical. Bxports having served as a consultant or adviser for Bristol Myers Squibb, MSD Oncology, and Pfizer/EMD Serono; honoraria from Bristol Myers Squibb, Eisai, EUSA Pharma, Ipsen, Merck, MSD Oncology, and Pfizer; research funding paid to institution from Calithera Biosciences, Ipsen, MSD Oncology, and Pfizer/EMD Serono; serving as a speaker for Eisai, MSD Oncology, and Pfizer; and travel, accommodations, and expenses from EUSA Pharma and Ipsen. Thomas Ferguson reports research funding paid to institution from AstraZeneca, Janssen, and MSD; and travel, accommodations, and expenses from Bristol Myers Squibb, MSD, and Roche. Stefan N. Symeonides reports having served as a consultant or adviser for Bicycle Therapeutics, Bristol Myers Squibb, Boxer Capital, Duke Street Bio, Eisai, Ellipses Pharma, EMD Serono, EUSA Pharma, MedAnnex, MSD, Pfizer, and Vaccitech; having served as a speaker for Bristol Myers Squibb, EUSA  Pharma, and Ipsen; research funding paid to institution from BiolineRx, BioNTech, Boston Pharmaceuticals, Incyte, MSD, Nouscom, Nucana, Roche, Sapience Therapeutics, Scancell, Sierra Oncology, and Verastem; and travel, accommodations, and expenses from Bristol Myers Squibb, EUSA Pharma, and Ipsen. Howard Gurney reports personal speaker fees from MSD; and personal advisory fees from MSD, Roche, Merck, Bristol Myers Squibb, Pfizer, and Ipsen. Jae Lyun Lee reports honoraria from Astellas Pharma, AstraZeneca, Bristol Myers Squibb, MSD, and Pfizer; having served as an advisr or consultant for Alteogen, AstraZeneca, BMS Korea, GI Innovation, Merck, MSD, Pfizer, and Sanofi/Aventis; research funding paid to institution from AstraZeneca/MedImmune, Bayer Schering Pharma, Bristol Myers Squibb, Janssen, MSD, Novartis, Pfizer, Roche/Genentech, and Seattle Genetics; and owns stock in Amgen, BeiGene, Black Diamond Therapeutics, Innovent Biologics, Johnson & Johnson/Janssen, Karyopharm Therapeutics, Merck, Myovant Sciences, and  Zymeworks. Naveed Sarwar reports having served as a consultant or adviser for Bristol Myers  Squibb, Eisai, EUSA Pharma, MSD, and Roche; having served as a speaker for Pfizer; and research funding from MSD. Antoine Thiery-Vuillemin-V reports honoraria from Astellas Pharma, AstraZeneca, Bristol Myers Squibb, Ipsen, Janssen, MSD, Novartis, Pfizer, Roche/Genentech, and Sanofi; having served as a consultant for Astellas Pharma, AstraZeneca, Bristol Myers Squibb, Ipsen, Janssen, MSD, Novartis, Pfizer, Roche,  and Sanofi; research funding paid to institution from Pfizer; and travel, accommodations, and expenses from Astellas Pharma, AstraZeneca, Bristol Myers Squibb, Ipsen, Janssen, MSD, Pfizer, and Roche. MG-G reports having served as a consultant or adviser for Amgen, Astellas Medivation, AstraZeneca, Bayer/Onyx, Bristol Myers Squibb, Ipsen, Janssen-Cilag, MSD Oncology, Pfizer, Roche, and Sanofi; research funding paid to institution from AstraZeneca, Ipsen, Janssen-Cilag, Merck, MSD Oncology, Pfizer, and Roche; and travel, accommodations, and expenses from Astellas Pharma, AstraZeneca, AstraZeneca, Ipsen, Janssen-Cilag, Pfizer, and Roche. MM reports research funding from MSD. NBH reports having served as a consultant or adviser for AVEO, Calithera Biosciences, Eisai, Exelixis, MSD, Pfizer, and Roche/Genentech; and has provided  expert testimony for Lilly. PS reports honoraria from Bristol Myers Squibb and Novartis; research funding paid to institution from Boehringer Ingelheim, Chiltern, G1 Therapeutics, Gilead Sciences, Merrimack, MSD, Parexel, PAREXEL/Puma Biotechnology, PPD Global, Regeneron, and Tesaro; and travel, accommodations, and expenses from Pierre Fabre and Roche. JEB and LX are employees of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co, Inc, Rahway, NJ, USA. KI is an employee of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co, Inc, and owns stock in Merck & Co, Inc, Rahway, NJ, USA. DIQ reports having served as a consultant or adviser  for Astellas Pharma, AstraZeneca, Bayer, Bristol Myers Squibb, Eisai, Exelixis, Genentech/Roche, Janssen Oncology, MSD, Myovant Sciences, Novartis, Pfizer, Seattle Genetics, and US Biotest; honoraria from Astellas Pharma, AstraZeneca, Bayer, Bristol Myers Squibb, Exelixis, Genentech/Roche, MSD, Myovant Sciences, Novartis, Pfizer, and Seattle Genetics; research funding paid to institution from Genentech/Roche, Merck, and Pfizer; and travel, accommodations, and expenses from Astellas Pharma, Bayer, Bristol Myers Squibb Japan, Exelexis, Merck, and Roche. TKC reports institutional and personal support, paid and unpaid support for research, participating in advisory boards, consultancy, and honoraria from AstraZeneca, Aravive, Aveo, Bayer, Bristol Myers Squibb, Calithera, Circle Pharma, Eisai, EMD Serono, Exelixis, GlaxoSmithKline, IQVA, Infinity, Ipsen, Jansen, Kanaph, Lilly, Merck, Nikang, Nuscan, Novartis, Pfizer, Roche, Sanofi/Aventis, Surface Oncology, Takeda, Tempest, UpToDate, and CME events (Peerview, OncLive, and MJaroslav Hajek), outside the submitted work; institutional patents filed on molecular mutations, immunotherapy response and toxicity, and ctDNA; equity in Tempest, Pionyr, Osel, Precede Bio; being part of committees in the National Comprehensive Cancer Network, GU Steering Committee, American Society of Clinical Oncology, European Society for Medical Oncology, Academic and Community  Cancer Research United, and KidneyCAN; having mentored several non-US citizens on research projects partly funded by non-US sources; and additional independent funding from drug companies or royalties for research around the subject matter paid to institution. All other authors declare no competing interests.\n",
      "\n",
      "Gross-Goupil, Marine\n",
      "Declaration of interests Thomas Powles reports having served as a consultant or adviser for  Astellas Pharma, AstraZeneca, Bristol Myers Squibb, Eisai, Exelixis, Incyte, Ipsen, Johnson & Johnson, Merck, Merck Serono, MSD, Novartis, Pfizer, Roche, and  Seattle Genetics; honoraria from Astellas Pharma, AstraZeneca, Bristol Myers Squibb, Eisai, Exelixis, Incyte, Ipsen, Johnson & Johnson, Merck, Merck Serono, MSD, Novartis, Pfizer, Roche, and Seattle Genetics; research funding paid to institution from Astellas Pharma, AstraZeneca, Bristol Myers Squibb, Eisai, Exelixis, Ipsen, Johnson & Johnson, Merck, Merck Serono, MSD, Novartis, Pfizer, Roche, and Seattle Genetics; and travel, accommodations, and expenses from AstraZeneca, Ipsen, MSD, Pfizer, and Roche. Piotr Tomczak reports research funding from MSD. Se Hoon Park reports having served as a consultant or adviser for Janssen Oncology and Lilly; and research funding from Ono Pharmaceutical. Bxports having served as a consultant or adviser for Bristol Myers Squibb, MSD Oncology, and Pfizer/EMD Serono; honoraria from Bristol Myers Squibb, Eisai, EUSA Pharma, Ipsen, Merck, MSD Oncology, and Pfizer; research funding paid to institution from Calithera Biosciences, Ipsen, MSD Oncology, and Pfizer/EMD Serono; serving as a speaker for Eisai, MSD Oncology, and Pfizer; and travel, accommodations, and expenses from EUSA Pharma and Ipsen. Thomas Ferguson reports research funding paid to institution from AstraZeneca, Janssen, and MSD; and travel, accommodations, and expenses from Bristol Myers Squibb, MSD, and Roche. Stefan N. Symeonides reports having served as a consultant or adviser for Bicycle Therapeutics, Bristol Myers Squibb, Boxer Capital, Duke Street Bio, Eisai, Ellipses Pharma, EMD Serono, EUSA Pharma, MedAnnex, MSD, Pfizer, and Vaccitech; having served as a speaker for Bristol Myers Squibb, EUSA  Pharma, and Ipsen; research funding paid to institution from BiolineRx, BioNTech, Boston Pharmaceuticals, Incyte, MSD, Nouscom, Nucana, Roche, Sapience Therapeutics, Scancell, Sierra Oncology, and Verastem; and travel, accommodations, and expenses from Bristol Myers Squibb, EUSA Pharma, and Ipsen. Howard Gurney reports personal speaker fees from MSD; and personal advisory fees from MSD, Roche, Merck, Bristol Myers Squibb, Pfizer, and Ipsen. Jae Lyun Lee reports honoraria from Astellas Pharma, AstraZeneca, Bristol Myers Squibb, MSD, and Pfizer; having served as an advisr or consultant for Alteogen, AstraZeneca, BMS Korea, GI Innovation, Merck, MSD, Pfizer, and Sanofi/Aventis; research funding paid to institution from AstraZeneca/MedImmune, Bayer Schering Pharma, Bristol Myers Squibb, Janssen, MSD, Novartis, Pfizer, Roche/Genentech, and Seattle Genetics; and owns stock in Amgen, BeiGene, Black Diamond Therapeutics, Innovent Biologics, Johnson & Johnson/Janssen, Karyopharm Therapeutics, Merck, Myovant Sciences, and  Zymeworks. Naveed Sarwar reports having served as a consultant or adviser for Bristol Myers  Squibb, Eisai, EUSA Pharma, MSD, and Roche; having served as a speaker for Pfizer; and research funding from MSD. Antoine Thiery-Vuillemin-V reports honoraria from Astellas Pharma, AstraZeneca, Bristol Myers Squibb, Ipsen, Janssen, MSD, Novartis, Pfizer, Roche/Genentech, and Sanofi; having served as a consultant for Astellas Pharma, AstraZeneca, Bristol Myers Squibb, Ipsen, Janssen, MSD, Novartis, Pfizer, Roche,  and Sanofi; research funding paid to institution from Pfizer; and travel, accommodations, and expenses from Astellas Pharma, AstraZeneca, Bristol Myers Squibb, Ipsen, Janssen, MSD, Pfizer, and Roche. Marine Gross-Goupil-G reports having served as a consultant or adviser for Amgen, Astellas Medivation, AstraZeneca, Bayer/Onyx, Bristol Myers Squibb, Ipsen, Janssen-Cilag, MSD Oncology, Pfizer, Roche, and Sanofi; research funding paid to institution from AstraZeneca, Ipsen, Janssen-Cilag, Merck, MSD Oncology, Pfizer, and Roche; and travel, accommodations, and expenses from Astellas Pharma, AstraZeneca, AstraZeneca, Ipsen, Janssen-Cilag, Pfizer, and Roche. MM reports research funding from MSD. NBH reports having served as a consultant or adviser for AVEO, Calithera Biosciences, Eisai, Exelixis, MSD, Pfizer, and Roche/Genentech; and has provided  expert testimony for Lilly. PS reports honoraria from Bristol Myers Squibb and Novartis; research funding paid to institution from Boehringer Ingelheim, Chiltern, G1 Therapeutics, Gilead Sciences, Merrimack, MSD, Parexel, PAREXEL/Puma Biotechnology, PPD Global, Regeneron, and Tesaro; and travel, accommodations, and expenses from Pierre Fabre and Roche. JEB and LX are employees of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co, Inc, Rahway, NJ, USA. KI is an employee of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co, Inc, and owns stock in Merck & Co, Inc, Rahway, NJ, USA. DIQ reports having served as a consultant or adviser  for Astellas Pharma, AstraZeneca, Bayer, Bristol Myers Squibb, Eisai, Exelixis, Genentech/Roche, Janssen Oncology, MSD, Myovant Sciences, Novartis, Pfizer, Seattle Genetics, and US Biotest; honoraria from Astellas Pharma, AstraZeneca, Bayer, Bristol Myers Squibb, Exelixis, Genentech/Roche, MSD, Myovant Sciences, Novartis, Pfizer, and Seattle Genetics; research funding paid to institution from Genentech/Roche, Merck, and Pfizer; and travel, accommodations, and expenses from Astellas Pharma, Bayer, Bristol Myers Squibb Japan, Exelexis, Merck, and Roche. TKC reports institutional and personal support, paid and unpaid support for research, participating in advisory boards, consultancy, and honoraria from AstraZeneca, Aravive, Aveo, Bayer, Bristol Myers Squibb, Calithera, Circle Pharma, Eisai, EMD Serono, Exelixis, GlaxoSmithKline, IQVA, Infinity, Ipsen, Jansen, Kanaph, Lilly, Merck, Nikang, Nuscan, Novartis, Pfizer, Roche, Sanofi/Aventis, Surface Oncology, Takeda, Tempest, UpToDate, and CME events (Peerview, OncLive, and MJaroslav Hajek), outside the submitted work; institutional patents filed on molecular mutations, immunotherapy response and toxicity, and ctDNA; equity in Tempest, Pionyr, Osel, Precede Bio; being part of committees in the National Comprehensive Cancer Network, GU Steering Committee, American Society of Clinical Oncology, European Society for Medical Oncology, Academic and Community  Cancer Research United, and KidneyCAN; having mentored several non-US citizens on research projects partly funded by non-US sources; and additional independent funding from drug companies or royalties for research around the subject matter paid to institution. All other authors declare no competing interests.\n",
      "\n",
      "Mahave, Mauricio\n",
      "Declaration of interests Thomas Powles reports having served as a consultant or adviser for  Astellas Pharma, AstraZeneca, Bristol Myers Squibb, Eisai, Exelixis, Incyte, Ipsen, Johnson & Johnson, Merck, Merck Serono, MSD, Novartis, Pfizer, Roche, and  Seattle Genetics; honoraria from Astellas Pharma, AstraZeneca, Bristol Myers Squibb, Eisai, Exelixis, Incyte, Ipsen, Johnson & Johnson, Merck, Merck Serono, MSD, Novartis, Pfizer, Roche, and Seattle Genetics; research funding paid to institution from Astellas Pharma, AstraZeneca, Bristol Myers Squibb, Eisai, Exelixis, Ipsen, Johnson & Johnson, Merck, Merck Serono, MSD, Novartis, Pfizer, Roche, and Seattle Genetics; and travel, accommodations, and expenses from AstraZeneca, Ipsen, MSD, Pfizer, and Roche. Piotr Tomczak reports research funding from MSD. Se Hoon Park reports having served as a consultant or adviser for Janssen Oncology and Lilly; and research funding from Ono Pharmaceutical. Bxports having served as a consultant or adviser for Bristol Myers Squibb, MSD Oncology, and Pfizer/EMD Serono; honoraria from Bristol Myers Squibb, Eisai, EUSA Pharma, Ipsen, Merck, MSD Oncology, and Pfizer; research funding paid to institution from Calithera Biosciences, Ipsen, MSD Oncology, and Pfizer/EMD Serono; serving as a speaker for Eisai, MSD Oncology, and Pfizer; and travel, accommodations, and expenses from EUSA Pharma and Ipsen. Thomas Ferguson reports research funding paid to institution from AstraZeneca, Janssen, and MSD; and travel, accommodations, and expenses from Bristol Myers Squibb, MSD, and Roche. Stefan N. Symeonides reports having served as a consultant or adviser for Bicycle Therapeutics, Bristol Myers Squibb, Boxer Capital, Duke Street Bio, Eisai, Ellipses Pharma, EMD Serono, EUSA Pharma, MedAnnex, MSD, Pfizer, and Vaccitech; having served as a speaker for Bristol Myers Squibb, EUSA  Pharma, and Ipsen; research funding paid to institution from BiolineRx, BioNTech, Boston Pharmaceuticals, Incyte, MSD, Nouscom, Nucana, Roche, Sapience Therapeutics, Scancell, Sierra Oncology, and Verastem; and travel, accommodations, and expenses from Bristol Myers Squibb, EUSA Pharma, and Ipsen. Howard Gurney reports personal speaker fees from MSD; and personal advisory fees from MSD, Roche, Merck, Bristol Myers Squibb, Pfizer, and Ipsen. Jae Lyun Lee reports honoraria from Astellas Pharma, AstraZeneca, Bristol Myers Squibb, MSD, and Pfizer; having served as an advisr or consultant for Alteogen, AstraZeneca, BMS Korea, GI Innovation, Merck, MSD, Pfizer, and Sanofi/Aventis; research funding paid to institution from AstraZeneca/MedImmune, Bayer Schering Pharma, Bristol Myers Squibb, Janssen, MSD, Novartis, Pfizer, Roche/Genentech, and Seattle Genetics; and owns stock in Amgen, BeiGene, Black Diamond Therapeutics, Innovent Biologics, Johnson & Johnson/Janssen, Karyopharm Therapeutics, Merck, Myovant Sciences, and  Zymeworks. Naveed Sarwar reports having served as a consultant or adviser for Bristol Myers  Squibb, Eisai, EUSA Pharma, MSD, and Roche; having served as a speaker for Pfizer; and research funding from MSD. Antoine Thiery-Vuillemin-V reports honoraria from Astellas Pharma, AstraZeneca, Bristol Myers Squibb, Ipsen, Janssen, MSD, Novartis, Pfizer, Roche/Genentech, and Sanofi; having served as a consultant for Astellas Pharma, AstraZeneca, Bristol Myers Squibb, Ipsen, Janssen, MSD, Novartis, Pfizer, Roche,  and Sanofi; research funding paid to institution from Pfizer; and travel, accommodations, and expenses from Astellas Pharma, AstraZeneca, Bristol Myers Squibb, Ipsen, Janssen, MSD, Pfizer, and Roche. Marine Gross-Goupil-G reports having served as a consultant or adviser for Amgen, Astellas Medivation, AstraZeneca, Bayer/Onyx, Bristol Myers Squibb, Ipsen, Janssen-Cilag, MSD Oncology, Pfizer, Roche, and Sanofi; research funding paid to institution from AstraZeneca, Ipsen, Janssen-Cilag, Merck, MSD Oncology, Pfizer, and Roche; and travel, accommodations, and expenses from Astellas Pharma, AstraZeneca, AstraZeneca, Ipsen, Janssen-Cilag, Pfizer, and Roche. Mauricio Mahave reports research funding from MSD. NBH reports having served as a consultant or adviser for AVEO, Calithera Biosciences, Eisai, Exelixis, MSD, Pfizer, and Roche/Genentech; and has provided  expert testimony for Lilly. PS reports honoraria from Bristol Myers Squibb and Novartis; research funding paid to institution from Boehringer Ingelheim, Chiltern, G1 Therapeutics, Gilead Sciences, Merrimack, MSD, Parexel, PAREXEL/Puma Biotechnology, PPD Global, Regeneron, and Tesaro; and travel, accommodations, and expenses from Pierre Fabre and Roche. JEB and LX are employees of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co, Inc, Rahway, NJ, USA. KI is an employee of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co, Inc, and owns stock in Merck & Co, Inc, Rahway, NJ, USA. DIQ reports having served as a consultant or adviser  for Astellas Pharma, AstraZeneca, Bayer, Bristol Myers Squibb, Eisai, Exelixis, Genentech/Roche, Janssen Oncology, MSD, Myovant Sciences, Novartis, Pfizer, Seattle Genetics, and US Biotest; honoraria from Astellas Pharma, AstraZeneca, Bayer, Bristol Myers Squibb, Exelixis, Genentech/Roche, MSD, Myovant Sciences, Novartis, Pfizer, and Seattle Genetics; research funding paid to institution from Genentech/Roche, Merck, and Pfizer; and travel, accommodations, and expenses from Astellas Pharma, Bayer, Bristol Myers Squibb Japan, Exelexis, Merck, and Roche. TKC reports institutional and personal support, paid and unpaid support for research, participating in advisory boards, consultancy, and honoraria from AstraZeneca, Aravive, Aveo, Bayer, Bristol Myers Squibb, Calithera, Circle Pharma, Eisai, EMD Serono, Exelixis, GlaxoSmithKline, IQVA, Infinity, Ipsen, Jansen, Kanaph, Lilly, Merck, Nikang, Nuscan, Novartis, Pfizer, Roche, Sanofi/Aventis, Surface Oncology, Takeda, Tempest, UpToDate, and CME events (Peerview, OncLive, and MJaroslav Hajek), outside the submitted work; institutional patents filed on molecular mutations, immunotherapy response and toxicity, and ctDNA; equity in Tempest, Pionyr, Osel, Precede Bio; being part of committees in the National Comprehensive Cancer Network, GU Steering Committee, American Society of Clinical Oncology, European Society for Medical Oncology, Academic and Community  Cancer Research United, and KidneyCAN; having mentored several non-US citizens on research projects partly funded by non-US sources; and additional independent funding from drug companies or royalties for research around the subject matter paid to institution. All other authors declare no competing interests.\n",
      "\n",
      "Haas, Naomi B.\n",
      "Declaration of interests Thomas Powles reports having served as a consultant or adviser for  Astellas Pharma, AstraZeneca, Bristol Myers Squibb, Eisai, Exelixis, Incyte, Ipsen, Johnson & Johnson, Merck, Merck Serono, MSD, Novartis, Pfizer, Roche, and  Seattle Genetics; honoraria from Astellas Pharma, AstraZeneca, Bristol Myers Squibb, Eisai, Exelixis, Incyte, Ipsen, Johnson & Johnson, Merck, Merck Serono, MSD, Novartis, Pfizer, Roche, and Seattle Genetics; research funding paid to institution from Astellas Pharma, AstraZeneca, Bristol Myers Squibb, Eisai, Exelixis, Ipsen, Johnson & Johnson, Merck, Merck Serono, MSD, Novartis, Pfizer, Roche, and Seattle Genetics; and travel, accommodations, and expenses from AstraZeneca, Ipsen, MSD, Pfizer, and Roche. Piotr Tomczak reports research funding from MSD. Se Hoon Park reports having served as a consultant or adviser for Janssen Oncology and Lilly; and research funding from Ono Pharmaceutical. Bxports having served as a consultant or adviser for Bristol Myers Squibb, MSD Oncology, and Pfizer/EMD Serono; honoraria from Bristol Myers Squibb, Eisai, EUSA Pharma, Ipsen, Merck, MSD Oncology, and Pfizer; research funding paid to institution from Calithera Biosciences, Ipsen, MSD Oncology, and Pfizer/EMD Serono; serving as a speaker for Eisai, MSD Oncology, and Pfizer; and travel, accommodations, and expenses from EUSA Pharma and Ipsen. Thomas Ferguson reports research funding paid to institution from AstraZeneca, Janssen, and MSD; and travel, accommodations, and expenses from Bristol Myers Squibb, MSD, and Roche. Stefan N. Symeonides reports having served as a consultant or adviser for Bicycle Therapeutics, Bristol Myers Squibb, Boxer Capital, Duke Street Bio, Eisai, Ellipses Pharma, EMD Serono, EUSA Pharma, MedAnnex, MSD, Pfizer, and Vaccitech; having served as a speaker for Bristol Myers Squibb, EUSA  Pharma, and Ipsen; research funding paid to institution from BiolineRx, BioNTech, Boston Pharmaceuticals, Incyte, MSD, Nouscom, Nucana, Roche, Sapience Therapeutics, Scancell, Sierra Oncology, and Verastem; and travel, accommodations, and expenses from Bristol Myers Squibb, EUSA Pharma, and Ipsen. Howard Gurney reports personal speaker fees from MSD; and personal advisory fees from MSD, Roche, Merck, Bristol Myers Squibb, Pfizer, and Ipsen. Jae Lyun Lee reports honoraria from Astellas Pharma, AstraZeneca, Bristol Myers Squibb, MSD, and Pfizer; having served as an advisr or consultant for Alteogen, AstraZeneca, BMS Korea, GI Innovation, Merck, MSD, Pfizer, and Sanofi/Aventis; research funding paid to institution from AstraZeneca/MedImmune, Bayer Schering Pharma, Bristol Myers Squibb, Janssen, MSD, Novartis, Pfizer, Roche/Genentech, and Seattle Genetics; and owns stock in Amgen, BeiGene, Black Diamond Therapeutics, Innovent Biologics, Johnson & Johnson/Janssen, Karyopharm Therapeutics, Merck, Myovant Sciences, and  Zymeworks. Naveed Sarwar reports having served as a consultant or adviser for Bristol Myers  Squibb, Eisai, EUSA Pharma, MSD, and Roche; having served as a speaker for Pfizer; and research funding from MSD. Antoine Thiery-Vuillemin-V reports honoraria from Astellas Pharma, AstraZeneca, Bristol Myers Squibb, Ipsen, Janssen, MSD, Novartis, Pfizer, Roche/Genentech, and Sanofi; having served as a consultant for Astellas Pharma, AstraZeneca, Bristol Myers Squibb, Ipsen, Janssen, MSD, Novartis, Pfizer, Roche,  and Sanofi; research funding paid to institution from Pfizer; and travel, accommodations, and expenses from Astellas Pharma, AstraZeneca, Bristol Myers Squibb, Ipsen, Janssen, MSD, Pfizer, and Roche. Marine Gross-Goupil-G reports having served as a consultant or adviser for Amgen, Astellas Medivation, AstraZeneca, Bayer/Onyx, Bristol Myers Squibb, Ipsen, Janssen-Cilag, MSD Oncology, Pfizer, Roche, and Sanofi; research funding paid to institution from AstraZeneca, Ipsen, Janssen-Cilag, Merck, MSD Oncology, Pfizer, and Roche; and travel, accommodations, and expenses from Astellas Pharma, AstraZeneca, AstraZeneca, Ipsen, Janssen-Cilag, Pfizer, and Roche. Mauricio Mahave reports research funding from MSD. Naomi B. Haas reports having served as a consultant or adviser for AVEO, Calithera Biosciences, Eisai, Exelixis, MSD, Pfizer, and Roche/Genentech; and has provided  expert testimony for Lilly. PS reports honoraria from Bristol Myers Squibb and Novartis; research funding paid to institution from Boehringer Ingelheim, Chiltern, G1 Therapeutics, Gilead Sciences, Merrimack, MSD, Parexel, PAREXEL/Puma Biotechnology, PPD Global, Regeneron, and Tesaro; and travel, accommodations, and expenses from Pierre Fabre and Roche. JEB and LX are employees of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co, Inc, Rahway, NJ, USA. KI is an employee of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co, Inc, and owns stock in Merck & Co, Inc, Rahway, NJ, USA. DIQ reports having served as a consultant or adviser  for Astellas Pharma, AstraZeneca, Bayer, Bristol Myers Squibb, Eisai, Exelixis, Genentech/Roche, Janssen Oncology, MSD, Myovant Sciences, Novartis, Pfizer, Seattle Genetics, and US Biotest; honoraria from Astellas Pharma, AstraZeneca, Bayer, Bristol Myers Squibb, Exelixis, Genentech/Roche, MSD, Myovant Sciences, Novartis, Pfizer, and Seattle Genetics; research funding paid to institution from Genentech/Roche, Merck, and Pfizer; and travel, accommodations, and expenses from Astellas Pharma, Bayer, Bristol Myers Squibb Japan, Exelexis, Merck, and Roche. TKC reports institutional and personal support, paid and unpaid support for research, participating in advisory boards, consultancy, and honoraria from AstraZeneca, Aravive, Aveo, Bayer, Bristol Myers Squibb, Calithera, Circle Pharma, Eisai, EMD Serono, Exelixis, GlaxoSmithKline, IQVA, Infinity, Ipsen, Jansen, Kanaph, Lilly, Merck, Nikang, Nuscan, Novartis, Pfizer, Roche, Sanofi/Aventis, Surface Oncology, Takeda, Tempest, UpToDate, and CME events (Peerview, OncLive, and MJaroslav Hajek), outside the submitted work; institutional patents filed on molecular mutations, immunotherapy response and toxicity, and ctDNA; equity in Tempest, Pionyr, Osel, Precede Bio; being part of committees in the National Comprehensive Cancer Network, GU Steering Committee, American Society of Clinical Oncology, European Society for Medical Oncology, Academic and Community  Cancer Research United, and KidneyCAN; having mentored several non-US citizens on research projects partly funded by non-US sources; and additional independent funding from drug companies or royalties for research around the subject matter paid to institution. All other authors declare no competing interests.\n",
      "\n",
      "Sawrycki, Piotr\n",
      "Declaration of interests Thomas Powles reports having served as a consultant or adviser for  Astellas Pharma, AstraZeneca, Bristol Myers Squibb, Eisai, Exelixis, Incyte, Ipsen, Johnson & Johnson, Merck, Merck Serono, MSD, Novartis, Pfizer, Roche, and  Seattle Genetics; honoraria from Astellas Pharma, AstraZeneca, Bristol Myers Squibb, Eisai, Exelixis, Incyte, Ipsen, Johnson & Johnson, Merck, Merck Serono, MSD, Novartis, Pfizer, Roche, and Seattle Genetics; research funding paid to institution from Astellas Pharma, AstraZeneca, Bristol Myers Squibb, Eisai, Exelixis, Ipsen, Johnson & Johnson, Merck, Merck Serono, MSD, Novartis, Pfizer, Roche, and Seattle Genetics; and travel, accommodations, and expenses from AstraZeneca, Ipsen, MSD, Pfizer, and Roche. Piotr Tomczak reports research funding from MSD. Se Hoon Park reports having served as a consultant or adviser for Janssen Oncology and Lilly; and research funding from Ono Pharmaceutical. Bxports having served as a consultant or adviser for Bristol Myers Squibb, MSD Oncology, and Pfizer/EMD Serono; honoraria from Bristol Myers Squibb, Eisai, EUSA Pharma, Ipsen, Merck, MSD Oncology, and Pfizer; research funding paid to institution from Calithera Biosciences, Ipsen, MSD Oncology, and Pfizer/EMD Serono; serving as a speaker for Eisai, MSD Oncology, and Pfizer; and travel, accommodations, and expenses from EUSA Pharma and Ipsen. Thomas Ferguson reports research funding paid to institution from AstraZeneca, Janssen, and MSD; and travel, accommodations, and expenses from Bristol Myers Squibb, MSD, and Roche. Stefan N. Symeonides reports having served as a consultant or adviser for Bicycle Therapeutics, Bristol Myers Squibb, Boxer Capital, Duke Street Bio, Eisai, Ellipses Pharma, EMD Serono, EUSA Pharma, MedAnnex, MSD, Pfizer, and Vaccitech; having served as a speaker for Bristol Myers Squibb, EUSA  Pharma, and Ipsen; research funding paid to institution from BiolineRx, BioNTech, Boston Pharmaceuticals, Incyte, MSD, Nouscom, Nucana, Roche, Sapience Therapeutics, Scancell, Sierra Oncology, and Verastem; and travel, accommodations, and expenses from Bristol Myers Squibb, EUSA Pharma, and Ipsen. Howard Gurney reports personal speaker fees from MSD; and personal advisory fees from MSD, Roche, Merck, Bristol Myers Squibb, Pfizer, and Ipsen. Jae Lyun Lee reports honoraria from Astellas Pharma, AstraZeneca, Bristol Myers Squibb, MSD, and Pfizer; having served as an advisr or consultant for Alteogen, AstraZeneca, BMS Korea, GI Innovation, Merck, MSD, Pfizer, and Sanofi/Aventis; research funding paid to institution from AstraZeneca/MedImmune, Bayer Schering Pharma, Bristol Myers Squibb, Janssen, MSD, Novartis, Pfizer, Roche/Genentech, and Seattle Genetics; and owns stock in Amgen, BeiGene, Black Diamond Therapeutics, Innovent Biologics, Johnson & Johnson/Janssen, Karyopharm Therapeutics, Merck, Myovant Sciences, and  Zymeworks. Naveed Sarwar reports having served as a consultant or adviser for Bristol Myers  Squibb, Eisai, EUSA Pharma, MSD, and Roche; having served as a speaker for Pfizer; and research funding from MSD. Antoine Thiery-Vuillemin-V reports honoraria from Astellas Pharma, AstraZeneca, Bristol Myers Squibb, Ipsen, Janssen, MSD, Novartis, Pfizer, Roche/Genentech, and Sanofi; having served as a consultant for Astellas Pharma, AstraZeneca, Bristol Myers Squibb, Ipsen, Janssen, MSD, Novartis, Pfizer, Roche,  and Sanofi; research funding paid to institution from Pfizer; and travel, accommodations, and expenses from Astellas Pharma, AstraZeneca, Bristol Myers Squibb, Ipsen, Janssen, MSD, Pfizer, and Roche. Marine Gross-Goupil-G reports having served as a consultant or adviser for Amgen, Astellas Medivation, AstraZeneca, Bayer/Onyx, Bristol Myers Squibb, Ipsen, Janssen-Cilag, MSD Oncology, Pfizer, Roche, and Sanofi; research funding paid to institution from AstraZeneca, Ipsen, Janssen-Cilag, Merck, MSD Oncology, Pfizer, and Roche; and travel, accommodations, and expenses from Astellas Pharma, AstraZeneca, AstraZeneca, Ipsen, Janssen-Cilag, Pfizer, and Roche. Mauricio Mahave reports research funding from MSD. Naomi B. Haas reports having served as a consultant or adviser for AVEO, Calithera Biosciences, Eisai, Exelixis, MSD, Pfizer, and Roche/Genentech; and has provided  expert testimony for Lilly. Piotr Sawrycki reports honoraria from Bristol Myers Squibb and Novartis; research funding paid to institution from Boehringer Ingelheim, Chiltern, G1 Therapeutics, Gilead Sciences, Merrimack, MSD, Parexel, PAREXEL/Puma Biotechnology, PPD Global, Regeneron, and Tesaro; and travel, accommodations, and expenses from Pierre Fabre and Roche. JEB and LX are employees of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co, Inc, Rahway, NJ, USA. KI is an employee of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co, Inc, and owns stock in Merck & Co, Inc, Rahway, NJ, USA. DIQ reports having served as a consultant or adviser  for Astellas Pharma, AstraZeneca, Bayer, Bristol Myers Squibb, Eisai, Exelixis, Genentech/Roche, Janssen Oncology, MSD, Myovant Sciences, Novartis, Pfizer, Seattle Genetics, and US Biotest; honoraria from Astellas Pharma, AstraZeneca, Bayer, Bristol Myers Squibb, Exelixis, Genentech/Roche, MSD, Myovant Sciences, Novartis, Pfizer, and Seattle Genetics; research funding paid to institution from Genentech/Roche, Merck, and Pfizer; and travel, accommodations, and expenses from Astellas Pharma, Bayer, Bristol Myers Squibb Japan, Exelexis, Merck, and Roche. TKC reports institutional and personal support, paid and unpaid support for research, participating in advisory boards, consultancy, and honoraria from AstraZeneca, Aravive, Aveo, Bayer, Bristol Myers Squibb, Calithera, Circle Pharma, Eisai, EMD Serono, Exelixis, GlaxoSmithKline, IQVA, Infinity, Ipsen, Jansen, Kanaph, Lilly, Merck, Nikang, Nuscan, Novartis, Pfizer, Roche, Sanofi/Aventis, Surface Oncology, Takeda, Tempest, UpToDate, and CME events (Peerview, OncLive, and MJaroslav Hajek), outside the submitted work; institutional patents filed on molecular mutations, immunotherapy response and toxicity, and ctDNA; equity in Tempest, Pionyr, Osel, Precede Bio; being part of committees in the National Comprehensive Cancer Network, GU Steering Committee, American Society of Clinical Oncology, European Society for Medical Oncology, Academic and Community  Cancer Research United, and KidneyCAN; having mentored several non-US citizens on research projects partly funded by non-US sources; and additional independent funding from drug companies or royalties for research around the subject matter paid to institution. All other authors declare no competing interests.\n",
      "\n",
      "Burgents, Joseph E.\n",
      "Declaration of interests Thomas Powles reports having served as a consultant or adviser for  Astellas Pharma, AstraZeneca, Bristol Myers Squibb, Eisai, Exelixis, Incyte, Ipsen, Johnson & Johnson, Merck, Merck Serono, MSD, Novartis, Pfizer, Roche, and  Seattle Genetics; honoraria from Astellas Pharma, AstraZeneca, Bristol Myers Squibb, Eisai, Exelixis, Incyte, Ipsen, Johnson & Johnson, Merck, Merck Serono, MSD, Novartis, Pfizer, Roche, and Seattle Genetics; research funding paid to institution from Astellas Pharma, AstraZeneca, Bristol Myers Squibb, Eisai, Exelixis, Ipsen, Johnson & Johnson, Merck, Merck Serono, MSD, Novartis, Pfizer, Roche, and Seattle Genetics; and travel, accommodations, and expenses from AstraZeneca, Ipsen, MSD, Pfizer, and Roche. Piotr Tomczak reports research funding from MSD. Se Hoon Park reports having served as a consultant or adviser for Janssen Oncology and Lilly; and research funding from Ono Pharmaceutical. Bxports having served as a consultant or adviser for Bristol Myers Squibb, MSD Oncology, and Pfizer/EMD Serono; honoraria from Bristol Myers Squibb, Eisai, EUSA Pharma, Ipsen, Merck, MSD Oncology, and Pfizer; research funding paid to institution from Calithera Biosciences, Ipsen, MSD Oncology, and Pfizer/EMD Serono; serving as a speaker for Eisai, MSD Oncology, and Pfizer; and travel, accommodations, and expenses from EUSA Pharma and Ipsen. Thomas Ferguson reports research funding paid to institution from AstraZeneca, Janssen, and MSD; and travel, accommodations, and expenses from Bristol Myers Squibb, MSD, and Roche. Stefan N. Symeonides reports having served as a consultant or adviser for Bicycle Therapeutics, Bristol Myers Squibb, Boxer Capital, Duke Street Bio, Eisai, Ellipses Pharma, EMD Serono, EUSA Pharma, MedAnnex, MSD, Pfizer, and Vaccitech; having served as a speaker for Bristol Myers Squibb, EUSA  Pharma, and Ipsen; research funding paid to institution from BiolineRx, BioNTech, Boston Pharmaceuticals, Incyte, MSD, Nouscom, Nucana, Roche, Sapience Therapeutics, Scancell, Sierra Oncology, and Verastem; and travel, accommodations, and expenses from Bristol Myers Squibb, EUSA Pharma, and Ipsen. Howard Gurney reports personal speaker fees from MSD; and personal advisory fees from MSD, Roche, Merck, Bristol Myers Squibb, Pfizer, and Ipsen. Jae Lyun Lee reports honoraria from Astellas Pharma, AstraZeneca, Bristol Myers Squibb, MSD, and Pfizer; having served as an advisr or consultant for Alteogen, AstraZeneca, BMS Korea, GI Innovation, Merck, MSD, Pfizer, and Sanofi/Aventis; research funding paid to institution from AstraZeneca/MedImmune, Bayer Schering Pharma, Bristol Myers Squibb, Janssen, MSD, Novartis, Pfizer, Roche/Genentech, and Seattle Genetics; and owns stock in Amgen, BeiGene, Black Diamond Therapeutics, Innovent Biologics, Johnson & Johnson/Janssen, Karyopharm Therapeutics, Merck, Myovant Sciences, and  Zymeworks. Naveed Sarwar reports having served as a consultant or adviser for Bristol Myers  Squibb, Eisai, EUSA Pharma, MSD, and Roche; having served as a speaker for Pfizer; and research funding from MSD. Antoine Thiery-Vuillemin-V reports honoraria from Astellas Pharma, AstraZeneca, Bristol Myers Squibb, Ipsen, Janssen, MSD, Novartis, Pfizer, Roche/Genentech, and Sanofi; having served as a consultant for Astellas Pharma, AstraZeneca, Bristol Myers Squibb, Ipsen, Janssen, MSD, Novartis, Pfizer, Roche,  and Sanofi; research funding paid to institution from Pfizer; and travel, accommodations, and expenses from Astellas Pharma, AstraZeneca, Bristol Myers Squibb, Ipsen, Janssen, MSD, Pfizer, and Roche. Marine Gross-Goupil-G reports having served as a consultant or adviser for Amgen, Astellas Medivation, AstraZeneca, Bayer/Onyx, Bristol Myers Squibb, Ipsen, Janssen-Cilag, MSD Oncology, Pfizer, Roche, and Sanofi; research funding paid to institution from AstraZeneca, Ipsen, Janssen-Cilag, Merck, MSD Oncology, Pfizer, and Roche; and travel, accommodations, and expenses from Astellas Pharma, AstraZeneca, AstraZeneca, Ipsen, Janssen-Cilag, Pfizer, and Roche. Mauricio Mahave reports research funding from MSD. Naomi B. Haas reports having served as a consultant or adviser for AVEO, Calithera Biosciences, Eisai, Exelixis, MSD, Pfizer, and Roche/Genentech; and has provided  expert testimony for Lilly. Piotr Sawrycki reports honoraria from Bristol Myers Squibb and Novartis; research funding paid to institution from Boehringer Ingelheim, Chiltern, G1 Therapeutics, Gilead Sciences, Merrimack, MSD, Parexel, PAREXEL/Puma Biotechnology, PPD Global, Regeneron, and Tesaro; and travel, accommodations, and expenses from Pierre Fabre and Roche. Joseph E. Burgents and LX are employees of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co, Inc, Rahway, NJ, USA. KI is an employee of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co, Inc, and owns stock in Merck & Co, Inc, Rahway, NJ, USA. DIQ reports having served as a consultant or adviser  for Astellas Pharma, AstraZeneca, Bayer, Bristol Myers Squibb, Eisai, Exelixis, Genentech/Roche, Janssen Oncology, MSD, Myovant Sciences, Novartis, Pfizer, Seattle Genetics, and US Biotest; honoraria from Astellas Pharma, AstraZeneca, Bayer, Bristol Myers Squibb, Exelixis, Genentech/Roche, MSD, Myovant Sciences, Novartis, Pfizer, and Seattle Genetics; research funding paid to institution from Genentech/Roche, Merck, and Pfizer; and travel, accommodations, and expenses from Astellas Pharma, Bayer, Bristol Myers Squibb Japan, Exelexis, Merck, and Roche. TKC reports institutional and personal support, paid and unpaid support for research, participating in advisory boards, consultancy, and honoraria from AstraZeneca, Aravive, Aveo, Bayer, Bristol Myers Squibb, Calithera, Circle Pharma, Eisai, EMD Serono, Exelixis, GlaxoSmithKline, IQVA, Infinity, Ipsen, Jansen, Kanaph, Lilly, Merck, Nikang, Nuscan, Novartis, Pfizer, Roche, Sanofi/Aventis, Surface Oncology, Takeda, Tempest, UpToDate, and CME events (Peerview, OncLive, and MJaroslav Hajek), outside the submitted work; institutional patents filed on molecular mutations, immunotherapy response and toxicity, and ctDNA; equity in Tempest, Pionyr, Osel, Precede Bio; being part of committees in the National Comprehensive Cancer Network, GU Steering Committee, American Society of Clinical Oncology, European Society for Medical Oncology, Academic and Community  Cancer Research United, and KidneyCAN; having mentored several non-US citizens on research projects partly funded by non-US sources; and additional independent funding from drug companies or royalties for research around the subject matter paid to institution. All other authors declare no competing interests.\n",
      "\n",
      "Xu, Lei\n",
      "Declaration of interests Thomas Powles reports having served as a consultant or adviser for  Astellas Pharma, AstraZeneca, Bristol Myers Squibb, Eisai, Exelixis, Incyte, Ipsen, Johnson & Johnson, Merck, Merck Serono, MSD, Novartis, Pfizer, Roche, and  Seattle Genetics; honoraria from Astellas Pharma, AstraZeneca, Bristol Myers Squibb, Eisai, Exelixis, Incyte, Ipsen, Johnson & Johnson, Merck, Merck Serono, MSD, Novartis, Pfizer, Roche, and Seattle Genetics; research funding paid to institution from Astellas Pharma, AstraZeneca, Bristol Myers Squibb, Eisai, Exelixis, Ipsen, Johnson & Johnson, Merck, Merck Serono, MSD, Novartis, Pfizer, Roche, and Seattle Genetics; and travel, accommodations, and expenses from AstraZeneca, Ipsen, MSD, Pfizer, and Roche. Piotr Tomczak reports research funding from MSD. Se Hoon Park reports having served as a consultant or adviser for Janssen Oncology and Lilly; and research funding from Ono Pharmaceutical. Bxports having served as a consultant or adviser for Bristol Myers Squibb, MSD Oncology, and Pfizer/EMD Serono; honoraria from Bristol Myers Squibb, Eisai, EUSA Pharma, Ipsen, Merck, MSD Oncology, and Pfizer; research funding paid to institution from Calithera Biosciences, Ipsen, MSD Oncology, and Pfizer/EMD Serono; serving as a speaker for Eisai, MSD Oncology, and Pfizer; and travel, accommodations, and expenses from EUSA Pharma and Ipsen. Thomas Ferguson reports research funding paid to institution from AstraZeneca, Janssen, and MSD; and travel, accommodations, and expenses from Bristol Myers Squibb, MSD, and Roche. Stefan N. Symeonides reports having served as a consultant or adviser for Bicycle Therapeutics, Bristol Myers Squibb, Boxer Capital, Duke Street Bio, Eisai, Ellipses Pharma, EMD Serono, EUSA Pharma, MedAnnex, MSD, Pfizer, and Vaccitech; having served as a speaker for Bristol Myers Squibb, EUSA  Pharma, and Ipsen; research funding paid to institution from BiolineRx, BioNTech, Boston Pharmaceuticals, Incyte, MSD, Nouscom, Nucana, Roche, Sapience Therapeutics, Scancell, Sierra Oncology, and Verastem; and travel, accommodations, and expenses from Bristol Myers Squibb, EUSA Pharma, and Ipsen. Howard Gurney reports personal speaker fees from MSD; and personal advisory fees from MSD, Roche, Merck, Bristol Myers Squibb, Pfizer, and Ipsen. Jae Lyun Lee reports honoraria from Astellas Pharma, AstraZeneca, Bristol Myers Squibb, MSD, and Pfizer; having served as an advisr or consultant for Alteogen, AstraZeneca, BMS Korea, GI Innovation, Merck, MSD, Pfizer, and Sanofi/Aventis; research funding paid to institution from AstraZeneca/MedImmune, Bayer Schering Pharma, Bristol Myers Squibb, Janssen, MSD, Novartis, Pfizer, Roche/Genentech, and Seattle Genetics; and owns stock in Amgen, BeiGene, Black Diamond Therapeutics, Innovent Biologics, Johnson & Johnson/Janssen, Karyopharm Therapeutics, Merck, Myovant Sciences, and  Zymeworks. Naveed Sarwar reports having served as a consultant or adviser for Bristol Myers  Squibb, Eisai, EUSA Pharma, MSD, and Roche; having served as a speaker for Pfizer; and research funding from MSD. Antoine Thiery-Vuillemin-V reports honoraria from Astellas Pharma, AstraZeneca, Bristol Myers Squibb, Ipsen, Janssen, MSD, Novartis, Pfizer, Roche/Genentech, and Sanofi; having served as a consultant for Astellas Pharma, AstraZeneca, Bristol Myers Squibb, Ipsen, Janssen, MSD, Novartis, Pfizer, Roche,  and Sanofi; research funding paid to institution from Pfizer; and travel, accommodations, and expenses from Astellas Pharma, AstraZeneca, Bristol Myers Squibb, Ipsen, Janssen, MSD, Pfizer, and Roche. Marine Gross-Goupil-G reports having served as a consultant or adviser for Amgen, Astellas Medivation, AstraZeneca, Bayer/Onyx, Bristol Myers Squibb, Ipsen, Janssen-Cilag, MSD Oncology, Pfizer, Roche, and Sanofi; research funding paid to institution from AstraZeneca, Ipsen, Janssen-Cilag, Merck, MSD Oncology, Pfizer, and Roche; and travel, accommodations, and expenses from Astellas Pharma, AstraZeneca, AstraZeneca, Ipsen, Janssen-Cilag, Pfizer, and Roche. Mauricio Mahave reports research funding from MSD. Naomi B. Haas reports having served as a consultant or adviser for AVEO, Calithera Biosciences, Eisai, Exelixis, MSD, Pfizer, and Roche/Genentech; and has provided  expert testimony for Lilly. Piotr Sawrycki reports honoraria from Bristol Myers Squibb and Novartis; research funding paid to institution from Boehringer Ingelheim, Chiltern, G1 Therapeutics, Gilead Sciences, Merrimack, MSD, Parexel, PAREXEL/Puma Biotechnology, PPD Global, Regeneron, and Tesaro; and travel, accommodations, and expenses from Pierre Fabre and Roche. Joseph E. Burgents and Lei Xu are employees of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co, Inc, Rahway, NJ, USA. KI is an employee of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co, Inc, and owns stock in Merck & Co, Inc, Rahway, NJ, USA. DIQ reports having served as a consultant or adviser  for Astellas Pharma, AstraZeneca, Bayer, Bristol Myers Squibb, Eisai, Exelixis, Genentech/Roche, Janssen Oncology, MSD, Myovant Sciences, Novartis, Pfizer, Seattle Genetics, and US Biotest; honoraria from Astellas Pharma, AstraZeneca, Bayer, Bristol Myers Squibb, Exelixis, Genentech/Roche, MSD, Myovant Sciences, Novartis, Pfizer, and Seattle Genetics; research funding paid to institution from Genentech/Roche, Merck, and Pfizer; and travel, accommodations, and expenses from Astellas Pharma, Bayer, Bristol Myers Squibb Japan, Exelexis, Merck, and Roche. TKC reports institutional and personal support, paid and unpaid support for research, participating in advisory boards, consultancy, and honoraria from AstraZeneca, Aravive, Aveo, Bayer, Bristol Myers Squibb, Calithera, Circle Pharma, Eisai, EMD Serono, Exelixis, GlaxoSmithKline, IQVA, Infinity, Ipsen, Jansen, Kanaph, Lilly, Merck, Nikang, Nuscan, Novartis, Pfizer, Roche, Sanofi/Aventis, Surface Oncology, Takeda, Tempest, UpToDate, and CME events (Peerview, OncLive, and MJaroslav Hajek), outside the submitted work; institutional patents filed on molecular mutations, immunotherapy response and toxicity, and ctDNA; equity in Tempest, Pionyr, Osel, Precede Bio; being part of committees in the National Comprehensive Cancer Network, GU Steering Committee, American Society of Clinical Oncology, European Society for Medical Oncology, Academic and Community  Cancer Research United, and KidneyCAN; having mentored several non-US citizens on research projects partly funded by non-US sources; and additional independent funding from drug companies or royalties for research around the subject matter paid to institution. All other authors declare no competing interests.\n",
      "\n",
      "Imai, Kentaro\n",
      "Declaration of interests Thomas Powles reports having served as a consultant or adviser for  Astellas Pharma, AstraZeneca, Bristol Myers Squibb, Eisai, Exelixis, Incyte, Ipsen, Johnson & Johnson, Merck, Merck Serono, MSD, Novartis, Pfizer, Roche, and  Seattle Genetics; honoraria from Astellas Pharma, AstraZeneca, Bristol Myers Squibb, Eisai, Exelixis, Incyte, Ipsen, Johnson & Johnson, Merck, Merck Serono, MSD, Novartis, Pfizer, Roche, and Seattle Genetics; research funding paid to institution from Astellas Pharma, AstraZeneca, Bristol Myers Squibb, Eisai, Exelixis, Ipsen, Johnson & Johnson, Merck, Merck Serono, MSD, Novartis, Pfizer, Roche, and Seattle Genetics; and travel, accommodations, and expenses from AstraZeneca, Ipsen, MSD, Pfizer, and Roche. Piotr Tomczak reports research funding from MSD. Se Hoon Park reports having served as a consultant or adviser for Janssen Oncology and Lilly; and research funding from Ono Pharmaceutical. Bxports having served as a consultant or adviser for Bristol Myers Squibb, MSD Oncology, and Pfizer/EMD Serono; honoraria from Bristol Myers Squibb, Eisai, EUSA Pharma, Ipsen, Merck, MSD Oncology, and Pfizer; research funding paid to institution from Calithera Biosciences, Ipsen, MSD Oncology, and Pfizer/EMD Serono; serving as a speaker for Eisai, MSD Oncology, and Pfizer; and travel, accommodations, and expenses from EUSA Pharma and Ipsen. Thomas Ferguson reports research funding paid to institution from AstraZeneca, Janssen, and MSD; and travel, accommodations, and expenses from Bristol Myers Squibb, MSD, and Roche. Stefan N. Symeonides reports having served as a consultant or adviser for Bicycle Therapeutics, Bristol Myers Squibb, Boxer Capital, Duke Street Bio, Eisai, Ellipses Pharma, EMD Serono, EUSA Pharma, MedAnnex, MSD, Pfizer, and Vaccitech; having served as a speaker for Bristol Myers Squibb, EUSA  Pharma, and Ipsen; research funding paid to institution from BiolineRx, BioNTech, Boston Pharmaceuticals, Incyte, MSD, Nouscom, Nucana, Roche, Sapience Therapeutics, Scancell, Sierra Oncology, and Verastem; and travel, accommodations, and expenses from Bristol Myers Squibb, EUSA Pharma, and Ipsen. Howard Gurney reports personal speaker fees from MSD; and personal advisory fees from MSD, Roche, Merck, Bristol Myers Squibb, Pfizer, and Ipsen. Jae Lyun Lee reports honoraria from Astellas Pharma, AstraZeneca, Bristol Myers Squibb, MSD, and Pfizer; having served as an advisr or consultant for Alteogen, AstraZeneca, BMS Korea, GI Innovation, Merck, MSD, Pfizer, and Sanofi/Aventis; research funding paid to institution from AstraZeneca/MedImmune, Bayer Schering Pharma, Bristol Myers Squibb, Janssen, MSD, Novartis, Pfizer, Roche/Genentech, and Seattle Genetics; and owns stock in Amgen, BeiGene, Black Diamond Therapeutics, Innovent Biologics, Johnson & Johnson/Janssen, Karyopharm Therapeutics, Merck, Myovant Sciences, and  Zymeworks. Naveed Sarwar reports having served as a consultant or adviser for Bristol Myers  Squibb, Eisai, EUSA Pharma, MSD, and Roche; having served as a speaker for Pfizer; and research funding from MSD. Antoine Thiery-Vuillemin-V reports honoraria from Astellas Pharma, AstraZeneca, Bristol Myers Squibb, Ipsen, Janssen, MSD, Novartis, Pfizer, Roche/Genentech, and Sanofi; having served as a consultant for Astellas Pharma, AstraZeneca, Bristol Myers Squibb, Ipsen, Janssen, MSD, Novartis, Pfizer, Roche,  and Sanofi; research funding paid to institution from Pfizer; and travel, accommodations, and expenses from Astellas Pharma, AstraZeneca, Bristol Myers Squibb, Ipsen, Janssen, MSD, Pfizer, and Roche. Marine Gross-Goupil-G reports having served as a consultant or adviser for Amgen, Astellas Medivation, AstraZeneca, Bayer/Onyx, Bristol Myers Squibb, Ipsen, Janssen-Cilag, MSD Oncology, Pfizer, Roche, and Sanofi; research funding paid to institution from AstraZeneca, Ipsen, Janssen-Cilag, Merck, MSD Oncology, Pfizer, and Roche; and travel, accommodations, and expenses from Astellas Pharma, AstraZeneca, AstraZeneca, Ipsen, Janssen-Cilag, Pfizer, and Roche. Mauricio Mahave reports research funding from MSD. Naomi B. Haas reports having served as a consultant or adviser for AVEO, Calithera Biosciences, Eisai, Exelixis, MSD, Pfizer, and Roche/Genentech; and has provided  expert testimony for Lilly. Piotr Sawrycki reports honoraria from Bristol Myers Squibb and Novartis; research funding paid to institution from Boehringer Ingelheim, Chiltern, G1 Therapeutics, Gilead Sciences, Merrimack, MSD, Parexel, PAREXEL/Puma Biotechnology, PPD Global, Regeneron, and Tesaro; and travel, accommodations, and expenses from Pierre Fabre and Roche. Joseph E. Burgents and Lei Xu are employees of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co, Inc, Rahway, NJ, USA. Kentaro Imai is an employee of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co, Inc, and owns stock in Merck & Co, Inc, Rahway, NJ, USA. DIQ reports having served as a consultant or adviser  for Astellas Pharma, AstraZeneca, Bayer, Bristol Myers Squibb, Eisai, Exelixis, Genentech/Roche, Janssen Oncology, MSD, Myovant Sciences, Novartis, Pfizer, Seattle Genetics, and US Biotest; honoraria from Astellas Pharma, AstraZeneca, Bayer, Bristol Myers Squibb, Exelixis, Genentech/Roche, MSD, Myovant Sciences, Novartis, Pfizer, and Seattle Genetics; research funding paid to institution from Genentech/Roche, Merck, and Pfizer; and travel, accommodations, and expenses from Astellas Pharma, Bayer, Bristol Myers Squibb Japan, Exelexis, Merck, and Roche. TKC reports institutional and personal support, paid and unpaid support for research, participating in advisory boards, consultancy, and honoraria from AstraZeneca, Aravive, Aveo, Bayer, Bristol Myers Squibb, Calithera, Circle Pharma, Eisai, EMD Serono, Exelixis, GlaxoSmithKline, IQVA, Infinity, Ipsen, Jansen, Kanaph, Lilly, Merck, Nikang, Nuscan, Novartis, Pfizer, Roche, Sanofi/Aventis, Surface Oncology, Takeda, Tempest, UpToDate, and CME events (Peerview, OncLive, and MJaroslav Hajek), outside the submitted work; institutional patents filed on molecular mutations, immunotherapy response and toxicity, and ctDNA; equity in Tempest, Pionyr, Osel, Precede Bio; being part of committees in the National Comprehensive Cancer Network, GU Steering Committee, American Society of Clinical Oncology, European Society for Medical Oncology, Academic and Community  Cancer Research United, and KidneyCAN; having mentored several non-US citizens on research projects partly funded by non-US sources; and additional independent funding from drug companies or royalties for research around the subject matter paid to institution. All other authors declare no competing interests.\n",
      "\n",
      "Quinn, David I.\n",
      "Declaration of interests Thomas Powles reports having served as a consultant or adviser for  Astellas Pharma, AstraZeneca, Bristol Myers Squibb, Eisai, Exelixis, Incyte, Ipsen, Johnson & Johnson, Merck, Merck Serono, MSD, Novartis, Pfizer, Roche, and  Seattle Genetics; honoraria from Astellas Pharma, AstraZeneca, Bristol Myers Squibb, Eisai, Exelixis, Incyte, Ipsen, Johnson & Johnson, Merck, Merck Serono, MSD, Novartis, Pfizer, Roche, and Seattle Genetics; research funding paid to institution from Astellas Pharma, AstraZeneca, Bristol Myers Squibb, Eisai, Exelixis, Ipsen, Johnson & Johnson, Merck, Merck Serono, MSD, Novartis, Pfizer, Roche, and Seattle Genetics; and travel, accommodations, and expenses from AstraZeneca, Ipsen, MSD, Pfizer, and Roche. Piotr Tomczak reports research funding from MSD. Se Hoon Park reports having served as a consultant or adviser for Janssen Oncology and Lilly; and research funding from Ono Pharmaceutical. Bxports having served as a consultant or adviser for Bristol Myers Squibb, MSD Oncology, and Pfizer/EMD Serono; honoraria from Bristol Myers Squibb, Eisai, EUSA Pharma, Ipsen, Merck, MSD Oncology, and Pfizer; research funding paid to institution from Calithera Biosciences, Ipsen, MSD Oncology, and Pfizer/EMD Serono; serving as a speaker for Eisai, MSD Oncology, and Pfizer; and travel, accommodations, and expenses from EUSA Pharma and Ipsen. Thomas Ferguson reports research funding paid to institution from AstraZeneca, Janssen, and MSD; and travel, accommodations, and expenses from Bristol Myers Squibb, MSD, and Roche. Stefan N. Symeonides reports having served as a consultant or adviser for Bicycle Therapeutics, Bristol Myers Squibb, Boxer Capital, Duke Street Bio, Eisai, Ellipses Pharma, EMD Serono, EUSA Pharma, MedAnnex, MSD, Pfizer, and Vaccitech; having served as a speaker for Bristol Myers Squibb, EUSA  Pharma, and Ipsen; research funding paid to institution from BiolineRx, BioNTech, Boston Pharmaceuticals, Incyte, MSD, Nouscom, Nucana, Roche, Sapience Therapeutics, Scancell, Sierra Oncology, and Verastem; and travel, accommodations, and expenses from Bristol Myers Squibb, EUSA Pharma, and Ipsen. Howard Gurney reports personal speaker fees from MSD; and personal advisory fees from MSD, Roche, Merck, Bristol Myers Squibb, Pfizer, and Ipsen. Jae Lyun Lee reports honoraria from Astellas Pharma, AstraZeneca, Bristol Myers Squibb, MSD, and Pfizer; having served as an advisr or consultant for Alteogen, AstraZeneca, BMS Korea, GI Innovation, Merck, MSD, Pfizer, and Sanofi/Aventis; research funding paid to institution from AstraZeneca/MedImmune, Bayer Schering Pharma, Bristol Myers Squibb, Janssen, MSD, Novartis, Pfizer, Roche/Genentech, and Seattle Genetics; and owns stock in Amgen, BeiGene, Black Diamond Therapeutics, Innovent Biologics, Johnson & Johnson/Janssen, Karyopharm Therapeutics, Merck, Myovant Sciences, and  Zymeworks. Naveed Sarwar reports having served as a consultant or adviser for Bristol Myers  Squibb, Eisai, EUSA Pharma, MSD, and Roche; having served as a speaker for Pfizer; and research funding from MSD. Antoine Thiery-Vuillemin-V reports honoraria from Astellas Pharma, AstraZeneca, Bristol Myers Squibb, Ipsen, Janssen, MSD, Novartis, Pfizer, Roche/Genentech, and Sanofi; having served as a consultant for Astellas Pharma, AstraZeneca, Bristol Myers Squibb, Ipsen, Janssen, MSD, Novartis, Pfizer, Roche,  and Sanofi; research funding paid to institution from Pfizer; and travel, accommodations, and expenses from Astellas Pharma, AstraZeneca, Bristol Myers Squibb, Ipsen, Janssen, MSD, Pfizer, and Roche. Marine Gross-Goupil-G reports having served as a consultant or adviser for Amgen, Astellas Medivation, AstraZeneca, Bayer/Onyx, Bristol Myers Squibb, Ipsen, Janssen-Cilag, MSD Oncology, Pfizer, Roche, and Sanofi; research funding paid to institution from AstraZeneca, Ipsen, Janssen-Cilag, Merck, MSD Oncology, Pfizer, and Roche; and travel, accommodations, and expenses from Astellas Pharma, AstraZeneca, AstraZeneca, Ipsen, Janssen-Cilag, Pfizer, and Roche. Mauricio Mahave reports research funding from MSD. Naomi B. Haas reports having served as a consultant or adviser for AVEO, Calithera Biosciences, Eisai, Exelixis, MSD, Pfizer, and Roche/Genentech; and has provided  expert testimony for Lilly. Piotr Sawrycki reports honoraria from Bristol Myers Squibb and Novartis; research funding paid to institution from Boehringer Ingelheim, Chiltern, G1 Therapeutics, Gilead Sciences, Merrimack, MSD, Parexel, PAREXEL/Puma Biotechnology, PPD Global, Regeneron, and Tesaro; and travel, accommodations, and expenses from Pierre Fabre and Roche. Joseph E. Burgents and Lei Xu are employees of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co, Inc, Rahway, NJ, USA. Kentaro Imai is an employee of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co, Inc, and owns stock in Merck & Co, Inc, Rahway, NJ, USA. David I. Quinn reports having served as a consultant or adviser  for Astellas Pharma, AstraZeneca, Bayer, Bristol Myers Squibb, Eisai, Exelixis, Genentech/Roche, Janssen Oncology, MSD, Myovant Sciences, Novartis, Pfizer, Seattle Genetics, and US Biotest; honoraria from Astellas Pharma, AstraZeneca, Bayer, Bristol Myers Squibb, Exelixis, Genentech/Roche, MSD, Myovant Sciences, Novartis, Pfizer, and Seattle Genetics; research funding paid to institution from Genentech/Roche, Merck, and Pfizer; and travel, accommodations, and expenses from Astellas Pharma, Bayer, Bristol Myers Squibb Japan, Exelexis, Merck, and Roche. TKC reports institutional and personal support, paid and unpaid support for research, participating in advisory boards, consultancy, and honoraria from AstraZeneca, Aravive, Aveo, Bayer, Bristol Myers Squibb, Calithera, Circle Pharma, Eisai, EMD Serono, Exelixis, GlaxoSmithKline, IQVA, Infinity, Ipsen, Jansen, Kanaph, Lilly, Merck, Nikang, Nuscan, Novartis, Pfizer, Roche, Sanofi/Aventis, Surface Oncology, Takeda, Tempest, UpToDate, and CME events (Peerview, OncLive, and MJaroslav Hajek), outside the submitted work; institutional patents filed on molecular mutations, immunotherapy response and toxicity, and ctDNA; equity in Tempest, Pionyr, Osel, Precede Bio; being part of committees in the National Comprehensive Cancer Network, GU Steering Committee, American Society of Clinical Oncology, European Society for Medical Oncology, Academic and Community  Cancer Research United, and KidneyCAN; having mentored several non-US citizens on research projects partly funded by non-US sources; and additional independent funding from drug companies or royalties for research around the subject matter paid to institution. All other authors declare no competing interests.\n",
      "\n",
      "Choueiri, Toni K.\n",
      "Declaration of interests Thomas Powles reports having served as a consultant or adviser for  Astellas Pharma, AstraZeneca, Bristol Myers Squibb, Eisai, Exelixis, Incyte, Ipsen, Johnson & Johnson, Merck, Merck Serono, MSD, Novartis, Pfizer, Roche, and  Seattle Genetics; honoraria from Astellas Pharma, AstraZeneca, Bristol Myers Squibb, Eisai, Exelixis, Incyte, Ipsen, Johnson & Johnson, Merck, Merck Serono, MSD, Novartis, Pfizer, Roche, and Seattle Genetics; research funding paid to institution from Astellas Pharma, AstraZeneca, Bristol Myers Squibb, Eisai, Exelixis, Ipsen, Johnson & Johnson, Merck, Merck Serono, MSD, Novartis, Pfizer, Roche, and Seattle Genetics; and travel, accommodations, and expenses from AstraZeneca, Ipsen, MSD, Pfizer, and Roche. Piotr Tomczak reports research funding from MSD. Se Hoon Park reports having served as a consultant or adviser for Janssen Oncology and Lilly; and research funding from Ono Pharmaceutical. Bxports having served as a consultant or adviser for Bristol Myers Squibb, MSD Oncology, and Pfizer/EMD Serono; honoraria from Bristol Myers Squibb, Eisai, EUSA Pharma, Ipsen, Merck, MSD Oncology, and Pfizer; research funding paid to institution from Calithera Biosciences, Ipsen, MSD Oncology, and Pfizer/EMD Serono; serving as a speaker for Eisai, MSD Oncology, and Pfizer; and travel, accommodations, and expenses from EUSA Pharma and Ipsen. Thomas Ferguson reports research funding paid to institution from AstraZeneca, Janssen, and MSD; and travel, accommodations, and expenses from Bristol Myers Squibb, MSD, and Roche. Stefan N. Symeonides reports having served as a consultant or adviser for Bicycle Therapeutics, Bristol Myers Squibb, Boxer Capital, Duke Street Bio, Eisai, Ellipses Pharma, EMD Serono, EUSA Pharma, MedAnnex, MSD, Pfizer, and Vaccitech; having served as a speaker for Bristol Myers Squibb, EUSA  Pharma, and Ipsen; research funding paid to institution from BiolineRx, BioNTech, Boston Pharmaceuticals, Incyte, MSD, Nouscom, Nucana, Roche, Sapience Therapeutics, Scancell, Sierra Oncology, and Verastem; and travel, accommodations, and expenses from Bristol Myers Squibb, EUSA Pharma, and Ipsen. Howard Gurney reports personal speaker fees from MSD; and personal advisory fees from MSD, Roche, Merck, Bristol Myers Squibb, Pfizer, and Ipsen. Jae Lyun Lee reports honoraria from Astellas Pharma, AstraZeneca, Bristol Myers Squibb, MSD, and Pfizer; having served as an advisr or consultant for Alteogen, AstraZeneca, BMS Korea, GI Innovation, Merck, MSD, Pfizer, and Sanofi/Aventis; research funding paid to institution from AstraZeneca/MedImmune, Bayer Schering Pharma, Bristol Myers Squibb, Janssen, MSD, Novartis, Pfizer, Roche/Genentech, and Seattle Genetics; and owns stock in Amgen, BeiGene, Black Diamond Therapeutics, Innovent Biologics, Johnson & Johnson/Janssen, Karyopharm Therapeutics, Merck, Myovant Sciences, and  Zymeworks. Naveed Sarwar reports having served as a consultant or adviser for Bristol Myers  Squibb, Eisai, EUSA Pharma, MSD, and Roche; having served as a speaker for Pfizer; and research funding from MSD. Antoine Thiery-Vuillemin-V reports honoraria from Astellas Pharma, AstraZeneca, Bristol Myers Squibb, Ipsen, Janssen, MSD, Novartis, Pfizer, Roche/Genentech, and Sanofi; having served as a consultant for Astellas Pharma, AstraZeneca, Bristol Myers Squibb, Ipsen, Janssen, MSD, Novartis, Pfizer, Roche,  and Sanofi; research funding paid to institution from Pfizer; and travel, accommodations, and expenses from Astellas Pharma, AstraZeneca, Bristol Myers Squibb, Ipsen, Janssen, MSD, Pfizer, and Roche. Marine Gross-Goupil-G reports having served as a consultant or adviser for Amgen, Astellas Medivation, AstraZeneca, Bayer/Onyx, Bristol Myers Squibb, Ipsen, Janssen-Cilag, MSD Oncology, Pfizer, Roche, and Sanofi; research funding paid to institution from AstraZeneca, Ipsen, Janssen-Cilag, Merck, MSD Oncology, Pfizer, and Roche; and travel, accommodations, and expenses from Astellas Pharma, AstraZeneca, AstraZeneca, Ipsen, Janssen-Cilag, Pfizer, and Roche. Mauricio Mahave reports research funding from MSD. Naomi B. Haas reports having served as a consultant or adviser for AVEO, Calithera Biosciences, Eisai, Exelixis, MSD, Pfizer, and Roche/Genentech; and has provided  expert testimony for Lilly. Piotr Sawrycki reports honoraria from Bristol Myers Squibb and Novartis; research funding paid to institution from Boehringer Ingelheim, Chiltern, G1 Therapeutics, Gilead Sciences, Merrimack, MSD, Parexel, PAREXEL/Puma Biotechnology, PPD Global, Regeneron, and Tesaro; and travel, accommodations, and expenses from Pierre Fabre and Roche. Joseph E. Burgents and Lei Xu are employees of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co, Inc, Rahway, NJ, USA. Kentaro Imai is an employee of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co, Inc, and owns stock in Merck & Co, Inc, Rahway, NJ, USA. David I. Quinn reports having served as a consultant or adviser  for Astellas Pharma, AstraZeneca, Bayer, Bristol Myers Squibb, Eisai, Exelixis, Genentech/Roche, Janssen Oncology, MSD, Myovant Sciences, Novartis, Pfizer, Seattle Genetics, and US Biotest; honoraria from Astellas Pharma, AstraZeneca, Bayer, Bristol Myers Squibb, Exelixis, Genentech/Roche, MSD, Myovant Sciences, Novartis, Pfizer, and Seattle Genetics; research funding paid to institution from Genentech/Roche, Merck, and Pfizer; and travel, accommodations, and expenses from Astellas Pharma, Bayer, Bristol Myers Squibb Japan, Exelexis, Merck, and Roche. Toni K. Choueiri reports institutional and personal support, paid and unpaid support for research, participating in advisory boards, consultancy, and honoraria from AstraZeneca, Aravive, Aveo, Bayer, Bristol Myers Squibb, Calithera, Circle Pharma, Eisai, EMD Serono, Exelixis, GlaxoSmithKline, IQVA, Infinity, Ipsen, Jansen, Kanaph, Lilly, Merck, Nikang, Nuscan, Novartis, Pfizer, Roche, Sanofi/Aventis, Surface Oncology, Takeda, Tempest, UpToDate, and CME events (Peerview, OncLive, and MJaroslav Hajek), outside the submitted work; institutional patents filed on molecular mutations, immunotherapy response and toxicity, and ctDNA; equity in Tempest, Pionyr, Osel, Precede Bio; being part of committees in the National Comprehensive Cancer Network, GU Steering Committee, American Society of Clinical Oncology, European Society for Medical Oncology, Academic and Community  Cancer Research United, and KidneyCAN; having mentored several non-US citizens on research projects partly funded by non-US sources; and additional independent funding from drug companies or royalties for research around the subject matter paid to institution. All other authors declare no competing interests.\n",
      "\n",
      "DSD reports institutional support from Bristol Myers Squibb and Pfizer; and consults for AstraZeneca, Clovis, Regeneron, and Pfizer. BHP receives consulting  and advisory board fees from Jackson Labs, EQRx, Sermonix, Hologics, Guardant Health, and Celcuity; has research contracts with GE Healthcare and Eli Lilly; and is entitled to royalties on sales of products licensed by Horizon Discovery and Johns Hopkins University. JP reports funding from the Color Foundation unrelated to this work. CAS-M reports funding from AstraZeneca, Pfizer, Bristol Myers Squibb, and Tesaro/GSK; and is on the advisory board of Seattle Genetics. AT reports royalties for breast cancer chapters written for an online UpToDate book; payment for expert testimony; plans to patent a device to be used in lymphoedema patients; non-paid advisory board service for Puretech; and received  Sozo bioimpedance equipment for an investigator-led study on lymphoedema. AN-R reports honoraria and support for attending meetings and travel from Roche, MSD,  Astra Zeneca, and Eisai; and leadership roles with the Brazilian Group of Gynecology Oncology and Brazilian Society of Medical Oncology. All other authors  declare no competing interests.\n",
      "\n",
      "DSD reports institutional support from Bristol Myers Squibb and Pfizer; and consults for AstraZeneca, Clovis, Regeneron, and Pfizer. BHP receives consulting  and advisory board fees from Jackson Labs, EQRx, Sermonix, Hologics, Guardant Health, and Celcuity; has research contracts with GE Healthcare and Eli Lilly; and is entitled to royalties on sales of products licensed by Horizon Discovery and Johns Hopkins University. JP reports funding from the Color Foundation unrelated to this work. CAS-M reports funding from AstraZeneca, Pfizer, Bristol Myers Squibb, and Tesaro/GSK; and is on the advisory board of Seattle Genetics. AT reports royalties for breast cancer chapters written for an online UpToDate book; payment for expert testimony; plans to patent a device to be used in lymphoedema patients; non-paid advisory board service for Puretech; and received  Sozo bioimpedance equipment for an investigator-led study on lymphoedema. AN-R reports honoraria and support for attending meetings and travel from Roche, MSD,  Astra Zeneca, and Eisai; and leadership roles with the Brazilian Group of Gynecology Oncology and Brazilian Society of Medical Oncology. All other authors  declare no competing interests.\n",
      "\n",
      "DSD reports institutional support from Bristol Myers Squibb and Pfizer; and consults for AstraZeneca, Clovis, Regeneron, and Pfizer. BHP receives consulting  and advisory board fees from Jackson Labs, EQRx, Sermonix, Hologics, Guardant Health, and Celcuity; has research contracts with GE Healthcare and Eli Lilly; and is entitled to royalties on sales of products licensed by Horizon Discovery and Johns Hopkins University. JP reports funding from the Color Foundation unrelated to this work. CAS-M reports funding from AstraZeneca, Pfizer, Bristol Myers Squibb, and Tesaro/GSK; and is on the advisory board of Seattle Genetics. AT reports royalties for breast cancer chapters written for an online UpToDate book; payment for expert testimony; plans to patent a device to be used in lymphoedema patients; non-paid advisory board service for Puretech; and received  Sozo bioimpedance equipment for an investigator-led study on lymphoedema. AN-R reports honoraria and support for attending meetings and travel from Roche, MSD,  Astra Zeneca, and Eisai; and leadership roles with the Brazilian Group of Gynecology Oncology and Brazilian Society of Medical Oncology. All other authors  declare no competing interests.\n",
      "\n",
      "Plichta, Jennifer\n",
      "DSD reports institutional support from Bristol Myers Squibb and Pfizer; and consults for AstraZeneca, Clovis, Regeneron, and Pfizer. BHP receives consulting  and advisory board fees from Jackson Labs, EQRx, Sermonix, Hologics, Guardant Health, and Celcuity; has research contracts with GE Healthcare and Eli Lilly; and is entitled to royalties on sales of products licensed by Horizon Discovery and Johns Hopkins University. Jennifer Plichta reports funding from the Color Foundation unrelated to this work. CAS-M reports funding from AstraZeneca, Pfizer, Bristol Myers Squibb, and Tesaro/GSK; and is on the advisory board of Seattle Genetics. AT reports royalties for breast cancer chapters written for an online UpToDate book; payment for expert testimony; plans to patent a device to be used in lymphoedema patients; non-paid advisory board service for Puretech; and received  Sozo bioimpedance equipment for an investigator-led study on lymphoedema. AN-R reports honoraria and support for attending meetings and travel from Roche, MSD,  Astra Zeneca, and Eisai; and leadership roles with the Brazilian Group of Gynecology Oncology and Brazilian Society of Medical Oncology. All other authors  declare no competing interests.\n",
      "\n",
      "DSD reports institutional support from Bristol Myers Squibb and Pfizer; and consults for AstraZeneca, Clovis, Regeneron, and Pfizer. BHP receives consulting  and advisory board fees from Jackson Labs, EQRx, Sermonix, Hologics, Guardant Health, and Celcuity; has research contracts with GE Healthcare and Eli Lilly; and is entitled to royalties on sales of products licensed by Horizon Discovery and Johns Hopkins University. Jennifer Plichta reports funding from the Color Foundation unrelated to this work. CAS-M reports funding from AstraZeneca, Pfizer, Bristol Myers Squibb, and Tesaro/GSK; and is on the advisory board of Seattle Genetics. AT reports royalties for breast cancer chapters written for an online UpToDate book; payment for expert testimony; plans to patent a device to be used in lymphoedema patients; non-paid advisory board service for Puretech; and received  Sozo bioimpedance equipment for an investigator-led study on lymphoedema. AN-R reports honoraria and support for attending meetings and travel from Roche, MSD,  Astra Zeneca, and Eisai; and leadership roles with the Brazilian Group of Gynecology Oncology and Brazilian Society of Medical Oncology. All other authors  declare no competing interests.\n",
      "\n",
      "Nogueira-Rodrigues, Angelica\n",
      "DSD reports institutional support from Bristol Myers Squibb and Pfizer; and consults for AstraZeneca, Clovis, Regeneron, and Pfizer. BHP receives consulting  and advisory board fees from Jackson Labs, EQRx, Sermonix, Hologics, Guardant Health, and Celcuity; has research contracts with GE Healthcare and Eli Lilly; and is entitled to royalties on sales of products licensed by Horizon Discovery and Johns Hopkins University. Jennifer Plichta reports funding from the Color Foundation unrelated to this work. CAS-M reports funding from AstraZeneca, Pfizer, Bristol Myers Squibb, and Tesaro/GSK; and is on the advisory board of Seattle Genetics. AT reports royalties for breast cancer chapters written for an online UpToDate book; payment for expert testimony; plans to patent a device to be used in lymphoedema patients; non-paid advisory board service for Puretech; and received  Sozo bioimpedance equipment for an investigator-led study on lymphoedema. Angelica Nogueira-Rodrigues-R reports honoraria and support for attending meetings and travel from Roche, MSD,  Astra Zeneca, and Eisai; and leadership roles with the Brazilian Group of Gynecology Oncology and Brazilian Society of Medical Oncology. All other authors  declare no competing interests.\n",
      "\n",
      "Santa-Maria, Cesar A.\n",
      "DSD reports institutional support from Bristol Myers Squibb and Pfizer; and consults for AstraZeneca, Clovis, Regeneron, and Pfizer. BHP receives consulting  and advisory board fees from Jackson Labs, EQRx, Sermonix, Hologics, Guardant Health, and Celcuity; has research contracts with GE Healthcare and Eli Lilly; and is entitled to royalties on sales of products licensed by Horizon Discovery and Johns Hopkins University. Jennifer Plichta reports funding from the Color Foundation unrelated to this work. Cesar A. Santa-Maria-M reports funding from AstraZeneca, Pfizer, Bristol Myers Squibb, and Tesaro/GSK; and is on the advisory board of Seattle Genetics. AT reports royalties for breast cancer chapters written for an online UpToDate book; payment for expert testimony; plans to patent a device to be used in lymphoedema patients; non-paid advisory board service for Puretech; and received  Sozo bioimpedance equipment for an investigator-led study on lymphoedema. Angelica Nogueira-Rodrigues-R reports honoraria and support for attending meetings and travel from Roche, MSD,  Astra Zeneca, and Eisai; and leadership roles with the Brazilian Group of Gynecology Oncology and Brazilian Society of Medical Oncology. All other authors  declare no competing interests.\n",
      "\n",
      "DSD reports institutional support from Bristol Myers Squibb and Pfizer; and consults for AstraZeneca, Clovis, Regeneron, and Pfizer. BHP receives consulting  and advisory board fees from Jackson Labs, EQRx, Sermonix, Hologics, Guardant Health, and Celcuity; has research contracts with GE Healthcare and Eli Lilly; and is entitled to royalties on sales of products licensed by Horizon Discovery and Johns Hopkins University. Jennifer Plichta reports funding from the Color Foundation unrelated to this work. Cesar A. Santa-Maria-M reports funding from AstraZeneca, Pfizer, Bristol Myers Squibb, and Tesaro/GSK; and is on the advisory board of Seattle Genetics. AT reports royalties for breast cancer chapters written for an online UpToDate book; payment for expert testimony; plans to patent a device to be used in lymphoedema patients; non-paid advisory board service for Puretech; and received  Sozo bioimpedance equipment for an investigator-led study on lymphoedema. Angelica Nogueira-Rodrigues-R reports honoraria and support for attending meetings and travel from Roche, MSD,  Astra Zeneca, and Eisai; and leadership roles with the Brazilian Group of Gynecology Oncology and Brazilian Society of Medical Oncology. All other authors  declare no competing interests.\n",
      "\n",
      "DSD reports institutional support from Bristol Myers Squibb and Pfizer; and consults for AstraZeneca, Clovis, Regeneron, and Pfizer. BHP receives consulting  and advisory board fees from Jackson Labs, EQRx, Sermonix, Hologics, Guardant Health, and Celcuity; has research contracts with GE Healthcare and Eli Lilly; and is entitled to royalties on sales of products licensed by Horizon Discovery and Johns Hopkins University. Jennifer Plichta reports funding from the Color Foundation unrelated to this work. Cesar A. Santa-Maria-M reports funding from AstraZeneca, Pfizer, Bristol Myers Squibb, and Tesaro/GSK; and is on the advisory board of Seattle Genetics. AT reports royalties for breast cancer chapters written for an online UpToDate book; payment for expert testimony; plans to patent a device to be used in lymphoedema patients; non-paid advisory board service for Puretech; and received  Sozo bioimpedance equipment for an investigator-led study on lymphoedema. Angelica Nogueira-Rodrigues-R reports honoraria and support for attending meetings and travel from Roche, MSD,  Astra Zeneca, and Eisai; and leadership roles with the Brazilian Group of Gynecology Oncology and Brazilian Society of Medical Oncology. All other authors  declare no competing interests.\n",
      "\n",
      "DSD reports institutional support from Bristol Myers Squibb and Pfizer; and consults for AstraZeneca, Clovis, Regeneron, and Pfizer. BHP receives consulting  and advisory board fees from Jackson Labs, EQRx, Sermonix, Hologics, Guardant Health, and Celcuity; has research contracts with GE Healthcare and Eli Lilly; and is entitled to royalties on sales of products licensed by Horizon Discovery and Johns Hopkins University. Jennifer Plichta reports funding from the Color Foundation unrelated to this work. Cesar A. Santa-Maria-M reports funding from AstraZeneca, Pfizer, Bristol Myers Squibb, and Tesaro/GSK; and is on the advisory board of Seattle Genetics. AT reports royalties for breast cancer chapters written for an online UpToDate book; payment for expert testimony; plans to patent a device to be used in lymphoedema patients; non-paid advisory board service for Puretech; and received  Sozo bioimpedance equipment for an investigator-led study on lymphoedema. Angelica Nogueira-Rodrigues-R reports honoraria and support for attending meetings and travel from Roche, MSD,  Astra Zeneca, and Eisai; and leadership roles with the Brazilian Group of Gynecology Oncology and Brazilian Society of Medical Oncology. All other authors  declare no competing interests.\n",
      "\n",
      "Taghian, Alphonse\n",
      "DSD reports institutional support from Bristol Myers Squibb and Pfizer; and consults for AstraZeneca, Clovis, Regeneron, and Pfizer. BHP receives consulting  and advisory board fees from Jackson Labs, EQRx, Sermonix, Hologics, Guardant Health, and Celcuity; has research contracts with GE Healthcare and Eli Lilly; and is entitled to royalties on sales of products licensed by Horizon Discovery and Johns Hopkins University. Jennifer Plichta reports funding from the Color Foundation unrelated to this work. Cesar A. Santa-Maria-M reports funding from AstraZeneca, Pfizer, Bristol Myers Squibb, and Tesaro/GSK; and is on the advisory board of Seattle Genetics. Alphonse Taghian reports royalties for breast cancer chapters written for an online UpToDate book; payment for expert testimony; plans to patent a device to be used in lymphoedema patients; non-paid advisory board service for Puretech; and received  Sozo bioimpedance equipment for an investigator-led study on lymphoedema. Angelica Nogueira-Rodrigues-R reports honoraria and support for attending meetings and travel from Roche, MSD,  Astra Zeneca, and Eisai; and leadership roles with the Brazilian Group of Gynecology Oncology and Brazilian Society of Medical Oncology. All other authors  declare no competing interests.\n",
      "\n",
      "DSD reports institutional support from Bristol Myers Squibb and Pfizer; and consults for AstraZeneca, Clovis, Regeneron, and Pfizer. BHP receives consulting  and advisory board fees from Jackson Labs, EQRx, Sermonix, Hologics, Guardant Health, and Celcuity; has research contracts with GE Healthcare and Eli Lilly; and is entitled to royalties on sales of products licensed by Horizon Discovery and Johns Hopkins University. Jennifer Plichta reports funding from the Color Foundation unrelated to this work. Cesar A. Santa-Maria-M reports funding from AstraZeneca, Pfizer, Bristol Myers Squibb, and Tesaro/GSK; and is on the advisory board of Seattle Genetics. Alphonse Taghian reports royalties for breast cancer chapters written for an online UpToDate book; payment for expert testimony; plans to patent a device to be used in lymphoedema patients; non-paid advisory board service for Puretech; and received  Sozo bioimpedance equipment for an investigator-led study on lymphoedema. Angelica Nogueira-Rodrigues-R reports honoraria and support for attending meetings and travel from Roche, MSD,  Astra Zeneca, and Eisai; and leadership roles with the Brazilian Group of Gynecology Oncology and Brazilian Society of Medical Oncology. All other authors  declare no competing interests.\n",
      "\n",
      "DSD reports institutional support from Bristol Myers Squibb and Pfizer; and consults for AstraZeneca, Clovis, Regeneron, and Pfizer. BHP receives consulting  and advisory board fees from Jackson Labs, EQRx, Sermonix, Hologics, Guardant Health, and Celcuity; has research contracts with GE Healthcare and Eli Lilly; and is entitled to royalties on sales of products licensed by Horizon Discovery and Johns Hopkins University. Jennifer Plichta reports funding from the Color Foundation unrelated to this work. Cesar A. Santa-Maria-M reports funding from AstraZeneca, Pfizer, Bristol Myers Squibb, and Tesaro/GSK; and is on the advisory board of Seattle Genetics. Alphonse Taghian reports royalties for breast cancer chapters written for an online UpToDate book; payment for expert testimony; plans to patent a device to be used in lymphoedema patients; non-paid advisory board service for Puretech; and received  Sozo bioimpedance equipment for an investigator-led study on lymphoedema. Angelica Nogueira-Rodrigues-R reports honoraria and support for attending meetings and travel from Roche, MSD,  Astra Zeneca, and Eisai; and leadership roles with the Brazilian Group of Gynecology Oncology and Brazilian Society of Medical Oncology. All other authors  declare no competing interests.\n",
      "\n",
      "Ho Park, Ben\n",
      "DSD reports institutional support from Bristol Myers Squibb and Pfizer; and consults for AstraZeneca, Clovis, Regeneron, and Pfizer. Ben Ho Park receives consulting  and advisory board fees from Jackson Labs, EQRx, Sermonix, Hologics, Guardant Health, and Celcuity; has research contracts with GE Healthcare and Eli Lilly; and is entitled to royalties on sales of products licensed by Horizon Discovery and Johns Hopkins University. Jennifer Plichta reports funding from the Color Foundation unrelated to this work. Cesar A. Santa-Maria-M reports funding from AstraZeneca, Pfizer, Bristol Myers Squibb, and Tesaro/GSK; and is on the advisory board of Seattle Genetics. Alphonse Taghian reports royalties for breast cancer chapters written for an online UpToDate book; payment for expert testimony; plans to patent a device to be used in lymphoedema patients; non-paid advisory board service for Puretech; and received  Sozo bioimpedance equipment for an investigator-led study on lymphoedema. Angelica Nogueira-Rodrigues-R reports honoraria and support for attending meetings and travel from Roche, MSD,  Astra Zeneca, and Eisai; and leadership roles with the Brazilian Group of Gynecology Oncology and Brazilian Society of Medical Oncology. All other authors  declare no competing interests.\n",
      "\n",
      "Dizon, Don S.\n",
      "Don S. Dizon reports institutional support from Bristol Myers Squibb and Pfizer; and consults for AstraZeneca, Clovis, Regeneron, and Pfizer. Ben Ho Park receives consulting  and advisory board fees from Jackson Labs, EQRx, Sermonix, Hologics, Guardant Health, and Celcuity; has research contracts with GE Healthcare and Eli Lilly; and is entitled to royalties on sales of products licensed by Horizon Discovery and Johns Hopkins University. Jennifer Plichta reports funding from the Color Foundation unrelated to this work. Cesar A. Santa-Maria-M reports funding from AstraZeneca, Pfizer, Bristol Myers Squibb, and Tesaro/GSK; and is on the advisory board of Seattle Genetics. Alphonse Taghian reports royalties for breast cancer chapters written for an online UpToDate book; payment for expert testimony; plans to patent a device to be used in lymphoedema patients; non-paid advisory board service for Puretech; and received  Sozo bioimpedance equipment for an investigator-led study on lymphoedema. Angelica Nogueira-Rodrigues-R reports honoraria and support for attending meetings and travel from Roche, MSD,  Astra Zeneca, and Eisai; and leadership roles with the Brazilian Group of Gynecology Oncology and Brazilian Society of Medical Oncology. All other authors  declare no competing interests.\n",
      "\n",
      "Schmitt, Andreas M.\n",
      "Andreas M. Schmitt has received an educational grant from Janssen-Cilag AG, and he has received  support for conference attendance from Novartis. LS has received advisory honoraria from Bristol Myers Squibb (BMS) and Ipsen and speaker fees from BMS. JL has received honoraria from Eisai, Novartis, Incyte, Merck, touchIME, touchEXPERTS, Pfizer, Royal College of Physicians, Cambridge Healthcare Research, Royal College of General Practitioners, VJOncology, Agence Unik, and BMS; consultancy fees from iOnctura, Apple Tree, Merck, BMS, Eisai, Debipharm, Incyte; speaker fees from Pierre Fabre, BMS, Ipsen, Roche, EUSA Pharma, Novartis, Aptitude, AstraZeneca, GSK, Eisai, Calithera, Ultimovacs, Seagen, Merck, eCancer, Inselgruppe, Pfizer, Goldman Sachs, and MSD; institutional research support from  BMS, MSD, Novartis, Pfizer, Achilles Therapeutics, Roche, Nektar Therapeutics, Covance, Immunocore, Pharmacyclics, and Aveo; and grants from Achilles, BMS, MSD, Nektar, Novartis, Pfizer, Roche, Immunocore, Aveo, and Pharmacyclics.\n",
      "\n",
      "Spain, Lavinia\n",
      "Andreas M. Schmitt has received an educational grant from Janssen-Cilag AG, and he has received  support for conference attendance from Novartis. Lavinia Spain has received advisory honoraria from Bristol Myers Squibb (BMS) and Ipsen and speaker fees from BMS. JL has received honoraria from Eisai, Novartis, Incyte, Merck, touchIME, touchEXPERTS, Pfizer, Royal College of Physicians, Cambridge Healthcare Research, Royal College of General Practitioners, VJOncology, Agence Unik, and BMS; consultancy fees from iOnctura, Apple Tree, Merck, BMS, Eisai, Debipharm, Incyte; speaker fees from Pierre Fabre, BMS, Ipsen, Roche, EUSA Pharma, Novartis, Aptitude, AstraZeneca, GSK, Eisai, Calithera, Ultimovacs, Seagen, Merck, eCancer, Inselgruppe, Pfizer, Goldman Sachs, and MSD; institutional research support from  BMS, MSD, Novartis, Pfizer, Achilles Therapeutics, Roche, Nektar Therapeutics, Covance, Immunocore, Pharmacyclics, and Aveo; and grants from Achilles, BMS, MSD, Nektar, Novartis, Pfizer, Roche, Immunocore, Aveo, and Pharmacyclics.\n",
      "\n",
      "Larkin, James\n",
      "Andreas M. Schmitt has received an educational grant from Janssen-Cilag AG, and he has received  support for conference attendance from Novartis. Lavinia Spain has received advisory honoraria from Bristol Myers Squibb (BMS) and Ipsen and speaker fees from BMS. James Larkin has received honoraria from Eisai, Novartis, Incyte, Merck, touchIME, touchEXPERTS, Pfizer, Royal College of Physicians, Cambridge Healthcare Research, Royal College of General Practitioners, VJOncology, Agence Unik, and BMS; consultancy fees from iOnctura, Apple Tree, Merck, BMS, Eisai, Debipharm, Incyte; speaker fees from Pierre Fabre, BMS, Ipsen, Roche, EUSA Pharma, Novartis, Aptitude, AstraZeneca, GSK, Eisai, Calithera, Ultimovacs, Seagen, Merck, eCancer, Inselgruppe, Pfizer, Goldman Sachs, and MSD; institutional research support from  BMS, MSD, Novartis, Pfizer, Achilles Therapeutics, Roche, Nektar Therapeutics, Covance, Immunocore, Pharmacyclics, and Aveo; and grants from Achilles, BMS, MSD, Nektar, Novartis, Pfizer, Roche, Immunocore, Aveo, and Pharmacyclics.\n",
      "\n",
      "Romesser, Paul B.\n",
      "JJS received travel support from Intuitive Surgical for fellow education (2015),  served as a clinical advisor for Guardant Health (2019), served as a clinical advisor for Foundation Medicine (2022), and served as a consultant and speaker for Johnson & Johnson (2022). Paul B. Romesser reports prior research funding from and is a consultant for EMD Serono.\n",
      "\n",
      "Joshua Smith, J.\n",
      "J. Joshua Smith received travel support from Intuitive Surgical for fellow education (2015),  served as a clinical advisor for Guardant Health (2019), served as a clinical advisor for Foundation Medicine (2022), and served as a consultant and speaker for Johnson & Johnson (2022). Paul B. Romesser reports prior research funding from and is a consultant for EMD Serono.\n",
      "\n",
      "Declaration of interests AT has received funding for her service on the Global Paediatrics Advisory Board between Oct 4, 2021, and Nov 14, 2021, with payments made to the MRC Clinical Trials Unit at University College London. All other authors declare no competing interests.\n",
      "\n",
      "Declaration of interests AT has received funding for her service on the Global Paediatrics Advisory Board between Oct 4, 2021, and Nov 14, 2021, with payments made to the MRC Clinical Trials Unit at University College London. All other authors declare no competing interests.\n",
      "\n",
      "Declaration of interests AT has received funding for her service on the Global Paediatrics Advisory Board between Oct 4, 2021, and Nov 14, 2021, with payments made to the MRC Clinical Trials Unit at University College London. All other authors declare no competing interests.\n",
      "\n",
      "Declaration of interests AT has received funding for her service on the Global Paediatrics Advisory Board between Oct 4, 2021, and Nov 14, 2021, with payments made to the MRC Clinical Trials Unit at University College London. All other authors declare no competing interests.\n",
      "\n",
      "Declaration of interests AT has received funding for her service on the Global Paediatrics Advisory Board between Oct 4, 2021, and Nov 14, 2021, with payments made to the MRC Clinical Trials Unit at University College London. All other authors declare no competing interests.\n",
      "\n",
      "Declaration of interests AT has received funding for her service on the Global Paediatrics Advisory Board between Oct 4, 2021, and Nov 14, 2021, with payments made to the MRC Clinical Trials Unit at University College London. All other authors declare no competing interests.\n",
      "\n",
      "Declaration of interests AT has received funding for her service on the Global Paediatrics Advisory Board between Oct 4, 2021, and Nov 14, 2021, with payments made to the MRC Clinical Trials Unit at University College London. All other authors declare no competing interests.\n",
      "\n",
      "Declaration of interests AT has received funding for her service on the Global Paediatrics Advisory Board between Oct 4, 2021, and Nov 14, 2021, with payments made to the MRC Clinical Trials Unit at University College London. All other authors declare no competing interests.\n",
      "\n",
      "Declaration of interests AT has received funding for her service on the Global Paediatrics Advisory Board between Oct 4, 2021, and Nov 14, 2021, with payments made to the MRC Clinical Trials Unit at University College London. All other authors declare no competing interests.\n",
      "\n",
      "Declaration of interests AT has received funding for her service on the Global Paediatrics Advisory Board between Oct 4, 2021, and Nov 14, 2021, with payments made to the MRC Clinical Trials Unit at University College London. All other authors declare no competing interests.\n",
      "\n",
      "Declaration of interests AT has received funding for her service on the Global Paediatrics Advisory Board between Oct 4, 2021, and Nov 14, 2021, with payments made to the MRC Clinical Trials Unit at University College London. All other authors declare no competing interests.\n",
      "\n",
      "Declaration of interests AT has received funding for her service on the Global Paediatrics Advisory Board between Oct 4, 2021, and Nov 14, 2021, with payments made to the MRC Clinical Trials Unit at University College London. All other authors declare no competing interests.\n",
      "\n",
      "Declaration of interests AT has received funding for her service on the Global Paediatrics Advisory Board between Oct 4, 2021, and Nov 14, 2021, with payments made to the MRC Clinical Trials Unit at University College London. All other authors declare no competing interests.\n",
      "\n",
      "Declaration of interests AT has received funding for her service on the Global Paediatrics Advisory Board between Oct 4, 2021, and Nov 14, 2021, with payments made to the MRC Clinical Trials Unit at University College London. All other authors declare no competing interests.\n",
      "\n",
      "Declaration of interests AT has received funding for her service on the Global Paediatrics Advisory Board between Oct 4, 2021, and Nov 14, 2021, with payments made to the MRC Clinical Trials Unit at University College London. All other authors declare no competing interests.\n",
      "\n",
      "Declaration of interests AT has received funding for her service on the Global Paediatrics Advisory Board between Oct 4, 2021, and Nov 14, 2021, with payments made to the MRC Clinical Trials Unit at University College London. All other authors declare no competing interests.\n",
      "\n",
      "Declaration of interests AT has received funding for her service on the Global Paediatrics Advisory Board between Oct 4, 2021, and Nov 14, 2021, with payments made to the MRC Clinical Trials Unit at University College London. All other authors declare no competing interests.\n",
      "\n",
      "Declaration of interests AT has received funding for her service on the Global Paediatrics Advisory Board between Oct 4, 2021, and Nov 14, 2021, with payments made to the MRC Clinical Trials Unit at University College London. All other authors declare no competing interests.\n",
      "\n",
      "Declaration of interests AT has received funding for her service on the Global Paediatrics Advisory Board between Oct 4, 2021, and Nov 14, 2021, with payments made to the MRC Clinical Trials Unit at University College London. All other authors declare no competing interests.\n",
      "\n",
      "Declaration of interests AT has received funding for her service on the Global Paediatrics Advisory Board between Oct 4, 2021, and Nov 14, 2021, with payments made to the MRC Clinical Trials Unit at University College London. All other authors declare no competing interests.\n",
      "\n",
      "Declaration of interests AT has received funding for her service on the Global Paediatrics Advisory Board between Oct 4, 2021, and Nov 14, 2021, with payments made to the MRC Clinical Trials Unit at University College London. All other authors declare no competing interests.\n",
      "\n",
      "Declaration of interests AT has received funding for her service on the Global Paediatrics Advisory Board between Oct 4, 2021, and Nov 14, 2021, with payments made to the MRC Clinical Trials Unit at University College London. All other authors declare no competing interests.\n",
      "\n",
      "Declaration of interests AT has received funding for her service on the Global Paediatrics Advisory Board between Oct 4, 2021, and Nov 14, 2021, with payments made to the MRC Clinical Trials Unit at University College London. All other authors declare no competing interests.\n",
      "\n",
      "Declaration of interests AT has received funding for her service on the Global Paediatrics Advisory Board between Oct 4, 2021, and Nov 14, 2021, with payments made to the MRC Clinical Trials Unit at University College London. All other authors declare no competing interests.\n",
      "\n",
      "Declaration of interests AT has received funding for her service on the Global Paediatrics Advisory Board between Oct 4, 2021, and Nov 14, 2021, with payments made to the MRC Clinical Trials Unit at University College London. All other authors declare no competing interests.\n",
      "\n",
      "Declaration of interests AT has received funding for her service on the Global Paediatrics Advisory Board between Oct 4, 2021, and Nov 14, 2021, with payments made to the MRC Clinical Trials Unit at University College London. All other authors declare no competing interests.\n",
      "\n",
      "Declaration of interests AT has received funding for her service on the Global Paediatrics Advisory Board between Oct 4, 2021, and Nov 14, 2021, with payments made to the MRC Clinical Trials Unit at University College London. All other authors declare no competing interests.\n",
      "\n",
      "Turkova, Anna\n",
      "Declaration of interests Anna Turkova has received funding for her service on the Global Paediatrics Advisory Board between Oct 4, 2021, and Nov 14, 2021, with payments made to the MRC Clinical Trials Unit at University College London. All other authors declare no competing interests.\n",
      "\n",
      "Declaration of interests Anna Turkova has received funding for her service on the Global Paediatrics Advisory Board between Oct 4, 2021, and Nov 14, 2021, with payments made to the MRC Clinical Trials Unit at University College London. All other authors declare no competing interests.\n",
      "\n",
      "Vermund, Sten H.\n",
      "I declare no competing interests. Sten H. Vermund is supported, in part, by National Institutes of Health (grant number P30MH062294). The funding agency had no role in this Comment.\n",
      "\n",
      "Die Autorinnen/Autoren geben an, dass kein Interessenkonflikt besteht.\n",
      "\n",
      "Die Autorinnen/Autoren geben an, dass kein Interessenkonflikt besteht.\n",
      "\n",
      "Die Autorinnen/Autoren geben an, dass kein Interessenkonflikt besteht.\n",
      "\n",
      "Die Autorinnen/Autoren geben an, dass kein Interessenkonflikt besteht.\n",
      "\n",
      "Die Autorinnen/Autoren geben an, dass kein Interessenkonflikt besteht.\n",
      "\n",
      "Die Autorinnen/Autoren geben an, dass kein Interessenkonflikt besteht.\n",
      "\n",
      "Die Autorinnen/Autoren geben an, dass kein Interessenkonflikt besteht.\n",
      "\n",
      "Die Autorinnen/Autoren geben an, dass kein Interessenkonflikt besteht.\n",
      "\n",
      "Die Autorinnen/Autoren geben an, dass kein Interessenkonflikt besteht.\n",
      "\n",
      "Die Autorinnen/Autoren geben an, dass kein Interessenkonflikt besteht.\n",
      "\n",
      "Declarations of Competing Interest None\n",
      "\n",
      "Declarations of Competing Interest None\n",
      "\n",
      "Declarations of Competing Interest None\n",
      "\n",
      "Declarations of Competing Interest None\n",
      "\n",
      "Declarations of Competing Interest None\n",
      "\n",
      "Declarations of Competing Interest None\n",
      "\n",
      "Salazar, Luis G.\n",
      "Conflict of Interest The authors of this manuscript (Luis G. Salazar, Nicolas Rose, Brandon H. Hayes, Pachka Hammami, Eric Baubet, Stephanie Desvaux, and Mathieu Andraud) certify that they have NO affiliations with or involvement in any organization or entity with any financial interest or non-financial interest  in the subject matter or materials discussed in this manuscript.\n",
      "\n",
      "Rose, Nicolas\n",
      "Conflict of Interest The authors of this manuscript (Luis G. Salazar, Nicolas Rose, Brandon H. Hayes, Pachka Hammami, Eric Baubet, Stephanie Desvaux, and Mathieu Andraud) certify that they have NO affiliations with or involvement in any organization or entity with any financial interest or non-financial interest  in the subject matter or materials discussed in this manuscript.\n",
      "\n",
      "Hayes, Brandon\n",
      "Conflict of Interest The authors of this manuscript (Luis G. Salazar, Nicolas Rose, Brandon Hayes Hayes, Pachka Hammami, Eric Baubet, Stephanie Desvaux, and Mathieu Andraud) certify that they have NO affiliations with or involvement in any organization or entity with any financial interest or non-financial interest  in the subject matter or materials discussed in this manuscript.\n",
      "\n",
      "Hammami, Pachka\n",
      "Conflict of Interest The authors of this manuscript (Luis G. Salazar, Nicolas Rose, Brandon Hayes Hayes, Pachka Hammami, Eric Baubet, Stephanie Desvaux, and Mathieu Andraud) certify that they have NO affiliations with or involvement in any organization or entity with any financial interest or non-financial interest  in the subject matter or materials discussed in this manuscript.\n",
      "\n",
      "Baubet, Eric\n",
      "Conflict of Interest The authors of this manuscript (Luis G. Salazar, Nicolas Rose, Brandon Hayes Hayes, Pachka Hammami, Eric Baubet, Stephanie Desvaux, and Mathieu Andraud) certify that they have NO affiliations with or involvement in any organization or entity with any financial interest or non-financial interest  in the subject matter or materials discussed in this manuscript.\n",
      "\n",
      "Desvaux, Stephanie\n",
      "Conflict of Interest The authors of this manuscript (Luis G. Salazar, Nicolas Rose, Brandon Hayes Hayes, Pachka Hammami, Eric Baubet, Stephanie Desvaux, and Mathieu Andraud) certify that they have NO affiliations with or involvement in any organization or entity with any financial interest or non-financial interest  in the subject matter or materials discussed in this manuscript.\n",
      "\n",
      "Andraud, Mathieu\n",
      "Conflict of Interest The authors of this manuscript (Luis G. Salazar, Nicolas Rose, Brandon Hayes Hayes, Pachka Hammami, Eric Baubet, Stephanie Desvaux, and Mathieu Andraud) certify that they have NO affiliations with or involvement in any organization or entity with any financial interest or non-financial interest  in the subject matter or materials discussed in this manuscript.\n",
      "\n",
      "Zhuang, Jiali\n",
      "Declaration of interests Jiali Zhuang, AI, AA, APK, JA, MN JJS and ST are past/current employees at Molecular Stethoscope Inc. JJS, SRQ and ST have company stock options. SRQ is a founder of Molecular Stethoscope Inc. and a member of scientific advisory board.\n",
      "\n",
      "Ibarra, Arkaitz\n",
      "Declaration of interests Jiali Zhuang, Arkaitz Ibarra, AA, APK, JA, MN JJS and ST are past/current employees at Molecular Stethoscope Inc. JJS, SRQ and ST have company stock options. SRQ is a founder of Molecular Stethoscope Inc. and a member of scientific advisory board.\n",
      "\n",
      "Acosta, Alexander\n",
      "Declaration of interests Jiali Zhuang, Arkaitz Ibarra, Alexander Acosta, APK, JA, MN JJS and ST are past/current employees at Molecular Stethoscope Inc. JJS, SRQ and ST have company stock options. SRQ is a founder of Molecular Stethoscope Inc. and a member of scientific advisory board.\n",
      "\n",
      "Karns, Amy P.\n",
      "Declaration of interests Jiali Zhuang, Arkaitz Ibarra, Alexander Acosta, Amy P. Karns, JA, MN JJS and ST are past/current employees at Molecular Stethoscope Inc. JJS, SRQ and ST have company stock options. SRQ is a founder of Molecular Stethoscope Inc. and a member of scientific advisory board.\n",
      "\n",
      "Aballi, Jonathan\n",
      "Declaration of interests Jiali Zhuang, Arkaitz Ibarra, Alexander Acosta, Amy P. Karns, Jonathan Aballi, MN JJS and ST are past/current employees at Molecular Stethoscope Inc. JJS, SRQ and ST have company stock options. SRQ is a founder of Molecular Stethoscope Inc. and a member of scientific advisory board.\n",
      "\n",
      "Nerenberg, Michael\n",
      "Declaration of interests Jiali Zhuang, Arkaitz Ibarra, Alexander Acosta, Amy P. Karns, Jonathan Aballi, Michael Nerenberg JJS and ST are past/current employees at Molecular Stethoscope Inc. JJS, SRQ and ST have company stock options. SRQ is a founder of Molecular Stethoscope Inc. and a member of scientific advisory board.\n",
      "\n",
      "Sninsky, John J.\n",
      "Declaration of interests Jiali Zhuang, Arkaitz Ibarra, Alexander Acosta, Amy P. Karns, Jonathan Aballi, Michael Nerenberg John J. Sninsky and ST are past/current employees at Molecular Stethoscope Inc. John J. Sninsky, SRQ and ST have company stock options. SRQ is a founder of Molecular Stethoscope Inc. and a member of scientific advisory board.\n",
      "\n",
      "Quake, Stephen R.\n",
      "Declaration of interests Jiali Zhuang, Arkaitz Ibarra, Alexander Acosta, Amy P. Karns, Jonathan Aballi, Michael Nerenberg John J. Sninsky and ST are past/current employees at Molecular Stethoscope Inc. John J. Sninsky, Stephen R. Quake and ST have company stock options. Stephen R. Quake is a founder of Molecular Stethoscope Inc. and a member of scientific advisory board.\n",
      "\n",
      "Toden, Shusuke\n",
      "Declaration of interests Jiali Zhuang, Arkaitz Ibarra, Alexander Acosta, Amy P. Karns, Jonathan Aballi, Michael Nerenberg John J. Sninsky and Shusuke Toden are past/current employees at Molecular Stethoscope Inc. John J. Sninsky, Stephen R. Quake and Shusuke Toden have company stock options. Stephen R. Quake is a founder of Molecular Stethoscope Inc. and a member of scientific advisory board.\n",
      "\n",
      "Padberg, Frank\n",
      "Frank Padberg is a member of the European Scientific Advisory Board of Brainsway Inc., Jerusalem, Israel, and the International Scientific Advisory Board of Sooma, Helsinki, Finland. He has received speaker's honoraria from Mag&More GmbH, the neuroCare Group, Munich, Germany, and Brainsway Inc. His lab has received support with equipment from neuroConn GmbH, Ilmenau, Germany, Mag&More GmbH and Brainsway Inc. AB is Chief Medical Advisor of Flow Neuroscience (Malmo, Sweden) and has a small equity in this company (2019-onwards).\n",
      "\n",
      "Frank Padberg is a member of the European Scientific Advisory Board of Brainsway Inc., Jerusalem, Israel, and the International Scientific Advisory Board of Sooma, Helsinki, Finland. He has received speaker's honoraria from Mag&More GmbH, the neuroCare Group, Munich, Germany, and Brainsway Inc. His lab has received support with equipment from neuroConn GmbH, Ilmenau, Germany, Mag&More GmbH and Brainsway Inc. AB is Chief Medical Advisor of Flow Neuroscience (Malmo, Sweden) and has a small equity in this company (2019-onwards).\n",
      "\n",
      "Frank Padberg is a member of the European Scientific Advisory Board of Brainsway Inc., Jerusalem, Israel, and the International Scientific Advisory Board of Sooma, Helsinki, Finland. He has received speaker's honoraria from Mag&More GmbH, the neuroCare Group, Munich, Germany, and Brainsway Inc. His lab has received support with equipment from neuroConn GmbH, Ilmenau, Germany, Mag&More GmbH and Brainsway Inc. AB is Chief Medical Advisor of Flow Neuroscience (Malmo, Sweden) and has a small equity in this company (2019-onwards).\n",
      "\n",
      "Brunoni, Andre R.\n",
      "Frank Padberg is a member of the European Scientific Advisory Board of Brainsway Inc., Jerusalem, Israel, and the International Scientific Advisory Board of Sooma, Helsinki, Finland. He has received speaker's honoraria from Mag&More GmbH, the neuroCare Group, Munich, Germany, and Brainsway Inc. His lab has received support with equipment from neuroConn GmbH, Ilmenau, Germany, Mag&More GmbH and Brainsway Inc. Andre R. Brunoni is Chief Medical Advisor of Flow Neuroscience (Malmo, Sweden) and has a small equity in this company (2019-onwards).\n",
      "\n",
      "Regis Peffault de LatourHonoraria: Alexion Pharmaceuticals, Novartis, PfizerConsulting or Advisory Role: Alexion Pharmaceuticals, NovartisResearch Funding: Alexion Pharmaceuticals (Inst), Pfizer (Inst), Novartis (Inst) Maria Teresa VosoHonoraria: AbbVie, Astellas Pharma, Jazz Pharmaceuticals, Celene/BMSSpeakers' Bureau: CelgeneResearch Funding: Celgene (Inst), Novartis (Inst) Flore Sicre de FontbruneHonoraria: Alexion Pharmaceuticals, SOBI, NovartisSpeakers' Bureau: Alexion Pharmaceuticals, NovartisResearch Funding: Alexion Pharmaceuticals (Inst), Novartis (Inst) Marie SebertHonoraria: AbbVie, Jazz Pharmaceuticals, SERVIER, Pfizer, Celgene/Bristol Myers SquibbTravel, Accommodations, Expenses: SERVIER Jean SoulierConsulting or Advisory Role: STRM.BIO Inc Jaroslaw P. MaciejewskiConsulting or Advisory Role: Celgene, Novartis, Bristol Myers Squibb/Celgene Sophie Caillat-ZucmanHonoraria: Kite/Gilead Rodrigo T. CaladoConsulting or Advisory Role: Novartis Brasil Bhumika J. PatelConsulting or Advisory Role: NovartisSpeakers' Bureau: Alexion Pharmaceuticals, Apellis Pharmaceuticals Gerard SocieConsulting or Advisory Role: Xenikos, NovartisResearch Funding: Alexion Pharmaceuticals (Inst)No other potential conflicts of interest were reported.\n",
      "\n",
      "Regis Peffault de LatourHonoraria: Alexion Pharmaceuticals, Novartis, PfizerConsulting or Advisory Role: Alexion Pharmaceuticals, NovartisResearch Funding: Alexion Pharmaceuticals (Inst), Pfizer (Inst), Novartis (Inst) Maria Teresa VosoHonoraria: AbbVie, Astellas Pharma, Jazz Pharmaceuticals, Celene/BMSSpeakers' Bureau: CelgeneResearch Funding: Celgene (Inst), Novartis (Inst) Flore Sicre de FontbruneHonoraria: Alexion Pharmaceuticals, SOBI, NovartisSpeakers' Bureau: Alexion Pharmaceuticals, NovartisResearch Funding: Alexion Pharmaceuticals (Inst), Novartis (Inst) Marie SebertHonoraria: AbbVie, Jazz Pharmaceuticals, SERVIER, Pfizer, Celgene/Bristol Myers SquibbTravel, Accommodations, Expenses: SERVIER Jean SoulierConsulting or Advisory Role: STRM.BIO Inc Jaroslaw P. MaciejewskiConsulting or Advisory Role: Celgene, Novartis, Bristol Myers Squibb/Celgene Sophie Caillat-ZucmanHonoraria: Kite/Gilead Rodrigo T. CaladoConsulting or Advisory Role: Novartis Brasil Bhumika J. PatelConsulting or Advisory Role: NovartisSpeakers' Bureau: Alexion Pharmaceuticals, Apellis Pharmaceuticals Gerard SocieConsulting or Advisory Role: Xenikos, NovartisResearch Funding: Alexion Pharmaceuticals (Inst)No other potential conflicts of interest were reported.\n",
      "\n",
      "Regis Peffault de LatourHonoraria: Alexion Pharmaceuticals, Novartis, PfizerConsulting or Advisory Role: Alexion Pharmaceuticals, NovartisResearch Funding: Alexion Pharmaceuticals (Inst), Pfizer (Inst), Novartis (Inst) Maria Teresa VosoHonoraria: AbbVie, Astellas Pharma, Jazz Pharmaceuticals, Celene/BMSSpeakers' Bureau: CelgeneResearch Funding: Celgene (Inst), Novartis (Inst) Flore Sicre de FontbruneHonoraria: Alexion Pharmaceuticals, SOBI, NovartisSpeakers' Bureau: Alexion Pharmaceuticals, NovartisResearch Funding: Alexion Pharmaceuticals (Inst), Novartis (Inst) Marie SebertHonoraria: AbbVie, Jazz Pharmaceuticals, SERVIER, Pfizer, Celgene/Bristol Myers SquibbTravel, Accommodations, Expenses: SERVIER Jean SoulierConsulting or Advisory Role: STRM.BIO Inc Jaroslaw P. MaciejewskiConsulting or Advisory Role: Celgene, Novartis, Bristol Myers Squibb/Celgene Sophie Caillat-ZucmanHonoraria: Kite/Gilead Rodrigo T. CaladoConsulting or Advisory Role: Novartis Brasil Bhumika J. PatelConsulting or Advisory Role: NovartisSpeakers' Bureau: Alexion Pharmaceuticals, Apellis Pharmaceuticals Gerard SocieConsulting or Advisory Role: Xenikos, NovartisResearch Funding: Alexion Pharmaceuticals (Inst)No other potential conflicts of interest were reported.\n",
      "\n",
      "Regis Peffault de LatourHonoraria: Alexion Pharmaceuticals, Novartis, PfizerConsulting or Advisory Role: Alexion Pharmaceuticals, NovartisResearch Funding: Alexion Pharmaceuticals (Inst), Pfizer (Inst), Novartis (Inst) Maria Teresa VosoHonoraria: AbbVie, Astellas Pharma, Jazz Pharmaceuticals, Celene/BMSSpeakers' Bureau: CelgeneResearch Funding: Celgene (Inst), Novartis (Inst) Flore Sicre de FontbruneHonoraria: Alexion Pharmaceuticals, SOBI, NovartisSpeakers' Bureau: Alexion Pharmaceuticals, NovartisResearch Funding: Alexion Pharmaceuticals (Inst), Novartis (Inst) Marie SebertHonoraria: AbbVie, Jazz Pharmaceuticals, SERVIER, Pfizer, Celgene/Bristol Myers SquibbTravel, Accommodations, Expenses: SERVIER Jean SoulierConsulting or Advisory Role: STRM.BIO Inc Jaroslaw P. MaciejewskiConsulting or Advisory Role: Celgene, Novartis, Bristol Myers Squibb/Celgene Sophie Caillat-ZucmanHonoraria: Kite/Gilead Rodrigo T. CaladoConsulting or Advisory Role: Novartis Brasil Bhumika J. PatelConsulting or Advisory Role: NovartisSpeakers' Bureau: Alexion Pharmaceuticals, Apellis Pharmaceuticals Gerard SocieConsulting or Advisory Role: Xenikos, NovartisResearch Funding: Alexion Pharmaceuticals (Inst)No other potential conflicts of interest were reported.\n",
      "\n",
      "Regis Peffault de LatourHonoraria: Alexion Pharmaceuticals, Novartis, PfizerConsulting or Advisory Role: Alexion Pharmaceuticals, NovartisResearch Funding: Alexion Pharmaceuticals (Inst), Pfizer (Inst), Novartis (Inst) Maria Teresa VosoHonoraria: AbbVie, Astellas Pharma, Jazz Pharmaceuticals, Celene/BMSSpeakers' Bureau: CelgeneResearch Funding: Celgene (Inst), Novartis (Inst) Flore Sicre de FontbruneHonoraria: Alexion Pharmaceuticals, SOBI, NovartisSpeakers' Bureau: Alexion Pharmaceuticals, NovartisResearch Funding: Alexion Pharmaceuticals (Inst), Novartis (Inst) Marie SebertHonoraria: AbbVie, Jazz Pharmaceuticals, SERVIER, Pfizer, Celgene/Bristol Myers SquibbTravel, Accommodations, Expenses: SERVIER Jean SoulierConsulting or Advisory Role: STRM.BIO Inc Jaroslaw P. MaciejewskiConsulting or Advisory Role: Celgene, Novartis, Bristol Myers Squibb/Celgene Sophie Caillat-ZucmanHonoraria: Kite/Gilead Rodrigo T. CaladoConsulting or Advisory Role: Novartis Brasil Bhumika J. PatelConsulting or Advisory Role: NovartisSpeakers' Bureau: Alexion Pharmaceuticals, Apellis Pharmaceuticals Gerard SocieConsulting or Advisory Role: Xenikos, NovartisResearch Funding: Alexion Pharmaceuticals (Inst)No other potential conflicts of interest were reported.\n",
      "\n",
      "Regis Peffault de LatourHonoraria: Alexion Pharmaceuticals, Novartis, PfizerConsulting or Advisory Role: Alexion Pharmaceuticals, NovartisResearch Funding: Alexion Pharmaceuticals (Inst), Pfizer (Inst), Novartis (Inst) Maria Teresa VosoHonoraria: AbbVie, Astellas Pharma, Jazz Pharmaceuticals, Celene/BMSSpeakers' Bureau: CelgeneResearch Funding: Celgene (Inst), Novartis (Inst) Flore Sicre de FontbruneHonoraria: Alexion Pharmaceuticals, SOBI, NovartisSpeakers' Bureau: Alexion Pharmaceuticals, NovartisResearch Funding: Alexion Pharmaceuticals (Inst), Novartis (Inst) Marie SebertHonoraria: AbbVie, Jazz Pharmaceuticals, SERVIER, Pfizer, Celgene/Bristol Myers SquibbTravel, Accommodations, Expenses: SERVIER Jean SoulierConsulting or Advisory Role: STRM.BIO Inc Jaroslaw P. MaciejewskiConsulting or Advisory Role: Celgene, Novartis, Bristol Myers Squibb/Celgene Sophie Caillat-ZucmanHonoraria: Kite/Gilead Rodrigo T. CaladoConsulting or Advisory Role: Novartis Brasil Bhumika J. PatelConsulting or Advisory Role: NovartisSpeakers' Bureau: Alexion Pharmaceuticals, Apellis Pharmaceuticals Gerard SocieConsulting or Advisory Role: Xenikos, NovartisResearch Funding: Alexion Pharmaceuticals (Inst)No other potential conflicts of interest were reported.\n",
      "\n",
      "Sebert, Marie\n",
      "Regis Peffault de LatourHonoraria: Alexion Pharmaceuticals, Novartis, PfizerConsulting or Advisory Role: Alexion Pharmaceuticals, NovartisResearch Funding: Alexion Pharmaceuticals (Inst), Pfizer (Inst), Novartis (Inst) Maria Teresa VosoHonoraria: AbbVie, Astellas Pharma, Jazz Pharmaceuticals, Celene/BMSSpeakers' Bureau: CelgeneResearch Funding: Celgene (Inst), Novartis (Inst) Flore Sicre de FontbruneHonoraria: Alexion Pharmaceuticals, SOBI, NovartisSpeakers' Bureau: Alexion Pharmaceuticals, NovartisResearch Funding: Alexion Pharmaceuticals (Inst), Novartis (Inst) Marie SebertHonoraria: AbbVie, Jazz Pharmaceuticals, SERVIER, Pfizer, Celgene/Bristol Myers SquibbTravel, Accommodations, Expenses: SERVIER Jean SoulierConsulting or Advisory Role: STRM.BIO Inc Jaroslaw P. MaciejewskiConsulting or Advisory Role: Celgene, Novartis, Bristol Myers Squibb/Celgene Sophie Caillat-ZucmanHonoraria: Kite/Gilead Rodrigo T. CaladoConsulting or Advisory Role: Novartis Brasil Bhumika J. PatelConsulting or Advisory Role: NovartisSpeakers' Bureau: Alexion Pharmaceuticals, Apellis Pharmaceuticals Gerard SocieConsulting or Advisory Role: Xenikos, NovartisResearch Funding: Alexion Pharmaceuticals (Inst)No other potential conflicts of interest were reported.\n",
      "\n",
      "Regis Peffault de LatourHonoraria: Alexion Pharmaceuticals, Novartis, PfizerConsulting or Advisory Role: Alexion Pharmaceuticals, NovartisResearch Funding: Alexion Pharmaceuticals (Inst), Pfizer (Inst), Novartis (Inst) Maria Teresa VosoHonoraria: AbbVie, Astellas Pharma, Jazz Pharmaceuticals, Celene/BMSSpeakers' Bureau: CelgeneResearch Funding: Celgene (Inst), Novartis (Inst) Flore Sicre de FontbruneHonoraria: Alexion Pharmaceuticals, SOBI, NovartisSpeakers' Bureau: Alexion Pharmaceuticals, NovartisResearch Funding: Alexion Pharmaceuticals (Inst), Novartis (Inst) Marie SebertHonoraria: AbbVie, Jazz Pharmaceuticals, SERVIER, Pfizer, Celgene/Bristol Myers SquibbTravel, Accommodations, Expenses: SERVIER Jean SoulierConsulting or Advisory Role: STRM.BIO Inc Jaroslaw P. MaciejewskiConsulting or Advisory Role: Celgene, Novartis, Bristol Myers Squibb/Celgene Sophie Caillat-ZucmanHonoraria: Kite/Gilead Rodrigo T. CaladoConsulting or Advisory Role: Novartis Brasil Bhumika J. PatelConsulting or Advisory Role: NovartisSpeakers' Bureau: Alexion Pharmaceuticals, Apellis Pharmaceuticals Gerard SocieConsulting or Advisory Role: Xenikos, NovartisResearch Funding: Alexion Pharmaceuticals (Inst)No other potential conflicts of interest were reported.\n",
      "\n",
      "Patel, Bhumika J.\n",
      "Regis Peffault de LatourHonoraria: Alexion Pharmaceuticals, Novartis, PfizerConsulting or Advisory Role: Alexion Pharmaceuticals, NovartisResearch Funding: Alexion Pharmaceuticals (Inst), Pfizer (Inst), Novartis (Inst) Maria Teresa VosoHonoraria: AbbVie, Astellas Pharma, Jazz Pharmaceuticals, Celene/BMSSpeakers' Bureau: CelgeneResearch Funding: Celgene (Inst), Novartis (Inst) Flore Sicre de FontbruneHonoraria: Alexion Pharmaceuticals, SOBI, NovartisSpeakers' Bureau: Alexion Pharmaceuticals, NovartisResearch Funding: Alexion Pharmaceuticals (Inst), Novartis (Inst) Marie SebertHonoraria: AbbVie, Jazz Pharmaceuticals, SERVIER, Pfizer, Celgene/Bristol Myers SquibbTravel, Accommodations, Expenses: SERVIER Jean SoulierConsulting or Advisory Role: STRM.BIO Inc Jaroslaw P. MaciejewskiConsulting or Advisory Role: Celgene, Novartis, Bristol Myers Squibb/Celgene Sophie Caillat-ZucmanHonoraria: Kite/Gilead Rodrigo T. CaladoConsulting or Advisory Role: Novartis Brasil Bhumika J. PatelConsulting or Advisory Role: NovartisSpeakers' Bureau: Alexion Pharmaceuticals, Apellis Pharmaceuticals Gerard SocieConsulting or Advisory Role: Xenikos, NovartisResearch Funding: Alexion Pharmaceuticals (Inst)No other potential conflicts of interest were reported.\n",
      "\n",
      "Regis Peffault de LatourHonoraria: Alexion Pharmaceuticals, Novartis, PfizerConsulting or Advisory Role: Alexion Pharmaceuticals, NovartisResearch Funding: Alexion Pharmaceuticals (Inst), Pfizer (Inst), Novartis (Inst) Maria Teresa VosoHonoraria: AbbVie, Astellas Pharma, Jazz Pharmaceuticals, Celene/BMSSpeakers' Bureau: CelgeneResearch Funding: Celgene (Inst), Novartis (Inst) Flore Sicre de FontbruneHonoraria: Alexion Pharmaceuticals, SOBI, NovartisSpeakers' Bureau: Alexion Pharmaceuticals, NovartisResearch Funding: Alexion Pharmaceuticals (Inst), Novartis (Inst) Marie SebertHonoraria: AbbVie, Jazz Pharmaceuticals, SERVIER, Pfizer, Celgene/Bristol Myers SquibbTravel, Accommodations, Expenses: SERVIER Jean SoulierConsulting or Advisory Role: STRM.BIO Inc Jaroslaw P. MaciejewskiConsulting or Advisory Role: Celgene, Novartis, Bristol Myers Squibb/Celgene Sophie Caillat-ZucmanHonoraria: Kite/Gilead Rodrigo T. CaladoConsulting or Advisory Role: Novartis Brasil Bhumika J. PatelConsulting or Advisory Role: NovartisSpeakers' Bureau: Alexion Pharmaceuticals, Apellis Pharmaceuticals Gerard SocieConsulting or Advisory Role: Xenikos, NovartisResearch Funding: Alexion Pharmaceuticals (Inst)No other potential conflicts of interest were reported.\n",
      "\n",
      "Regis Peffault de LatourHonoraria: Alexion Pharmaceuticals, Novartis, PfizerConsulting or Advisory Role: Alexion Pharmaceuticals, NovartisResearch Funding: Alexion Pharmaceuticals (Inst), Pfizer (Inst), Novartis (Inst) Maria Teresa VosoHonoraria: AbbVie, Astellas Pharma, Jazz Pharmaceuticals, Celene/BMSSpeakers' Bureau: CelgeneResearch Funding: Celgene (Inst), Novartis (Inst) Flore Sicre de FontbruneHonoraria: Alexion Pharmaceuticals, SOBI, NovartisSpeakers' Bureau: Alexion Pharmaceuticals, NovartisResearch Funding: Alexion Pharmaceuticals (Inst), Novartis (Inst) Marie SebertHonoraria: AbbVie, Jazz Pharmaceuticals, SERVIER, Pfizer, Celgene/Bristol Myers SquibbTravel, Accommodations, Expenses: SERVIER Jean SoulierConsulting or Advisory Role: STRM.BIO Inc Jaroslaw P. MaciejewskiConsulting or Advisory Role: Celgene, Novartis, Bristol Myers Squibb/Celgene Sophie Caillat-ZucmanHonoraria: Kite/Gilead Rodrigo T. CaladoConsulting or Advisory Role: Novartis Brasil Bhumika J. PatelConsulting or Advisory Role: NovartisSpeakers' Bureau: Alexion Pharmaceuticals, Apellis Pharmaceuticals Gerard SocieConsulting or Advisory Role: Xenikos, NovartisResearch Funding: Alexion Pharmaceuticals (Inst)No other potential conflicts of interest were reported.\n",
      "\n",
      "Regis Peffault de LatourHonoraria: Alexion Pharmaceuticals, Novartis, PfizerConsulting or Advisory Role: Alexion Pharmaceuticals, NovartisResearch Funding: Alexion Pharmaceuticals (Inst), Pfizer (Inst), Novartis (Inst) Maria Teresa VosoHonoraria: AbbVie, Astellas Pharma, Jazz Pharmaceuticals, Celene/BMSSpeakers' Bureau: CelgeneResearch Funding: Celgene (Inst), Novartis (Inst) Flore Sicre de FontbruneHonoraria: Alexion Pharmaceuticals, SOBI, NovartisSpeakers' Bureau: Alexion Pharmaceuticals, NovartisResearch Funding: Alexion Pharmaceuticals (Inst), Novartis (Inst) Marie SebertHonoraria: AbbVie, Jazz Pharmaceuticals, SERVIER, Pfizer, Celgene/Bristol Myers SquibbTravel, Accommodations, Expenses: SERVIER Jean SoulierConsulting or Advisory Role: STRM.BIO Inc Jaroslaw P. MaciejewskiConsulting or Advisory Role: Celgene, Novartis, Bristol Myers Squibb/Celgene Sophie Caillat-ZucmanHonoraria: Kite/Gilead Rodrigo T. CaladoConsulting or Advisory Role: Novartis Brasil Bhumika J. PatelConsulting or Advisory Role: NovartisSpeakers' Bureau: Alexion Pharmaceuticals, Apellis Pharmaceuticals Gerard SocieConsulting or Advisory Role: Xenikos, NovartisResearch Funding: Alexion Pharmaceuticals (Inst)No other potential conflicts of interest were reported.\n",
      "\n",
      "Regis Peffault de LatourHonoraria: Alexion Pharmaceuticals, Novartis, PfizerConsulting or Advisory Role: Alexion Pharmaceuticals, NovartisResearch Funding: Alexion Pharmaceuticals (Inst), Pfizer (Inst), Novartis (Inst) Maria Teresa VosoHonoraria: AbbVie, Astellas Pharma, Jazz Pharmaceuticals, Celene/BMSSpeakers' Bureau: CelgeneResearch Funding: Celgene (Inst), Novartis (Inst) Flore Sicre de FontbruneHonoraria: Alexion Pharmaceuticals, SOBI, NovartisSpeakers' Bureau: Alexion Pharmaceuticals, NovartisResearch Funding: Alexion Pharmaceuticals (Inst), Novartis (Inst) Marie SebertHonoraria: AbbVie, Jazz Pharmaceuticals, SERVIER, Pfizer, Celgene/Bristol Myers SquibbTravel, Accommodations, Expenses: SERVIER Jean SoulierConsulting or Advisory Role: STRM.BIO Inc Jaroslaw P. MaciejewskiConsulting or Advisory Role: Celgene, Novartis, Bristol Myers Squibb/Celgene Sophie Caillat-ZucmanHonoraria: Kite/Gilead Rodrigo T. CaladoConsulting or Advisory Role: Novartis Brasil Bhumika J. PatelConsulting or Advisory Role: NovartisSpeakers' Bureau: Alexion Pharmaceuticals, Apellis Pharmaceuticals Gerard SocieConsulting or Advisory Role: Xenikos, NovartisResearch Funding: Alexion Pharmaceuticals (Inst)No other potential conflicts of interest were reported.\n",
      "\n",
      "Regis Peffault de LatourHonoraria: Alexion Pharmaceuticals, Novartis, PfizerConsulting or Advisory Role: Alexion Pharmaceuticals, NovartisResearch Funding: Alexion Pharmaceuticals (Inst), Pfizer (Inst), Novartis (Inst) Maria Teresa VosoHonoraria: AbbVie, Astellas Pharma, Jazz Pharmaceuticals, Celene/BMSSpeakers' Bureau: CelgeneResearch Funding: Celgene (Inst), Novartis (Inst) Flore Sicre de FontbruneHonoraria: Alexion Pharmaceuticals, SOBI, NovartisSpeakers' Bureau: Alexion Pharmaceuticals, NovartisResearch Funding: Alexion Pharmaceuticals (Inst), Novartis (Inst) Marie SebertHonoraria: AbbVie, Jazz Pharmaceuticals, SERVIER, Pfizer, Celgene/Bristol Myers SquibbTravel, Accommodations, Expenses: SERVIER Jean SoulierConsulting or Advisory Role: STRM.BIO Inc Jaroslaw P. MaciejewskiConsulting or Advisory Role: Celgene, Novartis, Bristol Myers Squibb/Celgene Sophie Caillat-ZucmanHonoraria: Kite/Gilead Rodrigo T. CaladoConsulting or Advisory Role: Novartis Brasil Bhumika J. PatelConsulting or Advisory Role: NovartisSpeakers' Bureau: Alexion Pharmaceuticals, Apellis Pharmaceuticals Gerard SocieConsulting or Advisory Role: Xenikos, NovartisResearch Funding: Alexion Pharmaceuticals (Inst)No other potential conflicts of interest were reported.\n",
      "\n",
      "Caillat-Zucman, Sophie\n",
      "Regis Peffault de LatourHonoraria: Alexion Pharmaceuticals, Novartis, PfizerConsulting or Advisory Role: Alexion Pharmaceuticals, NovartisResearch Funding: Alexion Pharmaceuticals (Inst), Pfizer (Inst), Novartis (Inst) Maria Teresa VosoHonoraria: AbbVie, Astellas Pharma, Jazz Pharmaceuticals, Celene/BMSSpeakers' Bureau: CelgeneResearch Funding: Celgene (Inst), Novartis (Inst) Flore Sicre de FontbruneHonoraria: Alexion Pharmaceuticals, SOBI, NovartisSpeakers' Bureau: Alexion Pharmaceuticals, NovartisResearch Funding: Alexion Pharmaceuticals (Inst), Novartis (Inst) Marie SebertHonoraria: AbbVie, Jazz Pharmaceuticals, SERVIER, Pfizer, Celgene/Bristol Myers SquibbTravel, Accommodations, Expenses: SERVIER Jean SoulierConsulting or Advisory Role: STRM.BIO Inc Jaroslaw P. MaciejewskiConsulting or Advisory Role: Celgene, Novartis, Bristol Myers Squibb/Celgene Sophie Caillat-ZucmanHonoraria: Kite/Gilead Rodrigo T. CaladoConsulting or Advisory Role: Novartis Brasil Bhumika J. PatelConsulting or Advisory Role: NovartisSpeakers' Bureau: Alexion Pharmaceuticals, Apellis Pharmaceuticals Gerard SocieConsulting or Advisory Role: Xenikos, NovartisResearch Funding: Alexion Pharmaceuticals (Inst)No other potential conflicts of interest were reported.\n",
      "\n",
      "Regis Peffault de LatourHonoraria: Alexion Pharmaceuticals, Novartis, PfizerConsulting or Advisory Role: Alexion Pharmaceuticals, NovartisResearch Funding: Alexion Pharmaceuticals (Inst), Pfizer (Inst), Novartis (Inst) Maria Teresa VosoHonoraria: AbbVie, Astellas Pharma, Jazz Pharmaceuticals, Celene/BMSSpeakers' Bureau: CelgeneResearch Funding: Celgene (Inst), Novartis (Inst) Flore Sicre de FontbruneHonoraria: Alexion Pharmaceuticals, SOBI, NovartisSpeakers' Bureau: Alexion Pharmaceuticals, NovartisResearch Funding: Alexion Pharmaceuticals (Inst), Novartis (Inst) Marie SebertHonoraria: AbbVie, Jazz Pharmaceuticals, SERVIER, Pfizer, Celgene/Bristol Myers SquibbTravel, Accommodations, Expenses: SERVIER Jean SoulierConsulting or Advisory Role: STRM.BIO Inc Jaroslaw P. MaciejewskiConsulting or Advisory Role: Celgene, Novartis, Bristol Myers Squibb/Celgene Sophie Caillat-ZucmanHonoraria: Kite/Gilead Rodrigo T. CaladoConsulting or Advisory Role: Novartis Brasil Bhumika J. PatelConsulting or Advisory Role: NovartisSpeakers' Bureau: Alexion Pharmaceuticals, Apellis Pharmaceuticals Gerard SocieConsulting or Advisory Role: Xenikos, NovartisResearch Funding: Alexion Pharmaceuticals (Inst)No other potential conflicts of interest were reported.\n",
      "\n",
      "Sicre de Fontbrune, Flore\n",
      "Regis Peffault de LatourHonoraria: Alexion Pharmaceuticals, Novartis, PfizerConsulting or Advisory Role: Alexion Pharmaceuticals, NovartisResearch Funding: Alexion Pharmaceuticals (Inst), Pfizer (Inst), Novartis (Inst) Maria Teresa VosoHonoraria: AbbVie, Astellas Pharma, Jazz Pharmaceuticals, Celene/BMSSpeakers' Bureau: CelgeneResearch Funding: Celgene (Inst), Novartis (Inst) Flore Sicre de FontbruneHonoraria: Alexion Pharmaceuticals, SOBI, NovartisSpeakers' Bureau: Alexion Pharmaceuticals, NovartisResearch Funding: Alexion Pharmaceuticals (Inst), Novartis (Inst) Marie SebertHonoraria: AbbVie, Jazz Pharmaceuticals, SERVIER, Pfizer, Celgene/Bristol Myers SquibbTravel, Accommodations, Expenses: SERVIER Jean SoulierConsulting or Advisory Role: STRM.BIO Inc Jaroslaw P. MaciejewskiConsulting or Advisory Role: Celgene, Novartis, Bristol Myers Squibb/Celgene Sophie Caillat-ZucmanHonoraria: Kite/Gilead Rodrigo T. CaladoConsulting or Advisory Role: Novartis Brasil Bhumika J. PatelConsulting or Advisory Role: NovartisSpeakers' Bureau: Alexion Pharmaceuticals, Apellis Pharmaceuticals Gerard SocieConsulting or Advisory Role: Xenikos, NovartisResearch Funding: Alexion Pharmaceuticals (Inst)No other potential conflicts of interest were reported.\n",
      "\n",
      "Teresa Voso, Maria\n",
      "Regis Peffault de LatourHonoraria: Alexion Pharmaceuticals, Novartis, PfizerConsulting or Advisory Role: Alexion Pharmaceuticals, NovartisResearch Funding: Alexion Pharmaceuticals (Inst), Pfizer (Inst), Novartis (Inst) Maria Teresa VosoHonoraria: AbbVie, Astellas Pharma, Jazz Pharmaceuticals, Celene/BMSSpeakers' Bureau: CelgeneResearch Funding: Celgene (Inst), Novartis (Inst) Flore Sicre de FontbruneHonoraria: Alexion Pharmaceuticals, SOBI, NovartisSpeakers' Bureau: Alexion Pharmaceuticals, NovartisResearch Funding: Alexion Pharmaceuticals (Inst), Novartis (Inst) Marie SebertHonoraria: AbbVie, Jazz Pharmaceuticals, SERVIER, Pfizer, Celgene/Bristol Myers SquibbTravel, Accommodations, Expenses: SERVIER Jean SoulierConsulting or Advisory Role: STRM.BIO Inc Jaroslaw P. MaciejewskiConsulting or Advisory Role: Celgene, Novartis, Bristol Myers Squibb/Celgene Sophie Caillat-ZucmanHonoraria: Kite/Gilead Rodrigo T. CaladoConsulting or Advisory Role: Novartis Brasil Bhumika J. PatelConsulting or Advisory Role: NovartisSpeakers' Bureau: Alexion Pharmaceuticals, Apellis Pharmaceuticals Gerard SocieConsulting or Advisory Role: Xenikos, NovartisResearch Funding: Alexion Pharmaceuticals (Inst)No other potential conflicts of interest were reported.\n",
      "\n",
      "Regis Peffault de LatourHonoraria: Alexion Pharmaceuticals, Novartis, PfizerConsulting or Advisory Role: Alexion Pharmaceuticals, NovartisResearch Funding: Alexion Pharmaceuticals (Inst), Pfizer (Inst), Novartis (Inst) Maria Teresa VosoHonoraria: AbbVie, Astellas Pharma, Jazz Pharmaceuticals, Celene/BMSSpeakers' Bureau: CelgeneResearch Funding: Celgene (Inst), Novartis (Inst) Flore Sicre de FontbruneHonoraria: Alexion Pharmaceuticals, SOBI, NovartisSpeakers' Bureau: Alexion Pharmaceuticals, NovartisResearch Funding: Alexion Pharmaceuticals (Inst), Novartis (Inst) Marie SebertHonoraria: AbbVie, Jazz Pharmaceuticals, SERVIER, Pfizer, Celgene/Bristol Myers SquibbTravel, Accommodations, Expenses: SERVIER Jean SoulierConsulting or Advisory Role: STRM.BIO Inc Jaroslaw P. MaciejewskiConsulting or Advisory Role: Celgene, Novartis, Bristol Myers Squibb/Celgene Sophie Caillat-ZucmanHonoraria: Kite/Gilead Rodrigo T. CaladoConsulting or Advisory Role: Novartis Brasil Bhumika J. PatelConsulting or Advisory Role: NovartisSpeakers' Bureau: Alexion Pharmaceuticals, Apellis Pharmaceuticals Gerard SocieConsulting or Advisory Role: Xenikos, NovartisResearch Funding: Alexion Pharmaceuticals (Inst)No other potential conflicts of interest were reported.\n",
      "\n",
      "Peffault de Latour, Regis\n",
      "Regis Peffault de LatourHonoraria: Alexion Pharmaceuticals, Novartis, PfizerConsulting or Advisory Role: Alexion Pharmaceuticals, NovartisResearch Funding: Alexion Pharmaceuticals (Inst), Pfizer (Inst), Novartis (Inst) Maria Teresa VosoHonoraria: AbbVie, Astellas Pharma, Jazz Pharmaceuticals, Celene/BMSSpeakers' Bureau: CelgeneResearch Funding: Celgene (Inst), Novartis (Inst) Flore Sicre de FontbruneHonoraria: Alexion Pharmaceuticals, SOBI, NovartisSpeakers' Bureau: Alexion Pharmaceuticals, NovartisResearch Funding: Alexion Pharmaceuticals (Inst), Novartis (Inst) Marie SebertHonoraria: AbbVie, Jazz Pharmaceuticals, SERVIER, Pfizer, Celgene/Bristol Myers SquibbTravel, Accommodations, Expenses: SERVIER Jean SoulierConsulting or Advisory Role: STRM.BIO Inc Jaroslaw P. MaciejewskiConsulting or Advisory Role: Celgene, Novartis, Bristol Myers Squibb/Celgene Sophie Caillat-ZucmanHonoraria: Kite/Gilead Rodrigo T. CaladoConsulting or Advisory Role: Novartis Brasil Bhumika J. PatelConsulting or Advisory Role: NovartisSpeakers' Bureau: Alexion Pharmaceuticals, Apellis Pharmaceuticals Gerard SocieConsulting or Advisory Role: Xenikos, NovartisResearch Funding: Alexion Pharmaceuticals (Inst)No other potential conflicts of interest were reported.\n",
      "\n",
      "Soulier, Jean\n",
      "Regis Peffault de LatourHonoraria: Alexion Pharmaceuticals, Novartis, PfizerConsulting or Advisory Role: Alexion Pharmaceuticals, NovartisResearch Funding: Alexion Pharmaceuticals (Inst), Pfizer (Inst), Novartis (Inst) Maria Teresa VosoHonoraria: AbbVie, Astellas Pharma, Jazz Pharmaceuticals, Celene/BMSSpeakers' Bureau: CelgeneResearch Funding: Celgene (Inst), Novartis (Inst) Flore Sicre de FontbruneHonoraria: Alexion Pharmaceuticals, SOBI, NovartisSpeakers' Bureau: Alexion Pharmaceuticals, NovartisResearch Funding: Alexion Pharmaceuticals (Inst), Novartis (Inst) Marie SebertHonoraria: AbbVie, Jazz Pharmaceuticals, SERVIER, Pfizer, Celgene/Bristol Myers SquibbTravel, Accommodations, Expenses: SERVIER Jean SoulierConsulting or Advisory Role: STRM.BIO Inc Jaroslaw P. MaciejewskiConsulting or Advisory Role: Celgene, Novartis, Bristol Myers Squibb/Celgene Sophie Caillat-ZucmanHonoraria: Kite/Gilead Rodrigo T. CaladoConsulting or Advisory Role: Novartis Brasil Bhumika J. PatelConsulting or Advisory Role: NovartisSpeakers' Bureau: Alexion Pharmaceuticals, Apellis Pharmaceuticals Gerard SocieConsulting or Advisory Role: Xenikos, NovartisResearch Funding: Alexion Pharmaceuticals (Inst)No other potential conflicts of interest were reported.\n",
      "\n",
      "Calado, Rodrigo T.\n",
      "Regis Peffault de LatourHonoraria: Alexion Pharmaceuticals, Novartis, PfizerConsulting or Advisory Role: Alexion Pharmaceuticals, NovartisResearch Funding: Alexion Pharmaceuticals (Inst), Pfizer (Inst), Novartis (Inst) Maria Teresa VosoHonoraria: AbbVie, Astellas Pharma, Jazz Pharmaceuticals, Celene/BMSSpeakers' Bureau: CelgeneResearch Funding: Celgene (Inst), Novartis (Inst) Flore Sicre de FontbruneHonoraria: Alexion Pharmaceuticals, SOBI, NovartisSpeakers' Bureau: Alexion Pharmaceuticals, NovartisResearch Funding: Alexion Pharmaceuticals (Inst), Novartis (Inst) Marie SebertHonoraria: AbbVie, Jazz Pharmaceuticals, SERVIER, Pfizer, Celgene/Bristol Myers SquibbTravel, Accommodations, Expenses: SERVIER Jean SoulierConsulting or Advisory Role: STRM.BIO Inc Jaroslaw P. MaciejewskiConsulting or Advisory Role: Celgene, Novartis, Bristol Myers Squibb/Celgene Sophie Caillat-ZucmanHonoraria: Kite/Gilead Rodrigo T. CaladoConsulting or Advisory Role: Novartis Brasil Bhumika J. PatelConsulting or Advisory Role: NovartisSpeakers' Bureau: Alexion Pharmaceuticals, Apellis Pharmaceuticals Gerard SocieConsulting or Advisory Role: Xenikos, NovartisResearch Funding: Alexion Pharmaceuticals (Inst)No other potential conflicts of interest were reported.\n",
      "\n",
      "Socie, Gerard\n",
      "Regis Peffault de LatourHonoraria: Alexion Pharmaceuticals, Novartis, PfizerConsulting or Advisory Role: Alexion Pharmaceuticals, NovartisResearch Funding: Alexion Pharmaceuticals (Inst), Pfizer (Inst), Novartis (Inst) Maria Teresa VosoHonoraria: AbbVie, Astellas Pharma, Jazz Pharmaceuticals, Celene/BMSSpeakers' Bureau: CelgeneResearch Funding: Celgene (Inst), Novartis (Inst) Flore Sicre de FontbruneHonoraria: Alexion Pharmaceuticals, SOBI, NovartisSpeakers' Bureau: Alexion Pharmaceuticals, NovartisResearch Funding: Alexion Pharmaceuticals (Inst), Novartis (Inst) Marie SebertHonoraria: AbbVie, Jazz Pharmaceuticals, SERVIER, Pfizer, Celgene/Bristol Myers SquibbTravel, Accommodations, Expenses: SERVIER Jean SoulierConsulting or Advisory Role: STRM.BIO Inc Jaroslaw P. MaciejewskiConsulting or Advisory Role: Celgene, Novartis, Bristol Myers Squibb/Celgene Sophie Caillat-ZucmanHonoraria: Kite/Gilead Rodrigo T. CaladoConsulting or Advisory Role: Novartis Brasil Bhumika J. PatelConsulting or Advisory Role: NovartisSpeakers' Bureau: Alexion Pharmaceuticals, Apellis Pharmaceuticals Gerard SocieConsulting or Advisory Role: Xenikos, NovartisResearch Funding: Alexion Pharmaceuticals (Inst)No other potential conflicts of interest were reported.\n",
      "\n",
      "Maciejewski, Jaroslaw P.\n",
      "Regis Peffault de LatourHonoraria: Alexion Pharmaceuticals, Novartis, PfizerConsulting or Advisory Role: Alexion Pharmaceuticals, NovartisResearch Funding: Alexion Pharmaceuticals (Inst), Pfizer (Inst), Novartis (Inst) Maria Teresa VosoHonoraria: AbbVie, Astellas Pharma, Jazz Pharmaceuticals, Celene/BMSSpeakers' Bureau: CelgeneResearch Funding: Celgene (Inst), Novartis (Inst) Flore Sicre de FontbruneHonoraria: Alexion Pharmaceuticals, SOBI, NovartisSpeakers' Bureau: Alexion Pharmaceuticals, NovartisResearch Funding: Alexion Pharmaceuticals (Inst), Novartis (Inst) Marie SebertHonoraria: AbbVie, Jazz Pharmaceuticals, SERVIER, Pfizer, Celgene/Bristol Myers SquibbTravel, Accommodations, Expenses: SERVIER Jean SoulierConsulting or Advisory Role: STRM.BIO Inc Jaroslaw P. MaciejewskiConsulting or Advisory Role: Celgene, Novartis, Bristol Myers Squibb/Celgene Sophie Caillat-ZucmanHonoraria: Kite/Gilead Rodrigo T. CaladoConsulting or Advisory Role: Novartis Brasil Bhumika J. PatelConsulting or Advisory Role: NovartisSpeakers' Bureau: Alexion Pharmaceuticals, Apellis Pharmaceuticals Gerard SocieConsulting or Advisory Role: Xenikos, NovartisResearch Funding: Alexion Pharmaceuticals (Inst)No other potential conflicts of interest were reported.\n",
      "\n",
      "Fathi, Amir T.\n",
      "Amir T. FathiConsulting or Advisory Role: Agios, Novartis, Takeda, Astellas Pharma, AbbVie, Kite, a Gilead Company, Amgen, Bristol Myers Squibb, Foghorn Therapeutics, Genentech, Ipsen, MorphoSys, Servier, Orum Therapeutics, PureTech,  EnClear, Mablytics, Immunogen, Celgene, FORMA TherapeuticsResearch Funding: Takeda (Inst), Agios (Inst), Bristol Myers Squibb (Inst), AbbVie (Inst), Servier  (Inst)No other potential conflicts of interest were reported.\n",
      "\n",
      "Peppercorn, Jeffrey\n",
      "Jeffrey PeppercornThis author is the Editor-in-Chief designate of JCO Oncology Practice. Journal policy recused the author from having any role in the peer review of this manuscript.Employment: GlaxoSmithKline (I)Stock and Other Ownership Interests: GlaxoSmithKline (I)Consulting or Advisory Role: Athenex, Abbott LaboratoriesResearch Funding: Outcomes4MeNo other potential conflicts of interest were reported.\n",
      "\n",
      "Ramsey, Scott D.\n",
      "Scott D. RamseyThis author is a Consultant Editor for Journal of Clinical Oncology. Journal policy recused the author from having any role in the peer review of this manuscript.Consulting or Advisory Role: Bayer, Genentech (Inst), AstraZeneca, Merck, GRAIL, Seattle Genetics, Biovica, Flatiron HealthResearch Funding: Bayer (Inst), Genentech/Roche (Inst)Travel, Accommodations, Expenses: Bayer Jonathan W. FriedbergThis author is the Editor-in-Chief of Journal of Clinical Oncology. Journal policy recused the author from having any role in the  peer review of this manuscript.Research Funding: Enterome (Inst)Patents, Royalties, Other Intellectual Property: Patient on bone marrow microenvironment signals (I) John V. CoxThis author is the interim Editor-in-Chief of JCO Oncology Practice. Journal policy recused the author from having any role in the peer review of this manuscript.Employment: University of Texas Southwestern Medical Center-Simmons Cancer CenterLeadership: Parkland Health SystemStock and Other Ownership Interests: Amgen, Merck, Pfizer, Johnson & JohnsonOther Relationship: American Society of Clinical Oncology, Texas Oncology Jeffrey M. PeppercornThis author is the Editor-in-Chief designate of JCO Oncology Practice. Journal policy  recused the author from having any role in the peer review of this manuscript.Stock and Other Ownership Interests: GlaxoSmithKline (I)Consulting or  Advisory Role: Athenex, Abbott LaboratoriesResearch Funding: Outcomes4MeNo other  potential conflicts of interest were reported.\n",
      "\n",
      "Friedberg, Jonathan W.\n",
      "Scott D. RamseyThis author is a Consultant Editor for Journal of Clinical Oncology. Journal policy recused the author from having any role in the peer review of this manuscript.Consulting or Advisory Role: Bayer, Genentech (Inst), AstraZeneca, Merck, GRAIL, Seattle Genetics, Biovica, Flatiron HealthResearch Funding: Bayer (Inst), Genentech/Roche (Inst)Travel, Accommodations, Expenses: Bayer Jonathan W. FriedbergThis author is the Editor-in-Chief of Journal of Clinical Oncology. Journal policy recused the author from having any role in the  peer review of this manuscript.Research Funding: Enterome (Inst)Patents, Royalties, Other Intellectual Property: Patient on bone marrow microenvironment signals (I) John V. CoxThis author is the interim Editor-in-Chief of JCO Oncology Practice. Journal policy recused the author from having any role in the peer review of this manuscript.Employment: University of Texas Southwestern Medical Center-Simmons Cancer CenterLeadership: Parkland Health SystemStock and Other Ownership Interests: Amgen, Merck, Pfizer, Johnson & JohnsonOther Relationship: American Society of Clinical Oncology, Texas Oncology Jeffrey M. PeppercornThis author is the Editor-in-Chief designate of JCO Oncology Practice. Journal policy  recused the author from having any role in the peer review of this manuscript.Stock and Other Ownership Interests: GlaxoSmithKline (I)Consulting or  Advisory Role: Athenex, Abbott LaboratoriesResearch Funding: Outcomes4MeNo other  potential conflicts of interest were reported.\n",
      "\n",
      "Cox, John V.\n",
      "Scott D. RamseyThis author is a Consultant Editor for Journal of Clinical Oncology. Journal policy recused the author from having any role in the peer review of this manuscript.Consulting or Advisory Role: Bayer, Genentech (Inst), AstraZeneca, Merck, GRAIL, Seattle Genetics, Biovica, Flatiron HealthResearch Funding: Bayer (Inst), Genentech/Roche (Inst)Travel, Accommodations, Expenses: Bayer Jonathan W. FriedbergThis author is the Editor-in-Chief of Journal of Clinical Oncology. Journal policy recused the author from having any role in the  peer review of this manuscript.Research Funding: Enterome (Inst)Patents, Royalties, Other Intellectual Property: Patient on bone marrow microenvironment signals (I) John V. CoxThis author is the interim Editor-in-Chief of JCO Oncology Practice. Journal policy recused the author from having any role in the peer review of this manuscript.Employment: University of Texas Southwestern Medical Center-Simmons Cancer CenterLeadership: Parkland Health SystemStock and Other Ownership Interests: Amgen, Merck, Pfizer, Johnson & JohnsonOther Relationship: American Society of Clinical Oncology, Texas Oncology Jeffrey M. PeppercornThis author is the Editor-in-Chief designate of JCO Oncology Practice. Journal policy  recused the author from having any role in the peer review of this manuscript.Stock and Other Ownership Interests: GlaxoSmithKline (I)Consulting or  Advisory Role: Athenex, Abbott LaboratoriesResearch Funding: Outcomes4MeNo other  potential conflicts of interest were reported.\n",
      "\n",
      "Peppercorn, Jeffrey M.\n",
      "Scott D. RamseyThis author is a Consultant Editor for Journal of Clinical Oncology. Journal policy recused the author from having any role in the peer review of this manuscript.Consulting or Advisory Role: Bayer, Genentech (Inst), AstraZeneca, Merck, GRAIL, Seattle Genetics, Biovica, Flatiron HealthResearch Funding: Bayer (Inst), Genentech/Roche (Inst)Travel, Accommodations, Expenses: Bayer Jonathan W. FriedbergThis author is the Editor-in-Chief of Journal of Clinical Oncology. Journal policy recused the author from having any role in the  peer review of this manuscript.Research Funding: Enterome (Inst)Patents, Royalties, Other Intellectual Property: Patient on bone marrow microenvironment signals (I) John V. CoxThis author is the interim Editor-in-Chief of JCO Oncology Practice. Journal policy recused the author from having any role in the peer review of this manuscript.Employment: University of Texas Southwestern Medical Center-Simmons Cancer CenterLeadership: Parkland Health SystemStock and Other Ownership Interests: Amgen, Merck, Pfizer, Johnson & JohnsonOther Relationship: American Society of Clinical Oncology, Texas Oncology Jeffrey M. PeppercornThis author is the Editor-in-Chief designate of JCO Oncology Practice. Journal policy  recused the author from having any role in the peer review of this manuscript.Stock and Other Ownership Interests: GlaxoSmithKline (I)Consulting or  Advisory Role: Athenex, Abbott LaboratoriesResearch Funding: Outcomes4MeNo other  potential conflicts of interest were reported.\n",
      "\n",
      "Wheeler, Stephanie B.\n",
      "Stephanie B. WheelerThis author is an Associate Editor for Journal of Clinical Oncology. Journal policy recused the author from having any role in the peer review of this manuscript.Research Funding: Pfizer (Inst)Travel, Accommodations,  Expenses: Pfizer Anagha GogateEmployment: Bristol Myers Squibb/CelgeneStock and Other Ownership Interests: Bristol Myers Squibb/Celgene Katherine E. Reeder-HayesResearch Funding: Pfizer (Inst) Gabrielle RocqueConsulting or Advisory Role: Pfizer, Flatiron Health, Gilead SciencesResearch Funding: Carevive Systems, Genentech, PfizerNo other potential conflicts of interest were reported.\n",
      "\n",
      "Stephanie B. WheelerThis author is an Associate Editor for Journal of Clinical Oncology. Journal policy recused the author from having any role in the peer review of this manuscript.Research Funding: Pfizer (Inst)Travel, Accommodations,  Expenses: Pfizer Anagha GogateEmployment: Bristol Myers Squibb/CelgeneStock and Other Ownership Interests: Bristol Myers Squibb/Celgene Katherine E. Reeder-HayesResearch Funding: Pfizer (Inst) Gabrielle RocqueConsulting or Advisory Role: Pfizer, Flatiron Health, Gilead SciencesResearch Funding: Carevive Systems, Genentech, PfizerNo other potential conflicts of interest were reported.\n",
      "\n",
      "Gogate, Anagha\n",
      "Stephanie B. WheelerThis author is an Associate Editor for Journal of Clinical Oncology. Journal policy recused the author from having any role in the peer review of this manuscript.Research Funding: Pfizer (Inst)Travel, Accommodations,  Expenses: Pfizer Anagha GogateEmployment: Bristol Myers Squibb/CelgeneStock and Other Ownership Interests: Bristol Myers Squibb/Celgene Katherine E. Reeder-HayesResearch Funding: Pfizer (Inst) Gabrielle RocqueConsulting or Advisory Role: Pfizer, Flatiron Health, Gilead SciencesResearch Funding: Carevive Systems, Genentech, PfizerNo other potential conflicts of interest were reported.\n",
      "\n",
      "Reeder-Hayes, Katherine E.\n",
      "Stephanie B. WheelerThis author is an Associate Editor for Journal of Clinical Oncology. Journal policy recused the author from having any role in the peer review of this manuscript.Research Funding: Pfizer (Inst)Travel, Accommodations,  Expenses: Pfizer Anagha GogateEmployment: Bristol Myers Squibb/CelgeneStock and Other Ownership Interests: Bristol Myers Squibb/Celgene Katherine E. Reeder-HayesResearch Funding: Pfizer (Inst) Gabrielle RocqueConsulting or Advisory Role: Pfizer, Flatiron Health, Gilead SciencesResearch Funding: Carevive Systems, Genentech, PfizerNo other potential conflicts of interest were reported.\n",
      "\n",
      "Stephanie B. WheelerThis author is an Associate Editor for Journal of Clinical Oncology. Journal policy recused the author from having any role in the peer review of this manuscript.Research Funding: Pfizer (Inst)Travel, Accommodations,  Expenses: Pfizer Anagha GogateEmployment: Bristol Myers Squibb/CelgeneStock and Other Ownership Interests: Bristol Myers Squibb/Celgene Katherine E. Reeder-HayesResearch Funding: Pfizer (Inst) Gabrielle RocqueConsulting or Advisory Role: Pfizer, Flatiron Health, Gilead SciencesResearch Funding: Carevive Systems, Genentech, PfizerNo other potential conflicts of interest were reported.\n",
      "\n",
      "Stephanie B. WheelerThis author is an Associate Editor for Journal of Clinical Oncology. Journal policy recused the author from having any role in the peer review of this manuscript.Research Funding: Pfizer (Inst)Travel, Accommodations,  Expenses: Pfizer Anagha GogateEmployment: Bristol Myers Squibb/CelgeneStock and Other Ownership Interests: Bristol Myers Squibb/Celgene Katherine E. Reeder-HayesResearch Funding: Pfizer (Inst) Gabrielle RocqueConsulting or Advisory Role: Pfizer, Flatiron Health, Gilead SciencesResearch Funding: Carevive Systems, Genentech, PfizerNo other potential conflicts of interest were reported.\n",
      "\n",
      "Stephanie B. WheelerThis author is an Associate Editor for Journal of Clinical Oncology. Journal policy recused the author from having any role in the peer review of this manuscript.Research Funding: Pfizer (Inst)Travel, Accommodations,  Expenses: Pfizer Anagha GogateEmployment: Bristol Myers Squibb/CelgeneStock and Other Ownership Interests: Bristol Myers Squibb/Celgene Katherine E. Reeder-HayesResearch Funding: Pfizer (Inst) Gabrielle RocqueConsulting or Advisory Role: Pfizer, Flatiron Health, Gilead SciencesResearch Funding: Carevive Systems, Genentech, PfizerNo other potential conflicts of interest were reported.\n",
      "\n",
      "Rocque, Gabrielle B.\n",
      "Stephanie B. WheelerThis author is an Associate Editor for Journal of Clinical Oncology. Journal policy recused the author from having any role in the peer review of this manuscript.Research Funding: Pfizer (Inst)Travel, Accommodations,  Expenses: Pfizer Anagha GogateEmployment: Bristol Myers Squibb/CelgeneStock and Other Ownership Interests: Bristol Myers Squibb/Celgene Katherine E. Reeder-HayesResearch Funding: Pfizer (Inst) Gabrielle B. RocqueConsulting or Advisory Role: Pfizer, Flatiron Health, Gilead SciencesResearch Funding: Carevive Systems, Genentech, PfizerNo other potential conflicts of interest were reported.\n",
      "\n",
      "Stephanie B. WheelerThis author is an Associate Editor for Journal of Clinical Oncology. Journal policy recused the author from having any role in the peer review of this manuscript.Research Funding: Pfizer (Inst)Travel, Accommodations,  Expenses: Pfizer Anagha GogateEmployment: Bristol Myers Squibb/CelgeneStock and Other Ownership Interests: Bristol Myers Squibb/Celgene Katherine E. Reeder-HayesResearch Funding: Pfizer (Inst) Gabrielle B. RocqueConsulting or Advisory Role: Pfizer, Flatiron Health, Gilead SciencesResearch Funding: Carevive Systems, Genentech, PfizerNo other potential conflicts of interest were reported.\n",
      "\n",
      "Schwartz, Gary K.\n",
      "Gary K. SchwartzThis author is an Associate Editor for Journal of Clinical Oncology. Journal policy recused the author from having any role in the peer review of this manuscript.Stock and Other Ownership Interests: GenCirq, Bionaut Labs, January TherapeuticsConsulting or Advisory Role: Bionaut Labs, Ellipses Pharma, Gencirq, Epizyme, Array BioPharma, Apexigen, Oncogenuity, OnCusp Therapeutics, Concarlo, Shanghai Pharma, Astex Pharmaceuticals, January Therapeutics, Sellas Life Sciences, PureTech, Killys TherapeuticsResearch Funding: Astex Pharmaceuticals, Incyte (Inst), Calithera Biosciences (Inst), Lilly (Inst), Daiichi Sankyo (Inst), Fortress Biotech (Inst), Karyopharm Therapeutics (Inst), Oxford BioTherapeutics (Inst), Astex Pharmaceuticals (Inst), TopAlliance BioSciences Inc (Inst), Adaptimmune (Inst), SpringWorks Therapeutics  (Inst), TRACON Pharma (Inst)Patents, Royalties, Other Intellectual Property: Companion diagnostics for CD4 inhibitors (Inst), patent granted to develop a new  technology called PNAs for cancer therapyTravel, Accommodations, Expenses: Array  BioPharma, EpizymeNo other potential conflicts of interest were reported.\n",
      "\n",
      "The author reported no actual or potential conflict of interest in relation to this nursing continuing professional development (NCPD) activity.\n",
      "\n",
      "The authors reported no actual or potential conflict of interest in relation to this nursing continuing professional development (NCPD) activity.\n",
      "\n",
      "The authors reported no actual or potential conflict of interest in relation to this nursing continuing professional development (NCPD) activity.\n",
      "\n",
      "The authors reported no actual or potential conflict of interest in relation to this nursing continuing professional development (NCPD) activity.\n",
      "\n",
      "The author reported no actual or potential conflict of interest in relation to this nursing continuing professional development (NCPD) activity.\n",
      "\n",
      "The author reported no actual or potential conflict of interest in relation to this nursing continuing professional development (NCPD) activity.\n",
      "\n",
      "The author reported no actual or potential conflict of interest in relation to this nursing continuing professional development (NCPD) activity.\n",
      "\n",
      "The author reported no actual or potential conflict of interest in relation to this nursing continuing professional development (NCPD) activity.\n",
      "\n",
      "The authors reported no actual or potential conflict of interest in relation to this nursing continuing professional development (NCPD) activity.\n",
      "\n",
      "The authors reported no actual or potential conflict of interest in relation to this nursing continuing professional development (NCPD) activity.\n",
      "\n",
      "The author reported no actual or potential conflict of interest in relation to this nursing continuing professional development (NCPD) activity.\n",
      "\n",
      "The authors reported no actual or potential conflict of interest in relation to this nursing continuing professional development (NCPD) activity.\n",
      "\n",
      "The authors reported no actual or potential conflict of interest in relation to this nursing continuing professional development (NCPD) activity.\n",
      "\n",
      "The authors reported no actual or potential conflict of interest in relation to this nursing continuing professional development (NCPD) activity.\n",
      "\n",
      "The authors reported no actual or potential conflict of interest in relation to this nursing continuing professional development (NCPD) activity.\n",
      "\n",
      "The authors reported no actual or potential conflict of interest in relation to this nursing continuing professional development (NCPD) activity.\n",
      "\n",
      "The authors reported no actual or potential conflict of interest in relation to this nursing continuing professional development (NCPD) activity.\n",
      "\n",
      "The authors reported no actual or potential conflict of interest in relation to this nursing continuing professional development (NCPD) activity.\n",
      "\n",
      "The authors reported no actual or potential conflict of interest in relation to this nursing continuing professional development (NCPD) activity.\n",
      "\n",
      "Disclosure: The Disclosure of Potential Conflicts of Interest forms are provided  with the online version of the article (http://links.lww.com/JBJS/H227)\n",
      "\n",
      "Disclosure: The Disclosure of Potential Conflicts of Interest forms are provided  with the online version of the article (http://links.lww.com/JBJS/H227)\n",
      "\n",
      "Disclosure: The Disclosure of Potential Conflicts of Interest forms are provided  with the online version of the article (http://links.lww.com/JBJS/H227)\n",
      "\n",
      "Disclosure: The Disclosure of Potential Conflicts of Interest forms are provided  with the online version of the article (http://links.lww.com/JBJS/H227)\n",
      "\n",
      "Conflict of Interest: None Declared.\n",
      "\n",
      "Conflict of Interest: None Declared.\n",
      "\n",
      "Conflict of Interest: None Declared.\n",
      "\n",
      "Conflict of Interest: None Declared.\n",
      "\n",
      "Conflict of Interest: None Declared.\n",
      "\n",
      "Conflict of Interest: None Declared.\n",
      "\n",
      "Conflict of Interest: None Declared.\n",
      "\n",
      "Mullins, Edward\n",
      "Edward Mullins is an academic editor at PLOS One. MM is listed as an inventor in IPR filings  for the Imperial Hybrid DABA used in this analysis. Please see United Kingdom Patent Application No. 2011047.4 for \"SARS-CoV-2 antibody detection assay\". SMB is member of both Royal Statistical Society's COVID-19 Taskforce and Working Group on Diagnostic Tests. SMB serves on UKHSA/DHSC's Testing Initiatives Evaluation Board (January 2021 to present). All other authors declare no Conflicts of Interest. This does not alter our adherence to PLOS ONE policies on  sharing data and materials.\n",
      "\n",
      "Edward Mullins is an academic editor at PLOS One. MM is listed as an inventor in IPR filings  for the Imperial Hybrid DABA used in this analysis. Please see United Kingdom Patent Application No. 2011047.4 for \"SARS-CoV-2 antibody detection assay\". SMB is member of both Royal Statistical Society's COVID-19 Taskforce and Working Group on Diagnostic Tests. SMB serves on UKHSA/DHSC's Testing Initiatives Evaluation Board (January 2021 to present). All other authors declare no Conflicts of Interest. This does not alter our adherence to PLOS ONE policies on  sharing data and materials.\n",
      "\n",
      "Bird, Sheila M.\n",
      "Edward Mullins is an academic editor at PLOS One. MM is listed as an inventor in IPR filings  for the Imperial Hybrid DABA used in this analysis. Please see United Kingdom Patent Application No. 2011047.4 for \"SARS-CoV-2 antibody detection assay\". Sheila M. Bird is member of both Royal Statistical Society's COVID-19 Taskforce and Working Group on Diagnostic Tests. Sheila M. Bird serves on UKHSA/DHSC's Testing Initiatives Evaluation Board (January 2021 to present). All other authors declare no Conflicts of Interest. This does not alter our adherence to PLOS ONE policies on  sharing data and materials.\n",
      "\n",
      "Randell, Paul\n",
      "Edward Mullins is an academic editor at PLOS One. MM is listed as an inventor in IPaul Randell filings  for the Imperial Hybrid DABA used in this analysis. Please see United Kingdom Patent Application No. 2011047.4 for \"SARS-CoV-2 antibody detection assay\". Sheila M. Bird is member of both Royal Statistical Society's COVID-19 Taskforce and Working Group on Diagnostic Tests. Sheila M. Bird serves on UKHSA/DHSC's Testing Initiatives Evaluation Board (January 2021 to present). All other authors declare no Conflicts of Interest. This does not alter our adherence to PLOS ONE policies on  sharing data and materials.\n",
      "\n",
      "Edward Mullins is an academic editor at PLOS One. MM is listed as an inventor in IPaul Randell filings  for the Imperial Hybrid DABA used in this analysis. Please see United Kingdom Patent Application No. 2011047.4 for \"SARS-CoV-2 antibody detection assay\". Sheila M. Bird is member of both Royal Statistical Society's COVID-19 Taskforce and Working Group on Diagnostic Tests. Sheila M. Bird serves on UKHSA/DHSC's Testing Initiatives Evaluation Board (January 2021 to present). All other authors declare no Conflicts of Interest. This does not alter our adherence to PLOS ONE policies on  sharing data and materials.\n",
      "\n",
      "Edward Mullins is an academic editor at PLOS One. MM is listed as an inventor in IPaul Randell filings  for the Imperial Hybrid DABA used in this analysis. Please see United Kingdom Patent Application No. 2011047.4 for \"SARS-CoV-2 antibody detection assay\". Sheila M. Bird is member of both Royal Statistical Society's COVID-19 Taskforce and Working Group on Diagnostic Tests. Sheila M. Bird serves on UKHSA/DHSC's Testing Initiatives Evaluation Board (January 2021 to present). All other authors declare no Conflicts of Interest. This does not alter our adherence to PLOS ONE policies on  sharing data and materials.\n",
      "\n",
      "Edward Mullins is an academic editor at PLOS One. MM is listed as an inventor in IPaul Randell filings  for the Imperial Hybrid DABA used in this analysis. Please see United Kingdom Patent Application No. 2011047.4 for \"SARS-CoV-2 antibody detection assay\". Sheila M. Bird is member of both Royal Statistical Society's COVID-19 Taskforce and Working Group on Diagnostic Tests. Sheila M. Bird serves on UKHSA/DHSC's Testing Initiatives Evaluation Board (January 2021 to present). All other authors declare no Conflicts of Interest. This does not alter our adherence to PLOS ONE policies on  sharing data and materials.\n",
      "\n",
      "McClure, Myra\n",
      "Edward Mullins is an academic editor at PLOS One. Myra McClure is listed as an inventor in IPaul Randell filings  for the Imperial Hybrid DABA used in this analysis. Please see United Kingdom Patent Application No. 2011047.4 for \"SARS-CoV-2 antibody detection assay\". Sheila M. Bird is member of both Royal Statistical Society's COVID-19 Taskforce and Working Group on Diagnostic Tests. Sheila M. Bird serves on UKHSA/DHSC's Testing Initiatives Evaluation Board (January 2021 to present). All other authors declare no Conflicts of Interest. This does not alter our adherence to PLOS ONE policies on  sharing data and materials.\n",
      "\n",
      "Edward Mullins is an academic editor at PLOS One. Myra McClure is listed as an inventor in IPaul Randell filings  for the Imperial Hybrid DABA used in this analysis. Please see United Kingdom Patent Application No. 2011047.4 for \"SARS-CoV-2 antibody detection assay\". Sheila M. Bird is member of both Royal Statistical Society's COVID-19 Taskforce and Working Group on Diagnostic Tests. Sheila M. Bird serves on UKHSA/DHSC's Testing Initiatives Evaluation Board (January 2021 to present). All other authors declare no Conflicts of Interest. This does not alter our adherence to PLOS ONE policies on  sharing data and materials.\n",
      "\n",
      "Pinto, Lionel\n",
      "I have read the journal's policy and the authors of this manuscript have the following competing interests. Amgen Inc. has no conflict of interest to declare  related to patents, products in development and marketed products. Mohamed Farghaly has no conflict of interest to declare. Lionel Pinto was a full-time employee of Amgen Inc. during the conduct of the study. Badarinath Chickballapur  Ramachandrachar, Sri Harshadeep Chilukuri and Ashok Natarajan are employees of IQVIA who were paid consultants to Amgen Inc. in connection with the development  of this manuscript. Sasikiran Nunna was employed with IQVIA during the conduct of the study. These competing interests of the authors does not alter their adherence to PLOS One policies on sharing data and materials.\n",
      "\n",
      "Farghaly, Mohamed\n",
      "I have read the journal's policy and the authors of this manuscript have the following competing interests. Amgen Inc. has no conflict of interest to declare  related to patents, products in development and marketed products. Mohamed Farghaly has no conflict of interest to declare. Lionel Pinto was a full-time employee of Amgen Inc. during the conduct of the study. Badarinath Chickballapur  Ramachandrachar, Sri Harshadeep Chilukuri and Ashok Natarajan are employees of IQVIA who were paid consultants to Amgen Inc. in connection with the development  of this manuscript. Sasikiran Nunna was employed with IQVIA during the conduct of the study. These competing interests of the authors does not alter their adherence to PLOS One policies on sharing data and materials.\n",
      "\n",
      "Nunna, Sasikiran\n",
      "I have read the journal's policy and the authors of this manuscript have the following competing interests. Amgen Inc. has no conflict of interest to declare  related to patents, products in development and marketed products. Mohamed Farghaly has no conflict of interest to declare. Lionel Pinto was a full-time employee of Amgen Inc. during the conduct of the study. Badarinath Chickballapur  Ramachandrachar, Sri Harshadeep Chilukuri and Ashok Natarajan are employees of IQVIA who were paid consultants to Amgen Inc. in connection with the development  of this manuscript. Sasikiran Nunna was employed with IQVIA during the conduct of the study. These competing interests of the authors does not alter their adherence to PLOS One policies on sharing data and materials.\n",
      "\n",
      "Chickballapur Ramachandrachar, Badarinath\n",
      "I have read the journal's policy and the authors of this manuscript have the following competing interests. Amgen Inc. has no conflict of interest to declare  related to patents, products in development and marketed products. Mohamed Farghaly has no conflict of interest to declare. Lionel Pinto was a full-time employee of Amgen Inc. during the conduct of the study. Badarinath Chickballapur  Badarinath Chickballapur Ramachandrachar, Sri Harshadeep Chilukuri and Ashok Natarajan are employees of IQVIA who were paid consultants to Amgen Inc. in connection with the development  of this manuscript. Sasikiran Nunna was employed with IQVIA during the conduct of the study. These competing interests of the authors does not alter their adherence to PLOS One policies on sharing data and materials.\n",
      "\n",
      "Harshadeep Chilukuri, Sri\n",
      "I have read the journal's policy and the authors of this manuscript have the following competing interests. Amgen Inc. has no conflict of interest to declare  related to patents, products in development and marketed products. Mohamed Farghaly has no conflict of interest to declare. Lionel Pinto was a full-time employee of Amgen Inc. during the conduct of the study. Badarinath Chickballapur  Badarinath Chickballapur Ramachandrachar, Sri Harshadeep Chilukuri and Ashok Natarajan are employees of IQVIA who were paid consultants to Amgen Inc. in connection with the development  of this manuscript. Sasikiran Nunna was employed with IQVIA during the conduct of the study. These competing interests of the authors does not alter their adherence to PLOS One policies on sharing data and materials.\n",
      "\n",
      "Natarajan, Ashok\n",
      "I have read the journal's policy and the authors of this manuscript have the following competing interests. Amgen Inc. has no conflict of interest to declare  related to patents, products in development and marketed products. Mohamed Farghaly has no conflict of interest to declare. Lionel Pinto was a full-time employee of Amgen Inc. during the conduct of the study. Badarinath Chickballapur  Badarinath Chickballapur Ramachandrachar, Sri Harshadeep Chilukuri and Ashok Natarajan are employees of IQVIA who were paid consultants to Amgen Inc. in connection with the development  of this manuscript. Sasikiran Nunna was employed with IQVIA during the conduct of the study. These competing interests of the authors does not alter their adherence to PLOS One policies on sharing data and materials.\n",
      "\n",
      "Huschtscha, Zoya\n",
      "The authors, Zoya Huschtscha, Pascal Young, Judi Porter, Alexandra, Parr, and Ricardo Costa, declare that they have no competing interests.\n",
      "\n",
      "Young, Pascale\n",
      "The authors, Zoya Huschtscha, Pascal Pascale Young, Judi Porter, Alexandra, Parr, and Ricardo Costa, declare that they have no competing interests.\n",
      "\n",
      "Parr, Alexandra\n",
      "The authors, Zoya Huschtscha, Pascal Pascale Young, Judi Porter, Alexandra, Alexandra Parr, and Ricardo Costa, declare that they have no competing interests.\n",
      "\n",
      "Porter, Judi\n",
      "The authors, Zoya Huschtscha, Pascal Pascale Young, Judi Porter, Alexandra, Alexandra Parr, and Ricardo Costa, declare that they have no competing interests.\n",
      "\n",
      "Costa, Ricardo\n",
      "The authors, Zoya Huschtscha, Pascal Pascale Young, Judi Porter, Alexandra, Alexandra Parr, and Ricardo Costa, declare that they have no competing interests.\n",
      "\n",
      "The authors declare that no competing interests exist. This study was approved by Indiana University's Institutional Review Board (#2008204182) and all respondents received a study information sheet (mailed with the paper survey) that informed them of the purpose of the study, provided a statement that their participation is voluntary, and contact information for the principal investigator. This does not alter our adherence to PLOS ONE policies on sharing data and materials.\n",
      "\n",
      "The authors declare that no competing interests exist. This study was approved by Indiana University's Institutional Review Board (#2008204182) and all respondents received a study information sheet (mailed with the paper survey) that informed them of the purpose of the study, provided a statement that their participation is voluntary, and contact information for the principal investigator. This does not alter our adherence to PLOS ONE policies on sharing data and materials.\n",
      "\n",
      "The authors declare that no competing interests exist. This study was approved by Indiana University's Institutional Review Board (#2008204182) and all respondents received a study information sheet (mailed with the paper survey) that informed them of the purpose of the study, provided a statement that their participation is voluntary, and contact information for the principal investigator. This does not alter our adherence to PLOS ONE policies on sharing data and materials.\n",
      "\n",
      "The authors declare that no competing interests exist. This study was approved by Indiana University's Institutional Review Board (#2008204182) and all respondents received a study information sheet (mailed with the paper survey) that informed them of the purpose of the study, provided a statement that their participation is voluntary, and contact information for the principal investigator. This does not alter our adherence to PLOS ONE policies on sharing data and materials.\n",
      "\n",
      "The authors declare that no competing interests exist. This study was approved by Indiana University's Institutional Review Board (#2008204182) and all respondents received a study information sheet (mailed with the paper survey) that informed them of the purpose of the study, provided a statement that their participation is voluntary, and contact information for the principal investigator. This does not alter our adherence to PLOS ONE policies on sharing data and materials.\n",
      "\n",
      "The authors declare that no competing interests exist. This study was approved by Indiana University's Institutional Review Board (#2008204182) and all respondents received a study information sheet (mailed with the paper survey) that informed them of the purpose of the study, provided a statement that their participation is voluntary, and contact information for the principal investigator. This does not alter our adherence to PLOS ONE policies on sharing data and materials.\n",
      "\n",
      "The authors declare that no competing interests exist. This study was approved by Indiana University's Institutional Review Board (#2008204182) and all respondents received a study information sheet (mailed with the paper survey) that informed them of the purpose of the study, provided a statement that their participation is voluntary, and contact information for the principal investigator. This does not alter our adherence to PLOS ONE policies on sharing data and materials.\n",
      "\n",
      "The authors declare that no competing interests exist. This study was approved by Indiana University's Institutional Review Board (#2008204182) and all respondents received a study information sheet (mailed with the paper survey) that informed them of the purpose of the study, provided a statement that their participation is voluntary, and contact information for the principal investigator. This does not alter our adherence to PLOS ONE policies on sharing data and materials.\n",
      "\n",
      "The authors declare that no competing interests exist. This study was approved by Indiana University's Institutional Review Board (#2008204182) and all respondents received a study information sheet (mailed with the paper survey) that informed them of the purpose of the study, provided a statement that their participation is voluntary, and contact information for the principal investigator. This does not alter our adherence to PLOS ONE policies on sharing data and materials.\n",
      "\n",
      "Li, You\n",
      "You Li receives grants from WHO and Wellcome Trust, outside the submitted work. All other authors report no conflicts of interest. This does not alter our adherence to PLOS ONE policies on sharing data and materials.\n",
      "\n",
      "You Li receives grants from WHO and Wellcome Trust, outside the submitted work. All other authors report no conflicts of interest. This does not alter our adherence to PLOS ONE policies on sharing data and materials.\n",
      "\n",
      "You Li receives grants from WHO and Wellcome Trust, outside the submitted work. All other authors report no conflicts of interest. This does not alter our adherence to PLOS ONE policies on sharing data and materials.\n",
      "\n",
      "You Li receives grants from WHO and Wellcome Trust, outside the submitted work. All other authors report no conflicts of interest. This does not alter our adherence to PLOS ONE policies on sharing data and materials.\n",
      "\n",
      "The authors have read the journal's policy and have the following competing interests: Andrew W. Lo reports personal investments in private biotechnology companies, biotechnology venture capital funds, and mutual funds. Lo is a co-founder and principal of QLS Advisors LLC, a healthcare investments advisor, and QLS Technologies LLC, a healthcare analytics and consulting company; a director of AbCellera, Annual Reviews, Atomwise, BridgeBio Pharma, and Roivant Sciences; and an advisor to Apricity Health, Aracari Bio, BrightEdge Impact Fund, Enable Medicine, FINRA, Lazard, NIH/NCATS, Quantile Health, SalioGen Therapeutics, Swiss Finance Institute, and Thales. During the most recent six-year period, Lo has received speaking/consulting fees from AbCellera, AlphaSimplex Group, Annual Reviews, Apricity Health, Aracari Bio, Atomwise, Bernstein Fabozzi Jacobs Levy Award, BridgeBio, Cambridge Associates, Chicago Mercantile Exchange, Enable Medicine, Financial Times Prize, Harvard Kennedy School, IMF, Journal of Investment Management, Lazard, National Bank of Belgium,  New Frontier Advisors/Markowitz Award, Oppenheimer, Princeton University Press, Q Group, QLS Advisors, Quantile Health, Research Affiliates, Roivant Sciences, SalioGen Therapeutics, Swiss Finance Institute, and WW Norton. There are no patents, products in development or marketed products associated with this research to declare. This does not alter our adherence to PLOS ONE policies on sharing data and materials.\n",
      "\n",
      "The authors have read the journal's policy and have the following competing interests: Andrew W. Lo reports personal investments in private biotechnology companies, biotechnology venture capital funds, and mutual funds. Lo is a co-founder and principal of QLS Advisors LLC, a healthcare investments advisor, and QLS Technologies LLC, a healthcare analytics and consulting company; a director of AbCellera, Annual Reviews, Atomwise, BridgeBio Pharma, and Roivant Sciences; and an advisor to Apricity Health, Aracari Bio, BrightEdge Impact Fund, Enable Medicine, FINRA, Lazard, NIH/NCATS, Quantile Health, SalioGen Therapeutics, Swiss Finance Institute, and Thales. During the most recent six-year period, Lo has received speaking/consulting fees from AbCellera, AlphaSimplex Group, Annual Reviews, Apricity Health, Aracari Bio, Atomwise, Bernstein Fabozzi Jacobs Levy Award, BridgeBio, Cambridge Associates, Chicago Mercantile Exchange, Enable Medicine, Financial Times Prize, Harvard Kennedy School, IMF, Journal of Investment Management, Lazard, National Bank of Belgium,  New Frontier Advisors/Markowitz Award, Oppenheimer, Princeton University Press, Q Group, QLS Advisors, Quantile Health, Research Affiliates, Roivant Sciences, SalioGen Therapeutics, Swiss Finance Institute, and WW Norton. There are no patents, products in development or marketed products associated with this research to declare. This does not alter our adherence to PLOS ONE policies on sharing data and materials.\n",
      "\n",
      "The authors have read the journal's policy and have the following competing interests: Andrew W. Lo reports personal investments in private biotechnology companies, biotechnology venture capital funds, and mutual funds. Lo is a co-founder and principal of QLS Advisors LLC, a healthcare investments advisor, and QLS Technologies LLC, a healthcare analytics and consulting company; a director of AbCellera, Annual Reviews, Atomwise, BridgeBio Pharma, and Roivant Sciences; and an advisor to Apricity Health, Aracari Bio, BrightEdge Impact Fund, Enable Medicine, FINRA, Lazard, NIH/NCATS, Quantile Health, SalioGen Therapeutics, Swiss Finance Institute, and Thales. During the most recent six-year period, Lo has received speaking/consulting fees from AbCellera, AlphaSimplex Group, Annual Reviews, Apricity Health, Aracari Bio, Atomwise, Bernstein Fabozzi Jacobs Levy Award, BridgeBio, Cambridge Associates, Chicago Mercantile Exchange, Enable Medicine, Financial Times Prize, Harvard Kennedy School, IMF, Journal of Investment Management, Lazard, National Bank of Belgium,  New Frontier Advisors/Markowitz Award, Oppenheimer, Princeton University Press, Q Group, QLS Advisors, Quantile Health, Research Affiliates, Roivant Sciences, SalioGen Therapeutics, Swiss Finance Institute, and WW Norton. There are no patents, products in development or marketed products associated with this research to declare. This does not alter our adherence to PLOS ONE policies on sharing data and materials.\n",
      "\n",
      "The authors have read the journal's policy and have the following competing interests: Andrew W. Lo reports personal investments in private biotechnology companies, biotechnology venture capital funds, and mutual funds. Lo is a co-founder and principal of QLS Advisors LLC, a healthcare investments advisor, and QLS Technologies LLC, a healthcare analytics and consulting company; a director of AbCellera, Annual Reviews, Atomwise, BridgeBio Pharma, and Roivant Sciences; and an advisor to Apricity Health, Aracari Bio, BrightEdge Impact Fund, Enable Medicine, FINRA, Lazard, NIH/NCATS, Quantile Health, SalioGen Therapeutics, Swiss Finance Institute, and Thales. During the most recent six-year period, Lo has received speaking/consulting fees from AbCellera, AlphaSimplex Group, Annual Reviews, Apricity Health, Aracari Bio, Atomwise, Bernstein Fabozzi Jacobs Levy Award, BridgeBio, Cambridge Associates, Chicago Mercantile Exchange, Enable Medicine, Financial Times Prize, Harvard Kennedy School, IMF, Journal of Investment Management, Lazard, National Bank of Belgium,  New Frontier Advisors/Markowitz Award, Oppenheimer, Princeton University Press, Q Group, QLS Advisors, Quantile Health, Research Affiliates, Roivant Sciences, SalioGen Therapeutics, Swiss Finance Institute, and WW Norton. There are no patents, products in development or marketed products associated with this research to declare. This does not alter our adherence to PLOS ONE policies on sharing data and materials.\n",
      "\n",
      "Lo, Andrew W.\n",
      "The authors have read the journal's policy and have the following competing interests: Andrew W. Lo reports personal investments in private biotechnology companies, biotechnology venture capital funds, and mutual funds. Lo is a co-founder and principal of QLS Advisors LLC, a healthcare investments advisor, and QLS Technologies LLC, a healthcare analytics and consulting company; a director of AbCellera, Annual Reviews, Atomwise, BridgeBio Pharma, and Roivant Sciences; and an advisor to Apricity Health, Aracari Bio, BrightEdge Impact Fund, Enable Medicine, FINRA, Lazard, NIH/NCATS, Quantile Health, SalioGen Therapeutics, Swiss Finance Institute, and Thales. During the most recent six-year period, Lo has received speaking/consulting fees from AbCellera, AlphaSimplex Group, Annual Reviews, Apricity Health, Aracari Bio, Atomwise, Bernstein Fabozzi Jacobs Levy Award, BridgeBio, Cambridge Associates, Chicago Mercantile Exchange, Enable Medicine, Financial Times Prize, Harvard Kennedy School, IMF, Journal of Investment Management, Lazard, National Bank of Belgium,  New Frontier Advisors/Markowitz Award, Oppenheimer, Princeton University Press, Q Group, QLS Advisors, Quantile Health, Research Affiliates, Roivant Sciences, SalioGen Therapeutics, Swiss Finance Institute, and WW Norton. There are no patents, products in development or marketed products associated with this research to declare. This does not alter our adherence to PLOS ONE policies on sharing data and materials.\n",
      "\n",
      "We have read the journal's policy and the authors of this manuscript have the following competing interests: CM is a member of the Editorial Board of PLOS Medicine.\n",
      "\n",
      "We have read the journal's policy and the authors of this manuscript have the following competing interests: CM is a member of the Editorial Board of PLOS Medicine.\n",
      "\n",
      "We have read the journal's policy and the authors of this manuscript have the following competing interests: CM is a member of the Editorial Board of PLOS Medicine.\n",
      "\n",
      "We have read the journal's policy and the authors of this manuscript have the following competing interests: CM is a member of the Editorial Board of PLOS Medicine.\n",
      "\n",
      "We have read the journal's policy and the authors of this manuscript have the following competing interests: CM is a member of the Editorial Board of PLOS Medicine.\n",
      "\n",
      "We have read the journal's policy and the authors of this manuscript have the following competing interests: CM is a member of the Editorial Board of PLOS Medicine.\n",
      "\n",
      "We have read the journal's policy and the authors of this manuscript have the following competing interests: CM is a member of the Editorial Board of PLOS Medicine.\n",
      "\n",
      "We have read the journal's policy and the authors of this manuscript have the following competing interests: CM is a member of the Editorial Board of PLOS Medicine.\n",
      "\n",
      "We have read the journal's policy and the authors of this manuscript have the following competing interests: CM is a member of the Editorial Board of PLOS Medicine.\n",
      "\n",
      "We have read the journal's policy and the authors of this manuscript have the following competing interests: CM is a member of the Editorial Board of PLOS Medicine.\n",
      "\n",
      "We have read the journal's policy and the authors of this manuscript have the following competing interests: CM is a member of the Editorial Board of PLOS Medicine.\n",
      "\n",
      "We have read the journal's policy and the authors of this manuscript have the following competing interests: CM is a member of the Editorial Board of PLOS Medicine.\n",
      "\n",
      "We have read the journal's policy and the authors of this manuscript have the following competing interests: CM is a member of the Editorial Board of PLOS Medicine.\n",
      "\n",
      "We have read the journal's policy and the authors of this manuscript have the following competing interests: CM is a member of the Editorial Board of PLOS Medicine.\n",
      "\n",
      "We have read the journal's policy and the authors of this manuscript have the following competing interests: CM is a member of the Editorial Board of PLOS Medicine.\n",
      "\n",
      "We have read the journal's policy and the authors of this manuscript have the following competing interests: CM is a member of the Editorial Board of PLOS Medicine.\n",
      "\n",
      "We have read the journal's policy and the authors of this manuscript have the following competing interests: CM is a member of the Editorial Board of PLOS Medicine.\n",
      "\n",
      "We have read the journal's policy and the authors of this manuscript have the following competing interests: CM is a member of the Editorial Board of PLOS Medicine.\n",
      "\n",
      "Menendez, Clara\n",
      "We have read the journal's policy and the authors of this manuscript have the following competing interests: Clara Menendez is a member of the Editorial Board of PLOS Medicine.\n",
      "\n",
      "We have read the journal's policy and the authors of this manuscript have the following competing interests: Clara Menendez is a member of the Editorial Board of PLOS Medicine.\n",
      "\n",
      "McGrath, Michael\n",
      "Blatchford Clinical Services are contracted to run the Mobility & Specialised Rehabilitation Centre at Sheffield's Northern General Hospital, where KCD, ZS, JM and AS are employed. Michael McGrath and SZ employees of Blatchford Ltd. BR was an employee of Blatchford Ltd. at the time of her contribution to the current work. LG has no competing interests to declare. This does not alter our adherence to PLOS ONE policies on sharing data and materials. Please note that NHS ethical approval may be required to access the data.\n",
      "\n",
      "Gray, Laura A.\n",
      "Blatchford Clinical Services are contracted to run the Mobility & Specialised Rehabilitation Centre at Sheffield's Northern General Hospital, where KCD, ZS, JM and AS are employed. Michael McGrath and SZ employees of Blatchford Ltd. BR was an employee of Blatchford Ltd. at the time of her contribution to the current work. Laura A. Gray has no competing interests to declare. This does not alter our adherence to PLOS ONE policies on sharing data and materials. Please note that NHS ethical approval may be required to access the data.\n",
      "\n",
      "Rek, Beata\n",
      "Blatchford Clinical Services are contracted to run the Mobility & Specialised Rehabilitation Centre at Sheffield's Northern General Hospital, where KCD, ZS, JM and AS are employed. Michael McGrath and SZ employees of Blatchford Ltd. Beata Rek was an employee of Blatchford Ltd. at the time of her contribution to the current work. Laura A. Gray has no competing interests to declare. This does not alter our adherence to PLOS ONE policies on sharing data and materials. Please note that NHS ethical approval may be required to access the data.\n",
      "\n",
      "Davies, Kate C.\n",
      "Blatchford Clinical Services are contracted to run the Mobility & Specialised Rehabilitation Centre at Sheffield's Northern General Hospital, where Kate C. Davies, ZS, JM and AS are employed. Michael McGrath and SZ employees of Blatchford Ltd. Beata Rek was an employee of Blatchford Ltd. at the time of her contribution to the current work. Laura A. Gray has no competing interests to declare. This does not alter our adherence to PLOS ONE policies on sharing data and materials. Please note that NHS ethical approval may be required to access the data.\n",
      "\n",
      "Savage, Zoe\n",
      "Blatchford Clinical Services are contracted to run the Mobility & Specialised Rehabilitation Centre at Sheffield's Northern General Hospital, where Kate C. Davies, Zoe Savage, JM and AS are employed. Michael McGrath and SZ employees of Blatchford Ltd. Beata Rek was an employee of Blatchford Ltd. at the time of her contribution to the current work. Laura A. Gray has no competing interests to declare. This does not alter our adherence to PLOS ONE policies on sharing data and materials. Please note that NHS ethical approval may be required to access the data.\n",
      "\n",
      "McLean, Jane\n",
      "Blatchford Clinical Services are contracted to run the Mobility & Specialised Rehabilitation Centre at Sheffield's Northern General Hospital, where Kate C. Davies, Zoe Savage, Jane McLean and AS are employed. Michael McGrath and SZ employees of Blatchford Ltd. Beata Rek was an employee of Blatchford Ltd. at the time of her contribution to the current work. Laura A. Gray has no competing interests to declare. This does not alter our adherence to PLOS ONE policies on sharing data and materials. Please note that NHS ethical approval may be required to access the data.\n",
      "\n",
      "Stenson, Alison\n",
      "Blatchford Clinical Services are contracted to run the Mobility & Specialised Rehabilitation Centre at Sheffield's Northern General Hospital, where Kate C. Davies, Zoe Savage, Jane McLean and Alison Stenson are employed. Michael McGrath and SZ employees of Blatchford Ltd. Beata Rek was an employee of Blatchford Ltd. at the time of her contribution to the current work. Laura A. Gray has no competing interests to declare. This does not alter our adherence to PLOS ONE policies on sharing data and materials. Please note that NHS ethical approval may be required to access the data.\n",
      "\n",
      "Zahedi, Saeed\n",
      "Blatchford Clinical Services are contracted to run the Mobility & Specialised Rehabilitation Centre at Sheffield's Northern General Hospital, where Kate C. Davies, Zoe Savage, Jane McLean and Alison Stenson are employed. Michael McGrath and Saeed Zahedi employees of Blatchford Ltd. Beata Rek was an employee of Blatchford Ltd. at the time of her contribution to the current work. Laura A. Gray has no competing interests to declare. This does not alter our adherence to PLOS ONE policies on sharing data and materials. Please note that NHS ethical approval may be required to access the data.\n",
      "\n",
      "Marianni, Bruna\n",
      "The authors Bruna Marianni and Hudson Polinini are employees of Fagron BV who funded the study. The funder had no influence on the design of the study and the  collection and analyses of data. In addition, all authors declare that the results of the study are presented clearly, honestly, and without fabrication, falsification, or inappropriate data manipulation.\n",
      "\n",
      "Polonini, Hudson\n",
      "The authors Bruna Marianni and Hudson Poloniniolinini are employees of Fagron BV who funded the study. The funder had no influence on the design of the study and the  collection and analyses of data. In addition, all authors declare that the results of the study are presented clearly, honestly, and without fabrication, falsification, or inappropriate data manipulation.\n",
      "\n",
      "Ruiz Nishiki, Milagros\n",
      "Competing interests: RK holds an honorary clinical consultant contract with the ANNB screening programme, now hosted by NHS England and Improvement (formally with Public Health England). RK is also the chair of the ANNB Research Advisory Committee. Milagros Ruiz Nishiki holds an honorary contract with NHS Digital. No other authors have any competing interests to declare.\n",
      "\n",
      "Competing interests: RK holds an honorary clinical consultant contract with the ANNB screening programme, now hosted by NHS England and Improvement (formally with Public Health England). RK is also the chair of the ANNB Research Advisory Committee. Milagros Ruiz Nishiki holds an honorary contract with NHS Digital. No other authors have any competing interests to declare.\n",
      "\n",
      "Knowles, Rachel\n",
      "Competing interests: Rachel Knowles holds an honorary clinical consultant contract with the ANNB screening programme, now hosted by NHS England and Improvement (formally with Public Health England). Rachel Knowles is also the chair of the ANNB Research Advisory Committee. Milagros Ruiz Nishiki holds an honorary contract with NHS Digital. No other authors have any competing interests to declare.\n",
      "\n",
      "Competing interests: Rachel Knowles holds an honorary clinical consultant contract with the ANNB screening programme, now hosted by NHS England and Improvement (formally with Public Health England). Rachel Knowles is also the chair of the ANNB Research Advisory Committee. Milagros Ruiz Nishiki holds an honorary contract with NHS Digital. No other authors have any competing interests to declare.\n",
      "\n",
      "Competing interests: Rachel Knowles holds an honorary clinical consultant contract with the ANNB screening programme, now hosted by NHS England and Improvement (formally with Public Health England). Rachel Knowles is also the chair of the ANNB Research Advisory Committee. Milagros Ruiz Nishiki holds an honorary contract with NHS Digital. No other authors have any competing interests to declare.\n",
      "\n",
      "Competing interests: Rachel Knowles holds an honorary clinical consultant contract with the ANNB screening programme, now hosted by NHS England and Improvement (formally with Public Health England). Rachel Knowles is also the chair of the ANNB Research Advisory Committee. Milagros Ruiz Nishiki holds an honorary contract with NHS Digital. No other authors have any competing interests to declare.\n",
      "\n",
      "Competing interests: Rachel Knowles holds an honorary clinical consultant contract with the ANNB screening programme, now hosted by NHS England and Improvement (formally with Public Health England). Rachel Knowles is also the chair of the ANNB Research Advisory Committee. Milagros Ruiz Nishiki holds an honorary contract with NHS Digital. No other authors have any competing interests to declare.\n",
      "\n",
      "Competing interests: Rachel Knowles holds an honorary clinical consultant contract with the ANNB screening programme, now hosted by NHS England and Improvement (formally with Public Health England). Rachel Knowles is also the chair of the ANNB Research Advisory Committee. Milagros Ruiz Nishiki holds an honorary contract with NHS Digital. No other authors have any competing interests to declare.\n",
      "\n",
      "Competing interests: Rachel Knowles holds an honorary clinical consultant contract with the ANNB screening programme, now hosted by NHS England and Improvement (formally with Public Health England). Rachel Knowles is also the chair of the ANNB Research Advisory Committee. Milagros Ruiz Nishiki holds an honorary contract with NHS Digital. No other authors have any competing interests to declare.\n",
      "\n",
      "Competing interests: Rachel Knowles holds an honorary clinical consultant contract with the ANNB screening programme, now hosted by NHS England and Improvement (formally with Public Health England). Rachel Knowles is also the chair of the ANNB Research Advisory Committee. Milagros Ruiz Nishiki holds an honorary contract with NHS Digital. No other authors have any competing interests to declare.\n",
      "\n",
      "Conflicts of Interest: Alon Harris would like to disclose that he received remuneration from AdOM, Qlaris, Luseed, and Cipla for serving as a consultant, and he serves on the board of AdOM, Qlaris, and Phileas Pharma. Alon Harris holds an ownership interest in AdOM, Luseed, Oxymap, Qlaris, Phileas Pharma, and QuLent. All relationships listed above are pursuant to Icahn School of Medicine's policy on outside activities. None of the other authors listed have any financial disclosures.\n",
      "\n",
      "Conflicts of Interest: Alon Harris would like to disclose that he received remuneration from AdOM, Qlaris, Luseed, and Cipla for serving as a consultant, and he serves on the board of AdOM, Qlaris, and Phileas Pharma. Alon Harris holds an ownership interest in AdOM, Luseed, Oxymap, Qlaris, Phileas Pharma, and QuLent. All relationships listed above are pursuant to Icahn School of Medicine's policy on outside activities. None of the other authors listed have any financial disclosures.\n",
      "\n",
      "Conflicts of Interest: Alon Harris would like to disclose that he received remuneration from AdOM, Qlaris, Luseed, and Cipla for serving as a consultant, and he serves on the board of AdOM, Qlaris, and Phileas Pharma. Alon Harris holds an ownership interest in AdOM, Luseed, Oxymap, Qlaris, Phileas Pharma, and QuLent. All relationships listed above are pursuant to Icahn School of Medicine's policy on outside activities. None of the other authors listed have any financial disclosures.\n",
      "\n",
      "Conflicts of Interest: Alon Harris would like to disclose that he received remuneration from AdOM, Qlaris, Luseed, and Cipla for serving as a consultant, and he serves on the board of AdOM, Qlaris, and Phileas Pharma. Alon Harris holds an ownership interest in AdOM, Luseed, Oxymap, Qlaris, Phileas Pharma, and QuLent. All relationships listed above are pursuant to Icahn School of Medicine's policy on outside activities. None of the other authors listed have any financial disclosures.\n",
      "\n",
      "Conflicts of Interest: Alon Harris would like to disclose that he received remuneration from AdOM, Qlaris, Luseed, and Cipla for serving as a consultant, and he serves on the board of AdOM, Qlaris, and Phileas Pharma. Alon Harris holds an ownership interest in AdOM, Luseed, Oxymap, Qlaris, Phileas Pharma, and QuLent. All relationships listed above are pursuant to Icahn School of Medicine's policy on outside activities. None of the other authors listed have any financial disclosures.\n",
      "\n",
      "Conflicts of Interest: Alon Harris would like to disclose that he received remuneration from AdOM, Qlaris, Luseed, and Cipla for serving as a consultant, and he serves on the board of AdOM, Qlaris, and Phileas Pharma. Alon Harris holds an ownership interest in AdOM, Luseed, Oxymap, Qlaris, Phileas Pharma, and QuLent. All relationships listed above are pursuant to Icahn School of Medicine's policy on outside activities. None of the other authors listed have any financial disclosures.\n",
      "\n",
      "Conflicts of Interest: Alon Harris would like to disclose that he received remuneration from AdOM, Qlaris, Luseed, and Cipla for serving as a consultant, and he serves on the board of AdOM, Qlaris, and Phileas Pharma. Alon Harris holds an ownership interest in AdOM, Luseed, Oxymap, Qlaris, Phileas Pharma, and QuLent. All relationships listed above are pursuant to Icahn School of Medicine's policy on outside activities. None of the other authors listed have any financial disclosures.\n",
      "\n",
      "Conflicts of Interest: Alon Harris would like to disclose that he received remuneration from AdOM, Qlaris, Luseed, and Cipla for serving as a consultant, and he serves on the board of AdOM, Qlaris, and Phileas Pharma. Alon Harris holds an ownership interest in AdOM, Luseed, Oxymap, Qlaris, Phileas Pharma, and QuLent. All relationships listed above are pursuant to Icahn School of Medicine's policy on outside activities. None of the other authors listed have any financial disclosures.\n",
      "\n",
      "Harris, Alon\n",
      "Conflicts of Interest: Alon Harris would like to disclose that he received remuneration from AdOM, Qlaris, Luseed, and Cipla for serving as a consultant, and he serves on the board of AdOM, Qlaris, and Phileas Pharma. Alon Harris holds an ownership interest in AdOM, Luseed, Oxymap, Qlaris, Phileas Pharma, and QuLent. All relationships listed above are pursuant to Icahn School of Medicine's policy on outside activities. None of the other authors listed have any financial disclosures.\n",
      "\n",
      "Gorska, Katarzyna\n",
      "Competing interests: The authors declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article. Honoraria for lectures; payment to Author Support for attending meetings and/or travel - fee, travel, and accommodation. Katarzyna Gorska and M.M.-W. report honoraria for lectures by Roche and Boehringer Ingelheim, support for attending meetings and travel by Roche and Boehringer Ingelheim and participation in Advisory Boards by Boehringer Ingelheim, outside the submitted work; M.B. reports honoraria for lectures by Chiesi Pharmaceuticals GmbH, Roche and Boehringer Ingelheim. A.Bi. reports honoraria for lectures, payment for expert testimony and support for attending meetings and travel by Chiesi Poland; A.Ba. reports support for attending meetings and travel by Boehringer Ingelheim and participation in Advisory Boards by Boehringer Ingelheim; H.J.-L. reports honoraria for lectures,  receipt of equipment, materials, drugs, medical writing, gifts and other services and support for attending meetings and travel by Roche and Boehringer Ingelheim;  E.J. reports honoraria for lectures by Roche and Boehringer Ingelheim, support for attending meetings and travel by Roche and Boehringer Ingelheim and participation in Advisory Boards by Roche and Boehringer Ingelheim, outside the submitted work; A.K. reports honoraria for lectures by Roche and Boehringer Ingelheim, support for attending meetings and travel by Boehringer Ingelheim, outside the submitted work; K.L. reports honoraria for lectures and supports for  attending meetings and travels by Roche and Boehringer Ingelheim and declares participation on an advisory board by Boehringer Ingelheim and patients' advocacy advisory board by Roche, she reports the role as a leadership or fiduciary role in EU-IPFF Scientific Committee and in Polish IPF Patients' Support Society; S.M. and W.J.P. report consulting fees, honoraria for lectures, support for attending  meetings and travel by Boehringer Ingelheim and participation in Boehringer Ingelheim's Advisory Boards, outside the submitted work; M.M.-B. has nothing to disclose; A.S. reports honoraria for lectures by Roche and Boehringer Ingelheim,  support for attending meetings and travel by Roche and Boehringer Ingelheim; K.S. has nothing to disclose. M.S. reports honoraria for lectures by Roche and Boehringer Ingelheim, support for attending meetings and travel by Roche and Boehringer Ingelheim and participation in Advisory Boards by Boehringer Ingelheim and reports the role as a member of the Audit Committee in Polish IPF Patients' Support Society; M.T-S. and W.T. have nothing to disclose; B.Z. reports support for attending meetings and travel by Roche, Boehringer Ingelheim, Chiesi Pharmaceuticals GmbH; R.K. reports support for attending meetings and travel by Boehringer Ingelheim and participation in Advisory Boards for MSD, outside the submitted work.\n",
      "\n",
      "Maskey-Warzechowska, Marta\n",
      "Competing interests: The authors declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article. Honoraria for lectures; payment to Author Support for attending meetings and/or travel - fee, travel, and accommodation. Katarzyna Gorska and Marta Maskey-Warzechowska-W. report honoraria for lectures by Roche and Boehringer Ingelheim, support for attending meetings and travel by Roche and Boehringer Ingelheim and participation in Advisory Boards by Boehringer Ingelheim, outside the submitted work; M.B. reports honoraria for lectures by Chiesi Pharmaceuticals GmbH, Roche and Boehringer Ingelheim. A.Bi. reports honoraria for lectures, payment for expert testimony and support for attending meetings and travel by Chiesi Poland; A.Ba. reports support for attending meetings and travel by Boehringer Ingelheim and participation in Advisory Boards by Boehringer Ingelheim; H.J.-L. reports honoraria for lectures,  receipt of equipment, materials, drugs, medical writing, gifts and other services and support for attending meetings and travel by Roche and Boehringer Ingelheim;  E.J. reports honoraria for lectures by Roche and Boehringer Ingelheim, support for attending meetings and travel by Roche and Boehringer Ingelheim and participation in Advisory Boards by Roche and Boehringer Ingelheim, outside the submitted work; A.K. reports honoraria for lectures by Roche and Boehringer Ingelheim, support for attending meetings and travel by Boehringer Ingelheim, outside the submitted work; K.L. reports honoraria for lectures and supports for  attending meetings and travels by Roche and Boehringer Ingelheim and declares participation on an advisory board by Boehringer Ingelheim and patients' advocacy advisory board by Roche, she reports the role as a leadership or fiduciary role in EU-IPFF Scientific Committee and in Polish IPF Patients' Support Society; S.M. and W.J.P. report consulting fees, honoraria for lectures, support for attending  meetings and travel by Boehringer Ingelheim and participation in Boehringer Ingelheim's Advisory Boards, outside the submitted work; Marta Maskey-Warzechowska-B. has nothing to disclose; A.S. reports honoraria for lectures by Roche and Boehringer Ingelheim,  support for attending meetings and travel by Roche and Boehringer Ingelheim; K.S. has nothing to disclose. M.S. reports honoraria for lectures by Roche and Boehringer Ingelheim, support for attending meetings and travel by Roche and Boehringer Ingelheim and participation in Advisory Boards by Boehringer Ingelheim and reports the role as a member of the Audit Committee in Polish IPF Patients' Support Society; M.T-S. and W.T. have nothing to disclose; B.Z. reports support for attending meetings and travel by Roche, Boehringer Ingelheim, Chiesi Pharmaceuticals GmbH; R.K. reports support for attending meetings and travel by Boehringer Ingelheim and participation in Advisory Boards for MSD, outside the submitted work.\n",
      "\n",
      "Barnas, Malgorzata\n",
      "Competing interests: The authors declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article. Honoraria for lectures; payment to Author Support for attending meetings and/or travel - fee, travel, and accommodation. Katarzyna Gorska and Marta Maskey-Warzechowska-W. report honoraria for lectures by Roche and Boehringer Ingelheim, support for attending meetings and travel by Roche and Boehringer Ingelheim and participation in Advisory Boards by Boehringer Ingelheim, outside the submitted work; Malgorzata Barnas reports honoraria for lectures by Chiesi Pharmaceuticals GmbH, Roche and Boehringer Ingelheim. A.Bi. reports honoraria for lectures, payment for expert testimony and support for attending meetings and travel by Chiesi Poland; A.Ba. reports support for attending meetings and travel by Boehringer Ingelheim and participation in Advisory Boards by Boehringer Ingelheim; H.J.-L. reports honoraria for lectures,  receipt of equipment, materials, drugs, medical writing, gifts and other services and support for attending meetings and travel by Roche and Boehringer Ingelheim;  E.J. reports honoraria for lectures by Roche and Boehringer Ingelheim, support for attending meetings and travel by Roche and Boehringer Ingelheim and participation in Advisory Boards by Roche and Boehringer Ingelheim, outside the submitted work; A.K. reports honoraria for lectures by Roche and Boehringer Ingelheim, support for attending meetings and travel by Boehringer Ingelheim, outside the submitted work; K.L. reports honoraria for lectures and supports for  attending meetings and travels by Roche and Boehringer Ingelheim and declares participation on an advisory board by Boehringer Ingelheim and patients' advocacy advisory board by Roche, she reports the role as a leadership or fiduciary role in EU-IPFF Scientific Committee and in Polish IPF Patients' Support Society; S.M. and W.J.P. report consulting fees, honoraria for lectures, support for attending  meetings and travel by Boehringer Ingelheim and participation in Boehringer Ingelheim's Advisory Boards, outside the submitted work; Marta Maskey-Warzechowska-B. has nothing to disclose; A.S. reports honoraria for lectures by Roche and Boehringer Ingelheim,  support for attending meetings and travel by Roche and Boehringer Ingelheim; K.S. has nothing to disclose. M.S. reports honoraria for lectures by Roche and Boehringer Ingelheim, support for attending meetings and travel by Roche and Boehringer Ingelheim and participation in Advisory Boards by Boehringer Ingelheim and reports the role as a member of the Audit Committee in Polish IPF Patients' Support Society; M.T-S. and W.T. have nothing to disclose; B.Z. reports support for attending meetings and travel by Roche, Boehringer Ingelheim, Chiesi Pharmaceuticals GmbH; R.K. reports support for attending meetings and travel by Boehringer Ingelheim and participation in Advisory Boards for MSD, outside the submitted work.\n",
      "\n",
      "Competing interests: The authors declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article. Honoraria for lectures; payment to Author Support for attending meetings and/or travel - fee, travel, and accommodation. Katarzyna Gorska and Marta Maskey-Warzechowska-W. report honoraria for lectures by Roche and Boehringer Ingelheim, support for attending meetings and travel by Roche and Boehringer Ingelheim and participation in Advisory Boards by Boehringer Ingelheim, outside the submitted work; Malgorzata Barnas reports honoraria for lectures by Chiesi Pharmaceuticals GmbH, Roche and Boehringer Ingelheim. A.Bi. reports honoraria for lectures, payment for expert testimony and support for attending meetings and travel by Chiesi Poland; A.Ba. reports support for attending meetings and travel by Boehringer Ingelheim and participation in Advisory Boards by Boehringer Ingelheim; H.J.-L. reports honoraria for lectures,  receipt of equipment, materials, drugs, medical writing, gifts and other services and support for attending meetings and travel by Roche and Boehringer Ingelheim;  E.J. reports honoraria for lectures by Roche and Boehringer Ingelheim, support for attending meetings and travel by Roche and Boehringer Ingelheim and participation in Advisory Boards by Roche and Boehringer Ingelheim, outside the submitted work; A.K. reports honoraria for lectures by Roche and Boehringer Ingelheim, support for attending meetings and travel by Boehringer Ingelheim, outside the submitted work; K.L. reports honoraria for lectures and supports for  attending meetings and travels by Roche and Boehringer Ingelheim and declares participation on an advisory board by Boehringer Ingelheim and patients' advocacy advisory board by Roche, she reports the role as a leadership or fiduciary role in EU-IPFF Scientific Committee and in Polish IPF Patients' Support Society; S.M. and W.J.P. report consulting fees, honoraria for lectures, support for attending  meetings and travel by Boehringer Ingelheim and participation in Boehringer Ingelheim's Advisory Boards, outside the submitted work; Marta Maskey-Warzechowska-B. has nothing to disclose; A.S. reports honoraria for lectures by Roche and Boehringer Ingelheim,  support for attending meetings and travel by Roche and Boehringer Ingelheim; K.S. has nothing to disclose. M.S. reports honoraria for lectures by Roche and Boehringer Ingelheim, support for attending meetings and travel by Roche and Boehringer Ingelheim and participation in Advisory Boards by Boehringer Ingelheim and reports the role as a member of the Audit Committee in Polish IPF Patients' Support Society; M.T-S. and W.T. have nothing to disclose; B.Z. reports support for attending meetings and travel by Roche, Boehringer Ingelheim, Chiesi Pharmaceuticals GmbH; R.K. reports support for attending meetings and travel by Boehringer Ingelheim and participation in Advisory Boards for MSD, outside the submitted work.\n",
      "\n",
      "Competing interests: The authors declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article. Honoraria for lectures; payment to Author Support for attending meetings and/or travel - fee, travel, and accommodation. Katarzyna Gorska and Marta Maskey-Warzechowska-W. report honoraria for lectures by Roche and Boehringer Ingelheim, support for attending meetings and travel by Roche and Boehringer Ingelheim and participation in Advisory Boards by Boehringer Ingelheim, outside the submitted work; Malgorzata Barnas reports honoraria for lectures by Chiesi Pharmaceuticals GmbH, Roche and Boehringer Ingelheim. A.Bi. reports honoraria for lectures, payment for expert testimony and support for attending meetings and travel by Chiesi Poland; A.Ba. reports support for attending meetings and travel by Boehringer Ingelheim and participation in Advisory Boards by Boehringer Ingelheim; H.J.-L. reports honoraria for lectures,  receipt of equipment, materials, drugs, medical writing, gifts and other services and support for attending meetings and travel by Roche and Boehringer Ingelheim;  E.J. reports honoraria for lectures by Roche and Boehringer Ingelheim, support for attending meetings and travel by Roche and Boehringer Ingelheim and participation in Advisory Boards by Roche and Boehringer Ingelheim, outside the submitted work; A.K. reports honoraria for lectures by Roche and Boehringer Ingelheim, support for attending meetings and travel by Boehringer Ingelheim, outside the submitted work; K.L. reports honoraria for lectures and supports for  attending meetings and travels by Roche and Boehringer Ingelheim and declares participation on an advisory board by Boehringer Ingelheim and patients' advocacy advisory board by Roche, she reports the role as a leadership or fiduciary role in EU-IPFF Scientific Committee and in Polish IPF Patients' Support Society; S.M. and W.J.P. report consulting fees, honoraria for lectures, support for attending  meetings and travel by Boehringer Ingelheim and participation in Boehringer Ingelheim's Advisory Boards, outside the submitted work; Marta Maskey-Warzechowska-B. has nothing to disclose; A.S. reports honoraria for lectures by Roche and Boehringer Ingelheim,  support for attending meetings and travel by Roche and Boehringer Ingelheim; K.S. has nothing to disclose. M.S. reports honoraria for lectures by Roche and Boehringer Ingelheim, support for attending meetings and travel by Roche and Boehringer Ingelheim and participation in Advisory Boards by Boehringer Ingelheim and reports the role as a member of the Audit Committee in Polish IPF Patients' Support Society; M.T-S. and W.T. have nothing to disclose; B.Z. reports support for attending meetings and travel by Roche, Boehringer Ingelheim, Chiesi Pharmaceuticals GmbH; R.K. reports support for attending meetings and travel by Boehringer Ingelheim and participation in Advisory Boards for MSD, outside the submitted work.\n",
      "\n",
      "Jagielska-Len, Hanna\n",
      "Competing interests: The authors declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article. Honoraria for lectures; payment to Author Support for attending meetings and/or travel - fee, travel, and accommodation. Katarzyna Gorska and Marta Maskey-Warzechowska-W. report honoraria for lectures by Roche and Boehringer Ingelheim, support for attending meetings and travel by Roche and Boehringer Ingelheim and participation in Advisory Boards by Boehringer Ingelheim, outside the submitted work; Malgorzata Barnas reports honoraria for lectures by Chiesi Pharmaceuticals GmbH, Roche and Boehringer Ingelheim. A.Bi. reports honoraria for lectures, payment for expert testimony and support for attending meetings and travel by Chiesi Poland; A.Ba. reports support for attending meetings and travel by Boehringer Ingelheim and participation in Advisory Boards by Boehringer Ingelheim; Hanna Jagielska-Len-L. reports honoraria for lectures,  receipt of equipment, materials, drugs, medical writing, gifts and other services and support for attending meetings and travel by Roche and Boehringer Ingelheim;  E.J. reports honoraria for lectures by Roche and Boehringer Ingelheim, support for attending meetings and travel by Roche and Boehringer Ingelheim and participation in Advisory Boards by Roche and Boehringer Ingelheim, outside the submitted work; A.K. reports honoraria for lectures by Roche and Boehringer Ingelheim, support for attending meetings and travel by Boehringer Ingelheim, outside the submitted work; K.L. reports honoraria for lectures and supports for  attending meetings and travels by Roche and Boehringer Ingelheim and declares participation on an advisory board by Boehringer Ingelheim and patients' advocacy advisory board by Roche, she reports the role as a leadership or fiduciary role in EU-IPFF Scientific Committee and in Polish IPF Patients' Support Society; S.M. and W.J.P. report consulting fees, honoraria for lectures, support for attending  meetings and travel by Boehringer Ingelheim and participation in Boehringer Ingelheim's Advisory Boards, outside the submitted work; Marta Maskey-Warzechowska-B. has nothing to disclose; A.S. reports honoraria for lectures by Roche and Boehringer Ingelheim,  support for attending meetings and travel by Roche and Boehringer Ingelheim; K.S. has nothing to disclose. M.S. reports honoraria for lectures by Roche and Boehringer Ingelheim, support for attending meetings and travel by Roche and Boehringer Ingelheim and participation in Advisory Boards by Boehringer Ingelheim and reports the role as a member of the Audit Committee in Polish IPF Patients' Support Society; M.T-S. and W.T. have nothing to disclose; B.Z. reports support for attending meetings and travel by Roche, Boehringer Ingelheim, Chiesi Pharmaceuticals GmbH; R.K. reports support for attending meetings and travel by Boehringer Ingelheim and participation in Advisory Boards for MSD, outside the submitted work.\n",
      "\n",
      "Jassem, Ewa\n",
      "Competing interests: The authors declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article. Honoraria for lectures; payment to Author Support for attending meetings and/or travel - fee, travel, and accommodation. Katarzyna Gorska and Marta Maskey-Warzechowska-W. report honoraria for lectures by Roche and Boehringer Ingelheim, support for attending meetings and travel by Roche and Boehringer Ingelheim and participation in Advisory Boards by Boehringer Ingelheim, outside the submitted work; Malgorzata Barnas reports honoraria for lectures by Chiesi Pharmaceuticals GmbH, Roche and Boehringer Ingelheim. A.Bi. reports honoraria for lectures, payment for expert testimony and support for attending meetings and travel by Chiesi Poland; A.Ba. reports support for attending meetings and travel by Boehringer Ingelheim and participation in Advisory Boards by Boehringer Ingelheim; Hanna Jagielska-Len-L. reports honoraria for lectures,  receipt of equipment, materials, drugs, medical writing, gifts and other services and support for attending meetings and travel by Roche and Boehringer Ingelheim;  Ewa Jassem reports honoraria for lectures by Roche and Boehringer Ingelheim, support for attending meetings and travel by Roche and Boehringer Ingelheim and participation in Advisory Boards by Roche and Boehringer Ingelheim, outside the submitted work; A.K. reports honoraria for lectures by Roche and Boehringer Ingelheim, support for attending meetings and travel by Boehringer Ingelheim, outside the submitted work; K.L. reports honoraria for lectures and supports for  attending meetings and travels by Roche and Boehringer Ingelheim and declares participation on an advisory board by Boehringer Ingelheim and patients' advocacy advisory board by Roche, she reports the role as a leadership or fiduciary role in EU-IPFF Scientific Committee and in Polish IPF Patients' Support Society; S.M. and W.J.P. report consulting fees, honoraria for lectures, support for attending  meetings and travel by Boehringer Ingelheim and participation in Boehringer Ingelheim's Advisory Boards, outside the submitted work; Marta Maskey-Warzechowska-B. has nothing to disclose; A.S. reports honoraria for lectures by Roche and Boehringer Ingelheim,  support for attending meetings and travel by Roche and Boehringer Ingelheim; K.S. has nothing to disclose. M.S. reports honoraria for lectures by Roche and Boehringer Ingelheim, support for attending meetings and travel by Roche and Boehringer Ingelheim and participation in Advisory Boards by Boehringer Ingelheim and reports the role as a member of the Audit Committee in Polish IPF Patients' Support Society; M.T-S. and W.T. have nothing to disclose; B.Z. reports support for attending meetings and travel by Roche, Boehringer Ingelheim, Chiesi Pharmaceuticals GmbH; R.K. reports support for attending meetings and travel by Boehringer Ingelheim and participation in Advisory Boards for MSD, outside the submitted work.\n",
      "\n",
      "Kania, Aleksander\n",
      "Competing interests: The authors declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article. Honoraria for lectures; payment to Author Support for attending meetings and/or travel - fee, travel, and accommodation. Katarzyna Gorska and Marta Maskey-Warzechowska-W. report honoraria for lectures by Roche and Boehringer Ingelheim, support for attending meetings and travel by Roche and Boehringer Ingelheim and participation in Advisory Boards by Boehringer Ingelheim, outside the submitted work; Malgorzata Barnas reports honoraria for lectures by Chiesi Pharmaceuticals GmbH, Roche and Boehringer Ingelheim. A.Bi. reports honoraria for lectures, payment for expert testimony and support for attending meetings and travel by Chiesi Poland; A.Ba. reports support for attending meetings and travel by Boehringer Ingelheim and participation in Advisory Boards by Boehringer Ingelheim; Hanna Jagielska-Len-L. reports honoraria for lectures,  receipt of equipment, materials, drugs, medical writing, gifts and other services and support for attending meetings and travel by Roche and Boehringer Ingelheim;  Ewa Jassem reports honoraria for lectures by Roche and Boehringer Ingelheim, support for attending meetings and travel by Roche and Boehringer Ingelheim and participation in Advisory Boards by Roche and Boehringer Ingelheim, outside the submitted work; Aleksander Kania reports honoraria for lectures by Roche and Boehringer Ingelheim, support for attending meetings and travel by Boehringer Ingelheim, outside the submitted work; K.L. reports honoraria for lectures and supports for  attending meetings and travels by Roche and Boehringer Ingelheim and declares participation on an advisory board by Boehringer Ingelheim and patients' advocacy advisory board by Roche, she reports the role as a leadership or fiduciary role in EU-IPFF Scientific Committee and in Polish IPF Patients' Support Society; S.M. and W.J.P. report consulting fees, honoraria for lectures, support for attending  meetings and travel by Boehringer Ingelheim and participation in Boehringer Ingelheim's Advisory Boards, outside the submitted work; Marta Maskey-Warzechowska-B. has nothing to disclose; A.S. reports honoraria for lectures by Roche and Boehringer Ingelheim,  support for attending meetings and travel by Roche and Boehringer Ingelheim; K.S. has nothing to disclose. M.S. reports honoraria for lectures by Roche and Boehringer Ingelheim, support for attending meetings and travel by Roche and Boehringer Ingelheim and participation in Advisory Boards by Boehringer Ingelheim and reports the role as a member of the Audit Committee in Polish IPF Patients' Support Society; M.T-S. and W.T. have nothing to disclose; B.Z. reports support for attending meetings and travel by Roche, Boehringer Ingelheim, Chiesi Pharmaceuticals GmbH; R.K. reports support for attending meetings and travel by Boehringer Ingelheim and participation in Advisory Boards for MSD, outside the submitted work.\n",
      "\n",
      "Lewandowska, Katarzyna\n",
      "Competing interests: The authors declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article. Honoraria for lectures; payment to Author Support for attending meetings and/or travel - fee, travel, and accommodation. Katarzyna Gorska and Marta Maskey-Warzechowska-W. report honoraria for lectures by Roche and Boehringer Ingelheim, support for attending meetings and travel by Roche and Boehringer Ingelheim and participation in Advisory Boards by Boehringer Ingelheim, outside the submitted work; Malgorzata Barnas reports honoraria for lectures by Chiesi Pharmaceuticals GmbH, Roche and Boehringer Ingelheim. A.Bi. reports honoraria for lectures, payment for expert testimony and support for attending meetings and travel by Chiesi Poland; A.Ba. reports support for attending meetings and travel by Boehringer Ingelheim and participation in Advisory Boards by Boehringer Ingelheim; Hanna Jagielska-Len-L. reports honoraria for lectures,  receipt of equipment, materials, drugs, medical writing, gifts and other services and support for attending meetings and travel by Roche and Boehringer Ingelheim;  Ewa Jassem reports honoraria for lectures by Roche and Boehringer Ingelheim, support for attending meetings and travel by Roche and Boehringer Ingelheim and participation in Advisory Boards by Roche and Boehringer Ingelheim, outside the submitted work; Aleksander Kania reports honoraria for lectures by Roche and Boehringer Ingelheim, support for attending meetings and travel by Boehringer Ingelheim, outside the submitted work; Katarzyna Lewandowska reports honoraria for lectures and supports for  attending meetings and travels by Roche and Boehringer Ingelheim and declares participation on an advisory board by Boehringer Ingelheim and patients' advocacy advisory board by Roche, she reports the role as a leadership or fiduciary role in EU-IPFF Scientific Committee and in Polish IPF Patients' Support Society; S.M. and W.J.P. report consulting fees, honoraria for lectures, support for attending  meetings and travel by Boehringer Ingelheim and participation in Boehringer Ingelheim's Advisory Boards, outside the submitted work; Marta Maskey-Warzechowska-B. has nothing to disclose; A.S. reports honoraria for lectures by Roche and Boehringer Ingelheim,  support for attending meetings and travel by Roche and Boehringer Ingelheim; K.S. has nothing to disclose. M.S. reports honoraria for lectures by Roche and Boehringer Ingelheim, support for attending meetings and travel by Roche and Boehringer Ingelheim and participation in Advisory Boards by Boehringer Ingelheim and reports the role as a member of the Audit Committee in Polish IPF Patients' Support Society; M.T-S. and W.T. have nothing to disclose; B.Z. reports support for attending meetings and travel by Roche, Boehringer Ingelheim, Chiesi Pharmaceuticals GmbH; R.K. reports support for attending meetings and travel by Boehringer Ingelheim and participation in Advisory Boards for MSD, outside the submitted work.\n",
      "\n",
      "Majewski, Sebastian\n",
      "Competing interests: The authors declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article. Honoraria for lectures; payment to Author Support for attending meetings and/or travel - fee, travel, and accommodation. Katarzyna Gorska and Marta Maskey-Warzechowska-W. report honoraria for lectures by Roche and Boehringer Ingelheim, support for attending meetings and travel by Roche and Boehringer Ingelheim and participation in Advisory Boards by Boehringer Ingelheim, outside the submitted work; Malgorzata Barnas reports honoraria for lectures by Chiesi Pharmaceuticals GmbH, Roche and Boehringer Ingelheim. A.Bi. reports honoraria for lectures, payment for expert testimony and support for attending meetings and travel by Chiesi Poland; A.Ba. reports support for attending meetings and travel by Boehringer Ingelheim and participation in Advisory Boards by Boehringer Ingelheim; Hanna Jagielska-Len-L. reports honoraria for lectures,  receipt of equipment, materials, drugs, medical writing, gifts and other services and support for attending meetings and travel by Roche and Boehringer Ingelheim;  Ewa Jassem reports honoraria for lectures by Roche and Boehringer Ingelheim, support for attending meetings and travel by Roche and Boehringer Ingelheim and participation in Advisory Boards by Roche and Boehringer Ingelheim, outside the submitted work; Aleksander Kania reports honoraria for lectures by Roche and Boehringer Ingelheim, support for attending meetings and travel by Boehringer Ingelheim, outside the submitted work; Katarzyna Lewandowska reports honoraria for lectures and supports for  attending meetings and travels by Roche and Boehringer Ingelheim and declares participation on an advisory board by Boehringer Ingelheim and patients' advocacy advisory board by Roche, she reports the role as a leadership or fiduciary role in EU-IPFF Scientific Committee and in Polish IPF Patients' Support Society; Sebastian Majewski and W.J.P. report consulting fees, honoraria for lectures, support for attending  meetings and travel by Boehringer Ingelheim and participation in Boehringer Ingelheim's Advisory Boards, outside the submitted work; Marta Maskey-Warzechowska-B. has nothing to disclose; A.S. reports honoraria for lectures by Roche and Boehringer Ingelheim,  support for attending meetings and travel by Roche and Boehringer Ingelheim; K.S. has nothing to disclose. M.S. reports honoraria for lectures by Roche and Boehringer Ingelheim, support for attending meetings and travel by Roche and Boehringer Ingelheim and participation in Advisory Boards by Boehringer Ingelheim and reports the role as a member of the Audit Committee in Polish IPF Patients' Support Society; M.T-S. and W.T. have nothing to disclose; B.Z. reports support for attending meetings and travel by Roche, Boehringer Ingelheim, Chiesi Pharmaceuticals GmbH; R.K. reports support for attending meetings and travel by Boehringer Ingelheim and participation in Advisory Boards for MSD, outside the submitted work.\n",
      "\n",
      "Competing interests: The authors declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article. Honoraria for lectures; payment to Author Support for attending meetings and/or travel - fee, travel, and accommodation. Katarzyna Gorska and Marta Maskey-Warzechowska-W. report honoraria for lectures by Roche and Boehringer Ingelheim, support for attending meetings and travel by Roche and Boehringer Ingelheim and participation in Advisory Boards by Boehringer Ingelheim, outside the submitted work; Malgorzata Barnas reports honoraria for lectures by Chiesi Pharmaceuticals GmbH, Roche and Boehringer Ingelheim. A.Bi. reports honoraria for lectures, payment for expert testimony and support for attending meetings and travel by Chiesi Poland; A.Ba. reports support for attending meetings and travel by Boehringer Ingelheim and participation in Advisory Boards by Boehringer Ingelheim; Hanna Jagielska-Len-L. reports honoraria for lectures,  receipt of equipment, materials, drugs, medical writing, gifts and other services and support for attending meetings and travel by Roche and Boehringer Ingelheim;  Ewa Jassem reports honoraria for lectures by Roche and Boehringer Ingelheim, support for attending meetings and travel by Roche and Boehringer Ingelheim and participation in Advisory Boards by Roche and Boehringer Ingelheim, outside the submitted work; Aleksander Kania reports honoraria for lectures by Roche and Boehringer Ingelheim, support for attending meetings and travel by Boehringer Ingelheim, outside the submitted work; Katarzyna Lewandowska reports honoraria for lectures and supports for  attending meetings and travels by Roche and Boehringer Ingelheim and declares participation on an advisory board by Boehringer Ingelheim and patients' advocacy advisory board by Roche, she reports the role as a leadership or fiduciary role in EU-IPFF Scientific Committee and in Polish IPF Patients' Support Society; Sebastian Majewski and W.J.P. report consulting fees, honoraria for lectures, support for attending  meetings and travel by Boehringer Ingelheim and participation in Boehringer Ingelheim's Advisory Boards, outside the submitted work; Marta Maskey-Warzechowska-B. has nothing to disclose; A.S. reports honoraria for lectures by Roche and Boehringer Ingelheim,  support for attending meetings and travel by Roche and Boehringer Ingelheim; K.S. has nothing to disclose. M.S. reports honoraria for lectures by Roche and Boehringer Ingelheim, support for attending meetings and travel by Roche and Boehringer Ingelheim and participation in Advisory Boards by Boehringer Ingelheim and reports the role as a member of the Audit Committee in Polish IPF Patients' Support Society; M.T-S. and W.T. have nothing to disclose; B.Z. reports support for attending meetings and travel by Roche, Boehringer Ingelheim, Chiesi Pharmaceuticals GmbH; R.K. reports support for attending meetings and travel by Boehringer Ingelheim and participation in Advisory Boards for MSD, outside the submitted work.\n",
      "\n",
      "Piotrowski, Wojciech J.\n",
      "Competing interests: The authors declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article. Honoraria for lectures; payment to Author Support for attending meetings and/or travel - fee, travel, and accommodation. Katarzyna Gorska and Marta Maskey-Warzechowska-W. report honoraria for lectures by Roche and Boehringer Ingelheim, support for attending meetings and travel by Roche and Boehringer Ingelheim and participation in Advisory Boards by Boehringer Ingelheim, outside the submitted work; Malgorzata Barnas reports honoraria for lectures by Chiesi Pharmaceuticals GmbH, Roche and Boehringer Ingelheim. A.Bi. reports honoraria for lectures, payment for expert testimony and support for attending meetings and travel by Chiesi Poland; A.Ba. reports support for attending meetings and travel by Boehringer Ingelheim and participation in Advisory Boards by Boehringer Ingelheim; Hanna Jagielska-Len-L. reports honoraria for lectures,  receipt of equipment, materials, drugs, medical writing, gifts and other services and support for attending meetings and travel by Roche and Boehringer Ingelheim;  Ewa Jassem reports honoraria for lectures by Roche and Boehringer Ingelheim, support for attending meetings and travel by Roche and Boehringer Ingelheim and participation in Advisory Boards by Roche and Boehringer Ingelheim, outside the submitted work; Aleksander Kania reports honoraria for lectures by Roche and Boehringer Ingelheim, support for attending meetings and travel by Boehringer Ingelheim, outside the submitted work; Katarzyna Lewandowska reports honoraria for lectures and supports for  attending meetings and travels by Roche and Boehringer Ingelheim and declares participation on an advisory board by Boehringer Ingelheim and patients' advocacy advisory board by Roche, she reports the role as a leadership or fiduciary role in EU-IPFF Scientific Committee and in Polish IPF Patients' Support Society; Sebastian Majewski and Wojciech J. Piotrowski report consulting fees, honoraria for lectures, support for attending  meetings and travel by Boehringer Ingelheim and participation in Boehringer Ingelheim's Advisory Boards, outside the submitted work; Marta Maskey-Warzechowska-B. has nothing to disclose; A.S. reports honoraria for lectures by Roche and Boehringer Ingelheim,  support for attending meetings and travel by Roche and Boehringer Ingelheim; K.S. has nothing to disclose. M.S. reports honoraria for lectures by Roche and Boehringer Ingelheim, support for attending meetings and travel by Roche and Boehringer Ingelheim and participation in Advisory Boards by Boehringer Ingelheim and reports the role as a member of the Audit Committee in Polish IPF Patients' Support Society; M.T-S. and W.T. have nothing to disclose; B.Z. reports support for attending meetings and travel by Roche, Boehringer Ingelheim, Chiesi Pharmaceuticals GmbH; R.K. reports support for attending meetings and travel by Boehringer Ingelheim and participation in Advisory Boards for MSD, outside the submitted work.\n",
      "\n",
      "Sieminska, Alicja\n",
      "Competing interests: The authors declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article. Honoraria for lectures; payment to Author Support for attending meetings and/or travel - fee, travel, and accommodation. Katarzyna Gorska and Marta Maskey-Warzechowska-W. report honoraria for lectures by Roche and Boehringer Ingelheim, support for attending meetings and travel by Roche and Boehringer Ingelheim and participation in Advisory Boards by Boehringer Ingelheim, outside the submitted work; Malgorzata Barnas reports honoraria for lectures by Chiesi Pharmaceuticals GmbH, Roche and Boehringer Ingelheim. A.Bi. reports honoraria for lectures, payment for expert testimony and support for attending meetings and travel by Chiesi Poland; A.Ba. reports support for attending meetings and travel by Boehringer Ingelheim and participation in Advisory Boards by Boehringer Ingelheim; Hanna Jagielska-Len-L. reports honoraria for lectures,  receipt of equipment, materials, drugs, medical writing, gifts and other services and support for attending meetings and travel by Roche and Boehringer Ingelheim;  Ewa Jassem reports honoraria for lectures by Roche and Boehringer Ingelheim, support for attending meetings and travel by Roche and Boehringer Ingelheim and participation in Advisory Boards by Roche and Boehringer Ingelheim, outside the submitted work; Aleksander Kania reports honoraria for lectures by Roche and Boehringer Ingelheim, support for attending meetings and travel by Boehringer Ingelheim, outside the submitted work; Katarzyna Lewandowska reports honoraria for lectures and supports for  attending meetings and travels by Roche and Boehringer Ingelheim and declares participation on an advisory board by Boehringer Ingelheim and patients' advocacy advisory board by Roche, she reports the role as a leadership or fiduciary role in EU-IPFF Scientific Committee and in Polish IPF Patients' Support Society; Sebastian Majewski and Wojciech J. Piotrowski report consulting fees, honoraria for lectures, support for attending  meetings and travel by Boehringer Ingelheim and participation in Boehringer Ingelheim's Advisory Boards, outside the submitted work; Marta Maskey-Warzechowska-B. has nothing to disclose; Alicja Sieminska reports honoraria for lectures by Roche and Boehringer Ingelheim,  support for attending meetings and travel by Roche and Boehringer Ingelheim; K.S. has nothing to disclose. M.S. reports honoraria for lectures by Roche and Boehringer Ingelheim, support for attending meetings and travel by Roche and Boehringer Ingelheim and participation in Advisory Boards by Boehringer Ingelheim and reports the role as a member of the Audit Committee in Polish IPF Patients' Support Society; M.T-S. and W.T. have nothing to disclose; B.Z. reports support for attending meetings and travel by Roche, Boehringer Ingelheim, Chiesi Pharmaceuticals GmbH; R.K. reports support for attending meetings and travel by Boehringer Ingelheim and participation in Advisory Boards for MSD, outside the submitted work.\n",
      "\n",
      "Sladek, Krzysztof\n",
      "Competing interests: The authors declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article. Honoraria for lectures; payment to Author Support for attending meetings and/or travel - fee, travel, and accommodation. Katarzyna Gorska and Marta Maskey-Warzechowska-W. report honoraria for lectures by Roche and Boehringer Ingelheim, support for attending meetings and travel by Roche and Boehringer Ingelheim and participation in Advisory Boards by Boehringer Ingelheim, outside the submitted work; Malgorzata Barnas reports honoraria for lectures by Chiesi Pharmaceuticals GmbH, Roche and Boehringer Ingelheim. A.Bi. reports honoraria for lectures, payment for expert testimony and support for attending meetings and travel by Chiesi Poland; A.Ba. reports support for attending meetings and travel by Boehringer Ingelheim and participation in Advisory Boards by Boehringer Ingelheim; Hanna Jagielska-Len-L. reports honoraria for lectures,  receipt of equipment, materials, drugs, medical writing, gifts and other services and support for attending meetings and travel by Roche and Boehringer Ingelheim;  Ewa Jassem reports honoraria for lectures by Roche and Boehringer Ingelheim, support for attending meetings and travel by Roche and Boehringer Ingelheim and participation in Advisory Boards by Roche and Boehringer Ingelheim, outside the submitted work; Aleksander Kania reports honoraria for lectures by Roche and Boehringer Ingelheim, support for attending meetings and travel by Boehringer Ingelheim, outside the submitted work; Katarzyna Lewandowska reports honoraria for lectures and supports for  attending meetings and travels by Roche and Boehringer Ingelheim and declares participation on an advisory board by Boehringer Ingelheim and patients' advocacy advisory board by Roche, she reports the role as a leadership or fiduciary role in EU-IPFF Scientific Committee and in Polish IPF Patients' Support Society; Sebastian Majewski and Wojciech J. Piotrowski report consulting fees, honoraria for lectures, support for attending  meetings and travel by Boehringer Ingelheim and participation in Boehringer Ingelheim's Advisory Boards, outside the submitted work; Marta Maskey-Warzechowska-B. has nothing to disclose; Alicja Sieminska reports honoraria for lectures by Roche and Boehringer Ingelheim,  support for attending meetings and travel by Roche and Boehringer Ingelheim; Krzysztof Sladek has nothing to disclose. M.S. reports honoraria for lectures by Roche and Boehringer Ingelheim, support for attending meetings and travel by Roche and Boehringer Ingelheim and participation in Advisory Boards by Boehringer Ingelheim and reports the role as a member of the Audit Committee in Polish IPF Patients' Support Society; M.T-S. and W.T. have nothing to disclose; B.Z. reports support for attending meetings and travel by Roche, Boehringer Ingelheim, Chiesi Pharmaceuticals GmbH; R.K. reports support for attending meetings and travel by Boehringer Ingelheim and participation in Advisory Boards for MSD, outside the submitted work.\n",
      "\n",
      "Sobiecka, Malgorzata\n",
      "Competing interests: The authors declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article. Honoraria for lectures; payment to Author Support for attending meetings and/or travel - fee, travel, and accommodation. Katarzyna Gorska and Marta Maskey-Warzechowska-W. report honoraria for lectures by Roche and Boehringer Ingelheim, support for attending meetings and travel by Roche and Boehringer Ingelheim and participation in Advisory Boards by Boehringer Ingelheim, outside the submitted work; Malgorzata Barnas reports honoraria for lectures by Chiesi Pharmaceuticals GmbH, Roche and Boehringer Ingelheim. A.Bi. reports honoraria for lectures, payment for expert testimony and support for attending meetings and travel by Chiesi Poland; A.Ba. reports support for attending meetings and travel by Boehringer Ingelheim and participation in Advisory Boards by Boehringer Ingelheim; Hanna Jagielska-Len-L. reports honoraria for lectures,  receipt of equipment, materials, drugs, medical writing, gifts and other services and support for attending meetings and travel by Roche and Boehringer Ingelheim;  Ewa Jassem reports honoraria for lectures by Roche and Boehringer Ingelheim, support for attending meetings and travel by Roche and Boehringer Ingelheim and participation in Advisory Boards by Roche and Boehringer Ingelheim, outside the submitted work; Aleksander Kania reports honoraria for lectures by Roche and Boehringer Ingelheim, support for attending meetings and travel by Boehringer Ingelheim, outside the submitted work; Katarzyna Lewandowska reports honoraria for lectures and supports for  attending meetings and travels by Roche and Boehringer Ingelheim and declares participation on an advisory board by Boehringer Ingelheim and patients' advocacy advisory board by Roche, she reports the role as a leadership or fiduciary role in EU-IPFF Scientific Committee and in Polish IPF Patients' Support Society; Sebastian Majewski and Wojciech J. Piotrowski report consulting fees, honoraria for lectures, support for attending  meetings and travel by Boehringer Ingelheim and participation in Boehringer Ingelheim's Advisory Boards, outside the submitted work; Marta Maskey-Warzechowska-B. has nothing to disclose; Alicja Sieminska reports honoraria for lectures by Roche and Boehringer Ingelheim,  support for attending meetings and travel by Roche and Boehringer Ingelheim; Krzysztof Sladek has nothing to disclose. Malgorzata Sobiecka reports honoraria for lectures by Roche and Boehringer Ingelheim, support for attending meetings and travel by Roche and Boehringer Ingelheim and participation in Advisory Boards by Boehringer Ingelheim and reports the role as a member of the Audit Committee in Polish IPF Patients' Support Society; M.T-S. and W.T. have nothing to disclose; B.Z. reports support for attending meetings and travel by Roche, Boehringer Ingelheim, Chiesi Pharmaceuticals GmbH; R.K. reports support for attending meetings and travel by Boehringer Ingelheim and participation in Advisory Boards for MSD, outside the submitted work.\n",
      "\n",
      "Competing interests: The authors declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article. Honoraria for lectures; payment to Author Support for attending meetings and/or travel - fee, travel, and accommodation. Katarzyna Gorska and Marta Maskey-Warzechowska-W. report honoraria for lectures by Roche and Boehringer Ingelheim, support for attending meetings and travel by Roche and Boehringer Ingelheim and participation in Advisory Boards by Boehringer Ingelheim, outside the submitted work; Malgorzata Barnas reports honoraria for lectures by Chiesi Pharmaceuticals GmbH, Roche and Boehringer Ingelheim. A.Bi. reports honoraria for lectures, payment for expert testimony and support for attending meetings and travel by Chiesi Poland; A.Ba. reports support for attending meetings and travel by Boehringer Ingelheim and participation in Advisory Boards by Boehringer Ingelheim; Hanna Jagielska-Len-L. reports honoraria for lectures,  receipt of equipment, materials, drugs, medical writing, gifts and other services and support for attending meetings and travel by Roche and Boehringer Ingelheim;  Ewa Jassem reports honoraria for lectures by Roche and Boehringer Ingelheim, support for attending meetings and travel by Roche and Boehringer Ingelheim and participation in Advisory Boards by Roche and Boehringer Ingelheim, outside the submitted work; Aleksander Kania reports honoraria for lectures by Roche and Boehringer Ingelheim, support for attending meetings and travel by Boehringer Ingelheim, outside the submitted work; Katarzyna Lewandowska reports honoraria for lectures and supports for  attending meetings and travels by Roche and Boehringer Ingelheim and declares participation on an advisory board by Boehringer Ingelheim and patients' advocacy advisory board by Roche, she reports the role as a leadership or fiduciary role in EU-IPFF Scientific Committee and in Polish IPF Patients' Support Society; Sebastian Majewski and Wojciech J. Piotrowski report consulting fees, honoraria for lectures, support for attending  meetings and travel by Boehringer Ingelheim and participation in Boehringer Ingelheim's Advisory Boards, outside the submitted work; Marta Maskey-Warzechowska-B. has nothing to disclose; Alicja Sieminska reports honoraria for lectures by Roche and Boehringer Ingelheim,  support for attending meetings and travel by Roche and Boehringer Ingelheim; Krzysztof Sladek has nothing to disclose. Malgorzata Sobiecka reports honoraria for lectures by Roche and Boehringer Ingelheim, support for attending meetings and travel by Roche and Boehringer Ingelheim and participation in Advisory Boards by Boehringer Ingelheim and reports the role as a member of the Audit Committee in Polish IPF Patients' Support Society; M.T-S. and W.T. have nothing to disclose; B.Z. reports support for attending meetings and travel by Roche, Boehringer Ingelheim, Chiesi Pharmaceuticals GmbH; R.K. reports support for attending meetings and travel by Boehringer Ingelheim and participation in Advisory Boards for MSD, outside the submitted work.\n",
      "\n",
      "Tomkowski, Witold\n",
      "Competing interests: The authors declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article. Honoraria for lectures; payment to Author Support for attending meetings and/or travel - fee, travel, and accommodation. Katarzyna Gorska and Marta Maskey-Warzechowska-W. report honoraria for lectures by Roche and Boehringer Ingelheim, support for attending meetings and travel by Roche and Boehringer Ingelheim and participation in Advisory Boards by Boehringer Ingelheim, outside the submitted work; Malgorzata Barnas reports honoraria for lectures by Chiesi Pharmaceuticals GmbH, Roche and Boehringer Ingelheim. A.Bi. reports honoraria for lectures, payment for expert testimony and support for attending meetings and travel by Chiesi Poland; A.Ba. reports support for attending meetings and travel by Boehringer Ingelheim and participation in Advisory Boards by Boehringer Ingelheim; Hanna Jagielska-Len-L. reports honoraria for lectures,  receipt of equipment, materials, drugs, medical writing, gifts and other services and support for attending meetings and travel by Roche and Boehringer Ingelheim;  Ewa Jassem reports honoraria for lectures by Roche and Boehringer Ingelheim, support for attending meetings and travel by Roche and Boehringer Ingelheim and participation in Advisory Boards by Roche and Boehringer Ingelheim, outside the submitted work; Aleksander Kania reports honoraria for lectures by Roche and Boehringer Ingelheim, support for attending meetings and travel by Boehringer Ingelheim, outside the submitted work; Katarzyna Lewandowska reports honoraria for lectures and supports for  attending meetings and travels by Roche and Boehringer Ingelheim and declares participation on an advisory board by Boehringer Ingelheim and patients' advocacy advisory board by Roche, she reports the role as a leadership or fiduciary role in EU-IPFF Scientific Committee and in Polish IPF Patients' Support Society; Sebastian Majewski and Wojciech J. Piotrowski report consulting fees, honoraria for lectures, support for attending  meetings and travel by Boehringer Ingelheim and participation in Boehringer Ingelheim's Advisory Boards, outside the submitted work; Marta Maskey-Warzechowska-B. has nothing to disclose; Alicja Sieminska reports honoraria for lectures by Roche and Boehringer Ingelheim,  support for attending meetings and travel by Roche and Boehringer Ingelheim; Krzysztof Sladek has nothing to disclose. Malgorzata Sobiecka reports honoraria for lectures by Roche and Boehringer Ingelheim, support for attending meetings and travel by Roche and Boehringer Ingelheim and participation in Advisory Boards by Boehringer Ingelheim and reports the role as a member of the Audit Committee in Polish IPF Patients' Support Society; M.T-S. and Witold Tomkowski have nothing to disclose; B.Z. reports support for attending meetings and travel by Roche, Boehringer Ingelheim, Chiesi Pharmaceuticals GmbH; R.K. reports support for attending meetings and travel by Boehringer Ingelheim and participation in Advisory Boards for MSD, outside the submitted work.\n",
      "\n",
      "Zolnowska, Beata\n",
      "Competing interests: The authors declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article. Honoraria for lectures; payment to Author Support for attending meetings and/or travel - fee, travel, and accommodation. Katarzyna Gorska and Marta Maskey-Warzechowska-W. report honoraria for lectures by Roche and Boehringer Ingelheim, support for attending meetings and travel by Roche and Boehringer Ingelheim and participation in Advisory Boards by Boehringer Ingelheim, outside the submitted work; Malgorzata Barnas reports honoraria for lectures by Chiesi Pharmaceuticals GmbH, Roche and Boehringer Ingelheim. A.Bi. reports honoraria for lectures, payment for expert testimony and support for attending meetings and travel by Chiesi Poland; A.Ba. reports support for attending meetings and travel by Boehringer Ingelheim and participation in Advisory Boards by Boehringer Ingelheim; Hanna Jagielska-Len-L. reports honoraria for lectures,  receipt of equipment, materials, drugs, medical writing, gifts and other services and support for attending meetings and travel by Roche and Boehringer Ingelheim;  Ewa Jassem reports honoraria for lectures by Roche and Boehringer Ingelheim, support for attending meetings and travel by Roche and Boehringer Ingelheim and participation in Advisory Boards by Roche and Boehringer Ingelheim, outside the submitted work; Aleksander Kania reports honoraria for lectures by Roche and Boehringer Ingelheim, support for attending meetings and travel by Boehringer Ingelheim, outside the submitted work; Katarzyna Lewandowska reports honoraria for lectures and supports for  attending meetings and travels by Roche and Boehringer Ingelheim and declares participation on an advisory board by Boehringer Ingelheim and patients' advocacy advisory board by Roche, she reports the role as a leadership or fiduciary role in EU-IPFF Scientific Committee and in Polish IPF Patients' Support Society; Sebastian Majewski and Wojciech J. Piotrowski report consulting fees, honoraria for lectures, support for attending  meetings and travel by Boehringer Ingelheim and participation in Boehringer Ingelheim's Advisory Boards, outside the submitted work; Marta Maskey-Warzechowska-B. has nothing to disclose; Alicja Sieminska reports honoraria for lectures by Roche and Boehringer Ingelheim,  support for attending meetings and travel by Roche and Boehringer Ingelheim; Krzysztof Sladek has nothing to disclose. Malgorzata Sobiecka reports honoraria for lectures by Roche and Boehringer Ingelheim, support for attending meetings and travel by Roche and Boehringer Ingelheim and participation in Advisory Boards by Boehringer Ingelheim and reports the role as a member of the Audit Committee in Polish IPF Patients' Support Society; M.T-S. and Witold Tomkowski have nothing to disclose; Beata Zolnowska reports support for attending meetings and travel by Roche, Boehringer Ingelheim, Chiesi Pharmaceuticals GmbH; R.K. reports support for attending meetings and travel by Boehringer Ingelheim and participation in Advisory Boards for MSD, outside the submitted work.\n",
      "\n",
      "Krenke, Rafal\n",
      "Competing interests: The authors declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article. Honoraria for lectures; payment to Author Support for attending meetings and/or travel - fee, travel, and accommodation. Katarzyna Gorska and Marta Maskey-Warzechowska-W. report honoraria for lectures by Roche and Boehringer Ingelheim, support for attending meetings and travel by Roche and Boehringer Ingelheim and participation in Advisory Boards by Boehringer Ingelheim, outside the submitted work; Malgorzata Barnas reports honoraria for lectures by Chiesi Pharmaceuticals GmbH, Roche and Boehringer Ingelheim. A.Bi. reports honoraria for lectures, payment for expert testimony and support for attending meetings and travel by Chiesi Poland; A.Ba. reports support for attending meetings and travel by Boehringer Ingelheim and participation in Advisory Boards by Boehringer Ingelheim; Hanna Jagielska-Len-L. reports honoraria for lectures,  receipt of equipment, materials, drugs, medical writing, gifts and other services and support for attending meetings and travel by Roche and Boehringer Ingelheim;  Ewa Jassem reports honoraria for lectures by Roche and Boehringer Ingelheim, support for attending meetings and travel by Roche and Boehringer Ingelheim and participation in Advisory Boards by Roche and Boehringer Ingelheim, outside the submitted work; Aleksander Kania reports honoraria for lectures by Roche and Boehringer Ingelheim, support for attending meetings and travel by Boehringer Ingelheim, outside the submitted work; Katarzyna Lewandowska reports honoraria for lectures and supports for  attending meetings and travels by Roche and Boehringer Ingelheim and declares participation on an advisory board by Boehringer Ingelheim and patients' advocacy advisory board by Roche, she reports the role as a leadership or fiduciary role in EU-IPFF Scientific Committee and in Polish IPF Patients' Support Society; Sebastian Majewski and Wojciech J. Piotrowski report consulting fees, honoraria for lectures, support for attending  meetings and travel by Boehringer Ingelheim and participation in Boehringer Ingelheim's Advisory Boards, outside the submitted work; Marta Maskey-Warzechowska-B. has nothing to disclose; Alicja Sieminska reports honoraria for lectures by Roche and Boehringer Ingelheim,  support for attending meetings and travel by Roche and Boehringer Ingelheim; Krzysztof Sladek has nothing to disclose. Malgorzata Sobiecka reports honoraria for lectures by Roche and Boehringer Ingelheim, support for attending meetings and travel by Roche and Boehringer Ingelheim and participation in Advisory Boards by Boehringer Ingelheim and reports the role as a member of the Audit Committee in Polish IPF Patients' Support Society; M.T-S. and Witold Tomkowski have nothing to disclose; Beata Zolnowska reports support for attending meetings and travel by Roche, Boehringer Ingelheim, Chiesi Pharmaceuticals GmbH; Rafal Krenke reports support for attending meetings and travel by Boehringer Ingelheim and participation in Advisory Boards for MSD, outside the submitted work.\n",
      "\n",
      "Author BL is an employee of Microsoft Ltd, however, he was neither assigned or asked by Microsoft Ltd to participate in this research, nor did Microsoft Ltd have any interest in the current research or future application of this study. The author did not use any resource of Microsoft Ltd or work time to conduct this research. The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential  conflict of interest.\n",
      "\n",
      "Author BL is an employee of Microsoft Ltd, however, he was neither assigned or asked by Microsoft Ltd to participate in this research, nor did Microsoft Ltd have any interest in the current research or future application of this study. The author did not use any resource of Microsoft Ltd or work time to conduct this research. The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential  conflict of interest.\n",
      "\n",
      "Author BL is an employee of Microsoft Ltd, however, he was neither assigned or asked by Microsoft Ltd to participate in this research, nor did Microsoft Ltd have any interest in the current research or future application of this study. The author did not use any resource of Microsoft Ltd or work time to conduct this research. The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential  conflict of interest.\n",
      "\n",
      "Author BL is an employee of Microsoft Ltd, however, he was neither assigned or asked by Microsoft Ltd to participate in this research, nor did Microsoft Ltd have any interest in the current research or future application of this study. The author did not use any resource of Microsoft Ltd or work time to conduct this research. The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential  conflict of interest.\n",
      "\n",
      "Lu, Bo\n",
      "Author Bo Lu is an employee of Microsoft Ltd, however, he was neither assigned or asked by Microsoft Ltd to participate in this research, nor did Microsoft Ltd have any interest in the current research or future application of this study. The author did not use any resource of Microsoft Ltd or work time to conduct this research. The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential  conflict of interest.\n",
      "\n",
      "Author Bo Lu is an employee of Microsoft Ltd, however, he was neither assigned or asked by Microsoft Ltd to participate in this research, nor did Microsoft Ltd have any interest in the current research or future application of this study. The author did not use any resource of Microsoft Ltd or work time to conduct this research. The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential  conflict of interest.\n",
      "\n",
      "Author Bo Lu is an employee of Microsoft Ltd, however, he was neither assigned or asked by Microsoft Ltd to participate in this research, nor did Microsoft Ltd have any interest in the current research or future application of this study. The author did not use any resource of Microsoft Ltd or work time to conduct this research. The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential  conflict of interest.\n",
      "\n",
      "Author Bo Lu is an employee of Microsoft Ltd, however, he was neither assigned or asked by Microsoft Ltd to participate in this research, nor did Microsoft Ltd have any interest in the current research or future application of this study. The author did not use any resource of Microsoft Ltd or work time to conduct this research. The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential  conflict of interest.\n",
      "\n",
      "Author Bo Lu is an employee of Microsoft Ltd, however, he was neither assigned or asked by Microsoft Ltd to participate in this research, nor did Microsoft Ltd have any interest in the current research or future application of this study. The author did not use any resource of Microsoft Ltd or work time to conduct this research. The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential  conflict of interest.\n",
      "\n",
      "Author Bo Lu is an employee of Microsoft Ltd, however, he was neither assigned or asked by Microsoft Ltd to participate in this research, nor did Microsoft Ltd have any interest in the current research or future application of this study. The author did not use any resource of Microsoft Ltd or work time to conduct this research. The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential  conflict of interest.\n",
      "\n",
      "Author Bo Lu is an employee of Microsoft Ltd, however, he was neither assigned or asked by Microsoft Ltd to participate in this research, nor did Microsoft Ltd have any interest in the current research or future application of this study. The author did not use any resource of Microsoft Ltd or work time to conduct this research. The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential  conflict of interest.\n",
      "\n",
      "Author Bo Lu is an employee of Microsoft Ltd, however, he was neither assigned or asked by Microsoft Ltd to participate in this research, nor did Microsoft Ltd have any interest in the current research or future application of this study. The author did not use any resource of Microsoft Ltd or work time to conduct this research. The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential  conflict of interest.\n",
      "\n",
      "HK has received consulting fees from Bristol-Myers Squibb Co. Ltd., Eli Lilly Japan K.K., MSD K.K., Ono Pharmaceutical Co. Ltd., Daiichi-Sankyo Co. Ltd., and Taiho Pharmaceutical Co. Ltd.YC honoraria from Bristol-Myers Squibb Co. Ltd., Bayer Yakuhin Ltd., Eli Lilly Japan K.K., MSD K.K., Ono Pharmaceutical Co. Ltd.,  Chugai Pharmaceutical Co. Ltd., Daiichi Sankyo Co. Ltd., Merck Biopharma Co. Ltd., Takeda Pharmaceutical Co. Ltd., Yakult Pharmaceutical Industry, Teijin Pharma Ltd., and Taiho Pharmaceutical Co. Ltd.YC lecture fees from Glaxo Smith Kline K.K. and Otsuka Pharmaceutical Co. Ltd.YC and research funding from Chugai  Pharmaceutical Co. Ltd., Taiho Pharmaceutical Co. Ltd., Kobayashi Pharmaceutical  Co. Ltd., and Eisai Co. Ltd. TT has received speaker fees from MSD K.K., Ono Pharmaceutical Co. Ltd., and Bristol-Myers Squibb Co. Ltd. YC has received honoraria from Chugai Pharmaceutical Co. Ltd. KH has received lecture fees from AS ONE Corp., AstraZeneca K.K., Bristol-Myers Squibb Co. Ltd., MSD K.K., and Ono  Pharmaceutical Co. Ltd. as well as research funding from AstraZeneca K.K. and MSD K.K. KN has received honoraria from Astellas Pharma Inc., Takeda Pharmaceutical Co. Ltd., Nanzando Co. Ltd., AstraZeneca K.K., Chugai Pharmaceutical Co. Ltd., Roche Diagnostics K.K., MSD K.K., Eli Lilly Japan K.K., Nippon Kayaku Co. Ltd., Daiichi Sankyo Co. Ltd., Novartis Pharma K.K., Kyowa Kirin Co. Ltd., Taiho Pharmaceutical Co. Ltd., Pfizer Japan Inc., AbbVie Inc., Bristol-Myers Squibb Co. Ltd., CareNet Inc., Amgen Inc., Medical Review Co. Ltd., Yodosha Co. Ltd., 3H Clinical Trial Inc., Thermo Fisher Scientific K.K., Hisamitsu Pharmaceutical Co.  Inc., Nichi-Iko Pharmaceutical Co. Ltd., Kyorin Pharmaceutical Co. Ltd., Medicus  Shuppan Publishers Co. Ltd., Nippon Boehringer Ingelheim Co. Ltd., Nikkei Business Publications Inc., Yomiuri Telecasting Corp., and Medical Mobile Communications Co. Ltd.YC research funding from MSD K.K., AstraZeneca K.K., Pfizer Japan Inc., ICON Japan K.K., Astellas Pharma Inc., Bayer Yakuhin Ltd., Takeda Pharmaceutical Co. Ltd., Novartis Pharma K.K., Otsuka Pharmaceutical Co. Ltd., Eli Lilly Japan K.K., EPS International Co. Ltd., Bristol Myers Squibb Co.  Ltd., CMIC Shift Zero K.K., PRA Health Sciences, Taiho Pharmaceutical Co. Ltd., Eisai Co. Ltd., Merck Biopharma Co. Ltd., Parexel International Corp., Mochida Pharmaceutical Co. Ltd., Covance Japan Inc., Ono Pharmaceutical Co. Ltd., Kissei  Pharmaceutical Co. Ltd., Medical Research Support, Sysmex Corp., GlaxoSmithKline  K.K., Sanofi K.K., A2 Healthcare Corp., Kyowa Hakko Kirin Co. Ltd., Syneos Health, AbbVie Inc., EPS Corp., Pfizer R&D Japan G.K., Chugai Pharmaceutical Co.  Ltd., Daiichi Sankyo Co. Ltd., PPD-SNBL K.K., Nippon Boehringer Ingelheim Co. Ltd., IQVIA Services Japan K.K./Quintiles Inc., Japan Clinical Research Operations, and SymBio Pharmaceuticals Ltd.YC and consulting fees from Astellas Pharma Inc., Takeda Pharmaceutical Co. Ltd., Eli Lilly Japan K.K., Pfizer Japan Inc., Kyorin Pharmaceutical Co. Ltd., and Ono Pharmaceutical Co. Ltd. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.\n",
      "\n",
      "Kawakami, Hisato\n",
      "Hisato Kawakami has received consulting fees from Bristol-Myers Squibb Co. Ltd., Eli Lilly Japan K.K., MSD K.K., Ono Pharmaceutical Co. Ltd., Daiichi-Sankyo Co. Ltd., and Taiho Pharmaceutical Co. Ltd.YC honoraria from Bristol-Myers Squibb Co. Ltd., Bayer Yakuhin Ltd., Eli Lilly Japan K.K., MSD K.K., Ono Pharmaceutical Co. Ltd.,  Chugai Pharmaceutical Co. Ltd., Daiichi Sankyo Co. Ltd., Merck Biopharma Co. Ltd., Takeda Pharmaceutical Co. Ltd., Yakult Pharmaceutical Industry, Teijin Pharma Ltd., and Taiho Pharmaceutical Co. Ltd.YC lecture fees from Glaxo Smith Kline K.K. and Otsuka Pharmaceutical Co. Ltd.YC and research funding from Chugai  Pharmaceutical Co. Ltd., Taiho Pharmaceutical Co. Ltd., Kobayashi Pharmaceutical  Co. Ltd., and Eisai Co. Ltd. TT has received speaker fees from MSD K.K., Ono Pharmaceutical Co. Ltd., and Bristol-Myers Squibb Co. Ltd. YC has received honoraria from Chugai Pharmaceutical Co. Ltd. KH has received lecture fees from AS ONE Corp., AstraZeneca K.K., Bristol-Myers Squibb Co. Ltd., MSD K.K., and Ono  Pharmaceutical Co. Ltd. as well as research funding from AstraZeneca K.K. and MSD K.K. KN has received honoraria from Astellas Pharma Inc., Takeda Pharmaceutical Co. Ltd., Nanzando Co. Ltd., AstraZeneca K.K., Chugai Pharmaceutical Co. Ltd., Roche Diagnostics K.K., MSD K.K., Eli Lilly Japan K.K., Nippon Kayaku Co. Ltd., Daiichi Sankyo Co. Ltd., Novartis Pharma K.K., Kyowa Kirin Co. Ltd., Taiho Pharmaceutical Co. Ltd., Pfizer Japan Inc., AbbVie Inc., Bristol-Myers Squibb Co. Ltd., CareNet Inc., Amgen Inc., Medical Review Co. Ltd., Yodosha Co. Ltd., 3H Clinical Trial Inc., Thermo Fisher Scientific K.K., Hisamitsu Pharmaceutical Co.  Inc., Nichi-Iko Pharmaceutical Co. Ltd., Kyorin Pharmaceutical Co. Ltd., Medicus  Shuppan Publishers Co. Ltd., Nippon Boehringer Ingelheim Co. Ltd., Nikkei Business Publications Inc., Yomiuri Telecasting Corp., and Medical Mobile Communications Co. Ltd.YC research funding from MSD K.K., AstraZeneca K.K., Pfizer Japan Inc., ICON Japan K.K., Astellas Pharma Inc., Bayer Yakuhin Ltd., Takeda Pharmaceutical Co. Ltd., Novartis Pharma K.K., Otsuka Pharmaceutical Co. Ltd., Eli Lilly Japan K.K., EPS International Co. Ltd., Bristol Myers Squibb Co.  Ltd., CMIC Shift Zero K.K., PRA Health Sciences, Taiho Pharmaceutical Co. Ltd., Eisai Co. Ltd., Merck Biopharma Co. Ltd., Parexel International Corp., Mochida Pharmaceutical Co. Ltd., Covance Japan Inc., Ono Pharmaceutical Co. Ltd., Kissei  Pharmaceutical Co. Ltd., Medical Research Support, Sysmex Corp., GlaxoSmithKline  K.K., Sanofi K.K., A2 Healthcare Corp., Kyowa Hakko Kirin Co. Ltd., Syneos Health, AbbVie Inc., EPS Corp., Pfizer R&D Japan G.K., Chugai Pharmaceutical Co.  Ltd., Daiichi Sankyo Co. Ltd., PPD-SNBL K.K., Nippon Boehringer Ingelheim Co. Ltd., IQVIA Services Japan K.K./Quintiles Inc., Japan Clinical Research Operations, and SymBio Pharmaceuticals Ltd.YC and consulting fees from Astellas Pharma Inc., Takeda Pharmaceutical Co. Ltd., Eli Lilly Japan K.K., Pfizer Japan Inc., Kyorin Pharmaceutical Co. Ltd., and Ono Pharmaceutical Co. Ltd. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.\n",
      "\n",
      "Tsujikawa, Takahiro\n",
      "Hisato Kawakami has received consulting fees from Bristol-Myers Squibb Co. Ltd., Eli Lilly Japan K.K., MSD K.K., Ono Pharmaceutical Co. Ltd., Daiichi-Sankyo Co. Ltd., and Taiho Pharmaceutical Co. Ltd.YC honoraria from Bristol-Myers Squibb Co. Ltd., Bayer Yakuhin Ltd., Eli Lilly Japan K.K., MSD K.K., Ono Pharmaceutical Co. Ltd.,  Chugai Pharmaceutical Co. Ltd., Daiichi Sankyo Co. Ltd., Merck Biopharma Co. Ltd., Takeda Pharmaceutical Co. Ltd., Yakult Pharmaceutical Industry, Teijin Pharma Ltd., and Taiho Pharmaceutical Co. Ltd.YC lecture fees from Glaxo Smith Kline K.K. and Otsuka Pharmaceutical Co. Ltd.YC and research funding from Chugai  Pharmaceutical Co. Ltd., Taiho Pharmaceutical Co. Ltd., Kobayashi Pharmaceutical  Co. Ltd., and Eisai Co. Ltd. Takahiro Tsujikawa has received speaker fees from MSD K.K., Ono Pharmaceutical Co. Ltd., and Bristol-Myers Squibb Co. Ltd. YC has received honoraria from Chugai Pharmaceutical Co. Ltd. KH has received lecture fees from AS ONE Corp., AstraZeneca K.K., Bristol-Myers Squibb Co. Ltd., MSD K.K., and Ono  Pharmaceutical Co. Ltd. as well as research funding from AstraZeneca K.K. and MSD K.K. KN has received honoraria from Astellas Pharma Inc., Takeda Pharmaceutical Co. Ltd., Nanzando Co. Ltd., AstraZeneca K.K., Chugai Pharmaceutical Co. Ltd., Roche Diagnostics K.K., MSD K.K., Eli Lilly Japan K.K., Nippon Kayaku Co. Ltd., Daiichi Sankyo Co. Ltd., Novartis Pharma K.K., Kyowa Kirin Co. Ltd., Taiho Pharmaceutical Co. Ltd., Pfizer Japan Inc., AbbVie Inc., Bristol-Myers Squibb Co. Ltd., CareNet Inc., Amgen Inc., Medical Review Co. Ltd., Yodosha Co. Ltd., 3H Clinical Trial Inc., Thermo Fisher Scientific K.K., Hisamitsu Pharmaceutical Co.  Inc., Nichi-Iko Pharmaceutical Co. Ltd., Kyorin Pharmaceutical Co. Ltd., Medicus  Shuppan Publishers Co. Ltd., Nippon Boehringer Ingelheim Co. Ltd., Nikkei Business Publications Inc., Yomiuri Telecasting Corp., and Medical Mobile Communications Co. Ltd.YC research funding from MSD K.K., AstraZeneca K.K., Pfizer Japan Inc., ICON Japan K.K., Astellas Pharma Inc., Bayer Yakuhin Ltd., Takeda Pharmaceutical Co. Ltd., Novartis Pharma K.K., Otsuka Pharmaceutical Co. Ltd., Eli Lilly Japan K.K., EPS International Co. Ltd., Bristol Myers Squibb Co.  Ltd., CMIC Shift Zero K.K., PRA Health Sciences, Taiho Pharmaceutical Co. Ltd., Eisai Co. Ltd., Merck Biopharma Co. Ltd., Parexel International Corp., Mochida Pharmaceutical Co. Ltd., Covance Japan Inc., Ono Pharmaceutical Co. Ltd., Kissei  Pharmaceutical Co. Ltd., Medical Research Support, Sysmex Corp., GlaxoSmithKline  K.K., Sanofi K.K., A2 Healthcare Corp., Kyowa Hakko Kirin Co. Ltd., Syneos Health, AbbVie Inc., EPS Corp., Pfizer R&D Japan G.K., Chugai Pharmaceutical Co.  Ltd., Daiichi Sankyo Co. Ltd., PPD-SNBL K.K., Nippon Boehringer Ingelheim Co. Ltd., IQVIA Services Japan K.K./Quintiles Inc., Japan Clinical Research Operations, and SymBio Pharmaceuticals Ltd.YC and consulting fees from Astellas Pharma Inc., Takeda Pharmaceutical Co. Ltd., Eli Lilly Japan K.K., Pfizer Japan Inc., Kyorin Pharmaceutical Co. Ltd., and Ono Pharmaceutical Co. Ltd. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.\n",
      "\n",
      "Hisato Kawakami has received consulting fees from Bristol-Myers Squibb Co. Ltd., Eli Lilly Japan K.K., MSD K.K., Ono Pharmaceutical Co. Ltd., Daiichi-Sankyo Co. Ltd., and Taiho Pharmaceutical Co. Ltd.YC honoraria from Bristol-Myers Squibb Co. Ltd., Bayer Yakuhin Ltd., Eli Lilly Japan K.K., MSD K.K., Ono Pharmaceutical Co. Ltd.,  Chugai Pharmaceutical Co. Ltd., Daiichi Sankyo Co. Ltd., Merck Biopharma Co. Ltd., Takeda Pharmaceutical Co. Ltd., Yakult Pharmaceutical Industry, Teijin Pharma Ltd., and Taiho Pharmaceutical Co. Ltd.YC lecture fees from Glaxo Smith Kline K.K. and Otsuka Pharmaceutical Co. Ltd.YC and research funding from Chugai  Pharmaceutical Co. Ltd., Taiho Pharmaceutical Co. Ltd., Kobayashi Pharmaceutical  Co. Ltd., and Eisai Co. Ltd. Takahiro Tsujikawa has received speaker fees from MSD K.K., Ono Pharmaceutical Co. Ltd., and Bristol-Myers Squibb Co. Ltd. YC has received honoraria from Chugai Pharmaceutical Co. Ltd. KH has received lecture fees from AS ONE Corp., AstraZeneca K.K., Bristol-Myers Squibb Co. Ltd., MSD K.K., and Ono  Pharmaceutical Co. Ltd. as well as research funding from AstraZeneca K.K. and MSD K.K. KN has received honoraria from Astellas Pharma Inc., Takeda Pharmaceutical Co. Ltd., Nanzando Co. Ltd., AstraZeneca K.K., Chugai Pharmaceutical Co. Ltd., Roche Diagnostics K.K., MSD K.K., Eli Lilly Japan K.K., Nippon Kayaku Co. Ltd., Daiichi Sankyo Co. Ltd., Novartis Pharma K.K., Kyowa Kirin Co. Ltd., Taiho Pharmaceutical Co. Ltd., Pfizer Japan Inc., AbbVie Inc., Bristol-Myers Squibb Co. Ltd., CareNet Inc., Amgen Inc., Medical Review Co. Ltd., Yodosha Co. Ltd., 3H Clinical Trial Inc., Thermo Fisher Scientific K.K., Hisamitsu Pharmaceutical Co.  Inc., Nichi-Iko Pharmaceutical Co. Ltd., Kyorin Pharmaceutical Co. Ltd., Medicus  Shuppan Publishers Co. Ltd., Nippon Boehringer Ingelheim Co. Ltd., Nikkei Business Publications Inc., Yomiuri Telecasting Corp., and Medical Mobile Communications Co. Ltd.YC research funding from MSD K.K., AstraZeneca K.K., Pfizer Japan Inc., ICON Japan K.K., Astellas Pharma Inc., Bayer Yakuhin Ltd., Takeda Pharmaceutical Co. Ltd., Novartis Pharma K.K., Otsuka Pharmaceutical Co. Ltd., Eli Lilly Japan K.K., EPS International Co. Ltd., Bristol Myers Squibb Co.  Ltd., CMIC Shift Zero K.K., PRA Health Sciences, Taiho Pharmaceutical Co. Ltd., Eisai Co. Ltd., Merck Biopharma Co. Ltd., Parexel International Corp., Mochida Pharmaceutical Co. Ltd., Covance Japan Inc., Ono Pharmaceutical Co. Ltd., Kissei  Pharmaceutical Co. Ltd., Medical Research Support, Sysmex Corp., GlaxoSmithKline  K.K., Sanofi K.K., A2 Healthcare Corp., Kyowa Hakko Kirin Co. Ltd., Syneos Health, AbbVie Inc., EPS Corp., Pfizer R&D Japan G.K., Chugai Pharmaceutical Co.  Ltd., Daiichi Sankyo Co. Ltd., PPD-SNBL K.K., Nippon Boehringer Ingelheim Co. Ltd., IQVIA Services Japan K.K./Quintiles Inc., Japan Clinical Research Operations, and SymBio Pharmaceuticals Ltd.YC and consulting fees from Astellas Pharma Inc., Takeda Pharmaceutical Co. Ltd., Eli Lilly Japan K.K., Pfizer Japan Inc., Kyorin Pharmaceutical Co. Ltd., and Ono Pharmaceutical Co. Ltd. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.\n",
      "\n",
      "Chiba, Yasutaka\n",
      "Hisato Kawakami has received consulting fees from Bristol-Myers Squibb Co. Ltd., Eli Lilly Japan K.K., MSD K.K., Ono Pharmaceutical Co. Ltd., Daiichi-Sankyo Co. Ltd., and Taiho Pharmaceutical Co. Ltd.Yasutaka Chiba honoraria from Bristol-Myers Squibb Co. Ltd., Bayer Yakuhin Ltd., Eli Lilly Japan K.K., MSD K.K., Ono Pharmaceutical Co. Ltd.,  Chugai Pharmaceutical Co. Ltd., Daiichi Sankyo Co. Ltd., Merck Biopharma Co. Ltd., Takeda Pharmaceutical Co. Ltd., Yakult Pharmaceutical Industry, Teijin Pharma Ltd., and Taiho Pharmaceutical Co. Ltd.Yasutaka Chiba lecture fees from Glaxo Smith Kline K.K. and Otsuka Pharmaceutical Co. Ltd.Yasutaka Chiba and research funding from Chugai  Pharmaceutical Co. Ltd., Taiho Pharmaceutical Co. Ltd., Kobayashi Pharmaceutical  Co. Ltd., and Eisai Co. Ltd. Takahiro Tsujikawa has received speaker fees from MSD K.K., Ono Pharmaceutical Co. Ltd., and Bristol-Myers Squibb Co. Ltd. Yasutaka Chiba has received honoraria from Chugai Pharmaceutical Co. Ltd. KH has received lecture fees from AS ONE Corp., AstraZeneca K.K., Bristol-Myers Squibb Co. Ltd., MSD K.K., and Ono  Pharmaceutical Co. Ltd. as well as research funding from AstraZeneca K.K. and MSD K.K. KN has received honoraria from Astellas Pharma Inc., Takeda Pharmaceutical Co. Ltd., Nanzando Co. Ltd., AstraZeneca K.K., Chugai Pharmaceutical Co. Ltd., Roche Diagnostics K.K., MSD K.K., Eli Lilly Japan K.K., Nippon Kayaku Co. Ltd., Daiichi Sankyo Co. Ltd., Novartis Pharma K.K., Kyowa Kirin Co. Ltd., Taiho Pharmaceutical Co. Ltd., Pfizer Japan Inc., AbbVie Inc., Bristol-Myers Squibb Co. Ltd., CareNet Inc., Amgen Inc., Medical Review Co. Ltd., Yodosha Co. Ltd., 3H Clinical Trial Inc., Thermo Fisher Scientific K.K., Hisamitsu Pharmaceutical Co.  Inc., Nichi-Iko Pharmaceutical Co. Ltd., Kyorin Pharmaceutical Co. Ltd., Medicus  Shuppan Publishers Co. Ltd., Nippon Boehringer Ingelheim Co. Ltd., Nikkei Business Publications Inc., Yomiuri Telecasting Corp., and Medical Mobile Communications Co. Ltd.Yasutaka Chiba research funding from MSD K.K., AstraZeneca K.K., Pfizer Japan Inc., ICON Japan K.K., Astellas Pharma Inc., Bayer Yakuhin Ltd., Takeda Pharmaceutical Co. Ltd., Novartis Pharma K.K., Otsuka Pharmaceutical Co. Ltd., Eli Lilly Japan K.K., EPS International Co. Ltd., Bristol Myers Squibb Co.  Ltd., CMIC Shift Zero K.K., PRA Health Sciences, Taiho Pharmaceutical Co. Ltd., Eisai Co. Ltd., Merck Biopharma Co. Ltd., Parexel International Corp., Mochida Pharmaceutical Co. Ltd., Covance Japan Inc., Ono Pharmaceutical Co. Ltd., Kissei  Pharmaceutical Co. Ltd., Medical Research Support, Sysmex Corp., GlaxoSmithKline  K.K., Sanofi K.K., A2 Healthcare Corp., Kyowa Hakko Kirin Co. Ltd., Syneos Health, AbbVie Inc., EPS Corp., Pfizer R&D Japan G.K., Chugai Pharmaceutical Co.  Ltd., Daiichi Sankyo Co. Ltd., PPD-SNBL K.K., Nippon Boehringer Ingelheim Co. Ltd., IQVIA Services Japan K.K./Quintiles Inc., Japan Clinical Research Operations, and SymBio Pharmaceuticals Ltd.Yasutaka Chiba and consulting fees from Astellas Pharma Inc., Takeda Pharmaceutical Co. Ltd., Eli Lilly Japan K.K., Pfizer Japan Inc., Kyorin Pharmaceutical Co. Ltd., and Ono Pharmaceutical Co. Ltd. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.\n",
      "\n",
      "Hisato Kawakami has received consulting fees from Bristol-Myers Squibb Co. Ltd., Eli Lilly Japan K.K., MSD K.K., Ono Pharmaceutical Co. Ltd., Daiichi-Sankyo Co. Ltd., and Taiho Pharmaceutical Co. Ltd.Yasutaka Chiba honoraria from Bristol-Myers Squibb Co. Ltd., Bayer Yakuhin Ltd., Eli Lilly Japan K.K., MSD K.K., Ono Pharmaceutical Co. Ltd.,  Chugai Pharmaceutical Co. Ltd., Daiichi Sankyo Co. Ltd., Merck Biopharma Co. Ltd., Takeda Pharmaceutical Co. Ltd., Yakult Pharmaceutical Industry, Teijin Pharma Ltd., and Taiho Pharmaceutical Co. Ltd.Yasutaka Chiba lecture fees from Glaxo Smith Kline K.K. and Otsuka Pharmaceutical Co. Ltd.Yasutaka Chiba and research funding from Chugai  Pharmaceutical Co. Ltd., Taiho Pharmaceutical Co. Ltd., Kobayashi Pharmaceutical  Co. Ltd., and Eisai Co. Ltd. Takahiro Tsujikawa has received speaker fees from MSD K.K., Ono Pharmaceutical Co. Ltd., and Bristol-Myers Squibb Co. Ltd. Yasutaka Chiba has received honoraria from Chugai Pharmaceutical Co. Ltd. KH has received lecture fees from AS ONE Corp., AstraZeneca K.K., Bristol-Myers Squibb Co. Ltd., MSD K.K., and Ono  Pharmaceutical Co. Ltd. as well as research funding from AstraZeneca K.K. and MSD K.K. KN has received honoraria from Astellas Pharma Inc., Takeda Pharmaceutical Co. Ltd., Nanzando Co. Ltd., AstraZeneca K.K., Chugai Pharmaceutical Co. Ltd., Roche Diagnostics K.K., MSD K.K., Eli Lilly Japan K.K., Nippon Kayaku Co. Ltd., Daiichi Sankyo Co. Ltd., Novartis Pharma K.K., Kyowa Kirin Co. Ltd., Taiho Pharmaceutical Co. Ltd., Pfizer Japan Inc., AbbVie Inc., Bristol-Myers Squibb Co. Ltd., CareNet Inc., Amgen Inc., Medical Review Co. Ltd., Yodosha Co. Ltd., 3H Clinical Trial Inc., Thermo Fisher Scientific K.K., Hisamitsu Pharmaceutical Co.  Inc., Nichi-Iko Pharmaceutical Co. Ltd., Kyorin Pharmaceutical Co. Ltd., Medicus  Shuppan Publishers Co. Ltd., Nippon Boehringer Ingelheim Co. Ltd., Nikkei Business Publications Inc., Yomiuri Telecasting Corp., and Medical Mobile Communications Co. Ltd.Yasutaka Chiba research funding from MSD K.K., AstraZeneca K.K., Pfizer Japan Inc., ICON Japan K.K., Astellas Pharma Inc., Bayer Yakuhin Ltd., Takeda Pharmaceutical Co. Ltd., Novartis Pharma K.K., Otsuka Pharmaceutical Co. Ltd., Eli Lilly Japan K.K., EPS International Co. Ltd., Bristol Myers Squibb Co.  Ltd., CMIC Shift Zero K.K., PRA Health Sciences, Taiho Pharmaceutical Co. Ltd., Eisai Co. Ltd., Merck Biopharma Co. Ltd., Parexel International Corp., Mochida Pharmaceutical Co. Ltd., Covance Japan Inc., Ono Pharmaceutical Co. Ltd., Kissei  Pharmaceutical Co. Ltd., Medical Research Support, Sysmex Corp., GlaxoSmithKline  K.K., Sanofi K.K., A2 Healthcare Corp., Kyowa Hakko Kirin Co. Ltd., Syneos Health, AbbVie Inc., EPS Corp., Pfizer R&D Japan G.K., Chugai Pharmaceutical Co.  Ltd., Daiichi Sankyo Co. Ltd., PPD-SNBL K.K., Nippon Boehringer Ingelheim Co. Ltd., IQVIA Services Japan K.K./Quintiles Inc., Japan Clinical Research Operations, and SymBio Pharmaceuticals Ltd.Yasutaka Chiba and consulting fees from Astellas Pharma Inc., Takeda Pharmaceutical Co. Ltd., Eli Lilly Japan K.K., Pfizer Japan Inc., Kyorin Pharmaceutical Co. Ltd., and Ono Pharmaceutical Co. Ltd. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.\n",
      "\n",
      "Hisato Kawakami has received consulting fees from Bristol-Myers Squibb Co. Ltd., Eli Lilly Japan K.K., MSD K.K., Ono Pharmaceutical Co. Ltd., Daiichi-Sankyo Co. Ltd., and Taiho Pharmaceutical Co. Ltd.Yasutaka Chiba honoraria from Bristol-Myers Squibb Co. Ltd., Bayer Yakuhin Ltd., Eli Lilly Japan K.K., MSD K.K., Ono Pharmaceutical Co. Ltd.,  Chugai Pharmaceutical Co. Ltd., Daiichi Sankyo Co. Ltd., Merck Biopharma Co. Ltd., Takeda Pharmaceutical Co. Ltd., Yakult Pharmaceutical Industry, Teijin Pharma Ltd., and Taiho Pharmaceutical Co. Ltd.Yasutaka Chiba lecture fees from Glaxo Smith Kline K.K. and Otsuka Pharmaceutical Co. Ltd.Yasutaka Chiba and research funding from Chugai  Pharmaceutical Co. Ltd., Taiho Pharmaceutical Co. Ltd., Kobayashi Pharmaceutical  Co. Ltd., and Eisai Co. Ltd. Takahiro Tsujikawa has received speaker fees from MSD K.K., Ono Pharmaceutical Co. Ltd., and Bristol-Myers Squibb Co. Ltd. Yasutaka Chiba has received honoraria from Chugai Pharmaceutical Co. Ltd. KH has received lecture fees from AS ONE Corp., AstraZeneca K.K., Bristol-Myers Squibb Co. Ltd., MSD K.K., and Ono  Pharmaceutical Co. Ltd. as well as research funding from AstraZeneca K.K. and MSD K.K. KN has received honoraria from Astellas Pharma Inc., Takeda Pharmaceutical Co. Ltd., Nanzando Co. Ltd., AstraZeneca K.K., Chugai Pharmaceutical Co. Ltd., Roche Diagnostics K.K., MSD K.K., Eli Lilly Japan K.K., Nippon Kayaku Co. Ltd., Daiichi Sankyo Co. Ltd., Novartis Pharma K.K., Kyowa Kirin Co. Ltd., Taiho Pharmaceutical Co. Ltd., Pfizer Japan Inc., AbbVie Inc., Bristol-Myers Squibb Co. Ltd., CareNet Inc., Amgen Inc., Medical Review Co. Ltd., Yodosha Co. Ltd., 3H Clinical Trial Inc., Thermo Fisher Scientific K.K., Hisamitsu Pharmaceutical Co.  Inc., Nichi-Iko Pharmaceutical Co. Ltd., Kyorin Pharmaceutical Co. Ltd., Medicus  Shuppan Publishers Co. Ltd., Nippon Boehringer Ingelheim Co. Ltd., Nikkei Business Publications Inc., Yomiuri Telecasting Corp., and Medical Mobile Communications Co. Ltd.Yasutaka Chiba research funding from MSD K.K., AstraZeneca K.K., Pfizer Japan Inc., ICON Japan K.K., Astellas Pharma Inc., Bayer Yakuhin Ltd., Takeda Pharmaceutical Co. Ltd., Novartis Pharma K.K., Otsuka Pharmaceutical Co. Ltd., Eli Lilly Japan K.K., EPS International Co. Ltd., Bristol Myers Squibb Co.  Ltd., CMIC Shift Zero K.K., PRA Health Sciences, Taiho Pharmaceutical Co. Ltd., Eisai Co. Ltd., Merck Biopharma Co. Ltd., Parexel International Corp., Mochida Pharmaceutical Co. Ltd., Covance Japan Inc., Ono Pharmaceutical Co. Ltd., Kissei  Pharmaceutical Co. Ltd., Medical Research Support, Sysmex Corp., GlaxoSmithKline  K.K., Sanofi K.K., A2 Healthcare Corp., Kyowa Hakko Kirin Co. Ltd., Syneos Health, AbbVie Inc., EPS Corp., Pfizer R&D Japan G.K., Chugai Pharmaceutical Co.  Ltd., Daiichi Sankyo Co. Ltd., PPD-SNBL K.K., Nippon Boehringer Ingelheim Co. Ltd., IQVIA Services Japan K.K./Quintiles Inc., Japan Clinical Research Operations, and SymBio Pharmaceuticals Ltd.Yasutaka Chiba and consulting fees from Astellas Pharma Inc., Takeda Pharmaceutical Co. Ltd., Eli Lilly Japan K.K., Pfizer Japan Inc., Kyorin Pharmaceutical Co. Ltd., and Ono Pharmaceutical Co. Ltd. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.\n",
      "\n",
      "Haratani, Koji\n",
      "Hisato Kawakami has received consulting fees from Bristol-Myers Squibb Co. Ltd., Eli Lilly Japan K.K., MSD K.K., Ono Pharmaceutical Co. Ltd., Daiichi-Sankyo Co. Ltd., and Taiho Pharmaceutical Co. Ltd.Yasutaka Chiba honoraria from Bristol-Myers Squibb Co. Ltd., Bayer Yakuhin Ltd., Eli Lilly Japan K.K., MSD K.K., Ono Pharmaceutical Co. Ltd.,  Chugai Pharmaceutical Co. Ltd., Daiichi Sankyo Co. Ltd., Merck Biopharma Co. Ltd., Takeda Pharmaceutical Co. Ltd., Yakult Pharmaceutical Industry, Teijin Pharma Ltd., and Taiho Pharmaceutical Co. Ltd.Yasutaka Chiba lecture fees from Glaxo Smith Kline K.K. and Otsuka Pharmaceutical Co. Ltd.Yasutaka Chiba and research funding from Chugai  Pharmaceutical Co. Ltd., Taiho Pharmaceutical Co. Ltd., Kobayashi Pharmaceutical  Co. Ltd., and Eisai Co. Ltd. Takahiro Tsujikawa has received speaker fees from MSD K.K., Ono Pharmaceutical Co. Ltd., and Bristol-Myers Squibb Co. Ltd. Yasutaka Chiba has received honoraria from Chugai Pharmaceutical Co. Ltd. Koji Haratani has received lecture fees from AS ONE Corp., AstraZeneca K.K., Bristol-Myers Squibb Co. Ltd., MSD K.K., and Ono  Pharmaceutical Co. Ltd. as well as research funding from AstraZeneca K.K. and MSD K.K. KN has received honoraria from Astellas Pharma Inc., Takeda Pharmaceutical Co. Ltd., Nanzando Co. Ltd., AstraZeneca K.K., Chugai Pharmaceutical Co. Ltd., Roche Diagnostics K.K., MSD K.K., Eli Lilly Japan K.K., Nippon Kayaku Co. Ltd., Daiichi Sankyo Co. Ltd., Novartis Pharma K.K., Kyowa Kirin Co. Ltd., Taiho Pharmaceutical Co. Ltd., Pfizer Japan Inc., AbbVie Inc., Bristol-Myers Squibb Co. Ltd., CareNet Inc., Amgen Inc., Medical Review Co. Ltd., Yodosha Co. Ltd., 3H Clinical Trial Inc., Thermo Fisher Scientific K.K., Hisamitsu Pharmaceutical Co.  Inc., Nichi-Iko Pharmaceutical Co. Ltd., Kyorin Pharmaceutical Co. Ltd., Medicus  Shuppan Publishers Co. Ltd., Nippon Boehringer Ingelheim Co. Ltd., Nikkei Business Publications Inc., Yomiuri Telecasting Corp., and Medical Mobile Communications Co. Ltd.Yasutaka Chiba research funding from MSD K.K., AstraZeneca K.K., Pfizer Japan Inc., ICON Japan K.K., Astellas Pharma Inc., Bayer Yakuhin Ltd., Takeda Pharmaceutical Co. Ltd., Novartis Pharma K.K., Otsuka Pharmaceutical Co. Ltd., Eli Lilly Japan K.K., EPS International Co. Ltd., Bristol Myers Squibb Co.  Ltd., CMIC Shift Zero K.K., PRA Health Sciences, Taiho Pharmaceutical Co. Ltd., Eisai Co. Ltd., Merck Biopharma Co. Ltd., Parexel International Corp., Mochida Pharmaceutical Co. Ltd., Covance Japan Inc., Ono Pharmaceutical Co. Ltd., Kissei  Pharmaceutical Co. Ltd., Medical Research Support, Sysmex Corp., GlaxoSmithKline  K.K., Sanofi K.K., A2 Healthcare Corp., Kyowa Hakko Kirin Co. Ltd., Syneos Health, AbbVie Inc., EPS Corp., Pfizer R&D Japan G.K., Chugai Pharmaceutical Co.  Ltd., Daiichi Sankyo Co. Ltd., PPD-SNBL K.K., Nippon Boehringer Ingelheim Co. Ltd., IQVIA Services Japan K.K./Quintiles Inc., Japan Clinical Research Operations, and SymBio Pharmaceuticals Ltd.Yasutaka Chiba and consulting fees from Astellas Pharma Inc., Takeda Pharmaceutical Co. Ltd., Eli Lilly Japan K.K., Pfizer Japan Inc., Kyorin Pharmaceutical Co. Ltd., and Ono Pharmaceutical Co. Ltd. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.\n",
      "\n",
      "Nakagawa, Kazuhiko\n",
      "Hisato Kawakami has received consulting fees from Bristol-Myers Squibb Co. Ltd., Eli Lilly Japan K.K., MSD K.K., Ono Pharmaceutical Co. Ltd., Daiichi-Sankyo Co. Ltd., and Taiho Pharmaceutical Co. Ltd.Yasutaka Chiba honoraria from Bristol-Myers Squibb Co. Ltd., Bayer Yakuhin Ltd., Eli Lilly Japan K.K., MSD K.K., Ono Pharmaceutical Co. Ltd.,  Chugai Pharmaceutical Co. Ltd., Daiichi Sankyo Co. Ltd., Merck Biopharma Co. Ltd., Takeda Pharmaceutical Co. Ltd., Yakult Pharmaceutical Industry, Teijin Pharma Ltd., and Taiho Pharmaceutical Co. Ltd.Yasutaka Chiba lecture fees from Glaxo Smith Kline K.K. and Otsuka Pharmaceutical Co. Ltd.Yasutaka Chiba and research funding from Chugai  Pharmaceutical Co. Ltd., Taiho Pharmaceutical Co. Ltd., Kobayashi Pharmaceutical  Co. Ltd., and Eisai Co. Ltd. Takahiro Tsujikawa has received speaker fees from MSD K.K., Ono Pharmaceutical Co. Ltd., and Bristol-Myers Squibb Co. Ltd. Yasutaka Chiba has received honoraria from Chugai Pharmaceutical Co. Ltd. Koji Haratani has received lecture fees from AS ONE Corp., AstraZeneca K.K., Bristol-Myers Squibb Co. Ltd., MSD K.K., and Ono  Pharmaceutical Co. Ltd. as well as research funding from AstraZeneca K.K. and MSD K.K. Kazuhiko Nakagawa has received honoraria from Astellas Pharma Inc., Takeda Pharmaceutical Co. Ltd., Nanzando Co. Ltd., AstraZeneca K.K., Chugai Pharmaceutical Co. Ltd., Roche Diagnostics K.K., MSD K.K., Eli Lilly Japan K.K., Nippon Kayaku Co. Ltd., Daiichi Sankyo Co. Ltd., Novartis Pharma K.K., Kyowa Kirin Co. Ltd., Taiho Pharmaceutical Co. Ltd., Pfizer Japan Inc., AbbVie Inc., Bristol-Myers Squibb Co. Ltd., CareNet Inc., Amgen Inc., Medical Review Co. Ltd., Yodosha Co. Ltd., 3H Clinical Trial Inc., Thermo Fisher Scientific K.K., Hisamitsu Pharmaceutical Co.  Inc., Nichi-Iko Pharmaceutical Co. Ltd., Kyorin Pharmaceutical Co. Ltd., Medicus  Shuppan Publishers Co. Ltd., Nippon Boehringer Ingelheim Co. Ltd., Nikkei Business Publications Inc., Yomiuri Telecasting Corp., and Medical Mobile Communications Co. Ltd.Yasutaka Chiba research funding from MSD K.K., AstraZeneca K.K., Pfizer Japan Inc., ICON Japan K.K., Astellas Pharma Inc., Bayer Yakuhin Ltd., Takeda Pharmaceutical Co. Ltd., Novartis Pharma K.K., Otsuka Pharmaceutical Co. Ltd., Eli Lilly Japan K.K., EPS International Co. Ltd., Bristol Myers Squibb Co.  Ltd., CMIC Shift Zero K.K., PRA Health Sciences, Taiho Pharmaceutical Co. Ltd., Eisai Co. Ltd., Merck Biopharma Co. Ltd., Parexel International Corp., Mochida Pharmaceutical Co. Ltd., Covance Japan Inc., Ono Pharmaceutical Co. Ltd., Kissei  Pharmaceutical Co. Ltd., Medical Research Support, Sysmex Corp., GlaxoSmithKline  K.K., Sanofi K.K., A2 Healthcare Corp., Kyowa Hakko Kirin Co. Ltd., Syneos Health, AbbVie Inc., EPS Corp., Pfizer R&D Japan G.K., Chugai Pharmaceutical Co.  Ltd., Daiichi Sankyo Co. Ltd., PPD-SNBL K.K., Nippon Boehringer Ingelheim Co. Ltd., IQVIA Services Japan K.K./Quintiles Inc., Japan Clinical Research Operations, and SymBio Pharmaceuticals Ltd.Yasutaka Chiba and consulting fees from Astellas Pharma Inc., Takeda Pharmaceutical Co. Ltd., Eli Lilly Japan K.K., Pfizer Japan Inc., Kyorin Pharmaceutical Co. Ltd., and Ono Pharmaceutical Co. Ltd. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.\n",
      "\n",
      "SD is co-founder of Apmonia-Therapeutics and acts as the chair of the Scientific  and Clinical Advisory Board. The remaining authors declare that the research was  conducted in the absence of any commercial or financial relationships that could  be construed as a potential conflict of interest.\n",
      "\n",
      "SD is co-founder of Apmonia-Therapeutics and acts as the chair of the Scientific  and Clinical Advisory Board. The remaining authors declare that the research was  conducted in the absence of any commercial or financial relationships that could  be construed as a potential conflict of interest.\n",
      "\n",
      "SD is co-founder of Apmonia-Therapeutics and acts as the chair of the Scientific  and Clinical Advisory Board. The remaining authors declare that the research was  conducted in the absence of any commercial or financial relationships that could  be construed as a potential conflict of interest.\n",
      "\n",
      "SD is co-founder of Apmonia-Therapeutics and acts as the chair of the Scientific  and Clinical Advisory Board. The remaining authors declare that the research was  conducted in the absence of any commercial or financial relationships that could  be construed as a potential conflict of interest.\n",
      "\n",
      "SD is co-founder of Apmonia-Therapeutics and acts as the chair of the Scientific  and Clinical Advisory Board. The remaining authors declare that the research was  conducted in the absence of any commercial or financial relationships that could  be construed as a potential conflict of interest.\n",
      "\n",
      "SD is co-founder of Apmonia-Therapeutics and acts as the chair of the Scientific  and Clinical Advisory Board. The remaining authors declare that the research was  conducted in the absence of any commercial or financial relationships that could  be construed as a potential conflict of interest.\n",
      "\n",
      "SD is co-founder of Apmonia-Therapeutics and acts as the chair of the Scientific  and Clinical Advisory Board. The remaining authors declare that the research was  conducted in the absence of any commercial or financial relationships that could  be construed as a potential conflict of interest.\n",
      "\n",
      "SD is co-founder of Apmonia-Therapeutics and acts as the chair of the Scientific  and Clinical Advisory Board. The remaining authors declare that the research was  conducted in the absence of any commercial or financial relationships that could  be construed as a potential conflict of interest.\n",
      "\n",
      "SD is co-founder of Apmonia-Therapeutics and acts as the chair of the Scientific  and Clinical Advisory Board. The remaining authors declare that the research was  conducted in the absence of any commercial or financial relationships that could  be construed as a potential conflict of interest.\n",
      "\n",
      "Dedieu, Stephane\n",
      "Stephane Dedieu is co-founder of Apmonia-Therapeutics and acts as the chair of the Scientific  and Clinical Advisory Board. The remaining authors declare that the research was  conducted in the absence of any commercial or financial relationships that could  be construed as a potential conflict of interest.\n",
      "\n",
      "Author YF, WL, JC, XZ and TM are employed by Genetron Health (Beijing) Technology, Co. Ltd. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could  be construed as a potential conflict of interest.\n",
      "\n",
      "Fang, Yu\n",
      "Author Yu Fang, WL, JC, XZ and TM are employed by Genetron Health (Beijing) Technology, Co. Ltd. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could  be construed as a potential conflict of interest.\n",
      "\n",
      "Author Yu Fang, WL, JC, XZ and TM are employed by Genetron Health (Beijing) Technology, Co. Ltd. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could  be construed as a potential conflict of interest.\n",
      "\n",
      "Li, Wei\n",
      "Author Yu Fang, Wei Li, JC, XZ and TM are employed by Genetron Health (Beijing) Technology, Co. Ltd. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could  be construed as a potential conflict of interest.\n",
      "\n",
      "Author Yu Fang, Wei Li, JC, XZ and TM are employed by Genetron Health (Beijing) Technology, Co. Ltd. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could  be construed as a potential conflict of interest.\n",
      "\n",
      "Chen, Jing\n",
      "Author Yu Fang, Wei Li, Jing Chen, XZ and TM are employed by Genetron Health (Beijing) Technology, Co. Ltd. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could  be construed as a potential conflict of interest.\n",
      "\n",
      "Author Yu Fang, Wei Li, Jing Chen, XZ and TM are employed by Genetron Health (Beijing) Technology, Co. Ltd. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could  be construed as a potential conflict of interest.\n",
      "\n",
      "Author Yu Fang, Wei Li, Jing Chen, XZ and TM are employed by Genetron Health (Beijing) Technology, Co. Ltd. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could  be construed as a potential conflict of interest.\n",
      "\n",
      "Li, Xinru\n",
      "Author Yu Fang, Wei Xinru Li, Jing Chen, XZ and TM are employed by Genetron Health (Beijing) Technology, Co. Ltd. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could  be construed as a potential conflict of interest.\n",
      "\n",
      "Zhang, Xiaoyan\n",
      "Author Yu Fang, Wei Xinru Li, Jing Chen, Xiaoyan Zhang and TM are employed by Genetron Health (Beijing) Technology, Co. Ltd. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could  be construed as a potential conflict of interest.\n",
      "\n",
      "Ma, Tonghui\n",
      "Author Yu Fang, Wei Xinru Li, Jing Chen, Xiaoyan Zhang and Tonghui Ma are employed by Genetron Health (Beijing) Technology, Co. Ltd. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could  be construed as a potential conflict of interest.\n",
      "\n",
      "Shen, Ge\n",
      "Author Yu Fang, Wei Xinru Li, Jing Chen, Xiaoyan Zhang and Tonghui Ma are employed by Ge Shennetron Health (Beijing) Technology, Co. Ltd. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could  be construed as a potential conflict of interest.\n",
      "\n",
      "Author JR was employed by General Electric Pharmaceutical (Shanghai) Co., Ltd., Shanghai, China. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed  as a potential conflict of interest.\n",
      "\n",
      "Author JR was employed by General Electric Pharmaceutical (Shanghai) Co., Ltd., Shanghai, China. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed  as a potential conflict of interest.\n",
      "\n",
      "Ren, Jialiang\n",
      "Author Jialiang Ren was employed by General Electric Pharmaceutical (Shanghai) Co., Ltd., Shanghai, China. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed  as a potential conflict of interest.\n",
      "\n",
      "Jia, Linyi\n",
      "Author Linyi Jialiang Ren was employed by General Electric Pharmaceutical (Shanghai) Co., Ltd., Shanghai, China. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed  as a potential conflict of interest.\n",
      "\n",
      "Author Linyi Jialiang Ren was employed by General Electric Pharmaceutical (Shanghai) Co., Ltd., Shanghai, China. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed  as a potential conflict of interest.\n",
      "\n",
      "Author Linyi Jialiang Ren was employed by General Electric Pharmaceutical (Shanghai) Co., Ltd., Shanghai, China. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed  as a potential conflict of interest.\n",
      "\n",
      "Author Linyi Jialiang Ren was employed by General Electric Pharmaceutical (Shanghai) Co., Ltd., Shanghai, China. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed  as a potential conflict of interest.\n",
      "\n",
      "Author Linyi Jialiang Ren was employed by General Electric Pharmaceutical (Shanghai) Co., Ltd., Shanghai, China. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed  as a potential conflict of interest.\n",
      "\n",
      "The authors declare no conflicts of interest that pertain to this work. Please refer to the accompanying ICMJE disclosure forms for further details.\n",
      "\n",
      "The authors declare no conflicts of interest that pertain to this work. Please refer to the accompanying ICMJE disclosure forms for further details.\n",
      "\n",
      "The authors declare no conflicts of interest that pertain to this work. Please refer to the accompanying ICMJE disclosure forms for further details.\n",
      "\n",
      "The authors declare no conflicts of interest that pertain to this work. Please refer to the accompanying ICMJE disclosure forms for further details.\n",
      "\n",
      "The authors declare no conflicts of interest that pertain to this work. Please refer to the accompanying ICMJE disclosure forms for further details.\n",
      "\n",
      "The authors declare no conflicts of interest that pertain to this work. Please refer to the accompanying ICMJE disclosure forms for further details.\n",
      "\n",
      "The authors declare no conflicts of interest that pertain to this work. Please refer to the accompanying ICMJE disclosure forms for further details.\n",
      "\n",
      "The authors declare no conflicts of interest that pertain to this work. Please refer to the accompanying ICMJE disclosure forms for further details.\n",
      "\n",
      "The authors declare no conflicts of interest that pertain to this work. Please refer to the accompanying ICMJE disclosure forms for further details.\n",
      "\n",
      "The authors declare no conflicts of interest that pertain to this work. Please refer to the accompanying ICMJE disclosure forms for further details.\n",
      "\n",
      "The authors declare no conflicts of interest that pertain to this work. Please refer to the accompanying ICMJE disclosure forms for further details.\n",
      "\n",
      "The authors declare no conflicts of interest that pertain to this work. Please refer to the accompanying ICMJE disclosure forms for further details.\n",
      "\n",
      "The authors declare no conflicts of interest that pertain to this work. Please refer to the accompanying ICMJE disclosure forms for further details.\n",
      "\n",
      "The authors declare no conflicts of interest that pertain to this work. Please refer to the accompanying ICMJE disclosure forms for further details.\n",
      "\n",
      "The authors declare no conflicts of interest that pertain to this work. Please refer to the accompanying ICMJE disclosure forms for further details.\n",
      "\n",
      "The authors declare no conflicts of interest that pertain to this work. Please refer to the accompanying ICMJE disclosure forms for further details.\n",
      "\n",
      "The authors declare no conflicts of interest that pertain to this work. Please refer to the accompanying ICMJE disclosure forms for further details.\n",
      "\n",
      "The authors declare no conflicts of interest that pertain to this work. Please refer to the accompanying ICMJE disclosure forms for further details.\n",
      "\n",
      "The authors declare no conflicts of interest that pertain to this work. Please refer to the accompanying ICMJE disclosure forms for further details.\n",
      "\n",
      "The authors declare no conflicts of interest that pertain to this work. Please refer to the accompanying ICMJE disclosure forms for further details.\n",
      "\n",
      "The authors declare no conflicts of interest that pertain to this work. Please refer to the accompanying ICMJE disclosure forms for further details.\n",
      "\n",
      "The authors declare no conflicts of interest that pertain to this work. Please refer to the accompanying ICMJE disclosure forms for further details.\n",
      "\n",
      "The authors declare no conflicts of interest that pertain to this work. Please refer to the accompanying ICMJE disclosure forms for further details.\n",
      "\n",
      "The authors declare no conflicts of interest that pertain to this work. Please refer to the accompanying ICMJE disclosure forms for further details.\n",
      "\n",
      "The authors declare no conflicts of interest that pertain to this work. Please refer to the accompanying ICMJE disclosure forms for further details.\n",
      "\n",
      "The authors declare no conflicts of interest that pertain to this work. Please refer to the accompanying ICMJE disclosure forms for further details.\n",
      "\n",
      "The authors declare no conflicts of interest that pertain to this work. Please refer to the accompanying ICMJE disclosure forms for further details.\n",
      "\n",
      "The authors declare no conflicts of interest that pertain to this work. Please refer to the accompanying ICMJE disclosure forms for further details.\n",
      "\n",
      "The authors declare no conflicts of interest that pertain to this work. Please refer to the accompanying ICMJE disclosure forms for further details.\n",
      "\n",
      "The authors declare no conflicts of interest that pertain to this work. Please refer to the accompanying ICMJE disclosure forms for further details.\n",
      "\n",
      "The authors declare no conflicts of interest that pertain to this work. Please refer to the accompanying ICMJE disclosure forms for further details.\n",
      "\n",
      "The authors declare no conflicts of interest that pertain to this work. Please refer to the accompanying ICMJE disclosure forms for further details.\n",
      "\n",
      "The authors declare no conflicts of interest that pertain to this work. Please refer to the accompanying ICMJE disclosure forms for further details.\n",
      "\n",
      "The authors declare no conflicts of interest that pertain to this work. Please refer to the accompanying ICMJE disclosure forms for further details.\n",
      "\n",
      "The authors declare no conflicts of interest that pertain to this work. Please refer to the accompanying ICMJE disclosure forms for further details.\n",
      "\n",
      "The authors declare no conflicts of interest that pertain to this work. Please refer to the accompanying ICMJE disclosure forms for further details.\n",
      "\n",
      "The authors declare no conflicts of interest that pertain to this work. Please refer to the accompanying ICMJE disclosure forms for further details.\n",
      "\n",
      "The authors declare no conflicts of interest that pertain to this work. Please refer to the accompanying ICMJE disclosure forms for further details.\n",
      "\n",
      "The authors declare no conflicts of interest that pertain to this work. Please refer to the accompanying ICMJE disclosure forms for further details.\n",
      "\n",
      "The authors declare no conflicts of interest that pertain to this work. Please refer to the accompanying ICMJE disclosure forms for further details.\n",
      "\n",
      "The authors declare no conflicts of interest that pertain to this work. Please refer to the accompanying ICMJE disclosure forms for further details.\n",
      "\n",
      "The authors declare no conflicts of interest that pertain to this work. Please refer to the accompanying ICMJE disclosure forms for further details.\n",
      "\n",
      "The authors declare no conflicts of interest that pertain to this work. Please refer to the accompanying ICMJE disclosure forms for further details.\n",
      "\n",
      "ML, YS, SM, and MT have received consultancy fees and research support from Gilead Sciences. Please refer to the accompanying ICMJE disclosure forms for further details.\n",
      "\n",
      "Lemoine, Maud\n",
      "Maud Lemoine, YS, SM, and MT have received consultancy fees and research support from Gilead Sciences. Please refer to the accompanying ICMJE disclosure forms for further details.\n",
      "\n",
      "Maud Lemoine, YS, SM, and MT have received consultancy fees and research support from Gilead Sciences. Please refer to the accompanying ICMJE disclosure forms for further details.\n",
      "\n",
      "Maud Lemoine, YS, SM, and MT have received consultancy fees and research support from Gilead Sciences. Please refer to the accompanying ICMJE disclosure forms for further details.\n",
      "\n",
      "Maud Lemoine, YS, SM, and MT have received consultancy fees and research support from Gilead Sciences. Please refer to the accompanying ICMJE disclosure forms for further details.\n",
      "\n",
      "Maud Lemoine, YS, SM, and MT have received consultancy fees and research support from Gilead Sciences. Please refer to the accompanying ICMJE disclosure forms for further details.\n",
      "\n",
      "Maud Lemoine, YS, SM, and MT have received consultancy fees and research support from Gilead Sciences. Please refer to the accompanying ICMJE disclosure forms for further details.\n",
      "\n",
      "Maud Lemoine, YS, SM, and MT have received consultancy fees and research support from Gilead Sciences. Please refer to the accompanying ICMJE disclosure forms for further details.\n",
      "\n",
      "Maud Lemoine, YS, SM, and MT have received consultancy fees and research support from Gilead Sciences. Please refer to the accompanying ICMJE disclosure forms for further details.\n",
      "\n",
      "Maud Lemoine, YS, SM, and MT have received consultancy fees and research support from Gilead Sciences. Please refer to the accompanying ICMJE disclosure forms for further details.\n",
      "\n",
      "Maud Lemoine, YS, SM, and MT have received consultancy fees and research support from Gilead Sciences. Please refer to the accompanying ICMJE disclosure forms for further details.\n",
      "\n",
      "Maud Lemoine, YS, SM, and MT have received consultancy fees and research support from Gilead Sciences. Please refer to the accompanying ICMJE disclosure forms for further details.\n",
      "\n",
      "Maud Lemoine, YS, SM, and MT have received consultancy fees and research support from Gilead Sciences. Please refer to the accompanying ICMJE disclosure forms for further details.\n",
      "\n",
      "Maud Lemoine, YS, SM, and MT have received consultancy fees and research support from Gilead Sciences. Please refer to the accompanying ICMJE disclosure forms for further details.\n",
      "\n",
      "Maud Lemoine, YS, SM, and MT have received consultancy fees and research support from Gilead Sciences. Please refer to the accompanying ICMJE disclosure forms for further details.\n",
      "\n",
      "Chemin, Isabelle\n",
      "Maud Lemoine, YS, SM, and MT have received consultancy fees and research support from Gilead Sciences. Please refer to the accompanying Isabelle CheminMJE disclosure forms for further details.\n",
      "\n",
      "Maud Lemoine, YS, SM, and MT have received consultancy fees and research support from Gilead Sciences. Please refer to the accompanying Isabelle CheminMJE disclosure forms for further details.\n",
      "\n",
      "Maud Lemoine, YS, SM, and MT have received consultancy fees and research support from Gilead Sciences. Please refer to the accompanying Isabelle CheminMJE disclosure forms for further details.\n",
      "\n",
      "Thursz, Mark\n",
      "Maud Lemoine, YS, SM, and Mark Thursz have received consultancy fees and research support from Gilead Sciences. Please refer to the accompanying Isabelle CheminMJE disclosure forms for further details.\n",
      "\n",
      "Maud Lemoine, YS, SM, and Mark Thursz have received consultancy fees and research support from Gilead Sciences. Please refer to the accompanying Isabelle CheminMJE disclosure forms for further details.\n",
      "\n",
      "Shimakawa, Yusuke\n",
      "Maud Lemoine, Yusuke Shimakawa, SM, and Mark Thursz have received consultancy fees and research support from Gilead Sciences. Please refer to the accompanying Isabelle CheminMJE disclosure forms for further details.\n",
      "\n",
      "Mboup, Souleymane\n",
      "Maud Lemoine, Yusuke Shimakawa, Souleymane Mboup, and Mark Thursz have received consultancy fees and research support from Gilead Sciences. Please refer to the accompanying Isabelle CheminMJE disclosure forms for further details.\n",
      "\n",
      "Sridhar, Siddharth\n",
      "Siddharth Sridhar has received speaker's honoraria from Abbott Medical Laboratories. The other authors report that there are no competing interests to declare. Please refer to  the accompanying ICMJE disclosure forms for further details.\n",
      "\n",
      "Siddharth Sridhar has received speaker's honoraria from Abbott Medical Laboratories. The other authors report that there are no competing interests to declare. Please refer to  the accompanying ICMJE disclosure forms for further details.\n",
      "\n",
      "Siddharth Sridhar has received speaker's honoraria from Abbott Medical Laboratories. The other authors report that there are no competing interests to declare. Please refer to  the accompanying ICMJE disclosure forms for further details.\n",
      "\n",
      "Siddharth Sridhar has received speaker's honoraria from Abbott Medical Laboratories. The other authors report that there are no competing interests to declare. Please refer to  the accompanying ICMJE disclosure forms for further details.\n",
      "\n",
      "Siddharth Sridhar has received speaker's honoraria from Abbott Medical Laboratories. The other authors report that there are no competing interests to declare. Please refer to  the accompanying ICMJE disclosure forms for further details.\n",
      "\n",
      "Siddharth Sridhar has received speaker's honoraria from Abbott Medical Laboratories. The other authors report that there are no competing interests to declare. Please refer to  the accompanying ICMJE disclosure forms for further details.\n",
      "\n",
      "Siddharth Sridhar has received speaker's honoraria from Abbott Medical Laboratories. The other authors report that there are no competing interests to declare. Please refer to  the accompanying ICMJE disclosure forms for further details.\n",
      "\n",
      "Siddharth Sridhar has received speaker's honoraria from Abbott Medical Laboratories. The other authors report that there are no competing interests to declare. Please refer to  the accompanying ICMJE disclosure forms for further details.\n",
      "\n",
      "Siddharth Sridhar has received speaker's honoraria from Abbott Medical Laboratories. The other authors report that there are no competing interests to declare. Please refer to  the accompanying ICMJE disclosure forms for further details.\n",
      "\n",
      "Siddharth Sridhar has received speaker's honoraria from Abbott Medical Laboratories. The other authors report that there are no competing interests to declare. Please refer to  the accompanying ICMJE disclosure forms for further details.\n",
      "\n",
      "Siddharth Sridhar has received speaker's honoraria from Abbott Medical Laboratories. The other authors report that there are no competing interests to declare. Please refer to  the accompanying ICMJE disclosure forms for further details.\n",
      "\n",
      "Siddharth Sridhar has received speaker's honoraria from Abbott Medical Laboratories. The other authors report that there are no competing interests to declare. Please refer to  the accompanying ICMJE disclosure forms for further details.\n",
      "\n",
      "Siddharth Sridhar has received speaker's honoraria from Abbott Medical Laboratories. The other authors report that there are no competing interests to declare. Please refer to  the accompanying ICMJE disclosure forms for further details.\n",
      "\n",
      "Siddharth Sridhar has received speaker's honoraria from Abbott Medical Laboratories. The other authors report that there are no competing interests to declare. Please refer to  the accompanying ICMJE disclosure forms for further details.\n",
      "\n",
      "MB has served as a speaker and advisory board member for Gilead, Roche, and Arbutus. RE has served as a speaker and advisory board member for Gilead. MRB has served as a speaker for Abbvie and Gilead. Please refer to the accompanying ICMJE disclosure forms for further details.\n",
      "\n",
      "MB has served as a speaker and advisory board member for Gilead, Roche, and Arbutus. RE has served as a speaker and advisory board member for Gilead. MRB has served as a speaker for Abbvie and Gilead. Please refer to the accompanying ICMJE disclosure forms for further details.\n",
      "\n",
      "MB has served as a speaker and advisory board member for Gilead, Roche, and Arbutus. RE has served as a speaker and advisory board member for Gilead. MRB has served as a speaker for Abbvie and Gilead. Please refer to the accompanying ICMJE disclosure forms for further details.\n",
      "\n",
      "MB has served as a speaker and advisory board member for Gilead, Roche, and Arbutus. RE has served as a speaker and advisory board member for Gilead. MRB has served as a speaker for Abbvie and Gilead. Please refer to the accompanying ICMJE disclosure forms for further details.\n",
      "\n",
      "MB has served as a speaker and advisory board member for Gilead, Roche, and Arbutus. RE has served as a speaker and advisory board member for Gilead. MRB has served as a speaker for Abbvie and Gilead. Please refer to the accompanying ICMJE disclosure forms for further details.\n",
      "\n",
      "MB has served as a speaker and advisory board member for Gilead, Roche, and Arbutus. RE has served as a speaker and advisory board member for Gilead. MRB has served as a speaker for Abbvie and Gilead. Please refer to the accompanying ICMJE disclosure forms for further details.\n",
      "\n",
      "MB has served as a speaker and advisory board member for Gilead, Roche, and Arbutus. RE has served as a speaker and advisory board member for Gilead. MRB has served as a speaker for Abbvie and Gilead. Please refer to the accompanying ICMJE disclosure forms for further details.\n",
      "\n",
      "Riveiro-Barciela, Mar\n",
      "MB has served as a speaker and advisory board member for Gilead, Roche, and Arbutus. RE has served as a speaker and advisory board member for Gilead. Mar Riveiro-BarcielaB has served as a speaker for Abbvie and Gilead. Please refer to the accompanying ICMJE disclosure forms for further details.\n",
      "\n",
      "Esteban, Rafael\n",
      "MB has served as a speaker and advisory board member for Gilead, Roche, and Arbutus. Rafael Esteban has served as a speaker and advisory board member for Gilead. Mar Riveiro-BarcielaB has served as a speaker for Abbvie and Gilead. Please refer to the accompanying ICMJE disclosure forms for further details.\n",
      "\n",
      "Buti, Maria\n",
      "Maria Buti has served as a speaker and advisory board member for Gilead, Roche, and Arbutus. Rafael Esteban has served as a speaker and advisory board member for Gilead. Mar Riveiro-BarcielaB has served as a speaker for Abbvie and Gilead. Please refer to the accompanying ICMJE disclosure forms for further details.\n",
      "\n",
      "Lecoq, Ines\n",
      "Ines LecoqM, KLK, MC, EM and AWP are employed by IO Biotech. M-BZ is an employee and a shareholder in IO Biotech. MHA is Founder, a shareholder and a Scientific Advisory Board member in IO Biotech. The other authors declare no direct conflicts of interest.\n",
      "\n",
      "Kopp, Katharina L.\n",
      "Ines LecoqM, Katharina L. Kopp, MC, EM and AWP are employed by IO Biotech. M-BZ is an employee and a shareholder in IO Biotech. MHA is Founder, a shareholder and a Scientific Advisory Board member in IO Biotech. The other authors declare no direct conflicts of interest.\n",
      "\n",
      "Chapellier, Marion\n",
      "Ines LecoqM, Katharina L. Kopp, Marion Chapellier, EM and AWP are employed by IO Biotech. M-BZ is an employee and a shareholder in IO Biotech. MHA is Founder, a shareholder and a Scientific Advisory Board member in IO Biotech. The other authors declare no direct conflicts of interest.\n",
      "\n",
      "Ines LecoqM, Katharina L. Kopp, Marion Chapellier, EM and AWP are employed by IO Biotech. M-BZ is an employee and a shareholder in IO Biotech. MHA is Founder, a shareholder and a Scientific Advisory Board member in IO Biotech. The other authors declare no direct conflicts of interest.\n",
      "\n",
      "Martinenaite, Evelina\n",
      "Ines LecoqM, Katharina L. Kopp, Marion Chapellier, Evelina Martinenaite and AWP are employed by IO Biotech. M-BZ is an employee and a shareholder in IO Biotech. MHA is Founder, a shareholder and a Scientific Advisory Board member in IO Biotech. The other authors declare no direct conflicts of interest.\n",
      "\n",
      "Ines LecoqM, Katharina L. Kopp, Marion Chapellier, Evelina Martinenaite and AWP are employed by IO Biotech. M-BZ is an employee and a shareholder in IO Biotech. MHA is Founder, a shareholder and a Scientific Advisory Board member in IO Biotech. The other authors declare no direct conflicts of interest.\n",
      "\n",
      "Ines LecoqM, Katharina L. Kopp, Marion Chapellier, Evelina Martinenaite and AWP are employed by IO Biotech. M-BZ is an employee and a shareholder in IO Biotech. MHA is Founder, a shareholder and a Scientific Advisory Board member in IO Biotech. The other authors declare no direct conflicts of interest.\n",
      "\n",
      "Ines LecoqM, Katharina L. Kopp, Marion Chapellier, Evelina Martinenaite and AWP are employed by IO Biotech. M-BZ is an employee and a shareholder in IO Biotech. MHA is Founder, a shareholder and a Scientific Advisory Board member in IO Biotech. The other authors declare no direct conflicts of interest.\n",
      "\n",
      "Wakatsuki Pedersen, Ayako\n",
      "Ines LecoqM, Katharina L. Kopp, Marion Chapellier, Evelina Martinenaite and Ayako Wakatsuki Pedersen are employed by IO Biotech. M-BZ is an employee and a shareholder in IO Biotech. MHA is Founder, a shareholder and a Scientific Advisory Board member in IO Biotech. The other authors declare no direct conflicts of interest.\n",
      "\n",
      "Hald Andersen, Mads\n",
      "Ines LecoqM, Katharina L. Kopp, Marion Chapellier, Evelina Martinenaite and Ayako Wakatsuki Pedersen are employed by IO Biotech. M-BZ is an employee and a shareholder in IO Biotech. Mads Hald Andersen is Founder, a shareholder and a Scientific Advisory Board member in IO Biotech. The other authors declare no direct conflicts of interest.\n",
      "\n",
      "Song, Eunhye\n",
      "Eunhye Song, LA, and MSL are editors of the journal and this article was prepared for the  journal's 10th anniversary.\n",
      "\n",
      "Ang, Lin\n",
      "Eunhye Song, Lin Ang, and MSL are editors of the journal and this article was prepared for the  journal's 10th anniversary.\n",
      "\n",
      "Soo Lee, Myeong\n",
      "Eunhye Song, Lin Ang, and Myeong Soo Lee are editors of the journal and this article was prepared for the  journal's 10th anniversary.\n",
      "\n",
      "Michael Orsini, Muhsin\n",
      "The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Robert W. Strack has copyrighted the 4-Factor Critical Consciousness Scale to Robert Werner Strack, Muhsin Michael Orsini, D. Rose Ewald.\n",
      "\n",
      "Rose Ewald, D.\n",
      "The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Robert W. Strack has copyrighted the 4-Factor Critical Consciousness Scale to Robert Werner Strack, Muhsin Michael Orsini, D. Rose D. Rose Ewald.\n",
      "\n",
      "Strack, Robert W.\n",
      "The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Robert W. Strack has copyrighted the 4-Factor Critical Consciousness Scale to Robert Werner Strack, Muhsin Michael Orsini, D. Rose D. Rose Ewald.\n",
      "\n",
      "Makaryan, Vahagn\n",
      "Conflict of Interest Vahagn Makaryan, M.L.K., B.F., I.A. and T.P. declare no conflicts of interest. D.C.D. is an inventor on the joint University of Washington-Merck patent for the use of inhibitors of NE to treat inherited severe neutropenia. D.C.D. is also a consultant and receives research support from Amgen, a manufacturer of G-CSF, mentioned in the article.\n",
      "\n",
      "Conflict of Interest Vahagn Makaryan, M.L.K., B.F., I.A. and T.P. declare no conflicts of interest. D.C.D. is an inventor on the joint University of Washington-Merck patent for the use of inhibitors of NE to treat inherited severe neutropenia. D.C.D. is also a consultant and receives research support from Amgen, a manufacturer of G-CSF, mentioned in the article.\n",
      "\n",
      "Fletcher, Breanna\n",
      "Conflict of Interest Vahagn Makaryan, M.L.K., Breanna Fletcher, I.A. and T.P. declare no conflicts of interest. D.C.D. is an inventor on the joint University of Washington-Merck patent for the use of inhibitors of NE to treat inherited severe neutropenia. D.C.D. is also a consultant and receives research support from Amgen, a manufacturer of G-CSF, mentioned in the article.\n",
      "\n",
      "Archibald, Isabella\n",
      "Conflict of Interest Vahagn Makaryan, M.L.K., Breanna Fletcher, Isabella Archibald and T.P. declare no conflicts of interest. D.C.D. is an inventor on the joint University of Washington-Merck patent for the use of inhibitors of NE to treat inherited severe neutropenia. D.C.D. is also a consultant and receives research support from Amgen, a manufacturer of G-CSF, mentioned in the article.\n",
      "\n",
      "Poulsen, Tanoya\n",
      "Conflict of Interest Vahagn Makaryan, M.L.K., Breanna Fletcher, Isabella Archibald and Tanoya Poulsen declare no conflicts of interest. D.C.D. is an inventor on the joint University of Washington-Merck patent for the use of inhibitors of NE to treat inherited severe neutropenia. D.C.D. is also a consultant and receives research support from Amgen, a manufacturer of G-CSF, mentioned in the article.\n",
      "\n",
      "Conflict of Interest Vahagn Makaryan, M.L.K., Breanna Fletcher, Isabella Archibald and Tanoya Poulsen declare no conflicts of interest. D.C.D. is an inventor on the joint University of Washington-Merck patent for the use of inhibitors of NE to treat inherited severe neutropenia. D.C.D. is also a consultant and receives research support from Amgen, a manufacturer of G-CSF, mentioned in the article.\n",
      "\n",
      "TL was employed by Nanjing Kingmed Center for Clinical Laboratory Co., Ltd. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.\n",
      "\n",
      "TL was employed by Nanjing Kingmed Center for Clinical Laboratory Co., Ltd. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.\n",
      "\n",
      "TL was employed by Nanjing Kingmed Center for Clinical Laboratory Co., Ltd. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.\n",
      "\n",
      "TL was employed by Nanjing Kingmed Center for Clinical Laboratory Co., Ltd. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.\n",
      "\n",
      "TL was employed by Nanjing Kingmed Center for Clinical Laboratory Co., Ltd. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.\n",
      "\n",
      "TL was employed by Nanjing Kingmed Center for Clinical Laboratory Co., Ltd. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.\n",
      "\n",
      "Li, Tiekun\n",
      "Tiekun Li was employed by Nanjing Kingmed Center for Clinical Laboratory Co., Ltd. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.\n",
      "\n",
      "Tiekun Li was employed by Nanjing Kingmed Center for Clinical Laboratory Co., Ltd. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.\n",
      "\n",
      "Tiekun Li was employed by Nanjing Kingmed Center for Clinical Laboratory Co., Ltd. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.\n",
      "\n",
      "Tiekun Li was employed by Nanjing Kingmed Center for Clinical Laboratory Co., Ltd. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.\n",
      "\n",
      "Tiekun Li was employed by Nanjing Kingmed Center for Clinical Laboratory Co., Ltd. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.\n",
      "\n",
      "Tiekun Li was employed by Nanjing Kingmed Center for Clinical Laboratory Co., Ltd. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.\n",
      "\n",
      "Tiekun Li was employed by Nanjing Kingmed Center for Clinical Laboratory Co., Ltd. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.\n",
      "\n",
      "Tiekun Li was employed by Nanjing Kingmed Center for Clinical Laboratory Co., Ltd. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.\n",
      "\n",
      "Tiekun Li was employed by Nanjing Kingmed Center for Clinical Laboratory Co., Ltd. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.\n",
      "\n",
      "The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The handling editor (J-BW) declared a shared affiliation with the authors at the time of review.\n",
      "\n",
      "The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The handling editor (J-BW) declared a shared affiliation with the authors at the time of review.\n",
      "\n",
      "The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The handling editor (J-BW) declared a shared affiliation with the authors at the time of review.\n",
      "\n",
      "The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The handling editor (J-BW) declared a shared affiliation with the authors at the time of review.\n",
      "\n",
      "The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The handling editor (J-BW) declared a shared affiliation with the authors at the time of review.\n",
      "\n",
      "The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The handling editor (J-BW) declared a shared affiliation with the authors at the time of review.\n",
      "\n",
      "The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The handling editor (J-BW) declared a shared affiliation with the authors at the time of review.\n",
      "\n",
      "The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The handling editor (J-BW) declared a shared affiliation with the authors at the time of review.\n",
      "\n",
      "The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The handling editor (J-BW) declared a shared affiliation with the authors at the time of review.\n",
      "\n",
      "The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The handling editor (J-BW) declared a shared affiliation with the authors at the time of review.\n",
      "\n",
      "NT, LS, SS, and DP are employers of Fresenius Medical Care D GmbH. The collaboration study has received financial support by FME. The remaining authors  declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.\n",
      "\n",
      "NT, LS, SS, and DP are employers of Fresenius Medical Care D GmbH. The collaboration study has received financial support by FME. The remaining authors  declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.\n",
      "\n",
      "Toggweiler, Nora\n",
      "Nora Toggweiler, LS, SS, and DP are employers of Fresenius Medical Care D GmbH. The collaboration study has received financial support by FME. The remaining authors  declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.\n",
      "\n",
      "Nora Toggweiler, LS, SS, and DP are employers of Fresenius Medical Care D GmbH. The collaboration study has received financial support by FME. The remaining authors  declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.\n",
      "\n",
      "Strahl, Lisa\n",
      "Nora Toggweiler, Lisa Strahl, SS, and DP are employers of Fresenius Medical Care D GmbH. The collaboration study has received financial support by FME. The remaining authors  declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.\n",
      "\n",
      "Nora Toggweiler, Lisa Strahl, SS, and DP are employers of Fresenius Medical Care D GmbH. The collaboration study has received financial support by FME. The remaining authors  declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.\n",
      "\n",
      "Nora Toggweiler, Lisa Strahl, SS, and DP are employers of Fresenius Medical Care D GmbH. The collaboration study has received financial support by FME. The remaining authors  declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.\n",
      "\n",
      "Nora Toggweiler, Lisa Strahl, SS, and DP are employers of Fresenius Medical Care D GmbH. The collaboration study has received financial support by FME. The remaining authors  declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.\n",
      "\n",
      "Steppan, Sonja\n",
      "Nora Toggweiler, Lisa Strahl, Sonja Steppan, and DP are employers of Fresenius Medical Care D GmbH. The collaboration study has received financial support by FME. The remaining authors  declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.\n",
      "\n",
      "Piecha, Dorothea\n",
      "Nora Toggweiler, Lisa Strahl, Sonja Steppan, and Dorothea Piecha are employers of Fresenius Medical Care D GmbH. The collaboration study has received financial support by FME. The remaining authors  declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.\n",
      "\n",
      "Nora Toggweiler, Lisa Strahl, Sonja Steppan, and Dorothea Piecha are employers of Fresenius Medical Care D GmbH. The collaboration study has received financial support by FME. The remaining authors  declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.\n",
      "\n",
      "Nora Toggweiler, Lisa Strahl, Sonja Steppan, and Dorothea Piecha are employers of Fresenius Medical Care D GmbH. The collaboration study has received financial support by FME. The remaining authors  declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.\n",
      "\n",
      "BC, ZH, GW, XN, MW, MX, and BL were employed by Akeso Biopharma, Inc. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.\n",
      "\n",
      "BC, ZH, GW, XN, MW, MX, and BL were employed by Akeso Biopharma, Inc. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.\n",
      "\n",
      "BC, ZH, GW, XN, MW, MX, and BL were employed by Akeso Biopharma, Inc. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.\n",
      "\n",
      "Chen, Benchao\n",
      "Benchao Chen, ZH, GW, XN, MW, MX, and BL were employed by Akeso Biopharma, Inc. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.\n",
      "\n",
      "He, Zhimei\n",
      "Benchao Chen, Zhimei He, GW, XN, MW, MX, and BL were employed by Akeso Biopharma, Inc. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.\n",
      "\n",
      "Wang, Guoqin\n",
      "Benchao Chen, Zhimei He, Guoqin Wang, XN, MW, MX, and BL were employed by Akeso Biopharma, Inc. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.\n",
      "\n",
      "Ni, Xiang\n",
      "Benchao Chen, Zhimei He, Guoqin Wang, Xiang Ni, MW, MX, and BL were employed by Akeso Biopharma, Inc. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.\n",
      "\n",
      "Wang, Max\n",
      "Benchao Chen, Zhimei He, Guoqin Max Wang, Xiang Ni, MW, MX, and BL were employed by Akeso Biopharma, Inc. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.\n",
      "\n",
      "Xia, Michelle\n",
      "Benchao Chen, Zhimei He, Guoqin Max Wang, Michelle Xiang Ni, MW, MX, and BL were employed by Akeso Biopharma, Inc. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.\n",
      "\n",
      "Li, Baiyong\n",
      "Benchao Chen, Zhimei He, Guoqin Max Wang, Michelle Xiang Ni, MW, MX, and Baiyong Li were employed by Akeso Biopharma, Inc. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.\n",
      "\n",
      "Chen, Rui\n",
      "Benchao Rui Chen, Zhimei He, Guoqin Max Wang, Michelle Xiang Ni, MW, MX, and Baiyong Li were employed by Akeso Biopharma, Inc. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.\n",
      "\n",
      "Benchao Rui Chen, Zhimei He, Guoqin Max Wang, Michelle Xiang Ni, MW, MX, and Baiyong Li were employed by Akeso Biopharma, Inc. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.\n",
      "\n",
      "Prof. Dr. Colin A Espie reports personal fees from Big Health (Sleepio), grants from NIHR, outside the submitted work. Dr Kentaro Matsui reports personal fees from Eisai, personal fees from Meiji Seika Pharma, personal fees from Mochida, personal fees from MSD, personal fees from Otsuka Pharmaceutical, personal fees from Takeda Pharmaceutical, personal fees from Yoshitomi Pharmaceutical, outside  the submitted work. Prof. Dr. Charles M Morin reports grants from Eisai, Idorsia, Lallemand, personal fees from Eisai, Idorsia, Pear Therapeutics, royalities from  Mapi Research Trust, outside the submitted work. Prof. Dr. Markku Partinen reports clinical trials from Bioprojet, Jazz Pharmaceuticals and TEVA, personal fees from GSK and Takeda, personal fees and clinical trials from MSD, outside the submitted work. Prof. Dr. Giuseppe Plazzi reports personal fees from Jazz Pharmaceutical, personal fees from Takeda, personal fees from Idorsia, personal fees from Bioprojet, outside the submitted work. Prof. Dr. Thomas Penzel reports  grants from Cidelec, grants from Novartis, grants from Lowenstein Medical, personal fees from Lowenstein Medical, personal fees from Jazz Pharma, personal fees from Neuwirth, consultation to institution from Bayer Healthcare, personal fees from Cerebra, personal fees from National Sleep Foundation, grants from European Union, outside the submitted work; and Shareholder of Advanced Sleep Research, The Siestagroup GmbH, Nukute. Prof. Dr. Yun Kwok Wing reports personal  fees from Eisai Co, Ltd (HK), personal fees from Lundbeck HK Ltd, outside the submitted work. The authors report no other conflicts of interest in this work.\n",
      "\n",
      "Prof. Dr. Colin A Espie reports personal fees from Big Health (Sleepio), grants from NIHR, outside the submitted work. Dr Kentaro Matsui reports personal fees from Eisai, personal fees from Meiji Seika Pharma, personal fees from Mochida, personal fees from MSD, personal fees from Otsuka Pharmaceutical, personal fees from Takeda Pharmaceutical, personal fees from Yoshitomi Pharmaceutical, outside  the submitted work. Prof. Dr. Charles M Morin reports grants from Eisai, Idorsia, Lallemand, personal fees from Eisai, Idorsia, Pear Therapeutics, royalities from  Mapi Research Trust, outside the submitted work. Prof. Dr. Markku Partinen reports clinical trials from Bioprojet, Jazz Pharmaceuticals and TEVA, personal fees from GSK and Takeda, personal fees and clinical trials from MSD, outside the submitted work. Prof. Dr. Giuseppe Plazzi reports personal fees from Jazz Pharmaceutical, personal fees from Takeda, personal fees from Idorsia, personal fees from Bioprojet, outside the submitted work. Prof. Dr. Thomas Penzel reports  grants from Cidelec, grants from Novartis, grants from Lowenstein Medical, personal fees from Lowenstein Medical, personal fees from Jazz Pharma, personal fees from Neuwirth, consultation to institution from Bayer Healthcare, personal fees from Cerebra, personal fees from National Sleep Foundation, grants from European Union, outside the submitted work; and Shareholder of Advanced Sleep Research, The Siestagroup GmbH, Nukute. Prof. Dr. Yun Kwok Wing reports personal  fees from Eisai Co, Ltd (HK), personal fees from Lundbeck HK Ltd, outside the submitted work. The authors report no other conflicts of interest in this work.\n",
      "\n",
      "Prof. Dr. Colin A Espie reports personal fees from Big Health (Sleepio), grants from NIHR, outside the submitted work. Dr Kentaro Matsui reports personal fees from Eisai, personal fees from Meiji Seika Pharma, personal fees from Mochida, personal fees from MSD, personal fees from Otsuka Pharmaceutical, personal fees from Takeda Pharmaceutical, personal fees from Yoshitomi Pharmaceutical, outside  the submitted work. Prof. Dr. Charles M Morin reports grants from Eisai, Idorsia, Lallemand, personal fees from Eisai, Idorsia, Pear Therapeutics, royalities from  Mapi Research Trust, outside the submitted work. Prof. Dr. Markku Partinen reports clinical trials from Bioprojet, Jazz Pharmaceuticals and TEVA, personal fees from GSK and Takeda, personal fees and clinical trials from MSD, outside the submitted work. Prof. Dr. Giuseppe Plazzi reports personal fees from Jazz Pharmaceutical, personal fees from Takeda, personal fees from Idorsia, personal fees from Bioprojet, outside the submitted work. Prof. Dr. Thomas Penzel reports  grants from Cidelec, grants from Novartis, grants from Lowenstein Medical, personal fees from Lowenstein Medical, personal fees from Jazz Pharma, personal fees from Neuwirth, consultation to institution from Bayer Healthcare, personal fees from Cerebra, personal fees from National Sleep Foundation, grants from European Union, outside the submitted work; and Shareholder of Advanced Sleep Research, The Siestagroup GmbH, Nukute. Prof. Dr. Yun Kwok Wing reports personal  fees from Eisai Co, Ltd (HK), personal fees from Lundbeck HK Ltd, outside the submitted work. The authors report no other conflicts of interest in this work.\n",
      "\n",
      "Prof. Dr. Colin A Espie reports personal fees from Big Health (Sleepio), grants from NIHR, outside the submitted work. Dr Kentaro Matsui reports personal fees from Eisai, personal fees from Meiji Seika Pharma, personal fees from Mochida, personal fees from MSD, personal fees from Otsuka Pharmaceutical, personal fees from Takeda Pharmaceutical, personal fees from Yoshitomi Pharmaceutical, outside  the submitted work. Prof. Dr. Charles M Morin reports grants from Eisai, Idorsia, Lallemand, personal fees from Eisai, Idorsia, Pear Therapeutics, royalities from  Mapi Research Trust, outside the submitted work. Prof. Dr. Markku Partinen reports clinical trials from Bioprojet, Jazz Pharmaceuticals and TEVA, personal fees from GSK and Takeda, personal fees and clinical trials from MSD, outside the submitted work. Prof. Dr. Giuseppe Plazzi reports personal fees from Jazz Pharmaceutical, personal fees from Takeda, personal fees from Idorsia, personal fees from Bioprojet, outside the submitted work. Prof. Dr. Thomas Penzel reports  grants from Cidelec, grants from Novartis, grants from Lowenstein Medical, personal fees from Lowenstein Medical, personal fees from Jazz Pharma, personal fees from Neuwirth, consultation to institution from Bayer Healthcare, personal fees from Cerebra, personal fees from National Sleep Foundation, grants from European Union, outside the submitted work; and Shareholder of Advanced Sleep Research, The Siestagroup GmbH, Nukute. Prof. Dr. Yun Kwok Wing reports personal  fees from Eisai Co, Ltd (HK), personal fees from Lundbeck HK Ltd, outside the submitted work. The authors report no other conflicts of interest in this work.\n",
      "\n",
      "Prof. Dr. Colin A Espie reports personal fees from Big Health (Sleepio), grants from NIHR, outside the submitted work. Dr Kentaro Matsui reports personal fees from Eisai, personal fees from Meiji Seika Pharma, personal fees from Mochida, personal fees from MSD, personal fees from Otsuka Pharmaceutical, personal fees from Takeda Pharmaceutical, personal fees from Yoshitomi Pharmaceutical, outside  the submitted work. Prof. Dr. Charles M Morin reports grants from Eisai, Idorsia, Lallemand, personal fees from Eisai, Idorsia, Pear Therapeutics, royalities from  Mapi Research Trust, outside the submitted work. Prof. Dr. Markku Partinen reports clinical trials from Bioprojet, Jazz Pharmaceuticals and TEVA, personal fees from GSK and Takeda, personal fees and clinical trials from MSD, outside the submitted work. Prof. Dr. Giuseppe Plazzi reports personal fees from Jazz Pharmaceutical, personal fees from Takeda, personal fees from Idorsia, personal fees from Bioprojet, outside the submitted work. Prof. Dr. Thomas Penzel reports  grants from Cidelec, grants from Novartis, grants from Lowenstein Medical, personal fees from Lowenstein Medical, personal fees from Jazz Pharma, personal fees from Neuwirth, consultation to institution from Bayer Healthcare, personal fees from Cerebra, personal fees from National Sleep Foundation, grants from European Union, outside the submitted work; and Shareholder of Advanced Sleep Research, The Siestagroup GmbH, Nukute. Prof. Dr. Yun Kwok Wing reports personal  fees from Eisai Co, Ltd (HK), personal fees from Lundbeck HK Ltd, outside the submitted work. The authors report no other conflicts of interest in this work.\n",
      "\n",
      "Prof. Dr. Colin A Espie reports personal fees from Big Health (Sleepio), grants from NIHR, outside the submitted work. Dr Kentaro Matsui reports personal fees from Eisai, personal fees from Meiji Seika Pharma, personal fees from Mochida, personal fees from MSD, personal fees from Otsuka Pharmaceutical, personal fees from Takeda Pharmaceutical, personal fees from Yoshitomi Pharmaceutical, outside  the submitted work. Prof. Dr. Charles M Morin reports grants from Eisai, Idorsia, Lallemand, personal fees from Eisai, Idorsia, Pear Therapeutics, royalities from  Mapi Research Trust, outside the submitted work. Prof. Dr. Markku Partinen reports clinical trials from Bioprojet, Jazz Pharmaceuticals and TEVA, personal fees from GSK and Takeda, personal fees and clinical trials from MSD, outside the submitted work. Prof. Dr. Giuseppe Plazzi reports personal fees from Jazz Pharmaceutical, personal fees from Takeda, personal fees from Idorsia, personal fees from Bioprojet, outside the submitted work. Prof. Dr. Thomas Penzel reports  grants from Cidelec, grants from Novartis, grants from Lowenstein Medical, personal fees from Lowenstein Medical, personal fees from Jazz Pharma, personal fees from Neuwirth, consultation to institution from Bayer Healthcare, personal fees from Cerebra, personal fees from National Sleep Foundation, grants from European Union, outside the submitted work; and Shareholder of Advanced Sleep Research, The Siestagroup GmbH, Nukute. Prof. Dr. Yun Kwok Wing reports personal  fees from Eisai Co, Ltd (HK), personal fees from Lundbeck HK Ltd, outside the submitted work. The authors report no other conflicts of interest in this work.\n",
      "\n",
      "Prof. Dr. Colin A Espie reports personal fees from Big Health (Sleepio), grants from NIHR, outside the submitted work. Dr Kentaro Matsui reports personal fees from Eisai, personal fees from Meiji Seika Pharma, personal fees from Mochida, personal fees from MSD, personal fees from Otsuka Pharmaceutical, personal fees from Takeda Pharmaceutical, personal fees from Yoshitomi Pharmaceutical, outside  the submitted work. Prof. Dr. Charles M Morin reports grants from Eisai, Idorsia, Lallemand, personal fees from Eisai, Idorsia, Pear Therapeutics, royalities from  Mapi Research Trust, outside the submitted work. Prof. Dr. Markku Partinen reports clinical trials from Bioprojet, Jazz Pharmaceuticals and TEVA, personal fees from GSK and Takeda, personal fees and clinical trials from MSD, outside the submitted work. Prof. Dr. Giuseppe Plazzi reports personal fees from Jazz Pharmaceutical, personal fees from Takeda, personal fees from Idorsia, personal fees from Bioprojet, outside the submitted work. Prof. Dr. Thomas Penzel reports  grants from Cidelec, grants from Novartis, grants from Lowenstein Medical, personal fees from Lowenstein Medical, personal fees from Jazz Pharma, personal fees from Neuwirth, consultation to institution from Bayer Healthcare, personal fees from Cerebra, personal fees from National Sleep Foundation, grants from European Union, outside the submitted work; and Shareholder of Advanced Sleep Research, The Siestagroup GmbH, Nukute. Prof. Dr. Yun Kwok Wing reports personal  fees from Eisai Co, Ltd (HK), personal fees from Lundbeck HK Ltd, outside the submitted work. The authors report no other conflicts of interest in this work.\n",
      "\n",
      "Espie, Colin A.\n",
      "Prof. Dr. Colin A. Espie reports personal fees from Big Health (Sleepio), grants from NIHR, outside the submitted work. Dr Kentaro Matsui reports personal fees from Eisai, personal fees from Meiji Seika Pharma, personal fees from Mochida, personal fees from MSD, personal fees from Otsuka Pharmaceutical, personal fees from Takeda Pharmaceutical, personal fees from Yoshitomi Pharmaceutical, outside  the submitted work. Prof. Dr. Charles M Morin reports grants from Eisai, Idorsia, Lallemand, personal fees from Eisai, Idorsia, Pear Therapeutics, royalities from  Mapi Research Trust, outside the submitted work. Prof. Dr. Markku Partinen reports clinical trials from Bioprojet, Jazz Pharmaceuticals and TEVA, personal fees from GSK and Takeda, personal fees and clinical trials from MSD, outside the submitted work. Prof. Dr. Giuseppe Plazzi reports personal fees from Jazz Pharmaceutical, personal fees from Takeda, personal fees from Idorsia, personal fees from Bioprojet, outside the submitted work. Prof. Dr. Thomas Penzel reports  grants from Cidelec, grants from Novartis, grants from Lowenstein Medical, personal fees from Lowenstein Medical, personal fees from Jazz Pharma, personal fees from Neuwirth, consultation to institution from Bayer Healthcare, personal fees from Cerebra, personal fees from National Sleep Foundation, grants from European Union, outside the submitted work; and Shareholder of Advanced Sleep Research, The Siestagroup GmbH, Nukute. Prof. Dr. Yun Kwok Wing reports personal  fees from Eisai Co, Ltd (HK), personal fees from Lundbeck HK Ltd, outside the submitted work. The authors report no other conflicts of interest in this work.\n",
      "\n",
      "Prof. Dr. Colin A. Espie reports personal fees from Big Health (Sleepio), grants from NIHR, outside the submitted work. Dr Kentaro Matsui reports personal fees from Eisai, personal fees from Meiji Seika Pharma, personal fees from Mochida, personal fees from MSD, personal fees from Otsuka Pharmaceutical, personal fees from Takeda Pharmaceutical, personal fees from Yoshitomi Pharmaceutical, outside  the submitted work. Prof. Dr. Charles M Morin reports grants from Eisai, Idorsia, Lallemand, personal fees from Eisai, Idorsia, Pear Therapeutics, royalities from  Mapi Research Trust, outside the submitted work. Prof. Dr. Markku Partinen reports clinical trials from Bioprojet, Jazz Pharmaceuticals and TEVA, personal fees from GSK and Takeda, personal fees and clinical trials from MSD, outside the submitted work. Prof. Dr. Giuseppe Plazzi reports personal fees from Jazz Pharmaceutical, personal fees from Takeda, personal fees from Idorsia, personal fees from Bioprojet, outside the submitted work. Prof. Dr. Thomas Penzel reports  grants from Cidelec, grants from Novartis, grants from Lowenstein Medical, personal fees from Lowenstein Medical, personal fees from Jazz Pharma, personal fees from Neuwirth, consultation to institution from Bayer Healthcare, personal fees from Cerebra, personal fees from National Sleep Foundation, grants from European Union, outside the submitted work; and Shareholder of Advanced Sleep Research, The Siestagroup GmbH, Nukute. Prof. Dr. Yun Kwok Wing reports personal  fees from Eisai Co, Ltd (HK), personal fees from Lundbeck HK Ltd, outside the submitted work. The authors report no other conflicts of interest in this work.\n",
      "\n",
      "Prof. Dr. Colin A. Espie reports personal fees from Big Health (Sleepio), grants from NIHR, outside the submitted work. Dr Kentaro Matsui reports personal fees from Eisai, personal fees from Meiji Seika Pharma, personal fees from Mochida, personal fees from MSD, personal fees from Otsuka Pharmaceutical, personal fees from Takeda Pharmaceutical, personal fees from Yoshitomi Pharmaceutical, outside  the submitted work. Prof. Dr. Charles M Morin reports grants from Eisai, Idorsia, Lallemand, personal fees from Eisai, Idorsia, Pear Therapeutics, royalities from  Mapi Research Trust, outside the submitted work. Prof. Dr. Markku Partinen reports clinical trials from Bioprojet, Jazz Pharmaceuticals and TEVA, personal fees from GSK and Takeda, personal fees and clinical trials from MSD, outside the submitted work. Prof. Dr. Giuseppe Plazzi reports personal fees from Jazz Pharmaceutical, personal fees from Takeda, personal fees from Idorsia, personal fees from Bioprojet, outside the submitted work. Prof. Dr. Thomas Penzel reports  grants from Cidelec, grants from Novartis, grants from Lowenstein Medical, personal fees from Lowenstein Medical, personal fees from Jazz Pharma, personal fees from Neuwirth, consultation to institution from Bayer Healthcare, personal fees from Cerebra, personal fees from National Sleep Foundation, grants from European Union, outside the submitted work; and Shareholder of Advanced Sleep Research, The Siestagroup GmbH, Nukute. Prof. Dr. Yun Kwok Wing reports personal  fees from Eisai Co, Ltd (HK), personal fees from Lundbeck HK Ltd, outside the submitted work. The authors report no other conflicts of interest in this work.\n",
      "\n",
      "Prof. Dr. Colin A. Espie reports personal fees from Big Health (Sleepio), grants from NIHR, outside the submitted work. Dr Kentaro Matsui reports personal fees from Eisai, personal fees from Meiji Seika Pharma, personal fees from Mochida, personal fees from MSD, personal fees from Otsuka Pharmaceutical, personal fees from Takeda Pharmaceutical, personal fees from Yoshitomi Pharmaceutical, outside  the submitted work. Prof. Dr. Charles M Morin reports grants from Eisai, Idorsia, Lallemand, personal fees from Eisai, Idorsia, Pear Therapeutics, royalities from  Mapi Research Trust, outside the submitted work. Prof. Dr. Markku Partinen reports clinical trials from Bioprojet, Jazz Pharmaceuticals and TEVA, personal fees from GSK and Takeda, personal fees and clinical trials from MSD, outside the submitted work. Prof. Dr. Giuseppe Plazzi reports personal fees from Jazz Pharmaceutical, personal fees from Takeda, personal fees from Idorsia, personal fees from Bioprojet, outside the submitted work. Prof. Dr. Thomas Penzel reports  grants from Cidelec, grants from Novartis, grants from Lowenstein Medical, personal fees from Lowenstein Medical, personal fees from Jazz Pharma, personal fees from Neuwirth, consultation to institution from Bayer Healthcare, personal fees from Cerebra, personal fees from National Sleep Foundation, grants from European Union, outside the submitted work; and Shareholder of Advanced Sleep Research, The Siestagroup GmbH, Nukute. Prof. Dr. Yun Kwok Wing reports personal  fees from Eisai Co, Ltd (HK), personal fees from Lundbeck HK Ltd, outside the submitted work. The authors report no other conflicts of interest in this work.\n",
      "\n",
      "Prof. Dr. Colin A. Espie reports personal fees from Big Health (Sleepio), grants from NIHR, outside the submitted work. Dr Kentaro Matsui reports personal fees from Eisai, personal fees from Meiji Seika Pharma, personal fees from Mochida, personal fees from MSD, personal fees from Otsuka Pharmaceutical, personal fees from Takeda Pharmaceutical, personal fees from Yoshitomi Pharmaceutical, outside  the submitted work. Prof. Dr. Charles M Morin reports grants from Eisai, Idorsia, Lallemand, personal fees from Eisai, Idorsia, Pear Therapeutics, royalities from  Mapi Research Trust, outside the submitted work. Prof. Dr. Markku Partinen reports clinical trials from Bioprojet, Jazz Pharmaceuticals and TEVA, personal fees from GSK and Takeda, personal fees and clinical trials from MSD, outside the submitted work. Prof. Dr. Giuseppe Plazzi reports personal fees from Jazz Pharmaceutical, personal fees from Takeda, personal fees from Idorsia, personal fees from Bioprojet, outside the submitted work. Prof. Dr. Thomas Penzel reports  grants from Cidelec, grants from Novartis, grants from Lowenstein Medical, personal fees from Lowenstein Medical, personal fees from Jazz Pharma, personal fees from Neuwirth, consultation to institution from Bayer Healthcare, personal fees from Cerebra, personal fees from National Sleep Foundation, grants from European Union, outside the submitted work; and Shareholder of Advanced Sleep Research, The Siestagroup GmbH, Nukute. Prof. Dr. Yun Kwok Wing reports personal  fees from Eisai Co, Ltd (HK), personal fees from Lundbeck HK Ltd, outside the submitted work. The authors report no other conflicts of interest in this work.\n",
      "\n",
      "Matsui, Kentaro\n",
      "Prof. Dr. Colin A. Espie reports personal fees from Big Health (Sleepio), grants from NIHR, outside the submitted work. Dr Kentaro Matsui reports personal fees from Eisai, personal fees from Meiji Seika Pharma, personal fees from Mochida, personal fees from MSD, personal fees from Otsuka Pharmaceutical, personal fees from Takeda Pharmaceutical, personal fees from Yoshitomi Pharmaceutical, outside  the submitted work. Prof. Dr. Charles M Morin reports grants from Eisai, Idorsia, Lallemand, personal fees from Eisai, Idorsia, Pear Therapeutics, royalities from  Mapi Research Trust, outside the submitted work. Prof. Dr. Markku Partinen reports clinical trials from Bioprojet, Jazz Pharmaceuticals and TEVA, personal fees from GSK and Takeda, personal fees and clinical trials from MSD, outside the submitted work. Prof. Dr. Giuseppe Plazzi reports personal fees from Jazz Pharmaceutical, personal fees from Takeda, personal fees from Idorsia, personal fees from Bioprojet, outside the submitted work. Prof. Dr. Thomas Penzel reports  grants from Cidelec, grants from Novartis, grants from Lowenstein Medical, personal fees from Lowenstein Medical, personal fees from Jazz Pharma, personal fees from Neuwirth, consultation to institution from Bayer Healthcare, personal fees from Cerebra, personal fees from National Sleep Foundation, grants from European Union, outside the submitted work; and Shareholder of Advanced Sleep Research, The Siestagroup GmbH, Nukute. Prof. Dr. Yun Kwok Wing reports personal  fees from Eisai Co, Ltd (HK), personal fees from Lundbeck HK Ltd, outside the submitted work. The authors report no other conflicts of interest in this work.\n",
      "\n",
      "Prof. Dr. Colin A. Espie reports personal fees from Big Health (Sleepio), grants from NIHR, outside the submitted work. Dr Kentaro Matsui reports personal fees from Eisai, personal fees from Meiji Seika Pharma, personal fees from Mochida, personal fees from MSD, personal fees from Otsuka Pharmaceutical, personal fees from Takeda Pharmaceutical, personal fees from Yoshitomi Pharmaceutical, outside  the submitted work. Prof. Dr. Charles M Morin reports grants from Eisai, Idorsia, Lallemand, personal fees from Eisai, Idorsia, Pear Therapeutics, royalities from  Mapi Research Trust, outside the submitted work. Prof. Dr. Markku Partinen reports clinical trials from Bioprojet, Jazz Pharmaceuticals and TEVA, personal fees from GSK and Takeda, personal fees and clinical trials from MSD, outside the submitted work. Prof. Dr. Giuseppe Plazzi reports personal fees from Jazz Pharmaceutical, personal fees from Takeda, personal fees from Idorsia, personal fees from Bioprojet, outside the submitted work. Prof. Dr. Thomas Penzel reports  grants from Cidelec, grants from Novartis, grants from Lowenstein Medical, personal fees from Lowenstein Medical, personal fees from Jazz Pharma, personal fees from Neuwirth, consultation to institution from Bayer Healthcare, personal fees from Cerebra, personal fees from National Sleep Foundation, grants from European Union, outside the submitted work; and Shareholder of Advanced Sleep Research, The Siestagroup GmbH, Nukute. Prof. Dr. Yun Kwok Wing reports personal  fees from Eisai Co, Ltd (HK), personal fees from Lundbeck HK Ltd, outside the submitted work. The authors report no other conflicts of interest in this work.\n",
      "\n",
      "Morin, Charles M.\n",
      "Prof. Dr. Colin A. Espie reports personal fees from Big Health (Sleepio), grants from NIHR, outside the submitted work. Dr Kentaro Matsui reports personal fees from Eisai, personal fees from Meiji Seika Pharma, personal fees from Mochida, personal fees from MSD, personal fees from Otsuka Pharmaceutical, personal fees from Takeda Pharmaceutical, personal fees from Yoshitomi Pharmaceutical, outside  the submitted work. Prof. Dr. Charles M. Morin reports grants from Eisai, Idorsia, Lallemand, personal fees from Eisai, Idorsia, Pear Therapeutics, royalities from  Mapi Research Trust, outside the submitted work. Prof. Dr. Markku Partinen reports clinical trials from Bioprojet, Jazz Pharmaceuticals and TEVA, personal fees from GSK and Takeda, personal fees and clinical trials from MSD, outside the submitted work. Prof. Dr. Giuseppe Plazzi reports personal fees from Jazz Pharmaceutical, personal fees from Takeda, personal fees from Idorsia, personal fees from Bioprojet, outside the submitted work. Prof. Dr. Thomas Penzel reports  grants from Cidelec, grants from Novartis, grants from Lowenstein Medical, personal fees from Lowenstein Medical, personal fees from Jazz Pharma, personal fees from Neuwirth, consultation to institution from Bayer Healthcare, personal fees from Cerebra, personal fees from National Sleep Foundation, grants from European Union, outside the submitted work; and Shareholder of Advanced Sleep Research, The Siestagroup GmbH, Nukute. Prof. Dr. Yun Kwok Wing reports personal  fees from Eisai Co, Ltd (HK), personal fees from Lundbeck HK Ltd, outside the submitted work. The authors report no other conflicts of interest in this work.\n",
      "\n",
      "Prof. Dr. Colin A. Espie reports personal fees from Big Health (Sleepio), grants from NIHR, outside the submitted work. Dr Kentaro Matsui reports personal fees from Eisai, personal fees from Meiji Seika Pharma, personal fees from Mochida, personal fees from MSD, personal fees from Otsuka Pharmaceutical, personal fees from Takeda Pharmaceutical, personal fees from Yoshitomi Pharmaceutical, outside  the submitted work. Prof. Dr. Charles M. Morin reports grants from Eisai, Idorsia, Lallemand, personal fees from Eisai, Idorsia, Pear Therapeutics, royalities from  Mapi Research Trust, outside the submitted work. Prof. Dr. Markku Partinen reports clinical trials from Bioprojet, Jazz Pharmaceuticals and TEVA, personal fees from GSK and Takeda, personal fees and clinical trials from MSD, outside the submitted work. Prof. Dr. Giuseppe Plazzi reports personal fees from Jazz Pharmaceutical, personal fees from Takeda, personal fees from Idorsia, personal fees from Bioprojet, outside the submitted work. Prof. Dr. Thomas Penzel reports  grants from Cidelec, grants from Novartis, grants from Lowenstein Medical, personal fees from Lowenstein Medical, personal fees from Jazz Pharma, personal fees from Neuwirth, consultation to institution from Bayer Healthcare, personal fees from Cerebra, personal fees from National Sleep Foundation, grants from European Union, outside the submitted work; and Shareholder of Advanced Sleep Research, The Siestagroup GmbH, Nukute. Prof. Dr. Yun Kwok Wing reports personal  fees from Eisai Co, Ltd (HK), personal fees from Lundbeck HK Ltd, outside the submitted work. The authors report no other conflicts of interest in this work.\n",
      "\n",
      "Partinen, Markku\n",
      "Prof. Dr. Colin A. Espie reports personal fees from Big Health (Sleepio), grants from NIHR, outside the submitted work. Dr Kentaro Matsui reports personal fees from Eisai, personal fees from Meiji Seika Pharma, personal fees from Mochida, personal fees from MSD, personal fees from Otsuka Pharmaceutical, personal fees from Takeda Pharmaceutical, personal fees from Yoshitomi Pharmaceutical, outside  the submitted work. Prof. Dr. Charles M. Morin reports grants from Eisai, Idorsia, Lallemand, personal fees from Eisai, Idorsia, Pear Therapeutics, royalities from  Mapi Research Trust, outside the submitted work. Prof. Dr. Markku Partinen reports clinical trials from Bioprojet, Jazz Pharmaceuticals and TEVA, personal fees from GSK and Takeda, personal fees and clinical trials from MSD, outside the submitted work. Prof. Dr. Giuseppe Plazzi reports personal fees from Jazz Pharmaceutical, personal fees from Takeda, personal fees from Idorsia, personal fees from Bioprojet, outside the submitted work. Prof. Dr. Thomas Penzel reports  grants from Cidelec, grants from Novartis, grants from Lowenstein Medical, personal fees from Lowenstein Medical, personal fees from Jazz Pharma, personal fees from Neuwirth, consultation to institution from Bayer Healthcare, personal fees from Cerebra, personal fees from National Sleep Foundation, grants from European Union, outside the submitted work; and Shareholder of Advanced Sleep Research, The Siestagroup GmbH, Nukute. Prof. Dr. Yun Kwok Wing reports personal  fees from Eisai Co, Ltd (HK), personal fees from Lundbeck HK Ltd, outside the submitted work. The authors report no other conflicts of interest in this work.\n",
      "\n",
      "Plazzi, Giuseppe\n",
      "Prof. Dr. Colin A. Espie reports personal fees from Big Health (Sleepio), grants from NIHR, outside the submitted work. Dr Kentaro Matsui reports personal fees from Eisai, personal fees from Meiji Seika Pharma, personal fees from Mochida, personal fees from MSD, personal fees from Otsuka Pharmaceutical, personal fees from Takeda Pharmaceutical, personal fees from Yoshitomi Pharmaceutical, outside  the submitted work. Prof. Dr. Charles M. Morin reports grants from Eisai, Idorsia, Lallemand, personal fees from Eisai, Idorsia, Pear Therapeutics, royalities from  Mapi Research Trust, outside the submitted work. Prof. Dr. Markku Partinen reports clinical trials from Bioprojet, Jazz Pharmaceuticals and TEVA, personal fees from GSK and Takeda, personal fees and clinical trials from MSD, outside the submitted work. Prof. Dr. Giuseppe Plazzi reports personal fees from Jazz Pharmaceutical, personal fees from Takeda, personal fees from Idorsia, personal fees from Bioprojet, outside the submitted work. Prof. Dr. Thomas Penzel reports  grants from Cidelec, grants from Novartis, grants from Lowenstein Medical, personal fees from Lowenstein Medical, personal fees from Jazz Pharma, personal fees from Neuwirth, consultation to institution from Bayer Healthcare, personal fees from Cerebra, personal fees from National Sleep Foundation, grants from European Union, outside the submitted work; and Shareholder of Advanced Sleep Research, The Siestagroup GmbH, Nukute. Prof. Dr. Yun Kwok Wing reports personal  fees from Eisai Co, Ltd (HK), personal fees from Lundbeck HK Ltd, outside the submitted work. The authors report no other conflicts of interest in this work.\n",
      "\n",
      "Penzel, Thomas\n",
      "Prof. Dr. Colin A. Espie reports personal fees from Big Health (Sleepio), grants from NIHR, outside the submitted work. Dr Kentaro Matsui reports personal fees from Eisai, personal fees from Meiji Seika Pharma, personal fees from Mochida, personal fees from MSD, personal fees from Otsuka Pharmaceutical, personal fees from Takeda Pharmaceutical, personal fees from Yoshitomi Pharmaceutical, outside  the submitted work. Prof. Dr. Charles M. Morin reports grants from Eisai, Idorsia, Lallemand, personal fees from Eisai, Idorsia, Pear Therapeutics, royalities from  Mapi Research Trust, outside the submitted work. Prof. Dr. Markku Partinen reports clinical trials from Bioprojet, Jazz Pharmaceuticals and TEVA, personal fees from GSK and Takeda, personal fees and clinical trials from MSD, outside the submitted work. Prof. Dr. Giuseppe Plazzi reports personal fees from Jazz Pharmaceutical, personal fees from Takeda, personal fees from Idorsia, personal fees from Bioprojet, outside the submitted work. Prof. Dr. Thomas Penzel reports  grants from Cidelec, grants from Novartis, grants from Lowenstein Medical, personal fees from Lowenstein Medical, personal fees from Jazz Pharma, personal fees from Neuwirth, consultation to institution from Bayer Healthcare, personal fees from Cerebra, personal fees from National Sleep Foundation, grants from European Union, outside the submitted work; and Shareholder of Advanced Sleep Research, The Siestagroup GmbH, Nukute. Prof. Dr. Yun Kwok Wing reports personal  fees from Eisai Co, Ltd (HK), personal fees from Lundbeck HK Ltd, outside the submitted work. The authors report no other conflicts of interest in this work.\n",
      "\n",
      "Sieminski, Mariusz\n",
      "Prof. Dr. Colin A. Espie reports personal fees from Big Health (Sleepio), grants from NIHR, outside the submitted work. Dr Kentaro Matsui reports personal fees from Eisai, personal fees from Meiji Seika Pharma, personal fees from Mochida, personal fees from Mariusz SieminskiD, personal fees from Otsuka Pharmaceutical, personal fees from Takeda Pharmaceutical, personal fees from Yoshitomi Pharmaceutical, outside  the submitted work. Prof. Dr. Charles M. Morin reports grants from Eisai, Idorsia, Lallemand, personal fees from Eisai, Idorsia, Pear Therapeutics, royalities from  Mapi Research Trust, outside the submitted work. Prof. Dr. Markku Partinen reports clinical trials from Bioprojet, Jazz Pharmaceuticals and TEVA, personal fees from GSK and Takeda, personal fees and clinical trials from Mariusz SieminskiD, outside the submitted work. Prof. Dr. Giuseppe Plazzi reports personal fees from Jazz Pharmaceutical, personal fees from Takeda, personal fees from Idorsia, personal fees from Bioprojet, outside the submitted work. Prof. Dr. Thomas Penzel reports  grants from Cidelec, grants from Novartis, grants from Lowenstein Medical, personal fees from Lowenstein Medical, personal fees from Jazz Pharma, personal fees from Neuwirth, consultation to institution from Bayer Healthcare, personal fees from Cerebra, personal fees from National Sleep Foundation, grants from European Union, outside the submitted work; and Shareholder of Advanced Sleep Research, The Siestagroup GmbH, Nukute. Prof. Dr. Yun Kwok Wing reports personal  fees from Eisai Co, Ltd (HK), personal fees from Lundbeck HK Ltd, outside the submitted work. The authors report no other conflicts of interest in this work.\n",
      "\n",
      "Kwok Wing, Yun\n",
      "Prof. Dr. Colin A. Espie reports personal fees from Big Health (Sleepio), grants from NIHR, outside the submitted work. Dr Kentaro Matsui reports personal fees from Eisai, personal fees from Meiji Seika Pharma, personal fees from Mochida, personal fees from Mariusz SieminskiD, personal fees from Otsuka Pharmaceutical, personal fees from Takeda Pharmaceutical, personal fees from Yoshitomi Pharmaceutical, outside  the submitted work. Prof. Dr. Charles M. Morin reports grants from Eisai, Idorsia, Lallemand, personal fees from Eisai, Idorsia, Pear Therapeutics, royalities from  Mapi Research Trust, outside the submitted work. Prof. Dr. Markku Partinen reports clinical trials from Bioprojet, Jazz Pharmaceuticals and TEVA, personal fees from GSK and Takeda, personal fees and clinical trials from Mariusz SieminskiD, outside the submitted work. Prof. Dr. Giuseppe Plazzi reports personal fees from Jazz Pharmaceutical, personal fees from Takeda, personal fees from Idorsia, personal fees from Bioprojet, outside the submitted work. Prof. Dr. Thomas Penzel reports  grants from Cidelec, grants from Novartis, grants from Lowenstein Medical, personal fees from Lowenstein Medical, personal fees from Jazz Pharma, personal fees from Neuwirth, consultation to institution from Bayer Healthcare, personal fees from Cerebra, personal fees from National Sleep Foundation, grants from European Union, outside the submitted work; and Shareholder of Advanced Sleep Research, The Siestagroup GmbH, Nukute. Prof. Dr. Yun Kwok Wing reports personal  fees from Eisai Co, Ltd (HK), personal fees from Lundbeck HK Ltd, outside the submitted work. The authors report no other conflicts of interest in this work.\n",
      "\n",
      "Prof. Dr. Colin A. Espie reports personal fees from Big Health (Sleepio), grants from NIHR, outside the submitted work. Dr Kentaro Matsui reports personal fees from Eisai, personal fees from Meiji Seika Pharma, personal fees from Mochida, personal fees from Mariusz SieminskiD, personal fees from Otsuka Pharmaceutical, personal fees from Takeda Pharmaceutical, personal fees from Yoshitomi Pharmaceutical, outside  the submitted work. Prof. Dr. Charles M. Morin reports grants from Eisai, Idorsia, Lallemand, personal fees from Eisai, Idorsia, Pear Therapeutics, royalities from  Mapi Research Trust, outside the submitted work. Prof. Dr. Markku Partinen reports clinical trials from Bioprojet, Jazz Pharmaceuticals and TEVA, personal fees from GSK and Takeda, personal fees and clinical trials from Mariusz SieminskiD, outside the submitted work. Prof. Dr. Giuseppe Plazzi reports personal fees from Jazz Pharmaceutical, personal fees from Takeda, personal fees from Idorsia, personal fees from Bioprojet, outside the submitted work. Prof. Dr. Thomas Penzel reports  grants from Cidelec, grants from Novartis, grants from Lowenstein Medical, personal fees from Lowenstein Medical, personal fees from Jazz Pharma, personal fees from Neuwirth, consultation to institution from Bayer Healthcare, personal fees from Cerebra, personal fees from National Sleep Foundation, grants from European Union, outside the submitted work; and Shareholder of Advanced Sleep Research, The Siestagroup GmbH, Nukute. Prof. Dr. Yun Kwok Wing reports personal  fees from Eisai Co, Ltd (HK), personal fees from Lundbeck HK Ltd, outside the submitted work. The authors report no other conflicts of interest in this work.\n",
      "\n",
      "Prof. Dr. Colin A. Espie reports personal fees from Big Health (Sleepio), grants from NIHR, outside the submitted work. Dr Kentaro Matsui reports personal fees from Eisai, personal fees from Meiji Seika Pharma, personal fees from Mochida, personal fees from Mariusz SieminskiD, personal fees from Otsuka Pharmaceutical, personal fees from Takeda Pharmaceutical, personal fees from Yoshitomi Pharmaceutical, outside  the submitted work. Prof. Dr. Charles M. Morin reports grants from Eisai, Idorsia, Lallemand, personal fees from Eisai, Idorsia, Pear Therapeutics, royalities from  Mapi Research Trust, outside the submitted work. Prof. Dr. Markku Partinen reports clinical trials from Bioprojet, Jazz Pharmaceuticals and TEVA, personal fees from GSK and Takeda, personal fees and clinical trials from Mariusz SieminskiD, outside the submitted work. Prof. Dr. Giuseppe Plazzi reports personal fees from Jazz Pharmaceutical, personal fees from Takeda, personal fees from Idorsia, personal fees from Bioprojet, outside the submitted work. Prof. Dr. Thomas Penzel reports  grants from Cidelec, grants from Novartis, grants from Lowenstein Medical, personal fees from Lowenstein Medical, personal fees from Jazz Pharma, personal fees from Neuwirth, consultation to institution from Bayer Healthcare, personal fees from Cerebra, personal fees from National Sleep Foundation, grants from European Union, outside the submitted work; and Shareholder of Advanced Sleep Research, The Siestagroup GmbH, Nukute. Prof. Dr. Yun Kwok Wing reports personal  fees from Eisai Co, Ltd (HK), personal fees from Lundbeck HK Ltd, outside the submitted work. The authors report no other conflicts of interest in this work.\n",
      "\n",
      "Prof. Dr. Colin A. Espie reports personal fees from Big Health (Sleepio), grants from NIHR, outside the submitted work. Dr Kentaro Matsui reports personal fees from Eisai, personal fees from Meiji Seika Pharma, personal fees from Mochida, personal fees from Mariusz SieminskiD, personal fees from Otsuka Pharmaceutical, personal fees from Takeda Pharmaceutical, personal fees from Yoshitomi Pharmaceutical, outside  the submitted work. Prof. Dr. Charles M. Morin reports grants from Eisai, Idorsia, Lallemand, personal fees from Eisai, Idorsia, Pear Therapeutics, royalities from  Mapi Research Trust, outside the submitted work. Prof. Dr. Markku Partinen reports clinical trials from Bioprojet, Jazz Pharmaceuticals and TEVA, personal fees from GSK and Takeda, personal fees and clinical trials from Mariusz SieminskiD, outside the submitted work. Prof. Dr. Giuseppe Plazzi reports personal fees from Jazz Pharmaceutical, personal fees from Takeda, personal fees from Idorsia, personal fees from Bioprojet, outside the submitted work. Prof. Dr. Thomas Penzel reports  grants from Cidelec, grants from Novartis, grants from Lowenstein Medical, personal fees from Lowenstein Medical, personal fees from Jazz Pharma, personal fees from Neuwirth, consultation to institution from Bayer Healthcare, personal fees from Cerebra, personal fees from National Sleep Foundation, grants from European Union, outside the submitted work; and Shareholder of Advanced Sleep Research, The Siestagroup GmbH, Nukute. Prof. Dr. Yun Kwok Wing reports personal  fees from Eisai Co, Ltd (HK), personal fees from Lundbeck HK Ltd, outside the submitted work. The authors report no other conflicts of interest in this work.\n",
      "\n",
      "Wang, Guangwen\n",
      "Author Guangwen Wang is employed by company BlueRock Therapeutics. Author WW is employed by  company Metagenomi.\n",
      "\n",
      "Wang, Wenshi\n",
      "Author Guangwen Wenshi Wang is employed by company BlueRock Therapeutics. Author WW is employed by  company Metagenomi.\n",
      "\n",
      "Disclosures Dr. Recinos reported consulting fees from Stryker outside the submitted work, and ownership interest in Acera Surgical. No other disclosures were reported.\n",
      "\n",
      "Recinos, Pablo F.\n",
      "Disclosures Dr. Pablo F. Recinos reported consulting fees from Stryker outside the submitted work, and ownership interest in Acera Surgical. No other disclosures were reported.\n",
      "\n",
      "Disclosures Dr. Pablo F. Recinos reported consulting fees from Stryker outside the submitted work, and ownership interest in Acera Surgical. No other disclosures were reported.\n",
      "\n",
      "Disclosures Dr. Pablo F. Recinos reported consulting fees from Stryker outside the submitted work, and ownership interest in Acera Surgical. No other disclosures were reported.\n",
      "\n",
      "Disclosures Dr. Pablo F. Recinos reported consulting fees from Stryker outside the submitted work, and ownership interest in Acera Surgical. No other disclosures were reported.\n",
      "\n",
      "Disclosures Dr. Pablo F. Recinos reported consulting fees from Stryker outside the submitted work, and ownership interest in Acera Surgical. No other disclosures were reported.\n",
      "\n",
      "Disclosures Dr. Bartolini reported receiving a salary as editor of Neurology: Clinical Practice. No other disclosures were reported.\n",
      "\n",
      "Disclosures Dr. Bartolini reported receiving a salary as editor of Neurology: Clinical Practice. No other disclosures were reported.\n",
      "\n",
      "Disclosures Dr. Bartolini reported receiving a salary as editor of Neurology: Clinical Practice. No other disclosures were reported.\n",
      "\n",
      "Disclosures Dr. Bartolini reported receiving a salary as editor of Neurology: Clinical Practice. No other disclosures were reported.\n",
      "\n",
      "Disclosures Dr. Bartolini reported receiving a salary as editor of Neurology: Clinical Practice. No other disclosures were reported.\n",
      "\n",
      "Bartolini, Luca\n",
      "Disclosures Dr. Luca Bartolini reported receiving a salary as editor of Neurology: Clinical Practice. No other disclosures were reported.\n",
      "\n",
      "Disclosures Dr. Luca Bartolini reported receiving a salary as editor of Neurology: Clinical Practice. No other disclosures were reported.\n",
      "\n",
      "QP and HS is employed by Qingdao Phagepharm Bio-tech Co., Ltd. The remaining authors declare that the research was conducted in the absence of any commercial  or financial relationships that could be construed as a potential conflict of interest.\n",
      "\n",
      "QP and HS is employed by Qingdao Phagepharm Bio-tech Co., Ltd. The remaining authors declare that the research was conducted in the absence of any commercial  or financial relationships that could be construed as a potential conflict of interest.\n",
      "\n",
      "QP and HS is employed by Qingdao Phagepharm Bio-tech Co., Ltd. The remaining authors declare that the research was conducted in the absence of any commercial  or financial relationships that could be construed as a potential conflict of interest.\n",
      "\n",
      "Sun, Huzhi\n",
      "QP and Huzhi Sun is employed by Qingdao Phagepharm Bio-tech Co., Ltd. The remaining authors declare that the research was conducted in the absence of any commercial  or financial relationships that could be construed as a potential conflict of interest.\n",
      "\n",
      "QP and Huzhi Sun is employed by Qingdao Phagepharm Bio-tech Co., Ltd. The remaining authors declare that the research was conducted in the absence of any commercial  or financial relationships that could be construed as a potential conflict of interest.\n",
      "\n",
      "QP and Huzhi Sun is employed by Qingdao Phagepharm Bio-tech Co., Ltd. The remaining authors declare that the research was conducted in the absence of any commercial  or financial relationships that could be construed as a potential conflict of interest.\n",
      "\n",
      "QP and Huzhi Sun is employed by Qingdao Phagepharm Bio-tech Co., Ltd. The remaining authors declare that the research was conducted in the absence of any commercial  or financial relationships that could be construed as a potential conflict of interest.\n",
      "\n",
      "Pan, Qiang\n",
      "Qiang Pan and Huzhi Sun is employed by Qingdao Phagepharm Bio-tech Co., Ltd. The remaining authors declare that the research was conducted in the absence of any commercial  or financial relationships that could be construed as a potential conflict of interest.\n",
      "\n",
      "Qiang Pan and Huzhi Sun is employed by Qingdao Phagepharm Bio-tech Co., Ltd. The remaining authors declare that the research was conducted in the absence of any commercial  or financial relationships that could be construed as a potential conflict of interest.\n",
      "\n",
      "CB was employed by MerLion Pharmaceuticals. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.\n",
      "\n",
      "CB was employed by MerLion Pharmaceuticals. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.\n",
      "\n",
      "CB was employed by MerLion Pharmaceuticals. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.\n",
      "\n",
      "CB was employed by MerLion Pharmaceuticals. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.\n",
      "\n",
      "Bentley, Christine\n",
      "Christine Bentley was employed by MerLion Pharmaceuticals. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.\n",
      "\n",
      "Christine Bentley was employed by MerLion Pharmaceuticals. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.\n",
      "\n",
      "Christine Bentley was employed by MerLion Pharmaceuticals. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.\n",
      "\n",
      "Christine Bentley was employed by MerLion Pharmaceuticals. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.\n",
      "\n",
      "Christine Bentley was employed by MerLion Pharmaceuticals. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.\n",
      "\n",
      "Author KK was employed by MBFG. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.\n",
      "\n",
      "Author KK was employed by MBFG. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.\n",
      "\n",
      "Author KK was employed by MBFG. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.\n",
      "\n",
      "Kadlec, Kristina\n",
      "Author Kristina Kadlec was employed by MBFG. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.\n",
      "\n",
      "Author Kristina Kadlec was employed by MBFG. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.\n",
      "\n",
      "Wang, Louise\n",
      "CONFLICTS OF INTEREST Louise Wang: No relevant conflicts of interest; SMD: No relevant conflicts of interest; MLK: Consulting: Applied Clinical Intelligence, BSC, Castle Biosciences, Medtronic, Olympus, Equity: Dark Canyon Laboratory, Endosound, Virgo Systems; BWK: No relevant conflicts of interest.\n",
      "\n",
      "Domchek, Susan M.\n",
      "CONFLICTS OF INTEREST Louise Wang: No relevant conflicts of interest; Susan M. Domchek: No relevant conflicts of interest; MLK: Consulting: Applied Clinical Intelligence, BSC, Castle Biosciences, Medtronic, Olympus, Equity: Dark Canyon Laboratory, Endosound, Virgo Systems; BWK: No relevant conflicts of interest.\n",
      "\n",
      "Kochman, Michael L.\n",
      "CONFLICTS OF INTEREST Louise Wang: No relevant conflicts of interest; Susan M. Domchek: No relevant conflicts of interest; Michael L. Kochman: Consulting: Applied Clinical Intelligence, BSC, Castle Biosciences, Medtronic, Olympus, Equity: Dark Canyon Laboratory, Endosound, Virgo Systems; BWK: No relevant conflicts of interest.\n",
      "\n",
      "Katona, Bryson W.\n",
      "CONFLICTS OF INTEREST Louise Wang: No relevant conflicts of interest; Susan M. Domchek: No relevant conflicts of interest; Michael L. Kochman: Consulting: Applied Clinical Intelligence, BSC, Castle Biosciences, Medtronic, Olympus, Equity: Dark Canyon Laboratory, Endosound, Virgo Systems; Bryson W. Katona: No relevant conflicts of interest.\n",
      "\n",
      "Chen, KuanHui E.\n",
      "CONFLICTS OF INTEREST The University of California, Riverside holds the patent for this approach and KuanHui E. Chen and AMW are inventors.\n",
      "\n",
      "Walker, Ameae M.\n",
      "CONFLICTS OF INTEREST The University of California, Riverside holds the patent for this approach and KuanHui E. Chen and Ameae M. Walker are inventors.\n",
      "\n",
      "The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Dr L Naicker reports financial support was provided by National Research Foundation South Africa.\n",
      "\n",
      "Naicker, Leeann\n",
      "The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Dr Leeann Naicker reports financial support was provided by National Research Foundation South Africa.\n",
      "\n",
      "The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Dr Leeann Naicker reports financial support was provided by National Research Foundation South Africa.\n",
      "\n",
      "The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Dr Leeann Naicker reports financial support was provided by National Research Foundation South Africa.\n",
      "\n",
      "The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Dr Leeann Naicker reports financial support was provided by National Research Foundation South Africa.\n",
      "\n",
      "The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Dr Leeann Naicker reports financial support was provided by National Research Foundation South Africa.\n",
      "\n",
      "PaJ, SH, KK, JW, BB, MH, AJ, PeJ, KD, JM, and SR were employed by AgResearch Ltd.\n",
      "\n",
      "Hickey, Sharon\n",
      "PaJ, Sharon Hickey, KK, JW, BB, MH, AJ, PeJ, KD, JM, and SR were employed by AgResearch Ltd.\n",
      "\n",
      "Knowler, Kevin\n",
      "PaJ, Sharon Hickey, Kevin Knowler, JW, BB, MH, AJ, PeJ, KD, JM, and SR were employed by AgResearch Ltd.\n",
      "\n",
      "Wing, Janine\n",
      "PaJ, Sharon Hickey, Kevin Knowler, Janine Wing, BB, MH, AJ, PeJ, KD, JM, and SR were employed by AgResearch Ltd.\n",
      "\n",
      "Bryson, Brooke\n",
      "PaJ, Sharon Hickey, Kevin Knowler, Janine Wing, Brooke Bryson, MH, AJ, PeJ, KD, JM, and SR were employed by AgResearch Ltd.\n",
      "\n",
      "Hall, Melanie\n",
      "PaJ, Sharon Hickey, Kevin Knowler, Janine Wing, Brooke Bryson, Melanie Hall, AJ, PeJ, KD, JM, and SR were employed by AgResearch Ltd.\n",
      "\n",
      "Jonker, Arjan\n",
      "PaJ, Sharon Hickey, Kevin Knowler, Janine Wing, Brooke Bryson, Melanie Hall, Arjan Jonker, PeJ, KD, JM, and SR were employed by AgResearch Ltd.\n",
      "\n",
      "PaJ, Sharon Hickey, Kevin Knowler, Janine Wing, Brooke Bryson, Melanie Hall, Arjan Jonker, PeJ, KD, JM, and SR were employed by AgResearch Ltd.\n",
      "\n",
      "Dodds, Ken G.\n",
      "PaJ, Sharon Hickey, Kevin Knowler, Janine Wing, Brooke Bryson, Melanie Hall, Arjan Jonker, PeJ, Ken G. Dodds, JM, and SR were employed by AgResearch Ltd.\n",
      "\n",
      "McEwan, John C.\n",
      "PaJ, Sharon Hickey, Kevin Knowler, Janine Wing, Brooke Bryson, Melanie Hall, Arjan Jonker, PeJ, Ken G. Dodds, John C. McEwan, and SR were employed by AgResearch Ltd.\n",
      "\n",
      "Rowe, Suzanne J.\n",
      "PaJ, Sharon Hickey, Kevin Knowler, Janine Wing, Brooke Bryson, Melanie Hall, Arjan Jonker, PeJ, Ken G. Dodds, John C. McEwan, and Suzanne J. Rowe were employed by AgResearch Ltd.\n",
      "\n",
      "Heemskerk, Johan L.\n",
      "Conflicts of Interest: Dr. Quinones-Hinojosa: Grants from the National Cancer Institute/National Institute of Health for research on brain cancer. Dr. Neal: Consulting and contracting with Medtronic on robotics, MIS TLIF instrumentation <$20K. Dr. Johan L. Heemskerk: Travel grant from Medtronic to attend Scoliosis Research Society-congress. The other authors have no disclosures to report.\n",
      "\n",
      "Conflicts of Interest: Dr. Quinones-Hinojosa: Grants from the National Cancer Institute/National Institute of Health for research on brain cancer. Dr. Neal: Consulting and contracting with Medtronic on robotics, MIS TLIF instrumentation <$20K. Dr. Johan L. Heemskerk: Travel grant from Medtronic to attend Scoliosis Research Society-congress. The other authors have no disclosures to report.\n",
      "\n",
      "Conflicts of Interest: Dr. Quinones-Hinojosa: Grants from the National Cancer Institute/National Institute of Health for research on brain cancer. Dr. Neal: Consulting and contracting with Medtronic on robotics, MIS TLIF instrumentation <$20K. Dr. Johan L. Heemskerk: Travel grant from Medtronic to attend Scoliosis Research Society-congress. The other authors have no disclosures to report.\n",
      "\n",
      "Conflicts of Interest: Dr. Quinones-Hinojosa: Grants from the National Cancer Institute/National Institute of Health for research on brain cancer. Dr. Neal: Consulting and contracting with Medtronic on robotics, MIS TLIF instrumentation <$20K. Dr. Johan L. Heemskerk: Travel grant from Medtronic to attend Scoliosis Research Society-congress. The other authors have no disclosures to report.\n",
      "\n",
      "Conflicts of Interest: Dr. Quinones-Hinojosa: Grants from the National Cancer Institute/National Institute of Health for research on brain cancer. Dr. Neal: Consulting and contracting with Medtronic on robotics, MIS TLIF instrumentation <$20K. Dr. Johan L. Heemskerk: Travel grant from Medtronic to attend Scoliosis Research Society-congress. The other authors have no disclosures to report.\n",
      "\n",
      "Conflicts of Interest: Dr. Quinones-Hinojosa: Grants from the National Cancer Institute/National Institute of Health for research on brain cancer. Dr. Neal: Consulting and contracting with Medtronic on robotics, MIS TLIF instrumentation <$20K. Dr. Johan L. Heemskerk: Travel grant from Medtronic to attend Scoliosis Research Society-congress. The other authors have no disclosures to report.\n",
      "\n",
      "Neal, Matthew T.\n",
      "Conflicts of Interest: Dr. Quinones-Hinojosa: Grants from the National Cancer Institute/National Institute of Health for research on brain cancer. Dr. Matthew T. Neal: Consulting and contracting with Medtronic on robotics, MIS TLIF instrumentation <$20K. Dr. Johan L. Heemskerk: Travel grant from Medtronic to attend Scoliosis Research Society-congress. The other authors have no disclosures to report.\n",
      "\n",
      "Quinones-Hinojosa, Alfredo\n",
      "Conflicts of Interest: Dr. Alfredo Quinones-Hinojosa: Grants from the National Cancer Institute/National Institute of Health for research on brain cancer. Dr. Matthew T. Neal: Consulting and contracting with Medtronic on robotics, MIS TLIF instrumentation <$20K. Dr. Johan L. Heemskerk: Travel grant from Medtronic to attend Scoliosis Research Society-congress. The other authors have no disclosures to report.\n",
      "\n",
      "Conflicts of Interest: Dr. Alfredo Quinones-Hinojosa: Grants from the National Cancer Institute/National Institute of Health for research on brain cancer. Dr. Matthew T. Neal: Consulting and contracting with Medtronic on robotics, MIS TLIF instrumentation <$20K. Dr. Johan L. Heemskerk: Travel grant from Medtronic to attend Scoliosis Research Society-congress. The other authors have no disclosures to report.\n",
      "\n",
      "WVL is an employee of GE Healthcare, Beijing. The remaining authors declare that  the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.\n",
      "\n",
      "WVL is an employee of GE Healthcare, Beijing. The remaining authors declare that  the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.\n",
      "\n",
      "Vivian Liu, Weiyin\n",
      "Weiyin Vivian Liu is an employee of GE Healthcare, Beijing. The remaining authors declare that  the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.\n",
      "\n",
      "Weiyin Vivian Liu is an employee of GE Healthcare, Beijing. The remaining authors declare that  the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.\n",
      "\n",
      "Weiyin Vivian Liu is an employee of GE Healthcare, Beijing. The remaining authors declare that  the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.\n",
      "\n",
      "AG received funding from the organizations of Lundbeck, Pfizer, Otsuka, Asubio, Autofony, Janssen, Alkermes, SynAgile, Merck, and Newron outside of this work, but these funders were not involved in any way in the study design, collection, analysis, interpretation of data, the writing of this article or the decision to  submit it for publication.\n",
      "\n",
      "AG received funding from the organizations of Lundbeck, Pfizer, Otsuka, Asubio, Autofony, Janssen, Alkermes, SynAgile, Merck, and Newron outside of this work, but these funders were not involved in any way in the study design, collection, analysis, interpretation of data, the writing of this article or the decision to  submit it for publication.\n",
      "\n",
      "Grace, Anthony A.\n",
      "Anthony A. Grace received funding from the organizations of Lundbeck, Pfizer, Otsuka, Asubio, Autofony, Janssen, Alkermes, SynAgile, Merck, and Newron outside of this work, but these funders were not involved in any way in the study design, collection, analysis, interpretation of data, the writing of this article or the decision to  submit it for publication.\n",
      "\n",
      "Anthony A. Grace received funding from the organizations of Lundbeck, Pfizer, Otsuka, Asubio, Autofony, Janssen, Alkermes, SynAgile, Merck, and Newron outside of this work, but these funders were not involved in any way in the study design, collection, analysis, interpretation of data, the writing of this article or the decision to  submit it for publication.\n",
      "\n",
      "Anthony A. Grace received funding from the organizations of Lundbeck, Pfizer, Otsuka, Asubio, Autofony, Janssen, Alkermes, SynAgile, Merck, and Newron outside of this work, but these funders were not involved in any way in the study design, collection, analysis, interpretation of data, the writing of this article or the decision to  submit it for publication.\n",
      "\n",
      "Li, Mingqiang\n",
      "Mingqiang Li, ST, JG, and FZ were employed by Information Science Academy, China Electronics Technology Group Corporation. The remaining author declares that the  research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.\n",
      "\n",
      "Mingqiang Li, ST, JG, and FZ were employed by Information Science Academy, China Electronics Technology Group Corporation. The remaining author declares that the  research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.\n",
      "\n",
      "Tang, Siqi\n",
      "Mingqiang Li, Siqi Tang, JG, and FZ were employed by Information Science Academy, China Electronics Technology Group Corporation. The remaining author declares that the  research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.\n",
      "\n",
      "Ge, Jianjun\n",
      "Mingqiang Li, Siqi Tang, Jianjun Ge, and FZ were employed by Information Science Academy, China Electronics Technology Group Corporation. The remaining author declares that the  research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.\n",
      "\n",
      "Zhang, Feng\n",
      "Mingqiang Li, Siqi Tang, Jianjun Ge, and Feng Zhang were employed by Information Science Academy, China Electronics Technology Group Corporation. The remaining author declares that the  research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.\n",
      "\n",
      "Kiltz, Uta\n",
      "Competing interests: The authors declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: Dr. Uta Kiltz has received grant and research support and consultancy fees from AbbVie, Amgen, Biogen, Chugai, Eli Lilly, Grunenthal, GSK, Hexal, Janssen, MSD, Novartis, Pfizer, Roche and UCB. Dr. Tsiami did not declare a conflict of interest. Dr. Baraliakos has received grant and research support and consultancy  fees from AbbVie, Amgen, Chugai, Galapagos, Hexal, Lilly, MSD, Novartis, Pfizer and UCB. Dr. Andreica has received research support, consultancy fees and honoraria from Abbvie, Amgen, BMS, Chugai, Janssen, Eli Lilly, MSD, Novartis, Pfizer, Sobi, Takkeda and UCB. Dr. Kiefer has received grant and research support and consultancy fees from AbbVie, BMS, Boehringer Ingelheim, Chugai, Eli Lilly, Galapagos, Janssen, MSD, Novartis, Pfizer, Roche and UCB. Dr. Braun has received  honoraria for talks, advisory boards, paid consultancies and grants for studies from Abbvie (Abbott), Amgen, Baxter, Biogen, BMS, Boehringer, Celgene, Celltrion, Centocor, Chugai, Hexal, Janssen, Lilly, Medac, MSD (Schering-Plough), Mylan, Mundipharma, Novartis, Pfizer (Wyeth, Hospira), Roche, Sanofi-Aventis and UCB.\n",
      "\n",
      "Tsiami, Styliani\n",
      "Competing interests: The authors declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: Dr. Uta Kiltz has received grant and research support and consultancy fees from AbbVie, Amgen, Biogen, Chugai, Eli Lilly, Grunenthal, GSK, Hexal, Janssen, MSD, Novartis, Pfizer, Roche and UCB. Dr. Styliani Tsiami did not declare a conflict of interest. Dr. Baraliakos has received grant and research support and consultancy  fees from AbbVie, Amgen, Chugai, Galapagos, Hexal, Lilly, MSD, Novartis, Pfizer and UCB. Dr. Andreica has received research support, consultancy fees and honoraria from Abbvie, Amgen, BMS, Chugai, Janssen, Eli Lilly, MSD, Novartis, Pfizer, Sobi, Takkeda and UCB. Dr. Kiefer has received grant and research support and consultancy fees from AbbVie, BMS, Boehringer Ingelheim, Chugai, Eli Lilly, Galapagos, Janssen, MSD, Novartis, Pfizer, Roche and UCB. Dr. Braun has received  honoraria for talks, advisory boards, paid consultancies and grants for studies from Abbvie (Abbott), Amgen, Baxter, Biogen, BMS, Boehringer, Celgene, Celltrion, Centocor, Chugai, Hexal, Janssen, Lilly, Medac, MSD (Schering-Plough), Mylan, Mundipharma, Novartis, Pfizer (Wyeth, Hospira), Roche, Sanofi-Aventis and UCB.\n",
      "\n",
      "Baraliakos, Xenofon\n",
      "Competing interests: The authors declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: Dr. Uta Kiltz has received grant and research support and consultancy fees from AbbVie, Amgen, Biogen, Chugai, Eli Lilly, Grunenthal, GSK, Hexal, Janssen, MSD, Novartis, Pfizer, Roche and UCB. Dr. Styliani Tsiami did not declare a conflict of interest. Dr. Xenofon Baraliakos has received grant and research support and consultancy  fees from AbbVie, Amgen, Chugai, Galapagos, Hexal, Lilly, MSD, Novartis, Pfizer and UCB. Dr. Andreica has received research support, consultancy fees and honoraria from Abbvie, Amgen, BMS, Chugai, Janssen, Eli Lilly, MSD, Novartis, Pfizer, Sobi, Takkeda and UCB. Dr. Kiefer has received grant and research support and consultancy fees from AbbVie, BMS, Boehringer Ingelheim, Chugai, Eli Lilly, Galapagos, Janssen, MSD, Novartis, Pfizer, Roche and UCB. Dr. Braun has received  honoraria for talks, advisory boards, paid consultancies and grants for studies from Abbvie (Abbott), Amgen, Baxter, Biogen, BMS, Boehringer, Celgene, Celltrion, Centocor, Chugai, Hexal, Janssen, Lilly, Medac, MSD (Schering-Plough), Mylan, Mundipharma, Novartis, Pfizer (Wyeth, Hospira), Roche, Sanofi-Aventis and UCB.\n",
      "\n",
      "Andreica, Ioana\n",
      "Competing interests: The authors declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: Dr. Uta Kiltz has received grant and research support and consultancy fees from AbbVie, Amgen, Biogen, Chugai, Eli Lilly, Grunenthal, GSK, Hexal, Janssen, MSD, Novartis, Pfizer, Roche and UCB. Dr. Styliani Tsiami did not declare a conflict of interest. Dr. Xenofon Baraliakos has received grant and research support and consultancy  fees from AbbVie, Amgen, Chugai, Galapagos, Hexal, Lilly, MSD, Novartis, Pfizer and UCB. Dr. Ioana Andreica has received research support, consultancy fees and honoraria from Abbvie, Amgen, BMS, Chugai, Janssen, Eli Lilly, MSD, Novartis, Pfizer, Sobi, Takkeda and UCB. Dr. Kiefer has received grant and research support and consultancy fees from AbbVie, BMS, Boehringer Ingelheim, Chugai, Eli Lilly, Galapagos, Janssen, MSD, Novartis, Pfizer, Roche and UCB. Dr. Braun has received  honoraria for talks, advisory boards, paid consultancies and grants for studies from Abbvie (Abbott), Amgen, Baxter, Biogen, BMS, Boehringer, Celgene, Celltrion, Centocor, Chugai, Hexal, Janssen, Lilly, Medac, MSD (Schering-Plough), Mylan, Mundipharma, Novartis, Pfizer (Wyeth, Hospira), Roche, Sanofi-Aventis and UCB.\n",
      "\n",
      "Kiefer, David\n",
      "Competing interests: The authors declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: Dr. Uta Kiltz has received grant and research support and consultancy fees from AbbVie, Amgen, Biogen, Chugai, Eli Lilly, Grunenthal, GSK, Hexal, Janssen, MSD, Novartis, Pfizer, Roche and UCB. Dr. Styliani Tsiami did not declare a conflict of interest. Dr. Xenofon Baraliakos has received grant and research support and consultancy  fees from AbbVie, Amgen, Chugai, Galapagos, Hexal, Lilly, MSD, Novartis, Pfizer and UCB. Dr. Ioana Andreica has received research support, consultancy fees and honoraria from Abbvie, Amgen, BMS, Chugai, Janssen, Eli Lilly, MSD, Novartis, Pfizer, Sobi, Takkeda and UCB. Dr. David Kiefer has received grant and research support and consultancy fees from AbbVie, BMS, Boehringer Ingelheim, Chugai, Eli Lilly, Galapagos, Janssen, MSD, Novartis, Pfizer, Roche and UCB. Dr. Braun has received  honoraria for talks, advisory boards, paid consultancies and grants for studies from Abbvie (Abbott), Amgen, Baxter, Biogen, BMS, Boehringer, Celgene, Celltrion, Centocor, Chugai, Hexal, Janssen, Lilly, Medac, MSD (Schering-Plough), Mylan, Mundipharma, Novartis, Pfizer (Wyeth, Hospira), Roche, Sanofi-Aventis and UCB.\n",
      "\n",
      "Braun, Jurgen\n",
      "Competing interests: The authors declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: Dr. Uta Kiltz has received grant and research support and consultancy fees from AbbVie, Amgen, Biogen, Chugai, Eli Lilly, Grunenthal, GSK, Hexal, Janssen, MSD, Novartis, Pfizer, Roche and UCB. Dr. Styliani Tsiami did not declare a conflict of interest. Dr. Xenofon Baraliakos has received grant and research support and consultancy  fees from AbbVie, Amgen, Chugai, Galapagos, Hexal, Lilly, MSD, Novartis, Pfizer and UCB. Dr. Ioana Andreica has received research support, consultancy fees and honoraria from Abbvie, Amgen, BMS, Chugai, Janssen, Eli Lilly, MSD, Novartis, Pfizer, Sobi, Takkeda and UCB. Dr. David Kiefer has received grant and research support and consultancy fees from AbbVie, BMS, Boehringer Ingelheim, Chugai, Eli Lilly, Galapagos, Janssen, MSD, Novartis, Pfizer, Roche and UCB. Dr. Jurgen Braun has received  honoraria for talks, advisory boards, paid consultancies and grants for studies from Abbvie (Abbott), Amgen, Baxter, Biogen, BMS, Boehringer, Celgene, Celltrion, Centocor, Chugai, Hexal, Janssen, Lilly, Medac, MSD (Schering-Plough), Mylan, Mundipharma, Novartis, Pfizer (Wyeth, Hospira), Roche, Sanofi-Aventis and UCB.\n",
      "\n",
      "All authors have completed the ICMJE uniform disclosure form. The authors have no conflicts of interest to declare.\n",
      "\n",
      "All authors have completed the ICMJE uniform disclosure form. The authors have no conflicts of interest to declare.\n",
      "\n",
      "All authors have completed the ICMJE uniform disclosure form. The authors have no conflicts of interest to declare.\n",
      "\n",
      "All authors have completed the ICMJE uniform disclosure form. The authors have no conflicts of interest to declare.\n",
      "\n",
      "All authors have completed the ICMJE uniform disclosure form. The authors have no conflicts of interest to declare.\n",
      "\n",
      "All authors have completed the ICMJE uniform disclosure form. The authors have no conflicts of interest to declare.\n",
      "\n",
      "All authors have completed the ICMJE uniform disclosure form. The authors have no conflicts of interest to declare.\n",
      "\n",
      "All authors have completed the ICMJE uniform disclosure form. The authors have no conflicts of interest to declare.\n",
      "\n",
      "Fortune, Alice E.\n",
      "Conflict-of-interest statement: George Ampat, Jonathan M G Sims and Samantha J Rhodes are Directors/employees of Talita Cumi Ltd. Talita Cumi Ltd has a commercial relationship with Aetrex, Inc. 414 Alfred Avenue Teaneck, NJ 07666, USA. Alice E. Fortune has no conflict of interest.\n",
      "\n",
      "Sims, Jonathan M.G.\n",
      "Conflict-of-interest statement: George Ampat, Jonathan M.G. Sims and Samantha J Rhodes are Directors/employees of Talita Cumi Ltd. Talita Cumi Ltd has a commercial relationship with Aetrex, Inc. 414 Alfred Avenue Teaneck, NJ 07666, USA. Alice E. Fortune has no conflict of interest.\n",
      "\n",
      "Rhodes, Samantha J.\n",
      "Conflict-of-interest statement: George Ampat, Jonathan M.G. Sims and Samantha J. Rhodes are Directors/employees of Talita Cumi Ltd. Talita Cumi Ltd has a commercial relationship with Aetrex, Inc. 414 Alfred Avenue Teaneck, NJ 07666, USA. Alice E. Fortune has no conflict of interest.\n",
      "\n",
      "Ampat, George\n",
      "Conflict-of-interest statement: George Ampat, Jonathan M.G. Sims and Samantha J. Rhodes are Directors/employees of Talita Cumi Ltd. Talita Cumi Ltd has a commercial relationship with Aetrex, Inc. 414 Alfred Avenue Teaneck, NJ 07666, USA. Alice E. Fortune has no conflict of interest.\n",
      "\n",
      "Tachatos, Nikolaos\n",
      "Authors Nikolaos Tachatos, NSte, MZ, MM, and MS with the Product Development Group Zurich, ETH Zurich, declare that they have been involved in the development of each PDV presented in this study by actively testing several iterations and providing the  teams with feedback. No funding has been received by any of the teams associated  to the PDVs. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.\n",
      "\n",
      "Steffen, Nicola\n",
      "Authors Nikolaos Tachatos, Nicola Steffente, MZ, MM, and MS with the Product Development Group Zurich, ETH Zurich, declare that they have been involved in the development of each PDV presented in this study by actively testing several iterations and providing the  teams with feedback. No funding has been received by any of the teams associated  to the PDVs. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.\n",
      "\n",
      "Zander, Mark\n",
      "Authors Nikolaos Tachatos, Nicola Steffente, Mark Zander, MM, and MS with the Product Development Group Zurich, ETH Zurich, declare that they have been involved in the development of each PDV presented in this study by actively testing several iterations and providing the  teams with feedback. No funding has been received by any of the teams associated  to the PDVs. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.\n",
      "\n",
      "Stankovic, Nikola\n",
      "Authors Nikola Stankovicos Tachatos, Nicola Steffente, Mark Zander, MM, and MS with the Product Development Group Zurich, ETH Zurich, declare that they have been involved in the development of each PDV presented in this study by actively testing several iterations and providing the  teams with feedback. No funding has been received by any of the teams associated  to the PDVs. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.\n",
      "\n",
      "Meboldt, Mirko\n",
      "Authors Nikola Stankovicos Tachatos, Nicola Steffente, Mark Zander, Mirko Meboldt, and MS with the Product Development Group Zurich, ETH Zurich, declare that they have been involved in the development of each PDV presented in this study by actively testing several iterations and providing the  teams with feedback. No funding has been received by any of the teams associated  to the PDVs. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.\n",
      "\n",
      "Authors Nikola Stankovicos Tachatos, Nicola Steffente, Mark Zander, Mirko Meboldt, and MS with the Product Development Group Zurich, ETH Zurich, declare that they have been involved in the development of each PDV presented in this study by actively testing several iterations and providing the  teams with feedback. No funding has been received by any of the teams associated  to the PDVs. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.\n",
      "\n",
      "Authors Nikola Stankovicos Tachatos, Nicola Steffente, Mark Zander, Mirko Meboldt, and MS with the Product Development Group Zurich, ETH Zurich, declare that they have been involved in the development of each PDV presented in this study by actively testing several iterations and providing the  teams with feedback. No funding has been received by any of the teams associated  to the PDVs. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.\n",
      "\n",
      "Authors Nikola Stankovicos Tachatos, Nicola Steffente, Mark Zander, Mirko Meboldt, and MS with the Product Development Group Zurich, ETH Zurich, declare that they have been involved in the development of each PDV presented in this study by actively testing several iterations and providing the  teams with feedback. No funding has been received by any of the teams associated  to the PDVs. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.\n",
      "\n",
      "Castano-Bonilla, Tamara\n",
      "Tamara Castano-BonillaB. is a PhD candidate at Universidad Autonoma de Madrid (UAM). No other conflicts of interest were declared.\n",
      "\n",
      "Tamara Castano-BonillaB. is a PhD candidate at Universidad Autonoma de Madrid (UAM). No other conflicts of interest were declared.\n",
      "\n",
      "Tamara Castano-BonillaB. is a PhD candidate at Universidad Autonoma de Madrid (UAM). No other conflicts of interest were declared.\n",
      "\n",
      "Tamara Castano-BonillaB. is a PhD candidate at Universidad Autonoma de Madrid (UAM). No other conflicts of interest were declared.\n",
      "\n",
      "Tamara Castano-BonillaB. is a PhD candidate at Universidad Autonoma de Madrid (UAM). No other conflicts of interest were declared.\n",
      "\n",
      "Tamara Castano-BonillaB. is a PhD candidate at Universidad Autonoma de Madrid (UAM). No other conflicts of interest were declared.\n",
      "\n",
      "Tamara Castano-BonillaB. is a PhD candidate at Universidad Autonoma de Madrid (UAM). No other conflicts of interest were declared.\n",
      "\n",
      "Tamara Castano-BonillaB. is a PhD candidate at Universidad Autonoma de Madrid (UAM). No other conflicts of interest were declared.\n",
      "\n",
      "Tamara Castano-BonillaB. is a PhD candidate at Universidad Autonoma de Madrid (UAM). No other conflicts of interest were declared.\n",
      "\n",
      "Tamara Castano-BonillaB. is a PhD candidate at Universidad Autonoma de Madrid (UAM). No other conflicts of interest were declared.\n",
      "\n",
      "Tamara Castano-BonillaB. is a PhD candidate at Universidad Autonoma de Madrid (UAM). No other conflicts of interest were declared.\n",
      "\n",
      "Tamara Castano-BonillaB. is a PhD candidate at Universidad Autonoma de Madrid (UAM). No other conflicts of interest were declared.\n",
      "\n",
      "Tamara Castano-BonillaB. is a PhD candidate at Universidad Autonoma de Madrid (UAM). No other conflicts of interest were declared.\n",
      "\n",
      "Tamara Castano-BonillaB. is a PhD candidate at Universidad Autonoma de Madrid (UAM). No other conflicts of interest were declared.\n",
      "\n",
      "Tamara Castano-BonillaB. is a PhD candidate at Universidad Autonoma de Madrid (UAM). No other conflicts of interest were declared.\n",
      "\n",
      "Tamara Castano-BonillaB. is a PhD candidate at Universidad Autonoma de Madrid (UAM). No other conflicts of interest were declared.\n",
      "\n",
      "Tamara Castano-BonillaB. is a PhD candidate at Universidad Autonoma de Madrid (UAM). No other conflicts of interest were declared.\n",
      "\n",
      "Tamara Castano-BonillaB. is a PhD candidate at Universidad Autonoma de Madrid (UAM). No other conflicts of interest were declared.\n",
      "\n",
      "Tamara Castano-BonillaB. is a PhD candidate at Universidad Autonoma de Madrid (UAM). No other conflicts of interest were declared.\n",
      "\n",
      "Tamara Castano-BonillaB. is a PhD candidate at Universidad Autonoma de Madrid (UAM). No other conflicts of interest were declared.\n",
      "\n",
      "Tamara Castano-BonillaB. is a PhD candidate at Universidad Autonoma de Madrid (UAM). No other conflicts of interest were declared.\n",
      "\n",
      "Tamara Castano-BonillaB. is a PhD candidate at Universidad Autonoma de Madrid (UAM). No other conflicts of interest were declared.\n",
      "\n",
      "Tamara Castano-BonillaB. is a PhD candidate at Universidad Autonoma de Madrid (UAM). No other conflicts of interest were declared.\n",
      "\n",
      "Tamara Castano-BonillaB. is a PhD candidate at Universidad Autonoma de Madrid (UAM). No other conflicts of interest were declared.\n",
      "\n",
      "Tamara Castano-BonillaB. is a PhD candidate at Universidad Autonoma de Madrid (UAM). No other conflicts of interest were declared.\n",
      "\n",
      "Tamara Castano-BonillaB. is a PhD candidate at Universidad Autonoma de Madrid (UAM). No other conflicts of interest were declared.\n",
      "\n",
      "Tamara Castano-BonillaB. is a PhD candidate at Universidad Autonoma de Madrid (UAM). No other conflicts of interest were declared.\n",
      "\n",
      "Tamara Castano-BonillaB. is a PhD candidate at Universidad Autonoma de Madrid (UAM). No other conflicts of interest were declared.\n",
      "\n",
      "Tamara Castano-BonillaB. is a PhD candidate at Universidad Autonoma de Madrid (UAM). No other conflicts of interest were declared.\n",
      "\n",
      "Y.X., Y.W., S.W., and J.Z. were employed by the company Shanghai Biotecan Pharmaceuticals Co., Ltd. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could  be construed as a potential conflict of interest.\n",
      "\n",
      "Xu, Yue\n",
      "Yue Xu, Y.W., S.W., and J.Z. were employed by the company Shanghai Biotecan Pharmaceuticals Co., Ltd. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could  be construed as a potential conflict of interest.\n",
      "\n",
      "Yue Xu, Y.W., S.W., and J.Z. were employed by the company Shanghai Biotecan Pharmaceuticals Co., Ltd. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could  be construed as a potential conflict of interest.\n",
      "\n",
      "Yue Xu, Y.W., S.W., and J.Z. were employed by the company Shanghai Biotecan Pharmaceuticals Co., Ltd. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could  be construed as a potential conflict of interest.\n",
      "\n",
      "Wu, Shouxin\n",
      "Yue Xu, Y.W., Shouxin Wu, and J.Z. were employed by the company Shanghai Biotecan Pharmaceuticals Co., Ltd. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could  be construed as a potential conflict of interest.\n",
      "\n",
      "Wang, Yu\n",
      "Yue Xu, Yu Wang, Shouxin Wu, and J.Z. were employed by the company Shanghai Biotecan Pharmaceuticals Co., Ltd. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could  be construed as a potential conflict of interest.\n",
      "\n",
      "Zhao, Jiangman\n",
      "Yue Xu, Yu Wang, Shouxin Wu, and Jiangman Zhao were employed by the company Shanghai Biotecan Pharmaceuticals Co., Ltd. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could  be construed as a potential conflict of interest.\n",
      "\n",
      "Yue Xu, Yu Wang, Shouxin Wu, and Jiangman Zhao were employed by the company Shanghai Biotecan Pharmaceuticals Co., Ltd. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could  be construed as a potential conflict of interest.\n",
      "\n",
      "Yue Xu, Yu Wang, Shouxin Wu, and Jiangman Zhao were employed by the company Shanghai Biotecan Pharmaceuticals Co., Ltd. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could  be construed as a potential conflict of interest.\n",
      "\n",
      "This work has been funded by Korea government. The funders had no role in the design of the study; the collection, analysis, or interpretation of the data; the writing of the manuscript; or the decision to submit the manuscript for publication. The authors declare no financial competing interests or non-financial competing interests.\n",
      "\n",
      "This work has been funded by Korea government. The funders had no role in the design of the study; the collection, analysis, or interpretation of the data; the writing of the manuscript; or the decision to submit the manuscript for publication. The authors declare no financial competing interests or non-financial competing interests.\n",
      "\n",
      "This work has been funded by Korea government. The funders had no role in the design of the study; the collection, analysis, or interpretation of the data; the writing of the manuscript; or the decision to submit the manuscript for publication. The authors declare no financial competing interests or non-financial competing interests.\n",
      "\n",
      "This work has been funded by Korea government. The funders had no role in the design of the study; the collection, analysis, or interpretation of the data; the writing of the manuscript; or the decision to submit the manuscript for publication. The authors declare no financial competing interests or non-financial competing interests.\n",
      "\n",
      "This work has been funded by Korea government. The funders had no role in the design of the study; the collection, analysis, or interpretation of the data; the writing of the manuscript; or the decision to submit the manuscript for publication. The authors declare no financial competing interests or non-financial competing interests.\n",
      "\n",
      "This work has been funded by Korea government. The funders had no role in the design of the study; the collection, analysis, or interpretation of the data; the writing of the manuscript; or the decision to submit the manuscript for publication. The authors declare no financial competing interests or non-financial competing interests.\n",
      "\n",
      "This work has been funded by Korea government. The funders had no role in the design of the study; the collection, analysis, or interpretation of the data; the writing of the manuscript; or the decision to submit the manuscript for publication. The authors declare no financial competing interests or non-financial competing interests.\n",
      "\n",
      "This work has been funded by Korea government. The funders had no role in the design of the study; the collection, analysis, or interpretation of the data; the writing of the manuscript; or the decision to submit the manuscript for publication. The authors declare no financial competing interests or non-financial competing interests.\n",
      "\n",
      "This work has been funded by Korea government. The funders had no role in the design of the study; the collection, analysis, or interpretation of the data; the writing of the manuscript; or the decision to submit the manuscript for publication. The authors declare no financial competing interests or non-financial competing interests.\n",
      "\n",
      "This work has been funded by Korea government. The funders had no role in the design of the study; the collection, analysis, or interpretation of the data; the writing of the manuscript; or the decision to submit the manuscript for publication. The authors declare no financial competing interests or non-financial competing interests.\n",
      "\n",
      "Desole, Susanna\n",
      "RE: Honoraria for scientific lectures from Actelion, GSK, United Therapeutics, AstraZeneca, Novartis, Berlin Chemie, Boehringer Ingelheim, and OMT, and research funding from Boehringer Ingelheim and Actelion Germany. Susanna Desole, AO, DH, CFO, CK, FH,  AH, BS: No potential conflict of interest to report.\n",
      "\n",
      "Obst, Anne\n",
      "RE: Honoraria for scientific lectures from Actelion, GSK, United Therapeutics, AstraZeneca, Novartis, Berlin Chemie, Boehringer Ingelheim, and OMT, and research funding from Boehringer Ingelheim and Actelion Germany. Susanna Desole, Anne Obst, DH, CFO, CK, FH,  AH, BS: No potential conflict of interest to report.\n",
      "\n",
      "Habedank, Dirk\n",
      "RE: Honoraria for scientific lectures from Actelion, GSK, United Therapeutics, AstraZeneca, Novartis, Berlin Chemie, Boehringer Ingelheim, and OMT, and research funding from Boehringer Ingelheim and Actelion Germany. Susanna Desole, Anne Obst, Dirk Habedank, CFO, CK, FH,  AH, BS: No potential conflict of interest to report.\n",
      "\n",
      "Opitz, Christian F.\n",
      "RE: Honoraria for scientific lectures from Actelion, GSK, United Therapeutics, AstraZeneca, Novartis, Berlin Chemie, Boehringer Ingelheim, and OMT, and research funding from Boehringer Ingelheim and Actelion Germany. Susanna Desole, Anne Obst, Dirk Habedank, Christian F. Opitz, CK, FH,  AH, BS: No potential conflict of interest to report.\n",
      "\n",
      "Knaack, Christine\n",
      "RE: Honoraria for scientific lectures from Actelion, GSK, United Therapeutics, AstraZeneca, Novartis, Berlin Chemie, Boehringer Ingelheim, and OMT, and research funding from Boehringer Ingelheim and Actelion Germany. Susanna Desole, Anne Obst, Dirk Habedank, Christian F. Opitz, Christine Knaack, FH,  AH, BS: No potential conflict of interest to report.\n",
      "\n",
      "Hortien, Franziska\n",
      "RE: Honoraria for scientific lectures from Actelion, GSK, United Therapeutics, AstraZeneca, Novartis, Berlin Chemie, Boehringer Ingelheim, and OMT, and research funding from Boehringer Ingelheim and Actelion Germany. Susanna Desole, Anne Obst, Dirk Habedank, Christian F. Opitz, Christine Knaack, Franziska Hortien,  AH, BS: No potential conflict of interest to report.\n",
      "\n",
      "Heine, Alexander\n",
      "RE: Honoraria for scientific lectures from Actelion, GSK, United Therapeutics, AstraZeneca, Novartis, Berlin Chemie, Boehringer Ingelheim, and OMT, and research funding from Boehringer Ingelheim and Actelion Germany. Susanna Desole, Anne Obst, Dirk Habedank, Christian F. Opitz, Christine Knaack, Franziska Hortien,  Alexander Heine, BS: No potential conflict of interest to report.\n",
      "\n",
      "Stubbe, Beate\n",
      "RE: Honoraria for scientific lectures from Actelion, GSK, United Therapeutics, AstraZeneca, Novartis, Berlin Chemie, Boehringer Ingelheim, and OMT, and research funding from Boehringer Ingelheim and Actelion Germany. Susanna Desole, Anne Obst, Dirk Habedank, Christian F. Opitz, Christine Knaack, Franziska Hortien,  Alexander Heine, Beate Stubbe: No potential conflict of interest to report.\n",
      "\n",
      "Ewert, Ralf\n",
      "Ralf Ewert: Honoraria for scientific lectures from Actelion, GSK, United Therapeutics, AstraZeneca, Novartis, Berlin Chemie, Boehringer Ingelheim, and OMT, and research funding from Boehringer Ingelheim and Actelion Germany. Susanna Desole, Anne Obst, Dirk Habedank, Christian F. Opitz, Christine Knaack, Franziska Hortien,  Alexander Heine, Beate Stubbe: No potential conflict of interest to report.\n",
      "\n",
      "Conflict-of-interest statement: Dr. Bhat reports other from Novo Nordisk, other from Ipsen, grants from Paladin, grants from Natera, grants from Oncoustics, grants from MedoAI, grants from Lallemand, personal fees from Novartis, personal  fees from Lupin, outside the submitted work.\n",
      "\n",
      "Conflict-of-interest statement: Dr. Bhat reports other from Novo Nordisk, other from Ipsen, grants from Paladin, grants from Natera, grants from Oncoustics, grants from MedoAI, grants from Lallemand, personal fees from Novartis, personal  fees from Lupin, outside the submitted work.\n",
      "\n",
      "Conflict-of-interest statement: Dr. Bhat reports other from Novo Nordisk, other from Ipsen, grants from Paladin, grants from Natera, grants from Oncoustics, grants from MedoAI, grants from Lallemand, personal fees from Novartis, personal  fees from Lupin, outside the submitted work.\n",
      "\n",
      "Conflict-of-interest statement: Dr. Bhat reports other from Novo Nordisk, other from Ipsen, grants from Paladin, grants from Natera, grants from Oncoustics, grants from MedoAI, grants from Lallemand, personal fees from Novartis, personal  fees from Lupin, outside the submitted work.\n",
      "\n",
      "Conflict-of-interest statement: Dr. Bhat reports other from Novo Nordisk, other from Ipsen, grants from Paladin, grants from Natera, grants from Oncoustics, grants from MedoAI, grants from Lallemand, personal fees from Novartis, personal  fees from Lupin, outside the submitted work.\n",
      "\n",
      "Conflict-of-interest statement: Dr. Bhat reports other from Novo Nordisk, other from Ipsen, grants from Paladin, grants from Natera, grants from Oncoustics, grants from MedoAI, grants from Lallemand, personal fees from Novartis, personal  fees from Lupin, outside the submitted work.\n",
      "\n",
      "Conflict-of-interest statement: Dr. Bhat reports other from Novo Nordisk, other from Ipsen, grants from Paladin, grants from Natera, grants from Oncoustics, grants from MedoAI, grants from Lallemand, personal fees from Novartis, personal  fees from Lupin, outside the submitted work.\n",
      "\n",
      "Conflict-of-interest statement: Dr. Bhat reports other from Novo Nordisk, other from Ipsen, grants from Paladin, grants from Natera, grants from Oncoustics, grants from MedoAI, grants from Lallemand, personal fees from Novartis, personal  fees from Lupin, outside the submitted work.\n",
      "\n",
      "Conflict-of-interest statement: Dr. Bhat reports other from Novo Nordisk, other from Ipsen, grants from Paladin, grants from Natera, grants from Oncoustics, grants from MedoAI, grants from Lallemand, personal fees from Novartis, personal  fees from Lupin, outside the submitted work.\n",
      "\n",
      "Conflict-of-interest statement: Dr. Bhat reports other from Novo Nordisk, other from Ipsen, grants from Paladin, grants from Natera, grants from Oncoustics, grants from MedoAI, grants from Lallemand, personal fees from Novartis, personal  fees from Lupin, outside the submitted work.\n",
      "\n",
      "Conflict-of-interest statement: Dr. Bhat reports other from Novo Nordisk, other from Ipsen, grants from Paladin, grants from Natera, grants from Oncoustics, grants from MedoAI, grants from Lallemand, personal fees from Novartis, personal  fees from Lupin, outside the submitted work.\n",
      "\n",
      "Bhat, Mamatha\n",
      "Conflict-of-interest statement: Dr. Mamatha Bhat reports other from Novo Nordisk, other from Ipsen, grants from Paladin, grants from Natera, grants from Oncoustics, grants from MedoAI, grants from Lallemand, personal fees from Novartis, personal  fees from Lupin, outside the submitted work.\n",
      "\n",
      "Dr. Vaduganathan has received research grant support or served on advisory boards for American Regent, Amgen, AstraZeneca, Bayer AG, Baxter Healthcare, Boehringer  Ingelheim, Cytokinetics, Lexicon Pharmaceuticals, Novartis, Pharmacosmos, Relypsa, Roche Diagnostics, Sanofi, and Tricog Health; has speaker engagements with Boehringer Ingelheim, Novartis, and Roche Diagnostics; and participates on clinical trial committees for studies sponsored by Galmed, Novartis, Bayer AG, Occlutech, and Impulse Dynamics. Dr. Qamar reports receiving institutional grant  support from the NorthShore Auxiliary research scholar fund, Daiichi-Sankyo, American Heart Association, and fees for educational activities from the American College of Cardiology, Society for Vascular Medicine, Society for Cardiovascular  Angiography and Interventions, Janssen and Janssen, Pfizer, Medscape, and Clinical Exercise Physiology Association. Dr Pandey has served on the advisory board of Roche Diagnostics; has received nonfinancial support from Pfizer and Merck; and has received research support from the Texas Health Resources Clinical Scholarship, the Gilead Sciences Research Scholar Program, the National Institute on Aging Grants for Early Medical/Surgical Specialists' Transition to Aging Research (GEMSSTAR) Grant (1R03AG067960-01), Myovista, and Applied Therapeutics.  Dr Bhatt discloses the following relationships: Advisory Board: Boehringer Ingelheim, Cardax, CellProthera, Cereno Scientific, Elsevier Practice Update Cardiology, Janssen, Level Ex, Medscape Cardiology, MyoKardia, NirvaMed, Novo Nordisk, PhaseBio, PLx Pharma, Regado Biosciences, Stasys. Board of Directors: Boston VA Research Institute, Bristol Myers Squibb, Society of Cardiovascular Patient Care, TobeSoft. Inaugural Chair: American Heart Association Quality Oversight Committee. Data Monitoring Committees: Baim Institute for Clinical Research (formerly Harvard Clinical Research Institute, for the PORTICO trial, funded by St. Jude Medical, now Abbott), Boston Scientific (chair, PEITHO trial), Cleveland Clinic (including for the ExCEED trial, funded by Edwards), Contego Medical (chair, PERFORMANCE 2), Duke Clinical Research Institute, Mayo Clinic, Mount Sinai School of Medicine (for the ENVISAGE trial, funded by Daiichi Sankyo), Novartis, Population Health Research Institute. Honoraria: American College of Cardiology (senior associate editor, Clinical Trials and News, ACC.org; chair, ACC Accreditation Oversight Committee), Arnold and Porter law firm (work related to Sanofi/Bristol-Myers Squibb clopidogrel litigation), Baim Institute for Clinical Research (formerly Harvard Clinical Research Institute; RE-DUAL PCI clinical trial steering committee funded by Boehringer Ingelheim; AEGIS-II executive committee funded by CSL Behring), Belvoir Publications (editor in chief, Harvard Heart Letter), Canadian Medical and Surgical Knowledge Translation Research Group (clinical trial steering committees), Cowen and Company, Duke Clinical Research Institute (clinical trial steering committees, including for the PRONOUNCE trial, funded by Ferring Pharmaceuticals), HMP Global (editor in chief, Journal of Invasive Cardiology), Journal of the American College of Cardiology (guest editor, associate editor), K2P (co-chair, interdisciplinary curriculum), Level Ex, Medtelligence/ReachMD (CME steering committees), MJH Life Sciences, Piper Sandler, Population Health Research Institute (for the COMPASS operations committee, publications committee, steering committee, and USA national coleader, funded by Bayer), Slack Publications (chief medical editor, Cardiology Today's Intervention), Society of Cardiovascular Patient Care (secretary/treasurer), WebMD (CME steering committees). Other: Clinical Cardiology (deputy editor), NCDR-ACTION Registry Steering Committee (chair), VA CART Research and Publications Committee (chair). Research Funding: Abbott, Afimmune, Amarin, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Cardax, CellProthera, Cereno Scientific, Chiesi, CSL Behring, Eisai, Ethicon, Faraday Pharmaceuticals, Ferring Pharmaceuticals, Forest Laboratories, Fractyl, Garmin, HLS Therapeutics, Idorsia, Ironwood, Ischemix, Janssen, Javelin, Lexicon, Lilly, Medtronic, MyoKardia, NirvaMed, Novartis, Novo  Nordisk, Owkin, Pfizer, PhaseBio, PLx Pharma, Regeneron, Reid Hoffman Foundation, Roche, Sanofi, Stasys, Synaptic, The Medicines Company, 89Bio. Royalties: Elsevier (editor, Cardiovascular Intervention: A Companion to Braunwald's Heart Disease). Site Coinvestigator: Abbott, Biotronik, Boston Scientific, CSI, St. Jude Medical (now Abbott), Philips, Svelte. Trustee: American College of Cardiology. Unfunded Research: FlowCo, Merck, Takeda. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.\n",
      "\n",
      "Vaduganathan, Muthiah\n",
      "Dr. Muthiah Vaduganathan has received research grant support or served on advisory boards for American Regent, Amgen, AstraZeneca, Bayer AG, Baxter Healthcare, Boehringer  Ingelheim, Cytokinetics, Lexicon Pharmaceuticals, Novartis, Pharmacosmos, Relypsa, Roche Diagnostics, Sanofi, and Tricog Health; has speaker engagements with Boehringer Ingelheim, Novartis, and Roche Diagnostics; and participates on clinical trial committees for studies sponsored by Galmed, Novartis, Bayer AG, Occlutech, and Impulse Dynamics. Dr. Qamar reports receiving institutional grant  support from the NorthShore Auxiliary research scholar fund, Daiichi-Sankyo, American Heart Association, and fees for educational activities from the American College of Cardiology, Society for Vascular Medicine, Society for Cardiovascular  Angiography and Interventions, Janssen and Janssen, Pfizer, Medscape, and Clinical Exercise Physiology Association. Dr Pandey has served on the advisory board of Roche Diagnostics; has received nonfinancial support from Pfizer and Merck; and has received research support from the Texas Health Resources Clinical Scholarship, the Gilead Sciences Research Scholar Program, the National Institute on Aging Grants for Early Medical/Surgical Specialists' Transition to Aging Research (GEMSSTAR) Grant (1R03AG067960-01), Myovista, and Applied Therapeutics.  Dr Bhatt discloses the following relationships: Advisory Board: Boehringer Ingelheim, Cardax, CellProthera, Cereno Scientific, Elsevier Practice Update Cardiology, Janssen, Level Ex, Medscape Cardiology, MyoKardia, NirvaMed, Novo Nordisk, PhaseBio, PLx Pharma, Regado Biosciences, Stasys. Board of Directors: Boston VA Research Institute, Bristol Myers Squibb, Society of Cardiovascular Patient Care, TobeSoft. Inaugural Chair: American Heart Association Quality Oversight Committee. Data Monitoring Committees: Baim Institute for Clinical Research (formerly Harvard Clinical Research Institute, for the PORTICO trial, funded by St. Jude Medical, now Abbott), Boston Scientific (chair, PEITHO trial), Cleveland Clinic (including for the ExCEED trial, funded by Edwards), Contego Medical (chair, PERFORMANCE 2), Duke Clinical Research Institute, Mayo Clinic, Mount Sinai School of Medicine (for the ENVISAGE trial, funded by Daiichi Sankyo), Novartis, Population Health Research Institute. Honoraria: American College of Cardiology (senior associate editor, Clinical Trials and News, ACC.org; chair, ACC Accreditation Oversight Committee), Arnold and Porter law firm (work related to Sanofi/Bristol-Myers Squibb clopidogrel litigation), Baim Institute for Clinical Research (formerly Harvard Clinical Research Institute; RE-DUAL PCI clinical trial steering committee funded by Boehringer Ingelheim; AEGIS-II executive committee funded by CSL Behring), Belvoir Publications (editor in chief, Harvard Heart Letter), Canadian Medical and Surgical Knowledge Translation Research Group (clinical trial steering committees), Cowen and Company, Duke Clinical Research Institute (clinical trial steering committees, including for the PRONOUNCE trial, funded by Ferring Pharmaceuticals), HMP Global (editor in chief, Journal of Invasive Cardiology), Journal of the American College of Cardiology (guest editor, associate editor), K2P (co-chair, interdisciplinary curriculum), Level Ex, Medtelligence/ReachMD (CME steering committees), MJH Life Sciences, Piper Sandler, Population Health Research Institute (for the COMPASS operations committee, publications committee, steering committee, and USA national coleader, funded by Bayer), Slack Publications (chief medical editor, Cardiology Today's Intervention), Society of Cardiovascular Patient Care (secretary/treasurer), WebMD (CME steering committees). Other: Clinical Cardiology (deputy editor), NCDR-ACTION Registry Steering Committee (chair), VA CART Research and Publications Committee (chair). Research Funding: Abbott, Afimmune, Amarin, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Cardax, CellProthera, Cereno Scientific, Chiesi, CSL Behring, Eisai, Ethicon, Faraday Pharmaceuticals, Ferring Pharmaceuticals, Forest Laboratories, Fractyl, Garmin, HLS Therapeutics, Idorsia, Ironwood, Ischemix, Janssen, Javelin, Lexicon, Lilly, Medtronic, MyoKardia, NirvaMed, Novartis, Novo  Nordisk, Owkin, Pfizer, PhaseBio, PLx Pharma, Regeneron, Reid Hoffman Foundation, Roche, Sanofi, Stasys, Synaptic, The Medicines Company, 89Bio. Royalties: Elsevier (editor, Cardiovascular Intervention: A Companion to Braunwald's Heart Disease). Site Coinvestigator: Abbott, Biotronik, Boston Scientific, CSI, St. Jude Medical (now Abbott), Philips, Svelte. Trustee: American College of Cardiology. Unfunded Research: FlowCo, Merck, Takeda. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.\n",
      "\n",
      "Dr. Muthiah Vaduganathan has received research grant support or served on advisory boards for American Regent, Amgen, AstraZeneca, Bayer AG, Baxter Healthcare, Boehringer  Ingelheim, Cytokinetics, Lexicon Pharmaceuticals, Novartis, Pharmacosmos, Relypsa, Roche Diagnostics, Sanofi, and Tricog Health; has speaker engagements with Boehringer Ingelheim, Novartis, and Roche Diagnostics; and participates on clinical trial committees for studies sponsored by Galmed, Novartis, Bayer AG, Occlutech, and Impulse Dynamics. Dr. Qamar reports receiving institutional grant  support from the NorthShore Auxiliary research scholar fund, Daiichi-Sankyo, American Heart Association, and fees for educational activities from the American College of Cardiology, Society for Vascular Medicine, Society for Cardiovascular  Angiography and Interventions, Janssen and Janssen, Pfizer, Medscape, and Clinical Exercise Physiology Association. Dr Pandey has served on the advisory board of Roche Diagnostics; has received nonfinancial support from Pfizer and Merck; and has received research support from the Texas Health Resources Clinical Scholarship, the Gilead Sciences Research Scholar Program, the National Institute on Aging Grants for Early Medical/Surgical Specialists' Transition to Aging Research (GEMSSTAR) Grant (1R03AG067960-01), Myovista, and Applied Therapeutics.  Dr Bhatt discloses the following relationships: Advisory Board: Boehringer Ingelheim, Cardax, CellProthera, Cereno Scientific, Elsevier Practice Update Cardiology, Janssen, Level Ex, Medscape Cardiology, MyoKardia, NirvaMed, Novo Nordisk, PhaseBio, PLx Pharma, Regado Biosciences, Stasys. Board of Directors: Boston VA Research Institute, Bristol Myers Squibb, Society of Cardiovascular Patient Care, TobeSoft. Inaugural Chair: American Heart Association Quality Oversight Committee. Data Monitoring Committees: Baim Institute for Clinical Research (formerly Harvard Clinical Research Institute, for the PORTICO trial, funded by St. Jude Medical, now Abbott), Boston Scientific (chair, PEITHO trial), Cleveland Clinic (including for the ExCEED trial, funded by Edwards), Contego Medical (chair, PERFORMANCE 2), Duke Clinical Research Institute, Mayo Clinic, Mount Sinai School of Medicine (for the ENVISAGE trial, funded by Daiichi Sankyo), Novartis, Population Health Research Institute. Honoraria: American College of Cardiology (senior associate editor, Clinical Trials and News, ACC.org; chair, ACC Accreditation Oversight Committee), Arnold and Porter law firm (work related to Sanofi/Bristol-Myers Squibb clopidogrel litigation), Baim Institute for Clinical Research (formerly Harvard Clinical Research Institute; RE-DUAL PCI clinical trial steering committee funded by Boehringer Ingelheim; AEGIS-II executive committee funded by CSL Behring), Belvoir Publications (editor in chief, Harvard Heart Letter), Canadian Medical and Surgical Knowledge Translation Research Group (clinical trial steering committees), Cowen and Company, Duke Clinical Research Institute (clinical trial steering committees, including for the PRONOUNCE trial, funded by Ferring Pharmaceuticals), HMP Global (editor in chief, Journal of Invasive Cardiology), Journal of the American College of Cardiology (guest editor, associate editor), K2P (co-chair, interdisciplinary curriculum), Level Ex, Medtelligence/ReachMD (CME steering committees), MJH Life Sciences, Piper Sandler, Population Health Research Institute (for the COMPASS operations committee, publications committee, steering committee, and USA national coleader, funded by Bayer), Slack Publications (chief medical editor, Cardiology Today's Intervention), Society of Cardiovascular Patient Care (secretary/treasurer), WebMD (CME steering committees). Other: Clinical Cardiology (deputy editor), NCDR-ACTION Registry Steering Committee (chair), VA CART Research and Publications Committee (chair). Research Funding: Abbott, Afimmune, Amarin, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Cardax, CellProthera, Cereno Scientific, Chiesi, CSL Behring, Eisai, Ethicon, Faraday Pharmaceuticals, Ferring Pharmaceuticals, Forest Laboratories, Fractyl, Garmin, HLS Therapeutics, Idorsia, Ironwood, Ischemix, Janssen, Javelin, Lexicon, Lilly, Medtronic, MyoKardia, NirvaMed, Novartis, Novo  Nordisk, Owkin, Pfizer, PhaseBio, PLx Pharma, Regeneron, Reid Hoffman Foundation, Roche, Sanofi, Stasys, Synaptic, The Medicines Company, 89Bio. Royalties: Elsevier (editor, Cardiovascular Intervention: A Companion to Braunwald's Heart Disease). Site Coinvestigator: Abbott, Biotronik, Boston Scientific, CSI, St. Jude Medical (now Abbott), Philips, Svelte. Trustee: American College of Cardiology. Unfunded Research: FlowCo, Merck, Takeda. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.\n",
      "\n",
      "Dr. Muthiah Vaduganathan has received research grant support or served on advisory boards for American Regent, Amgen, AstraZeneca, Bayer AG, Baxter Healthcare, Boehringer  Ingelheim, Cytokinetics, Lexicon Pharmaceuticals, Novartis, Pharmacosmos, Relypsa, Roche Diagnostics, Sanofi, and Tricog Health; has speaker engagements with Boehringer Ingelheim, Novartis, and Roche Diagnostics; and participates on clinical trial committees for studies sponsored by Galmed, Novartis, Bayer AG, Occlutech, and Impulse Dynamics. Dr. Qamar reports receiving institutional grant  support from the NorthShore Auxiliary research scholar fund, Daiichi-Sankyo, American Heart Association, and fees for educational activities from the American College of Cardiology, Society for Vascular Medicine, Society for Cardiovascular  Angiography and Interventions, Janssen and Janssen, Pfizer, Medscape, and Clinical Exercise Physiology Association. Dr Pandey has served on the advisory board of Roche Diagnostics; has received nonfinancial support from Pfizer and Merck; and has received research support from the Texas Health Resources Clinical Scholarship, the Gilead Sciences Research Scholar Program, the National Institute on Aging Grants for Early Medical/Surgical Specialists' Transition to Aging Research (GEMSSTAR) Grant (1R03AG067960-01), Myovista, and Applied Therapeutics.  Dr Bhatt discloses the following relationships: Advisory Board: Boehringer Ingelheim, Cardax, CellProthera, Cereno Scientific, Elsevier Practice Update Cardiology, Janssen, Level Ex, Medscape Cardiology, MyoKardia, NirvaMed, Novo Nordisk, PhaseBio, PLx Pharma, Regado Biosciences, Stasys. Board of Directors: Boston VA Research Institute, Bristol Myers Squibb, Society of Cardiovascular Patient Care, TobeSoft. Inaugural Chair: American Heart Association Quality Oversight Committee. Data Monitoring Committees: Baim Institute for Clinical Research (formerly Harvard Clinical Research Institute, for the PORTICO trial, funded by St. Jude Medical, now Abbott), Boston Scientific (chair, PEITHO trial), Cleveland Clinic (including for the ExCEED trial, funded by Edwards), Contego Medical (chair, PERFORMANCE 2), Duke Clinical Research Institute, Mayo Clinic, Mount Sinai School of Medicine (for the ENVISAGE trial, funded by Daiichi Sankyo), Novartis, Population Health Research Institute. Honoraria: American College of Cardiology (senior associate editor, Clinical Trials and News, ACC.org; chair, ACC Accreditation Oversight Committee), Arnold and Porter law firm (work related to Sanofi/Bristol-Myers Squibb clopidogrel litigation), Baim Institute for Clinical Research (formerly Harvard Clinical Research Institute; RE-DUAL PCI clinical trial steering committee funded by Boehringer Ingelheim; AEGIS-II executive committee funded by CSL Behring), Belvoir Publications (editor in chief, Harvard Heart Letter), Canadian Medical and Surgical Knowledge Translation Research Group (clinical trial steering committees), Cowen and Company, Duke Clinical Research Institute (clinical trial steering committees, including for the PRONOUNCE trial, funded by Ferring Pharmaceuticals), HMP Global (editor in chief, Journal of Invasive Cardiology), Journal of the American College of Cardiology (guest editor, associate editor), K2P (co-chair, interdisciplinary curriculum), Level Ex, Medtelligence/ReachMD (CME steering committees), MJH Life Sciences, Piper Sandler, Population Health Research Institute (for the COMPASS operations committee, publications committee, steering committee, and USA national coleader, funded by Bayer), Slack Publications (chief medical editor, Cardiology Today's Intervention), Society of Cardiovascular Patient Care (secretary/treasurer), WebMD (CME steering committees). Other: Clinical Cardiology (deputy editor), NCDR-ACTION Registry Steering Committee (chair), VA CART Research and Publications Committee (chair). Research Funding: Abbott, Afimmune, Amarin, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Cardax, CellProthera, Cereno Scientific, Chiesi, CSL Behring, Eisai, Ethicon, Faraday Pharmaceuticals, Ferring Pharmaceuticals, Forest Laboratories, Fractyl, Garmin, HLS Therapeutics, Idorsia, Ironwood, Ischemix, Janssen, Javelin, Lexicon, Lilly, Medtronic, MyoKardia, NirvaMed, Novartis, Novo  Nordisk, Owkin, Pfizer, PhaseBio, PLx Pharma, Regeneron, Reid Hoffman Foundation, Roche, Sanofi, Stasys, Synaptic, The Medicines Company, 89Bio. Royalties: Elsevier (editor, Cardiovascular Intervention: A Companion to Braunwald's Heart Disease). Site Coinvestigator: Abbott, Biotronik, Boston Scientific, CSI, St. Jude Medical (now Abbott), Philips, Svelte. Trustee: American College of Cardiology. Unfunded Research: FlowCo, Merck, Takeda. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.\n",
      "\n",
      "Hendrickson, Michael J.\n",
      "Dr. Muthiah Vaduganathan has received research grant support or served on advisory boards for American Regent, Amgen, AstraZeneca, Bayer AG, Baxter Healthcare, Boehringer  Ingelheim, Cytokinetics, Lexicon Pharmaceuticals, Novartis, Pharmacosmos, Relypsa, Roche Diagnostics, Sanofi, and Tricog Health; has speaker engagements with Boehringer Ingelheim, Novartis, and Roche Diagnostics; and participates on clinical trial committees for studies sponsored by Galmed, Novartis, Bayer AG, Occlutech, and Impulse Dynamics. Dr. Qamar reports receiving institutional grant  support from the NorthShore Auxiliary research scholar fund, Daiichi-Sankyo, American Heart Association, and fees for educational activities from the American College of Cardiology, Society for Vascular Medicine, Society for Cardiovascular  Angiography and Interventions, Janssen and Janssen, Pfizer, Medscape, and Clinical Exercise Physiology Association. Dr Pandey has served on the advisory board of Roche Diagnostics; has received nonfinancial support from Pfizer and Merck; and has received research support from the Texas Health Resources Clinical Scholarship, the Gilead Sciences Research Scholar Program, the National Institute on Aging Grants for Early Medical/Surgical Specialists' Transition to Aging Research (GEMSSTAR) Grant (1R03AG067960-01), Myovista, and Applied Therapeutics.  Dr Bhatt discloses the following relationships: Advisory Board: Boehringer Ingelheim, Cardax, CellProthera, Cereno Scientific, Elsevier Practice Update Cardiology, Janssen, Level Ex, Medscape Cardiology, MyoKardia, NirvaMed, Novo Nordisk, PhaseBio, PLx Pharma, Regado Biosciences, Stasys. Board of Directors: Boston VA Research Institute, Bristol Myers Squibb, Society of Cardiovascular Patient Care, TobeSoft. Inaugural Chair: American Heart Association Quality Oversight Committee. Data Monitoring Committees: Baim Institute for Clinical Research (formerly Harvard Clinical Research Institute, for the PORTICO trial, funded by St. Jude Medical, now Abbott), Boston Scientific (chair, PEITHO trial), Cleveland Clinic (including for the ExCEED trial, funded by Edwards), Contego Medical (chair, PERFORMANCE 2), Duke Clinical Research Institute, Mayo Clinic, Mount Sinai School of Medicine (for the ENVISAGE trial, funded by Daiichi Sankyo), Novartis, Population Health Research Institute. Honoraria: American College of Cardiology (senior associate editor, Clinical Trials and News, ACC.org; chair, ACC Accreditation Oversight Committee), Arnold and Porter law firm (work related to Sanofi/Bristol-Myers Squibb clopidogrel litigation), Baim Institute for Clinical Research (formerly Harvard Clinical Research Institute; RE-DUAL PCI clinical trial steering committee funded by Boehringer Ingelheim; AEGIS-II executive committee funded by CSL Behring), Belvoir Publications (editor in chief, Harvard Heart Letter), Canadian Medical and Surgical Knowledge Translation Research Group (clinical trial steering committees), Cowen and Company, Duke Clinical Research Institute (clinical trial steering committees, including for the PRONOUNCE trial, funded by Ferring Pharmaceuticals), HMP Global (editor in chief, Journal of Invasive Cardiology), Journal of the American College of Cardiology (guest editor, associate editor), K2P (co-chair, interdisciplinary curriculum), Level Ex, Medtelligence/ReachMD (CME steering committees), Michael J. Hendrickson Life Sciences, Piper Sandler, Population Health Research Institute (for the COMPASS operations committee, publications committee, steering committee, and USA national coleader, funded by Bayer), Slack Publications (chief medical editor, Cardiology Today's Intervention), Society of Cardiovascular Patient Care (secretary/treasurer), WebMD (CME steering committees). Other: Clinical Cardiology (deputy editor), NCDR-ACTION Registry Steering Committee (chair), VA CART Research and Publications Committee (chair). Research Funding: Abbott, Afimmune, Amarin, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Cardax, CellProthera, Cereno Scientific, Chiesi, CSL Behring, Eisai, Ethicon, Faraday Pharmaceuticals, Ferring Pharmaceuticals, Forest Laboratories, Fractyl, Garmin, HLS Therapeutics, Idorsia, Ironwood, Ischemix, Janssen, Javelin, Lexicon, Lilly, Medtronic, MyoKardia, NirvaMed, Novartis, Novo  Nordisk, Owkin, Pfizer, PhaseBio, PLx Pharma, Regeneron, Reid Hoffman Foundation, Roche, Sanofi, Stasys, Synaptic, The Medicines Company, 89Bio. Royalties: Elsevier (editor, Cardiovascular Intervention: A Companion to Braunwald's Heart Disease). Site Coinvestigator: Abbott, Biotronik, Boston Scientific, CSI, St. Jude Medical (now Abbott), Philips, Svelte. Trustee: American College of Cardiology. Unfunded Research: FlowCo, Merck, Takeda. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.\n",
      "\n",
      "Qamar, Arman\n",
      "Dr. Muthiah Vaduganathan has received research grant support or served on advisory boards for American Regent, Amgen, AstraZeneca, Bayer AG, Baxter Healthcare, Boehringer  Ingelheim, Cytokinetics, Lexicon Pharmaceuticals, Novartis, Pharmacosmos, Relypsa, Roche Diagnostics, Sanofi, and Tricog Health; has speaker engagements with Boehringer Ingelheim, Novartis, and Roche Diagnostics; and participates on clinical trial committees for studies sponsored by Galmed, Novartis, Bayer AG, Occlutech, and Impulse Dynamics. Dr. Arman Qamar reports receiving institutional grant  support from the NorthShore Auxiliary research scholar fund, Daiichi-Sankyo, American Heart Association, and fees for educational activities from the American College of Cardiology, Society for Vascular Medicine, Society for Cardiovascular  Angiography and Interventions, Janssen and Janssen, Pfizer, Medscape, and Clinical Exercise Physiology Association. Dr Pandey has served on the advisory board of Roche Diagnostics; has received nonfinancial support from Pfizer and Merck; and has received research support from the Texas Health Resources Clinical Scholarship, the Gilead Sciences Research Scholar Program, the National Institute on Aging Grants for Early Medical/Surgical Specialists' Transition to Aging Research (GEMSSTAR) Grant (1R03AG067960-01), Myovista, and Applied Therapeutics.  Dr Bhatt discloses the following relationships: Advisory Board: Boehringer Ingelheim, Cardax, CellProthera, Cereno Scientific, Elsevier Practice Update Cardiology, Janssen, Level Ex, Medscape Cardiology, MyoKardia, NirvaMed, Novo Nordisk, PhaseBio, PLx Pharma, Regado Biosciences, Stasys. Board of Directors: Boston VA Research Institute, Bristol Myers Squibb, Society of Cardiovascular Patient Care, TobeSoft. Inaugural Chair: American Heart Association Quality Oversight Committee. Data Monitoring Committees: Baim Institute for Clinical Research (formerly Harvard Clinical Research Institute, for the PORTICO trial, funded by St. Jude Medical, now Abbott), Boston Scientific (chair, PEITHO trial), Cleveland Clinic (including for the ExCEED trial, funded by Edwards), Contego Medical (chair, PERFORMANCE 2), Duke Clinical Research Institute, Mayo Clinic, Mount Sinai School of Medicine (for the ENVISAGE trial, funded by Daiichi Sankyo), Novartis, Population Health Research Institute. Honoraria: American College of Cardiology (senior associate editor, Clinical Trials and News, ACC.org; chair, ACC Accreditation Oversight Committee), Arnold and Porter law firm (work related to Sanofi/Bristol-Myers Squibb clopidogrel litigation), Baim Institute for Clinical Research (formerly Harvard Clinical Research Institute; RE-DUAL PCI clinical trial steering committee funded by Boehringer Ingelheim; AEGIS-II executive committee funded by CSL Behring), Belvoir Publications (editor in chief, Harvard Heart Letter), Canadian Medical and Surgical Knowledge Translation Research Group (clinical trial steering committees), Cowen and Company, Duke Clinical Research Institute (clinical trial steering committees, including for the PRONOUNCE trial, funded by Ferring Pharmaceuticals), HMP Global (editor in chief, Journal of Invasive Cardiology), Journal of the American College of Cardiology (guest editor, associate editor), K2P (co-chair, interdisciplinary curriculum), Level Ex, Medtelligence/ReachMD (CME steering committees), Michael J. Hendrickson Life Sciences, Piper Sandler, Population Health Research Institute (for the COMPASS operations committee, publications committee, steering committee, and USA national coleader, funded by Bayer), Slack Publications (chief medical editor, Cardiology Today's Intervention), Society of Cardiovascular Patient Care (secretary/treasurer), WebMD (CME steering committees). Other: Clinical Cardiology (deputy editor), NCDR-ACTION Registry Steering Committee (chair), VA CART Research and Publications Committee (chair). Research Funding: Abbott, Afimmune, Amarin, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Cardax, CellProthera, Cereno Scientific, Chiesi, CSL Behring, Eisai, Ethicon, Faraday Pharmaceuticals, Ferring Pharmaceuticals, Forest Laboratories, Fractyl, Garmin, HLS Therapeutics, Idorsia, Ironwood, Ischemix, Janssen, Javelin, Lexicon, Lilly, Medtronic, MyoKardia, NirvaMed, Novartis, Novo  Nordisk, Owkin, Pfizer, PhaseBio, PLx Pharma, Regeneron, Reid Hoffman Foundation, Roche, Sanofi, Stasys, Synaptic, The Medicines Company, 89Bio. Royalties: Elsevier (editor, Cardiovascular Intervention: A Companion to Braunwald's Heart Disease). Site Coinvestigator: Abbott, Biotronik, Boston Scientific, CSI, St. Jude Medical (now Abbott), Philips, Svelte. Trustee: American College of Cardiology. Unfunded Research: FlowCo, Merck, Takeda. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.\n",
      "\n",
      "Arora, Sameer\n",
      "Dr. Muthiah Vaduganathan has received research grant support or served on advisory boards for American Regent, Amgen, AstraZeneca, Bayer AG, Baxter Healthcare, Boehringer  Ingelheim, Cytokinetics, Lexicon Pharmaceuticals, Novartis, Pharmacosmos, Relypsa, Roche Diagnostics, Sanofi, and Tricog Health; has speaker engagements with Boehringer Ingelheim, Novartis, and Roche Diagnostics; and participates on clinical trial committees for studies sponsored by Galmed, Novartis, Bayer AG, Occlutech, and Impulse Dynamics. Dr. Arman Qamar reports receiving institutional grant  support from the NorthShore Auxiliary research scholar fund, Daiichi-Sankyo, American Heart Association, and fees for educational activities from the American College of Cardiology, Society for Vascular Medicine, Society for Cardiovascular  Angiography and Interventions, Janssen and Janssen, Pfizer, Medscape, and Clinical Exercise Physiology Association. Dr Pandey has served on the advisory board of Roche Diagnostics; has received nonfinancial support from Pfizer and Merck; and has received research support from the Texas Health Resources Clinical Scholarship, the Gilead Sciences Research Scholar Program, the National Institute on Aging Grants for Early Medical/Surgical Specialists' Transition to Aging Research (GEMSSTAR) Grant (1R03AG067960-01), Myovista, and Applied Therapeutics.  Dr Bhatt discloses the following relationships: Advisory Board: Boehringer Ingelheim, Cardax, CellProthera, Cereno Scientific, Elsevier Practice Update Cardiology, Janssen, Level Ex, Medscape Cardiology, MyoKardia, NirvaMed, Novo Nordisk, PhaseBio, PLx Pharma, Regado Biosciences, Stasys. Board of Directors: Boston VA Research Institute, Bristol Myers Squibb, Society of Cardiovascular Patient Care, TobeSoft. Inaugural Chair: American Heart Association Quality Oversight Committee. Data Monitoring Committees: Baim Institute for Clinical Research (formerly Harvard Clinical Research Institute, for the PORTICO trial, funded by St. Jude Medical, now Abbott), Boston Scientific (chair, PEITHO trial), Cleveland Clinic (including for the ExCEED trial, funded by Edwards), Contego Medical (chair, PERFORMANCE 2), Duke Clinical Research Institute, Mayo Clinic, Mount Sinai School of Medicine (for the ENVISameer AroraGE trial, funded by Daiichi Sankyo), Novartis, Population Health Research Institute. Honoraria: American College of Cardiology (senior associate editor, Clinical Trials and News, ACC.org; chair, ACC Accreditation Oversight Committee), Arnold and Porter law firm (work related to Sanofi/Bristol-Myers Squibb clopidogrel litigation), Baim Institute for Clinical Research (formerly Harvard Clinical Research Institute; RE-DUAL PCI clinical trial steering committee funded by Boehringer Ingelheim; AEGIS-II executive committee funded by CSL Behring), Belvoir Publications (editor in chief, Harvard Heart Letter), Canadian Medical and Surgical Knowledge Translation Research Group (clinical trial steering committees), Cowen and Company, Duke Clinical Research Institute (clinical trial steering committees, including for the PRONOUNCE trial, funded by Ferring Pharmaceuticals), HMP Global (editor in chief, Journal of Invasive Cardiology), Journal of the American College of Cardiology (guest editor, associate editor), K2P (co-chair, interdisciplinary curriculum), Level Ex, Medtelligence/ReachMD (CME steering committees), Michael J. Hendrickson Life Sciences, Piper Sandler, Population Health Research Institute (for the COMPASS operations committee, publications committee, steering committee, and USameer Arora national coleader, funded by Bayer), Slack Publications (chief medical editor, Cardiology Today's Intervention), Society of Cardiovascular Patient Care (secretary/treasurer), WebMD (CME steering committees). Other: Clinical Cardiology (deputy editor), NCDR-ACTION Registry Steering Committee (chair), VA CART Research and Publications Committee (chair). Research Funding: Abbott, Afimmune, Amarin, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Cardax, CellProthera, Cereno Scientific, Chiesi, CSL Behring, Eisai, Ethicon, Faraday Pharmaceuticals, Ferring Pharmaceuticals, Forest Laboratories, Fractyl, Garmin, HLS Therapeutics, Idorsia, Ironwood, Ischemix, Janssen, Javelin, Lexicon, Lilly, Medtronic, MyoKardia, NirvaMed, Novartis, Novo  Nordisk, Owkin, Pfizer, PhaseBio, PLx Pharma, Regeneron, Reid Hoffman Foundation, Roche, Sanofi, Stasys, Synaptic, The Medicines Company, 89Bio. Royalties: Elsevier (editor, Cardiovascular Intervention: A Companion to Braunwald's Heart Disease). Site Coinvestigator: Abbott, Biotronik, Boston Scientific, CSI, St. Jude Medical (now Abbott), Philips, Svelte. Trustee: American College of Cardiology. Unfunded Research: FlowCo, Merck, Takeda. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.\n",
      "\n",
      "Pandey, Ambarish\n",
      "Dr. Muthiah Vaduganathan has received research grant support or served on advisory boards for American Regent, Amgen, AstraZeneca, Bayer AG, Baxter Healthcare, Boehringer  Ingelheim, Cytokinetics, Lexicon Pharmaceuticals, Novartis, Pharmacosmos, Relypsa, Roche Diagnostics, Sanofi, and Tricog Health; has speaker engagements with Boehringer Ingelheim, Novartis, and Roche Diagnostics; and participates on clinical trial committees for studies sponsored by Galmed, Novartis, Bayer AG, Occlutech, and Impulse Dynamics. Dr. Arman Qamar reports receiving institutional grant  support from the NorthShore Auxiliary research scholar fund, Daiichi-Sankyo, American Heart Association, and fees for educational activities from the American College of Cardiology, Society for Vascular Medicine, Society for Cardiovascular  Angiography and Interventions, Janssen and Janssen, Pfizer, Medscape, and Clinical Exercise Physiology Association. Dr Ambarish Pandey has served on the advisory board of Roche Diagnostics; has received nonfinancial support from Pfizer and Merck; and has received research support from the Texas Health Resources Clinical Scholarship, the Gilead Sciences Research Scholar Program, the National Institute on Aging Grants for Early Medical/Surgical Specialists' Transition to Aging Research (GEMSSTAR) Grant (1R03AG067960-01), Myovista, and Applied Therapeutics.  Dr Bhatt discloses the following relationships: Advisory Board: Boehringer Ingelheim, Cardax, CellProthera, Cereno Scientific, Elsevier Practice Update Cardiology, Janssen, Level Ex, Medscape Cardiology, MyoKardia, NirvaMed, Novo Nordisk, PhaseBio, PLx Pharma, Regado Biosciences, Stasys. Board of Directors: Boston VA Research Institute, Bristol Myers Squibb, Society of Cardiovascular Patient Care, TobeSoft. Inaugural Chair: American Heart Association Quality Oversight Committee. Data Monitoring Committees: Baim Institute for Clinical Research (formerly Harvard Clinical Research Institute, for the PORTICO trial, funded by St. Jude Medical, now Abbott), Boston Scientific (chair, PEITHO trial), Cleveland Clinic (including for the ExCEED trial, funded by Edwards), Contego Medical (chair, PERFORMANCE 2), Duke Clinical Research Institute, Mayo Clinic, Mount Sinai School of Medicine (for the ENVISameer AroraGE trial, funded by Daiichi Sankyo), Novartis, Population Health Research Institute. Honoraria: American College of Cardiology (senior associate editor, Clinical Trials and News, ACC.org; chair, ACC Accreditation Oversight Committee), Arnold and Porter law firm (work related to Sanofi/Bristol-Myers Squibb clopidogrel litigation), Baim Institute for Clinical Research (formerly Harvard Clinical Research Institute; RE-DUAL PCI clinical trial steering committee funded by Boehringer Ingelheim; AEGIS-II executive committee funded by CSL Behring), Belvoir Publications (editor in chief, Harvard Heart Letter), Canadian Medical and Surgical Knowledge Translation Research Group (clinical trial steering committees), Cowen and Company, Duke Clinical Research Institute (clinical trial steering committees, including for the PRONOUNCE trial, funded by Ferring Pharmaceuticals), HMP Global (editor in chief, Journal of Invasive Cardiology), Journal of the American College of Cardiology (guest editor, associate editor), K2P (co-chair, interdisciplinary curriculum), Level Ex, Medtelligence/ReachMD (CME steering committees), Michael J. Hendrickson Life Sciences, Piper Sandler, Population Health Research Institute (for the COMPASS operations committee, publications committee, steering committee, and USameer Arora national coleader, funded by Bayer), Slack Publications (chief medical editor, Cardiology Today's Intervention), Society of Cardiovascular Patient Care (secretary/treasurer), WebMD (CME steering committees). Other: Clinical Cardiology (deputy editor), NCDR-ACTION Registry Steering Committee (chair), VA CART Research and Publications Committee (chair). Research Funding: Abbott, Afimmune, Amarin, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Cardax, CellProthera, Cereno Scientific, Chiesi, CSL Behring, Eisai, Ethicon, Faraday Pharmaceuticals, Ferring Pharmaceuticals, Forest Laboratories, Fractyl, Garmin, HLS Therapeutics, Idorsia, Ironwood, Ischemix, Janssen, Javelin, Lexicon, Lilly, Medtronic, MyoKardia, NirvaMed, Novartis, Novo  Nordisk, Owkin, Pfizer, PhaseBio, PLx Pharma, Regeneron, Reid Hoffman Foundation, Roche, Sanofi, Stasys, Synaptic, The Medicines Company, 89Bio. Royalties: Elsevier (editor, Cardiovascular Intervention: A Companion to Braunwald's Heart Disease). Site Coinvestigator: Abbott, Biotronik, Boston Scientific, CSI, St. Jude Medical (now Abbott), Philips, Svelte. Trustee: American College of Cardiology. Unfunded Research: FlowCo, Merck, Takeda. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.\n",
      "\n",
      "Dr. Muthiah Vaduganathan has received research grant support or served on advisory boards for American Regent, Amgen, AstraZeneca, Bayer AG, Baxter Healthcare, Boehringer  Ingelheim, Cytokinetics, Lexicon Pharmaceuticals, Novartis, Pharmacosmos, Relypsa, Roche Diagnostics, Sanofi, and Tricog Health; has speaker engagements with Boehringer Ingelheim, Novartis, and Roche Diagnostics; and participates on clinical trial committees for studies sponsored by Galmed, Novartis, Bayer AG, Occlutech, and Impulse Dynamics. Dr. Arman Qamar reports receiving institutional grant  support from the NorthShore Auxiliary research scholar fund, Daiichi-Sankyo, American Heart Association, and fees for educational activities from the American College of Cardiology, Society for Vascular Medicine, Society for Cardiovascular  Angiography and Interventions, Janssen and Janssen, Pfizer, Medscape, and Clinical Exercise Physiology Association. Dr Ambarish Pandey has served on the advisory board of Roche Diagnostics; has received nonfinancial support from Pfizer and Merck; and has received research support from the Texas Health Resources Clinical Scholarship, the Gilead Sciences Research Scholar Program, the National Institute on Aging Grants for Early Medical/Surgical Specialists' Transition to Aging Research (GEMSSTAR) Grant (1R03AG067960-01), Myovista, and Applied Therapeutics.  Dr Bhatt discloses the following relationships: Advisory Board: Boehringer Ingelheim, Cardax, CellProthera, Cereno Scientific, Elsevier Practice Update Cardiology, Janssen, Level Ex, Medscape Cardiology, MyoKardia, NirvaMed, Novo Nordisk, PhaseBio, PLx Pharma, Regado Biosciences, Stasys. Board of Directors: Boston VA Research Institute, Bristol Myers Squibb, Society of Cardiovascular Patient Care, TobeSoft. Inaugural Chair: American Heart Association Quality Oversight Committee. Data Monitoring Committees: Baim Institute for Clinical Research (formerly Harvard Clinical Research Institute, for the PORTICO trial, funded by St. Jude Medical, now Abbott), Boston Scientific (chair, PEITHO trial), Cleveland Clinic (including for the ExCEED trial, funded by Edwards), Contego Medical (chair, PERFORMANCE 2), Duke Clinical Research Institute, Mayo Clinic, Mount Sinai School of Medicine (for the ENVISameer AroraGE trial, funded by Daiichi Sankyo), Novartis, Population Health Research Institute. Honoraria: American College of Cardiology (senior associate editor, Clinical Trials and News, ACC.org; chair, ACC Accreditation Oversight Committee), Arnold and Porter law firm (work related to Sanofi/Bristol-Myers Squibb clopidogrel litigation), Baim Institute for Clinical Research (formerly Harvard Clinical Research Institute; RE-DUAL PCI clinical trial steering committee funded by Boehringer Ingelheim; AEGIS-II executive committee funded by CSL Behring), Belvoir Publications (editor in chief, Harvard Heart Letter), Canadian Medical and Surgical Knowledge Translation Research Group (clinical trial steering committees), Cowen and Company, Duke Clinical Research Institute (clinical trial steering committees, including for the PRONOUNCE trial, funded by Ferring Pharmaceuticals), HMP Global (editor in chief, Journal of Invasive Cardiology), Journal of the American College of Cardiology (guest editor, associate editor), K2P (co-chair, interdisciplinary curriculum), Level Ex, Medtelligence/ReachMD (CME steering committees), Michael J. Hendrickson Life Sciences, Piper Sandler, Population Health Research Institute (for the COMPASS operations committee, publications committee, steering committee, and USameer Arora national coleader, funded by Bayer), Slack Publications (chief medical editor, Cardiology Today's Intervention), Society of Cardiovascular Patient Care (secretary/treasurer), WebMD (CME steering committees). Other: Clinical Cardiology (deputy editor), NCDR-ACTION Registry Steering Committee (chair), VA CART Research and Publications Committee (chair). Research Funding: Abbott, Afimmune, Amarin, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Cardax, CellProthera, Cereno Scientific, Chiesi, CSL Behring, Eisai, Ethicon, Faraday Pharmaceuticals, Ferring Pharmaceuticals, Forest Laboratories, Fractyl, Garmin, HLS Therapeutics, Idorsia, Ironwood, Ischemix, Janssen, Javelin, Lexicon, Lilly, Medtronic, MyoKardia, NirvaMed, Novartis, Novo  Nordisk, Owkin, Pfizer, PhaseBio, PLx Pharma, Regeneron, Reid Hoffman Foundation, Roche, Sanofi, Stasys, Synaptic, The Medicines Company, 89Bio. Royalties: Elsevier (editor, Cardiovascular Intervention: A Companion to Braunwald's Heart Disease). Site Coinvestigator: Abbott, Biotronik, Boston Scientific, CSI, St. Jude Medical (now Abbott), Philips, Svelte. Trustee: American College of Cardiology. Unfunded Research: FlowCo, Merck, Takeda. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.\n",
      "\n",
      "Dr. Muthiah Vaduganathan has received research grant support or served on advisory boards for American Regent, Amgen, AstraZeneca, Bayer AG, Baxter Healthcare, Boehringer  Ingelheim, Cytokinetics, Lexicon Pharmaceuticals, Novartis, Pharmacosmos, Relypsa, Roche Diagnostics, Sanofi, and Tricog Health; has speaker engagements with Boehringer Ingelheim, Novartis, and Roche Diagnostics; and participates on clinical trial committees for studies sponsored by Galmed, Novartis, Bayer AG, Occlutech, and Impulse Dynamics. Dr. Arman Qamar reports receiving institutional grant  support from the NorthShore Auxiliary research scholar fund, Daiichi-Sankyo, American Heart Association, and fees for educational activities from the American College of Cardiology, Society for Vascular Medicine, Society for Cardiovascular  Angiography and Interventions, Janssen and Janssen, Pfizer, Medscape, and Clinical Exercise Physiology Association. Dr Ambarish Pandey has served on the advisory board of Roche Diagnostics; has received nonfinancial support from Pfizer and Merck; and has received research support from the Texas Health Resources Clinical Scholarship, the Gilead Sciences Research Scholar Program, the National Institute on Aging Grants for Early Medical/Surgical Specialists' Transition to Aging Research (GEMSSTAR) Grant (1R03AG067960-01), Myovista, and Applied Therapeutics.  Dr Bhatt discloses the following relationships: Advisory Board: Boehringer Ingelheim, Cardax, CellProthera, Cereno Scientific, Elsevier Practice Update Cardiology, Janssen, Level Ex, Medscape Cardiology, MyoKardia, NirvaMed, Novo Nordisk, PhaseBio, PLx Pharma, Regado Biosciences, Stasys. Board of Directors: Boston VA Research Institute, Bristol Myers Squibb, Society of Cardiovascular Patient Care, TobeSoft. Inaugural Chair: American Heart Association Quality Oversight Committee. Data Monitoring Committees: Baim Institute for Clinical Research (formerly Harvard Clinical Research Institute, for the PORTICO trial, funded by St. Jude Medical, now Abbott), Boston Scientific (chair, PEITHO trial), Cleveland Clinic (including for the ExCEED trial, funded by Edwards), Contego Medical (chair, PERFORMANCE 2), Duke Clinical Research Institute, Mayo Clinic, Mount Sinai School of Medicine (for the ENVISameer AroraGE trial, funded by Daiichi Sankyo), Novartis, Population Health Research Institute. Honoraria: American College of Cardiology (senior associate editor, Clinical Trials and News, ACC.org; chair, ACC Accreditation Oversight Committee), Arnold and Porter law firm (work related to Sanofi/Bristol-Myers Squibb clopidogrel litigation), Baim Institute for Clinical Research (formerly Harvard Clinical Research Institute; RE-DUAL PCI clinical trial steering committee funded by Boehringer Ingelheim; AEGIS-II executive committee funded by CSL Behring), Belvoir Publications (editor in chief, Harvard Heart Letter), Canadian Medical and Surgical Knowledge Translation Research Group (clinical trial steering committees), Cowen and Company, Duke Clinical Research Institute (clinical trial steering committees, including for the PRONOUNCE trial, funded by Ferring Pharmaceuticals), HMP Global (editor in chief, Journal of Invasive Cardiology), Journal of the American College of Cardiology (guest editor, associate editor), K2P (co-chair, interdisciplinary curriculum), Level Ex, Medtelligence/ReachMD (CME steering committees), Michael J. Hendrickson Life Sciences, Piper Sandler, Population Health Research Institute (for the COMPASS operations committee, publications committee, steering committee, and USameer Arora national coleader, funded by Bayer), Slack Publications (chief medical editor, Cardiology Today's Intervention), Society of Cardiovascular Patient Care (secretary/treasurer), WebMD (CME steering committees). Other: Clinical Cardiology (deputy editor), NCDR-ACTION Registry Steering Committee (chair), VA CART Research and Publications Committee (chair). Research Funding: Abbott, Afimmune, Amarin, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Cardax, CellProthera, Cereno Scientific, Chiesi, CSL Behring, Eisai, Ethicon, Faraday Pharmaceuticals, Ferring Pharmaceuticals, Forest Laboratories, Fractyl, Garmin, HLS Therapeutics, Idorsia, Ironwood, Ischemix, Janssen, Javelin, Lexicon, Lilly, Medtronic, MyoKardia, NirvaMed, Novartis, Novo  Nordisk, Owkin, Pfizer, PhaseBio, PLx Pharma, Regeneron, Reid Hoffman Foundation, Roche, Sanofi, Stasys, Synaptic, The Medicines Company, 89Bio. Royalties: Elsevier (editor, Cardiovascular Intervention: A Companion to Braunwald's Heart Disease). Site Coinvestigator: Abbott, Biotronik, Boston Scientific, CSI, St. Jude Medical (now Abbott), Philips, Svelte. Trustee: American College of Cardiology. Unfunded Research: FlowCo, Merck, Takeda. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.\n",
      "\n",
      "Dr. Muthiah Vaduganathan has received research grant support or served on advisory boards for American Regent, Amgen, AstraZeneca, Bayer AG, Baxter Healthcare, Boehringer  Ingelheim, Cytokinetics, Lexicon Pharmaceuticals, Novartis, Pharmacosmos, Relypsa, Roche Diagnostics, Sanofi, and Tricog Health; has speaker engagements with Boehringer Ingelheim, Novartis, and Roche Diagnostics; and participates on clinical trial committees for studies sponsored by Galmed, Novartis, Bayer AG, Occlutech, and Impulse Dynamics. Dr. Arman Qamar reports receiving institutional grant  support from the NorthShore Auxiliary research scholar fund, Daiichi-Sankyo, American Heart Association, and fees for educational activities from the American College of Cardiology, Society for Vascular Medicine, Society for Cardiovascular  Angiography and Interventions, Janssen and Janssen, Pfizer, Medscape, and Clinical Exercise Physiology Association. Dr Ambarish Pandey has served on the advisory board of Roche Diagnostics; has received nonfinancial support from Pfizer and Merck; and has received research support from the Texas Health Resources Clinical Scholarship, the Gilead Sciences Research Scholar Program, the National Institute on Aging Grants for Early Medical/Surgical Specialists' Transition to Aging Research (GEMSSTAR) Grant (1R03AG067960-01), Myovista, and Applied Therapeutics.  Dr Bhatt discloses the following relationships: Advisory Board: Boehringer Ingelheim, Cardax, CellProthera, Cereno Scientific, Elsevier Practice Update Cardiology, Janssen, Level Ex, Medscape Cardiology, MyoKardia, NirvaMed, Novo Nordisk, PhaseBio, PLx Pharma, Regado Biosciences, Stasys. Board of Directors: Boston VA Research Institute, Bristol Myers Squibb, Society of Cardiovascular Patient Care, TobeSoft. Inaugural Chair: American Heart Association Quality Oversight Committee. Data Monitoring Committees: Baim Institute for Clinical Research (formerly Harvard Clinical Research Institute, for the PORTICO trial, funded by St. Jude Medical, now Abbott), Boston Scientific (chair, PEITHO trial), Cleveland Clinic (including for the ExCEED trial, funded by Edwards), Contego Medical (chair, PERFORMANCE 2), Duke Clinical Research Institute, Mayo Clinic, Mount Sinai School of Medicine (for the ENVISameer AroraGE trial, funded by Daiichi Sankyo), Novartis, Population Health Research Institute. Honoraria: American College of Cardiology (senior associate editor, Clinical Trials and News, ACC.org; chair, ACC Accreditation Oversight Committee), Arnold and Porter law firm (work related to Sanofi/Bristol-Myers Squibb clopidogrel litigation), Baim Institute for Clinical Research (formerly Harvard Clinical Research Institute; RE-DUAL PCI clinical trial steering committee funded by Boehringer Ingelheim; AEGIS-II executive committee funded by CSL Behring), Belvoir Publications (editor in chief, Harvard Heart Letter), Canadian Medical and Surgical Knowledge Translation Research Group (clinical trial steering committees), Cowen and Company, Duke Clinical Research Institute (clinical trial steering committees, including for the PRONOUNCE trial, funded by Ferring Pharmaceuticals), HMP Global (editor in chief, Journal of Invasive Cardiology), Journal of the American College of Cardiology (guest editor, associate editor), K2P (co-chair, interdisciplinary curriculum), Level Ex, Medtelligence/ReachMD (CME steering committees), Michael J. Hendrickson Life Sciences, Piper Sandler, Population Health Research Institute (for the COMPASS operations committee, publications committee, steering committee, and USameer Arora national coleader, funded by Bayer), Slack Publications (chief medical editor, Cardiology Today's Intervention), Society of Cardiovascular Patient Care (secretary/treasurer), WebMD (CME steering committees). Other: Clinical Cardiology (deputy editor), NCDR-ACTION Registry Steering Committee (chair), VA CART Research and Publications Committee (chair). Research Funding: Abbott, Afimmune, Amarin, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Cardax, CellProthera, Cereno Scientific, Chiesi, CSL Behring, Eisai, Ethicon, Faraday Pharmaceuticals, Ferring Pharmaceuticals, Forest Laboratories, Fractyl, Garmin, HLS Therapeutics, Idorsia, Ironwood, Ischemix, Janssen, Javelin, Lexicon, Lilly, Medtronic, MyoKardia, NirvaMed, Novartis, Novo  Nordisk, Owkin, Pfizer, PhaseBio, PLx Pharma, Regeneron, Reid Hoffman Foundation, Roche, Sanofi, Stasys, Synaptic, The Medicines Company, 89Bio. Royalties: Elsevier (editor, Cardiovascular Intervention: A Companion to Braunwald's Heart Disease). Site Coinvestigator: Abbott, Biotronik, Boston Scientific, CSI, St. Jude Medical (now Abbott), Philips, Svelte. Trustee: American College of Cardiology. Unfunded Research: FlowCo, Merck, Takeda. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.\n",
      "\n",
      "Dr. Muthiah Vaduganathan has received research grant support or served on advisory boards for American Regent, Amgen, AstraZeneca, Bayer AG, Baxter Healthcare, Boehringer  Ingelheim, Cytokinetics, Lexicon Pharmaceuticals, Novartis, Pharmacosmos, Relypsa, Roche Diagnostics, Sanofi, and Tricog Health; has speaker engagements with Boehringer Ingelheim, Novartis, and Roche Diagnostics; and participates on clinical trial committees for studies sponsored by Galmed, Novartis, Bayer AG, Occlutech, and Impulse Dynamics. Dr. Arman Qamar reports receiving institutional grant  support from the NorthShore Auxiliary research scholar fund, Daiichi-Sankyo, American Heart Association, and fees for educational activities from the American College of Cardiology, Society for Vascular Medicine, Society for Cardiovascular  Angiography and Interventions, Janssen and Janssen, Pfizer, Medscape, and Clinical Exercise Physiology Association. Dr Ambarish Pandey has served on the advisory board of Roche Diagnostics; has received nonfinancial support from Pfizer and Merck; and has received research support from the Texas Health Resources Clinical Scholarship, the Gilead Sciences Research Scholar Program, the National Institute on Aging Grants for Early Medical/Surgical Specialists' Transition to Aging Research (GEMSSTAR) Grant (1R03AG067960-01), Myovista, and Applied Therapeutics.  Dr Bhatt discloses the following relationships: Advisory Board: Boehringer Ingelheim, Cardax, CellProthera, Cereno Scientific, Elsevier Practice Update Cardiology, Janssen, Level Ex, Medscape Cardiology, MyoKardia, NirvaMed, Novo Nordisk, PhaseBio, PLx Pharma, Regado Biosciences, Stasys. Board of Directors: Boston VA Research Institute, Bristol Myers Squibb, Society of Cardiovascular Patient Care, TobeSoft. Inaugural Chair: American Heart Association Quality Oversight Committee. Data Monitoring Committees: Baim Institute for Clinical Research (formerly Harvard Clinical Research Institute, for the PORTICO trial, funded by St. Jude Medical, now Abbott), Boston Scientific (chair, PEITHO trial), Cleveland Clinic (including for the ExCEED trial, funded by Edwards), Contego Medical (chair, PERFORMANCE 2), Duke Clinical Research Institute, Mayo Clinic, Mount Sinai School of Medicine (for the ENVISameer AroraGE trial, funded by Daiichi Sankyo), Novartis, Population Health Research Institute. Honoraria: American College of Cardiology (senior associate editor, Clinical Trials and News, ACC.org; chair, ACC Accreditation Oversight Committee), Arnold and Porter law firm (work related to Sanofi/Bristol-Myers Squibb clopidogrel litigation), Baim Institute for Clinical Research (formerly Harvard Clinical Research Institute; RE-DUAL PCI clinical trial steering committee funded by Boehringer Ingelheim; AEGIS-II executive committee funded by CSL Behring), Belvoir Publications (editor in chief, Harvard Heart Letter), Canadian Medical and Surgical Knowledge Translation Research Group (clinical trial steering committees), Cowen and Company, Duke Clinical Research Institute (clinical trial steering committees, including for the PRONOUNCE trial, funded by Ferring Pharmaceuticals), HMP Global (editor in chief, Journal of Invasive Cardiology), Journal of the American College of Cardiology (guest editor, associate editor), K2P (co-chair, interdisciplinary curriculum), Level Ex, Medtelligence/ReachMD (CME steering committees), Michael J. Hendrickson Life Sciences, Piper Sandler, Population Health Research Institute (for the COMPASS operations committee, publications committee, steering committee, and USameer Arora national coleader, funded by Bayer), Slack Publications (chief medical editor, Cardiology Today's Intervention), Society of Cardiovascular Patient Care (secretary/treasurer), WebMD (CME steering committees). Other: Clinical Cardiology (deputy editor), NCDR-ACTION Registry Steering Committee (chair), VA CART Research and Publications Committee (chair). Research Funding: Abbott, Afimmune, Amarin, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Cardax, CellProthera, Cereno Scientific, Chiesi, CSL Behring, Eisai, Ethicon, Faraday Pharmaceuticals, Ferring Pharmaceuticals, Forest Laboratories, Fractyl, Garmin, HLS Therapeutics, Idorsia, Ironwood, Ischemix, Janssen, Javelin, Lexicon, Lilly, Medtronic, MyoKardia, NirvaMed, Novartis, Novo  Nordisk, Owkin, Pfizer, PhaseBio, PLx Pharma, Regeneron, Reid Hoffman Foundation, Roche, Sanofi, Stasys, Synaptic, The Medicines Company, 89Bio. Royalties: Elsevier (editor, Cardiovascular Intervention: A Companion to Braunwald's Heart Disease). Site Coinvestigator: Abbott, Biotronik, Boston Scientific, CSI, St. Jude Medical (now Abbott), Philips, Svelte. Trustee: American College of Cardiology. Unfunded Research: FlowCo, Merck, Takeda. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.\n",
      "\n",
      "Dr. Muthiah Vaduganathan has received research grant support or served on advisory boards for American Regent, Amgen, AstraZeneca, Bayer AG, Baxter Healthcare, Boehringer  Ingelheim, Cytokinetics, Lexicon Pharmaceuticals, Novartis, Pharmacosmos, Relypsa, Roche Diagnostics, Sanofi, and Tricog Health; has speaker engagements with Boehringer Ingelheim, Novartis, and Roche Diagnostics; and participates on clinical trial committees for studies sponsored by Galmed, Novartis, Bayer AG, Occlutech, and Impulse Dynamics. Dr. Arman Qamar reports receiving institutional grant  support from the NorthShore Auxiliary research scholar fund, Daiichi-Sankyo, American Heart Association, and fees for educational activities from the American College of Cardiology, Society for Vascular Medicine, Society for Cardiovascular  Angiography and Interventions, Janssen and Janssen, Pfizer, Medscape, and Clinical Exercise Physiology Association. Dr Ambarish Pandey has served on the advisory board of Roche Diagnostics; has received nonfinancial support from Pfizer and Merck; and has received research support from the Texas Health Resources Clinical Scholarship, the Gilead Sciences Research Scholar Program, the National Institute on Aging Grants for Early Medical/Surgical Specialists' Transition to Aging Research (GEMSSTAR) Grant (1R03AG067960-01), Myovista, and Applied Therapeutics.  Dr Bhatt discloses the following relationships: Advisory Board: Boehringer Ingelheim, Cardax, CellProthera, Cereno Scientific, Elsevier Practice Update Cardiology, Janssen, Level Ex, Medscape Cardiology, MyoKardia, NirvaMed, Novo Nordisk, PhaseBio, PLx Pharma, Regado Biosciences, Stasys. Board of Directors: Boston VA Research Institute, Bristol Myers Squibb, Society of Cardiovascular Patient Care, TobeSoft. Inaugural Chair: American Heart Association Quality Oversight Committee. Data Monitoring Committees: Baim Institute for Clinical Research (formerly Harvard Clinical Research Institute, for the PORTICO trial, funded by St. Jude Medical, now Abbott), Boston Scientific (chair, PEITHO trial), Cleveland Clinic (including for the ExCEED trial, funded by Edwards), Contego Medical (chair, PERFORMANCE 2), Duke Clinical Research Institute, Mayo Clinic, Mount Sinai School of Medicine (for the ENVISameer AroraGE trial, funded by Daiichi Sankyo), Novartis, Population Health Research Institute. Honoraria: American College of Cardiology (senior associate editor, Clinical Trials and News, ACC.org; chair, ACC Accreditation Oversight Committee), Arnold and Porter law firm (work related to Sanofi/Bristol-Myers Squibb clopidogrel litigation), Baim Institute for Clinical Research (formerly Harvard Clinical Research Institute; RE-DUAL PCI clinical trial steering committee funded by Boehringer Ingelheim; AEGIS-II executive committee funded by CSL Behring), Belvoir Publications (editor in chief, Harvard Heart Letter), Canadian Medical and Surgical Knowledge Translation Research Group (clinical trial steering committees), Cowen and Company, Duke Clinical Research Institute (clinical trial steering committees, including for the PRONOUNCE trial, funded by Ferring Pharmaceuticals), HMP Global (editor in chief, Journal of Invasive Cardiology), Journal of the American College of Cardiology (guest editor, associate editor), K2P (co-chair, interdisciplinary curriculum), Level Ex, Medtelligence/ReachMD (CME steering committees), Michael J. Hendrickson Life Sciences, Piper Sandler, Population Health Research Institute (for the COMPASS operations committee, publications committee, steering committee, and USameer Arora national coleader, funded by Bayer), Slack Publications (chief medical editor, Cardiology Today's Intervention), Society of Cardiovascular Patient Care (secretary/treasurer), WebMD (CME steering committees). Other: Clinical Cardiology (deputy editor), NCDR-ACTION Registry Steering Committee (chair), VA CART Research and Publications Committee (chair). Research Funding: Abbott, Afimmune, Amarin, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Cardax, CellProthera, Cereno Scientific, Chiesi, CSL Behring, Eisai, Ethicon, Faraday Pharmaceuticals, Ferring Pharmaceuticals, Forest Laboratories, Fractyl, Garmin, HLS Therapeutics, Idorsia, Ironwood, Ischemix, Janssen, Javelin, Lexicon, Lilly, Medtronic, MyoKardia, NirvaMed, Novartis, Novo  Nordisk, Owkin, Pfizer, PhaseBio, PLx Pharma, Regeneron, Reid Hoffman Foundation, Roche, Sanofi, Stasys, Synaptic, The Medicines Company, 89Bio. Royalties: Elsevier (editor, Cardiovascular Intervention: A Companion to Braunwald's Heart Disease). Site Coinvestigator: Abbott, Biotronik, Boston Scientific, CSI, St. Jude Medical (now Abbott), Philips, Svelte. Trustee: American College of Cardiology. Unfunded Research: FlowCo, Merck, Takeda. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.\n",
      "\n",
      "Tyagi, Sanjay\n",
      "Dr. Muthiah Vaduganathan has received research grant support or served on advisory boards for American Regent, Amgen, AstraZeneca, Bayer AG, Baxter Healthcare, Boehringer  Ingelheim, Cytokinetics, Lexicon Pharmaceuticals, Novartis, Pharmacosmos, Relypsa, Roche Diagnostics, Sanofi, and Tricog Health; has speaker engagements with Boehringer Ingelheim, Novartis, and Roche Diagnostics; and participates on clinical trial committees for studies sponsored by Galmed, Novartis, Bayer AG, Occlutech, and Impulse Dynamics. Dr. Arman Qamar reports receiving institutional grant  support from the NorthShore Auxiliary research scholar fund, Daiichi-Sankyo, American Heart Association, and fees for educational activities from the American College of Cardiology, Society for Vascular Medicine, Society for Cardiovascular  Angiography and Interventions, Janssen and Janssen, Pfizer, Medscape, and Clinical Exercise Physiology Association. Dr Ambarish Pandey has served on the advisory board of Roche Diagnostics; has received nonfinancial support from Pfizer and Merck; and has received research support from the Texas Health Resources Clinical Scholarship, the Gilead Sciences Research Scholar Program, the National Institute on Aging Grants for Early Medical/Surgical Specialists' Transition to Aging Research (GEMSSanjay TyagiAR) Grant (1R03AG067960-01), Myovista, and Applied Therapeutics.  Dr Bhatt discloses the following relationships: Advisory Board: Boehringer Ingelheim, Cardax, CellProthera, Cereno Scientific, Elsevier Practice Update Cardiology, Janssen, Level Ex, Medscape Cardiology, MyoKardia, NirvaMed, Novo Nordisk, PhaseBio, PLx Pharma, Regado Biosciences, Stasys. Board of Directors: Boston VA Research Institute, Bristol Myers Squibb, Society of Cardiovascular Patient Care, TobeSoft. Inaugural Chair: American Heart Association Quality Oversight Committee. Data Monitoring Committees: Baim Institute for Clinical Research (formerly Harvard Clinical Research Institute, for the PORTICO trial, funded by St. Jude Medical, now Abbott), Boston Scientific (chair, PEITHO trial), Cleveland Clinic (including for the ExCEED trial, funded by Edwards), Contego Medical (chair, PERFORMANCE 2), Duke Clinical Research Institute, Mayo Clinic, Mount Sinai School of Medicine (for the ENVISameer AroraGE trial, funded by Daiichi Sankyo), Novartis, Population Health Research Institute. Honoraria: American College of Cardiology (senior associate editor, Clinical Trials and News, ACC.org; chair, ACC Accreditation Oversight Committee), Arnold and Porter law firm (work related to Sanofi/Bristol-Myers Squibb clopidogrel litigation), Baim Institute for Clinical Research (formerly Harvard Clinical Research Institute; RE-DUAL PCI clinical trial steering committee funded by Boehringer Ingelheim; AEGIS-II executive committee funded by CSL Behring), Belvoir Publications (editor in chief, Harvard Heart Letter), Canadian Medical and Surgical Knowledge Translation Research Group (clinical trial steering committees), Cowen and Company, Duke Clinical Research Institute (clinical trial steering committees, including for the PRONOUNCE trial, funded by Ferring Pharmaceuticals), HMP Global (editor in chief, Journal of Invasive Cardiology), Journal of the American College of Cardiology (guest editor, associate editor), K2P (co-chair, interdisciplinary curriculum), Level Ex, Medtelligence/ReachMD (CME steering committees), Michael J. Hendrickson Life Sciences, Piper Sandler, Population Health Research Institute (for the COMPASS operations committee, publications committee, steering committee, and USameer Arora national coleader, funded by Bayer), Slack Publications (chief medical editor, Cardiology Today's Intervention), Society of Cardiovascular Patient Care (secretary/treasurer), WebMD (CME steering committees). Other: Clinical Cardiology (deputy editor), NCDR-ACTION Registry Steering Committee (chair), VA CART Research and Publications Committee (chair). Research Funding: Abbott, Afimmune, Amarin, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Cardax, CellProthera, Cereno Scientific, Chiesi, CSL Behring, Eisai, Ethicon, Faraday Pharmaceuticals, Ferring Pharmaceuticals, Forest Laboratories, Fractyl, Garmin, HLS Therapeutics, Idorsia, Ironwood, Ischemix, Janssen, Javelin, Lexicon, Lilly, Medtronic, MyoKardia, NirvaMed, Novartis, Novo  Nordisk, Owkin, Pfizer, PhaseBio, PLx Pharma, Regeneron, Reid Hoffman Foundation, Roche, Sanofi, Stasys, Synaptic, The Medicines Company, 89Bio. Royalties: Elsevier (editor, Cardiovascular Intervention: A Companion to Braunwald's Heart Disease). Site Coinvestigator: Abbott, Biotronik, Boston Scientific, CSI, St. Jude Medical (now Abbott), Philips, Svelte. Trustee: American College of Cardiology. Unfunded Research: FlowCo, Merck, Takeda. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.\n",
      "\n",
      "Bhatt, Deepak L.\n",
      "Dr. Muthiah Vaduganathan has received research grant support or served on advisory boards for American Regent, Amgen, AstraZeneca, Bayer AG, Baxter Healthcare, Boehringer  Ingelheim, Cytokinetics, Lexicon Pharmaceuticals, Novartis, Pharmacosmos, Relypsa, Roche Diagnostics, Sanofi, and Tricog Health; has speaker engagements with Boehringer Ingelheim, Novartis, and Roche Diagnostics; and participates on clinical trial committees for studies sponsored by Galmed, Novartis, Bayer AG, Occlutech, and Impulse Dynamics. Dr. Arman Qamar reports receiving institutional grant  support from the NorthShore Auxiliary research scholar fund, Daiichi-Sankyo, American Heart Association, and fees for educational activities from the American College of Cardiology, Society for Vascular Medicine, Society for Cardiovascular  Angiography and Interventions, Janssen and Janssen, Pfizer, Medscape, and Clinical Exercise Physiology Association. Dr Ambarish Pandey has served on the advisory board of Roche Diagnostics; has received nonfinancial support from Pfizer and Merck; and has received research support from the Texas Health Resources Clinical Scholarship, the Gilead Sciences Research Scholar Program, the National Institute on Aging Grants for Early Medical/Surgical Specialists' Transition to Aging Research (GEMSSanjay TyagiAR) Grant (1R03AG067960-01), Myovista, and Applied Therapeutics.  Dr Deepak L. Bhatt discloses the following relationships: Advisory Board: Boehringer Ingelheim, Cardax, CellProthera, Cereno Scientific, Elsevier Practice Update Cardiology, Janssen, Level Ex, Medscape Cardiology, MyoKardia, NirvaMed, Novo Nordisk, PhaseBio, PLx Pharma, Regado Biosciences, Stasys. Board of Directors: Boston VA Research Institute, Bristol Myers Squibb, Society of Cardiovascular Patient Care, TobeSoft. Inaugural Chair: American Heart Association Quality Oversight Committee. Data Monitoring Committees: Baim Institute for Clinical Research (formerly Harvard Clinical Research Institute, for the PORTICO trial, funded by St. Jude Medical, now Abbott), Boston Scientific (chair, PEITHO trial), Cleveland Clinic (including for the ExCEED trial, funded by Edwards), Contego Medical (chair, PERFORMANCE 2), Duke Clinical Research Institute, Mayo Clinic, Mount Sinai School of Medicine (for the ENVISameer AroraGE trial, funded by Daiichi Sankyo), Novartis, Population Health Research Institute. Honoraria: American College of Cardiology (senior associate editor, Clinical Trials and News, ACC.org; chair, ACC Accreditation Oversight Committee), Arnold and Porter law firm (work related to Sanofi/Bristol-Myers Squibb clopidogrel litigation), Baim Institute for Clinical Research (formerly Harvard Clinical Research Institute; RE-DUAL PCI clinical trial steering committee funded by Boehringer Ingelheim; AEGIS-II executive committee funded by CSL Behring), Belvoir Publications (editor in chief, Harvard Heart Letter), Canadian Medical and Surgical Knowledge Translation Research Group (clinical trial steering committees), Cowen and Company, Duke Clinical Research Institute (clinical trial steering committees, including for the PRONOUNCE trial, funded by Ferring Pharmaceuticals), HMP Global (editor in chief, Journal of Invasive Cardiology), Journal of the American College of Cardiology (guest editor, associate editor), K2P (co-chair, interdisciplinary curriculum), Level Ex, Medtelligence/ReachMD (CME steering committees), Michael J. Hendrickson Life Sciences, Piper Sandler, Population Health Research Institute (for the COMPASS operations committee, publications committee, steering committee, and USameer Arora national coleader, funded by Bayer), Slack Publications (chief medical editor, Cardiology Today's Intervention), Society of Cardiovascular Patient Care (secretary/treasurer), WebMD (CME steering committees). Other: Clinical Cardiology (deputy editor), NCDR-ACTION Registry Steering Committee (chair), VA CART Research and Publications Committee (chair). Research Funding: Abbott, Afimmune, Amarin, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Cardax, CellProthera, Cereno Scientific, Chiesi, CSL Behring, Eisai, Ethicon, Faraday Pharmaceuticals, Ferring Pharmaceuticals, Forest Laboratories, Fractyl, Garmin, HLS Therapeutics, Idorsia, Ironwood, Ischemix, Janssen, Javelin, Lexicon, Lilly, Medtronic, MyoKardia, NirvaMed, Novartis, Novo  Nordisk, Owkin, Pfizer, PhaseBio, PLx Pharma, Regeneron, Reid Hoffman Foundation, Roche, Sanofi, Stasys, Synaptic, The Medicines Company, 89Bio. Royalties: Elsevier (editor, Cardiovascular Intervention: A Companion to Braunwald's Heart Disease). Site Coinvestigator: Abbott, Biotronik, Boston Scientific, CSI, St. Jude Medical (now Abbott), Philips, Svelte. Trustee: American College of Cardiology. Unfunded Research: FlowCo, Merck, Takeda. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.\n",
      "\n",
      "Dr. Muthiah Vaduganathan has received research grant support or served on advisory boards for American Regent, Amgen, AstraZeneca, Bayer AG, Baxter Healthcare, Boehringer  Ingelheim, Cytokinetics, Lexicon Pharmaceuticals, Novartis, Pharmacosmos, Relypsa, Roche Diagnostics, Sanofi, and Tricog Health; has speaker engagements with Boehringer Ingelheim, Novartis, and Roche Diagnostics; and participates on clinical trial committees for studies sponsored by Galmed, Novartis, Bayer AG, Occlutech, and Impulse Dynamics. Dr. Arman Qamar reports receiving institutional grant  support from the NorthShore Auxiliary research scholar fund, Daiichi-Sankyo, American Heart Association, and fees for educational activities from the American College of Cardiology, Society for Vascular Medicine, Society for Cardiovascular  Angiography and Interventions, Janssen and Janssen, Pfizer, Medscape, and Clinical Exercise Physiology Association. Dr Ambarish Pandey has served on the advisory board of Roche Diagnostics; has received nonfinancial support from Pfizer and Merck; and has received research support from the Texas Health Resources Clinical Scholarship, the Gilead Sciences Research Scholar Program, the National Institute on Aging Grants for Early Medical/Surgical Specialists' Transition to Aging Research (GEMSSanjay TyagiAR) Grant (1R03AG067960-01), Myovista, and Applied Therapeutics.  Dr Deepak L. Bhatt discloses the following relationships: Advisory Board: Boehringer Ingelheim, Cardax, CellProthera, Cereno Scientific, Elsevier Practice Update Cardiology, Janssen, Level Ex, Medscape Cardiology, MyoKardia, NirvaMed, Novo Nordisk, PhaseBio, PLx Pharma, Regado Biosciences, Stasys. Board of Directors: Boston VA Research Institute, Bristol Myers Squibb, Society of Cardiovascular Patient Care, TobeSoft. Inaugural Chair: American Heart Association Quality Oversight Committee. Data Monitoring Committees: Baim Institute for Clinical Research (formerly Harvard Clinical Research Institute, for the PORTICO trial, funded by St. Jude Medical, now Abbott), Boston Scientific (chair, PEITHO trial), Cleveland Clinic (including for the ExCEED trial, funded by Edwards), Contego Medical (chair, PERFORMANCE 2), Duke Clinical Research Institute, Mayo Clinic, Mount Sinai School of Medicine (for the ENVISameer AroraGE trial, funded by Daiichi Sankyo), Novartis, Population Health Research Institute. Honoraria: American College of Cardiology (senior associate editor, Clinical Trials and News, ACC.org; chair, ACC Accreditation Oversight Committee), Arnold and Porter law firm (work related to Sanofi/Bristol-Myers Squibb clopidogrel litigation), Baim Institute for Clinical Research (formerly Harvard Clinical Research Institute; RE-DUAL PCI clinical trial steering committee funded by Boehringer Ingelheim; AEGIS-II executive committee funded by CSL Behring), Belvoir Publications (editor in chief, Harvard Heart Letter), Canadian Medical and Surgical Knowledge Translation Research Group (clinical trial steering committees), Cowen and Company, Duke Clinical Research Institute (clinical trial steering committees, including for the PRONOUNCE trial, funded by Ferring Pharmaceuticals), HMP Global (editor in chief, Journal of Invasive Cardiology), Journal of the American College of Cardiology (guest editor, associate editor), K2P (co-chair, interdisciplinary curriculum), Level Ex, Medtelligence/ReachMD (CME steering committees), Michael J. Hendrickson Life Sciences, Piper Sandler, Population Health Research Institute (for the COMPASS operations committee, publications committee, steering committee, and USameer Arora national coleader, funded by Bayer), Slack Publications (chief medical editor, Cardiology Today's Intervention), Society of Cardiovascular Patient Care (secretary/treasurer), WebMD (CME steering committees). Other: Clinical Cardiology (deputy editor), NCDR-ACTION Registry Steering Committee (chair), VA CART Research and Publications Committee (chair). Research Funding: Abbott, Afimmune, Amarin, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Cardax, CellProthera, Cereno Scientific, Chiesi, CSL Behring, Eisai, Ethicon, Faraday Pharmaceuticals, Ferring Pharmaceuticals, Forest Laboratories, Fractyl, Garmin, HLS Therapeutics, Idorsia, Ironwood, Ischemix, Janssen, Javelin, Lexicon, Lilly, Medtronic, MyoKardia, NirvaMed, Novartis, Novo  Nordisk, Owkin, Pfizer, PhaseBio, PLx Pharma, Regeneron, Reid Hoffman Foundation, Roche, Sanofi, Stasys, Synaptic, The Medicines Company, 89Bio. Royalties: Elsevier (editor, Cardiovascular Intervention: A Companion to Braunwald's Heart Disease). Site Coinvestigator: Abbott, Biotronik, Boston Scientific, CSI, St. Jude Medical (now Abbott), Philips, Svelte. Trustee: American College of Cardiology. Unfunded Research: FlowCo, Merck, Takeda. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.\n",
      "\n",
      "Tromp, Jasper\n",
      "Dr Jasper Tromp is supported by the National University of Singapore Start-up grant, the tier 1 grant from the ministry of education and the CS-IRG New Investigator Grant from the National Medical Research Council; has received consulting or speaker fees from Daiichi-Sankyo, Boehringer Ingelheim, Roche diagnostics and Us2.ai, owns patent US-10702247-B2 related to artificial intelligence and echocardiography. Dr Devraj Jindal holds a copyright for the CARDIOMETCARE-M software which is a clinical decision support system. Dr Julie Redfern owns a portion of the IP for the TEXTCARE software that was developed following the TEXTME study. She is also funded by a NHMRC Investigator Grant Leadership Level 2 [GNT2007946]. Dr Khung Keong Yeo has received research funding from Amgen, Astra Zeneca, Abbott Vascular, Bayer, Boston Scientific, Shockwave Medical, Nestle, Novartis (all significant, via institution); Consulting or honoraria feeds (all modest) from Abbott Vascular, Boston Scientific, Medtronic,  Amgen, Bayer, Novartis, Astra Zeneca, Peijia Medical; Speaker or Proctor fees from Shockwave Medical, Abbott Vascular, Boston Scientific, Medtronic, Philips, Alvimedica, Bayer, Biotronik, Orbus Neich, Shockwave Medical, Amgen, Novartis, Astra Zeneca, Microport, Terumo. Dr. Lopez-Jimenez is co-inventor of several AI algorithms that have been licensed to digital health companies and may receive financial compensation in the future. He is member of the advisory board for Anumana, an AI-based technology company. He has co-developed digital health technology to use 3D volumes to assess cardiometabolic risk with Selected Research Inc, and may receive financial benefit in the future. Dr Dorairaj Prabhakaran holds a copyright for the CARDIOMETCARE-M software which is a clinical decision support system. Prof Carolyn SP Lam is supported by a Clinician Scientist Award from the National Medical Research Council of Singapore; has received research support from Bayer and Roche Diagnostics; has served as consultant or on the Advisory Board/Steering Committee/Executive Committee for Abbott, Actelion, Alleviant Medical, Allysta Pharma, Amgen, AnaCardio AB, Applied Therapeutics, AstraZeneca, Bayer, Boehringer Ingelheim, Boston Scientific, Cytokinetics, Darma Inc., EchoNous Inc, Impulse Dynamics, Ionis Pharmaceutical, Janssen Research & Development LLC, Medscape/WebMD Global LLC, Merck, Novartis, Novo Nordisk, Prosciento Inc, Radcliffe Group Ltd., Roche Diagnostics, Sanofi, Siemens Healthcare Diagnostics and Us2.ai; and serves as co-founder & non-executive director of Us2.ai. Dr Martin R Cowie has provided consultancy advice to Medtronic, Boston Scientific, Abbott and AstraZeneca, related to aspects of digital health. As from 1 August 2022 he has been employed by AstraZeneca as Clinical Vice-President in Late Stage Research (Biopharmaceuticals).\n",
      "\n",
      "Jindal, Devraj\n",
      "Dr Jasper Tromp is supported by the National University of Singapore Start-up grant, the tier 1 grant from the ministry of education and the CS-IRG New Investigator Grant from the National Medical Research Council; has received consulting or speaker fees from Daiichi-Sankyo, Boehringer Ingelheim, Roche diagnostics and Us2.ai, owns patent US-10702247-B2 related to artificial intelligence and echocardiography. Dr Devraj Jindal holds a copyright for the CARDIOMETCARE-M software which is a clinical decision support system. Dr Julie Redfern owns a portion of the IP for the TEXTCARE software that was developed following the TEXTME study. She is also funded by a NHMRC Investigator Grant Leadership Level 2 [GNT2007946]. Dr Khung Keong Yeo has received research funding from Amgen, Astra Zeneca, Abbott Vascular, Bayer, Boston Scientific, Shockwave Medical, Nestle, Novartis (all significant, via institution); Consulting or honoraria feeds (all modest) from Abbott Vascular, Boston Scientific, Medtronic,  Amgen, Bayer, Novartis, Astra Zeneca, Peijia Medical; Speaker or Proctor fees from Shockwave Medical, Abbott Vascular, Boston Scientific, Medtronic, Philips, Alvimedica, Bayer, Biotronik, Orbus Neich, Shockwave Medical, Amgen, Novartis, Astra Zeneca, Microport, Terumo. Dr. Lopez-Jimenez is co-inventor of several AI algorithms that have been licensed to digital health companies and may receive financial compensation in the future. He is member of the advisory board for Anumana, an AI-based technology company. He has co-developed digital health technology to use 3D volumes to assess cardiometabolic risk with Selected Research Inc, and may receive financial benefit in the future. Dr Dorairaj Prabhakaran holds a copyright for the CARDIOMETCARE-M software which is a clinical decision support system. Prof Carolyn SP Lam is supported by a Clinician Scientist Award from the National Medical Research Council of Singapore; has received research support from Bayer and Roche Diagnostics; has served as consultant or on the Advisory Board/Steering Committee/Executive Committee for Abbott, Actelion, Alleviant Medical, Allysta Pharma, Amgen, AnaCardio AB, Applied Therapeutics, AstraZeneca, Bayer, Boehringer Ingelheim, Boston Scientific, Cytokinetics, Darma Inc., EchoNous Inc, Impulse Dynamics, Ionis Pharmaceutical, Janssen Research & Development LLC, Medscape/WebMD Global LLC, Merck, Novartis, Novo Nordisk, Prosciento Inc, Radcliffe Group Ltd., Roche Diagnostics, Sanofi, Siemens Healthcare Diagnostics and Us2.ai; and serves as co-founder & non-executive director of Us2.ai. Dr Martin R Cowie has provided consultancy advice to Medtronic, Boston Scientific, Abbott and AstraZeneca, related to aspects of digital health. As from 1 August 2022 he has been employed by AstraZeneca as Clinical Vice-President in Late Stage Research (Biopharmaceuticals).\n",
      "\n",
      "Redfern, Julie\n",
      "Dr Jasper Tromp is supported by the National University of Singapore Start-up grant, the tier 1 grant from the ministry of education and the CS-IRG New Investigator Grant from the National Medical Research Council; has received consulting or speaker fees from Daiichi-Sankyo, Boehringer Ingelheim, Roche diagnostics and Us2.ai, owns patent US-10702247-B2 related to artificial intelligence and echocardiography. Dr Devraj Jindal holds a copyright for the CARDIOMETCARE-M software which is a clinical decision support system. Dr Julie Redfern owns a portion of the IP for the TEXTCARE software that was developed following the TEXTME study. She is also funded by a NHMRC Investigator Grant Leadership Level 2 [GNT2007946]. Dr Khung Keong Yeo has received research funding from Amgen, Astra Zeneca, Abbott Vascular, Bayer, Boston Scientific, Shockwave Medical, Nestle, Novartis (all significant, via institution); Consulting or honoraria feeds (all modest) from Abbott Vascular, Boston Scientific, Medtronic,  Amgen, Bayer, Novartis, Astra Zeneca, Peijia Medical; Speaker or Proctor fees from Shockwave Medical, Abbott Vascular, Boston Scientific, Medtronic, Philips, Alvimedica, Bayer, Biotronik, Orbus Neich, Shockwave Medical, Amgen, Novartis, Astra Zeneca, Microport, Terumo. Dr. Lopez-Jimenez is co-inventor of several AI algorithms that have been licensed to digital health companies and may receive financial compensation in the future. He is member of the advisory board for Anumana, an AI-based technology company. He has co-developed digital health technology to use 3D volumes to assess cardiometabolic risk with Selected Research Inc, and may receive financial benefit in the future. Dr Dorairaj Prabhakaran holds a copyright for the CARDIOMETCARE-M software which is a clinical decision support system. Prof Carolyn SP Lam is supported by a Clinician Scientist Award from the National Medical Research Council of Singapore; has received research support from Bayer and Roche Diagnostics; has served as consultant or on the Advisory Board/Steering Committee/Executive Committee for Abbott, Actelion, Alleviant Medical, Allysta Pharma, Amgen, AnaCardio AB, Applied Therapeutics, AstraZeneca, Bayer, Boehringer Ingelheim, Boston Scientific, Cytokinetics, Darma Inc., EchoNous Inc, Impulse Dynamics, Ionis Pharmaceutical, Janssen Research & Development LLC, Medscape/WebMD Global LLC, Merck, Novartis, Novo Nordisk, Prosciento Inc, Radcliffe Group Ltd., Roche Diagnostics, Sanofi, Siemens Healthcare Diagnostics and Us2.ai; and serves as co-founder & non-executive director of Us2.ai. Dr Martin R Cowie has provided consultancy advice to Medtronic, Boston Scientific, Abbott and AstraZeneca, related to aspects of digital health. As from 1 August 2022 he has been employed by AstraZeneca as Clinical Vice-President in Late Stage Research (Biopharmaceuticals).\n",
      "\n",
      "Bhatt, Ami\n",
      "Dr Jasper Tromp is supported by the National University of Singapore Start-up grant, the tier 1 grant from the ministry of education and the CS-IRG New Investigator Grant from the National Medical Research Council; has received consulting or speaker fees from Daiichi-Sankyo, Boehringer Ingelheim, Roche diagnostics and Us2.ai, owns patent US-10702247-B2 related to artificial intelligence and echocardiography. Dr Devraj Jindal holds a copyright for the CARDIOMETCARE-M software which is a clinical decision support system. Dr Julie Redfern owns a portion of the IP for the TEXTCARE software that was developed following the TEXTME study. She is also funded by a NHMRC Investigator Grant Leadership Level 2 [GNT2007946]. Dr Khung Keong Yeo has received research funding from Amgen, Astra Zeneca, Abbott Vascular, Bayer, Boston Scientific, Shockwave Medical, Nestle, Novartis (all significant, via institution); Consulting or honoraria feeds (all modest) from Abbott Vascular, Boston Scientific, Medtronic,  Amgen, Bayer, Novartis, Astra Zeneca, Peijia Medical; Speaker or Proctor fees from Shockwave Medical, Abbott Vascular, Boston Scientific, Medtronic, Philips, Alvimedica, Bayer, Biotronik, Orbus Neich, Shockwave Medical, Amgen, Novartis, Astra Zeneca, Microport, Terumo. Dr. Lopez-Jimenez is co-inventor of several AI algorithms that have been licensed to digital health companies and may receive financial compensation in the future. He is member of the advisory board for Anumana, an AI-based technology company. He has co-developed digital health technology to use 3D volumes to assess cardiometabolic risk with Selected Research Inc, and may receive financial benefit in the future. Dr Dorairaj Prabhakaran holds a copyright for the CARDIOMETCARE-M software which is a clinical decision support system. Prof Carolyn SP Lam is supported by a Clinician Scientist Award from the National Medical Research Council of Singapore; has received research support from Bayer and Roche Diagnostics; has served as consultant or on the Advisory Board/Steering Committee/Executive Committee for Abbott, Actelion, Alleviant Medical, Allysta Pharma, Amgen, AnaCardio Ami Bhatt, Applied Therapeutics, AstraZeneca, Bayer, Boehringer Ingelheim, Boston Scientific, Cytokinetics, Darma Inc., EchoNous Inc, Impulse Dynamics, Ionis Pharmaceutical, Janssen Research & Development LLC, Medscape/WebMD Global LLC, Merck, Novartis, Novo Nordisk, Prosciento Inc, Radcliffe Group Ltd., Roche Diagnostics, Sanofi, Siemens Healthcare Diagnostics and Us2.ai; and serves as co-founder & non-executive director of Us2.ai. Dr Martin R Cowie has provided consultancy advice to Medtronic, Boston Scientific, Abbott and AstraZeneca, related to aspects of digital health. As from 1 August 2022 he has been employed by AstraZeneca as Clinical Vice-President in Late Stage Research (Biopharmaceuticals).\n",
      "\n",
      "Dr Jasper Tromp is supported by the National University of Singapore Start-up grant, the tier 1 grant from the ministry of education and the CS-IRG New Investigator Grant from the National Medical Research Council; has received consulting or speaker fees from Daiichi-Sankyo, Boehringer Ingelheim, Roche diagnostics and Us2.ai, owns patent US-10702247-B2 related to artificial intelligence and echocardiography. Dr Devraj Jindal holds a copyright for the CARDIOMETCARE-M software which is a clinical decision support system. Dr Julie Redfern owns a portion of the IP for the TEXTCARE software that was developed following the TEXTME study. She is also funded by a NHMRC Investigator Grant Leadership Level 2 [GNT2007946]. Dr Khung Keong Yeo has received research funding from Amgen, Astra Zeneca, Abbott Vascular, Bayer, Boston Scientific, Shockwave Medical, Nestle, Novartis (all significant, via institution); Consulting or honoraria feeds (all modest) from Abbott Vascular, Boston Scientific, Medtronic,  Amgen, Bayer, Novartis, Astra Zeneca, Peijia Medical; Speaker or Proctor fees from Shockwave Medical, Abbott Vascular, Boston Scientific, Medtronic, Philips, Alvimedica, Bayer, Biotronik, Orbus Neich, Shockwave Medical, Amgen, Novartis, Astra Zeneca, Microport, Terumo. Dr. Lopez-Jimenez is co-inventor of several AI algorithms that have been licensed to digital health companies and may receive financial compensation in the future. He is member of the advisory board for Anumana, an AI-based technology company. He has co-developed digital health technology to use 3D volumes to assess cardiometabolic risk with Selected Research Inc, and may receive financial benefit in the future. Dr Dorairaj Prabhakaran holds a copyright for the CARDIOMETCARE-M software which is a clinical decision support system. Prof Carolyn SP Lam is supported by a Clinician Scientist Award from the National Medical Research Council of Singapore; has received research support from Bayer and Roche Diagnostics; has served as consultant or on the Advisory Board/Steering Committee/Executive Committee for Abbott, Actelion, Alleviant Medical, Allysta Pharma, Amgen, AnaCardio Ami Bhatt, Applied Therapeutics, AstraZeneca, Bayer, Boehringer Ingelheim, Boston Scientific, Cytokinetics, Darma Inc., EchoNous Inc, Impulse Dynamics, Ionis Pharmaceutical, Janssen Research & Development LLC, Medscape/WebMD Global LLC, Merck, Novartis, Novo Nordisk, Prosciento Inc, Radcliffe Group Ltd., Roche Diagnostics, Sanofi, Siemens Healthcare Diagnostics and Us2.ai; and serves as co-founder & non-executive director of Us2.ai. Dr Martin R Cowie has provided consultancy advice to Medtronic, Boston Scientific, Abbott and AstraZeneca, related to aspects of digital health. As from 1 August 2022 he has been employed by AstraZeneca as Clinical Vice-President in Late Stage Research (Biopharmaceuticals).\n",
      "\n",
      "Dr Jasper Tromp is supported by the National University of Singapore Start-up grant, the tier 1 grant from the ministry of education and the CS-IRG New Investigator Grant from the National Medical Research Council; has received consulting or speaker fees from Daiichi-Sankyo, Boehringer Ingelheim, Roche diagnostics and Us2.ai, owns patent US-10702247-B2 related to artificial intelligence and echocardiography. Dr Devraj Jindal holds a copyright for the CARDIOMETCARE-M software which is a clinical decision support system. Dr Julie Redfern owns a portion of the IP for the TEXTCARE software that was developed following the TEXTME study. She is also funded by a NHMRC Investigator Grant Leadership Level 2 [GNT2007946]. Dr Khung Keong Yeo has received research funding from Amgen, Astra Zeneca, Abbott Vascular, Bayer, Boston Scientific, Shockwave Medical, Nestle, Novartis (all significant, via institution); Consulting or honoraria feeds (all modest) from Abbott Vascular, Boston Scientific, Medtronic,  Amgen, Bayer, Novartis, Astra Zeneca, Peijia Medical; Speaker or Proctor fees from Shockwave Medical, Abbott Vascular, Boston Scientific, Medtronic, Philips, Alvimedica, Bayer, Biotronik, Orbus Neich, Shockwave Medical, Amgen, Novartis, Astra Zeneca, Microport, Terumo. Dr. Lopez-Jimenez is co-inventor of several AI algorithms that have been licensed to digital health companies and may receive financial compensation in the future. He is member of the advisory board for Anumana, an AI-based technology company. He has co-developed digital health technology to use 3D volumes to assess cardiometabolic risk with Selected Research Inc, and may receive financial benefit in the future. Dr Dorairaj Prabhakaran holds a copyright for the CARDIOMETCARE-M software which is a clinical decision support system. Prof Carolyn SP Lam is supported by a Clinician Scientist Award from the National Medical Research Council of Singapore; has received research support from Bayer and Roche Diagnostics; has served as consultant or on the Advisory Board/Steering Committee/Executive Committee for Abbott, Actelion, Alleviant Medical, Allysta Pharma, Amgen, AnaCardio Ami Bhatt, Applied Therapeutics, AstraZeneca, Bayer, Boehringer Ingelheim, Boston Scientific, Cytokinetics, Darma Inc., EchoNous Inc, Impulse Dynamics, Ionis Pharmaceutical, Janssen Research & Development LLC, Medscape/WebMD Global LLC, Merck, Novartis, Novo Nordisk, Prosciento Inc, Radcliffe Group Ltd., Roche Diagnostics, Sanofi, Siemens Healthcare Diagnostics and Us2.ai; and serves as co-founder & non-executive director of Us2.ai. Dr Martin R Cowie has provided consultancy advice to Medtronic, Boston Scientific, Abbott and AstraZeneca, related to aspects of digital health. As from 1 August 2022 he has been employed by AstraZeneca as Clinical Vice-President in Late Stage Research (Biopharmaceuticals).\n",
      "\n",
      "Dr Jasper Tromp is supported by the National University of Singapore Start-up grant, the tier 1 grant from the ministry of education and the CS-IRG New Investigator Grant from the National Medical Research Council; has received consulting or speaker fees from Daiichi-Sankyo, Boehringer Ingelheim, Roche diagnostics and Us2.ai, owns patent US-10702247-B2 related to artificial intelligence and echocardiography. Dr Devraj Jindal holds a copyright for the CARDIOMETCARE-M software which is a clinical decision support system. Dr Julie Redfern owns a portion of the IP for the TEXTCARE software that was developed following the TEXTME study. She is also funded by a NHMRC Investigator Grant Leadership Level 2 [GNT2007946]. Dr Khung Keong Yeo has received research funding from Amgen, Astra Zeneca, Abbott Vascular, Bayer, Boston Scientific, Shockwave Medical, Nestle, Novartis (all significant, via institution); Consulting or honoraria feeds (all modest) from Abbott Vascular, Boston Scientific, Medtronic,  Amgen, Bayer, Novartis, Astra Zeneca, Peijia Medical; Speaker or Proctor fees from Shockwave Medical, Abbott Vascular, Boston Scientific, Medtronic, Philips, Alvimedica, Bayer, Biotronik, Orbus Neich, Shockwave Medical, Amgen, Novartis, Astra Zeneca, Microport, Terumo. Dr. Lopez-Jimenez is co-inventor of several AI algorithms that have been licensed to digital health companies and may receive financial compensation in the future. He is member of the advisory board for Anumana, an AI-based technology company. He has co-developed digital health technology to use 3D volumes to assess cardiometabolic risk with Selected Research Inc, and may receive financial benefit in the future. Dr Dorairaj Prabhakaran holds a copyright for the CARDIOMETCARE-M software which is a clinical decision support system. Prof Carolyn SP Lam is supported by a Clinician Scientist Award from the National Medical Research Council of Singapore; has received research support from Bayer and Roche Diagnostics; has served as consultant or on the Advisory Board/Steering Committee/Executive Committee for Abbott, Actelion, Alleviant Medical, Allysta Pharma, Amgen, AnaCardio Ami Bhatt, Applied Therapeutics, AstraZeneca, Bayer, Boehringer Ingelheim, Boston Scientific, Cytokinetics, Darma Inc., EchoNous Inc, Impulse Dynamics, Ionis Pharmaceutical, Janssen Research & Development LLC, Medscape/WebMD Global LLC, Merck, Novartis, Novo Nordisk, Prosciento Inc, Radcliffe Group Ltd., Roche Diagnostics, Sanofi, Siemens Healthcare Diagnostics and Us2.ai; and serves as co-founder & non-executive director of Us2.ai. Dr Martin R Cowie has provided consultancy advice to Medtronic, Boston Scientific, Abbott and AstraZeneca, related to aspects of digital health. As from 1 August 2022 he has been employed by AstraZeneca as Clinical Vice-President in Late Stage Research (Biopharmaceuticals).\n",
      "\n",
      "Itchhaporia, Dipti\n",
      "Dr Jasper Tromp is supported by the National University of Singapore Start-up grant, the tier 1 grant from the ministry of education and the CS-IRG New Investigator Grant from the National Medical Research Council; has received consulting or speaker fees from Daiichi-Sankyo, Boehringer Ingelheim, Roche diagnostics and Us2.ai, owns patent US-10702247-B2 related to artificial intelligence and echocardiography. Dr Devraj Jindal holds a copyright for the CARDipti ItchhaporiaOMETCARE-M software which is a clinical decision support system. Dr Julie Redfern owns a portion of the IP for the TEXTCARE software that was developed following the TEXTME study. She is also funded by a NHMRC Investigator Grant Leadership Level 2 [GNT2007946]. Dr Khung Keong Yeo has received research funding from Amgen, Astra Zeneca, Abbott Vascular, Bayer, Boston Scientific, Shockwave Medical, Nestle, Novartis (all significant, via institution); Consulting or honoraria feeds (all modest) from Abbott Vascular, Boston Scientific, Medtronic,  Amgen, Bayer, Novartis, Astra Zeneca, Peijia Medical; Speaker or Proctor fees from Shockwave Medical, Abbott Vascular, Boston Scientific, Medtronic, Philips, Alvimedica, Bayer, Biotronik, Orbus Neich, Shockwave Medical, Amgen, Novartis, Astra Zeneca, Microport, Terumo. Dr. Lopez-Jimenez is co-inventor of several AI algorithms that have been licensed to digital health companies and may receive financial compensation in the future. He is member of the advisory board for Anumana, an AI-based technology company. He has co-developed digital health technology to use 3D volumes to assess cardiometabolic risk with Selected Research Inc, and may receive financial benefit in the future. Dr Dorairaj Prabhakaran holds a copyright for the CARDipti ItchhaporiaOMETCARE-M software which is a clinical decision support system. Prof Carolyn SP Lam is supported by a Clinician Scientist Award from the National Medical Research Council of Singapore; has received research support from Bayer and Roche Diagnostics; has served as consultant or on the Advisory Board/Steering Committee/Executive Committee for Abbott, Actelion, Alleviant Medical, Allysta Pharma, Amgen, AnaCardio Ami Bhatt, Applied Therapeutics, AstraZeneca, Bayer, Boehringer Ingelheim, Boston Scientific, Cytokinetics, Darma Inc., EchoNous Inc, Impulse Dynamics, Ionis Pharmaceutical, Janssen Research & Development LLC, Medscape/WebMD Global LLC, Merck, Novartis, Novo Nordisk, Prosciento Inc, Radcliffe Group Ltd., Roche Diagnostics, Sanofi, Siemens Healthcare Diagnostics and Us2.ai; and serves as co-founder & non-executive director of Us2.ai. Dr Martin R Cowie has provided consultancy advice to Medtronic, Boston Scientific, Abbott and AstraZeneca, related to aspects of digital health. As from 1 August 2022 he has been employed by AstraZeneca as Clinical Vice-President in Late Stage Research (Biopharmaceuticals).\n",
      "\n",
      "Dr Jasper Tromp is supported by the National University of Singapore Start-up grant, the tier 1 grant from the ministry of education and the CS-IRG New Investigator Grant from the National Medical Research Council; has received consulting or speaker fees from Daiichi-Sankyo, Boehringer Ingelheim, Roche diagnostics and Us2.ai, owns patent US-10702247-B2 related to artificial intelligence and echocardiography. Dr Devraj Jindal holds a copyright for the CARDipti ItchhaporiaOMETCARE-M software which is a clinical decision support system. Dr Julie Redfern owns a portion of the IP for the TEXTCARE software that was developed following the TEXTME study. She is also funded by a NHMRC Investigator Grant Leadership Level 2 [GNT2007946]. Dr Khung Keong Yeo has received research funding from Amgen, Astra Zeneca, Abbott Vascular, Bayer, Boston Scientific, Shockwave Medical, Nestle, Novartis (all significant, via institution); Consulting or honoraria feeds (all modest) from Abbott Vascular, Boston Scientific, Medtronic,  Amgen, Bayer, Novartis, Astra Zeneca, Peijia Medical; Speaker or Proctor fees from Shockwave Medical, Abbott Vascular, Boston Scientific, Medtronic, Philips, Alvimedica, Bayer, Biotronik, Orbus Neich, Shockwave Medical, Amgen, Novartis, Astra Zeneca, Microport, Terumo. Dr. Lopez-Jimenez is co-inventor of several AI algorithms that have been licensed to digital health companies and may receive financial compensation in the future. He is member of the advisory board for Anumana, an AI-based technology company. He has co-developed digital health technology to use 3D volumes to assess cardiometabolic risk with Selected Research Inc, and may receive financial benefit in the future. Dr Dorairaj Prabhakaran holds a copyright for the CARDipti ItchhaporiaOMETCARE-M software which is a clinical decision support system. Prof Carolyn SP Lam is supported by a Clinician Scientist Award from the National Medical Research Council of Singapore; has received research support from Bayer and Roche Diagnostics; has served as consultant or on the Advisory Board/Steering Committee/Executive Committee for Abbott, Actelion, Alleviant Medical, Allysta Pharma, Amgen, AnaCardio Ami Bhatt, Applied Therapeutics, AstraZeneca, Bayer, Boehringer Ingelheim, Boston Scientific, Cytokinetics, Darma Inc., EchoNous Inc, Impulse Dynamics, Ionis Pharmaceutical, Janssen Research & Development LLC, Medscape/WebMD Global LLC, Merck, Novartis, Novo Nordisk, Prosciento Inc, Radcliffe Group Ltd., Roche Diagnostics, Sanofi, Siemens Healthcare Diagnostics and Us2.ai; and serves as co-founder & non-executive director of Us2.ai. Dr Martin R Cowie has provided consultancy advice to Medtronic, Boston Scientific, Abbott and AstraZeneca, related to aspects of digital health. As from 1 August 2022 he has been employed by AstraZeneca as Clinical Vice-President in Late Stage Research (Biopharmaceuticals).\n",
      "\n",
      "Dr Jasper Tromp is supported by the National University of Singapore Start-up grant, the tier 1 grant from the ministry of education and the CS-IRG New Investigator Grant from the National Medical Research Council; has received consulting or speaker fees from Daiichi-Sankyo, Boehringer Ingelheim, Roche diagnostics and Us2.ai, owns patent US-10702247-B2 related to artificial intelligence and echocardiography. Dr Devraj Jindal holds a copyright for the CARDipti ItchhaporiaOMETCARE-M software which is a clinical decision support system. Dr Julie Redfern owns a portion of the IP for the TEXTCARE software that was developed following the TEXTME study. She is also funded by a NHMRC Investigator Grant Leadership Level 2 [GNT2007946]. Dr Khung Keong Yeo has received research funding from Amgen, Astra Zeneca, Abbott Vascular, Bayer, Boston Scientific, Shockwave Medical, Nestle, Novartis (all significant, via institution); Consulting or honoraria feeds (all modest) from Abbott Vascular, Boston Scientific, Medtronic,  Amgen, Bayer, Novartis, Astra Zeneca, Peijia Medical; Speaker or Proctor fees from Shockwave Medical, Abbott Vascular, Boston Scientific, Medtronic, Philips, Alvimedica, Bayer, Biotronik, Orbus Neich, Shockwave Medical, Amgen, Novartis, Astra Zeneca, Microport, Terumo. Dr. Lopez-Jimenez is co-inventor of several AI algorithms that have been licensed to digital health companies and may receive financial compensation in the future. He is member of the advisory board for Anumana, an AI-based technology company. He has co-developed digital health technology to use 3D volumes to assess cardiometabolic risk with Selected Research Inc, and may receive financial benefit in the future. Dr Dorairaj Prabhakaran holds a copyright for the CARDipti ItchhaporiaOMETCARE-M software which is a clinical decision support system. Prof Carolyn SP Lam is supported by a Clinician Scientist Award from the National Medical Research Council of Singapore; has received research support from Bayer and Roche Diagnostics; has served as consultant or on the Advisory Board/Steering Committee/Executive Committee for Abbott, Actelion, Alleviant Medical, Allysta Pharma, Amgen, AnaCardio Ami Bhatt, Applied Therapeutics, AstraZeneca, Bayer, Boehringer Ingelheim, Boston Scientific, Cytokinetics, Darma Inc., EchoNous Inc, Impulse Dynamics, Ionis Pharmaceutical, Janssen Research & Development LLC, Medscape/WebMD Global LLC, Merck, Novartis, Novo Nordisk, Prosciento Inc, Radcliffe Group Ltd., Roche Diagnostics, Sanofi, Siemens Healthcare Diagnostics and Us2.ai; and serves as co-founder & non-executive director of Us2.ai. Dr Martin R Cowie has provided consultancy advice to Medtronic, Boston Scientific, Abbott and AstraZeneca, related to aspects of digital health. As from 1 August 2022 he has been employed by AstraZeneca as Clinical Vice-President in Late Stage Research (Biopharmaceuticals).\n",
      "\n",
      "Lopez-Jimenez, Francisco\n",
      "Dr Jasper Tromp is supported by the National University of Singapore Start-up grant, the tier 1 grant from the ministry of education and the CS-IRG New Investigator Grant from the National Medical Research Council; has received consulting or speaker fees from Daiichi-Sankyo, Boehringer Ingelheim, Roche diagnostics and Us2.ai, owns patent US-10702247-B2 related to artificial intelligence and echocardiography. Dr Devraj Jindal holds a copyright for the CARDipti ItchhaporiaOMETCARE-M software which is a clinical decision support system. Dr Julie Redfern owns a portion of the IP for the TEXTCARE software that was developed following the TEXTME study. She is also funded by a NHMRC Investigator Grant Leadership Level 2 [GNT2007946]. Dr Khung Keong Yeo has received research funding from Amgen, Astra Zeneca, Abbott Vascular, Bayer, Boston Scientific, Shockwave Medical, Nestle, Novartis (all significant, via institution); Consulting or honoraria feeds (all modest) from Abbott Vascular, Boston Scientific, Medtronic,  Amgen, Bayer, Novartis, Astra Zeneca, Peijia Medical; Speaker or Proctor fees from Shockwave Medical, Abbott Vascular, Boston Scientific, Medtronic, Philips, Alvimedica, Bayer, Biotronik, Orbus Neich, Shockwave Medical, Amgen, Novartis, Astra Zeneca, Microport, Terumo. Dr. Francisco Lopez-Jimenez is co-inventor of several AI algorithms that have been licensed to digital health companies and may receive financial compensation in the future. He is member of the advisory board for Anumana, an AI-based technology company. He has co-developed digital health technology to use 3D volumes to assess cardiometabolic risk with Selected Research Inc, and may receive financial benefit in the future. Dr Dorairaj Prabhakaran holds a copyright for the CARDipti ItchhaporiaOMETCARE-M software which is a clinical decision support system. Prof Carolyn SP Lam is supported by a Clinician Scientist Award from the National Medical Research Council of Singapore; has received research support from Bayer and Roche Diagnostics; has served as consultant or on the Advisory Board/Steering Committee/Executive Committee for Abbott, Actelion, Alleviant Medical, Allysta Pharma, Amgen, AnaCardio Ami Bhatt, Applied Therapeutics, AstraZeneca, Bayer, Boehringer Ingelheim, Boston Scientific, Cytokinetics, Darma Inc., EchoNous Inc, Impulse Dynamics, Ionis Pharmaceutical, Janssen Research & Development LLC, Medscape/WebMD Global LLC, Merck, Novartis, Novo Nordisk, Prosciento Inc, Radcliffe Group Ltd., Roche Diagnostics, Sanofi, Siemens Healthcare Diagnostics and Us2.ai; and serves as co-founder & non-executive director of Us2.ai. Dr Martin R Cowie has provided consultancy advice to Medtronic, Boston Scientific, Abbott and AstraZeneca, related to aspects of digital health. As from 1 August 2022 he has been employed by AstraZeneca as Clinical Vice-President in Late Stage Research (Biopharmaceuticals).\n",
      "\n",
      "Dr Jasper Tromp is supported by the National University of Singapore Start-up grant, the tier 1 grant from the ministry of education and the CS-IRG New Investigator Grant from the National Medical Research Council; has received consulting or speaker fees from Daiichi-Sankyo, Boehringer Ingelheim, Roche diagnostics and Us2.ai, owns patent US-10702247-B2 related to artificial intelligence and echocardiography. Dr Devraj Jindal holds a copyright for the CARDipti ItchhaporiaOMETCARE-M software which is a clinical decision support system. Dr Julie Redfern owns a portion of the IP for the TEXTCARE software that was developed following the TEXTME study. She is also funded by a NHMRC Investigator Grant Leadership Level 2 [GNT2007946]. Dr Khung Keong Yeo has received research funding from Amgen, Astra Zeneca, Abbott Vascular, Bayer, Boston Scientific, Shockwave Medical, Nestle, Novartis (all significant, via institution); Consulting or honoraria feeds (all modest) from Abbott Vascular, Boston Scientific, Medtronic,  Amgen, Bayer, Novartis, Astra Zeneca, Peijia Medical; Speaker or Proctor fees from Shockwave Medical, Abbott Vascular, Boston Scientific, Medtronic, Philips, Alvimedica, Bayer, Biotronik, Orbus Neich, Shockwave Medical, Amgen, Novartis, Astra Zeneca, Microport, Terumo. Dr. Francisco Lopez-Jimenez is co-inventor of several AI algorithms that have been licensed to digital health companies and may receive financial compensation in the future. He is member of the advisory board for Anumana, an AI-based technology company. He has co-developed digital health technology to use 3D volumes to assess cardiometabolic risk with Selected Research Inc, and may receive financial benefit in the future. Dr Dorairaj Prabhakaran holds a copyright for the CARDipti ItchhaporiaOMETCARE-M software which is a clinical decision support system. Prof Carolyn SP Lam is supported by a Clinician Scientist Award from the National Medical Research Council of Singapore; has received research support from Bayer and Roche Diagnostics; has served as consultant or on the Advisory Board/Steering Committee/Executive Committee for Abbott, Actelion, Alleviant Medical, Allysta Pharma, Amgen, AnaCardio Ami Bhatt, Applied Therapeutics, AstraZeneca, Bayer, Boehringer Ingelheim, Boston Scientific, Cytokinetics, Darma Inc., EchoNous Inc, Impulse Dynamics, Ionis Pharmaceutical, Janssen Research & Development LLC, Medscape/WebMD Global LLC, Merck, Novartis, Novo Nordisk, Prosciento Inc, Radcliffe Group Ltd., Roche Diagnostics, Sanofi, Siemens Healthcare Diagnostics and Us2.ai; and serves as co-founder & non-executive director of Us2.ai. Dr Martin R Cowie has provided consultancy advice to Medtronic, Boston Scientific, Abbott and AstraZeneca, related to aspects of digital health. As from 1 August 2022 he has been employed by AstraZeneca as Clinical Vice-President in Late Stage Research (Biopharmaceuticals).\n",
      "\n",
      "Dr Jasper Tromp is supported by the National University of Singapore Start-up grant, the tier 1 grant from the ministry of education and the CS-IRG New Investigator Grant from the National Medical Research Council; has received consulting or speaker fees from Daiichi-Sankyo, Boehringer Ingelheim, Roche diagnostics and Us2.ai, owns patent US-10702247-B2 related to artificial intelligence and echocardiography. Dr Devraj Jindal holds a copyright for the CARDipti ItchhaporiaOMETCARE-M software which is a clinical decision support system. Dr Julie Redfern owns a portion of the IP for the TEXTCARE software that was developed following the TEXTME study. She is also funded by a NHMRC Investigator Grant Leadership Level 2 [GNT2007946]. Dr Khung Keong Yeo has received research funding from Amgen, Astra Zeneca, Abbott Vascular, Bayer, Boston Scientific, Shockwave Medical, Nestle, Novartis (all significant, via institution); Consulting or honoraria feeds (all modest) from Abbott Vascular, Boston Scientific, Medtronic,  Amgen, Bayer, Novartis, Astra Zeneca, Peijia Medical; Speaker or Proctor fees from Shockwave Medical, Abbott Vascular, Boston Scientific, Medtronic, Philips, Alvimedica, Bayer, Biotronik, Orbus Neich, Shockwave Medical, Amgen, Novartis, Astra Zeneca, Microport, Terumo. Dr. Francisco Lopez-Jimenez is co-inventor of several AI algorithms that have been licensed to digital health companies and may receive financial compensation in the future. He is member of the advisory board for Anumana, an AI-based technology company. He has co-developed digital health technology to use 3D volumes to assess cardiometabolic risk with Selected Research Inc, and may receive financial benefit in the future. Dr Dorairaj Prabhakaran holds a copyright for the CARDipti ItchhaporiaOMETCARE-M software which is a clinical decision support system. Prof Carolyn SP Lam is supported by a Clinician Scientist Award from the National Medical Research Council of Singapore; has received research support from Bayer and Roche Diagnostics; has served as consultant or on the Advisory Board/Steering Committee/Executive Committee for Abbott, Actelion, Alleviant Medical, Allysta Pharma, Amgen, AnaCardio Ami Bhatt, Applied Therapeutics, AstraZeneca, Bayer, Boehringer Ingelheim, Boston Scientific, Cytokinetics, Darma Inc., EchoNous Inc, Impulse Dynamics, Ionis Pharmaceutical, Janssen Research & Development LLC, Medscape/WebMD Global LLC, Merck, Novartis, Novo Nordisk, Prosciento Inc, Radcliffe Group Ltd., Roche Diagnostics, Sanofi, Siemens Healthcare Diagnostics and Us2.ai; and serves as co-founder & non-executive director of Us2.ai. Dr Martin R Cowie has provided consultancy advice to Medtronic, Boston Scientific, Abbott and AstraZeneca, related to aspects of digital health. As from 1 August 2022 he has been employed by AstraZeneca as Clinical Vice-President in Late Stage Research (Biopharmaceuticals).\n",
      "\n",
      "Dr Jasper Tromp is supported by the National University of Singapore Start-up grant, the tier 1 grant from the ministry of education and the CS-IRG New Investigator Grant from the National Medical Research Council; has received consulting or speaker fees from Daiichi-Sankyo, Boehringer Ingelheim, Roche diagnostics and Us2.ai, owns patent US-10702247-B2 related to artificial intelligence and echocardiography. Dr Devraj Jindal holds a copyright for the CARDipti ItchhaporiaOMETCARE-M software which is a clinical decision support system. Dr Julie Redfern owns a portion of the IP for the TEXTCARE software that was developed following the TEXTME study. She is also funded by a NHMRC Investigator Grant Leadership Level 2 [GNT2007946]. Dr Khung Keong Yeo has received research funding from Amgen, Astra Zeneca, Abbott Vascular, Bayer, Boston Scientific, Shockwave Medical, Nestle, Novartis (all significant, via institution); Consulting or honoraria feeds (all modest) from Abbott Vascular, Boston Scientific, Medtronic,  Amgen, Bayer, Novartis, Astra Zeneca, Peijia Medical; Speaker or Proctor fees from Shockwave Medical, Abbott Vascular, Boston Scientific, Medtronic, Philips, Alvimedica, Bayer, Biotronik, Orbus Neich, Shockwave Medical, Amgen, Novartis, Astra Zeneca, Microport, Terumo. Dr. Francisco Lopez-Jimenez is co-inventor of several AI algorithms that have been licensed to digital health companies and may receive financial compensation in the future. He is member of the advisory board for Anumana, an AI-based technology company. He has co-developed digital health technology to use 3D volumes to assess cardiometabolic risk with Selected Research Inc, and may receive financial benefit in the future. Dr Dorairaj Prabhakaran holds a copyright for the CARDipti ItchhaporiaOMETCARE-M software which is a clinical decision support system. Prof Carolyn SP Lam is supported by a Clinician Scientist Award from the National Medical Research Council of Singapore; has received research support from Bayer and Roche Diagnostics; has served as consultant or on the Advisory Board/Steering Committee/Executive Committee for Abbott, Actelion, Alleviant Medical, Allysta Pharma, Amgen, AnaCardio Ami Bhatt, Applied Therapeutics, AstraZeneca, Bayer, Boehringer Ingelheim, Boston Scientific, Cytokinetics, Darma Inc., EchoNous Inc, Impulse Dynamics, Ionis Pharmaceutical, Janssen Research & Development LLC, Medscape/WebMD Global LLC, Merck, Novartis, Novo Nordisk, Prosciento Inc, Radcliffe Group Ltd., Roche Diagnostics, Sanofi, Siemens Healthcare Diagnostics and Us2.ai; and serves as co-founder & non-executive director of Us2.ai. Dr Martin R Cowie has provided consultancy advice to Medtronic, Boston Scientific, Abbott and AstraZeneca, related to aspects of digital health. As from 1 August 2022 he has been employed by AstraZeneca as Clinical Vice-President in Late Stage Research (Biopharmaceuticals).\n",
      "\n",
      "Dr Jasper Tromp is supported by the National University of Singapore Start-up grant, the tier 1 grant from the ministry of education and the CS-IRG New Investigator Grant from the National Medical Research Council; has received consulting or speaker fees from Daiichi-Sankyo, Boehringer Ingelheim, Roche diagnostics and Us2.ai, owns patent US-10702247-B2 related to artificial intelligence and echocardiography. Dr Devraj Jindal holds a copyright for the CARDipti ItchhaporiaOMETCARE-M software which is a clinical decision support system. Dr Julie Redfern owns a portion of the IP for the TEXTCARE software that was developed following the TEXTME study. She is also funded by a NHMRC Investigator Grant Leadership Level 2 [GNT2007946]. Dr Khung Keong Yeo has received research funding from Amgen, Astra Zeneca, Abbott Vascular, Bayer, Boston Scientific, Shockwave Medical, Nestle, Novartis (all significant, via institution); Consulting or honoraria feeds (all modest) from Abbott Vascular, Boston Scientific, Medtronic,  Amgen, Bayer, Novartis, Astra Zeneca, Peijia Medical; Speaker or Proctor fees from Shockwave Medical, Abbott Vascular, Boston Scientific, Medtronic, Philips, Alvimedica, Bayer, Biotronik, Orbus Neich, Shockwave Medical, Amgen, Novartis, Astra Zeneca, Microport, Terumo. Dr. Francisco Lopez-Jimenez is co-inventor of several AI algorithms that have been licensed to digital health companies and may receive financial compensation in the future. He is member of the advisory board for Anumana, an AI-based technology company. He has co-developed digital health technology to use 3D volumes to assess cardiometabolic risk with Selected Research Inc, and may receive financial benefit in the future. Dr Dorairaj Prabhakaran holds a copyright for the CARDipti ItchhaporiaOMETCARE-M software which is a clinical decision support system. Prof Carolyn SP Lam is supported by a Clinician Scientist Award from the National Medical Research Council of Singapore; has received research support from Bayer and Roche Diagnostics; has served as consultant or on the Advisory Board/Steering Committee/Executive Committee for Abbott, Actelion, Alleviant Medical, Allysta Pharma, Amgen, AnaCardio Ami Bhatt, Applied Therapeutics, AstraZeneca, Bayer, Boehringer Ingelheim, Boston Scientific, Cytokinetics, Darma Inc., EchoNous Inc, Impulse Dynamics, Ionis Pharmaceutical, Janssen Research & Development LLC, Medscape/WebMD Global LLC, Merck, Novartis, Novo Nordisk, Prosciento Inc, Radcliffe Group Ltd., Roche Diagnostics, Sanofi, Siemens Healthcare Diagnostics and Us2.ai; and serves as co-founder & non-executive director of Us2.ai. Dr Martin R Cowie has provided consultancy advice to Medtronic, Boston Scientific, Abbott and AstraZeneca, related to aspects of digital health. As from 1 August 2022 he has been employed by AstraZeneca as Clinical Vice-President in Late Stage Research (Biopharmaceuticals).\n",
      "\n",
      "Dr Jasper Tromp is supported by the National University of Singapore Start-up grant, the tier 1 grant from the ministry of education and the CS-IRG New Investigator Grant from the National Medical Research Council; has received consulting or speaker fees from Daiichi-Sankyo, Boehringer Ingelheim, Roche diagnostics and Us2.ai, owns patent US-10702247-B2 related to artificial intelligence and echocardiography. Dr Devraj Jindal holds a copyright for the CARDipti ItchhaporiaOMETCARE-M software which is a clinical decision support system. Dr Julie Redfern owns a portion of the IP for the TEXTCARE software that was developed following the TEXTME study. She is also funded by a NHMRC Investigator Grant Leadership Level 2 [GNT2007946]. Dr Khung Keong Yeo has received research funding from Amgen, Astra Zeneca, Abbott Vascular, Bayer, Boston Scientific, Shockwave Medical, Nestle, Novartis (all significant, via institution); Consulting or honoraria feeds (all modest) from Abbott Vascular, Boston Scientific, Medtronic,  Amgen, Bayer, Novartis, Astra Zeneca, Peijia Medical; Speaker or Proctor fees from Shockwave Medical, Abbott Vascular, Boston Scientific, Medtronic, Philips, Alvimedica, Bayer, Biotronik, Orbus Neich, Shockwave Medical, Amgen, Novartis, Astra Zeneca, Microport, Terumo. Dr. Francisco Lopez-Jimenez is co-inventor of several AI algorithms that have been licensed to digital health companies and may receive financial compensation in the future. He is member of the advisory board for Anumana, an AI-based technology company. He has co-developed digital health technology to use 3D volumes to assess cardiometabolic risk with Selected Research Inc, and may receive financial benefit in the future. Dr Dorairaj Prabhakaran holds a copyright for the CARDipti ItchhaporiaOMETCARE-M software which is a clinical decision support system. Prof Carolyn SP Lam is supported by a Clinician Scientist Award from the National Medical Research Council of Singapore; has received research support from Bayer and Roche Diagnostics; has served as consultant or on the Advisory Board/Steering Committee/Executive Committee for Abbott, Actelion, Alleviant Medical, Allysta Pharma, Amgen, AnaCardio Ami Bhatt, Applied Therapeutics, AstraZeneca, Bayer, Boehringer Ingelheim, Boston Scientific, Cytokinetics, Darma Inc., EchoNous Inc, Impulse Dynamics, Ionis Pharmaceutical, Janssen Research & Development LLC, Medscape/WebMD Global LLC, Merck, Novartis, Novo Nordisk, Prosciento Inc, Radcliffe Group Ltd., Roche Diagnostics, Sanofi, Siemens Healthcare Diagnostics and Us2.ai; and serves as co-founder & non-executive director of Us2.ai. Dr Martin R Cowie has provided consultancy advice to Medtronic, Boston Scientific, Abbott and AstraZeneca, related to aspects of digital health. As from 1 August 2022 he has been employed by AstraZeneca as Clinical Vice-President in Late Stage Research (Biopharmaceuticals).\n",
      "\n",
      "Dr Jasper Tromp is supported by the National University of Singapore Start-up grant, the tier 1 grant from the ministry of education and the CS-IRG New Investigator Grant from the National Medical Research Council; has received consulting or speaker fees from Daiichi-Sankyo, Boehringer Ingelheim, Roche diagnostics and Us2.ai, owns patent US-10702247-B2 related to artificial intelligence and echocardiography. Dr Devraj Jindal holds a copyright for the CARDipti ItchhaporiaOMETCARE-M software which is a clinical decision support system. Dr Julie Redfern owns a portion of the IP for the TEXTCARE software that was developed following the TEXTME study. She is also funded by a NHMRC Investigator Grant Leadership Level 2 [GNT2007946]. Dr Khung Keong Yeo has received research funding from Amgen, Astra Zeneca, Abbott Vascular, Bayer, Boston Scientific, Shockwave Medical, Nestle, Novartis (all significant, via institution); Consulting or honoraria feeds (all modest) from Abbott Vascular, Boston Scientific, Medtronic,  Amgen, Bayer, Novartis, Astra Zeneca, Peijia Medical; Speaker or Proctor fees from Shockwave Medical, Abbott Vascular, Boston Scientific, Medtronic, Philips, Alvimedica, Bayer, Biotronik, Orbus Neich, Shockwave Medical, Amgen, Novartis, Astra Zeneca, Microport, Terumo. Dr. Francisco Lopez-Jimenez is co-inventor of several AI algorithms that have been licensed to digital health companies and may receive financial compensation in the future. He is member of the advisory board for Anumana, an AI-based technology company. He has co-developed digital health technology to use 3D volumes to assess cardiometabolic risk with Selected Research Inc, and may receive financial benefit in the future. Dr Dorairaj Prabhakaran holds a copyright for the CARDipti ItchhaporiaOMETCARE-M software which is a clinical decision support system. Prof Carolyn SP Lam is supported by a Clinician Scientist Award from the National Medical Research Council of Singapore; has received research support from Bayer and Roche Diagnostics; has served as consultant or on the Advisory Board/Steering Committee/Executive Committee for Abbott, Actelion, Alleviant Medical, Allysta Pharma, Amgen, AnaCardio Ami Bhatt, Applied Therapeutics, AstraZeneca, Bayer, Boehringer Ingelheim, Boston Scientific, Cytokinetics, Darma Inc., EchoNous Inc, Impulse Dynamics, Ionis Pharmaceutical, Janssen Research & Development LLC, Medscape/WebMD Global LLC, Merck, Novartis, Novo Nordisk, Prosciento Inc, Radcliffe Group Ltd., Roche Diagnostics, Sanofi, Siemens Healthcare Diagnostics and Us2.ai; and serves as co-founder & non-executive director of Us2.ai. Dr Martin R Cowie has provided consultancy advice to Medtronic, Boston Scientific, Abbott and AstraZeneca, related to aspects of digital health. As from 1 August 2022 he has been employed by AstraZeneca as Clinical Vice-President in Late Stage Research (Biopharmaceuticals).\n",
      "\n",
      "Keong Yeo, Khung\n",
      "Dr Jasper Tromp is supported by the National University of Singapore Start-up grant, the tier 1 grant from the ministry of education and the CS-IRG New Investigator Grant from the National Medical Research Council; has received consulting or speaker fees from Daiichi-Sankyo, Boehringer Ingelheim, Roche diagnostics and Us2.ai, owns patent US-10702247-B2 related to artificial intelligence and echocardiography. Dr Devraj Jindal holds a copyright for the CARDipti ItchhaporiaOMETCARE-M software which is a clinical decision support system. Dr Julie Redfern owns a portion of the IP for the TEXTCARE software that was developed following the TEXTME study. She is also funded by a NHMRC Investigator Grant Leadership Level 2 [GNT2007946]. Dr Khung Keong Yeo has received research funding from Amgen, Astra Zeneca, Abbott Vascular, Bayer, Boston Scientific, Shockwave Medical, Nestle, Novartis (all significant, via institution); Consulting or honoraria feeds (all modest) from Abbott Vascular, Boston Scientific, Medtronic,  Amgen, Bayer, Novartis, Astra Zeneca, Peijia Medical; Speaker or Proctor fees from Shockwave Medical, Abbott Vascular, Boston Scientific, Medtronic, Philips, Alvimedica, Bayer, Biotronik, Orbus Neich, Shockwave Medical, Amgen, Novartis, Astra Zeneca, Microport, Terumo. Dr. Francisco Lopez-Jimenez is co-inventor of several AI algorithms that have been licensed to digital health companies and may receive financial compensation in the future. He is member of the advisory board for Anumana, an AI-based technology company. He has co-developed digital health technology to use 3D volumes to assess cardiometabolic risk with Selected Research Inc, and may receive financial benefit in the future. Dr Dorairaj Prabhakaran holds a copyright for the CARDipti ItchhaporiaOMETCARE-M software which is a clinical decision support system. Prof Carolyn SP Lam is supported by a Clinician Scientist Award from the National Medical Research Council of Singapore; has received research support from Bayer and Roche Diagnostics; has served as consultant or on the Advisory Board/Steering Committee/Executive Committee for Abbott, Actelion, Alleviant Medical, Allysta Pharma, Amgen, AnaCardio Ami Bhatt, Applied Therapeutics, AstraZeneca, Bayer, Boehringer Ingelheim, Boston Scientific, Cytokinetics, Darma Inc., EchoNous Inc, Impulse Dynamics, Ionis Pharmaceutical, Janssen Research & Development LLC, Medscape/WebMD Global LLC, Merck, Novartis, Novo Nordisk, Prosciento Inc, Radcliffe Group Ltd., Roche Diagnostics, Sanofi, Siemens Healthcare Diagnostics and Us2.ai; and serves as co-founder & non-executive director of Us2.ai. Dr Martin R Cowie has provided consultancy advice to Medtronic, Boston Scientific, Abbott and AstraZeneca, related to aspects of digital health. As from 1 August 2022 he has been employed by AstraZeneca as Clinical Vice-President in Late Stage Research (Biopharmaceuticals).\n",
      "\n",
      "Dr Jasper Tromp is supported by the National University of Singapore Start-up grant, the tier 1 grant from the ministry of education and the CS-IRG New Investigator Grant from the National Medical Research Council; has received consulting or speaker fees from Daiichi-Sankyo, Boehringer Ingelheim, Roche diagnostics and Us2.ai, owns patent US-10702247-B2 related to artificial intelligence and echocardiography. Dr Devraj Jindal holds a copyright for the CARDipti ItchhaporiaOMETCARE-M software which is a clinical decision support system. Dr Julie Redfern owns a portion of the IP for the TEXTCARE software that was developed following the TEXTME study. She is also funded by a NHMRC Investigator Grant Leadership Level 2 [GNT2007946]. Dr Khung Keong Yeo has received research funding from Amgen, Astra Zeneca, Abbott Vascular, Bayer, Boston Scientific, Shockwave Medical, Nestle, Novartis (all significant, via institution); Consulting or honoraria feeds (all modest) from Abbott Vascular, Boston Scientific, Medtronic,  Amgen, Bayer, Novartis, Astra Zeneca, Peijia Medical; Speaker or Proctor fees from Shockwave Medical, Abbott Vascular, Boston Scientific, Medtronic, Philips, Alvimedica, Bayer, Biotronik, Orbus Neich, Shockwave Medical, Amgen, Novartis, Astra Zeneca, Microport, Terumo. Dr. Francisco Lopez-Jimenez is co-inventor of several AI algorithms that have been licensed to digital health companies and may receive financial compensation in the future. He is member of the advisory board for Anumana, an AI-based technology company. He has co-developed digital health technology to use 3D volumes to assess cardiometabolic risk with Selected Research Inc, and may receive financial benefit in the future. Dr Dorairaj Prabhakaran holds a copyright for the CARDipti ItchhaporiaOMETCARE-M software which is a clinical decision support system. Prof Carolyn SP Lam is supported by a Clinician Scientist Award from the National Medical Research Council of Singapore; has received research support from Bayer and Roche Diagnostics; has served as consultant or on the Advisory Board/Steering Committee/Executive Committee for Abbott, Actelion, Alleviant Medical, Allysta Pharma, Amgen, AnaCardio Ami Bhatt, Applied Therapeutics, AstraZeneca, Bayer, Boehringer Ingelheim, Boston Scientific, Cytokinetics, Darma Inc., EchoNous Inc, Impulse Dynamics, Ionis Pharmaceutical, Janssen Research & Development LLC, Medscape/WebMD Global LLC, Merck, Novartis, Novo Nordisk, Prosciento Inc, Radcliffe Group Ltd., Roche Diagnostics, Sanofi, Siemens Healthcare Diagnostics and Us2.ai; and serves as co-founder & non-executive director of Us2.ai. Dr Martin R Cowie has provided consultancy advice to Medtronic, Boston Scientific, Abbott and AstraZeneca, related to aspects of digital health. As from 1 August 2022 he has been employed by AstraZeneca as Clinical Vice-President in Late Stage Research (Biopharmaceuticals).\n",
      "\n",
      "Prabhakaran, Dorairaj\n",
      "Dr Jasper Tromp is supported by the National University of Singapore Start-up grant, the tier 1 grant from the ministry of education and the CS-IRG New Investigator Grant from the National Medical Research Council; has received consulting or speaker fees from Daiichi-Sankyo, Boehringer Ingelheim, Roche diagnostics and Us2.ai, owns patent US-10702247-B2 related to artificial intelligence and echocardiography. Dr Devraj Jindal holds a copyright for the CARDipti ItchhaporiaOMETCARE-M software which is a clinical decision support system. Dr Julie Redfern owns a portion of the IP for the TEXTCARE software that was developed following the TEXTME study. She is also funded by a NHMRC Investigator Grant Leadership Level 2 [GNT2007946]. Dr Khung Keong Yeo has received research funding from Amgen, Astra Zeneca, Abbott Vascular, Bayer, Boston Scientific, Shockwave Medical, Nestle, Novartis (all significant, via institution); Consulting or honoraria feeds (all modest) from Abbott Vascular, Boston Scientific, Medtronic,  Amgen, Bayer, Novartis, Astra Zeneca, Peijia Medical; Speaker or Proctor fees from Shockwave Medical, Abbott Vascular, Boston Scientific, Medtronic, Philips, Alvimedica, Bayer, Biotronik, Orbus Neich, Shockwave Medical, Amgen, Novartis, Astra Zeneca, Microport, Terumo. Dr. Francisco Lopez-Jimenez is co-inventor of several AI algorithms that have been licensed to digital health companies and may receive financial compensation in the future. He is member of the advisory board for Anumana, an AI-based technology company. He has co-developed digital health technology to use 3D volumes to assess cardiometabolic risk with Selected Research Inc, and may receive financial benefit in the future. Dr Dorairaj Prabhakaran holds a copyright for the CARDipti ItchhaporiaOMETCARE-M software which is a clinical decision support system. Prof Carolyn SP Lam is supported by a Clinician Scientist Award from the National Medical Research Council of Singapore; has received research support from Bayer and Roche Diagnostics; has served as consultant or on the Advisory Board/Steering Committee/Executive Committee for Abbott, Actelion, Alleviant Medical, Allysta Pharma, Amgen, AnaCardio Ami Bhatt, Applied Therapeutics, AstraZeneca, Bayer, Boehringer Ingelheim, Boston Scientific, Cytokinetics, Darma Inc., EchoNous Inc, Impulse Dynamics, Ionis Pharmaceutical, Janssen Research & Development LLC, Medscape/WebMD Global LLC, Merck, Novartis, Novo Nordisk, Prosciento Inc, Radcliffe Group Ltd., Roche Diagnostics, Sanofi, Siemens Healthcare Diagnostics and Us2.ai; and serves as co-founder & non-executive director of Us2.ai. Dr Martin R Cowie has provided consultancy advice to Medtronic, Boston Scientific, Abbott and AstraZeneca, related to aspects of digital health. As from 1 August 2022 he has been employed by AstraZeneca as Clinical Vice-President in Late Stage Research (Biopharmaceuticals).\n",
      "\n",
      "Lam, Carolyn S.P.\n",
      "Dr Jasper Tromp is supported by the National University of Singapore Start-up grant, the tier 1 grant from the ministry of education and the CS-IRG New Investigator Grant from the National Medical Research Council; has received consulting or speaker fees from Daiichi-Sankyo, Boehringer Ingelheim, Roche diagnostics and Us2.ai, owns patent US-10702247-B2 related to artificial intelligence and echocardiography. Dr Devraj Jindal holds a copyright for the CARDipti ItchhaporiaOMETCARE-M software which is a clinical decision support system. Dr Julie Redfern owns a portion of the IP for the TEXTCARE software that was developed following the TEXTME study. She is also funded by a NHMRC Investigator Grant Leadership Level 2 [GNT2007946]. Dr Khung Keong Yeo has received research funding from Amgen, Astra Zeneca, Abbott Vascular, Bayer, Boston Scientific, Shockwave Medical, Nestle, Novartis (all significant, via institution); Consulting or honoraria feeds (all modest) from Abbott Vascular, Boston Scientific, Medtronic,  Amgen, Bayer, Novartis, Astra Zeneca, Peijia Medical; Speaker or Proctor fees from Shockwave Medical, Abbott Vascular, Boston Scientific, Medtronic, Philips, Alvimedica, Bayer, Biotronik, Orbus Neich, Shockwave Medical, Amgen, Novartis, Astra Zeneca, Microport, Terumo. Dr. Francisco Lopez-Jimenez is co-inventor of several AI algorithms that have been licensed to digital health companies and may receive financial compensation in the future. He is member of the advisory board for Anumana, an AI-based technology company. He has co-developed digital health technology to use 3D volumes to assess cardiometabolic risk with Selected Research Inc, and may receive financial benefit in the future. Dr Dorairaj Prabhakaran holds a copyright for the CARDipti ItchhaporiaOMETCARE-M software which is a clinical decision support system. Prof Carolyn S.P. Lam is supported by a Clinician Scientist Award from the National Medical Research Council of Singapore; has received research support from Bayer and Roche Diagnostics; has served as consultant or on the Advisory Board/Steering Committee/Executive Committee for Abbott, Actelion, Alleviant Medical, Allysta Pharma, Amgen, AnaCardio Ami Bhatt, Applied Therapeutics, AstraZeneca, Bayer, Boehringer Ingelheim, Boston Scientific, Cytokinetics, Darma Inc., EchoNous Inc, Impulse Dynamics, Ionis Pharmaceutical, Janssen Research & Development LLC, Medscape/WebMD Global LLC, Merck, Novartis, Novo Nordisk, Prosciento Inc, Radcliffe Group Ltd., Roche Diagnostics, Sanofi, Siemens Healthcare Diagnostics and Us2.ai; and serves as co-founder & non-executive director of Us2.ai. Dr Martin R Cowie has provided consultancy advice to Medtronic, Boston Scientific, Abbott and AstraZeneca, related to aspects of digital health. As from 1 August 2022 he has been employed by AstraZeneca as Clinical Vice-President in Late Stage Research (Biopharmaceuticals).\n",
      "\n",
      "Cowie, Martin R.\n",
      "Dr Jasper Tromp is supported by the National University of Singapore Start-up grant, the tier 1 grant from the ministry of education and the CS-IRG New Investigator Grant from the National Medical Research Council; has received consulting or speaker fees from Daiichi-Sankyo, Boehringer Ingelheim, Roche diagnostics and Us2.ai, owns patent US-10702247-B2 related to artificial intelligence and echocardiography. Dr Devraj Jindal holds a copyright for the CARDipti ItchhaporiaOMETCARE-M software which is a clinical decision support system. Dr Julie Redfern owns a portion of the IP for the TEXTCARE software that was developed following the TEXTME study. She is also funded by a NHMRC Investigator Grant Leadership Level 2 [GNT2007946]. Dr Khung Keong Yeo has received research funding from Amgen, Astra Zeneca, Abbott Vascular, Bayer, Boston Scientific, Shockwave Medical, Nestle, Novartis (all significant, via institution); Consulting or honoraria feeds (all modest) from Abbott Vascular, Boston Scientific, Medtronic,  Amgen, Bayer, Novartis, Astra Zeneca, Peijia Medical; Speaker or Proctor fees from Shockwave Medical, Abbott Vascular, Boston Scientific, Medtronic, Philips, Alvimedica, Bayer, Biotronik, Orbus Neich, Shockwave Medical, Amgen, Novartis, Astra Zeneca, Microport, Terumo. Dr. Francisco Lopez-Jimenez is co-inventor of several AI algorithms that have been licensed to digital health companies and may receive financial compensation in the future. He is member of the advisory board for Anumana, an AI-based technology company. He has co-developed digital health technology to use 3D volumes to assess cardiometabolic risk with Selected Research Inc, and may receive financial benefit in the future. Dr Dorairaj Prabhakaran holds a copyright for the CARDipti ItchhaporiaOMETCARE-M software which is a clinical decision support system. Prof Carolyn S.P. Lam is supported by a Clinician Scientist Award from the National Medical Research Council of Singapore; has received research support from Bayer and Roche Diagnostics; has served as consultant or on the Advisory Board/Steering Committee/Executive Committee for Abbott, Actelion, Alleviant Medical, Allysta Pharma, Amgen, AnaCardio Ami Bhatt, Applied Therapeutics, AstraZeneca, Bayer, Boehringer Ingelheim, Boston Scientific, Cytokinetics, Darma Inc., EchoNous Inc, Impulse Dynamics, Ionis Pharmaceutical, Janssen Research & Development LLC, Medscape/WebMD Global LLC, Merck, Novartis, Novo Nordisk, Prosciento Inc, Radcliffe Group Ltd., Roche Diagnostics, Sanofi, Siemens Healthcare Diagnostics and Us2.ai; and serves as co-founder & non-executive director of Us2.ai. Dr Martin R. Cowie has provided consultancy advice to Medtronic, Boston Scientific, Abbott and AstraZeneca, related to aspects of digital health. As from 1 August 2022 he has been employed by AstraZeneca as Clinical Vice-President in Late Stage Research (Biopharmaceuticals).\n",
      "\n",
      "Samad, Zainab\n",
      "The following authors declare that there is no conflict of interest: Zainab Samad MBBS, MHS, FACC Ali Aahil Noorali MBBS Awais Farhad MBBS, FCPS Safia Awan MSc Nada Qaiser Qureshi MBBS Minaz Mawani MPH Mushyada Ali BE Laiba Masood Ghufran Adnan MBBS, FCPS, MRCP Linda K Shaw MS Fahim Haider Jafary MD, FACC, FSCAI Eric J Velazquez MD Gerald S Bloomfield MD, MPH, FACC, FASE, FAHA Javed Tai MBBS, FCPS COI for remaining authors: Salim S. Virani MD, PhD, FACC, FAHA, FASPC Research support: U.S. Department of Veterans Affairs, World Heart Federation, Tahir and Jooma Family; Honorarium: American College of Cardiology (Associate Editor for Innovations, acc.org). Zulfiqar Bhutta MBBS, FRCPCH, FAAP, PhD Executive Director of NCD Child Other authors declare that there is no conflict of interest.\n",
      "\n",
      "Aahil Noorali, Ali\n",
      "The following authors declare that there is no conflict of interest: Zainab Samad MBBS, MHS, FACC Ali Aahil Noorali MBBS Awais Farhad MBBS, FCPS Safia Awan MSc Nada Qaiser Qureshi MBBS Minaz Mawani MPH Mushyada Ali BE Laiba Masood Ghufran Adnan MBBS, FCPS, MRCP Linda K Shaw MS Fahim Haider Jafary MD, FACC, FSCAI Eric J Velazquez MD Gerald S Bloomfield MD, MPH, FACC, FASE, FAHA Javed Tai MBBS, FCPS COI for remaining authors: Salim S. Virani MD, PhD, FACC, FAHA, FASPC Research support: U.S. Department of Veterans Affairs, World Heart Federation, Tahir and Jooma Family; Honorarium: American College of Cardiology (Associate Editor for Innovations, acc.org). Zulfiqar Bhutta MBBS, FRCPCH, FAAP, PhD Executive Director of NCD Child Other authors declare that there is no conflict of interest.\n",
      "\n",
      "Farhad, Awais\n",
      "The following authors declare that there is no conflict of interest: Zainab Samad MBBS, MHS, FACC Ali Aahil Noorali MBBS Awais Farhad MBBS, FCPS Safia Awan MSc Nada Qaiser Qureshi MBBS Minaz Mawani MPH Mushyada Ali BE Laiba Masood Ghufran Adnan MBBS, FCPS, MRCP Linda K Shaw MS Fahim Haider Jafary MD, FACC, FSCAI Eric J Velazquez MD Gerald S Bloomfield MD, MPH, FACC, FASE, FAHA Javed Tai MBBS, FCPS COI for remaining authors: Salim S. Virani MD, PhD, FACC, FAHA, FASPC Research support: U.S. Department of Veterans Affairs, World Heart Federation, Tahir and Jooma Family; Honorarium: American College of Cardiology (Associate Editor for Innovations, acc.org). Zulfiqar Bhutta MBBS, FRCPCH, FAAP, PhD Executive Director of NCD Child Other authors declare that there is no conflict of interest.\n",
      "\n",
      "Awan, Safia\n",
      "The following authors declare that there is no conflict of interest: Zainab Samad MBBS, MHS, FACC Ali Aahil Noorali MBBS Awais Farhad MBBS, FCPS Safia Awan MSc Nada Qaiser Qureshi MBBS Minaz Mawani MPH Mushyada Ali BE Laiba Masood Ghufran Adnan MBBS, FCPS, MRCP Linda K Shaw MS Fahim Haider Jafary MD, FACC, FSCAI Eric J Velazquez MD Gerald S Bloomfield MD, MPH, FACC, FASE, FAHA Javed Tai MBBS, FCPS COI for remaining authors: Salim S. Virani MD, PhD, FACC, FAHA, FASPC Research support: U.S. Department of Veterans Affairs, World Heart Federation, Tahir and Jooma Family; Honorarium: American College of Cardiology (Associate Editor for Innovations, acc.org). Zulfiqar Bhutta MBBS, FRCPCH, FAAP, PhD Executive Director of NCD Child Other authors declare that there is no conflict of interest.\n",
      "\n",
      "Qaiser Qureshi, Nada\n",
      "The following authors declare that there is no conflict of interest: Zainab Samad MBBS, MHS, FACC Ali Aahil Noorali MBBS Awais Farhad MBBS, FCPS Safia Awan MSc Nada Qaiser Qureshi MBBS Minaz Mawani MPH Mushyada Ali BE Laiba Masood Ghufran Adnan MBBS, FCPS, MRCP Linda K Shaw MS Fahim Haider Jafary MD, FACC, FSCAI Eric J Velazquez MD Gerald S Bloomfield MD, MPH, FACC, FASE, FAHA Javed Tai MBBS, FCPS COI for remaining authors: Salim S. Virani MD, PhD, FACC, FAHA, FASPC Research support: U.S. Department of Veterans Affairs, World Heart Federation, Tahir and Jooma Family; Honorarium: American College of Cardiology (Associate Editor for Innovations, acc.org). Zulfiqar Bhutta MBBS, FRCPCH, FAAP, PhD Executive Director of NCD Child Other authors declare that there is no conflict of interest.\n",
      "\n",
      "Mawani, Minaz\n",
      "The following authors declare that there is no conflict of interest: Zainab Samad MBBS, MHS, FACC Ali Aahil Noorali MBBS Awais Farhad MBBS, FCPS Safia Awan MSc Nada Qaiser Qureshi MBBS Minaz Mawani MPH Mushyada Ali BE Laiba Masood Ghufran Adnan MBBS, FCPS, MRCP Linda K Shaw MS Fahim Haider Jafary MD, FACC, FSCAI Eric J Velazquez MD Gerald S Bloomfield MD, MPH, FACC, FASE, FAHA Javed Tai MBBS, FCPS COI for remaining authors: Salim S. Virani MD, PhD, FACC, FAHA, FASPC Research support: U.S. Department of Veterans Affairs, World Heart Federation, Tahir and Jooma Family; Honorarium: American College of Cardiology (Associate Editor for Innovations, acc.org). Zulfiqar Bhutta MBBS, FRCPCH, FAAP, PhD Executive Director of NCD Child Other authors declare that there is no conflict of interest.\n",
      "\n",
      "Ali, Mushyada\n",
      "The following authors declare that there is no conflict of interest: Zainab Samad MBBS, MHS, FACC Ali Aahil Noorali MBBS Awais Farhad MBBS, FCPS Safia Awan MSc Nada Qaiser Qureshi MBBS Minaz Mawani MPH Mushyada Ali BE Laiba Masood Ghufran Adnan MBBS, FCPS, MRCP Linda K Shaw MS Fahim Haider Jafary MD, FACC, FSCAI Eric J Velazquez MD Gerald S Bloomfield MD, MPH, FACC, FASE, FAHA Javed Tai MBBS, FCPS COI for remaining authors: Salim S. Virani MD, PhD, FACC, FAHA, FASPC Research support: U.S. Department of Veterans Affairs, World Heart Federation, Tahir and Jooma Family; Honorarium: American College of Cardiology (Associate Editor for Innovations, acc.org). Zulfiqar Bhutta MBBS, FRCPCH, FAAP, PhD Executive Director of NCD Child Other authors declare that there is no conflict of interest.\n",
      "\n",
      "Masood, Laiba\n",
      "The following authors declare that there is no conflict of interest: Zainab Samad MBBS, MHS, FACC Ali Aahil Noorali MBBS Awais Farhad MBBS, FCPS Safia Awan MSc Nada Qaiser Qureshi MBBS Minaz Mawani MPH Mushyada Ali BE Laiba Masood Ghufran Adnan MBBS, FCPS, MRCP Linda K Shaw MS Fahim Haider Jafary MD, FACC, FSCAI Eric J Velazquez MD Gerald S Bloomfield MD, MPH, FACC, FASE, FAHA Javed Tai MBBS, FCPS COI for remaining authors: Salim S. Virani MD, PhD, FACC, FAHA, FASPC Research support: U.S. Department of Veterans Affairs, World Heart Federation, Tahir and Jooma Family; Honorarium: American College of Cardiology (Associate Editor for Innovations, acc.org). Zulfiqar Bhutta MBBS, FRCPCH, FAAP, PhD Executive Director of NCD Child Other authors declare that there is no conflict of interest.\n",
      "\n",
      "Adnan, Ghufran\n",
      "The following authors declare that there is no conflict of interest: Zainab Samad MBBS, MHS, FACC Ali Aahil Noorali MBBS Awais Farhad MBBS, FCPS Safia Awan MSc Nada Qaiser Qureshi MBBS Minaz Mawani MPH Mushyada Ali BE Laiba Masood Ghufran Adnan MBBS, FCPS, MRCP Linda K Shaw MS Fahim Haider Jafary MD, FACC, FSCAI Eric J Velazquez MD Gerald S Bloomfield MD, MPH, FACC, FASE, FAHA Javed Tai MBBS, FCPS COI for remaining authors: Salim S. Virani MD, PhD, FACC, FAHA, FASPC Research support: U.S. Department of Veterans Affairs, World Heart Federation, Tahir and Jooma Family; Honorarium: American College of Cardiology (Associate Editor for Innovations, acc.org). Zulfiqar Bhutta MBBS, FRCPCH, FAAP, PhD Executive Director of NCD Child Other authors declare that there is no conflict of interest.\n",
      "\n",
      "Shaw, Linda K.\n",
      "The following authors declare that there is no conflict of interest: Zainab Samad MBBS, MHS, FACC Ali Aahil Noorali MBBS Awais Farhad MBBS, FCPS Safia Awan MSc Nada Qaiser Qureshi MBBS Minaz Mawani MPH Mushyada Ali BE Laiba Masood Ghufran Adnan MBBS, FCPS, MRCP Linda K. Shaw MS Fahim Haider Jafary MD, FACC, FSCAI Eric J Velazquez MD Gerald S Bloomfield MD, MPH, FACC, FASE, FAHA Javed Tai MBBS, FCPS COI for remaining authors: Salim S. Virani MD, PhD, FACC, FAHA, FASPC Research support: U.S. Department of Veterans Affairs, World Heart Federation, Tahir and Jooma Family; Honorarium: American College of Cardiology (Associate Editor for Innovations, acc.org). Zulfiqar Bhutta MBBS, FRCPCH, FAAP, PhD Executive Director of NCD Child Other authors declare that there is no conflict of interest.\n",
      "\n",
      "Haider Jafary, Fahim\n",
      "The following authors declare that there is no conflict of interest: Zainab Samad MBBS, MHS, FACC Ali Aahil Noorali MBBS Awais Farhad MBBS, FCPS Safia Awan MSc Nada Qaiser Qureshi MBBS Minaz Mawani MPH Mushyada Ali BE Laiba Masood Ghufran Adnan MBBS, FCPS, MRCP Linda K. Shaw MS Fahim Haider Jafary MD, FACC, FSCAI Eric J Velazquez MD Gerald S Bloomfield MD, MPH, FACC, FASE, FAHA Javed Tai MBBS, FCPS COI for remaining authors: Salim S. Virani MD, PhD, FACC, FAHA, FASPC Research support: U.S. Department of Veterans Affairs, World Heart Federation, Tahir and Jooma Family; Honorarium: American College of Cardiology (Associate Editor for Innovations, acc.org). Zulfiqar Bhutta MBBS, FRCPCH, FAAP, PhD Executive Director of NCD Child Other authors declare that there is no conflict of interest.\n",
      "\n",
      "Virani, Salim S.\n",
      "The following authors declare that there is no conflict of interest: Zainab Samad MBBS, MHS, FACC Ali Aahil Noorali MBBS Awais Farhad MBBS, FCPS Safia Awan MSc Nada Qaiser Qureshi MBBS Minaz Mawani MPH Mushyada Ali BE Laiba Masood Ghufran Adnan MBBS, FCPS, MRCP Linda K. Shaw MS Fahim Haider Jafary MD, FACC, FSCAI Eric J Velazquez MD Gerald S Bloomfield MD, MPH, FACC, FASE, FAHA Javed Tai MBBS, FCPS COI for remaining authors: Salim S. Virani MD, PhD, FACC, FAHA, FASPC Research support: U.S. Department of Veterans Affairs, World Heart Federation, Tahir and Jooma Family; Honorarium: American College of Cardiology (Associate Editor for Innovations, acc.org). Zulfiqar Bhutta MBBS, FRCPCH, FAAP, PhD Executive Director of NCD Child Other authors declare that there is no conflict of interest.\n",
      "\n",
      "Velazquez, Eric J.\n",
      "The following authors declare that there is no conflict of interest: Zainab Samad MBBS, MHS, FACC Ali Aahil Noorali MBBS Awais Farhad MBBS, FCPS Safia Awan MSc Nada Qaiser Qureshi MBBS Minaz Mawani MPH Mushyada Ali BE Laiba Masood Ghufran Adnan MBBS, FCPS, MRCP Linda K. Shaw MS Fahim Haider Jafary MD, FACC, FSCAI Eric J. Velazquez MD Gerald S Bloomfield MD, MPH, FACC, FASE, FAHA Javed Tai MBBS, FCPS COI for remaining authors: Salim S. Virani MD, PhD, FACC, FAHA, FASPC Research support: U.S. Department of Veterans Affairs, World Heart Federation, Tahir and Jooma Family; Honorarium: American College of Cardiology (Associate Editor for Innovations, acc.org). Zulfiqar Bhutta MBBS, FRCPCH, FAAP, PhD Executive Director of NCD Child Other authors declare that there is no conflict of interest.\n",
      "\n",
      "Bhutta, Zulfiqar\n",
      "The following authors declare that there is no conflict of interest: Zainab Samad MBBS, MHS, FACC Ali Aahil Noorali MBBS Awais Farhad MBBS, FCPS Safia Awan MSc Nada Qaiser Qureshi MBBS Minaz Mawani MPH Mushyada Ali BE Laiba Masood Ghufran Adnan MBBS, FCPS, MRCP Linda K. Shaw MS Fahim Haider Jafary MD, FACC, FSCAI Eric J. Velazquez MD Gerald S Bloomfield MD, MPH, FACC, FASE, FAHA Javed Tai MBBS, FCPS COI for remaining authors: Salim S. Virani MD, PhD, FACC, FAHA, FASPC Research support: U.S. Department of Veterans Affairs, World Heart Federation, Tahir and Jooma Family; Honorarium: American College of Cardiology (Associate Editor for Innovations, acc.org). Zulfiqar Bhutta MBBS, FRCPCH, FAAP, PhD Executive Director of NCD Child Other authors declare that there is no conflict of interest.\n",
      "\n",
      "Bloomfield, Gerald S.\n",
      "The following authors declare that there is no conflict of interest: Zainab Samad MBBS, MHS, FACC Ali Aahil Noorali MBBS Awais Farhad MBBS, FCPS Safia Awan MSc Nada Qaiser Qureshi MBBS Minaz Mawani MPH Mushyada Ali BE Laiba Masood Ghufran Adnan MBBS, FCPS, MRCP Linda K. Shaw MS Fahim Haider Jafary MD, FACC, FSCAI Eric J. Velazquez MD Gerald S. Bloomfield MD, MPH, FACC, FASE, FAHA Javed Tai MBBS, FCPS COI for remaining authors: Salim S. Virani MD, PhD, FACC, FAHA, FASPC Research support: U.S. Department of Veterans Affairs, World Heart Federation, Tahir and Jooma Family; Honorarium: American College of Cardiology (Associate Editor for Innovations, acc.org). Zulfiqar Bhutta MBBS, FRCPCH, FAAP, PhD Executive Director of NCD Child Other authors declare that there is no conflict of interest.\n",
      "\n",
      "Tai, Javed\n",
      "The following authors declare that there is no conflict of interest: Zainab Samad MBBS, MHS, FACC Ali Aahil Noorali MBBS Awais Farhad MBBS, FCPS Safia Awan MSc Nada Qaiser Qureshi MBBS Minaz Mawani MPH Mushyada Ali BE Laiba Masood Ghufran Adnan MBBS, FCPS, MRCP Linda K. Shaw MS Fahim Haider Jafary MD, FACC, FSCAI Eric J. Velazquez MD Gerald S. Bloomfield MD, MPH, FACC, FASE, FAHA Javed Tai MBBS, FCPS COI for remaining authors: Salim S. Virani MD, PhD, FACC, FAHA, FASPC Research support: U.S. Department of Veterans Affairs, World Heart Federation, Tahir and Jooma Family; Honorarium: American College of Cardiology (Associate Editor for Innovations, acc.org). Zulfiqar Bhutta MBBS, FRCPCH, FAAP, PhD Executive Director of NCD Child Other authors declare that there is no conflict of interest.\n",
      "\n",
      "FB consultant for: Alcon (Fort Worth, Texas, United States), Alimera Sciences (Alpharetta, Georgia, United States), Allergan Inc. (Irvine, California, United States), Farmila-Thea (Clermont-Ferrand, France), Bayer Shering-Pharma (Berlin, Germany), Bausch And Lomb (Rochester, New York, United States), Genentech (San Francisco, California, United States), Hoffmann-La-Roche (Basel, Switzerland), NovagaliPharma (Evry, France), Novartis (Basel, Switzerland), Sanofi-Aventis (Paris, France), Thrombogenics (Heverlee, Belgium), and Zeiss (Dublin, United States). The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.\n",
      "\n",
      "FB consultant for: Alcon (Fort Worth, Texas, United States), Alimera Sciences (Alpharetta, Georgia, United States), Allergan Inc. (Irvine, California, United States), Farmila-Thea (Clermont-Ferrand, France), Bayer Shering-Pharma (Berlin, Germany), Bausch And Lomb (Rochester, New York, United States), Genentech (San Francisco, California, United States), Hoffmann-La-Roche (Basel, Switzerland), NovagaliPharma (Evry, France), Novartis (Basel, Switzerland), Sanofi-Aventis (Paris, France), Thrombogenics (Heverlee, Belgium), and Zeiss (Dublin, United States). The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.\n",
      "\n",
      "FB consultant for: Alcon (Fort Worth, Texas, United States), Alimera Sciences (Alpharetta, Georgia, United States), Allergan Inc. (Irvine, California, United States), Farmila-Thea (Clermont-Ferrand, France), Bayer Shering-Pharma (Berlin, Germany), Bausch And Lomb (Rochester, New York, United States), Genentech (San Francisco, California, United States), Hoffmann-La-Roche (Basel, Switzerland), NovagaliPharma (Evry, France), Novartis (Basel, Switzerland), Sanofi-Aventis (Paris, France), Thrombogenics (Heverlee, Belgium), and Zeiss (Dublin, United States). The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.\n",
      "\n",
      "FB consultant for: Alcon (Fort Worth, Texas, United States), Alimera Sciences (Alpharetta, Georgia, United States), Allergan Inc. (Irvine, California, United States), Farmila-Thea (Clermont-Ferrand, France), Bayer Shering-Pharma (Berlin, Germany), Bausch And Lomb (Rochester, New York, United States), Genentech (San Francisco, California, United States), Hoffmann-La-Roche (Basel, Switzerland), NovagaliPharma (Evry, France), Novartis (Basel, Switzerland), Sanofi-Aventis (Paris, France), Thrombogenics (Heverlee, Belgium), and Zeiss (Dublin, United States). The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.\n",
      "\n",
      "FB consultant for: Alcon (Fort Worth, Texas, United States), Alimera Sciences (Alpharetta, Georgia, United States), Allergan Inc. (Irvine, California, United States), Farmila-Thea (Clermont-Ferrand, France), Bayer Shering-Pharma (Berlin, Germany), Bausch And Lomb (Rochester, New York, United States), Genentech (San Francisco, California, United States), Hoffmann-La-Roche (Basel, Switzerland), NovagaliPharma (Evry, France), Novartis (Basel, Switzerland), Sanofi-Aventis (Paris, France), Thrombogenics (Heverlee, Belgium), and Zeiss (Dublin, United States). The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.\n",
      "\n",
      "FB consultant for: Alcon (Fort Worth, Texas, United States), Alimera Sciences (Alpharetta, Georgia, United States), Allergan Inc. (Irvine, California, United States), Farmila-Thea (Clermont-Ferrand, France), Bayer Shering-Pharma (Berlin, Germany), Bausch And Lomb (Rochester, New York, United States), Genentech (San Francisco, California, United States), Hoffmann-La-Roche (Basel, Switzerland), NovagaliPharma (Evry, France), Novartis (Basel, Switzerland), Sanofi-Aventis (Paris, France), Thrombogenics (Heverlee, Belgium), and Zeiss (Dublin, United States). The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.\n",
      "\n",
      "FB consultant for: Alcon (Fort Worth, Texas, United States), Alimera Sciences (Alpharetta, Georgia, United States), Allergan Inc. (Irvine, California, United States), Farmila-Thea (Clermont-Ferrand, France), Bayer Shering-Pharma (Berlin, Germany), Bausch And Lomb (Rochester, New York, United States), Genentech (San Francisco, California, United States), Hoffmann-La-Roche (Basel, Switzerland), NovagaliPharma (Evry, France), Novartis (Basel, Switzerland), Sanofi-Aventis (Paris, France), Thrombogenics (Heverlee, Belgium), and Zeiss (Dublin, United States). The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.\n",
      "\n",
      "Bandello, Francesco\n",
      "Francesco Bandello consultant for: Alcon (Fort Worth, Texas, United States), Alimera Sciences (Alpharetta, Georgia, United States), Allergan Inc. (Irvine, California, United States), Farmila-Thea (Clermont-Ferrand, France), Bayer Shering-Pharma (Berlin, Germany), Bausch And Lomb (Rochester, New York, United States), Genentech (San Francisco, California, United States), Hoffmann-La-Roche (Basel, Switzerland), NovagaliPharma (Evry, France), Novartis (Basel, Switzerland), Sanofi-Aventis (Paris, France), Thrombogenics (Heverlee, Belgium), and Zeiss (Dublin, United States). The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.\n",
      "\n",
      "Li, Kailimi\n",
      "The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The handling editor LL is currently organizing a Research Topic with the author Kailimi Li.\n",
      "\n",
      "The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The handling editor LL is currently organizing a Research Topic with the author Kailimi Li.\n",
      "\n",
      "The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The handling editor LL is currently organizing a Research Topic with the author Kailimi Li.\n",
      "\n",
      "The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The handling editor LL is currently organizing a Research Topic with the author Kailimi Li.\n",
      "\n",
      "Li, Rui\n",
      "The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The handling editor LL is currently organizing a Research Topic with the author Kailimi Rui Li.\n",
      "\n",
      "The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The handling editor LL is currently organizing a Research Topic with the author Kailimi Rui Li.\n",
      "\n",
      "GS and MG were employed by company Gruppo Padana Ortofloricoltura S.S. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.\n",
      "\n",
      "GS and MG were employed by company Gruppo Padana Ortofloricoltura S.S. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.\n",
      "\n",
      "GS and MG were employed by company Gruppo Padana Ortofloricoltura S.S. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.\n",
      "\n",
      "GS and MG were employed by company Gruppo Padana Ortofloricoltura S.S. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.\n",
      "\n",
      "Batta Sacilotto, Gio\n",
      "Gio Batta Sacilotto and MG were employed by company Gruppo Padana Ortofloricoltura S.S. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.\n",
      "\n",
      "Gazzola, Marco\n",
      "Gio Batta Sacilotto and Marco Gazzola were employed by company Gruppo Padana Ortofloricoltura S.S. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.\n",
      "\n",
      "Gio Batta Sacilotto and Marco Gazzola were employed by company Gruppo Padana Ortofloricoltura S.S. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.\n",
      "\n",
      "MA has received educational grants from Abbott, is consultant for Biosense Webster and proctor for Medtronic. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.\n",
      "\n",
      "MA has received educational grants from Abbott, is consultant for Biosense Webster and proctor for Medtronic. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.\n",
      "\n",
      "Anselmino, Matteo\n",
      "Matteo Anselmino has received educational grants from Abbott, is consultant for Biosense Webster and proctor for Medtronic. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.\n",
      "\n",
      "PJ reports a consulting or advisory role, received honoraria, research funding, and/or travel/accommodation expenses from: Abbvie, Bayer, Boehringer, Novartis, Pfizer, Servier, Roche, BMS, and Celgene. The remaining authors declare that the  research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.\n",
      "\n",
      "PJ reports a consulting or advisory role, received honoraria, research funding, and/or travel/accommodation expenses from: Abbvie, Bayer, Boehringer, Novartis, Pfizer, Servier, Roche, BMS, and Celgene. The remaining authors declare that the  research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.\n",
      "\n",
      "PJ reports a consulting or advisory role, received honoraria, research funding, and/or travel/accommodation expenses from: Abbvie, Bayer, Boehringer, Novartis, Pfizer, Servier, Roche, BMS, and Celgene. The remaining authors declare that the  research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.\n",
      "\n",
      "PJ reports a consulting or advisory role, received honoraria, research funding, and/or travel/accommodation expenses from: Abbvie, Bayer, Boehringer, Novartis, Pfizer, Servier, Roche, BMS, and Celgene. The remaining authors declare that the  research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.\n",
      "\n",
      "PJ reports a consulting or advisory role, received honoraria, research funding, and/or travel/accommodation expenses from: Abbvie, Bayer, Boehringer, Novartis, Pfizer, Servier, Roche, BMS, and Celgene. The remaining authors declare that the  research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.\n",
      "\n",
      "PJ reports a consulting or advisory role, received honoraria, research funding, and/or travel/accommodation expenses from: Abbvie, Bayer, Boehringer, Novartis, Pfizer, Servier, Roche, BMS, and Celgene. The remaining authors declare that the  research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.\n",
      "\n",
      "PJ reports a consulting or advisory role, received honoraria, research funding, and/or travel/accommodation expenses from: Abbvie, Bayer, Boehringer, Novartis, Pfizer, Servier, Roche, BMS, and Celgene. The remaining authors declare that the  research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.\n",
      "\n",
      "PJ reports a consulting or advisory role, received honoraria, research funding, and/or travel/accommodation expenses from: Abbvie, Bayer, Boehringer, Novartis, Pfizer, Servier, Roche, BMS, and Celgene. The remaining authors declare that the  research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.\n",
      "\n",
      "Jost, Philipp J.\n",
      "Philipp J. Jost reports a consulting or advisory role, received honoraria, research funding, and/or travel/accommodation expenses from: Abbvie, Bayer, Boehringer, Novartis, Pfizer, Servier, Roche, BMS, and Celgene. The remaining authors declare that the  research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.\n",
      "\n",
      "Philipp J. Jost reports a consulting or advisory role, received honoraria, research funding, and/or travel/accommodation expenses from: Abbvie, Bayer, Boehringer, Novartis, Pfizer, Servier, Roche, BMS, and Celgene. The remaining authors declare that the  research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.\n",
      "\n",
      "Philipp J. Jost reports a consulting or advisory role, received honoraria, research funding, and/or travel/accommodation expenses from: Abbvie, Bayer, Boehringer, Novartis, Pfizer, Servier, Roche, BMS, and Celgene. The remaining authors declare that the  research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.\n",
      "\n",
      "Philipp J. Jost reports a consulting or advisory role, received honoraria, research funding, and/or travel/accommodation expenses from: Abbvie, Bayer, Boehringer, Novartis, Pfizer, Servier, Roche, BMS, and Celgene. The remaining authors declare that the  research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.\n",
      "\n",
      "Philipp J. Jost reports a consulting or advisory role, received honoraria, research funding, and/or travel/accommodation expenses from: Abbvie, Bayer, Boehringer, Novartis, Pfizer, Servier, Roche, BMS, and Celgene. The remaining authors declare that the  research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.\n",
      "\n",
      "AS, AA-K, and PB were employed by Circle Cardiovascular Imaging Inc. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.\n",
      "\n",
      "AS, AA-K, and PB were employed by Circle Cardiovascular Imaging Inc. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.\n",
      "\n",
      "AS, AA-K, and PB were employed by Circle Cardiovascular Imaging Inc. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.\n",
      "\n",
      "AS, AA-K, and PB were employed by Circle Cardiovascular Imaging Inc. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.\n",
      "\n",
      "Sojoudi, Alireza\n",
      "Alireza Sojoudi, AA-K, and PB were employed by Circle Cardiovascular Imaging Inc. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.\n",
      "\n",
      "Amir-Khalili, Alborz\n",
      "Alireza Sojoudi, Alborz Amir-Khalili-K, and PB were employed by Circle Cardiovascular Imaging Inc. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.\n",
      "\n",
      "Alireza Sojoudi, Alborz Amir-Khalili-K, and PB were employed by Circle Cardiovascular Imaging Inc. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.\n",
      "\n",
      "Alireza Sojoudi, Alborz Amir-Khalili-K, and PB were employed by Circle Cardiovascular Imaging Inc. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.\n",
      "\n",
      "Alireza Sojoudi, Alborz Amir-Khalili-K, and PB were employed by Circle Cardiovascular Imaging Inc. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.\n",
      "\n",
      "Barckow, Philipp\n",
      "Alireza Sojoudi, Alborz Amir-Khalili-K, and Philipp Barckow were employed by Circle Cardiovascular Imaging Inc. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.\n",
      "\n",
      "Alireza Sojoudi, Alborz Amir-Khalili-K, and Philipp Barckow were employed by Circle Cardiovascular Imaging Inc. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.\n",
      "\n",
      "Alireza Sojoudi, Alborz Amir-Khalili-K, and Philipp Barckow were employed by Circle Cardiovascular Imaging Inc. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.\n",
      "\n",
      "Alireza Sojoudi, Alborz Amir-Khalili-K, and Philipp Barckow were employed by Circle Cardiovascular Imaging Inc. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.\n",
      "\n",
      "The authors declare the following conflict of interests: Maxim Untesco was employed by the company UNIM Ltd. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.\n",
      "\n",
      "The authors declare the following conflict of interests: Maxim Untesco was employed by the company UNIM Ltd. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.\n",
      "\n",
      "The authors declare the following conflict of interests: Maxim Untesco was employed by the company UNIM Ltd. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.\n",
      "\n",
      "Untesco, Maxim\n",
      "The authors declare the following conflict of interests: Maxim Untesco was employed by the company UNIM Ltd. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.\n",
      "\n",
      "The authors declare the following conflict of interests: Maxim Untesco was employed by the company UNIM Ltd. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.\n",
      "\n",
      "The authors declare the following conflict of interests: Maxim Untesco was employed by the company UNIM Ltd. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.\n",
      "\n",
      "The authors declare the following conflict of interests: Maxim Untesco was employed by the company UNIM Ltd. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.\n",
      "\n",
      "The authors declare the following conflict of interests: Maxim Untesco was employed by the company UNIM Ltd. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.\n",
      "\n",
      "The authors declare the following conflict of interests: Maxim Untesco was employed by the company UNIM Ltd. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.\n",
      "\n",
      "The authors declare the following conflict of interests: Maxim Untesco was employed by the company UNIM Ltd. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.\n",
      "\n",
      "The authors declare the following conflict of interests: Maxim Untesco was employed by the company UNIM Ltd. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.\n",
      "\n",
      "The authors declare the following conflict of interests: Maxim Untesco was employed by the company UNIM Ltd. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.\n",
      "\n",
      "Author NS was employed by GlaxoSmithKline and TV was employed by Merck Research Laboratories. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed  as a potential conflict of interest.\n",
      "\n",
      "Author NS was employed by GlaxoSmithKline and TV was employed by Merck Research Laboratories. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed  as a potential conflict of interest.\n",
      "\n",
      "Author NS was employed by GlaxoSmithKline and TV was employed by Merck Research Laboratories. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed  as a potential conflict of interest.\n",
      "\n",
      "Author NS was employed by GlaxoSmithKline and TV was employed by Merck Research Laboratories. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed  as a potential conflict of interest.\n",
      "\n",
      "Author NS was employed by GlaxoSmithKline and TV was employed by Merck Research Laboratories. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed  as a potential conflict of interest.\n",
      "\n",
      "Author NS was employed by GlaxoSmithKline and TV was employed by Merck Research Laboratories. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed  as a potential conflict of interest.\n",
      "\n",
      "Author NS was employed by GlaxoSmithKline and TV was employed by Merck Research Laboratories. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed  as a potential conflict of interest.\n",
      "\n",
      "Author NS was employed by GlaxoSmithKline and TV was employed by Merck Research Laboratories. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed  as a potential conflict of interest.\n",
      "\n",
      "Somanna, Naveen\n",
      "Author Naveen Somanna was employed by GlaxoSmithKline and TV was employed by Merck Research Laboratories. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed  as a potential conflict of interest.\n",
      "\n",
      "Author Naveen Somanna was employed by GlaxoSmithKline and TV was employed by Merck Research Laboratories. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed  as a potential conflict of interest.\n",
      "\n",
      "Author Naveen Somanna was employed by GlaxoSmithKline and TV was employed by Merck Research Laboratories. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed  as a potential conflict of interest.\n",
      "\n",
      "Author Naveen Somanna was employed by GlaxoSmithKline and TV was employed by Merck Research Laboratories. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed  as a potential conflict of interest.\n",
      "\n",
      "Author Naveen Somanna was employed by GlaxoSmithKline and TV was employed by Merck Research Laboratories. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed  as a potential conflict of interest.\n",
      "\n",
      "Author Naveen Somanna was employed by GlaxoSmithKline and TV was employed by Merck Research Laboratories. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed  as a potential conflict of interest.\n",
      "\n",
      "Author Naveen Somanna was employed by GlaxoSmithKline and TV was employed by Merck Research Laboratories. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed  as a potential conflict of interest.\n",
      "\n",
      "Author Naveen Somanna was employed by GlaxoSmithKline and TV was employed by Merck Research Laboratories. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed  as a potential conflict of interest.\n",
      "\n",
      "Voss, Thomas\n",
      "Author Naveen Somanna was employed by GlaxoSmithKline and Thomas Voss was employed by Merck Research Laboratories. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed  as a potential conflict of interest.\n",
      "\n",
      "Author Naveen Somanna was employed by GlaxoSmithKline and Thomas Voss was employed by Merck Research Laboratories. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed  as a potential conflict of interest.\n",
      "\n",
      "Author Naveen Somanna was employed by GlaxoSmithKline and Thomas Voss was employed by Merck Research Laboratories. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed  as a potential conflict of interest.\n",
      "\n",
      "Author Naveen Somanna was employed by GlaxoSmithKline and Thomas Voss was employed by Merck Research Laboratories. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed  as a potential conflict of interest.\n",
      "\n",
      "Author Naveen Somanna was employed by GlaxoSmithKline and Thomas Voss was employed by Merck Research Laboratories. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed  as a potential conflict of interest.\n",
      "\n",
      "Author Naveen Somanna was employed by GlaxoSmithKline and Thomas Voss was employed by Merck Research Laboratories. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed  as a potential conflict of interest.\n",
      "\n",
      "Author Naveen Somanna was employed by GlaxoSmithKline and Thomas Voss was employed by Merck Research Laboratories. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed  as a potential conflict of interest.\n",
      "\n",
      "Author Naveen Somanna was employed by GlaxoSmithKline and Thomas Voss was employed by Merck Research Laboratories. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed  as a potential conflict of interest.\n",
      "\n",
      "Author Naveen Somanna was employed by GlaxoSmithKline and Thomas Voss was employed by Merck Research Laboratories. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed  as a potential conflict of interest.\n",
      "\n",
      "Author Naveen Somanna was employed by GlaxoSmithKline and Thomas Voss was employed by Merck Research Laboratories. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed  as a potential conflict of interest.\n",
      "\n",
      "Conflict of interestWe declare that we have no financial and personal relationships with other people or organizations that can inappropriately influence our work, there is no professional or other personal interest of any nature or kind in any product, service and/or company that could be construed as  influencing the position presented in, or the review of, the manuscript entitled  \"Cis-element amplified polymorphism (CEAP), a novel promoter- and gene-targeted molecular marker of plants\". All authors have seen the manuscript and approved the submittal to your journal. None of the material in the paper has been published or is under consideration for publication elsewhere. We thank Bao-Xiang Qin, Rong-Bai Li, Xian-Yu Wang, Ying-Yi Deng, Zheng-Guo Liu (College of agriculture, Guangxi University, Nanning, GX) for kindly providing the materials  of rice, tomato, potato, wax gourd, citrus and longan, respectively.\n",
      "\n",
      "Conflict of interestWe declare that we have no financial and personal relationships with other people or organizations that can inappropriately influence our work, there is no professional or other personal interest of any nature or kind in any product, service and/or company that could be construed as  influencing the position presented in, or the review of, the manuscript entitled  \"Cis-element amplified polymorphism (CEAP), a novel promoter- and gene-targeted molecular marker of plants\". All authors have seen the manuscript and approved the submittal to your journal. None of the material in the paper has been published or is under consideration for publication elsewhere. We thank Bao-Xiang Qin, Rong-Bai Li, Xian-Yu Wang, Ying-Yi Deng, Zheng-Guo Liu (College of agriculture, Guangxi University, Nanning, GX) for kindly providing the materials  of rice, tomato, potato, wax gourd, citrus and longan, respectively.\n",
      "\n",
      "Conflict of interestWe declare that we have no financial and personal relationships with other people or organizations that can inappropriately influence our work, there is no professional or other personal interest of any nature or kind in any product, service and/or company that could be construed as  influencing the position presented in, or the review of, the manuscript entitled  \"Cis-element amplified polymorphism (CEAP), a novel promoter- and gene-targeted molecular marker of plants\". All authors have seen the manuscript and approved the submittal to your journal. None of the material in the paper has been published or is under consideration for publication elsewhere. We thank Bao-Xiang Qin, Rong-Bai Li, Xian-Yu Wang, Ying-Yi Deng, Zheng-Guo Liu (College of agriculture, Guangxi University, Nanning, GX) for kindly providing the materials  of rice, tomato, potato, wax gourd, citrus and longan, respectively.\n",
      "\n",
      "Conflict of interestWe declare that we have no financial and personal relationships with other people or organizations that can inappropriately influence our work, there is no professional or other personal interest of any nature or kind in any product, service and/or company that could be construed as  influencing the position presented in, or the review of, the manuscript entitled  \"Cis-element amplified polymorphism (CEAP), a novel promoter- and gene-targeted molecular marker of plants\". All authors have seen the manuscript and approved the submittal to your journal. None of the material in the paper has been published or is under consideration for publication elsewhere. We thank Bao-Xiang Qin, Rong-Bai Li, Xian-Yu Wang, Ying-Yi Deng, Zheng-Guo Liu (College of agriculture, Guangxi University, Nanning, GX) for kindly providing the materials  of rice, tomato, potato, wax gourd, citrus and longan, respectively.\n",
      "\n",
      "Conflict of interestWe declare that we have no financial and personal relationships with other people or organizations that can inappropriately influence our work, there is no professional or other personal interest of any nature or kind in any product, service and/or company that could be construed as  influencing the position presented in, or the review of, the manuscript entitled  \"Cis-element amplified polymorphism (CEAP), a novel promoter- and gene-targeted molecular marker of plants\". All authors have seen the manuscript and approved the submittal to your journal. None of the material in the paper has been published or is under consideration for publication elsewhere. We thank Bao-Xiang Qin, Rong-Bai Li, Xian-Yu Wang, Ying-Yi Deng, Zheng-Guo Liu (College of agriculture, Guangxi University, Nanning, GX) for kindly providing the materials  of rice, tomato, potato, wax gourd, citrus and longan, respectively.\n",
      "\n",
      "Conflict of interestWe declare that we have no financial and personal relationships with other people or organizations that can inappropriately influence our work, there is no professional or other personal interest of any nature or kind in any product, service and/or company that could be construed as  influencing the position presented in, or the review of, the manuscript entitled  \"Cis-element amplified polymorphism (CEAP), a novel promoter- and gene-targeted molecular marker of plants\". All authors have seen the manuscript and approved the submittal to your journal. None of the material in the paper has been published or is under consideration for publication elsewhere. We thank Bao-Xiang Qin, Rong-Bai Li, Xian-Yu Wang, Ying-Yi Deng, Zheng-Guo Liu (College of agriculture, Guangxi University, Nanning, GX) for kindly providing the materials  of rice, tomato, potato, wax gourd, citrus and longan, respectively.\n",
      "\n",
      "Yu, Haixia\n",
      "Conflict of interestWe declare that we have no financial and personal relationships with other people or organizations that can inappropriately influence our work, there is no professional or other personal interest of any nature or kind in any product, service and/or company that could be construed as  influencing the position presented in, or the review of, the manuscript entitled  \"Cis-element amplified polymorphism (CEAP), a novel promoter- and gene-targeted molecular marker of plants\". All authors have seen the manuscript and approved the submittal to your journal. None of the material in the paper has been published or is under consideration for publication elsewhere. We thank Bao-Xiang Qin, Rong-Bai Li, Xian-Haixia Yu Wang, Ying-Yi Deng, Zheng-Guo Liu (College of agriculture, Guangxi University, Nanning, GX) for kindly providing the materials  of rice, tomato, potato, wax gourd, citrus and longan, respectively.\n",
      "\n",
      "Conflict of interestWe declare that we have no financial and personal relationships with other people or organizations that can inappropriately influence our work, there is no professional or other personal interest of any nature or kind in any product, service and/or company that could be construed as  influencing the position presented in, or the review of, the manuscript entitled  \"Cis-element amplified polymorphism (CEAP), a novel promoter- and gene-targeted molecular marker of plants\". All authors have seen the manuscript and approved the submittal to your journal. None of the material in the paper has been published or is under consideration for publication elsewhere. We thank Bao-Xiang Qin, Rong-Bai Li, Xian-Haixia Yu Wang, Ying-Yi Deng, Zheng-Guo Liu (College of agriculture, Guangxi University, Nanning, GX) for kindly providing the materials  of rice, tomato, potato, wax gourd, citrus and longan, respectively.\n",
      "\n",
      "Kanter, Jacob A.\n",
      "The following authors have no financial disclosures: Jacob A. Kanter, PA, RK, AGM, DD, LTS, DS, MQ.\n",
      "\n",
      "Amin, Pathik\n",
      "The following authors have no financial disclosures: Jacob A. Kanter, Pathik Amin, RK, AGM, DD, LTS, DS, MQ.\n",
      "\n",
      "Komati, Rahul\n",
      "The following authors have no financial disclosures: Jacob A. Kanter, Pathik Amin, Rahul Komati, AGM, DD, LTS, DS, MQ.\n",
      "\n",
      "Mackin, Anna G.\n",
      "The following authors have no financial disclosures: Jacob A. Kanter, Pathik Amin, Rahul Komati, Anna G. Mackin, DD, LTS, DS, MQ.\n",
      "\n",
      "Dao, David\n",
      "The following authors have no financial disclosures: Jacob A. Kanter, Pathik Amin, Rahul Komati, Anna G. Mackin, David Dao, LTS, DS, MQ.\n",
      "\n",
      "Shaw, Lincoln T.\n",
      "The following authors have no financial disclosures: Jacob A. Kanter, Pathik Amin, Rahul Komati, Anna G. Mackin, David Dao, Lincoln T. Shaw, DS, MQ.\n",
      "\n",
      "Skondra, Dimitra\n",
      "The following authors have no financial disclosures: Jacob A. Kanter, Pathik Amin, Rahul Komati, Anna G. Mackin, David Dao, Lincoln T. Shaw, Dimitra Skondra, MQ.\n",
      "\n",
      "Qiu, Mary\n",
      "The following authors have no financial disclosures: Jacob A. Kanter, Pathik Amin, Rahul Komati, Anna G. Mackin, David Dao, Lincoln T. Shaw, Dimitra Skondra, Mary Qiu.\n",
      "\n",
      "Coauthor Zhenhong Lin (Z. L.) is currently an editorial board member of the journal. All coauthors declare scientific independence with no competing interests.\n",
      "\n",
      "Lin, Zhenhong\n",
      "Coauthor Zhenhong Lin (Z. L.) is currently an editorial board member of the journal. All coauthors declare scientific independence with no competing interests.\n",
      "\n",
      "Coauthor Zhenhong Lin (Z. L.) is currently an editorial board member of the journal. All coauthors declare scientific independence with no competing interests.\n",
      "\n",
      "Coauthor Zhenhong Lin (Z. L.) is currently an editorial board member of the journal. All coauthors declare scientific independence with no competing interests.\n",
      "\n",
      "Coauthor Zhenhong Lin (Z. L.) is currently an editorial board member of the journal. All coauthors declare scientific independence with no competing interests.\n",
      "\n",
      "Coauthor Zhenhong Lin (Z. L.) is currently an editorial board member of the journal. All coauthors declare scientific independence with no competing interests.\n",
      "\n",
      "Coauthor Zhenhong Lin (Z. L.) is currently an editorial board member of the journal. All coauthors declare scientific independence with no competing interests.\n",
      "\n",
      "Coauthor Zhenhong Lin (Z. L.) is currently an editorial board member of the journal. All coauthors declare scientific independence with no competing interests.\n",
      "\n",
      "Coauthor Zhenhong Lin (Z. L.) is currently an editorial board member of the journal. All coauthors declare scientific independence with no competing interests.\n",
      "\n",
      "Competing interests: The authors declare that there is no conflict of interest. C.T. is the CEO and co-owner of AgenDix GmbH.\n",
      "\n",
      "Competing interests: The authors declare that there is no conflict of interest. C.T. is the CEO and co-owner of AgenDix GmbH.\n",
      "\n",
      "Competing interests: The authors declare that there is no conflict of interest. C.T. is the CEO and co-owner of AgenDix GmbH.\n",
      "\n",
      "Competing interests: The authors declare that there is no conflict of interest. C.T. is the CEO and co-owner of AgenDix GmbH.\n",
      "\n",
      "Competing interests: The authors declare that there is no conflict of interest. C.T. is the CEO and co-owner of AgenDix GmbH.\n",
      "\n",
      "Competing interests: The authors declare that there is no conflict of interest. C.T. is the CEO and co-owner of AgenDix GmbH.\n",
      "\n",
      "Competing interests: The authors declare that there is no conflict of interest. C.T. is the CEO and co-owner of AgenDix GmbH.\n",
      "\n",
      "Competing interests: The authors declare that there is no conflict of interest. C.T. is the CEO and co-owner of AgenDix GmbH.\n",
      "\n",
      "Competing interests: The authors declare that there is no conflict of interest. C.T. is the CEO and co-owner of AgenDix GmbH.\n",
      "\n",
      "Competing interests: The authors declare that there is no conflict of interest. C.T. is the CEO and co-owner of AgenDix GmbH.\n",
      "\n",
      "Competing interests: The authors declare that there is no conflict of interest. C.T. is the CEO and co-owner of AgenDix GmbH.\n",
      "\n",
      "Competing interests: The authors declare that there is no conflict of interest. C.T. is the CEO and co-owner of AgenDix GmbH.\n",
      "\n",
      "Thiede, Christian\n",
      "Competing interests: The authors declare that there is no conflict of interest. Christian Thiede is the CEO and co-owner of AgenDix GmbH.\n",
      "\n",
      "Competing interests: The authors declare that there is no conflict of interest. Christian Thiede is the CEO and co-owner of AgenDix GmbH.\n",
      "\n",
      "Competing interests: The authors declare that there is no conflict of interest. Christian Thiede is the CEO and co-owner of AgenDix GmbH.\n",
      "\n",
      "Competing interests: The authors declare that there is no conflict of interest. Christian Thiede is the CEO and co-owner of AgenDix GmbH.\n",
      "\n",
      "Kotecha, Dipak\n",
      "Declaration of interests The BigData@Heart project has received funding from the  Innovative Medicines Initiative (IMI) 2 Joint Undertaking (grant 116074) which receives support from the Horizon 2020 research and innovation programme of the European Union and the European Federation of Pharmaceutical Industries and Associations. The funders had no role in considering the study design; in the collection, analysis, or interpretation of data; in the writing of the report; or in the decision to submit the Review for publication. Dipak Kotecha reports grants from the  European Union and the European Federation of Pharmaceutical Industries and Associations Innovative Medicines Initiative (116074), the National Institute for Health Research (NIHR CDF-2015-08-074 RATE-AF; NIHR130280 DaRe2THINK; and NIHR132974 D2T-NeuroVascular), the British Heart Foundation (PG/17/55/33087, AA/18/2/34218 and FS/CDRF/21/21032), and the ESC. Dipak Kotecha is supported by educational  grants from Boehringer Ingelheim, Bristol Myers Squibb (BMS)-Pfizer Alliance, Bayer, Daiichi Sankyo, Boston Scientific, the NIHR and University of Oxford Biomedical Research Centre, the British Heart Foundation and University of Birmingham Accelerator Award (STEEER-AF NCT04396418), Amomed Pharma, Istituto Di  Ricovero e Cura a Carattere Scientifico San Raffaele, and Menarini (NCT0083244).  Dipak Kotecha receives advisory board personal fees from Bayer, Amomed, Protherics Medicines Development, and Myokardia. FWA reports grants from IMI BigData@Heart. SDA reports grants and personal fees from Vifor Pharma, Abbott, and Abbott Vascular;  and personal fees from Bayer, Boehringer Ingelheim, Servier, Cardiac Dimensions,  Actimed, AstraZeneca, Amgen, Bioventrix, Janssen, Respicardia, V-Wave, Brahms, Cordio, and Occlutech. CB reports grants from Medical Research Council, Boehringer Ingelheim, and NIHR. AB reports grants from AstraZeneca. BB reports grants from the European Commission. GB reports grants from the European Commission (IMI project support) and Bayer. BC reports non-financial support from Roche Diagnostics and iRhythm. CC reports grants from the European Commission. MRC reports personal fees from AstraZeneca. FC reports personal fees from Amgen,  AstraZeneca, Servier, and BMS; and advisory board fees from GlyCardial Diagnostics. MC reports personal fees from Vifor Pharma. AD reports salary from Bayer. MF reports salary from AstraZeneca. CPG reports personal fees from AstraZeneca, Amgen, Bayer, Boehringer Ingelheim, Daiichi Sankyo, Vifor Pharma, Menarini, Wondr Medical, Raisio Group, and Oxford University Press; and grants from BMS, Abbott, British Heart Foundation, NIHR, and ESC. MI reports grants from World Economic Forum, Swedish Innovation Agency, and the European Commission; and collaboration with Frisq. SL reports grants from the European Commission. TFL reports grants from Abbott, Amgen, Novartis, Boehringer Ingelheim, Servier, Vifor Pharma, Sanofi, and AstraZeneca; and personal fees from Daichi Sankyo, Pfizer, and Menarini. LR reports salary from Bayer. CS reports personal fees from Bayer.  BT reports personal fees from Servier. GvT reports grants from IMI. KvB reports grants from IMI BigData@Heart. PEV reports personal fees from Hygeia Hospitals Group, Hellenic Healthcare Group, ESC, and Servier. TV is working as an editor at The BMJ and Acta Medica Portuguesa and is Vice President of the European Union of General Practitioners. MV reports grants from the European Commission. SW reports grants from Abbott, Amgen, AstraZeneca, BMS, Bayer, Biotronik, Boston Scientific, Cardinal Health, CardioValve, CSL Behring, Daiichi Sankyo, Edwards Lifesciences,  Guerbet, InfraRedx, Johnson & Johnson, Medicure, Medtronic, Novartis, Polares, OrPha Suisse, Pfizer, Regeneron, Sanofi-Aventis, Sinomed, Terumo, and V-Wave. SW  serves as an unpaid advisory board member or unpaid member of the steering or executive group of trials funded by Abbott, Abiomed, Amgen, AstraZeneca, BMS, Boston Scientific, Biotronik, Cardiovalve, Edwards Lifesciences, MedAlliance, Medtronic, Novartis, Polares, Sinomed, V-Wave, and Xeltis. He has not received personal payments by pharmaceutical companies or device manufacturers. SW is a member of the steering or executive committee group of several investigator-initiated trials that receive funding by industry without effect on  his personal remuneration. SW is an unpaid member of the Pfizer Research Award selection committee in Switzerland and of the Women as One Awards Committee. SW is a member of the Clinical Study Group of the Deutsches Zentrum fur Herz Kreislauf-Forschung and of the Advisory Board of the Australian Victorian Heart Institute. He is Chairperson of the ESC Congress Program Committee, former Chairperson of the ESC Clinical Practice Guidelines Committee, and Deputy Editor  of the Journal of the American College of Cardiology Cardiovascular Interventions. All other authors declare no competing interests.\n",
      "\n",
      "Asselbergs, Folkert W.\n",
      "Declaration of interests The BigData@Heart project has received funding from the  Innovative Medicines Initiative (IMI) 2 Joint Undertaking (grant 116074) which receives support from the Horizon 2020 research and innovation programme of the European Union and the European Federation of Pharmaceutical Industries and Associations. The funders had no role in considering the study design; in the collection, analysis, or interpretation of data; in the writing of the report; or in the decision to submit the Review for publication. Dipak Kotecha reports grants from the  European Union and the European Federation of Pharmaceutical Industries and Associations Innovative Medicines Initiative (116074), the National Institute for Health Research (NIHR CDF-2015-08-074 RATE-AF; NIHR130280 DaRe2THINK; and NIHR132974 D2T-NeuroVascular), the British Heart Foundation (PG/17/55/33087, AA/18/2/34218 and FS/CDRF/21/21032), and the ESC. Dipak Kotecha is supported by educational  grants from Boehringer Ingelheim, Bristol Myers Squibb (BMS)-Pfizer Alliance, Bayer, Daiichi Sankyo, Boston Scientific, the NIHR and University of Oxford Biomedical Research Centre, the British Heart Foundation and University of Birmingham Accelerator Award (STEEER-AF NCT04396418), Amomed Pharma, Istituto Di  Ricovero e Cura a Carattere Scientifico San Raffaele, and Menarini (NCT0083244).  Dipak Kotecha receives advisory board personal fees from Bayer, Amomed, Protherics Medicines Development, and Myokardia. Folkert W. Asselbergs reports grants from IMI BigData@Heart. SDA reports grants and personal fees from Vifor Pharma, Abbott, and Abbott Vascular;  and personal fees from Bayer, Boehringer Ingelheim, Servier, Cardiac Dimensions,  Actimed, AstraZeneca, Amgen, Bioventrix, Janssen, Respicardia, V-Wave, Brahms, Cordio, and Occlutech. CB reports grants from Medical Research Council, Boehringer Ingelheim, and NIHR. AB reports grants from AstraZeneca. BB reports grants from the European Commission. GB reports grants from the European Commission (IMI project support) and Bayer. BC reports non-financial support from Roche Diagnostics and iRhythm. CC reports grants from the European Commission. MRC reports personal fees from AstraZeneca. FC reports personal fees from Amgen,  AstraZeneca, Servier, and BMS; and advisory board fees from GlyCardial Diagnostics. MC reports personal fees from Vifor Pharma. AD reports salary from Bayer. MF reports salary from AstraZeneca. CPG reports personal fees from AstraZeneca, Amgen, Bayer, Boehringer Ingelheim, Daiichi Sankyo, Vifor Pharma, Menarini, Wondr Medical, Raisio Group, and Oxford University Press; and grants from BMS, Abbott, British Heart Foundation, NIHR, and ESC. MI reports grants from World Economic Forum, Swedish Innovation Agency, and the European Commission; and collaboration with Frisq. SL reports grants from the European Commission. TFL reports grants from Abbott, Amgen, Novartis, Boehringer Ingelheim, Servier, Vifor Pharma, Sanofi, and AstraZeneca; and personal fees from Daichi Sankyo, Pfizer, and Menarini. LR reports salary from Bayer. CS reports personal fees from Bayer.  BT reports personal fees from Servier. GvT reports grants from IMI. KvB reports grants from IMI BigData@Heart. PEV reports personal fees from Hygeia Hospitals Group, Hellenic Healthcare Group, ESC, and Servier. TV is working as an editor at The BMJ and Acta Medica Portuguesa and is Vice President of the European Union of General Practitioners. MV reports grants from the European Commission. SW reports grants from Abbott, Amgen, AstraZeneca, BMS, Bayer, Biotronik, Boston Scientific, Cardinal Health, CardioValve, CSL Behring, Daiichi Sankyo, Edwards Lifesciences,  Guerbet, InfraRedx, Johnson & Johnson, Medicure, Medtronic, Novartis, Polares, OrPha Suisse, Pfizer, Regeneron, Sanofi-Aventis, Sinomed, Terumo, and V-Wave. SW  serves as an unpaid advisory board member or unpaid member of the steering or executive group of trials funded by Abbott, Abiomed, Amgen, AstraZeneca, BMS, Boston Scientific, Biotronik, Cardiovalve, Edwards Lifesciences, MedAlliance, Medtronic, Novartis, Polares, Sinomed, V-Wave, and Xeltis. He has not received personal payments by pharmaceutical companies or device manufacturers. SW is a member of the steering or executive committee group of several investigator-initiated trials that receive funding by industry without effect on  his personal remuneration. SW is an unpaid member of the Pfizer Research Award selection committee in Switzerland and of the Women as One Awards Committee. SW is a member of the Clinical Study Group of the Deutsches Zentrum fur Herz Kreislauf-Forschung and of the Advisory Board of the Australian Victorian Heart Institute. He is Chairperson of the ESC Congress Program Committee, former Chairperson of the ESC Clinical Practice Guidelines Committee, and Deputy Editor  of the Journal of the American College of Cardiology Cardiovascular Interventions. All other authors declare no competing interests.\n",
      "\n",
      "Declaration of interests The BigData@Heart project has received funding from the  Innovative Medicines Initiative (IMI) 2 Joint Undertaking (grant 116074) which receives support from the Horizon 2020 research and innovation programme of the European Union and the European Federation of Pharmaceutical Industries and Associations. The funders had no role in considering the study design; in the collection, analysis, or interpretation of data; in the writing of the report; or in the decision to submit the Review for publication. Dipak Kotecha reports grants from the  European Union and the European Federation of Pharmaceutical Industries and Associations Innovative Medicines Initiative (116074), the National Institute for Health Research (NIHR CDF-2015-08-074 RATE-AF; NIHR130280 DaRe2THINK; and NIHR132974 D2T-NeuroVascular), the British Heart Foundation (PG/17/55/33087, AA/18/2/34218 and FS/CDRF/21/21032), and the ESC. Dipak Kotecha is supported by educational  grants from Boehringer Ingelheim, Bristol Myers Squibb (BMS)-Pfizer Alliance, Bayer, Daiichi Sankyo, Boston Scientific, the NIHR and University of Oxford Biomedical Research Centre, the British Heart Foundation and University of Birmingham Accelerator Award (STEEER-AF NCT04396418), Amomed Pharma, Istituto Di  Ricovero e Cura a Carattere Scientifico San Raffaele, and Menarini (NCT0083244).  Dipak Kotecha receives advisory board personal fees from Bayer, Amomed, Protherics Medicines Development, and Myokardia. Folkert W. Asselbergs reports grants from IMI BigData@Heart. SDA reports grants and personal fees from Vifor Pharma, Abbott, and Abbott Vascular;  and personal fees from Bayer, Boehringer Ingelheim, Servier, Cardiac Dimensions,  Actimed, AstraZeneca, Amgen, Bioventrix, Janssen, Respicardia, V-Wave, Brahms, Cordio, and Occlutech. CB reports grants from Medical Research Council, Boehringer Ingelheim, and NIHR. AB reports grants from AstraZeneca. BB reports grants from the European Commission. GB reports grants from the European Commission (IMI project support) and Bayer. BC reports non-financial support from Roche Diagnostics and iRhythm. CC reports grants from the European Commission. MRC reports personal fees from AstraZeneca. FC reports personal fees from Amgen,  AstraZeneca, Servier, and BMS; and advisory board fees from GlyCardial Diagnostics. MC reports personal fees from Vifor Pharma. AD reports salary from Bayer. MF reports salary from AstraZeneca. CPG reports personal fees from AstraZeneca, Amgen, Bayer, Boehringer Ingelheim, Daiichi Sankyo, Vifor Pharma, Menarini, Wondr Medical, Raisio Group, and Oxford University Press; and grants from BMS, Abbott, British Heart Foundation, NIHR, and ESC. MI reports grants from World Economic Forum, Swedish Innovation Agency, and the European Commission; and collaboration with Frisq. SL reports grants from the European Commission. TFL reports grants from Abbott, Amgen, Novartis, Boehringer Ingelheim, Servier, Vifor Pharma, Sanofi, and AstraZeneca; and personal fees from Daichi Sankyo, Pfizer, and Menarini. LR reports salary from Bayer. CS reports personal fees from Bayer.  BT reports personal fees from Servier. GvT reports grants from IMI. KvB reports grants from IMI BigData@Heart. PEV reports personal fees from Hygeia Hospitals Group, Hellenic Healthcare Group, ESC, and Servier. TV is working as an editor at The BMJ and Acta Medica Portuguesa and is Vice President of the European Union of General Practitioners. MV reports grants from the European Commission. SW reports grants from Abbott, Amgen, AstraZeneca, BMS, Bayer, Biotronik, Boston Scientific, Cardinal Health, CardioValve, CSL Behring, Daiichi Sankyo, Edwards Lifesciences,  Guerbet, InfraRedx, Johnson & Johnson, Medicure, Medtronic, Novartis, Polares, OrPha Suisse, Pfizer, Regeneron, Sanofi-Aventis, Sinomed, Terumo, and V-Wave. SW  serves as an unpaid advisory board member or unpaid member of the steering or executive group of trials funded by Abbott, Abiomed, Amgen, AstraZeneca, BMS, Boston Scientific, Biotronik, Cardiovalve, Edwards Lifesciences, MedAlliance, Medtronic, Novartis, Polares, Sinomed, V-Wave, and Xeltis. He has not received personal payments by pharmaceutical companies or device manufacturers. SW is a member of the steering or executive committee group of several investigator-initiated trials that receive funding by industry without effect on  his personal remuneration. SW is an unpaid member of the Pfizer Research Award selection committee in Switzerland and of the Women as One Awards Committee. SW is a member of the Clinical Study Group of the Deutsches Zentrum fur Herz Kreislauf-Forschung and of the Advisory Board of the Australian Victorian Heart Institute. He is Chairperson of the ESC Congress Program Committee, former Chairperson of the ESC Clinical Practice Guidelines Committee, and Deputy Editor  of the Journal of the American College of Cardiology Cardiovascular Interventions. All other authors declare no competing interests.\n",
      "\n",
      "Anker, Stefan D.\n",
      "Declaration of interests The BigData@Heart project has received funding from the  Innovative Medicines Initiative (IMI) 2 Joint Undertaking (grant 116074) which receives support from the Horizon 2020 research and innovation programme of the European Union and the European Federation of Pharmaceutical Industries and Associations. The funders had no role in considering the study design; in the collection, analysis, or interpretation of data; in the writing of the report; or in the decision to submit the Review for publication. Dipak Kotecha reports grants from the  European Union and the European Federation of Pharmaceutical Industries and Associations Innovative Medicines Initiative (116074), the National Institute for Health Research (NIHR CDF-2015-08-074 RATE-AF; NIHR130280 DaRe2THINK; and NIHR132974 D2T-NeuroVascular), the British Heart Foundation (PG/17/55/33087, AA/18/2/34218 and FS/CDRF/21/21032), and the ESC. Dipak Kotecha is supported by educational  grants from Boehringer Ingelheim, Bristol Myers Squibb (BMS)-Pfizer Alliance, Bayer, Daiichi Sankyo, Boston Scientific, the NIHR and University of Oxford Biomedical Research Centre, the British Heart Foundation and University of Birmingham Accelerator Award (STEEER-AF NCT04396418), Amomed Pharma, Istituto Di  Ricovero e Cura a Carattere Scientifico San Raffaele, and Menarini (NCT0083244).  Dipak Kotecha receives advisory board personal fees from Bayer, Amomed, Protherics Medicines Development, and Myokardia. Folkert W. Asselbergs reports grants from IMI BigData@Heart. Stefan D. Anker reports grants and personal fees from Vifor Pharma, Abbott, and Abbott Vascular;  and personal fees from Bayer, Boehringer Ingelheim, Servier, Cardiac Dimensions,  Actimed, AstraZeneca, Amgen, Bioventrix, Janssen, Respicardia, V-Wave, Brahms, Cordio, and Occlutech. CB reports grants from Medical Research Council, Boehringer Ingelheim, and NIHR. AB reports grants from AstraZeneca. BB reports grants from the European Commission. GB reports grants from the European Commission (IMI project support) and Bayer. BC reports non-financial support from Roche Diagnostics and iRhythm. CC reports grants from the European Commission. MRC reports personal fees from AstraZeneca. FC reports personal fees from Amgen,  AstraZeneca, Servier, and BMS; and advisory board fees from GlyCardial Diagnostics. MC reports personal fees from Vifor Pharma. AD reports salary from Bayer. MF reports salary from AstraZeneca. CPG reports personal fees from AstraZeneca, Amgen, Bayer, Boehringer Ingelheim, Daiichi Sankyo, Vifor Pharma, Menarini, Wondr Medical, Raisio Group, and Oxford University Press; and grants from BMS, Abbott, British Heart Foundation, NIHR, and ESC. MI reports grants from World Economic Forum, Swedish Innovation Agency, and the European Commission; and collaboration with Frisq. SL reports grants from the European Commission. TFL reports grants from Abbott, Amgen, Novartis, Boehringer Ingelheim, Servier, Vifor Pharma, Sanofi, and AstraZeneca; and personal fees from Daichi Sankyo, Pfizer, and Menarini. LR reports salary from Bayer. CS reports personal fees from Bayer.  BT reports personal fees from Servier. GvT reports grants from IMI. KvB reports grants from IMI BigData@Heart. PEV reports personal fees from Hygeia Hospitals Group, Hellenic Healthcare Group, ESC, and Servier. TV is working as an editor at The BMJ and Acta Medica Portuguesa and is Vice President of the European Union of General Practitioners. MV reports grants from the European Commission. SW reports grants from Abbott, Amgen, AstraZeneca, BMS, Bayer, Biotronik, Boston Scientific, Cardinal Health, CardioValve, CSL Behring, Daiichi Sankyo, Edwards Lifesciences,  Guerbet, InfraRedx, Johnson & Johnson, Medicure, Medtronic, Novartis, Polares, OrPha Suisse, Pfizer, Regeneron, Sanofi-Aventis, Sinomed, Terumo, and V-Wave. SW  serves as an unpaid advisory board member or unpaid member of the steering or executive group of trials funded by Abbott, Abiomed, Amgen, AstraZeneca, BMS, Boston Scientific, Biotronik, Cardiovalve, Edwards Lifesciences, MedAlliance, Medtronic, Novartis, Polares, Sinomed, V-Wave, and Xeltis. He has not received personal payments by pharmaceutical companies or device manufacturers. SW is a member of the steering or executive committee group of several investigator-initiated trials that receive funding by industry without effect on  his personal remuneration. SW is an unpaid member of the Pfizer Research Award selection committee in Switzerland and of the Women as One Awards Committee. SW is a member of the Clinical Study Group of the Deutsches Zentrum fur Herz Kreislauf-Forschung and of the Advisory Board of the Australian Victorian Heart Institute. He is Chairperson of the ESC Congress Program Committee, former Chairperson of the ESC Clinical Practice Guidelines Committee, and Deputy Editor  of the Journal of the American College of Cardiology Cardiovascular Interventions. All other authors declare no competing interests.\n",
      "\n",
      "Declaration of interests The BigData@Heart project has received funding from the  Innovative Medicines Initiative (IMI) 2 Joint Undertaking (grant 116074) which receives support from the Horizon 2020 research and innovation programme of the European Union and the European Federation of Pharmaceutical Industries and Associations. The funders had no role in considering the study design; in the collection, analysis, or interpretation of data; in the writing of the report; or in the decision to submit the Review for publication. Dipak Kotecha reports grants from the  European Union and the European Federation of Pharmaceutical Industries and Associations Innovative Medicines Initiative (116074), the National Institute for Health Research (NIHR CDF-2015-08-074 RATE-AF; NIHR130280 DaRe2THINK; and NIHR132974 D2T-NeuroVascular), the British Heart Foundation (PG/17/55/33087, AA/18/2/34218 and FS/CDRF/21/21032), and the ESC. Dipak Kotecha is supported by educational  grants from Boehringer Ingelheim, Bristol Myers Squibb (BMS)-Pfizer Alliance, Bayer, Daiichi Sankyo, Boston Scientific, the NIHR and University of Oxford Biomedical Research Centre, the British Heart Foundation and University of Birmingham Accelerator Award (STEEER-AF NCT04396418), Amomed Pharma, Istituto Di  Ricovero e Cura a Carattere Scientifico San Raffaele, and Menarini (NCT0083244).  Dipak Kotecha receives advisory board personal fees from Bayer, Amomed, Protherics Medicines Development, and Myokardia. Folkert W. Asselbergs reports grants from IMI BigData@Heart. Stefan D. Anker reports grants and personal fees from Vifor Pharma, Abbott, and Abbott Vascular;  and personal fees from Bayer, Boehringer Ingelheim, Servier, Cardiac Dimensions,  Actimed, AstraZeneca, Amgen, Bioventrix, Janssen, Respicardia, V-Wave, Brahms, Cordio, and Occlutech. CB reports grants from Medical Research Council, Boehringer Ingelheim, and NIHR. AB reports grants from AstraZeneca. BB reports grants from the European Commission. GB reports grants from the European Commission (IMI project support) and Bayer. BC reports non-financial support from Roche Diagnostics and iRhythm. CC reports grants from the European Commission. MRC reports personal fees from AstraZeneca. FC reports personal fees from Amgen,  AstraZeneca, Servier, and BMS; and advisory board fees from GlyCardial Diagnostics. MC reports personal fees from Vifor Pharma. AD reports salary from Bayer. MF reports salary from AstraZeneca. CPG reports personal fees from AstraZeneca, Amgen, Bayer, Boehringer Ingelheim, Daiichi Sankyo, Vifor Pharma, Menarini, Wondr Medical, Raisio Group, and Oxford University Press; and grants from BMS, Abbott, British Heart Foundation, NIHR, and ESC. MI reports grants from World Economic Forum, Swedish Innovation Agency, and the European Commission; and collaboration with Frisq. SL reports grants from the European Commission. TFL reports grants from Abbott, Amgen, Novartis, Boehringer Ingelheim, Servier, Vifor Pharma, Sanofi, and AstraZeneca; and personal fees from Daichi Sankyo, Pfizer, and Menarini. LR reports salary from Bayer. CS reports personal fees from Bayer.  BT reports personal fees from Servier. GvT reports grants from IMI. KvB reports grants from IMI BigData@Heart. PEV reports personal fees from Hygeia Hospitals Group, Hellenic Healthcare Group, ESC, and Servier. TV is working as an editor at The BMJ and Acta Medica Portuguesa and is Vice President of the European Union of General Practitioners. MV reports grants from the European Commission. SW reports grants from Abbott, Amgen, AstraZeneca, BMS, Bayer, Biotronik, Boston Scientific, Cardinal Health, CardioValve, CSL Behring, Daiichi Sankyo, Edwards Lifesciences,  Guerbet, InfraRedx, Johnson & Johnson, Medicure, Medtronic, Novartis, Polares, OrPha Suisse, Pfizer, Regeneron, Sanofi-Aventis, Sinomed, Terumo, and V-Wave. SW  serves as an unpaid advisory board member or unpaid member of the steering or executive group of trials funded by Abbott, Abiomed, Amgen, AstraZeneca, BMS, Boston Scientific, Biotronik, Cardiovalve, Edwards Lifesciences, MedAlliance, Medtronic, Novartis, Polares, Sinomed, V-Wave, and Xeltis. He has not received personal payments by pharmaceutical companies or device manufacturers. SW is a member of the steering or executive committee group of several investigator-initiated trials that receive funding by industry without effect on  his personal remuneration. SW is an unpaid member of the Pfizer Research Award selection committee in Switzerland and of the Women as One Awards Committee. SW is a member of the Clinical Study Group of the Deutsches Zentrum fur Herz Kreislauf-Forschung and of the Advisory Board of the Australian Victorian Heart Institute. He is Chairperson of the ESC Congress Program Committee, former Chairperson of the ESC Clinical Practice Guidelines Committee, and Deputy Editor  of the Journal of the American College of Cardiology Cardiovascular Interventions. All other authors declare no competing interests.\n",
      "\n",
      "Baigent, Colin\n",
      "Declaration of interests The BigData@Heart project has received funding from the  Innovative Medicines Initiative (IMI) 2 Joint Undertaking (grant 116074) which receives support from the Horizon 2020 research and innovation programme of the European Union and the European Federation of Pharmaceutical Industries and Associations. The funders had no role in considering the study design; in the collection, analysis, or interpretation of data; in the writing of the report; or in the decision to submit the Review for publication. Dipak Kotecha reports grants from the  European Union and the European Federation of Pharmaceutical Industries and Associations Innovative Medicines Initiative (116074), the National Institute for Health Research (NIHR CDF-2015-08-074 RATE-AF; NIHR130280 DaRe2THINK; and NIHR132974 D2T-NeuroVascular), the British Heart Foundation (PG/17/55/33087, AA/18/2/34218 and FS/CDRF/21/21032), and the ESC. Dipak Kotecha is supported by educational  grants from Boehringer Ingelheim, Bristol Myers Squibb (BMS)-Pfizer Alliance, Bayer, Daiichi Sankyo, Boston Scientific, the NIHR and University of Oxford Biomedical Research Centre, the British Heart Foundation and University of Birmingham Accelerator Award (STEEER-AF NCT04396418), Amomed Pharma, Istituto Di  Ricovero e Cura a Carattere Scientifico San Raffaele, and Menarini (NCT0083244).  Dipak Kotecha receives advisory board personal fees from Bayer, Amomed, Protherics Medicines Development, and Myokardia. Folkert W. Asselbergs reports grants from IMI BigData@Heart. Stefan D. Anker reports grants and personal fees from Vifor Pharma, Abbott, and Abbott Vascular;  and personal fees from Bayer, Boehringer Ingelheim, Servier, Cardiac Dimensions,  Actimed, AstraZeneca, Amgen, Bioventrix, Janssen, Respicardia, V-Wave, Brahms, Cordio, and Occlutech. Colin Baigent reports grants from Medical Research Council, Boehringer Ingelheim, and NIHR. AB reports grants from AstraZeneca. BB reports grants from the European Commission. GB reports grants from the European Commission (IMI project support) and Bayer. BC reports non-financial support from Roche Diagnostics and iRhythm. CC reports grants from the European Commission. MRC reports personal fees from AstraZeneca. FC reports personal fees from Amgen,  AstraZeneca, Servier, and BMS; and advisory board fees from GlyCardial Diagnostics. MC reports personal fees from Vifor Pharma. AD reports salary from Bayer. MF reports salary from AstraZeneca. CPG reports personal fees from AstraZeneca, Amgen, Bayer, Boehringer Ingelheim, Daiichi Sankyo, Vifor Pharma, Menarini, Wondr Medical, Raisio Group, and Oxford University Press; and grants from BMS, Abbott, British Heart Foundation, NIHR, and ESC. MI reports grants from World Economic Forum, Swedish Innovation Agency, and the European Commission; and collaboration with Frisq. SL reports grants from the European Commission. TFL reports grants from Abbott, Amgen, Novartis, Boehringer Ingelheim, Servier, Vifor Pharma, Sanofi, and AstraZeneca; and personal fees from Daichi Sankyo, Pfizer, and Menarini. LR reports salary from Bayer. CS reports personal fees from Bayer.  BT reports personal fees from Servier. GvT reports grants from IMI. KvB reports grants from IMI BigData@Heart. PEV reports personal fees from Hygeia Hospitals Group, Hellenic Healthcare Group, ESC, and Servier. TV is working as an editor at The BMJ and Acta Medica Portuguesa and is Vice President of the European Union of General Practitioners. MV reports grants from the European Commission. SW reports grants from Abbott, Amgen, AstraZeneca, BMS, Bayer, Biotronik, Boston Scientific, Cardinal Health, CardioValve, CSL Behring, Daiichi Sankyo, Edwards Lifesciences,  Guerbet, InfraRedx, Johnson & Johnson, Medicure, Medtronic, Novartis, Polares, OrPha Suisse, Pfizer, Regeneron, Sanofi-Aventis, Sinomed, Terumo, and V-Wave. SW  serves as an unpaid advisory board member or unpaid member of the steering or executive group of trials funded by Abbott, Abiomed, Amgen, AstraZeneca, BMS, Boston Scientific, Biotronik, Cardiovalve, Edwards Lifesciences, MedAlliance, Medtronic, Novartis, Polares, Sinomed, V-Wave, and Xeltis. He has not received personal payments by pharmaceutical companies or device manufacturers. SW is a member of the steering or executive committee group of several investigator-initiated trials that receive funding by industry without effect on  his personal remuneration. SW is an unpaid member of the Pfizer Research Award selection committee in Switzerland and of the Women as One Awards Committee. SW is a member of the Clinical Study Group of the Deutsches Zentrum fur Herz Kreislauf-Forschung and of the Advisory Board of the Australian Victorian Heart Institute. He is Chairperson of the ESC Congress Program Committee, former Chairperson of the ESC Clinical Practice Guidelines Committee, and Deputy Editor  of the Journal of the American College of Cardiology Cardiovascular Interventions. All other authors declare no competing interests.\n",
      "\n",
      "Banerjee, Amitava\n",
      "Declaration of interests The BigData@Heart project has received funding from the  Innovative Medicines Initiative (IMI) 2 Joint Undertaking (grant 116074) which receives support from the Horizon 2020 research and innovation programme of the European Union and the European Federation of Pharmaceutical Industries and Associations. The funders had no role in considering the study design; in the collection, analysis, or interpretation of data; in the writing of the report; or in the decision to submit the Review for publication. Dipak Kotecha reports grants from the  European Union and the European Federation of Pharmaceutical Industries and Associations Innovative Medicines Initiative (116074), the National Institute for Health Research (NIHR CDF-2015-08-074 RATE-AF; NIHR130280 DaRe2THINK; and NIHR132974 D2T-NeuroVascular), the British Heart Foundation (PG/17/55/33087, AA/18/2/34218 and FS/CDRF/21/21032), and the ESC. Dipak Kotecha is supported by educational  grants from Boehringer Ingelheim, Bristol Myers Squibb (BMS)-Pfizer Alliance, Bayer, Daiichi Sankyo, Boston Scientific, the NIHR and University of Oxford Biomedical Research Centre, the British Heart Foundation and University of Birmingham Accelerator Award (STEEER-AF NCT04396418), Amomed Pharma, Istituto Di  Ricovero e Cura a Carattere Scientifico San Raffaele, and Menarini (NCT0083244).  Dipak Kotecha receives advisory board personal fees from Bayer, Amomed, Protherics Medicines Development, and Myokardia. Folkert W. Asselbergs reports grants from IMI BigData@Heart. Stefan D. Anker reports grants and personal fees from Vifor Pharma, Abbott, and Abbott Vascular;  and personal fees from Bayer, Boehringer Ingelheim, Servier, Cardiac Dimensions,  Actimed, AstraZeneca, Amgen, Bioventrix, Janssen, Respicardia, V-Wave, Brahms, Cordio, and Occlutech. Colin Baigent reports grants from Medical Research Council, Boehringer Ingelheim, and NIHR. Amitava Banerjee reports grants from AstraZeneca. BB reports grants from the European Commission. GB reports grants from the European Commission (IMI project support) and Bayer. BC reports non-financial support from Roche Diagnostics and iRhythm. CC reports grants from the European Commission. MRC reports personal fees from AstraZeneca. FC reports personal fees from Amgen,  AstraZeneca, Servier, and BMS; and advisory board fees from GlyCardial Diagnostics. MC reports personal fees from Vifor Pharma. AD reports salary from Bayer. MF reports salary from AstraZeneca. CPG reports personal fees from AstraZeneca, Amgen, Bayer, Boehringer Ingelheim, Daiichi Sankyo, Vifor Pharma, Menarini, Wondr Medical, Raisio Group, and Oxford University Press; and grants from BMS, Abbott, British Heart Foundation, NIHR, and ESC. MI reports grants from World Economic Forum, Swedish Innovation Agency, and the European Commission; and collaboration with Frisq. SL reports grants from the European Commission. TFL reports grants from Abbott, Amgen, Novartis, Boehringer Ingelheim, Servier, Vifor Pharma, Sanofi, and AstraZeneca; and personal fees from Daichi Sankyo, Pfizer, and Menarini. LR reports salary from Bayer. CS reports personal fees from Bayer.  BT reports personal fees from Servier. GvT reports grants from IMI. KvB reports grants from IMI BigData@Heart. PEV reports personal fees from Hygeia Hospitals Group, Hellenic Healthcare Group, ESC, and Servier. TV is working as an editor at The BMJ and Acta Medica Portuguesa and is Vice President of the European Union of General Practitioners. MV reports grants from the European Commission. SW reports grants from Abbott, Amgen, AstraZeneca, BMS, Bayer, Biotronik, Boston Scientific, Cardinal Health, CardioValve, CSL Behring, Daiichi Sankyo, Edwards Lifesciences,  Guerbet, InfraRedx, Johnson & Johnson, Medicure, Medtronic, Novartis, Polares, OrPha Suisse, Pfizer, Regeneron, Sanofi-Aventis, Sinomed, Terumo, and V-Wave. SW  serves as an unpaid advisory board member or unpaid member of the steering or executive group of trials funded by Abbott, Abiomed, Amgen, AstraZeneca, BMS, Boston Scientific, Biotronik, Cardiovalve, Edwards Lifesciences, MedAlliance, Medtronic, Novartis, Polares, Sinomed, V-Wave, and Xeltis. He has not received personal payments by pharmaceutical companies or device manufacturers. SW is a member of the steering or executive committee group of several investigator-initiated trials that receive funding by industry without effect on  his personal remuneration. SW is an unpaid member of the Pfizer Research Award selection committee in Switzerland and of the Women as One Awards Committee. SW is a member of the Clinical Study Group of the Deutsches Zentrum fur Herz Kreislauf-Forschung and of the Advisory Board of the Australian Victorian Heart Institute. He is Chairperson of the ESC Congress Program Committee, former Chairperson of the ESC Clinical Practice Guidelines Committee, and Deputy Editor  of the Journal of the American College of Cardiology Cardiovascular Interventions. All other authors declare no competing interests.\n",
      "\n",
      "Beger, Birgit\n",
      "Declaration of interests The BigData@Heart project has received funding from the  Innovative Medicines Initiative (IMI) 2 Joint Undertaking (grant 116074) which receives support from the Horizon 2020 research and innovation programme of the European Union and the European Federation of Pharmaceutical Industries and Associations. The funders had no role in considering the study design; in the collection, analysis, or interpretation of data; in the writing of the report; or in the decision to submit the Review for publication. Dipak Kotecha reports grants from the  European Union and the European Federation of Pharmaceutical Industries and Associations Innovative Medicines Initiative (116074), the National Institute for Health Research (NIHR CDF-2015-08-074 RATE-AF; NIHR130280 DaRe2THINK; and NIHR132974 D2T-NeuroVascular), the British Heart Foundation (PG/17/55/33087, AA/18/2/34218 and FS/CDRF/21/21032), and the ESC. Dipak Kotecha is supported by educational  grants from Boehringer Ingelheim, Bristol Myers Squibb (BMS)-Pfizer Alliance, Bayer, Daiichi Sankyo, Boston Scientific, the NIHR and University of Oxford Biomedical Research Centre, the British Heart Foundation and University of Birmingham Accelerator Award (STEEER-AF NCT04396418), Amomed Pharma, Istituto Di  Ricovero e Cura a Carattere Scientifico San Raffaele, and Menarini (NCT0083244).  Dipak Kotecha receives advisory board personal fees from Bayer, Amomed, Protherics Medicines Development, and Myokardia. Folkert W. Asselbergs reports grants from IMI BigData@Heart. Stefan D. Anker reports grants and personal fees from Vifor Pharma, Abbott, and Abbott Vascular;  and personal fees from Bayer, Boehringer Ingelheim, Servier, Cardiac Dimensions,  Actimed, AstraZeneca, Amgen, Bioventrix, Janssen, Respicardia, V-Wave, Brahms, Cordio, and Occlutech. Colin Baigent reports grants from Medical Research Council, Boehringer Ingelheim, and NIHR. Amitava Banerjee reports grants from AstraZeneca. Birgit Beger reports grants from the European Commission. GB reports grants from the European Commission (IMI project support) and Bayer. BC reports non-financial support from Roche Diagnostics and iRhythm. CC reports grants from the European Commission. MRC reports personal fees from AstraZeneca. FC reports personal fees from Amgen,  AstraZeneca, Servier, and BMS; and advisory board fees from GlyCardial Diagnostics. MC reports personal fees from Vifor Pharma. AD reports salary from Bayer. MF reports salary from AstraZeneca. CPG reports personal fees from AstraZeneca, Amgen, Bayer, Boehringer Ingelheim, Daiichi Sankyo, Vifor Pharma, Menarini, Wondr Medical, Raisio Group, and Oxford University Press; and grants from BMS, Abbott, British Heart Foundation, NIHR, and ESC. MI reports grants from World Economic Forum, Swedish Innovation Agency, and the European Commission; and collaboration with Frisq. SL reports grants from the European Commission. TFL reports grants from Abbott, Amgen, Novartis, Boehringer Ingelheim, Servier, Vifor Pharma, Sanofi, and AstraZeneca; and personal fees from Daichi Sankyo, Pfizer, and Menarini. LR reports salary from Bayer. CS reports personal fees from Bayer.  BT reports personal fees from Servier. GvT reports grants from IMI. KvB reports grants from IMI BigData@Heart. PEV reports personal fees from Hygeia Hospitals Group, Hellenic Healthcare Group, ESC, and Servier. TV is working as an editor at The BMJ and Acta Medica Portuguesa and is Vice President of the European Union of General Practitioners. MV reports grants from the European Commission. SW reports grants from Abbott, Amgen, AstraZeneca, BMS, Bayer, Biotronik, Boston Scientific, Cardinal Health, CardioValve, CSL Behring, Daiichi Sankyo, Edwards Lifesciences,  Guerbet, InfraRedx, Johnson & Johnson, Medicure, Medtronic, Novartis, Polares, OrPha Suisse, Pfizer, Regeneron, Sanofi-Aventis, Sinomed, Terumo, and V-Wave. SW  serves as an unpaid advisory board member or unpaid member of the steering or executive group of trials funded by Abbott, Abiomed, Amgen, AstraZeneca, BMS, Boston Scientific, Biotronik, Cardiovalve, Edwards Lifesciences, MedAlliance, Medtronic, Novartis, Polares, Sinomed, V-Wave, and Xeltis. He has not received personal payments by pharmaceutical companies or device manufacturers. SW is a member of the steering or executive committee group of several investigator-initiated trials that receive funding by industry without effect on  his personal remuneration. SW is an unpaid member of the Pfizer Research Award selection committee in Switzerland and of the Women as One Awards Committee. SW is a member of the Clinical Study Group of the Deutsches Zentrum fur Herz Kreislauf-Forschung and of the Advisory Board of the Australian Victorian Heart Institute. He is Chairperson of the ESC Congress Program Committee, former Chairperson of the ESC Clinical Practice Guidelines Committee, and Deputy Editor  of the Journal of the American College of Cardiology Cardiovascular Interventions. All other authors declare no competing interests.\n",
      "\n",
      "Brobert, Gunnar\n",
      "Declaration of interests The BigData@Heart project has received funding from the  Innovative Medicines Initiative (IMI) 2 Joint Undertaking (grant 116074) which receives support from the Horizon 2020 research and innovation programme of the European Union and the European Federation of Pharmaceutical Industries and Associations. The funders had no role in considering the study design; in the collection, analysis, or interpretation of data; in the writing of the report; or in the decision to submit the Review for publication. Dipak Kotecha reports grants from the  European Union and the European Federation of Pharmaceutical Industries and Associations Innovative Medicines Initiative (116074), the National Institute for Health Research (NIHR CDF-2015-08-074 RATE-AF; NIHR130280 DaRe2THINK; and NIHR132974 D2T-NeuroVascular), the British Heart Foundation (PG/17/55/33087, AA/18/2/34218 and FS/CDRF/21/21032), and the ESC. Dipak Kotecha is supported by educational  grants from Boehringer Ingelheim, Bristol Myers Squibb (BMS)-Pfizer Alliance, Bayer, Daiichi Sankyo, Boston Scientific, the NIHR and University of Oxford Biomedical Research Centre, the British Heart Foundation and University of Birmingham Accelerator Award (STEEER-AF NCT04396418), Amomed Pharma, Istituto Di  Ricovero e Cura a Carattere Scientifico San Raffaele, and Menarini (NCT0083244).  Dipak Kotecha receives advisory board personal fees from Bayer, Amomed, Protherics Medicines Development, and Myokardia. Folkert W. Asselbergs reports grants from IMI BigData@Heart. Stefan D. Anker reports grants and personal fees from Vifor Pharma, Abbott, and Abbott Vascular;  and personal fees from Bayer, Boehringer Ingelheim, Servier, Cardiac Dimensions,  Actimed, AstraZeneca, Amgen, Bioventrix, Janssen, Respicardia, V-Wave, Brahms, Cordio, and Occlutech. Colin Baigent reports grants from Medical Research Council, Boehringer Ingelheim, and NIHR. Amitava Banerjee reports grants from AstraZeneca. Birgit Beger reports grants from the European Commission. Gunnar Brobert reports grants from the European Commission (IMI project support) and Bayer. BC reports non-financial support from Roche Diagnostics and iRhythm. CC reports grants from the European Commission. MRC reports personal fees from AstraZeneca. FC reports personal fees from Amgen,  AstraZeneca, Servier, and BMS; and advisory board fees from GlyCardial Diagnostics. MC reports personal fees from Vifor Pharma. AD reports salary from Bayer. MF reports salary from AstraZeneca. CPG reports personal fees from AstraZeneca, Amgen, Bayer, Boehringer Ingelheim, Daiichi Sankyo, Vifor Pharma, Menarini, Wondr Medical, Raisio Group, and Oxford University Press; and grants from BMS, Abbott, British Heart Foundation, NIHR, and ESC. MI reports grants from World Economic Forum, Swedish Innovation Agency, and the European Commission; and collaboration with Frisq. SL reports grants from the European Commission. TFL reports grants from Abbott, Amgen, Novartis, Boehringer Ingelheim, Servier, Vifor Pharma, Sanofi, and AstraZeneca; and personal fees from Daichi Sankyo, Pfizer, and Menarini. LR reports salary from Bayer. CS reports personal fees from Bayer.  BT reports personal fees from Servier. GvT reports grants from IMI. KvB reports grants from IMI BigData@Heart. PEV reports personal fees from Hygeia Hospitals Group, Hellenic Healthcare Group, ESC, and Servier. TV is working as an editor at The BMJ and Acta Medica Portuguesa and is Vice President of the European Union of General Practitioners. MV reports grants from the European Commission. SW reports grants from Abbott, Amgen, AstraZeneca, BMS, Bayer, Biotronik, Boston Scientific, Cardinal Health, CardioValve, CSL Behring, Daiichi Sankyo, Edwards Lifesciences,  Guerbet, InfraRedx, Johnson & Johnson, Medicure, Medtronic, Novartis, Polares, OrPha Suisse, Pfizer, Regeneron, Sanofi-Aventis, Sinomed, Terumo, and V-Wave. SW  serves as an unpaid advisory board member or unpaid member of the steering or executive group of trials funded by Abbott, Abiomed, Amgen, AstraZeneca, BMS, Boston Scientific, Biotronik, Cardiovalve, Edwards Lifesciences, MedAlliance, Medtronic, Novartis, Polares, Sinomed, V-Wave, and Xeltis. He has not received personal payments by pharmaceutical companies or device manufacturers. SW is a member of the steering or executive committee group of several investigator-initiated trials that receive funding by industry without effect on  his personal remuneration. SW is an unpaid member of the Pfizer Research Award selection committee in Switzerland and of the Women as One Awards Committee. SW is a member of the Clinical Study Group of the Deutsches Zentrum fur Herz Kreislauf-Forschung and of the Advisory Board of the Australian Victorian Heart Institute. He is Chairperson of the ESC Congress Program Committee, former Chairperson of the ESC Clinical Practice Guidelines Committee, and Deputy Editor  of the Journal of the American College of Cardiology Cardiovascular Interventions. All other authors declare no competing interests.\n",
      "\n",
      "Casadei, Barbara\n",
      "Declaration of interests The BigData@Heart project has received funding from the  Innovative Medicines Initiative (IMI) 2 Joint Undertaking (grant 116074) which receives support from the Horizon 2020 research and innovation programme of the European Union and the European Federation of Pharmaceutical Industries and Associations. The funders had no role in considering the study design; in the collection, analysis, or interpretation of data; in the writing of the report; or in the decision to submit the Review for publication. Dipak Kotecha reports grants from the  European Union and the European Federation of Pharmaceutical Industries and Associations Innovative Medicines Initiative (116074), the National Institute for Health Research (NIHR CDF-2015-08-074 RATE-AF; NIHR130280 DaRe2THINK; and NIHR132974 D2T-NeuroVascular), the British Heart Foundation (PG/17/55/33087, AA/18/2/34218 and FS/CDRF/21/21032), and the ESC. Dipak Kotecha is supported by educational  grants from Boehringer Ingelheim, Bristol Myers Squibb (BMS)-Pfizer Alliance, Bayer, Daiichi Sankyo, Boston Scientific, the NIHR and University of Oxford Biomedical Research Centre, the British Heart Foundation and University of Birmingham Accelerator Award (STEEER-AF NCT04396418), Amomed Pharma, Istituto Di  Ricovero e Cura a Carattere Scientifico San Raffaele, and Menarini (NCT0083244).  Dipak Kotecha receives advisory board personal fees from Bayer, Amomed, Protherics Medicines Development, and Myokardia. Folkert W. Asselbergs reports grants from IMI BigData@Heart. Stefan D. Anker reports grants and personal fees from Vifor Pharma, Abbott, and Abbott Vascular;  and personal fees from Bayer, Boehringer Ingelheim, Servier, Cardiac Dimensions,  Actimed, AstraZeneca, Amgen, Bioventrix, Janssen, Respicardia, V-Wave, Brahms, Cordio, and Occlutech. Colin Baigent reports grants from Medical Research Council, Boehringer Ingelheim, and NIHR. Amitava Banerjee reports grants from AstraZeneca. Birgit Beger reports grants from the European Commission. Gunnar Brobert reports grants from the European Commission (IMI project support) and Bayer. Barbara Casadei reports non-financial support from Roche Diagnostics and iRhythm. CC reports grants from the European Commission. MRC reports personal fees from AstraZeneca. FC reports personal fees from Amgen,  AstraZeneca, Servier, and BMS; and advisory board fees from GlyCardial Diagnostics. MC reports personal fees from Vifor Pharma. AD reports salary from Bayer. MF reports salary from AstraZeneca. CPG reports personal fees from AstraZeneca, Amgen, Bayer, Boehringer Ingelheim, Daiichi Sankyo, Vifor Pharma, Menarini, Wondr Medical, Raisio Group, and Oxford University Press; and grants from BMS, Abbott, British Heart Foundation, NIHR, and ESC. MI reports grants from World Economic Forum, Swedish Innovation Agency, and the European Commission; and collaboration with Frisq. SL reports grants from the European Commission. TFL reports grants from Abbott, Amgen, Novartis, Boehringer Ingelheim, Servier, Vifor Pharma, Sanofi, and AstraZeneca; and personal fees from Daichi Sankyo, Pfizer, and Menarini. LR reports salary from Bayer. CS reports personal fees from Bayer.  BT reports personal fees from Servier. GvT reports grants from IMI. KvB reports grants from IMI BigData@Heart. PEV reports personal fees from Hygeia Hospitals Group, Hellenic Healthcare Group, ESC, and Servier. TV is working as an editor at The BMJ and Acta Medica Portuguesa and is Vice President of the European Union of General Practitioners. MV reports grants from the European Commission. SW reports grants from Abbott, Amgen, AstraZeneca, BMS, Bayer, Biotronik, Boston Scientific, Cardinal Health, CardioValve, CSL Behring, Daiichi Sankyo, Edwards Lifesciences,  Guerbet, InfraRedx, Johnson & Johnson, Medicure, Medtronic, Novartis, Polares, OrPha Suisse, Pfizer, Regeneron, Sanofi-Aventis, Sinomed, Terumo, and V-Wave. SW  serves as an unpaid advisory board member or unpaid member of the steering or executive group of trials funded by Abbott, Abiomed, Amgen, AstraZeneca, BMS, Boston Scientific, Biotronik, Cardiovalve, Edwards Lifesciences, MedAlliance, Medtronic, Novartis, Polares, Sinomed, V-Wave, and Xeltis. He has not received personal payments by pharmaceutical companies or device manufacturers. SW is a member of the steering or executive committee group of several investigator-initiated trials that receive funding by industry without effect on  his personal remuneration. SW is an unpaid member of the Pfizer Research Award selection committee in Switzerland and of the Women as One Awards Committee. SW is a member of the Clinical Study Group of the Deutsches Zentrum fur Herz Kreislauf-Forschung and of the Advisory Board of the Australian Victorian Heart Institute. He is Chairperson of the ESC Congress Program Committee, former Chairperson of the ESC Clinical Practice Guidelines Committee, and Deputy Editor  of the Journal of the American College of Cardiology Cardiovascular Interventions. All other authors declare no competing interests.\n",
      "\n",
      "Ceccarelli, Cinzia\n",
      "Declaration of interests The BigData@Heart project has received funding from the  Innovative Medicines Initiative (IMI) 2 Joint Undertaking (grant 116074) which receives support from the Horizon 2020 research and innovation programme of the European Union and the European Federation of Pharmaceutical Industries and Associations. The funders had no role in considering the study design; in the collection, analysis, or interpretation of data; in the writing of the report; or in the decision to submit the Review for publication. Dipak Kotecha reports grants from the  European Union and the European Federation of Pharmaceutical Industries and Associations Innovative Medicines Initiative (116074), the National Institute for Health Research (NIHR CDF-2015-08-074 RATE-AF; NIHR130280 DaRe2THINK; and NIHR132974 D2T-NeuroVascular), the British Heart Foundation (PG/17/55/33087, AA/18/2/34218 and FS/CDRF/21/21032), and the ESC. Dipak Kotecha is supported by educational  grants from Boehringer Ingelheim, Bristol Myers Squibb (BMS)-Pfizer Alliance, Bayer, Daiichi Sankyo, Boston Scientific, the NIHR and University of Oxford Biomedical Research Centre, the British Heart Foundation and University of Birmingham Accelerator Award (STEEER-AF NCT04396418), Amomed Pharma, Istituto Di  Ricovero e Cura a Carattere Scientifico San Raffaele, and Menarini (NCT0083244).  Dipak Kotecha receives advisory board personal fees from Bayer, Amomed, Protherics Medicines Development, and Myokardia. Folkert W. Asselbergs reports grants from IMI BigData@Heart. Stefan D. Anker reports grants and personal fees from Vifor Pharma, Abbott, and Abbott Vascular;  and personal fees from Bayer, Boehringer Ingelheim, Servier, Cardiac Dimensions,  Actimed, AstraZeneca, Amgen, Bioventrix, Janssen, Respicardia, V-Wave, Brahms, Cordio, and Occlutech. Colin Baigent reports grants from Medical Research Council, Boehringer Ingelheim, and NIHR. Amitava Banerjee reports grants from AstraZeneca. Birgit Beger reports grants from the European Commission. Gunnar Brobert reports grants from the European Commission (IMI project support) and Bayer. Barbara Casadei reports non-financial support from Roche Diagnostics and iRhythm. Cinzia Ceccarelli reports grants from the European Commission. MRC reports personal fees from AstraZeneca. FC reports personal fees from Amgen,  AstraZeneca, Servier, and BMS; and advisory board fees from GlyCardial Diagnostics. MC reports personal fees from Vifor Pharma. AD reports salary from Bayer. MF reports salary from AstraZeneca. CPG reports personal fees from AstraZeneca, Amgen, Bayer, Boehringer Ingelheim, Daiichi Sankyo, Vifor Pharma, Menarini, Wondr Medical, Raisio Group, and Oxford University Press; and grants from BMS, Abbott, British Heart Foundation, NIHR, and ESC. MI reports grants from World Economic Forum, Swedish Innovation Agency, and the European Commission; and collaboration with Frisq. SL reports grants from the European Commission. TFL reports grants from Abbott, Amgen, Novartis, Boehringer Ingelheim, Servier, Vifor Pharma, Sanofi, and AstraZeneca; and personal fees from Daichi Sankyo, Pfizer, and Menarini. LR reports salary from Bayer. CS reports personal fees from Bayer.  BT reports personal fees from Servier. GvT reports grants from IMI. KvB reports grants from IMI BigData@Heart. PEV reports personal fees from Hygeia Hospitals Group, Hellenic Healthcare Group, ESC, and Servier. TV is working as an editor at The BMJ and Acta Medica Portuguesa and is Vice President of the European Union of General Practitioners. MV reports grants from the European Commission. SW reports grants from Abbott, Amgen, AstraZeneca, BMS, Bayer, Biotronik, Boston Scientific, Cardinal Health, CardioValve, CSL Behring, Daiichi Sankyo, Edwards Lifesciences,  Guerbet, InfraRedx, Johnson & Johnson, Medicure, Medtronic, Novartis, Polares, OrPha Suisse, Pfizer, Regeneron, Sanofi-Aventis, Sinomed, Terumo, and V-Wave. SW  serves as an unpaid advisory board member or unpaid member of the steering or executive group of trials funded by Abbott, Abiomed, Amgen, AstraZeneca, BMS, Boston Scientific, Biotronik, Cardiovalve, Edwards Lifesciences, MedAlliance, Medtronic, Novartis, Polares, Sinomed, V-Wave, and Xeltis. He has not received personal payments by pharmaceutical companies or device manufacturers. SW is a member of the steering or executive committee group of several investigator-initiated trials that receive funding by industry without effect on  his personal remuneration. SW is an unpaid member of the Pfizer Research Award selection committee in Switzerland and of the Women as One Awards Committee. SW is a member of the Clinical Study Group of the Deutsches Zentrum fur Herz Kreislauf-Forschung and of the Advisory Board of the Australian Victorian Heart Institute. He is Chairperson of the ESC Congress Program Committee, former Chairperson of the ESC Clinical Practice Guidelines Committee, and Deputy Editor  of the Journal of the American College of Cardiology Cardiovascular Interventions. All other authors declare no competing interests.\n",
      "\n",
      "Cowie, Martin R.\n",
      "Declaration of interests The BigData@Heart project has received funding from the  Innovative Medicines Initiative (IMI) 2 Joint Undertaking (grant 116074) which receives support from the Horizon 2020 research and innovation programme of the European Union and the European Federation of Pharmaceutical Industries and Associations. The funders had no role in considering the study design; in the collection, analysis, or interpretation of data; in the writing of the report; or in the decision to submit the Review for publication. Dipak Kotecha reports grants from the  European Union and the European Federation of Pharmaceutical Industries and Associations Innovative Medicines Initiative (116074), the National Institute for Health Research (NIHR CDF-2015-08-074 RATE-AF; NIHR130280 DaRe2THINK; and NIHR132974 D2T-NeuroVascular), the British Heart Foundation (PG/17/55/33087, AA/18/2/34218 and FS/CDRF/21/21032), and the ESC. Dipak Kotecha is supported by educational  grants from Boehringer Ingelheim, Bristol Myers Squibb (BMS)-Pfizer Alliance, Bayer, Daiichi Sankyo, Boston Scientific, the NIHR and University of Oxford Biomedical Research Centre, the British Heart Foundation and University of Birmingham Accelerator Award (STEEER-AF NCT04396418), Amomed Pharma, Istituto Di  Ricovero e Cura a Carattere Scientifico San Raffaele, and Menarini (NCT0083244).  Dipak Kotecha receives advisory board personal fees from Bayer, Amomed, Protherics Medicines Development, and Myokardia. Folkert W. Asselbergs reports grants from IMI BigData@Heart. Stefan D. Anker reports grants and personal fees from Vifor Pharma, Abbott, and Abbott Vascular;  and personal fees from Bayer, Boehringer Ingelheim, Servier, Cardiac Dimensions,  Actimed, AstraZeneca, Amgen, Bioventrix, Janssen, Respicardia, V-Wave, Brahms, Cordio, and Occlutech. Colin Baigent reports grants from Medical Research Council, Boehringer Ingelheim, and NIHR. Amitava Banerjee reports grants from AstraZeneca. Birgit Beger reports grants from the European Commission. Gunnar Brobert reports grants from the European Commission (IMI project support) and Bayer. Barbara Casadei reports non-financial support from Roche Diagnostics and iRhythm. Cinzia Ceccarelli reports grants from the European Commission. Martin R. Cowie reports personal fees from AstraZeneca. FC reports personal fees from Amgen,  AstraZeneca, Servier, and BMS; and advisory board fees from GlyCardial Diagnostics. MC reports personal fees from Vifor Pharma. AD reports salary from Bayer. MF reports salary from AstraZeneca. CPG reports personal fees from AstraZeneca, Amgen, Bayer, Boehringer Ingelheim, Daiichi Sankyo, Vifor Pharma, Menarini, Wondr Medical, Raisio Group, and Oxford University Press; and grants from BMS, Abbott, British Heart Foundation, NIHR, and ESC. MI reports grants from World Economic Forum, Swedish Innovation Agency, and the European Commission; and collaboration with Frisq. SL reports grants from the European Commission. TFL reports grants from Abbott, Amgen, Novartis, Boehringer Ingelheim, Servier, Vifor Pharma, Sanofi, and AstraZeneca; and personal fees from Daichi Sankyo, Pfizer, and Menarini. LR reports salary from Bayer. CS reports personal fees from Bayer.  BT reports personal fees from Servier. GvT reports grants from IMI. KvB reports grants from IMI BigData@Heart. PEV reports personal fees from Hygeia Hospitals Group, Hellenic Healthcare Group, ESC, and Servier. TV is working as an editor at The BMJ and Acta Medica Portuguesa and is Vice President of the European Union of General Practitioners. MV reports grants from the European Commission. SW reports grants from Abbott, Amgen, AstraZeneca, BMS, Bayer, Biotronik, Boston Scientific, Cardinal Health, CardioValve, CSL Behring, Daiichi Sankyo, Edwards Lifesciences,  Guerbet, InfraRedx, Johnson & Johnson, Medicure, Medtronic, Novartis, Polares, OrPha Suisse, Pfizer, Regeneron, Sanofi-Aventis, Sinomed, Terumo, and V-Wave. SW  serves as an unpaid advisory board member or unpaid member of the steering or executive group of trials funded by Abbott, Abiomed, Amgen, AstraZeneca, BMS, Boston Scientific, Biotronik, Cardiovalve, Edwards Lifesciences, MedAlliance, Medtronic, Novartis, Polares, Sinomed, V-Wave, and Xeltis. He has not received personal payments by pharmaceutical companies or device manufacturers. SW is a member of the steering or executive committee group of several investigator-initiated trials that receive funding by industry without effect on  his personal remuneration. SW is an unpaid member of the Pfizer Research Award selection committee in Switzerland and of the Women as One Awards Committee. SW is a member of the Clinical Study Group of the Deutsches Zentrum fur Herz Kreislauf-Forschung and of the Advisory Board of the Australian Victorian Heart Institute. He is Chairperson of the ESC Congress Program Committee, former Chairperson of the ESC Clinical Practice Guidelines Committee, and Deputy Editor  of the Journal of the American College of Cardiology Cardiovascular Interventions. All other authors declare no competing interests.\n",
      "\n",
      "Crea, Filippo\n",
      "Declaration of interests The BigData@Heart project has received funding from the  Innovative Medicines Initiative (IMI) 2 Joint Undertaking (grant 116074) which receives support from the Horizon 2020 research and innovation programme of the European Union and the European Federation of Pharmaceutical Industries and Associations. The funders had no role in considering the study design; in the collection, analysis, or interpretation of data; in the writing of the report; or in the decision to submit the Review for publication. Dipak Kotecha reports grants from the  European Union and the European Federation of Pharmaceutical Industries and Associations Innovative Medicines Initiative (116074), the National Institute for Health Research (NIHR CDF-2015-08-074 RATE-AF; NIHR130280 DaRe2THINK; and NIHR132974 D2T-NeuroVascular), the British Heart Foundation (PG/17/55/33087, AA/18/2/34218 and FS/CDRF/21/21032), and the ESC. Dipak Kotecha is supported by educational  grants from Boehringer Ingelheim, Bristol Myers Squibb (BMS)-Pfizer Alliance, Bayer, Daiichi Sankyo, Boston Scientific, the NIHR and University of Oxford Biomedical Research Centre, the British Heart Foundation and University of Birmingham Accelerator Award (STEEER-AF NCT04396418), Amomed Pharma, Istituto Di  Ricovero e Cura a Carattere Scientifico San Raffaele, and Menarini (NCT0083244).  Dipak Kotecha receives advisory board personal fees from Bayer, Amomed, Protherics Medicines Development, and Myokardia. Folkert W. Asselbergs reports grants from IMI BigData@Heart. Stefan D. Anker reports grants and personal fees from Vifor Pharma, Abbott, and Abbott Vascular;  and personal fees from Bayer, Boehringer Ingelheim, Servier, Cardiac Dimensions,  Actimed, AstraZeneca, Amgen, Bioventrix, Janssen, Respicardia, V-Wave, Brahms, Cordio, and Occlutech. Colin Baigent reports grants from Medical Research Council, Boehringer Ingelheim, and NIHR. Amitava Banerjee reports grants from AstraZeneca. Birgit Beger reports grants from the European Commission. Gunnar Brobert reports grants from the European Commission (IMI project support) and Bayer. Barbara Casadei reports non-financial support from Roche Diagnostics and iRhythm. Cinzia Ceccarelli reports grants from the European Commission. Martin R. Cowie reports personal fees from AstraZeneca. Filippo Crea reports personal fees from Amgen,  AstraZeneca, Servier, and BMS; and advisory board fees from GlyCardial Diagnostics. MC reports personal fees from Vifor Pharma. AD reports salary from Bayer. MF reports salary from AstraZeneca. CPG reports personal fees from AstraZeneca, Amgen, Bayer, Boehringer Ingelheim, Daiichi Sankyo, Vifor Pharma, Menarini, Wondr Medical, Raisio Group, and Oxford University Press; and grants from BMS, Abbott, British Heart Foundation, NIHR, and ESC. MI reports grants from World Economic Forum, Swedish Innovation Agency, and the European Commission; and collaboration with Frisq. SL reports grants from the European Commission. TFL reports grants from Abbott, Amgen, Novartis, Boehringer Ingelheim, Servier, Vifor Pharma, Sanofi, and AstraZeneca; and personal fees from Daichi Sankyo, Pfizer, and Menarini. LR reports salary from Bayer. CS reports personal fees from Bayer.  BT reports personal fees from Servier. GvT reports grants from IMI. KvB reports grants from IMI BigData@Heart. PEV reports personal fees from Hygeia Hospitals Group, Hellenic Healthcare Group, ESC, and Servier. TV is working as an editor at The BMJ and Acta Medica Portuguesa and is Vice President of the European Union of General Practitioners. MV reports grants from the European Commission. SW reports grants from Abbott, Amgen, AstraZeneca, BMS, Bayer, Biotronik, Boston Scientific, Cardinal Health, CardioValve, CSL Behring, Daiichi Sankyo, Edwards Lifesciences,  Guerbet, InfraRedx, Johnson & Johnson, Medicure, Medtronic, Novartis, Polares, OrPha Suisse, Pfizer, Regeneron, Sanofi-Aventis, Sinomed, Terumo, and V-Wave. SW  serves as an unpaid advisory board member or unpaid member of the steering or executive group of trials funded by Abbott, Abiomed, Amgen, AstraZeneca, BMS, Boston Scientific, Biotronik, Cardiovalve, Edwards Lifesciences, MedAlliance, Medtronic, Novartis, Polares, Sinomed, V-Wave, and Xeltis. He has not received personal payments by pharmaceutical companies or device manufacturers. SW is a member of the steering or executive committee group of several investigator-initiated trials that receive funding by industry without effect on  his personal remuneration. SW is an unpaid member of the Pfizer Research Award selection committee in Switzerland and of the Women as One Awards Committee. SW is a member of the Clinical Study Group of the Deutsches Zentrum fur Herz Kreislauf-Forschung and of the Advisory Board of the Australian Victorian Heart Institute. He is Chairperson of the ESC Congress Program Committee, former Chairperson of the ESC Clinical Practice Guidelines Committee, and Deputy Editor  of the Journal of the American College of Cardiology Cardiovascular Interventions. All other authors declare no competing interests.\n",
      "\n",
      "Cronin, Maureen\n",
      "Declaration of interests The BigData@Heart project has received funding from the  Innovative Medicines Initiative (IMI) 2 Joint Undertaking (grant 116074) which receives support from the Horizon 2020 research and innovation programme of the European Union and the European Federation of Pharmaceutical Industries and Associations. The funders had no role in considering the study design; in the collection, analysis, or interpretation of data; in the writing of the report; or in the decision to submit the Review for publication. Dipak Kotecha reports grants from the  European Union and the European Federation of Pharmaceutical Industries and Associations Innovative Medicines Initiative (116074), the National Institute for Health Research (NIHR CDF-2015-08-074 RATE-AF; NIHR130280 DaRe2THINK; and NIHR132974 D2T-NeuroVascular), the British Heart Foundation (PG/17/55/33087, AA/18/2/34218 and FS/CDRF/21/21032), and the ESC. Dipak Kotecha is supported by educational  grants from Boehringer Ingelheim, Bristol Myers Squibb (BMS)-Pfizer Alliance, Bayer, Daiichi Sankyo, Boston Scientific, the NIHR and University of Oxford Biomedical Research Centre, the British Heart Foundation and University of Birmingham Accelerator Award (STEEER-AF NCT04396418), Amomed Pharma, Istituto Di  Ricovero e Cura a Carattere Scientifico San Raffaele, and Menarini (NCT0083244).  Dipak Kotecha receives advisory board personal fees from Bayer, Amomed, Protherics Medicines Development, and Myokardia. Folkert W. Asselbergs reports grants from IMI BigData@Heart. Stefan D. Anker reports grants and personal fees from Vifor Pharma, Abbott, and Abbott Vascular;  and personal fees from Bayer, Boehringer Ingelheim, Servier, Cardiac Dimensions,  Actimed, AstraZeneca, Amgen, Bioventrix, Janssen, Respicardia, V-Wave, Brahms, Cordio, and Occlutech. Colin Baigent reports grants from Medical Research Council, Boehringer Ingelheim, and NIHR. Amitava Banerjee reports grants from AstraZeneca. Birgit Beger reports grants from the European Commission. Gunnar Brobert reports grants from the European Commission (IMI project support) and Bayer. Barbara Casadei reports non-financial support from Roche Diagnostics and iRhythm. Cinzia Ceccarelli reports grants from the European Commission. Martin R. Cowie reports personal fees from AstraZeneca. Filippo Crea reports personal fees from Amgen,  AstraZeneca, Servier, and BMS; and advisory board fees from GlyCardial Diagnostics. Maureen Cronin reports personal fees from Vifor Pharma. AD reports salary from Bayer. MF reports salary from AstraZeneca. CPG reports personal fees from AstraZeneca, Amgen, Bayer, Boehringer Ingelheim, Daiichi Sankyo, Vifor Pharma, Menarini, Wondr Medical, Raisio Group, and Oxford University Press; and grants from BMS, Abbott, British Heart Foundation, NIHR, and ESC. MI reports grants from World Economic Forum, Swedish Innovation Agency, and the European Commission; and collaboration with Frisq. SL reports grants from the European Commission. TFL reports grants from Abbott, Amgen, Novartis, Boehringer Ingelheim, Servier, Vifor Pharma, Sanofi, and AstraZeneca; and personal fees from Daichi Sankyo, Pfizer, and Menarini. LR reports salary from Bayer. CS reports personal fees from Bayer.  BT reports personal fees from Servier. GvT reports grants from IMI. KvB reports grants from IMI BigData@Heart. PEV reports personal fees from Hygeia Hospitals Group, Hellenic Healthcare Group, ESC, and Servier. TV is working as an editor at The BMJ and Acta Medica Portuguesa and is Vice President of the European Union of General Practitioners. MV reports grants from the European Commission. SW reports grants from Abbott, Amgen, AstraZeneca, BMS, Bayer, Biotronik, Boston Scientific, Cardinal Health, CardioValve, CSL Behring, Daiichi Sankyo, Edwards Lifesciences,  Guerbet, InfraRedx, Johnson & Johnson, Medicure, Medtronic, Novartis, Polares, OrPha Suisse, Pfizer, Regeneron, Sanofi-Aventis, Sinomed, Terumo, and V-Wave. SW  serves as an unpaid advisory board member or unpaid member of the steering or executive group of trials funded by Abbott, Abiomed, Amgen, AstraZeneca, BMS, Boston Scientific, Biotronik, Cardiovalve, Edwards Lifesciences, MedAlliance, Medtronic, Novartis, Polares, Sinomed, V-Wave, and Xeltis. He has not received personal payments by pharmaceutical companies or device manufacturers. SW is a member of the steering or executive committee group of several investigator-initiated trials that receive funding by industry without effect on  his personal remuneration. SW is an unpaid member of the Pfizer Research Award selection committee in Switzerland and of the Women as One Awards Committee. SW is a member of the Clinical Study Group of the Deutsches Zentrum fur Herz Kreislauf-Forschung and of the Advisory Board of the Australian Victorian Heart Institute. He is Chairperson of the ESC Congress Program Committee, former Chairperson of the ESC Clinical Practice Guidelines Committee, and Deputy Editor  of the Journal of the American College of Cardiology Cardiovascular Interventions. All other authors declare no competing interests.\n",
      "\n",
      "Declaration of interests The BigData@Heart project has received funding from the  Innovative Medicines Initiative (IMI) 2 Joint Undertaking (grant 116074) which receives support from the Horizon 2020 research and innovation programme of the European Union and the European Federation of Pharmaceutical Industries and Associations. The funders had no role in considering the study design; in the collection, analysis, or interpretation of data; in the writing of the report; or in the decision to submit the Review for publication. Dipak Kotecha reports grants from the  European Union and the European Federation of Pharmaceutical Industries and Associations Innovative Medicines Initiative (116074), the National Institute for Health Research (NIHR CDF-2015-08-074 RATE-AF; NIHR130280 DaRe2THINK; and NIHR132974 D2T-NeuroVascular), the British Heart Foundation (PG/17/55/33087, AA/18/2/34218 and FS/CDRF/21/21032), and the ESC. Dipak Kotecha is supported by educational  grants from Boehringer Ingelheim, Bristol Myers Squibb (BMS)-Pfizer Alliance, Bayer, Daiichi Sankyo, Boston Scientific, the NIHR and University of Oxford Biomedical Research Centre, the British Heart Foundation and University of Birmingham Accelerator Award (STEEER-AF NCT04396418), Amomed Pharma, Istituto Di  Ricovero e Cura a Carattere Scientifico San Raffaele, and Menarini (NCT0083244).  Dipak Kotecha receives advisory board personal fees from Bayer, Amomed, Protherics Medicines Development, and Myokardia. Folkert W. Asselbergs reports grants from IMI BigData@Heart. Stefan D. Anker reports grants and personal fees from Vifor Pharma, Abbott, and Abbott Vascular;  and personal fees from Bayer, Boehringer Ingelheim, Servier, Cardiac Dimensions,  Actimed, AstraZeneca, Amgen, Bioventrix, Janssen, Respicardia, V-Wave, Brahms, Cordio, and Occlutech. Colin Baigent reports grants from Medical Research Council, Boehringer Ingelheim, and NIHR. Amitava Banerjee reports grants from AstraZeneca. Birgit Beger reports grants from the European Commission. Gunnar Brobert reports grants from the European Commission (IMI project support) and Bayer. Barbara Casadei reports non-financial support from Roche Diagnostics and iRhythm. Cinzia Ceccarelli reports grants from the European Commission. Martin R. Cowie reports personal fees from AstraZeneca. Filippo Crea reports personal fees from Amgen,  AstraZeneca, Servier, and BMS; and advisory board fees from GlyCardial Diagnostics. Maureen Cronin reports personal fees from Vifor Pharma. AD reports salary from Bayer. MF reports salary from AstraZeneca. CPG reports personal fees from AstraZeneca, Amgen, Bayer, Boehringer Ingelheim, Daiichi Sankyo, Vifor Pharma, Menarini, Wondr Medical, Raisio Group, and Oxford University Press; and grants from BMS, Abbott, British Heart Foundation, NIHR, and ESC. MI reports grants from World Economic Forum, Swedish Innovation Agency, and the European Commission; and collaboration with Frisq. SL reports grants from the European Commission. TFL reports grants from Abbott, Amgen, Novartis, Boehringer Ingelheim, Servier, Vifor Pharma, Sanofi, and AstraZeneca; and personal fees from Daichi Sankyo, Pfizer, and Menarini. LR reports salary from Bayer. CS reports personal fees from Bayer.  BT reports personal fees from Servier. GvT reports grants from IMI. KvB reports grants from IMI BigData@Heart. PEV reports personal fees from Hygeia Hospitals Group, Hellenic Healthcare Group, ESC, and Servier. TV is working as an editor at The BMJ and Acta Medica Portuguesa and is Vice President of the European Union of General Practitioners. MV reports grants from the European Commission. SW reports grants from Abbott, Amgen, AstraZeneca, BMS, Bayer, Biotronik, Boston Scientific, Cardinal Health, CardioValve, CSL Behring, Daiichi Sankyo, Edwards Lifesciences,  Guerbet, InfraRedx, Johnson & Johnson, Medicure, Medtronic, Novartis, Polares, OrPha Suisse, Pfizer, Regeneron, Sanofi-Aventis, Sinomed, Terumo, and V-Wave. SW  serves as an unpaid advisory board member or unpaid member of the steering or executive group of trials funded by Abbott, Abiomed, Amgen, AstraZeneca, BMS, Boston Scientific, Biotronik, Cardiovalve, Edwards Lifesciences, MedAlliance, Medtronic, Novartis, Polares, Sinomed, V-Wave, and Xeltis. He has not received personal payments by pharmaceutical companies or device manufacturers. SW is a member of the steering or executive committee group of several investigator-initiated trials that receive funding by industry without effect on  his personal remuneration. SW is an unpaid member of the Pfizer Research Award selection committee in Switzerland and of the Women as One Awards Committee. SW is a member of the Clinical Study Group of the Deutsches Zentrum fur Herz Kreislauf-Forschung and of the Advisory Board of the Australian Victorian Heart Institute. He is Chairperson of the ESC Congress Program Committee, former Chairperson of the ESC Clinical Practice Guidelines Committee, and Deputy Editor  of the Journal of the American College of Cardiology Cardiovascular Interventions. All other authors declare no competing interests.\n",
      "\n",
      "Derix, Andrea\n",
      "Declaration of interests The BigData@Heart project has received funding from the  Innovative Medicines Initiative (IMI) 2 Joint Undertaking (grant 116074) which receives support from the Horizon 2020 research and innovation programme of the European Union and the European Federation of Pharmaceutical Industries and Associations. The funders had no role in considering the study design; in the collection, analysis, or interpretation of data; in the writing of the report; or in the decision to submit the Review for publication. Dipak Kotecha reports grants from the  European Union and the European Federation of Pharmaceutical Industries and Associations Innovative Medicines Initiative (116074), the National Institute for Health Research (NIHR CDF-2015-08-074 RATE-AF; NIHR130280 DaRe2THINK; and NIHR132974 D2T-NeuroVascular), the British Heart Foundation (PG/17/55/33087, AA/18/2/34218 and FS/CDRF/21/21032), and the ESC. Dipak Kotecha is supported by educational  grants from Boehringer Ingelheim, Bristol Myers Squibb (BMS)-Pfizer Alliance, Bayer, Daiichi Sankyo, Boston Scientific, the NIHR and University of Oxford Biomedical Research Centre, the British Heart Foundation and University of Birmingham Accelerator Award (STEEER-AF NCT04396418), Amomed Pharma, Istituto Di  Ricovero e Cura a Carattere Scientifico San Raffaele, and Menarini (NCT0083244).  Dipak Kotecha receives advisory board personal fees from Bayer, Amomed, Protherics Medicines Development, and Myokardia. Folkert W. Asselbergs reports grants from IMI BigData@Heart. Stefan D. Anker reports grants and personal fees from Vifor Pharma, Abbott, and Abbott Vascular;  and personal fees from Bayer, Boehringer Ingelheim, Servier, Cardiac Dimensions,  Actimed, AstraZeneca, Amgen, Bioventrix, Janssen, Respicardia, V-Wave, Brahms, Cordio, and Occlutech. Colin Baigent reports grants from Medical Research Council, Boehringer Ingelheim, and NIHR. Amitava Banerjee reports grants from AstraZeneca. Birgit Beger reports grants from the European Commission. Gunnar Brobert reports grants from the European Commission (IMI project support) and Bayer. Barbara Casadei reports non-financial support from Roche Diagnostics and iRhythm. Cinzia Ceccarelli reports grants from the European Commission. Martin R. Cowie reports personal fees from AstraZeneca. Filippo Crea reports personal fees from Amgen,  AstraZeneca, Servier, and BMS; and advisory board fees from GlyCardial Diagnostics. Maureen Cronin reports personal fees from Vifor Pharma. Andrea Derix reports salary from Bayer. MF reports salary from AstraZeneca. CPG reports personal fees from AstraZeneca, Amgen, Bayer, Boehringer Ingelheim, Daiichi Sankyo, Vifor Pharma, Menarini, Wondr Medical, Raisio Group, and Oxford University Press; and grants from BMS, Abbott, British Heart Foundation, NIHR, and ESC. MI reports grants from World Economic Forum, Swedish Innovation Agency, and the European Commission; and collaboration with Frisq. SL reports grants from the European Commission. TFL reports grants from Abbott, Amgen, Novartis, Boehringer Ingelheim, Servier, Vifor Pharma, Sanofi, and AstraZeneca; and personal fees from Daichi Sankyo, Pfizer, and Menarini. LR reports salary from Bayer. CS reports personal fees from Bayer.  BT reports personal fees from Servier. GvT reports grants from IMI. KvB reports grants from IMI BigData@Heart. PEV reports personal fees from Hygeia Hospitals Group, Hellenic Healthcare Group, ESC, and Servier. TV is working as an editor at The BMJ and Acta Medica Portuguesa and is Vice President of the European Union of General Practitioners. MV reports grants from the European Commission. SW reports grants from Abbott, Amgen, AstraZeneca, BMS, Bayer, Biotronik, Boston Scientific, Cardinal Health, CardioValve, CSL Behring, Daiichi Sankyo, Edwards Lifesciences,  Guerbet, InfraRedx, Johnson & Johnson, Medicure, Medtronic, Novartis, Polares, OrPha Suisse, Pfizer, Regeneron, Sanofi-Aventis, Sinomed, Terumo, and V-Wave. SW  serves as an unpaid advisory board member or unpaid member of the steering or executive group of trials funded by Abbott, Abiomed, Amgen, AstraZeneca, BMS, Boston Scientific, Biotronik, Cardiovalve, Edwards Lifesciences, MedAlliance, Medtronic, Novartis, Polares, Sinomed, V-Wave, and Xeltis. He has not received personal payments by pharmaceutical companies or device manufacturers. SW is a member of the steering or executive committee group of several investigator-initiated trials that receive funding by industry without effect on  his personal remuneration. SW is an unpaid member of the Pfizer Research Award selection committee in Switzerland and of the Women as One Awards Committee. SW is a member of the Clinical Study Group of the Deutsches Zentrum fur Herz Kreislauf-Forschung and of the Advisory Board of the Australian Victorian Heart Institute. He is Chairperson of the ESC Congress Program Committee, former Chairperson of the ESC Clinical Practice Guidelines Committee, and Deputy Editor  of the Journal of the American College of Cardiology Cardiovascular Interventions. All other authors declare no competing interests.\n",
      "\n",
      "Fitzsimons, Donna\n",
      "Declaration of interests The BigData@Heart project has received funding from the  Innovative Medicines Initiative (IMI) 2 Joint Undertaking (grant 116074) which receives support from the Horizon 2020 research and innovation programme of the European Union and the European Federation of Pharmaceutical Industries and Associations. The funders had no role in considering the study design; in the collection, analysis, or interpretation of data; in the writing of the report; or in the decision to submit the Review for publication. Dipak Kotecha reports grants from the  European Union and the European Federation of Pharmaceutical Industries and Associations Innovative Medicines Initiative (116074), the National Institute for Health Research (NIHR CDonna Fitzsimons-2015-08-074 RATE-AF; NIHR130280 DaRe2THINK; and NIHR132974 D2T-NeuroVascular), the British Heart Foundation (PG/17/55/33087, AA/18/2/34218 and FS/CDRF/21/21032), and the ESC. Dipak Kotecha is supported by educational  grants from Boehringer Ingelheim, Bristol Myers Squibb (BMS)-Pfizer Alliance, Bayer, Daiichi Sankyo, Boston Scientific, the NIHR and University of Oxford Biomedical Research Centre, the British Heart Foundation and University of Birmingham Accelerator Award (STEEER-AF NCT04396418), Amomed Pharma, Istituto Di  Ricovero e Cura a Carattere Scientifico San Raffaele, and Menarini (NCT0083244).  Dipak Kotecha receives advisory board personal fees from Bayer, Amomed, Protherics Medicines Development, and Myokardia. Folkert W. Asselbergs reports grants from IMI BigData@Heart. Stefan D. Anker reports grants and personal fees from Vifor Pharma, Abbott, and Abbott Vascular;  and personal fees from Bayer, Boehringer Ingelheim, Servier, Cardiac Dimensions,  Actimed, AstraZeneca, Amgen, Bioventrix, Janssen, Respicardia, V-Wave, Brahms, Cordio, and Occlutech. Colin Baigent reports grants from Medical Research Council, Boehringer Ingelheim, and NIHR. Amitava Banerjee reports grants from AstraZeneca. Birgit Beger reports grants from the European Commission. Gunnar Brobert reports grants from the European Commission (IMI project support) and Bayer. Barbara Casadei reports non-financial support from Roche Diagnostics and iRhythm. Cinzia Ceccarelli reports grants from the European Commission. Martin R. Cowie reports personal fees from AstraZeneca. Filippo Crea reports personal fees from Amgen,  AstraZeneca, Servier, and BMS; and advisory board fees from GlyCardial Diagnostics. Maureen Cronin reports personal fees from Vifor Pharma. Andrea Derix reports salary from Bayer. MF reports salary from AstraZeneca. CPG reports personal fees from AstraZeneca, Amgen, Bayer, Boehringer Ingelheim, Daiichi Sankyo, Vifor Pharma, Menarini, Wondr Medical, Raisio Group, and Oxford University Press; and grants from BMS, Abbott, British Heart Foundation, NIHR, and ESC. MI reports grants from World Economic Forum, Swedish Innovation Agency, and the European Commission; and collaboration with Frisq. SL reports grants from the European Commission. TFL reports grants from Abbott, Amgen, Novartis, Boehringer Ingelheim, Servier, Vifor Pharma, Sanofi, and AstraZeneca; and personal fees from Daichi Sankyo, Pfizer, and Menarini. LR reports salary from Bayer. CS reports personal fees from Bayer.  BT reports personal fees from Servier. GvT reports grants from IMI. KvB reports grants from IMI BigData@Heart. PEV reports personal fees from Hygeia Hospitals Group, Hellenic Healthcare Group, ESC, and Servier. TV is working as an editor at The BMJ and Acta Medica Portuguesa and is Vice President of the European Union of General Practitioners. MV reports grants from the European Commission. SW reports grants from Abbott, Amgen, AstraZeneca, BMS, Bayer, Biotronik, Boston Scientific, Cardinal Health, CardioValve, CSL Behring, Daiichi Sankyo, Edwards Lifesciences,  Guerbet, InfraRedx, Johnson & Johnson, Medicure, Medtronic, Novartis, Polares, OrPha Suisse, Pfizer, Regeneron, Sanofi-Aventis, Sinomed, Terumo, and V-Wave. SW  serves as an unpaid advisory board member or unpaid member of the steering or executive group of trials funded by Abbott, Abiomed, Amgen, AstraZeneca, BMS, Boston Scientific, Biotronik, Cardiovalve, Edwards Lifesciences, MedAlliance, Medtronic, Novartis, Polares, Sinomed, V-Wave, and Xeltis. He has not received personal payments by pharmaceutical companies or device manufacturers. SW is a member of the steering or executive committee group of several investigator-initiated trials that receive funding by industry without effect on  his personal remuneration. SW is an unpaid member of the Pfizer Research Award selection committee in Switzerland and of the Women as One Awards Committee. SW is a member of the Clinical Study Group of the Deutsches Zentrum fur Herz Kreislauf-Forschung and of the Advisory Board of the Australian Victorian Heart Institute. He is Chairperson of the ESC Congress Program Committee, former Chairperson of the ESC Clinical Practice Guidelines Committee, and Deputy Editor  of the Journal of the American College of Cardiology Cardiovascular Interventions. All other authors declare no competing interests.\n",
      "\n",
      "Fredriksson, Martin\n",
      "Declaration of interests The BigData@Heart project has received funding from the  Innovative Medicines Initiative (IMI) 2 Joint Undertaking (grant 116074) which receives support from the Horizon 2020 research and innovation programme of the European Union and the European Federation of Pharmaceutical Industries and Associations. The funders had no role in considering the study design; in the collection, analysis, or interpretation of data; in the writing of the report; or in the decision to submit the Review for publication. Dipak Kotecha reports grants from the  European Union and the European Federation of Pharmaceutical Industries and Associations Innovative Medicines Initiative (116074), the National Institute for Health Research (NIHR CDonna Fitzsimons-2015-08-074 RATE-AF; NIHR130280 DaRe2THINK; and NIHR132974 D2T-NeuroVascular), the British Heart Foundation (PG/17/55/33087, AA/18/2/34218 and FS/CDRF/21/21032), and the ESC. Dipak Kotecha is supported by educational  grants from Boehringer Ingelheim, Bristol Myers Squibb (BMS)-Pfizer Alliance, Bayer, Daiichi Sankyo, Boston Scientific, the NIHR and University of Oxford Biomedical Research Centre, the British Heart Foundation and University of Birmingham Accelerator Award (STEEER-AF NCT04396418), Amomed Pharma, Istituto Di  Ricovero e Cura a Carattere Scientifico San Raffaele, and Menarini (NCT0083244).  Dipak Kotecha receives advisory board personal fees from Bayer, Amomed, Protherics Medicines Development, and Myokardia. Folkert W. Asselbergs reports grants from IMI BigData@Heart. Stefan D. Anker reports grants and personal fees from Vifor Pharma, Abbott, and Abbott Vascular;  and personal fees from Bayer, Boehringer Ingelheim, Servier, Cardiac Dimensions,  Actimed, AstraZeneca, Amgen, Bioventrix, Janssen, Respicardia, V-Wave, Brahms, Cordio, and Occlutech. Colin Baigent reports grants from Medical Research Council, Boehringer Ingelheim, and NIHR. Amitava Banerjee reports grants from AstraZeneca. Birgit Beger reports grants from the European Commission. Gunnar Brobert reports grants from the European Commission (IMI project support) and Bayer. Barbara Casadei reports non-financial support from Roche Diagnostics and iRhythm. Cinzia Ceccarelli reports grants from the European Commission. Martin R. Cowie reports personal fees from AstraZeneca. Filippo Crea reports personal fees from Amgen,  AstraZeneca, Servier, and BMS; and advisory board fees from GlyCardial Diagnostics. Maureen Cronin reports personal fees from Vifor Pharma. Andrea Derix reports salary from Bayer. Martin Fredriksson reports salary from AstraZeneca. CPG reports personal fees from AstraZeneca, Amgen, Bayer, Boehringer Ingelheim, Daiichi Sankyo, Vifor Pharma, Menarini, Wondr Medical, Raisio Group, and Oxford University Press; and grants from BMS, Abbott, British Heart Foundation, NIHR, and ESC. MI reports grants from World Economic Forum, Swedish Innovation Agency, and the European Commission; and collaboration with Frisq. SL reports grants from the European Commission. TFL reports grants from Abbott, Amgen, Novartis, Boehringer Ingelheim, Servier, Vifor Pharma, Sanofi, and AstraZeneca; and personal fees from Daichi Sankyo, Pfizer, and Menarini. LR reports salary from Bayer. CS reports personal fees from Bayer.  BT reports personal fees from Servier. GvT reports grants from IMI. KvB reports grants from IMI BigData@Heart. PEV reports personal fees from Hygeia Hospitals Group, Hellenic Healthcare Group, ESC, and Servier. TV is working as an editor at The BMJ and Acta Medica Portuguesa and is Vice President of the European Union of General Practitioners. MV reports grants from the European Commission. SW reports grants from Abbott, Amgen, AstraZeneca, BMS, Bayer, Biotronik, Boston Scientific, Cardinal Health, CardioValve, CSL Behring, Daiichi Sankyo, Edwards Lifesciences,  Guerbet, InfraRedx, Johnson & Johnson, Medicure, Medtronic, Novartis, Polares, OrPha Suisse, Pfizer, Regeneron, Sanofi-Aventis, Sinomed, Terumo, and V-Wave. SW  serves as an unpaid advisory board member or unpaid member of the steering or executive group of trials funded by Abbott, Abiomed, Amgen, AstraZeneca, BMS, Boston Scientific, Biotronik, Cardiovalve, Edwards Lifesciences, MedAlliance, Medtronic, Novartis, Polares, Sinomed, V-Wave, and Xeltis. He has not received personal payments by pharmaceutical companies or device manufacturers. SW is a member of the steering or executive committee group of several investigator-initiated trials that receive funding by industry without effect on  his personal remuneration. SW is an unpaid member of the Pfizer Research Award selection committee in Switzerland and of the Women as One Awards Committee. SW is a member of the Clinical Study Group of the Deutsches Zentrum fur Herz Kreislauf-Forschung and of the Advisory Board of the Australian Victorian Heart Institute. He is Chairperson of the ESC Congress Program Committee, former Chairperson of the ESC Clinical Practice Guidelines Committee, and Deputy Editor  of the Journal of the American College of Cardiology Cardiovascular Interventions. All other authors declare no competing interests.\n",
      "\n",
      "Gale, Chris P.\n",
      "Declaration of interests The BigData@Heart project has received funding from the  Innovative Medicines Initiative (IMI) 2 Joint Undertaking (grant 116074) which receives support from the Horizon 2020 research and innovation programme of the European Union and the European Federation of Pharmaceutical Industries and Associations. The funders had no role in considering the study design; in the collection, analysis, or interpretation of data; in the writing of the report; or in the decision to submit the Review for publication. Dipak Kotecha reports grants from the  European Union and the European Federation of Pharmaceutical Industries and Associations Innovative Medicines Initiative (116074), the National Institute for Health Research (NIHR CDonna Fitzsimons-2015-08-074 RATE-AF; NIHR130280 DaRe2THINK; and NIHR132974 D2T-NeuroVascular), the British Heart Foundation (PG/17/55/33087, AA/18/2/34218 and FS/CDRF/21/21032), and the ESC. Dipak Kotecha is supported by educational  grants from Boehringer Ingelheim, Bristol Myers Squibb (BMS)-Pfizer Alliance, Bayer, Daiichi Sankyo, Boston Scientific, the NIHR and University of Oxford Biomedical Research Centre, the British Heart Foundation and University of Birmingham Accelerator Award (STEEER-AF NCT04396418), Amomed Pharma, Istituto Di  Ricovero e Cura a Carattere Scientifico San Raffaele, and Menarini (NCT0083244).  Dipak Kotecha receives advisory board personal fees from Bayer, Amomed, Protherics Medicines Development, and Myokardia. Folkert W. Asselbergs reports grants from IMI BigData@Heart. Stefan D. Anker reports grants and personal fees from Vifor Pharma, Abbott, and Abbott Vascular;  and personal fees from Bayer, Boehringer Ingelheim, Servier, Cardiac Dimensions,  Actimed, AstraZeneca, Amgen, Bioventrix, Janssen, Respicardia, V-Wave, Brahms, Cordio, and Occlutech. Colin Baigent reports grants from Medical Research Council, Boehringer Ingelheim, and NIHR. Amitava Banerjee reports grants from AstraZeneca. Birgit Beger reports grants from the European Commission. Gunnar Brobert reports grants from the European Commission (IMI project support) and Bayer. Barbara Casadei reports non-financial support from Roche Diagnostics and iRhythm. Cinzia Ceccarelli reports grants from the European Commission. Martin R. Cowie reports personal fees from AstraZeneca. Filippo Crea reports personal fees from Amgen,  AstraZeneca, Servier, and BMS; and advisory board fees from GlyCardial Diagnostics. Maureen Cronin reports personal fees from Vifor Pharma. Andrea Derix reports salary from Bayer. Martin Fredriksson reports salary from AstraZeneca. Chris P. Gale reports personal fees from AstraZeneca, Amgen, Bayer, Boehringer Ingelheim, Daiichi Sankyo, Vifor Pharma, Menarini, Wondr Medical, Raisio Group, and Oxford University Press; and grants from BMS, Abbott, British Heart Foundation, NIHR, and ESC. MI reports grants from World Economic Forum, Swedish Innovation Agency, and the European Commission; and collaboration with Frisq. SL reports grants from the European Commission. TFL reports grants from Abbott, Amgen, Novartis, Boehringer Ingelheim, Servier, Vifor Pharma, Sanofi, and AstraZeneca; and personal fees from Daichi Sankyo, Pfizer, and Menarini. LR reports salary from Bayer. CS reports personal fees from Bayer.  BT reports personal fees from Servier. GvT reports grants from IMI. KvB reports grants from IMI BigData@Heart. PEV reports personal fees from Hygeia Hospitals Group, Hellenic Healthcare Group, ESC, and Servier. TV is working as an editor at The BMJ and Acta Medica Portuguesa and is Vice President of the European Union of General Practitioners. MV reports grants from the European Commission. SW reports grants from Abbott, Amgen, AstraZeneca, BMS, Bayer, Biotronik, Boston Scientific, Cardinal Health, CardioValve, CSL Behring, Daiichi Sankyo, Edwards Lifesciences,  Guerbet, InfraRedx, Johnson & Johnson, Medicure, Medtronic, Novartis, Polares, OrPha Suisse, Pfizer, Regeneron, Sanofi-Aventis, Sinomed, Terumo, and V-Wave. SW  serves as an unpaid advisory board member or unpaid member of the steering or executive group of trials funded by Abbott, Abiomed, Amgen, AstraZeneca, BMS, Boston Scientific, Biotronik, Cardiovalve, Edwards Lifesciences, MedAlliance, Medtronic, Novartis, Polares, Sinomed, V-Wave, and Xeltis. He has not received personal payments by pharmaceutical companies or device manufacturers. SW is a member of the steering or executive committee group of several investigator-initiated trials that receive funding by industry without effect on  his personal remuneration. SW is an unpaid member of the Pfizer Research Award selection committee in Switzerland and of the Women as One Awards Committee. SW is a member of the Clinical Study Group of the Deutsches Zentrum fur Herz Kreislauf-Forschung and of the Advisory Board of the Australian Victorian Heart Institute. He is Chairperson of the ESC Congress Program Committee, former Chairperson of the ESC Clinical Practice Guidelines Committee, and Deputy Editor  of the Journal of the American College of Cardiology Cardiovascular Interventions. All other authors declare no competing interests.\n",
      "\n",
      "Declaration of interests The BigData@Heart project has received funding from the  Innovative Medicines Initiative (IMI) 2 Joint Undertaking (grant 116074) which receives support from the Horizon 2020 research and innovation programme of the European Union and the European Federation of Pharmaceutical Industries and Associations. The funders had no role in considering the study design; in the collection, analysis, or interpretation of data; in the writing of the report; or in the decision to submit the Review for publication. Dipak Kotecha reports grants from the  European Union and the European Federation of Pharmaceutical Industries and Associations Innovative Medicines Initiative (116074), the National Institute for Health Research (NIHR CDonna Fitzsimons-2015-08-074 RATE-AF; NIHR130280 DaRe2THINK; and NIHR132974 D2T-NeuroVascular), the British Heart Foundation (PG/17/55/33087, AA/18/2/34218 and FS/CDRF/21/21032), and the ESC. Dipak Kotecha is supported by educational  grants from Boehringer Ingelheim, Bristol Myers Squibb (BMS)-Pfizer Alliance, Bayer, Daiichi Sankyo, Boston Scientific, the NIHR and University of Oxford Biomedical Research Centre, the British Heart Foundation and University of Birmingham Accelerator Award (STEEER-AF NCT04396418), Amomed Pharma, Istituto Di  Ricovero e Cura a Carattere Scientifico San Raffaele, and Menarini (NCT0083244).  Dipak Kotecha receives advisory board personal fees from Bayer, Amomed, Protherics Medicines Development, and Myokardia. Folkert W. Asselbergs reports grants from IMI BigData@Heart. Stefan D. Anker reports grants and personal fees from Vifor Pharma, Abbott, and Abbott Vascular;  and personal fees from Bayer, Boehringer Ingelheim, Servier, Cardiac Dimensions,  Actimed, AstraZeneca, Amgen, Bioventrix, Janssen, Respicardia, V-Wave, Brahms, Cordio, and Occlutech. Colin Baigent reports grants from Medical Research Council, Boehringer Ingelheim, and NIHR. Amitava Banerjee reports grants from AstraZeneca. Birgit Beger reports grants from the European Commission. Gunnar Brobert reports grants from the European Commission (IMI project support) and Bayer. Barbara Casadei reports non-financial support from Roche Diagnostics and iRhythm. Cinzia Ceccarelli reports grants from the European Commission. Martin R. Cowie reports personal fees from AstraZeneca. Filippo Crea reports personal fees from Amgen,  AstraZeneca, Servier, and BMS; and advisory board fees from GlyCardial Diagnostics. Maureen Cronin reports personal fees from Vifor Pharma. Andrea Derix reports salary from Bayer. Martin Fredriksson reports salary from AstraZeneca. Chris P. Gale reports personal fees from AstraZeneca, Amgen, Bayer, Boehringer Ingelheim, Daiichi Sankyo, Vifor Pharma, Menarini, Wondr Medical, Raisio Group, and Oxford University Press; and grants from BMS, Abbott, British Heart Foundation, NIHR, and ESC. MI reports grants from World Economic Forum, Swedish Innovation Agency, and the European Commission; and collaboration with Frisq. SL reports grants from the European Commission. TFL reports grants from Abbott, Amgen, Novartis, Boehringer Ingelheim, Servier, Vifor Pharma, Sanofi, and AstraZeneca; and personal fees from Daichi Sankyo, Pfizer, and Menarini. LR reports salary from Bayer. CS reports personal fees from Bayer.  BT reports personal fees from Servier. GvT reports grants from IMI. KvB reports grants from IMI BigData@Heart. PEV reports personal fees from Hygeia Hospitals Group, Hellenic Healthcare Group, ESC, and Servier. TV is working as an editor at The BMJ and Acta Medica Portuguesa and is Vice President of the European Union of General Practitioners. MV reports grants from the European Commission. SW reports grants from Abbott, Amgen, AstraZeneca, BMS, Bayer, Biotronik, Boston Scientific, Cardinal Health, CardioValve, CSL Behring, Daiichi Sankyo, Edwards Lifesciences,  Guerbet, InfraRedx, Johnson & Johnson, Medicure, Medtronic, Novartis, Polares, OrPha Suisse, Pfizer, Regeneron, Sanofi-Aventis, Sinomed, Terumo, and V-Wave. SW  serves as an unpaid advisory board member or unpaid member of the steering or executive group of trials funded by Abbott, Abiomed, Amgen, AstraZeneca, BMS, Boston Scientific, Biotronik, Cardiovalve, Edwards Lifesciences, MedAlliance, Medtronic, Novartis, Polares, Sinomed, V-Wave, and Xeltis. He has not received personal payments by pharmaceutical companies or device manufacturers. SW is a member of the steering or executive committee group of several investigator-initiated trials that receive funding by industry without effect on  his personal remuneration. SW is an unpaid member of the Pfizer Research Award selection committee in Switzerland and of the Women as One Awards Committee. SW is a member of the Clinical Study Group of the Deutsches Zentrum fur Herz Kreislauf-Forschung and of the Advisory Board of the Australian Victorian Heart Institute. He is Chairperson of the ESC Congress Program Committee, former Chairperson of the ESC Clinical Practice Guidelines Committee, and Deputy Editor  of the Journal of the American College of Cardiology Cardiovascular Interventions. All other authors declare no competing interests.\n",
      "\n",
      "Declaration of interests The BigData@Heart project has received funding from the  Innovative Medicines Initiative (IMI) 2 Joint Undertaking (grant 116074) which receives support from the Horizon 2020 research and innovation programme of the European Union and the European Federation of Pharmaceutical Industries and Associations. The funders had no role in considering the study design; in the collection, analysis, or interpretation of data; in the writing of the report; or in the decision to submit the Review for publication. Dipak Kotecha reports grants from the  European Union and the European Federation of Pharmaceutical Industries and Associations Innovative Medicines Initiative (116074), the National Institute for Health Research (NIHR CDonna Fitzsimons-2015-08-074 RATE-AF; NIHR130280 DaRe2THINK; and NIHR132974 D2T-NeuroVascular), the British Heart Foundation (PG/17/55/33087, AA/18/2/34218 and FS/CDRF/21/21032), and the ESC. Dipak Kotecha is supported by educational  grants from Boehringer Ingelheim, Bristol Myers Squibb (BMS)-Pfizer Alliance, Bayer, Daiichi Sankyo, Boston Scientific, the NIHR and University of Oxford Biomedical Research Centre, the British Heart Foundation and University of Birmingham Accelerator Award (STEEER-AF NCT04396418), Amomed Pharma, Istituto Di  Ricovero e Cura a Carattere Scientifico San Raffaele, and Menarini (NCT0083244).  Dipak Kotecha receives advisory board personal fees from Bayer, Amomed, Protherics Medicines Development, and Myokardia. Folkert W. Asselbergs reports grants from IMI BigData@Heart. Stefan D. Anker reports grants and personal fees from Vifor Pharma, Abbott, and Abbott Vascular;  and personal fees from Bayer, Boehringer Ingelheim, Servier, Cardiac Dimensions,  Actimed, AstraZeneca, Amgen, Bioventrix, Janssen, Respicardia, V-Wave, Brahms, Cordio, and Occlutech. Colin Baigent reports grants from Medical Research Council, Boehringer Ingelheim, and NIHR. Amitava Banerjee reports grants from AstraZeneca. Birgit Beger reports grants from the European Commission. Gunnar Brobert reports grants from the European Commission (IMI project support) and Bayer. Barbara Casadei reports non-financial support from Roche Diagnostics and iRhythm. Cinzia Ceccarelli reports grants from the European Commission. Martin R. Cowie reports personal fees from AstraZeneca. Filippo Crea reports personal fees from Amgen,  AstraZeneca, Servier, and BMS; and advisory board fees from GlyCardial Diagnostics. Maureen Cronin reports personal fees from Vifor Pharma. Andrea Derix reports salary from Bayer. Martin Fredriksson reports salary from AstraZeneca. Chris P. Gale reports personal fees from AstraZeneca, Amgen, Bayer, Boehringer Ingelheim, Daiichi Sankyo, Vifor Pharma, Menarini, Wondr Medical, Raisio Group, and Oxford University Press; and grants from BMS, Abbott, British Heart Foundation, NIHR, and ESC. MI reports grants from World Economic Forum, Swedish Innovation Agency, and the European Commission; and collaboration with Frisq. SL reports grants from the European Commission. TFL reports grants from Abbott, Amgen, Novartis, Boehringer Ingelheim, Servier, Vifor Pharma, Sanofi, and AstraZeneca; and personal fees from Daichi Sankyo, Pfizer, and Menarini. LR reports salary from Bayer. CS reports personal fees from Bayer.  BT reports personal fees from Servier. GvT reports grants from IMI. KvB reports grants from IMI BigData@Heart. PEV reports personal fees from Hygeia Hospitals Group, Hellenic Healthcare Group, ESC, and Servier. TV is working as an editor at The BMJ and Acta Medica Portuguesa and is Vice President of the European Union of General Practitioners. MV reports grants from the European Commission. SW reports grants from Abbott, Amgen, AstraZeneca, BMS, Bayer, Biotronik, Boston Scientific, Cardinal Health, CardioValve, CSL Behring, Daiichi Sankyo, Edwards Lifesciences,  Guerbet, InfraRedx, Johnson & Johnson, Medicure, Medtronic, Novartis, Polares, OrPha Suisse, Pfizer, Regeneron, Sanofi-Aventis, Sinomed, Terumo, and V-Wave. SW  serves as an unpaid advisory board member or unpaid member of the steering or executive group of trials funded by Abbott, Abiomed, Amgen, AstraZeneca, BMS, Boston Scientific, Biotronik, Cardiovalve, Edwards Lifesciences, MedAlliance, Medtronic, Novartis, Polares, Sinomed, V-Wave, and Xeltis. He has not received personal payments by pharmaceutical companies or device manufacturers. SW is a member of the steering or executive committee group of several investigator-initiated trials that receive funding by industry without effect on  his personal remuneration. SW is an unpaid member of the Pfizer Research Award selection committee in Switzerland and of the Women as One Awards Committee. SW is a member of the Clinical Study Group of the Deutsches Zentrum fur Herz Kreislauf-Forschung and of the Advisory Board of the Australian Victorian Heart Institute. He is Chairperson of the ESC Congress Program Committee, former Chairperson of the ESC Clinical Practice Guidelines Committee, and Deputy Editor  of the Journal of the American College of Cardiology Cardiovascular Interventions. All other authors declare no competing interests.\n",
      "\n",
      "Declaration of interests The BigData@Heart project has received funding from the  Innovative Medicines Initiative (IMI) 2 Joint Undertaking (grant 116074) which receives support from the Horizon 2020 research and innovation programme of the European Union and the European Federation of Pharmaceutical Industries and Associations. The funders had no role in considering the study design; in the collection, analysis, or interpretation of data; in the writing of the report; or in the decision to submit the Review for publication. Dipak Kotecha reports grants from the  European Union and the European Federation of Pharmaceutical Industries and Associations Innovative Medicines Initiative (116074), the National Institute for Health Research (NIHR CDonna Fitzsimons-2015-08-074 RATE-AF; NIHR130280 DaRe2THINK; and NIHR132974 D2T-NeuroVascular), the British Heart Foundation (PG/17/55/33087, AA/18/2/34218 and FS/CDRF/21/21032), and the ESC. Dipak Kotecha is supported by educational  grants from Boehringer Ingelheim, Bristol Myers Squibb (BMS)-Pfizer Alliance, Bayer, Daiichi Sankyo, Boston Scientific, the NIHR and University of Oxford Biomedical Research Centre, the British Heart Foundation and University of Birmingham Accelerator Award (STEEER-AF NCT04396418), Amomed Pharma, Istituto Di  Ricovero e Cura a Carattere Scientifico San Raffaele, and Menarini (NCT0083244).  Dipak Kotecha receives advisory board personal fees from Bayer, Amomed, Protherics Medicines Development, and Myokardia. Folkert W. Asselbergs reports grants from IMI BigData@Heart. Stefan D. Anker reports grants and personal fees from Vifor Pharma, Abbott, and Abbott Vascular;  and personal fees from Bayer, Boehringer Ingelheim, Servier, Cardiac Dimensions,  Actimed, AstraZeneca, Amgen, Bioventrix, Janssen, Respicardia, V-Wave, Brahms, Cordio, and Occlutech. Colin Baigent reports grants from Medical Research Council, Boehringer Ingelheim, and NIHR. Amitava Banerjee reports grants from AstraZeneca. Birgit Beger reports grants from the European Commission. Gunnar Brobert reports grants from the European Commission (IMI project support) and Bayer. Barbara Casadei reports non-financial support from Roche Diagnostics and iRhythm. Cinzia Ceccarelli reports grants from the European Commission. Martin R. Cowie reports personal fees from AstraZeneca. Filippo Crea reports personal fees from Amgen,  AstraZeneca, Servier, and BMS; and advisory board fees from GlyCardial Diagnostics. Maureen Cronin reports personal fees from Vifor Pharma. Andrea Derix reports salary from Bayer. Martin Fredriksson reports salary from AstraZeneca. Chris P. Gale reports personal fees from AstraZeneca, Amgen, Bayer, Boehringer Ingelheim, Daiichi Sankyo, Vifor Pharma, Menarini, Wondr Medical, Raisio Group, and Oxford University Press; and grants from BMS, Abbott, British Heart Foundation, NIHR, and ESC. MI reports grants from World Economic Forum, Swedish Innovation Agency, and the European Commission; and collaboration with Frisq. SL reports grants from the European Commission. TFL reports grants from Abbott, Amgen, Novartis, Boehringer Ingelheim, Servier, Vifor Pharma, Sanofi, and AstraZeneca; and personal fees from Daichi Sankyo, Pfizer, and Menarini. LR reports salary from Bayer. CS reports personal fees from Bayer.  BT reports personal fees from Servier. GvT reports grants from IMI. KvB reports grants from IMI BigData@Heart. PEV reports personal fees from Hygeia Hospitals Group, Hellenic Healthcare Group, ESC, and Servier. TV is working as an editor at The BMJ and Acta Medica Portuguesa and is Vice President of the European Union of General Practitioners. MV reports grants from the European Commission. SW reports grants from Abbott, Amgen, AstraZeneca, BMS, Bayer, Biotronik, Boston Scientific, Cardinal Health, CardioValve, CSL Behring, Daiichi Sankyo, Edwards Lifesciences,  Guerbet, InfraRedx, Johnson & Johnson, Medicure, Medtronic, Novartis, Polares, OrPha Suisse, Pfizer, Regeneron, Sanofi-Aventis, Sinomed, Terumo, and V-Wave. SW  serves as an unpaid advisory board member or unpaid member of the steering or executive group of trials funded by Abbott, Abiomed, Amgen, AstraZeneca, BMS, Boston Scientific, Biotronik, Cardiovalve, Edwards Lifesciences, MedAlliance, Medtronic, Novartis, Polares, Sinomed, V-Wave, and Xeltis. He has not received personal payments by pharmaceutical companies or device manufacturers. SW is a member of the steering or executive committee group of several investigator-initiated trials that receive funding by industry without effect on  his personal remuneration. SW is an unpaid member of the Pfizer Research Award selection committee in Switzerland and of the Women as One Awards Committee. SW is a member of the Clinical Study Group of the Deutsches Zentrum fur Herz Kreislauf-Forschung and of the Advisory Board of the Australian Victorian Heart Institute. He is Chairperson of the ESC Congress Program Committee, former Chairperson of the ESC Clinical Practice Guidelines Committee, and Deputy Editor  of the Journal of the American College of Cardiology Cardiovascular Interventions. All other authors declare no competing interests.\n",
      "\n",
      "Ingvar, Martin\n",
      "Declaration of interests The BigData@Heart project has received funding from the  Innovative Medicines Initiative (IMartin Ingvar) 2 Joint Undertaking (grant 116074) which receives support from the Horizon 2020 research and innovation programme of the European Union and the European Federation of Pharmaceutical Industries and Associations. The funders had no role in considering the study design; in the collection, analysis, or interpretation of data; in the writing of the report; or in the decision to submit the Review for publication. Dipak Kotecha reports grants from the  European Union and the European Federation of Pharmaceutical Industries and Associations Innovative Medicines Initiative (116074), the National Institute for Health Research (NIHR CDonna Fitzsimons-2015-08-074 RATE-AF; NIHR130280 DaRe2THINK; and NIHR132974 D2T-NeuroVascular), the British Heart Foundation (PG/17/55/33087, AA/18/2/34218 and FS/CDRF/21/21032), and the ESC. Dipak Kotecha is supported by educational  grants from Boehringer Ingelheim, Bristol Myers Squibb (BMS)-Pfizer Alliance, Bayer, Daiichi Sankyo, Boston Scientific, the NIHR and University of Oxford Biomedical Research Centre, the British Heart Foundation and University of Birmingham Accelerator Award (STEEER-AF NCT04396418), Amomed Pharma, Istituto Di  Ricovero e Cura a Carattere Scientifico San Raffaele, and Menarini (NCT0083244).  Dipak Kotecha receives advisory board personal fees from Bayer, Amomed, Protherics Medicines Development, and Myokardia. Folkert W. Asselbergs reports grants from IMartin Ingvar BigData@Heart. Stefan D. Anker reports grants and personal fees from Vifor Pharma, Abbott, and Abbott Vascular;  and personal fees from Bayer, Boehringer Ingelheim, Servier, Cardiac Dimensions,  Actimed, AstraZeneca, Amgen, Bioventrix, Janssen, Respicardia, V-Wave, Brahms, Cordio, and Occlutech. Colin Baigent reports grants from Medical Research Council, Boehringer Ingelheim, and NIHR. Amitava Banerjee reports grants from AstraZeneca. Birgit Beger reports grants from the European Commission. Gunnar Brobert reports grants from the European Commission (IMartin Ingvar project support) and Bayer. Barbara Casadei reports non-financial support from Roche Diagnostics and iRhythm. Cinzia Ceccarelli reports grants from the European Commission. Martin R. Cowie reports personal fees from AstraZeneca. Filippo Crea reports personal fees from Amgen,  AstraZeneca, Servier, and BMS; and advisory board fees from GlyCardial Diagnostics. Maureen Cronin reports personal fees from Vifor Pharma. Andrea Derix reports salary from Bayer. Martin Fredriksson reports salary from AstraZeneca. Chris P. Gale reports personal fees from AstraZeneca, Amgen, Bayer, Boehringer Ingelheim, Daiichi Sankyo, Vifor Pharma, Menarini, Wondr Medical, Raisio Group, and Oxford University Press; and grants from BMS, Abbott, British Heart Foundation, NIHR, and ESC. Martin Ingvar reports grants from World Economic Forum, Swedish Innovation Agency, and the European Commission; and collaboration with Frisq. SL reports grants from the European Commission. TFL reports grants from Abbott, Amgen, Novartis, Boehringer Ingelheim, Servier, Vifor Pharma, Sanofi, and AstraZeneca; and personal fees from Daichi Sankyo, Pfizer, and Menarini. LR reports salary from Bayer. CS reports personal fees from Bayer.  BT reports personal fees from Servier. GvT reports grants from IMartin Ingvar. KvB reports grants from IMartin Ingvar BigData@Heart. PEV reports personal fees from Hygeia Hospitals Group, Hellenic Healthcare Group, ESC, and Servier. TV is working as an editor at The BMJ and Acta Medica Portuguesa and is Vice President of the European Union of General Practitioners. MV reports grants from the European Commission. SW reports grants from Abbott, Amgen, AstraZeneca, BMS, Bayer, Biotronik, Boston Scientific, Cardinal Health, CardioValve, CSL Behring, Daiichi Sankyo, Edwards Lifesciences,  Guerbet, InfraRedx, Johnson & Johnson, Medicure, Medtronic, Novartis, Polares, OrPha Suisse, Pfizer, Regeneron, Sanofi-Aventis, Sinomed, Terumo, and V-Wave. SW  serves as an unpaid advisory board member or unpaid member of the steering or executive group of trials funded by Abbott, Abiomed, Amgen, AstraZeneca, BMS, Boston Scientific, Biotronik, Cardiovalve, Edwards Lifesciences, MedAlliance, Medtronic, Novartis, Polares, Sinomed, V-Wave, and Xeltis. He has not received personal payments by pharmaceutical companies or device manufacturers. SW is a member of the steering or executive committee group of several investigator-initiated trials that receive funding by industry without effect on  his personal remuneration. SW is an unpaid member of the Pfizer Research Award selection committee in Switzerland and of the Women as One Awards Committee. SW is a member of the Clinical Study Group of the Deutsches Zentrum fur Herz Kreislauf-Forschung and of the Advisory Board of the Australian Victorian Heart Institute. He is Chairperson of the ESC Congress Program Committee, former Chairperson of the ESC Clinical Practice Guidelines Committee, and Deputy Editor  of the Journal of the American College of Cardiology Cardiovascular Interventions. All other authors declare no competing interests.\n",
      "\n",
      "Declaration of interests The BigData@Heart project has received funding from the  Innovative Medicines Initiative (IMartin Ingvar) 2 Joint Undertaking (grant 116074) which receives support from the Horizon 2020 research and innovation programme of the European Union and the European Federation of Pharmaceutical Industries and Associations. The funders had no role in considering the study design; in the collection, analysis, or interpretation of data; in the writing of the report; or in the decision to submit the Review for publication. Dipak Kotecha reports grants from the  European Union and the European Federation of Pharmaceutical Industries and Associations Innovative Medicines Initiative (116074), the National Institute for Health Research (NIHR CDonna Fitzsimons-2015-08-074 RATE-AF; NIHR130280 DaRe2THINK; and NIHR132974 D2T-NeuroVascular), the British Heart Foundation (PG/17/55/33087, AA/18/2/34218 and FS/CDRF/21/21032), and the ESC. Dipak Kotecha is supported by educational  grants from Boehringer Ingelheim, Bristol Myers Squibb (BMS)-Pfizer Alliance, Bayer, Daiichi Sankyo, Boston Scientific, the NIHR and University of Oxford Biomedical Research Centre, the British Heart Foundation and University of Birmingham Accelerator Award (STEEER-AF NCT04396418), Amomed Pharma, Istituto Di  Ricovero e Cura a Carattere Scientifico San Raffaele, and Menarini (NCT0083244).  Dipak Kotecha receives advisory board personal fees from Bayer, Amomed, Protherics Medicines Development, and Myokardia. Folkert W. Asselbergs reports grants from IMartin Ingvar BigData@Heart. Stefan D. Anker reports grants and personal fees from Vifor Pharma, Abbott, and Abbott Vascular;  and personal fees from Bayer, Boehringer Ingelheim, Servier, Cardiac Dimensions,  Actimed, AstraZeneca, Amgen, Bioventrix, Janssen, Respicardia, V-Wave, Brahms, Cordio, and Occlutech. Colin Baigent reports grants from Medical Research Council, Boehringer Ingelheim, and NIHR. Amitava Banerjee reports grants from AstraZeneca. Birgit Beger reports grants from the European Commission. Gunnar Brobert reports grants from the European Commission (IMartin Ingvar project support) and Bayer. Barbara Casadei reports non-financial support from Roche Diagnostics and iRhythm. Cinzia Ceccarelli reports grants from the European Commission. Martin R. Cowie reports personal fees from AstraZeneca. Filippo Crea reports personal fees from Amgen,  AstraZeneca, Servier, and BMS; and advisory board fees from GlyCardial Diagnostics. Maureen Cronin reports personal fees from Vifor Pharma. Andrea Derix reports salary from Bayer. Martin Fredriksson reports salary from AstraZeneca. Chris P. Gale reports personal fees from AstraZeneca, Amgen, Bayer, Boehringer Ingelheim, Daiichi Sankyo, Vifor Pharma, Menarini, Wondr Medical, Raisio Group, and Oxford University Press; and grants from BMS, Abbott, British Heart Foundation, NIHR, and ESC. Martin Ingvar reports grants from World Economic Forum, Swedish Innovation Agency, and the European Commission; and collaboration with Frisq. SL reports grants from the European Commission. TFL reports grants from Abbott, Amgen, Novartis, Boehringer Ingelheim, Servier, Vifor Pharma, Sanofi, and AstraZeneca; and personal fees from Daichi Sankyo, Pfizer, and Menarini. LR reports salary from Bayer. CS reports personal fees from Bayer.  BT reports personal fees from Servier. GvT reports grants from IMartin Ingvar. KvB reports grants from IMartin Ingvar BigData@Heart. PEV reports personal fees from Hygeia Hospitals Group, Hellenic Healthcare Group, ESC, and Servier. TV is working as an editor at The BMJ and Acta Medica Portuguesa and is Vice President of the European Union of General Practitioners. MV reports grants from the European Commission. SW reports grants from Abbott, Amgen, AstraZeneca, BMS, Bayer, Biotronik, Boston Scientific, Cardinal Health, CardioValve, CSL Behring, Daiichi Sankyo, Edwards Lifesciences,  Guerbet, InfraRedx, Johnson & Johnson, Medicure, Medtronic, Novartis, Polares, OrPha Suisse, Pfizer, Regeneron, Sanofi-Aventis, Sinomed, Terumo, and V-Wave. SW  serves as an unpaid advisory board member or unpaid member of the steering or executive group of trials funded by Abbott, Abiomed, Amgen, AstraZeneca, BMS, Boston Scientific, Biotronik, Cardiovalve, Edwards Lifesciences, MedAlliance, Medtronic, Novartis, Polares, Sinomed, V-Wave, and Xeltis. He has not received personal payments by pharmaceutical companies or device manufacturers. SW is a member of the steering or executive committee group of several investigator-initiated trials that receive funding by industry without effect on  his personal remuneration. SW is an unpaid member of the Pfizer Research Award selection committee in Switzerland and of the Women as One Awards Committee. SW is a member of the Clinical Study Group of the Deutsches Zentrum fur Herz Kreislauf-Forschung and of the Advisory Board of the Australian Victorian Heart Institute. He is Chairperson of the ESC Congress Program Committee, former Chairperson of the ESC Clinical Practice Guidelines Committee, and Deputy Editor  of the Journal of the American College of Cardiology Cardiovascular Interventions. All other authors declare no competing interests.\n",
      "\n",
      "Declaration of interests The BigData@Heart project has received funding from the  Innovative Medicines Initiative (IMartin Ingvar) 2 Joint Undertaking (grant 116074) which receives support from the Horizon 2020 research and innovation programme of the European Union and the European Federation of Pharmaceutical Industries and Associations. The funders had no role in considering the study design; in the collection, analysis, or interpretation of data; in the writing of the report; or in the decision to submit the Review for publication. Dipak Kotecha reports grants from the  European Union and the European Federation of Pharmaceutical Industries and Associations Innovative Medicines Initiative (116074), the National Institute for Health Research (NIHR CDonna Fitzsimons-2015-08-074 RATE-AF; NIHR130280 DaRe2THINK; and NIHR132974 D2T-NeuroVascular), the British Heart Foundation (PG/17/55/33087, AA/18/2/34218 and FS/CDRF/21/21032), and the ESC. Dipak Kotecha is supported by educational  grants from Boehringer Ingelheim, Bristol Myers Squibb (BMS)-Pfizer Alliance, Bayer, Daiichi Sankyo, Boston Scientific, the NIHR and University of Oxford Biomedical Research Centre, the British Heart Foundation and University of Birmingham Accelerator Award (STEEER-AF NCT04396418), Amomed Pharma, Istituto Di  Ricovero e Cura a Carattere Scientifico San Raffaele, and Menarini (NCT0083244).  Dipak Kotecha receives advisory board personal fees from Bayer, Amomed, Protherics Medicines Development, and Myokardia. Folkert W. Asselbergs reports grants from IMartin Ingvar BigData@Heart. Stefan D. Anker reports grants and personal fees from Vifor Pharma, Abbott, and Abbott Vascular;  and personal fees from Bayer, Boehringer Ingelheim, Servier, Cardiac Dimensions,  Actimed, AstraZeneca, Amgen, Bioventrix, Janssen, Respicardia, V-Wave, Brahms, Cordio, and Occlutech. Colin Baigent reports grants from Medical Research Council, Boehringer Ingelheim, and NIHR. Amitava Banerjee reports grants from AstraZeneca. Birgit Beger reports grants from the European Commission. Gunnar Brobert reports grants from the European Commission (IMartin Ingvar project support) and Bayer. Barbara Casadei reports non-financial support from Roche Diagnostics and iRhythm. Cinzia Ceccarelli reports grants from the European Commission. Martin R. Cowie reports personal fees from AstraZeneca. Filippo Crea reports personal fees from Amgen,  AstraZeneca, Servier, and BMS; and advisory board fees from GlyCardial Diagnostics. Maureen Cronin reports personal fees from Vifor Pharma. Andrea Derix reports salary from Bayer. Martin Fredriksson reports salary from AstraZeneca. Chris P. Gale reports personal fees from AstraZeneca, Amgen, Bayer, Boehringer Ingelheim, Daiichi Sankyo, Vifor Pharma, Menarini, Wondr Medical, Raisio Group, and Oxford University Press; and grants from BMS, Abbott, British Heart Foundation, NIHR, and ESC. Martin Ingvar reports grants from World Economic Forum, Swedish Innovation Agency, and the European Commission; and collaboration with Frisq. SL reports grants from the European Commission. TFL reports grants from Abbott, Amgen, Novartis, Boehringer Ingelheim, Servier, Vifor Pharma, Sanofi, and AstraZeneca; and personal fees from Daichi Sankyo, Pfizer, and Menarini. LR reports salary from Bayer. CS reports personal fees from Bayer.  BT reports personal fees from Servier. GvT reports grants from IMartin Ingvar. KvB reports grants from IMartin Ingvar BigData@Heart. PEV reports personal fees from Hygeia Hospitals Group, Hellenic Healthcare Group, ESC, and Servier. TV is working as an editor at The BMJ and Acta Medica Portuguesa and is Vice President of the European Union of General Practitioners. MV reports grants from the European Commission. SW reports grants from Abbott, Amgen, AstraZeneca, BMS, Bayer, Biotronik, Boston Scientific, Cardinal Health, CardioValve, CSL Behring, Daiichi Sankyo, Edwards Lifesciences,  Guerbet, InfraRedx, Johnson & Johnson, Medicure, Medtronic, Novartis, Polares, OrPha Suisse, Pfizer, Regeneron, Sanofi-Aventis, Sinomed, Terumo, and V-Wave. SW  serves as an unpaid advisory board member or unpaid member of the steering or executive group of trials funded by Abbott, Abiomed, Amgen, AstraZeneca, BMS, Boston Scientific, Biotronik, Cardiovalve, Edwards Lifesciences, MedAlliance, Medtronic, Novartis, Polares, Sinomed, V-Wave, and Xeltis. He has not received personal payments by pharmaceutical companies or device manufacturers. SW is a member of the steering or executive committee group of several investigator-initiated trials that receive funding by industry without effect on  his personal remuneration. SW is an unpaid member of the Pfizer Research Award selection committee in Switzerland and of the Women as One Awards Committee. SW is a member of the Clinical Study Group of the Deutsches Zentrum fur Herz Kreislauf-Forschung and of the Advisory Board of the Australian Victorian Heart Institute. He is Chairperson of the ESC Congress Program Committee, former Chairperson of the ESC Clinical Practice Guidelines Committee, and Deputy Editor  of the Journal of the American College of Cardiology Cardiovascular Interventions. All other authors declare no competing interests.\n",
      "\n",
      "Logstrup, Susanne\n",
      "Declaration of interests The BigData@Heart project has received funding from the  Innovative Medicines Initiative (IMartin Ingvar) 2 Joint Undertaking (grant 116074) which receives support from the Horizon 2020 research and innovation programme of the European Union and the European Federation of Pharmaceutical Industries and Associations. The funders had no role in considering the study design; in the collection, analysis, or interpretation of data; in the writing of the report; or in the decision to submit the Review for publication. Dipak Kotecha reports grants from the  European Union and the European Federation of Pharmaceutical Industries and Associations Innovative Medicines Initiative (116074), the National Institute for Health Research (NIHR CDonna Fitzsimons-2015-08-074 RATE-AF; NIHR130280 DaRe2THINK; and NIHR132974 D2T-NeuroVascular), the British Heart Foundation (PG/17/55/33087, AA/18/2/34218 and FS/CDRF/21/21032), and the ESC. Dipak Kotecha is supported by educational  grants from Boehringer Ingelheim, Bristol Myers Squibb (BMS)-Pfizer Alliance, Bayer, Daiichi Sankyo, Boston Scientific, the NIHR and University of Oxford Biomedical Research Centre, the British Heart Foundation and University of Birmingham Accelerator Award (STEEER-AF NCT04396418), Amomed Pharma, Istituto Di  Ricovero e Cura a Carattere Scientifico San Raffaele, and Menarini (NCT0083244).  Dipak Kotecha receives advisory board personal fees from Bayer, Amomed, Protherics Medicines Development, and Myokardia. Folkert W. Asselbergs reports grants from IMartin Ingvar BigData@Heart. Stefan D. Anker reports grants and personal fees from Vifor Pharma, Abbott, and Abbott Vascular;  and personal fees from Bayer, Boehringer Ingelheim, Servier, Cardiac Dimensions,  Actimed, AstraZeneca, Amgen, Bioventrix, Janssen, Respicardia, V-Wave, Brahms, Cordio, and Occlutech. Colin Baigent reports grants from Medical Research Council, Boehringer Ingelheim, and NIHR. Amitava Banerjee reports grants from AstraZeneca. Birgit Beger reports grants from the European Commission. Gunnar Brobert reports grants from the European Commission (IMartin Ingvar project support) and Bayer. Barbara Casadei reports non-financial support from Roche Diagnostics and iRhythm. Cinzia Ceccarelli reports grants from the European Commission. Martin R. Cowie reports personal fees from AstraZeneca. Filippo Crea reports personal fees from Amgen,  AstraZeneca, Servier, and BMS; and advisory board fees from GlyCardial Diagnostics. Maureen Cronin reports personal fees from Vifor Pharma. Andrea Derix reports salary from Bayer. Martin Fredriksson reports salary from AstraZeneca. Chris P. Gale reports personal fees from AstraZeneca, Amgen, Bayer, Boehringer Ingelheim, Daiichi Sankyo, Vifor Pharma, Menarini, Wondr Medical, Raisio Group, and Oxford University Press; and grants from BMS, Abbott, British Heart Foundation, NIHR, and ESC. Martin Ingvar reports grants from World Economic Forum, Swedish Innovation Agency, and the European Commission; and collaboration with Frisq. Susanne Logstrup reports grants from the European Commission. TFL reports grants from Abbott, Amgen, Novartis, Boehringer Ingelheim, Servier, Vifor Pharma, Sanofi, and AstraZeneca; and personal fees from Daichi Sankyo, Pfizer, and Menarini. LR reports salary from Bayer. CS reports personal fees from Bayer.  BT reports personal fees from Servier. GvT reports grants from IMartin Ingvar. KvB reports grants from IMartin Ingvar BigData@Heart. PEV reports personal fees from Hygeia Hospitals Group, Hellenic Healthcare Group, ESC, and Servier. TV is working as an editor at The BMJ and Acta Medica Portuguesa and is Vice President of the European Union of General Practitioners. MV reports grants from the European Commission. SW reports grants from Abbott, Amgen, AstraZeneca, BMS, Bayer, Biotronik, Boston Scientific, Cardinal Health, CardioValve, CSusanne Logstrup Behring, Daiichi Sankyo, Edwards Lifesciences,  Guerbet, InfraRedx, Johnson & Johnson, Medicure, Medtronic, Novartis, Polares, OrPha Suisse, Pfizer, Regeneron, Sanofi-Aventis, Sinomed, Terumo, and V-Wave. SW  serves as an unpaid advisory board member or unpaid member of the steering or executive group of trials funded by Abbott, Abiomed, Amgen, AstraZeneca, BMS, Boston Scientific, Biotronik, Cardiovalve, Edwards Lifesciences, MedAlliance, Medtronic, Novartis, Polares, Sinomed, V-Wave, and Xeltis. He has not received personal payments by pharmaceutical companies or device manufacturers. SW is a member of the steering or executive committee group of several investigator-initiated trials that receive funding by industry without effect on  his personal remuneration. SW is an unpaid member of the Pfizer Research Award selection committee in Switzerland and of the Women as One Awards Committee. SW is a member of the Clinical Study Group of the Deutsches Zentrum fur Herz Kreislauf-Forschung and of the Advisory Board of the Australian Victorian Heart Institute. He is Chairperson of the ESC Congress Program Committee, former Chairperson of the ESC Clinical Practice Guidelines Committee, and Deputy Editor  of the Journal of the American College of Cardiology Cardiovascular Interventions. All other authors declare no competing interests.\n",
      "\n",
      "Thomas Lumbers, R.\n",
      "Declaration of interests The BigData@Heart project has received funding from the  Innovative Medicines Initiative (IMartin Ingvar) 2 Joint Undertaking (grant 116074) which receives support from the Horizon 2020 research and innovation programme of the European Union and the European Federation of Pharmaceutical Industries and Associations. The funders had no role in considering the study design; in the collection, analysis, or interpretation of data; in the writing of the report; or in the decision to submit the Review for publication. Dipak Kotecha reports grants from the  European Union and the European Federation of Pharmaceutical Industries and Associations Innovative Medicines Initiative (116074), the National Institute for Health Research (NIHR CDonna Fitzsimons-2015-08-074 RATE-AF; NIHR130280 DaRe2THINK; and NIHR132974 D2T-NeuroVascular), the British Heart Foundation (PG/17/55/33087, AA/18/2/34218 and FS/CDRF/21/21032), and the ESC. Dipak Kotecha is supported by educational  grants from Boehringer Ingelheim, Bristol Myers Squibb (BMS)-Pfizer Alliance, Bayer, Daiichi Sankyo, Boston Scientific, the NIHR and University of Oxford Biomedical Research Centre, the British Heart Foundation and University of Birmingham Accelerator Award (STEEER-AF NCT04396418), Amomed Pharma, Istituto Di  Ricovero e Cura a Carattere Scientifico San Raffaele, and Menarini (NCT0083244).  Dipak Kotecha receives advisory board personal fees from Bayer, Amomed, Protherics Medicines Development, and Myokardia. Folkert W. Asselbergs reports grants from IMartin Ingvar BigData@Heart. Stefan D. Anker reports grants and personal fees from Vifor Pharma, Abbott, and Abbott Vascular;  and personal fees from Bayer, Boehringer Ingelheim, Servier, Cardiac Dimensions,  Actimed, AstraZeneca, Amgen, Bioventrix, Janssen, Respicardia, V-Wave, Brahms, Cordio, and Occlutech. Colin Baigent reports grants from Medical Research Council, Boehringer Ingelheim, and NIHR. Thomas Lumbers Amitava Banerjee reports grants from AstraZeneca. Birgit Beger reports grants from the European Commission. Gunnar Brobert reports grants from the European Commission (IMartin Ingvar project support) and Bayer. Barbara Casadei reports non-financial support from Roche Diagnostics and iRhythm. Cinzia Ceccarelli reports grants from the European Commission. Martin R. Thomas Lumbers Cowie reports personal fees from AstraZeneca. Filippo Crea reports personal fees from Amgen,  AstraZeneca, Servier, and BMS; and advisory board fees from GlyCardial Diagnostics. Maureen Cronin reports personal fees from Vifor Pharma. Andrea Derix reports salary from Bayer. Martin Fredriksson reports salary from AstraZeneca. Chris P. Gale reports personal fees from AstraZeneca, Amgen, Bayer, Boehringer Ingelheim, Daiichi Sankyo, Vifor Pharma, Menarini, Wondr Medical, Raisio Group, and Oxford University Press; and grants from BMS, Abbott, British Heart Foundation, NIHR, and ESC. Martin Ingvar reports grants from World Economic Forum, Swedish Innovation Agency, and the European Commission; and collaboration with Frisq. Susanne Logstrup reports grants from the European Commission. TFL reports grants from Abbott, Amgen, Novartis, Boehringer Ingelheim, Servier, Vifor Pharma, Sanofi, and AstraZeneca; and personal fees from Daichi Sankyo, Pfizer, and Menarini. LR reports salary from Bayer. CS reports personal fees from Bayer.  BT reports personal fees from Servier. GvT reports grants from IMartin Ingvar. KvB reports grants from IMartin Ingvar BigData@Heart. PEV reports personal fees from Hygeia Hospitals Group, Hellenic Healthcare Group, ESC, and Servier. TV is working as an editor at The BMJ and Acta Medica Portuguesa and is Vice President of the European Union of General Practitioners. MV reports grants from the European Commission. SW reports grants from Abbott, Amgen, AstraZeneca, BMS, Bayer, Biotronik, Boston Scientific, Cardinal Health, CardioValve, CSusanne Logstrup Behring, Daiichi Sankyo, Edwards Lifesciences,  Guerbet, InfraRedx, Johnson & Johnson, Medicure, Medtronic, Novartis, Polares, OrPha Suisse, Pfizer, Regeneron, Sanofi-Aventis, Sinomed, Terumo, and V-Wave. SW  serves as an unpaid advisory board member or unpaid member of the steering or executive group of trials funded by Abbott, Abiomed, Amgen, AstraZeneca, BMS, Boston Scientific, Biotronik, Cardiovalve, Edwards Lifesciences, MedAlliance, Medtronic, Novartis, Polares, Sinomed, V-Wave, and Xeltis. He has not received personal payments by pharmaceutical companies or device manufacturers. SW is a member of the steering or executive committee group of several investigator-initiated trials that receive funding by industry without effect on  his personal remuneration. SW is an unpaid member of the Pfizer Research Award selection committee in Switzerland and of the Women as One Awards Committee. SW is a member of the Clinical Study Group of the Deutsches Zentrum fur Herz Kreislauf-Forschung and of the Advisory Board of the Australian Victorian Heart Institute. He is Chairperson of the ESC Congress Program Committee, former Chairperson of the ESC Clinical Practice Guidelines Committee, and Deputy Editor  of the Journal of the American College of Cardiology Cardiovascular Interventions. All other authors declare no competing interests.\n",
      "\n",
      "Luscher, Thomas F.\n",
      "Declaration of interests The BigData@Heart project has received funding from the  Innovative Medicines Initiative (IMartin Ingvar) 2 Joint Undertaking (grant 116074) which receives support from the Horizon 2020 research and innovation programme of the European Union and the European Federation of Pharmaceutical Industries and Associations. The funders had no role in considering the study design; in the collection, analysis, or interpretation of data; in the writing of the report; or in the decision to submit the Review for publication. Dipak Kotecha reports grants from the  European Union and the European Federation of Pharmaceutical Industries and Associations Innovative Medicines Initiative (116074), the National Institute for Health Research (NIHR CDonna Fitzsimons-2015-08-074 RATE-AF; NIHR130280 DaRe2THINK; and NIHR132974 D2T-NeuroVascular), the British Heart Foundation (PG/17/55/33087, AA/18/2/34218 and FS/CDRF/21/21032), and the ESC. Dipak Kotecha is supported by educational  grants from Boehringer Ingelheim, Bristol Myers Squibb (BMS)-Pfizer Alliance, Bayer, Daiichi Sankyo, Boston Scientific, the NIHR and University of Oxford Biomedical Research Centre, the British Heart Foundation and University of Birmingham Accelerator Award (STEEER-AF NCT04396418), Amomed Pharma, Istituto Di  Ricovero e Cura a Carattere Scientifico San Raffaele, and Menarini (NCT0083244).  Dipak Kotecha receives advisory board personal fees from Bayer, Amomed, Protherics Medicines Development, and Myokardia. Folkert W. Asselbergs reports grants from IMartin Ingvar BigData@Heart. Stefan D. Anker reports grants and personal fees from Vifor Pharma, Abbott, and Abbott Vascular;  and personal fees from Bayer, Boehringer Ingelheim, Servier, Cardiac Dimensions,  Actimed, AstraZeneca, Amgen, Bioventrix, Janssen, Respicardia, V-Wave, Brahms, Cordio, and Occlutech. Colin Baigent reports grants from Medical Research Council, Boehringer Ingelheim, and NIHR. Thomas F. Luscherumbers Amitava Banerjee reports grants from AstraZeneca. Birgit Beger reports grants from the European Commission. Gunnar Brobert reports grants from the European Commission (IMartin Ingvar project support) and Bayer. Barbara Casadei reports non-financial support from Roche Diagnostics and iRhythm. Cinzia Ceccarelli reports grants from the European Commission. Martin R. Thomas F. Luscherumbers Cowie reports personal fees from AstraZeneca. Filippo Crea reports personal fees from Amgen,  AstraZeneca, Servier, and BMS; and advisory board fees from GlyCardial Diagnostics. Maureen Cronin reports personal fees from Vifor Pharma. Andrea Derix reports salary from Bayer. Martin Fredriksson reports salary from AstraZeneca. Chris P. Gale reports personal fees from AstraZeneca, Amgen, Bayer, Boehringer Ingelheim, Daiichi Sankyo, Vifor Pharma, Menarini, Wondr Medical, Raisio Group, and Oxford University Press; and grants from BMS, Abbott, British Heart Foundation, NIHR, and ESC. Martin Ingvar reports grants from World Economic Forum, Swedish Innovation Agency, and the European Commission; and collaboration with Frisq. Susanne Logstrup reports grants from the European Commission. TFL reports grants from Abbott, Amgen, Novartis, Boehringer Ingelheim, Servier, Vifor Pharma, Sanofi, and AstraZeneca; and personal fees from Daichi Sankyo, Pfizer, and Menarini. LR reports salary from Bayer. CS reports personal fees from Bayer.  BT reports personal fees from Servier. GvT reports grants from IMartin Ingvar. KvB reports grants from IMartin Ingvar BigData@Heart. PEV reports personal fees from Hygeia Hospitals Group, Hellenic Healthcare Group, ESC, and Servier. TV is working as an editor at The BMJ and Acta Medica Portuguesa and is Vice President of the European Union of General Practitioners. MV reports grants from the European Commission. SW reports grants from Abbott, Amgen, AstraZeneca, BMS, Bayer, Biotronik, Boston Scientific, Cardinal Health, CardioValve, CSusanne Logstrup Behring, Daiichi Sankyo, Edwards Lifesciences,  Guerbet, InfraRedx, Johnson & Johnson, Medicure, Medtronic, Novartis, Polares, OrPha Suisse, Pfizer, Regeneron, Sanofi-Aventis, Sinomed, Terumo, and V-Wave. SW  serves as an unpaid advisory board member or unpaid member of the steering or executive group of trials funded by Abbott, Abiomed, Amgen, AstraZeneca, BMS, Boston Scientific, Biotronik, Cardiovalve, Edwards Lifesciences, MedAlliance, Medtronic, Novartis, Polares, Sinomed, V-Wave, and Xeltis. He has not received personal payments by pharmaceutical companies or device manufacturers. SW is a member of the steering or executive committee group of several investigator-initiated trials that receive funding by industry without effect on  his personal remuneration. SW is an unpaid member of the Pfizer Research Award selection committee in Switzerland and of the Women as One Awards Committee. SW is a member of the Clinical Study Group of the Deutsches Zentrum fur Herz Kreislauf-Forschung and of the Advisory Board of the Australian Victorian Heart Institute. He is Chairperson of the ESC Congress Program Committee, former Chairperson of the ESC Clinical Practice Guidelines Committee, and Deputy Editor  of the Journal of the American College of Cardiology Cardiovascular Interventions. All other authors declare no competing interests.\n",
      "\n",
      "Declaration of interests The BigData@Heart project has received funding from the  Innovative Medicines Initiative (IMartin Ingvar) 2 Joint Undertaking (grant 116074) which receives support from the Horizon 2020 research and innovation programme of the European Union and the European Federation of Pharmaceutical Industries and Associations. The funders had no role in considering the study design; in the collection, analysis, or interpretation of data; in the writing of the report; or in the decision to submit the Review for publication. Dipak Kotecha reports grants from the  European Union and the European Federation of Pharmaceutical Industries and Associations Innovative Medicines Initiative (116074), the National Institute for Health Research (NIHR CDonna Fitzsimons-2015-08-074 RATE-AF; NIHR130280 DaRe2THINK; and NIHR132974 D2T-NeuroVascular), the British Heart Foundation (PG/17/55/33087, AA/18/2/34218 and FS/CDRF/21/21032), and the ESC. Dipak Kotecha is supported by educational  grants from Boehringer Ingelheim, Bristol Myers Squibb (BMS)-Pfizer Alliance, Bayer, Daiichi Sankyo, Boston Scientific, the NIHR and University of Oxford Biomedical Research Centre, the British Heart Foundation and University of Birmingham Accelerator Award (STEEER-AF NCT04396418), Amomed Pharma, Istituto Di  Ricovero e Cura a Carattere Scientifico San Raffaele, and Menarini (NCT0083244).  Dipak Kotecha receives advisory board personal fees from Bayer, Amomed, Protherics Medicines Development, and Myokardia. Folkert W. Asselbergs reports grants from IMartin Ingvar BigData@Heart. Stefan D. Anker reports grants and personal fees from Vifor Pharma, Abbott, and Abbott Vascular;  and personal fees from Bayer, Boehringer Ingelheim, Servier, Cardiac Dimensions,  Actimed, AstraZeneca, Amgen, Bioventrix, Janssen, Respicardia, V-Wave, Brahms, Cordio, and Occlutech. Colin Baigent reports grants from Medical Research Council, Boehringer Ingelheim, and NIHR. Thomas F. Luscherumbers Amitava Banerjee reports grants from AstraZeneca. Birgit Beger reports grants from the European Commission. Gunnar Brobert reports grants from the European Commission (IMartin Ingvar project support) and Bayer. Barbara Casadei reports non-financial support from Roche Diagnostics and iRhythm. Cinzia Ceccarelli reports grants from the European Commission. Martin R. Thomas F. Luscherumbers Cowie reports personal fees from AstraZeneca. Filippo Crea reports personal fees from Amgen,  AstraZeneca, Servier, and BMS; and advisory board fees from GlyCardial Diagnostics. Maureen Cronin reports personal fees from Vifor Pharma. Andrea Derix reports salary from Bayer. Martin Fredriksson reports salary from AstraZeneca. Chris P. Gale reports personal fees from AstraZeneca, Amgen, Bayer, Boehringer Ingelheim, Daiichi Sankyo, Vifor Pharma, Menarini, Wondr Medical, Raisio Group, and Oxford University Press; and grants from BMS, Abbott, British Heart Foundation, NIHR, and ESC. Martin Ingvar reports grants from World Economic Forum, Swedish Innovation Agency, and the European Commission; and collaboration with Frisq. Susanne Logstrup reports grants from the European Commission. TFL reports grants from Abbott, Amgen, Novartis, Boehringer Ingelheim, Servier, Vifor Pharma, Sanofi, and AstraZeneca; and personal fees from Daichi Sankyo, Pfizer, and Menarini. LR reports salary from Bayer. CS reports personal fees from Bayer.  BT reports personal fees from Servier. GvT reports grants from IMartin Ingvar. KvB reports grants from IMartin Ingvar BigData@Heart. PEV reports personal fees from Hygeia Hospitals Group, Hellenic Healthcare Group, ESC, and Servier. TV is working as an editor at The BMJ and Acta Medica Portuguesa and is Vice President of the European Union of General Practitioners. MV reports grants from the European Commission. SW reports grants from Abbott, Amgen, AstraZeneca, BMS, Bayer, Biotronik, Boston Scientific, Cardinal Health, CardioValve, CSusanne Logstrup Behring, Daiichi Sankyo, Edwards Lifesciences,  Guerbet, InfraRedx, Johnson & Johnson, Medicure, Medtronic, Novartis, Polares, OrPha Suisse, Pfizer, Regeneron, Sanofi-Aventis, Sinomed, Terumo, and V-Wave. SW  serves as an unpaid advisory board member or unpaid member of the steering or executive group of trials funded by Abbott, Abiomed, Amgen, AstraZeneca, BMS, Boston Scientific, Biotronik, Cardiovalve, Edwards Lifesciences, MedAlliance, Medtronic, Novartis, Polares, Sinomed, V-Wave, and Xeltis. He has not received personal payments by pharmaceutical companies or device manufacturers. SW is a member of the steering or executive committee group of several investigator-initiated trials that receive funding by industry without effect on  his personal remuneration. SW is an unpaid member of the Pfizer Research Award selection committee in Switzerland and of the Women as One Awards Committee. SW is a member of the Clinical Study Group of the Deutsches Zentrum fur Herz Kreislauf-Forschung and of the Advisory Board of the Australian Victorian Heart Institute. He is Chairperson of the ESC Congress Program Committee, former Chairperson of the ESC Clinical Practice Guidelines Committee, and Deputy Editor  of the Journal of the American College of Cardiology Cardiovascular Interventions. All other authors declare no competing interests.\n",
      "\n",
      "Declaration of interests The BigData@Heart project has received funding from the  Innovative Medicines Initiative (IMartin Ingvar) 2 Joint Undertaking (grant 116074) which receives support from the Horizon 2020 research and innovation programme of the European Union and the European Federation of Pharmaceutical Industries and Associations. The funders had no role in considering the study design; in the collection, analysis, or interpretation of data; in the writing of the report; or in the decision to submit the Review for publication. Dipak Kotecha reports grants from the  European Union and the European Federation of Pharmaceutical Industries and Associations Innovative Medicines Initiative (116074), the National Institute for Health Research (NIHR CDonna Fitzsimons-2015-08-074 RATE-AF; NIHR130280 DaRe2THINK; and NIHR132974 D2T-NeuroVascular), the British Heart Foundation (PG/17/55/33087, AA/18/2/34218 and FS/CDRF/21/21032), and the ESC. Dipak Kotecha is supported by educational  grants from Boehringer Ingelheim, Bristol Myers Squibb (BMS)-Pfizer Alliance, Bayer, Daiichi Sankyo, Boston Scientific, the NIHR and University of Oxford Biomedical Research Centre, the British Heart Foundation and University of Birmingham Accelerator Award (STEEER-AF NCT04396418), Amomed Pharma, Istituto Di  Ricovero e Cura a Carattere Scientifico San Raffaele, and Menarini (NCT0083244).  Dipak Kotecha receives advisory board personal fees from Bayer, Amomed, Protherics Medicines Development, and Myokardia. Folkert W. Asselbergs reports grants from IMartin Ingvar BigData@Heart. Stefan D. Anker reports grants and personal fees from Vifor Pharma, Abbott, and Abbott Vascular;  and personal fees from Bayer, Boehringer Ingelheim, Servier, Cardiac Dimensions,  Actimed, AstraZeneca, Amgen, Bioventrix, Janssen, Respicardia, V-Wave, Brahms, Cordio, and Occlutech. Colin Baigent reports grants from Medical Research Council, Boehringer Ingelheim, and NIHR. Thomas F. Luscherumbers Amitava Banerjee reports grants from AstraZeneca. Birgit Beger reports grants from the European Commission. Gunnar Brobert reports grants from the European Commission (IMartin Ingvar project support) and Bayer. Barbara Casadei reports non-financial support from Roche Diagnostics and iRhythm. Cinzia Ceccarelli reports grants from the European Commission. Martin R. Thomas F. Luscherumbers Cowie reports personal fees from AstraZeneca. Filippo Crea reports personal fees from Amgen,  AstraZeneca, Servier, and BMS; and advisory board fees from GlyCardial Diagnostics. Maureen Cronin reports personal fees from Vifor Pharma. Andrea Derix reports salary from Bayer. Martin Fredriksson reports salary from AstraZeneca. Chris P. Gale reports personal fees from AstraZeneca, Amgen, Bayer, Boehringer Ingelheim, Daiichi Sankyo, Vifor Pharma, Menarini, Wondr Medical, Raisio Group, and Oxford University Press; and grants from BMS, Abbott, British Heart Foundation, NIHR, and ESC. Martin Ingvar reports grants from World Economic Forum, Swedish Innovation Agency, and the European Commission; and collaboration with Frisq. Susanne Logstrup reports grants from the European Commission. TFL reports grants from Abbott, Amgen, Novartis, Boehringer Ingelheim, Servier, Vifor Pharma, Sanofi, and AstraZeneca; and personal fees from Daichi Sankyo, Pfizer, and Menarini. LR reports salary from Bayer. CS reports personal fees from Bayer.  BT reports personal fees from Servier. GvT reports grants from IMartin Ingvar. KvB reports grants from IMartin Ingvar BigData@Heart. PEV reports personal fees from Hygeia Hospitals Group, Hellenic Healthcare Group, ESC, and Servier. TV is working as an editor at The BMJ and Acta Medica Portuguesa and is Vice President of the European Union of General Practitioners. MV reports grants from the European Commission. SW reports grants from Abbott, Amgen, AstraZeneca, BMS, Bayer, Biotronik, Boston Scientific, Cardinal Health, CardioValve, CSusanne Logstrup Behring, Daiichi Sankyo, Edwards Lifesciences,  Guerbet, InfraRedx, Johnson & Johnson, Medicure, Medtronic, Novartis, Polares, OrPha Suisse, Pfizer, Regeneron, Sanofi-Aventis, Sinomed, Terumo, and V-Wave. SW  serves as an unpaid advisory board member or unpaid member of the steering or executive group of trials funded by Abbott, Abiomed, Amgen, AstraZeneca, BMS, Boston Scientific, Biotronik, Cardiovalve, Edwards Lifesciences, MedAlliance, Medtronic, Novartis, Polares, Sinomed, V-Wave, and Xeltis. He has not received personal payments by pharmaceutical companies or device manufacturers. SW is a member of the steering or executive committee group of several investigator-initiated trials that receive funding by industry without effect on  his personal remuneration. SW is an unpaid member of the Pfizer Research Award selection committee in Switzerland and of the Women as One Awards Committee. SW is a member of the Clinical Study Group of the Deutsches Zentrum fur Herz Kreislauf-Forschung and of the Advisory Board of the Australian Victorian Heart Institute. He is Chairperson of the ESC Congress Program Committee, former Chairperson of the ESC Clinical Practice Guidelines Committee, and Deputy Editor  of the Journal of the American College of Cardiology Cardiovascular Interventions. All other authors declare no competing interests.\n",
      "\n",
      "Roessig, Lothar\n",
      "Declaration of interests The BigData@Heart project has received funding from the  Innovative Medicines Initiative (IMartin Ingvar) 2 Joint Undertaking (grant 116074) which receives support from the Horizon 2020 research and innovation programme of the European Union and the European Federation of Pharmaceutical Industries and Associations. The funders had no role in considering the study design; in the collection, analysis, or interpretation of data; in the writing of the report; or in the decision to submit the Review for publication. Dipak Kotecha reports grants from the  European Union and the European Federation of Pharmaceutical Industries and Associations Innovative Medicines Initiative (116074), the National Institute for Health Research (NIHR CDonna Fitzsimons-2015-08-074 RATE-AF; NIHR130280 DaRe2THINK; and NIHR132974 D2T-NeuroVascular), the British Heart Foundation (PG/17/55/33087, AA/18/2/34218 and FS/CDRF/21/21032), and the ESC. Dipak Kotecha is supported by educational  grants from Boehringer Ingelheim, Bristol Myers Squibb (BMS)-Pfizer Alliance, Bayer, Daiichi Sankyo, Boston Scientific, the NIHR and University of Oxford Biomedical Research Centre, the British Heart Foundation and University of Birmingham Accelerator Award (STEEER-AF NCT04396418), Amomed Pharma, Istituto Di  Ricovero e Cura a Carattere Scientifico San Raffaele, and Menarini (NCT0083244).  Dipak Kotecha receives advisory board personal fees from Bayer, Amomed, Protherics Medicines Development, and Myokardia. Folkert W. Asselbergs reports grants from IMartin Ingvar BigData@Heart. Stefan D. Anker reports grants and personal fees from Vifor Pharma, Abbott, and Abbott Vascular;  and personal fees from Bayer, Boehringer Ingelheim, Servier, Cardiac Dimensions,  Actimed, AstraZeneca, Amgen, Bioventrix, Janssen, Respicardia, V-Wave, Brahms, Cordio, and Occlutech. Colin Baigent reports grants from Medical Research Council, Boehringer Ingelheim, and NIHR. Thomas F. Luscherumbers Amitava Banerjee reports grants from AstraZeneca. Birgit Beger reports grants from the European Commission. Gunnar Brobert reports grants from the European Commission (IMartin Ingvar project support) and Bayer. Barbara Casadei reports non-financial support from Roche Diagnostics and iRhythm. Cinzia Ceccarelli reports grants from the European Commission. Martin R. Thomas F. Luscherumbers Cowie reports personal fees from AstraZeneca. Filippo Crea reports personal fees from Amgen,  AstraZeneca, Servier, and BMS; and advisory board fees from GlyCardial Diagnostics. Maureen Cronin reports personal fees from Vifor Pharma. Andrea Derix reports salary from Bayer. Martin Fredriksson reports salary from AstraZeneca. Chris P. Gale reports personal fees from AstraZeneca, Amgen, Bayer, Boehringer Ingelheim, Daiichi Sankyo, Vifor Pharma, Menarini, Wondr Medical, Raisio Group, and Oxford University Press; and grants from BMS, Abbott, British Heart Foundation, NIHR, and ESC. Martin Ingvar reports grants from World Economic Forum, Swedish Innovation Agency, and the European Commission; and collaboration with Frisq. Susanne Logstrup reports grants from the European Commission. TFL reports grants from Abbott, Amgen, Novartis, Boehringer Ingelheim, Servier, Vifor Pharma, Sanofi, and AstraZeneca; and personal fees from Daichi Sankyo, Pfizer, and Menarini. Lothar Roessig reports salary from Bayer. CS reports personal fees from Bayer.  BT reports personal fees from Servier. GvT reports grants from IMartin Ingvar. KvB reports grants from IMartin Ingvar BigData@Heart. PEV reports personal fees from Hygeia Hospitals Group, Hellenic Healthcare Group, ESC, and Servier. TV is working as an editor at The BMJ and Acta Medica Portuguesa and is Vice President of the European Union of General Practitioners. MV reports grants from the European Commission. SW reports grants from Abbott, Amgen, AstraZeneca, BMS, Bayer, Biotronik, Boston Scientific, Cardinal Health, CardioValve, CSusanne Logstrup Behring, Daiichi Sankyo, Edwards Lifesciences,  Guerbet, InfraRedx, Johnson & Johnson, Medicure, Medtronic, Novartis, Polares, OrPha Suisse, Pfizer, Regeneron, Sanofi-Aventis, Sinomed, Terumo, and V-Wave. SW  serves as an unpaid advisory board member or unpaid member of the steering or executive group of trials funded by Abbott, Abiomed, Amgen, AstraZeneca, BMS, Boston Scientific, Biotronik, Cardiovalve, Edwards Lifesciences, MedAlliance, Medtronic, Novartis, Polares, Sinomed, V-Wave, and Xeltis. He has not received personal payments by pharmaceutical companies or device manufacturers. SW is a member of the steering or executive committee group of several investigator-initiated trials that receive funding by industry without effect on  his personal remuneration. SW is an unpaid member of the Pfizer Research Award selection committee in Switzerland and of the Women as One Awards Committee. SW is a member of the Clinical Study Group of the Deutsches Zentrum fur Herz Kreislauf-Forschung and of the Advisory Board of the Australian Victorian Heart Institute. He is Chairperson of the ESC Congress Program Committee, former Chairperson of the ESC Clinical Practice Guidelines Committee, and Deputy Editor  of the Journal of the American College of Cardiology Cardiovascular Interventions. All other authors declare no competing interests.\n",
      "\n",
      "Steinbeisser, Carl\n",
      "Declaration of interests The BigData@Heart project has received funding from the  Innovative Medicines Initiative (IMartin Ingvar) 2 Joint Undertaking (grant 116074) which receives support from the Horizon 2020 research and innovation programme of the European Union and the European Federation of Pharmaceutical Industries and Associations. The funders had no role in considering the study design; in the collection, analysis, or interpretation of data; in the writing of the report; or in the decision to submit the Review for publication. Dipak Kotecha reports grants from the  European Union and the European Federation of Pharmaceutical Industries and Associations Innovative Medicines Initiative (116074), the National Institute for Health Research (NIHR CDonna Fitzsimons-2015-08-074 RATE-AF; NIHR130280 DaRe2THINK; and NIHR132974 D2T-NeuroVascular), the British Heart Foundation (PG/17/55/33087, AA/18/2/34218 and FS/CDRF/21/21032), and the ESC. Dipak Kotecha is supported by educational  grants from Boehringer Ingelheim, Bristol Myers Squibb (BMS)-Pfizer Alliance, Bayer, Daiichi Sankyo, Boston Scientific, the NIHR and University of Oxford Biomedical Research Centre, the British Heart Foundation and University of Birmingham Accelerator Award (STEEER-AF NCT04396418), Amomed Pharma, Istituto Di  Ricovero e Cura a Carattere Scientifico San Raffaele, and Menarini (NCT0083244).  Dipak Kotecha receives advisory board personal fees from Bayer, Amomed, Protherics Medicines Development, and Myokardia. Folkert W. Asselbergs reports grants from IMartin Ingvar BigData@Heart. Stefan D. Anker reports grants and personal fees from Vifor Pharma, Abbott, and Abbott Vascular;  and personal fees from Bayer, Boehringer Ingelheim, Servier, Cardiac Dimensions,  Actimed, AstraZeneca, Amgen, Bioventrix, Janssen, Respicardia, V-Wave, Brahms, Cordio, and Occlutech. Colin Baigent reports grants from Medical Research Council, Boehringer Ingelheim, and NIHR. Thomas F. Luscherumbers Amitava Banerjee reports grants from AstraZeneca. Birgit Beger reports grants from the European Commission. Gunnar Brobert reports grants from the European Commission (IMartin Ingvar project support) and Bayer. Barbara Casadei reports non-financial support from Roche Diagnostics and iRhythm. Cinzia Ceccarelli reports grants from the European Commission. Martin R. Thomas F. Luscherumbers Cowie reports personal fees from AstraZeneca. Filippo Crea reports personal fees from Amgen,  AstraZeneca, Servier, and BMS; and advisory board fees from GlyCardial Diagnostics. Maureen Cronin reports personal fees from Vifor Pharma. Andrea Derix reports salary from Bayer. Martin Fredriksson reports salary from AstraZeneca. Chris P. Gale reports personal fees from AstraZeneca, Amgen, Bayer, Boehringer Ingelheim, Daiichi Sankyo, Vifor Pharma, Menarini, Wondr Medical, Raisio Group, and Oxford University Press; and grants from BMS, Abbott, British Heart Foundation, NIHR, and ESC. Martin Ingvar reports grants from World Economic Forum, Swedish Innovation Agency, and the European Commission; and collaboration with Frisq. Susanne Logstrup reports grants from the European Commission. TFL reports grants from Abbott, Amgen, Novartis, Boehringer Ingelheim, Servier, Vifor Pharma, Sanofi, and AstraZeneca; and personal fees from Daichi Sankyo, Pfizer, and Menarini. Lothar Roessig reports salary from Bayer. Carl Steinbeisser reports personal fees from Bayer.  BT reports personal fees from Servier. GvT reports grants from IMartin Ingvar. KvB reports grants from IMartin Ingvar BigData@Heart. PEV reports personal fees from Hygeia Hospitals Group, Hellenic Healthcare Group, ESC, and Servier. TV is working as an editor at The BMJ and Acta Medica Portuguesa and is Vice President of the European Union of General Practitioners. MV reports grants from the European Commission. SW reports grants from Abbott, Amgen, AstraZeneca, BMS, Bayer, Biotronik, Boston Scientific, Cardinal Health, CardioValve, Carl Steinbeisserusanne Logstrup Behring, Daiichi Sankyo, Edwards Lifesciences,  Guerbet, InfraRedx, Johnson & Johnson, Medicure, Medtronic, Novartis, Polares, OrPha Suisse, Pfizer, Regeneron, Sanofi-Aventis, Sinomed, Terumo, and V-Wave. SW  serves as an unpaid advisory board member or unpaid member of the steering or executive group of trials funded by Abbott, Abiomed, Amgen, AstraZeneca, BMS, Boston Scientific, Biotronik, Cardiovalve, Edwards Lifesciences, MedAlliance, Medtronic, Novartis, Polares, Sinomed, V-Wave, and Xeltis. He has not received personal payments by pharmaceutical companies or device manufacturers. SW is a member of the steering or executive committee group of several investigator-initiated trials that receive funding by industry without effect on  his personal remuneration. SW is an unpaid member of the Pfizer Research Award selection committee in Switzerland and of the Women as One Awards Committee. SW is a member of the Clinical Study Group of the Deutsches Zentrum fur Herz Kreislauf-Forschung and of the Advisory Board of the Australian Victorian Heart Institute. He is Chairperson of the ESC Congress Program Committee, former Chairperson of the ESC Clinical Practice Guidelines Committee, and Deputy Editor  of the Journal of the American College of Cardiology Cardiovascular Interventions. All other authors declare no competing interests.\n",
      "\n",
      "Sundgren, Mats\n",
      "Declaration of interests The BigData@Heart project has received funding from the  Innovative Medicines Initiative (IMartin Ingvar) 2 Joint Undertaking (grant 116074) which receives support from the Horizon 2020 research and innovation programme of the European Union and the European Federation of Pharmaceutical Industries and Associations. The funders had no role in considering the study design; in the collection, analysis, or interpretation of data; in the writing of the report; or in the decision to submit the Review for publication. Dipak Kotecha reports grants from the  European Union and the European Federation of Pharmaceutical Industries and Associations Innovative Medicines Initiative (116074), the National Institute for Health Research (NIHR CDonna Fitzsimons-2015-08-074 RATE-AF; NIHR130280 DaRe2THINK; and NIHR132974 D2T-NeuroVascular), the British Heart Foundation (PG/17/55/33087, AA/18/2/34218 and FS/CDRF/21/21032), and the ESC. Dipak Kotecha is supported by educational  grants from Boehringer Ingelheim, Bristol Myers Squibb (BMats Sundgren)-Pfizer Alliance, Bayer, Daiichi Sankyo, Boston Scientific, the NIHR and University of Oxford Biomedical Research Centre, the British Heart Foundation and University of Birmingham Accelerator Award (STEEER-AF NCT04396418), Amomed Pharma, Istituto Di  Ricovero e Cura a Carattere Scientifico San Raffaele, and Menarini (NCT0083244).  Dipak Kotecha receives advisory board personal fees from Bayer, Amomed, Protherics Medicines Development, and Myokardia. Folkert W. Asselbergs reports grants from IMartin Ingvar BigData@Heart. Stefan D. Anker reports grants and personal fees from Vifor Pharma, Abbott, and Abbott Vascular;  and personal fees from Bayer, Boehringer Ingelheim, Servier, Cardiac Dimensions,  Actimed, AstraZeneca, Amgen, Bioventrix, Janssen, Respicardia, V-Wave, Brahms, Cordio, and Occlutech. Colin Baigent reports grants from Medical Research Council, Boehringer Ingelheim, and NIHR. Thomas F. Luscherumbers Amitava Banerjee reports grants from AstraZeneca. Birgit Beger reports grants from the European Commission. Gunnar Brobert reports grants from the European Commission (IMartin Ingvar project support) and Bayer. Barbara Casadei reports non-financial support from Roche Diagnostics and iRhythm. Cinzia Ceccarelli reports grants from the European Commission. Martin R. Thomas F. Luscherumbers Cowie reports personal fees from AstraZeneca. Filippo Crea reports personal fees from Amgen,  AstraZeneca, Servier, and BMats Sundgren; and advisory board fees from GlyCardial Diagnostics. Maureen Cronin reports personal fees from Vifor Pharma. Andrea Derix reports salary from Bayer. Martin Fredriksson reports salary from AstraZeneca. Chris P. Gale reports personal fees from AstraZeneca, Amgen, Bayer, Boehringer Ingelheim, Daiichi Sankyo, Vifor Pharma, Menarini, Wondr Medical, Raisio Group, and Oxford University Press; and grants from BMats Sundgren, Abbott, British Heart Foundation, NIHR, and ESC. Martin Ingvar reports grants from World Economic Forum, Swedish Innovation Agency, and the European Commission; and collaboration with Frisq. Susanne Logstrup reports grants from the European Commission. TFL reports grants from Abbott, Amgen, Novartis, Boehringer Ingelheim, Servier, Vifor Pharma, Sanofi, and AstraZeneca; and personal fees from Daichi Sankyo, Pfizer, and Menarini. Lothar Roessig reports salary from Bayer. Carl Steinbeisser reports personal fees from Bayer.  BT reports personal fees from Servier. GvT reports grants from IMartin Ingvar. KvB reports grants from IMartin Ingvar BigData@Heart. PEV reports personal fees from Hygeia Hospitals Group, Hellenic Healthcare Group, ESC, and Servier. TV is working as an editor at The BMJ and Acta Medica Portuguesa and is Vice President of the European Union of General Practitioners. MV reports grants from the European Commission. SW reports grants from Abbott, Amgen, AstraZeneca, BMats Sundgren, Bayer, Biotronik, Boston Scientific, Cardinal Health, CardioValve, Carl Steinbeisserusanne Logstrup Behring, Daiichi Sankyo, Edwards Lifesciences,  Guerbet, InfraRedx, Johnson & Johnson, Medicure, Medtronic, Novartis, Polares, OrPha Suisse, Pfizer, Regeneron, Sanofi-Aventis, Sinomed, Terumo, and V-Wave. SW  serves as an unpaid advisory board member or unpaid member of the steering or executive group of trials funded by Abbott, Abiomed, Amgen, AstraZeneca, BMats Sundgren, Boston Scientific, Biotronik, Cardiovalve, Edwards Lifesciences, MedAlliance, Medtronic, Novartis, Polares, Sinomed, V-Wave, and Xeltis. He has not received personal payments by pharmaceutical companies or device manufacturers. SW is a member of the steering or executive committee group of several investigator-initiated trials that receive funding by industry without effect on  his personal remuneration. SW is an unpaid member of the Pfizer Research Award selection committee in Switzerland and of the Women as One Awards Committee. SW is a member of the Clinical Study Group of the Deutsches Zentrum fur Herz Kreislauf-Forschung and of the Advisory Board of the Australian Victorian Heart Institute. He is Chairperson of the ESC Congress Program Committee, former Chairperson of the ESC Clinical Practice Guidelines Committee, and Deputy Editor  of the Journal of the American College of Cardiology Cardiovascular Interventions. All other authors declare no competing interests.\n",
      "\n",
      "Tyl, Benoit\n",
      "Declaration of interests The BigData@Heart project has received funding from the  Innovative Medicines Initiative (IMartin Ingvar) 2 Joint Undertaking (grant 116074) which receives support from the Horizon 2020 research and innovation programme of the European Union and the European Federation of Pharmaceutical Industries and Associations. The funders had no role in considering the study design; in the collection, analysis, or interpretation of data; in the writing of the report; or in the decision to submit the Review for publication. Dipak Kotecha reports grants from the  European Union and the European Federation of Pharmaceutical Industries and Associations Innovative Medicines Initiative (116074), the National Institute for Health Research (NIHR CDonna Fitzsimons-2015-08-074 RATE-AF; NIHR130280 DaRe2THINK; and NIHR132974 D2T-NeuroVascular), the British Heart Foundation (PG/17/55/33087, AA/18/2/34218 and FS/CDRF/21/21032), and the ESC. Dipak Kotecha is supported by educational  grants from Boehringer Ingelheim, Bristol Myers Squibb (BMats Sundgren)-Pfizer Alliance, Bayer, Daiichi Sankyo, Boston Scientific, the NIHR and University of Oxford Biomedical Research Centre, the British Heart Foundation and University of Birmingham Accelerator Award (STEEER-AF NCT04396418), Amomed Pharma, Istituto Di  Ricovero e Cura a Carattere Scientifico San Raffaele, and Menarini (NCT0083244).  Dipak Kotecha receives advisory board personal fees from Bayer, Amomed, Protherics Medicines Development, and Myokardia. Folkert W. Asselbergs reports grants from IMartin Ingvar BigData@Heart. Stefan D. Anker reports grants and personal fees from Vifor Pharma, Abbott, and Abbott Vascular;  and personal fees from Bayer, Boehringer Ingelheim, Servier, Cardiac Dimensions,  Actimed, AstraZeneca, Amgen, Bioventrix, Janssen, Respicardia, V-Wave, Brahms, Cordio, and Occlutech. Colin Baigent reports grants from Medical Research Council, Boehringer Ingelheim, and NIHR. Thomas F. Luscherumbers Amitava Banerjee reports grants from AstraZeneca. Birgit Beger reports grants from the European Commission. Gunnar Brobert reports grants from the European Commission (IMartin Ingvar project support) and Bayer. Barbara Casadei reports non-financial support from Roche Diagnostics and iRhythm. Cinzia Ceccarelli reports grants from the European Commission. Martin R. Thomas F. Luscherumbers Cowie reports personal fees from AstraZeneca. Filippo Crea reports personal fees from Amgen,  AstraZeneca, Servier, and BMats Sundgren; and advisory board fees from GlyCardial Diagnostics. Maureen Cronin reports personal fees from Vifor Pharma. Andrea Derix reports salary from Bayer. Martin Fredriksson reports salary from AstraZeneca. Chris P. Gale reports personal fees from AstraZeneca, Amgen, Bayer, Boehringer Ingelheim, Daiichi Sankyo, Vifor Pharma, Menarini, Wondr Medical, Raisio Group, and Oxford University Press; and grants from BMats Sundgren, Abbott, British Heart Foundation, NIHR, and ESC. Martin Ingvar reports grants from World Economic Forum, Swedish Innovation Agency, and the European Commission; and collaboration with Frisq. Susanne Logstrup reports grants from the European Commission. TFL reports grants from Abbott, Amgen, Novartis, Boehringer Ingelheim, Servier, Vifor Pharma, Sanofi, and AstraZeneca; and personal fees from Daichi Sankyo, Pfizer, and Menarini. Lothar Roessig reports salary from Bayer. Carl Steinbeisser reports personal fees from Bayer.  Benoit Tyl reports personal fees from Servier. GvT reports grants from IMartin Ingvar. KvB reports grants from IMartin Ingvar BigData@Heart. PEV reports personal fees from Hygeia Hospitals Group, Hellenic Healthcare Group, ESC, and Servier. TV is working as an editor at The BMJ and Acta Medica Portuguesa and is Vice President of the European Union of General Practitioners. MV reports grants from the European Commission. SW reports grants from Abbott, Amgen, AstraZeneca, BMats Sundgren, Bayer, Biotronik, Boston Scientific, Cardinal Health, CardioValve, Carl Steinbeisserusanne Logstrup Behring, Daiichi Sankyo, Edwards Lifesciences,  Guerbet, InfraRedx, Johnson & Johnson, Medicure, Medtronic, Novartis, Polares, OrPha Suisse, Pfizer, Regeneron, Sanofi-Aventis, Sinomed, Terumo, and V-Wave. SW  serves as an unpaid advisory board member or unpaid member of the steering or executive group of trials funded by Abbott, Abiomed, Amgen, AstraZeneca, BMats Sundgren, Boston Scientific, Biotronik, Cardiovalve, Edwards Lifesciences, MedAlliance, Medtronic, Novartis, Polares, Sinomed, V-Wave, and Xeltis. He has not received personal payments by pharmaceutical companies or device manufacturers. SW is a member of the steering or executive committee group of several investigator-initiated trials that receive funding by industry without effect on  his personal remuneration. SW is an unpaid member of the Pfizer Research Award selection committee in Switzerland and of the Women as One Awards Committee. SW is a member of the Clinical Study Group of the Deutsches Zentrum fur Herz Kreislauf-Forschung and of the Advisory Board of the Australian Victorian Heart Institute. He is Chairperson of the ESC Congress Program Committee, former Chairperson of the ESC Clinical Practice Guidelines Committee, and Deputy Editor  of the Journal of the American College of Cardiology Cardiovascular Interventions. All other authors declare no competing interests.\n",
      "\n",
      "van Thiel, Ghislaine\n",
      "Declaration of interests The BigData@Heart project has received funding from the  Innovative Medicines Initiative (IMartin Ingvar) 2 Joint Undertaking (grant 116074) which receives support from the Horizon 2020 research and innovation programme of the European Union and the European Federation of Pharmaceutical Industries and Associations. The funders had no role in considering the study design; in the collection, analysis, or interpretation of data; in the writing of the report; or in the decision to submit the Review for publication. Dipak Kotecha reports grants from the  European Union and the European Federation of Pharmaceutical Industries and Associations Innovative Medicines Initiative (116074), the National Institute for Health Research (NIHR CDonna Fitzsimons-2015-08-074 RATE-AF; NIHR130280 DaRe2THINK; and NIHR132974 D2T-NeuroVascular), the British Heart Foundation (PG/17/55/33087, AA/18/2/34218 and FS/CDRF/21/21032), and the ESC. Dipak Kotecha is supported by educational  grants from Boehringer Ingelheim, Bristol Myers Squibb (BMats Sundgren)-Pfizer Alliance, Bayer, Daiichi Sankyo, Boston Scientific, the NIHR and University of Oxford Biomedical Research Centre, the British Heart Foundation and University of Birmingham Accelerator Award (STEEER-AF NCT04396418), Amomed Pharma, Istituto Di  Ricovero e Cura a Carattere Scientifico San Raffaele, and Menarini (NCT0083244).  Dipak Kotecha receives advisory board personal fees from Bayer, Amomed, Protherics Medicines Development, and Myokardia. Folkert W. Asselbergs reports grants from IMartin Ingvar BigData@Heart. Stefan D. Anker reports grants and personal fees from Vifor Pharma, Abbott, and Abbott Vascular;  and personal fees from Bayer, Boehringer Ingelheim, Servier, Cardiac Dimensions,  Actimed, AstraZeneca, Amgen, Bioventrix, Janssen, Respicardia, V-Wave, Brahms, Cordio, and Occlutech. Colin Baigent reports grants from Medical Research Council, Boehringer Ingelheim, and NIHR. Thomas F. Luscherumbers Amitava Banerjee reports grants from AstraZeneca. Birgit Beger reports grants from the European Commission. Gunnar Brobert reports grants from the European Commission (IMartin Ingvar project support) and Bayer. Barbara Casadei reports non-financial support from Roche Diagnostics and iRhythm. Cinzia Ceccarelli reports grants from the European Commission. Martin R. Thomas F. Luscherumbers Cowie reports personal fees from AstraZeneca. Filippo Crea reports personal fees from Amgen,  AstraZeneca, Servier, and BMats Sundgren; and advisory board fees from GlyCardial Diagnostics. Maureen Cronin reports personal fees from Vifor Pharma. Andrea Derix reports salary from Bayer. Martin Fredriksson reports salary from AstraZeneca. Chris P. Gale reports personal fees from AstraZeneca, Amgen, Bayer, Boehringer Ingelheim, Daiichi Sankyo, Vifor Pharma, Menarini, Wondr Medical, Raisio Group, and Oxford University Press; and grants from BMats Sundgren, Abbott, British Heart Foundation, NIHR, and ESC. Martin Ingvar reports grants from World Economic Forum, Swedish Innovation Agency, and the European Commission; and collaboration with Frisq. Susanne Logstrup reports grants from the European Commission. TFL reports grants from Abbott, Amgen, Novartis, Boehringer Ingelheim, Servier, Vifor Pharma, Sanofi, and AstraZeneca; and personal fees from Daichi Sankyo, Pfizer, and Menarini. Lothar Roessig reports salary from Bayer. Carl Steinbeisser reports personal fees from Bayer.  Benoit Tyl reports personal fees from Servier. Ghislaine van Thiel reports grants from IMartin Ingvar. KvB reports grants from IMartin Ingvar BigData@Heart. PEV reports personal fees from Hygeia Hospitals Group, Hellenic Healthcare Group, ESC, and Servier. TV is working as an editor at The BMJ and Acta Medica Portuguesa and is Vice President of the European Union of General Practitioners. MV reports grants from the European Commission. SW reports grants from Abbott, Amgen, AstraZeneca, BMats Sundgren, Bayer, Biotronik, Boston Scientific, Cardinal Health, CardioValve, Carl Steinbeisserusanne Logstrup Behring, Daiichi Sankyo, Edwards Lifesciences,  Guerbet, InfraRedx, Johnson & Johnson, Medicure, Medtronic, Novartis, Polares, OrPha Suisse, Pfizer, Regeneron, Sanofi-Aventis, Sinomed, Terumo, and V-Wave. SW  serves as an unpaid advisory board member or unpaid member of the steering or executive group of trials funded by Abbott, Abiomed, Amgen, AstraZeneca, BMats Sundgren, Boston Scientific, Biotronik, Cardiovalve, Edwards Lifesciences, MedAlliance, Medtronic, Novartis, Polares, Sinomed, V-Wave, and Xeltis. He has not received personal payments by pharmaceutical companies or device manufacturers. SW is a member of the steering or executive committee group of several investigator-initiated trials that receive funding by industry without effect on  his personal remuneration. SW is an unpaid member of the Pfizer Research Award selection committee in Switzerland and of the Women as One Awards Committee. SW is a member of the Clinical Study Group of the Deutsches Zentrum fur Herz Kreislauf-Forschung and of the Advisory Board of the Australian Victorian Heart Institute. He is Chairperson of the ESC Congress Program Committee, former Chairperson of the ESC Clinical Practice Guidelines Committee, and Deputy Editor  of the Journal of the American College of Cardiology Cardiovascular Interventions. All other authors declare no competing interests.\n",
      "\n",
      "van Bochove, Kees\n",
      "Declaration of interests The BigData@Heart project has received funding from the  Innovative Medicines Initiative (IMartin Ingvar) 2 Joint Undertaking (grant 116074) which receives support from the Horizon 2020 research and innovation programme of the European Union and the European Federation of Pharmaceutical Industries and Associations. The funders had no role in considering the study design; in the collection, analysis, or interpretation of data; in the writing of the report; or in the decision to submit the Review for publication. Dipak Kotecha reports grants from the  European Union and the European Federation of Pharmaceutical Industries and Associations Innovative Medicines Initiative (116074), the National Institute for Health Research (NIHR CDonna Fitzsimons-2015-08-074 RATE-AF; NIHR130280 DaRe2THINK; and NIHR132974 D2T-NeuroVascular), the British Heart Foundation (PG/17/55/33087, AA/18/2/34218 and FS/CDRF/21/21032), and the ESC. Dipak Kotecha is supported by educational  grants from Boehringer Ingelheim, Bristol Myers Squibb (BMats Sundgren)-Pfizer Alliance, Bayer, Daiichi Sankyo, Boston Scientific, the NIHR and University of Oxford Biomedical Research Centre, the British Heart Foundation and University of Birmingham Accelerator Award (STEEER-AF NCT04396418), Amomed Pharma, Istituto Di  Ricovero e Cura a Carattere Scientifico San Raffaele, and Menarini (NCT0083244).  Dipak Kotecha receives advisory board personal fees from Bayer, Amomed, Protherics Medicines Development, and Myokardia. Folkert W. Asselbergs reports grants from IMartin Ingvar BigData@Heart. Stefan D. Anker reports grants and personal fees from Vifor Pharma, Abbott, and Abbott Vascular;  and personal fees from Bayer, Boehringer Ingelheim, Servier, Cardiac Dimensions,  Actimed, AstraZeneca, Amgen, Bioventrix, Janssen, Respicardia, V-Wave, Brahms, Cordio, and Occlutech. Colin Baigent reports grants from Medical Research Council, Boehringer Ingelheim, and NIHR. Thomas F. Luscherumbers Amitava Banerjee reports grants from AstraZeneca. Birgit Beger reports grants from the European Commission. Gunnar Brobert reports grants from the European Commission (IMartin Ingvar project support) and Bayer. Barbara Casadei reports non-financial support from Roche Diagnostics and iRhythm. Cinzia Ceccarelli reports grants from the European Commission. Martin R. Thomas F. Luscherumbers Cowie reports personal fees from AstraZeneca. Filippo Crea reports personal fees from Amgen,  AstraZeneca, Servier, and BMats Sundgren; and advisory board fees from GlyCardial Diagnostics. Maureen Cronin reports personal fees from Vifor Pharma. Andrea Derix reports salary from Bayer. Martin Fredriksson reports salary from AstraZeneca. Chris P. Gale reports personal fees from AstraZeneca, Amgen, Bayer, Boehringer Ingelheim, Daiichi Sankyo, Vifor Pharma, Menarini, Wondr Medical, Raisio Group, and Oxford University Press; and grants from BMats Sundgren, Abbott, British Heart Foundation, NIHR, and ESC. Martin Ingvar reports grants from World Economic Forum, Swedish Innovation Agency, and the European Commission; and collaboration with Frisq. Susanne Logstrup reports grants from the European Commission. TFL reports grants from Abbott, Amgen, Novartis, Boehringer Ingelheim, Servier, Vifor Pharma, Sanofi, and AstraZeneca; and personal fees from Daichi Sankyo, Pfizer, and Menarini. Lothar Roessig reports salary from Bayer. Carl Steinbeisser reports personal fees from Bayer.  Benoit Tyl reports personal fees from Servier. Ghislaine van Thiel reports grants from IMartin Ingvar. Kees van Bochove reports grants from IMartin Ingvar BigData@Heart. PEV reports personal fees from Hygeia Hospitals Group, Hellenic Healthcare Group, ESC, and Servier. TV is working as an editor at The BMJ and Acta Medica Portuguesa and is Vice President of the European Union of General Practitioners. MV reports grants from the European Commission. SW reports grants from Abbott, Amgen, AstraZeneca, BMats Sundgren, Bayer, Biotronik, Boston Scientific, Cardinal Health, CardioValve, Carl Steinbeisserusanne Logstrup Behring, Daiichi Sankyo, Edwards Lifesciences,  Guerbet, InfraRedx, Johnson & Johnson, Medicure, Medtronic, Novartis, Polares, OrPha Suisse, Pfizer, Regeneron, Sanofi-Aventis, Sinomed, Terumo, and V-Wave. SW  serves as an unpaid advisory board member or unpaid member of the steering or executive group of trials funded by Abbott, Abiomed, Amgen, AstraZeneca, BMats Sundgren, Boston Scientific, Biotronik, Cardiovalve, Edwards Lifesciences, MedAlliance, Medtronic, Novartis, Polares, Sinomed, V-Wave, and Xeltis. He has not received personal payments by pharmaceutical companies or device manufacturers. SW is a member of the steering or executive committee group of several investigator-initiated trials that receive funding by industry without effect on  his personal remuneration. SW is an unpaid member of the Pfizer Research Award selection committee in Switzerland and of the Women as One Awards Committee. SW is a member of the Clinical Study Group of the Deutsches Zentrum fur Herz Kreislauf-Forschung and of the Advisory Board of the Australian Victorian Heart Institute. He is Chairperson of the ESC Congress Program Committee, former Chairperson of the ESC Clinical Practice Guidelines Committee, and Deputy Editor  of the Journal of the American College of Cardiology Cardiovascular Interventions. All other authors declare no competing interests.\n",
      "\n",
      "Vardas, Panos E.\n",
      "Declaration of interests The BigData@Heart project has received funding from the  Innovative Medicines Initiative (IMartin Ingvar) 2 Joint Undertaking (grant 116074) which receives support from the Horizon 2020 research and innovation programme of the European Union and the European Federation of Pharmaceutical Industries and Associations. The funders had no role in considering the study design; in the collection, analysis, or interpretation of data; in the writing of the report; or in the decision to submit the Review for publication. Dipak Kotecha reports grants from the  European Union and the European Federation of Pharmaceutical Industries and Associations Innovative Medicines Initiative (116074), the National Institute for Health Research (NIHR CDonna Fitzsimons-2015-08-074 RATE-AF; NIHR130280 DaRe2THINK; and NIHR132974 D2T-NeuroVascular), the British Heart Foundation (PG/17/55/33087, AA/18/2/34218 and FS/CDRF/21/21032), and the ESC. Dipak Kotecha is supported by educational  grants from Boehringer Ingelheim, Bristol Myers Squibb (BMats Sundgren)-Pfizer Alliance, Bayer, Daiichi Sankyo, Boston Scientific, the NIHR and University of Oxford Biomedical Research Centre, the British Heart Foundation and University of Birmingham Accelerator Award (STEEER-AF NCT04396418), Amomed Pharma, Istituto Di  Ricovero e Cura a Carattere Scientifico San Raffaele, and Menarini (NCT0083244).  Dipak Kotecha receives advisory board personal fees from Bayer, Amomed, Protherics Medicines Development, and Myokardia. Folkert W. Asselbergs reports grants from IMartin Ingvar BigData@Heart. Stefan D. Anker reports grants and personal fees from Vifor Pharma, Abbott, and Abbott Vascular;  and personal fees from Bayer, Boehringer Ingelheim, Servier, Cardiac Dimensions,  Actimed, AstraZeneca, Amgen, Bioventrix, Janssen, Respicardia, V-Wave, Brahms, Cordio, and Occlutech. Colin Baigent reports grants from Medical Research Council, Boehringer Ingelheim, and NIHR. Thomas F. Luscherumbers Amitava Banerjee reports grants from AstraZeneca. Birgit Beger reports grants from the European Commission. Gunnar Brobert reports grants from the European Commission (IMartin Ingvar project support) and Bayer. Barbara Casadei reports non-financial support from Roche Diagnostics and iRhythm. Cinzia Ceccarelli reports grants from the European Commission. Martin R. Thomas F. Luscherumbers Cowie reports personal fees from AstraZeneca. Filippo Crea reports personal fees from Amgen,  AstraZeneca, Servier, and BMats Sundgren; and advisory board fees from GlyCardial Diagnostics. Maureen Cronin reports personal fees from Vifor Pharma. Andrea Derix reports salary from Bayer. Martin Fredriksson reports salary from AstraZeneca. Chris P. Gale reports personal fees from AstraZeneca, Amgen, Bayer, Boehringer Ingelheim, Daiichi Sankyo, Vifor Pharma, Menarini, Wondr Medical, Raisio Group, and Oxford University Press; and grants from BMats Sundgren, Abbott, British Heart Foundation, NIHR, and ESC. Martin Ingvar reports grants from World Economic Forum, Swedish Innovation Agency, and the European Commission; and collaboration with Frisq. Susanne Logstrup reports grants from the European Commission. TFL reports grants from Abbott, Amgen, Novartis, Boehringer Ingelheim, Servier, Vifor Pharma, Sanofi, and AstraZeneca; and personal fees from Daichi Sankyo, Pfizer, and Menarini. Lothar Roessig reports salary from Bayer. Carl Steinbeisser reports personal fees from Bayer.  Benoit Tyl reports personal fees from Servier. Ghislaine van Thiel reports grants from IMartin Ingvar. Kees van Bochove reports grants from IMartin Ingvar BigData@Heart. Panos E. Vardas reports personal fees from Hygeia Hospitals Group, Hellenic Healthcare Group, ESC, and Servier. TV is working as an editor at The BMJ and Acta Medica Portuguesa and is Vice President of the European Union of General Practitioners. MV reports grants from the European Commission. SW reports grants from Abbott, Amgen, AstraZeneca, BMats Sundgren, Bayer, Biotronik, Boston Scientific, Cardinal Health, CardioValve, Carl Steinbeisserusanne Logstrup Behring, Daiichi Sankyo, Edwards Lifesciences,  Guerbet, InfraRedx, Johnson & Johnson, Medicure, Medtronic, Novartis, Polares, OrPha Suisse, Pfizer, Regeneron, Sanofi-Aventis, Sinomed, Terumo, and V-Wave. SW  serves as an unpaid advisory board member or unpaid member of the steering or executive group of trials funded by Abbott, Abiomed, Amgen, AstraZeneca, BMats Sundgren, Boston Scientific, Biotronik, Cardiovalve, Edwards Lifesciences, MedAlliance, Medtronic, Novartis, Polares, Sinomed, V-Wave, and Xeltis. He has not received personal payments by pharmaceutical companies or device manufacturers. SW is a member of the steering or executive committee group of several investigator-initiated trials that receive funding by industry without effect on  his personal remuneration. SW is an unpaid member of the Pfizer Research Award selection committee in Switzerland and of the Women as One Awards Committee. SW is a member of the Clinical Study Group of the Deutsches Zentrum fur Herz Kreislauf-Forschung and of the Advisory Board of the Australian Victorian Heart Institute. He is Chairperson of the ESC Congress Program Committee, former Chairperson of the ESC Clinical Practice Guidelines Committee, and Deputy Editor  of the Journal of the American College of Cardiology Cardiovascular Interventions. All other authors declare no competing interests.\n",
      "\n",
      "Villanueva, Tiago\n",
      "Declaration of interests The BigData@Heart project has received funding from the  Innovative Medicines Initiative (IMartin Ingvar) 2 Joint Undertaking (grant 116074) which receives support from the Horizon 2020 research and innovation programme of the European Union and the European Federation of Pharmaceutical Industries and Associations. The funders had no role in considering the study design; in the collection, analysis, or interpretation of data; in the writing of the report; or in the decision to submit the Review for publication. Dipak Kotecha reports grants from the  European Union and the European Federation of Pharmaceutical Industries and Associations Innovative Medicines Initiative (116074), the National Institute for Health Research (NIHR CDonna Fitzsimons-2015-08-074 RATE-AF; NIHR130280 DaRe2THINK; and NIHR132974 D2T-NeuroVascular), the British Heart Foundation (PG/17/55/33087, AA/18/2/34218 and FS/CDRF/21/21032), and the ESC. Dipak Kotecha is supported by educational  grants from Boehringer Ingelheim, Bristol Myers Squibb (BMats Sundgren)-Pfizer Alliance, Bayer, Daiichi Sankyo, Boston Scientific, the NIHR and University of Oxford Biomedical Research Centre, the British Heart Foundation and University of Birmingham Accelerator Award (STEEER-AF NCT04396418), Amomed Pharma, Istituto Di  Ricovero e Cura a Carattere Scientifico San Raffaele, and Menarini (NCT0083244).  Dipak Kotecha receives advisory board personal fees from Bayer, Amomed, Protherics Medicines Development, and Myokardia. Folkert W. Asselbergs reports grants from IMartin Ingvar BigData@Heart. Stefan D. Anker reports grants and personal fees from Vifor Pharma, Abbott, and Abbott Vascular;  and personal fees from Bayer, Boehringer Ingelheim, Servier, Cardiac Dimensions,  Actimed, AstraZeneca, Amgen, Bioventrix, Janssen, Respicardia, V-Wave, Brahms, Cordio, and Occlutech. Colin Baigent reports grants from Medical Research Council, Boehringer Ingelheim, and NIHR. Thomas F. Luscherumbers Amitava Banerjee reports grants from AstraZeneca. Birgit Beger reports grants from the European Commission. Gunnar Brobert reports grants from the European Commission (IMartin Ingvar project support) and Bayer. Barbara Casadei reports non-financial support from Roche Diagnostics and iRhythm. Cinzia Ceccarelli reports grants from the European Commission. Martin R. Thomas F. Luscherumbers Cowie reports personal fees from AstraZeneca. Filippo Crea reports personal fees from Amgen,  AstraZeneca, Servier, and BMats Sundgren; and advisory board fees from GlyCardial Diagnostics. Maureen Cronin reports personal fees from Vifor Pharma. Andrea Derix reports salary from Bayer. Martin Fredriksson reports salary from AstraZeneca. Chris P. Gale reports personal fees from AstraZeneca, Amgen, Bayer, Boehringer Ingelheim, Daiichi Sankyo, Vifor Pharma, Menarini, Wondr Medical, Raisio Group, and Oxford University Press; and grants from BMats Sundgren, Abbott, British Heart Foundation, NIHR, and ESC. Martin Ingvar reports grants from World Economic Forum, Swedish Innovation Agency, and the European Commission; and collaboration with Frisq. Susanne Logstrup reports grants from the European Commission. TFL reports grants from Abbott, Amgen, Novartis, Boehringer Ingelheim, Servier, Vifor Pharma, Sanofi, and AstraZeneca; and personal fees from Daichi Sankyo, Pfizer, and Menarini. Lothar Roessig reports salary from Bayer. Carl Steinbeisser reports personal fees from Bayer.  Benoit Tyl reports personal fees from Servier. Ghislaine van Thiel reports grants from IMartin Ingvar. Kees van Bochove reports grants from IMartin Ingvar BigData@Heart. Panos E. Vardas reports personal fees from Hygeia Hospitals Group, Hellenic Healthcare Group, ESC, and Servier. Tiago Villanueva is working as an editor at The BMJ and Acta Medica Portuguesa and is Vice President of the European Union of General Practitioners. MV reports grants from the European Commission. SW reports grants from Abbott, Amgen, AstraZeneca, BMats Sundgren, Bayer, Biotronik, Boston Scientific, Cardinal Health, CardioValve, Carl Steinbeisserusanne Logstrup Behring, Daiichi Sankyo, Edwards Lifesciences,  Guerbet, InfraRedx, Johnson & Johnson, Medicure, Medtronic, Novartis, Polares, OrPha Suisse, Pfizer, Regeneron, Sanofi-Aventis, Sinomed, Terumo, and V-Wave. SW  serves as an unpaid advisory board member or unpaid member of the steering or executive group of trials funded by Abbott, Abiomed, Amgen, AstraZeneca, BMats Sundgren, Boston Scientific, Biotronik, Cardiovalve, Edwards Lifesciences, MedAlliance, Medtronic, Novartis, Polares, Sinomed, V-Wave, and Xeltis. He has not received personal payments by pharmaceutical companies or device manufacturers. SW is a member of the steering or executive committee group of several investigator-initiated trials that receive funding by industry without effect on  his personal remuneration. SW is an unpaid member of the Pfizer Research Award selection committee in Switzerland and of the Women as One Awards Committee. SW is a member of the Clinical Study Group of the Deutsches Zentrum fur Herz Kreislauf-Forschung and of the Advisory Board of the Australian Victorian Heart Institute. He is Chairperson of the ESC Congress Program Committee, former Chairperson of the ESC Clinical Practice Guidelines Committee, and Deputy Editor  of the Journal of the American College of Cardiology Cardiovascular Interventions. All other authors declare no competing interests.\n",
      "\n",
      "Vrana, Marilena\n",
      "Declaration of interests The BigData@Heart project has received funding from the  Innovative Medicines Initiative (IMartin Ingvar) 2 Joint Undertaking (grant 116074) which receives support from the Horizon 2020 research and innovation programme of the European Union and the European Federation of Pharmaceutical Industries and Associations. The funders had no role in considering the study design; in the collection, analysis, or interpretation of data; in the writing of the report; or in the decision to submit the Review for publication. Dipak Kotecha reports grants from the  European Union and the European Federation of Pharmaceutical Industries and Associations Innovative Medicines Initiative (116074), the National Institute for Health Research (NIHR CDonna Fitzsimons-2015-08-074 RATE-AF; NIHR130280 DaRe2THINK; and NIHR132974 D2T-NeuroVascular), the British Heart Foundation (PG/17/55/33087, AA/18/2/34218 and FS/CDRF/21/21032), and the ESC. Dipak Kotecha is supported by educational  grants from Boehringer Ingelheim, Bristol Myers Squibb (BMats Sundgren)-Pfizer Alliance, Bayer, Daiichi Sankyo, Boston Scientific, the NIHR and University of Oxford Biomedical Research Centre, the British Heart Foundation and University of Birmingham Accelerator Award (STEEER-AF NCT04396418), Amomed Pharma, Istituto Di  Ricovero e Cura a Carattere Scientifico San Raffaele, and Menarini (NCT0083244).  Dipak Kotecha receives advisory board personal fees from Bayer, Amomed, Protherics Medicines Development, and Myokardia. Folkert W. Asselbergs reports grants from IMartin Ingvar BigData@Heart. Stefan D. Anker reports grants and personal fees from Vifor Pharma, Abbott, and Abbott Vascular;  and personal fees from Bayer, Boehringer Ingelheim, Servier, Cardiac Dimensions,  Actimed, AstraZeneca, Amgen, Bioventrix, Janssen, Respicardia, V-Wave, Brahms, Cordio, and Occlutech. Colin Baigent reports grants from Medical Research Council, Boehringer Ingelheim, and NIHR. Thomas F. Luscherumbers Amitava Banerjee reports grants from AstraZeneca. Birgit Beger reports grants from the European Commission. Gunnar Brobert reports grants from the European Commission (IMartin Ingvar project support) and Bayer. Barbara Casadei reports non-financial support from Roche Diagnostics and iRhythm. Cinzia Ceccarelli reports grants from the European Commission. Martin R. Thomas F. Luscherumbers Cowie reports personal fees from AstraZeneca. Filippo Crea reports personal fees from Amgen,  AstraZeneca, Servier, and BMats Sundgren; and advisory board fees from GlyCardial Diagnostics. Maureen Cronin reports personal fees from Vifor Pharma. Andrea Derix reports salary from Bayer. Martin Fredriksson reports salary from AstraZeneca. Chris P. Gale reports personal fees from AstraZeneca, Amgen, Bayer, Boehringer Ingelheim, Daiichi Sankyo, Vifor Pharma, Menarini, Wondr Medical, Raisio Group, and Oxford University Press; and grants from BMats Sundgren, Abbott, British Heart Foundation, NIHR, and ESC. Martin Ingvar reports grants from World Economic Forum, Swedish Innovation Agency, and the European Commission; and collaboration with Frisq. Susanne Logstrup reports grants from the European Commission. TFL reports grants from Abbott, Amgen, Novartis, Boehringer Ingelheim, Servier, Vifor Pharma, Sanofi, and AstraZeneca; and personal fees from Daichi Sankyo, Pfizer, and Menarini. Lothar Roessig reports salary from Bayer. Carl Steinbeisser reports personal fees from Bayer.  Benoit Tyl reports personal fees from Servier. Ghislaine van Thiel reports grants from IMartin Ingvar. Kees van Bochove reports grants from IMartin Ingvar BigData@Heart. Panos E. Vardas reports personal fees from Hygeia Hospitals Group, Hellenic Healthcare Group, ESC, and Servier. Tiago Villanueva is working as an editor at The BMJ and Acta Medica Portuguesa and is Vice President of the European Union of General Practitioners. Marilena Vrana reports grants from the European Commission. SW reports grants from Abbott, Amgen, AstraZeneca, BMats Sundgren, Bayer, Biotronik, Boston Scientific, Cardinal Health, CardioValve, Carl Steinbeisserusanne Logstrup Behring, Daiichi Sankyo, Edwards Lifesciences,  Guerbet, InfraRedx, Johnson & Johnson, Medicure, Medtronic, Novartis, Polares, OrPha Suisse, Pfizer, Regeneron, Sanofi-Aventis, Sinomed, Terumo, and V-Wave. SW  serves as an unpaid advisory board member or unpaid member of the steering or executive group of trials funded by Abbott, Abiomed, Amgen, AstraZeneca, BMats Sundgren, Boston Scientific, Biotronik, Cardiovalve, Edwards Lifesciences, MedAlliance, Medtronic, Novartis, Polares, Sinomed, V-Wave, and Xeltis. He has not received personal payments by pharmaceutical companies or device manufacturers. SW is a member of the steering or executive committee group of several investigator-initiated trials that receive funding by industry without effect on  his personal remuneration. SW is an unpaid member of the Pfizer Research Award selection committee in Switzerland and of the Women as One Awards Committee. SW is a member of the Clinical Study Group of the Deutsches Zentrum fur Herz Kreislauf-Forschung and of the Advisory Board of the Australian Victorian Heart Institute. He is Chairperson of the ESC Congress Program Committee, former Chairperson of the ESC Clinical Practice Guidelines Committee, and Deputy Editor  of the Journal of the American College of Cardiology Cardiovascular Interventions. All other authors declare no competing interests.\n",
      "\n",
      "Declaration of interests The BigData@Heart project has received funding from the  Innovative Medicines Initiative (IMartin Ingvar) 2 Joint Undertaking (grant 116074) which receives support from the Horizon 2020 research and innovation programme of the European Union and the European Federation of Pharmaceutical Industries and Associations. The funders had no role in considering the study design; in the collection, analysis, or interpretation of data; in the writing of the report; or in the decision to submit the Review for publication. Dipak Kotecha reports grants from the  European Union and the European Federation of Pharmaceutical Industries and Associations Innovative Medicines Initiative (116074), the National Institute for Health Research (NIHR CDonna Fitzsimons-2015-08-074 RATE-AF; NIHR130280 DaRe2THINK; and NIHR132974 D2T-NeuroVascular), the British Heart Foundation (PG/17/55/33087, AA/18/2/34218 and FS/CDRF/21/21032), and the ESC. Dipak Kotecha is supported by educational  grants from Boehringer Ingelheim, Bristol Myers Squibb (BMats Sundgren)-Pfizer Alliance, Bayer, Daiichi Sankyo, Boston Scientific, the NIHR and University of Oxford Biomedical Research Centre, the British Heart Foundation and University of Birmingham Accelerator Award (STEEER-AF NCT04396418), Amomed Pharma, Istituto Di  Ricovero e Cura a Carattere Scientifico San Raffaele, and Menarini (NCT0083244).  Dipak Kotecha receives advisory board personal fees from Bayer, Amomed, Protherics Medicines Development, and Myokardia. Folkert W. Asselbergs reports grants from IMartin Ingvar BigData@Heart. Stefan D. Anker reports grants and personal fees from Vifor Pharma, Abbott, and Abbott Vascular;  and personal fees from Bayer, Boehringer Ingelheim, Servier, Cardiac Dimensions,  Actimed, AstraZeneca, Amgen, Bioventrix, Janssen, Respicardia, V-Wave, Brahms, Cordio, and Occlutech. Colin Baigent reports grants from Medical Research Council, Boehringer Ingelheim, and NIHR. Thomas F. Luscherumbers Amitava Banerjee reports grants from AstraZeneca. Birgit Beger reports grants from the European Commission. Gunnar Brobert reports grants from the European Commission (IMartin Ingvar project support) and Bayer. Barbara Casadei reports non-financial support from Roche Diagnostics and iRhythm. Cinzia Ceccarelli reports grants from the European Commission. Martin R. Thomas F. Luscherumbers Cowie reports personal fees from AstraZeneca. Filippo Crea reports personal fees from Amgen,  AstraZeneca, Servier, and BMats Sundgren; and advisory board fees from GlyCardial Diagnostics. Maureen Cronin reports personal fees from Vifor Pharma. Andrea Derix reports salary from Bayer. Martin Fredriksson reports salary from AstraZeneca. Chris P. Gale reports personal fees from AstraZeneca, Amgen, Bayer, Boehringer Ingelheim, Daiichi Sankyo, Vifor Pharma, Menarini, Wondr Medical, Raisio Group, and Oxford University Press; and grants from BMats Sundgren, Abbott, British Heart Foundation, NIHR, and ESC. Martin Ingvar reports grants from World Economic Forum, Swedish Innovation Agency, and the European Commission; and collaboration with Frisq. Susanne Logstrup reports grants from the European Commission. TFL reports grants from Abbott, Amgen, Novartis, Boehringer Ingelheim, Servier, Vifor Pharma, Sanofi, and AstraZeneca; and personal fees from Daichi Sankyo, Pfizer, and Menarini. Lothar Roessig reports salary from Bayer. Carl Steinbeisser reports personal fees from Bayer.  Benoit Tyl reports personal fees from Servier. Ghislaine van Thiel reports grants from IMartin Ingvar. Kees van Bochove reports grants from IMartin Ingvar BigData@Heart. Panos E. Vardas reports personal fees from Hygeia Hospitals Group, Hellenic Healthcare Group, ESC, and Servier. Tiago Villanueva is working as an editor at The BMJ and Acta Medica Portuguesa and is Vice President of the European Union of General Practitioners. Marilena Vrana reports grants from the European Commission. SW reports grants from Abbott, Amgen, AstraZeneca, BMats Sundgren, Bayer, Biotronik, Boston Scientific, Cardinal Health, CardioValve, Carl Steinbeisserusanne Logstrup Behring, Daiichi Sankyo, Edwards Lifesciences,  Guerbet, InfraRedx, Johnson & Johnson, Medicure, Medtronic, Novartis, Polares, OrPha Suisse, Pfizer, Regeneron, Sanofi-Aventis, Sinomed, Terumo, and V-Wave. SW  serves as an unpaid advisory board member or unpaid member of the steering or executive group of trials funded by Abbott, Abiomed, Amgen, AstraZeneca, BMats Sundgren, Boston Scientific, Biotronik, Cardiovalve, Edwards Lifesciences, MedAlliance, Medtronic, Novartis, Polares, Sinomed, V-Wave, and Xeltis. He has not received personal payments by pharmaceutical companies or device manufacturers. SW is a member of the steering or executive committee group of several investigator-initiated trials that receive funding by industry without effect on  his personal remuneration. SW is an unpaid member of the Pfizer Research Award selection committee in Switzerland and of the Women as One Awards Committee. SW is a member of the Clinical Study Group of the Deutsches Zentrum fur Herz Kreislauf-Forschung and of the Advisory Board of the Australian Victorian Heart Institute. He is Chairperson of the ESC Congress Program Committee, former Chairperson of the ESC Clinical Practice Guidelines Committee, and Deputy Editor  of the Journal of the American College of Cardiology Cardiovascular Interventions. All other authors declare no competing interests.\n",
      "\n",
      "Declaration of interests The BigData@Heart project has received funding from the  Innovative Medicines Initiative (IMartin Ingvar) 2 Joint Undertaking (grant 116074) which receives support from the Horizon 2020 research and innovation programme of the European Union and the European Federation of Pharmaceutical Industries and Associations. The funders had no role in considering the study design; in the collection, analysis, or interpretation of data; in the writing of the report; or in the decision to submit the Review for publication. Dipak Kotecha reports grants from the  European Union and the European Federation of Pharmaceutical Industries and Associations Innovative Medicines Initiative (116074), the National Institute for Health Research (NIHR CDonna Fitzsimons-2015-08-074 RATE-AF; NIHR130280 DaRe2THINK; and NIHR132974 D2T-NeuroVascular), the British Heart Foundation (PG/17/55/33087, AA/18/2/34218 and FS/CDRF/21/21032), and the ESC. Dipak Kotecha is supported by educational  grants from Boehringer Ingelheim, Bristol Myers Squibb (BMats Sundgren)-Pfizer Alliance, Bayer, Daiichi Sankyo, Boston Scientific, the NIHR and University of Oxford Biomedical Research Centre, the British Heart Foundation and University of Birmingham Accelerator Award (STEEER-AF NCT04396418), Amomed Pharma, Istituto Di  Ricovero e Cura a Carattere Scientifico San Raffaele, and Menarini (NCT0083244).  Dipak Kotecha receives advisory board personal fees from Bayer, Amomed, Protherics Medicines Development, and Myokardia. Folkert W. Asselbergs reports grants from IMartin Ingvar BigData@Heart. Stefan D. Anker reports grants and personal fees from Vifor Pharma, Abbott, and Abbott Vascular;  and personal fees from Bayer, Boehringer Ingelheim, Servier, Cardiac Dimensions,  Actimed, AstraZeneca, Amgen, Bioventrix, Janssen, Respicardia, V-Wave, Brahms, Cordio, and Occlutech. Colin Baigent reports grants from Medical Research Council, Boehringer Ingelheim, and NIHR. Thomas F. Luscherumbers Amitava Banerjee reports grants from AstraZeneca. Birgit Beger reports grants from the European Commission. Gunnar Brobert reports grants from the European Commission (IMartin Ingvar project support) and Bayer. Barbara Casadei reports non-financial support from Roche Diagnostics and iRhythm. Cinzia Ceccarelli reports grants from the European Commission. Martin R. Thomas F. Luscherumbers Cowie reports personal fees from AstraZeneca. Filippo Crea reports personal fees from Amgen,  AstraZeneca, Servier, and BMats Sundgren; and advisory board fees from GlyCardial Diagnostics. Maureen Cronin reports personal fees from Vifor Pharma. Andrea Derix reports salary from Bayer. Martin Fredriksson reports salary from AstraZeneca. Chris P. Gale reports personal fees from AstraZeneca, Amgen, Bayer, Boehringer Ingelheim, Daiichi Sankyo, Vifor Pharma, Menarini, Wondr Medical, Raisio Group, and Oxford University Press; and grants from BMats Sundgren, Abbott, British Heart Foundation, NIHR, and ESC. Martin Ingvar reports grants from World Economic Forum, Swedish Innovation Agency, and the European Commission; and collaboration with Frisq. Susanne Logstrup reports grants from the European Commission. TFL reports grants from Abbott, Amgen, Novartis, Boehringer Ingelheim, Servier, Vifor Pharma, Sanofi, and AstraZeneca; and personal fees from Daichi Sankyo, Pfizer, and Menarini. Lothar Roessig reports salary from Bayer. Carl Steinbeisser reports personal fees from Bayer.  Benoit Tyl reports personal fees from Servier. Ghislaine van Thiel reports grants from IMartin Ingvar. Kees van Bochove reports grants from IMartin Ingvar BigData@Heart. Panos E. Vardas reports personal fees from Hygeia Hospitals Group, Hellenic Healthcare Group, ESC, and Servier. Tiago Villanueva is working as an editor at The BMJ and Acta Medica Portuguesa and is Vice President of the European Union of General Practitioners. Marilena Vrana reports grants from the European Commission. SW reports grants from Abbott, Amgen, AstraZeneca, BMats Sundgren, Bayer, Biotronik, Boston Scientific, Cardinal Health, CardioValve, Carl Steinbeisserusanne Logstrup Behring, Daiichi Sankyo, Edwards Lifesciences,  Guerbet, InfraRedx, Johnson & Johnson, Medicure, Medtronic, Novartis, Polares, OrPha Suisse, Pfizer, Regeneron, Sanofi-Aventis, Sinomed, Terumo, and V-Wave. SW  serves as an unpaid advisory board member or unpaid member of the steering or executive group of trials funded by Abbott, Abiomed, Amgen, AstraZeneca, BMats Sundgren, Boston Scientific, Biotronik, Cardiovalve, Edwards Lifesciences, MedAlliance, Medtronic, Novartis, Polares, Sinomed, V-Wave, and Xeltis. He has not received personal payments by pharmaceutical companies or device manufacturers. SW is a member of the steering or executive committee group of several investigator-initiated trials that receive funding by industry without effect on  his personal remuneration. SW is an unpaid member of the Pfizer Research Award selection committee in Switzerland and of the Women as One Awards Committee. SW is a member of the Clinical Study Group of the Deutsches Zentrum fur Herz Kreislauf-Forschung and of the Advisory Board of the Australian Victorian Heart Institute. He is Chairperson of the ESC Congress Program Committee, former Chairperson of the ESC Clinical Practice Guidelines Committee, and Deputy Editor  of the Journal of the American College of Cardiology Cardiovascular Interventions. All other authors declare no competing interests.\n",
      "\n",
      "Windecker, Stephan\n",
      "Declaration of interests The BigData@Heart project has received funding from the  Innovative Medicines Initiative (IMartin Ingvar) 2 Joint Undertaking (grant 116074) which receives support from the Horizon 2020 research and innovation programme of the European Union and the European Federation of Pharmaceutical Industries and Associations. The funders had no role in considering the study design; in the collection, analysis, or interpretation of data; in the writing of the report; or in the decision to submit the Review for publication. Dipak Kotecha reports grants from the  European Union and the European Federation of Pharmaceutical Industries and Associations Innovative Medicines Initiative (116074), the National Institute for Health Research (NIHR CDonna Fitzsimons-2015-08-074 RATE-AF; NIHR130280 DaRe2THINK; and NIHR132974 D2T-NeuroVascular), the British Heart Foundation (PG/17/55/33087, AA/18/2/34218 and FS/CDRF/21/21032), and the ESC. Dipak Kotecha is supported by educational  grants from Boehringer Ingelheim, Bristol Myers Squibb (BMats Sundgren)-Pfizer Alliance, Bayer, Daiichi Sankyo, Boston Scientific, the NIHR and University of Oxford Biomedical Research Centre, the British Heart Foundation and University of Birmingham Accelerator Award (STEEER-AF NCT04396418), Amomed Pharma, Istituto Di  Ricovero e Cura a Carattere Scientifico San Raffaele, and Menarini (NCT0083244).  Dipak Kotecha receives advisory board personal fees from Bayer, Amomed, Protherics Medicines Development, and Myokardia. Folkert W. Asselbergs reports grants from IMartin Ingvar BigData@Heart. Stefan D. Anker reports grants and personal fees from Vifor Pharma, Abbott, and Abbott Vascular;  and personal fees from Bayer, Boehringer Ingelheim, Servier, Cardiac Dimensions,  Actimed, AstraZeneca, Amgen, Bioventrix, Janssen, Respicardia, V-Wave, Brahms, Cordio, and Occlutech. Colin Baigent reports grants from Medical Research Council, Boehringer Ingelheim, and NIHR. Thomas F. Luscherumbers Amitava Banerjee reports grants from AstraZeneca. Birgit Beger reports grants from the European Commission. Gunnar Brobert reports grants from the European Commission (IMartin Ingvar project support) and Bayer. Barbara Casadei reports non-financial support from Roche Diagnostics and iRhythm. Cinzia Ceccarelli reports grants from the European Commission. Martin R. Thomas F. Luscherumbers Cowie reports personal fees from AstraZeneca. Filippo Crea reports personal fees from Amgen,  AstraZeneca, Servier, and BMats Sundgren; and advisory board fees from GlyCardial Diagnostics. Maureen Cronin reports personal fees from Vifor Pharma. Andrea Derix reports salary from Bayer. Martin Fredriksson reports salary from AstraZeneca. Chris P. Gale reports personal fees from AstraZeneca, Amgen, Bayer, Boehringer Ingelheim, Daiichi Sankyo, Vifor Pharma, Menarini, Wondr Medical, Raisio Group, and Oxford University Press; and grants from BMats Sundgren, Abbott, British Heart Foundation, NIHR, and ESC. Martin Ingvar reports grants from World Economic Forum, Swedish Innovation Agency, and the European Commission; and collaboration with Frisq. Susanne Logstrup reports grants from the European Commission. TFL reports grants from Abbott, Amgen, Novartis, Boehringer Ingelheim, Servier, Vifor Pharma, Sanofi, and AstraZeneca; and personal fees from Daichi Sankyo, Pfizer, and Menarini. Lothar Roessig reports salary from Bayer. Carl Steinbeisser reports personal fees from Bayer.  Benoit Tyl reports personal fees from Servier. Ghislaine van Thiel reports grants from IMartin Ingvar. Kees van Bochove reports grants from IMartin Ingvar BigData@Heart. Panos E. Vardas reports personal fees from Hygeia Hospitals Group, Hellenic Healthcare Group, ESC, and Servier. Tiago Villanueva is working as an editor at The BMJ and Acta Medica Portuguesa and is Vice President of the European Union of General Practitioners. Marilena Vrana reports grants from the European Commission. Stephan Windecker reports grants from Abbott, Amgen, AstraZeneca, BMats Sundgren, Bayer, Biotronik, Boston Scientific, Cardinal Health, CardioValve, Carl Steinbeisserusanne Logstrup Behring, Daiichi Sankyo, Edwards Lifesciences,  Guerbet, InfraRedx, Johnson & Johnson, Medicure, Medtronic, Novartis, Polares, OrPha Suisse, Pfizer, Regeneron, Sanofi-Aventis, Sinomed, Terumo, and V-Wave. Stephan Windecker  serves as an unpaid advisory board member or unpaid member of the steering or executive group of trials funded by Abbott, Abiomed, Amgen, AstraZeneca, BMats Sundgren, Boston Scientific, Biotronik, Cardiovalve, Edwards Lifesciences, MedAlliance, Medtronic, Novartis, Polares, Sinomed, V-Wave, and Xeltis. He has not received personal payments by pharmaceutical companies or device manufacturers. Stephan Windecker is a member of the steering or executive committee group of several investigator-initiated trials that receive funding by industry without effect on  his personal remuneration. Stephan Windecker is an unpaid member of the Pfizer Research Award selection committee in Switzerland and of the Women as One Awards Committee. Stephan Windecker is a member of the Clinical Study Group of the Deutsches Zentrum fur Herz Kreislauf-Forschung and of the Advisory Board of the Australian Victorian Heart Institute. He is Chairperson of the ESC Congress Program Committee, former Chairperson of the ESC Clinical Practice Guidelines Committee, and Deputy Editor  of the Journal of the American College of Cardiology Cardiovascular Interventions. All other authors declare no competing interests.\n",
      "\n",
      "Declaration of interests The BigData@Heart project has received funding from the  Innovative Medicines Initiative (IMartin Ingvar) 2 Joint Undertaking (grant 116074) which receives support from the Horizon 2020 research and innovation programme of the European Union and the European Federation of Pharmaceutical Industries and Associations. The funders had no role in considering the study design; in the collection, analysis, or interpretation of data; in the writing of the report; or in the decision to submit the Review for publication. Dipak Kotecha reports grants from the  European Union and the European Federation of Pharmaceutical Industries and Associations Innovative Medicines Initiative (116074), the National Institute for Health Research (NIHR CDonna Fitzsimons-2015-08-074 RATE-AF; NIHR130280 DaRe2THINK; and NIHR132974 D2T-NeuroVascular), the British Heart Foundation (PG/17/55/33087, AA/18/2/34218 and FS/CDRF/21/21032), and the ESC. Dipak Kotecha is supported by educational  grants from Boehringer Ingelheim, Bristol Myers Squibb (BMats Sundgren)-Pfizer Alliance, Bayer, Daiichi Sankyo, Boston Scientific, the NIHR and University of Oxford Biomedical Research Centre, the British Heart Foundation and University of Birmingham Accelerator Award (STEEER-AF NCT04396418), Amomed Pharma, Istituto Di  Ricovero e Cura a Carattere Scientifico San Raffaele, and Menarini (NCT0083244).  Dipak Kotecha receives advisory board personal fees from Bayer, Amomed, Protherics Medicines Development, and Myokardia. Folkert W. Asselbergs reports grants from IMartin Ingvar BigData@Heart. Stefan D. Anker reports grants and personal fees from Vifor Pharma, Abbott, and Abbott Vascular;  and personal fees from Bayer, Boehringer Ingelheim, Servier, Cardiac Dimensions,  Actimed, AstraZeneca, Amgen, Bioventrix, Janssen, Respicardia, V-Wave, Brahms, Cordio, and Occlutech. Colin Baigent reports grants from Medical Research Council, Boehringer Ingelheim, and NIHR. Thomas F. Luscherumbers Amitava Banerjee reports grants from AstraZeneca. Birgit Beger reports grants from the European Commission. Gunnar Brobert reports grants from the European Commission (IMartin Ingvar project support) and Bayer. Barbara Casadei reports non-financial support from Roche Diagnostics and iRhythm. Cinzia Ceccarelli reports grants from the European Commission. Martin R. Thomas F. Luscherumbers Cowie reports personal fees from AstraZeneca. Filippo Crea reports personal fees from Amgen,  AstraZeneca, Servier, and BMats Sundgren; and advisory board fees from GlyCardial Diagnostics. Maureen Cronin reports personal fees from Vifor Pharma. Andrea Derix reports salary from Bayer. Martin Fredriksson reports salary from AstraZeneca. Chris P. Gale reports personal fees from AstraZeneca, Amgen, Bayer, Boehringer Ingelheim, Daiichi Sankyo, Vifor Pharma, Menarini, Wondr Medical, Raisio Group, and Oxford University Press; and grants from BMats Sundgren, Abbott, British Heart Foundation, NIHR, and ESC. Martin Ingvar reports grants from World Economic Forum, Swedish Innovation Agency, and the European Commission; and collaboration with Frisq. Susanne Logstrup reports grants from the European Commission. TFL reports grants from Abbott, Amgen, Novartis, Boehringer Ingelheim, Servier, Vifor Pharma, Sanofi, and AstraZeneca; and personal fees from Daichi Sankyo, Pfizer, and Menarini. Lothar Roessig reports salary from Bayer. Carl Steinbeisser reports personal fees from Bayer.  Benoit Tyl reports personal fees from Servier. Ghislaine van Thiel reports grants from IMartin Ingvar. Kees van Bochove reports grants from IMartin Ingvar BigData@Heart. Panos E. Vardas reports personal fees from Hygeia Hospitals Group, Hellenic Healthcare Group, ESC, and Servier. Tiago Villanueva is working as an editor at The BMJ and Acta Medica Portuguesa and is Vice President of the European Union of General Practitioners. Marilena Vrana reports grants from the European Commission. Stephan Windecker reports grants from Abbott, Amgen, AstraZeneca, BMats Sundgren, Bayer, Biotronik, Boston Scientific, Cardinal Health, CardioValve, Carl Steinbeisserusanne Logstrup Behring, Daiichi Sankyo, Edwards Lifesciences,  Guerbet, InfraRedx, Johnson & Johnson, Medicure, Medtronic, Novartis, Polares, OrPha Suisse, Pfizer, Regeneron, Sanofi-Aventis, Sinomed, Terumo, and V-Wave. Stephan Windecker  serves as an unpaid advisory board member or unpaid member of the steering or executive group of trials funded by Abbott, Abiomed, Amgen, AstraZeneca, BMats Sundgren, Boston Scientific, Biotronik, Cardiovalve, Edwards Lifesciences, MedAlliance, Medtronic, Novartis, Polares, Sinomed, V-Wave, and Xeltis. He has not received personal payments by pharmaceutical companies or device manufacturers. Stephan Windecker is a member of the steering or executive committee group of several investigator-initiated trials that receive funding by industry without effect on  his personal remuneration. Stephan Windecker is an unpaid member of the Pfizer Research Award selection committee in Switzerland and of the Women as One Awards Committee. Stephan Windecker is a member of the Clinical Study Group of the Deutsches Zentrum fur Herz Kreislauf-Forschung and of the Advisory Board of the Australian Victorian Heart Institute. He is Chairperson of the ESC Congress Program Committee, former Chairperson of the ESC Clinical Practice Guidelines Committee, and Deputy Editor  of the Journal of the American College of Cardiology Cardiovascular Interventions. All other authors declare no competing interests.\n",
      "\n",
      "Declaration of interests The BigData@Heart project has received funding from the  Innovative Medicines Initiative (IMartin Ingvar) 2 Joint Undertaking (grant 116074) which receives support from the Horizon 2020 research and innovation programme of the European Union and the European Federation of Pharmaceutical Industries and Associations. The funders had no role in considering the study design; in the collection, analysis, or interpretation of data; in the writing of the report; or in the decision to submit the Review for publication. Dipak Kotecha reports grants from the  European Union and the European Federation of Pharmaceutical Industries and Associations Innovative Medicines Initiative (116074), the National Institute for Health Research (NIHR CDonna Fitzsimons-2015-08-074 RATE-AF; NIHR130280 DaRe2THINK; and NIHR132974 D2T-NeuroVascular), the British Heart Foundation (PG/17/55/33087, AA/18/2/34218 and FS/CDRF/21/21032), and the ESC. Dipak Kotecha is supported by educational  grants from Boehringer Ingelheim, Bristol Myers Squibb (BMats Sundgren)-Pfizer Alliance, Bayer, Daiichi Sankyo, Boston Scientific, the NIHR and University of Oxford Biomedical Research Centre, the British Heart Foundation and University of Birmingham Accelerator Award (STEEER-AF NCT04396418), Amomed Pharma, Istituto Di  Ricovero e Cura a Carattere Scientifico San Raffaele, and Menarini (NCT0083244).  Dipak Kotecha receives advisory board personal fees from Bayer, Amomed, Protherics Medicines Development, and Myokardia. Folkert W. Asselbergs reports grants from IMartin Ingvar BigData@Heart. Stefan D. Anker reports grants and personal fees from Vifor Pharma, Abbott, and Abbott Vascular;  and personal fees from Bayer, Boehringer Ingelheim, Servier, Cardiac Dimensions,  Actimed, AstraZeneca, Amgen, Bioventrix, Janssen, Respicardia, V-Wave, Brahms, Cordio, and Occlutech. Colin Baigent reports grants from Medical Research Council, Boehringer Ingelheim, and NIHR. Thomas F. Luscherumbers Amitava Banerjee reports grants from AstraZeneca. Birgit Beger reports grants from the European Commission. Gunnar Brobert reports grants from the European Commission (IMartin Ingvar project support) and Bayer. Barbara Casadei reports non-financial support from Roche Diagnostics and iRhythm. Cinzia Ceccarelli reports grants from the European Commission. Martin R. Thomas F. Luscherumbers Cowie reports personal fees from AstraZeneca. Filippo Crea reports personal fees from Amgen,  AstraZeneca, Servier, and BMats Sundgren; and advisory board fees from GlyCardial Diagnostics. Maureen Cronin reports personal fees from Vifor Pharma. Andrea Derix reports salary from Bayer. Martin Fredriksson reports salary from AstraZeneca. Chris P. Gale reports personal fees from AstraZeneca, Amgen, Bayer, Boehringer Ingelheim, Daiichi Sankyo, Vifor Pharma, Menarini, Wondr Medical, Raisio Group, and Oxford University Press; and grants from BMats Sundgren, Abbott, British Heart Foundation, NIHR, and ESC. Martin Ingvar reports grants from World Economic Forum, Swedish Innovation Agency, and the European Commission; and collaboration with Frisq. Susanne Logstrup reports grants from the European Commission. TFL reports grants from Abbott, Amgen, Novartis, Boehringer Ingelheim, Servier, Vifor Pharma, Sanofi, and AstraZeneca; and personal fees from Daichi Sankyo, Pfizer, and Menarini. Lothar Roessig reports salary from Bayer. Carl Steinbeisser reports personal fees from Bayer.  Benoit Tyl reports personal fees from Servier. Ghislaine van Thiel reports grants from IMartin Ingvar. Kees van Bochove reports grants from IMartin Ingvar BigData@Heart. Panos E. Vardas reports personal fees from Hygeia Hospitals Group, Hellenic Healthcare Group, ESC, and Servier. Tiago Villanueva is working as an editor at The BMJ and Acta Medica Portuguesa and is Vice President of the European Union of General Practitioners. Marilena Vrana reports grants from the European Commission. Stephan Windecker reports grants from Abbott, Amgen, AstraZeneca, BMats Sundgren, Bayer, Biotronik, Boston Scientific, Cardinal Health, CardioValve, Carl Steinbeisserusanne Logstrup Behring, Daiichi Sankyo, Edwards Lifesciences,  Guerbet, InfraRedx, Johnson & Johnson, Medicure, Medtronic, Novartis, Polares, OrPha Suisse, Pfizer, Regeneron, Sanofi-Aventis, Sinomed, Terumo, and V-Wave. Stephan Windecker  serves as an unpaid advisory board member or unpaid member of the steering or executive group of trials funded by Abbott, Abiomed, Amgen, AstraZeneca, BMats Sundgren, Boston Scientific, Biotronik, Cardiovalve, Edwards Lifesciences, MedAlliance, Medtronic, Novartis, Polares, Sinomed, V-Wave, and Xeltis. He has not received personal payments by pharmaceutical companies or device manufacturers. Stephan Windecker is a member of the steering or executive committee group of several investigator-initiated trials that receive funding by industry without effect on  his personal remuneration. Stephan Windecker is an unpaid member of the Pfizer Research Award selection committee in Switzerland and of the Women as One Awards Committee. Stephan Windecker is a member of the Clinical Study Group of the Deutsches Zentrum fur Herz Kreislauf-Forschung and of the Advisory Board of the Australian Victorian Heart Institute. He is Chairperson of the ESC Congress Program Committee, former Chairperson of the ESC Clinical Practice Guidelines Committee, and Deputy Editor  of the Journal of the American College of Cardiology Cardiovascular Interventions. All other authors declare no competing interests.\n",
      "\n",
      "Declaration of Competing Interest S.A.G. is an inventor of intellectual property  related to myositis diagnostics and therapeutics, owned and managed by Brigham and Women's Hospital (BWH); he is a founder of Abcuro, Inc. Partners HealthCare,  the owner of BWH, and S.A.G. have financial interests in Abcuro. The financial interests were reviewed and managed in accordance with the conflict-of-interest policies of Partners HealthCare. A.M.P. was supported by the National Center for  Research Resources and the National Center for Advancing Translational Sciences,  National Institutes of Health, through Grant UL1 TR001414. S.A.V. was supported by PHS grants R01NS120060, R21NS114918, and KL2TR001416. T.M. was supported by PHS grants R01AR078340, UL1TR001414 and U24NS107210. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. The rest of the authors report no relevant disclosures.\n",
      "\n",
      "Greenberg, Steven A.\n",
      "Declaration of Competing Interest Steven A. Greenberg is an inventor of intellectual property  related to myositis diagnostics and therapeutics, owned and managed by Brigham and Women's Hospital (BWH); he is a founder of Abcuro, Inc. Partners HealthCare,  the owner of BWH, and Steven A. Greenberg have financial interests in Abcuro. The financial interests were reviewed and managed in accordance with the conflict-of-interest policies of Partners HealthCare. A.M.P. was supported by the National Center for  Research Resources and the National Center for Advancing Translational Sciences,  National Institutes of Health, through Grant UL1 TR001414. S.A.V. was supported by PHS grants R01NS120060, R21NS114918, and KL2TR001416. T.M. was supported by PHS grants R01AR078340, UL1TR001414 and U24NS107210. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. The rest of the authors report no relevant disclosures.\n",
      "\n",
      "Declaration of Competing Interest Steven A. Greenberg is an inventor of intellectual property  related to myositis diagnostics and therapeutics, owned and managed by Brigham and Women's Hospital (BWH); he is a founder of Abcuro, Inc. Partners HealthCare,  the owner of BWH, and Steven A. Greenberg have financial interests in Abcuro. The financial interests were reviewed and managed in accordance with the conflict-of-interest policies of Partners HealthCare. A.M.P. was supported by the National Center for  Research Resources and the National Center for Advancing Translational Sciences,  National Institutes of Health, through Grant UL1 TR001414. S.A.V. was supported by PHS grants R01NS120060, R21NS114918, and KL2TR001416. T.M. was supported by PHS grants R01AR078340, UL1TR001414 and U24NS107210. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. The rest of the authors report no relevant disclosures.\n",
      "\n",
      "Declaration of Competing Interest Steven A. Greenberg is an inventor of intellectual property  related to myositis diagnostics and therapeutics, owned and managed by Brigham and Women's Hospital (BWH); he is a founder of Abcuro, Inc. Partners HealthCare,  the owner of BWH, and Steven A. Greenberg have financial interests in Abcuro. The financial interests were reviewed and managed in accordance with the conflict-of-interest policies of Partners HealthCare. A.M.P. was supported by the National Center for  Research Resources and the National Center for Advancing Translational Sciences,  National Institutes of Health, through Grant UL1 TR001414. S.A.V. was supported by PHS grants R01NS120060, R21NS114918, and KL2TR001416. T.M. was supported by PHS grants R01AR078340, UL1TR001414 and U24NS107210. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. The rest of the authors report no relevant disclosures.\n",
      "\n",
      "Declaration of Competing Interest Steven A. Greenberg is an inventor of intellectual property  related to myositis diagnostics and therapeutics, owned and managed by Brigham and Women's Hospital (BWH); he is a founder of Abcuro, Inc. Partners HealthCare,  the owner of BWH, and Steven A. Greenberg have financial interests in Abcuro. The financial interests were reviewed and managed in accordance with the conflict-of-interest policies of Partners HealthCare. A.M.P. was supported by the National Center for  Research Resources and the National Center for Advancing Translational Sciences,  National Institutes of Health, through Grant UL1 TR001414. S.A.V. was supported by PHS grants R01NS120060, R21NS114918, and KL2TR001416. T.M. was supported by PHS grants R01AR078340, UL1TR001414 and U24NS107210. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. The rest of the authors report no relevant disclosures.\n",
      "\n",
      "Declaration of Competing Interest Steven A. Greenberg is an inventor of intellectual property  related to myositis diagnostics and therapeutics, owned and managed by Brigham and Women's Hospital (BWH); he is a founder of Abcuro, Inc. Partners HealthCare,  the owner of BWH, and Steven A. Greenberg have financial interests in Abcuro. The financial interests were reviewed and managed in accordance with the conflict-of-interest policies of Partners HealthCare. A.M.P. was supported by the National Center for  Research Resources and the National Center for Advancing Translational Sciences,  National Institutes of Health, through Grant UL1 TR001414. S.A.V. was supported by PHS grants R01NS120060, R21NS114918, and KL2TR001416. T.M. was supported by PHS grants R01AR078340, UL1TR001414 and U24NS107210. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. The rest of the authors report no relevant disclosures.\n",
      "\n",
      "Declaration of Competing Interest Steven A. Greenberg is an inventor of intellectual property  related to myositis diagnostics and therapeutics, owned and managed by Brigham and Women's Hospital (BWH); he is a founder of Abcuro, Inc. Partners HealthCare,  the owner of BWH, and Steven A. Greenberg have financial interests in Abcuro. The financial interests were reviewed and managed in accordance with the conflict-of-interest policies of Partners HealthCare. A.M.P. was supported by the National Center for  Research Resources and the National Center for Advancing Translational Sciences,  National Institutes of Health, through Grant UL1 TR001414. S.A.V. was supported by PHS grants R01NS120060, R21NS114918, and KL2TR001416. T.M. was supported by PHS grants R01AR078340, UL1TR001414 and U24NS107210. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. The rest of the authors report no relevant disclosures.\n",
      "\n",
      "Declaration of Competing Interest Steven A. Greenberg is an inventor of intellectual property  related to myositis diagnostics and therapeutics, owned and managed by Brigham and Women's Hospital (BWH); he is a founder of Abcuro, Inc. Partners HealthCare,  the owner of BWH, and Steven A. Greenberg have financial interests in Abcuro. The financial interests were reviewed and managed in accordance with the conflict-of-interest policies of Partners HealthCare. A.M.P. was supported by the National Center for  Research Resources and the National Center for Advancing Translational Sciences,  National Institutes of Health, through Grant UL1 TR001414. S.A.V. was supported by PHS grants R01NS120060, R21NS114918, and KL2TR001416. T.M. was supported by PHS grants R01AR078340, UL1TR001414 and U24NS107210. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. The rest of the authors report no relevant disclosures.\n",
      "\n",
      "Palma, Anton M.\n",
      "Declaration of Competing Interest Steven A. Greenberg is an inventor of intellectual property  related to myositis diagnostics and therapeutics, owned and managed by Brigham and Women's Hospital (BWH); he is a founder of Abcuro, Inc. Partners HealthCare,  the owner of BWH, and Steven A. Greenberg have financial interests in Abcuro. The financial interests were reviewed and managed in accordance with the conflict-of-interest policies of Partners HealthCare. Anton M. Palma was supported by the National Center for  Research Resources and the National Center for Advancing Translational Sciences,  National Institutes of Health, through Grant UL1 TR001414. S.A.V. was supported by PHS grants R01NS120060, R21NS114918, and KL2TR001416. T.M. was supported by PHS grants R01AR078340, UL1TR001414 and U24NS107210. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. The rest of the authors report no relevant disclosures.\n",
      "\n",
      "Armando Villalta, S.\n",
      "Declaration of Competing Interest Steven A. Greenberg is an inventor of intellectual property  related to myositis diagnostics and therapeutics, owned and managed by Brigham and Women's Hospital (BWH); he is a founder of Abcuro, Inc. Partners HealthCare,  the owner of BWH, and Steven A. Greenberg have financial interests in Abcuro. The financial interests were reviewed and managed in accordance with the conflict-of-interest policies of Partners HealthCare. Anton M. Palma was supported by the National Center for  Research Resources and the National Center for Advancing Translational Sciences,  National Institutes of Health, through Grant UL1 TR001414. S. Armando Villalta was supported by PHS grants R01NS120060, R21NS114918, and KL2TR001416. T.M. was supported by PHS grants R01AR078340, UL1TR001414 and U24NS107210. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. The rest of the authors report no relevant disclosures.\n",
      "\n",
      "Mozaffar, Tahseen\n",
      "Declaration of Competing Interest Steven A. Greenberg is an inventor of intellectual property  related to myositis diagnostics and therapeutics, owned and managed by Brigham and Women's Hospital (BWH); he is a founder of Abcuro, Inc. Partners HealthCare,  the owner of BWH, and Steven A. Greenberg have financial interests in Abcuro. The financial interests were reviewed and managed in accordance with the conflict-of-interest policies of Partners HealthCare. Anton M. Palma was supported by the National Center for  Research Resources and the National Center for Advancing Translational Sciences,  National Institutes of Health, through Grant UL1 TR001414. S. Armando Villalta was supported by PHS grants R01NS120060, R21NS114918, and KL2TR001416. Tahseen Mozaffar was supported by PHS grants R01AR078340, UL1TR001414 and U24NS107210. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. The rest of the authors report no relevant disclosures.\n",
      "\n",
      "Declaration of Competing Interest ES received research support from ONK Therapeutics Ltd., of which MOD is chief scientific officer. EOR and SB are current employees of ONK Therapeutics Ltd. DH and NO are current employees of Bio-Techne.\n",
      "\n",
      "O'Reilly, Eimear\n",
      "Declaration of Competing Interest ES received research support from ONK Therapeutics Ltd., of which MOD is chief scientific officer. Eimear O'ReillyR and SB are current employees of ONK Therapeutics Ltd. DH and NO are current employees of Bio-Techne.\n",
      "\n",
      "Declaration of Competing Interest ES received research support from ONK Therapeutics Ltd., of which MOD is chief scientific officer. Eimear O'ReillyR and SB are current employees of ONK Therapeutics Ltd. DH and NO are current employees of Bio-Techne.\n",
      "\n",
      "Brophy, Sarah\n",
      "Declaration of Competing Interest ES received research support from ONK Therapeutics Ltd., of which MOD is chief scientific officer. Eimear O'ReillyR and Sarah Brophy are current employees of ONK Therapeutics Ltd. DH and NO are current employees of Bio-Techne.\n",
      "\n",
      "Declaration of Competing Interest ES received research support from ONK Therapeutics Ltd., of which MOD is chief scientific officer. Eimear O'ReillyR and Sarah Brophy are current employees of ONK Therapeutics Ltd. DH and NO are current employees of Bio-Techne.\n",
      "\n",
      "Otto, Neil M.\n",
      "Declaration of Competing Interest ES received research support from ONK Therapeutics Ltd., of which MOD is chief scientific officer. Eimear O'ReillyR and Sarah Brophy are current employees of ONK Therapeutics Ltd. DH and Neil M. Otto are current employees of Bio-Techne.\n",
      "\n",
      "Hermanson, David L.\n",
      "Declaration of Competing Interest ES received research support from ONK Therapeutics Ltd., of which MOD is chief scientific officer. Eimear O'ReillyR and Sarah Brophy are current employees of ONK Therapeutics Ltd. David L. Hermanson and Neil M. Otto are current employees of Bio-Techne.\n",
      "\n",
      "Declaration of Competing Interest ES received research support from ONK Therapeutics Ltd., of which MOD is chief scientific officer. Eimear O'ReillyR and Sarah Brophy are current employees of ONK Therapeutics Ltd. David L. Hermanson and Neil M. Otto are current employees of Bio-Techne.\n",
      "\n",
      "Szegezdi, Eva\n",
      "Declaration of Competing Interest Eva Szegezdi received research support from ONK Therapeutics Ltd., of which MOD is chief scientific officer. Eimear O'ReillyR and Sarah Brophy are current employees of ONK Therapeutics Ltd. David L. Hermanson and Neil M. Otto are current employees of Bio-Techne.\n",
      "\n",
      "O'Dwyer, Michael E.\n",
      "Declaration of Competing Interest Eva Szegezdi received research support from ONK Therapeutics Ltd., of which Michael E. O'DwyerD is chief scientific officer. Eimear O'ReillyR and Sarah Brophy are current employees of ONK Therapeutics Ltd. David L. Hermanson and Neil M. Otto are current employees of Bio-Techne.\n",
      "\n",
      "Cassinotto, Christophe\n",
      "Declaration of Competing Interest The study was performed without any financial or material support. Christophe Cassinotto has received lecture fees from General Electric Healthcare. V.D.L. has received consultant fees from Echosens (Paris, France) and Supersonic Imagine (Aix-en-Provence, France). The other authors disclose no conflicts of interest.\n",
      "\n",
      "Declaration of Competing Interest The study was performed without any financial or material support. Christophe Cassinotto has received lecture fees from General Electric Healthcare. V.D.L. has received consultant fees from Echosens (Paris, France) and Supersonic Imagine (Aix-en-Provence, France). The other authors disclose no conflicts of interest.\n",
      "\n",
      "Declaration of Competing Interest The study was performed without any financial or material support. Christophe Cassinotto has received lecture fees from General Electric Healthcare. V.D.L. has received consultant fees from Echosens (Paris, France) and Supersonic Imagine (Aix-en-Provence, France). The other authors disclose no conflicts of interest.\n",
      "\n",
      "Declaration of Competing Interest The study was performed without any financial or material support. Christophe Cassinotto has received lecture fees from General Electric Healthcare. V.D.L. has received consultant fees from Echosens (Paris, France) and Supersonic Imagine (Aix-en-Provence, France). The other authors disclose no conflicts of interest.\n",
      "\n",
      "Declaration of Competing Interest The study was performed without any financial or material support. Christophe Cassinotto has received lecture fees from General Electric Healthcare. V.D.L. has received consultant fees from Echosens (Paris, France) and Supersonic Imagine (Aix-en-Provence, France). The other authors disclose no conflicts of interest.\n",
      "\n",
      "Declaration of Competing Interest The study was performed without any financial or material support. Christophe Cassinotto has received lecture fees from General Electric Healthcare. V.D.L. has received consultant fees from Echosens (Paris, France) and Supersonic Imagine (Aix-en-Provence, France). The other authors disclose no conflicts of interest.\n",
      "\n",
      "Declaration of Competing Interest The study was performed without any financial or material support. Christophe Cassinotto has received lecture fees from General Electric Healthcare. V.D.L. has received consultant fees from Echosens (Paris, France) and Supersonic Imagine (Aix-en-Provence, France). The other authors disclose no conflicts of interest.\n",
      "\n",
      "De Ledinghen, Victor\n",
      "Declaration of Competing Interest The study was performed without any financial or material support. Christophe Cassinotto has received lecture fees from General Electric Healthcare. Victor De Ledinghen has received consultant fees from Echosens (Paris, France) and Supersonic Imagine (Aix-en-Provence, France). The other authors disclose no conflicts of interest.\n",
      "\n",
      "Heckman, George A.\n",
      "Funding Support and Author Disclosures Dr George A. Heckman is a Fellow of interRAI, a not-for-profit international scientific organization. Dr Rockwood has asserted copyright of the Clinical Frailty Scale through Dalhousie University's Industry,  Liaison, and Innovation Office. Use is free for education, research, and not-for-profit health care; users agree not to change or commercialize the scale. In addition to academic and hospital appointments, Dr Rockwood is co-founder of Ardea Outcomes, which (as DGI Clinical) in the last 3 years has contracts with pharma and device manufacturers (Danone, Hollister, INmune, Novartis, and Takeda) on individualized outcome measurement; in 2020, he attended an advisory board meeting with Nutricia on dementia and chaired a Scientific Workshop & Technical Review Panel on frailty for the Singapore National Research Foundation; and he is Associate Director of the Canadian Consortium on Neurodegeneration in Aging, itself funded by the Canadian Institutes of Health Research, the Alzheimer Society of Canada, and several other charities.\n",
      "\n",
      "Rockwood, Kenneth\n",
      "Funding Support and Author Disclosures Dr George A. Heckman is a Fellow of interRAI, a not-for-profit international scientific organization. Dr Kenneth Rockwood has asserted copyright of the Clinical Frailty Scale through Dalhousie University's Industry,  Liaison, and Innovation Office. Use is free for education, research, and not-for-profit health care; users agree not to change or commercialize the scale. In addition to academic and hospital appointments, Dr Kenneth Rockwood is co-founder of Ardea Outcomes, which (as DGI Clinical) in the last 3 years has contracts with pharma and device manufacturers (Danone, Hollister, INmune, Novartis, and Takeda) on individualized outcome measurement; in 2020, he attended an advisory board meeting with Nutricia on dementia and chaired a Scientific Workshop & Technical Review Panel on frailty for the Singapore National Research Foundation; and he is Associate Director of the Canadian Consortium on Neurodegeneration in Aging, itself funded by the Canadian Institutes of Health Research, the Alzheimer Society of Canada, and several other charities.\n",
      "\n",
      "Butt, Jawad H.\n",
      "Funding Support and Author Disclosures The PARAGON-HF trial was funded by Novartis. Dr McMurray is supported by British Heart Foundation Centre of Research Excellence Grant RE/18/6/34217. Dr Jawad H. Butt has received advisory board honoraria from Bayer, outside the submitted work. Dr Jhund has received consulting fees from Novo Nordisk AS, Novartis, AstraZeneca, and Boehringer Ingelheim. Dr Anand has received consulting fees from Amgen, ARCA Biopharma, AstraZeneca, Boston Scientific Corporation, Boehringer Ingelheim, LivaNova, Novartis, and Zensun. Dr. Atar has received honoraria from Actelion, AstraZeneca, Bayer-Healthcare, Bristol Myers Squibb/Pfizer, Boehringer Ingelheim, Merck, and Novartis. Dr Desai has received grants and personal fees from AstraZeneca during the conduct of the study; has received personal fees from Abbott, Biofourmis, Boston Scientific, Boehringer Ingelheim, Corvidia, DalCor Pharma, Relypsa, Regeneron, and Merck; has received grants and personal fees from Alnylam and Novartis; and has received personal fees from Amgen, outside the submitted work. Dr Kober has received compensation from Novartis, Novo Nordisk, and AstraZeneca for consulting. Dr Lam  is supported by a Clinician Scientist Award from the National Medical Research Council of Singapore; has received research support from AstraZeneca, Bayer, Boston Scientific, and Roche Diagnostics; has served as a consultant or on the advisory board/steering committee/executive committee for Actelion, Amgen, Applied Therapeutics, AstraZeneca, Bayer, Boehringer Ingelheim, Boston Scientific, Cytokinetics, Darma Inc, Us2.ai, Janssen Research & Development LLC,  Medscape, Merck, Novartis, Novo Nordisk, Radcliffe Group Ltd, Roche Diagnostics,  Sanofi, and WebMD Global LLC; and serves as the cofounder and non-executive director of Us2.ai. Dr Maggioni has received fees for serving on a study committee from Bayer and Fresenius. Dr. Martinez has received personal fees from  Novartis. Dr Packer has received consulting fees from AbbVie, Akcea, Actavis, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Cardiorentis, Daiichi-Sankyo, Gilead, Johnson & Johnson, Novo Nordisk, Pfizer, Relypsa, Sanofi, Synthetic Biologics, and Theravance. Dr Rouleau has received grants and consulting fees from Novartis; and has received consulting fees from Abbott, AstraZeneca, MyoKardia, and Sanofi. Dr Veldhuisen has received fees for serving on a steering  committee and travel support from ARCA biopharma and Corvia Medical. Dr Zannad has received personal fees from Novartis, Janssen, Bayer, Boston Scientific, Amgen, CVRx, Boehringer Ingelheim, Cardiorenal, AstraZeneca, Vifor Fresenius, Cardior, Cereno Pharmaceutical, Applied Therapeutics, Merck, and CardioVascular Clinical Trialists (CVCT). Dr Zile has received research funding from Novartis; and has been a consultant for Novartis, Abbott, Boston Scientific, CVRx, EBR, Endotronics, Ironwood, Merck, Medtronic, and Myokardia V Wave. Dr Gong is an employee of Novartis. Dr Lefkowitz is an employee of Novartis. Dr Rizkala is an employee of and owns stock in Novartis. Dr Solomon has received research grants from Actelion, Alnylam, Amgen, AstraZeneca, Bellerophon, Bayer, Bristol Myers Squibb, Celladon, Cytokinetics, Eidos, Gilead, GlaxoSmithKline, Ionis, Lilly, Mesoblast, MyoKardia, National Institutes of Health/NHLBI, Neurotronik, Novartis, NovoNordisk, Respicardia, Sanofi Pasteur, Theracos, and US2.AI; and has consulted for Abbott, Action, Akros, Alnylam, Amgen, Arena, AstraZeneca, Bayer, Boehringer  Ingelheim, Bristol Myers Squibb, Cardior, Cardurion, Corvia, Cytokinetics, Daiichi-Sankyo, GlaxoSmithKline, Lilly, Merck, Myokardia, Novartis, Roche, Theracos, Quantum Genomics, Cardurion, Janssen, Cardiac Dimensions, Tenaya, Sanofi-Pasteur, Dinaqor, Tremeau, CellPro-Thera, Moderna, American Regent, and Sarepta. Dr McMurray has received payments through Glasgow University from work on clinical trials, consulting and other activities from Alnylam, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Cardurion, Cytokinetics, Dal-Cor, GlaxoSmithKline, Ionis, KBP Biosciences, Novartis, Pfizer, and Theracos; has received personal lecture fees from the Corpus, Abbott, Hikma,  Sun Pharmaceuticals, Medscape/Heart.Org, Radcliffe Cardiology, Servier Director,  and Global Clinical Trial Partners (GCTP). All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.\n",
      "\n",
      "Funding Support and Author Disclosures The PARAGON-HF trial was funded by Novartis. Dr McMurray is supported by British Heart Foundation Centre of Research Excellence Grant RE/18/6/34217. Dr Jawad H. Butt has received advisory board honoraria from Bayer, outside the submitted work. Dr Jhund has received consulting fees from Novo Nordisk AS, Novartis, AstraZeneca, and Boehringer Ingelheim. Dr Anand has received consulting fees from Amgen, ARCA Biopharma, AstraZeneca, Boston Scientific Corporation, Boehringer Ingelheim, LivaNova, Novartis, and Zensun. Dr. Atar has received honoraria from Actelion, AstraZeneca, Bayer-Healthcare, Bristol Myers Squibb/Pfizer, Boehringer Ingelheim, Merck, and Novartis. Dr Desai has received grants and personal fees from AstraZeneca during the conduct of the study; has received personal fees from Abbott, Biofourmis, Boston Scientific, Boehringer Ingelheim, Corvidia, DalCor Pharma, Relypsa, Regeneron, and Merck; has received grants and personal fees from Alnylam and Novartis; and has received personal fees from Amgen, outside the submitted work. Dr Kober has received compensation from Novartis, Novo Nordisk, and AstraZeneca for consulting. Dr Lam  is supported by a Clinician Scientist Award from the National Medical Research Council of Singapore; has received research support from AstraZeneca, Bayer, Boston Scientific, and Roche Diagnostics; has served as a consultant or on the advisory board/steering committee/executive committee for Actelion, Amgen, Applied Therapeutics, AstraZeneca, Bayer, Boehringer Ingelheim, Boston Scientific, Cytokinetics, Darma Inc, Us2.ai, Janssen Research & Development LLC,  Medscape, Merck, Novartis, Novo Nordisk, Radcliffe Group Ltd, Roche Diagnostics,  Sanofi, and WebMD Global LLC; and serves as the cofounder and non-executive director of Us2.ai. Dr Maggioni has received fees for serving on a study committee from Bayer and Fresenius. Dr. Martinez has received personal fees from  Novartis. Dr Packer has received consulting fees from AbbVie, Akcea, Actavis, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Cardiorentis, Daiichi-Sankyo, Gilead, Johnson & Johnson, Novo Nordisk, Pfizer, Relypsa, Sanofi, Synthetic Biologics, and Theravance. Dr Rouleau has received grants and consulting fees from Novartis; and has received consulting fees from Abbott, AstraZeneca, MyoKardia, and Sanofi. Dr Veldhuisen has received fees for serving on a steering  committee and travel support from ARCA biopharma and Corvia Medical. Dr Zannad has received personal fees from Novartis, Janssen, Bayer, Boston Scientific, Amgen, CVRx, Boehringer Ingelheim, Cardiorenal, AstraZeneca, Vifor Fresenius, Cardior, Cereno Pharmaceutical, Applied Therapeutics, Merck, and CardioVascular Clinical Trialists (CVCT). Dr Zile has received research funding from Novartis; and has been a consultant for Novartis, Abbott, Boston Scientific, CVRx, EBR, Endotronics, Ironwood, Merck, Medtronic, and Myokardia V Wave. Dr Gong is an employee of Novartis. Dr Lefkowitz is an employee of Novartis. Dr Rizkala is an employee of and owns stock in Novartis. Dr Solomon has received research grants from Actelion, Alnylam, Amgen, AstraZeneca, Bellerophon, Bayer, Bristol Myers Squibb, Celladon, Cytokinetics, Eidos, Gilead, GlaxoSmithKline, Ionis, Lilly, Mesoblast, MyoKardia, National Institutes of Health/NHLBI, Neurotronik, Novartis, NovoNordisk, Respicardia, Sanofi Pasteur, Theracos, and US2.AI; and has consulted for Abbott, Action, Akros, Alnylam, Amgen, Arena, AstraZeneca, Bayer, Boehringer  Ingelheim, Bristol Myers Squibb, Cardior, Cardurion, Corvia, Cytokinetics, Daiichi-Sankyo, GlaxoSmithKline, Lilly, Merck, Myokardia, Novartis, Roche, Theracos, Quantum Genomics, Cardurion, Janssen, Cardiac Dimensions, Tenaya, Sanofi-Pasteur, Dinaqor, Tremeau, CellPro-Thera, Moderna, American Regent, and Sarepta. Dr McMurray has received payments through Glasgow University from work on clinical trials, consulting and other activities from Alnylam, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Cardurion, Cytokinetics, Dal-Cor, GlaxoSmithKline, Ionis, KBP Biosciences, Novartis, Pfizer, and Theracos; has received personal lecture fees from the Corpus, Abbott, Hikma,  Sun Pharmaceuticals, Medscape/Heart.Org, Radcliffe Cardiology, Servier Director,  and Global Clinical Trial Partners (GCTP). All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.\n",
      "\n",
      "Jhund, Pardeep S.\n",
      "Funding Support and Author Disclosures The PARAGON-HF trial was funded by Novartis. Dr McMurray is supported by British Heart Foundation Centre of Research Excellence Grant RE/18/6/34217. Dr Jawad H. Butt has received advisory board honoraria from Bayer, outside the submitted work. Dr Pardeep S. Jhund has received consulting fees from Novo Nordisk AS, Novartis, AstraZeneca, and Boehringer Ingelheim. Dr Anand has received consulting fees from Amgen, ARCA Biopharma, AstraZeneca, Boston Scientific Corporation, Boehringer Ingelheim, LivaNova, Novartis, and Zensun. Dr. Atar has received honoraria from Actelion, AstraZeneca, Bayer-Healthcare, Bristol Myers Squibb/Pfizer, Boehringer Ingelheim, Merck, and Novartis. Dr Desai has received grants and personal fees from AstraZeneca during the conduct of the study; has received personal fees from Abbott, Biofourmis, Boston Scientific, Boehringer Ingelheim, Corvidia, DalCor Pharma, Relypsa, Regeneron, and Merck; has received grants and personal fees from Alnylam and Novartis; and has received personal fees from Amgen, outside the submitted work. Dr Kober has received compensation from Novartis, Novo Nordisk, and AstraZeneca for consulting. Dr Lam  is supported by a Clinician Scientist Award from the National Medical Research Council of Singapore; has received research support from AstraZeneca, Bayer, Boston Scientific, and Roche Diagnostics; has served as a consultant or on the advisory board/steering committee/executive committee for Actelion, Amgen, Applied Therapeutics, AstraZeneca, Bayer, Boehringer Ingelheim, Boston Scientific, Cytokinetics, Darma Inc, Us2.ai, Janssen Research & Development LLC,  Medscape, Merck, Novartis, Novo Nordisk, Radcliffe Group Ltd, Roche Diagnostics,  Sanofi, and WebMD Global LLC; and serves as the cofounder and non-executive director of Us2.ai. Dr Maggioni has received fees for serving on a study committee from Bayer and Fresenius. Dr. Martinez has received personal fees from  Novartis. Dr Packer has received consulting fees from AbbVie, Akcea, Actavis, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Cardiorentis, Daiichi-Sankyo, Gilead, Johnson & Johnson, Novo Nordisk, Pfizer, Relypsa, Sanofi, Synthetic Biologics, and Theravance. Dr Rouleau has received grants and consulting fees from Novartis; and has received consulting fees from Abbott, AstraZeneca, MyoKardia, and Sanofi. Dr Veldhuisen has received fees for serving on a steering  committee and travel support from ARCA biopharma and Corvia Medical. Dr Zannad has received personal fees from Novartis, Janssen, Bayer, Boston Scientific, Amgen, CVRx, Boehringer Ingelheim, Cardiorenal, AstraZeneca, Vifor Fresenius, Cardior, Cereno Pharmaceutical, Applied Therapeutics, Merck, and CardioVascular Clinical Trialists (CVCT). Dr Zile has received research funding from Novartis; and has been a consultant for Novartis, Abbott, Boston Scientific, CVRx, EBR, Endotronics, Ironwood, Merck, Medtronic, and Myokardia V Wave. Dr Gong is an employee of Novartis. Dr Lefkowitz is an employee of Novartis. Dr Rizkala is an employee of and owns stock in Novartis. Dr Solomon has received research grants from Actelion, Alnylam, Amgen, AstraZeneca, Bellerophon, Bayer, Bristol Myers Squibb, Celladon, Cytokinetics, Eidos, Gilead, GlaxoSmithKline, Ionis, Lilly, Mesoblast, MyoKardia, National Institutes of Health/NHLBI, Neurotronik, Novartis, NovoNordisk, Respicardia, Sanofi Pasteur, Theracos, and US2.AI; and has consulted for Abbott, Action, Akros, Alnylam, Amgen, Arena, AstraZeneca, Bayer, Boehringer  Ingelheim, Bristol Myers Squibb, Cardior, Cardurion, Corvia, Cytokinetics, Daiichi-Sankyo, GlaxoSmithKline, Lilly, Merck, Myokardia, Novartis, Roche, Theracos, Quantum Genomics, Cardurion, Janssen, Cardiac Dimensions, Tenaya, Sanofi-Pasteur, Dinaqor, Tremeau, CellPro-Thera, Moderna, American Regent, and Sarepta. Dr McMurray has received payments through Glasgow University from work on clinical trials, consulting and other activities from Alnylam, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Cardurion, Cytokinetics, Dal-Cor, GlaxoSmithKline, Ionis, KBP Biosciences, Novartis, Pfizer, and Theracos; has received personal lecture fees from the Corpus, Abbott, Hikma,  Sun Pharmaceuticals, Medscape/Heart.Org, Radcliffe Cardiology, Servier Director,  and Global Clinical Trial Partners (GCTP). All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.\n",
      "\n",
      "Anand, Inder S.\n",
      "Funding Support and Author Disclosures The PARAGON-HF trial was funded by Novartis. Dr McMurray is supported by British Heart Foundation Centre of Research Excellence Grant RE/18/6/34217. Dr Jawad H. Butt has received advisory board honoraria from Bayer, outside the submitted work. Dr Pardeep S. Jhund has received consulting fees from Novo Nordisk AS, Novartis, AstraZeneca, and Boehringer Ingelheim. Dr Inder S. Anand has received consulting fees from Amgen, ARCA Biopharma, AstraZeneca, Boston Scientific Corporation, Boehringer Ingelheim, LivaNova, Novartis, and Zensun. Dr. Atar has received honoraria from Actelion, AstraZeneca, Bayer-Healthcare, Bristol Myers Squibb/Pfizer, Boehringer Ingelheim, Merck, and Novartis. Dr Desai has received grants and personal fees from AstraZeneca during the conduct of the study; has received personal fees from Abbott, Biofourmis, Boston Scientific, Boehringer Ingelheim, Corvidia, DalCor Pharma, Relypsa, Regeneron, and Merck; has received grants and personal fees from Alnylam and Novartis; and has received personal fees from Amgen, outside the submitted work. Dr Kober has received compensation from Novartis, Novo Nordisk, and AstraZeneca for consulting. Dr Lam  is supported by a Clinician Scientist Award from the National Medical Research Council of Singapore; has received research support from AstraZeneca, Bayer, Boston Scientific, and Roche Diagnostics; has served as a consultant or on the advisory board/steering committee/executive committee for Actelion, Amgen, Applied Therapeutics, AstraZeneca, Bayer, Boehringer Ingelheim, Boston Scientific, Cytokinetics, Darma Inc, Us2.ai, Janssen Research & Development LLC,  Medscape, Merck, Novartis, Novo Nordisk, Radcliffe Group Ltd, Roche Diagnostics,  Sanofi, and WebMD Global LLC; and serves as the cofounder and non-executive director of Us2.ai. Dr Maggioni has received fees for serving on a study committee from Bayer and Fresenius. Dr. Martinez has received personal fees from  Novartis. Dr Packer has received consulting fees from AbbVie, Akcea, Actavis, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Cardiorentis, Daiichi-Sankyo, Gilead, Johnson & Johnson, Novo Nordisk, Pfizer, Relypsa, Sanofi, Synthetic Biologics, and Theravance. Dr Rouleau has received grants and consulting fees from Novartis; and has received consulting fees from Abbott, AstraZeneca, MyoKardia, and Sanofi. Dr Veldhuisen has received fees for serving on a steering  committee and travel support from ARCA biopharma and Corvia Medical. Dr Zannad has received personal fees from Novartis, Janssen, Bayer, Boston Scientific, Amgen, CVRx, Boehringer Ingelheim, Cardiorenal, AstraZeneca, Vifor Fresenius, Cardior, Cereno Pharmaceutical, Applied Therapeutics, Merck, and CardioVascular Clinical Trialists (CVCT). Dr Zile has received research funding from Novartis; and has been a consultant for Novartis, Abbott, Boston Scientific, CVRx, EBR, Endotronics, Ironwood, Merck, Medtronic, and Myokardia V Wave. Dr Gong is an employee of Novartis. Dr Lefkowitz is an employee of Novartis. Dr Rizkala is an employee of and owns stock in Novartis. Dr Solomon has received research grants from Actelion, Alnylam, Amgen, AstraZeneca, Bellerophon, Bayer, Bristol Myers Squibb, Celladon, Cytokinetics, Eidos, Gilead, GlaxoSmithKline, Ionis, Lilly, Mesoblast, MyoKardia, National Institutes of Health/NHLBI, Neurotronik, Novartis, NovoNordisk, Respicardia, Sanofi Pasteur, Theracos, and US2.AI; and has consulted for Abbott, Action, Akros, Alnylam, Amgen, Arena, AstraZeneca, Bayer, Boehringer  Ingelheim, Bristol Myers Squibb, Cardior, Cardurion, Corvia, Cytokinetics, Daiichi-Sankyo, GlaxoSmithKline, Lilly, Merck, Myokardia, Novartis, Roche, Theracos, Quantum Genomics, Cardurion, Janssen, Cardiac Dimensions, Tenaya, Sanofi-Pasteur, Dinaqor, Tremeau, CellPro-Thera, Moderna, American Regent, and Sarepta. Dr McMurray has received payments through Glasgow University from work on clinical trials, consulting and other activities from Alnylam, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Cardurion, Cytokinetics, Dal-Cor, GlaxoSmithKline, Ionis, KBP Biosciences, Novartis, Pfizer, and Theracos; has received personal lecture fees from the Corpus, Abbott, Hikma,  Sun Pharmaceuticals, Medscape/Heart.Org, Radcliffe Cardiology, Servier Director,  and Global Clinical Trial Partners (GCTP). All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.\n",
      "\n",
      "Atar, Dan\n",
      "Funding Support and Author Disclosures The PARAGON-HF trial was funded by Novartis. Dr McMurray is supported by British Heart Foundation Centre of Research Excellence Grant RE/18/6/34217. Dr Jawad H. Butt has received advisory board honoraria from Bayer, outside the submitted work. Dr Pardeep S. Jhund has received consulting fees from Novo Nordisk AS, Novartis, AstraZeneca, and Boehringer Ingelheim. Dr Inder S. Anand has received consulting fees from Amgen, ARCA Biopharma, AstraZeneca, Boston Scientific Corporation, Boehringer Ingelheim, LivaNova, Novartis, and Zensun. Dr. Dan Atar has received honoraria from Actelion, AstraZeneca, Bayer-Healthcare, Bristol Myers Squibb/Pfizer, Boehringer Ingelheim, Merck, and Novartis. Dr Desai has received grants and personal fees from AstraZeneca during the conduct of the study; has received personal fees from Abbott, Biofourmis, Boston Scientific, Boehringer Ingelheim, Corvidia, DalCor Pharma, Relypsa, Regeneron, and Merck; has received grants and personal fees from Alnylam and Novartis; and has received personal fees from Amgen, outside the submitted work. Dr Kober has received compensation from Novartis, Novo Nordisk, and AstraZeneca for consulting. Dr Lam  is supported by a Clinician Scientist Award from the National Medical Research Council of Singapore; has received research support from AstraZeneca, Bayer, Boston Scientific, and Roche Diagnostics; has served as a consultant or on the advisory board/steering committee/executive committee for Actelion, Amgen, Applied Therapeutics, AstraZeneca, Bayer, Boehringer Ingelheim, Boston Scientific, Cytokinetics, Darma Inc, Us2.ai, Janssen Research & Development LLC,  Medscape, Merck, Novartis, Novo Nordisk, Radcliffe Group Ltd, Roche Diagnostics,  Sanofi, and WebMD Global LLC; and serves as the cofounder and non-executive director of Us2.ai. Dr Maggioni has received fees for serving on a study committee from Bayer and Fresenius. Dr. Martinez has received personal fees from  Novartis. Dr Packer has received consulting fees from AbbVie, Akcea, Actavis, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Cardiorentis, Daiichi-Sankyo, Gilead, Johnson & Johnson, Novo Nordisk, Pfizer, Relypsa, Sanofi, Synthetic Biologics, and Theravance. Dr Rouleau has received grants and consulting fees from Novartis; and has received consulting fees from Abbott, AstraZeneca, MyoKardia, and Sanofi. Dr Veldhuisen has received fees for serving on a steering  committee and travel support from ARCA biopharma and Corvia Medical. Dr Zannad has received personal fees from Novartis, Janssen, Bayer, Boston Scientific, Amgen, CVRx, Boehringer Ingelheim, Cardiorenal, AstraZeneca, Vifor Fresenius, Cardior, Cereno Pharmaceutical, Applied Therapeutics, Merck, and CardioVascular Clinical Trialists (CVCT). Dr Zile has received research funding from Novartis; and has been a consultant for Novartis, Abbott, Boston Scientific, CVRx, EBR, Endotronics, Ironwood, Merck, Medtronic, and Myokardia V Wave. Dr Gong is an employee of Novartis. Dr Lefkowitz is an employee of Novartis. Dr Rizkala is an employee of and owns stock in Novartis. Dr Solomon has received research grants from Actelion, Alnylam, Amgen, AstraZeneca, Bellerophon, Bayer, Bristol Myers Squibb, Celladon, Cytokinetics, Eidos, Gilead, GlaxoSmithKline, Ionis, Lilly, Mesoblast, MyoKardia, National Institutes of Health/NHLBI, Neurotronik, Novartis, NovoNordisk, Respicardia, Sanofi Pasteur, Theracos, and US2.AI; and has consulted for Abbott, Action, Akros, Alnylam, Amgen, Arena, AstraZeneca, Bayer, Boehringer  Ingelheim, Bristol Myers Squibb, Cardior, Cardurion, Corvia, Cytokinetics, Daiichi-Sankyo, GlaxoSmithKline, Lilly, Merck, Myokardia, Novartis, Roche, Theracos, Quantum Genomics, Cardurion, Janssen, Cardiac Dimensions, Tenaya, Sanofi-Pasteur, Dinaqor, Tremeau, CellPro-Thera, Moderna, American Regent, and Sarepta. Dr McMurray has received payments through Glasgow University from work on clinical trials, consulting and other activities from Alnylam, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Cardurion, Cytokinetics, Dal-Cor, GlaxoSmithKline, Ionis, KBP Biosciences, Novartis, Pfizer, and Theracos; has received personal lecture fees from the Corpus, Abbott, Hikma,  Sun Pharmaceuticals, Medscape/Heart.Org, Radcliffe Cardiology, Servier Director,  and Global Clinical Trial Partners (GCTP). All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.\n",
      "\n",
      "Ge, Junbo\n",
      "Funding Support and Author Disclosures The PARAGON-HF trial was funded by Novartis. Dr McMurray is supported by British Heart Foundation Centre of Research Excellence Grant RE/18/6/34217. Dr Jawad H. Butt has received advisory board honoraria from Bayer, outside the submitted work. Dr Pardeep S. Jhund has received consulting fees from Novo Nordisk AS, Novartis, AstraZeneca, and Boehringer Ingelheim. Dr Inder S. Anand has received consulting fees from Amgen, ARCA Biopharma, AstraZeneca, Boston Scientific Corporation, Boehringer Ingelheim, LivaNova, Novartis, and Zensun. Dr. Dan Atar has received honoraria from Actelion, AstraZeneca, Bayer-Healthcare, Bristol Myers Squibb/Pfizer, Boehringer Ingelheim, Merck, and Novartis. Dr Desai has received grants and personal fees from AstraZeneca during the conduct of the study; has received personal fees from Abbott, Biofourmis, Boston Scientific, Boehringer Ingelheim, Corvidia, DalCor Pharma, Relypsa, Regeneron, and Merck; has received grants and personal fees from Alnylam and Novartis; and has received personal fees from Amgen, outside the submitted work. Dr Kober has received compensation from Novartis, Novo Nordisk, and AstraZeneca for consulting. Dr Lam  is supported by a Clinician Scientist Award from the National Medical Research Council of Singapore; has received research support from AstraZeneca, Bayer, Boston Scientific, and Roche Diagnostics; has served as a consultant or on the advisory board/steering committee/executive committee for Actelion, Amgen, Applied Therapeutics, AstraZeneca, Bayer, Boehringer Ingelheim, Boston Scientific, Cytokinetics, Darma Inc, Us2.ai, Janssen Research & Development LLC,  Medscape, Merck, Novartis, Novo Nordisk, Radcliffe Group Ltd, Roche Diagnostics,  Sanofi, and WebMD Global LLC; and serves as the cofounder and non-executive director of Us2.ai. Dr Maggioni has received fees for serving on a study committee from Bayer and Fresenius. Dr. Martinez has received personal fees from  Novartis. Dr Packer has received consulting fees from AbbVie, Akcea, Actavis, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Cardiorentis, Daiichi-Sankyo, Gilead, Johnson & Johnson, Novo Nordisk, Pfizer, Relypsa, Sanofi, Synthetic Biologics, and Theravance. Dr Rouleau has received grants and consulting fees from Novartis; and has received consulting fees from Abbott, AstraZeneca, MyoKardia, and Sanofi. Dr Veldhuisen has received fees for serving on a steering  committee and travel support from ARCA biopharma and Corvia Medical. Dr Zannad has received personal fees from Novartis, Janssen, Bayer, Boston Scientific, Amgen, CVRx, Boehringer Ingelheim, Cardiorenal, AstraZeneca, Vifor Fresenius, Cardior, Cereno Pharmaceutical, Applied Therapeutics, Merck, and CardioVascular Clinical Trialists (CVCT). Dr Zile has received research funding from Novartis; and has been a consultant for Novartis, Abbott, Boston Scientific, CVRx, EBR, Endotronics, Ironwood, Merck, Medtronic, and Myokardia V Wave. Dr Gong is an employee of Novartis. Dr Lefkowitz is an employee of Novartis. Dr Rizkala is an employee of and owns stock in Novartis. Dr Solomon has received research grants from Actelion, Alnylam, Amgen, AstraZeneca, Bellerophon, Bayer, Bristol Myers Squibb, Celladon, Cytokinetics, Eidos, Gilead, GlaxoSmithKline, Ionis, Lilly, Mesoblast, MyoKardia, National Institutes of Health/NHLBI, Neurotronik, Novartis, NovoNordisk, Respicardia, Sanofi Pasteur, Theracos, and US2.AI; and has consulted for Abbott, Action, Akros, Alnylam, Amgen, Arena, AstraZeneca, Bayer, Boehringer  Ingelheim, Bristol Myers Squibb, Cardior, Cardurion, Corvia, Cytokinetics, Daiichi-Sankyo, GlaxoSmithKline, Lilly, Merck, Myokardia, Novartis, Roche, Theracos, Quantum Junbo Genomics, Cardurion, Janssen, Cardiac Dimensions, Tenaya, Sanofi-Pasteur, Dinaqor, Tremeau, CellPro-Thera, Moderna, American Regent, and Sarepta. Dr McMurray has received payments through Glasgow University from work on clinical trials, consulting and other activities from Alnylam, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Cardurion, Cytokinetics, Dal-Cor, GlaxoSmithKline, Ionis, KBP Biosciences, Novartis, Pfizer, and Theracos; has received personal lecture fees from the Corpus, Abbott, Hikma,  Sun Pharmaceuticals, Medscape/Heart.Org, Radcliffe Cardiology, Servier Director,  and Global Clinical Trial Partners (GCTP). All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.\n",
      "\n",
      "Desai, Akshay S.\n",
      "Funding Support and Author Disclosures The PARAGON-HF trial was funded by Novartis. Dr McMurray is supported by British Heart Foundation Centre of Research Excellence Grant RE/18/6/34217. Dr Jawad H. Butt has received advisory board honoraria from Bayer, outside the submitted work. Dr Pardeep S. Jhund has received consulting fees from Novo Nordisk AS, Novartis, AstraZeneca, and Boehringer Ingelheim. Dr Inder S. Anand has received consulting fees from Amgen, ARCA Biopharma, AstraZeneca, Boston Scientific Corporation, Boehringer Ingelheim, LivaNova, Novartis, and Zensun. Dr. Dan Atar has received honoraria from Actelion, AstraZeneca, Bayer-Healthcare, Bristol Myers Squibb/Pfizer, Boehringer Ingelheim, Merck, and Novartis. Dr Akshay S. Desai has received grants and personal fees from AstraZeneca during the conduct of the study; has received personal fees from Abbott, Biofourmis, Boston Scientific, Boehringer Ingelheim, Corvidia, DalCor Pharma, Relypsa, Regeneron, and Merck; has received grants and personal fees from Alnylam and Novartis; and has received personal fees from Amgen, outside the submitted work. Dr Kober has received compensation from Novartis, Novo Nordisk, and AstraZeneca for consulting. Dr Lam  is supported by a Clinician Scientist Award from the National Medical Research Council of Singapore; has received research support from AstraZeneca, Bayer, Boston Scientific, and Roche Diagnostics; has served as a consultant or on the advisory board/steering committee/executive committee for Actelion, Amgen, Applied Therapeutics, AstraZeneca, Bayer, Boehringer Ingelheim, Boston Scientific, Cytokinetics, Darma Inc, Us2.ai, Janssen Research & Development LLC,  Medscape, Merck, Novartis, Novo Nordisk, Radcliffe Group Ltd, Roche Diagnostics,  Sanofi, and WebMD Global LLC; and serves as the cofounder and non-executive director of Us2.ai. Dr Maggioni has received fees for serving on a study committee from Bayer and Fresenius. Dr. Martinez has received personal fees from  Novartis. Dr Packer has received consulting fees from AbbVie, Akcea, Actavis, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Cardiorentis, Daiichi-Sankyo, Gilead, Johnson & Johnson, Novo Nordisk, Pfizer, Relypsa, Sanofi, Synthetic Biologics, and Theravance. Dr Rouleau has received grants and consulting fees from Novartis; and has received consulting fees from Abbott, AstraZeneca, MyoKardia, and Sanofi. Dr Veldhuisen has received fees for serving on a steering  committee and travel support from ARCA biopharma and Corvia Medical. Dr Zannad has received personal fees from Novartis, Janssen, Bayer, Boston Scientific, Amgen, CVRx, Boehringer Ingelheim, Cardiorenal, AstraZeneca, Vifor Fresenius, Cardior, Cereno Pharmaceutical, Applied Therapeutics, Merck, and CardioVascular Clinical Trialists (CVCT). Dr Zile has received research funding from Novartis; and has been a consultant for Novartis, Abbott, Boston Scientific, CVRx, EBR, Endotronics, Ironwood, Merck, Medtronic, and Myokardia V Wave. Dr Gong is an employee of Novartis. Dr Lefkowitz is an employee of Novartis. Dr Rizkala is an employee of and owns stock in Novartis. Dr Solomon has received research grants from Actelion, Alnylam, Amgen, AstraZeneca, Bellerophon, Bayer, Bristol Myers Squibb, Celladon, Cytokinetics, Eidos, Gilead, GlaxoSmithKline, Ionis, Lilly, Mesoblast, MyoKardia, National Institutes of Health/NHLBI, Neurotronik, Novartis, NovoNordisk, Respicardia, Sanofi Pasteur, Theracos, and US2.AI; and has consulted for Abbott, Action, Akros, Alnylam, Amgen, Arena, AstraZeneca, Bayer, Boehringer  Ingelheim, Bristol Myers Squibb, Cardior, Cardurion, Corvia, Cytokinetics, Daiichi-Sankyo, GlaxoSmithKline, Lilly, Merck, Myokardia, Novartis, Roche, Theracos, Quantum Junbo Genomics, Cardurion, Janssen, Cardiac Dimensions, Tenaya, Sanofi-Pasteur, Dinaqor, Tremeau, CellPro-Thera, Moderna, American Regent, and Sarepta. Dr McMurray has received payments through Glasgow University from work on clinical trials, consulting and other activities from Alnylam, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Cardurion, Cytokinetics, Dal-Cor, GlaxoSmithKline, Ionis, KBP Biosciences, Novartis, Pfizer, and Theracos; has received personal lecture fees from the Corpus, Abbott, Hikma,  Sun Pharmaceuticals, Medscape/Heart.Org, Radcliffe Cardiology, Servier Director,  and Global Clinical Trial Partners (GCTP). All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.\n",
      "\n",
      "Funding Support and Author Disclosures The PARAGON-HF trial was funded by Novartis. Dr McMurray is supported by British Heart Foundation Centre of Research Excellence Grant RE/18/6/34217. Dr Jawad H. Butt has received advisory board honoraria from Bayer, outside the submitted work. Dr Pardeep S. Jhund has received consulting fees from Novo Nordisk AS, Novartis, AstraZeneca, and Boehringer Ingelheim. Dr Inder S. Anand has received consulting fees from Amgen, ARCA Biopharma, AstraZeneca, Boston Scientific Corporation, Boehringer Ingelheim, LivaNova, Novartis, and Zensun. Dr. Dan Atar has received honoraria from Actelion, AstraZeneca, Bayer-Healthcare, Bristol Myers Squibb/Pfizer, Boehringer Ingelheim, Merck, and Novartis. Dr Akshay S. Desai has received grants and personal fees from AstraZeneca during the conduct of the study; has received personal fees from Abbott, Biofourmis, Boston Scientific, Boehringer Ingelheim, Corvidia, DalCor Pharma, Relypsa, Regeneron, and Merck; has received grants and personal fees from Alnylam and Novartis; and has received personal fees from Amgen, outside the submitted work. Dr Kober has received compensation from Novartis, Novo Nordisk, and AstraZeneca for consulting. Dr Lam  is supported by a Clinician Scientist Award from the National Medical Research Council of Singapore; has received research support from AstraZeneca, Bayer, Boston Scientific, and Roche Diagnostics; has served as a consultant or on the advisory board/steering committee/executive committee for Actelion, Amgen, Applied Therapeutics, AstraZeneca, Bayer, Boehringer Ingelheim, Boston Scientific, Cytokinetics, Darma Inc, Us2.ai, Janssen Research & Development LLC,  Medscape, Merck, Novartis, Novo Nordisk, Radcliffe Group Ltd, Roche Diagnostics,  Sanofi, and WebMD Global LLC; and serves as the cofounder and non-executive director of Us2.ai. Dr Maggioni has received fees for serving on a study committee from Bayer and Fresenius. Dr. Martinez has received personal fees from  Novartis. Dr Packer has received consulting fees from AbbVie, Akcea, Actavis, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Cardiorentis, Daiichi-Sankyo, Gilead, Johnson & Johnson, Novo Nordisk, Pfizer, Relypsa, Sanofi, Synthetic Biologics, and Theravance. Dr Rouleau has received grants and consulting fees from Novartis; and has received consulting fees from Abbott, AstraZeneca, MyoKardia, and Sanofi. Dr Veldhuisen has received fees for serving on a steering  committee and travel support from ARCA biopharma and Corvia Medical. Dr Zannad has received personal fees from Novartis, Janssen, Bayer, Boston Scientific, Amgen, CVRx, Boehringer Ingelheim, Cardiorenal, AstraZeneca, Vifor Fresenius, Cardior, Cereno Pharmaceutical, Applied Therapeutics, Merck, and CardioVascular Clinical Trialists (CVCT). Dr Zile has received research funding from Novartis; and has been a consultant for Novartis, Abbott, Boston Scientific, CVRx, EBR, Endotronics, Ironwood, Merck, Medtronic, and Myokardia V Wave. Dr Gong is an employee of Novartis. Dr Lefkowitz is an employee of Novartis. Dr Rizkala is an employee of and owns stock in Novartis. Dr Solomon has received research grants from Actelion, Alnylam, Amgen, AstraZeneca, Bellerophon, Bayer, Bristol Myers Squibb, Celladon, Cytokinetics, Eidos, Gilead, GlaxoSmithKline, Ionis, Lilly, Mesoblast, MyoKardia, National Institutes of Health/NHLBI, Neurotronik, Novartis, NovoNordisk, Respicardia, Sanofi Pasteur, Theracos, and US2.AI; and has consulted for Abbott, Action, Akros, Alnylam, Amgen, Arena, AstraZeneca, Bayer, Boehringer  Ingelheim, Bristol Myers Squibb, Cardior, Cardurion, Corvia, Cytokinetics, Daiichi-Sankyo, GlaxoSmithKline, Lilly, Merck, Myokardia, Novartis, Roche, Theracos, Quantum Junbo Genomics, Cardurion, Janssen, Cardiac Dimensions, Tenaya, Sanofi-Pasteur, Dinaqor, Tremeau, CellPro-Thera, Moderna, American Regent, and Sarepta. Dr McMurray has received payments through Glasgow University from work on clinical trials, consulting and other activities from Alnylam, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Cardurion, Cytokinetics, Dal-Cor, GlaxoSmithKline, Ionis, KBP Biosciences, Novartis, Pfizer, and Theracos; has received personal lecture fees from the Corpus, Abbott, Hikma,  Sun Pharmaceuticals, Medscape/Heart.Org, Radcliffe Cardiology, Servier Director,  and Global Clinical Trial Partners (GCTP). All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.\n",
      "\n",
      "Kober, Lars\n",
      "Funding Support and Author Disclosures The PARAGON-HF trial was funded by Novartis. Dr McMurray is supported by British Heart Foundation Centre of Research Excellence Grant RE/18/6/34217. Dr Jawad H. Butt has received advisory board honoraria from Bayer, outside the submitted work. Dr Pardeep S. Jhund has received consulting fees from Novo Nordisk AS, Novartis, AstraZeneca, and Boehringer Ingelheim. Dr Inder S. Anand has received consulting fees from Amgen, ARCA Biopharma, AstraZeneca, Boston Scientific Corporation, Boehringer Ingelheim, LivaNova, Novartis, and Zensun. Dr. Dan Atar has received honoraria from Actelion, AstraZeneca, Bayer-Healthcare, Bristol Myers Squibb/Pfizer, Boehringer Ingelheim, Merck, and Novartis. Dr Akshay S. Desai has received grants and personal fees from AstraZeneca during the conduct of the study; has received personal fees from Abbott, Biofourmis, Boston Scientific, Boehringer Ingelheim, Corvidia, DalCor Pharma, Relypsa, Regeneron, and Merck; has received grants and personal fees from Alnylam and Novartis; and has received personal fees from Amgen, outside the submitted work. Dr Lars Kober has received compensation from Novartis, Novo Nordisk, and AstraZeneca for consulting. Dr Lam  is supported by a Clinician Scientist Award from the National Medical Research Council of Singapore; has received research support from AstraZeneca, Bayer, Boston Scientific, and Roche Diagnostics; has served as a consultant or on the advisory board/steering committee/executive committee for Actelion, Amgen, Applied Therapeutics, AstraZeneca, Bayer, Boehringer Ingelheim, Boston Scientific, Cytokinetics, Darma Inc, Us2.ai, Janssen Research & Development LLC,  Medscape, Merck, Novartis, Novo Nordisk, Radcliffe Group Ltd, Roche Diagnostics,  Sanofi, and WebMD Global LLC; and serves as the cofounder and non-executive director of Us2.ai. Dr Maggioni has received fees for serving on a study committee from Bayer and Fresenius. Dr. Martinez has received personal fees from  Novartis. Dr Packer has received consulting fees from AbbVie, Akcea, Actavis, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Cardiorentis, Daiichi-Sankyo, Gilead, Johnson & Johnson, Novo Nordisk, Pfizer, Relypsa, Sanofi, Synthetic Biologics, and Theravance. Dr Rouleau has received grants and consulting fees from Novartis; and has received consulting fees from Abbott, AstraZeneca, MyoKardia, and Sanofi. Dr Veldhuisen has received fees for serving on a steering  committee and travel support from ARCA biopharma and Corvia Medical. Dr Zannad has received personal fees from Novartis, Janssen, Bayer, Boston Scientific, Amgen, CVRx, Boehringer Ingelheim, Cardiorenal, AstraZeneca, Vifor Fresenius, Cardior, Cereno Pharmaceutical, Applied Therapeutics, Merck, and CardioVascular Clinical Trialists (CVCT). Dr Zile has received research funding from Novartis; and has been a consultant for Novartis, Abbott, Boston Scientific, CVRx, EBR, Endotronics, Ironwood, Merck, Medtronic, and Myokardia V Wave. Dr Gong is an employee of Novartis. Dr Lefkowitz is an employee of Novartis. Dr Rizkala is an employee of and owns stock in Novartis. Dr Solomon has received research grants from Actelion, Alnylam, Amgen, AstraZeneca, Bellerophon, Bayer, Bristol Myers Squibb, Celladon, Cytokinetics, Eidos, Gilead, GlaxoSmithKline, Ionis, Lilly, Mesoblast, MyoKardia, National Institutes of Health/NHLBI, Neurotronik, Novartis, NovoNordisk, Respicardia, Sanofi Pasteur, Theracos, and US2.AI; and has consulted for Abbott, Action, Akros, Alnylam, Amgen, Arena, AstraZeneca, Bayer, Boehringer  Ingelheim, Bristol Myers Squibb, Cardior, Cardurion, Corvia, Cytokinetics, Daiichi-Sankyo, GlaxoSmithKline, Lilly, Merck, Myokardia, Novartis, Roche, Theracos, Quantum Junbo Genomics, Cardurion, Janssen, Cardiac Dimensions, Tenaya, Sanofi-Pasteur, Dinaqor, Tremeau, CellPro-Thera, Moderna, American Regent, and Sarepta. Dr McMurray has received payments through Glasgow University from work on clinical trials, consulting and other activities from Alnylam, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Cardurion, Cytokinetics, Dal-Cor, GlaxoSmithKline, Ionis, KBP Biosciences, Novartis, Pfizer, and Theracos; has received personal lecture fees from the Corpus, Abbott, Hikma,  Sun Pharmaceuticals, Medscape/Heart.Org, Radcliffe Cardiology, Servier Director,  and Global Clinical Trial Partners (GCTP). All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.\n",
      "\n",
      "Lam, Carolyn S.P.\n",
      "Funding Support and Author Disclosures The PARAGON-HF trial was funded by Novartis. Dr McMurray is supported by British Heart Foundation Centre of Research Excellence Grant RE/18/6/34217. Dr Jawad H. Butt has received advisory board honoraria from Bayer, outside the submitted work. Dr Pardeep S. Jhund has received consulting fees from Novo Nordisk AS, Novartis, AstraZeneca, and Boehringer Ingelheim. Dr Inder S. Anand has received consulting fees from Amgen, ARCA Biopharma, AstraZeneca, Boston Scientific Corporation, Boehringer Ingelheim, LivaNova, Novartis, and Zensun. Dr. Dan Atar has received honoraria from Actelion, AstraZeneca, Bayer-Healthcare, Bristol Myers Squibb/Pfizer, Boehringer Ingelheim, Merck, and Novartis. Dr Akshay S. Desai has received grants and personal fees from AstraZeneca during the conduct of the study; has received personal fees from Abbott, Biofourmis, Boston Scientific, Boehringer Ingelheim, Corvidia, DalCor Pharma, Relypsa, Regeneron, and Merck; has received grants and personal fees from Alnylam and Novartis; and has received personal fees from Amgen, outside the submitted work. Dr Lars Kober has received compensation from Novartis, Novo Nordisk, and AstraZeneca for consulting. Dr Carolyn S.P. Lam  is supported by a Clinician Scientist Award from the National Medical Research Council of Singapore; has received research support from AstraZeneca, Bayer, Boston Scientific, and Roche Diagnostics; has served as a consultant or on the advisory board/steering committee/executive committee for Actelion, Amgen, Applied Therapeutics, AstraZeneca, Bayer, Boehringer Ingelheim, Boston Scientific, Cytokinetics, Darma Inc, Us2.ai, Janssen Research & Development LLC,  Medscape, Merck, Novartis, Novo Nordisk, Radcliffe Group Ltd, Roche Diagnostics,  Sanofi, and WebMD Global LLC; and serves as the cofounder and non-executive director of Us2.ai. Dr Maggioni has received fees for serving on a study committee from Bayer and Fresenius. Dr. Martinez has received personal fees from  Novartis. Dr Packer has received consulting fees from AbbVie, Akcea, Actavis, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Cardiorentis, Daiichi-Sankyo, Gilead, Johnson & Johnson, Novo Nordisk, Pfizer, Relypsa, Sanofi, Synthetic Biologics, and Theravance. Dr Rouleau has received grants and consulting fees from Novartis; and has received consulting fees from Abbott, AstraZeneca, MyoKardia, and Sanofi. Dr Veldhuisen has received fees for serving on a steering  committee and travel support from ARCA biopharma and Corvia Medical. Dr Zannad has received personal fees from Novartis, Janssen, Bayer, Boston Scientific, Amgen, CVRx, Boehringer Ingelheim, Cardiorenal, AstraZeneca, Vifor Fresenius, Cardior, Cereno Pharmaceutical, Applied Therapeutics, Merck, and CardioVascular Clinical Trialists (CVCT). Dr Zile has received research funding from Novartis; and has been a consultant for Novartis, Abbott, Boston Scientific, CVRx, EBR, Endotronics, Ironwood, Merck, Medtronic, and Myokardia V Wave. Dr Gong is an employee of Novartis. Dr Lefkowitz is an employee of Novartis. Dr Rizkala is an employee of and owns stock in Novartis. Dr Solomon has received research grants from Actelion, Alnylam, Amgen, AstraZeneca, Bellerophon, Bayer, Bristol Myers Squibb, Celladon, Cytokinetics, Eidos, Gilead, GlaxoSmithKline, Ionis, Lilly, Mesoblast, MyoKardia, National Institutes of Health/NHLBI, Neurotronik, Novartis, NovoNordisk, Respicardia, Sanofi Pasteur, Theracos, and US2.AI; and has consulted for Abbott, Action, Akros, Alnylam, Amgen, Arena, AstraZeneca, Bayer, Boehringer  Ingelheim, Bristol Myers Squibb, Cardior, Cardurion, Corvia, Cytokinetics, Daiichi-Sankyo, GlaxoSmithKline, Lilly, Merck, Myokardia, Novartis, Roche, Theracos, Quantum Junbo Genomics, Cardurion, Janssen, Cardiac Dimensions, Tenaya, Sanofi-Pasteur, Dinaqor, Tremeau, CellPro-Thera, Moderna, American Regent, and Sarepta. Dr McMurray has received payments through Glasgow University from work on clinical trials, consulting and other activities from Alnylam, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Cardurion, Cytokinetics, Dal-Cor, GlaxoSmithKline, Ionis, KBP Biosciences, Novartis, Pfizer, and Theracos; has received personal lecture fees from the Corpus, Abbott, Hikma,  Sun Pharmaceuticals, Medscape/Heart.Org, Radcliffe Cardiology, Servier Director,  and Global Clinical Trial Partners (GCTP). All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.\n",
      "\n",
      "Maggioni, Aldo P.\n",
      "Funding Support and Author Disclosures The PARAGON-HF trial was funded by Novartis. Dr McMurray is supported by British Heart Foundation Centre of Research Excellence Grant RE/18/6/34217. Dr Jawad H. Butt has received advisory board honoraria from Bayer, outside the submitted work. Dr Pardeep S. Jhund has received consulting fees from Novo Nordisk AS, Novartis, AstraZeneca, and Boehringer Ingelheim. Dr Inder S. Anand has received consulting fees from Amgen, ARCA Biopharma, AstraZeneca, Boston Scientific Corporation, Boehringer Ingelheim, LivaNova, Novartis, and Zensun. Dr. Dan Atar has received honoraria from Actelion, AstraZeneca, Bayer-Healthcare, Bristol Myers Squibb/Pfizer, Boehringer Ingelheim, Merck, and Novartis. Dr Akshay S. Desai has received grants and personal fees from AstraZeneca during the conduct of the study; has received personal fees from Abbott, Biofourmis, Boston Scientific, Boehringer Ingelheim, Corvidia, DalCor Pharma, Relypsa, Regeneron, and Merck; has received grants and personal fees from Alnylam and Novartis; and has received personal fees from Amgen, outside the submitted work. Dr Lars Kober has received compensation from Novartis, Novo Nordisk, and AstraZeneca for consulting. Dr Carolyn S.P. Lam  is supported by a Clinician Scientist Award from the National Medical Research Council of Singapore; has received research support from AstraZeneca, Bayer, Boston Scientific, and Roche Diagnostics; has served as a consultant or on the advisory board/steering committee/executive committee for Actelion, Amgen, Applied Therapeutics, AstraZeneca, Bayer, Boehringer Ingelheim, Boston Scientific, Cytokinetics, Darma Inc, Us2.ai, Janssen Research & Development LLC,  Medscape, Merck, Novartis, Novo Nordisk, Radcliffe Group Ltd, Roche Diagnostics,  Sanofi, and WebMD Global LLC; and serves as the cofounder and non-executive director of Us2.ai. Dr Aldo P. Maggioni has received fees for serving on a study committee from Bayer and Fresenius. Dr. Martinez has received personal fees from  Novartis. Dr Packer has received consulting fees from AbbVie, Akcea, Actavis, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Cardiorentis, Daiichi-Sankyo, Gilead, Johnson & Johnson, Novo Nordisk, Pfizer, Relypsa, Sanofi, Synthetic Biologics, and Theravance. Dr Rouleau has received grants and consulting fees from Novartis; and has received consulting fees from Abbott, AstraZeneca, MyoKardia, and Sanofi. Dr Veldhuisen has received fees for serving on a steering  committee and travel support from ARCA biopharma and Corvia Medical. Dr Zannad has received personal fees from Novartis, Janssen, Bayer, Boston Scientific, Amgen, CVRx, Boehringer Ingelheim, Cardiorenal, AstraZeneca, Vifor Fresenius, Cardior, Cereno Pharmaceutical, Applied Therapeutics, Merck, and CardioVascular Clinical Trialists (CVCT). Dr Zile has received research funding from Novartis; and has been a consultant for Novartis, Abbott, Boston Scientific, CVRx, EBR, Endotronics, Ironwood, Merck, Medtronic, and Myokardia V Wave. Dr Gong is an employee of Novartis. Dr Lefkowitz is an employee of Novartis. Dr Rizkala is an employee of and owns stock in Novartis. Dr Solomon has received research grants from Actelion, Alnylam, Amgen, AstraZeneca, Bellerophon, Bayer, Bristol Myers Squibb, Celladon, Cytokinetics, Eidos, Gilead, GlaxoSmithKline, Ionis, Lilly, Mesoblast, MyoKardia, National Institutes of Health/NHLBI, Neurotronik, Novartis, NovoNordisk, Respicardia, Sanofi Pasteur, Theracos, and US2.AI; and has consulted for Abbott, Action, Akros, Alnylam, Amgen, Arena, AstraZeneca, Bayer, Boehringer  Ingelheim, Bristol Myers Squibb, Cardior, Cardurion, Corvia, Cytokinetics, Daiichi-Sankyo, GlaxoSmithKline, Lilly, Merck, Myokardia, Novartis, Roche, Theracos, Quantum Junbo Genomics, Cardurion, Janssen, Cardiac Dimensions, Tenaya, Sanofi-Pasteur, Dinaqor, Tremeau, CellPro-Thera, Moderna, American Regent, and Sarepta. Dr McMurray has received payments through Glasgow University from work on clinical trials, consulting and other activities from Alnylam, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Cardurion, Cytokinetics, Dal-Cor, GlaxoSmithKline, Ionis, KBP Biosciences, Novartis, Pfizer, and Theracos; has received personal lecture fees from the Corpus, Abbott, Hikma,  Sun Pharmaceuticals, Medscape/Heart.Org, Radcliffe Cardiology, Servier Director,  and Global Clinical Trial Partners (GCTP). All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.\n",
      "\n",
      "Martinez, Felipe\n",
      "Funding Support and Author Disclosures The PARAGON-HF trial was funded by Novartis. Dr McMurray is supported by British Heart Foundation Centre of Research Excellence Grant RE/18/6/34217. Dr Jawad H. Butt has received advisory board honoraria from Bayer, outside the submitted work. Dr Pardeep S. Jhund has received consulting fees from Novo Nordisk AS, Novartis, AstraZeneca, and Boehringer Ingelheim. Dr Inder S. Anand has received consulting fees from Amgen, ARCA Biopharma, AstraZeneca, Boston Scientific Corporation, Boehringer Ingelheim, LivaNova, Novartis, and Zensun. Dr. Dan Atar has received honoraria from Actelion, AstraZeneca, Bayer-Healthcare, Bristol Myers Squibb/Pfizer, Boehringer Ingelheim, Merck, and Novartis. Dr Akshay S. Desai has received grants and personal fees from AstraZeneca during the conduct of the study; has received personal fees from Abbott, Biofourmis, Boston Scientific, Boehringer Ingelheim, Corvidia, DalCor Pharma, Relypsa, Regeneron, and Merck; has received grants and personal fees from Alnylam and Novartis; and has received personal fees from Amgen, outside the submitted work. Dr Lars Kober has received compensation from Novartis, Novo Nordisk, and AstraZeneca for consulting. Dr Carolyn S.P. Lam  is supported by a Clinician Scientist Award from the National Medical Research Council of Singapore; has received research support from AstraZeneca, Bayer, Boston Scientific, and Roche Diagnostics; has served as a consultant or on the advisory board/steering committee/executive committee for Actelion, Amgen, Applied Therapeutics, AstraZeneca, Bayer, Boehringer Ingelheim, Boston Scientific, Cytokinetics, Darma Inc, Us2.ai, Janssen Research & Development LLC,  Medscape, Merck, Novartis, Novo Nordisk, Radcliffe Group Ltd, Roche Diagnostics,  Sanofi, and WebMD Global LLC; and serves as the cofounder and non-executive director of Us2.ai. Dr Aldo P. Maggioni has received fees for serving on a study committee from Bayer and Fresenius. Dr. Felipe Martinez has received personal fees from  Novartis. Dr Packer has received consulting fees from AbbVie, Akcea, Actavis, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Cardiorentis, Daiichi-Sankyo, Gilead, Johnson & Johnson, Novo Nordisk, Pfizer, Relypsa, Sanofi, Synthetic Biologics, and Theravance. Dr Rouleau has received grants and consulting fees from Novartis; and has received consulting fees from Abbott, AstraZeneca, MyoKardia, and Sanofi. Dr Veldhuisen has received fees for serving on a steering  committee and travel support from ARCA biopharma and Corvia Medical. Dr Zannad has received personal fees from Novartis, Janssen, Bayer, Boston Scientific, Amgen, CVRx, Boehringer Ingelheim, Cardiorenal, AstraZeneca, Vifor Fresenius, Cardior, Cereno Pharmaceutical, Applied Therapeutics, Merck, and CardioVascular Clinical Trialists (CVCT). Dr Zile has received research funding from Novartis; and has been a consultant for Novartis, Abbott, Boston Scientific, CVRx, EBR, Endotronics, Ironwood, Merck, Medtronic, and Myokardia V Wave. Dr Gong is an employee of Novartis. Dr Lefkowitz is an employee of Novartis. Dr Rizkala is an employee of and owns stock in Novartis. Dr Solomon has received research grants from Actelion, Alnylam, Amgen, AstraZeneca, Bellerophon, Bayer, Bristol Myers Squibb, Celladon, Cytokinetics, Eidos, Gilead, GlaxoSmithKline, Ionis, Lilly, Mesoblast, MyoKardia, National Institutes of Health/NHLBI, Neurotronik, Novartis, NovoNordisk, Respicardia, Sanofi Pasteur, Theracos, and US2.AI; and has consulted for Abbott, Action, Akros, Alnylam, Amgen, Arena, AstraZeneca, Bayer, Boehringer  Ingelheim, Bristol Myers Squibb, Cardior, Cardurion, Corvia, Cytokinetics, Daiichi-Sankyo, GlaxoSmithKline, Lilly, Merck, Myokardia, Novartis, Roche, Theracos, Quantum Junbo Genomics, Cardurion, Janssen, Cardiac Dimensions, Tenaya, Sanofi-Pasteur, Dinaqor, Tremeau, CellPro-Thera, Moderna, American Regent, and Sarepta. Dr McMurray has received payments through Glasgow University from work on clinical trials, consulting and other activities from Alnylam, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Cardurion, Cytokinetics, Dal-Cor, GlaxoSmithKline, Ionis, KBP Biosciences, Novartis, Pfizer, and Theracos; has received personal lecture fees from the Corpus, Abbott, Hikma,  Sun Pharmaceuticals, Medscape/Heart.Org, Radcliffe Cardiology, Servier Director,  and Global Clinical Trial Partners (GCTP). All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.\n",
      "\n",
      "Packer, Milton\n",
      "Funding Support and Author Disclosures The PARAGON-HF trial was funded by Novartis. Dr McMurray is supported by British Heart Foundation Centre of Research Excellence Grant RE/18/6/34217. Dr Jawad H. Butt has received advisory board honoraria from Bayer, outside the submitted work. Dr Pardeep S. Jhund has received consulting fees from Novo Nordisk AS, Novartis, AstraZeneca, and Boehringer Ingelheim. Dr Inder S. Anand has received consulting fees from Amgen, ARCA Biopharma, AstraZeneca, Boston Scientific Corporation, Boehringer Ingelheim, LivaNova, Novartis, and Zensun. Dr. Dan Atar has received honoraria from Actelion, AstraZeneca, Bayer-Healthcare, Bristol Myers Squibb/Pfizer, Boehringer Ingelheim, Merck, and Novartis. Dr Akshay S. Desai has received grants and personal fees from AstraZeneca during the conduct of the study; has received personal fees from Abbott, Biofourmis, Boston Scientific, Boehringer Ingelheim, Corvidia, DalCor Pharma, Relypsa, Regeneron, and Merck; has received grants and personal fees from Alnylam and Novartis; and has received personal fees from Amgen, outside the submitted work. Dr Lars Kober has received compensation from Novartis, Novo Nordisk, and AstraZeneca for consulting. Dr Carolyn S.P. Lam  is supported by a Clinician Scientist Award from the National Medical Research Council of Singapore; has received research support from AstraZeneca, Bayer, Boston Scientific, and Roche Diagnostics; has served as a consultant or on the advisory board/steering committee/executive committee for Actelion, Amgen, Applied Therapeutics, AstraZeneca, Bayer, Boehringer Ingelheim, Boston Scientific, Cytokinetics, Darma Inc, Us2.ai, Janssen Research & Development LLC,  Medscape, Merck, Novartis, Novo Nordisk, Radcliffe Group Ltd, Roche Diagnostics,  Sanofi, and WebMD Global LLC; and serves as the cofounder and non-executive director of Us2.ai. Dr Aldo P. Maggioni has received fees for serving on a study committee from Bayer and Fresenius. Dr. Felipe Martinez has received personal fees from  Novartis. Dr Milton Packer has received consulting fees from AbbVie, Akcea, Actavis, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Cardiorentis, Daiichi-Sankyo, Gilead, Johnson & Johnson, Novo Nordisk, Pfizer, Relypsa, Sanofi, Synthetic Biologics, and Theravance. Dr Rouleau has received grants and consulting fees from Novartis; and has received consulting fees from Abbott, AstraZeneca, MyoKardia, and Sanofi. Dr Veldhuisen has received fees for serving on a steering  committee and travel support from ARCA biopharma and Corvia Medical. Dr Zannad has received personal fees from Novartis, Janssen, Bayer, Boston Scientific, Amgen, CVRx, Boehringer Ingelheim, Cardiorenal, AstraZeneca, Vifor Fresenius, Cardior, Cereno Pharmaceutical, Applied Therapeutics, Merck, and CardioVascular Clinical Trialists (CVCT). Dr Zile has received research funding from Novartis; and has been a consultant for Novartis, Abbott, Boston Scientific, CVRx, EBR, Endotronics, Ironwood, Merck, Medtronic, and Myokardia V Wave. Dr Gong is an employee of Novartis. Dr Lefkowitz is an employee of Novartis. Dr Rizkala is an employee of and owns stock in Novartis. Dr Solomon has received research grants from Actelion, Alnylam, Amgen, AstraZeneca, Bellerophon, Bayer, Bristol Myers Squibb, Celladon, Cytokinetics, Eidos, Gilead, GlaxoSmithKline, Ionis, Lilly, Mesoblast, MyoKardia, National Institutes of Health/NHLBI, Neurotronik, Novartis, NovoNordisk, Respicardia, Sanofi Pasteur, Theracos, and US2.AI; and has consulted for Abbott, Action, Akros, Alnylam, Amgen, Arena, AstraZeneca, Bayer, Boehringer  Ingelheim, Bristol Myers Squibb, Cardior, Cardurion, Corvia, Cytokinetics, Daiichi-Sankyo, GlaxoSmithKline, Lilly, Merck, Myokardia, Novartis, Roche, Theracos, Quantum Junbo Genomics, Cardurion, Janssen, Cardiac Dimensions, Tenaya, Sanofi-Pasteur, Dinaqor, Tremeau, CellPro-Thera, Moderna, American Regent, and Sarepta. Dr McMurray has received payments through Glasgow University from work on clinical trials, consulting and other activities from Alnylam, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Cardurion, Cytokinetics, Dal-Cor, GlaxoSmithKline, Ionis, KBP Biosciences, Novartis, Pfizer, and Theracos; has received personal lecture fees from the Corpus, Abbott, Hikma,  Sun Pharmaceuticals, Medscape/Heart.Org, Radcliffe Cardiology, Servier Director,  and Global Clinical Trial Partners (GCTP). All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.\n",
      "\n",
      "Rouleau, Jean L.\n",
      "Funding Support and Author Disclosures The PARAGON-HF trial was funded by Novartis. Dr McMurray is supported by British Heart Foundation Centre of Research Excellence Grant RE/18/6/34217. Dr Jawad H. Butt has received advisory board honoraria from Bayer, outside the submitted work. Dr Pardeep S. Jhund has received consulting fees from Novo Nordisk AS, Novartis, AstraZeneca, and Boehringer Ingelheim. Dr Inder S. Anand has received consulting fees from Amgen, ARCA Biopharma, AstraZeneca, Boston Scientific Corporation, Boehringer Ingelheim, LivaNova, Novartis, and Zensun. Dr. Dan Atar has received honoraria from Actelion, AstraZeneca, Bayer-Healthcare, Bristol Myers Squibb/Pfizer, Boehringer Ingelheim, Merck, and Novartis. Dr Akshay S. Desai has received grants and personal fees from AstraZeneca during the conduct of the study; has received personal fees from Abbott, Biofourmis, Boston Scientific, Boehringer Ingelheim, Corvidia, DalCor Pharma, Relypsa, Regeneron, and Merck; has received grants and personal fees from Alnylam and Novartis; and has received personal fees from Amgen, outside the submitted work. Dr Lars Kober has received compensation from Novartis, Novo Nordisk, and AstraZeneca for consulting. Dr Carolyn S.P. Lam  is supported by a Clinician Scientist Award from the National Medical Research Council of Singapore; has received research support from AstraZeneca, Bayer, Boston Scientific, and Roche Diagnostics; has served as a consultant or on the advisory board/steering committee/executive committee for Actelion, Amgen, Applied Therapeutics, AstraZeneca, Bayer, Boehringer Ingelheim, Boston Scientific, Cytokinetics, Darma Inc, Us2.ai, Janssen Research & Development LLC,  Medscape, Merck, Novartis, Novo Nordisk, Radcliffe Group Ltd, Roche Diagnostics,  Sanofi, and WebMD Global LLC; and serves as the cofounder and non-executive director of Us2.ai. Dr Aldo P. Maggioni has received fees for serving on a study committee from Bayer and Fresenius. Dr. Felipe Martinez has received personal fees from  Novartis. Dr Milton Packer has received consulting fees from AbbVie, Akcea, Actavis, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Cardiorentis, Daiichi-Sankyo, Gilead, Johnson & Johnson, Novo Nordisk, Pfizer, Relypsa, Sanofi, Synthetic Biologics, and Theravance. Dr Jean L. Rouleau has received grants and consulting fees from Novartis; and has received consulting fees from Abbott, AstraZeneca, MyoKardia, and Sanofi. Dr Veldhuisen has received fees for serving on a steering  committee and travel support from ARCA biopharma and Corvia Medical. Dr Zannad has received personal fees from Novartis, Janssen, Bayer, Boston Scientific, Amgen, CVRx, Boehringer Ingelheim, Cardiorenal, AstraZeneca, Vifor Fresenius, Cardior, Cereno Pharmaceutical, Applied Therapeutics, Merck, and CardioVascular Clinical Trialists (CVCT). Dr Zile has received research funding from Novartis; and has been a consultant for Novartis, Abbott, Boston Scientific, CVRx, EBR, Endotronics, Ironwood, Merck, Medtronic, and Myokardia V Wave. Dr Gong is an employee of Novartis. Dr Lefkowitz is an employee of Novartis. Dr Rizkala is an employee of and owns stock in Novartis. Dr Solomon has received research grants from Actelion, Alnylam, Amgen, AstraZeneca, Bellerophon, Bayer, Bristol Myers Squibb, Celladon, Cytokinetics, Eidos, Gilead, GlaxoSmithKline, Ionis, Lilly, Mesoblast, MyoKardia, National Institutes of Health/NHLBI, Neurotronik, Novartis, NovoNordisk, Respicardia, Sanofi Pasteur, Theracos, and US2.AI; and has consulted for Abbott, Action, Akros, Alnylam, Amgen, Arena, AstraZeneca, Bayer, Boehringer  Ingelheim, Bristol Myers Squibb, Cardior, Cardurion, Corvia, Cytokinetics, Daiichi-Sankyo, GlaxoSmithKline, Lilly, Merck, Myokardia, Novartis, Roche, Theracos, Quantum Junbo Genomics, Cardurion, Janssen, Cardiac Dimensions, Tenaya, Sanofi-Pasteur, Dinaqor, Tremeau, CellPro-Thera, Moderna, American Regent, and Sarepta. Dr McMurray has received payments through Glasgow University from work on clinical trials, consulting and other activities from Alnylam, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Cardurion, Cytokinetics, Dal-Cor, GlaxoSmithKline, Ionis, KBP Biosciences, Novartis, Pfizer, and Theracos; has received personal lecture fees from the Corpus, Abbott, Hikma,  Sun Pharmaceuticals, Medscape/Heart.Org, Radcliffe Cardiology, Servier Director,  and Global Clinical Trial Partners (GCTP). All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.\n",
      "\n",
      "Funding Support and Author Disclosures The PARAGON-HF trial was funded by Novartis. Dr McMurray is supported by British Heart Foundation Centre of Research Excellence Grant RE/18/6/34217. Dr Jawad H. Butt has received advisory board honoraria from Bayer, outside the submitted work. Dr Pardeep S. Jhund has received consulting fees from Novo Nordisk AS, Novartis, AstraZeneca, and Boehringer Ingelheim. Dr Inder S. Anand has received consulting fees from Amgen, ARCA Biopharma, AstraZeneca, Boston Scientific Corporation, Boehringer Ingelheim, LivaNova, Novartis, and Zensun. Dr. Dan Atar has received honoraria from Actelion, AstraZeneca, Bayer-Healthcare, Bristol Myers Squibb/Pfizer, Boehringer Ingelheim, Merck, and Novartis. Dr Akshay S. Desai has received grants and personal fees from AstraZeneca during the conduct of the study; has received personal fees from Abbott, Biofourmis, Boston Scientific, Boehringer Ingelheim, Corvidia, DalCor Pharma, Relypsa, Regeneron, and Merck; has received grants and personal fees from Alnylam and Novartis; and has received personal fees from Amgen, outside the submitted work. Dr Lars Kober has received compensation from Novartis, Novo Nordisk, and AstraZeneca for consulting. Dr Carolyn S.P. Lam  is supported by a Clinician Scientist Award from the National Medical Research Council of Singapore; has received research support from AstraZeneca, Bayer, Boston Scientific, and Roche Diagnostics; has served as a consultant or on the advisory board/steering committee/executive committee for Actelion, Amgen, Applied Therapeutics, AstraZeneca, Bayer, Boehringer Ingelheim, Boston Scientific, Cytokinetics, Darma Inc, Us2.ai, Janssen Research & Development LLC,  Medscape, Merck, Novartis, Novo Nordisk, Radcliffe Group Ltd, Roche Diagnostics,  Sanofi, and WebMD Global LLC; and serves as the cofounder and non-executive director of Us2.ai. Dr Aldo P. Maggioni has received fees for serving on a study committee from Bayer and Fresenius. Dr. Felipe Martinez has received personal fees from  Novartis. Dr Milton Packer has received consulting fees from AbbVie, Akcea, Actavis, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Cardiorentis, Daiichi-Sankyo, Gilead, Johnson & Johnson, Novo Nordisk, Pfizer, Relypsa, Sanofi, Synthetic Biologics, and Theravance. Dr Jean L. Rouleau has received grants and consulting fees from Novartis; and has received consulting fees from Abbott, AstraZeneca, MyoKardia, and Sanofi. Dr Veldhuisen has received fees for serving on a steering  committee and travel support from ARCA biopharma and Corvia Medical. Dr Zannad has received personal fees from Novartis, Janssen, Bayer, Boston Scientific, Amgen, CVRx, Boehringer Ingelheim, Cardiorenal, AstraZeneca, Vifor Fresenius, Cardior, Cereno Pharmaceutical, Applied Therapeutics, Merck, and CardioVascular Clinical Trialists (CVCT). Dr Zile has received research funding from Novartis; and has been a consultant for Novartis, Abbott, Boston Scientific, CVRx, EBR, Endotronics, Ironwood, Merck, Medtronic, and Myokardia V Wave. Dr Gong is an employee of Novartis. Dr Lefkowitz is an employee of Novartis. Dr Rizkala is an employee of and owns stock in Novartis. Dr Solomon has received research grants from Actelion, Alnylam, Amgen, AstraZeneca, Bellerophon, Bayer, Bristol Myers Squibb, Celladon, Cytokinetics, Eidos, Gilead, GlaxoSmithKline, Ionis, Lilly, Mesoblast, MyoKardia, National Institutes of Health/NHLBI, Neurotronik, Novartis, NovoNordisk, Respicardia, Sanofi Pasteur, Theracos, and US2.AI; and has consulted for Abbott, Action, Akros, Alnylam, Amgen, Arena, AstraZeneca, Bayer, Boehringer  Ingelheim, Bristol Myers Squibb, Cardior, Cardurion, Corvia, Cytokinetics, Daiichi-Sankyo, GlaxoSmithKline, Lilly, Merck, Myokardia, Novartis, Roche, Theracos, Quantum Junbo Genomics, Cardurion, Janssen, Cardiac Dimensions, Tenaya, Sanofi-Pasteur, Dinaqor, Tremeau, CellPro-Thera, Moderna, American Regent, and Sarepta. Dr McMurray has received payments through Glasgow University from work on clinical trials, consulting and other activities from Alnylam, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Cardurion, Cytokinetics, Dal-Cor, GlaxoSmithKline, Ionis, KBP Biosciences, Novartis, Pfizer, and Theracos; has received personal lecture fees from the Corpus, Abbott, Hikma,  Sun Pharmaceuticals, Medscape/Heart.Org, Radcliffe Cardiology, Servier Director,  and Global Clinical Trial Partners (GCTP). All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.\n",
      "\n",
      "J Van Veldhuisen, Dirk\n",
      "Funding Support and Author Disclosures The PARAGON-HF trial was funded by Novartis. Dr McMurray is supported by British Heart Foundation Centre of Research Excellence Grant RE/18/6/34217. Dr Jawad H. Butt has received advisory board honoraria from Bayer, outside the submitted work. Dr Pardeep S. Jhund has received consulting fees from Novo Nordisk AS, Novartis, AstraZeneca, and Boehringer Ingelheim. Dr Inder S. Anand has received consulting fees from Amgen, ARCA Biopharma, AstraZeneca, Boston Scientific Corporation, Boehringer Ingelheim, LivaNova, Novartis, and Zensun. Dr. Dan Atar has received honoraria from Actelion, AstraZeneca, Bayer-Healthcare, Bristol Myers Squibb/Pfizer, Boehringer Ingelheim, Merck, and Novartis. Dr Akshay S. Desai has received grants and personal fees from AstraZeneca during the conduct of the study; has received personal fees from Abbott, Biofourmis, Boston Scientific, Boehringer Ingelheim, Corvidia, DalCor Pharma, Relypsa, Regeneron, and Merck; has received grants and personal fees from Alnylam and Novartis; and has received personal fees from Amgen, outside the submitted work. Dr Lars Kober has received compensation from Novartis, Novo Nordisk, and AstraZeneca for consulting. Dr Carolyn S.P. Lam  is supported by a Clinician Scientist Award from the National Medical Research Council of Singapore; has received research support from AstraZeneca, Bayer, Boston Scientific, and Roche Diagnostics; has served as a consultant or on the advisory board/steering committee/executive committee for Actelion, Amgen, Applied Therapeutics, AstraZeneca, Bayer, Boehringer Ingelheim, Boston Scientific, Cytokinetics, Darma Inc, Us2.ai, Janssen Research & Development LLC,  Medscape, Merck, Novartis, Novo Nordisk, Radcliffe Group Ltd, Roche Diagnostics,  Sanofi, and WebMD Global LLC; and serves as the cofounder and non-executive director of Us2.ai. Dr Aldo P. Maggioni has received fees for serving on a study committee from Bayer and Fresenius. Dr. Felipe Martinez has received personal fees from  Novartis. Dr Milton Packer has received consulting fees from AbbVie, Akcea, Actavis, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Cardiorentis, Daiichi-Sankyo, Gilead, Johnson & Johnson, Novo Nordisk, Pfizer, Relypsa, Sanofi, Synthetic Biologics, and Theravance. Dr Jean L. Rouleau has received grants and consulting fees from Novartis; and has received consulting fees from Abbott, AstraZeneca, MyoKardia, and Sanofi. Dr Dirk J Van Veldhuisen has received fees for serving on a steering  committee and travel support from ARCA biopharma and Corvia Medical. Dr Zannad has received personal fees from Novartis, Janssen, Bayer, Boston Scientific, Amgen, CVRx, Boehringer Ingelheim, Cardiorenal, AstraZeneca, Vifor Fresenius, Cardior, Cereno Pharmaceutical, Applied Therapeutics, Merck, and CardioVascular Clinical Trialists (CVCT). Dr Zile has received research funding from Novartis; and has been a consultant for Novartis, Abbott, Boston Scientific, CVRx, EBR, Endotronics, Ironwood, Merck, Medtronic, and Myokardia V Wave. Dr Gong is an employee of Novartis. Dr Lefkowitz is an employee of Novartis. Dr Rizkala is an employee of and owns stock in Novartis. Dr Solomon has received research grants from Actelion, Alnylam, Amgen, AstraZeneca, Bellerophon, Bayer, Bristol Myers Squibb, Celladon, Cytokinetics, Eidos, Gilead, GlaxoSmithKline, Ionis, Lilly, Mesoblast, MyoKardia, National Institutes of Health/NHLBI, Neurotronik, Novartis, NovoNordisk, Respicardia, Sanofi Pasteur, Theracos, and US2.AI; and has consulted for Abbott, Action, Akros, Alnylam, Amgen, Arena, AstraZeneca, Bayer, Boehringer  Ingelheim, Bristol Myers Squibb, Cardior, Cardurion, Corvia, Cytokinetics, Daiichi-Sankyo, GlaxoSmithKline, Lilly, Merck, Myokardia, Novartis, Roche, Theracos, Quantum Junbo Genomics, Cardurion, Janssen, Cardiac Dimensions, Tenaya, Sanofi-Pasteur, Dinaqor, Tremeau, CellPro-Thera, Moderna, American Regent, and Sarepta. Dr McMurray has received payments through Glasgow University from work on clinical trials, consulting and other activities from Alnylam, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Cardurion, Cytokinetics, Dal-Cor, GlaxoSmithKline, Ionis, KBP Biosciences, Novartis, Pfizer, and Theracos; has received personal lecture fees from the Corpus, Abbott, Hikma,  Sun Pharmaceuticals, Medscape/Heart.Org, Radcliffe Cardiology, Servier Director,  and Global Clinical Trial Partners (GCTP). All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.\n",
      "\n",
      "Funding Support and Author Disclosures The PARAGON-HF trial was funded by Novartis. Dr McMurray is supported by British Heart Foundation Centre of Research Excellence Grant RE/18/6/34217. Dr Jawad H. Butt has received advisory board honoraria from Bayer, outside the submitted work. Dr Pardeep S. Jhund has received consulting fees from Novo Nordisk AS, Novartis, AstraZeneca, and Boehringer Ingelheim. Dr Inder S. Anand has received consulting fees from Amgen, ARCA Biopharma, AstraZeneca, Boston Scientific Corporation, Boehringer Ingelheim, LivaNova, Novartis, and Zensun. Dr. Dan Atar has received honoraria from Actelion, AstraZeneca, Bayer-Healthcare, Bristol Myers Squibb/Pfizer, Boehringer Ingelheim, Merck, and Novartis. Dr Akshay S. Desai has received grants and personal fees from AstraZeneca during the conduct of the study; has received personal fees from Abbott, Biofourmis, Boston Scientific, Boehringer Ingelheim, Corvidia, DalCor Pharma, Relypsa, Regeneron, and Merck; has received grants and personal fees from Alnylam and Novartis; and has received personal fees from Amgen, outside the submitted work. Dr Lars Kober has received compensation from Novartis, Novo Nordisk, and AstraZeneca for consulting. Dr Carolyn S.P. Lam  is supported by a Clinician Scientist Award from the National Medical Research Council of Singapore; has received research support from AstraZeneca, Bayer, Boston Scientific, and Roche Diagnostics; has served as a consultant or on the advisory board/steering committee/executive committee for Actelion, Amgen, Applied Therapeutics, AstraZeneca, Bayer, Boehringer Ingelheim, Boston Scientific, Cytokinetics, Darma Inc, Us2.ai, Janssen Research & Development LLC,  Medscape, Merck, Novartis, Novo Nordisk, Radcliffe Group Ltd, Roche Diagnostics,  Sanofi, and WebMD Global LLC; and serves as the cofounder and non-executive director of Us2.ai. Dr Aldo P. Maggioni has received fees for serving on a study committee from Bayer and Fresenius. Dr. Felipe Martinez has received personal fees from  Novartis. Dr Milton Packer has received consulting fees from AbbVie, Akcea, Actavis, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Cardiorentis, Daiichi-Sankyo, Gilead, Johnson & Johnson, Novo Nordisk, Pfizer, Relypsa, Sanofi, Synthetic Biologics, and Theravance. Dr Jean L. Rouleau has received grants and consulting fees from Novartis; and has received consulting fees from Abbott, AstraZeneca, MyoKardia, and Sanofi. Dr Dirk J Van Veldhuisen has received fees for serving on a steering  committee and travel support from ARCA biopharma and Corvia Medical. Dr Zannad has received personal fees from Novartis, Janssen, Bayer, Boston Scientific, Amgen, CVRx, Boehringer Ingelheim, Cardiorenal, AstraZeneca, Vifor Fresenius, Cardior, Cereno Pharmaceutical, Applied Therapeutics, Merck, and CardioVascular Clinical Trialists (CVCT). Dr Zile has received research funding from Novartis; and has been a consultant for Novartis, Abbott, Boston Scientific, CVRx, EBR, Endotronics, Ironwood, Merck, Medtronic, and Myokardia V Wave. Dr Gong is an employee of Novartis. Dr Lefkowitz is an employee of Novartis. Dr Rizkala is an employee of and owns stock in Novartis. Dr Solomon has received research grants from Actelion, Alnylam, Amgen, AstraZeneca, Bellerophon, Bayer, Bristol Myers Squibb, Celladon, Cytokinetics, Eidos, Gilead, GlaxoSmithKline, Ionis, Lilly, Mesoblast, MyoKardia, National Institutes of Health/NHLBI, Neurotronik, Novartis, NovoNordisk, Respicardia, Sanofi Pasteur, Theracos, and US2.AI; and has consulted for Abbott, Action, Akros, Alnylam, Amgen, Arena, AstraZeneca, Bayer, Boehringer  Ingelheim, Bristol Myers Squibb, Cardior, Cardurion, Corvia, Cytokinetics, Daiichi-Sankyo, GlaxoSmithKline, Lilly, Merck, Myokardia, Novartis, Roche, Theracos, Quantum Junbo Genomics, Cardurion, Janssen, Cardiac Dimensions, Tenaya, Sanofi-Pasteur, Dinaqor, Tremeau, CellPro-Thera, Moderna, American Regent, and Sarepta. Dr McMurray has received payments through Glasgow University from work on clinical trials, consulting and other activities from Alnylam, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Cardurion, Cytokinetics, Dal-Cor, GlaxoSmithKline, Ionis, KBP Biosciences, Novartis, Pfizer, and Theracos; has received personal lecture fees from the Corpus, Abbott, Hikma,  Sun Pharmaceuticals, Medscape/Heart.Org, Radcliffe Cardiology, Servier Director,  and Global Clinical Trial Partners (GCTP). All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.\n",
      "\n",
      "Zannad, Faiez\n",
      "Funding Support and Author Disclosures The PARAGON-HF trial was funded by Novartis. Dr McMurray is supported by British Heart Foundation Centre of Research Excellence Grant RE/18/6/34217. Dr Jawad H. Butt has received advisory board honoraria from Bayer, outside the submitted work. Dr Pardeep S. Jhund has received consulting fees from Novo Nordisk AS, Novartis, AstraZeneca, and Boehringer Ingelheim. Dr Inder S. Anand has received consulting fees from Amgen, ARCA Biopharma, AstraZeneca, Boston Scientific Corporation, Boehringer Ingelheim, LivaNova, Novartis, and Zensun. Dr. Dan Atar has received honoraria from Actelion, AstraZeneca, Bayer-Healthcare, Bristol Myers Squibb/Pfizer, Boehringer Ingelheim, Merck, and Novartis. Dr Akshay S. Desai has received grants and personal fees from AstraZeneca during the conduct of the study; has received personal fees from Abbott, Biofourmis, Boston Scientific, Boehringer Ingelheim, Corvidia, DalCor Pharma, Relypsa, Regeneron, and Merck; has received grants and personal fees from Alnylam and Novartis; and has received personal fees from Amgen, outside the submitted work. Dr Lars Kober has received compensation from Novartis, Novo Nordisk, and AstraZeneca for consulting. Dr Carolyn S.P. Lam  is supported by a Clinician Scientist Award from the National Medical Research Council of Singapore; has received research support from AstraZeneca, Bayer, Boston Scientific, and Roche Diagnostics; has served as a consultant or on the advisory board/steering committee/executive committee for Actelion, Amgen, Applied Therapeutics, AstraZeneca, Bayer, Boehringer Ingelheim, Boston Scientific, Cytokinetics, Darma Inc, Us2.ai, Janssen Research & Development LLC,  Medscape, Merck, Novartis, Novo Nordisk, Radcliffe Group Ltd, Roche Diagnostics,  Sanofi, and WebMD Global LLC; and serves as the cofounder and non-executive director of Us2.ai. Dr Aldo P. Maggioni has received fees for serving on a study committee from Bayer and Fresenius. Dr. Felipe Martinez has received personal fees from  Novartis. Dr Milton Packer has received consulting fees from AbbVie, Akcea, Actavis, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Cardiorentis, Daiichi-Sankyo, Gilead, Johnson & Johnson, Novo Nordisk, Pfizer, Relypsa, Sanofi, Synthetic Biologics, and Theravance. Dr Jean L. Rouleau has received grants and consulting fees from Novartis; and has received consulting fees from Abbott, AstraZeneca, MyoKardia, and Sanofi. Dr Dirk J Van Veldhuisen has received fees for serving on a steering  committee and travel support from ARCA biopharma and Corvia Medical. Dr Faiez Zannad has received personal fees from Novartis, Janssen, Bayer, Boston Scientific, Amgen, CVRx, Boehringer Ingelheim, Cardiorenal, AstraZeneca, Vifor Fresenius, Cardior, Cereno Pharmaceutical, Applied Therapeutics, Merck, and CardioVascular Clinical Trialists (CVCT). Dr Zile has received research funding from Novartis; and has been a consultant for Novartis, Abbott, Boston Scientific, CVRx, EBR, Endotronics, Ironwood, Merck, Medtronic, and Myokardia V Wave. Dr Gong is an employee of Novartis. Dr Lefkowitz is an employee of Novartis. Dr Rizkala is an employee of and owns stock in Novartis. Dr Solomon has received research grants from Actelion, Alnylam, Amgen, AstraZeneca, Bellerophon, Bayer, Bristol Myers Squibb, Celladon, Cytokinetics, Eidos, Gilead, GlaxoSmithKline, Ionis, Lilly, Mesoblast, MyoKardia, National Institutes of Health/NHLBI, Neurotronik, Novartis, NovoNordisk, Respicardia, Sanofi Pasteur, Theracos, and US2.AI; and has consulted for Abbott, Action, Akros, Alnylam, Amgen, Arena, AstraZeneca, Bayer, Boehringer  Ingelheim, Bristol Myers Squibb, Cardior, Cardurion, Corvia, Cytokinetics, Daiichi-Sankyo, GlaxoSmithKline, Lilly, Merck, Myokardia, Novartis, Roche, Theracos, Quantum Junbo Genomics, Cardurion, Janssen, Cardiac Dimensions, Tenaya, Sanofi-Pasteur, Dinaqor, Tremeau, CellPro-Thera, Moderna, American Regent, and Sarepta. Dr McMurray has received payments through Glasgow University from work on clinical trials, consulting and other activities from Alnylam, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Cardurion, Cytokinetics, Dal-Cor, GlaxoSmithKline, Ionis, KBP Biosciences, Novartis, Pfizer, and Theracos; has received personal lecture fees from the Corpus, Abbott, Hikma,  Sun Pharmaceuticals, Medscape/Heart.Org, Radcliffe Cardiology, Servier Director,  and Global Clinical Trial Partners (GCTP). All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.\n",
      "\n",
      "Zile, Michael R.\n",
      "Funding Support and Author Disclosures The PARAGON-HF trial was funded by Novartis. Dr McMurray is supported by British Heart Foundation Centre of Research Excellence Grant RE/18/6/34217. Dr Jawad H. Butt has received advisory board honoraria from Bayer, outside the submitted work. Dr Pardeep S. Jhund has received consulting fees from Novo Nordisk AS, Novartis, AstraZeneca, and Boehringer Ingelheim. Dr Inder S. Anand has received consulting fees from Amgen, ARCA Biopharma, AstraZeneca, Boston Scientific Corporation, Boehringer Ingelheim, LivaNova, Novartis, and Zensun. Dr. Dan Atar has received honoraria from Actelion, AstraZeneca, Bayer-Healthcare, Bristol Myers Squibb/Pfizer, Boehringer Ingelheim, Merck, and Novartis. Dr Akshay S. Desai has received grants and personal fees from AstraZeneca during the conduct of the study; has received personal fees from Abbott, Biofourmis, Boston Scientific, Boehringer Ingelheim, Corvidia, DalCor Pharma, Relypsa, Regeneron, and Merck; has received grants and personal fees from Alnylam and Novartis; and has received personal fees from Amgen, outside the submitted work. Dr Lars Kober has received compensation from Novartis, Novo Nordisk, and AstraZeneca for consulting. Dr Carolyn S.P. Lam  is supported by a Clinician Scientist Award from the National Medical Research Council of Singapore; has received research support from AstraZeneca, Bayer, Boston Scientific, and Roche Diagnostics; has served as a consultant or on the advisory board/steering committee/executive committee for Actelion, Amgen, Applied Therapeutics, AstraZeneca, Bayer, Boehringer Ingelheim, Boston Scientific, Cytokinetics, Darma Inc, Us2.ai, Janssen Research & Development LLC,  Medscape, Merck, Novartis, Novo Nordisk, Radcliffe Group Ltd, Roche Diagnostics,  Sanofi, and WebMD Global LLC; and serves as the cofounder and non-executive director of Us2.ai. Dr Aldo P. Maggioni has received fees for serving on a study committee from Bayer and Fresenius. Dr. Felipe Martinez has received personal fees from  Novartis. Dr Milton Packer has received consulting fees from AbbVie, Akcea, Actavis, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Cardiorentis, Daiichi-Sankyo, Gilead, Johnson & Johnson, Novo Nordisk, Pfizer, Relypsa, Sanofi, Synthetic Biologics, and Theravance. Dr Jean L. Rouleau has received grants and consulting fees from Novartis; and has received consulting fees from Abbott, AstraZeneca, MyoKardia, and Sanofi. Dr Dirk J Van Veldhuisen has received fees for serving on a steering  committee and travel support from ARCA biopharma and Corvia Medical. Dr Faiez Zannad has received personal fees from Novartis, Janssen, Bayer, Boston Scientific, Amgen, CVRx, Boehringer Ingelheim, Cardiorenal, AstraZeneca, Vifor Fresenius, Cardior, Cereno Pharmaceutical, Applied Therapeutics, Merck, and CardioVascular Clinical Trialists (CVCT). Dr Michael R. Zile has received research funding from Novartis; and has been a consultant for Novartis, Abbott, Boston Scientific, CVRx, EBR, Endotronics, Ironwood, Merck, Medtronic, and Myokardia V Wave. Dr Gong is an employee of Novartis. Dr Lefkowitz is an employee of Novartis. Dr Rizkala is an employee of and owns stock in Novartis. Dr Solomon has received research grants from Actelion, Alnylam, Amgen, AstraZeneca, Bellerophon, Bayer, Bristol Myers Squibb, Celladon, Cytokinetics, Eidos, Gilead, GlaxoSmithKline, Ionis, Lilly, Mesoblast, MyoKardia, National Institutes of Health/NHLBI, Neurotronik, Novartis, NovoNordisk, Respicardia, Sanofi Pasteur, Theracos, and US2.AI; and has consulted for Abbott, Action, Akros, Alnylam, Amgen, Arena, AstraZeneca, Bayer, Boehringer  Ingelheim, Bristol Myers Squibb, Cardior, Cardurion, Corvia, Cytokinetics, Daiichi-Sankyo, GlaxoSmithKline, Lilly, Merck, Myokardia, Novartis, Roche, Theracos, Quantum Junbo Genomics, Cardurion, Janssen, Cardiac Dimensions, Tenaya, Sanofi-Pasteur, Dinaqor, Tremeau, CellPro-Thera, Moderna, American Regent, and Sarepta. Dr McMurray has received payments through Glasgow University from work on clinical trials, consulting and other activities from Alnylam, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Cardurion, Cytokinetics, Dal-Cor, GlaxoSmithKline, Ionis, KBP Biosciences, Novartis, Pfizer, and Theracos; has received personal lecture fees from the Corpus, Abbott, Hikma,  Sun Pharmaceuticals, Medscape/Heart.Org, Radcliffe Cardiology, Servier Director,  and Global Clinical Trial Partners (GCTP). All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.\n",
      "\n",
      "Gong, Jianjian\n",
      "Funding Support and Author Disclosures The PARAGON-HF trial was funded by Novartis. Dr McMurray is supported by British Heart Foundation Centre of Research Excellence Grant RE/18/6/34217. Dr Jawad H. Butt has received advisory board honoraria from Bayer, outside the submitted work. Dr Pardeep S. Jhund has received consulting fees from Novo Nordisk AS, Novartis, AstraZeneca, and Boehringer Ingelheim. Dr Inder S. Anand has received consulting fees from Amgen, ARCA Biopharma, AstraZeneca, Boston Scientific Corporation, Boehringer Ingelheim, LivaNova, Novartis, and Zensun. Dr. Dan Atar has received honoraria from Actelion, AstraZeneca, Bayer-Healthcare, Bristol Myers Squibb/Pfizer, Boehringer Ingelheim, Merck, and Novartis. Dr Akshay S. Desai has received grants and personal fees from AstraZeneca during the conduct of the study; has received personal fees from Abbott, Biofourmis, Boston Scientific, Boehringer Ingelheim, Corvidia, DalCor Pharma, Relypsa, Regeneron, and Merck; has received grants and personal fees from Alnylam and Novartis; and has received personal fees from Amgen, outside the submitted work. Dr Lars Kober has received compensation from Novartis, Novo Nordisk, and AstraZeneca for consulting. Dr Carolyn S.P. Lam  is supported by a Clinician Scientist Award from the National Medical Research Council of Singapore; has received research support from AstraZeneca, Bayer, Boston Scientific, and Roche Diagnostics; has served as a consultant or on the advisory board/steering committee/executive committee for Actelion, Amgen, Applied Therapeutics, AstraZeneca, Bayer, Boehringer Ingelheim, Boston Scientific, Cytokinetics, Darma Inc, Us2.ai, Janssen Research & Development LLC,  Medscape, Merck, Novartis, Novo Nordisk, Radcliffe Group Ltd, Roche Diagnostics,  Sanofi, and WebMD Global LLC; and serves as the cofounder and non-executive director of Us2.ai. Dr Aldo P. Maggioni has received fees for serving on a study committee from Bayer and Fresenius. Dr. Felipe Martinez has received personal fees from  Novartis. Dr Milton Packer has received consulting fees from AbbVie, Akcea, Actavis, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Cardiorentis, Daiichi-Sankyo, Gilead, Johnson & Johnson, Novo Nordisk, Pfizer, Relypsa, Sanofi, Synthetic Biologics, and Theravance. Dr Jean L. Rouleau has received grants and consulting fees from Novartis; and has received consulting fees from Abbott, AstraZeneca, MyoKardia, and Sanofi. Dr Dirk J Van Veldhuisen has received fees for serving on a steering  committee and travel support from ARCA biopharma and Corvia Medical. Dr Faiez Zannad has received personal fees from Novartis, Janssen, Bayer, Boston Scientific, Amgen, CVRx, Boehringer Ingelheim, Cardiorenal, AstraZeneca, Vifor Fresenius, Cardior, Cereno Pharmaceutical, Applied Therapeutics, Merck, and CardioVascular Clinical Trialists (CVCT). Dr Michael R. Zile has received research funding from Novartis; and has been a consultant for Novartis, Abbott, Boston Scientific, CVRx, EBR, Endotronics, Ironwood, Merck, Medtronic, and Myokardia V Wave. Dr Jianjian Gong is an employee of Novartis. Dr Lefkowitz is an employee of Novartis. Dr Rizkala is an employee of and owns stock in Novartis. Dr Solomon has received research grants from Actelion, Alnylam, Amgen, AstraZeneca, Bellerophon, Bayer, Bristol Myers Squibb, Celladon, Cytokinetics, Eidos, Gilead, GlaxoSmithKline, Ionis, Lilly, Mesoblast, MyoKardia, National Institutes of Health/NHLBI, Neurotronik, Novartis, NovoNordisk, Respicardia, Sanofi Pasteur, Theracos, and US2.AI; and has consulted for Abbott, Action, Akros, Alnylam, Amgen, Arena, AstraZeneca, Bayer, Boehringer  Ingelheim, Bristol Myers Squibb, Cardior, Cardurion, Corvia, Cytokinetics, Daiichi-Sankyo, GlaxoSmithKline, Lilly, Merck, Myokardia, Novartis, Roche, Theracos, Quantum Junbo Genomics, Cardurion, Janssen, Cardiac Dimensions, Tenaya, Sanofi-Pasteur, Dinaqor, Tremeau, CellPro-Thera, Moderna, American Regent, and Sarepta. Dr McMurray has received payments through Glasgow University from work on clinical trials, consulting and other activities from Alnylam, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Cardurion, Cytokinetics, Dal-Cor, GlaxoSmithKline, Ionis, KBP Biosciences, Novartis, Pfizer, and Theracos; has received personal lecture fees from the Corpus, Abbott, Hikma,  Sun Pharmaceuticals, Medscape/Heart.Org, Radcliffe Cardiology, Servier Director,  and Global Clinical Trial Partners (GCTP). All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.\n",
      "\n",
      "Lefkowitz, Martin P.\n",
      "Funding Support and Author Disclosures The PARAGON-HF trial was funded by Novartis. Dr McMurray is supported by British Heart Foundation Centre of Research Excellence Grant RE/18/6/34217. Dr Jawad H. Butt has received advisory board honoraria from Bayer, outside the submitted work. Dr Pardeep S. Jhund has received consulting fees from Novo Nordisk AS, Novartis, AstraZeneca, and Boehringer Ingelheim. Dr Inder S. Anand has received consulting fees from Amgen, ARCA Biopharma, AstraZeneca, Boston Scientific Corporation, Boehringer Ingelheim, LivaNova, Novartis, and Zensun. Dr. Dan Atar has received honoraria from Actelion, AstraZeneca, Bayer-Healthcare, Bristol Myers Squibb/Pfizer, Boehringer Ingelheim, Merck, and Novartis. Dr Akshay S. Desai has received grants and personal fees from AstraZeneca during the conduct of the study; has received personal fees from Abbott, Biofourmis, Boston Scientific, Boehringer Ingelheim, Corvidia, DalCor Pharma, Relypsa, Regeneron, and Merck; has received grants and personal fees from Alnylam and Novartis; and has received personal fees from Amgen, outside the submitted work. Dr Lars Kober has received compensation from Novartis, Novo Nordisk, and AstraZeneca for consulting. Dr Carolyn S.P. Lam  is supported by a Clinician Scientist Award from the National Medical Research Council of Singapore; has received research support from AstraZeneca, Bayer, Boston Scientific, and Roche Diagnostics; has served as a consultant or on the advisory board/steering committee/executive committee for Actelion, Amgen, Applied Therapeutics, AstraZeneca, Bayer, Boehringer Ingelheim, Boston Scientific, Cytokinetics, Darma Inc, Us2.ai, Janssen Research & Development LLC,  Medscape, Merck, Novartis, Novo Nordisk, Radcliffe Group Ltd, Roche Diagnostics,  Sanofi, and WebMD Global LLC; and serves as the cofounder and non-executive director of Us2.ai. Dr Aldo P. Maggioni has received fees for serving on a study committee from Bayer and Fresenius. Dr. Felipe Martinez has received personal fees from  Novartis. Dr Milton Packer has received consulting fees from AbbVie, Akcea, Actavis, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Cardiorentis, Daiichi-Sankyo, Gilead, Johnson & Johnson, Novo Nordisk, Pfizer, Relypsa, Sanofi, Synthetic Biologics, and Theravance. Dr Jean L. Rouleau has received grants and consulting fees from Novartis; and has received consulting fees from Abbott, AstraZeneca, MyoKardia, and Sanofi. Dr Dirk J Van Veldhuisen has received fees for serving on a steering  committee and travel support from ARCA biopharma and Corvia Medical. Dr Faiez Zannad has received personal fees from Novartis, Janssen, Bayer, Boston Scientific, Amgen, CVRx, Boehringer Ingelheim, Cardiorenal, AstraZeneca, Vifor Fresenius, Cardior, Cereno Pharmaceutical, Applied Therapeutics, Merck, and CardioVascular Clinical Trialists (CVCT). Dr Michael R. Zile has received research funding from Novartis; and has been a consultant for Novartis, Abbott, Boston Scientific, CVRx, EBR, Endotronics, Ironwood, Merck, Medtronic, and Myokardia V Wave. Dr Jianjian Gong is an employee of Novartis. Dr Martin P. Lefkowitz is an employee of Novartis. Dr Rizkala is an employee of and owns stock in Novartis. Dr Solomon has received research grants from Actelion, Alnylam, Amgen, AstraZeneca, Bellerophon, Bayer, Bristol Myers Squibb, Celladon, Cytokinetics, Eidos, Gilead, GlaxoSmithKline, Ionis, Lilly, Mesoblast, MyoKardia, National Institutes of Health/NHLBI, Neurotronik, Novartis, NovoNordisk, Respicardia, Sanofi Pasteur, Theracos, and US2.AI; and has consulted for Abbott, Action, Akros, Alnylam, Amgen, Arena, AstraZeneca, Bayer, Boehringer  Ingelheim, Bristol Myers Squibb, Cardior, Cardurion, Corvia, Cytokinetics, Daiichi-Sankyo, GlaxoSmithKline, Lilly, Merck, Myokardia, Novartis, Roche, Theracos, Quantum Junbo Genomics, Cardurion, Janssen, Cardiac Dimensions, Tenaya, Sanofi-Pasteur, Dinaqor, Tremeau, CellPro-Thera, Moderna, American Regent, and Sarepta. Dr McMurray has received payments through Glasgow University from work on clinical trials, consulting and other activities from Alnylam, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Cardurion, Cytokinetics, Dal-Cor, GlaxoSmithKline, Ionis, KBP Biosciences, Novartis, Pfizer, and Theracos; has received personal lecture fees from the Corpus, Abbott, Hikma,  Sun Pharmaceuticals, Medscape/Heart.Org, Radcliffe Cardiology, Servier Director,  and Global Clinical Trial Partners (GCTP). All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.\n",
      "\n",
      "Rizkala, Adel R.\n",
      "Funding Support and Author Disclosures The PARAGON-HF trial was funded by Novartis. Dr McMurray is supported by British Heart Foundation Centre of Research Excellence Grant RE/18/6/34217. Dr Jawad H. Butt has received advisory board honoraria from Bayer, outside the submitted work. Dr Pardeep S. Jhund has received consulting fees from Novo Nordisk AS, Novartis, AstraZeneca, and Boehringer Ingelheim. Dr Inder S. Anand has received consulting fees from Amgen, ARCA Biopharma, AstraZeneca, Boston Scientific Corporation, Boehringer Ingelheim, LivaNova, Novartis, and Zensun. Dr. Dan Atar has received honoraria from Actelion, AstraZeneca, Bayer-Healthcare, Bristol Myers Squibb/Pfizer, Boehringer Ingelheim, Merck, and Novartis. Dr Akshay S. Desai has received grants and personal fees from AstraZeneca during the conduct of the study; has received personal fees from Abbott, Biofourmis, Boston Scientific, Boehringer Ingelheim, Corvidia, DalCor Pharma, Relypsa, Regeneron, and Merck; has received grants and personal fees from Alnylam and Novartis; and has received personal fees from Amgen, outside the submitted work. Dr Lars Kober has received compensation from Novartis, Novo Nordisk, and AstraZeneca for consulting. Dr Carolyn S.P. Lam  is supported by a Clinician Scientist Award from the National Medical Research Council of Singapore; has received research support from AstraZeneca, Bayer, Boston Scientific, and Roche Diagnostics; has served as a consultant or on the advisory board/steering committee/executive committee for Actelion, Amgen, Applied Therapeutics, AstraZeneca, Bayer, Boehringer Ingelheim, Boston Scientific, Cytokinetics, Darma Inc, Us2.ai, Janssen Research & Development LLC,  Medscape, Merck, Novartis, Novo Nordisk, Radcliffe Group Ltd, Roche Diagnostics,  Sanofi, and WebMD Global LLC; and serves as the cofounder and non-executive director of Us2.ai. Dr Aldo P. Maggioni has received fees for serving on a study committee from Bayer and Fresenius. Dr. Felipe Martinez has received personal fees from  Novartis. Dr Milton Packer has received consulting fees from AbbVie, Akcea, Actavis, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Cardiorentis, Daiichi-Sankyo, Gilead, Johnson & Johnson, Novo Nordisk, Pfizer, Relypsa, Sanofi, Synthetic Biologics, and Theravance. Dr Jean L. Rouleau has received grants and consulting fees from Novartis; and has received consulting fees from Abbott, AstraZeneca, MyoKardia, and Sanofi. Dr Dirk J Van Veldhuisen has received fees for serving on a steering  committee and travel support from ARCA biopharma and Corvia Medical. Dr Faiez Zannad has received personal fees from Novartis, Janssen, Bayer, Boston Scientific, Amgen, CVRx, Boehringer Ingelheim, Cardiorenal, AstraZeneca, Vifor Fresenius, Cardior, Cereno Pharmaceutical, Applied Therapeutics, Merck, and CardioVascular Clinical Trialists (CVCT). Dr Michael R. Zile has received research funding from Novartis; and has been a consultant for Novartis, Abbott, Boston Scientific, CVRx, EBR, Endotronics, Ironwood, Merck, Medtronic, and Myokardia V Wave. Dr Jianjian Gong is an employee of Novartis. Dr Martin P. Lefkowitz is an employee of Novartis. Dr Adel R. Rizkala is an employee of and owns stock in Novartis. Dr Solomon has received research grants from Actelion, Alnylam, Amgen, AstraZeneca, Bellerophon, Bayer, Bristol Myers Squibb, Celladon, Cytokinetics, Eidos, Gilead, GlaxoSmithKline, Ionis, Lilly, Mesoblast, MyoKardia, National Institutes of Health/NHLBI, Neurotronik, Novartis, NovoNordisk, Respicardia, Sanofi Pasteur, Theracos, and US2.AI; and has consulted for Abbott, Action, Akros, Alnylam, Amgen, Arena, AstraZeneca, Bayer, Boehringer  Ingelheim, Bristol Myers Squibb, Cardior, Cardurion, Corvia, Cytokinetics, Daiichi-Sankyo, GlaxoSmithKline, Lilly, Merck, Myokardia, Novartis, Roche, Theracos, Quantum Junbo Genomics, Cardurion, Janssen, Cardiac Dimensions, Tenaya, Sanofi-Pasteur, Dinaqor, Tremeau, CellPro-Thera, Moderna, American Regent, and Sarepta. Dr McMurray has received payments through Glasgow University from work on clinical trials, consulting and other activities from Alnylam, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Cardurion, Cytokinetics, Dal-Cor, GlaxoSmithKline, Ionis, KBP Biosciences, Novartis, Pfizer, and Theracos; has received personal lecture fees from the Corpus, Abbott, Hikma,  Sun Pharmaceuticals, Medscape/Heart.Org, Radcliffe Cardiology, Servier Director,  and Global Clinical Trial Partners (GCTP). All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.\n",
      "\n",
      "Solomon, Scott D.\n",
      "Funding Support and Author Disclosures The PARAGON-HF trial was funded by Novartis. Dr McMurray is supported by British Heart Foundation Centre of Research Excellence Grant RE/18/6/34217. Dr Jawad H. Butt has received advisory board honoraria from Bayer, outside the submitted work. Dr Pardeep S. Jhund has received consulting fees from Novo Nordisk AS, Novartis, AstraZeneca, and Boehringer Ingelheim. Dr Inder S. Anand has received consulting fees from Amgen, ARCA Biopharma, AstraZeneca, Boston Scientific Corporation, Boehringer Ingelheim, LivaNova, Novartis, and Zensun. Dr. Dan Atar has received honoraria from Actelion, AstraZeneca, Bayer-Healthcare, Bristol Myers Squibb/Pfizer, Boehringer Ingelheim, Merck, and Novartis. Dr Akshay S. Desai has received grants and personal fees from AstraZeneca during the conduct of the study; has received personal fees from Abbott, Biofourmis, Boston Scientific, Boehringer Ingelheim, Corvidia, DalCor Pharma, Relypsa, Regeneron, and Merck; has received grants and personal fees from Alnylam and Novartis; and has received personal fees from Amgen, outside the submitted work. Dr Lars Kober has received compensation from Novartis, Novo Nordisk, and AstraZeneca for consulting. Dr Carolyn S.P. Lam  is supported by a Clinician Scientist Award from the National Medical Research Council of Singapore; has received research support from AstraZeneca, Bayer, Boston Scientific, and Roche Diagnostics; has served as a consultant or on the advisory board/steering committee/executive committee for Actelion, Amgen, Applied Therapeutics, AstraZeneca, Bayer, Boehringer Ingelheim, Boston Scientific, Cytokinetics, Darma Inc, Us2.ai, Janssen Research & Development LLC,  Medscape, Merck, Novartis, Novo Nordisk, Radcliffe Group Ltd, Roche Diagnostics,  Sanofi, and WebMD Global LLC; and serves as the cofounder and non-executive director of Us2.ai. Dr Aldo P. Maggioni has received fees for serving on a study committee from Bayer and Fresenius. Dr. Felipe Martinez has received personal fees from  Novartis. Dr Milton Packer has received consulting fees from AbbVie, Akcea, Actavis, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Cardiorentis, Daiichi-Sankyo, Gilead, Johnson & Johnson, Novo Nordisk, Pfizer, Relypsa, Sanofi, Synthetic Biologics, and Theravance. Dr Jean L. Rouleau has received grants and consulting fees from Novartis; and has received consulting fees from Abbott, AstraZeneca, MyoKardia, and Sanofi. Dr Dirk J Van Veldhuisen has received fees for serving on a steering  committee and travel support from ARCA biopharma and Corvia Medical. Dr Faiez Zannad has received personal fees from Novartis, Janssen, Bayer, Boston Scientific, Amgen, CVRx, Boehringer Ingelheim, Cardiorenal, AstraZeneca, Vifor Fresenius, Cardior, Cereno Pharmaceutical, Applied Therapeutics, Merck, and CardioVascular Clinical Trialists (CVCT). Dr Michael R. Zile has received research funding from Novartis; and has been a consultant for Novartis, Abbott, Boston Scientific, CVRx, EBR, Endotronics, Ironwood, Merck, Medtronic, and Myokardia V Wave. Dr Jianjian Gong is an employee of Novartis. Dr Martin P. Lefkowitz is an employee of Novartis. Dr Adel R. Rizkala is an employee of and owns stock in Novartis. Dr Scott D. Solomon has received research grants from Actelion, Alnylam, Amgen, AstraZeneca, Bellerophon, Bayer, Bristol Myers Squibb, Celladon, Cytokinetics, Eidos, Gilead, GlaxoSmithKline, Ionis, Lilly, Mesoblast, MyoKardia, National Institutes of Health/NHLBI, Neurotronik, Novartis, NovoNordisk, Respicardia, Sanofi Pasteur, Theracos, and US2.AI; and has consulted for Abbott, Action, Akros, Alnylam, Amgen, Arena, AstraZeneca, Bayer, Boehringer  Ingelheim, Bristol Myers Squibb, Cardior, Cardurion, Corvia, Cytokinetics, Daiichi-Sankyo, GlaxoSmithKline, Lilly, Merck, Myokardia, Novartis, Roche, Theracos, Quantum Junbo Genomics, Cardurion, Janssen, Cardiac Dimensions, Tenaya, Sanofi-Pasteur, Dinaqor, Tremeau, CellPro-Thera, Moderna, American Regent, and Sarepta. Dr McMurray has received payments through Glasgow University from work on clinical trials, consulting and other activities from Alnylam, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Cardurion, Cytokinetics, Dal-Cor, GlaxoSmithKline, Ionis, KBP Biosciences, Novartis, Pfizer, and Theracos; has received personal lecture fees from the Corpus, Abbott, Hikma,  Sun Pharmaceuticals, Medscape/Heart.Org, Radcliffe Cardiology, Servier Director,  and Global Clinical Trial Partners (GCTP). All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.\n",
      "\n",
      "McMurray, John J.V.\n",
      "Funding Support and Author Disclosures The PARAGON-HF trial was funded by Novartis. Dr John J.V. McMurray is supported by British Heart Foundation Centre of Research Excellence Grant RE/18/6/34217. Dr Jawad H. Butt has received advisory board honoraria from Bayer, outside the submitted work. Dr Pardeep S. Jhund has received consulting fees from Novo Nordisk AS, Novartis, AstraZeneca, and Boehringer Ingelheim. Dr Inder S. Anand has received consulting fees from Amgen, ARCA Biopharma, AstraZeneca, Boston Scientific Corporation, Boehringer Ingelheim, LivaNova, Novartis, and Zensun. Dr. Dan Atar has received honoraria from Actelion, AstraZeneca, Bayer-Healthcare, Bristol Myers Squibb/Pfizer, Boehringer Ingelheim, Merck, and Novartis. Dr Akshay S. Desai has received grants and personal fees from AstraZeneca during the conduct of the study; has received personal fees from Abbott, Biofourmis, Boston Scientific, Boehringer Ingelheim, Corvidia, DalCor Pharma, Relypsa, Regeneron, and Merck; has received grants and personal fees from Alnylam and Novartis; and has received personal fees from Amgen, outside the submitted work. Dr Lars Kober has received compensation from Novartis, Novo Nordisk, and AstraZeneca for consulting. Dr Carolyn S.P. Lam  is supported by a Clinician Scientist Award from the National Medical Research Council of Singapore; has received research support from AstraZeneca, Bayer, Boston Scientific, and Roche Diagnostics; has served as a consultant or on the advisory board/steering committee/executive committee for Actelion, Amgen, Applied Therapeutics, AstraZeneca, Bayer, Boehringer Ingelheim, Boston Scientific, Cytokinetics, Darma Inc, Us2.ai, Janssen Research & Development LLC,  Medscape, Merck, Novartis, Novo Nordisk, Radcliffe Group Ltd, Roche Diagnostics,  Sanofi, and WebMD Global LLC; and serves as the cofounder and non-executive director of Us2.ai. Dr Aldo P. Maggioni has received fees for serving on a study committee from Bayer and Fresenius. Dr. Felipe Martinez has received personal fees from  Novartis. Dr Milton Packer has received consulting fees from AbbVie, Akcea, Actavis, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Cardiorentis, Daiichi-Sankyo, Gilead, Johnson & Johnson, Novo Nordisk, Pfizer, Relypsa, Sanofi, Synthetic Biologics, and Theravance. Dr Jean L. Rouleau has received grants and consulting fees from Novartis; and has received consulting fees from Abbott, AstraZeneca, MyoKardia, and Sanofi. Dr Dirk J Van Veldhuisen has received fees for serving on a steering  committee and travel support from ARCA biopharma and Corvia Medical. Dr Faiez Zannad has received personal fees from Novartis, Janssen, Bayer, Boston Scientific, Amgen, CVRx, Boehringer Ingelheim, Cardiorenal, AstraZeneca, Vifor Fresenius, Cardior, Cereno Pharmaceutical, Applied Therapeutics, Merck, and CardioVascular Clinical Trialists (CVCT). Dr Michael R. Zile has received research funding from Novartis; and has been a consultant for Novartis, Abbott, Boston Scientific, CVRx, EBR, Endotronics, Ironwood, Merck, Medtronic, and Myokardia V Wave. Dr Jianjian Gong is an employee of Novartis. Dr Martin P. Lefkowitz is an employee of Novartis. Dr Adel R. Rizkala is an employee of and owns stock in Novartis. Dr Scott D. Solomon has received research grants from Actelion, Alnylam, Amgen, AstraZeneca, Bellerophon, Bayer, Bristol Myers Squibb, Celladon, Cytokinetics, Eidos, Gilead, GlaxoSmithKline, Ionis, Lilly, Mesoblast, MyoKardia, National Institutes of Health/NHLBI, Neurotronik, Novartis, NovoNordisk, Respicardia, Sanofi Pasteur, Theracos, and US2.AI; and has consulted for Abbott, Action, Akros, Alnylam, Amgen, Arena, AstraZeneca, Bayer, Boehringer  Ingelheim, Bristol Myers Squibb, Cardior, Cardurion, Corvia, Cytokinetics, Daiichi-Sankyo, GlaxoSmithKline, Lilly, Merck, Myokardia, Novartis, Roche, Theracos, Quantum Junbo Genomics, Cardurion, Janssen, Cardiac Dimensions, Tenaya, Sanofi-Pasteur, Dinaqor, Tremeau, CellPro-Thera, Moderna, American Regent, and Sarepta. Dr John J.V. McMurray has received payments through Glasgow University from work on clinical trials, consulting and other activities from Alnylam, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Cardurion, Cytokinetics, Dal-Cor, GlaxoSmithKline, Ionis, KBP Biosciences, Novartis, Pfizer, and Theracos; has received personal lecture fees from the Corpus, Abbott, Hikma,  Sun Pharmaceuticals, Medscape/Heart.Org, Radcliffe Cardiology, Servier Director,  and Global Clinical Trial Partners (GCTP). All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.\n",
      "\n",
      "Declaration of Competing Interest I am the owner of trademark P.E.R.F.E.C.T. for  PTERYGIUM(R) Ethical approval was provided by HREC of The Queensland Eye Institute. All patients consented to this study. Patient permissions was obtained for all photos.\n",
      "\n",
      "Conflict of Interest None\n",
      "\n",
      "Conflict of Interest None\n",
      "\n",
      "Conflict of Interest None\n",
      "\n",
      "Conflict of Interest None.\n",
      "\n",
      "Conflict of Interest None.\n",
      "\n",
      "Conflict of Interest None.\n",
      "\n",
      "Conflict of Interest None.\n",
      "\n",
      "Carey, John J.\n",
      "Declaration of competing interest Professor John J. Carey is a Past-President and ex-Officio Board Member of The International Society for Clinical Densitometry (ISCD), and ISCD faculty for teaching their Osteoporosis Essentials Course, Vertebral Fracture Assessment Course, Body Composition Course and Pediatric Densitometry Course, and President of The Irish DXA Society. Professor Chih-Hsing Wu is an ISCD faculty for teaching their Osteoporosis Essentials Course, Vertebral Fracture Assessment Course and Body Composition Course. All authors declare no other conflicts of interest.\n",
      "\n",
      "Chih-Hsing Wu, Paulo\n",
      "Declaration of competing interest Professor John J. Carey is a Past-President and ex-Officio Board Member of The International Society for Clinical Densitometry (ISCD), and ISCD faculty for teaching their Osteoporosis Essentials Course, Vertebral Fracture Assessment Course, Body Composition Course and Pediatric Densitometry Course, and President of The Irish DXA Society. Professor Chih-Hsing Paulo Chih-Hsing Wu is an ISCD faculty for teaching their Osteoporosis Essentials Course, Vertebral Fracture Assessment Course and Body Composition Course. All authors declare no other conflicts of interest.\n",
      "\n",
      "Declaration of competing interest Professor John J. Carey is a Past-President and ex-Officio Board Member of The International Society for Clinical Densitometry (ISCD), and ISCD faculty for teaching their Osteoporosis Essentials Course, Vertebral Fracture Assessment Course, Body Composition Course and Pediatric Densitometry Course, and President of The Irish DXA Society. Professor Chih-Hsing Paulo Chih-Hsing Wu is an ISCD faculty for teaching their Osteoporosis Essentials Course, Vertebral Fracture Assessment Course and Body Composition Course. All authors declare no other conflicts of interest.\n",
      "\n",
      "Disclosure The authors do not have any commercial or financial conflicts of interest. This study is supported by the Dutch Cancer Society (KWF grant 12978 to L.A.A. Brosens) and by the American Cancer Society (Boston University-Boston Medical Center Pilot and Feasibility Program to C.M. Heaphy).\n",
      "\n",
      "Disclosure The authors do not have any commercial or financial conflicts of interest. This study is supported by the Dutch Cancer Society (KWF grant 12978 to L.A.A. Brosens) and by the American Cancer Society (Boston University-Boston Medical Center Pilot and Feasibility Program to C.M. Heaphy).\n",
      "\n",
      "Disclosure The authors do not have any commercial or financial conflicts of interest. This study is supported by the Dutch Cancer Society (KWF grant 12978 to L.A.A. Brosens) and by the American Cancer Society (Boston University-Boston Medical Center Pilot and Feasibility Program to C.M. Heaphy).\n",
      "\n",
      "Brosens, Lodewijk A.A.\n",
      "Disclosure The authors do not have any commercial or financial conflicts of interest. This study is supported by the Dutch Cancer Society (KWF grant 12978 to L.A.A. Lodewijk A.A. Brosens) and by the American Cancer Society (Boston University-Boston Medical Center Pilot and Feasibility Program to C.M. Heaphy).\n",
      "\n",
      "Heaphy, Christopher M.\n",
      "Disclosure The authors do not have any commercial or financial conflicts of interest. This study is supported by the Dutch Cancer Society (KWF grant 12978 to L.A.A. Lodewijk A.A. Brosens) and by the American Cancer Society (Boston University-Boston Medical Center Pilot and Feasibility Program to C.M. Christopher M. Heaphy).\n",
      "\n",
      "Bakhshwin, Ahmed\n",
      "Disclaimer Dr Ahmed Bakhshwin has nothing to disclose. Dr D.S. Allende has participated as Advisory Board member for Incyte.\n",
      "\n",
      "Allende, Daniela S.\n",
      "Disclaimer Dr Ahmed Bakhshwin has nothing to disclose. Dr D.S. Daniela S. Allende has participated as Advisory Board member for Incyte.\n",
      "\n",
      "Finn, Sade M.B.\n",
      "Disclosure Dr S.M.B. Sade M.B. Finn has nothing to disclose. Dr M.D. Bellin was supported by R01-DK109124 and also discloses relationships with Insulet (DSMB member), Ariel Precision Medicine (advisory board), and Viaycte (research support).\n",
      "\n",
      "Bellin, Melena D.\n",
      "Disclosure Dr S.M.B. Sade M.B. Finn has nothing to disclose. Dr M.D. Melena D. Bellin was supported by R01-DK109124 and also discloses relationships with Insulet (DSMB member), Ariel Precision Medicine (advisory board), and Viaycte (research support).\n",
      "\n",
      "Disclosure A. Maitra receives royalties for a pancreatic cancer biomarker test from Cosmos Wisdom Biotechnology, and this financial relationship is managed and  monitored by the UTMDACC Conflict of Interest Committee. A. Maitra is also listed as an inventor on a patent that has been licensed by Johns Hopkins University to  Thrive Earlier Detection. A. Maitra is a consultant for Freenome and Tezcat Biotechnology. F. McAllister is an SAB Member at Neologics Bio.M.B. Yurgelun receives research funding from Janssen Pharmaceuticals.\n",
      "\n",
      "Disclosure A. Maitra receives royalties for a pancreatic cancer biomarker test from Cosmos Wisdom Biotechnology, and this financial relationship is managed and  monitored by the UTMDACC Conflict of Interest Committee. A. Maitra is also listed as an inventor on a patent that has been licensed by Johns Hopkins University to  Thrive Earlier Detection. A. Maitra is a consultant for Freenome and Tezcat Biotechnology. F. McAllister is an SAB Member at Neologics Bio.M.B. Yurgelun receives research funding from Janssen Pharmaceuticals.\n",
      "\n",
      "Yurgelun, Matthew B.\n",
      "Disclosure A. Maitra receives royalties for a pancreatic cancer biomarker test from Cosmos Wisdom Biotechnology, and this financial relationship is managed and  monitored by the UTMDACC Conflict of Interest Committee. A. Maitra is also listed as an inventor on a patent that has been licensed by Johns Hopkins University to  Thrive Earlier Detection. A. Maitra is a consultant for Freenome and Tezcat Biotechnology. F. McAllister is an SAB Member at Neologics Bio.M.B. Matthew B. Yurgelun receives research funding from Janssen Pharmaceuticals.\n",
      "\n",
      "Maitra, Anirban\n",
      "Disclosure Anirban Maitra receives royalties for a pancreatic cancer biomarker test from Cosmos Wisdom Biotechnology, and this financial relationship is managed and  monitored by the UTMDACC Conflict of Interest Committee. Anirban Maitra is also listed as an inventor on a patent that has been licensed by Johns Hopkins University to  Thrive Earlier Detection. Anirban Maitra is a consultant for Freenome and Tezcat Biotechnology. F. McAllister is an SAB Member at Neologics Bio.M.B. Matthew B. Yurgelun receives research funding from Janssen Pharmaceuticals.\n",
      "\n",
      "Disclosure Anirban Maitra receives royalties for a pancreatic cancer biomarker test from Cosmos Wisdom Biotechnology, and this financial relationship is managed and  monitored by the UTMDACC Conflict of Interest Committee. Anirban Maitra is also listed as an inventor on a patent that has been licensed by Johns Hopkins University to  Thrive Earlier Detection. Anirban Maitra is a consultant for Freenome and Tezcat Biotechnology. F. McAllister is an SAB Member at Neologics Bio.M.B. Matthew B. Yurgelun receives research funding from Janssen Pharmaceuticals.\n",
      "\n",
      "McAllister, Florencia\n",
      "Disclosure Anirban Maitra receives royalties for a pancreatic cancer biomarker test from Cosmos Wisdom Biotechnology, and this financial relationship is managed and  monitored by the UTMDACC Conflict of Interest Committee. Anirban Maitra is also listed as an inventor on a patent that has been licensed by Johns Hopkins University to  Thrive Earlier Detection. Anirban Maitra is a consultant for Freenome and Tezcat Biotechnology. Florencia McAllister is an SAB Member at Neologics Bio.M.B. Matthew B. Yurgelun receives research funding from Janssen Pharmaceuticals.\n",
      "\n",
      "Armstrong, Paul W.\n",
      "Funding Support and Author Disclosures The VICTORIA trial was funded by Merck Sharp & Dohme Corporation, a subsidiary of Merck & Co, Inc, and Bayer AG. Dr Paul W. Armstrong has received research grants from Merck, Bayer, Sanofi-Aventis Recherche & Developpement, Boehringer Ingelheim, and CSL Limited; and consulting  fees from Merck, Bayer, AstraZeneca, and Novartis. Dr Troughton has received research grants and personal fees from Merck and Roche Diagnostics. Dr Lund has received consulting honoraria from Bayer/Merck; and unrelated to this present work, he has received grants from AstraZeneca, Vifor, Boston Scientific, Boehringer Ingelheim, and Novartis; he has received consulting fees from Merck, Vifor, AstraZeneca, Bayer, Pharmacosmos, MedScape, Sanofi, Lexicon, Myokardia, Boehringer Ingelheim, and Servier; he has received speaker's honoraria from Abbott, MedScape, Radcliffe, AstraZeneca, and Novartis; and he has a patent and stock ownership with AnaCardio. Dr Lam has received research grants from Bayer, National Medical Research Council of Singapore, Boston Scientific, Roche Diagnostic, Medtronic, Vifor Pharma, and AstraZeneca; and consulting fees from Merck, Bayer, Boston Scientific, Roche Diagnostic, Vifor Pharma, AstraZeneca, Novartis, Amgen, Janssen Research & Development LLC, Menarini, Boehringer Ingelheim, Abbott Diagnostics, Corvia, Stealth BioTherapeutics, Novo Nordisk, JanaCare, Biofourmis, Darma, Applied Therapeutics, MyoKardia, Cytokinetics, WebMD Global LLC, Radcliffe Group Ltd, and Corpus. Dr Lam also has patent PCT/SG2016/050217 pending and patent 16/216929 pending and is co-founder and non-executive director of eKo.ai. Dr Westerhout has received consulting fees from Bayer Canada. Dr Blaustein is an employee of Merck & Co. Dr Butler has received consulting fees from Abbott, Adrenomed, Amgen, Array, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, CVRx, G3 Pharmaceutical, Impulse Dynamics, Innolife, Janssen, LivaNova, Luitpold, Medtronic, Merck, Novartis, Novo Nordisk, Roche, and Vifor. Dr Hernandez has received research grants from Merck,  AstraZeneca, Novartis, and Verily; and honoraria from Merck, Bayer, Amgen, AstraZeneca, and Novartis. Dr Roessig is an employee of Bayer AG. Dr O'Connor has received research funding from Merck; and consulting fees from Bayer, Dey LP, and Bristol Myers Squibb Foundation. Dr Voors has received research grants from Boehringer Ingelheim and Roche Diagnostics; and consulting fees from Merck, Bayer, Amgen, AstraZeneca, Boehringer Ingelheim, Cytokinetics, MyoKardia, Novartis, Servier, and Roche Diagnostics. Dr Ezekowitz has received research grants from Bayer, Merck, Servier, Amgen Sanofi, Novartis, Cytokinetics, American Regent, and Applied Therapeutics; and consulting fees from Bayer, Merck, Servier, Amgen, Sanofi, Novartis, Cytokinetics, American Regent, and Applied Therapeutics. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.\n",
      "\n",
      "Funding Support and Author Disclosures The VICTORIA trial was funded by Merck Sharp & Dohme Corporation, a subsidiary of Merck & Co, Inc, and Bayer AG. Dr Paul W. Armstrong has received research grants from Merck, Bayer, Sanofi-Aventis Recherche & Developpement, Boehringer Ingelheim, and CSL Limited; and consulting  fees from Merck, Bayer, AstraZeneca, and Novartis. Dr Troughton has received research grants and personal fees from Merck and Roche Diagnostics. Dr Lund has received consulting honoraria from Bayer/Merck; and unrelated to this present work, he has received grants from AstraZeneca, Vifor, Boston Scientific, Boehringer Ingelheim, and Novartis; he has received consulting fees from Merck, Vifor, AstraZeneca, Bayer, Pharmacosmos, MedScape, Sanofi, Lexicon, Myokardia, Boehringer Ingelheim, and Servier; he has received speaker's honoraria from Abbott, MedScape, Radcliffe, AstraZeneca, and Novartis; and he has a patent and stock ownership with AnaCardio. Dr Lam has received research grants from Bayer, National Medical Research Council of Singapore, Boston Scientific, Roche Diagnostic, Medtronic, Vifor Pharma, and AstraZeneca; and consulting fees from Merck, Bayer, Boston Scientific, Roche Diagnostic, Vifor Pharma, AstraZeneca, Novartis, Amgen, Janssen Research & Development LLC, Menarini, Boehringer Ingelheim, Abbott Diagnostics, Corvia, Stealth BioTherapeutics, Novo Nordisk, JanaCare, Biofourmis, Darma, Applied Therapeutics, MyoKardia, Cytokinetics, WebMD Global LLC, Radcliffe Group Ltd, and Corpus. Dr Lam also has patent PCT/SG2016/050217 pending and patent 16/216929 pending and is co-founder and non-executive director of eKo.ai. Dr Westerhout has received consulting fees from Bayer Canada. Dr Blaustein is an employee of Merck & Co. Dr Butler has received consulting fees from Abbott, Adrenomed, Amgen, Array, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, CVRx, G3 Pharmaceutical, Impulse Dynamics, Innolife, Janssen, LivaNova, Luitpold, Medtronic, Merck, Novartis, Novo Nordisk, Roche, and Vifor. Dr Hernandez has received research grants from Merck,  AstraZeneca, Novartis, and Verily; and honoraria from Merck, Bayer, Amgen, AstraZeneca, and Novartis. Dr Roessig is an employee of Bayer AG. Dr O'Connor has received research funding from Merck; and consulting fees from Bayer, Dey LP, and Bristol Myers Squibb Foundation. Dr Voors has received research grants from Boehringer Ingelheim and Roche Diagnostics; and consulting fees from Merck, Bayer, Amgen, AstraZeneca, Boehringer Ingelheim, Cytokinetics, MyoKardia, Novartis, Servier, and Roche Diagnostics. Dr Ezekowitz has received research grants from Bayer, Merck, Servier, Amgen Sanofi, Novartis, Cytokinetics, American Regent, and Applied Therapeutics; and consulting fees from Bayer, Merck, Servier, Amgen, Sanofi, Novartis, Cytokinetics, American Regent, and Applied Therapeutics. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.\n",
      "\n",
      "Troughton, Richard W.\n",
      "Funding Support and Author Disclosures The VICTORIA trial was funded by Merck Sharp & Dohme Corporation, a subsidiary of Merck & Co, Inc, and Bayer AG. Dr Paul W. Armstrong has received research grants from Merck, Bayer, Sanofi-Aventis Recherche & Developpement, Boehringer Ingelheim, and CSL Limited; and consulting  fees from Merck, Bayer, AstraZeneca, and Novartis. Dr Richard W. Troughton has received research grants and personal fees from Merck and Roche Diagnostics. Dr Lund has received consulting honoraria from Bayer/Merck; and unrelated to this present work, he has received grants from AstraZeneca, Vifor, Boston Scientific, Boehringer Ingelheim, and Novartis; he has received consulting fees from Merck, Vifor, AstraZeneca, Bayer, Pharmacosmos, MedScape, Sanofi, Lexicon, Myokardia, Boehringer Ingelheim, and Servier; he has received speaker's honoraria from Abbott, MedScape, Radcliffe, AstraZeneca, and Novartis; and he has a patent and stock ownership with AnaCardio. Dr Lam has received research grants from Bayer, National Medical Research Council of Singapore, Boston Scientific, Roche Diagnostic, Medtronic, Vifor Pharma, and AstraZeneca; and consulting fees from Merck, Bayer, Boston Scientific, Roche Diagnostic, Vifor Pharma, AstraZeneca, Novartis, Amgen, Janssen Research & Development LLC, Menarini, Boehringer Ingelheim, Abbott Diagnostics, Corvia, Stealth BioTherapeutics, Novo Nordisk, JanaCare, Biofourmis, Darma, Applied Therapeutics, MyoKardia, Cytokinetics, WebMD Global LLC, Radcliffe Group Ltd, and Corpus. Dr Lam also has patent PCT/SG2016/050217 pending and patent 16/216929 pending and is co-founder and non-executive director of eKo.ai. Dr Westerhout has received consulting fees from Bayer Canada. Dr Blaustein is an employee of Merck & Co. Dr Butler has received consulting fees from Abbott, Adrenomed, Amgen, Array, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, CVRx, G3 Pharmaceutical, Impulse Dynamics, Innolife, Janssen, LivaNova, Luitpold, Medtronic, Merck, Novartis, Novo Nordisk, Roche, and Vifor. Dr Hernandez has received research grants from Merck,  AstraZeneca, Novartis, and Verily; and honoraria from Merck, Bayer, Amgen, AstraZeneca, and Novartis. Dr Roessig is an employee of Bayer AG. Dr O'Connor has received research funding from Merck; and consulting fees from Bayer, Dey LP, and Bristol Myers Squibb Foundation. Dr Voors has received research grants from Boehringer Ingelheim and Roche Diagnostics; and consulting fees from Merck, Bayer, Amgen, AstraZeneca, Boehringer Ingelheim, Cytokinetics, MyoKardia, Novartis, Servier, and Roche Diagnostics. Dr Ezekowitz has received research grants from Bayer, Merck, Servier, Amgen Sanofi, Novartis, Cytokinetics, American Regent, and Applied Therapeutics; and consulting fees from Bayer, Merck, Servier, Amgen, Sanofi, Novartis, Cytokinetics, American Regent, and Applied Therapeutics. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.\n",
      "\n",
      "Lund, Lars H.\n",
      "Funding Support and Author Disclosures The VICTORIA trial was funded by Merck Sharp & Dohme Corporation, a subsidiary of Merck & Co, Inc, and Bayer AG. Dr Paul W. Armstrong has received research grants from Merck, Bayer, Sanofi-Aventis Recherche & Developpement, Boehringer Ingelheim, and CSL Limited; and consulting  fees from Merck, Bayer, AstraZeneca, and Novartis. Dr Richard W. Troughton has received research grants and personal fees from Merck and Roche Diagnostics. Dr Lars H. Lund has received consulting honoraria from Bayer/Merck; and unrelated to this present work, he has received grants from AstraZeneca, Vifor, Boston Scientific, Boehringer Ingelheim, and Novartis; he has received consulting fees from Merck, Vifor, AstraZeneca, Bayer, Pharmacosmos, MedScape, Sanofi, Lexicon, Myokardia, Boehringer Ingelheim, and Servier; he has received speaker's honoraria from Abbott, MedScape, Radcliffe, AstraZeneca, and Novartis; and he has a patent and stock ownership with AnaCardio. Dr Lam has received research grants from Bayer, National Medical Research Council of Singapore, Boston Scientific, Roche Diagnostic, Medtronic, Vifor Pharma, and AstraZeneca; and consulting fees from Merck, Bayer, Boston Scientific, Roche Diagnostic, Vifor Pharma, AstraZeneca, Novartis, Amgen, Janssen Research & Development LLC, Menarini, Boehringer Ingelheim, Abbott Diagnostics, Corvia, Stealth BioTherapeutics, Novo Nordisk, JanaCare, Biofourmis, Darma, Applied Therapeutics, MyoKardia, Cytokinetics, WebMD Global LLC, Radcliffe Group Ltd, and Corpus. Dr Lam also has patent PCT/SG2016/050217 pending and patent 16/216929 pending and is co-founder and non-executive director of eKo.ai. Dr Westerhout has received consulting fees from Bayer Canada. Dr Blaustein is an employee of Merck & Co. Dr Butler has received consulting fees from Abbott, Adrenomed, Amgen, Array, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, CVRx, G3 Pharmaceutical, Impulse Dynamics, Innolife, Janssen, LivaNova, Luitpold, Medtronic, Merck, Novartis, Novo Nordisk, Roche, and Vifor. Dr Hernandez has received research grants from Merck,  AstraZeneca, Novartis, and Verily; and honoraria from Merck, Bayer, Amgen, AstraZeneca, and Novartis. Dr Roessig is an employee of Bayer AG. Dr O'Connor has received research funding from Merck; and consulting fees from Bayer, Dey LP, and Bristol Myers Squibb Foundation. Dr Voors has received research grants from Boehringer Ingelheim and Roche Diagnostics; and consulting fees from Merck, Bayer, Amgen, AstraZeneca, Boehringer Ingelheim, Cytokinetics, MyoKardia, Novartis, Servier, and Roche Diagnostics. Dr Ezekowitz has received research grants from Bayer, Merck, Servier, Amgen Sanofi, Novartis, Cytokinetics, American Regent, and Applied Therapeutics; and consulting fees from Bayer, Merck, Servier, Amgen, Sanofi, Novartis, Cytokinetics, American Regent, and Applied Therapeutics. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.\n",
      "\n",
      "Funding Support and Author Disclosures The VICTORIA trial was funded by Merck Sharp & Dohme Corporation, a subsidiary of Merck & Co, Inc, and Bayer AG. Dr Paul W. Armstrong has received research grants from Merck, Bayer, Sanofi-Aventis Recherche & Developpement, Boehringer Ingelheim, and CSL Limited; and consulting  fees from Merck, Bayer, AstraZeneca, and Novartis. Dr Richard W. Troughton has received research grants and personal fees from Merck and Roche Diagnostics. Dr Lars H. Lund has received consulting honoraria from Bayer/Merck; and unrelated to this present work, he has received grants from AstraZeneca, Vifor, Boston Scientific, Boehringer Ingelheim, and Novartis; he has received consulting fees from Merck, Vifor, AstraZeneca, Bayer, Pharmacosmos, MedScape, Sanofi, Lexicon, Myokardia, Boehringer Ingelheim, and Servier; he has received speaker's honoraria from Abbott, MedScape, Radcliffe, AstraZeneca, and Novartis; and he has a patent and stock ownership with AnaCardio. Dr Lam has received research grants from Bayer, National Medical Research Council of Singapore, Boston Scientific, Roche Diagnostic, Medtronic, Vifor Pharma, and AstraZeneca; and consulting fees from Merck, Bayer, Boston Scientific, Roche Diagnostic, Vifor Pharma, AstraZeneca, Novartis, Amgen, Janssen Research & Development LLC, Menarini, Boehringer Ingelheim, Abbott Diagnostics, Corvia, Stealth BioTherapeutics, Novo Nordisk, JanaCare, Biofourmis, Darma, Applied Therapeutics, MyoKardia, Cytokinetics, WebMD Global LLC, Radcliffe Group Ltd, and Corpus. Dr Lam also has patent PCT/SG2016/050217 pending and patent 16/216929 pending and is co-founder and non-executive director of eKo.ai. Dr Westerhout has received consulting fees from Bayer Canada. Dr Blaustein is an employee of Merck & Co. Dr Butler has received consulting fees from Abbott, Adrenomed, Amgen, Array, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, CVRx, G3 Pharmaceutical, Impulse Dynamics, Innolife, Janssen, LivaNova, Luitpold, Medtronic, Merck, Novartis, Novo Nordisk, Roche, and Vifor. Dr Hernandez has received research grants from Merck,  AstraZeneca, Novartis, and Verily; and honoraria from Merck, Bayer, Amgen, AstraZeneca, and Novartis. Dr Roessig is an employee of Bayer AG. Dr O'Connor has received research funding from Merck; and consulting fees from Bayer, Dey LP, and Bristol Myers Squibb Foundation. Dr Voors has received research grants from Boehringer Ingelheim and Roche Diagnostics; and consulting fees from Merck, Bayer, Amgen, AstraZeneca, Boehringer Ingelheim, Cytokinetics, MyoKardia, Novartis, Servier, and Roche Diagnostics. Dr Ezekowitz has received research grants from Bayer, Merck, Servier, Amgen Sanofi, Novartis, Cytokinetics, American Regent, and Applied Therapeutics; and consulting fees from Bayer, Merck, Servier, Amgen, Sanofi, Novartis, Cytokinetics, American Regent, and Applied Therapeutics. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.\n",
      "\n",
      "Lam, Carolyn S.P.\n",
      "Funding Support and Author Disclosures The VICTORIA trial was funded by Merck Sharp & Dohme Corporation, a subsidiary of Merck & Co, Inc, and Bayer AG. Dr Paul W. Armstrong has received research grants from Merck, Bayer, Sanofi-Aventis Recherche & Developpement, Boehringer Ingelheim, and Carolyn S.P. Lam Limited; and consulting  fees from Merck, Bayer, AstraZeneca, and Novartis. Dr Richard W. Troughton has received research grants and personal fees from Merck and Roche Diagnostics. Dr Lars H. Lund has received consulting honoraria from Bayer/Merck; and unrelated to this present work, he has received grants from AstraZeneca, Vifor, Boston Scientific, Boehringer Ingelheim, and Novartis; he has received consulting fees from Merck, Vifor, AstraZeneca, Bayer, Pharmacosmos, MedScape, Sanofi, Lexicon, Myokardia, Boehringer Ingelheim, and Servier; he has received speaker's honoraria from Abbott, MedScape, Radcliffe, AstraZeneca, and Novartis; and he has a patent and stock ownership with AnaCardio. Dr Lam has received research grants from Bayer, National Medical Research Council of Singapore, Boston Scientific, Roche Diagnostic, Medtronic, Vifor Pharma, and AstraZeneca; and consulting fees from Merck, Bayer, Boston Scientific, Roche Diagnostic, Vifor Pharma, AstraZeneca, Novartis, Amgen, Janssen Research & Development LLC, Menarini, Boehringer Ingelheim, Abbott Diagnostics, Corvia, Stealth BioTherapeutics, Novo Nordisk, JanaCare, Biofourmis, Darma, Applied Therapeutics, MyoKardia, Cytokinetics, WebMD Global LLC, Radcliffe Group Ltd, and Corpus. Dr Lam also has patent PCT/SG2016/050217 pending and patent 16/216929 pending and is co-founder and non-executive director of eKo.ai. Dr Westerhout has received consulting fees from Bayer Canada. Dr Blaustein is an employee of Merck & Co. Dr Butler has received consulting fees from Abbott, Adrenomed, Amgen, Array, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, CVRx, G3 Pharmaceutical, Impulse Dynamics, Innolife, Janssen, LivaNova, Luitpold, Medtronic, Merck, Novartis, Novo Nordisk, Roche, and Vifor. Dr Hernandez has received research grants from Merck,  AstraZeneca, Novartis, and Verily; and honoraria from Merck, Bayer, Amgen, AstraZeneca, and Novartis. Dr Roessig is an employee of Bayer AG. Dr O'Connor has received research funding from Merck; and consulting fees from Bayer, Dey LP, and Bristol Myers Squibb Foundation. Dr Voors has received research grants from Boehringer Ingelheim and Roche Diagnostics; and consulting fees from Merck, Bayer, Amgen, AstraZeneca, Boehringer Ingelheim, Cytokinetics, MyoKardia, Novartis, Servier, and Roche Diagnostics. Dr Ezekowitz has received research grants from Bayer, Merck, Servier, Amgen Sanofi, Novartis, Cytokinetics, American Regent, and Applied Therapeutics; and consulting fees from Bayer, Merck, Servier, Amgen, Sanofi, Novartis, Cytokinetics, American Regent, and Applied Therapeutics. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.\n",
      "\n",
      "Westerhout, Cynthia M.\n",
      "Funding Support and Author Disclosures The VICTORIA trial was funded by Merck Sharp & Dohme Corporation, a subsidiary of Merck & Co, Inc, and Bayer AG. Dr Paul W. Armstrong has received research grants from Merck, Bayer, Sanofi-Aventis Recherche & Developpement, Boehringer Ingelheim, and Carolyn S.P. Lam Limited; and consulting  fees from Merck, Bayer, AstraZeneca, and Novartis. Dr Richard W. Troughton has received research grants and personal fees from Merck and Roche Diagnostics. Dr Lars H. Lund has received consulting honoraria from Bayer/Merck; and unrelated to this present work, he has received grants from AstraZeneca, Vifor, Boston Scientific, Boehringer Ingelheim, and Novartis; he has received consulting fees from Merck, Vifor, AstraZeneca, Bayer, Pharmacosmos, MedScape, Sanofi, Lexicon, Myokardia, Boehringer Ingelheim, and Servier; he has received speaker's honoraria from Abbott, MedScape, Radcliffe, AstraZeneca, and Novartis; and he has a patent and stock ownership with AnaCardio. Dr Lam has received research grants from Bayer, National Medical Research Council of Singapore, Boston Scientific, Roche Diagnostic, Medtronic, Vifor Pharma, and AstraZeneca; and consulting fees from Merck, Bayer, Boston Scientific, Roche Diagnostic, Vifor Pharma, AstraZeneca, Novartis, Amgen, Janssen Research & Development LLC, Menarini, Boehringer Ingelheim, Abbott Diagnostics, Corvia, Stealth BioTherapeutics, Novo Nordisk, JanaCare, Biofourmis, Darma, Applied Therapeutics, MyoKardia, Cytokinetics, WebMD Global LLC, Radcliffe Group Ltd, and Corpus. Dr Lam also has patent PCT/SG2016/050217 pending and patent 16/216929 pending and is co-founder and non-executive director of eKo.ai. Dr Cynthia M. Westerhout has received consulting fees from Bayer Canada. Dr Blaustein is an employee of Merck & Co. Dr Butler has received consulting fees from Abbott, Adrenomed, Amgen, Array, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, CVRx, G3 Pharmaceutical, Impulse Dynamics, Innolife, Janssen, LivaNova, Luitpold, Medtronic, Merck, Novartis, Novo Nordisk, Roche, and Vifor. Dr Hernandez has received research grants from Merck,  AstraZeneca, Novartis, and Verily; and honoraria from Merck, Bayer, Amgen, AstraZeneca, and Novartis. Dr Roessig is an employee of Bayer AG. Dr O'Connor has received research funding from Merck; and consulting fees from Bayer, Dey LP, and Bristol Myers Squibb Foundation. Dr Voors has received research grants from Boehringer Ingelheim and Roche Diagnostics; and consulting fees from Merck, Bayer, Amgen, AstraZeneca, Boehringer Ingelheim, Cytokinetics, MyoKardia, Novartis, Servier, and Roche Diagnostics. Dr Ezekowitz has received research grants from Bayer, Merck, Servier, Amgen Sanofi, Novartis, Cytokinetics, American Regent, and Applied Therapeutics; and consulting fees from Bayer, Merck, Servier, Amgen, Sanofi, Novartis, Cytokinetics, American Regent, and Applied Therapeutics. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.\n",
      "\n",
      "Blaustein, Robert O.\n",
      "Funding Support and Author Disclosures The VICTORIA trial was funded by Merck Sharp & Dohme Corporation, a subsidiary of Merck & Co, Inc, and Bayer AG. Dr Paul W. Armstrong has received research grants from Merck, Bayer, Sanofi-Aventis Recherche & Developpement, Boehringer Ingelheim, and Carolyn S.P. Lam Limited; and consulting  fees from Merck, Bayer, AstraZeneca, and Novartis. Dr Richard W. Troughton has received research grants and personal fees from Merck and Roche Diagnostics. Dr Lars H. Lund has received consulting honoraria from Bayer/Merck; and unrelated to this present work, he has received grants from AstraZeneca, Vifor, Boston Scientific, Boehringer Ingelheim, and Novartis; he has received consulting fees from Merck, Vifor, AstraZeneca, Bayer, Pharmacosmos, MedScape, Sanofi, Lexicon, Myokardia, Boehringer Ingelheim, and Servier; he has received speaker's honoraria from Abbott, MedScape, Radcliffe, AstraZeneca, and Novartis; and he has a patent and stock ownership with AnaCardio. Dr Lam has received research grants from Bayer, National Medical Research Council of Singapore, Boston Scientific, Roche Diagnostic, Medtronic, Vifor Pharma, and AstraZeneca; and consulting fees from Merck, Bayer, Boston Scientific, Roche Diagnostic, Vifor Pharma, AstraZeneca, Novartis, Amgen, Janssen Research & Development LLC, Menarini, Boehringer Ingelheim, Abbott Diagnostics, Corvia, Stealth BioTherapeutics, Novo Nordisk, JanaCare, Biofourmis, Darma, Applied Therapeutics, MyoKardia, Cytokinetics, WebMD Global LLC, Radcliffe Group Ltd, and Corpus. Dr Lam also has patent PCT/SG2016/050217 pending and patent 16/216929 pending and is co-founder and non-executive director of eKo.ai. Dr Cynthia M. Westerhout has received consulting fees from Bayer Canada. Dr Robert O. Blaustein is an employee of Merck & Co. Dr Butler has received consulting fees from Abbott, Adrenomed, Amgen, Array, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, CVRx, G3 Pharmaceutical, Impulse Dynamics, Innolife, Janssen, LivaNova, Luitpold, Medtronic, Merck, Novartis, Novo Nordisk, Roche, and Vifor. Dr Hernandez has received research grants from Merck,  AstraZeneca, Novartis, and Verily; and honoraria from Merck, Bayer, Amgen, AstraZeneca, and Novartis. Dr Roessig is an employee of Bayer AG. Dr O'Connor has received research funding from Merck; and consulting fees from Bayer, Dey LP, and Bristol Myers Squibb Foundation. Dr Voors has received research grants from Boehringer Ingelheim and Roche Diagnostics; and consulting fees from Merck, Bayer, Amgen, AstraZeneca, Boehringer Ingelheim, Cytokinetics, MyoKardia, Novartis, Servier, and Roche Diagnostics. Dr Ezekowitz has received research grants from Bayer, Merck, Servier, Amgen Sanofi, Novartis, Cytokinetics, American Regent, and Applied Therapeutics; and consulting fees from Bayer, Merck, Servier, Amgen, Sanofi, Novartis, Cytokinetics, American Regent, and Applied Therapeutics. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.\n",
      "\n",
      "Butler, Javed\n",
      "Funding Support and Author Disclosures The VICTORIA trial was funded by Merck Sharp & Dohme Corporation, a subsidiary of Merck & Co, Inc, and Bayer AG. Dr Paul W. Armstrong has received research grants from Merck, Bayer, Sanofi-Aventis Recherche & Developpement, Boehringer Ingelheim, and Carolyn S.P. Lam Limited; and consulting  fees from Merck, Bayer, AstraZeneca, and Novartis. Dr Richard W. Troughton has received research grants and personal fees from Merck and Roche Diagnostics. Dr Lars H. Lund has received consulting honoraria from Bayer/Merck; and unrelated to this present work, he has received grants from AstraZeneca, Vifor, Boston Scientific, Boehringer Ingelheim, and Novartis; he has received consulting fees from Merck, Vifor, AstraZeneca, Bayer, Pharmacosmos, MedScape, Sanofi, Lexicon, Myokardia, Boehringer Ingelheim, and Servier; he has received speaker's honoraria from Abbott, MedScape, Radcliffe, AstraZeneca, and Novartis; and he has a patent and stock ownership with AnaCardio. Dr Lam has received research grants from Bayer, National Medical Research Council of Singapore, Boston Scientific, Roche Diagnostic, Medtronic, Vifor Pharma, and AstraZeneca; and consulting fees from Merck, Bayer, Boston Scientific, Roche Diagnostic, Vifor Pharma, AstraZeneca, Novartis, Amgen, Janssen Research & Development LLC, Menarini, Boehringer Ingelheim, Abbott Diagnostics, Corvia, Stealth BioTherapeutics, Novo Nordisk, JanaCare, Biofourmis, Darma, Applied Therapeutics, MyoKardia, Cytokinetics, WebMD Global LLC, Radcliffe Group Ltd, and Corpus. Dr Lam also has patent PCT/SG2016/050217 pending and patent 16/216929 pending and is co-founder and non-executive director of eKo.ai. Dr Cynthia M. Westerhout has received consulting fees from Bayer Canada. Dr Robert O. Blaustein is an employee of Merck & Co. Dr Javed Butler has received consulting fees from Abbott, Adrenomed, Amgen, Array, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, CVRx, G3 Pharmaceutical, Impulse Dynamics, Innolife, Janssen, LivaNova, Luitpold, Medtronic, Merck, Novartis, Novo Nordisk, Roche, and Vifor. Dr Hernandez has received research grants from Merck,  AstraZeneca, Novartis, and Verily; and honoraria from Merck, Bayer, Amgen, AstraZeneca, and Novartis. Dr Roessig is an employee of Bayer AG. Dr O'Connor has received research funding from Merck; and consulting fees from Bayer, Dey LP, and Bristol Myers Squibb Foundation. Dr Voors has received research grants from Boehringer Ingelheim and Roche Diagnostics; and consulting fees from Merck, Bayer, Amgen, AstraZeneca, Boehringer Ingelheim, Cytokinetics, MyoKardia, Novartis, Servier, and Roche Diagnostics. Dr Ezekowitz has received research grants from Bayer, Merck, Servier, Amgen Sanofi, Novartis, Cytokinetics, American Regent, and Applied Therapeutics; and consulting fees from Bayer, Merck, Servier, Amgen, Sanofi, Novartis, Cytokinetics, American Regent, and Applied Therapeutics. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.\n",
      "\n",
      "Hernandez, Adrian F.\n",
      "Funding Support and Author Disclosures The VICTORIA trial was funded by Merck Sharp & Dohme Corporation, a subsidiary of Merck & Co, Inc, and Bayer AG. Dr Paul W. Armstrong has received research grants from Merck, Bayer, Sanofi-Aventis Recherche & Developpement, Boehringer Ingelheim, and Carolyn S.P. Lam Limited; and consulting  fees from Merck, Bayer, AstraZeneca, and Novartis. Dr Richard W. Troughton has received research grants and personal fees from Merck and Roche Diagnostics. Dr Lars H. Lund has received consulting honoraria from Bayer/Merck; and unrelated to this present work, he has received grants from AstraZeneca, Vifor, Boston Scientific, Boehringer Ingelheim, and Novartis; he has received consulting fees from Merck, Vifor, AstraZeneca, Bayer, Pharmacosmos, MedScape, Sanofi, Lexicon, Myokardia, Boehringer Ingelheim, and Servier; he has received speaker's honoraria from Abbott, MedScape, Radcliffe, AstraZeneca, and Novartis; and he has a patent and stock ownership with AnaCardio. Dr Lam has received research grants from Bayer, National Medical Research Council of Singapore, Boston Scientific, Roche Diagnostic, Medtronic, Vifor Pharma, and AstraZeneca; and consulting fees from Merck, Bayer, Boston Scientific, Roche Diagnostic, Vifor Pharma, AstraZeneca, Novartis, Amgen, Janssen Research & Development LLC, Menarini, Boehringer Ingelheim, Abbott Diagnostics, Corvia, Stealth BioTherapeutics, Novo Nordisk, JanaCare, Biofourmis, Darma, Applied Therapeutics, MyoKardia, Cytokinetics, WebMD Global LLC, Radcliffe Group Ltd, and Corpus. Dr Lam also has patent PCT/SG2016/050217 pending and patent 16/216929 pending and is co-founder and non-executive director of eKo.ai. Dr Cynthia M. Westerhout has received consulting fees from Bayer Canada. Dr Robert O. Blaustein is an employee of Merck & Co. Dr Javed Butler has received consulting fees from Abbott, Adrenomed, Amgen, Array, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, CVRx, G3 Pharmaceutical, Impulse Dynamics, Innolife, Janssen, LivaNova, Luitpold, Medtronic, Merck, Novartis, Novo Nordisk, Roche, and Vifor. Dr Adrian F. Hernandez has received research grants from Merck,  AstraZeneca, Novartis, and Verily; and honoraria from Merck, Bayer, Amgen, AstraZeneca, and Novartis. Dr Roessig is an employee of Bayer AG. Dr O'Connor has received research funding from Merck; and consulting fees from Bayer, Dey LP, and Bristol Myers Squibb Foundation. Dr Voors has received research grants from Boehringer Ingelheim and Roche Diagnostics; and consulting fees from Merck, Bayer, Amgen, AstraZeneca, Boehringer Ingelheim, Cytokinetics, MyoKardia, Novartis, Servier, and Roche Diagnostics. Dr Ezekowitz has received research grants from Bayer, Merck, Servier, Amgen Sanofi, Novartis, Cytokinetics, American Regent, and Applied Therapeutics; and consulting fees from Bayer, Merck, Servier, Amgen, Sanofi, Novartis, Cytokinetics, American Regent, and Applied Therapeutics. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.\n",
      "\n",
      "Roessig, Lothar\n",
      "Funding Support and Author Disclosures The VICTORIA trial was funded by Merck Sharp & Dohme Corporation, a subsidiary of Merck & Co, Inc, and Bayer AG. Dr Paul W. Armstrong has received research grants from Merck, Bayer, Sanofi-Aventis Recherche & Developpement, Boehringer Ingelheim, and Carolyn S.P. Lam Limited; and consulting  fees from Merck, Bayer, AstraZeneca, and Novartis. Dr Richard W. Troughton has received research grants and personal fees from Merck and Roche Diagnostics. Dr Lars H. Lund has received consulting honoraria from Bayer/Merck; and unrelated to this present work, he has received grants from AstraZeneca, Vifor, Boston Scientific, Boehringer Ingelheim, and Novartis; he has received consulting fees from Merck, Vifor, AstraZeneca, Bayer, Pharmacosmos, MedScape, Sanofi, Lexicon, Myokardia, Boehringer Ingelheim, and Servier; he has received speaker's honoraria from Abbott, MedScape, Radcliffe, AstraZeneca, and Novartis; and he has a patent and stock ownership with AnaCardio. Dr Lam has received research grants from Bayer, National Medical Research Council of Singapore, Boston Scientific, Roche Diagnostic, Medtronic, Vifor Pharma, and AstraZeneca; and consulting fees from Merck, Bayer, Boston Scientific, Roche Diagnostic, Vifor Pharma, AstraZeneca, Novartis, Amgen, Janssen Research & Development LLC, Menarini, Boehringer Ingelheim, Abbott Diagnostics, Corvia, Stealth BioTherapeutics, Novo Nordisk, JanaCare, Biofourmis, Darma, Applied Therapeutics, MyoKardia, Cytokinetics, WebMD Global LLC, Radcliffe Group Ltd, and Corpus. Dr Lam also has patent PCT/SG2016/050217 pending and patent 16/216929 pending and is co-founder and non-executive director of eKo.ai. Dr Cynthia M. Westerhout has received consulting fees from Bayer Canada. Dr Robert O. Blaustein is an employee of Merck & Co. Dr Javed Butler has received consulting fees from Abbott, Adrenomed, Amgen, Array, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, CVRx, G3 Pharmaceutical, Impulse Dynamics, Innolife, Janssen, LivaNova, Luitpold, Medtronic, Merck, Novartis, Novo Nordisk, Roche, and Vifor. Dr Adrian F. Hernandez has received research grants from Merck,  AstraZeneca, Novartis, and Verily; and honoraria from Merck, Bayer, Amgen, AstraZeneca, and Novartis. Dr Lothar Roessig is an employee of Bayer AG. Dr O'Connor has received research funding from Merck; and consulting fees from Bayer, Dey LP, and Bristol Myers Squibb Foundation. Dr Voors has received research grants from Boehringer Ingelheim and Roche Diagnostics; and consulting fees from Merck, Bayer, Amgen, AstraZeneca, Boehringer Ingelheim, Cytokinetics, MyoKardia, Novartis, Servier, and Roche Diagnostics. Dr Ezekowitz has received research grants from Bayer, Merck, Servier, Amgen Sanofi, Novartis, Cytokinetics, American Regent, and Applied Therapeutics; and consulting fees from Bayer, Merck, Servier, Amgen, Sanofi, Novartis, Cytokinetics, American Regent, and Applied Therapeutics. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.\n",
      "\n",
      "O'Connor, Christopher M.\n",
      "Funding Support and Author Disclosures The VICTORIA trial was funded by Merck Sharp & Dohme Corporation, a subsidiary of Merck & Co, Inc, and Bayer AG. Dr Paul W. Armstrong has received research grants from Merck, Bayer, Sanofi-Aventis Recherche & Developpement, Boehringer Ingelheim, and Carolyn S.P. Lam Limited; and consulting  fees from Merck, Bayer, AstraZeneca, and Novartis. Dr Richard W. Troughton has received research grants and personal fees from Merck and Roche Diagnostics. Dr Lars H. Lund has received consulting honoraria from Bayer/Merck; and unrelated to this present work, he has received grants from AstraZeneca, Vifor, Boston Scientific, Boehringer Ingelheim, and Novartis; he has received consulting fees from Merck, Vifor, AstraZeneca, Bayer, Pharmacosmos, MedScape, Sanofi, Lexicon, Myokardia, Boehringer Ingelheim, and Servier; he has received speaker's honoraria from Abbott, MedScape, Radcliffe, AstraZeneca, and Novartis; and he has a patent and stock ownership with AnaCardio. Dr Lam has received research grants from Bayer, National Medical Research Council of Singapore, Boston Scientific, Roche Diagnostic, Medtronic, Vifor Pharma, and AstraZeneca; and consulting fees from Merck, Bayer, Boston Scientific, Roche Diagnostic, Vifor Pharma, AstraZeneca, Novartis, Amgen, Janssen Research & Development LLC, Menarini, Boehringer Ingelheim, Abbott Diagnostics, Corvia, Stealth BioTherapeutics, Novo Nordisk, JanaCare, Biofourmis, Darma, Applied Therapeutics, MyoKardia, Cytokinetics, WebMD Global LLC, Radcliffe Group Ltd, and Corpus. Dr Lam also has patent PCT/SG2016/050217 pending and patent 16/216929 pending and is co-founder and non-executive director of eKo.ai. Dr Cynthia M. Westerhout has received consulting fees from Bayer Canada. Dr Robert O. Blaustein is an employee of Merck & Co. Dr Javed Butler has received consulting fees from Abbott, Adrenomed, Amgen, Array, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, CVRx, G3 Pharmaceutical, Impulse Dynamics, Innolife, Janssen, LivaNova, Luitpold, Medtronic, Merck, Novartis, Novo Nordisk, Roche, and Vifor. Dr Adrian F. Hernandez has received research grants from Merck,  AstraZeneca, Novartis, and Verily; and honoraria from Merck, Bayer, Amgen, AstraZeneca, and Novartis. Dr Lothar Roessig is an employee of Bayer AG. Dr Christopher M. O'Connor has received research funding from Merck; and consulting fees from Bayer, Dey LP, and Bristol Myers Squibb Foundation. Dr Voors has received research grants from Boehringer Ingelheim and Roche Diagnostics; and consulting fees from Merck, Bayer, Amgen, AstraZeneca, Boehringer Ingelheim, Cytokinetics, MyoKardia, Novartis, Servier, and Roche Diagnostics. Dr Ezekowitz has received research grants from Bayer, Merck, Servier, Amgen Sanofi, Novartis, Cytokinetics, American Regent, and Applied Therapeutics; and consulting fees from Bayer, Merck, Servier, Amgen, Sanofi, Novartis, Cytokinetics, American Regent, and Applied Therapeutics. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.\n",
      "\n",
      "Voors, Adrian A.\n",
      "Funding Support and Author Disclosures The VICTORIA trial was funded by Merck Sharp & Dohme Corporation, a subsidiary of Merck & Co, Inc, and Bayer AG. Dr Paul W. Armstrong has received research grants from Merck, Bayer, Sanofi-Aventis Recherche & Developpement, Boehringer Ingelheim, and Carolyn S.P. Lam Limited; and consulting  fees from Merck, Bayer, AstraZeneca, and Novartis. Dr Richard W. Troughton has received research grants and personal fees from Merck and Roche Diagnostics. Dr Lars H. Lund has received consulting honoraria from Bayer/Merck; and unrelated to this present work, he has received grants from AstraZeneca, Vifor, Boston Scientific, Boehringer Ingelheim, and Novartis; he has received consulting fees from Merck, Vifor, AstraZeneca, Bayer, Pharmacosmos, MedScape, Sanofi, Lexicon, Myokardia, Boehringer Ingelheim, and Servier; he has received speaker's honoraria from Abbott, MedScape, Radcliffe, AstraZeneca, and Novartis; and he has a patent and stock ownership with AnaCardio. Dr Lam has received research grants from Bayer, National Medical Research Council of Singapore, Boston Scientific, Roche Diagnostic, Medtronic, Vifor Pharma, and AstraZeneca; and consulting fees from Merck, Bayer, Boston Scientific, Roche Diagnostic, Vifor Pharma, AstraZeneca, Novartis, Amgen, Janssen Research & Development LLC, Menarini, Boehringer Ingelheim, Abbott Diagnostics, Corvia, Stealth BioTherapeutics, Novo Nordisk, JanaCare, Biofourmis, Darma, Applied Therapeutics, MyoKardia, Cytokinetics, WebMD Global LLC, Radcliffe Group Ltd, and Corpus. Dr Lam also has patent PCT/SG2016/050217 pending and patent 16/216929 pending and is co-founder and non-executive director of eKo.ai. Dr Cynthia M. Westerhout has received consulting fees from Bayer Canada. Dr Robert O. Blaustein is an employee of Merck & Co. Dr Javed Butler has received consulting fees from Abbott, Adrenomed, Amgen, Array, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, CVRx, G3 Pharmaceutical, Impulse Dynamics, Innolife, Janssen, LivaNova, Luitpold, Medtronic, Merck, Novartis, Novo Nordisk, Roche, and Vifor. Dr Adrian F. Hernandez has received research grants from Merck,  AstraZeneca, Novartis, and Verily; and honoraria from Merck, Bayer, Amgen, AstraZeneca, and Novartis. Dr Lothar Roessig is an employee of Bayer AG. Dr Christopher M. O'Connor has received research funding from Merck; and consulting fees from Bayer, Dey LP, and Bristol Myers Squibb Foundation. Dr Adrian A. Voors has received research grants from Boehringer Ingelheim and Roche Diagnostics; and consulting fees from Merck, Bayer, Amgen, AstraZeneca, Boehringer Ingelheim, Cytokinetics, MyoKardia, Novartis, Servier, and Roche Diagnostics. Dr Ezekowitz has received research grants from Bayer, Merck, Servier, Amgen Sanofi, Novartis, Cytokinetics, American Regent, and Applied Therapeutics; and consulting fees from Bayer, Merck, Servier, Amgen, Sanofi, Novartis, Cytokinetics, American Regent, and Applied Therapeutics. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.\n",
      "\n",
      "Ezekowitz, Justin A.\n",
      "Funding Support and Author Disclosures The VICTORIA trial was funded by Merck Sharp & Dohme Corporation, a subsidiary of Merck & Co, Inc, and Bayer AG. Dr Paul W. Armstrong has received research grants from Merck, Bayer, Sanofi-Aventis Recherche & Developpement, Boehringer Ingelheim, and Carolyn S.P. Lam Limited; and consulting  fees from Merck, Bayer, AstraZeneca, and Novartis. Dr Richard W. Troughton has received research grants and personal fees from Merck and Roche Diagnostics. Dr Lars H. Lund has received consulting honoraria from Bayer/Merck; and unrelated to this present work, he has received grants from AstraZeneca, Vifor, Boston Scientific, Boehringer Ingelheim, and Novartis; he has received consulting fees from Merck, Vifor, AstraZeneca, Bayer, Pharmacosmos, MedScape, Sanofi, Lexicon, Myokardia, Boehringer Ingelheim, and Servier; he has received speaker's honoraria from Abbott, MedScape, Radcliffe, AstraZeneca, and Novartis; and he has a patent and stock ownership with AnaCardio. Dr Lam has received research grants from Bayer, National Medical Research Council of Singapore, Boston Scientific, Roche Diagnostic, Medtronic, Vifor Pharma, and AstraZeneca; and consulting fees from Merck, Bayer, Boston Scientific, Roche Diagnostic, Vifor Pharma, AstraZeneca, Novartis, Amgen, Janssen Research & Development LLC, Menarini, Boehringer Ingelheim, Abbott Diagnostics, Corvia, Stealth BioTherapeutics, Novo Nordisk, JanaCare, Biofourmis, Darma, Applied Therapeutics, MyoKardia, Cytokinetics, WebMD Global LLC, Radcliffe Group Ltd, and Corpus. Dr Lam also has patent PCT/SG2016/050217 pending and patent 16/216929 pending and is co-founder and non-executive director of eKo.ai. Dr Cynthia M. Westerhout has received consulting fees from Bayer Canada. Dr Robert O. Blaustein is an employee of Merck & Co. Dr Javed Butler has received consulting fees from Abbott, Adrenomed, Amgen, Array, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, CVRx, G3 Pharmaceutical, Impulse Dynamics, Innolife, Janssen, LivaNova, Luitpold, Medtronic, Merck, Novartis, Novo Nordisk, Roche, and Vifor. Dr Adrian F. Hernandez has received research grants from Merck,  AstraZeneca, Novartis, and Verily; and honoraria from Merck, Bayer, Amgen, AstraZeneca, and Novartis. Dr Lothar Roessig is an employee of Bayer AG. Dr Christopher M. O'Connor has received research funding from Merck; and consulting fees from Bayer, Dey LP, and Bristol Myers Squibb Foundation. Dr Adrian A. Voors has received research grants from Boehringer Ingelheim and Roche Diagnostics; and consulting fees from Merck, Bayer, Amgen, AstraZeneca, Boehringer Ingelheim, Cytokinetics, MyoKardia, Novartis, Servier, and Roche Diagnostics. Dr Justin A. Ezekowitz has received research grants from Bayer, Merck, Servier, Amgen Sanofi, Novartis, Cytokinetics, American Regent, and Applied Therapeutics; and consulting fees from Bayer, Merck, Servier, Amgen, Sanofi, Novartis, Cytokinetics, American Regent, and Applied Therapeutics. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.\n",
      "\n",
      "Funding Support and Author Disclosures Dr Felker has received research grants from the National Heart, Lung, and Blood Institute, American Heart Association, Amgen, Bayer, BMS, Merck, Cytokinetics, and CSL Behring; has acted as a consultant to Novartis, Amgen, BMS, Cytokinetics, Medtronic, Cardionomic, Boehringer Ingelheim, American Regent, Abbott, AstraZeneca, Reprieve, Myovant, Sequana, Windtree Therapeutics, and WhiteSwell; and has served on clinical endpoint committees/data safety monitoring boards for Amgen, Merck, Medtronic, EBR Systems, V-Wave, LivaNova, Siemens, and Rocket Pharma. Dr Fudim was supported by the National Heart, Lung, and Blood Institute (K23HL151744), the American Heart Association (20IPA35310955), Bayer, Bodyport, BTG Specialty Pharmaceuticals, and Verily; and has received consulting fees from Abbott, Alleviant, Audicor, Axon Therapies, Bayer, Bodyguide, Bodyport, Boston Scientific, Coridea, CVRx, Daxor, Deerfield Catalyst, Edwards Lifesciences, the Joseph Feldschuh Foundation, Fire1, Gradient, Intershunt, Medtronic, NXT Biomedical, Pharmacosmos, PreHealth, Shifamed, Splendo, Vironix, VisCardia, and Zoll.\n",
      "\n",
      "Michael Felker, G.\n",
      "Funding Support and Author Disclosures Dr G. Michael Felker has received research grants from the National Heart, Lung, and Blood Institute, American Heart Association, Amgen, Bayer, BMS, Merck, Cytokinetics, and CSL Behring; has acted as a consultant to Novartis, Amgen, BMS, Cytokinetics, Medtronic, Cardionomic, Boehringer Ingelheim, American Regent, Abbott, AstraZeneca, Reprieve, Myovant, Sequana, Windtree Therapeutics, and WhiteSwell; and has served on clinical endpoint committees/data safety monitoring boards for Amgen, Merck, Medtronic, EBR Systems, V-Wave, LivaNova, Siemens, and Rocket Pharma. Dr Fudim was supported by the National Heart, Lung, and Blood Institute (K23HL151744), the American Heart Association (20IPA35310955), Bayer, Bodyport, BTG Specialty Pharmaceuticals, and Verily; and has received consulting fees from Abbott, Alleviant, Audicor, Axon Therapies, Bayer, Bodyguide, Bodyport, Boston Scientific, Coridea, CVRx, Daxor, Deerfield Catalyst, Edwards Lifesciences, the Joseph Feldschuh Foundation, Fire1, Gradient, Intershunt, Medtronic, NXT Biomedical, Pharmacosmos, PreHealth, Shifamed, Splendo, Vironix, VisCardia, and Zoll.\n",
      "\n",
      "Fudim, Marat\n",
      "Funding Support and Author Disclosures Dr G. Michael Felker has received research grants from the National Heart, Lung, and Blood Institute, American Heart Association, Amgen, Bayer, BMS, Merck, Cytokinetics, and CSL Behring; has acted as a consultant to Novartis, Amgen, BMS, Cytokinetics, Medtronic, Cardionomic, Boehringer Ingelheim, American Regent, Abbott, AstraZeneca, Reprieve, Myovant, Sequana, Windtree Therapeutics, and WhiteSwell; and has served on clinical endpoint committees/data safety monitoring boards for Amgen, Merck, Medtronic, EBR Systems, V-Wave, LivaNova, Siemens, and Rocket Pharma. Dr Marat Fudim was supported by the National Heart, Lung, and Blood Institute (K23HL151744), the American Heart Association (20IPA35310955), Bayer, Bodyport, BTG Specialty Pharmaceuticals, and Verily; and has received consulting fees from Abbott, Alleviant, Audicor, Axon Therapies, Bayer, Bodyguide, Bodyport, Boston Scientific, Coridea, CVRx, Daxor, Deerfield Catalyst, Edwards Lifesciences, the Joseph Feldschuh Foundation, Fire1, Gradient, Intershunt, Medtronic, NXT Biomedical, Pharmacosmos, PreHealth, Shifamed, Splendo, Vironix, VisCardia, and Zoll.\n",
      "\n",
      "Funding Support and Author Disclosures The University Medical Center Groningen, which employs some of the authors, has received research grants and/or fees from  Abbott, AstraZeneca, Boehringer Ingelheim, Cardior Pharmaceuticals, Ionis Pharmaceuticals, Novo Nordisk, and Roche (outside the submitted work). Dr de Boer is supported by a grant from the European Research Council (ERC CoG 818715, SECRETE-HF). Dr Anker has been a consultant and/or received speaker fees from Abbott, Astra, Bayer, Boehringer Ingelheim, Brahms, Cardiac Dimension, Impulse Dynamics, Janssen, Novartis, Respicardia, Servier, Stealth Peptides, St. Jude Medical, and Vifor Pharma; and has received grant support from Abbott Vascular and Vifor Pharma. Dr Metra has received personal fees from Actelion, Amgen, AstraZeneca, Abbott Vascular, Bayer, Servier, Edwards Therapeutics, Livanova, Vifor Pharma, and WindTree Therapeutics as member of trial committees or for speeches at sponsored meetings in the past 3 years. Dr Lang has received consultancy fees and/or research grants from Amgen, Applied Therapeutics, AstraZeneca, Boehringher Ingelheim, Merck Sharp & Dohme, Novartis, and Novo Nordisk. Dr de Boer has received speaker fees from Abbott, AstraZeneca, Bayer, Novartis, and Roche (outside the submitted work). Dr Voors has received fees and/or grants from Amgen, Applied Therapeutics, AstraZeneca, Bayer, Boehringer Ingelheim, Cytokinetics, GlaxoSmithKline, Merck, Myokardia, Novacardia, Novartis, Roche Diagnostics, Servier, and Vifor International. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.\n",
      "\n",
      "Funding Support and Author Disclosures The University Medical Center Groningen, which employs some of the authors, has received research grants and/or fees from  Abbott, AstraZeneca, Boehringer Ingelheim, Cardior Pharmaceuticals, Ionis Pharmaceuticals, Novo Nordisk, and Roche (outside the submitted work). Dr de Boer is supported by a grant from the European Research Council (ERC CoG 818715, SECRETE-HF). Dr Anker has been a consultant and/or received speaker fees from Abbott, Astra, Bayer, Boehringer Ingelheim, Brahms, Cardiac Dimension, Impulse Dynamics, Janssen, Novartis, Respicardia, Servier, Stealth Peptides, St. Jude Medical, and Vifor Pharma; and has received grant support from Abbott Vascular and Vifor Pharma. Dr Metra has received personal fees from Actelion, Amgen, AstraZeneca, Abbott Vascular, Bayer, Servier, Edwards Therapeutics, Livanova, Vifor Pharma, and WindTree Therapeutics as member of trial committees or for speeches at sponsored meetings in the past 3 years. Dr Lang has received consultancy fees and/or research grants from Amgen, Applied Therapeutics, AstraZeneca, Boehringher Ingelheim, Merck Sharp & Dohme, Novartis, and Novo Nordisk. Dr de Boer has received speaker fees from Abbott, AstraZeneca, Bayer, Novartis, and Roche (outside the submitted work). Dr Voors has received fees and/or grants from Amgen, Applied Therapeutics, AstraZeneca, Bayer, Boehringer Ingelheim, Cytokinetics, GlaxoSmithKline, Merck, Myokardia, Novacardia, Novartis, Roche Diagnostics, Servier, and Vifor International. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.\n",
      "\n",
      "Anker, Stefan D.\n",
      "Funding Support and Author Disclosures The University Medical Center Groningen, which employs some of the authors, has received research grants and/or fees from  Abbott, AstraZeneca, Boehringer Ingelheim, Cardior Pharmaceuticals, Ionis Pharmaceuticals, Novo Nordisk, and Roche (outside the submitted work). Dr de Boer is supported by a grant from the European Research Council (ERC CoG 818715, SECRETE-HF). Dr Stefan D. Anker has been a consultant and/or received speaker fees from Abbott, Astra, Bayer, Boehringer Ingelheim, Brahms, Cardiac Dimension, Impulse Dynamics, Janssen, Novartis, Respicardia, Servier, Stealth Peptides, St. Jude Medical, and Vifor Pharma; and has received grant support from Abbott Vascular and Vifor Pharma. Dr Metra has received personal fees from Actelion, Amgen, AstraZeneca, Abbott Vascular, Bayer, Servier, Edwards Therapeutics, Livanova, Vifor Pharma, and WindTree Therapeutics as member of trial committees or for speeches at sponsored meetings in the past 3 years. Dr Lang has received consultancy fees and/or research grants from Amgen, Applied Therapeutics, AstraZeneca, Boehringher Ingelheim, Merck Sharp & Dohme, Novartis, and Novo Nordisk. Dr de Boer has received speaker fees from Abbott, AstraZeneca, Bayer, Novartis, and Roche (outside the submitted work). Dr Voors has received fees and/or grants from Amgen, Applied Therapeutics, AstraZeneca, Bayer, Boehringer Ingelheim, Cytokinetics, GlaxoSmithKline, Merck, Myokardia, Novacardia, Novartis, Roche Diagnostics, Servier, and Vifor International. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.\n",
      "\n",
      "Funding Support and Author Disclosures The University Medical Center Groningen, which employs some of the authors, has received research grants and/or fees from  Abbott, AstraZeneca, Boehringer Ingelheim, Cardior Pharmaceuticals, Ionis Pharmaceuticals, Novo Nordisk, and Roche (outside the submitted work). Dr de Boer is supported by a grant from the European Research Council (ERC CoG 818715, SECRETE-HF). Dr Stefan D. Anker has been a consultant and/or received speaker fees from Abbott, Astra, Bayer, Boehringer Ingelheim, Brahms, Cardiac Dimension, Impulse Dynamics, Janssen, Novartis, Respicardia, Servier, Stealth Peptides, St. Jude Medical, and Vifor Pharma; and has received grant support from Abbott Vascular and Vifor Pharma. Dr Metra has received personal fees from Actelion, Amgen, AstraZeneca, Abbott Vascular, Bayer, Servier, Edwards Therapeutics, Livanova, Vifor Pharma, and WindTree Therapeutics as member of trial committees or for speeches at sponsored meetings in the past 3 years. Dr Lang has received consultancy fees and/or research grants from Amgen, Applied Therapeutics, AstraZeneca, Boehringher Ingelheim, Merck Sharp & Dohme, Novartis, and Novo Nordisk. Dr de Boer has received speaker fees from Abbott, AstraZeneca, Bayer, Novartis, and Roche (outside the submitted work). Dr Voors has received fees and/or grants from Amgen, Applied Therapeutics, AstraZeneca, Bayer, Boehringer Ingelheim, Cytokinetics, GlaxoSmithKline, Merck, Myokardia, Novacardia, Novartis, Roche Diagnostics, Servier, and Vifor International. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.\n",
      "\n",
      "Metra, Marco\n",
      "Funding Support and Author Disclosures The University Medical Center Groningen, which employs some of the authors, has received research grants and/or fees from  Abbott, AstraZeneca, Boehringer Ingelheim, Cardior Pharmaceuticals, Ionis Pharmaceuticals, Novo Nordisk, and Roche (outside the submitted work). Dr de Boer is supported by a grant from the European Research Council (ERC CoG 818715, SECRETE-HF). Dr Stefan D. Anker has been a consultant and/or received speaker fees from Abbott, Astra, Bayer, Boehringer Ingelheim, Brahms, Cardiac Dimension, Impulse Dynamics, Janssen, Novartis, Respicardia, Servier, Stealth Peptides, St. Jude Medical, and Vifor Pharma; and has received grant support from Abbott Vascular and Vifor Pharma. Dr Marco Metra has received personal fees from Actelion, Amgen, AstraZeneca, Abbott Vascular, Bayer, Servier, Edwards Therapeutics, Livanova, Vifor Pharma, and WindTree Therapeutics as member of trial committees or for speeches at sponsored meetings in the past 3 years. Dr Lang has received consultancy fees and/or research grants from Amgen, Applied Therapeutics, AstraZeneca, Boehringher Ingelheim, Merck Sharp & Dohme, Novartis, and Novo Nordisk. Dr de Boer has received speaker fees from Abbott, AstraZeneca, Bayer, Novartis, and Roche (outside the submitted work). Dr Voors has received fees and/or grants from Amgen, Applied Therapeutics, AstraZeneca, Bayer, Boehringer Ingelheim, Cytokinetics, GlaxoSmithKline, Merck, Myokardia, Novacardia, Novartis, Roche Diagnostics, Servier, and Vifor International. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.\n",
      "\n",
      "Funding Support and Author Disclosures The University Medical Center Groningen, which employs some of the authors, has received research grants and/or fees from  Abbott, AstraZeneca, Boehringer Ingelheim, Cardior Pharmaceuticals, Ionis Pharmaceuticals, Novo Nordisk, and Roche (outside the submitted work). Dr de Boer is supported by a grant from the European Research Council (ERC CoG 818715, SECRETE-HF). Dr Stefan D. Anker has been a consultant and/or received speaker fees from Abbott, Astra, Bayer, Boehringer Ingelheim, Brahms, Cardiac Dimension, Impulse Dynamics, Janssen, Novartis, Respicardia, Servier, Stealth Peptides, St. Jude Medical, and Vifor Pharma; and has received grant support from Abbott Vascular and Vifor Pharma. Dr Marco Metra has received personal fees from Actelion, Amgen, AstraZeneca, Abbott Vascular, Bayer, Servier, Edwards Therapeutics, Livanova, Vifor Pharma, and WindTree Therapeutics as member of trial committees or for speeches at sponsored meetings in the past 3 years. Dr Lang has received consultancy fees and/or research grants from Amgen, Applied Therapeutics, AstraZeneca, Boehringher Ingelheim, Merck Sharp & Dohme, Novartis, and Novo Nordisk. Dr de Boer has received speaker fees from Abbott, AstraZeneca, Bayer, Novartis, and Roche (outside the submitted work). Dr Voors has received fees and/or grants from Amgen, Applied Therapeutics, AstraZeneca, Bayer, Boehringer Ingelheim, Cytokinetics, GlaxoSmithKline, Merck, Myokardia, Novacardia, Novartis, Roche Diagnostics, Servier, and Vifor International. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.\n",
      "\n",
      "Lang, Chim C.\n",
      "Funding Support and Author Disclosures The University Medical Center Groningen, which employs some of the authors, has received research grants and/or fees from  Abbott, AstraZeneca, Boehringer Ingelheim, Cardior Pharmaceuticals, Ionis Pharmaceuticals, Novo Nordisk, and Roche (outside the submitted work). Dr de Boer is supported by a grant from the European Research Council (ERC CoG 818715, SECRETE-HF). Dr Stefan D. Anker has been a consultant and/or received speaker fees from Abbott, Astra, Bayer, Boehringer Ingelheim, Brahms, Cardiac Dimension, Impulse Dynamics, Janssen, Novartis, Respicardia, Servier, Stealth Peptides, St. Jude Medical, and Vifor Pharma; and has received grant support from Abbott Vascular and Vifor Pharma. Dr Marco Metra has received personal fees from Actelion, Amgen, AstraZeneca, Abbott Vascular, Bayer, Servier, Edwards Therapeutics, Livanova, Vifor Pharma, and WindTree Therapeutics as member of trial committees or for speeches at sponsored meetings in the past 3 years. Dr Chim C. Lang has received consultancy fees and/or research grants from Amgen, Applied Therapeutics, AstraZeneca, Boehringher Ingelheim, Merck Sharp & Dohme, Novartis, and Novo Nordisk. Dr de Boer has received speaker fees from Abbott, AstraZeneca, Bayer, Novartis, and Roche (outside the submitted work). Dr Voors has received fees and/or grants from Amgen, Applied Therapeutics, AstraZeneca, Bayer, Boehringer Ingelheim, Cytokinetics, GlaxoSmithKline, Merck, Myokardia, Novacardia, Novartis, Roche Diagnostics, Servier, and Vifor International. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.\n",
      "\n",
      "Funding Support and Author Disclosures The University Medical Center Groningen, which employs some of the authors, has received research grants and/or fees from  Abbott, AstraZeneca, Boehringer Ingelheim, Cardior Pharmaceuticals, Ionis Pharmaceuticals, Novo Nordisk, and Roche (outside the submitted work). Dr de Boer is supported by a grant from the European Research Council (ERC CoG 818715, SECRETE-HF). Dr Stefan D. Anker has been a consultant and/or received speaker fees from Abbott, Astra, Bayer, Boehringer Ingelheim, Brahms, Cardiac Dimension, Impulse Dynamics, Janssen, Novartis, Respicardia, Servier, Stealth Peptides, St. Jude Medical, and Vifor Pharma; and has received grant support from Abbott Vascular and Vifor Pharma. Dr Marco Metra has received personal fees from Actelion, Amgen, AstraZeneca, Abbott Vascular, Bayer, Servier, Edwards Therapeutics, Livanova, Vifor Pharma, and WindTree Therapeutics as member of trial committees or for speeches at sponsored meetings in the past 3 years. Dr Chim C. Lang has received consultancy fees and/or research grants from Amgen, Applied Therapeutics, AstraZeneca, Boehringher Ingelheim, Merck Sharp & Dohme, Novartis, and Novo Nordisk. Dr de Boer has received speaker fees from Abbott, AstraZeneca, Bayer, Novartis, and Roche (outside the submitted work). Dr Voors has received fees and/or grants from Amgen, Applied Therapeutics, AstraZeneca, Bayer, Boehringer Ingelheim, Cytokinetics, GlaxoSmithKline, Merck, Myokardia, Novacardia, Novartis, Roche Diagnostics, Servier, and Vifor International. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.\n",
      "\n",
      "A de Boer, Rudolf\n",
      "Funding Support and Author Disclosures The University Medical Center Groningen, which employs some of the authors, has received research grants and/or fees from  Abbott, AstraZeneca, Boehringer Ingelheim, Cardior Pharmaceuticals, Ionis Pharmaceuticals, Novo Nordisk, and Roche (outside the submitted work). Dr de Rudolf A de Boer is supported by a grant from the European Research Council (ERC CoG 818715, SECRETE-HF). Dr Stefan D. Anker has been a consultant and/or received speaker fees from Abbott, Astra, Bayer, Boehringer Ingelheim, Brahms, Cardiac Dimension, Impulse Dynamics, Janssen, Novartis, Respicardia, Servier, Stealth Peptides, St. Jude Medical, and Vifor Pharma; and has received grant support from Abbott Vascular and Vifor Pharma. Dr Marco Metra has received personal fees from Actelion, Amgen, AstraZeneca, Abbott Vascular, Bayer, Servier, Edwards Therapeutics, Livanova, Vifor Pharma, and WindTree Therapeutics as member of trial committees or for speeches at sponsored meetings in the past 3 years. Dr Chim C. Lang has received consultancy fees and/or research grants from Amgen, Applied Therapeutics, AstraZeneca, Boehringher Ingelheim, Merck Sharp & Dohme, Novartis, and Novo Nordisk. Dr de Rudolf A de Boer has received speaker fees from Abbott, AstraZeneca, Bayer, Novartis, and Roche (outside the submitted work). Dr Voors has received fees and/or grants from Amgen, Applied Therapeutics, AstraZeneca, Bayer, Boehringer Ingelheim, Cytokinetics, GlaxoSmithKline, Merck, Myokardia, Novacardia, Novartis, Roche Diagnostics, Servier, and Vifor International. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.\n",
      "\n",
      "Funding Support and Author Disclosures The University Medical Center Groningen, which employs some of the authors, has received research grants and/or fees from  Abbott, AstraZeneca, Boehringer Ingelheim, Cardior Pharmaceuticals, Ionis Pharmaceuticals, Novo Nordisk, and Roche (outside the submitted work). Dr de Rudolf A de Boer is supported by a grant from the European Research Council (ERC CoG 818715, SECRETE-HF). Dr Stefan D. Anker has been a consultant and/or received speaker fees from Abbott, Astra, Bayer, Boehringer Ingelheim, Brahms, Cardiac Dimension, Impulse Dynamics, Janssen, Novartis, Respicardia, Servier, Stealth Peptides, St. Jude Medical, and Vifor Pharma; and has received grant support from Abbott Vascular and Vifor Pharma. Dr Marco Metra has received personal fees from Actelion, Amgen, AstraZeneca, Abbott Vascular, Bayer, Servier, Edwards Therapeutics, Livanova, Vifor Pharma, and WindTree Therapeutics as member of trial committees or for speeches at sponsored meetings in the past 3 years. Dr Chim C. Lang has received consultancy fees and/or research grants from Amgen, Applied Therapeutics, AstraZeneca, Boehringher Ingelheim, Merck Sharp & Dohme, Novartis, and Novo Nordisk. Dr de Rudolf A de Boer has received speaker fees from Abbott, AstraZeneca, Bayer, Novartis, and Roche (outside the submitted work). Dr Voors has received fees and/or grants from Amgen, Applied Therapeutics, AstraZeneca, Bayer, Boehringer Ingelheim, Cytokinetics, GlaxoSmithKline, Merck, Myokardia, Novacardia, Novartis, Roche Diagnostics, Servier, and Vifor International. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.\n",
      "\n",
      "Voors, Adriaan A.\n",
      "Funding Support and Author Disclosures The University Medical Center Groningen, which employs some of the authors, has received research grants and/or fees from  Abbott, AstraZeneca, Boehringer Ingelheim, Cardior Pharmaceuticals, Ionis Pharmaceuticals, Novo Nordisk, and Roche (outside the submitted work). Dr de Rudolf A de Boer is supported by a grant from the European Research Council (ERC CoG 818715, SECRETE-HF). Dr Stefan D. Anker has been a consultant and/or received speaker fees from Abbott, Astra, Bayer, Boehringer Ingelheim, Brahms, Cardiac Dimension, Impulse Dynamics, Janssen, Novartis, Respicardia, Servier, Stealth Peptides, St. Jude Medical, and Vifor Pharma; and has received grant support from Abbott Vascular and Vifor Pharma. Dr Marco Metra has received personal fees from Actelion, Amgen, AstraZeneca, Abbott Vascular, Bayer, Servier, Edwards Therapeutics, Livanova, Vifor Pharma, and WindTree Therapeutics as member of trial committees or for speeches at sponsored meetings in the past 3 years. Dr Chim C. Lang has received consultancy fees and/or research grants from Amgen, Applied Therapeutics, AstraZeneca, Boehringher Ingelheim, Merck Sharp & Dohme, Novartis, and Novo Nordisk. Dr de Rudolf A de Boer has received speaker fees from Abbott, AstraZeneca, Bayer, Novartis, and Roche (outside the submitted work). Dr Adriaan A. Voors has received fees and/or grants from Amgen, Applied Therapeutics, AstraZeneca, Bayer, Boehringer Ingelheim, Cytokinetics, GlaxoSmithKline, Merck, Myokardia, Novacardia, Novartis, Roche Diagnostics, Servier, and Vifor International. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.\n",
      "\n",
      "Funding Support and Author Disclosures The University Medical Center Groningen, which employs some of the authors, has received research grants and/or fees from  Abbott, AstraZeneca, Boehringer Ingelheim, Cardior Pharmaceuticals, Ionis Pharmaceuticals, Novo Nordisk, and Roche (outside the submitted work). Dr de Rudolf A de Boer is supported by a grant from the European Research Council (ERC CoG 818715, SECRETE-HF). Dr Stefan D. Anker has been a consultant and/or received speaker fees from Abbott, Astra, Bayer, Boehringer Ingelheim, Brahms, Cardiac Dimension, Impulse Dynamics, Janssen, Novartis, Respicardia, Servier, Stealth Peptides, St. Jude Medical, and Vifor Pharma; and has received grant support from Abbott Vascular and Vifor Pharma. Dr Marco Metra has received personal fees from Actelion, Amgen, AstraZeneca, Abbott Vascular, Bayer, Servier, Edwards Therapeutics, Livanova, Vifor Pharma, and WindTree Therapeutics as member of trial committees or for speeches at sponsored meetings in the past 3 years. Dr Chim C. Lang has received consultancy fees and/or research grants from Amgen, Applied Therapeutics, AstraZeneca, Boehringher Ingelheim, Merck Sharp & Dohme, Novartis, and Novo Nordisk. Dr de Rudolf A de Boer has received speaker fees from Abbott, AstraZeneca, Bayer, Novartis, and Roche (outside the submitted work). Dr Adriaan A. Voors has received fees and/or grants from Amgen, Applied Therapeutics, AstraZeneca, Bayer, Boehringer Ingelheim, Cytokinetics, GlaxoSmithKline, Merck, Myokardia, Novacardia, Novartis, Roche Diagnostics, Servier, and Vifor International. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.\n",
      "\n",
      "Funding Support and Author Disclosures Dr Greene has received research support from the Duke University Department of Medicine Chair's Research Award, American  Heart Association, Amgen, AstraZeneca, Bristol Myers Squibb, Cytokinetics, Merck, Novartis, Pfizer, and Sanofi; has served on advisory boards for Amgen, AstraZeneca, Bristol Myers Squibb, Cytokinetics, Roche Diagnostics, and Sanofi; has received speaker fees from Boehringer Ingelheim; and serves as a consultant for Amgen, Bayer, Bristol Myers Squibb, Merck, PharmaIN, Sanofi, Tricog Health, Urovant Pharmaceuticals, and Vifor. Dr Al'Aref is supported by National Institutes of Health 2R01 HL12766105 and 1R21 EB030654; and has received royalty  fees from Elsevier. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.\n",
      "\n",
      "Funding Support and Author Disclosures Dr Greene has received research support from the Duke University Department of Medicine Chair's Research Award, American  Heart Association, Amgen, AstraZeneca, Bristol Myers Squibb, Cytokinetics, Merck, Novartis, Pfizer, and Sanofi; has served on advisory boards for Amgen, AstraZeneca, Bristol Myers Squibb, Cytokinetics, Roche Diagnostics, and Sanofi; has received speaker fees from Boehringer Ingelheim; and serves as a consultant for Amgen, Bayer, Bristol Myers Squibb, Merck, PharmaIN, Sanofi, Tricog Health, Urovant Pharmaceuticals, and Vifor. Dr Al'Aref is supported by National Institutes of Health 2R01 HL12766105 and 1R21 EB030654; and has received royalty  fees from Elsevier. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.\n",
      "\n",
      "Funding Support and Author Disclosures Dr Greene has received research support from the Duke University Department of Medicine Chair's Research Award, American  Heart Association, Amgen, AstraZeneca, Bristol Myers Squibb, Cytokinetics, Merck, Novartis, Pfizer, and Sanofi; has served on advisory boards for Amgen, AstraZeneca, Bristol Myers Squibb, Cytokinetics, Roche Diagnostics, and Sanofi; has received speaker fees from Boehringer Ingelheim; and serves as a consultant for Amgen, Bayer, Bristol Myers Squibb, Merck, PharmaIN, Sanofi, Tricog Health, Urovant Pharmaceuticals, and Vifor. Dr Al'Aref is supported by National Institutes of Health 2R01 HL12766105 and 1R21 EB030654; and has received royalty  fees from Elsevier. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.\n",
      "\n",
      "Funding Support and Author Disclosures Dr Greene has received research support from the Duke University Department of Medicine Chair's Research Award, American  Heart Association, Amgen, AstraZeneca, Bristol Myers Squibb, Cytokinetics, Merck, Novartis, Pfizer, and Sanofi; has served on advisory boards for Amgen, AstraZeneca, Bristol Myers Squibb, Cytokinetics, Roche Diagnostics, and Sanofi; has received speaker fees from Boehringer Ingelheim; and serves as a consultant for Amgen, Bayer, Bristol Myers Squibb, Merck, PharmaIN, Sanofi, Tricog Health, Urovant Pharmaceuticals, and Vifor. Dr Al'Aref is supported by National Institutes of Health 2R01 HL12766105 and 1R21 EB030654; and has received royalty  fees from Elsevier. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.\n",
      "\n",
      "Funding Support and Author Disclosures Dr Greene has received research support from the Duke University Department of Medicine Chair's Research Award, American  Heart Association, Amgen, AstraZeneca, Bristol Myers Squibb, Cytokinetics, Merck, Novartis, Pfizer, and Sanofi; has served on advisory boards for Amgen, AstraZeneca, Bristol Myers Squibb, Cytokinetics, Roche Diagnostics, and Sanofi; has received speaker fees from Boehringer Ingelheim; and serves as a consultant for Amgen, Bayer, Bristol Myers Squibb, Merck, PharmaIN, Sanofi, Tricog Health, Urovant Pharmaceuticals, and Vifor. Dr Al'Aref is supported by National Institutes of Health 2R01 HL12766105 and 1R21 EB030654; and has received royalty  fees from Elsevier. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.\n",
      "\n",
      "Funding Support and Author Disclosures Dr Greene has received research support from the Duke University Department of Medicine Chair's Research Award, American  Heart Association, Amgen, AstraZeneca, Bristol Myers Squibb, Cytokinetics, Merck, Novartis, Pfizer, and Sanofi; has served on advisory boards for Amgen, AstraZeneca, Bristol Myers Squibb, Cytokinetics, Roche Diagnostics, and Sanofi; has received speaker fees from Boehringer Ingelheim; and serves as a consultant for Amgen, Bayer, Bristol Myers Squibb, Merck, PharmaIN, Sanofi, Tricog Health, Urovant Pharmaceuticals, and Vifor. Dr Al'Aref is supported by National Institutes of Health 2R01 HL12766105 and 1R21 EB030654; and has received royalty  fees from Elsevier. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.\n",
      "\n",
      "Funding Support and Author Disclosures Dr Greene has received research support from the Duke University Department of Medicine Chair's Research Award, American  Heart Association, Amgen, AstraZeneca, Bristol Myers Squibb, Cytokinetics, Merck, Novartis, Pfizer, and Sanofi; has served on advisory boards for Amgen, AstraZeneca, Bristol Myers Squibb, Cytokinetics, Roche Diagnostics, and Sanofi; has received speaker fees from Boehringer Ingelheim; and serves as a consultant for Amgen, Bayer, Bristol Myers Squibb, Merck, PharmaIN, Sanofi, Tricog Health, Urovant Pharmaceuticals, and Vifor. Dr Al'Aref is supported by National Institutes of Health 2R01 HL12766105 and 1R21 EB030654; and has received royalty  fees from Elsevier. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.\n",
      "\n",
      "Funding Support and Author Disclosures Dr Greene has received research support from the Duke University Department of Medicine Chair's Research Award, American  Heart Association, Amgen, AstraZeneca, Bristol Myers Squibb, Cytokinetics, Merck, Novartis, Pfizer, and Sanofi; has served on advisory boards for Amgen, AstraZeneca, Bristol Myers Squibb, Cytokinetics, Roche Diagnostics, and Sanofi; has received speaker fees from Boehringer Ingelheim; and serves as a consultant for Amgen, Bayer, Bristol Myers Squibb, Merck, PharmaIN, Sanofi, Tricog Health, Urovant Pharmaceuticals, and Vifor. Dr Al'Aref is supported by National Institutes of Health 2R01 HL12766105 and 1R21 EB030654; and has received royalty  fees from Elsevier. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.\n",
      "\n",
      "Funding Support and Author Disclosures Dr Greene has received research support from the Duke University Department of Medicine Chair's Research Award, American  Heart Association, Amgen, AstraZeneca, Bristol Myers Squibb, Cytokinetics, Merck, Novartis, Pfizer, and Sanofi; has served on advisory boards for Amgen, AstraZeneca, Bristol Myers Squibb, Cytokinetics, Roche Diagnostics, and Sanofi; has received speaker fees from Boehringer Ingelheim; and serves as a consultant for Amgen, Bayer, Bristol Myers Squibb, Merck, PharmaIN, Sanofi, Tricog Health, Urovant Pharmaceuticals, and Vifor. Dr Al'Aref is supported by National Institutes of Health 2R01 HL12766105 and 1R21 EB030654; and has received royalty  fees from Elsevier. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.\n",
      "\n",
      "Greene, Stephen J.\n",
      "Funding Support and Author Disclosures Dr Stephen J. Greene has received research support from the Duke University Department of Medicine Chair's Research Award, American  Heart Association, Amgen, AstraZeneca, Bristol Myers Squibb, Cytokinetics, Merck, Novartis, Pfizer, and Sanofi; has served on advisory boards for Amgen, AstraZeneca, Bristol Myers Squibb, Cytokinetics, Roche Diagnostics, and Sanofi; has received speaker fees from Boehringer Ingelheim; and serves as a consultant for Amgen, Bayer, Bristol Myers Squibb, Merck, PharmaIN, Sanofi, Tricog Health, Urovant Pharmaceuticals, and Vifor. Dr Al'Aref is supported by National Institutes of Health 2R01 HL12766105 and 1R21 EB030654; and has received royalty  fees from Elsevier. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.\n",
      "\n",
      "Funding Support and Author Disclosures Dr Stephen J. Greene has received research support from the Duke University Department of Medicine Chair's Research Award, American  Heart Association, Amgen, AstraZeneca, Bristol Myers Squibb, Cytokinetics, Merck, Novartis, Pfizer, and Sanofi; has served on advisory boards for Amgen, AstraZeneca, Bristol Myers Squibb, Cytokinetics, Roche Diagnostics, and Sanofi; has received speaker fees from Boehringer Ingelheim; and serves as a consultant for Amgen, Bayer, Bristol Myers Squibb, Merck, PharmaIN, Sanofi, Tricog Health, Urovant Pharmaceuticals, and Vifor. Dr Al'Aref is supported by National Institutes of Health 2R01 HL12766105 and 1R21 EB030654; and has received royalty  fees from Elsevier. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.\n",
      "\n",
      "Al'Aref, Subhi J.\n",
      "Funding Support and Author Disclosures Dr Stephen J. Greene has received research support from the Duke University Department of Medicine Chair's Research Award, American  Heart Association, Amgen, AstraZeneca, Bristol Myers Squibb, Cytokinetics, Merck, Novartis, Pfizer, and Sanofi; has served on advisory boards for Amgen, AstraZeneca, Bristol Myers Squibb, Cytokinetics, Roche Diagnostics, and Sanofi; has received speaker fees from Boehringer Ingelheim; and serves as a consultant for Amgen, Bayer, Bristol Myers Squibb, Merck, PharmaIN, Sanofi, Tricog Health, Urovant Pharmaceuticals, and Vifor. Dr Subhi J. Al'Aref is supported by National Institutes of Health 2R01 HL12766105 and 1R21 EB030654; and has received royalty  fees from Elsevier. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.\n",
      "\n",
      "Funding Support and Author Disclosures This research was funded by the German Research Foundation DFG (SFB834 project number 75732319) and the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation program (grant agreement No 759248) (to Dr Stellos). Dr Sopova was supported with a scholarship from the German Heart Foundation (Deutsche Herzstiftung). The authors have reported that they have no relationships relevant to the contents of this paper to disclose.\n",
      "\n",
      "Funding Support and Author Disclosures This research was funded by the German Research Foundation DFG (SFB834 project number 75732319) and the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation program (grant agreement No 759248) (to Dr Stellos). Dr Sopova was supported with a scholarship from the German Heart Foundation (Deutsche Herzstiftung). The authors have reported that they have no relationships relevant to the contents of this paper to disclose.\n",
      "\n",
      "Funding Support and Author Disclosures This research was funded by the German Research Foundation DFG (SFB834 project number 75732319) and the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation program (grant agreement No 759248) (to Dr Stellos). Dr Sopova was supported with a scholarship from the German Heart Foundation (Deutsche Herzstiftung). The authors have reported that they have no relationships relevant to the contents of this paper to disclose.\n",
      "\n",
      "Funding Support and Author Disclosures This research was funded by the German Research Foundation DFG (SFB834 project number 75732319) and the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation program (grant agreement No 759248) (to Dr Stellos). Dr Sopova was supported with a scholarship from the German Heart Foundation (Deutsche Herzstiftung). The authors have reported that they have no relationships relevant to the contents of this paper to disclose.\n",
      "\n",
      "Funding Support and Author Disclosures This research was funded by the German Research Foundation DFG (SFB834 project number 75732319) and the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation program (grant agreement No 759248) (to Dr Stellos). Dr Sopova was supported with a scholarship from the German Heart Foundation (Deutsche Herzstiftung). The authors have reported that they have no relationships relevant to the contents of this paper to disclose.\n",
      "\n",
      "Funding Support and Author Disclosures This research was funded by the German Research Foundation DFG (SFB834 project number 75732319) and the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation program (grant agreement No 759248) (to Dr Stellos). Dr Sopova was supported with a scholarship from the German Heart Foundation (Deutsche Herzstiftung). The authors have reported that they have no relationships relevant to the contents of this paper to disclose.\n",
      "\n",
      "Sopova, Kateryna\n",
      "Funding Support and Author Disclosures This research was funded by the German Research Foundation DFG (SFB834 project number 75732319) and the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation program (grant agreement No 759248) (to Dr Stellos). Dr Kateryna Sopova was supported with a scholarship from the German Heart Foundation (Deutsche Herzstiftung). The authors have reported that they have no relationships relevant to the contents of this paper to disclose.\n",
      "\n",
      "Funding Support and Author Disclosures This research was funded by the German Research Foundation DFG (SFB834 project number 75732319) and the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation program (grant agreement No 759248) (to Dr Stellos). Dr Kateryna Sopova was supported with a scholarship from the German Heart Foundation (Deutsche Herzstiftung). The authors have reported that they have no relationships relevant to the contents of this paper to disclose.\n",
      "\n",
      "Bonini, Francesca\n",
      "Funding Support and Author Disclosures This research was funded by the German Research Foundation DFG (SFrancesca Bonini834 project number 75732319) and the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation program (grant agreement No 759248) (to Dr Stellos). Dr Kateryna Sopova was supported with a scholarship from the German Heart Foundation (Deutsche Herzstiftung). The authors have reported that they have no relationships relevant to the contents of this paper to disclose.\n",
      "\n",
      "Funding Support and Author Disclosures This research was funded by the German Research Foundation DFG (SFrancesca Bonini834 project number 75732319) and the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation program (grant agreement No 759248) (to Dr Stellos). Dr Kateryna Sopova was supported with a scholarship from the German Heart Foundation (Deutsche Herzstiftung). The authors have reported that they have no relationships relevant to the contents of this paper to disclose.\n",
      "\n",
      "Funding Support and Author Disclosures This research was funded by the German Research Foundation DFG (SFrancesca Bonini834 project number 75732319) and the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation program (grant agreement No 759248) (to Dr Stellos). Dr Kateryna Sopova was supported with a scholarship from the German Heart Foundation (Deutsche Herzstiftung). The authors have reported that they have no relationships relevant to the contents of this paper to disclose.\n",
      "\n",
      "Funding Support and Author Disclosures This research was funded by the German Research Foundation DFG (SFrancesca Bonini834 project number 75732319) and the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation program (grant agreement No 759248) (to Dr Stellos). Dr Kateryna Sopova was supported with a scholarship from the German Heart Foundation (Deutsche Herzstiftung). The authors have reported that they have no relationships relevant to the contents of this paper to disclose.\n",
      "\n",
      "Funding Support and Author Disclosures This research was funded by the German Research Foundation DFG (SFrancesca Bonini834 project number 75732319) and the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation program (grant agreement No 759248) (to Dr Stellos). Dr Kateryna Sopova was supported with a scholarship from the German Heart Foundation (Deutsche Herzstiftung). The authors have reported that they have no relationships relevant to the contents of this paper to disclose.\n",
      "\n",
      "Funding Support and Author Disclosures This research was funded by the German Research Foundation DFG (SFrancesca Bonini834 project number 75732319) and the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation program (grant agreement No 759248) (to Dr Stellos). Dr Kateryna Sopova was supported with a scholarship from the German Heart Foundation (Deutsche Herzstiftung). The authors have reported that they have no relationships relevant to the contents of this paper to disclose.\n",
      "\n",
      "Funding Support and Author Disclosures This research was funded by the German Research Foundation DFG (SFrancesca Bonini834 project number 75732319) and the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation program (grant agreement No 759248) (to Dr Stellos). Dr Kateryna Sopova was supported with a scholarship from the German Heart Foundation (Deutsche Herzstiftung). The authors have reported that they have no relationships relevant to the contents of this paper to disclose.\n",
      "\n",
      "Funding Support and Author Disclosures This research was funded by the German Research Foundation DFG (SFrancesca Bonini834 project number 75732319) and the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation program (grant agreement No 759248) (to Dr Stellos). Dr Kateryna Sopova was supported with a scholarship from the German Heart Foundation (Deutsche Herzstiftung). The authors have reported that they have no relationships relevant to the contents of this paper to disclose.\n",
      "\n",
      "Funding Support and Author Disclosures This research was funded by the German Research Foundation DFG (SFrancesca Bonini834 project number 75732319) and the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation program (grant agreement No 759248) (to Dr Stellos). Dr Kateryna Sopova was supported with a scholarship from the German Heart Foundation (Deutsche Herzstiftung). The authors have reported that they have no relationships relevant to the contents of this paper to disclose.\n",
      "\n",
      "Funding Support and Author Disclosures This research was funded by the German Research Foundation DFG (SFrancesca Bonini834 project number 75732319) and the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation program (grant agreement No 759248) (to Dr Stellos). Dr Kateryna Sopova was supported with a scholarship from the German Heart Foundation (Deutsche Herzstiftung). The authors have reported that they have no relationships relevant to the contents of this paper to disclose.\n",
      "\n",
      "Funding Support and Author Disclosures This research was funded by the German Research Foundation DFG (SFrancesca Bonini834 project number 75732319) and the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation program (grant agreement No 759248) (to Dr Stellos). Dr Kateryna Sopova was supported with a scholarship from the German Heart Foundation (Deutsche Herzstiftung). The authors have reported that they have no relationships relevant to the contents of this paper to disclose.\n",
      "\n",
      "Funding Support and Author Disclosures This research was funded by the German Research Foundation DFG (SFrancesca Bonini834 project number 75732319) and the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation program (grant agreement No 759248) (to Dr Stellos). Dr Kateryna Sopova was supported with a scholarship from the German Heart Foundation (Deutsche Herzstiftung). The authors have reported that they have no relationships relevant to the contents of this paper to disclose.\n",
      "\n",
      "Funding Support and Author Disclosures This research was funded by the German Research Foundation DFG (SFrancesca Bonini834 project number 75732319) and the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation program (grant agreement No 759248) (to Dr Stellos). Dr Kateryna Sopova was supported with a scholarship from the German Heart Foundation (Deutsche Herzstiftung). The authors have reported that they have no relationships relevant to the contents of this paper to disclose.\n",
      "\n",
      "Funding Support and Author Disclosures This research was funded by the German Research Foundation DFG (SFrancesca Bonini834 project number 75732319) and the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation program (grant agreement No 759248) (to Dr Stellos). Dr Kateryna Sopova was supported with a scholarship from the German Heart Foundation (Deutsche Herzstiftung). The authors have reported that they have no relationships relevant to the contents of this paper to disclose.\n",
      "\n",
      "Funding Support and Author Disclosures This research was funded by the German Research Foundation DFG (SFrancesca Bonini834 project number 75732319) and the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation program (grant agreement No 759248) (to Dr Stellos). Dr Kateryna Sopova was supported with a scholarship from the German Heart Foundation (Deutsche Herzstiftung). The authors have reported that they have no relationships relevant to the contents of this paper to disclose.\n",
      "\n",
      "Stellos, Konstantinos\n",
      "Funding Support and Author Disclosures This research was funded by the German Research Foundation DFG (SFrancesca Bonini834 project number 75732319) and the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation program (grant agreement No 759248) (to Dr Konstantinos Stellos). Dr Kateryna Sopova was supported with a scholarship from the German Heart Foundation (Deutsche Herzstiftung). The authors have reported that they have no relationships relevant to the contents of this paper to disclose.\n",
      "\n",
      "Orsborne, Christopher\n",
      "Funding Support and Author Disclosures Siemens provided access to Work in Progress sequences. Siemens had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation or  approval of the manuscript; and decision to submit the manuscript for publication. Drs Christopher Orsborne, Schmitt, Jovanovic, and Miller have received research  support from Amicus Therapeutics. Dr Naish has a part time appointment at Bioxydyn Ltd, a company that provides MRI services. Dr Miller has an Advanced Fellowship, NIHR301338, funded by the National Institute for Health Research; has received research support from Guerbet Laboratories Limited, Roche, and Univar Solutions BV; has served on advisory boards for Novartis, Boehringer Ingelheim and Lilly Alliance, and AstraZeneca; and serves as an advisor for HAYA Therapeutics and PureTech Health. Dr Reid has received honoraria from Shire and Sanofi Genzyme. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.\n",
      "\n",
      "Funding Support and Author Disclosures Siemens provided access to Work in Progress sequences. Siemens had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation or  approval of the manuscript; and decision to submit the manuscript for publication. Drs Christopher Orsborne, Schmitt, Jovanovic, and Miller have received research  support from Amicus Therapeutics. Dr Naish has a part time appointment at Bioxydyn Ltd, a company that provides MRI services. Dr Miller has an Advanced Fellowship, NIHR301338, funded by the National Institute for Health Research; has received research support from Guerbet Laboratories Limited, Roche, and Univar Solutions BV; has served on advisory boards for Novartis, Boehringer Ingelheim and Lilly Alliance, and AstraZeneca; and serves as an advisor for HAYA Therapeutics and PureTech Health. Dr Reid has received honoraria from Shire and Sanofi Genzyme. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.\n",
      "\n",
      "Funding Support and Author Disclosures Siemens provided access to Work in Progress sequences. Siemens had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation or  approval of the manuscript; and decision to submit the manuscript for publication. Drs Christopher Orsborne, Schmitt, Jovanovic, and Miller have received research  support from Amicus Therapeutics. Dr Naish has a part time appointment at Bioxydyn Ltd, a company that provides MRI services. Dr Miller has an Advanced Fellowship, NIHR301338, funded by the National Institute for Health Research; has received research support from Guerbet Laboratories Limited, Roche, and Univar Solutions BV; has served on advisory boards for Novartis, Boehringer Ingelheim and Lilly Alliance, and AstraZeneca; and serves as an advisor for HAYA Therapeutics and PureTech Health. Dr Reid has received honoraria from Shire and Sanofi Genzyme. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.\n",
      "\n",
      "Funding Support and Author Disclosures Siemens provided access to Work in Progress sequences. Siemens had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation or  approval of the manuscript; and decision to submit the manuscript for publication. Drs Christopher Orsborne, Schmitt, Jovanovic, and Miller have received research  support from Amicus Therapeutics. Dr Naish has a part time appointment at Bioxydyn Ltd, a company that provides MRI services. Dr Miller has an Advanced Fellowship, NIHR301338, funded by the National Institute for Health Research; has received research support from Guerbet Laboratories Limited, Roche, and Univar Solutions BV; has served on advisory boards for Novartis, Boehringer Ingelheim and Lilly Alliance, and AstraZeneca; and serves as an advisor for HAYA Therapeutics and PureTech Health. Dr Reid has received honoraria from Shire and Sanofi Genzyme. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.\n",
      "\n",
      "Naish, Josephine H.\n",
      "Funding Support and Author Disclosures Siemens provided access to Work in Progress sequences. Siemens had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation or  approval of the manuscript; and decision to submit the manuscript for publication. Drs Christopher Orsborne, Schmitt, Jovanovic, and Miller have received research  support from Amicus Therapeutics. Dr Josephine H. Naish has a part time appointment at Bioxydyn Ltd, a company that provides MRI services. Dr Miller has an Advanced Fellowship, NIHR301338, funded by the National Institute for Health Research; has received research support from Guerbet Laboratories Limited, Roche, and Univar Solutions BV; has served on advisory boards for Novartis, Boehringer Ingelheim and Lilly Alliance, and AstraZeneca; and serves as an advisor for HAYA Therapeutics and PureTech Health. Dr Reid has received honoraria from Shire and Sanofi Genzyme. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.\n",
      "\n",
      "Funding Support and Author Disclosures Siemens provided access to Work in Progress sequences. Siemens had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation or  approval of the manuscript; and decision to submit the manuscript for publication. Drs Christopher Orsborne, Schmitt, Jovanovic, and Miller have received research  support from Amicus Therapeutics. Dr Josephine H. Naish has a part time appointment at Bioxydyn Ltd, a company that provides MRI services. Dr Miller has an Advanced Fellowship, NIHR301338, funded by the National Institute for Health Research; has received research support from Guerbet Laboratories Limited, Roche, and Univar Solutions BV; has served on advisory boards for Novartis, Boehringer Ingelheim and Lilly Alliance, and AstraZeneca; and serves as an advisor for HAYA Therapeutics and PureTech Health. Dr Reid has received honoraria from Shire and Sanofi Genzyme. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.\n",
      "\n",
      "Funding Support and Author Disclosures Siemens provided access to Work in Progress sequences. Siemens had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation or  approval of the manuscript; and decision to submit the manuscript for publication. Drs Christopher Orsborne, Schmitt, Jovanovic, and Miller have received research  support from Amicus Therapeutics. Dr Josephine H. Naish has a part time appointment at Bioxydyn Ltd, a company that provides MRI services. Dr Miller has an Advanced Fellowship, NIHR301338, funded by the National Institute for Health Research; has received research support from Guerbet Laboratories Limited, Roche, and Univar Solutions BV; has served on advisory boards for Novartis, Boehringer Ingelheim and Lilly Alliance, and AstraZeneca; and serves as an advisor for HAYA Therapeutics and PureTech Health. Dr Reid has received honoraria from Shire and Sanofi Genzyme. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.\n",
      "\n",
      "Funding Support and Author Disclosures Siemens provided access to Work in Progress sequences. Siemens had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation or  approval of the manuscript; and decision to submit the manuscript for publication. Drs Christopher Orsborne, Schmitt, Jovanovic, and Miller have received research  support from Amicus Therapeutics. Dr Josephine H. Naish has a part time appointment at Bioxydyn Ltd, a company that provides MRI services. Dr Miller has an Advanced Fellowship, NIHR301338, funded by the National Institute for Health Research; has received research support from Guerbet Laboratories Limited, Roche, and Univar Solutions BV; has served on advisory boards for Novartis, Boehringer Ingelheim and Lilly Alliance, and AstraZeneca; and serves as an advisor for HAYA Therapeutics and PureTech Health. Dr Reid has received honoraria from Shire and Sanofi Genzyme. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.\n",
      "\n",
      "Funding Support and Author Disclosures Siemens provided access to Work in Progress sequences. Siemens had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation or  approval of the manuscript; and decision to submit the manuscript for publication. Drs Christopher Orsborne, Schmitt, Jovanovic, and Miller have received research  support from Amicus Therapeutics. Dr Josephine H. Naish has a part time appointment at Bioxydyn Ltd, a company that provides MRI services. Dr Miller has an Advanced Fellowship, NIHR301338, funded by the National Institute for Health Research; has received research support from Guerbet Laboratories Limited, Roche, and Univar Solutions BV; has served on advisory boards for Novartis, Boehringer Ingelheim and Lilly Alliance, and AstraZeneca; and serves as an advisor for HAYA Therapeutics and PureTech Health. Dr Reid has received honoraria from Shire and Sanofi Genzyme. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.\n",
      "\n",
      "Schmitt, Matthias\n",
      "Funding Support and Author Disclosures Siemens provided access to Work in Progress sequences. Siemens had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation or  approval of the manuscript; and decision to submit the manuscript for publication. Drs Christopher Orsborne, Matthias Schmitt, Jovanovic, and Miller have received research  support from Amicus Therapeutics. Dr Josephine H. Naish has a part time appointment at Bioxydyn Ltd, a company that provides MRI services. Dr Miller has an Advanced Fellowship, NIHR301338, funded by the National Institute for Health Research; has received research support from Guerbet Laboratories Limited, Roche, and Univar Solutions BV; has served on advisory boards for Novartis, Boehringer Ingelheim and Lilly Alliance, and AstraZeneca; and serves as an advisor for HAYA Therapeutics and PureTech Health. Dr Reid has received honoraria from Shire and Sanofi Genzyme. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.\n",
      "\n",
      "Jovanovic, Ana\n",
      "Funding Support and Author Disclosures Siemens provided access to Work in Progress sequences. Siemens had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation or  approval of the manuscript; and decision to submit the manuscript for publication. Drs Christopher Orsborne, Matthias Schmitt, Ana Jovanovic, and Miller have received research  support from Amicus Therapeutics. Dr Josephine H. Naish has a part time appointment at Bioxydyn Ltd, a company that provides MRI services. Dr Miller has an Advanced Fellowship, NIHR301338, funded by the National Institute for Health Research; has received research support from Guerbet Laboratories Limited, Roche, and Univar Solutions BV; has served on advisory boards for Novartis, Boehringer Ingelheim and Lilly Alliance, and AstraZeneca; and serves as an advisor for HAYA Therapeutics and PureTech Health. Dr Reid has received honoraria from Shire and Sanofi Genzyme. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.\n",
      "\n",
      "Miller, Christopher A.\n",
      "Funding Support and Author Disclosures Siemens provided access to Work in Progress sequences. Siemens had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation or  approval of the manuscript; and decision to submit the manuscript for publication. Drs Christopher Orsborne, Matthias Schmitt, Ana Jovanovic, and Christopher A. Miller have received research  support from Amicus Therapeutics. Dr Josephine H. Naish has a part time appointment at Bioxydyn Ltd, a company that provides MRI services. Dr Christopher A. Miller has an Advanced Fellowship, NIHR301338, funded by the National Institute for Health Research; has received research support from Guerbet Laboratories Limited, Roche, and Univar Solutions BV; has served on advisory boards for Novartis, Boehringer Ingelheim and Lilly Alliance, and AstraZeneca; and serves as an advisor for HAYA Therapeutics and PureTech Health. Dr Reid has received honoraria from Shire and Sanofi Genzyme. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.\n",
      "\n",
      "Reid, Anna B.\n",
      "Funding Support and Author Disclosures Siemens provided access to Work in Progress sequences. Siemens had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation or  approval of the manuscript; and decision to submit the manuscript for publication. Drs Christopher Orsborne, Matthias Schmitt, Ana Jovanovic, and Christopher A. Miller have received research  support from Amicus Therapeutics. Dr Josephine H. Naish has a part time appointment at Bioxydyn Ltd, a company that provides MRI services. Dr Christopher A. Miller has an Advanced Fellowship, NIHR301338, funded by the National Institute for Health Research; has received research support from Guerbet Laboratories Limited, Roche, and Univar Solutions BV; has served on advisory boards for Novartis, Boehringer Ingelheim and Lilly Alliance, and AstraZeneca; and serves as an advisor for HAYA Therapeutics and PureTech Health. Dr Anna B. Reid has received honoraria from Shire and Sanofi Genzyme. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.\n",
      "\n",
      "Grogan, Martha\n",
      "Funding Support and Author Disclosures Dr Martha Grogan has received institutional research grant support from Alnylam, Eidos, Pfizer, Prothena, and Janssen; and has received advisory board/consulting fees from Novo Nordisk and Janssen, all paid to Mayo Clinic. Dr Dispenzieri has received research support from Celgene, Takeda, Janssen, Pfizer, and Alnylam; and is on the advisory board for Janssen.\n",
      "\n",
      "Dispenzieri, Angela\n",
      "Funding Support and Author Disclosures Dr Martha Grogan has received institutional research grant support from Alnylam, Eidos, Pfizer, Prothena, and Janssen; and has received advisory board/consulting fees from Novo Nordisk and Janssen, all paid to Mayo Clinic. Dr Angela Dispenzieri has received research support from Celgene, Takeda, Janssen, Pfizer, and Alnylam; and is on the advisory board for Janssen.\n",
      "\n",
      "Westin, Oscar\n",
      "Funding Support and Author Disclosures The study was funded by independent research grants from Erik og Susanna Olesens Almenvelgorende Fond, Pfizer, Arvid  Nilssons Fond, Hojmosegard-legatet, Frimodt-Heineke Fonden, and Hjertecentrets forskningsudvalg, Rigshospitalet (Dr Oscar Westin). Dr Fosbol has received an independent research grant from Novo Nordisk Foundation, outside the submitted work. Dr Maurer has received grant support from NIH grants R01HL139671, R21AG058348, and K24AG036778; has been a consultant for Intellia, Novo-Nordisk, Pfizer, Eidos, Prothena, Akcea, and Alnylam; and his institution has received clinical trial funding from Pfizer, Prothena, Eidos, and Alnylam. Dr Gustafsson has received personal fees from Abbott, AstraZeneca, Pfizer, Boehringer Ingelheim, Novartis, and Orion Pharma outside the submitted work. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.\n",
      "\n",
      "Fosbol, Emil L.\n",
      "Funding Support and Author Disclosures The study was funded by independent research grants from Erik og Susanna Olesens Almenvelgorende Fond, Pfizer, Arvid  Nilssons Fond, Hojmosegard-legatet, Frimodt-Heineke Fonden, and Hjertecentrets forskningsudvalg, Rigshospitalet (Dr Oscar Westin). Dr Emil L. Fosbol has received an independent research grant from Novo Nordisk Foundation, outside the submitted work. Dr Maurer has received grant support from NIH grants R01HL139671, R21AG058348, and K24AG036778; has been a consultant for Intellia, Novo-Nordisk, Pfizer, Eidos, Prothena, Akcea, and Alnylam; and his institution has received clinical trial funding from Pfizer, Prothena, Eidos, and Alnylam. Dr Gustafsson has received personal fees from Abbott, AstraZeneca, Pfizer, Boehringer Ingelheim, Novartis, and Orion Pharma outside the submitted work. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.\n",
      "\n",
      "Maurer, Mathew S.\n",
      "Funding Support and Author Disclosures The study was funded by independent research grants from Erik og Susanna Olesens Almenvelgorende Fond, Pfizer, Arvid  Nilssons Fond, Hojmosegard-legatet, Frimodt-Heineke Fonden, and Hjertecentrets forskningsudvalg, Rigshospitalet (Dr Oscar Westin). Dr Emil L. Fosbol has received an independent research grant from Novo Nordisk Foundation, outside the submitted work. Dr Mathew S. Maurer has received grant support from NIH grants R01HL139671, R21AG058348, and K24AG036778; has been a consultant for Intellia, Novo-Nordisk, Pfizer, Eidos, Prothena, Akcea, and Alnylam; and his institution has received clinical trial funding from Pfizer, Prothena, Eidos, and Alnylam. Dr Gustafsson has received personal fees from Abbott, AstraZeneca, Pfizer, Boehringer Ingelheim, Novartis, and Orion Pharma outside the submitted work. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.\n",
      "\n",
      "Funding Support and Author Disclosures The study was funded by independent research grants from Erik og Susanna Olesens Almenvelgorende Fond, Pfizer, Arvid  Nilssons Fond, Hojmosegard-legatet, Frimodt-Heineke Fonden, and Hjertecentrets forskningsudvalg, Rigshospitalet (Dr Oscar Westin). Dr Emil L. Fosbol has received an independent research grant from Novo Nordisk Foundation, outside the submitted work. Dr Mathew S. Maurer has received grant support from NIH grants R01HL139671, R21AG058348, and K24AG036778; has been a consultant for Intellia, Novo-Nordisk, Pfizer, Eidos, Prothena, Akcea, and Alnylam; and his institution has received clinical trial funding from Pfizer, Prothena, Eidos, and Alnylam. Dr Gustafsson has received personal fees from Abbott, AstraZeneca, Pfizer, Boehringer Ingelheim, Novartis, and Orion Pharma outside the submitted work. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.\n",
      "\n",
      "Funding Support and Author Disclosures The study was funded by independent research grants from Erik og Susanna Olesens Almenvelgorende Fond, Pfizer, Arvid  Nilssons Fond, Hojmosegard-legatet, Frimodt-Heineke Fonden, and Hjertecentrets forskningsudvalg, Rigshospitalet (Dr Oscar Westin). Dr Emil L. Fosbol has received an independent research grant from Novo Nordisk Foundation, outside the submitted work. Dr Mathew S. Maurer has received grant support from NIH grants R01HL139671, R21AG058348, and K24AG036778; has been a consultant for Intellia, Novo-Nordisk, Pfizer, Eidos, Prothena, Akcea, and Alnylam; and his institution has received clinical trial funding from Pfizer, Prothena, Eidos, and Alnylam. Dr Gustafsson has received personal fees from Abbott, AstraZeneca, Pfizer, Boehringer Ingelheim, Novartis, and Orion Pharma outside the submitted work. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.\n",
      "\n",
      "Funding Support and Author Disclosures The study was funded by independent research grants from Erik og Susanna Olesens Almenvelgorende Fond, Pfizer, Arvid  Nilssons Fond, Hojmosegard-legatet, Frimodt-Heineke Fonden, and Hjertecentrets forskningsudvalg, Rigshospitalet (Dr Oscar Westin). Dr Emil L. Fosbol has received an independent research grant from Novo Nordisk Foundation, outside the submitted work. Dr Mathew S. Maurer has received grant support from NIH grants R01HL139671, R21AG058348, and K24AG036778; has been a consultant for Intellia, Novo-Nordisk, Pfizer, Eidos, Prothena, Akcea, and Alnylam; and his institution has received clinical trial funding from Pfizer, Prothena, Eidos, and Alnylam. Dr Gustafsson has received personal fees from Abbott, AstraZeneca, Pfizer, Boehringer Ingelheim, Novartis, and Orion Pharma outside the submitted work. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.\n",
      "\n",
      "Funding Support and Author Disclosures The study was funded by independent research grants from Erik og Susanna Olesens Almenvelgorende Fond, Pfizer, Arvid  Nilssons Fond, Hojmosegard-legatet, Frimodt-Heineke Fonden, and Hjertecentrets forskningsudvalg, Rigshospitalet (Dr Oscar Westin). Dr Emil L. Fosbol has received an independent research grant from Novo Nordisk Foundation, outside the submitted work. Dr Mathew S. Maurer has received grant support from NIH grants R01HL139671, R21AG058348, and K24AG036778; has been a consultant for Intellia, Novo-Nordisk, Pfizer, Eidos, Prothena, Akcea, and Alnylam; and his institution has received clinical trial funding from Pfizer, Prothena, Eidos, and Alnylam. Dr Gustafsson has received personal fees from Abbott, AstraZeneca, Pfizer, Boehringer Ingelheim, Novartis, and Orion Pharma outside the submitted work. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.\n",
      "\n",
      "Funding Support and Author Disclosures The study was funded by independent research grants from Erik og Susanna Olesens Almenvelgorende Fond, Pfizer, Arvid  Nilssons Fond, Hojmosegard-legatet, Frimodt-Heineke Fonden, and Hjertecentrets forskningsudvalg, Rigshospitalet (Dr Oscar Westin). Dr Emil L. Fosbol has received an independent research grant from Novo Nordisk Foundation, outside the submitted work. Dr Mathew S. Maurer has received grant support from NIH grants R01HL139671, R21AG058348, and K24AG036778; has been a consultant for Intellia, Novo-Nordisk, Pfizer, Eidos, Prothena, Akcea, and Alnylam; and his institution has received clinical trial funding from Pfizer, Prothena, Eidos, and Alnylam. Dr Gustafsson has received personal fees from Abbott, AstraZeneca, Pfizer, Boehringer Ingelheim, Novartis, and Orion Pharma outside the submitted work. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.\n",
      "\n",
      "Funding Support and Author Disclosures The study was funded by independent research grants from Erik og Susanna Olesens Almenvelgorende Fond, Pfizer, Arvid  Nilssons Fond, Hojmosegard-legatet, Frimodt-Heineke Fonden, and Hjertecentrets forskningsudvalg, Rigshospitalet (Dr Oscar Westin). Dr Emil L. Fosbol has received an independent research grant from Novo Nordisk Foundation, outside the submitted work. Dr Mathew S. Maurer has received grant support from NIH grants R01HL139671, R21AG058348, and K24AG036778; has been a consultant for Intellia, Novo-Nordisk, Pfizer, Eidos, Prothena, Akcea, and Alnylam; and his institution has received clinical trial funding from Pfizer, Prothena, Eidos, and Alnylam. Dr Gustafsson has received personal fees from Abbott, AstraZeneca, Pfizer, Boehringer Ingelheim, Novartis, and Orion Pharma outside the submitted work. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.\n",
      "\n",
      "Gustafsson, Finn\n",
      "Funding Support and Author Disclosures The study was funded by independent research grants from Erik og Susanna Olesens Almenvelgorende Fond, Pfizer, Arvid  Nilssons Fond, Hojmosegard-legatet, Frimodt-Heineke Fonden, and Hjertecentrets forskningsudvalg, Rigshospitalet (Dr Oscar Westin). Dr Emil L. Fosbol has received an independent research grant from Novo Nordisk Foundation, outside the submitted work. Dr Mathew S. Maurer has received grant support from NIH grants R01HL139671, R21AG058348, and K24AG036778; has been a consultant for Intellia, Novo-Nordisk, Pfizer, Eidos, Prothena, Akcea, and Alnylam; and his institution has received clinical trial funding from Pfizer, Prothena, Eidos, and Alnylam. Dr Finn Gustafsson has received personal fees from Abbott, AstraZeneca, Pfizer, Boehringer Ingelheim, Novartis, and Orion Pharma outside the submitted work. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.\n",
      "\n",
      "Funding Support and Author Disclosures This study was funded by a joint grant from the Children's Heart Foundation and the American Heart Association (17GRNT33670334). Dr Opotowsky was supported by the Heart Institute Research Core at Cincinnati Children's Hospital and the Dunlevie Family Fund. The authors used  the Research Electronic Data Capture (REDCap) online database, which is funded by the National Institutes of Health (UL1TR002369). All other authors have reported  that they have no relationships relevant to the contents of this paper to disclose.\n",
      "\n",
      "Funding Support and Author Disclosures This study was funded by a joint grant from the Children's Heart Foundation and the American Heart Association (17GRNT33670334). Dr Opotowsky was supported by the Heart Institute Research Core at Cincinnati Children's Hospital and the Dunlevie Family Fund. The authors used  the Research Electronic Data Capture (REDCap) online database, which is funded by the National Institutes of Health (UL1TR002369). All other authors have reported  that they have no relationships relevant to the contents of this paper to disclose.\n",
      "\n",
      "Funding Support and Author Disclosures This study was funded by a joint grant from the Children's Heart Foundation and the American Heart Association (17GRNT33670334). Dr Opotowsky was supported by the Heart Institute Research Core at Cincinnati Children's Hospital and the Dunlevie Family Fund. The authors used  the Research Electronic Data Capture (REDCap) online database, which is funded by the National Institutes of Health (UL1TR002369). All other authors have reported  that they have no relationships relevant to the contents of this paper to disclose.\n",
      "\n",
      "Funding Support and Author Disclosures This study was funded by a joint grant from the Children's Heart Foundation and the American Heart Association (17GRNT33670334). Dr Opotowsky was supported by the Heart Institute Research Core at Cincinnati Children's Hospital and the Dunlevie Family Fund. The authors used  the Research Electronic Data Capture (REDCap) online database, which is funded by the National Institutes of Health (UL1TR002369). All other authors have reported  that they have no relationships relevant to the contents of this paper to disclose.\n",
      "\n",
      "Funding Support and Author Disclosures This study was funded by a joint grant from the Children's Heart Foundation and the American Heart Association (17GRNT33670334). Dr Opotowsky was supported by the Heart Institute Research Core at Cincinnati Children's Hospital and the Dunlevie Family Fund. The authors used  the Research Electronic Data Capture (REDCap) online database, which is funded by the National Institutes of Health (UL1TR002369). All other authors have reported  that they have no relationships relevant to the contents of this paper to disclose.\n",
      "\n",
      "Funding Support and Author Disclosures This study was funded by a joint grant from the Children's Heart Foundation and the American Heart Association (17GRNT33670334). Dr Opotowsky was supported by the Heart Institute Research Core at Cincinnati Children's Hospital and the Dunlevie Family Fund. The authors used  the Research Electronic Data Capture (REDCap) online database, which is funded by the National Institutes of Health (UL1TR002369). All other authors have reported  that they have no relationships relevant to the contents of this paper to disclose.\n",
      "\n",
      "Funding Support and Author Disclosures This study was funded by a joint grant from the Children's Heart Foundation and the American Heart Association (17GRNT33670334). Dr Opotowsky was supported by the Heart Institute Research Core at Cincinnati Children's Hospital and the Dunlevie Family Fund. The authors used  the Research Electronic Data Capture (REDCap) online database, which is funded by the National Institutes of Health (UL1TR002369). All other authors have reported  that they have no relationships relevant to the contents of this paper to disclose.\n",
      "\n",
      "Funding Support and Author Disclosures This study was funded by a joint grant from the Children's Heart Foundation and the American Heart Association (17GRNT33670334). Dr Opotowsky was supported by the Heart Institute Research Core at Cincinnati Children's Hospital and the Dunlevie Family Fund. The authors used  the Research Electronic Data Capture (REDCap) online database, which is funded by the National Institutes of Health (UL1TR002369). All other authors have reported  that they have no relationships relevant to the contents of this paper to disclose.\n",
      "\n",
      "Funding Support and Author Disclosures This study was funded by a joint grant from the Children's Heart Foundation and the American Heart Association (17GRNT33670334). Dr Opotowsky was supported by the Heart Institute Research Core at Cincinnati Children's Hospital and the Dunlevie Family Fund. The authors used  the Research Electronic Data Capture (REDCap) online database, which is funded by the National Institutes of Health (UL1TR002369). All other authors have reported  that they have no relationships relevant to the contents of this paper to disclose.\n",
      "\n",
      "Funding Support and Author Disclosures This study was funded by a joint grant from the Children's Heart Foundation and the American Heart Association (17GRNT33670334). Dr Opotowsky was supported by the Heart Institute Research Core at Cincinnati Children's Hospital and the Dunlevie Family Fund. The authors used  the Research Electronic Data Capture (REDCap) online database, which is funded by the National Institutes of Health (UL1TR002369). All other authors have reported  that they have no relationships relevant to the contents of this paper to disclose.\n",
      "\n",
      "Funding Support and Author Disclosures This study was funded by a joint grant from the Children's Heart Foundation and the American Heart Association (17GRNT33670334). Dr Opotowsky was supported by the Heart Institute Research Core at Cincinnati Children's Hospital and the Dunlevie Family Fund. The authors used  the Research Electronic Data Capture (REDCap) online database, which is funded by the National Institutes of Health (UL1TR002369). All other authors have reported  that they have no relationships relevant to the contents of this paper to disclose.\n",
      "\n",
      "Funding Support and Author Disclosures This study was funded by a joint grant from the Children's Heart Foundation and the American Heart Association (17GRNT33670334). Dr Opotowsky was supported by the Heart Institute Research Core at Cincinnati Children's Hospital and the Dunlevie Family Fund. The authors used  the Research Electronic Data Capture (REDCap) online database, which is funded by the National Institutes of Health (UL1TR002369). All other authors have reported  that they have no relationships relevant to the contents of this paper to disclose.\n",
      "\n",
      "Funding Support and Author Disclosures This study was funded by a joint grant from the Children's Heart Foundation and the American Heart Association (17GRNT33670334). Dr Opotowsky was supported by the Heart Institute Research Core at Cincinnati Children's Hospital and the Dunlevie Family Fund. The authors used  the Research Electronic Data Capture (REDCap) online database, which is funded by the National Institutes of Health (UL1TR002369). All other authors have reported  that they have no relationships relevant to the contents of this paper to disclose.\n",
      "\n",
      "Funding Support and Author Disclosures This study was funded by a joint grant from the Children's Heart Foundation and the American Heart Association (17GRNT33670334). Dr Opotowsky was supported by the Heart Institute Research Core at Cincinnati Children's Hospital and the Dunlevie Family Fund. The authors used  the Research Electronic Data Capture (REDCap) online database, which is funded by the National Institutes of Health (UL1TR002369). All other authors have reported  that they have no relationships relevant to the contents of this paper to disclose.\n",
      "\n",
      "Funding Support and Author Disclosures This study was funded by a joint grant from the Children's Heart Foundation and the American Heart Association (17GRNT33670334). Dr Opotowsky was supported by the Heart Institute Research Core at Cincinnati Children's Hospital and the Dunlevie Family Fund. The authors used  the Research Electronic Data Capture (REDCap) online database, which is funded by the National Institutes of Health (UL1TR002369). All other authors have reported  that they have no relationships relevant to the contents of this paper to disclose.\n",
      "\n",
      "Funding Support and Author Disclosures This study was funded by a joint grant from the Children's Heart Foundation and the American Heart Association (17GRNT33670334). Dr Opotowsky was supported by the Heart Institute Research Core at Cincinnati Children's Hospital and the Dunlevie Family Fund. The authors used  the Research Electronic Data Capture (REDCap) online database, which is funded by the National Institutes of Health (UL1TR002369). All other authors have reported  that they have no relationships relevant to the contents of this paper to disclose.\n",
      "\n",
      "Funding Support and Author Disclosures This study was funded by a joint grant from the Children's Heart Foundation and the American Heart Association (17GRNT33670334). Dr Opotowsky was supported by the Heart Institute Research Core at Cincinnati Children's Hospital and the Dunlevie Family Fund. The authors used  the Research Electronic Data Capture (REDCap) online database, which is funded by the National Institutes of Health (UL1TR002369). All other authors have reported  that they have no relationships relevant to the contents of this paper to disclose.\n",
      "\n",
      "Funding Support and Author Disclosures This study was funded by a joint grant from the Children's Heart Foundation and the American Heart Association (17GRNT33670334). Dr Opotowsky was supported by the Heart Institute Research Core at Cincinnati Children's Hospital and the Dunlevie Family Fund. The authors used  the Research Electronic Data Capture (REDCap) online database, which is funded by the National Institutes of Health (UL1TR002369). All other authors have reported  that they have no relationships relevant to the contents of this paper to disclose.\n",
      "\n",
      "Funding Support and Author Disclosures This study was funded by a joint grant from the Children's Heart Foundation and the American Heart Association (17GRNT33670334). Dr Opotowsky was supported by the Heart Institute Research Core at Cincinnati Children's Hospital and the Dunlevie Family Fund. The authors used  the Research Electronic Data Capture (REDCap) online database, which is funded by the National Institutes of Health (UL1TR002369). All other authors have reported  that they have no relationships relevant to the contents of this paper to disclose.\n",
      "\n",
      "Funding Support and Author Disclosures This study was funded by a joint grant from the Children's Heart Foundation and the American Heart Association (17GRNT33670334). Dr Opotowsky was supported by the Heart Institute Research Core at Cincinnati Children's Hospital and the Dunlevie Family Fund. The authors used  the Research Electronic Data Capture (REDCap) online database, which is funded by the National Institutes of Health (UL1TR002369). All other authors have reported  that they have no relationships relevant to the contents of this paper to disclose.\n",
      "\n",
      "Funding Support and Author Disclosures This study was funded by a joint grant from the Children's Heart Foundation and the American Heart Association (17GRNT33670334). Dr Opotowsky was supported by the Heart Institute Research Core at Cincinnati Children's Hospital and the Dunlevie Family Fund. The authors used  the Research Electronic Data Capture (REDCap) online database, which is funded by the National Institutes of Health (UL1TR002369). All other authors have reported  that they have no relationships relevant to the contents of this paper to disclose.\n",
      "\n",
      "Funding Support and Author Disclosures This study was funded by a joint grant from the Children's Heart Foundation and the American Heart Association (17GRNT33670334). Dr Opotowsky was supported by the Heart Institute Research Core at Cincinnati Children's Hospital and the Dunlevie Family Fund. The authors used  the Research Electronic Data Capture (REDCap) online database, which is funded by the National Institutes of Health (UL1TR002369). All other authors have reported  that they have no relationships relevant to the contents of this paper to disclose.\n",
      "\n",
      "Funding Support and Author Disclosures This study was funded by a joint grant from the Children's Heart Foundation and the American Heart Association (17GRNT33670334). Dr Opotowsky was supported by the Heart Institute Research Core at Cincinnati Children's Hospital and the Dunlevie Family Fund. The authors used  the Research Electronic Data Capture (REDCap) online database, which is funded by the National Institutes of Health (UL1TR002369). All other authors have reported  that they have no relationships relevant to the contents of this paper to disclose.\n",
      "\n",
      "Funding Support and Author Disclosures This study was funded by a joint grant from the Children's Heart Foundation and the American Heart Association (17GRNT33670334). Dr Opotowsky was supported by the Heart Institute Research Core at Cincinnati Children's Hospital and the Dunlevie Family Fund. The authors used  the Research Electronic Data Capture (REDCap) online database, which is funded by the National Institutes of Health (UL1TR002369). All other authors have reported  that they have no relationships relevant to the contents of this paper to disclose.\n",
      "\n",
      "Funding Support and Author Disclosures This study was funded by a joint grant from the Children's Heart Foundation and the American Heart Association (17GRNT33670334). Dr Opotowsky was supported by the Heart Institute Research Core at Cincinnati Children's Hospital and the Dunlevie Family Fund. The authors used  the Research Electronic Data Capture (REDCap) online database, which is funded by the National Institutes of Health (UL1TR002369). All other authors have reported  that they have no relationships relevant to the contents of this paper to disclose.\n",
      "\n",
      "Funding Support and Author Disclosures This study was funded by a joint grant from the Children's Heart Foundation and the American Heart Association (17GRNT33670334). Dr Opotowsky was supported by the Heart Institute Research Core at Cincinnati Children's Hospital and the Dunlevie Family Fund. The authors used  the Research Electronic Data Capture (REDCap) online database, which is funded by the National Institutes of Health (UL1TR002369). All other authors have reported  that they have no relationships relevant to the contents of this paper to disclose.\n",
      "\n",
      "Funding Support and Author Disclosures This study was funded by a joint grant from the Children's Heart Foundation and the American Heart Association (17GRNT33670334). Dr Opotowsky was supported by the Heart Institute Research Core at Cincinnati Children's Hospital and the Dunlevie Family Fund. The authors used  the Research Electronic Data Capture (REDCap) online database, which is funded by the National Institutes of Health (UL1TR002369). All other authors have reported  that they have no relationships relevant to the contents of this paper to disclose.\n",
      "\n",
      "Funding Support and Author Disclosures This study was funded by a joint grant from the Children's Heart Foundation and the American Heart Association (17GRNT33670334). Dr Opotowsky was supported by the Heart Institute Research Core at Cincinnati Children's Hospital and the Dunlevie Family Fund. The authors used  the Research Electronic Data Capture (REDCap) online database, which is funded by the National Institutes of Health (UL1TR002369). All other authors have reported  that they have no relationships relevant to the contents of this paper to disclose.\n",
      "\n",
      "Funding Support and Author Disclosures This study was funded by a joint grant from the Children's Heart Foundation and the American Heart Association (17GRNT33670334). Dr Opotowsky was supported by the Heart Institute Research Core at Cincinnati Children's Hospital and the Dunlevie Family Fund. The authors used  the Research Electronic Data Capture (REDCap) online database, which is funded by the National Institutes of Health (UL1TR002369). All other authors have reported  that they have no relationships relevant to the contents of this paper to disclose.\n",
      "\n",
      "Funding Support and Author Disclosures This study was funded by a joint grant from the Children's Heart Foundation and the American Heart Association (17GRNT33670334). Dr Opotowsky was supported by the Heart Institute Research Core at Cincinnati Children's Hospital and the Dunlevie Family Fund. The authors used  the Research Electronic Data Capture (REDCap) online database, which is funded by the National Institutes of Health (UL1TR002369). All other authors have reported  that they have no relationships relevant to the contents of this paper to disclose.\n",
      "\n",
      "Funding Support and Author Disclosures This study was funded by a joint grant from the Children's Heart Foundation and the American Heart Association (17GRNT33670334). Dr Opotowsky was supported by the Heart Institute Research Core at Cincinnati Children's Hospital and the Dunlevie Family Fund. The authors used  the Research Electronic Data Capture (REDCap) online database, which is funded by the National Institutes of Health (UL1TR002369). All other authors have reported  that they have no relationships relevant to the contents of this paper to disclose.\n",
      "\n",
      "Funding Support and Author Disclosures This study was funded by a joint grant from the Children's Heart Foundation and the American Heart Association (17GRNT33670334). Dr Opotowsky was supported by the Heart Institute Research Core at Cincinnati Children's Hospital and the Dunlevie Family Fund. The authors used  the Research Electronic Data Capture (REDCap) online database, which is funded by the National Institutes of Health (UL1TR002369). All other authors have reported  that they have no relationships relevant to the contents of this paper to disclose.\n",
      "\n",
      "Funding Support and Author Disclosures This study was funded by a joint grant from the Children's Heart Foundation and the American Heart Association (17GRNT33670334). Dr Opotowsky was supported by the Heart Institute Research Core at Cincinnati Children's Hospital and the Dunlevie Family Fund. The authors used  the Research Electronic Data Capture (REDCap) online database, which is funded by the National Institutes of Health (UL1TR002369). All other authors have reported  that they have no relationships relevant to the contents of this paper to disclose.\n",
      "\n",
      "Funding Support and Author Disclosures This study was funded by a joint grant from the Children's Heart Foundation and the American Heart Association (17GRNT33670334). Dr Opotowsky was supported by the Heart Institute Research Core at Cincinnati Children's Hospital and the Dunlevie Family Fund. The authors used  the Research Electronic Data Capture (REDCap) online database, which is funded by the National Institutes of Health (UL1TR002369). All other authors have reported  that they have no relationships relevant to the contents of this paper to disclose.\n",
      "\n",
      "Funding Support and Author Disclosures This study was funded by a joint grant from the Children's Heart Foundation and the American Heart Association (17GRNT33670334). Dr Opotowsky was supported by the Heart Institute Research Core at Cincinnati Children's Hospital and the Dunlevie Family Fund. The authors used  the Research Electronic Data Capture (REDCap) online database, which is funded by the National Institutes of Health (UL1TR002369). All other authors have reported  that they have no relationships relevant to the contents of this paper to disclose.\n",
      "\n",
      "Funding Support and Author Disclosures This study was funded by a joint grant from the Children's Heart Foundation and the American Heart Association (17GRNT33670334). Dr Opotowsky was supported by the Heart Institute Research Core at Cincinnati Children's Hospital and the Dunlevie Family Fund. The authors used  the Research Electronic Data Capture (REDCap) online database, which is funded by the National Institutes of Health (UL1TR002369). All other authors have reported  that they have no relationships relevant to the contents of this paper to disclose.\n",
      "\n",
      "Funding Support and Author Disclosures This study was funded by a joint grant from the Children's Heart Foundation and the American Heart Association (17GRNT33670334). Dr Opotowsky was supported by the Heart Institute Research Core at Cincinnati Children's Hospital and the Dunlevie Family Fund. The authors used  the Research Electronic Data Capture (REDCap) online database, which is funded by the National Institutes of Health (UL1TR002369). All other authors have reported  that they have no relationships relevant to the contents of this paper to disclose.\n",
      "\n",
      "Funding Support and Author Disclosures This study was funded by a joint grant from the Children's Heart Foundation and the American Heart Association (17GRNT33670334). Dr Opotowsky was supported by the Heart Institute Research Core at Cincinnati Children's Hospital and the Dunlevie Family Fund. The authors used  the Research Electronic Data Capture (REDCap) online database, which is funded by the National Institutes of Health (UL1TR002369). All other authors have reported  that they have no relationships relevant to the contents of this paper to disclose.\n",
      "\n",
      "Celermajer, David S.\n",
      "Funding Support and Author Disclosures This study was funded by a joint grant from the Children's Heart Foundation and the American Heart Association (17GRNT33670334). Dr Opotowsky was supported by the Heart Institute Research Core at Cincinnati Children's Hospital and the Dunlevie Family Fund. The authors used  the Research Electronic Data Capture (REDavid S. Celermajerap) online database, which is funded by the National Institutes of Health (UL1TR002369). All other authors have reported  that they have no relationships relevant to the contents of this paper to disclose.\n",
      "\n",
      "Funding Support and Author Disclosures This study was funded by a joint grant from the Children's Heart Foundation and the American Heart Association (17GRNT33670334). Dr Opotowsky was supported by the Heart Institute Research Core at Cincinnati Children's Hospital and the Dunlevie Family Fund. The authors used  the Research Electronic Data Capture (REDavid S. Celermajerap) online database, which is funded by the National Institutes of Health (UL1TR002369). All other authors have reported  that they have no relationships relevant to the contents of this paper to disclose.\n",
      "\n",
      "Funding Support and Author Disclosures This study was funded by a joint grant from the Children's Heart Foundation and the American Heart Association (17GRNT33670334). Dr Opotowsky was supported by the Heart Institute Research Core at Cincinnati Children's Hospital and the Dunlevie Family Fund. The authors used  the Research Electronic Data Capture (REDavid S. Celermajerap) online database, which is funded by the National Institutes of Health (UL1TR002369). All other authors have reported  that they have no relationships relevant to the contents of this paper to disclose.\n",
      "\n",
      "Funding Support and Author Disclosures This study was funded by a joint grant from the Children's Heart Foundation and the American Heart Association (17GRNT33670334). Dr Opotowsky was supported by the Heart Institute Research Core at Cincinnati Children's Hospital and the Dunlevie Family Fund. The authors used  the Research Electronic Data Capture (REDavid S. Celermajerap) online database, which is funded by the National Institutes of Health (UL1TR002369). All other authors have reported  that they have no relationships relevant to the contents of this paper to disclose.\n",
      "\n",
      "Funding Support and Author Disclosures This study was funded by a joint grant from the Children's Heart Foundation and the American Heart Association (17GRNT33670334). Dr Opotowsky was supported by the Heart Institute Research Core at Cincinnati Children's Hospital and the Dunlevie Family Fund. The authors used  the Research Electronic Data Capture (REDavid S. Celermajerap) online database, which is funded by the National Institutes of Health (UL1TR002369). All other authors have reported  that they have no relationships relevant to the contents of this paper to disclose.\n",
      "\n",
      "Opotowsky, Alexander R.\n",
      "Funding Support and Author Disclosures This study was funded by a joint grant from the Children's Heart Foundation and the American Heart Association (17GRNT33670334). Dr Alexander R. Opotowsky was supported by the Heart Institute Research Core at Cincinnati Children's Hospital and the Dunlevie Family Fund. The authors used  the Research Electronic Data Capture (REDavid S. Celermajerap) online database, which is funded by the National Institutes of Health (UL1TR002369). All other authors have reported  that they have no relationships relevant to the contents of this paper to disclose.\n",
      "\n",
      "Bhatt, Ankeet S.\n",
      "Funding Support and Author Disclosures Dr Ankeet S. Bhatt has received consulting fees from Sanofi-Pasteur; and is supported by the National Heart, Lung, and Blood Institute T32 postdoctoral training grant T32HL007604. Dr Lee is supported by the National  Heart, Lung, and Blood Institute T32 postdoctoral training grant T32HL007604. Dr  Vaduganathan has received research grant support or served on advisory boards for American Regent, Amgen, AstraZeneca, Bayer AG, Baxter Healthcare, Boehringer Ingelheim, Cytokinetics, Lexicon Pharmaceuticals, Novartis, Pharmacosmos, Relypsa, Roche Diagnostics, and Sanofi; has speaker engagements with Novartis and Roche Diagnostics; and participates on clinical trial committees for studies sponsored by Bayer AG, Galmed, Occlutech, Novartis, and Impulse Dynamics.\n",
      "\n",
      "Lee, Simin\n",
      "Funding Support and Author Disclosures Dr Ankeet S. Bhatt has received consulting fees from Sanofi-Pasteur; and is supported by the National Heart, Lung, and Blood Institute T32 postdoctoral training grant T32HL007604. Dr Simin Lee is supported by the National  Heart, Lung, and Blood Institute T32 postdoctoral training grant T32HL007604. Dr  Vaduganathan has received research grant support or served on advisory boards for American Regent, Amgen, AstraZeneca, Bayer AG, Baxter Healthcare, Boehringer Ingelheim, Cytokinetics, Lexicon Pharmaceuticals, Novartis, Pharmacosmos, Relypsa, Roche Diagnostics, and Sanofi; has speaker engagements with Novartis and Roche Diagnostics; and participates on clinical trial committees for studies sponsored by Bayer AG, Galmed, Occlutech, Novartis, and Impulse Dynamics.\n",
      "\n",
      "Vaduganathan, Muthiah\n",
      "Funding Support and Author Disclosures Dr Ankeet S. Bhatt has received consulting fees from Sanofi-Pasteur; and is supported by the National Heart, Lung, and Blood Institute T32 postdoctoral training grant T32HL007604. Dr Simin Lee is supported by the National  Heart, Lung, and Blood Institute T32 postdoctoral training grant T32HL007604. Dr  Muthiah Vaduganathan has received research grant support or served on advisory boards for American Regent, Amgen, AstraZeneca, Bayer AG, Baxter Healthcare, Boehringer Ingelheim, Cytokinetics, Lexicon Pharmaceuticals, Novartis, Pharmacosmos, Relypsa, Roche Diagnostics, and Sanofi; has speaker engagements with Novartis and Roche Diagnostics; and participates on clinical trial committees for studies sponsored by Bayer AG, Galmed, Occlutech, Novartis, and Impulse Dynamics.\n",
      "\n",
      "Minissian, Margo B.\n",
      "Funding Support and Author Disclosures This study was funded by National Institute for Nursing Research grants 1K99NR018679-01 and F31NR015725, UCLA Clinical and Translational Science Institutes grants UL1TR000124 and UL1TR001881-01, and the Preventive Cardiovascular Nurses Association grant #5362  through the American Nurses Foundation (Dr Margo B. Minissian). Additional support was provided by the Cedars-Sinai Department of Obstetrics and Gynecology, the Cedars-Sinai Brawerman Nursing Institute, Department of Nursing Research, and the Cedars-Sinai Barbra Streisand Women's Heart Center, Beta Chi Chapter, and Cedars-Sinai Precision Health Institute grant #42254 (Dr Margo B. Minissian). Dr Wei is supported by National Institutes of Health (NIH) grants K23HL125941 and R01HL146158. Dr Bairey Merz is supported by NIH grants R01HL124649 and U54 AG065141, the Barbra Streisand Women's Cardiovascular Research and Education Program, Cedars-Sinai Medical Center Los Angeles, the Linda Joy Pollin Women's Heart Health Program, the Erika Glazer Women's Heart Health Project, and the Adelson Family Foundation, Cedars-Sinai Medical Center, Los Angeles, California.  Dr Reynolds is supported by American Heart Association grant SFRN 20-A0-00-1005066. Dr Quesada is supported by NIH grants T32HL116273 and K23HL151867. Dr Margo B. Minissian has received honoraria from the National Lipid Association, North American Menopause Society, MJH Life Sciences, Vox Media, Medtelligence, Minneapolis Heart Institute, Primed, Good Samaritan Hospital Los Angeles, California, Cardiometabolic Health Congress, American Heart Association, Preventive Cardiovascular Nurses Association, and the American College of Cardiology; has been a consultant for and served on a medical advisory board for  Amgen; and has served as a co-chair for CME for the North American Center for Continuing Medical Education honorarium. Dr Wei has received institutional fees for serving on an advisory board for Abbott Vascular. Dr Bairey Merz has received consulting fees from Abbott Diagnostics, Caladrius, and Sanofi Vascular; and receives consulting fees, is on the board of directors and owns stock in iRhythm. Dr Volgman has served as a consultant and on advisory boards for Merck, Bristol Myers Squibb Foundation, Novo Nordisk, and Janssen; has received research funding from Novartis; and hold stocks in Apple, Inc. Dr Elgendy has received research grants from Caladrius Biosciences, Inc, unrelated to this paper. Dr Mamas has been a speaker for Daiichi-Sankyo. Dr Reynolds has received in-kind donations for research from Abbott Vascular, Siemens, and BioTelemetry, Inc. Dr Piazza has received research grants from BMS/Pfizer, Janssen, Alexion, Bayer, Amgen, and BSC; and has an advisory role in BSC, Amgen, BCRI, PERC, Syntactx, BMS, and Janssen. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.\n",
      "\n",
      "Funding Support and Author Disclosures This study was funded by National Institute for Nursing Research grants 1K99NR018679-01 and F31NR015725, UCLA Clinical and Translational Science Institutes grants UL1TR000124 and UL1TR001881-01, and the Preventive Cardiovascular Nurses Association grant #5362  through the American Nurses Foundation (Dr Margo B. Minissian). Additional support was provided by the Cedars-Sinai Department of Obstetrics and Gynecology, the Cedars-Sinai Brawerman Nursing Institute, Department of Nursing Research, and the Cedars-Sinai Barbra Streisand Women's Heart Center, Beta Chi Chapter, and Cedars-Sinai Precision Health Institute grant #42254 (Dr Margo B. Minissian). Dr Wei is supported by National Institutes of Health (NIH) grants K23HL125941 and R01HL146158. Dr Bairey Merz is supported by NIH grants R01HL124649 and U54 AG065141, the Barbra Streisand Women's Cardiovascular Research and Education Program, Cedars-Sinai Medical Center Los Angeles, the Linda Joy Pollin Women's Heart Health Program, the Erika Glazer Women's Heart Health Project, and the Adelson Family Foundation, Cedars-Sinai Medical Center, Los Angeles, California.  Dr Reynolds is supported by American Heart Association grant SFRN 20-A0-00-1005066. Dr Quesada is supported by NIH grants T32HL116273 and K23HL151867. Dr Margo B. Minissian has received honoraria from the National Lipid Association, North American Menopause Society, MJH Life Sciences, Vox Media, Medtelligence, Minneapolis Heart Institute, Primed, Good Samaritan Hospital Los Angeles, California, Cardiometabolic Health Congress, American Heart Association, Preventive Cardiovascular Nurses Association, and the American College of Cardiology; has been a consultant for and served on a medical advisory board for  Amgen; and has served as a co-chair for CME for the North American Center for Continuing Medical Education honorarium. Dr Wei has received institutional fees for serving on an advisory board for Abbott Vascular. Dr Bairey Merz has received consulting fees from Abbott Diagnostics, Caladrius, and Sanofi Vascular; and receives consulting fees, is on the board of directors and owns stock in iRhythm. Dr Volgman has served as a consultant and on advisory boards for Merck, Bristol Myers Squibb Foundation, Novo Nordisk, and Janssen; has received research funding from Novartis; and hold stocks in Apple, Inc. Dr Elgendy has received research grants from Caladrius Biosciences, Inc, unrelated to this paper. Dr Mamas has been a speaker for Daiichi-Sankyo. Dr Reynolds has received in-kind donations for research from Abbott Vascular, Siemens, and BioTelemetry, Inc. Dr Piazza has received research grants from BMS/Pfizer, Janssen, Alexion, Bayer, Amgen, and BSC; and has an advisory role in BSC, Amgen, BCRI, PERC, Syntactx, BMS, and Janssen. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.\n",
      "\n",
      "Funding Support and Author Disclosures This study was funded by National Institute for Nursing Research grants 1K99NR018679-01 and F31NR015725, UCLA Clinical and Translational Science Institutes grants UL1TR000124 and UL1TR001881-01, and the Preventive Cardiovascular Nurses Association grant #5362  through the American Nurses Foundation (Dr Margo B. Minissian). Additional support was provided by the Cedars-Sinai Department of Obstetrics and Gynecology, the Cedars-Sinai Brawerman Nursing Institute, Department of Nursing Research, and the Cedars-Sinai Barbra Streisand Women's Heart Center, Beta Chi Chapter, and Cedars-Sinai Precision Health Institute grant #42254 (Dr Margo B. Minissian). Dr Wei is supported by National Institutes of Health (NIH) grants K23HL125941 and R01HL146158. Dr Bairey Merz is supported by NIH grants R01HL124649 and U54 AG065141, the Barbra Streisand Women's Cardiovascular Research and Education Program, Cedars-Sinai Medical Center Los Angeles, the Linda Joy Pollin Women's Heart Health Program, the Erika Glazer Women's Heart Health Project, and the Adelson Family Foundation, Cedars-Sinai Medical Center, Los Angeles, California.  Dr Reynolds is supported by American Heart Association grant SFRN 20-A0-00-1005066. Dr Quesada is supported by NIH grants T32HL116273 and K23HL151867. Dr Margo B. Minissian has received honoraria from the National Lipid Association, North American Menopause Society, MJH Life Sciences, Vox Media, Medtelligence, Minneapolis Heart Institute, Primed, Good Samaritan Hospital Los Angeles, California, Cardiometabolic Health Congress, American Heart Association, Preventive Cardiovascular Nurses Association, and the American College of Cardiology; has been a consultant for and served on a medical advisory board for  Amgen; and has served as a co-chair for CME for the North American Center for Continuing Medical Education honorarium. Dr Wei has received institutional fees for serving on an advisory board for Abbott Vascular. Dr Bairey Merz has received consulting fees from Abbott Diagnostics, Caladrius, and Sanofi Vascular; and receives consulting fees, is on the board of directors and owns stock in iRhythm. Dr Volgman has served as a consultant and on advisory boards for Merck, Bristol Myers Squibb Foundation, Novo Nordisk, and Janssen; has received research funding from Novartis; and hold stocks in Apple, Inc. Dr Elgendy has received research grants from Caladrius Biosciences, Inc, unrelated to this paper. Dr Mamas has been a speaker for Daiichi-Sankyo. Dr Reynolds has received in-kind donations for research from Abbott Vascular, Siemens, and BioTelemetry, Inc. Dr Piazza has received research grants from BMS/Pfizer, Janssen, Alexion, Bayer, Amgen, and BSC; and has an advisory role in BSC, Amgen, BCRI, PERC, Syntactx, BMS, and Janssen. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.\n",
      "\n",
      "Funding Support and Author Disclosures This study was funded by National Institute for Nursing Research grants 1K99NR018679-01 and F31NR015725, UCLA Clinical and Translational Science Institutes grants UL1TR000124 and UL1TR001881-01, and the Preventive Cardiovascular Nurses Association grant #5362  through the American Nurses Foundation (Dr Margo B. Minissian). Additional support was provided by the Cedars-Sinai Department of Obstetrics and Gynecology, the Cedars-Sinai Brawerman Nursing Institute, Department of Nursing Research, and the Cedars-Sinai Barbra Streisand Women's Heart Center, Beta Chi Chapter, and Cedars-Sinai Precision Health Institute grant #42254 (Dr Margo B. Minissian). Dr Wei is supported by National Institutes of Health (NIH) grants K23HL125941 and R01HL146158. Dr Bairey Merz is supported by NIH grants R01HL124649 and U54 AG065141, the Barbra Streisand Women's Cardiovascular Research and Education Program, Cedars-Sinai Medical Center Los Angeles, the Linda Joy Pollin Women's Heart Health Program, the Erika Glazer Women's Heart Health Project, and the Adelson Family Foundation, Cedars-Sinai Medical Center, Los Angeles, California.  Dr Reynolds is supported by American Heart Association grant SFRN 20-A0-00-1005066. Dr Quesada is supported by NIH grants T32HL116273 and K23HL151867. Dr Margo B. Minissian has received honoraria from the National Lipid Association, North American Menopause Society, MJH Life Sciences, Vox Media, Medtelligence, Minneapolis Heart Institute, Primed, Good Samaritan Hospital Los Angeles, California, Cardiometabolic Health Congress, American Heart Association, Preventive Cardiovascular Nurses Association, and the American College of Cardiology; has been a consultant for and served on a medical advisory board for  Amgen; and has served as a co-chair for CME for the North American Center for Continuing Medical Education honorarium. Dr Wei has received institutional fees for serving on an advisory board for Abbott Vascular. Dr Bairey Merz has received consulting fees from Abbott Diagnostics, Caladrius, and Sanofi Vascular; and receives consulting fees, is on the board of directors and owns stock in iRhythm. Dr Volgman has served as a consultant and on advisory boards for Merck, Bristol Myers Squibb Foundation, Novo Nordisk, and Janssen; has received research funding from Novartis; and hold stocks in Apple, Inc. Dr Elgendy has received research grants from Caladrius Biosciences, Inc, unrelated to this paper. Dr Mamas has been a speaker for Daiichi-Sankyo. Dr Reynolds has received in-kind donations for research from Abbott Vascular, Siemens, and BioTelemetry, Inc. Dr Piazza has received research grants from BMS/Pfizer, Janssen, Alexion, Bayer, Amgen, and BSC; and has an advisory role in BSC, Amgen, BCRI, PERC, Syntactx, BMS, and Janssen. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.\n",
      "\n",
      "Wei, Janet\n",
      "Funding Support and Author Disclosures This study was funded by National Institute for Nursing Research grants 1K99NR018679-01 and F31NR015725, UCLA Clinical and Translational Science Institutes grants UL1TR000124 and UL1TR001881-01, and the Preventive Cardiovascular Nurses Association grant #5362  through the American Nurses Foundation (Dr Margo B. Minissian). Additional support was provided by the Cedars-Sinai Department of Obstetrics and Gynecology, the Cedars-Sinai Brawerman Nursing Institute, Department of Nursing Research, and the Cedars-Sinai Barbra Streisand Women's Heart Center, Beta Chi Chapter, and Cedars-Sinai Precision Health Institute grant #42254 (Dr Margo B. Minissian). Dr Janet Wei is supported by National Institutes of Health (NIH) grants K23HL125941 and R01HL146158. Dr Bairey Merz is supported by NIH grants R01HL124649 and U54 AG065141, the Barbra Streisand Women's Cardiovascular Research and Education Program, Cedars-Sinai Medical Center Los Angeles, the Linda Joy Pollin Women's Heart Health Program, the Erika Glazer Women's Heart Health Project, and the Adelson Family Foundation, Cedars-Sinai Medical Center, Los Angeles, California.  Dr Reynolds is supported by American Heart Association grant SFRN 20-A0-00-1005066. Dr Quesada is supported by NIH grants T32HL116273 and K23HL151867. Dr Margo B. Minissian has received honoraria from the National Lipid Association, North American Menopause Society, MJH Life Sciences, Vox Media, Medtelligence, Minneapolis Heart Institute, Primed, Good Samaritan Hospital Los Angeles, California, Cardiometabolic Health Congress, American Heart Association, Preventive Cardiovascular Nurses Association, and the American College of Cardiology; has been a consultant for and served on a medical advisory board for  Amgen; and has served as a co-chair for CME for the North American Center for Continuing Medical Education honorarium. Dr Janet Wei has received institutional fees for serving on an advisory board for Abbott Vascular. Dr Bairey Merz has received consulting fees from Abbott Diagnostics, Caladrius, and Sanofi Vascular; and receives consulting fees, is on the board of directors and owns stock in iRhythm. Dr Volgman has served as a consultant and on advisory boards for Merck, Bristol Myers Squibb Foundation, Novo Nordisk, and Janssen; has received research funding from Novartis; and hold stocks in Apple, Inc. Dr Elgendy has received research grants from Caladrius Biosciences, Inc, unrelated to this paper. Dr Mamas has been a speaker for Daiichi-Sankyo. Dr Reynolds has received in-kind donations for research from Abbott Vascular, Siemens, and BioTelemetry, Inc. Dr Piazza has received research grants from BMS/Pfizer, Janssen, Alexion, Bayer, Amgen, and BSC; and has an advisory role in BSC, Amgen, BCRI, PERC, Syntactx, BMS, and Janssen. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.\n",
      "\n",
      "Noel Bairey Merz, C.\n",
      "Funding Support and Author Disclosures This study was funded by National Institute for Nursing Research grants 1K99NR018679-01 and F31NR015725, UCLA Clinical and Translational Science Institutes grants UL1TR000124 and UL1TR001881-01, and the Preventive Cardiovascular Nurses Association grant #5362  through the American Nurses Foundation (Dr Margo B. Minissian). Additional support was provided by the Cedars-Sinai Department of Obstetrics and Gynecology, the Cedars-Sinai Brawerman Nursing Institute, Department of Nursing Research, and the Cedars-Sinai Barbra Streisand Women's Heart Center, Beta Chi Chapter, and Cedars-Sinai Precision Health Institute grant #42254 (Dr Margo B. Minissian). Dr Janet Wei is supported by National Institutes of Health (NIH) grants K23HL125941 and R01HL146158. Dr Bairey C. Noel Bairey Merz is supported by NIH grants R01HL124649 and U54 AG065141, the Barbra Streisand Women's Cardiovascular Research and Education Program, Cedars-Sinai Medical Center Los Angeles, the Linda Joy Pollin Women's Heart Health Program, the Erika Glazer Women's Heart Health Project, and the Adelson Family Foundation, Cedars-Sinai Medical Center, Los Angeles, California.  Dr Reynolds is supported by American Heart Association grant SFRN 20-A0-00-1005066. Dr Quesada is supported by NIH grants T32HL116273 and K23HL151867. Dr Margo B. Minissian has received honoraria from the National Lipid Association, North American Menopause Society, MJH Life Sciences, Vox Media, Medtelligence, Minneapolis Heart Institute, Primed, Good Samaritan Hospital Los Angeles, California, Cardiometabolic Health Congress, American Heart Association, Preventive Cardiovascular Nurses Association, and the American College of Cardiology; has been a consultant for and served on a medical advisory board for  Amgen; and has served as a co-chair for CME for the North American Center for Continuing Medical Education honorarium. Dr Janet Wei has received institutional fees for serving on an advisory board for Abbott Vascular. Dr Bairey C. Noel Bairey Merz has received consulting fees from Abbott Diagnostics, Caladrius, and Sanofi Vascular; and receives consulting fees, is on the board of directors and owns stock in iRhythm. Dr Volgman has served as a consultant and on advisory boards for Merck, Bristol Myers Squibb Foundation, Novo Nordisk, and Janssen; has received research funding from Novartis; and hold stocks in Apple, Inc. Dr Elgendy has received research grants from Caladrius Biosciences, Inc, unrelated to this paper. Dr Mamas has been a speaker for Daiichi-Sankyo. Dr Reynolds has received in-kind donations for research from Abbott Vascular, Siemens, and BioTelemetry, Inc. Dr Piazza has received research grants from BMS/Pfizer, Janssen, Alexion, Bayer, Amgen, and BSC; and has an advisory role in BSC, Amgen, BCRI, PERC, Syntactx, BMS, and Janssen. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.\n",
      "\n",
      "Funding Support and Author Disclosures This study was funded by National Institute for Nursing Research grants 1K99NR018679-01 and F31NR015725, UCLA Clinical and Translational Science Institutes grants UL1TR000124 and UL1TR001881-01, and the Preventive Cardiovascular Nurses Association grant #5362  through the American Nurses Foundation (Dr Margo B. Minissian). Additional support was provided by the Cedars-Sinai Department of Obstetrics and Gynecology, the Cedars-Sinai Brawerman Nursing Institute, Department of Nursing Research, and the Cedars-Sinai Barbra Streisand Women's Heart Center, Beta Chi Chapter, and Cedars-Sinai Precision Health Institute grant #42254 (Dr Margo B. Minissian). Dr Janet Wei is supported by National Institutes of Health (NIH) grants K23HL125941 and R01HL146158. Dr Bairey C. Noel Bairey Merz is supported by NIH grants R01HL124649 and U54 AG065141, the Barbra Streisand Women's Cardiovascular Research and Education Program, Cedars-Sinai Medical Center Los Angeles, the Linda Joy Pollin Women's Heart Health Program, the Erika Glazer Women's Heart Health Project, and the Adelson Family Foundation, Cedars-Sinai Medical Center, Los Angeles, California.  Dr Reynolds is supported by American Heart Association grant SFRN 20-A0-00-1005066. Dr Quesada is supported by NIH grants T32HL116273 and K23HL151867. Dr Margo B. Minissian has received honoraria from the National Lipid Association, North American Menopause Society, MJH Life Sciences, Vox Media, Medtelligence, Minneapolis Heart Institute, Primed, Good Samaritan Hospital Los Angeles, California, Cardiometabolic Health Congress, American Heart Association, Preventive Cardiovascular Nurses Association, and the American College of Cardiology; has been a consultant for and served on a medical advisory board for  Amgen; and has served as a co-chair for CME for the North American Center for Continuing Medical Education honorarium. Dr Janet Wei has received institutional fees for serving on an advisory board for Abbott Vascular. Dr Bairey C. Noel Bairey Merz has received consulting fees from Abbott Diagnostics, Caladrius, and Sanofi Vascular; and receives consulting fees, is on the board of directors and owns stock in iRhythm. Dr Volgman has served as a consultant and on advisory boards for Merck, Bristol Myers Squibb Foundation, Novo Nordisk, and Janssen; has received research funding from Novartis; and hold stocks in Apple, Inc. Dr Elgendy has received research grants from Caladrius Biosciences, Inc, unrelated to this paper. Dr Mamas has been a speaker for Daiichi-Sankyo. Dr Reynolds has received in-kind donations for research from Abbott Vascular, Siemens, and BioTelemetry, Inc. Dr Piazza has received research grants from BMS/Pfizer, Janssen, Alexion, Bayer, Amgen, and BSC; and has an advisory role in BSC, Amgen, BCRI, PERC, Syntactx, BMS, and Janssen. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.\n",
      "\n",
      "Santos Volgman, Annabelle\n",
      "Funding Support and Author Disclosures This study was funded by National Institute for Nursing Research grants 1K99NR018679-01 and F31NR015725, UCLA Clinical and Translational Science Institutes grants UL1TR000124 and UL1TR001881-01, and the Preventive Cardiovascular Nurses Association grant #5362  through the American Nurses Foundation (Dr Margo B. Minissian). Additional support was provided by the Cedars-Sinai Department of Obstetrics and Gynecology, the Cedars-Sinai Brawerman Nursing Institute, Department of Nursing Research, and the Cedars-Sinai Barbra Streisand Women's Heart Center, Beta Chi Chapter, and Cedars-Sinai Precision Health Institute grant #42254 (Dr Margo B. Minissian). Dr Janet Wei is supported by National Institutes of Health (NIH) grants K23HL125941 and R01HL146158. Dr Bairey C. Noel Bairey Merz is supported by NIH grants R01HL124649 and U54 AG065141, the Barbra Streisand Women's Cardiovascular Research and Education Program, Cedars-Sinai Medical Center Los Angeles, the Linda Joy Pollin Women's Heart Health Program, the Erika Glazer Women's Heart Health Project, and the Adelson Family Foundation, Cedars-Sinai Medical Center, Los Angeles, California.  Dr Reynolds is supported by American Heart Association grant SFRN 20-A0-00-1005066. Dr Quesada is supported by NIH grants T32HL116273 and K23HL151867. Dr Margo B. Minissian has received honoraria from the National Lipid Association, North American Menopause Society, MJH Life Sciences, Vox Media, Medtelligence, Minneapolis Heart Institute, Primed, Good Samaritan Hospital Los Angeles, California, Cardiometabolic Health Congress, American Heart Association, Preventive Cardiovascular Nurses Association, and the American College of Cardiology; has been a consultant for and served on a medical advisory board for  Amgen; and has served as a co-chair for CME for the North American Center for Continuing Medical Education honorarium. Dr Janet Wei has received institutional fees for serving on an advisory board for Abbott Vascular. Dr Bairey C. Noel Bairey Merz has received consulting fees from Abbott Diagnostics, Caladrius, and Sanofi Vascular; and receives consulting fees, is on the board of directors and owns stock in iRhythm. Dr Annabelle Santos Volgman has served as a consultant and on advisory boards for Merck, Bristol Myers Squibb Foundation, Novo Nordisk, and Janssen; has received research funding from Novartis; and hold stocks in Apple, Inc. Dr Elgendy has received research grants from Caladrius Biosciences, Inc, unrelated to this paper. Dr Mamas has been a speaker for Daiichi-Sankyo. Dr Reynolds has received in-kind donations for research from Abbott Vascular, Siemens, and BioTelemetry, Inc. Dr Piazza has received research grants from BMS/Pfizer, Janssen, Alexion, Bayer, Amgen, and BSC; and has an advisory role in BSC, Amgen, BCRI, PERC, Syntactx, BMS, and Janssen. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.\n",
      "\n",
      "Elgendy, Islam Y.\n",
      "Funding Support and Author Disclosures This study was funded by National Institute for Nursing Research grants 1K99NR018679-01 and F31NR015725, UCLA Clinical and Translational Science Institutes grants UL1TR000124 and UL1TR001881-01, and the Preventive Cardiovascular Nurses Association grant #5362  through the American Nurses Foundation (Dr Margo B. Minissian). Additional support was provided by the Cedars-Sinai Department of Obstetrics and Gynecology, the Cedars-Sinai Brawerman Nursing Institute, Department of Nursing Research, and the Cedars-Sinai Barbra Streisand Women's Heart Center, Beta Chi Chapter, and Cedars-Sinai Precision Health Institute grant #42254 (Dr Margo B. Minissian). Dr Janet Wei is supported by National Institutes of Health (NIH) grants K23HL125941 and R01HL146158. Dr Bairey C. Noel Bairey Merz is supported by NIH grants R01HL124649 and U54 AG065141, the Barbra Streisand Women's Cardiovascular Research and Education Program, Cedars-Sinai Medical Center Los Angeles, the Linda Joy Pollin Women's Heart Health Program, the Erika Glazer Women's Heart Health Project, and the Adelson Family Foundation, Cedars-Sinai Medical Center, Los Angeles, California.  Dr Reynolds is supported by American Heart Association grant SFRN 20-A0-00-1005066. Dr Quesada is supported by NIH grants T32HL116273 and K23HL151867. Dr Margo B. Minissian has received honoraria from the National Lipid Association, North American Menopause Society, MJH Life Sciences, Vox Media, Medtelligence, Minneapolis Heart Institute, Primed, Good Samaritan Hospital Los Angeles, California, Cardiometabolic Health Congress, American Heart Association, Preventive Cardiovascular Nurses Association, and the American College of Cardiology; has been a consultant for and served on a medical advisory board for  Amgen; and has served as a co-chair for CME for the North American Center for Continuing Medical Education honorarium. Dr Janet Wei has received institutional fees for serving on an advisory board for Abbott Vascular. Dr Bairey C. Noel Bairey Merz has received consulting fees from Abbott Diagnostics, Caladrius, and Sanofi Vascular; and receives consulting fees, is on the board of directors and owns stock in iRhythm. Dr Annabelle Santos Volgman has served as a consultant and on advisory boards for Merck, Bristol Myers Squibb Foundation, Novo Nordisk, and Janssen; has received research funding from Novartis; and hold stocks in Apple, Inc. Dr Islam Y. Elgendy has received research grants from Caladrius Biosciences, Inc, unrelated to this paper. Dr Mamas has been a speaker for Daiichi-Sankyo. Dr Reynolds has received in-kind donations for research from Abbott Vascular, Siemens, and BioTelemetry, Inc. Dr Piazza has received research grants from BMS/Pfizer, Janssen, Alexion, Bayer, Amgen, and BSC; and has an advisory role in BSC, Amgen, BCRI, PERC, Syntactx, BMS, and Janssen. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.\n",
      "\n",
      "Mamas, Mamas\n",
      "Funding Support and Author Disclosures This study was funded by National Institute for Nursing Research grants 1K99NR018679-01 and F31NR015725, UCLA Clinical and Translational Science Institutes grants UL1TR000124 and UL1TR001881-01, and the Preventive Cardiovascular Nurses Association grant #5362  through the American Nurses Foundation (Dr Margo B. Minissian). Additional support was provided by the Cedars-Sinai Department of Obstetrics and Gynecology, the Cedars-Sinai Brawerman Nursing Institute, Department of Nursing Research, and the Cedars-Sinai Barbra Streisand Women's Heart Center, Beta Chi Chapter, and Cedars-Sinai Precision Health Institute grant #42254 (Dr Margo B. Minissian). Dr Janet Wei is supported by National Institutes of Health (NIH) grants K23HL125941 and R01HL146158. Dr Bairey C. Noel Bairey Merz is supported by NIH grants R01HL124649 and U54 AG065141, the Barbra Streisand Women's Cardiovascular Research and Education Program, Cedars-Sinai Medical Center Los Angeles, the Linda Joy Pollin Women's Heart Health Program, the Erika Glazer Women's Heart Health Project, and the Adelson Family Foundation, Cedars-Sinai Medical Center, Los Angeles, California.  Dr Reynolds is supported by American Heart Association grant SFRN 20-A0-00-1005066. Dr Quesada is supported by NIH grants T32HL116273 and K23HL151867. Dr Margo B. Minissian has received honoraria from the National Lipid Association, North American Menopause Society, MJH Life Sciences, Vox Media, Medtelligence, Minneapolis Heart Institute, Primed, Good Samaritan Hospital Los Angeles, California, Cardiometabolic Health Congress, American Heart Association, Preventive Cardiovascular Nurses Association, and the American College of Cardiology; has been a consultant for and served on a medical advisory board for  Amgen; and has served as a co-chair for CME for the North American Center for Continuing Medical Education honorarium. Dr Janet Wei has received institutional fees for serving on an advisory board for Abbott Vascular. Dr Bairey C. Noel Bairey Merz has received consulting fees from Abbott Diagnostics, Caladrius, and Sanofi Vascular; and receives consulting fees, is on the board of directors and owns stock in iRhythm. Dr Annabelle Santos Volgman has served as a consultant and on advisory boards for Merck, Bristol Myers Squibb Foundation, Novo Nordisk, and Janssen; has received research funding from Novartis; and hold stocks in Apple, Inc. Dr Islam Y. Elgendy has received research grants from Caladrius Biosciences, Inc, unrelated to this paper. Dr Mamas Mamas has been a speaker for Daiichi-Sankyo. Dr Reynolds has received in-kind donations for research from Abbott Vascular, Siemens, and BioTelemetry, Inc. Dr Piazza has received research grants from BMS/Pfizer, Janssen, Alexion, Bayer, Amgen, and BSC; and has an advisory role in BSC, Amgen, BCRI, PERC, Syntactx, BMS, and Janssen. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.\n",
      "\n",
      "Funding Support and Author Disclosures This study was funded by National Institute for Nursing Research grants 1K99NR018679-01 and F31NR015725, UCLA Clinical and Translational Science Institutes grants UL1TR000124 and UL1TR001881-01, and the Preventive Cardiovascular Nurses Association grant #5362  through the American Nurses Foundation (Dr Margo B. Minissian). Additional support was provided by the Cedars-Sinai Department of Obstetrics and Gynecology, the Cedars-Sinai Brawerman Nursing Institute, Department of Nursing Research, and the Cedars-Sinai Barbra Streisand Women's Heart Center, Beta Chi Chapter, and Cedars-Sinai Precision Health Institute grant #42254 (Dr Margo B. Minissian). Dr Janet Wei is supported by National Institutes of Health (NIH) grants K23HL125941 and R01HL146158. Dr Bairey C. Noel Bairey Merz is supported by NIH grants R01HL124649 and U54 AG065141, the Barbra Streisand Women's Cardiovascular Research and Education Program, Cedars-Sinai Medical Center Los Angeles, the Linda Joy Pollin Women's Heart Health Program, the Erika Glazer Women's Heart Health Project, and the Adelson Family Foundation, Cedars-Sinai Medical Center, Los Angeles, California.  Dr Reynolds is supported by American Heart Association grant SFRN 20-A0-00-1005066. Dr Quesada is supported by NIH grants T32HL116273 and K23HL151867. Dr Margo B. Minissian has received honoraria from the National Lipid Association, North American Menopause Society, MJH Life Sciences, Vox Media, Medtelligence, Minneapolis Heart Institute, Primed, Good Samaritan Hospital Los Angeles, California, Cardiometabolic Health Congress, American Heart Association, Preventive Cardiovascular Nurses Association, and the American College of Cardiology; has been a consultant for and served on a medical advisory board for  Amgen; and has served as a co-chair for CME for the North American Center for Continuing Medical Education honorarium. Dr Janet Wei has received institutional fees for serving on an advisory board for Abbott Vascular. Dr Bairey C. Noel Bairey Merz has received consulting fees from Abbott Diagnostics, Caladrius, and Sanofi Vascular; and receives consulting fees, is on the board of directors and owns stock in iRhythm. Dr Annabelle Santos Volgman has served as a consultant and on advisory boards for Merck, Bristol Myers Squibb Foundation, Novo Nordisk, and Janssen; has received research funding from Novartis; and hold stocks in Apple, Inc. Dr Islam Y. Elgendy has received research grants from Caladrius Biosciences, Inc, unrelated to this paper. Dr Mamas Mamas has been a speaker for Daiichi-Sankyo. Dr Reynolds has received in-kind donations for research from Abbott Vascular, Siemens, and BioTelemetry, Inc. Dr Piazza has received research grants from BMS/Pfizer, Janssen, Alexion, Bayer, Amgen, and BSC; and has an advisory role in BSC, Amgen, BCRI, PERC, Syntactx, BMS, and Janssen. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.\n",
      "\n",
      "Reynolds, Harmony R.\n",
      "Funding Support and Author Disclosures This study was funded by National Institute for Nursing Research grants 1K99NR018679-01 and F31NR015725, UCLA Clinical and Translational Science Institutes grants UL1TR000124 and UL1TR001881-01, and the Preventive Cardiovascular Nurses Association grant #5362  through the American Nurses Foundation (Dr Margo B. Minissian). Additional support was provided by the Cedars-Sinai Department of Obstetrics and Gynecology, the Cedars-Sinai Brawerman Nursing Institute, Department of Nursing Research, and the Cedars-Sinai Barbra Streisand Women's Heart Center, Beta Chi Chapter, and Cedars-Sinai Precision Health Institute grant #42254 (Dr Margo B. Minissian). Dr Janet Wei is supported by National Institutes of Health (NIH) grants K23HL125941 and R01HL146158. Dr Bairey C. Noel Bairey Merz is supported by NIH grants R01HL124649 and U54 AG065141, the Barbra Streisand Women's Cardiovascular Research and Education Program, Cedars-Sinai Medical Center Los Angeles, the Linda Joy Pollin Women's Heart Health Program, the Erika Glazer Women's Heart Health Project, and the Adelson Family Foundation, Cedars-Sinai Medical Center, Los Angeles, California.  Dr Harmony R. Reynolds is supported by American Heart Association grant SFRN 20-A0-00-1005066. Dr Quesada is supported by NIH grants T32HL116273 and K23HL151867. Dr Margo B. Minissian has received honoraria from the National Lipid Association, North American Menopause Society, MJH Life Sciences, Vox Media, Medtelligence, Minneapolis Heart Institute, Primed, Good Samaritan Hospital Los Angeles, California, Cardiometabolic Health Congress, American Heart Association, Preventive Cardiovascular Nurses Association, and the American College of Cardiology; has been a consultant for and served on a medical advisory board for  Amgen; and has served as a co-chair for CME for the North American Center for Continuing Medical Education honorarium. Dr Janet Wei has received institutional fees for serving on an advisory board for Abbott Vascular. Dr Bairey C. Noel Bairey Merz has received consulting fees from Abbott Diagnostics, Caladrius, and Sanofi Vascular; and receives consulting fees, is on the board of directors and owns stock in iRhythm. Dr Annabelle Santos Volgman has served as a consultant and on advisory boards for Merck, Bristol Myers Squibb Foundation, Novo Nordisk, and Janssen; has received research funding from Novartis; and hold stocks in Apple, Inc. Dr Islam Y. Elgendy has received research grants from Caladrius Biosciences, Inc, unrelated to this paper. Dr Mamas Mamas has been a speaker for Daiichi-Sankyo. Dr Harmony R. Reynolds has received in-kind donations for research from Abbott Vascular, Siemens, and BioTelemetry, Inc. Dr Piazza has received research grants from BMS/Pfizer, Janssen, Alexion, Bayer, Amgen, and BSC; and has an advisory role in BSC, Amgen, BCRI, PERC, Syntactx, BMS, and Janssen. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.\n",
      "\n",
      "Funding Support and Author Disclosures This study was funded by National Institute for Nursing Research grants 1K99NR018679-01 and F31NR015725, UCLA Clinical and Translational Science Institutes grants UL1TR000124 and UL1TR001881-01, and the Preventive Cardiovascular Nurses Association grant #5362  through the American Nurses Foundation (Dr Margo B. Minissian). Additional support was provided by the Cedars-Sinai Department of Obstetrics and Gynecology, the Cedars-Sinai Brawerman Nursing Institute, Department of Nursing Research, and the Cedars-Sinai Barbra Streisand Women's Heart Center, Beta Chi Chapter, and Cedars-Sinai Precision Health Institute grant #42254 (Dr Margo B. Minissian). Dr Janet Wei is supported by National Institutes of Health (NIH) grants K23HL125941 and R01HL146158. Dr Bairey C. Noel Bairey Merz is supported by NIH grants R01HL124649 and U54 AG065141, the Barbra Streisand Women's Cardiovascular Research and Education Program, Cedars-Sinai Medical Center Los Angeles, the Linda Joy Pollin Women's Heart Health Program, the Erika Glazer Women's Heart Health Project, and the Adelson Family Foundation, Cedars-Sinai Medical Center, Los Angeles, California.  Dr Harmony R. Reynolds is supported by American Heart Association grant SFRN 20-A0-00-1005066. Dr Quesada is supported by NIH grants T32HL116273 and K23HL151867. Dr Margo B. Minissian has received honoraria from the National Lipid Association, North American Menopause Society, MJH Life Sciences, Vox Media, Medtelligence, Minneapolis Heart Institute, Primed, Good Samaritan Hospital Los Angeles, California, Cardiometabolic Health Congress, American Heart Association, Preventive Cardiovascular Nurses Association, and the American College of Cardiology; has been a consultant for and served on a medical advisory board for  Amgen; and has served as a co-chair for CME for the North American Center for Continuing Medical Education honorarium. Dr Janet Wei has received institutional fees for serving on an advisory board for Abbott Vascular. Dr Bairey C. Noel Bairey Merz has received consulting fees from Abbott Diagnostics, Caladrius, and Sanofi Vascular; and receives consulting fees, is on the board of directors and owns stock in iRhythm. Dr Annabelle Santos Volgman has served as a consultant and on advisory boards for Merck, Bristol Myers Squibb Foundation, Novo Nordisk, and Janssen; has received research funding from Novartis; and hold stocks in Apple, Inc. Dr Islam Y. Elgendy has received research grants from Caladrius Biosciences, Inc, unrelated to this paper. Dr Mamas Mamas has been a speaker for Daiichi-Sankyo. Dr Harmony R. Reynolds has received in-kind donations for research from Abbott Vascular, Siemens, and BioTelemetry, Inc. Dr Piazza has received research grants from BMS/Pfizer, Janssen, Alexion, Bayer, Amgen, and BSC; and has an advisory role in BSC, Amgen, BCRI, PERC, Syntactx, BMS, and Janssen. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.\n",
      "\n",
      "Funding Support and Author Disclosures This study was funded by National Institute for Nursing Research grants 1K99NR018679-01 and F31NR015725, UCLA Clinical and Translational Science Institutes grants UL1TR000124 and UL1TR001881-01, and the Preventive Cardiovascular Nurses Association grant #5362  through the American Nurses Foundation (Dr Margo B. Minissian). Additional support was provided by the Cedars-Sinai Department of Obstetrics and Gynecology, the Cedars-Sinai Brawerman Nursing Institute, Department of Nursing Research, and the Cedars-Sinai Barbra Streisand Women's Heart Center, Beta Chi Chapter, and Cedars-Sinai Precision Health Institute grant #42254 (Dr Margo B. Minissian). Dr Janet Wei is supported by National Institutes of Health (NIH) grants K23HL125941 and R01HL146158. Dr Bairey C. Noel Bairey Merz is supported by NIH grants R01HL124649 and U54 AG065141, the Barbra Streisand Women's Cardiovascular Research and Education Program, Cedars-Sinai Medical Center Los Angeles, the Linda Joy Pollin Women's Heart Health Program, the Erika Glazer Women's Heart Health Project, and the Adelson Family Foundation, Cedars-Sinai Medical Center, Los Angeles, California.  Dr Harmony R. Reynolds is supported by American Heart Association grant SFRN 20-A0-00-1005066. Dr Quesada is supported by NIH grants T32HL116273 and K23HL151867. Dr Margo B. Minissian has received honoraria from the National Lipid Association, North American Menopause Society, MJH Life Sciences, Vox Media, Medtelligence, Minneapolis Heart Institute, Primed, Good Samaritan Hospital Los Angeles, California, Cardiometabolic Health Congress, American Heart Association, Preventive Cardiovascular Nurses Association, and the American College of Cardiology; has been a consultant for and served on a medical advisory board for  Amgen; and has served as a co-chair for CME for the North American Center for Continuing Medical Education honorarium. Dr Janet Wei has received institutional fees for serving on an advisory board for Abbott Vascular. Dr Bairey C. Noel Bairey Merz has received consulting fees from Abbott Diagnostics, Caladrius, and Sanofi Vascular; and receives consulting fees, is on the board of directors and owns stock in iRhythm. Dr Annabelle Santos Volgman has served as a consultant and on advisory boards for Merck, Bristol Myers Squibb Foundation, Novo Nordisk, and Janssen; has received research funding from Novartis; and hold stocks in Apple, Inc. Dr Islam Y. Elgendy has received research grants from Caladrius Biosciences, Inc, unrelated to this paper. Dr Mamas Mamas has been a speaker for Daiichi-Sankyo. Dr Harmony R. Reynolds has received in-kind donations for research from Abbott Vascular, Siemens, and BioTelemetry, Inc. Dr Piazza has received research grants from BMS/Pfizer, Janssen, Alexion, Bayer, Amgen, and BSC; and has an advisory role in BSC, Amgen, BCRI, PERC, Syntactx, BMS, and Janssen. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.\n",
      "\n",
      "Funding Support and Author Disclosures This study was funded by National Institute for Nursing Research grants 1K99NR018679-01 and F31NR015725, UCLA Clinical and Translational Science Institutes grants UL1TR000124 and UL1TR001881-01, and the Preventive Cardiovascular Nurses Association grant #5362  through the American Nurses Foundation (Dr Margo B. Minissian). Additional support was provided by the Cedars-Sinai Department of Obstetrics and Gynecology, the Cedars-Sinai Brawerman Nursing Institute, Department of Nursing Research, and the Cedars-Sinai Barbra Streisand Women's Heart Center, Beta Chi Chapter, and Cedars-Sinai Precision Health Institute grant #42254 (Dr Margo B. Minissian). Dr Janet Wei is supported by National Institutes of Health (NIH) grants K23HL125941 and R01HL146158. Dr Bairey C. Noel Bairey Merz is supported by NIH grants R01HL124649 and U54 AG065141, the Barbra Streisand Women's Cardiovascular Research and Education Program, Cedars-Sinai Medical Center Los Angeles, the Linda Joy Pollin Women's Heart Health Program, the Erika Glazer Women's Heart Health Project, and the Adelson Family Foundation, Cedars-Sinai Medical Center, Los Angeles, California.  Dr Harmony R. Reynolds is supported by American Heart Association grant SFRN 20-A0-00-1005066. Dr Quesada is supported by NIH grants T32HL116273 and K23HL151867. Dr Margo B. Minissian has received honoraria from the National Lipid Association, North American Menopause Society, MJH Life Sciences, Vox Media, Medtelligence, Minneapolis Heart Institute, Primed, Good Samaritan Hospital Los Angeles, California, Cardiometabolic Health Congress, American Heart Association, Preventive Cardiovascular Nurses Association, and the American College of Cardiology; has been a consultant for and served on a medical advisory board for  Amgen; and has served as a co-chair for CME for the North American Center for Continuing Medical Education honorarium. Dr Janet Wei has received institutional fees for serving on an advisory board for Abbott Vascular. Dr Bairey C. Noel Bairey Merz has received consulting fees from Abbott Diagnostics, Caladrius, and Sanofi Vascular; and receives consulting fees, is on the board of directors and owns stock in iRhythm. Dr Annabelle Santos Volgman has served as a consultant and on advisory boards for Merck, Bristol Myers Squibb Foundation, Novo Nordisk, and Janssen; has received research funding from Novartis; and hold stocks in Apple, Inc. Dr Islam Y. Elgendy has received research grants from Caladrius Biosciences, Inc, unrelated to this paper. Dr Mamas Mamas has been a speaker for Daiichi-Sankyo. Dr Harmony R. Reynolds has received in-kind donations for research from Abbott Vascular, Siemens, and BioTelemetry, Inc. Dr Piazza has received research grants from BMS/Pfizer, Janssen, Alexion, Bayer, Amgen, and BSC; and has an advisory role in BSC, Amgen, BCRI, PERC, Syntactx, BMS, and Janssen. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.\n",
      "\n",
      "Quesada, Odayme\n",
      "Funding Support and Author Disclosures This study was funded by National Institute for Nursing Research grants 1K99NR018679-01 and F31NR015725, UCLA Clinical and Translational Science Institutes grants UL1TR000124 and UL1TR001881-01, and the Preventive Cardiovascular Nurses Association grant #5362  through the American Nurses Foundation (Dr Margo B. Minissian). Additional support was provided by the Cedars-Sinai Department of Obstetrics and Gynecology, the Cedars-Sinai Brawerman Nursing Institute, Department of Nursing Research, and the Cedars-Sinai Barbra Streisand Women's Heart Center, Beta Chi Chapter, and Cedars-Sinai Precision Health Institute grant #42254 (Dr Margo B. Minissian). Dr Janet Wei is supported by National Institutes of Health (NIH) grants K23HL125941 and R01HL146158. Dr Bairey C. Noel Bairey Merz is supported by NIH grants R01HL124649 and U54 AG065141, the Barbra Streisand Women's Cardiovascular Research and Education Program, Cedars-Sinai Medical Center Los Angeles, the Linda Joy Pollin Women's Heart Health Program, the Erika Glazer Women's Heart Health Project, and the Adelson Family Foundation, Cedars-Sinai Medical Center, Los Angeles, California.  Dr Harmony R. Reynolds is supported by American Heart Association grant SFRN 20-A0-00-1005066. Dr Odayme Quesada is supported by NIH grants T32HL116273 and K23HL151867. Dr Margo B. Minissian has received honoraria from the National Lipid Association, North American Menopause Society, MJH Life Sciences, Vox Media, Medtelligence, Minneapolis Heart Institute, Primed, Good Samaritan Hospital Los Angeles, California, Cardiometabolic Health Congress, American Heart Association, Preventive Cardiovascular Nurses Association, and the American College of Cardiology; has been a consultant for and served on a medical advisory board for  Amgen; and has served as a co-chair for CME for the North American Center for Continuing Medical Education honorarium. Dr Janet Wei has received institutional fees for serving on an advisory board for Abbott Vascular. Dr Bairey C. Noel Bairey Merz has received consulting fees from Abbott Diagnostics, Caladrius, and Sanofi Vascular; and receives consulting fees, is on the board of directors and owns stock in iRhythm. Dr Annabelle Santos Volgman has served as a consultant and on advisory boards for Merck, Bristol Myers Squibb Foundation, Novo Nordisk, and Janssen; has received research funding from Novartis; and hold stocks in Apple, Inc. Dr Islam Y. Elgendy has received research grants from Caladrius Biosciences, Inc, unrelated to this paper. Dr Mamas Mamas has been a speaker for Daiichi-Sankyo. Dr Harmony R. Reynolds has received in-kind donations for research from Abbott Vascular, Siemens, and BioTelemetry, Inc. Dr Piazza has received research grants from BMS/Pfizer, Janssen, Alexion, Bayer, Amgen, and BSC; and has an advisory role in BSC, Amgen, BCRI, PERC, Syntactx, BMS, and Janssen. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.\n",
      "\n",
      "Piazza, Gregory\n",
      "Funding Support and Author Disclosures This study was funded by National Institute for Nursing Research grants 1K99NR018679-01 and F31NR015725, UCLA Clinical and Translational Science Institutes grants UL1TR000124 and UL1TR001881-01, and the Preventive Cardiovascular Nurses Association grant #5362  through the American Nurses Foundation (Dr Margo B. Minissian). Additional support was provided by the Cedars-Sinai Department of Obstetrics and Gynecology, the Cedars-Sinai Brawerman Nursing Institute, Department of Nursing Research, and the Cedars-Sinai Barbra Streisand Women's Heart Center, Beta Chi Chapter, and Cedars-Sinai Precision Health Institute grant #42254 (Dr Margo B. Minissian). Dr Janet Wei is supported by National Institutes of Health (NIH) grants K23HL125941 and R01HL146158. Dr Bairey C. Noel Bairey Merz is supported by NIH grants R01HL124649 and U54 AG065141, the Barbra Streisand Women's Cardiovascular Research and Education Program, Cedars-Sinai Medical Center Los Angeles, the Linda Joy Pollin Women's Heart Health Program, the Erika Glazer Women's Heart Health Project, and the Adelson Family Foundation, Cedars-Sinai Medical Center, Los Angeles, California.  Dr Harmony R. Reynolds is supported by American Heart Association grant SFRN 20-A0-00-1005066. Dr Odayme Quesada is supported by NIH grants T32HL116273 and K23HL151867. Dr Margo B. Minissian has received honoraria from the National Lipid Association, North American Menopause Society, MJH Life Sciences, Vox Media, Medtelligence, Minneapolis Heart Institute, Primed, Good Samaritan Hospital Los Angeles, California, Cardiometabolic Health Congress, American Heart Association, Preventive Cardiovascular Nurses Association, and the American College of Cardiology; has been a consultant for and served on a medical advisory board for  Amgen; and has served as a co-chair for CME for the North American Center for Continuing Medical Education honorarium. Dr Janet Wei has received institutional fees for serving on an advisory board for Abbott Vascular. Dr Bairey C. Noel Bairey Merz has received consulting fees from Abbott Diagnostics, Caladrius, and Sanofi Vascular; and receives consulting fees, is on the board of directors and owns stock in iRhythm. Dr Annabelle Santos Volgman has served as a consultant and on advisory boards for Merck, Bristol Myers Squibb Foundation, Novo Nordisk, and Janssen; has received research funding from Novartis; and hold stocks in Apple, Inc. Dr Islam Y. Elgendy has received research grants from Caladrius Biosciences, Inc, unrelated to this paper. Dr Mamas Mamas has been a speaker for Daiichi-Sankyo. Dr Harmony R. Reynolds has received in-kind donations for research from Abbott Vascular, Siemens, and BioTelemetry, Inc. Dr Gregory Piazza has received research grants from BMS/Pfizer, Janssen, Alexion, Bayer, Amgen, and BSC; and has an advisory role in BSC, Amgen, BCRI, PERC, Syntactx, BMS, and Janssen. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.\n",
      "\n",
      "Funding Support and Author Disclosures This study was funded by National Institute for Nursing Research grants 1K99NR018679-01 and F31NR015725, UCLA Clinical and Translational Science Institutes grants UL1TR000124 and UL1TR001881-01, and the Preventive Cardiovascular Nurses Association grant #5362  through the American Nurses Foundation (Dr Margo B. Minissian). Additional support was provided by the Cedars-Sinai Department of Obstetrics and Gynecology, the Cedars-Sinai Brawerman Nursing Institute, Department of Nursing Research, and the Cedars-Sinai Barbra Streisand Women's Heart Center, Beta Chi Chapter, and Cedars-Sinai Precision Health Institute grant #42254 (Dr Margo B. Minissian). Dr Janet Wei is supported by National Institutes of Health (NIH) grants K23HL125941 and R01HL146158. Dr Bairey C. Noel Bairey Merz is supported by NIH grants R01HL124649 and U54 AG065141, the Barbra Streisand Women's Cardiovascular Research and Education Program, Cedars-Sinai Medical Center Los Angeles, the Linda Joy Pollin Women's Heart Health Program, the Erika Glazer Women's Heart Health Project, and the Adelson Family Foundation, Cedars-Sinai Medical Center, Los Angeles, California.  Dr Harmony R. Reynolds is supported by American Heart Association grant SFRN 20-A0-00-1005066. Dr Odayme Quesada is supported by NIH grants T32HL116273 and K23HL151867. Dr Margo B. Minissian has received honoraria from the National Lipid Association, North American Menopause Society, MJH Life Sciences, Vox Media, Medtelligence, Minneapolis Heart Institute, Primed, Good Samaritan Hospital Los Angeles, California, Cardiometabolic Health Congress, American Heart Association, Preventive Cardiovascular Nurses Association, and the American College of Cardiology; has been a consultant for and served on a medical advisory board for  Amgen; and has served as a co-chair for CME for the North American Center for Continuing Medical Education honorarium. Dr Janet Wei has received institutional fees for serving on an advisory board for Abbott Vascular. Dr Bairey C. Noel Bairey Merz has received consulting fees from Abbott Diagnostics, Caladrius, and Sanofi Vascular; and receives consulting fees, is on the board of directors and owns stock in iRhythm. Dr Annabelle Santos Volgman has served as a consultant and on advisory boards for Merck, Bristol Myers Squibb Foundation, Novo Nordisk, and Janssen; has received research funding from Novartis; and hold stocks in Apple, Inc. Dr Islam Y. Elgendy has received research grants from Caladrius Biosciences, Inc, unrelated to this paper. Dr Mamas Mamas has been a speaker for Daiichi-Sankyo. Dr Harmony R. Reynolds has received in-kind donations for research from Abbott Vascular, Siemens, and BioTelemetry, Inc. Dr Gregory Piazza has received research grants from BMS/Pfizer, Janssen, Alexion, Bayer, Amgen, and BSC; and has an advisory role in BSC, Amgen, BCRI, PERC, Syntactx, BMS, and Janssen. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.\n",
      "\n",
      "Antoniades, Charalambos\n",
      "Funding Support and Author Disclosures Dr Charalambos Antoniades is founder, shareholder, and director of Caristo Diagnostics, a CT image analysis company; and acknowledges support from the British Heart Foundation (CH/F/21/90009, TG/19/2/34831 and RG/F/21/110040), and the NIHR Oxford Biomedical Research Centre. Dr Polkinghorne  has reported that he has no relationships relevant to the contents of this paper  to disclose.\n",
      "\n",
      "Polkinghorne, Murray D.\n",
      "Funding Support and Author Disclosures Dr Charalambos Antoniades is founder, shareholder, and director of Caristo Diagnostics, a CT image analysis company; and acknowledges support from the British Heart Foundation (CH/F/21/90009, TG/19/2/34831 and RG/F/21/110040), and the NIHR Oxford Biomedical Research Centre. Dr Murray D. Polkinghorne  has reported that he has no relationships relevant to the contents of this paper  to disclose.\n",
      "\n",
      "NG is Programme Manager for hepatitis C at the Northern Regional Alliance. All authors have been involved in the \"lookback and treat service\" for people previously diagnosed but potentially untreated Hepatitis C in the Northern Region.\n",
      "\n",
      "NG is Programme Manager for hepatitis C at the Northern Regional Alliance. All authors have been involved in the \"lookback and treat service\" for people previously diagnosed but potentially untreated Hepatitis C in the Northern Region.\n",
      "\n",
      "Gauld, Natalie\n",
      "Natalie Gauld is Programme Manager for hepatitis C at the Northern Regional Alliance. All authors have been involved in the \"lookback and treat service\" for people previously diagnosed but potentially untreated Hepatitis C in the Northern Region.\n",
      "\n",
      "Natalie Gauld is Programme Manager for hepatitis C at the Northern Regional Alliance. All authors have been involved in the \"lookback and treat service\" for people previously diagnosed but potentially untreated Hepatitis C in the Northern Region.\n",
      "\n",
      "Natalie Gauld is Programme Manager for hepatitis C at the Northern Regional Alliance. All authors have been involved in the \"lookback and treat service\" for people previously diagnosed but potentially untreated Hepatitis C in the Northern Region.\n",
      "\n",
      "Natalie Gauld is Programme Manager for hepatitis C at the Northern Regional Alliance. All authors have been involved in the \"lookback and treat service\" for people previously diagnosed but potentially untreated Hepatitis C in the Northern Region.\n",
      "\n",
      "Natalie Gauld is Programme Manager for hepatitis C at the Northern Regional Alliance. All authors have been involved in the \"lookback and treat service\" for people previously diagnosed but potentially untreated Hepatitis C in the Northern Region.\n",
      "\n",
      "Die Autorinnen/Autoren geben an, dass kein Interessenkonflikt besteht.\n",
      "\n",
      "Die Autorinnen/Autoren geben an, dass kein Interessenkonflikt besteht.\n",
      "\n",
      "Die Autorinnen/Autoren geben an, dass kein Interessenkonflikt besteht.\n",
      "\n",
      "Die Autorinnen/Autoren geben an, dass kein Interessenkonflikt besteht.\n",
      "\n",
      "Die Autorinnen/Autoren geben an, dass kein Interessenkonflikt besteht.\n",
      "\n",
      "Die AutorInnen/Autoren geben an, dass kein Interessenkonflikt besteht.\n",
      "\n",
      "Die AutorInnen/Autoren geben an, dass kein Interessenkonflikt besteht.\n",
      "\n",
      "Die AutorInnen/Autoren geben an, dass kein Interessenkonflikt besteht.\n",
      "\n",
      "Die AutorInnen/Autoren geben an, dass kein Interessenkonflikt besteht.\n",
      "\n",
      "Die Autorinnen/Autoren geben an, dass kein Interessenkonflikt besteht.\n",
      "\n",
      "Die Autorinnen/Autoren geben an, dass kein Interessenkonflikt besteht.\n",
      "\n",
      "Die Autorinnen/Autoren geben an, dass kein Interessenkonflikt besteht.\n",
      "\n",
      "Die Autorinnen/Autoren geben an, dass kein Interessenkonflikt besteht.\n",
      "\n",
      "Die Autorinnen/Autoren geben an, dass kein Interessenkonflikt besteht.\n",
      "\n",
      "Die Autorinnen/Autoren geben an, dass kein Interessenkonflikt besteht.\n",
      "\n",
      "Die Autorinnen/Autoren geben an, dass kein Interessenkonflikt besteht.\n",
      "\n",
      "Die Autorinnen/Autoren geben an, dass kein Interessenkonflikt besteht.\n",
      "\n",
      "Dr. Mihir S Wagh is a consultant for Olympus, Medtronic, Boston Scientific, Fujifilm, Conmed. He also receives research support from Steris and US Endoscopy. Other Authors do not have any conflicts of interest to disclose.\n",
      "\n",
      "Wagh, Mihir S.\n",
      "Dr. Mihir S. Wagh is a consultant for Olympus, Medtronic, Boston Scientific, Fujifilm, Conmed. He also receives research support from Steris and US Endoscopy. Other Authors do not have any conflicts of interest to disclose.\n",
      "\n",
      "Dr. Mihir S. Wagh is a consultant for Olympus, Medtronic, Boston Scientific, Fujifilm, Conmed. He also receives research support from Steris and US Endoscopy. Other Authors do not have any conflicts of interest to disclose.\n",
      "\n",
      "Dr. Mihir S. Wagh is a consultant for Olympus, Medtronic, Boston Scientific, Fujifilm, Conmed. He also receives research support from Steris and US Endoscopy. Other Authors do not have any conflicts of interest to disclose.\n",
      "\n",
      "Kurtz, Steven M.\n",
      "M.A.M. reports grants from 3M, Centrexion, CERAS Health, Flexion Therapeutics, Johnson & Johnson, Kolon Tissuegene, Mirror-AR, NXSCI, Pacira, Peerwell, Pfizer-Lily, Skye Biologics, SOLVD Health, Smith & Nephew, Stryker, US Medical Innovations, other from Stryker, other from Journal of Arthroplasty, Journal of Knee Surgery, Surgical Technology International, Orthopaedics, other from The Hip Society, The Knee Society, outside the submitted work.W.J.K. reports other from Exponent, Inc., outside the submitted work.G.B.H. reports other from Exponent, Inc., outside the submitted work.Steven M. Kurtz reports grants from Ferring Pharmaceuticals, during the conduct of the study; grants from Stryker, Zimmer Biomet, Invibio, Wright Medical Technology, Ceramtec, Celanese, Ferring Pharmaceuticals, Formae, Lima Corporate, SINTX Technologies, Orthoplastics, Osteal Therapeutics, 3Spine, DePuy Synthes, and other from Exponent, Inc., outside the submitted work.\n",
      "\n",
      "Higgs, Genymphas B.\n",
      "M.A.M. reports grants from 3M, Centrexion, CERAS Health, Flexion Therapeutics, Johnson & Johnson, Kolon Tissuegene, Mirror-AR, NXSCI, Pacira, Peerwell, Pfizer-Lily, Skye Biologics, SOLVD Health, Smith & Nephew, Stryker, US Medical Innovations, other from Stryker, other from Journal of Arthroplasty, Journal of Knee Surgery, Surgical Technology International, Orthopaedics, other from The Hip Society, The Knee Society, outside the submitted work.W.J.K. reports other from Exponent, Inc., outside the submitted work.Genymphas B. Higgs reports other from Exponent, Inc., outside the submitted work.Steven M. Kurtz reports grants from Ferring Pharmaceuticals, during the conduct of the study; grants from Stryker, Zimmer Biomet, Invibio, Wright Medical Technology, Ceramtec, Celanese, Ferring Pharmaceuticals, Formae, Lima Corporate, SINTX Technologies, Orthoplastics, Osteal Therapeutics, 3Spine, DePuy Synthes, and other from Exponent, Inc., outside the submitted work.\n",
      "\n",
      "M.A.M. reports grants from 3M, Centrexion, CERAS Health, Flexion Therapeutics, Johnson & Johnson, Kolon Tissuegene, Mirror-AR, NXSCI, Pacira, Peerwell, Pfizer-Lily, Skye Biologics, SOLVD Health, Smith & Nephew, Stryker, US Medical Innovations, other from Stryker, other from Journal of Arthroplasty, Journal of Knee Surgery, Surgical Technology International, Orthopaedics, other from The Hip Society, The Knee Society, outside the submitted work.W.J.K. reports other from Exponent, Inc., outside the submitted work.Genymphas B. Higgs reports other from Exponent, Inc., outside the submitted work.Steven M. Kurtz reports grants from Ferring Pharmaceuticals, during the conduct of the study; grants from Stryker, Zimmer Biomet, Invibio, Wright Medical Technology, Ceramtec, Celanese, Ferring Pharmaceuticals, Formae, Lima Corporate, SINTX Technologies, Orthoplastics, Osteal Therapeutics, 3Spine, DePuy Synthes, and other from Exponent, Inc., outside the submitted work.\n",
      "\n",
      "Koshut, William J.\n",
      "M.A.M. reports grants from 3M, Centrexion, CERAS Health, Flexion Therapeutics, Johnson & Johnson, Kolon Tissuegene, Mirror-AR, NXSCI, Pacira, Peerwell, Pfizer-Lily, Skye Biologics, SOLVD Health, Smith & Nephew, Stryker, US Medical Innovations, other from Stryker, other from Journal of Arthroplasty, Journal of Knee Surgery, Surgical Technology International, Orthopaedics, other from The Hip Society, The Knee Society, outside the submitted work.William J. Koshut reports other from Exponent, Inc., outside the submitted work.Genymphas B. Higgs reports other from Exponent, Inc., outside the submitted work.Steven M. Kurtz reports grants from Ferring Pharmaceuticals, during the conduct of the study; grants from Stryker, Zimmer Biomet, Invibio, Wright Medical Technology, Ceramtec, Celanese, Ferring Pharmaceuticals, Formae, Lima Corporate, SINTX Technologies, Orthoplastics, Osteal Therapeutics, 3Spine, DePuy Synthes, and other from Exponent, Inc., outside the submitted work.\n",
      "\n",
      "M.A.M. reports grants from 3M, Centrexion, CERAS Health, Flexion Therapeutics, Johnson & Johnson, Kolon Tissuegene, Mirror-AR, NXSCI, Pacira, Peerwell, Pfizer-Lily, Skye Biologics, SOLVD Health, Smith & Nephew, Stryker, US Medical Innovations, other from Stryker, other from Journal of Arthroplasty, Journal of Knee Surgery, Surgical Technology International, Orthopaedics, other from The Hip Society, The Knee Society, outside the submitted work.William J. Koshut reports other from Exponent, Inc., outside the submitted work.Genymphas B. Higgs reports other from Exponent, Inc., outside the submitted work.Steven M. Kurtz reports grants from Ferring Pharmaceuticals, during the conduct of the study; grants from Stryker, Zimmer Biomet, Invibio, Wright Medical Technology, Ceramtec, Celanese, Ferring Pharmaceuticals, Formae, Lima Corporate, SINTX Technologies, Orthoplastics, Osteal Therapeutics, 3Spine, DePuy Synthes, and other from Exponent, Inc., outside the submitted work.\n",
      "\n",
      "Sherman, Alain E.\n",
      "M.A.M. reports grants from 3M, Centrexion, CERAlain E. Sherman Health, Flexion Therapeutics, Johnson & Johnson, Kolon Tissuegene, Mirror-AR, NXSCI, Pacira, Peerwell, Pfizer-Lily, Skye Biologics, SOLVD Health, Smith & Nephew, Stryker, US Medical Innovations, other from Stryker, other from Journal of Arthroplasty, Journal of Knee Surgery, Surgical Technology International, Orthopaedics, other from The Hip Society, The Knee Society, outside the submitted work.William J. Koshut reports other from Exponent, Inc., outside the submitted work.Genymphas B. Higgs reports other from Exponent, Inc., outside the submitted work.Steven M. Kurtz reports grants from Ferring Pharmaceuticals, during the conduct of the study; grants from Stryker, Zimmer Biomet, Invibio, Wright Medical Technology, Ceramtec, Celanese, Ferring Pharmaceuticals, Formae, Lima Corporate, SINTX Technologies, Orthoplastics, Osteal Therapeutics, 3Spine, DePuy Synthes, and other from Exponent, Inc., outside the submitted work.\n",
      "\n",
      "M.A.M. reports grants from 3M, Centrexion, CERAlain E. Sherman Health, Flexion Therapeutics, Johnson & Johnson, Kolon Tissuegene, Mirror-AR, NXSCI, Pacira, Peerwell, Pfizer-Lily, Skye Biologics, SOLVD Health, Smith & Nephew, Stryker, US Medical Innovations, other from Stryker, other from Journal of Arthroplasty, Journal of Knee Surgery, Surgical Technology International, Orthopaedics, other from The Hip Society, The Knee Society, outside the submitted work.William J. Koshut reports other from Exponent, Inc., outside the submitted work.Genymphas B. Higgs reports other from Exponent, Inc., outside the submitted work.Steven M. Kurtz reports grants from Ferring Pharmaceuticals, during the conduct of the study; grants from Stryker, Zimmer Biomet, Invibio, Wright Medical Technology, Ceramtec, Celanese, Ferring Pharmaceuticals, Formae, Lima Corporate, SINTX Technologies, Orthoplastics, Osteal Therapeutics, 3Spine, DePuy Synthes, and other from Exponent, Inc., outside the submitted work.\n",
      "\n",
      "Mont, Michael A.\n",
      "Michael A. Mont reports grants from 3M, Centrexion, CERAlain E. Sherman Health, Flexion Therapeutics, Johnson & Johnson, Kolon Tissuegene, Mirror-AR, NXSCI, Pacira, Peerwell, Pfizer-Lily, Skye Biologics, SOLVD Health, Smith & Nephew, Stryker, US Medical Innovations, other from Stryker, other from Journal of Arthroplasty, Journal of Knee Surgery, Surgical Technology International, Orthopaedics, other from The Hip Society, The Knee Society, outside the submitted work.William J. Koshut reports other from Exponent, Inc., outside the submitted work.Genymphas B. Higgs reports other from Exponent, Inc., outside the submitted work.Steven M. Kurtz reports grants from Ferring Pharmaceuticals, during the conduct of the study; grants from Stryker, Zimmer Biomet, Invibio, Wright Medical Technology, Ceramtec, Celanese, Ferring Pharmaceuticals, Formae, Lima Corporate, SINTX Technologies, Orthoplastics, Osteal Therapeutics, 3Spine, DePuy Synthes, and other from Exponent, Inc., outside the submitted work.\n",
      "\n",
      "Takashi Kanesaka has received personal fees from Olympus Corporation. Ryu Ishihara has received personal fees from Olympus Corporation and FUJIFILM Medical Co., Ltd. Other authors have no financial relationships to disclose.\n",
      "\n",
      "Kanesaka, Takashi\n",
      "Takashi Kanesaka has received personal fees from Olympus Corporation. Ryu Ishihara has received personal fees from Olympus Corporation and FUJIFILM Medical Co., Ltd. Other authors have no financial relationships to disclose.\n",
      "\n",
      "Takashi Kanesaka has received personal fees from Olympus Corporation. Ryu Ishihara has received personal fees from Olympus Corporation and FUJIFILM Medical Co., Ltd. Other authors have no financial relationships to disclose.\n",
      "\n",
      "Takashi Kanesaka has received personal fees from Olympus Corporation. Ryu Ishihara has received personal fees from Olympus Corporation and FUJIFILM Medical Co., Ltd. Other authors have no financial relationships to disclose.\n",
      "\n",
      "Fujii, Takashi\n",
      "Takashi Fujii Kanesaka has received personal fees from Olympus Corporation. Ryu Ishihara has received personal fees from Olympus Corporation and FUJIFILM Medical Co., Ltd. Other authors have no financial relationships to disclose.\n",
      "\n",
      "Takashi Fujii Kanesaka has received personal fees from Olympus Corporation. Ryu Ishihara has received personal fees from Olympus Corporation and FUJIFILM Medical Co., Ltd. Other authors have no financial relationships to disclose.\n",
      "\n",
      "Ishihara, Ryu\n",
      "Takashi Fujii Kanesaka has received personal fees from Olympus Corporation. Ryu Ishihara has received personal fees from Olympus Corporation and FUJIFILM Medical Co., Ltd. Other authors have no financial relationships to disclose.\n",
      "\n",
      "Iwano, Kosuke\n",
      "Akio Katanuma, as a guest lecturer, received honoraria from Olympus Co., Tokyo, Japan. Kosuke Iwano, Tsuyoshi Hayashi, Tatsuya Ishi, and Kuniyuki Takahashi declare that they have no conflict of interest.\n",
      "\n",
      "Hayashi, Tsuyoshi\n",
      "Akio Katanuma, as a guest lecturer, received honoraria from Olympus Co., Tokyo, Japan. Kosuke Iwano, Tsuyoshi Hayashi, Tatsuya Ishi, and Kuniyuki Takahashi declare that they have no conflict of interest.\n",
      "\n",
      "Ishii, Tatsuya\n",
      "Akio Katanuma, as a guest lecturer, received honoraria from Olympus Co., Tokyo, Japan. Kosuke Iwano, Tsuyoshi Hayashi, Tatsuya Ishiishi, and Kuniyuki Takahashi declare that they have no conflict of interest.\n",
      "\n",
      "Takahashi, Kuniyuki\n",
      "Akio Katanuma, as a guest lecturer, received honoraria from Olympus Co., Tokyo, Japan. Kosuke Iwano, Tsuyoshi Hayashi, Tatsuya Ishiishi, and Kuniyuki Takahashi declare that they have no conflict of interest.\n",
      "\n",
      "Katanuma, Akio\n",
      "Akio Katanuma, as a guest lecturer, received honoraria from Olympus Co., Tokyo, Japan. Kosuke Iwano, Tsuyoshi Hayashi, Tatsuya Ishiishi, and Kuniyuki Takahashi declare that they have no conflict of interest.\n",
      "\n",
      "H. Yamamoto is a consultant for Fujifilm Corporation and has received honoraria,  a grant and royalties from the company. The remaining authors declare that they have no conflict of interest.\n",
      "\n",
      "H. Yamamoto is a consultant for Fujifilm Corporation and has received honoraria,  a grant and royalties from the company. The remaining authors declare that they have no conflict of interest.\n",
      "\n",
      "H. Yamamoto is a consultant for Fujifilm Corporation and has received honoraria,  a grant and royalties from the company. The remaining authors declare that they have no conflict of interest.\n",
      "\n",
      "H. Yamamoto is a consultant for Fujifilm Corporation and has received honoraria,  a grant and royalties from the company. The remaining authors declare that they have no conflict of interest.\n",
      "\n",
      "H. Yamamoto is a consultant for Fujifilm Corporation and has received honoraria,  a grant and royalties from the company. The remaining authors declare that they have no conflict of interest.\n",
      "\n",
      "H. Yamamoto is a consultant for Fujifilm Corporation and has received honoraria,  a grant and royalties from the company. The remaining authors declare that they have no conflict of interest.\n",
      "\n",
      "Yamamoto, Hironori\n",
      "Hironori Yamamoto is a consultant for Fujifilm Corporation and has received honoraria,  a grant and royalties from the company. The remaining authors declare that they have no conflict of interest.\n",
      "\n",
      "Die Autorinnen/Autoren geben an, dass kein Interessenkonflikt besteht.\n",
      "\n",
      "Die Autorinnen/Autoren geben an, dass kein Interessenkonflikt besteht.\n",
      "\n",
      "Erklarung zu finanziellen Interessen Forschungsforderung erhalten: nein; Honorar/geldwerten Vorteil fur Referententatigkeit erhalten: nein; Bezahlter Berater/interner Schulungsreferent/Gehaltsempfanger: nein; Patent/Geschaftsanteile/Aktien (Autor/Partner, Ehepartner, Kinder) an im Bereich  der Medizin aktiven Firma: nein; Patent/Geschaftsanteile/Aktien (Autor/Partner, Ehepartner, Kinder) an zu Sponsoren dieser Fortbildung bzw. durch die Fortbildung in ihren Geschaftsinteressen beruhrten Firma: nein Erklarung zu nichtfinanziellen Interessen Die Autorinnen/Autoren geben an, dass kein Interessenkonflikt besteht.\n",
      "\n",
      "Erklarung zu finanziellen Interessen Forschungsforderung erhalten: nein; Honorar/geldwerten Vorteil fur Referententatigkeit erhalten: nein; Bezahlter Berater/interner Schulungsreferent/Gehaltsempfanger: nein; Patent/Geschaftsanteile/Aktien (Autor/Partner, Ehepartner, Kinder) an im Bereich  der Medizin aktiven Firma: nein; Patent/Geschaftsanteile/Aktien (Autor/Partner, Ehepartner, Kinder) an zu Sponsoren dieser Fortbildung bzw. durch die Fortbildung in ihren Geschaftsinteressen beruhrten Firma: nein Erklarung zu nichtfinanziellen Interessen Die Autorinnen/Autoren geben an, dass kein Interessenkonflikt besteht.\n",
      "\n",
      "Erklarung zu finanziellen Interessen Forschungsforderung erhalten: nein; Honorar/geldwerten Vorteil fur Referententatigkeit erhalten: nein; Bezahlter Berater/interner Schulungsreferent/Gehaltsempfanger: nein; Patent/Geschaftsanteile/Aktien (Autor/Partner, Ehepartner, Kinder) an im Bereich  der Medizin aktiven Firma: nein; Patent/Geschaftsanteile/Aktien (Autor/Partner, Ehepartner, Kinder) an zu Sponsoren dieser Fortbildung bzw. durch die Fortbildung in ihren Geschaftsinteressen beruhrten Firma: nein Erklarung zu nichtfinanziellen Interessen Die Autorinnen/Autoren geben an, dass kein Interessenkonflikt besteht.\n",
      "\n",
      "Erklarung zu finanziellen Interessen Forschungsforderung erhalten: nein; Honorar/geldwerten Vorteil fur Referententatigkeit erhalten: nein; Bezahlter Berater/interner Schulungsreferent/Gehaltsempfanger: nein; Patent/Geschaftsanteile/Aktien (Autor/Partner, Ehepartner, Kinder) an im Bereich  der Medizin aktiven Firma: nein; Patent/Geschaftsanteile/Aktien (Autor/Partner, Ehepartner, Kinder) an zu Sponsoren dieser Fortbildung bzw. durch die Fortbildung in ihren Geschaftsinteressen beruhrten Firma: nein Erklarung zu nichtfinanziellen Interessen Die Autorinnen/Autoren geben an, dass kein Interessenkonflikt besteht.\n",
      "\n",
      "Erklarung zu finanziellen Interessen Forschungsforderung erhalten: nein; Honorar/geldwerten Vorteil fur Referententatigkeit erhalten: nein; Bezahlter Berater/interner Schulungsreferent/Gehaltsempfanger: nein; Patent/Geschaftsanteile/Aktien (Autor/Partner, Ehepartner, Kinder) an im Bereich  der Medizin aktiven Firma: nein; Patent/Geschaftsanteile/Aktien (Autor/Partner, Ehepartner, Kinder) an zu Sponsoren dieser Fortbildung bzw. durch die Fortbildung in ihren Geschaftsinteressen beruhrten Firma: nein Erklarung zu nichtfinanziellen Interessen Deutschland: Mitglied DGAI; WAKKAm Niederlande: Mitglied NVA (Nederlandse vereniging voor anesthesiologen; SKA (sectie kinderanesthesiologie): SKA Vorstandsmitglied Mitglied ESPA (European Society for Paediatric Anaesthesiology)\n",
      "\n",
      "Erklarung zu finanziellen Interessen Forschungsforderung erhalten: nein; Honorar/geldwerten Vorteil fur Referententatigkeit erhalten: nein; Bezahlter Berater/interner Schulungsreferent/Gehaltsempfanger: nein; Patent/Geschaftsanteile/Aktien (Autor/Partner, Ehepartner, Kinder) an im Bereich  der Medizin aktiven Firma: nein; Patent/Geschaftsanteile/Aktien (Autor/Partner, Ehepartner, Kinder) an zu Sponsoren dieser Fortbildung bzw. durch die Fortbildung in ihren Geschaftsinteressen beruhrten Firma: nein Erklarung zu nichtfinanziellen Interessen Deutschland: Mitglied DGAI; WAKKAm Niederlande: Mitglied NVA (Nederlandse vereniging voor anesthesiologen; SKA (sectie kinderanesthesiologie): SKA Vorstandsmitglied Mitglied ESPA (European Society for Paediatric Anaesthesiology)\n",
      "\n",
      "Erklarung zu finanziellen Interessen Forschungsforderung erhalten: nein; Honorar/geldwerten Vorteil fur Referententatigkeit erhalten: nein; Bezahlter Berater/interner Schulungsreferent/Gehaltsempfanger: nein; Patent/Geschaftsanteile/Aktien (Autor/Partner, Ehepartner, Kinder) an im Bereich  der Medizin aktiven Firma: nein; Patent/Geschaftsanteile/Aktien (Autor/Partner, Ehepartner, Kinder) an zu Sponsoren dieser Fortbildung bzw. durch die Fortbildung in ihren Geschaftsinteressen beruhrten Firma: nein Erklarung zu nichtfinanziellen Interessen Deutschland: Mitglied DGAI; WAKKAm Niederlande: Mitglied NVA (Nederlandse vereniging voor anesthesiologen; SKA (sectie kinderanesthesiologie): SKA Vorstandsmitglied Mitglied ESPA (European Society for Paediatric Anaesthesiology)\n",
      "\n",
      "Erklarung zu finanziellen Interessen Forschungsforderung erhalten: nein; Honorar/geldwerten Vorteil fur Referententatigkeit erhalten: nein; Bezahlter Berater/interner Schulungsreferent/Gehaltsempfanger: nein; Patent/Geschaftsanteile/Aktien (Autor/Partner, Ehepartner, Kinder) an im Bereich  der Medizin aktiven Firma: nein; Patent/Geschaftsanteile/Aktien (Autor/Partner, Ehepartner, Kinder) an zu Sponsoren dieser Fortbildung bzw. durch die Fortbildung in ihren Geschaftsinteressen beruhrten Firma: nein Erklarung zu nichtfinanziellen Interessen Die Autorinnen/Autoren geben an, dass kein Interessenkonflikt besteht.\n",
      "\n",
      "Erklarung zu finanziellen Interessen Forschungsforderung erhalten: nein; Honorar/geldwerten Vorteil fur Referententatigkeit erhalten: nein; Bezahlter Berater/interner Schulungsreferent/Gehaltsempfanger: nein; Patent/Geschaftsanteile/Aktien (Autor/Partner, Ehepartner, Kinder) an im Bereich  der Medizin aktiven Firma: nein; Patent/Geschaftsanteile/Aktien (Autor/Partner, Ehepartner, Kinder) an zu Sponsoren dieser Fortbildung bzw. durch die Fortbildung in ihren Geschaftsinteressen beruhrten Firma: nein Erklarung zu nichtfinanziellen Interessen Die Autorinnen/Autoren geben an, dass kein Interessenkonflikt besteht.\n",
      "\n",
      "Declarations of Competing Interest None\n",
      "\n",
      "Declarations of Competing Interest None\n",
      "\n",
      "Declarations of Competing Interest None\n",
      "\n",
      "Declarations of Competing Interest None\n",
      "\n",
      "Declarations of Competing Interest None\n",
      "\n",
      "Declarations of Competing Interest None\n",
      "\n",
      "Rendeiro C.\n",
      "Declarations of R e n d e i r o   C .ompeting Interest None\n",
      "\n",
      "Declarations of R e n d e i r o   C .ompeting Interest None\n",
      "\n",
      "Conflict of Interest Dr. Roger S. McIntyre has received research grant support from Global Alliance for Chronic Diseases/Canadian Institutes of Health Research  (CIHR)/National Natural Science Foundation of China's Mental Health Team Grant; speaker/consultation fees from Lundbeck, Janssen, Purdue, Pfizer, Otsuka, Takeda, Neurocrine, Sunovion, Bausch Health, Novo Nordisk, Kris, Sanofi, Eisai, Intra-Cellular, NewBridge Pharmaceuticals, Abbvie. Dr. Roger McIntyre is a CEO of Braxia Scientific Corp. Dr. Joshua D. Rosenblat is the medical director of the Braxia Health (formally known as the Canadian Rapid Treatment Center of Excellence and is a fully owned subsidiary of Braxia Scientific Corp) which provides ketamine and esketamine treatment for depression; he has received research grant support from the American Psychiatric Association, the American Society of Psychopharmacology, the Canadian Cancer Society, the Canadian Psychiatric Association, the Joseph M. West Family Memorial Fund, the Timeposters Fellowship, the University Health Network Centre for Mental Health, and the University of Toronto and speaking, consultation, or research fees from Allergan, COMPASS, Janssen, Lundbeck, and Sunovion. Yena Lee has received personal fees from Braxia Scientific Corp. Leanna M. W. Lui is a contractor to Braxia Scientific Corp. Nelson B Rodrigues has received consulting fees from Braxia Scientific Corp. Joshua D. Di Vincenzo is a consultant to Braxia Scientific Corp.\n",
      "\n",
      "Conflict of Interest Dr. Roger S. McIntyre has received research grant support from Global Alliance for Chronic Diseases/Canadian Institutes of Health Research  (CIHR)/National Natural Science Foundation of China's Mental Health Team Grant; speaker/consultation fees from Lundbeck, Janssen, Purdue, Pfizer, Otsuka, Takeda, Neurocrine, Sunovion, Bausch Health, Novo Nordisk, Kris, Sanofi, Eisai, Intra-Cellular, NewBridge Pharmaceuticals, Abbvie. Dr. Roger McIntyre is a CEO of Braxia Scientific Corp. Dr. Joshua D. Rosenblat is the medical director of the Braxia Health (formally known as the Canadian Rapid Treatment Center of Excellence and is a fully owned subsidiary of Braxia Scientific Corp) which provides ketamine and esketamine treatment for depression; he has received research grant support from the American Psychiatric Association, the American Society of Psychopharmacology, the Canadian Cancer Society, the Canadian Psychiatric Association, the Joseph M. West Family Memorial Fund, the Timeposters Fellowship, the University Health Network Centre for Mental Health, and the University of Toronto and speaking, consultation, or research fees from Allergan, COMPASS, Janssen, Lundbeck, and Sunovion. Yena Lee has received personal fees from Braxia Scientific Corp. Leanna M. W. Lui is a contractor to Braxia Scientific Corp. Nelson B Rodrigues has received consulting fees from Braxia Scientific Corp. Joshua D. Di Vincenzo is a consultant to Braxia Scientific Corp.\n",
      "\n",
      "McIntyre, Roger S.\n",
      "Conflict of Interest Dr. Roger S. McIntyre has received research grant support from Global Alliance for Chronic Diseases/Canadian Institutes of Health Research  (CIHR)/National Natural Science Foundation of China's Mental Health Team Grant; speaker/consultation fees from Lundbeck, Janssen, Purdue, Pfizer, Otsuka, Takeda, Neurocrine, Sunovion, Bausch Health, Novo Nordisk, Kris, Sanofi, Eisai, Intra-Cellular, NewBridge Pharmaceuticals, Abbvie. Dr. Roger McIntyre is a CEO of Braxia Scientific Corp. Dr. Joshua D. Rosenblat is the medical director of the Braxia Health (formally known as the Canadian Rapid Treatment Center of Excellence and is a fully owned subsidiary of Braxia Scientific Corp) which provides ketamine and esketamine treatment for depression; he has received research grant support from the American Psychiatric Association, the American Society of Psychopharmacology, the Canadian Cancer Society, the Canadian Psychiatric Association, the Joseph M. West Family Memorial Fund, the Timeposters Fellowship, the University Health Network Centre for Mental Health, and the University of Toronto and speaking, consultation, or research fees from Allergan, COMPASS, Janssen, Lundbeck, and Sunovion. Yena Lee has received personal fees from Braxia Scientific Corp. Leanna M. W. Lui is a contractor to Braxia Scientific Corp. Nelson B Rodrigues has received consulting fees from Braxia Scientific Corp. Joshua D. Di Vincenzo is a consultant to Braxia Scientific Corp.\n",
      "\n",
      "Conflict of Interest Dr. Roger S. McIntyre has received research grant support from Global Alliance for Chronic Diseases/Canadian Institutes of Health Research  (CIHR)/National Natural Science Foundation of China's Mental Health Team Grant; speaker/consultation fees from Lundbeck, Janssen, Purdue, Pfizer, Otsuka, Takeda, Neurocrine, Sunovion, Bausch Health, Novo Nordisk, Kris, Sanofi, Eisai, Intra-Cellular, NewBridge Pharmaceuticals, Abbvie. Dr. Roger McIntyre is a CEO of Braxia Scientific Corp. Dr. Joshua D. Rosenblat is the medical director of the Braxia Health (formally known as the Canadian Rapid Treatment Center of Excellence and is a fully owned subsidiary of Braxia Scientific Corp) which provides ketamine and esketamine treatment for depression; he has received research grant support from the American Psychiatric Association, the American Society of Psychopharmacology, the Canadian Cancer Society, the Canadian Psychiatric Association, the Joseph M. West Family Memorial Fund, the Timeposters Fellowship, the University Health Network Centre for Mental Health, and the University of Toronto and speaking, consultation, or research fees from Allergan, COMPASS, Janssen, Lundbeck, and Sunovion. Yena Lee has received personal fees from Braxia Scientific Corp. Leanna M. W. Lui is a contractor to Braxia Scientific Corp. Nelson B Rodrigues has received consulting fees from Braxia Scientific Corp. Joshua D. Di Vincenzo is a consultant to Braxia Scientific Corp.\n",
      "\n",
      "Lui, Leanna M.W.\n",
      "Conflict of Interest Dr. Roger S. McIntyre has received research grant support from Global Alliance for Chronic Diseases/Canadian Institutes of Health Research  (CIHR)/National Natural Science Foundation of China's Mental Health Team Grant; speaker/consultation fees from Lundbeck, Janssen, Purdue, Pfizer, Otsuka, Takeda, Neurocrine, Sunovion, Bausch Health, Novo Nordisk, Kris, Sanofi, Eisai, Intra-Cellular, NewBridge Pharmaceuticals, Abbvie. Dr. Roger McIntyre is a CEO of Braxia Scientific Corp. Dr. Joshua D. Rosenblat is the medical director of the Braxia Health (formally known as the Canadian Rapid Treatment Center of Excellence and is a fully owned subsidiary of Braxia Scientific Corp) which provides ketamine and esketamine treatment for depression; he has received research grant support from the American Psychiatric Association, the American Society of Psychopharmacology, the Canadian Cancer Society, the Canadian Psychiatric Association, the Joseph M. West Family Memorial Fund, the Timeposters Fellowship, the University Health Network Centre for Mental Health, and the University of Toronto and speaking, consultation, or research fees from Allergan, COMPASS, Janssen, Lundbeck, and Sunovion. Yena Lee has received personal fees from Braxia Scientific Corp. Leanna M. W. Leanna M.W. Lui is a contractor to Braxia Scientific Corp. Nelson B Rodrigues has received consulting fees from Braxia Scientific Corp. Joshua D. Di Vincenzo is a consultant to Braxia Scientific Corp.\n",
      "\n",
      "Lee, Yena\n",
      "Conflict of Interest Dr. Roger S. McIntyre has received research grant support from Global Alliance for Chronic Diseases/Canadian Institutes of Health Research  (CIHR)/National Natural Science Foundation of China's Mental Health Team Grant; speaker/consultation fees from Lundbeck, Janssen, Purdue, Pfizer, Otsuka, Takeda, Neurocrine, Sunovion, Bausch Health, Novo Nordisk, Kris, Sanofi, Eisai, Intra-Cellular, NewBridge Pharmaceuticals, Abbvie. Dr. Roger McIntyre is a CEO of Braxia Scientific Corp. Dr. Joshua D. Rosenblat is the medical director of the Braxia Health (formally known as the Canadian Rapid Treatment Center of Excellence and is a fully owned subsidiary of Braxia Scientific Corp) which provides ketamine and esketamine treatment for depression; he has received research grant support from the American Psychiatric Association, the American Society of Psychopharmacology, the Canadian Cancer Society, the Canadian Psychiatric Association, the Joseph M. West Family Memorial Fund, the Timeposters Fellowship, the University Health Network Centre for Mental Health, and the University of Toronto and speaking, consultation, or research fees from Allergan, COMPASS, Janssen, Lundbeck, and Sunovion. Yena Lee has received personal fees from Braxia Scientific Corp. Leanna M. W. Leanna M.W. Lui is a contractor to Braxia Scientific Corp. Nelson B Rodrigues has received consulting fees from Braxia Scientific Corp. Joshua D. Di Vincenzo is a consultant to Braxia Scientific Corp.\n",
      "\n",
      "Conflict of Interest Dr. Roger S. McIntyre has received research grant support from Global Alliance for Chronic Diseases/Canadian Institutes of Health Research  (CIHR)/National Natural Science Foundation of China's Mental Health Team Grant; speaker/consultation fees from Lundbeck, Janssen, Purdue, Pfizer, Otsuka, Takeda, Neurocrine, Sunovion, Bausch Health, Novo Nordisk, Kris, Sanofi, Eisai, Intra-Cellular, NewBridge Pharmaceuticals, Abbvie. Dr. Roger McIntyre is a CEO of Braxia Scientific Corp. Dr. Joshua D. Rosenblat is the medical director of the Braxia Health (formally known as the Canadian Rapid Treatment Center of Excellence and is a fully owned subsidiary of Braxia Scientific Corp) which provides ketamine and esketamine treatment for depression; he has received research grant support from the American Psychiatric Association, the American Society of Psychopharmacology, the Canadian Cancer Society, the Canadian Psychiatric Association, the Joseph M. West Family Memorial Fund, the Timeposters Fellowship, the University Health Network Centre for Mental Health, and the University of Toronto and speaking, consultation, or research fees from Allergan, COMPASS, Janssen, Lundbeck, and Sunovion. Yena Lee has received personal fees from Braxia Scientific Corp. Leanna M. W. Leanna M.W. Lui is a contractor to Braxia Scientific Corp. Nelson B Rodrigues has received consulting fees from Braxia Scientific Corp. Joshua D. Di Vincenzo is a consultant to Braxia Scientific Corp.\n",
      "\n",
      "Conflict of Interest Dr. Roger S. McIntyre has received research grant support from Global Alliance for Chronic Diseases/Canadian Institutes of Health Research  (CIHR)/National Natural Science Foundation of China's Mental Health Team Grant; speaker/consultation fees from Lundbeck, Janssen, Purdue, Pfizer, Otsuka, Takeda, Neurocrine, Sunovion, Bausch Health, Novo Nordisk, Kris, Sanofi, Eisai, Intra-Cellular, NewBridge Pharmaceuticals, Abbvie. Dr. Roger McIntyre is a CEO of Braxia Scientific Corp. Dr. Joshua D. Rosenblat is the medical director of the Braxia Health (formally known as the Canadian Rapid Treatment Center of Excellence and is a fully owned subsidiary of Braxia Scientific Corp) which provides ketamine and esketamine treatment for depression; he has received research grant support from the American Psychiatric Association, the American Society of Psychopharmacology, the Canadian Cancer Society, the Canadian Psychiatric Association, the Joseph M. West Family Memorial Fund, the Timeposters Fellowship, the University Health Network Centre for Mental Health, and the University of Toronto and speaking, consultation, or research fees from Allergan, COMPASS, Janssen, Lundbeck, and Sunovion. Yena Lee has received personal fees from Braxia Scientific Corp. Leanna M. W. Leanna M.W. Lui is a contractor to Braxia Scientific Corp. Nelson B Rodrigues has received consulting fees from Braxia Scientific Corp. Joshua D. Di Vincenzo is a consultant to Braxia Scientific Corp.\n",
      "\n",
      "Rodrigues, Nelson B.\n",
      "Conflict of Interest Dr. Roger S. McIntyre has received research grant support from Global Alliance for Chronic Diseases/Canadian Institutes of Health Research  (CIHR)/National Natural Science Foundation of China's Mental Health Team Grant; speaker/consultation fees from Lundbeck, Janssen, Purdue, Pfizer, Otsuka, Takeda, Neurocrine, Sunovion, Bausch Health, Novo Nordisk, Kris, Sanofi, Eisai, Intra-Cellular, NewBridge Pharmaceuticals, Abbvie. Dr. Roger McIntyre is a CEO of Braxia Scientific Corp. Dr. Joshua D. Rosenblat is the medical director of the Braxia Health (formally known as the Canadian Rapid Treatment Center of Excellence and is a fully owned subsidiary of Braxia Scientific Corp) which provides ketamine and esketamine treatment for depression; he has received research grant support from the American Psychiatric Association, the American Society of Psychopharmacology, the Canadian Cancer Society, the Canadian Psychiatric Association, the Joseph M. West Family Memorial Fund, the Timeposters Fellowship, the University Health Network Centre for Mental Health, and the University of Toronto and speaking, consultation, or research fees from Allergan, COMPASS, Janssen, Lundbeck, and Sunovion. Yena Lee has received personal fees from Braxia Scientific Corp. Leanna M. W. Leanna M.W. Lui is a contractor to Braxia Scientific Corp. Nelson B. Rodrigues has received consulting fees from Braxia Scientific Corp. Joshua D. Di Vincenzo is a consultant to Braxia Scientific Corp.\n",
      "\n",
      "D Di Vincenzo, Joshua\n",
      "Conflict of Interest Dr. Roger S. McIntyre has received research grant support from Global Alliance for Chronic Diseases/Canadian Institutes of Health Research  (CIHR)/National Natural Science Foundation of China's Mental Health Team Grant; speaker/consultation fees from Lundbeck, Janssen, Purdue, Pfizer, Otsuka, Takeda, Neurocrine, Sunovion, Bausch Health, Novo Nordisk, Kris, Sanofi, Eisai, Intra-Cellular, NewBridge Pharmaceuticals, Abbvie. Dr. Roger McIntyre is a CEO of Braxia Scientific Corp. Dr. Joshua D. Rosenblat is the medical director of the Braxia Health (formally known as the Canadian Rapid Treatment Center of Excellence and is a fully owned subsidiary of Braxia Scientific Corp) which provides ketamine and esketamine treatment for depression; he has received research grant support from the American Psychiatric Association, the American Society of Psychopharmacology, the Canadian Cancer Society, the Canadian Psychiatric Association, the Joseph M. West Family Memorial Fund, the Timeposters Fellowship, the University Health Network Centre for Mental Health, and the University of Toronto and speaking, consultation, or research fees from Allergan, COMPASS, Janssen, Lundbeck, and Sunovion. Yena Lee has received personal fees from Braxia Scientific Corp. Leanna M. W. Leanna M.W. Lui is a contractor to Braxia Scientific Corp. Nelson B. Rodrigues has received consulting fees from Braxia Scientific Corp. Joshua D. Di Joshua D Di Vincenzo is a consultant to Braxia Scientific Corp.\n",
      "\n",
      "Conflict of Interest Dr. Roger S. McIntyre has received research grant support from Global Alliance for Chronic Diseases/Canadian Institutes of Health Research  (CIHR)/National Natural Science Foundation of China's Mental Health Team Grant; speaker/consultation fees from Lundbeck, Janssen, Purdue, Pfizer, Otsuka, Takeda, Neurocrine, Sunovion, Bausch Health, Novo Nordisk, Kris, Sanofi, Eisai, Intra-Cellular, NewBridge Pharmaceuticals, Abbvie. Dr. Roger McIntyre is a CEO of Braxia Scientific Corp. Dr. Joshua D. Rosenblat is the medical director of the Braxia Health (formally known as the Canadian Rapid Treatment Center of Excellence and is a fully owned subsidiary of Braxia Scientific Corp) which provides ketamine and esketamine treatment for depression; he has received research grant support from the American Psychiatric Association, the American Society of Psychopharmacology, the Canadian Cancer Society, the Canadian Psychiatric Association, the Joseph M. West Family Memorial Fund, the Timeposters Fellowship, the University Health Network Centre for Mental Health, and the University of Toronto and speaking, consultation, or research fees from Allergan, COMPASS, Janssen, Lundbeck, and Sunovion. Yena Lee has received personal fees from Braxia Scientific Corp. Leanna M. W. Leanna M.W. Lui is a contractor to Braxia Scientific Corp. Nelson B. Rodrigues has received consulting fees from Braxia Scientific Corp. Joshua D. Di Joshua D Di Vincenzo is a consultant to Braxia Scientific Corp.\n",
      "\n",
      "Rosenblat, Joshua D.\n",
      "Conflict of Interest Dr. Roger S. McIntyre has received research grant support from Global Alliance for Chronic Diseases/Canadian Institutes of Health Research  (CIHR)/National Natural Science Foundation of China's Mental Health Team Grant; speaker/consultation fees from Lundbeck, Janssen, Purdue, Pfizer, Otsuka, Takeda, Neurocrine, Sunovion, Bausch Health, Novo Nordisk, Kris, Sanofi, Eisai, Intra-Cellular, NewBridge Pharmaceuticals, Abbvie. Dr. Roger McIntyre is a CEO of Braxia Scientific Corp. Dr. Joshua D. Rosenblat is the medical director of the Braxia Health (formally known as the Canadian Rapid Treatment Center of Excellence and is a fully owned subsidiary of Braxia Scientific Corp) which provides ketamine and esketamine treatment for depression; he has received research grant support from the American Psychiatric Association, the American Society of Psychopharmacology, the Canadian Cancer Society, the Canadian Psychiatric Association, the Joseph M. West Family Memorial Fund, the Timeposters Fellowship, the University Health Network Centre for Mental Health, and the University of Toronto and speaking, consultation, or research fees from Allergan, COMPASS, Janssen, Lundbeck, and Sunovion. Yena Lee has received personal fees from Braxia Scientific Corp. Leanna M. W. Leanna M.W. Lui is a contractor to Braxia Scientific Corp. Nelson B. Rodrigues has received consulting fees from Braxia Scientific Corp. Joshua D. Di Joshua D Di Vincenzo is a consultant to Braxia Scientific Corp.\n",
      "\n",
      "Declaration of Competing Interest LAH has received salary support from CARRA; consulting fees from Sobi, Pfizer, and Adaptive Biotechnologies; and investigator-initiated research grants from Bristol-Myers Squibb.\n",
      "\n",
      "Declaration of Competing Interest LAH has received salary support from CARRA; consulting fees from Sobi, Pfizer, and Adaptive Biotechnologies; and investigator-initiated research grants from Bristol-Myers Squibb.\n",
      "\n",
      "Declaration of Competing Interest LAH has received salary support from CARRA; consulting fees from Sobi, Pfizer, and Adaptive Biotechnologies; and investigator-initiated research grants from Bristol-Myers Squibb.\n",
      "\n",
      "Declaration of Competing Interest LAH has received salary support from CARRA; consulting fees from Sobi, Pfizer, and Adaptive Biotechnologies; and investigator-initiated research grants from Bristol-Myers Squibb.\n",
      "\n",
      "Declaration of Competing Interest LAH has received salary support from CARRA; consulting fees from Sobi, Pfizer, and Adaptive Biotechnologies; and investigator-initiated research grants from Bristol-Myers Squibb.\n",
      "\n",
      "Declaration of Competing Interest LAH has received salary support from CARRA; consulting fees from Sobi, Pfizer, and Adaptive Biotechnologies; and investigator-initiated research grants from Bristol-Myers Squibb.\n",
      "\n",
      "Declaration of Competing Interest LAH has received salary support from CARRA; consulting fees from Sobi, Pfizer, and Adaptive Biotechnologies; and investigator-initiated research grants from Bristol-Myers Squibb.\n",
      "\n",
      "Declaration of Competing Interest LAH has received salary support from CARRA; consulting fees from Sobi, Pfizer, and Adaptive Biotechnologies; and investigator-initiated research grants from Bristol-Myers Squibb.\n",
      "\n",
      "Declaration of Competing Interest LAH has received salary support from CARRA; consulting fees from Sobi, Pfizer, and Adaptive Biotechnologies; and investigator-initiated research grants from Bristol-Myers Squibb.\n",
      "\n",
      "Declaration of Competing Interest LAH has received salary support from CARRA; consulting fees from Sobi, Pfizer, and Adaptive Biotechnologies; and investigator-initiated research grants from Bristol-Myers Squibb.\n",
      "\n",
      "Declaration of Competing Interest LAH has received salary support from CARRA; consulting fees from Sobi, Pfizer, and Adaptive Biotechnologies; and investigator-initiated research grants from Bristol-Myers Squibb.\n",
      "\n",
      "Declaration of Competing Interest LAH has received salary support from CARRA; consulting fees from Sobi, Pfizer, and Adaptive Biotechnologies; and investigator-initiated research grants from Bristol-Myers Squibb.\n",
      "\n",
      "Randolph, Adrienne\n",
      "Declaration of Competing Interest LAH has received salary support from CAdrienne RandolphRA; consulting fees from Sobi, Pfizer, and Adaptive Biotechnologies; and investigator-initiated research grants from Bristol-Myers Squibb.\n",
      "\n",
      "Declaration of Competing Interest LAH has received salary support from CAdrienne RandolphRA; consulting fees from Sobi, Pfizer, and Adaptive Biotechnologies; and investigator-initiated research grants from Bristol-Myers Squibb.\n",
      "\n",
      "Henderson, Lauren A.\n",
      "Declaration of Competing Interest Lauren A. Henderson has received salary support from CAdrienne RandolphRA; consulting fees from Sobi, Pfizer, and Adaptive Biotechnologies; and investigator-initiated research grants from Bristol-Myers Squibb.\n",
      "\n",
      "Wang, Shan\n",
      "Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Shan Wang reports financial support was provided by Chinese Scholarship Council. Corinne Spooren reports financial support was provided by European Commission. Daisy Jonkers reports financial support was provided by European Commission. Corinne Spooren reports a relationship with Janssen Pharmaceuticals that includes: consulting or advisory. Marlijne de Graaf reports  a relationship with Top Knowledge Institute that includes: funding grants. Daisy  Jonkers reports a relationship with Top Knowledge Institute that includes: funding grants. Daisy Jonkers reports a relationship with The Carbokinetics program as part of the NWO-CCC partnership programme that includes: funding grants. Daisy Jonkers reports a relationship with Dutch national NWO Vidi committee that includes: paid expert testimony. Daisy Jonkers reports a relationship with School on Nutrition and Translational Research in Metabolism of Maastricht University that includes: board membership. Daisy Jonkers reports a relationship with Maastricht Comprehensive Cancer Center of Maastricht University that includes: board membership. Frederik-Jan van Schooten reports a relationship with Ministry of Agriculture, Nature and Food Quality. Directorate Strategy, Knowledge and Innovation that includes: funding grants. Frederik-Jan van Schooten reports a relationship with Dutch Cancer Society that includes: funding grants. Frederik-Jan van Schooten reports a relationship with Netherlands Food and Consumer Product Safety Authority grant that includes: funding grants. Frederik-Jan van Schooten reports a relationship with Maastricht Education and Research Centre that includes: board membership. Frederik-Jan van Schooten reports a relationship with Chemosphere, Elsevier that includes: employment.\n",
      "\n",
      "Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Shan Wang reports financial support was provided by Chinese Scholarship Council. Corinne Spooren reports financial support was provided by European Commission. Daisy Jonkers reports financial support was provided by European Commission. Corinne Spooren reports a relationship with Janssen Pharmaceuticals that includes: consulting or advisory. Marlijne de Graaf reports  a relationship with Top Knowledge Institute that includes: funding grants. Daisy  Jonkers reports a relationship with Top Knowledge Institute that includes: funding grants. Daisy Jonkers reports a relationship with The Carbokinetics program as part of the NWO-CCC partnership programme that includes: funding grants. Daisy Jonkers reports a relationship with Dutch national NWO Vidi committee that includes: paid expert testimony. Daisy Jonkers reports a relationship with School on Nutrition and Translational Research in Metabolism of Maastricht University that includes: board membership. Daisy Jonkers reports a relationship with Maastricht Comprehensive Cancer Center of Maastricht University that includes: board membership. Frederik-Jan van Schooten reports a relationship with Ministry of Agriculture, Nature and Food Quality. Directorate Strategy, Knowledge and Innovation that includes: funding grants. Frederik-Jan van Schooten reports a relationship with Dutch Cancer Society that includes: funding grants. Frederik-Jan van Schooten reports a relationship with Netherlands Food and Consumer Product Safety Authority grant that includes: funding grants. Frederik-Jan van Schooten reports a relationship with Maastricht Education and Research Centre that includes: board membership. Frederik-Jan van Schooten reports a relationship with Chemosphere, Elsevier that includes: employment.\n",
      "\n",
      "Spooren, Corinne\n",
      "Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Shan Wang reports financial support was provided by Chinese Scholarship Council. Corinne Spooren reports financial support was provided by European Commission. Daisy Jonkers reports financial support was provided by European Commission. Corinne Spooren reports a relationship with Janssen Pharmaceuticals that includes: consulting or advisory. Marlijne de Graaf reports  a relationship with Top Knowledge Institute that includes: funding grants. Daisy  Jonkers reports a relationship with Top Knowledge Institute that includes: funding grants. Daisy Jonkers reports a relationship with The Carbokinetics program as part of the NWO-CCC partnership programme that includes: funding grants. Daisy Jonkers reports a relationship with Dutch national NWO Vidi committee that includes: paid expert testimony. Daisy Jonkers reports a relationship with School on Nutrition and Translational Research in Metabolism of Maastricht University that includes: board membership. Daisy Jonkers reports a relationship with Maastricht Comprehensive Cancer Center of Maastricht University that includes: board membership. Frederik-Jan van Schooten reports a relationship with Ministry of Agriculture, Nature and Food Quality. Directorate Strategy, Knowledge and Innovation that includes: funding grants. Frederik-Jan van Schooten reports a relationship with Dutch Cancer Society that includes: funding grants. Frederik-Jan van Schooten reports a relationship with Netherlands Food and Consumer Product Safety Authority grant that includes: funding grants. Frederik-Jan van Schooten reports a relationship with Maastricht Education and Research Centre that includes: board membership. Frederik-Jan van Schooten reports a relationship with Chemosphere, Elsevier that includes: employment.\n",
      "\n",
      "de Graaf, Marlijne\n",
      "Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Shan Wang reports financial support was provided by Chinese Scholarship Council. Corinne Spooren reports financial support was provided by European Commission. Daisy Jonkers reports financial support was provided by European Commission. Corinne Spooren reports a relationship with Janssen Pharmaceuticals that includes: consulting or advisory. Marlijne de Graaf reports  a relationship with Top Knowledge Institute that includes: funding grants. Daisy  Jonkers reports a relationship with Top Knowledge Institute that includes: funding grants. Daisy Jonkers reports a relationship with The Carbokinetics program as part of the NWO-CCC partnership programme that includes: funding grants. Daisy Jonkers reports a relationship with Dutch national NWO Vidi committee that includes: paid expert testimony. Daisy Jonkers reports a relationship with School on Nutrition and Translational Research in Metabolism of Maastricht University that includes: board membership. Daisy Jonkers reports a relationship with Maastricht Comprehensive Cancer Center of Maastricht University that includes: board membership. Frederik-Jan van Schooten reports a relationship with Ministry of Agriculture, Nature and Food Quality. Directorate Strategy, Knowledge and Innovation that includes: funding grants. Frederik-Jan van Schooten reports a relationship with Dutch Cancer Society that includes: funding grants. Frederik-Jan van Schooten reports a relationship with Netherlands Food and Consumer Product Safety Authority grant that includes: funding grants. Frederik-Jan van Schooten reports a relationship with Maastricht Education and Research Centre that includes: board membership. Frederik-Jan van Schooten reports a relationship with Chemosphere, Elsevier that includes: employment.\n",
      "\n",
      "Jonkers, Daisy\n",
      "Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Shan Wang reports financial support was provided by Chinese Scholarship Council. Corinne Spooren reports financial support was provided by European Commission. Daisy Jonkers reports financial support was provided by European Commission. Corinne Spooren reports a relationship with Janssen Pharmaceuticals that includes: consulting or advisory. Marlijne de Graaf reports  a relationship with Top Knowledge Institute that includes: funding grants. Daisy  Jonkers reports a relationship with Top Knowledge Institute that includes: funding grants. Daisy Jonkers reports a relationship with The Carbokinetics program as part of the NWO-CCC partnership programme that includes: funding grants. Daisy Jonkers reports a relationship with Dutch national NWO Vidi committee that includes: paid expert testimony. Daisy Jonkers reports a relationship with School on Nutrition and Translational Research in Metabolism of Maastricht University that includes: board membership. Daisy Jonkers reports a relationship with Maastricht Comprehensive Cancer Center of Maastricht University that includes: board membership. Frederik-Jan van Schooten reports a relationship with Ministry of Agriculture, Nature and Food Quality. Directorate Strategy, Knowledge and Innovation that includes: funding grants. Frederik-Jan van Schooten reports a relationship with Dutch Cancer Society that includes: funding grants. Frederik-Jan van Schooten reports a relationship with Netherlands Food and Consumer Product Safety Authority grant that includes: funding grants. Frederik-Jan van Schooten reports a relationship with Maastricht Education and Research Centre that includes: board membership. Frederik-Jan van Schooten reports a relationship with Chemosphere, Elsevier that includes: employment.\n",
      "\n",
      "van Schooten, Frederik-Jan\n",
      "Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Shan Wang reports financial support was provided by Chinese Scholarship Council. Corinne Spooren reports financial support was provided by European Commission. Daisy Jonkers reports financial support was provided by European Commission. Corinne Spooren reports a relationship with Janssen Pharmaceuticals that includes: consulting or advisory. Marlijne de Graaf reports  a relationship with Top Knowledge Institute that includes: funding grants. Daisy  Jonkers reports a relationship with Top Knowledge Institute that includes: funding grants. Daisy Jonkers reports a relationship with The Carbokinetics program as part of the NWO-CCC partnership programme that includes: funding grants. Daisy Jonkers reports a relationship with Dutch national NWO Vidi committee that includes: paid expert testimony. Daisy Jonkers reports a relationship with School on Nutrition and Translational Research in Metabolism of Maastricht University that includes: board membership. Daisy Jonkers reports a relationship with Maastricht Comprehensive Cancer Center of Maastricht University that includes: board membership. Frederik-Jan van Schooten reports a relationship with Ministry of Agriculture, Nature and Food Quality. Directorate Strategy, Knowledge and Innovation that includes: funding grants. Frederik-Jan van Schooten reports a relationship with Dutch Cancer Society that includes: funding grants. Frederik-Jan van Schooten reports a relationship with Netherlands Food and Consumer Product Safety Authority grant that includes: funding grants. Frederik-Jan van Schooten reports a relationship with Maastricht Education and Research Centre that includes: board membership. Frederik-Jan van Schooten reports a relationship with Chemosphere, Elsevier that includes: employment.\n",
      "\n",
      "Beausoleil, Christopher\n",
      "Disclosures This project was funded by Becton, Dickinson and Company (BD). Mr. Christopher Beausoleil and Ms. Comstock are employees of BioScience Laboratories, LLC, which  was contracted by BD to perform testing for this study. Dr. Zook, Dr. Eby, Dr. Werner, and Ms. Li are employees of Becton, Dickinson and Company. Dr. Zook holds stock in BD. All conflicts of interest have been declared in the title page of the manuscript, as well as in the submitted forms accompanying submission.\n",
      "\n",
      "Comstock, Samantha L.\n",
      "Disclosures This project was funded by Becton, Dickinson and Company (BD). Mr. Christopher Beausoleil and Ms. Samantha L. Comstock are employees of BioScience Laboratories, LLC, which  was contracted by BD to perform testing for this study. Dr. Zook, Dr. Eby, Dr. Werner, and Ms. Li are employees of Becton, Dickinson and Company. Dr. Zook holds stock in BD. All conflicts of interest have been declared in the title page of the manuscript, as well as in the submitted forms accompanying submission.\n",
      "\n",
      "Werner, Donna\n",
      "Disclosures This project was funded by Becton, Dickinson and Company (BD). Mr. Christopher Beausoleil and Ms. Samantha L. Comstock are employees of BioScience Laboratories, LLC, which  was contracted by BD to perform testing for this study. Dr. Zook, Dr. Eby, Dr. Donna Werner, and Ms. Li are employees of Becton, Dickinson and Company. Dr. Zook holds stock in BD. All conflicts of interest have been declared in the title page of the manuscript, as well as in the submitted forms accompanying submission.\n",
      "\n",
      "Li, Lingzhi\n",
      "Disclosures This project was funded by Becton, Dickinson and Company (BD). Mr. Christopher Beausoleil and Ms. Samantha L. Comstock are employees of BioScience Laboratories, Lingzhi LiC, which  was contracted by BD to perform testing for this study. Dr. Zook, Dr. Eby, Dr. Donna Werner, and Ms. Li are employees of Becton, Dickinson and Company. Dr. Zook holds stock in BD. All conflicts of interest have been declared in the title page of the manuscript, as well as in the submitted forms accompanying submission.\n",
      "\n",
      "Eby, Jonathan M.\n",
      "Disclosures This project was funded by Becton, Dickinson and Company (BD). Mr. Christopher Beausoleil and Ms. Samantha L. Comstock are employees of BioScience Laboratories, Lingzhi LiC, which  was contracted by BD to perform testing for this study. Dr. Zook, Dr. Jonathan M. Eby, Dr. Donna Werner, and Ms. Li are employees of Becton, Dickinson and Company. Dr. Zook holds stock in BD. All conflicts of interest have been declared in the title page of the manuscript, as well as in the submitted forms accompanying submission.\n",
      "\n",
      "Zook, Erin C.\n",
      "Disclosures This project was funded by Becton, Dickinson and Company (BD). Mr. Christopher Beausoleil and Ms. Samantha L. Comstock are employees of BioScience Laboratories, Lingzhi LiC, which  was contracted by BD to perform testing for this study. Dr. Erin C. Zook, Dr. Jonathan M. Eby, Dr. Donna Werner, and Ms. Li are employees of Becton, Dickinson and Company. Dr. Erin C. Zook holds stock in BD. All conflicts of interest have been declared in the title page of the manuscript, as well as in the submitted forms accompanying submission.\n",
      "\n",
      "I have read the journal's policy and the authors of this manuscript have the following competing interests: SK is an employee of Verve Therapeutics; holds equity in Verve Therapeutics, Maze Therapeutics, Catabasis, and San Therapeutics; has served on scientific advisory boards for Regeneron Genetics Center and Corvidia Therapeutics; has served as a consultant for Acceleron, Eli Lilly, Novartis, Merck, Novo Nordisk, Novo Ventures, Ionis, Alnylam, Aegerion, Haug Partners, Noble Insights, Leerink Partners, Bayer Healthcare, Illumina, Color Genomics, MedGenome, Quest, Pfizer, and Medscape; and has patents related to a method of identifying and treating a person having a predisposition to or afflicted with cardiometabolic disease (20180010185) and a genetics risk predictor (20190017119). ASB has received grants from AstraZeneca, Bayer, Biogen, Bioverativ, Novartis and Sanofi. A.V.K. is an employee and holds equity in Verve  Therapeutics; has served as a scientific advisor to Amgen, Maze Therapeutics, Navitor Pharmaceuticals, Sarepta Therapeutics, Novartis, Silence Therapeutics, Korro Bio, Veritas International, Color Health, Third Rock Ventures, Illumina, Foresite Labs, and Columbia University (NIH); received speaking fees from Illumina, MedGenome, Amgen, and the Novartis Institute for Biomedical Research; received a sponsored research agreement from IBM Research, and is listed as a co-inventor on a patent application for use of imaging data in assessing body fat distribution and associated cardiometabolic risk.\n",
      "\n",
      "I have read the journal's policy and the authors of this manuscript have the following competing interests: SK is an employee of Verve Therapeutics; holds equity in Verve Therapeutics, Maze Therapeutics, Catabasis, and San Therapeutics; has served on scientific advisory boards for Regeneron Genetics Center and Corvidia Therapeutics; has served as a consultant for Acceleron, Eli Lilly, Novartis, Merck, Novo Nordisk, Novo Ventures, Ionis, Alnylam, Aegerion, Haug Partners, Noble Insights, Leerink Partners, Bayer Healthcare, Illumina, Color Genomics, MedGenome, Quest, Pfizer, and Medscape; and has patents related to a method of identifying and treating a person having a predisposition to or afflicted with cardiometabolic disease (20180010185) and a genetics risk predictor (20190017119). ASB has received grants from AstraZeneca, Bayer, Biogen, Bioverativ, Novartis and Sanofi. A.V.K. is an employee and holds equity in Verve  Therapeutics; has served as a scientific advisor to Amgen, Maze Therapeutics, Navitor Pharmaceuticals, Sarepta Therapeutics, Novartis, Silence Therapeutics, Korro Bio, Veritas International, Color Health, Third Rock Ventures, Illumina, Foresite Labs, and Columbia University (NIH); received speaking fees from Illumina, MedGenome, Amgen, and the Novartis Institute for Biomedical Research; received a sponsored research agreement from IBM Research, and is listed as a co-inventor on a patent application for use of imaging data in assessing body fat distribution and associated cardiometabolic risk.\n",
      "\n",
      "I have read the journal's policy and the authors of this manuscript have the following competing interests: SK is an employee of Verve Therapeutics; holds equity in Verve Therapeutics, Maze Therapeutics, Catabasis, and San Therapeutics; has served on scientific advisory boards for Regeneron Genetics Center and Corvidia Therapeutics; has served as a consultant for Acceleron, Eli Lilly, Novartis, Merck, Novo Nordisk, Novo Ventures, Ionis, Alnylam, Aegerion, Haug Partners, Noble Insights, Leerink Partners, Bayer Healthcare, Illumina, Color Genomics, MedGenome, Quest, Pfizer, and Medscape; and has patents related to a method of identifying and treating a person having a predisposition to or afflicted with cardiometabolic disease (20180010185) and a genetics risk predictor (20190017119). ASB has received grants from AstraZeneca, Bayer, Biogen, Bioverativ, Novartis and Sanofi. A.V.K. is an employee and holds equity in Verve  Therapeutics; has served as a scientific advisor to Amgen, Maze Therapeutics, Navitor Pharmaceuticals, Sarepta Therapeutics, Novartis, Silence Therapeutics, Korro Bio, Veritas International, Color Health, Third Rock Ventures, Illumina, Foresite Labs, and Columbia University (NIH); received speaking fees from Illumina, MedGenome, Amgen, and the Novartis Institute for Biomedical Research; received a sponsored research agreement from IBM Research, and is listed as a co-inventor on a patent application for use of imaging data in assessing body fat distribution and associated cardiometabolic risk.\n",
      "\n",
      "I have read the journal's policy and the authors of this manuscript have the following competing interests: SK is an employee of Verve Therapeutics; holds equity in Verve Therapeutics, Maze Therapeutics, Catabasis, and San Therapeutics; has served on scientific advisory boards for Regeneron Genetics Center and Corvidia Therapeutics; has served as a consultant for Acceleron, Eli Lilly, Novartis, Merck, Novo Nordisk, Novo Ventures, Ionis, Alnylam, Aegerion, Haug Partners, Noble Insights, Leerink Partners, Bayer Healthcare, Illumina, Color Genomics, MedGenome, Quest, Pfizer, and Medscape; and has patents related to a method of identifying and treating a person having a predisposition to or afflicted with cardiometabolic disease (20180010185) and a genetics risk predictor (20190017119). ASB has received grants from AstraZeneca, Bayer, Biogen, Bioverativ, Novartis and Sanofi. A.V.K. is an employee and holds equity in Verve  Therapeutics; has served as a scientific advisor to Amgen, Maze Therapeutics, Navitor Pharmaceuticals, Sarepta Therapeutics, Novartis, Silence Therapeutics, Korro Bio, Veritas International, Color Health, Third Rock Ventures, Illumina, Foresite Labs, and Columbia University (NIH); received speaking fees from Illumina, MedGenome, Amgen, and the Novartis Institute for Biomedical Research; received a sponsored research agreement from IBM Research, and is listed as a co-inventor on a patent application for use of imaging data in assessing body fat distribution and associated cardiometabolic risk.\n",
      "\n",
      "I have read the journal's policy and the authors of this manuscript have the following competing interests: SK is an employee of Verve Therapeutics; holds equity in Verve Therapeutics, Maze Therapeutics, Catabasis, and San Therapeutics; has served on scientific advisory boards for Regeneron Genetics Center and Corvidia Therapeutics; has served as a consultant for Acceleron, Eli Lilly, Novartis, Merck, Novo Nordisk, Novo Ventures, Ionis, Alnylam, Aegerion, Haug Partners, Noble Insights, Leerink Partners, Bayer Healthcare, Illumina, Color Genomics, MedGenome, Quest, Pfizer, and Medscape; and has patents related to a method of identifying and treating a person having a predisposition to or afflicted with cardiometabolic disease (20180010185) and a genetics risk predictor (20190017119). ASB has received grants from AstraZeneca, Bayer, Biogen, Bioverativ, Novartis and Sanofi. A.V.K. is an employee and holds equity in Verve  Therapeutics; has served as a scientific advisor to Amgen, Maze Therapeutics, Navitor Pharmaceuticals, Sarepta Therapeutics, Novartis, Silence Therapeutics, Korro Bio, Veritas International, Color Health, Third Rock Ventures, Illumina, Foresite Labs, and Columbia University (NIH); received speaking fees from Illumina, MedGenome, Amgen, and the Novartis Institute for Biomedical Research; received a sponsored research agreement from IBM Research, and is listed as a co-inventor on a patent application for use of imaging data in assessing body fat distribution and associated cardiometabolic risk.\n",
      "\n",
      "I have read the journal's policy and the authors of this manuscript have the following competing interests: SK is an employee of Verve Therapeutics; holds equity in Verve Therapeutics, Maze Therapeutics, Catabasis, and San Therapeutics; has served on scientific advisory boards for Regeneron Genetics Center and Corvidia Therapeutics; has served as a consultant for Acceleron, Eli Lilly, Novartis, Merck, Novo Nordisk, Novo Ventures, Ionis, Alnylam, Aegerion, Haug Partners, Noble Insights, Leerink Partners, Bayer Healthcare, Illumina, Color Genomics, MedGenome, Quest, Pfizer, and Medscape; and has patents related to a method of identifying and treating a person having a predisposition to or afflicted with cardiometabolic disease (20180010185) and a genetics risk predictor (20190017119). ASB has received grants from AstraZeneca, Bayer, Biogen, Bioverativ, Novartis and Sanofi. A.V.K. is an employee and holds equity in Verve  Therapeutics; has served as a scientific advisor to Amgen, Maze Therapeutics, Navitor Pharmaceuticals, Sarepta Therapeutics, Novartis, Silence Therapeutics, Korro Bio, Veritas International, Color Health, Third Rock Ventures, Illumina, Foresite Labs, and Columbia University (NIH); received speaking fees from Illumina, MedGenome, Amgen, and the Novartis Institute for Biomedical Research; received a sponsored research agreement from IBM Research, and is listed as a co-inventor on a patent application for use of imaging data in assessing body fat distribution and associated cardiometabolic risk.\n",
      "\n",
      "I have read the journal's policy and the authors of this manuscript have the following competing interests: SK is an employee of Verve Therapeutics; holds equity in Verve Therapeutics, Maze Therapeutics, Catabasis, and San Therapeutics; has served on scientific advisory boards for Regeneron Genetics Center and Corvidia Therapeutics; has served as a consultant for Acceleron, Eli Lilly, Novartis, Merck, Novo Nordisk, Novo Ventures, Ionis, Alnylam, Aegerion, Haug Partners, Noble Insights, Leerink Partners, Bayer Healthcare, Illumina, Color Genomics, MedGenome, Quest, Pfizer, and Medscape; and has patents related to a method of identifying and treating a person having a predisposition to or afflicted with cardiometabolic disease (20180010185) and a genetics risk predictor (20190017119). ASB has received grants from AstraZeneca, Bayer, Biogen, Bioverativ, Novartis and Sanofi. A.V.K. is an employee and holds equity in Verve  Therapeutics; has served as a scientific advisor to Amgen, Maze Therapeutics, Navitor Pharmaceuticals, Sarepta Therapeutics, Novartis, Silence Therapeutics, Korro Bio, Veritas International, Color Health, Third Rock Ventures, Illumina, Foresite Labs, and Columbia University (NIH); received speaking fees from Illumina, MedGenome, Amgen, and the Novartis Institute for Biomedical Research; received a sponsored research agreement from IBM Research, and is listed as a co-inventor on a patent application for use of imaging data in assessing body fat distribution and associated cardiometabolic risk.\n",
      "\n",
      "I have read the journal's policy and the authors of this manuscript have the following competing interests: SK is an employee of Verve Therapeutics; holds equity in Verve Therapeutics, Maze Therapeutics, Catabasis, and San Therapeutics; has served on scientific advisory boards for Regeneron Genetics Center and Corvidia Therapeutics; has served as a consultant for Acceleron, Eli Lilly, Novartis, Merck, Novo Nordisk, Novo Ventures, Ionis, Alnylam, Aegerion, Haug Partners, Noble Insights, Leerink Partners, Bayer Healthcare, Illumina, Color Genomics, MedGenome, Quest, Pfizer, and Medscape; and has patents related to a method of identifying and treating a person having a predisposition to or afflicted with cardiometabolic disease (20180010185) and a genetics risk predictor (20190017119). ASB has received grants from AstraZeneca, Bayer, Biogen, Bioverativ, Novartis and Sanofi. A.V.K. is an employee and holds equity in Verve  Therapeutics; has served as a scientific advisor to Amgen, Maze Therapeutics, Navitor Pharmaceuticals, Sarepta Therapeutics, Novartis, Silence Therapeutics, Korro Bio, Veritas International, Color Health, Third Rock Ventures, Illumina, Foresite Labs, and Columbia University (NIH); received speaking fees from Illumina, MedGenome, Amgen, and the Novartis Institute for Biomedical Research; received a sponsored research agreement from IBM Research, and is listed as a co-inventor on a patent application for use of imaging data in assessing body fat distribution and associated cardiometabolic risk.\n",
      "\n",
      "I have read the journal's policy and the authors of this manuscript have the following competing interests: SK is an employee of Verve Therapeutics; holds equity in Verve Therapeutics, Maze Therapeutics, Catabasis, and San Therapeutics; has served on scientific advisory boards for Regeneron Genetics Center and Corvidia Therapeutics; has served as a consultant for Acceleron, Eli Lilly, Novartis, Merck, Novo Nordisk, Novo Ventures, Ionis, Alnylam, Aegerion, Haug Partners, Noble Insights, Leerink Partners, Bayer Healthcare, Illumina, Color Genomics, MedGenome, Quest, Pfizer, and Medscape; and has patents related to a method of identifying and treating a person having a predisposition to or afflicted with cardiometabolic disease (20180010185) and a genetics risk predictor (20190017119). ASB has received grants from AstraZeneca, Bayer, Biogen, Bioverativ, Novartis and Sanofi. A.V.K. is an employee and holds equity in Verve  Therapeutics; has served as a scientific advisor to Amgen, Maze Therapeutics, Navitor Pharmaceuticals, Sarepta Therapeutics, Novartis, Silence Therapeutics, Korro Bio, Veritas International, Color Health, Third Rock Ventures, Illumina, Foresite Labs, and Columbia University (NIH); received speaking fees from Illumina, MedGenome, Amgen, and the Novartis Institute for Biomedical Research; received a sponsored research agreement from IBM Research, and is listed as a co-inventor on a patent application for use of imaging data in assessing body fat distribution and associated cardiometabolic risk.\n",
      "\n",
      "I have read the journal's policy and the authors of this manuscript have the following competing interests: SK is an employee of Verve Therapeutics; holds equity in Verve Therapeutics, Maze Therapeutics, Catabasis, and San Therapeutics; has served on scientific advisory boards for Regeneron Genetics Center and Corvidia Therapeutics; has served as a consultant for Acceleron, Eli Lilly, Novartis, Merck, Novo Nordisk, Novo Ventures, Ionis, Alnylam, Aegerion, Haug Partners, Noble Insights, Leerink Partners, Bayer Healthcare, Illumina, Color Genomics, MedGenome, Quest, Pfizer, and Medscape; and has patents related to a method of identifying and treating a person having a predisposition to or afflicted with cardiometabolic disease (20180010185) and a genetics risk predictor (20190017119). ASB has received grants from AstraZeneca, Bayer, Biogen, Bioverativ, Novartis and Sanofi. A.V.K. is an employee and holds equity in Verve  Therapeutics; has served as a scientific advisor to Amgen, Maze Therapeutics, Navitor Pharmaceuticals, Sarepta Therapeutics, Novartis, Silence Therapeutics, Korro Bio, Veritas International, Color Health, Third Rock Ventures, Illumina, Foresite Labs, and Columbia University (NIH); received speaking fees from Illumina, MedGenome, Amgen, and the Novartis Institute for Biomedical Research; received a sponsored research agreement from IBM Research, and is listed as a co-inventor on a patent application for use of imaging data in assessing body fat distribution and associated cardiometabolic risk.\n",
      "\n",
      "I have read the journal's policy and the authors of this manuscript have the following competing interests: SK is an employee of Verve Therapeutics; holds equity in Verve Therapeutics, Maze Therapeutics, Catabasis, and San Therapeutics; has served on scientific advisory boards for Regeneron Genetics Center and Corvidia Therapeutics; has served as a consultant for Acceleron, Eli Lilly, Novartis, Merck, Novo Nordisk, Novo Ventures, Ionis, Alnylam, Aegerion, Haug Partners, Noble Insights, Leerink Partners, Bayer Healthcare, Illumina, Color Genomics, MedGenome, Quest, Pfizer, and Medscape; and has patents related to a method of identifying and treating a person having a predisposition to or afflicted with cardiometabolic disease (20180010185) and a genetics risk predictor (20190017119). ASB has received grants from AstraZeneca, Bayer, Biogen, Bioverativ, Novartis and Sanofi. A.V.K. is an employee and holds equity in Verve  Therapeutics; has served as a scientific advisor to Amgen, Maze Therapeutics, Navitor Pharmaceuticals, Sarepta Therapeutics, Novartis, Silence Therapeutics, Korro Bio, Veritas International, Color Health, Third Rock Ventures, Illumina, Foresite Labs, and Columbia University (NIH); received speaking fees from Illumina, MedGenome, Amgen, and the Novartis Institute for Biomedical Research; received a sponsored research agreement from IBM Research, and is listed as a co-inventor on a patent application for use of imaging data in assessing body fat distribution and associated cardiometabolic risk.\n",
      "\n",
      "I have read the journal's policy and the authors of this manuscript have the following competing interests: SK is an employee of Verve Therapeutics; holds equity in Verve Therapeutics, Maze Therapeutics, Catabasis, and San Therapeutics; has served on scientific advisory boards for Regeneron Genetics Center and Corvidia Therapeutics; has served as a consultant for Acceleron, Eli Lilly, Novartis, Merck, Novo Nordisk, Novo Ventures, Ionis, Alnylam, Aegerion, Haug Partners, Noble Insights, Leerink Partners, Bayer Healthcare, Illumina, Color Genomics, MedGenome, Quest, Pfizer, and Medscape; and has patents related to a method of identifying and treating a person having a predisposition to or afflicted with cardiometabolic disease (20180010185) and a genetics risk predictor (20190017119). ASB has received grants from AstraZeneca, Bayer, Biogen, Bioverativ, Novartis and Sanofi. A.V.K. is an employee and holds equity in Verve  Therapeutics; has served as a scientific advisor to Amgen, Maze Therapeutics, Navitor Pharmaceuticals, Sarepta Therapeutics, Novartis, Silence Therapeutics, Korro Bio, Veritas International, Color Health, Third Rock Ventures, Illumina, Foresite Labs, and Columbia University (NIH); received speaking fees from Illumina, MedGenome, Amgen, and the Novartis Institute for Biomedical Research; received a sponsored research agreement from IBM Research, and is listed as a co-inventor on a patent application for use of imaging data in assessing body fat distribution and associated cardiometabolic risk.\n",
      "\n",
      "I have read the journal's policy and the authors of this manuscript have the following competing interests: SK is an employee of Verve Therapeutics; holds equity in Verve Therapeutics, Maze Therapeutics, Catabasis, and San Therapeutics; has served on scientific advisory boards for Regeneron Genetics Center and Corvidia Therapeutics; has served as a consultant for Acceleron, Eli Lilly, Novartis, Merck, Novo Nordisk, Novo Ventures, Ionis, Alnylam, Aegerion, Haug Partners, Noble Insights, Leerink Partners, Bayer Healthcare, Illumina, Color Genomics, MedGenome, Quest, Pfizer, and Medscape; and has patents related to a method of identifying and treating a person having a predisposition to or afflicted with cardiometabolic disease (20180010185) and a genetics risk predictor (20190017119). ASB has received grants from AstraZeneca, Bayer, Biogen, Bioverativ, Novartis and Sanofi. A.V.K. is an employee and holds equity in Verve  Therapeutics; has served as a scientific advisor to Amgen, Maze Therapeutics, Navitor Pharmaceuticals, Sarepta Therapeutics, Novartis, Silence Therapeutics, Korro Bio, Veritas International, Color Health, Third Rock Ventures, Illumina, Foresite Labs, and Columbia University (NIH); received speaking fees from Illumina, MedGenome, Amgen, and the Novartis Institute for Biomedical Research; received a sponsored research agreement from IBM Research, and is listed as a co-inventor on a patent application for use of imaging data in assessing body fat distribution and associated cardiometabolic risk.\n",
      "\n",
      "Kathiresan, Sekar\n",
      "I have read the journal's policy and the authors of this manuscript have the following competing interests: Sekar Kathiresan is an employee of Verve Therapeutics; holds equity in Verve Therapeutics, Maze Therapeutics, Catabasis, and San Therapeutics; has served on scientific advisory boards for Regeneron Genetics Center and Corvidia Therapeutics; has served as a consultant for Acceleron, Eli Lilly, Novartis, Merck, Novo Nordisk, Novo Ventures, Ionis, Alnylam, Aegerion, Haug Partners, Noble Insights, Leerink Partners, Bayer Healthcare, Illumina, Color Genomics, MedGenome, Quest, Pfizer, and Medscape; and has patents related to a method of identifying and treating a person having a predisposition to or afflicted with cardiometabolic disease (20180010185) and a genetics risk predictor (20190017119). ASB has received grants from AstraZeneca, Bayer, Biogen, Bioverativ, Novartis and Sanofi. A.V.K. is an employee and holds equity in Verve  Therapeutics; has served as a scientific advisor to Amgen, Maze Therapeutics, Navitor Pharmaceuticals, Sarepta Therapeutics, Novartis, Silence Therapeutics, Korro Bio, Veritas International, Color Health, Third Rock Ventures, Illumina, Foresite Labs, and Columbia University (NIH); received speaking fees from Illumina, MedGenome, Amgen, and the Novartis Institute for Biomedical Research; received a sponsored research agreement from IBM Research, and is listed as a co-inventor on a patent application for use of imaging data in assessing body fat distribution and associated cardiometabolic risk.\n",
      "\n",
      "Butterworth, Adam S.\n",
      "I have read the journal's policy and the authors of this manuscript have the following competing interests: Sekar Kathiresan is an employee of Verve Therapeutics; holds equity in Verve Therapeutics, Maze Therapeutics, Catabasis, and San Therapeutics; has served on scientific advisory boards for Regeneron Genetics Center and Corvidia Therapeutics; has served as a consultant for Acceleron, Eli Lilly, Novartis, Merck, Novo Nordisk, Novo Ventures, Ionis, Alnylam, Aegerion, Haug Partners, Noble Insights, Leerink Partners, Bayer Healthcare, Illumina, Color Genomics, MedGenome, Quest, Pfizer, and Medscape; and has patents related to a method of identifying and treating a person having a predisposition to or afflicted with cardiometabolic disease (20180010185) and a genetics risk predictor (20190017119). Adam S. Butterworth has received grants from AstraZeneca, Bayer, Biogen, Bioverativ, Novartis and Sanofi. A.V.K. is an employee and holds equity in Verve  Therapeutics; has served as a scientific advisor to Amgen, Maze Therapeutics, Navitor Pharmaceuticals, Sarepta Therapeutics, Novartis, Silence Therapeutics, Korro Bio, Veritas International, Color Health, Third Rock Ventures, Illumina, Foresite Labs, and Columbia University (NIH); received speaking fees from Illumina, MedGenome, Amgen, and the Novartis Institute for Biomedical Research; received a sponsored research agreement from IBM Research, and is listed as a co-inventor on a patent application for use of imaging data in assessing body fat distribution and associated cardiometabolic risk.\n",
      "\n",
      "Khera, Amit V.\n",
      "I have read the journal's policy and the authors of this manuscript have the following competing interests: Sekar Kathiresan is an employee of Verve Therapeutics; holds equity in Verve Therapeutics, Maze Therapeutics, Catabasis, and San Therapeutics; has served on scientific advisory boards for Regeneron Genetics Center and Corvidia Therapeutics; has served as a consultant for Acceleron, Eli Lilly, Novartis, Merck, Novo Nordisk, Novo Ventures, Ionis, Alnylam, Aegerion, Haug Partners, Noble Insights, Leerink Partners, Bayer Healthcare, Illumina, Color Genomics, MedGenome, Quest, Pfizer, and Medscape; and has patents related to a method of identifying and treating a person having a predisposition to or afflicted with cardiometabolic disease (20180010185) and a genetics risk predictor (20190017119). Adam S. Butterworth has received grants from AstraZeneca, Bayer, Biogen, Bioverativ, Novartis and Sanofi. Amit V. Khera is an employee and holds equity in Verve  Therapeutics; has served as a scientific advisor to Amgen, Maze Therapeutics, Navitor Pharmaceuticals, Sarepta Therapeutics, Novartis, Silence Therapeutics, Korro Bio, Veritas International, Color Health, Third Rock Ventures, Illumina, Foresite Labs, and Columbia University (NIH); received speaking fees from Illumina, MedGenome, Amgen, and the Novartis Institute for Biomedical Research; received a sponsored research agreement from IBM Research, and is listed as a co-inventor on a patent application for use of imaging data in assessing body fat distribution and associated cardiometabolic risk.\n",
      "\n",
      "The authors are employed by a commercial company, MED-EL GmbH and MED-EL Corporation. This does not alter our adherence to PLOS ONE policies on sharing data and materials. The authors have made all data fully available within the manuscript and Supporting information files.\n",
      "\n",
      "The authors are employed by a commercial company, MED-EL GmbH and MED-EL Corporation. This does not alter our adherence to PLOS ONE policies on sharing data and materials. The authors have made all data fully available within the manuscript and Supporting information files.\n",
      "\n",
      "The authors are employed by a commercial company, MED-EL GmbH and MED-EL Corporation. This does not alter our adherence to PLOS ONE policies on sharing data and materials. The authors have made all data fully available within the manuscript and Supporting information files.\n",
      "\n",
      "The authors are employed by a commercial company, MED-EL GmbH and MED-EL Corporation. This does not alter our adherence to PLOS ONE policies on sharing data and materials. The authors have made all data fully available within the manuscript and Supporting information files.\n",
      "\n",
      "The authors are employed by a commercial company, MED-EL GmbH and MED-EL Corporation. This does not alter our adherence to PLOS ONE policies on sharing data and materials. The authors have made all data fully available within the manuscript and Supporting information files.\n",
      "\n",
      "de Lusignan, Simon\n",
      "The authors have read the journal's policy and have the following competing interests: Simon de Lusignan is the Director of the Oxford RCGP RSC and has received funding through his University for studies from Eli Lilly, Astra-Zeneca, Sanofi, GSK, Seqirus and Takeda; and been member of advisory boards for influenza for Seqirus and Sanofi. FDRH has received occasional fees from Bayer and Boehringer Ingelheim for speaking or consulting on atrial fibrillation related stroke risk. All other authors have declared no financial relationships with any  organisations that might have an interest in the submitted work in the previous three years, no other relationships or activities that could appear to have influenced the submitted work. This does not alter our adherence to PLOS ONE policies on sharing data and materials. There are no patents, products in development or marketed products associated with this research to declare.\n",
      "\n",
      "D Richard Hobbs, F.\n",
      "The authors have read the journal's policy and have the following competing interests: Simon de Lusignan is the Director of the Oxford RCGP RSC and has received funding through his University for studies from Eli Lilly, Astra-Zeneca, Sanofi, GSK, Seqirus and Takeda; and been member of advisory boards for influenza for Seqirus and Sanofi. F. D Richard Hobbs has received occasional fees from Bayer and Boehringer Ingelheim for speaking or consulting on atrial fibrillation related stroke risk. All other authors have declared no financial relationships with any  organisations that might have an interest in the submitted work in the previous three years, no other relationships or activities that could appear to have influenced the submitted work. This does not alter our adherence to PLOS ONE policies on sharing data and materials. There are no patents, products in development or marketed products associated with this research to declare.\n",
      "\n",
      "The authors have read the journal's policy and have the following competing interests: Simon de Lusignan is the Director of the Oxford RCGP RSC and has received funding through his University for studies from Eli Lilly, Astra-Zeneca, Sanofi, GSK, Seqirus and Takeda; and been member of advisory boards for influenza for Seqirus and Sanofi. F. D Richard Hobbs has received occasional fees from Bayer and Boehringer Ingelheim for speaking or consulting on atrial fibrillation related stroke risk. All other authors have declared no financial relationships with any  organisations that might have an interest in the submitted work in the previous three years, no other relationships or activities that could appear to have influenced the submitted work. This does not alter our adherence to PLOS ONE policies on sharing data and materials. There are no patents, products in development or marketed products associated with this research to declare.\n",
      "\n",
      "The authors have read the journal's policy and have the following competing interests: Simon de Lusignan is the Director of the Oxford RCGP RSC and has received funding through his University for studies from Eli Lilly, Astra-Zeneca, Sanofi, GSK, Seqirus and Takeda; and been member of advisory boards for influenza for Seqirus and Sanofi. F. D Richard Hobbs has received occasional fees from Bayer and Boehringer Ingelheim for speaking or consulting on atrial fibrillation related stroke risk. All other authors have declared no financial relationships with any  organisations that might have an interest in the submitted work in the previous three years, no other relationships or activities that could appear to have influenced the submitted work. This does not alter our adherence to PLOS ONE policies on sharing data and materials. There are no patents, products in development or marketed products associated with this research to declare.\n",
      "\n",
      "The authors have read the journal's policy and have the following competing interests: Simon de Lusignan is the Director of the Oxford RCGP RSC and has received funding through his University for studies from Eli Lilly, Astra-Zeneca, Sanofi, GSK, Seqirus and Takeda; and been member of advisory boards for influenza for Seqirus and Sanofi. F. D Richard Hobbs has received occasional fees from Bayer and Boehringer Ingelheim for speaking or consulting on atrial fibrillation related stroke risk. All other authors have declared no financial relationships with any  organisations that might have an interest in the submitted work in the previous three years, no other relationships or activities that could appear to have influenced the submitted work. This does not alter our adherence to PLOS ONE policies on sharing data and materials. There are no patents, products in development or marketed products associated with this research to declare.\n",
      "\n",
      "The authors have read the journal's policy and have the following competing interests: Simon de Lusignan is the Director of the Oxford RCGP RSC and has received funding through his University for studies from Eli Lilly, Astra-Zeneca, Sanofi, GSK, Seqirus and Takeda; and been member of advisory boards for influenza for Seqirus and Sanofi. F. D Richard Hobbs has received occasional fees from Bayer and Boehringer Ingelheim for speaking or consulting on atrial fibrillation related stroke risk. All other authors have declared no financial relationships with any  organisations that might have an interest in the submitted work in the previous three years, no other relationships or activities that could appear to have influenced the submitted work. This does not alter our adherence to PLOS ONE policies on sharing data and materials. There are no patents, products in development or marketed products associated with this research to declare.\n",
      "\n",
      "The authors have read the journal's policy and have the following competing interests: Simon de Lusignan is the Director of the Oxford RCGP RSC and has received funding through his University for studies from Eli Lilly, Astra-Zeneca, Sanofi, GSK, Seqirus and Takeda; and been member of advisory boards for influenza for Seqirus and Sanofi. F. D Richard Hobbs has received occasional fees from Bayer and Boehringer Ingelheim for speaking or consulting on atrial fibrillation related stroke risk. All other authors have declared no financial relationships with any  organisations that might have an interest in the submitted work in the previous three years, no other relationships or activities that could appear to have influenced the submitted work. This does not alter our adherence to PLOS ONE policies on sharing data and materials. There are no patents, products in development or marketed products associated with this research to declare.\n",
      "\n",
      "The authors have read the journal's policy and have the following competing interests: Simon de Lusignan is the Director of the Oxford RCGP RSC and has received funding through his University for studies from Eli Lilly, Astra-Zeneca, Sanofi, GSK, Seqirus and Takeda; and been member of advisory boards for influenza for Seqirus and Sanofi. F. D Richard Hobbs has received occasional fees from Bayer and Boehringer Ingelheim for speaking or consulting on atrial fibrillation related stroke risk. All other authors have declared no financial relationships with any  organisations that might have an interest in the submitted work in the previous three years, no other relationships or activities that could appear to have influenced the submitted work. This does not alter our adherence to PLOS ONE policies on sharing data and materials. There are no patents, products in development or marketed products associated with this research to declare.\n",
      "\n",
      "The authors have read the journal's policy and have the following competing interests: Simon de Lusignan is the Director of the Oxford RCGP RSC and has received funding through his University for studies from Eli Lilly, Astra-Zeneca, Sanofi, GSK, Seqirus and Takeda; and been member of advisory boards for influenza for Seqirus and Sanofi. F. D Richard Hobbs has received occasional fees from Bayer and Boehringer Ingelheim for speaking or consulting on atrial fibrillation related stroke risk. All other authors have declared no financial relationships with any  organisations that might have an interest in the submitted work in the previous three years, no other relationships or activities that could appear to have influenced the submitted work. This does not alter our adherence to PLOS ONE policies on sharing data and materials. There are no patents, products in development or marketed products associated with this research to declare.\n",
      "\n",
      "Storrar, Joshua\n",
      "I have read the journal's policy and the authors of this manuscript have the following competing interests. S Sinha has received grants from Johnson and Johnson and AstraZeneca; speaker and lecture fees from AstraZeneca, Napp, Bayer,  Sanofi-Genzyme, Novartis, and Vifor Pharma; is on advisory boards for Novartis, AstraZeneca, Bayer, and Travere; and has a clinical consultancy role with Sanifit. PA Kalra has received grants from Astellas, Vifor Pharma, BergenBio and  Evotec; speaker and lecture fees from AstraZeneca, Napp, Bayer, Novartis, Vifor Pharma, Pharmacosmos, Boehringer Ingelheim; is on advisory boards for AstraZeneca and Vifor Pharma; and has a consultancy role with Bayer, Astella, Otsuka and Unicyte. Joshua Storrar and RC have no conflicts of interest to report. These do not alter out adherence to PLOS ONE policies on sharing data and materials\n",
      "\n",
      "Chinnadurai, Rajkumar\n",
      "I have read the journal's policy and the authors of this manuscript have the following competing interests. S Sinha has received grants from Johnson and Johnson and AstraZeneca; speaker and lecture fees from AstraZeneca, Napp, Bayer,  Sanofi-Genzyme, Novartis, and Vifor Pharma; is on advisory boards for Novartis, AstraZeneca, Bayer, and Travere; and has a clinical consultancy role with Sanifit. PA Kalra has received grants from Astellas, Vifor Pharma, BergenBio and  Evotec; speaker and lecture fees from AstraZeneca, Napp, Bayer, Novartis, Vifor Pharma, Pharmacosmos, Boehringer Ingelheim; is on advisory boards for AstraZeneca and Vifor Pharma; and has a consultancy role with Bayer, Astella, Otsuka and Unicyte. Joshua Storrar and Rajkumar Chinnadurai have no conflicts of interest to report. These do not alter out adherence to PLOS ONE policies on sharing data and materials\n",
      "\n",
      "Sinha, Smeeta\n",
      "I have read the journal's policy and the authors of this manuscript have the following competing interests. Smeeta Sinha has received grants from Johnson and Johnson and AstraZeneca; speaker and lecture fees from AstraZeneca, Napp, Bayer,  Sanofi-Genzyme, Novartis, and Vifor Pharma; is on advisory boards for Novartis, AstraZeneca, Bayer, and Travere; and has a clinical consultancy role with Sanifit. PA Kalra has received grants from Astellas, Vifor Pharma, BergenBio and  Evotec; speaker and lecture fees from AstraZeneca, Napp, Bayer, Novartis, Vifor Pharma, Pharmacosmos, Boehringer Ingelheim; is on advisory boards for AstraZeneca and Vifor Pharma; and has a consultancy role with Bayer, Astella, Otsuka and Unicyte. Joshua Storrar and Rajkumar Chinnadurai have no conflicts of interest to report. These do not alter out adherence to PLOS ONE policies on sharing data and materials\n",
      "\n",
      "Kalra, Philip A.\n",
      "I have read the journal's policy and the authors of this manuscript have the following competing interests. Smeeta Sinha has received grants from Johnson and Johnson and AstraZeneca; speaker and lecture fees from AstraZeneca, Napp, Bayer,  Sanofi-Genzyme, Novartis, and Vifor Pharma; is on advisory boards for Novartis, AstraZeneca, Bayer, and Travere; and has a clinical consultancy role with Sanifit. PA Philip A. Kalra has received grants from Astellas, Vifor Pharma, BergenBio and  Evotec; speaker and lecture fees from AstraZeneca, Napp, Bayer, Novartis, Vifor Pharma, Pharmacosmos, Boehringer Ingelheim; is on advisory boards for AstraZeneca and Vifor Pharma; and has a consultancy role with Bayer, Astella, Otsuka and Unicyte. Joshua Storrar and Rajkumar Chinnadurai have no conflicts of interest to report. These do not alter out adherence to PLOS ONE policies on sharing data and materials\n",
      "\n",
      "All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. No potential conflicts of interest were disclosed.\n",
      "\n",
      "All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. No potential conflicts of interest were disclosed.\n",
      "\n",
      "All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. No potential conflicts of interest were disclosed.\n",
      "\n",
      "All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. No potential conflicts of interest were disclosed.\n",
      "\n",
      "All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. No potential conflicts of interest were disclosed.\n",
      "\n",
      "All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. No potential conflicts of interest were disclosed.\n",
      "\n",
      "All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. No potential conflicts of interest were disclosed.\n",
      "\n",
      "All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. No potential conflicts of interest were disclosed.\n",
      "\n",
      "All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. No potential conflicts of interest were disclosed.\n",
      "\n",
      "All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. No potential conflicts of interest were disclosed.\n",
      "\n",
      "All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. No potential conflicts of interest were disclosed.\n",
      "\n",
      "All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. No potential conflicts of interest were disclosed.\n",
      "\n",
      "All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. No potential conflicts of interest were disclosed.\n",
      "\n",
      "All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. No potential conflicts of interest were disclosed.\n",
      "\n",
      "All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. No potential conflicts of interest were disclosed.\n",
      "\n",
      "All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. No potential conflicts of interest were disclosed.\n",
      "\n",
      "All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. No potential conflicts of interest were disclosed.\n",
      "\n",
      "All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. No potential conflicts of interest were disclosed.\n",
      "\n",
      "All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. No potential conflicts of interest were disclosed.\n",
      "\n",
      "All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. No potential conflicts of interest were disclosed.\n",
      "\n",
      "All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. Manjusha  Gaglani reports being co-chair of the Infectious Diseases and Immunization Committee, Texas Pediatric Society and support from Janssen for a respiratory syncytial virus birth cohort observational study. No other potential conflicts of interest were disclosed.\n",
      "\n",
      "All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. Manjusha  Gaglani reports being co-chair of the Infectious Diseases and Immunization Committee, Texas Pediatric Society and support from Janssen for a respiratory syncytial virus birth cohort observational study. No other potential conflicts of interest were disclosed.\n",
      "\n",
      "All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. Manjusha  Gaglani reports being co-chair of the Infectious Diseases and Immunization Committee, Texas Pediatric Society and support from Janssen for a respiratory syncytial virus birth cohort observational study. No other potential conflicts of interest were disclosed.\n",
      "\n",
      "All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. Manjusha  Gaglani reports being co-chair of the Infectious Diseases and Immunization Committee, Texas Pediatric Society and support from Janssen for a respiratory syncytial virus birth cohort observational study. No other potential conflicts of interest were disclosed.\n",
      "\n",
      "All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. Manjusha  Gaglani reports being co-chair of the Infectious Diseases and Immunization Committee, Texas Pediatric Society and support from Janssen for a respiratory syncytial virus birth cohort observational study. No other potential conflicts of interest were disclosed.\n",
      "\n",
      "All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. Manjusha  Gaglani reports being co-chair of the Infectious Diseases and Immunization Committee, Texas Pediatric Society and support from Janssen for a respiratory syncytial virus birth cohort observational study. No other potential conflicts of interest were disclosed.\n",
      "\n",
      "All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. Manjusha  Gaglani reports being co-chair of the Infectious Diseases and Immunization Committee, Texas Pediatric Society and support from Janssen for a respiratory syncytial virus birth cohort observational study. No other potential conflicts of interest were disclosed.\n",
      "\n",
      "All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. Manjusha  Gaglani reports being co-chair of the Infectious Diseases and Immunization Committee, Texas Pediatric Society and support from Janssen for a respiratory syncytial virus birth cohort observational study. No other potential conflicts of interest were disclosed.\n",
      "\n",
      "All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. Manjusha  Gaglani reports being co-chair of the Infectious Diseases and Immunization Committee, Texas Pediatric Society and support from Janssen for a respiratory syncytial virus birth cohort observational study. No other potential conflicts of interest were disclosed.\n",
      "\n",
      "All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. Manjusha  Gaglani reports being co-chair of the Infectious Diseases and Immunization Committee, Texas Pediatric Society and support from Janssen for a respiratory syncytial virus birth cohort observational study. No other potential conflicts of interest were disclosed.\n",
      "\n",
      "All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. Manjusha  Gaglani reports being co-chair of the Infectious Diseases and Immunization Committee, Texas Pediatric Society and support from Janssen for a respiratory syncytial virus birth cohort observational study. No other potential conflicts of interest were disclosed.\n",
      "\n",
      "All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. Manjusha  Gaglani reports being co-chair of the Infectious Diseases and Immunization Committee, Texas Pediatric Society and support from Janssen for a respiratory syncytial virus birth cohort observational study. No other potential conflicts of interest were disclosed.\n",
      "\n",
      "All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. Manjusha  Gaglani reports being co-chair of the Infectious Diseases and Immunization Committee, Texas Pediatric Society and support from Janssen for a respiratory syncytial virus birth cohort observational study. No other potential conflicts of interest were disclosed.\n",
      "\n",
      "All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. Manjusha  Gaglani reports being co-chair of the Infectious Diseases and Immunization Committee, Texas Pediatric Society and support from Janssen for a respiratory syncytial virus birth cohort observational study. No other potential conflicts of interest were disclosed.\n",
      "\n",
      "All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. Manjusha  Gaglani reports being co-chair of the Infectious Diseases and Immunization Committee, Texas Pediatric Society and support from Janssen for a respiratory syncytial virus birth cohort observational study. No other potential conflicts of interest were disclosed.\n",
      "\n",
      "All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. Manjusha  Gaglani reports being co-chair of the Infectious Diseases and Immunization Committee, Texas Pediatric Society and support from Janssen for a respiratory syncytial virus birth cohort observational study. No other potential conflicts of interest were disclosed.\n",
      "\n",
      "All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. Manjusha  Gaglani reports being co-chair of the Infectious Diseases and Immunization Committee, Texas Pediatric Society and support from Janssen for a respiratory syncytial virus birth cohort observational study. No other potential conflicts of interest were disclosed.\n",
      "\n",
      "All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. Manjusha  Gaglani reports being co-chair of the Infectious Diseases and Immunization Committee, Texas Pediatric Society and support from Janssen for a respiratory syncytial virus birth cohort observational study. No other potential conflicts of interest were disclosed.\n",
      "\n",
      "All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. Manjusha  Gaglani reports being co-chair of the Infectious Diseases and Immunization Committee, Texas Pediatric Society and support from Janssen for a respiratory syncytial virus birth cohort observational study. No other potential conflicts of interest were disclosed.\n",
      "\n",
      "All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. Manjusha  Gaglani reports being co-chair of the Infectious Diseases and Immunization Committee, Texas Pediatric Society and support from Janssen for a respiratory syncytial virus birth cohort observational study. No other potential conflicts of interest were disclosed.\n",
      "\n",
      "All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. Manjusha  Gaglani reports being co-chair of the Infectious Diseases and Immunization Committee, Texas Pediatric Society and support from Janssen for a respiratory syncytial virus birth cohort observational study. No other potential conflicts of interest were disclosed.\n",
      "\n",
      "All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. Manjusha  Gaglani reports being co-chair of the Infectious Diseases and Immunization Committee, Texas Pediatric Society and support from Janssen for a respiratory syncytial virus birth cohort observational study. No other potential conflicts of interest were disclosed.\n",
      "\n",
      "All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. Manjusha  Gaglani reports being co-chair of the Infectious Diseases and Immunization Committee, Texas Pediatric Society and support from Janssen for a respiratory syncytial virus birth cohort observational study. No other potential conflicts of interest were disclosed.\n",
      "\n",
      "All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. Manjusha  Gaglani reports being co-chair of the Infectious Diseases and Immunization Committee, Texas Pediatric Society and support from Janssen for a respiratory syncytial virus birth cohort observational study. No other potential conflicts of interest were disclosed.\n",
      "\n",
      "All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. Manjusha  Gaglani reports being co-chair of the Infectious Diseases and Immunization Committee, Texas Pediatric Society and support from Janssen for a respiratory syncytial virus birth cohort observational study. No other potential conflicts of interest were disclosed.\n",
      "\n",
      "All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. Manjusha  Gaglani reports being co-chair of the Infectious Diseases and Immunization Committee, Texas Pediatric Society and support from Janssen for a respiratory syncytial virus birth cohort observational study. No other potential conflicts of interest were disclosed.\n",
      "\n",
      "All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. Manjusha  Gaglani reports being co-chair of the Infectious Diseases and Immunization Committee, Texas Pediatric Society and support from Janssen for a respiratory syncytial virus birth cohort observational study. No other potential conflicts of interest were disclosed.\n",
      "\n",
      "All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. Manjusha  Gaglani reports being co-chair of the Infectious Diseases and Immunization Committee, Texas Pediatric Society and support from Janssen for a respiratory syncytial virus birth cohort observational study. No other potential conflicts of interest were disclosed.\n",
      "\n",
      "All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. Manjusha  Gaglani reports being co-chair of the Infectious Diseases and Immunization Committee, Texas Pediatric Society and support from Janssen for a respiratory syncytial virus birth cohort observational study. No other potential conflicts of interest were disclosed.\n",
      "\n",
      "All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. Manjusha  Gaglani reports being co-chair of the Infectious Diseases and Immunization Committee, Texas Pediatric Society and support from Janssen for a respiratory syncytial virus birth cohort observational study. No other potential conflicts of interest were disclosed.\n",
      "\n",
      "All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. Manjusha  Gaglani reports being co-chair of the Infectious Diseases and Immunization Committee, Texas Pediatric Society and support from Janssen for a respiratory syncytial virus birth cohort observational study. No other potential conflicts of interest were disclosed.\n",
      "\n",
      "Gaglani, Manjusha\n",
      "All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. Manjusha  Manjusha Gaglani reports being co-chair of the Infectious Diseases and Immunization Committee, Texas Pediatric Society and support from Janssen for a respiratory syncytial virus birth cohort observational study. No other potential conflicts of interest were disclosed.\n",
      "\n",
      "All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. Manjusha  Manjusha Gaglani reports being co-chair of the Infectious Diseases and Immunization Committee, Texas Pediatric Society and support from Janssen for a respiratory syncytial virus birth cohort observational study. No other potential conflicts of interest were disclosed.\n",
      "\n",
      "All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. Manjusha  Manjusha Gaglani reports being co-chair of the Infectious Diseases and Immunization Committee, Texas Pediatric Society and support from Janssen for a respiratory syncytial virus birth cohort observational study. No other potential conflicts of interest were disclosed.\n",
      "\n",
      "All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. Manjusha  Manjusha Gaglani reports being co-chair of the Infectious Diseases and Immunization Committee, Texas Pediatric Society and support from Janssen for a respiratory syncytial virus birth cohort observational study. No other potential conflicts of interest were disclosed.\n",
      "\n",
      "All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. No potential conflicts of interest were disclosed.\n",
      "\n",
      "All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. No potential conflicts of interest were disclosed.\n",
      "\n",
      "All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. No potential conflicts of interest were disclosed.\n",
      "\n",
      "Zhang, Shengnan\n",
      "Shengnan Zhang, YZ, JL, ZL, AL, WZ, JL, JQ, Shengnan Zhang, YZ, CL, JL, ZH, RZ, DL No competing interests declared\n",
      "\n",
      "Zhu, Yi\n",
      "Shengnan Zhang, Yi Zhu, JL, ZL, AL, WZ, JL, JQ, Shengnan Zhang, Yi Zhu, CL, JL, ZH, RZ, DL No competing interests declared\n",
      "\n",
      "Lu, Jinxia\n",
      "Shengnan Zhang, Yi Zhu, Jinxia Lu, ZL, AL, WZ, Jinxia Lu, JQ, Shengnan Zhang, Yi Zhu, CL, Jinxia Lu, ZH, RZ, DL No competing interests declared\n",
      "\n",
      "Liu, Zhenying\n",
      "Shengnan Zhang, Yi Zhu, Jinxia Lu, Zhenying Liu, AL, WZ, Jinxia Lu, JQ, Shengnan Zhang, Yi Zhu, CL, Jinxia Lu, ZH, RZ, DL No competing interests declared\n",
      "\n",
      "Lobato, Amanda G.\n",
      "Shengnan Zhang, Yi Zhu, Jinxia Lu, Zhenying Liu, Amanda G. Lobato, WZ, Jinxia Lu, JQ, Shengnan Zhang, Yi Zhu, CL, Jinxia Lu, ZH, RZ, DL No competing interests declared\n",
      "\n",
      "Zeng, Wen\n",
      "Shengnan Zhang, Yi Zhu, Jinxia Lu, Zhenying Liu, Amanda G. Lobato, Wen Zeng, Jinxia Lu, JQ, Shengnan Zhang, Yi Zhu, CL, Jinxia Lu, ZH, RZ, DL No competing interests declared\n",
      "\n",
      "Liu, Jiaqi\n",
      "Shengnan Zhang, Yi Zhu, Jinxia Lu, Zhenying Jiaqi Liu, Amanda G. Lobato, Wen Zeng, Jinxia Lu, JQ, Shengnan Zhang, Yi Zhu, CL, Jinxia Lu, ZH, RZ, DL No competing interests declared\n",
      "\n",
      "Qiang, Jiali\n",
      "Shengnan Zhang, Yi Zhu, Jinxia Lu, Zhenying Jiaqi Liu, Amanda G. Lobato, Wen Zeng, Jinxia Lu, Jiali Qiang, Shengnan Zhang, Yi Zhu, CL, Jinxia Lu, ZH, RZ, DL No competing interests declared\n",
      "\n",
      "Zeng, Shuyi\n",
      "Shengnan Zhang, Yi Zhu, Jinxia Lu, Zhenying Jiaqi Liu, Amanda G. Lobato, Wen Shuyi Zeng, Jinxia Lu, Jiali Qiang, Shengnan Zhang, Yi Zhu, CL, Jinxia Lu, ZH, RZ, DL No competing interests declared\n",
      "\n",
      "Zhang, Yaoyang\n",
      "Shengnan Yaoyang Zhang, Yi Zhu, Jinxia Lu, Zhenying Jiaqi Liu, Amanda G. Lobato, Wen Shuyi Zeng, Jinxia Lu, Jiali Qiang, Shengnan Yaoyang Zhang, Yi Zhu, CL, Jinxia Lu, ZH, RZ, DL No competing interests declared\n",
      "\n",
      "Liu, Cong\n",
      "Shengnan Yaoyang Zhang, Yi Zhu, Jinxia Lu, Zhenying Jiaqi Cong Liu, Amanda G. Lobato, Wen Shuyi Zeng, Jinxia Lu, Jiali Qiang, Shengnan Yaoyang Zhang, Yi Zhu, CL, Jinxia Lu, ZH, RZ, DL No competing interests declared\n",
      "\n",
      "Liu, Jun\n",
      "Shengnan Yaoyang Zhang, Yi Zhu, Jinxia Lu, Zhenying Jiaqi Cong Jun Liu, Amanda G. Lobato, Wen Shuyi Zeng, Jinxia Lu, Jiali Qiang, Shengnan Yaoyang Zhang, Yi Zhu, CL, Jinxia Lu, ZH, RZ, DL No competing interests declared\n",
      "\n",
      "He, Zhuohao\n",
      "Shengnan Yaoyang Zhang, Yi Zhu, Jinxia Lu, Zhenying Jiaqi Cong Jun Liu, Amanda G. Lobato, Wen Shuyi Zeng, Jinxia Lu, Jiali Qiang, Shengnan Yaoyang Zhang, Yi Zhu, CL, Jinxia Lu, Zhuohao He, RZ, DL No competing interests declared\n",
      "\n",
      "Grace Zhai, R.\n",
      "Shengnan Yaoyang Zhang, Yi Zhu, Jinxia Lu, Zhenying Jiaqi Cong Jun Liu, Amanda G. Lobato, Wen Shuyi Zeng, Jinxia Lu, Jiali Qiang, Shengnan Yaoyang Zhang, Yi Zhu, CL, Jinxia Lu, Zhuohao He, R. Grace Zhai, DL No competing interests declared\n",
      "\n",
      "Li, Dan\n",
      "Shengnan Yaoyang Zhang, Yi Zhu, Jinxia Lu, Zhenying Jiaqi Cong Jun Liu, Amanda G. Lobato, Wen Shuyi Zeng, Jinxia Lu, Jiali Qiang, Shengnan Yaoyang Zhang, Yi Zhu, CL, Jinxia Lu, Zhuohao He, R. Grace Zhai, Dan Li No competing interests declared\n",
      "\n",
      "All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. No potential conflicts of interest were disclosed.\n",
      "\n",
      "All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. No potential conflicts of interest were disclosed.\n",
      "\n",
      "All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. No potential conflicts of interest were disclosed.\n",
      "\n",
      "All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. No potential conflicts of interest were disclosed.\n",
      "\n",
      "All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. No potential conflicts of interest were disclosed.\n",
      "\n",
      "All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. No potential conflicts of interest were disclosed.\n",
      "\n",
      "All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. No potential conflicts of interest were disclosed.\n",
      "\n",
      "All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. No potential conflicts of interest were disclosed.\n",
      "\n",
      "All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. No potential conflicts of interest were disclosed.\n",
      "\n",
      "All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. No potential conflicts of interest were disclosed.\n",
      "\n",
      "All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. Travis Sanchez reports institutional support from the National Institutes of Health (NIH) that partly fund the American Men's Interview Survey, though not specifically the monkeypox survey, and honoraria for serving as Editor in Chief of JMIR Public Health and Surveillance. Christine Agnew-Brune received support for attending the Harm Reduction Conference, through a speaker discount. Thomas Carpino reports institutional support from the NIH, National Institute of Nursing Research (NINR) and the National Institute of Mental Health (NIMH), a predoctoral NIH T32 Grant on HIV Prevention and Implementation Science, and an unpaid position as co-president of the Epidemiological Student Organization at Johns Hopkins University. Patrick Sullivan reports institutional support from Gilead Sciences, Viiv, and Merck, and personal payments from Gilead Sciences and Merck.  O. Winslow Edwards reports NIH support for the present manuscript. Stefan Baral reports NIH support from NINR and NIMH; travel support to a meeting focused on HIV among gay men internationally from the Global Fund for AIDS, Tuberculosis, and Malaria, and support for participation on an NIH Data Safety Monitoring Board for a study focused on younger gay men and suicidality. No other potential conflicts of interest were disclosed.\n",
      "\n",
      "Sanchez, Travis\n",
      "All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. Travis Sanchez reports institutional support from the National Institutes of Health (NIH) that partly fund the American Men's Interview Survey, though not specifically the monkeypox survey, and honoraria for serving as Editor in Chief of JMIR Public Health and Surveillance. Christine Agnew-Brune received support for attending the Harm Reduction Conference, through a speaker discount. Thomas Carpino reports institutional support from the NIH, National Institute of Nursing Research (NINR) and the National Institute of Mental Health (NIMH), a predoctoral NIH T32 Grant on HIV Prevention and Implementation Science, and an unpaid position as co-president of the Epidemiological Student Organization at Johns Hopkins University. Patrick Sullivan reports institutional support from Gilead Sciences, Viiv, and Merck, and personal payments from Gilead Sciences and Merck.  O. Winslow Edwards reports NIH support for the present manuscript. Stefan Baral reports NIH support from NINR and NIMH; travel support to a meeting focused on HIV among gay men internationally from the Global Fund for AIDS, Tuberculosis, and Malaria, and support for participation on an NIH Data Safety Monitoring Board for a study focused on younger gay men and suicidality. No other potential conflicts of interest were disclosed.\n",
      "\n",
      "Hannah, Marissa\n",
      "All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. Travis Sanchez reports institutional support from the National Institutes of Health (NIH) that partly fund the American Men's Interview Survey, though not specifically the monkeypox survey, and honoraria for serving as Editor in Chief of JMIR Public Health and Surveillance. Christine Agnew-Brune received support for attending the Harm Reduction Conference, through a speaker discount. Thomas Carpino reports institutional support from the NIH, National Institute of Nursing Research (NINR) and the National Institute of Mental Health (NIMarissa Hannah), a predoctoral NIH T32 Grant on HIV Prevention and Implementation Science, and an unpaid position as co-president of the Epidemiological Student Organization at Johns Hopkins University. Patrick Sullivan reports institutional support from Gilead Sciences, Viiv, and Merck, and personal payments from Gilead Sciences and Merck.  O. Winslow Edwards reports NIH support for the present manuscript. Stefan Baral reports NIH support from NINR and NIMarissa Hannah; travel support to a meeting focused on HIV among gay men internationally from the Global Fund for AIDS, Tuberculosis, and Malaria, and support for participation on an NIH Data Safety Monitoring Board for a study focused on younger gay men and suicidality. No other potential conflicts of interest were disclosed.\n",
      "\n",
      "Winslow Edwards, O.\n",
      "All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. Travis Sanchez reports institutional support from the National Institutes of Health (NIH) that partly fund the American Men's Interview Survey, though not specifically the monkeypox survey, and honoraria for serving as Editor in Chief of JMIR Public Health and Surveillance. Christine Agnew-Brune received support for attending the Harm Reduction Conference, through a speaker discount. Thomas Carpino reports institutional support from the NIH, National Institute of Nursing Research (NINR) and the National Institute of Mental Health (NIMarissa Hannah), a predoctoral NIH T32 Grant on HIV Prevention and Implementation Science, and an unpaid position as co-president of the Epidemiological Student Organization at Johns Hopkins University. Patrick Sullivan reports institutional support from Gilead Sciences, Viiv, and Merck, and personal payments from Gilead Sciences and Merck.  O. Winslow O. Winslow Edwards reports NIH support for the present manuscript. Stefan Baral reports NIH support from NINR and NIMarissa Hannah; travel support to a meeting focused on HIV among gay men internationally from the Global Fund for AIDS, Tuberculosis, and Malaria, and support for participation on an NIH Data Safety Monitoring Board for a study focused on younger gay men and suicidality. No other potential conflicts of interest were disclosed.\n",
      "\n",
      "Carpino, Thomas\n",
      "All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. Travis Sanchez reports institutional support from the National Institutes of Health (NIH) that partly fund the American Men's Interview Survey, though not specifically the monkeypox survey, and honoraria for serving as Editor in Chief of JMIR Public Health and Surveillance. Christine Agnew-Brune received support for attending the Harm Reduction Conference, through a speaker discount. Thomas Carpino reports institutional support from the NIH, National Institute of Nursing Research (NINR) and the National Institute of Mental Health (NIMarissa Hannah), a predoctoral NIH T32 Grant on HIV Prevention and Implementation Science, and an unpaid position as co-president of the Epidemiological Student Organization at Johns Hopkins University. Patrick Sullivan reports institutional support from Gilead Sciences, Viiv, and Merck, and personal payments from Gilead Sciences and Merck.  O. Winslow O. Winslow Edwards reports NIH support for the present manuscript. Stefan Baral reports NIH support from NINR and NIMarissa Hannah; travel support to a meeting focused on HIV among gay men internationally from the Global Fund for AIDS, Tuberculosis, and Malaria, and support for participation on an NIH Data Safety Monitoring Board for a study focused on younger gay men and suicidality. No other potential conflicts of interest were disclosed.\n",
      "\n",
      "Agnew-Brune, Christine\n",
      "All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. Travis Sanchez reports institutional support from the National Institutes of Health (NIH) that partly fund the American Men's Interview Survey, though not specifically the monkeypox survey, and honoraria for serving as Editor in Chief of JMIR Public Health and Surveillance. Christine Agnew-Brune received support for attending the Harm Reduction Conference, through a speaker discount. Thomas Carpino reports institutional support from the NIH, National Institute of Nursing Research (NINR) and the National Institute of Mental Health (NIMarissa Hannah), a predoctoral NIH T32 Grant on HIV Prevention and Implementation Science, and an unpaid position as co-president of the Epidemiological Student Organization at Johns Hopkins University. Patrick Sullivan reports institutional support from Gilead Sciences, Viiv, and Merck, and personal payments from Gilead Sciences and Merck.  O. Winslow O. Winslow Edwards reports NIH support for the present manuscript. Stefan Baral reports NIH support from NINR and NIMarissa Hannah; travel support to a meeting focused on HIV among gay men internationally from the Global Fund for AIDS, Tuberculosis, and Malaria, and support for participation on an NIH Data Safety Monitoring Board for a study focused on younger gay men and suicidality. No other potential conflicts of interest were disclosed.\n",
      "\n",
      "All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. Travis Sanchez reports institutional support from the National Institutes of Health (NIH) that partly fund the American Men's Interview Survey, though not specifically the monkeypox survey, and honoraria for serving as Editor in Chief of JMIR Public Health and Surveillance. Christine Agnew-Brune received support for attending the Harm Reduction Conference, through a speaker discount. Thomas Carpino reports institutional support from the NIH, National Institute of Nursing Research (NINR) and the National Institute of Mental Health (NIMarissa Hannah), a predoctoral NIH T32 Grant on HIV Prevention and Implementation Science, and an unpaid position as co-president of the Epidemiological Student Organization at Johns Hopkins University. Patrick Sullivan reports institutional support from Gilead Sciences, Viiv, and Merck, and personal payments from Gilead Sciences and Merck.  O. Winslow O. Winslow Edwards reports NIH support for the present manuscript. Stefan Baral reports NIH support from NINR and NIMarissa Hannah; travel support to a meeting focused on HIV among gay men internationally from the Global Fund for AIDS, Tuberculosis, and Malaria, and support for participation on an NIH Data Safety Monitoring Board for a study focused on younger gay men and suicidality. No other potential conflicts of interest were disclosed.\n",
      "\n",
      "All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. Travis Sanchez reports institutional support from the National Institutes of Health (NIH) that partly fund the American Men's Interview Survey, though not specifically the monkeypox survey, and honoraria for serving as Editor in Chief of JMIR Public Health and Surveillance. Christine Agnew-Brune received support for attending the Harm Reduction Conference, through a speaker discount. Thomas Carpino reports institutional support from the NIH, National Institute of Nursing Research (NINR) and the National Institute of Mental Health (NIMarissa Hannah), a predoctoral NIH T32 Grant on HIV Prevention and Implementation Science, and an unpaid position as co-president of the Epidemiological Student Organization at Johns Hopkins University. Patrick Sullivan reports institutional support from Gilead Sciences, Viiv, and Merck, and personal payments from Gilead Sciences and Merck.  O. Winslow O. Winslow Edwards reports NIH support for the present manuscript. Stefan Baral reports NIH support from NINR and NIMarissa Hannah; travel support to a meeting focused on HIV among gay men internationally from the Global Fund for AIDS, Tuberculosis, and Malaria, and support for participation on an NIH Data Safety Monitoring Board for a study focused on younger gay men and suicidality. No other potential conflicts of interest were disclosed.\n",
      "\n",
      "All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. Travis Sanchez reports institutional support from the National Institutes of Health (NIH) that partly fund the American Men's Interview Survey, though not specifically the monkeypox survey, and honoraria for serving as Editor in Chief of JMIR Public Health and Surveillance. Christine Agnew-Brune received support for attending the Harm Reduction Conference, through a speaker discount. Thomas Carpino reports institutional support from the NIH, National Institute of Nursing Research (NINR) and the National Institute of Mental Health (NIMarissa Hannah), a predoctoral NIH T32 Grant on HIV Prevention and Implementation Science, and an unpaid position as co-president of the Epidemiological Student Organization at Johns Hopkins University. Patrick Sullivan reports institutional support from Gilead Sciences, Viiv, and Merck, and personal payments from Gilead Sciences and Merck.  O. Winslow O. Winslow Edwards reports NIH support for the present manuscript. Stefan Baral reports NIH support from NINR and NIMarissa Hannah; travel support to a meeting focused on HIV among gay men internationally from the Global Fund for AIDS, Tuberculosis, and Malaria, and support for participation on an NIH Data Safety Monitoring Board for a study focused on younger gay men and suicidality. No other potential conflicts of interest were disclosed.\n",
      "\n",
      "All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. Travis Sanchez reports institutional support from the National Institutes of Health (NIH) that partly fund the American Men's Interview Survey, though not specifically the monkeypox survey, and honoraria for serving as Editor in Chief of JMIR Public Health and Surveillance. Christine Agnew-Brune received support for attending the Harm Reduction Conference, through a speaker discount. Thomas Carpino reports institutional support from the NIH, National Institute of Nursing Research (NINR) and the National Institute of Mental Health (NIMarissa Hannah), a predoctoral NIH T32 Grant on HIV Prevention and Implementation Science, and an unpaid position as co-president of the Epidemiological Student Organization at Johns Hopkins University. Patrick Sullivan reports institutional support from Gilead Sciences, Viiv, and Merck, and personal payments from Gilead Sciences and Merck.  O. Winslow O. Winslow Edwards reports NIH support for the present manuscript. Stefan Baral reports NIH support from NINR and NIMarissa Hannah; travel support to a meeting focused on HIV among gay men internationally from the Global Fund for AIDS, Tuberculosis, and Malaria, and support for participation on an NIH Data Safety Monitoring Board for a study focused on younger gay men and suicidality. No other potential conflicts of interest were disclosed.\n",
      "\n",
      "All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. Travis Sanchez reports institutional support from the National Institutes of Health (NIH) that partly fund the American Men's Interview Survey, though not specifically the monkeypox survey, and honoraria for serving as Editor in Chief of JMIR Public Health and Surveillance. Christine Agnew-Brune received support for attending the Harm Reduction Conference, through a speaker discount. Thomas Carpino reports institutional support from the NIH, National Institute of Nursing Research (NINR) and the National Institute of Mental Health (NIMarissa Hannah), a predoctoral NIH T32 Grant on HIV Prevention and Implementation Science, and an unpaid position as co-president of the Epidemiological Student Organization at Johns Hopkins University. Patrick Sullivan reports institutional support from Gilead Sciences, Viiv, and Merck, and personal payments from Gilead Sciences and Merck.  O. Winslow O. Winslow Edwards reports NIH support for the present manuscript. Stefan Baral reports NIH support from NINR and NIMarissa Hannah; travel support to a meeting focused on HIV among gay men internationally from the Global Fund for AIDS, Tuberculosis, and Malaria, and support for participation on an NIH Data Safety Monitoring Board for a study focused on younger gay men and suicidality. No other potential conflicts of interest were disclosed.\n",
      "\n",
      "All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. Travis Sanchez reports institutional support from the National Institutes of Health (NIH) that partly fund the American Men's Interview Survey, though not specifically the monkeypox survey, and honoraria for serving as Editor in Chief of JMIR Public Health and Surveillance. Christine Agnew-Brune received support for attending the Harm Reduction Conference, through a speaker discount. Thomas Carpino reports institutional support from the NIH, National Institute of Nursing Research (NINR) and the National Institute of Mental Health (NIMarissa Hannah), a predoctoral NIH T32 Grant on HIV Prevention and Implementation Science, and an unpaid position as co-president of the Epidemiological Student Organization at Johns Hopkins University. Patrick Sullivan reports institutional support from Gilead Sciences, Viiv, and Merck, and personal payments from Gilead Sciences and Merck.  O. Winslow O. Winslow Edwards reports NIH support for the present manuscript. Stefan Baral reports NIH support from NINR and NIMarissa Hannah; travel support to a meeting focused on HIV among gay men internationally from the Global Fund for AIDS, Tuberculosis, and Malaria, and support for participation on an NIH Data Safety Monitoring Board for a study focused on younger gay men and suicidality. No other potential conflicts of interest were disclosed.\n",
      "\n",
      "Sullivan, Patrick\n",
      "All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. Travis Sanchez reports institutional support from the National Institutes of Health (NIH) that partly fund the American Men's Interview Survey, though not specifically the monkeypox survey, and honoraria for serving as Editor in Chief of JMIR Public Health and Surveillance. Christine Agnew-Brune received support for attending the Harm Reduction Conference, through a speaker discount. Thomas Carpino reports institutional support from the NIH, National Institute of Nursing Research (NINR) and the National Institute of Mental Health (NIMarissa Hannah), a predoctoral NIH T32 Grant on HIV Prevention and Implementation Science, and an unpaid position as co-president of the Epidemiological Student Organization at Johns Hopkins University. Patrick Sullivan reports institutional support from Gilead Sciences, Viiv, and Merck, and personal payments from Gilead Sciences and Merck.  O. Winslow O. Winslow Edwards reports NIH support for the present manuscript. Stefan Baral reports NIH support from NINR and NIMarissa Hannah; travel support to a meeting focused on HIV among gay men internationally from the Global Fund for AIDS, Tuberculosis, and Malaria, and support for participation on an NIH Data Safety Monitoring Board for a study focused on younger gay men and suicidality. No other potential conflicts of interest were disclosed.\n",
      "\n",
      "Baral, Stefan\n",
      "All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. Travis Sanchez reports institutional support from the National Institutes of Health (NIH) that partly fund the American Men's Interview Survey, though not specifically the monkeypox survey, and honoraria for serving as Editor in Chief of JMIR Public Health and Surveillance. Christine Agnew-Brune received support for attending the Harm Reduction Conference, through a speaker discount. Thomas Carpino reports institutional support from the NIH, National Institute of Nursing Research (NINR) and the National Institute of Mental Health (NIMarissa Hannah), a predoctoral NIH T32 Grant on HIV Prevention and Implementation Science, and an unpaid position as co-president of the Epidemiological Student Organization at Johns Hopkins University. Patrick Sullivan reports institutional support from Gilead Sciences, Viiv, and Merck, and personal payments from Gilead Sciences and Merck.  O. Winslow O. Winslow Edwards reports NIH support for the present manuscript. Stefan Baral reports NIH support from NINR and NIMarissa Hannah; travel support to a meeting focused on HIV among gay men internationally from the Global Fund for AIDS, Tuberculosis, and Malaria, and support for participation on an NIH Data Safety Monitoring Board for a study focused on younger gay men and suicidality. No other potential conflicts of interest were disclosed.\n",
      "\n",
      "All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. Travis Sanchez reports institutional support from the National Institutes of Health (NIH) that partly fund the American Men's Interview Survey, though not specifically the monkeypox survey, and honoraria for serving as Editor in Chief of JMIR Public Health and Surveillance. Christine Agnew-Brune received support for attending the Harm Reduction Conference, through a speaker discount. Thomas Carpino reports institutional support from the NIH, National Institute of Nursing Research (NINR) and the National Institute of Mental Health (NIMarissa Hannah), a predoctoral NIH T32 Grant on HIV Prevention and Implementation Science, and an unpaid position as co-president of the Epidemiological Student Organization at Johns Hopkins University. Patrick Sullivan reports institutional support from Gilead Sciences, Viiv, and Merck, and personal payments from Gilead Sciences and Merck.  O. Winslow O. Winslow Edwards reports NIH support for the present manuscript. Stefan Baral reports NIH support from NINR and NIMarissa Hannah; travel support to a meeting focused on HIV among gay men internationally from the Global Fund for AIDS, Tuberculosis, and Malaria, and support for participation on an NIH Data Safety Monitoring Board for a study focused on younger gay men and suicidality. No other potential conflicts of interest were disclosed.\n",
      "\n",
      "Manu, Peter\n",
      "Peter Manu has contributed a chapter to each of the last 4 editions of Cecil Medicine (2008, 2012, 2016, and 2020). The remaining authors have no conflicts of interest to declare.\n",
      "\n",
      "Peter Manu has contributed a chapter to each of the last 4 editions of Cecil Medicine (2008, 2012, 2016, and 2020). The remaining authors have no conflicts of interest to declare.\n",
      "\n",
      "Peter Manu has contributed a chapter to each of the last 4 editions of Cecil Medicine (2008, 2012, 2016, and 2020). The remaining authors have no conflicts of interest to declare.\n",
      "\n",
      "Lawrence, Sally\n",
      "Disclosure of financial conflict of interest: Sally Lawrence: Advisory boards, Speaker's bureau: AbbVie, Takeda. VG: Speaker's fees: Ferring. Conference fees: AbbVie. LC: Conference fees: Ferring, Tillots. Accommodation and travel fees: Ferring. LG Consultancy fees: Lilly. KJ: Research grant: Janssen, AbbVie, adMare Bioinnovations. Advisory boards: Janssen, AbbVie, Merck, Mylan Inc. Speaker's bureau: Abbvie. RKR: speaker's fees, travel support, advisory boards: Nestle, AbbVie, Dr Falk, Takeda, Napp, Mead Johnson, Nutricia,. FF, MI, EC, GS, BC, RT, RH, MR: No conflict of interest.\n",
      "\n",
      "Faytrouni, Farah\n",
      "Disclosure of financial conflict of interest: Sally Lawrence: Advisory boards, Speaker's bureau: AbbVie, Takeda. VG: Speaker's fees: Ferring. Conference fees: AbbVie. LC: Conference fees: Ferring, Tillots. Accommodation and travel fees: Ferring. LG Consultancy fees: Lilly. KJ: Research grant: Janssen, AbbVie, adMare Bioinnovations. Advisory boards: Janssen, AbbVie, Merck, Mylan Inc. Speaker's bureau: Abbvie. RKR: speaker's fees, travel support, advisory boards: Nestle, AbbVie, Dr Falk, Takeda, Napp, Mead Johnson, Nutricia,. Farah Faytrouni, MI, EC, GS, BC, RT, RH, MR: No conflict of interest.\n",
      "\n",
      "Harris, Rachel E.\n",
      "Disclosure of financial conflict of interest: Sally Lawrence: Advisory boards, Speaker's bureau: AbbVie, Takeda. VG: Speaker's fees: Ferring. Conference fees: AbbVie. LC: Conference fees: Ferring, Tillots. Accommodation and travel fees: Ferring. LG Consultancy fees: Lilly. KJ: Research grant: Janssen, AbbVie, adMare Bioinnovations. Advisory boards: Janssen, AbbVie, Merck, Mylan Inc. Speaker's bureau: Abbvie. RKR: speaker's fees, travel support, advisory boards: Nestle, AbbVie, Dr Falk, Takeda, Napp, Mead Johnson, Nutricia,. Farah Faytrouni, MI, EC, GS, BC, RT, Rachel E. Harris, MR: No conflict of interest.\n",
      "\n",
      "Irvine, Mike\n",
      "Disclosure of financial conflict of interest: Sally Lawrence: Advisory boards, Speaker's bureau: AbbVie, Takeda. VG: Speaker's fees: Ferring. Conference fees: AbbVie. LC: Conference fees: Ferring, Tillots. Accommodation and travel fees: Ferring. LG Consultancy fees: Lilly. KJ: Research grant: Janssen, AbbVie, adMare Bioinnovations. Advisory boards: Janssen, AbbVie, Merck, Mylan Inc. Speaker's bureau: Abbvie. RKR: speaker's fees, travel support, advisory boards: Nestle, AbbVie, Dr Falk, Takeda, Napp, Mead Johnson, Nutricia,. Farah Faytrouni, Mike Irvine, EC, GS, BC, RT, Rachel E. Harris, MR: No conflict of interest.\n",
      "\n",
      "Carrion, Estefania\n",
      "Disclosure of financial conflict of interest: Sally Lawrence: Advisory boards, Speaker's bureau: AbbVie, Takeda. VG: Speaker's fees: Ferring. Conference fees: AbbVie. LC: Conference fees: Ferring, Tillots. Accommodation and travel fees: Ferring. LG Consultancy fees: Lilly. KJ: Research grant: Janssen, AbbVie, adMare Bioinnovations. Advisory boards: Janssen, AbbVie, Merck, Mylan Inc. Speaker's bureau: Abbvie. RKR: speaker's fees, travel support, advisory boards: Nestle, AbbVie, Dr Falk, Takeda, Napp, Mead Johnson, Nutricia,. Farah Faytrouni, Mike Irvine, Estefania Carrion, GS, BC, RT, Rachel E. Harris, MR: No conflict of interest.\n",
      "\n",
      "Scott, Gregor\n",
      "Disclosure of financial conflict of interest: Sally Lawrence: Advisory boards, Speaker's bureau: AbbVie, Takeda. VG: Speaker's fees: Ferring. Conference fees: AbbVie. LC: Conference fees: Ferring, Tillots. Accommodation and travel fees: Ferring. LG Consultancy fees: Lilly. KJ: Research grant: Janssen, AbbVie, adMare Bioinnovations. Advisory boards: Janssen, AbbVie, Merck, Mylan Inc. Speaker's bureau: Abbvie. RKR: speaker's fees, travel support, advisory boards: Nestle, AbbVie, Dr Falk, Takeda, Napp, Mead Johnson, Nutricia,. Farah Faytrouni, Mike Irvine, Estefania Carrion, Gregor Scott, BC, RT, Rachel E. Harris, MR: No conflict of interest.\n",
      "\n",
      "Clarke, Benjamin\n",
      "Disclosure of financial conflict of interest: Sally Lawrence: Advisory boards, Speaker's bureau: AbbVie, Takeda. VG: Speaker's fees: Ferring. Conference fees: AbbVie. LC: Conference fees: Ferring, Tillots. Accommodation and travel fees: Ferring. LG Consultancy fees: Lilly. KJ: Research grant: Janssen, AbbVie, adMare Bioinnovations. Advisory boards: Janssen, AbbVie, Merck, Mylan Inc. Speaker's bureau: Abbvie. RKR: speaker's fees, travel support, advisory boards: Nestle, AbbVie, Dr Falk, Takeda, Napp, Mead Johnson, Nutricia,. Farah Faytrouni, Mike Irvine, Estefania Carrion, Gregor Scott, Benjamin Clarke, RT, Rachel E. Harris, MR: No conflict of interest.\n",
      "\n",
      "Garrick, Vikki\n",
      "Disclosure of financial conflict of interest: Sally Lawrence: Advisory boards, Speaker's bureau: AbbVie, Takeda. Vikki Garrick: Speaker's fees: Ferring. Conference fees: AbbVie. LC: Conference fees: Ferring, Tillots. Accommodation and travel fees: Ferring. LG Consultancy fees: Lilly. KJ: Research grant: Janssen, AbbVie, adMare Bioinnovations. Advisory boards: Janssen, AbbVie, Merck, Mylan Inc. Speaker's bureau: Abbvie. RKR: speaker's fees, travel support, advisory boards: Nestle, AbbVie, Dr Falk, Takeda, Napp, Mead Johnson, Nutricia,. Farah Faytrouni, Mike Irvine, Estefania Carrion, Gregor Scott, Benjamin Clarke, RT, Rachel E. Harris, MR: No conflict of interest.\n",
      "\n",
      "Curtis, Lee\n",
      "Disclosure of financial conflict of interest: Sally Lawrence: Advisory boards, Speaker's bureau: AbbVie, Takeda. Vikki Garrick: Speaker's fees: Ferring. Conference fees: AbbVie. Lee Curtis: Conference fees: Ferring, Tillots. Accommodation and travel fees: Ferring. LG Consultancy fees: Lilly. KJ: Research grant: Janssen, AbbVie, adMare Bioinnovations. Advisory boards: Janssen, AbbVie, Merck, Mylan Inc. Speaker's bureau: Abbvie. RKR: speaker's fees, travel support, advisory boards: Nestle, AbbVie, Dr Falk, Takeda, Napp, Mead Johnson, Nutricia,. Farah Faytrouni, Mike Irvine, Estefania Carrion, Gregor Scott, Benjamin Clarke, RT, Rachel E. Harris, MR: No conflict of interest.\n",
      "\n",
      "Gervais, Lisa\n",
      "Disclosure of financial conflict of interest: Sally Lawrence: Advisory boards, Speaker's bureau: AbbVie, Takeda. Vikki Garrick: Speaker's fees: Ferring. Conference fees: AbbVie. Lee Curtis: Conference fees: Ferring, Tillots. Accommodation and travel fees: Ferring. Lisa Gervais Consultancy fees: Lilly. KJ: Research grant: Janssen, AbbVie, adMare Bioinnovations. Advisory boards: Janssen, AbbVie, Merck, Mylan Inc. Speaker's bureau: Abbvie. RKR: speaker's fees, travel support, advisory boards: Nestle, AbbVie, Dr Falk, Takeda, Napp, Mead Johnson, Nutricia,. Farah Faytrouni, Mike Irvine, Estefania Carrion, Gregor Scott, Benjamin Clarke, RT, Rachel E. Harris, MR: No conflict of interest.\n",
      "\n",
      "Tayler, Rachel\n",
      "Disclosure of financial conflict of interest: Sally Lawrence: Advisory boards, Speaker's bureau: AbbVie, Takeda. Vikki Garrick: Speaker's fees: Ferring. Conference fees: AbbVie. Lee Curtis: Conference fees: Ferring, Tillots. Accommodation and travel fees: Ferring. Lisa Gervais Consultancy fees: Lilly. KJ: Research grant: Janssen, AbbVie, adMare Bioinnovations. Advisory boards: Janssen, AbbVie, Merck, Mylan Inc. Speaker's bureau: Abbvie. RKR: speaker's fees, travel support, advisory boards: Nestle, AbbVie, Dr Falk, Takeda, Napp, Mead Johnson, Nutricia,. Farah Faytrouni, Mike Irvine, Estefania Carrion, Gregor Scott, Benjamin Clarke, Rachel Tayler, Rachel E. Harris, MR: No conflict of interest.\n",
      "\n",
      "Riou, Marliss\n",
      "Disclosure of financial conflict of interest: Sally Lawrence: Advisory boards, Speaker's bureau: AbbVie, Takeda. Vikki Garrick: Speaker's fees: Ferring. Conference fees: AbbVie. Lee Curtis: Conference fees: Ferring, Tillots. Accommodation and travel fees: Ferring. Lisa Gervais Consultancy fees: Lilly. KJ: Research grant: Janssen, AbbVie, adMare Bioinnovations. Advisory boards: Janssen, AbbVie, Merck, Mylan Inc. Speaker's bureau: Abbvie. RKR: speaker's fees, travel support, advisory boards: Nestle, AbbVie, Dr Falk, Takeda, Napp, Mead Johnson, Nutricia,. Farah Faytrouni, Mike Irvine, Estefania Carrion, Gregor Scott, Benjamin Clarke, Rachel Tayler, Rachel E. Harris, Marliss Riou: No conflict of interest.\n",
      "\n",
      "Disclosure of financial conflict of interest: Sally Lawrence: Advisory boards, Speaker's bureau: AbbVie, Takeda. Vikki Garrick: Speaker's fees: Ferring. Conference fees: AbbVie. Lee Curtis: Conference fees: Ferring, Tillots. Accommodation and travel fees: Ferring. Lisa Gervais Consultancy fees: Lilly. KJ: Research grant: Janssen, AbbVie, adMare Bioinnovations. Advisory boards: Janssen, AbbVie, Merck, Mylan Inc. Speaker's bureau: Abbvie. RKR: speaker's fees, travel support, advisory boards: Nestle, AbbVie, Dr Falk, Takeda, Napp, Mead Johnson, Nutricia,. Farah Faytrouni, Mike Irvine, Estefania Carrion, Gregor Scott, Benjamin Clarke, Rachel Tayler, Rachel E. Harris, Marliss Riou: No conflict of interest.\n",
      "\n",
      "Jacobson, Kevan\n",
      "Disclosure of financial conflict of interest: Sally Lawrence: Advisory boards, Speaker's bureau: AbbVie, Takeda. Vikki Garrick: Speaker's fees: Ferring. Conference fees: AbbVie. Lee Curtis: Conference fees: Ferring, Tillots. Accommodation and travel fees: Ferring. Lisa Gervais Consultancy fees: Lilly. Kevan Jacobson: Research grant: Janssen, AbbVie, adMare Bioinnovations. Advisory boards: Janssen, AbbVie, Merck, Mylan Inc. Speaker's bureau: Abbvie. RKR: speaker's fees, travel support, advisory boards: Nestle, AbbVie, Dr Falk, Takeda, Napp, Mead Johnson, Nutricia,. Farah Faytrouni, Mike Irvine, Estefania Carrion, Gregor Scott, Benjamin Clarke, Rachel Tayler, Rachel E. Harris, Marliss Riou: No conflict of interest.\n",
      "\n",
      "Russell, Richard K.\n",
      "Disclosure of financial conflict of interest: Sally Lawrence: Advisory boards, Speaker's bureau: AbbVie, Takeda. Vikki Garrick: Speaker's fees: Ferring. Conference fees: AbbVie. Lee Curtis: Conference fees: Ferring, Tillots. Accommodation and travel fees: Ferring. Lisa Gervais Consultancy fees: Lilly. Kevan Jacobson: Research grant: Janssen, AbbVie, adMare Bioinnovations. Advisory boards: Janssen, AbbVie, Merck, Mylan Inc. Speaker's bureau: Abbvie. Richard K. Russell: speaker's fees, travel support, advisory boards: Nestle, AbbVie, Dr Falk, Takeda, Napp, Mead Johnson, Nutricia,. Farah Faytrouni, Mike Irvine, Estefania Carrion, Gregor Scott, Benjamin Clarke, Rachel Tayler, Rachel E. Harris, Marliss Riou: No conflict of interest.\n",
      "\n",
      "Nichols, James H.\n",
      "Authors' Disclosures or Potential Conflicts of Interest: Upon manuscript submission, all authors completed the author disclosure form. Disclosures and/or  potential conflicts of interest: Employment or Leadership: J.H. James H. Nichols, The Journal of Applied Laboratory Medicine, AACC; Z. Shajani-Yi, labcorp. Consultant  or Advisory Role: J.H. James H. Nichols, IL/Werfen, Diabetes Technology Society, Abbott. Stock Ownership: Z. Shajani-Yi, labcorp. Honoraria: J.H. James H. Nichols, IL/Werfen, Siemens, BioRad. Research Funding: J.H. James H. Nichols, Roche Diagnostics, IL Werfen, Abbott Diagnostics. Expert Testimony: None declared. Patents: None declared. Other Remuneration: J.H. James H. Nichols, support for attending meetings and/or travel from IFCC, CLSI, AACC, CAP.\n",
      "\n",
      "Authors' Disclosures or Potential Conflicts of Interest: Upon manuscript submission, all authors completed the author disclosure form. Disclosures and/or  potential conflicts of interest: Employment or Leadership: J.H. James H. Nichols, The Journal of Applied Laboratory Medicine, AACC; Z. Shajani-Yi, labcorp. Consultant  or Advisory Role: J.H. James H. Nichols, IL/Werfen, Diabetes Technology Society, Abbott. Stock Ownership: Z. Shajani-Yi, labcorp. Honoraria: J.H. James H. Nichols, IL/Werfen, Siemens, BioRad. Research Funding: J.H. James H. Nichols, Roche Diagnostics, IL Werfen, Abbott Diagnostics. Expert Testimony: None declared. Patents: None declared. Other Remuneration: J.H. James H. Nichols, support for attending meetings and/or travel from IFCC, CLSI, AACC, CAP.\n",
      "\n",
      "Authors' Disclosures or Potential Conflicts of Interest: Upon manuscript submission, all authors completed the author disclosure form. Disclosures and/or  potential conflicts of interest: Employment or Leadership: J.H. James H. Nichols, The Journal of Applied Laboratory Medicine, AACC; Z. Shajani-Yi, labcorp. Consultant  or Advisory Role: J.H. James H. Nichols, IL/Werfen, Diabetes Technology Society, Abbott. Stock Ownership: Z. Shajani-Yi, labcorp. Honoraria: J.H. James H. Nichols, IL/Werfen, Siemens, BioRad. Research Funding: J.H. James H. Nichols, Roche Diagnostics, IL Werfen, Abbott Diagnostics. Expert Testimony: None declared. Patents: None declared. Other Remuneration: J.H. James H. Nichols, support for attending meetings and/or travel from IFCC, CLSI, AACC, CAP.\n",
      "\n",
      "Authors' Disclosures or Potential Conflicts of Interest: Upon manuscript submission, all authors completed the author disclosure form. Disclosures and/or  potential conflicts of interest: Employment or Leadership: J.H. James H. Nichols, The Journal of Applied Laboratory Medicine, AACC; Z. Shajani-Yi, labcorp. Consultant  or Advisory Role: J.H. James H. Nichols, IL/Werfen, Diabetes Technology Society, Abbott. Stock Ownership: Z. Shajani-Yi, labcorp. Honoraria: J.H. James H. Nichols, IL/Werfen, Siemens, BioRad. Research Funding: J.H. James H. Nichols, Roche Diagnostics, IL Werfen, Abbott Diagnostics. Expert Testimony: None declared. Patents: None declared. Other Remuneration: J.H. James H. Nichols, support for attending meetings and/or travel from IFCC, CLSI, AACC, CAP.\n",
      "\n",
      "Authors' Disclosures or Potential Conflicts of Interest: Upon manuscript submission, all authors completed the author disclosure form. Disclosures and/or  potential conflicts of interest: Employment or Leadership: J.H. James H. Nichols, The Journal of Applied Laboratory Medicine, AACC; Z. Shajani-Yi, labcorp. Consultant  or Advisory Role: J.H. James H. Nichols, IL/Werfen, Diabetes Technology Society, Abbott. Stock Ownership: Z. Shajani-Yi, labcorp. Honoraria: J.H. James H. Nichols, IL/Werfen, Siemens, BioRad. Research Funding: J.H. James H. Nichols, Roche Diagnostics, IL Werfen, Abbott Diagnostics. Expert Testimony: None declared. Patents: None declared. Other Remuneration: J.H. James H. Nichols, support for attending meetings and/or travel from IFCC, CLSI, AACC, CAP.\n",
      "\n",
      "Authors' Disclosures or Potential Conflicts of Interest: Upon manuscript submission, all authors completed the author disclosure form. Disclosures and/or  potential conflicts of interest: Employment or Leadership: J.H. James H. Nichols, The Journal of Applied Laboratory Medicine, AACC; Z. Shajani-Yi, labcorp. Consultant  or Advisory Role: J.H. James H. Nichols, IL/Werfen, Diabetes Technology Society, Abbott. Stock Ownership: Z. Shajani-Yi, labcorp. Honoraria: J.H. James H. Nichols, IL/Werfen, Siemens, BioRad. Research Funding: J.H. James H. Nichols, Roche Diagnostics, IL Werfen, Abbott Diagnostics. Expert Testimony: None declared. Patents: None declared. Other Remuneration: J.H. James H. Nichols, support for attending meetings and/or travel from IFCC, CLSI, AACC, CAP.\n",
      "\n",
      "Authors' Disclosures or Potential Conflicts of Interest: Upon manuscript submission, all authors completed the author disclosure form. Disclosures and/or  potential conflicts of interest: Employment or Leadership: J.H. James H. Nichols, The Journal of Applied Laboratory Medicine, AACC; Z. Shajani-Yi, labcorp. Consultant  or Advisory Role: J.H. James H. Nichols, IL/Werfen, Diabetes Technology Society, Abbott. Stock Ownership: Z. Shajani-Yi, labcorp. Honoraria: J.H. James H. Nichols, IL/Werfen, Siemens, BioRad. Research Funding: J.H. James H. Nichols, Roche Diagnostics, IL Werfen, Abbott Diagnostics. Expert Testimony: None declared. Patents: None declared. Other Remuneration: J.H. James H. Nichols, support for attending meetings and/or travel from IFCC, CLSI, AACC, CAP.\n",
      "\n",
      "Authors' Disclosures or Potential Conflicts of Interest: Upon manuscript submission, all authors completed the author disclosure form. Disclosures and/or  potential conflicts of interest: Employment or Leadership: J.H. James H. Nichols, The Journal of Applied Laboratory Medicine, AACC; Z. Shajani-Yi, labcorp. Consultant  or Advisory Role: J.H. James H. Nichols, IL/Werfen, Diabetes Technology Society, Abbott. Stock Ownership: Z. Shajani-Yi, labcorp. Honoraria: J.H. James H. Nichols, IL/Werfen, Siemens, BioRad. Research Funding: J.H. James H. Nichols, Roche Diagnostics, IL Werfen, Abbott Diagnostics. Expert Testimony: None declared. Patents: None declared. Other Remuneration: J.H. James H. Nichols, support for attending meetings and/or travel from IFCC, CLSI, AACC, CAP.\n",
      "\n",
      "Fu, Lei\n",
      "Authors' Disclosures or Potential Conflicts of Interest: Upon manuscript submission, all authors completed the author disclosure form. Disclosures and/or  potential conflicts of interest: Employment or Leadership: J.H. James H. Nichols, The Journal of Applied Laboratory Medicine, AACC; Z. Shajani-Yi, labcorp. Consultant  or Advisory Role: J.H. James H. Nichols, IL/Werfen, Diabetes Technology Society, Abbott. Stock Ownership: Z. Shajani-Yi, labcorp. Honoraria: J.H. James H. Nichols, IL/Werfen, Siemens, BioRad. Research Lei Funding: J.H. James H. Nichols, Roche Diagnostics, IL Werfen, Abbott Diagnostics. Expert Testimony: None declared. Patents: None declared. Other Remuneration: J.H. James H. Nichols, support for attending meetings and/or travel from IFCC, CLSI, AACC, CAP.\n",
      "\n",
      "Authors' Disclosures or Potential Conflicts of Interest: Upon manuscript submission, all authors completed the author disclosure form. Disclosures and/or  potential conflicts of interest: Employment or Leadership: J.H. James H. Nichols, The Journal of Applied Laboratory Medicine, AACC; Z. Shajani-Yi, labcorp. Consultant  or Advisory Role: J.H. James H. Nichols, IL/Werfen, Diabetes Technology Society, Abbott. Stock Ownership: Z. Shajani-Yi, labcorp. Honoraria: J.H. James H. Nichols, IL/Werfen, Siemens, BioRad. Research Lei Funding: J.H. James H. Nichols, Roche Diagnostics, IL Werfen, Abbott Diagnostics. Expert Testimony: None declared. Patents: None declared. Other Remuneration: J.H. James H. Nichols, support for attending meetings and/or travel from IFCC, CLSI, AACC, CAP.\n",
      "\n",
      "Authors' Disclosures or Potential Conflicts of Interest: Upon manuscript submission, all authors completed the author disclosure form. Disclosures and/or  potential conflicts of interest: Employment or Leadership: J.H. James H. Nichols, The Journal of Applied Laboratory Medicine, AACC; Z. Shajani-Yi, labcorp. Consultant  or Advisory Role: J.H. James H. Nichols, IL/Werfen, Diabetes Technology Society, Abbott. Stock Ownership: Z. Shajani-Yi, labcorp. Honoraria: J.H. James H. Nichols, IL/Werfen, Siemens, BioRad. Research Lei Funding: J.H. James H. Nichols, Roche Diagnostics, IL Werfen, Abbott Diagnostics. Expert Testimony: None declared. Patents: None declared. Other Remuneration: J.H. James H. Nichols, support for attending meetings and/or travel from IFCC, CLSI, AACC, CAP.\n",
      "\n",
      "Authors' Disclosures or Potential Conflicts of Interest: Upon manuscript submission, all authors completed the author disclosure form. Disclosures and/or  potential conflicts of interest: Employment or Leadership: J.H. James H. Nichols, The Journal of Applied Laboratory Medicine, AACC; Z. Shajani-Yi, labcorp. Consultant  or Advisory Role: J.H. James H. Nichols, IL/Werfen, Diabetes Technology Society, Abbott. Stock Ownership: Z. Shajani-Yi, labcorp. Honoraria: J.H. James H. Nichols, IL/Werfen, Siemens, BioRad. Research Lei Funding: J.H. James H. Nichols, Roche Diagnostics, IL Werfen, Abbott Diagnostics. Expert Testimony: None declared. Patents: None declared. Other Remuneration: J.H. James H. Nichols, support for attending meetings and/or travel from IFCC, CLSI, AACC, CAP.\n",
      "\n",
      "Authors' Disclosures or Potential Conflicts of Interest: Upon manuscript submission, all authors completed the author disclosure form. Disclosures and/or  potential conflicts of interest: Employment or Leadership: J.H. James H. Nichols, The Journal of Applied Laboratory Medicine, AACC; Z. Shajani-Yi, labcorp. Consultant  or Advisory Role: J.H. James H. Nichols, IL/Werfen, Diabetes Technology Society, Abbott. Stock Ownership: Z. Shajani-Yi, labcorp. Honoraria: J.H. James H. Nichols, IL/Werfen, Siemens, BioRad. Research Lei Funding: J.H. James H. Nichols, Roche Diagnostics, IL Werfen, Abbott Diagnostics. Expert Testimony: None declared. Patents: None declared. Other Remuneration: J.H. James H. Nichols, support for attending meetings and/or travel from IFCC, CLSI, AACC, CAP.\n",
      "\n",
      "Shajani-Yi, Zahra\n",
      "Authors' Disclosures or Potential Conflicts of Interest: Upon manuscript submission, all authors completed the author disclosure form. Disclosures and/or  potential conflicts of interest: Employment or Leadership: J.H. James H. Nichols, The Journal of Applied Laboratory Medicine, AACC; Zahra Shajani-Yi, labcorp. Consultant  or Advisory Role: J.H. James H. Nichols, IL/Werfen, Diabetes Technology Society, Abbott. Stock Ownership: Zahra Shajani-Yi, labcorp. Honoraria: J.H. James H. Nichols, IL/Werfen, Siemens, BioRad. Research Lei Funding: J.H. James H. Nichols, Roche Diagnostics, IL Werfen, Abbott Diagnostics. Expert Testimony: None declared. Patents: None declared. Other Remuneration: J.H. James H. Nichols, support for attending meetings and/or travel from IFCC, CLSI, AACC, CAP.\n",
      "\n",
      "Authors' Disclosures or Potential Conflicts of Interest: Upon manuscript submission, all authors completed the author disclosure form. Disclosures and/or  potential conflicts of interest: Employment or Leadership: J.H. James H. Nichols, The Journal of Applied Laboratory Medicine, AACC; Zahra Shajani-Yi, labcorp. Consultant  or Advisory Role: J.H. James H. Nichols, IL/Werfen, Diabetes Technology Society, Abbott. Stock Ownership: Zahra Shajani-Yi, labcorp. Honoraria: J.H. James H. Nichols, IL/Werfen, Siemens, BioRad. Research Lei Funding: J.H. James H. Nichols, Roche Diagnostics, IL Werfen, Abbott Diagnostics. Expert Testimony: None declared. Patents: None declared. Other Remuneration: J.H. James H. Nichols, support for attending meetings and/or travel from IFCC, CLSI, AACC, CAP.\n",
      "\n",
      "Authors' Disclosures or Potential Conflicts of Interest: Upon manuscript submission, all authors completed the author disclosure form. Disclosures and/or  potential conflicts of interest: Employment or Leadership: J.H. James H. Nichols, The Journal of Applied Laboratory Medicine, AACC; Zahra Shajani-Yi, labcorp. Consultant  or Advisory Role: J.H. James H. Nichols, IL/Werfen, Diabetes Technology Society, Abbott. Stock Ownership: Zahra Shajani-Yi, labcorp. Honoraria: J.H. James H. Nichols, IL/Werfen, Siemens, BioRad. Research Lei Funding: J.H. James H. Nichols, Roche Diagnostics, IL Werfen, Abbott Diagnostics. Expert Testimony: None declared. Patents: None declared. Other Remuneration: J.H. James H. Nichols, support for attending meetings and/or travel from IFCC, CLSI, AACC, CAP.\n",
      "\n",
      "Authors' Disclosures or Potential Conflicts of Interest: Upon manuscript submission, all authors completed the author disclosure form. Disclosures and/or  potential conflicts of interest: Employment or Leadership: J.H. James H. Nichols, The Journal of Applied Laboratory Medicine, AACC; Zahra Shajani-Yi, labcorp. Consultant  or Advisory Role: J.H. James H. Nichols, IL/Werfen, Diabetes Technology Society, Abbott. Stock Ownership: Zahra Shajani-Yi, labcorp. Honoraria: J.H. James H. Nichols, IL/Werfen, Siemens, BioRad. Research Lei Funding: J.H. James H. Nichols, Roche Diagnostics, IL Werfen, Abbott Diagnostics. Expert Testimony: None declared. Patents: None declared. Other Remuneration: J.H. James H. Nichols, support for attending meetings and/or travel from IFCC, CLSI, AACC, CAP.\n",
      "\n",
      "Authors' Disclosures or Potential Conflicts of Interest: Upon manuscript submission, all authors completed the author disclosure form. Disclosures and/or  potential conflicts of interest: Employment or Leadership: J.H. James H. Nichols, The Journal of Applied Laboratory Medicine, AACC; Zahra Shajani-Yi, labcorp. Consultant  or Advisory Role: J.H. James H. Nichols, IL/Werfen, Diabetes Technology Society, Abbott. Stock Ownership: Zahra Shajani-Yi, labcorp. Honoraria: J.H. James H. Nichols, IL/Werfen, Siemens, BioRad. Research Lei Funding: J.H. James H. Nichols, Roche Diagnostics, IL Werfen, Abbott Diagnostics. Expert Testimony: None declared. Patents: None declared. Other Remuneration: J.H. James H. Nichols, support for attending meetings and/or travel from IFCC, CLSI, AACC, CAP.\n",
      "\n",
      "Tilk, Susanne\n",
      "Susanne Tilk, Susanne Tilk, CC, DP, CM The authors declare that no competing interests exist.\n",
      "\n",
      "Susanne Tilk, Susanne Tilk, CC, DP, CM The authors declare that no competing interests exist.\n",
      "\n",
      "Curtis, Christina\n",
      "Susanne Tilk, Susanne Tilk, Christina Curtis, DP, CM The authors declare that no competing interests exist.\n",
      "\n",
      "Petrov, Dmitri A.\n",
      "Susanne Tilk, Susanne Tilk, Christina Curtis, Dmitri A. Petrov, CM The authors declare that no competing interests exist.\n",
      "\n",
      "McFarland, Christopher D.\n",
      "Susanne Tilk, Susanne Tilk, Christina Curtis, Dmitri A. Petrov, Christopher D. McFarland The authors declare that no competing interests exist.\n",
      "\n",
      "Wallace, Ryan L.\n",
      "Ryan L. Wallace, EL, XL, AC The authors declare that no competing interests exist.\n",
      "\n",
      "Lu, Eric\n",
      "Ryan L. Wallace, Eric Lu, XL, AC The authors declare that no competing interests exist.\n",
      "\n",
      "Luo, Xiangxia\n",
      "Ryan L. Wallace, Eric Lu, Xiangxia Luo, AC The authors declare that no competing interests exist.\n",
      "\n",
      "Capaldi, Andrew P.\n",
      "Ryan L. Wallace, Eric Lu, Xiangxia Luo, Andrew P. Capaldi The authors declare that no competing interests exist.\n",
      "\n",
      "Riley, Lance A.\n",
      "Lance A. Riley, XZ, CD, JM, DH, CW, NW, HO, PD, SL, MP, EW, KE The authors declare that no competing interests exist.\n",
      "\n",
      "Zhang, Xiping\n",
      "Lance A. Riley, Xiping Zhang, CD, JM, DH, CW, NW, HO, PD, SL, MP, EW, KE The authors declare that no competing interests exist.\n",
      "\n",
      "Douglas, Collin M.\n",
      "Lance A. Riley, Xiping Zhang, Collin M. Douglas, JM, DH, CW, NW, HO, PD, SL, MP, EW, KE The authors declare that no competing interests exist.\n",
      "\n",
      "Mijares, Joseph M.\n",
      "Lance A. Riley, Xiping Zhang, Collin M. Douglas, Joseph M. Mijares, DH, CW, NW, HO, PD, SL, MP, EW, KE The authors declare that no competing interests exist.\n",
      "\n",
      "Hammers, David W.\n",
      "Lance A. Riley, Xiping Zhang, Collin M. Douglas, Joseph M. Mijares, David W. Hammers, CW, NW, HO, PD, SL, MP, EW, KE The authors declare that no competing interests exist.\n",
      "\n",
      "Wolff, Christopher A.\n",
      "Lance A. Riley, Xiping Zhang, Collin M. Douglas, Joseph M. Mijares, David W. Hammers, Christopher A. Wolff, NW, HO, PD, SL, MP, EW, KE The authors declare that no competing interests exist.\n",
      "\n",
      "Wood, Neil B.\n",
      "Lance A. Riley, Xiping Zhang, Collin M. Douglas, Joseph M. Mijares, David W. Hammers, Christopher A. Wolff, Neil B. Wood, HO, PD, SL, MP, EW, KE The authors declare that no competing interests exist.\n",
      "\n",
      "Olafson, Hailey R.\n",
      "Lance A. Riley, Xiping Zhang, Collin M. Douglas, Joseph M. Mijares, David W. Hammers, Christopher A. Wolff, Neil B. Wood, Hailey R. Olafson, PD, SL, MP, EW, KE The authors declare that no competing interests exist.\n",
      "\n",
      "Du, Ping\n",
      "Lance A. Riley, Xiping Zhang, Collin M. Douglas, Joseph M. Mijares, David W. Hammers, Christopher A. Wolff, Neil B. Wood, Hailey R. Olafson, Ping Du, SL, MP, EW, KE The authors declare that no competing interests exist.\n",
      "\n",
      "Labeit, Siegfried\n",
      "Lance A. Riley, Xiping Zhang, Collin M. Douglas, Joseph M. Mijares, David W. Hammers, Christopher A. Wolff, Neil B. Wood, Hailey R. Olafson, Ping Du, Siegfried Labeit, MP, EW, KE The authors declare that no competing interests exist.\n",
      "\n",
      "Previs, Michael J.\n",
      "Lance A. Riley, Xiping Zhang, Collin M. Douglas, Joseph M. Mijares, David W. Hammers, Christopher A. Wolff, Neil B. Wood, Hailey R. Olafson, Ping Du, Siegfried Labeit, Michael J. Previs, EW, KE The authors declare that no competing interests exist.\n",
      "\n",
      "Wang, Eric T.\n",
      "Lance A. Riley, Xiping Zhang, Collin M. Douglas, Joseph M. Mijares, David W. Hammers, Christopher A. Wolff, Neil B. Wood, Hailey R. Olafson, Ping Du, Siegfried Labeit, Michael J. Previs, Eric T. Wang, KE The authors declare that no competing interests exist.\n",
      "\n",
      "Esser, Karyn A.\n",
      "Lance A. Riley, Xiping Zhang, Collin M. Douglas, Joseph M. Mijares, David W. Hammers, Christopher A. Wolff, Neil B. Wood, Hailey R. Olafson, Ping Du, Siegfried Labeit, Michael J. Previs, Eric T. Wang, Karyn A. Esser The authors declare that no competing interests exist.\n",
      "\n",
      "Conflicts of Interest: K.O.T. has served as an advisory board member for GlaxoSmithKline. D.S.H. is a consultant for Advanced Bionics, Cochlear Americas,  MED-EL GmbH, Stryker, Synthes, Grace Medical, and Oticon. R.G. is a consultant for Advanced Bionics, Akouos, and Cochlear Americas, is on the clinical advisory  board for Frequency Therapeutics, and is on the Board of Directors for the American Auditory Society. The remaining authors disclose no conflicts of interest.\n",
      "\n",
      "Conflicts of Interest: K.O.T. has served as an advisory board member for GlaxoSmithKline. D.S.H. is a consultant for Advanced Bionics, Cochlear Americas,  MED-EL GmbH, Stryker, Synthes, Grace Medical, and Oticon. R.G. is a consultant for Advanced Bionics, Akouos, and Cochlear Americas, is on the clinical advisory  board for Frequency Therapeutics, and is on the Board of Directors for the American Auditory Society. The remaining authors disclose no conflicts of interest.\n",
      "\n",
      "Tawfik, Kareem O.\n",
      "Conflicts of Interest: Kareem O. Tawfik has served as an advisory board member for GlaxoSmithKline. D.S.H. is a consultant for Advanced Bionics, Cochlear Americas,  MED-EL GmbH, Stryker, Synthes, Grace Medical, and Oticon. R.G. is a consultant for Advanced Bionics, Akouos, and Cochlear Americas, is on the clinical advisory  board for Frequency Therapeutics, and is on the Board of Directors for the American Auditory Society. The remaining authors disclose no conflicts of interest.\n",
      "\n",
      "Conflicts of Interest: Kareem O. Tawfik has served as an advisory board member for GlaxoSmithKline. D.S.H. is a consultant for Advanced Bionics, Cochlear Americas,  MED-EL GmbH, Stryker, Synthes, Grace Medical, and Oticon. R.G. is a consultant for Advanced Bionics, Akouos, and Cochlear Americas, is on the clinical advisory  board for Frequency Therapeutics, and is on the Board of Directors for the American Auditory Society. The remaining authors disclose no conflicts of interest.\n",
      "\n",
      "Conflicts of Interest: Kareem O. Tawfik has served as an advisory board member for GlaxoSmithKline. D.S.H. is a consultant for Advanced Bionics, Cochlear Americas,  MED-EL GmbH, Stryker, Synthes, Grace Medical, and Oticon. R.G. is a consultant for Advanced Bionics, Akouos, and Cochlear Americas, is on the clinical advisory  board for Frequency Therapeutics, and is on the Board of Directors for the American Auditory Society. The remaining authors disclose no conflicts of interest.\n",
      "\n",
      "Haynes, David S.\n",
      "Conflicts of Interest: Kareem O. Tawfik has served as an advisory board member for GlaxoSmithKline. David S. Haynes is a consultant for Advanced Bionics, Cochlear Americas,  MED-EL GmbH, Stryker, Synthes, Grace Medical, and Oticon. R.G. is a consultant for Advanced Bionics, Akouos, and Cochlear Americas, is on the clinical advisory  board for Frequency Therapeutics, and is on the Board of Directors for the American Auditory Society. The remaining authors disclose no conflicts of interest.\n",
      "\n",
      "Gifford, Rene H.\n",
      "Conflicts of Interest: Kareem O. Tawfik has served as an advisory board member for GlaxoSmithKline. David S. Haynes is a consultant for Advanced Bionics, Cochlear Americas,  MED-EL GmbH, Stryker, Synthes, Grace Medical, and Oticon. Rene H. Gifford is a consultant for Advanced Bionics, Akouos, and Cochlear Americas, is on the clinical advisory  board for Frequency Therapeutics, and is on the Board of Directors for the American Auditory Society. The remaining authors disclose no conflicts of interest.\n",
      "\n",
      "Conflicts of Interest: Kareem O. Tawfik has served as an advisory board member for GlaxoSmithKline. David S. Haynes is a consultant for Advanced Bionics, Cochlear Americas,  MED-EL GmbH, Stryker, Synthes, Grace Medical, and Oticon. Rene H. Gifford is a consultant for Advanced Bionics, Akouos, and Cochlear Americas, is on the clinical advisory  board for Frequency Therapeutics, and is on the Board of Directors for the American Auditory Society. The remaining authors disclose no conflicts of interest.\n",
      "\n",
      "Conflicts of Interest: Kareem O. Tawfik has served as an advisory board member for GlaxoSmithKline. David S. Haynes is a consultant for Advanced Bionics, Cochlear Americas,  MED-EL GmbH, Stryker, Synthes, Grace Medical, and Oticon. Rene H. Gifford is a consultant for Advanced Bionics, Akouos, and Cochlear Americas, is on the clinical advisory  board for Frequency Therapeutics, and is on the Board of Directors for the American Auditory Society. The remaining authors disclose no conflicts of interest.\n",
      "\n",
      "Lee, David S.\n",
      "J.A.H. is a consultant for Cochlear Ltd. J.B.F. has served on the Audiology Advisory Board for Cochlear Ltd and Advanced Bionics. C.C.W. is a consultant for  Stryker and Cochlear Ltd. C.A.B. is a consultant for Advanced Bionics, Cochlear Ltd., Envoy, and IotaMotion, and has equity interest in Advanced Cochlear Diagnostics, LLC. David S. Lee, A.W., K.Y.Z., N.D., and M.A.S. disclose no conflicts of interest.\n",
      "\n",
      "Herzog, Jacques A.\n",
      "Jacques A. Herzog is a consultant for Cochlear Ltd. J.B.F. has served on the Audiology Advisory Board for Cochlear Ltd and Advanced Bionics. C.C.W. is a consultant for  Stryker and Cochlear Ltd. C.A.B. is a consultant for Advanced Bionics, Cochlear Ltd., Envoy, and IotaMotion, and has equity interest in Advanced Cochlear Diagnostics, LLC. David S. Lee, A.W., K.Y.Z., N.D., and M.A.S. disclose no conflicts of interest.\n",
      "\n",
      "Walia, Amit\n",
      "Jacques A. Herzog is a consultant for Cochlear Ltd. J.B.F. has served on the Audiology Advisory Board for Cochlear Ltd and Advanced Bionics. C.C.W. is a consultant for  Stryker and Cochlear Ltd. C.A.B. is a consultant for Advanced Bionics, Cochlear Ltd., Envoy, and IotaMotion, and has equity interest in Advanced Cochlear Diagnostics, LLC. David S. Lee, Amit Walia, K.Y.Z., N.D., and M.A.S. disclose no conflicts of interest.\n",
      "\n",
      "Firszt, Jill B.\n",
      "Jacques A. Herzog is a consultant for Cochlear Ltd. Jill B. Firszt has served on the Audiology Advisory Board for Cochlear Ltd and Advanced Bionics. C.C.W. is a consultant for  Stryker and Cochlear Ltd. C.A.B. is a consultant for Advanced Bionics, Cochlear Ltd., Envoy, and IotaMotion, and has equity interest in Advanced Cochlear Diagnostics, LLC. David S. Lee, Amit Walia, K.Y.Z., N.D., and M.A.S. disclose no conflicts of interest.\n",
      "\n",
      "Zhan, Kevin Y.\n",
      "Jacques A. Herzog is a consultant for Cochlear Ltd. Jill B. Firszt has served on the Audiology Advisory Board for Cochlear Ltd and Advanced Bionics. C.C.W. is a consultant for  Stryker and Cochlear Ltd. C.A.B. is a consultant for Advanced Bionics, Cochlear Ltd., Envoy, and IotaMotion, and has equity interest in Advanced Cochlear Diagnostics, LLC. David S. Lee, Amit Walia, Kevin Y. Zhan, N.D., and M.A.S. disclose no conflicts of interest.\n",
      "\n",
      "Durakovic, Nedim\n",
      "Jacques A. Herzog is a consultant for Cochlear Ltd. Jill B. Firszt has served on the Audiology Advisory Board for Cochlear Ltd and Advanced Bionics. C.C.W. is a consultant for  Stryker and Cochlear Ltd. C.A.B. is a consultant for Advanced Bionics, Cochlear Ltd., Envoy, and IotaMotion, and has equity interest in Advanced Cochlear Diagnostics, LLC. David S. Lee, Amit Walia, Kevin Y. Zhan, Nedim Durakovic, and M.A.S. disclose no conflicts of interest.\n",
      "\n",
      "Wick, Cameron C.\n",
      "Jacques A. Herzog is a consultant for Cochlear Ltd. Jill B. Firszt has served on the Audiology Advisory Board for Cochlear Ltd and Advanced Bionics. Cameron C. Wick is a consultant for  Stryker and Cochlear Ltd. C.A.B. is a consultant for Advanced Bionics, Cochlear Ltd., Envoy, and IotaMotion, and has equity interest in Advanced Cochlear Diagnostics, LLC. David S. Lee, Amit Walia, Kevin Y. Zhan, Nedim Durakovic, and M.A.S. disclose no conflicts of interest.\n",
      "\n",
      "Buchman, Craig A.\n",
      "Jacques A. Herzog is a consultant for Cochlear Ltd. Jill B. Firszt has served on the Audiology Advisory Board for Cochlear Ltd and Advanced Bionics. Cameron C. Wick is a consultant for  Stryker and Cochlear Ltd. Craig A. Buchman is a consultant for Advanced Bionics, Cochlear Ltd., Envoy, and IotaMotion, and has equity interest in Advanced Cochlear Diagnostics, LLC. David S. Lee, Amit Walia, Kevin Y. Zhan, Nedim Durakovic, and M.A.S. disclose no conflicts of interest.\n",
      "\n",
      "Shew, Matthew A.\n",
      "Jacques A. Herzog is a consultant for Cochlear Ltd. Jill B. Firszt has served on the Audiology Advisory Board for Cochlear Ltd and Advanced Bionics. Cameron C. Wick is a consultant for  Stryker and Cochlear Ltd. Craig A. Buchman is a consultant for Advanced Bionics, Cochlear Ltd., Envoy, and IotaMotion, and has equity interest in Advanced Cochlear Diagnostics, LLC. David S. Lee, Amit Walia, Kevin Y. Zhan, Nedim Durakovic, and Matthew A. Shew disclose no conflicts of interest.\n",
      "\n",
      "J.T.R. is on the advisory board for Cochlear Pty Limited. S.O.M. is an advisor for Advanced Bionics. The remaining authors disclose no conflicts of interest.\n",
      "\n",
      "J.T.R. is on the advisory board for Cochlear Pty Limited. S.O.M. is an advisor for Advanced Bionics. The remaining authors disclose no conflicts of interest.\n",
      "\n",
      "J.T.R. is on the advisory board for Cochlear Pty Limited. S.O.M. is an advisor for Advanced Bionics. The remaining authors disclose no conflicts of interest.\n",
      "\n",
      "J.T.R. is on the advisory board for Cochlear Pty Limited. S.O.M. is an advisor for Advanced Bionics. The remaining authors disclose no conflicts of interest.\n",
      "\n",
      "J.T.R. is on the advisory board for Cochlear Pty Limited. S.O.M. is an advisor for Advanced Bionics. The remaining authors disclose no conflicts of interest.\n",
      "\n",
      "J.T.R. is on the advisory board for Cochlear Pty Limited. S.O.M. is an advisor for Advanced Bionics. The remaining authors disclose no conflicts of interest.\n",
      "\n",
      "J.T.R. is on the advisory board for Cochlear Pty Limited. S.O.M. is an advisor for Advanced Bionics. The remaining authors disclose no conflicts of interest.\n",
      "\n",
      "McMenomey, Sean O.\n",
      "J.T.R. is on the advisory board for Cochlear Pty Limited. Sean O. McMenomey is an advisor for Advanced Bionics. The remaining authors disclose no conflicts of interest.\n",
      "\n",
      "Thomas Jr Roland, J.\n",
      "J. Thomas Jr Roland is on the advisory board for Cochlear Pty Limited. Sean O. McMenomey is an advisor for Advanced Bionics. The remaining authors disclose no conflicts of interest.\n",
      "\n",
      "Burnim, Audrey A.\n",
      "Audrey A. Burnim, MS, DX, CJ, NA The authors declare that no competing interests exist.\n",
      "\n",
      "Spence, Matthew A.\n",
      "Audrey A. Burnim, Matthew A. Spence, DX, CJ, NA The authors declare that no competing interests exist.\n",
      "\n",
      "Xu, Da\n",
      "Audrey A. Burnim, Matthew A. Spence, Da Xu, CJ, NA The authors declare that no competing interests exist.\n",
      "\n",
      "Jackson, Colin J.\n",
      "Audrey A. Burnim, Matthew A. Spence, Da Xu, Colin J. Jackson, NA The authors declare that no competing interests exist.\n",
      "\n",
      "Ando, Nozomi\n",
      "Audrey A. Burnim, Matthew A. Spence, Da Xu, Colin J. Jackson, Nozomi Ando The authors declare that no competing interests exist.\n",
      "\n",
      "Lukasz, Daria\n",
      "Daria Lukasz, AB, KK The authors declare that no competing interests exist.\n",
      "\n",
      "Beirl, Alisha\n",
      "Daria Lukasz, Alisha Beirl, KK The authors declare that no competing interests exist.\n",
      "\n",
      "Kindt, Katie\n",
      "Daria Lukasz, Alisha Beirl, Katie Kindt The authors declare that no competing interests exist.\n",
      "\n",
      "LaRue, Therese\n",
      "Therese LaRue, HL, AS, ME, GL, JD The authors declare that no competing interests exist.\n",
      "\n",
      "Lindner, Heike\n",
      "Therese LaRue, Heike Lindner, AS, ME, GL, JD The authors declare that no competing interests exist.\n",
      "\n",
      "Srinivas, Ankit\n",
      "Therese LaRue, Heike Lindner, Ankit Srinivas, ME, GL, JD The authors declare that no competing interests exist.\n",
      "\n",
      "Exposito-Alonso, Moises\n",
      "Therese LaRue, Heike Lindner, Ankit Srinivas, Moises Exposito-Alonso, GL, JD The authors declare that no competing interests exist.\n",
      "\n",
      "Lobet, Guillaume\n",
      "Therese LaRue, Heike Lindner, Ankit Srinivas, Moises Exposito-Alonso, Guillaume Lobet, JD The authors declare that no competing interests exist.\n",
      "\n",
      "Dinneny, Jose R.\n",
      "Therese LaRue, Heike Lindner, Ankit Srinivas, Moises Exposito-Alonso, Guillaume Lobet, Jose R. Dinneny The authors declare that no competing interests exist.\n",
      "\n",
      "Cynthia H. McCollough: Research Grant to institution, Siemens Healthcare GmbH. Joel G. Fletcher: Research Grant to institution, Siemens Healthcare GmbH.\n",
      "\n",
      "Cynthia H. McCollough: Research Grant to institution, Siemens Healthcare GmbH. Joel G. Fletcher: Research Grant to institution, Siemens Healthcare GmbH.\n",
      "\n",
      "Cynthia H. McCollough: Research Grant to institution, Siemens Healthcare GmbH. Joel G. Fletcher: Research Grant to institution, Siemens Healthcare GmbH.\n",
      "\n",
      "Cynthia H. McCollough: Research Grant to institution, Siemens Healthcare GmbH. Joel G. Fletcher: Research Grant to institution, Siemens Healthcare GmbH.\n",
      "\n",
      "Cynthia H. McCollough: Research Grant to institution, Siemens Healthcare GmbH. Joel G. Fletcher: Research Grant to institution, Siemens Healthcare GmbH.\n",
      "\n",
      "Cynthia H. McCollough: Research Grant to institution, Siemens Healthcare GmbH. Joel G. Fletcher: Research Grant to institution, Siemens Healthcare GmbH.\n",
      "\n",
      "Cynthia H. McCollough: Research Grant to institution, Siemens Healthcare GmbH. Joel G. Fletcher: Research Grant to institution, Siemens Healthcare GmbH.\n",
      "\n",
      "Cynthia H. McCollough: Research Grant to institution, Siemens Healthcare GmbH. Joel G. Fletcher: Research Grant to institution, Siemens Healthcare GmbH.\n",
      "\n",
      "McCollough, Cynthia\n",
      "Cynthia H. Cynthia McCollough: Research Grant to institution, Siemens Healthcare GmbH. Joel G. Fletcher: Research Grant to institution, Siemens Healthcare GmbH.\n",
      "\n",
      "Fletcher, Joel G.\n",
      "Cynthia H. Cynthia McCollough: Research Grant to institution, Siemens Healthcare GmbH. Joel G. Fletcher: Research Grant to institution, Siemens Healthcare GmbH.\n",
      "\n",
      "Wang, Xu\n",
      "Conflict of interest: Dr Xu Wang is supported by a research grant from the University of Turku. Dr Saraste received speaker or consultancy fees from Amgen,  Abbott, Astra Zeneca, Bayer, Boehringer Ingelheim, and Pfizer. Dr Knuuti received consultancy fees from GE Healthcare and AstraZeneca and speaker fees from GE Healthcare, Bayer, Lundbeck, Boehringer Ingelheim, Pfizer, and Merck, outside of  the submitted work. Dr Bax received speaker fees from Abbot Vascular and Edwards  Lifesciences. The Department of Cardiology, Leiden University Medical Center, Leiden, the Netherlands has received unrestricted research grants from Bayer, Abbott Vascular, Medtronic, Biotronik, Boston Scientific, GE Healthcare, and Edwards Lifesciences. The remaining authors have no relevant disclosures.\n",
      "\n",
      "J van den Hoogen, Inge\n",
      "Conflict of interest: Dr Xu Wang is supported by a research grant from the University of Turku. Dr Saraste received speaker or consultancy fees from Amgen,  Abbott, Astra Zeneca, Bayer, Boehringer Inge J van den Hoogenlheim, and Pfizer. Dr Knuuti received consultancy fees from GE Healthcare and AstraZeneca and speaker fees from GE Healthcare, Bayer, Lundbeck, Boehringer Inge J van den Hoogenlheim, Pfizer, and Merck, outside of  the submitted work. Dr Bax received speaker fees from Abbot Vascular and Edwards  Lifesciences. The Department of Cardiology, Leiden University Medical Center, Leiden, the Netherlands has received unrestricted research grants from Bayer, Abbott Vascular, Medtronic, Biotronik, Boston Scientific, GE Healthcare, and Edwards Lifesciences. The remaining authors have no relevant disclosures.\n",
      "\n",
      "Conflict of interest: Dr Xu Wang is supported by a research grant from the University of Turku. Dr Saraste received speaker or consultancy fees from Amgen,  Abbott, Astra Zeneca, Bayer, Boehringer Inge J van den Hoogenlheim, and Pfizer. Dr Knuuti received consultancy fees from GE Healthcare and AstraZeneca and speaker fees from GE Healthcare, Bayer, Lundbeck, Boehringer Inge J van den Hoogenlheim, Pfizer, and Merck, outside of  the submitted work. Dr Bax received speaker fees from Abbot Vascular and Edwards  Lifesciences. The Department of Cardiology, Leiden University Medical Center, Leiden, the Netherlands has received unrestricted research grants from Bayer, Abbott Vascular, Medtronic, Biotronik, Boston Scientific, GE Healthcare, and Edwards Lifesciences. The remaining authors have no relevant disclosures.\n",
      "\n",
      "Conflict of interest: Dr Xu Wang is supported by a research grant from the University of Turku. Dr Saraste received speaker or consultancy fees from Amgen,  Abbott, Astra Zeneca, Bayer, Boehringer Inge J van den Hoogenlheim, and Pfizer. Dr Knuuti received consultancy fees from GE Healthcare and AstraZeneca and speaker fees from GE Healthcare, Bayer, Lundbeck, Boehringer Inge J van den Hoogenlheim, Pfizer, and Merck, outside of  the submitted work. Dr Bax received speaker fees from Abbot Vascular and Edwards  Lifesciences. The Department of Cardiology, Leiden University Medical Center, Leiden, the Netherlands has received unrestricted research grants from Bayer, Abbott Vascular, Medtronic, Biotronik, Boston Scientific, GE Healthcare, and Edwards Lifesciences. The remaining authors have no relevant disclosures.\n",
      "\n",
      "Conflict of interest: Dr Xu Wang is supported by a research grant from the University of Turku. Dr Saraste received speaker or consultancy fees from Amgen,  Abbott, Astra Zeneca, Bayer, Boehringer Inge J van den Hoogenlheim, and Pfizer. Dr Knuuti received consultancy fees from GE Healthcare and AstraZeneca and speaker fees from GE Healthcare, Bayer, Lundbeck, Boehringer Inge J van den Hoogenlheim, Pfizer, and Merck, outside of  the submitted work. Dr Bax received speaker fees from Abbot Vascular and Edwards  Lifesciences. The Department of Cardiology, Leiden University Medical Center, Leiden, the Netherlands has received unrestricted research grants from Bayer, Abbott Vascular, Medtronic, Biotronik, Boston Scientific, GE Healthcare, and Edwards Lifesciences. The remaining authors have no relevant disclosures.\n",
      "\n",
      "Conflict of interest: Dr Xu Wang is supported by a research grant from the University of Turku. Dr Saraste received speaker or consultancy fees from Amgen,  Abbott, Astra Zeneca, Bayer, Boehringer Inge J van den Hoogenlheim, and Pfizer. Dr Knuuti received consultancy fees from GE Healthcare and AstraZeneca and speaker fees from GE Healthcare, Bayer, Lundbeck, Boehringer Inge J van den Hoogenlheim, Pfizer, and Merck, outside of  the submitted work. Dr Bax received speaker fees from Abbot Vascular and Edwards  Lifesciences. The Department of Cardiology, Leiden University Medical Center, Leiden, the Netherlands has received unrestricted research grants from Bayer, Abbott Vascular, Medtronic, Biotronik, Boston Scientific, GE Healthcare, and Edwards Lifesciences. The remaining authors have no relevant disclosures.\n",
      "\n",
      "Conflict of interest: Dr Xu Wang is supported by a research grant from the University of Turku. Dr Saraste received speaker or consultancy fees from Amgen,  Abbott, Astra Zeneca, Bayer, Boehringer Inge J van den Hoogenlheim, and Pfizer. Dr Knuuti received consultancy fees from GE Healthcare and AstraZeneca and speaker fees from GE Healthcare, Bayer, Lundbeck, Boehringer Inge J van den Hoogenlheim, Pfizer, and Merck, outside of  the submitted work. Dr Bax received speaker fees from Abbot Vascular and Edwards  Lifesciences. The Department of Cardiology, Leiden University Medical Center, Leiden, the Netherlands has received unrestricted research grants from Bayer, Abbott Vascular, Medtronic, Biotronik, Boston Scientific, GE Healthcare, and Edwards Lifesciences. The remaining authors have no relevant disclosures.\n",
      "\n",
      "Conflict of interest: Dr Xu Wang is supported by a research grant from the University of Turku. Dr Saraste received speaker or consultancy fees from Amgen,  Abbott, Astra Zeneca, Bayer, Boehringer Inge J van den Hoogenlheim, and Pfizer. Dr Knuuti received consultancy fees from GE Healthcare and AstraZeneca and speaker fees from GE Healthcare, Bayer, Lundbeck, Boehringer Inge J van den Hoogenlheim, Pfizer, and Merck, outside of  the submitted work. Dr Bax received speaker fees from Abbot Vascular and Edwards  Lifesciences. The Department of Cardiology, Leiden University Medical Center, Leiden, the Netherlands has received unrestricted research grants from Bayer, Abbott Vascular, Medtronic, Biotronik, Boston Scientific, GE Healthcare, and Edwards Lifesciences. The remaining authors have no relevant disclosures.\n",
      "\n",
      "Conflict of interest: Dr Xu Wang is supported by a research grant from the University of Turku. Dr Saraste received speaker or consultancy fees from Amgen,  Abbott, Astra Zeneca, Bayer, Boehringer Inge J van den Hoogenlheim, and Pfizer. Dr Knuuti received consultancy fees from GE Healthcare and AstraZeneca and speaker fees from GE Healthcare, Bayer, Lundbeck, Boehringer Inge J van den Hoogenlheim, Pfizer, and Merck, outside of  the submitted work. Dr Bax received speaker fees from Abbot Vascular and Edwards  Lifesciences. The Department of Cardiology, Leiden University Medical Center, Leiden, the Netherlands has received unrestricted research grants from Bayer, Abbott Vascular, Medtronic, Biotronik, Boston Scientific, GE Healthcare, and Edwards Lifesciences. The remaining authors have no relevant disclosures.\n",
      "\n",
      "Conflict of interest: Dr Xu Wang is supported by a research grant from the University of Turku. Dr Saraste received speaker or consultancy fees from Amgen,  Abbott, Astra Zeneca, Bayer, Boehringer Inge J van den Hoogenlheim, and Pfizer. Dr Knuuti received consultancy fees from GE Healthcare and AstraZeneca and speaker fees from GE Healthcare, Bayer, Lundbeck, Boehringer Inge J van den Hoogenlheim, Pfizer, and Merck, outside of  the submitted work. Dr Bax received speaker fees from Abbot Vascular and Edwards  Lifesciences. The Department of Cardiology, Leiden University Medical Center, Leiden, the Netherlands has received unrestricted research grants from Bayer, Abbott Vascular, Medtronic, Biotronik, Boston Scientific, GE Healthcare, and Edwards Lifesciences. The remaining authors have no relevant disclosures.\n",
      "\n",
      "Saraste, Antti\n",
      "Conflict of interest: Dr Xu Wang is supported by a research grant from the University of Turku. Dr Antti Saraste received speaker or consultancy fees from Amgen,  Abbott, Astra Zeneca, Bayer, Boehringer Inge J van den Hoogenlheim, and Pfizer. Dr Knuuti received consultancy fees from GE Healthcare and AstraZeneca and speaker fees from GE Healthcare, Bayer, Lundbeck, Boehringer Inge J van den Hoogenlheim, Pfizer, and Merck, outside of  the submitted work. Dr Bax received speaker fees from Abbot Vascular and Edwards  Lifesciences. The Department of Cardiology, Leiden University Medical Center, Leiden, the Netherlands has received unrestricted research grants from Bayer, Abbott Vascular, Medtronic, Biotronik, Boston Scientific, GE Healthcare, and Edwards Lifesciences. The remaining authors have no relevant disclosures.\n",
      "\n",
      "Knuuti, Juhani\n",
      "Conflict of interest: Dr Xu Wang is supported by a research grant from the University of Turku. Dr Antti Saraste received speaker or consultancy fees from Amgen,  Abbott, Astra Zeneca, Bayer, Boehringer Inge J van den Hoogenlheim, and Pfizer. Dr Juhani Knuuti received consultancy fees from GE Healthcare and AstraZeneca and speaker fees from GE Healthcare, Bayer, Lundbeck, Boehringer Inge J van den Hoogenlheim, Pfizer, and Merck, outside of  the submitted work. Dr Bax received speaker fees from Abbot Vascular and Edwards  Lifesciences. The Department of Cardiology, Leiden University Medical Center, Leiden, the Netherlands has received unrestricted research grants from Bayer, Abbott Vascular, Medtronic, Biotronik, Boston Scientific, GE Healthcare, and Edwards Lifesciences. The remaining authors have no relevant disclosures.\n",
      "\n",
      "Bax, Jeroen J.\n",
      "Conflict of interest: Dr Xu Wang is supported by a research grant from the University of Turku. Dr Antti Saraste received speaker or consultancy fees from Amgen,  Abbott, Astra Zeneca, Bayer, Boehringer Inge J van den Hoogenlheim, and Pfizer. Dr Juhani Knuuti received consultancy fees from GE Healthcare and AstraZeneca and speaker fees from GE Healthcare, Bayer, Lundbeck, Boehringer Inge J van den Hoogenlheim, Pfizer, and Merck, outside of  the submitted work. Dr Jeroen J. Bax received speaker fees from Abbot Vascular and Edwards  Lifesciences. The Department of Cardiology, Leiden University Medical Center, Leiden, the Netherlands has received unrestricted research grants from Bayer, Abbott Vascular, Medtronic, Biotronik, Boston Scientific, GE Healthcare, and Edwards Lifesciences. The remaining authors have no relevant disclosures.\n",
      "\n",
      "J De Jonge, Christopher\n",
      "Christopher J De Jonge De Jonge is Associate Editor, Frontiers in Molecular and Cellular  Reproduction. Steven A. Gellatly: no conflicts to disclose. Monica H. Vazquez-Levin (MHVL) is Editor for Fertility &amp; Sterility and for F&amp;S Science, and Associate Editor for Human Reproduction. Christopher L.R. Barratt (CLRB), as an employee of the University of Dundee, serves on the Scientific Advisory board of ExSeed Health (from October 2021, financial compensation to the University of Dundee) and is a scientific consultant for Exscientia (from September 2021-Feb 2022, financial compensation to the University of Dundee). CLRB has previously received a fee from Cooper Surgical for lectures on scientific research methods outside the submitted work (2020) and Ferring for a lecture on male reproductive health (2021). CLRB is Editor for RBMO. Satu Rautakallio-Hokkanen: no conflicts to disclose.\n",
      "\n",
      "Gellatly, Steven A.\n",
      "Christopher J De Jonge De Jonge is Associate Editor, Frontiers in Molecular and Cellular  Reproduction. Steven A. Gellatly: no conflicts to disclose. Monica H. Vazquez-Levin (MHVL) is Editor for Fertility &amp; Sterility and for F&amp;S Science, and Associate Editor for Human Reproduction. Christopher L.R. Barratt (CLRB), as an employee of the University of Dundee, serves on the Scientific Advisory board of ExSeed Health (from October 2021, financial compensation to the University of Dundee) and is a scientific consultant for Exscientia (from September 2021-Feb 2022, financial compensation to the University of Dundee). CLRB has previously received a fee from Cooper Surgical for lectures on scientific research methods outside the submitted work (2020) and Ferring for a lecture on male reproductive health (2021). CLRB is Editor for RBMO. Satu Rautakallio-Hokkanen: no conflicts to disclose.\n",
      "\n",
      "Vazquez-Levin, Monica H.\n",
      "Christopher J De Jonge De Jonge is Associate Editor, Frontiers in Molecular and Cellular  Reproduction. Steven A. Gellatly: no conflicts to disclose. Monica H. Vazquez-Levin (MHVL) is Editor for Fertility &amp; Sterility and for F&amp;S Science, and Associate Editor for Human Reproduction. Christopher L.R. Barratt (CLRB), as an employee of the University of Dundee, serves on the Scientific Advisory board of ExSeed Health (from October 2021, financial compensation to the University of Dundee) and is a scientific consultant for Exscientia (from September 2021-Feb 2022, financial compensation to the University of Dundee). CLRB has previously received a fee from Cooper Surgical for lectures on scientific research methods outside the submitted work (2020) and Ferring for a lecture on male reproductive health (2021). CLRB is Editor for RBMO. Satu Rautakallio-Hokkanen: no conflicts to disclose.\n",
      "\n",
      "Barratt, Christopher L.R.\n",
      "Christopher J De Jonge De Jonge is Associate Editor, Frontiers in Molecular and Cellular  Reproduction. Steven A. Gellatly: no conflicts to disclose. Monica H. Vazquez-Levin (MHVL) is Editor for Fertility &amp; Sterility and for F&amp;S Science, and Associate Editor for Human Reproduction. Christopher L.R. Barratt (CLRB), as an employee of the University of Dundee, serves on the Scientific Advisory board of ExSeed Health (from October 2021, financial compensation to the University of Dundee) and is a scientific consultant for Exscientia (from September 2021-Feb 2022, financial compensation to the University of Dundee). CLRB has previously received a fee from Cooper Surgical for lectures on scientific research methods outside the submitted work (2020) and Ferring for a lecture on male reproductive health (2021). CLRB is Editor for RBMO. Satu Rautakallio-Hokkanen: no conflicts to disclose.\n",
      "\n",
      "Rautakallio-Hokkanen, Satu\n",
      "Christopher J De Jonge De Jonge is Associate Editor, Frontiers in Molecular and Cellular  Reproduction. Steven A. Gellatly: no conflicts to disclose. Monica H. Vazquez-Levin (MHVL) is Editor for Fertility &amp; Sterility and for F&amp;S Science, and Associate Editor for Human Reproduction. Christopher L.R. Barratt (CLRB), as an employee of the University of Dundee, serves on the Scientific Advisory board of ExSeed Health (from October 2021, financial compensation to the University of Dundee) and is a scientific consultant for Exscientia (from September 2021-Feb 2022, financial compensation to the University of Dundee). CLRB has previously received a fee from Cooper Surgical for lectures on scientific research methods outside the submitted work (2020) and Ferring for a lecture on male reproductive health (2021). CLRB is Editor for RBMO. Satu Rautakallio-Hokkanen: no conflicts to disclose.\n",
      "\n",
      "Palmer, Ty B.\n",
      "Ty B. Palmer co-invented the Dynamo Torque Analyzer. Kazuma Akehi has nothing to  disclose.\n",
      "\n",
      "Akehi, Kazuma\n",
      "Ty B. Palmer co-invented the Dynamo Torque Analyzer. Kazuma Akehi has nothing to  disclose.\n",
      "\n",
      "NN: personal financial interests (speaker's fees and/or advisory boards): MSD, QIAGEN, Bayer, Biocartis, Incyte, Roche, BMS, MERCK, Thermo Fisher, Boehringer Ingelheim, AstraZeneca, Sanofi, Eli Lilly, Illumina, and Amgen Institutional; financial interests (financial support to research projects): MERCK, Sysmex, Thermo Fisher, QIAGEN, Roche, AstraZeneca, Biocartis, and Illumina. NN: non-financial interests: President, International Quality Network for Pathology (IQN Path); President-Elect, Italian Cancer Society (SIC).\n",
      "\n",
      "NN: personal financial interests (speaker's fees and/or advisory boards): MSD, QIAGEN, Bayer, Biocartis, Incyte, Roche, BMS, MERCK, Thermo Fisher, Boehringer Ingelheim, AstraZeneca, Sanofi, Eli Lilly, Illumina, and Amgen Institutional; financial interests (financial support to research projects): MERCK, Sysmex, Thermo Fisher, QIAGEN, Roche, AstraZeneca, Biocartis, and Illumina. NN: non-financial interests: President, International Quality Network for Pathology (IQN Path); President-Elect, Italian Cancer Society (SIC).\n",
      "\n",
      "NN: personal financial interests (speaker's fees and/or advisory boards): MSD, QIAGEN, Bayer, Biocartis, Incyte, Roche, BMS, MERCK, Thermo Fisher, Boehringer Ingelheim, AstraZeneca, Sanofi, Eli Lilly, Illumina, and Amgen Institutional; financial interests (financial support to research projects): MERCK, Sysmex, Thermo Fisher, QIAGEN, Roche, AstraZeneca, Biocartis, and Illumina. NN: non-financial interests: President, International Quality Network for Pathology (IQN Path); President-Elect, Italian Cancer Society (SIC).\n",
      "\n",
      "Normanno, Nicola\n",
      "Nicola Normanno: personal financial interests (speaker's fees and/or advisory boards): MSD, QIAGEN, Bayer, Biocartis, Incyte, Roche, BMS, MERCK, Thermo Fisher, Boehringer Ingelheim, AstraZeneca, Sanofi, Eli Lilly, Illumina, and Amgen Institutional; financial interests (financial support to research projects): MERCK, Sysmex, Thermo Fisher, QIAGEN, Roche, AstraZeneca, Biocartis, and Illumina. Nicola Normanno: non-financial interests: President, International Quality Network for Pathology (IQN Path); President-Elect, Italian Cancer Society (SIC).\n",
      "\n",
      "Ilaria Colombo: travel grants from Tesaro; technical support from: AstraZeneca (AZ), GlaxoSmithKline (GSK), Novartis, Merck Sharpe and Dohme (MSD); institutional grants for clinical trials (PI) from MSD, Bayer, Oasmia. None of the other authors have a conflict of interest.\n",
      "\n",
      "Ilaria Colombo: travel grants from Tesaro; technical support from: AstraZeneca (AZ), GlaxoSmithKline (GSK), Novartis, Merck Sharpe and Dohme (MSD); institutional grants for clinical trials (PI) from MSD, Bayer, Oasmia. None of the other authors have a conflict of interest.\n",
      "\n",
      "Ilaria Colombo: travel grants from Tesaro; technical support from: AstraZeneca (AZ), GlaxoSmithKline (GSK), Novartis, Merck Sharpe and Dohme (MSD); institutional grants for clinical trials (PI) from MSD, Bayer, Oasmia. None of the other authors have a conflict of interest.\n",
      "\n",
      "Colombo, Ilaria\n",
      "Ilaria Colombo: travel grants from Tesaro; technical support from: AstraZeneca (AZ), GlaxoSmithKline (GSK), Novartis, Merck Sharpe and Dohme (MSD); institutional grants for clinical trials (PI) from MSD, Bayer, Oasmia. None of the other authors have a conflict of interest.\n",
      "\n",
      "Blum, Kenneth\n",
      "CONFLICT OF INTEREST Kenneth Blum and RB are executives of the Geneus Health LLC and are members of the Board of Directors. Kenneth Blum owns units in the Geneus Health LLC. RDB, PKT, DB, and MGL are unpaid members of the Geneus Health Scientific Advisory Board. MSG is an unpaid honorary member of the Geneus Health Scientific Advisory  Board. There are no other conflicts to report.\n",
      "\n",
      "Gold, Mark S.\n",
      "CONFLICT OF INTEREST Kenneth Blum and RB are executives of the Geneus Health LLC and are members of the Board of Directors. Kenneth Blum owns units in the Geneus Health LLC. RDB, PKT, DB, and MGL are unpaid members of the Geneus Health Scientific Advisory Board. Mark S. Gold is an unpaid honorary member of the Geneus Health Scientific Advisory  Board. There are no other conflicts to report.\n",
      "\n",
      "CONFLICT OF INTEREST Kenneth Blum and RB are executives of the Geneus Health LLC and are members of the Board of Directors. Kenneth Blum owns units in the Geneus Health LLC. RDB, PKT, DB, and MGL are unpaid members of the Geneus Health Scientific Advisory Board. Mark S. Gold is an unpaid honorary member of the Geneus Health Scientific Advisory  Board. There are no other conflicts to report.\n",
      "\n",
      "Baron, David\n",
      "CONFLICT OF INTEREST Kenneth Blum and RB are executives of the Geneus Health LLC and are members of the Board of Directors. Kenneth Blum owns units in the Geneus Health LLC. RDavid Baron, PKT, David Baron, and MGL are unpaid members of the Geneus Health Scientific Advisory Board. Mark S. Gold is an unpaid honorary member of the Geneus Health Scientific Advisory  Board. There are no other conflicts to report.\n",
      "\n",
      "CONFLICT OF INTEREST Kenneth Blum and RB are executives of the Geneus Health LLC and are members of the Board of Directors. Kenneth Blum owns units in the Geneus Health LLC. RDavid Baron, PKT, David Baron, and MGL are unpaid members of the Geneus Health Scientific Advisory Board. Mark S. Gold is an unpaid honorary member of the Geneus Health Scientific Advisory  Board. There are no other conflicts to report.\n",
      "\n",
      "Thanos, Panayotis K.\n",
      "CONFLICT OF INTEREST Kenneth Blum and RB are executives of the Geneus Health LLC and are members of the Board of Directors. Kenneth Blum owns units in the Geneus Health LLC. RDavid Baron, Panayotis K. Thanos, David Baron, and MGL are unpaid members of the Geneus Health Scientific Advisory Board. Mark S. Gold is an unpaid honorary member of the Geneus Health Scientific Advisory  Board. There are no other conflicts to report.\n",
      "\n",
      "Brewer, Raymond\n",
      "CONFLICT OF INTEREST Kenneth Blum and Raymond Brewer are executives of the Geneus Health LLC and are members of the Board of Directors. Kenneth Blum owns units in the Geneus Health LLC. RDavid Baron, Panayotis K. Thanos, David Baron, and MGL are unpaid members of the Geneus Health Scientific Advisory Board. Mark S. Gold is an unpaid honorary member of the Geneus Health Scientific Advisory  Board. There are no other conflicts to report.\n",
      "\n",
      "CONFLICT OF INTEREST Kenneth Blum and Raymond Brewer are executives of the Geneus Health LLC and are members of the Board of Directors. Kenneth Blum owns units in the Geneus Health LLC. RDavid Baron, Panayotis K. Thanos, David Baron, and MGL are unpaid members of the Geneus Health Scientific Advisory Board. Mark S. Gold is an unpaid honorary member of the Geneus Health Scientific Advisory  Board. There are no other conflicts to report.\n",
      "\n",
      "Gondre-Lewis, Marjorie C.\n",
      "CONFLICT OF INTEREST Kenneth Blum and Raymond Brewer are executives of the Geneus Health LLC and are members of the Board of Directors. Kenneth Blum owns units in the Geneus Health LLC. RDavid Baron, Panayotis K. Thanos, David Baron, and Marjorie C. Gondre-LewisL are unpaid members of the Geneus Health Scientific Advisory Board. Mark S. Gold is an unpaid honorary member of the Geneus Health Scientific Advisory  Board. There are no other conflicts to report.\n",
      "\n",
      "QW is employed as a part-time scientist by the company Qingdao Gui-Hong Intelligent Medical Technology Co, Ltd. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.\n",
      "\n",
      "QW is employed as a part-time scientist by the company Qingdao Gui-Hong Intelligent Medical Technology Co, Ltd. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.\n",
      "\n",
      "QW is employed as a part-time scientist by the company Qingdao Gui-Hong Intelligent Medical Technology Co, Ltd. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.\n",
      "\n",
      "QW is employed as a part-time scientist by the company Qingdao Gui-Hong Intelligent Medical Technology Co, Ltd. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.\n",
      "\n",
      "QW is employed as a part-time scientist by the company Qingdao Gui-Hong Intelligent Medical Technology Co, Ltd. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.\n",
      "\n",
      "QW is employed as a part-time scientist by the company Qingdao Gui-Hong Intelligent Medical Technology Co, Ltd. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.\n",
      "\n",
      "QW is employed as a part-time scientist by the company Qingdao Gui-Hong Intelligent Medical Technology Co, Ltd. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.\n",
      "\n",
      "QW is employed as a part-time scientist by the company Qingdao Gui-Hong Intelligent Medical Technology Co, Ltd. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.\n",
      "\n",
      "QW is employed as a part-time scientist by the company Qingdao Gui-Hong Intelligent Medical Technology Co, Ltd. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.\n",
      "\n",
      "QW is employed as a part-time scientist by the company Qingdao Gui-Hong Intelligent Medical Technology Co, Ltd. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.\n",
      "\n",
      "QW is employed as a part-time scientist by the company Qingdao Gui-Hong Intelligent Medical Technology Co, Ltd. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.\n",
      "\n",
      "QW is employed as a part-time scientist by the company Qingdao Gui-Hong Intelligent Medical Technology Co, Ltd. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.\n",
      "\n",
      "QW is employed as a part-time scientist by the company Qingdao Gui-Hong Intelligent Medical Technology Co, Ltd. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.\n",
      "\n",
      "Wan, Qi\n",
      "Qi Wan is employed as a part-time scientist by the company Qingdao Gui-Hong Intelligent Medical Technology Co, Ltd. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.\n",
      "\n",
      "Author MS is employed by Daiichi Sankyo, Inc. The remaining author declares that  the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.\n",
      "\n",
      "Salas, Maribel\n",
      "Author Maribel Salas is employed by Daiichi Sankyo, Inc. The remaining author declares that  the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.\n",
      "\n",
      "Author LL was employed by Bausch & Lomb-Iom S.p.A. The remaining authors declare  that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.\n",
      "\n",
      "Author LL was employed by Bausch & Lomb-Iom S.p.A. The remaining authors declare  that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.\n",
      "\n",
      "Author LL was employed by Bausch & Lomb-Iom S.p.A. The remaining authors declare  that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.\n",
      "\n",
      "L. Landini\n",
      "Author L .   L a n d i n i was employed by Bausch & Lomb-Iom S.p.A. The remaining authors declare  that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.\n",
      "\n",
      "Author L .   L a n d i n i was employed by Bausch & Lomb-Iom S.p.A. The remaining authors declare  that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.\n",
      "\n",
      "Author L .   L a n d i n i was employed by Bausch & Lomb-Iom S.p.A. The remaining authors declare  that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.\n",
      "\n",
      "Author L .   L a n d i n i was employed by Bausch & Lomb-Iom S.p.A. The remaining authors declare  that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.\n",
      "\n",
      "Author L .   L a n d i n i was employed by Bausch & Lomb-Iom S.p.A. The remaining authors declare  that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.\n",
      "\n",
      "Vignot, Stephane\n",
      "Authors Stephane Vignot, AD, IS, LL, GE, ME, NH, CM, PM, and CR-C are employed by Agence Nationale de Securite du Medicament et des produits de sante (ANSM).\n",
      "\n",
      "Dhanani, Alban\n",
      "Authors Stephane Vignot, Alban Dhanani, IS, LL, GE, ME, NH, CM, PM, and CR-C are employed by Agence Nationale de Securite du Medicament et des produits de sante (ANSM).\n",
      "\n",
      "Sainte-Marie, Isabelle\n",
      "Authors Stephane Vignot, Alban Dhanani, Isabelle Sainte-Marie, LL, GE, ME, NH, CM, PM, and CR-C are employed by Agence Nationale de Securite du Medicament et des produits de sante (ANSM).\n",
      "\n",
      "de Ligniville Lajavardi, Laure\n",
      "Authors Stephane Vignot, Alban Dhanani, Isabelle Sainte-Marie, Laure de Ligniville Lajavardi, GE, ME, NH, CM, PM, and CR-C are employed by Agence Nationale de Securite du Medicament et des produits de sante (ANSM).\n",
      "\n",
      "Even, Gwennaelle\n",
      "Authors Stephane Vignot, Alban Dhanani, Isabelle Sainte-Marie, Laure de Ligniville Lajavardi, Gwennaelle Even, ME, NH, CM, PM, and CR-C are employed by Agence Nationale de Securite du Medicament et des produits de sante (ANSM).\n",
      "\n",
      "Echemann, Muriel\n",
      "Authors Stephane Vignot, Alban Dhanani, Isabelle Sainte-Marie, Laure de Ligniville Lajavardi, Gwennaelle Even, Muriel Echemann, NH, CM, PM, and CR-C are employed by Agence Nationale de Securite du Medicament et des produits de sante (ANSM).\n",
      "\n",
      "Hulin, Nina\n",
      "Authors Stephane Vignot, Alban Dhanani, Isabelle Sainte-Marie, Laure de Ligniville Lajavardi, Gwennaelle Even, Muriel Echemann, Nina Hulin, CM, PM, and CR-C are employed by Agence Nationale de Securite du Medicament et des produits de sante (ANSM).\n",
      "\n",
      "Menoret, Claire\n",
      "Authors Stephane Vignot, Alban Dhanani, Isabelle Sainte-Marie, Laure de Ligniville Lajavardi, Gwennaelle Even, Muriel Echemann, Nina Hulin, Claire Menoret, PM, and CR-C are employed by Agence Nationale de Securite du Medicament et des produits de sante (ANSM).\n",
      "\n",
      "Maison, Patrick\n",
      "Authors Stephane Vignot, Alban Dhanani, Isabelle Sainte-Marie, Laure de Ligniville Lajavardi, Gwennaelle Even, Muriel Echemann, Nina Hulin, Claire Menoret, Patrick Maison, and CR-C are employed by Agence Nationale de Securite du Medicament et des produits de sante (ANSM).\n",
      "\n",
      "Ratignier-Carbonneil, Christelle\n",
      "Authors Stephane Vignot, Alban Dhanani, Isabelle Sainte-Marie, Laure de Ligniville Lajavardi, Gwennaelle Even, Muriel Echemann, Nina Hulin, Claire Menoret, Patrick Maison, and Christelle Ratignier-Carbonneil-C are employed by Agence Nationale de Securite du Medicament et des produits de sante (ANSM).\n",
      "\n",
      "The authors declare that this study received funding from Merck Ltd., an affiliate of Merck Healthcare KGaA, Darmstadt, Germany. The funder had the following involvement with the study: writing assistance.\n",
      "\n",
      "The authors declare that this study received funding from Merck Ltd., an affiliate of Merck Healthcare KGaA, Darmstadt, Germany. The funder had the following involvement with the study: writing assistance.\n",
      "\n",
      "The authors declare that this study received funding from Merck Ltd., an affiliate of Merck Healthcare KGaA, Darmstadt, Germany. The funder had the following involvement with the study: writing assistance.\n",
      "\n",
      "The authors declare that this study received funding from Merck Ltd., an affiliate of Merck Healthcare KGaA, Darmstadt, Germany. The funder had the following involvement with the study: writing assistance.\n",
      "\n",
      "The authors declare that this study received funding from Merck Ltd., an affiliate of Merck Healthcare KGaA, Darmstadt, Germany. The funder had the following involvement with the study: writing assistance.\n",
      "\n",
      "The authors declare that this study received funding from Merck Ltd., an affiliate of Merck Healthcare KGaA, Darmstadt, Germany. The funder had the following involvement with the study: writing assistance.\n",
      "\n",
      "The authors declare that this study received funding from Merck Ltd., an affiliate of Merck Healthcare KGaA, Darmstadt, Germany. The funder had the following involvement with the study: writing assistance.\n",
      "\n",
      "The authors declare that this study received funding from Merck Ltd., an affiliate of Merck Healthcare KGaA, Darmstadt, Germany. The funder had the following involvement with the study: writing assistance.\n",
      "\n",
      "The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The reviewer YW declared a shared affiliation with the authors to the handling editor at the time of review.\n",
      "\n",
      "The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The reviewer YW declared a shared affiliation with the authors to the handling editor at the time of review.\n",
      "\n",
      "The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The reviewer YW declared a shared affiliation with the authors to the handling editor at the time of review.\n",
      "\n",
      "The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The reviewer YW declared a shared affiliation with the authors to the handling editor at the time of review.\n",
      "\n",
      "The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The reviewer YW declared a shared affiliation with the authors to the handling editor at the time of review.\n",
      "\n",
      "Prof. Dr. Gregoire Wuerzner reports consultancy and/or advisory board from Aktiia, Bayer, Servier and AstraZeneca, outside the submitted work. Prof. Dr. Gilles Wandeler reports grants, Speaker and advisory board fees paid to their institution from Gilead Sciences and MSD, grants from Roche Diagnostics, advisory board fees paid to their institution from ViiV, outside the submitted work. Dr Anna Dorothea Wagner reports personal fees, non-financial support from Merck, personal fees from Lily, personal fees from Pierre-Fabre Pharma, is coordinating  investigator of EORTC trial 1203 \"INNOVATION\", which is supported by an educational grant to EORTC from Hoffmann La Roche, personal fees from Sanofi, personal fees from Daiichi Sankyo, personal fees from Dragonfly Therapeutics, personal fees from Servier, personal fees from Bristol-Myers Squibb, personal fees from Astellas Pharma, outside the submitted work. Professor Chantal Csajka reports grants from Swiss Cancer Research, during the conduct of the study. Prof. Dr. Matthias Cavassini reports grants from Gilead, ViiV and MSD, outside the submitted work. Professor Marie Schneider reports grants from Swiss Cancer Research Foundation, grants from Research and quality fund of Santesuisse, Curafutura and PharmaSuisse, during the conduct of the study. The authors declare that they have no other competing interests.\n",
      "\n",
      "Prof. Dr. Gregoire Wuerzner reports consultancy and/or advisory board from Aktiia, Bayer, Servier and AstraZeneca, outside the submitted work. Prof. Dr. Gilles Wandeler reports grants, Speaker and advisory board fees paid to their institution from Gilead Sciences and MSD, grants from Roche Diagnostics, advisory board fees paid to their institution from ViiV, outside the submitted work. Dr Anna Dorothea Wagner reports personal fees, non-financial support from Merck, personal fees from Lily, personal fees from Pierre-Fabre Pharma, is coordinating  investigator of EORTC trial 1203 \"INNOVATION\", which is supported by an educational grant to EORTC from Hoffmann La Roche, personal fees from Sanofi, personal fees from Daiichi Sankyo, personal fees from Dragonfly Therapeutics, personal fees from Servier, personal fees from Bristol-Myers Squibb, personal fees from Astellas Pharma, outside the submitted work. Professor Chantal Csajka reports grants from Swiss Cancer Research, during the conduct of the study. Prof. Dr. Matthias Cavassini reports grants from Gilead, ViiV and MSD, outside the submitted work. Professor Marie Schneider reports grants from Swiss Cancer Research Foundation, grants from Research and quality fund of Santesuisse, Curafutura and PharmaSuisse, during the conduct of the study. The authors declare that they have no other competing interests.\n",
      "\n",
      "Prof. Dr. Gregoire Wuerzner reports consultancy and/or advisory board from Aktiia, Bayer, Servier and AstraZeneca, outside the submitted work. Prof. Dr. Gilles Wandeler reports grants, Speaker and advisory board fees paid to their institution from Gilead Sciences and MSD, grants from Roche Diagnostics, advisory board fees paid to their institution from ViiV, outside the submitted work. Dr Anna Dorothea Wagner reports personal fees, non-financial support from Merck, personal fees from Lily, personal fees from Pierre-Fabre Pharma, is coordinating  investigator of EORTC trial 1203 \"INNOVATION\", which is supported by an educational grant to EORTC from Hoffmann La Roche, personal fees from Sanofi, personal fees from Daiichi Sankyo, personal fees from Dragonfly Therapeutics, personal fees from Servier, personal fees from Bristol-Myers Squibb, personal fees from Astellas Pharma, outside the submitted work. Professor Chantal Csajka reports grants from Swiss Cancer Research, during the conduct of the study. Prof. Dr. Matthias Cavassini reports grants from Gilead, ViiV and MSD, outside the submitted work. Professor Marie Schneider reports grants from Swiss Cancer Research Foundation, grants from Research and quality fund of Santesuisse, Curafutura and PharmaSuisse, during the conduct of the study. The authors declare that they have no other competing interests.\n",
      "\n",
      "Prof. Dr. Gregoire Wuerzner reports consultancy and/or advisory board from Aktiia, Bayer, Servier and AstraZeneca, outside the submitted work. Prof. Dr. Gilles Wandeler reports grants, Speaker and advisory board fees paid to their institution from Gilead Sciences and MSD, grants from Roche Diagnostics, advisory board fees paid to their institution from ViiV, outside the submitted work. Dr Anna Dorothea Wagner reports personal fees, non-financial support from Merck, personal fees from Lily, personal fees from Pierre-Fabre Pharma, is coordinating  investigator of EORTC trial 1203 \"INNOVATION\", which is supported by an educational grant to EORTC from Hoffmann La Roche, personal fees from Sanofi, personal fees from Daiichi Sankyo, personal fees from Dragonfly Therapeutics, personal fees from Servier, personal fees from Bristol-Myers Squibb, personal fees from Astellas Pharma, outside the submitted work. Professor Chantal Csajka reports grants from Swiss Cancer Research, during the conduct of the study. Prof. Dr. Matthias Cavassini reports grants from Gilead, ViiV and MSD, outside the submitted work. Professor Marie Schneider reports grants from Swiss Cancer Research Foundation, grants from Research and quality fund of Santesuisse, Curafutura and PharmaSuisse, during the conduct of the study. The authors declare that they have no other competing interests.\n",
      "\n",
      "Wuerzner, Gregoire\n",
      "Prof. Dr. Gregoire Wuerzner reports consultancy and/or advisory board from Aktiia, Bayer, Servier and AstraZeneca, outside the submitted work. Prof. Dr. Gilles Wandeler reports grants, Speaker and advisory board fees paid to their institution from Gilead Sciences and MSD, grants from Roche Diagnostics, advisory board fees paid to their institution from ViiV, outside the submitted work. Dr Anna Dorothea Wagner reports personal fees, non-financial support from Merck, personal fees from Lily, personal fees from Pierre-Fabre Pharma, is coordinating  investigator of EORTC trial 1203 \"INNOVATION\", which is supported by an educational grant to EORTC from Hoffmann La Roche, personal fees from Sanofi, personal fees from Daiichi Sankyo, personal fees from Dragonfly Therapeutics, personal fees from Servier, personal fees from Bristol-Myers Squibb, personal fees from Astellas Pharma, outside the submitted work. Professor Chantal Csajka reports grants from Swiss Cancer Research, during the conduct of the study. Prof. Dr. Matthias Cavassini reports grants from Gilead, ViiV and MSD, outside the submitted work. Professor Marie Schneider reports grants from Swiss Cancer Research Foundation, grants from Research and quality fund of Santesuisse, Curafutura and PharmaSuisse, during the conduct of the study. The authors declare that they have no other competing interests.\n",
      "\n",
      "Prof. Dr. Gregoire Wuerzner reports consultancy and/or advisory board from Aktiia, Bayer, Servier and AstraZeneca, outside the submitted work. Prof. Dr. Gilles Wandeler reports grants, Speaker and advisory board fees paid to their institution from Gilead Sciences and MSD, grants from Roche Diagnostics, advisory board fees paid to their institution from ViiV, outside the submitted work. Dr Anna Dorothea Wagner reports personal fees, non-financial support from Merck, personal fees from Lily, personal fees from Pierre-Fabre Pharma, is coordinating  investigator of EORTC trial 1203 \"INNOVATION\", which is supported by an educational grant to EORTC from Hoffmann La Roche, personal fees from Sanofi, personal fees from Daiichi Sankyo, personal fees from Dragonfly Therapeutics, personal fees from Servier, personal fees from Bristol-Myers Squibb, personal fees from Astellas Pharma, outside the submitted work. Professor Chantal Csajka reports grants from Swiss Cancer Research, during the conduct of the study. Prof. Dr. Matthias Cavassini reports grants from Gilead, ViiV and MSD, outside the submitted work. Professor Marie Schneider reports grants from Swiss Cancer Research Foundation, grants from Research and quality fund of Santesuisse, Curafutura and PharmaSuisse, during the conduct of the study. The authors declare that they have no other competing interests.\n",
      "\n",
      "Hachfeld, Anna\n",
      "Prof. Dr. Gregoire Wuerzner reports consultancy and/or advisory board from Aktiia, Bayer, Servier and AstraZeneca, outside the submitted work. Prof. Dr. Gilles Wandeler reports grants, Speaker and advisory board fees paid to their institution from Gilead Sciences and MSD, grants from Roche Diagnostics, advisory board fees paid to their institution from ViiV, outside the submitted work. Dr Anna Hachfeld Dorothea Wagner reports personal fees, non-financial support from Merck, personal fees from Lily, personal fees from Pierre-Fabre Pharma, is coordinating  investigator of EORTC trial 1203 \"INNOVATION\", which is supported by an educational grant to EORTC from Hoffmann La Roche, personal fees from Sanofi, personal fees from Daiichi Sankyo, personal fees from Dragonfly Therapeutics, personal fees from Servier, personal fees from Bristol-Myers Squibb, personal fees from Astellas Pharma, outside the submitted work. Professor Chantal Csajka reports grants from Swiss Cancer Research, during the conduct of the study. Prof. Dr. Matthias Cavassini reports grants from Gilead, ViiV and MSD, outside the submitted work. Professor Marie Schneider reports grants from Swiss Cancer Research Foundation, grants from Research and quality fund of Santesuisse, Curafutura and PharmaSuisse, during the conduct of the study. The authors declare that they have no other competing interests.\n",
      "\n",
      "Wandeler, Gilles\n",
      "Prof. Dr. Gregoire Wuerzner reports consultancy and/or advisory board from Aktiia, Bayer, Servier and AstraZeneca, outside the submitted work. Prof. Dr. Gilles Wandeler reports grants, Speaker and advisory board fees paid to their institution from Gilead Sciences and MSD, grants from Roche Diagnostics, advisory board fees paid to their institution from ViiV, outside the submitted work. Dr Anna Hachfeld Dorothea Wagner reports personal fees, non-financial support from Merck, personal fees from Lily, personal fees from Pierre-Fabre Pharma, is coordinating  investigator of EORTC trial 1203 \"INNOVATION\", which is supported by an educational grant to EORTC from Hoffmann La Roche, personal fees from Sanofi, personal fees from Daiichi Sankyo, personal fees from Dragonfly Therapeutics, personal fees from Servier, personal fees from Bristol-Myers Squibb, personal fees from Astellas Pharma, outside the submitted work. Professor Chantal Csajka reports grants from Swiss Cancer Research, during the conduct of the study. Prof. Dr. Matthias Cavassini reports grants from Gilead, ViiV and MSD, outside the submitted work. Professor Marie Schneider reports grants from Swiss Cancer Research Foundation, grants from Research and quality fund of Santesuisse, Curafutura and PharmaSuisse, during the conduct of the study. The authors declare that they have no other competing interests.\n",
      "\n",
      "Dorothea Wagner, Anna\n",
      "Prof. Dr. Gregoire Wuerzner reports consultancy and/or advisory board from Aktiia, Bayer, Servier and AstraZeneca, outside the submitted work. Prof. Dr. Gilles Wandeler reports grants, Speaker and advisory board fees paid to their institution from Gilead Sciences and MSD, grants from Roche Diagnostics, advisory board fees paid to their institution from ViiV, outside the submitted work. Dr Anna Hachfeld Dorothea Anna Dorothea Wagner reports personal fees, non-financial support from Merck, personal fees from Lily, personal fees from Pierre-Fabre Pharma, is coordinating  investigator of EORTC trial 1203 \"INNOVATION\", which is supported by an educational grant to EORTC from Hoffmann La Roche, personal fees from Sanofi, personal fees from Daiichi Sankyo, personal fees from Dragonfly Therapeutics, personal fees from Servier, personal fees from Bristol-Myers Squibb, personal fees from Astellas Pharma, outside the submitted work. Professor Chantal Csajka reports grants from Swiss Cancer Research, during the conduct of the study. Prof. Dr. Matthias Cavassini reports grants from Gilead, ViiV and MSD, outside the submitted work. Professor Marie Schneider reports grants from Swiss Cancer Research Foundation, grants from Research and quality fund of Santesuisse, Curafutura and PharmaSuisse, during the conduct of the study. The authors declare that they have no other competing interests.\n",
      "\n",
      "Csajka, Chantal\n",
      "Prof. Dr. Gregoire Wuerzner reports consultancy and/or advisory board from Aktiia, Bayer, Servier and AstraZeneca, outside the submitted work. Prof. Dr. Gilles Wandeler reports grants, Speaker and advisory board fees paid to their institution from Gilead Sciences and MSD, grants from Roche Diagnostics, advisory board fees paid to their institution from ViiV, outside the submitted work. Dr Anna Hachfeld Dorothea Anna Dorothea Wagner reports personal fees, non-financial support from Merck, personal fees from Lily, personal fees from Pierre-Fabre Pharma, is coordinating  investigator of EORTC trial 1203 \"INNOVATION\", which is supported by an educational grant to EORTC from Hoffmann La Roche, personal fees from Sanofi, personal fees from Daiichi Sankyo, personal fees from Dragonfly Therapeutics, personal fees from Servier, personal fees from Bristol-Myers Squibb, personal fees from Astellas Pharma, outside the submitted work. Professor Chantal Csajka reports grants from Swiss Cancer Research, during the conduct of the study. Prof. Dr. Matthias Cavassini reports grants from Gilead, ViiV and MSD, outside the submitted work. Professor Marie Schneider reports grants from Swiss Cancer Research Foundation, grants from Research and quality fund of Santesuisse, Curafutura and PharmaSuisse, during the conduct of the study. The authors declare that they have no other competing interests.\n",
      "\n",
      "Prof. Dr. Gregoire Wuerzner reports consultancy and/or advisory board from Aktiia, Bayer, Servier and AstraZeneca, outside the submitted work. Prof. Dr. Gilles Wandeler reports grants, Speaker and advisory board fees paid to their institution from Gilead Sciences and MSD, grants from Roche Diagnostics, advisory board fees paid to their institution from ViiV, outside the submitted work. Dr Anna Hachfeld Dorothea Anna Dorothea Wagner reports personal fees, non-financial support from Merck, personal fees from Lily, personal fees from Pierre-Fabre Pharma, is coordinating  investigator of EORTC trial 1203 \"INNOVATION\", which is supported by an educational grant to EORTC from Hoffmann La Roche, personal fees from Sanofi, personal fees from Daiichi Sankyo, personal fees from Dragonfly Therapeutics, personal fees from Servier, personal fees from Bristol-Myers Squibb, personal fees from Astellas Pharma, outside the submitted work. Professor Chantal Csajka reports grants from Swiss Cancer Research, during the conduct of the study. Prof. Dr. Matthias Cavassini reports grants from Gilead, ViiV and MSD, outside the submitted work. Professor Marie Schneider reports grants from Swiss Cancer Research Foundation, grants from Research and quality fund of Santesuisse, Curafutura and PharmaSuisse, during the conduct of the study. The authors declare that they have no other competing interests.\n",
      "\n",
      "Cavassini, Matthias\n",
      "Prof. Dr. Gregoire Wuerzner reports consultancy and/or advisory board from Aktiia, Bayer, Servier and AstraZeneca, outside the submitted work. Prof. Dr. Gilles Wandeler reports grants, Speaker and advisory board fees paid to their institution from Gilead Sciences and MSD, grants from Roche Diagnostics, advisory board fees paid to their institution from ViiV, outside the submitted work. Dr Anna Hachfeld Dorothea Anna Dorothea Wagner reports personal fees, non-financial support from Merck, personal fees from Lily, personal fees from Pierre-Fabre Pharma, is coordinating  investigator of EORTC trial 1203 \"INNOVATION\", which is supported by an educational grant to EORTC from Hoffmann La Roche, personal fees from Sanofi, personal fees from Daiichi Sankyo, personal fees from Dragonfly Therapeutics, personal fees from Servier, personal fees from Bristol-Myers Squibb, personal fees from Astellas Pharma, outside the submitted work. Professor Chantal Csajka reports grants from Swiss Cancer Research, during the conduct of the study. Prof. Dr. Matthias Cavassini reports grants from Gilead, ViiV and MSD, outside the submitted work. Professor Marie Schneider reports grants from Swiss Cancer Research Foundation, grants from Research and quality fund of Santesuisse, Curafutura and PharmaSuisse, during the conduct of the study. The authors declare that they have no other competing interests.\n",
      "\n",
      "Schneider, Marie P.\n",
      "Prof. Dr. Gregoire Wuerzner reports consultancy and/or advisory board from Aktiia, Bayer, Servier and AstraZeneca, outside the submitted work. Prof. Dr. Gilles Wandeler reports grants, Speaker and advisory board fees paid to their institution from Gilead Sciences and MSD, grants from Roche Diagnostics, advisory board fees paid to their institution from ViiV, outside the submitted work. Dr Anna Hachfeld Dorothea Anna Dorothea Wagner reports personal fees, non-financial support from Merck, personal fees from Lily, personal fees from Pierre-Fabre Pharma, is coordinating  investigator of EORTC trial 1203 \"INNOVATION\", which is supported by an educational grant to EORTC from Hoffmann La Roche, personal fees from Sanofi, personal fees from Daiichi Sankyo, personal fees from Dragonfly Therapeutics, personal fees from Servier, personal fees from Bristol-Myers Squibb, personal fees from Astellas Pharma, outside the submitted work. Professor Chantal Csajka reports grants from Swiss Cancer Research, during the conduct of the study. Prof. Dr. Matthias Cavassini reports grants from Gilead, ViiV and MSD, outside the submitted work. Professor Marie P. Schneider reports grants from Swiss Cancer Research Foundation, grants from Research and quality fund of Santesuisse, Curafutura and PharmaSuisse, during the conduct of the study. The authors declare that they have no other competing interests.\n",
      "\n",
      "Dr. Packreports grants via her University from NIH, RRF Foundation for Aging, Pfizer, Merck, Gordon and Betty Moore Foundation, Lundbeck and Eli Lilly during the conduct of the study. Dr. Bailey reports grants from the NIH, Retirement Research Foundation, during the conduct of the study; grants from Pfizer, Gordon  and Betty Moore Foundation, Merck, Lundbeck, and Eli Lilly and personal fees from Sanofi, Pfizer, University of Westminster, Lundbeck and Luto outside the submitted work. Dr. Wolf reports grants from RRF Foundation for Aging, during the conduct of the study; grants from the NIH (NIA, NIDDK, NINR, NHLBI, NINDS), Gordon and Betty Moore Foundation, Pfizer, Merck and Eli Lilly, and personal fees from Pfizer, Sanofi, Luto UK, University of Westminster, Lundbeck and GlaxoSmithKline, outside the submitted work.\n",
      "\n",
      "Pack, Allison\n",
      "Dr. Allison Packreports grants via her University from NIH, RRF Foundation for Aging, Pfizer, Merck, Gordon and Betty Moore Foundation, Lundbeck and Eli Lilly during the conduct of the study. Dr. Bailey reports grants from the NIH, Retirement Research Foundation, during the conduct of the study; grants from Pfizer, Gordon  and Betty Moore Foundation, Merck, Lundbeck, and Eli Lilly and personal fees from Sanofi, Pfizer, University of Westminster, Lundbeck and Luto outside the submitted work. Dr. Wolf reports grants from RRF Foundation for Aging, during the conduct of the study; grants from the NIH (NIA, NIDDK, NINR, NHLBI, NINDS), Gordon and Betty Moore Foundation, Pfizer, Merck and Eli Lilly, and personal fees from Pfizer, Sanofi, Luto UK, University of Westminster, Lundbeck and GlaxoSmithKline, outside the submitted work.\n",
      "\n",
      "Dr. Allison Packreports grants via her University from NIH, RRF Foundation for Aging, Pfizer, Merck, Gordon and Betty Moore Foundation, Lundbeck and Eli Lilly during the conduct of the study. Dr. Bailey reports grants from the NIH, Retirement Research Foundation, during the conduct of the study; grants from Pfizer, Gordon  and Betty Moore Foundation, Merck, Lundbeck, and Eli Lilly and personal fees from Sanofi, Pfizer, University of Westminster, Lundbeck and Luto outside the submitted work. Dr. Wolf reports grants from RRF Foundation for Aging, during the conduct of the study; grants from the NIH (NIA, NIDDK, NINR, NHLBI, NINDS), Gordon and Betty Moore Foundation, Pfizer, Merck and Eli Lilly, and personal fees from Pfizer, Sanofi, Luto UK, University of Westminster, Lundbeck and GlaxoSmithKline, outside the submitted work.\n",
      "\n",
      "Bailey, Stacy C.\n",
      "Dr. Allison Packreports grants via her University from NIH, RRF Foundation for Aging, Pfizer, Merck, Gordon and Betty Moore Foundation, Lundbeck and Eli Lilly during the conduct of the study. Dr. Stacy C. Bailey reports grants from the NIH, Retirement Research Foundation, during the conduct of the study; grants from Pfizer, Gordon  and Betty Moore Foundation, Merck, Lundbeck, and Eli Lilly and personal fees from Sanofi, Pfizer, University of Westminster, Lundbeck and Luto outside the submitted work. Dr. Wolf reports grants from RRF Foundation for Aging, during the conduct of the study; grants from the NIH (NIA, NIDDK, NINR, NHLBI, NINDS), Gordon and Betty Moore Foundation, Pfizer, Merck and Eli Lilly, and personal fees from Pfizer, Sanofi, Luto UK, University of Westminster, Lundbeck and GlaxoSmithKline, outside the submitted work.\n",
      "\n",
      "Dr. Allison Packreports grants via her University from NIH, RRF Foundation for Aging, Pfizer, Merck, Gordon and Betty Moore Foundation, Lundbeck and Eli Lilly during the conduct of the study. Dr. Stacy C. Bailey reports grants from the NIH, Retirement Research Foundation, during the conduct of the study; grants from Pfizer, Gordon  and Betty Moore Foundation, Merck, Lundbeck, and Eli Lilly and personal fees from Sanofi, Pfizer, University of Westminster, Lundbeck and Luto outside the submitted work. Dr. Wolf reports grants from RRF Foundation for Aging, during the conduct of the study; grants from the NIH (NIA, NIDDK, NINR, NHLBI, NINDS), Gordon and Betty Moore Foundation, Pfizer, Merck and Eli Lilly, and personal fees from Pfizer, Sanofi, Luto UK, University of Westminster, Lundbeck and GlaxoSmithKline, outside the submitted work.\n",
      "\n",
      "Dr. Allison Packreports grants via her University from NIH, RRF Foundation for Aging, Pfizer, Merck, Gordon and Betty Moore Foundation, Lundbeck and Eli Lilly during the conduct of the study. Dr. Stacy C. Bailey reports grants from the NIH, Retirement Research Foundation, during the conduct of the study; grants from Pfizer, Gordon  and Betty Moore Foundation, Merck, Lundbeck, and Eli Lilly and personal fees from Sanofi, Pfizer, University of Westminster, Lundbeck and Luto outside the submitted work. Dr. Wolf reports grants from RRF Foundation for Aging, during the conduct of the study; grants from the NIH (NIA, NIDDK, NINR, NHLBI, NINDS), Gordon and Betty Moore Foundation, Pfizer, Merck and Eli Lilly, and personal fees from Pfizer, Sanofi, Luto UK, University of Westminster, Lundbeck and GlaxoSmithKline, outside the submitted work.\n",
      "\n",
      "Wolf, Michael S.\n",
      "Dr. Allison Packreports grants via her University from NIH, RRF Foundation for Aging, Pfizer, Merck, Gordon and Betty Moore Foundation, Lundbeck and Eli Lilly during the conduct of the study. Dr. Stacy C. Bailey reports grants from the NIH, Retirement Research Foundation, during the conduct of the study; grants from Pfizer, Gordon  and Betty Moore Foundation, Merck, Lundbeck, and Eli Lilly and personal fees from Sanofi, Pfizer, University of Westminster, Lundbeck and Luto outside the submitted work. Dr. Michael S. Wolf reports grants from RRF Foundation for Aging, during the conduct of the study; grants from the NIH (NIA, NIDDK, NINR, NHLBI, NINDS), Gordon and Betty Moore Foundation, Pfizer, Merck and Eli Lilly, and personal fees from Pfizer, Sanofi, Luto UK, University of Westminster, Lundbeck and GlaxoSmithKline, outside the submitted work.\n",
      "\n",
      "Competing interests: SM: consultancy/speakers fees-Abbvie, Allergan, BMS, Gilead, Intercept, MSD, Novo Nordisk, Norgine, Novartis, Sequana. DM: consultancy-intercept.\n",
      "\n",
      "Competing interests: SM: consultancy/speakers fees-Abbvie, Allergan, BMS, Gilead, Intercept, MSD, Novo Nordisk, Norgine, Novartis, Sequana. DM: consultancy-intercept.\n",
      "\n",
      "Competing interests: SM: consultancy/speakers fees-Abbvie, Allergan, BMS, Gilead, Intercept, MSD, Novo Nordisk, Norgine, Novartis, Sequana. DM: consultancy-intercept.\n",
      "\n",
      "Competing interests: SM: consultancy/speakers fees-Abbvie, Allergan, BMS, Gilead, Intercept, MSD, Novo Nordisk, Norgine, Novartis, Sequana. DM: consultancy-intercept.\n",
      "\n",
      "Competing interests: SM: consultancy/speakers fees-Abbvie, Allergan, BMS, Gilead, Intercept, MSD, Novo Nordisk, Norgine, Novartis, Sequana. DM: consultancy-intercept.\n",
      "\n",
      "Competing interests: SM: consultancy/speakers fees-Abbvie, Allergan, BMS, Gilead, Intercept, MSD, Novo Nordisk, Norgine, Novartis, Sequana. DM: consultancy-intercept.\n",
      "\n",
      "Mansour, Dina\n",
      "Competing interests: SM: consultancy/speakers fees-Abbvie, Allergan, BMS, Gilead, Intercept, MSD, Novo Nordisk, Norgine, Novartis, Sequana. Dina Mansour: consultancy-intercept.\n",
      "\n",
      "McPherson, Stuart\n",
      "Competing interests: Stuart McPherson: consultancy/speakers fees-Abbvie, Allergan, BMS, Gilead, Intercept, MSD, Novo Nordisk, Norgine, Novartis, Sequana. Dina Mansour: consultancy-intercept.\n",
      "\n",
      "Kader, Rawen\n",
      "Competing interests: Rawen Kader, RFB, OFA, NP, GC and SD declared no competing interests. MH received speaker fees from Cook Medical. DS is a shareholder in Odin Vision and Digital Surgery. LBL is a consultant and minor shareholder in Odin Vision. He has received research grants from Medtronic, Pentax Medical and DynamX; he is also on the advisory board for DynamX and Ninepoint Medical.\n",
      "\n",
      "Baggaley, Rebecca F.\n",
      "Competing interests: Rawen Kader, Rebecca F. Baggaley, OFA, NP, GC and SD declared no competing interests. MH received speaker fees from Cook Medical. DS is a shareholder in Odin Vision and Digital Surgery. LBL is a consultant and minor shareholder in Odin Vision. He has received research grants from Medtronic, Pentax Medical and DynamX; he is also on the advisory board for DynamX and Ninepoint Medical.\n",
      "\n",
      "Hussein, Mohamed\n",
      "Competing interests: Rawen Kader, Rebecca F. Baggaley, OFA, NP, GC and SD declared no competing interests. Mohamed Hussein received speaker fees from Cook Medical. DS is a shareholder in Odin Vision and Digital Surgery. LBL is a consultant and minor shareholder in Odin Vision. He has received research grants from Medtronic, Pentax Medical and DynamX; he is also on the advisory board for DynamX and Ninepoint Medical.\n",
      "\n",
      "Ahmad, Omer F.\n",
      "Competing interests: Rawen Kader, Rebecca F. Baggaley, Omer F. Ahmad, NP, GC and SD declared no competing interests. Mohamed Hussein received speaker fees from Cook Medical. DS is a shareholder in Odin Vision and Digital Surgery. LBL is a consultant and minor shareholder in Odin Vision. He has received research grants from Medtronic, Pentax Medical and DynamX; he is also on the advisory board for DynamX and Ninepoint Medical.\n",
      "\n",
      "Patel, Nisha\n",
      "Competing interests: Rawen Kader, Rebecca F. Baggaley, Omer F. Ahmad, Nisha Patel, GC and SD declared no competing interests. Mohamed Hussein received speaker fees from Cook Medical. DS is a shareholder in Odin Vision and Digital Surgery. LBL is a consultant and minor shareholder in Odin Vision. He has received research grants from Medtronic, Pentax Medical and DynamX; he is also on the advisory board for DynamX and Ninepoint Medical.\n",
      "\n",
      "Corbett, Gareth\n",
      "Competing interests: Rawen Kader, Rebecca F. Baggaley, Omer F. Ahmad, Nisha Patel, Gareth Corbett and SD declared no competing interests. Mohamed Hussein received speaker fees from Cook Medical. DS is a shareholder in Odin Vision and Digital Surgery. LBL is a consultant and minor shareholder in Odin Vision. He has received research grants from Medtronic, Pentax Medical and DynamX; he is also on the advisory board for DynamX and Ninepoint Medical.\n",
      "\n",
      "Dolwani, Sunil\n",
      "Competing interests: Rawen Kader, Rebecca F. Baggaley, Omer F. Ahmad, Nisha Patel, Gareth Corbett and Sunil Dolwani declared no competing interests. Mohamed Hussein received speaker fees from Cook Medical. DS is a shareholder in Odin Vision and Digital Surgery. LBL is a consultant and minor shareholder in Odin Vision. He has received research grants from Medtronic, Pentax Medical and DynamX; he is also on the advisory board for DynamX and Ninepoint Medical.\n",
      "\n",
      "Stoyanov, Danail\n",
      "Competing interests: Rawen Kader, Rebecca F. Baggaley, Omer F. Ahmad, Nisha Patel, Gareth Corbett and Sunil Dolwani declared no competing interests. Mohamed Hussein received speaker fees from Cook Medical. Danail Stoyanov is a shareholder in Odin Vision and Digital Surgery. LBL is a consultant and minor shareholder in Odin Vision. He has received research grants from Medtronic, Pentax Medical and DynamX; he is also on the advisory board for DynamX and Ninepoint Medical.\n",
      "\n",
      "Lovat, Laurence B.\n",
      "Competing interests: Rawen Kader, Rebecca F. Baggaley, Omer F. Ahmad, Nisha Patel, Gareth Corbett and Sunil Dolwani declared no competing interests. Mohamed Hussein received speaker fees from Cook Medical. Danail Stoyanov is a shareholder in Odin Vision and Digital Surgery. Laurence B. Lovat is a consultant and minor shareholder in Odin Vision. He has received research grants from Medtronic, Pentax Medical and DynamX; he is also on the advisory board for DynamX and Ninepoint Medical.\n",
      "\n",
      "Competing interests: CJvdW has served on advisory boards for Abbvie, Takeda, Pfizer and Celltrion. She is supported by research funding from ZonMW, Tramedico, and Pfizer. ACdV has participated in advisory board and/or received financial compensation from the following companies: Jansen, Takeda, Abbvie and Tramedico.\n",
      "\n",
      "Competing interests: CJvdW has served on advisory boards for Abbvie, Takeda, Pfizer and Celltrion. She is supported by research funding from ZonMW, Tramedico, and Pfizer. ACdV has participated in advisory board and/or received financial compensation from the following companies: Jansen, Takeda, Abbvie and Tramedico.\n",
      "\n",
      "C de Vries, Annemarie\n",
      "Competing interests: CJvdW has served on advisory boards for Abbvie, Takeda, Pfizer and Celltrion. She is supported by research funding from ZonMW, Tramedico, and Pfizer. Annemarie C de Vries has participated in advisory board and/or received financial compensation from the following companies: Jansen, Takeda, Abbvie and Tramedico.\n",
      "\n",
      "Janneke van der Woude, C.\n",
      "Competing interests: C. Janneke van der Woude has served on advisory boards for Abbvie, Takeda, Pfizer and Celltrion. She is supported by research funding from ZonMW, Tramedico, and Pfizer. Annemarie C de Vries has participated in advisory board and/or received financial compensation from the following companies: Jansen, Takeda, Abbvie and Tramedico.\n",
      "\n",
      "Whitcomb, David C.\n",
      "Author David C. Whitcomb is a consultant to Nestle', Regeneron and Ariel Precision Medicine. He  is a co-founder of Ariel Precision Medicine and may have equity.\n",
      "\n",
      "Levman, Jacob\n",
      "Jacob Levman was founder of Time Will Tell Technologies, Inc. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.\n",
      "\n",
      "Jacob Levman was founder of Time Will Tell Technologies, Inc. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.\n",
      "\n",
      "Jacob Levman was founder of Time Will Tell Technologies, Inc. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.\n",
      "\n",
      "Jacob Levman was founder of Time Will Tell Technologies, Inc. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.\n",
      "\n",
      "Jacob Levman was founder of Time Will Tell Technologies, Inc. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.\n",
      "\n",
      "Jacob Levman was founder of Time Will Tell Technologies, Inc. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.\n",
      "\n",
      "Jacob Levman was founder of Time Will Tell Technologies, Inc. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.\n",
      "\n",
      "Jacob Levman was founder of Time Will Tell Technologies, Inc. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.\n",
      "\n",
      "Author LB is currently employed by Pixelcore Research. Author PD was employed by  Pixelcore Research. Author WM-C was employed by Amazon.com. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.\n",
      "\n",
      "Bose, Laurie\n",
      "Author Laurie Bose is currently employed by Pixelcore Research. Author PD was employed by  Pixelcore Research. Author WM-C was employed by Amazon.com. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.\n",
      "\n",
      "Author Laurie Bose is currently employed by Pixelcore Research. Author PD was employed by  Pixelcore Research. Author WM-C was employed by Amazon.com. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.\n",
      "\n",
      "Dudek, Piotr\n",
      "Author Laurie Bose is currently employed by Pixelcore Research. Author Piotr Dudek was employed by  Pixelcore Research. Author WM-C was employed by Amazon.com. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.\n",
      "\n",
      "Mayol-Cuevas, Walterio\n",
      "Author Laurie Bose is currently employed by Pixelcore Research. Author Piotr Dudek was employed by  Pixelcore Research. Author Walterio Mayol-Cuevas-C was employed by Amazon.com. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.\n",
      "\n",
      "Vucko, Erika R.\n",
      "Erika R. Vucko, JB, and BB are investigators of BioMarin Pharmaceutical Inc. clinical trials. Erika R. Vucko and BB are on the BioMarin Pharmaceutical Inc. Speakers Bureau.\n",
      "\n",
      "Erika R. Vucko, JB, and BB are investigators of BioMarin Pharmaceutical Inc. clinical trials. Erika R. Vucko and BB are on the BioMarin Pharmaceutical Inc. Speakers Bureau.\n",
      "\n",
      "Baker, Joshua J.\n",
      "Erika R. Vucko, Joshua J. Baker, and BB are investigators of BioMarin Pharmaceutical Inc. clinical trials. Erika R. Vucko and BB are on the BioMarin Pharmaceutical Inc. Speakers Bureau.\n",
      "\n",
      "Burton, Barbara K.\n",
      "Erika R. Vucko, Joshua J. Baker, and Barbara K. Burton are investigators of BioMarin Pharmaceutical Inc. clinical trials. Erika R. Vucko and Barbara K. Burton are on the BioMarin Pharmaceutical Inc. Speakers Bureau.\n",
      "\n",
      "Inagaki, Natsuko\n",
      "Natsuko Inagaki has no conflict of interest to disclose. Takeo Nakayama received  grants or contracts from I&H Co., Ltd. and Nakagawa Pharmacy Co., consulting fees from Otsuka Pharmaceutical Co., Ltd., and payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Pfizer Japan Inc., MSD K.K., Chugai Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd., Janssen Pharmaceutical K.K., Boehringer Ingelheim International GmbH, Eli Lilly Japan K.K., Baxter Ltd., Mitsubishi Tanabe Pharma Corporation, Novartis Pharma K.K., and Allergan Japan K.K. Kazuki Otani and Mio Tsuchiya are full-time employees of Amicus Therapeutics K.K., Japan.\n",
      "\n",
      "Tsuchiya, Mio\n",
      "Natsuko Inagaki has no conflict of interest to disclose. Takeo Nakayama received  grants or contracts from I&H Co., Ltd. and Nakagawa Pharmacy Co., consulting fees from Otsuka Pharmaceutical Co., Ltd., and payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Pfizer Japan Inc., MSD K.K., Chugai Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd., Janssen Pharmaceutical K.K., Boehringer Ingelheim International GmbH, Eli Lilly Japan K.K., Baxter Ltd., Mitsubishi Tanabe Pharma Corporation, Novartis Pharma K.K., and Allergan Japan K.K. Kazuki Otani and Mio Tsuchiya are full-time employees of Amicus Therapeutics K.K., Japan.\n",
      "\n",
      "Otani, Kazuki\n",
      "Natsuko Inagaki has no conflict of interest to disclose. Takeo Nakayama received  grants or contracts from I&H Co., Ltd. and Nakagawa Pharmacy Co., consulting fees from Otsuka Pharmaceutical Co., Ltd., and payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Pfizer Japan Inc., MSD K.K., Chugai Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd., Janssen Pharmaceutical K.K., Boehringer Ingelheim International GmbH, Eli Lilly Japan K.K., Baxter Ltd., Mitsubishi Tanabe Pharma Corporation, Novartis Pharma K.K., and Allergan Japan K.K. Kazuki Otani and Mio Tsuchiya are full-time employees of Amicus Therapeutics K.K., Japan.\n",
      "\n",
      "Nakayama, Takeo\n",
      "Natsuko Inagaki has no conflict of interest to disclose. Takeo Nakayama received  grants or contracts from I&H Co., Ltd. and Nakagawa Pharmacy Co., consulting fees from Otsuka Pharmaceutical Co., Ltd., and payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Pfizer Japan Inc., MSD K.K., Chugai Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd., Janssen Pharmaceutical K.K., Boehringer Ingelheim International GmbH, Eli Lilly Japan K.K., Baxter Ltd., Mitsubishi Tanabe Pharma Corporation, Novartis Pharma K.K., and Allergan Japan K.K. Kazuki Otani and Mio Tsuchiya are full-time employees of Amicus Therapeutics K.K., Japan.\n",
      "\n",
      "YA and EM have received speaker honoraria from Sanofi. There are no other no competing interests.\n",
      "\n",
      "Mengel, Eugen\n",
      "YA and Eugen Mengel have received speaker honoraria from Sanofi. There are no other no competing interests.\n",
      "\n",
      "Amraoui, Yasmina\n",
      "Yasmina Amraoui and Eugen Mengel have received speaker honoraria from Sanofi. There are no other no competing interests.\n",
      "\n",
      "This work was predominately performed under the employment of NYU Langone Medical Center.\n",
      "\n",
      "This work was predominately performed under the employment of NYU Langone Medical Center.\n",
      "\n",
      "This work was predominately performed under the employment of NYU Langone Medical Center.\n",
      "\n",
      "This work was predominately performed under the employment of NYU Langone Medical Center.\n",
      "\n",
      "Rajagopalan, Murlidhar\n",
      "Dr Pallavi Kawatra is an employee of Novartis Healthcare Pvt Ltd, India. Dr Murlidhar Rajagopalan reports personal fees from Novartis, during the conduct of  the study; is a speaker and advisor for Novartis,Sanofi, Janssen, Pfizer, Sun Pharma, Gracewell, Dr Reddy's Labs, Eli Lilly, Zydus Cadila, Merck Sharpe and Dohme and has received honoraria for lectures. The authors report no other conflicts of interest in this work.\n",
      "\n",
      "Dr Pallavi Kawatra is an employee of Novartis Healthcare Pvt Ltd, India. Dr Murlidhar Rajagopalan reports personal fees from Novartis, during the conduct of  the study; is a speaker and advisor for Novartis,Sanofi, Janssen, Pfizer, Sun Pharma, Gracewell, Dr Reddy's Labs, Eli Lilly, Zydus Cadila, Merck Sharpe and Dohme and has received honoraria for lectures. The authors report no other conflicts of interest in this work.\n",
      "\n",
      "Dr Pallavi Kawatra is an employee of Novartis Healthcare Pvt Ltd, India. Dr Murlidhar Rajagopalan reports personal fees from Novartis, during the conduct of  the study; is a speaker and advisor for Novartis,Sanofi, Janssen, Pfizer, Sun Pharma, Gracewell, Dr Reddy's Labs, Eli Lilly, Zydus Cadila, Merck Sharpe and Dohme and has received honoraria for lectures. The authors report no other conflicts of interest in this work.\n",
      "\n",
      "Dr Pallavi Kawatra is an employee of Novartis Healthcare Pvt Ltd, India. Dr Murlidhar Rajagopalan reports personal fees from Novartis, during the conduct of  the study; is a speaker and advisor for Novartis,Sanofi, Janssen, Pfizer, Sun Pharma, Gracewell, Dr Reddy's Labs, Eli Lilly, Zydus Cadila, Merck Sharpe and Dohme and has received honoraria for lectures. The authors report no other conflicts of interest in this work.\n",
      "\n",
      "Dr Pallavi Kawatra is an employee of Novartis Healthcare Pvt Ltd, India. Dr Murlidhar Rajagopalan reports personal fees from Novartis, during the conduct of  the study; is a speaker and advisor for Novartis,Sanofi, Janssen, Pfizer, Sun Pharma, Gracewell, Dr Reddy's Labs, Eli Lilly, Zydus Cadila, Merck Sharpe and Dohme and has received honoraria for lectures. The authors report no other conflicts of interest in this work.\n",
      "\n",
      "Dr Pallavi Kawatra is an employee of Novartis Healthcare Pvt Ltd, India. Dr Murlidhar Rajagopalan reports personal fees from Novartis, during the conduct of  the study; is a speaker and advisor for Novartis,Sanofi, Janssen, Pfizer, Sun Pharma, Gracewell, Dr Reddy's Labs, Eli Lilly, Zydus Cadila, Merck Sharpe and Dohme and has received honoraria for lectures. The authors report no other conflicts of interest in this work.\n",
      "\n",
      "Dr Pallavi Kawatra is an employee of Novartis Healthcare Pvt Ltd, India. Dr Murlidhar Rajagopalan reports personal fees from Novartis, during the conduct of  the study; is a speaker and advisor for Novartis,Sanofi, Janssen, Pfizer, Sun Pharma, Gracewell, Dr Reddy's Labs, Eli Lilly, Zydus Cadila, Merck Sharpe and Dohme and has received honoraria for lectures. The authors report no other conflicts of interest in this work.\n",
      "\n",
      "Dr Pallavi Kawatra is an employee of Novartis Healthcare Pvt Ltd, India. Dr Murlidhar Rajagopalan reports personal fees from Novartis, during the conduct of  the study; is a speaker and advisor for Novartis,Sanofi, Janssen, Pfizer, Sun Pharma, Gracewell, Dr Reddy's Labs, Eli Lilly, Zydus Cadila, Merck Sharpe and Dohme and has received honoraria for lectures. The authors report no other conflicts of interest in this work.\n",
      "\n",
      "Dr Pallavi Kawatra is an employee of Novartis Healthcare Pvt Ltd, India. Dr Murlidhar Rajagopalan reports personal fees from Novartis, during the conduct of  the study; is a speaker and advisor for Novartis,Sanofi, Janssen, Pfizer, Sun Pharma, Gracewell, Dr Reddy's Labs, Eli Lilly, Zydus Cadila, Merck Sharpe and Dohme and has received honoraria for lectures. The authors report no other conflicts of interest in this work.\n",
      "\n",
      "Dr Pallavi Kawatra is an employee of Novartis Healthcare Pvt Ltd, India. Dr Murlidhar Rajagopalan reports personal fees from Novartis, during the conduct of  the study; is a speaker and advisor for Novartis,Sanofi, Janssen, Pfizer, Sun Pharma, Gracewell, Dr Reddy's Labs, Eli Lilly, Zydus Cadila, Merck Sharpe and Dohme and has received honoraria for lectures. The authors report no other conflicts of interest in this work.\n",
      "\n",
      "Dr Pallavi Kawatra is an employee of Novartis Healthcare Pvt Ltd, India. Dr Murlidhar Rajagopalan reports personal fees from Novartis, during the conduct of  the study; is a speaker and advisor for Novartis,Sanofi, Janssen, Pfizer, Sun Pharma, Gracewell, Dr Reddy's Labs, Eli Lilly, Zydus Cadila, Merck Sharpe and Dohme and has received honoraria for lectures. The authors report no other conflicts of interest in this work.\n",
      "\n",
      "Dr Pallavi Kawatra is an employee of Novartis Healthcare Pvt Ltd, India. Dr Murlidhar Rajagopalan reports personal fees from Novartis, during the conduct of  the study; is a speaker and advisor for Novartis,Sanofi, Janssen, Pfizer, Sun Pharma, Gracewell, Dr Reddy's Labs, Eli Lilly, Zydus Cadila, Merck Sharpe and Dohme and has received honoraria for lectures. The authors report no other conflicts of interest in this work.\n",
      "\n",
      "Dr Pallavi Kawatra is an employee of Novartis Healthcare Pvt Ltd, India. Dr Murlidhar Rajagopalan reports personal fees from Novartis, during the conduct of  the study; is a speaker and advisor for Novartis,Sanofi, Janssen, Pfizer, Sun Pharma, Gracewell, Dr Reddy's Labs, Eli Lilly, Zydus Cadila, Merck Sharpe and Dohme and has received honoraria for lectures. The authors report no other conflicts of interest in this work.\n",
      "\n",
      "Kawatra, Pallavi\n",
      "Dr Pallavi Kawatra is an employee of Novartis Healthcare Pvt Ltd, India. Dr Murlidhar Rajagopalan reports personal fees from Novartis, during the conduct of  the study; is a speaker and advisor for Novartis,Sanofi, Janssen, Pfizer, Sun Pharma, Gracewell, Dr Reddy's Labs, Eli Lilly, Zydus Cadila, Merck Sharpe and Dohme and has received honoraria for lectures. The authors report no other conflicts of interest in this work.\n",
      "\n",
      "Hartley-Brown, Monique\n",
      "Monique Hartley-Brown has received consulting fees from the following companies:  GlaskoSmithKline, Janssen, Bristol Myers Squibb, Cardinal Health, and Karyopharm. Paul Richardson has received grant support and honoraria for service on advisory  committees from Celgene/BMS, Karyopharm, Oncopeptides, and Takeda, and honoraria  for service on advisory committees from Janssen, Sanofi, and Secura Bio.\n",
      "\n",
      "Richardson, Paul\n",
      "Monique Hartley-Brown has received consulting fees from the following companies:  GlaskoSmithKline, Janssen, Bristol Myers Squibb, Cardinal Health, and Karyopharm. Paul Richardson has received grant support and honoraria for service on advisory  committees from Celgene/BMS, Karyopharm, Oncopeptides, and Takeda, and honoraria  for service on advisory committees from Janssen, Sanofi, and Secura Bio.\n",
      "\n",
      "KLK declares that she has no conflicts of interest. MJ is the investigator in Daiichi-Sankyo trials. JH receives research funding (top institution) from Celgene, Novartis, Hexal, Lilly; receives honoraria from Lilly, Novartis, Roche,  Pfizer, AstraZeneca, MSD, Celgene, Eisai, Abbvie, Seagen, Gilead; has consulting  advisory relationship with Lilly, Novartis, Roche, Pfizer, Hexal, AstraZeneca, MSD, Celgene, Abbvie, Seagen, Gilead; receives travel expenses from Roche, Pfizer, Novartis, Celgene, Daiichi.\n",
      "\n",
      "Huober, Jens\n",
      "KLK declares that she has no conflicts of interest. MJ is the investigator in Daiichi-Sankyo trials. Jens Huober receives research funding (top institution) from Celgene, Novartis, Hexal, Lilly; receives honoraria from Lilly, Novartis, Roche,  Pfizer, AstraZeneca, MSD, Celgene, Eisai, Abbvie, Seagen, Gilead; has consulting  advisory relationship with Lilly, Novartis, Roche, Pfizer, Hexal, AstraZeneca, MSD, Celgene, Abbvie, Seagen, Gilead; receives travel expenses from Roche, Pfizer, Novartis, Celgene, Daiichi.\n",
      "\n",
      "Joerger, Markus\n",
      "KLK declares that she has no conflicts of interest. Markus Joerger is the investigator in Daiichi-Sankyo trials. Jens Huober receives research funding (top institution) from Celgene, Novartis, Hexal, Lilly; receives honoraria from Lilly, Novartis, Roche,  Pfizer, AstraZeneca, MSD, Celgene, Eisai, Abbvie, Seagen, Gilead; has consulting  advisory relationship with Lilly, Novartis, Roche, Pfizer, Hexal, AstraZeneca, MSD, Celgene, Abbvie, Seagen, Gilead; receives travel expenses from Roche, Pfizer, Novartis, Celgene, Daiichi.\n",
      "\n",
      "Raval, Amit D.\n",
      "MG, KF, and AL are employed by Evidera. SS was employed by Evidera and Amit D. Raval and YT  were employed by MSD while this study was conducted. MG is a minor shareholder of Thermo Fisher Scientific stock. CS received consulting fees from MSD for his work on this study. This work was funded by Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, United States. The funder had the following involvement with the study: study design, data acquisition, interpretation of results, critical review of manuscript, and the decision to publish.\n",
      "\n",
      "Ganz, Michael L.\n",
      "Michael L. Ganz, KF, and AL are employed by Evidera. SS was employed by Evidera and Amit D. Raval and YT  were employed by MSD while this study was conducted. Michael L. Ganz is a minor shareholder of Thermo Fisher Scientific stock. CS received consulting fees from MSD for his work on this study. This work was funded by Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, United States. The funder had the following involvement with the study: study design, data acquisition, interpretation of results, critical review of manuscript, and the decision to publish.\n",
      "\n",
      "Fraeman, Kathy\n",
      "Michael L. Ganz, Kathy Fraeman, and AL are employed by Evidera. SS was employed by Evidera and Amit D. Raval and YT  were employed by MSD while this study was conducted. Michael L. Ganz is a minor shareholder of Thermo Fisher Scientific stock. CS received consulting fees from MSD for his work on this study. This work was funded by Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, United States. The funder had the following involvement with the study: study design, data acquisition, interpretation of results, critical review of manuscript, and the decision to publish.\n",
      "\n",
      "Lorden, Andrea L.\n",
      "Michael L. Ganz, Kathy Fraeman, and Andrea L. Lorden are employed by Evidera. SS was employed by Evidera and Amit D. Raval and YT  were employed by MSD while this study was conducted. Michael L. Ganz is a minor shareholder of Thermo Fisher Scientific stock. CS received consulting fees from MSD for his work on this study. This work was funded by Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, United States. The funder had the following involvement with the study: study design, data acquisition, interpretation of results, critical review of manuscript, and the decision to publish.\n",
      "\n",
      "Saravanan, Shanmugapriya\n",
      "Michael L. Ganz, Kathy Fraeman, and Andrea L. Lorden are employed by Evidera. Shanmugapriya Saravanan was employed by Evidera and Amit D. Raval and YT  were employed by MSD while this study was conducted. Michael L. Ganz is a minor shareholder of Thermo Fisher Scientific stock. CS received consulting fees from MSD for his work on this study. This work was funded by Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, United States. The funder had the following involvement with the study: study design, data acquisition, interpretation of results, critical review of manuscript, and the decision to publish.\n",
      "\n",
      "Tang, Yuexin\n",
      "Michael L. Ganz, Kathy Fraeman, and Andrea L. Lorden are employed by Evidera. Shanmugapriya Saravanan was employed by Evidera and Amit D. Raval and Yuexin Tang  were employed by MSD while this study was conducted. Michael L. Ganz is a minor shareholder of Thermo Fisher Scientific stock. CS received consulting fees from MSD for his work on this study. This work was funded by Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, United States. The funder had the following involvement with the study: study design, data acquisition, interpretation of results, critical review of manuscript, and the decision to publish.\n",
      "\n",
      "Santos, Carlos A.Q.\n",
      "Michael L. Ganz, Kathy Fraeman, and Andrea L. Lorden are employed by Evidera. Shanmugapriya Saravanan was employed by Evidera and Amit D. Raval and Yuexin Tang  were employed by MSD while this study was conducted. Michael L. Ganz is a minor shareholder of Thermo Fisher Scientific stock. Carlos A.Q. Santos received consulting fees from MSD for his work on this study. This work was funded by Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, United States. The funder had the following involvement with the study: study design, data acquisition, interpretation of results, critical review of manuscript, and the decision to publish.\n",
      "\n",
      "Declaration of Conflicting Interests: The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or  publication of this article: Dr Rey is a paid consultant for Alkermes, maker of OLZ/SAM, his Conflict of Interest (COI) is minimal in this article as he only serves as an advisor for the writing and editing of this article.\n",
      "\n",
      "Declaration of Conflicting Interests: The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or  publication of this article: Dr Rey is a paid consultant for Alkermes, maker of OLZ/SAM, his Conflict of Interest (COI) is minimal in this article as he only serves as an advisor for the writing and editing of this article.\n",
      "\n",
      "Declaration of Conflicting Interests: The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or  publication of this article: Dr Rey is a paid consultant for Alkermes, maker of OLZ/SAM, his Conflict of Interest (COI) is minimal in this article as he only serves as an advisor for the writing and editing of this article.\n",
      "\n",
      "Declaration of Conflicting Interests: The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or  publication of this article: Dr Rey is a paid consultant for Alkermes, maker of OLZ/SAM, his Conflict of Interest (COI) is minimal in this article as he only serves as an advisor for the writing and editing of this article.\n",
      "\n",
      "Rey, Jose A.\n",
      "Declaration of Conflicting Interests: The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or  publication of this article: Dr Jose A. Rey is a paid consultant for Alkermes, maker of OLZ/SAM, his Conflict of Interest (COI) is minimal in this article as he only serves as an advisor for the writing and editing of this article.\n",
      "\n",
      "RM is a co-inventor on patents (PCT/US2018/036677) that are assigned to President and Fellows of Harvard College and Mass General Brigham. RM serves on the Scientific Advisory Board of Trestle Biotherapeutics. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.\n",
      "\n",
      "RM is a co-inventor on patents (PCT/US2018/036677) that are assigned to President and Fellows of Harvard College and Mass General Brigham. RM serves on the Scientific Advisory Board of Trestle Biotherapeutics. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.\n",
      "\n",
      "RM is a co-inventor on patents (PCT/US2018/036677) that are assigned to President and Fellows of Harvard College and Mass General Brigham. RM serves on the Scientific Advisory Board of Trestle Biotherapeutics. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.\n",
      "\n",
      "RM is a co-inventor on patents (PCT/US2018/036677) that are assigned to President and Fellows of Harvard College and Mass General Brigham. RM serves on the Scientific Advisory Board of Trestle Biotherapeutics. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.\n",
      "\n",
      "RM is a co-inventor on patents (PCT/US2018/036677) that are assigned to President and Fellows of Harvard College and Mass General Brigham. RM serves on the Scientific Advisory Board of Trestle Biotherapeutics. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.\n",
      "\n",
      "RM is a co-inventor on patents (PCT/US2018/036677) that are assigned to President and Fellows of Harvard College and Mass General Brigham. RM serves on the Scientific Advisory Board of Trestle Biotherapeutics. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.\n",
      "\n",
      "RM is a co-inventor on patents (PCT/US2018/036677) that are assigned to President and Fellows of Harvard College and Mass General Brigham. RM serves on the Scientific Advisory Board of Trestle Biotherapeutics. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.\n",
      "\n",
      "Morizane, Ryuji\n",
      "Ryuji Morizane is a co-inventor on patents (PCT/US2018/036677) that are assigned to President and Fellows of Harvard College and Mass General Brigham. Ryuji Morizane serves on the Scientific Advisory Board of Trestle Biotherapeutics. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.\n",
      "\n",
      "The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Dr. Andratschke reports personal fees from AstraZeneca, personal fees from Debiopharm, grants, personal fees and non-financial support from ViewRay, grants and personal fees from Brainlab, outside the submitted work The remaining authors declare that they have no known competing financial interests or personal relationships that could have  appeared to influence the work reported in this paper.\n",
      "\n",
      "The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Dr. Andratschke reports personal fees from AstraZeneca, personal fees from Debiopharm, grants, personal fees and non-financial support from ViewRay, grants and personal fees from Brainlab, outside the submitted work The remaining authors declare that they have no known competing financial interests or personal relationships that could have  appeared to influence the work reported in this paper.\n",
      "\n",
      "The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Dr. Andratschke reports personal fees from AstraZeneca, personal fees from Debiopharm, grants, personal fees and non-financial support from ViewRay, grants and personal fees from Brainlab, outside the submitted work The remaining authors declare that they have no known competing financial interests or personal relationships that could have  appeared to influence the work reported in this paper.\n",
      "\n",
      "The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Dr. Andratschke reports personal fees from AstraZeneca, personal fees from Debiopharm, grants, personal fees and non-financial support from ViewRay, grants and personal fees from Brainlab, outside the submitted work The remaining authors declare that they have no known competing financial interests or personal relationships that could have  appeared to influence the work reported in this paper.\n",
      "\n",
      "The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Dr. Andratschke reports personal fees from AstraZeneca, personal fees from Debiopharm, grants, personal fees and non-financial support from ViewRay, grants and personal fees from Brainlab, outside the submitted work The remaining authors declare that they have no known competing financial interests or personal relationships that could have  appeared to influence the work reported in this paper.\n",
      "\n",
      "The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Dr. Andratschke reports personal fees from AstraZeneca, personal fees from Debiopharm, grants, personal fees and non-financial support from ViewRay, grants and personal fees from Brainlab, outside the submitted work The remaining authors declare that they have no known competing financial interests or personal relationships that could have  appeared to influence the work reported in this paper.\n",
      "\n",
      "The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Dr. Andratschke reports personal fees from AstraZeneca, personal fees from Debiopharm, grants, personal fees and non-financial support from ViewRay, grants and personal fees from Brainlab, outside the submitted work The remaining authors declare that they have no known competing financial interests or personal relationships that could have  appeared to influence the work reported in this paper.\n",
      "\n",
      "Andratschke, Nicolaus\n",
      "The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Dr. Nicolaus Andratschke reports personal fees from AstraZeneca, personal fees from Debiopharm, grants, personal fees and non-financial support from ViewRay, grants and personal fees from Brainlab, outside the submitted work The remaining authors declare that they have no known competing financial interests or personal relationships that could have  appeared to influence the work reported in this paper.\n",
      "\n",
      "Gueneau, Virgile\n",
      "Authors Virgile Gueneau, AR, BF, MC, and JP-G were employed by Lallemand SAS marketing the product LALFILM PRO(R) used as a positive biofilm in this study. The remaining authors declare that the research was conducted in the absence of any commercial  or financial relationships that could be construed as a potential conflict of interest.\n",
      "\n",
      "Rodiles, Ana\n",
      "Authors Virgile Gueneau, Ana Rodiles, BF, MC, and JP-G were employed by Lallemand SAS marketing the product LALFILM PRO(R) used as a positive biofilm in this study. The remaining authors declare that the research was conducted in the absence of any commercial  or financial relationships that could be construed as a potential conflict of interest.\n",
      "\n",
      "Frayssinet, Bastien\n",
      "Authors Virgile Gueneau, Ana Rodiles, Bastien Frayssinet, MC, and JP-G were employed by Lallemand SAS marketing the product LALFILM PRO(R) used as a positive biofilm in this study. The remaining authors declare that the research was conducted in the absence of any commercial  or financial relationships that could be construed as a potential conflict of interest.\n",
      "\n",
      "Piard, Jean-Christophe\n",
      "Authors Virgile Gueneau, Ana Rodiles, Bastien Frayssinet, MC, and Jean-Christophe Piard-G were employed by Lallemand SAS marketing the product LALFILM PRO(R) used as a positive biofilm in this study. The remaining authors declare that the research was conducted in the absence of any commercial  or financial relationships that could be construed as a potential conflict of interest.\n",
      "\n",
      "Castex, Mathieu\n",
      "Authors Virgile Gueneau, Ana Rodiles, Bastien Frayssinet, Mathieu Castex, and Jean-Christophe Piard-G were employed by Lallemand SAS marketing the product LALFILM PRO(R) used as a positive biofilm in this study. The remaining authors declare that the research was conducted in the absence of any commercial  or financial relationships that could be construed as a potential conflict of interest.\n",
      "\n",
      "Authors Virgile Gueneau, Ana Rodiles, Bastien Frayssinet, Mathieu Castex, and Jean-Christophe Piard-G were employed by Lallemand SAS marketing the product LALFILM PRO(R) used as a positive biofilm in this study. The remaining authors declare that the research was conducted in the absence of any commercial  or financial relationships that could be construed as a potential conflict of interest.\n",
      "\n",
      "Authors Virgile Gueneau, Ana Rodiles, Bastien Frayssinet, Mathieu Castex, and Jean-Christophe Piard-G were employed by Lallemand SAS marketing the product LALFILM PRO(R) used as a positive biofilm in this study. The remaining authors declare that the research was conducted in the absence of any commercial  or financial relationships that could be construed as a potential conflict of interest.\n",
      "\n",
      "Watanabe, Ryu\n",
      "Author Ryu Watanabe receives speaker's fee from Eli Lilly. Author MH receives research grants from AbbVie, Asahi-Kasei, Brystol-Meyers, Eisai, Eli Lilly, and Novartis Pharma. The remaining author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.\n",
      "\n",
      "Author Ryu Watanabe receives speaker's fee from Eli Lilly. Author MH receives research grants from AbbVie, Asahi-Kasei, Brystol-Meyers, Eisai, Eli Lilly, and Novartis Pharma. The remaining author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.\n",
      "\n",
      "Hashimoto, Motomu\n",
      "Author Ryu Watanabe receives speaker's fee from Eli Lilly. Author Motomu Hashimoto receives research grants from AbbVie, Asahi-Kasei, Brystol-Meyers, Eisai, Eli Lilly, and Novartis Pharma. The remaining author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.\n",
      "\n",
      "Feldman, Peter R.\n",
      "Peter R. Feldman was employed by Arbor Life Labs (ALL). OJF and KMF received honoraria from ALL. The author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.\n",
      "\n",
      "Feldman, Oriel J.\n",
      "Peter R. Oriel J. Feldman was employed by Arbor Life Labs (ALL). OJF and KMF received honoraria from ALL. The author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.\n",
      "\n",
      "Peter R. Oriel J. Feldman was employed by Arbor Life Labs (ALL). OJF and KMF received honoraria from ALL. The author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.\n",
      "\n",
      "Fiebig, Klaus M.\n",
      "Peter R. Oriel J. Feldman was employed by Arbor Life Labs (ALL). OJF and Klaus M. Fiebig received honoraria from ALL. The author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.\n",
      "\n",
      "Carmo, Thomas A.\n",
      "Authors Thomas A. Carmo, IF, RM, MA, KA, and BA were employed by fellows from Multinational Organization Network Sponsoring Translational and Epidemiological Research Initiative. The remaining authors declare that the research was conducted in the  absence of any commercial or financial relationships that could be construed as a potential conflict of interest.\n",
      "\n",
      "Ferreira, Isabella B.B.\n",
      "Authors Thomas A. Carmo, Isabella B.B. Ferreira, RM, MA, KA, and BA were employed by fellows from Multinational Organization Network Sponsoring Translational and Epidemiological Research Initiative. The remaining authors declare that the research was conducted in the  absence of any commercial or financial relationships that could be construed as a potential conflict of interest.\n",
      "\n",
      "Menezes, Rodrigo C.\n",
      "Authors Thomas A. Carmo, Isabella B.B. Ferreira, Rodrigo C. Menezes, MA, KA, and BA were employed by fellows from Multinational Organization Network Sponsoring Translational and Epidemiological Research Initiative. The remaining authors declare that the research was conducted in the  absence of any commercial or financial relationships that could be construed as a potential conflict of interest.\n",
      "\n",
      "Authors Thomas A. Carmo, Isabella B.B. Ferreira, Rodrigo C. Menezes, MA, KA, and BA were employed by fellows from Multinational Organization Network Sponsoring Translational and Epidemiological Research Initiative. The remaining authors declare that the research was conducted in the  absence of any commercial or financial relationships that could be construed as a potential conflict of interest.\n",
      "\n",
      "Authors Thomas A. Carmo, Isabella B.B. Ferreira, Rodrigo C. Menezes, MA, KA, and BA were employed by fellows from Multinational Organization Network Sponsoring Translational and Epidemiological Research Initiative. The remaining authors declare that the research was conducted in the  absence of any commercial or financial relationships that could be construed as a potential conflict of interest.\n",
      "\n",
      "Authors Thomas A. Carmo, Isabella B.B. Ferreira, Rodrigo C. Menezes, MA, KA, and BA were employed by fellows from Multinational Organization Network Sponsoring Translational and Epidemiological Research Initiative. The remaining authors declare that the research was conducted in the  absence of any commercial or financial relationships that could be construed as a potential conflict of interest.\n",
      "\n",
      "Authors Thomas A. Carmo, Isabella B.B. Ferreira, Rodrigo C. Menezes, MA, KA, and BA were employed by fellows from Multinational Organization Network Sponsoring Translational and Epidemiological Research Initiative. The remaining authors declare that the research was conducted in the  absence of any commercial or financial relationships that could be construed as a potential conflict of interest.\n",
      "\n",
      "Authors Thomas A. Carmo, Isabella B.B. Ferreira, Rodrigo C. Menezes, MA, KA, and BA were employed by fellows from Multinational Organization Network Sponsoring Translational and Epidemiological Research Initiative. The remaining authors declare that the research was conducted in the  absence of any commercial or financial relationships that could be construed as a potential conflict of interest.\n",
      "\n",
      "Authors Thomas A. Carmo, Isabella B.B. Ferreira, Rodrigo C. Menezes, MA, KA, and BA were employed by fellows from Multinational Organization Network Sponsoring Translational and Epidemiological Research Initiative. The remaining authors declare that the research was conducted in the  absence of any commercial or financial relationships that could be construed as a potential conflict of interest.\n",
      "\n",
      "Arriaga, Maria B.\n",
      "Authors Thomas A. Carmo, Isabella B.B. Ferreira, Rodrigo C. Menezes, Maria B. Arriaga, KA, and BA were employed by fellows from Multinational Organization Network Sponsoring Translational and Epidemiological Research Initiative. The remaining authors declare that the research was conducted in the  absence of any commercial or financial relationships that could be construed as a potential conflict of interest.\n",
      "\n",
      "Akrami, Kevan M.\n",
      "Authors Thomas A. Carmo, Isabella B.B. Ferreira, Rodrigo C. Menezes, Maria B. Arriaga, Kevan M. Akrami, and BA were employed by fellows from Multinational Organization Network Sponsoring Translational and Epidemiological Research Initiative. The remaining authors declare that the research was conducted in the  absence of any commercial or financial relationships that could be construed as a potential conflict of interest.\n",
      "\n",
      "Authors Thomas A. Carmo, Isabella B.B. Ferreira, Rodrigo C. Menezes, Maria B. Arriaga, Kevan M. Akrami, and BA were employed by fellows from Multinational Organization Network Sponsoring Translational and Epidemiological Research Initiative. The remaining authors declare that the research was conducted in the  absence of any commercial or financial relationships that could be construed as a potential conflict of interest.\n",
      "\n",
      "Andrade, Bruno B.\n",
      "Authors Thomas A. Carmo, Isabella B.B. Ferreira, Rodrigo C. Menezes, Maria B. Arriaga, Kevan M. Akrami, and Bruno B. Andrade were employed by fellows from Multinational Organization Network Sponsoring Translational and Epidemiological Research Initiative. The remaining authors declare that the research was conducted in the  absence of any commercial or financial relationships that could be construed as a potential conflict of interest.\n",
      "\n",
      "The authors have no financial disclosures or conflicts of interest. Jonathan Grauer, North American Spine Society Journal Editor-in-Chief.\n",
      "\n",
      "Grauer, Jonathan N.\n",
      "The authors have no financial disclosures or conflicts of interest. Jonathan N. Grauer, North American Spine Society Journal Editor-in-Chief.\n",
      "\n",
      "Sanabria, Mauricio\n",
      "Dr Mauricio Sanabria is a full-time employee of Baxter Renal Care Services-Latin-America,  Bogota, Colombia. Ms. Vesga is a full-time employee of Baxter Renal Care Services-Colombia, Bucaramanga, Colombia. Dr. Lindholm is an employee of Baxter Healthcare Corporation and Karolinska Institutet, Stockholm, Sweden. Dr. Rivera is an employee of Baxter Healthcare Corporation, Deerfield, Illinois, USA. Dr. Rutherford is an employee of Baxter Healthcare Corporation, Zurich, Switzerland.\n",
      "\n",
      "Vesga, Jasmin\n",
      "Dr Mauricio Sanabria is a full-time employee of Baxter Renal Care Services-Latin-America,  Bogota, Colombia. Ms. Jasmin Vesga is a full-time employee of Baxter Renal Care Services-Colombia, Bucaramanga, Colombia. Dr. Lindholm is an employee of Baxter Healthcare Corporation and Karolinska Institutet, Stockholm, Sweden. Dr. Rivera is an employee of Baxter Healthcare Corporation, Deerfield, Illinois, USA. Dr. Rutherford is an employee of Baxter Healthcare Corporation, Zurich, Switzerland.\n",
      "\n",
      "Lindholm, Bengt\n",
      "Dr Mauricio Sanabria is a full-time employee of Baxter Renal Care Services-Latin-America,  Bogota, Colombia. Ms. Jasmin Vesga is a full-time employee of Baxter Renal Care Services-Colombia, Bucaramanga, Colombia. Dr. Bengt Lindholm is an employee of Baxter Healthcare Corporation and Karolinska Institutet, Stockholm, Sweden. Dr. Rivera is an employee of Baxter Healthcare Corporation, Deerfield, Illinois, USA. Dr. Rutherford is an employee of Baxter Healthcare Corporation, Zurich, Switzerland.\n",
      "\n",
      "Rivera, Angela\n",
      "Dr Mauricio Sanabria is a full-time employee of Baxter Renal Care Services-Latin-America,  Bogota, Colombia. Ms. Jasmin Vesga is a full-time employee of Baxter Renal Care Services-Colombia, Bucaramanga, Colombia. Dr. Bengt Lindholm is an employee of Baxter Healthcare Corporation and Karolinska Institutet, Stockholm, Sweden. Dr. Angela Rivera is an employee of Baxter Healthcare Corporation, Deerfield, Illinois, USA. Dr. Rutherford is an employee of Baxter Healthcare Corporation, Zurich, Switzerland.\n",
      "\n",
      "Rutherford, Peter\n",
      "Dr Mauricio Sanabria is a full-time employee of Baxter Renal Care Services-Latin-America,  Bogota, Colombia. Ms. Jasmin Vesga is a full-time employee of Baxter Renal Care Services-Colombia, Bucaramanga, Colombia. Dr. Bengt Lindholm is an employee of Baxter Healthcare Corporation and Karolinska Institutet, Stockholm, Sweden. Dr. Angela Rivera is an employee of Baxter Healthcare Corporation, Deerfield, Illinois, USA. Dr. Peter Rutherford is an employee of Baxter Healthcare Corporation, Zurich, Switzerland.\n",
      "\n",
      "Pergola, Pablo E.\n",
      "Dr. Pablo E. Pergola is a consultant for Ardelyx. He reports personal fees from Akebia Therapeutics, AstraZeneca, Bayer, Reata Pharmaceuticals, Gilead Sciences, Corvidia Therapeutics, FibroGen, Tricida, Ardelyx, Unicycive Therapeutic, and Otsuka Pharmaceuticals. For his performance as a PI, his employer Renal Associates, PA receives funding. He has no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflicts with the subject matter or materials discussed in the manuscript apart from those disclosed. The results presented in this paper have not been published previously in whole or part, except in abstract format.\n",
      "\n",
      "Conflict of Interest There is no conflict of interest.\n",
      "\n",
      "Conflict of Interest There is no conflict of interest.\n",
      "\n",
      "Conflict of Interest There is no conflict of interest.\n",
      "\n",
      "Conflict of Interest There is no conflict of interest.\n",
      "\n",
      "Conflict of Interest There is no conflict of interest.\n",
      "\n",
      "Conflict of Interest There is no conflict of interest.\n",
      "\n",
      "Conflict of Interest There is no conflict of interest.\n",
      "\n",
      "Rahmawati, Yuly\n",
      "Yuly Rahmawatiachmawati and Daniel Maranatha declare that they have no conflict of interest.\n",
      "\n",
      "Maranatha, Daniel\n",
      "Yuly Rahmawatiachmawati and Daniel Maranatha declare that they have no conflict of interest.\n",
      "\n",
      "We did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. This research was undertaken as partial fulfilment of the requirements for the MSc Surgical Sciences at The University of Edinburgh.\n",
      "\n",
      "We did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. This research was undertaken as partial fulfilment of the requirements for the MSc Surgical Sciences at The University of Edinburgh.\n",
      "\n",
      "We did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. This research was undertaken as partial fulfilment of the requirements for the MSc Surgical Sciences at The University of Edinburgh.\n",
      "\n",
      "We did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. This research was undertaken as partial fulfilment of the requirements for the MSc Surgical Sciences at The University of Edinburgh.\n",
      "\n",
      "We did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. This research was undertaken as partial fulfilment of the requirements for the MSc Surgical Sciences at The University of Edinburgh.\n",
      "\n",
      "1) Mriganka De is an employed consultant for 3D Matrix Ltd who manufacture Purabond(R) 2) All other authors have no conflicts of interest to declare. Georgios Garas is Consultant ENT, Head and Neck Surgeon (Surgical Oncology) at University Hospitals Birmingham NHS Foundation Trust (Birmingham, UK) and Honorary Clinical Senior Lecturer (Surgery and Cancer) at Imperial College London (London, UK). There are no commercial interests to declare.\n",
      "\n",
      "Garas, Georgios\n",
      "1) Mriganka De is an employed consultant for 3D Matrix Ltd who manufacture Purabond(R) 2) All other authors have no conflicts of interest to declare. Georgios Garas is Consultant ENT, Head and Neck Surgeon (Surgical Oncology) at University Hospitals Birmingham NHS Foundation Trust (Birmingham, UK) and Honorary Clinical Senior Lecturer (Surgery and Cancer) at Imperial College London (London, UK). There are no commercial interests to declare.\n",
      "\n",
      "1) Mriganka De is an employed consultant for 3D Matrix Ltd who manufacture Purabond(R) 2) All other authors have no conflicts of interest to declare. Georgios Garas is Consultant ENT, Head and Neck Surgeon (Surgical Oncology) at University Hospitals Birmingham NHS Foundation Trust (Birmingham, UK) and Honorary Clinical Senior Lecturer (Surgery and Cancer) at Imperial College London (London, UK). There are no commercial interests to declare.\n",
      "\n",
      "1) Mriganka De is an employed consultant for 3D Matrix Ltd who manufacture Purabond(R) 2) All other authors have no conflicts of interest to declare. Georgios Garas is Consultant ENT, Head and Neck Surgeon (Surgical Oncology) at University Hospitals Birmingham NHS Foundation Trust (Birmingham, UK) and Honorary Clinical Senior Lecturer (Surgery and Cancer) at Imperial College London (London, UK). There are no commercial interests to declare.\n",
      "\n",
      "De, Mriganka\n",
      "1) Mriganka De is an employed consultant for 3D Matrix Ltd who manufacture Purabond(R) 2) All other authors have no conflicts of interest to declare. Georgios Garas is Consultant ENT, Head and Neck Surgeon (Surgical Oncology) at University Hospitals Birmingham NHS Foundation Trust (Birmingham, UK) and Honorary Clinical Senior Lecturer (Surgery and Cancer) at Imperial College London (London, UK). There are no commercial interests to declare.\n",
      "\n",
      "Yilmaz, Mehmet\n",
      "A. Miernik receives research funds of the German 10.13039/501100002347Federal Ministry of Education and Research, Berlin (D). He receives support for his travel activities from the European Society of Urology, Arnhem (NL), and the 10.13039/501100006186German Society of Urology, Dusseldorf (D). Furthermore, A. Miernik is consulted for: KLS Martin, Tuttlingen (D), Avateramedical, Jena (D), LISA LaserProducts GmbH, Katlenburg-Lindau (D), Schoellyfiberoptics GmbH, Denzlingen (D), Dornier MedTech Laser GmbH (D), Medi-Tate Ltd. (IL, USA) and B. BraunNewventures GmbH, Freiburg (D). A. Miernik is speaker for the companies Richard Wolf GmbH (D) and Boston Scientific (USA). Additionally, he performed expert activities for the Ludwig Boltzmann Gesellschaft, Wien (A). A. Miernik is  involved in numerous patents and inventions in the field of medical technology. C. Gratzke is advisor for Astellas Pharma GmbH, Munich (D), Ipsen Pharma GmbH, Munich (D), Steba Biotech S.A., Luxembourg (LUX), Bayer Pharma, Leverkusen (D), Olympus Winter &Ibe GmbH, Hamburg (D), Medi-Tate Ltd., Or Akiva (IL), MSD, Haar (D), Astra-Zeneca, Cambridge (UK) and Roche, Basel (CH). C. Gratzke receives speaker fees from 10.13039/100002429Amgen, California (10.13039/100011408USA), 10.13039/501100004948Astellas Pharma GmbH, Munich (D), 10.13039/501100014382Ipsen Pharma GmbH, Munich (D), 10.13039/100015756Janssen-Cilag GmbH, Neuss (D), 10.13039/100004326Bayer Pharma, Leverkusen (D), Takeda Pharmaceuticals, Tokio (JPN) and 10.13039/501100014841medac GmbH, Wedel (D). Mehmet Yilmaz, MK, HCA, MFB, ST, and TT declare to have no conflicts of interest.\n",
      "\n",
      "Karaaslan, Mustafa\n",
      "A. Miernik receives research funds of the German 10.13039/501100002347Federal Ministry of Education and Research, Berlin (D). He receives support for his travel activities from the European Society of Urology, Arnhem (NL), and the 10.13039/501100006186German Society of Urology, Dusseldorf (D). Furthermore, A. Miernik is consulted for: KLS Martin, Tuttlingen (D), Avateramedical, Jena (D), LISA LaserProducts GmbH, Katlenburg-Lindau (D), Schoellyfiberoptics GmbH, Denzlingen (D), Dornier MedTech Laser GmbH (D), Medi-Tate Ltd. (IL, USA) and B. BraunNewventures GmbH, Freiburg (D). A. Miernik is speaker for the companies Richard Wolf GmbH (D) and Boston Scientific (USA). Additionally, he performed expert activities for the Ludwig Boltzmann Gesellschaft, Wien (A). A. Miernik is  involved in numerous patents and inventions in the field of medical technology. C. Gratzke is advisor for Astellas Pharma GmbH, Munich (D), Ipsen Pharma GmbH, Munich (D), Steba Biotech S.A., Luxembourg (LUX), Bayer Pharma, Leverkusen (D), Olympus Winter &Ibe GmbH, Hamburg (D), Medi-Tate Ltd., Or Akiva (IL), MSD, Haar (D), Astra-Zeneca, Cambridge (UK) and Roche, Basel (CH). C. Gratzke receives speaker fees from 10.13039/100002429Amgen, California (10.13039/100011408USA), 10.13039/501100004948Astellas Pharma GmbH, Munich (D), 10.13039/501100014382Ipsen Pharma GmbH, Munich (D), 10.13039/100015756Janssen-Cilag GmbH, Neuss (D), 10.13039/100004326Bayer Pharma, Leverkusen (D), Takeda Pharmaceuticals, Tokio (JPN) and 10.13039/501100014841medac GmbH, Wedel (D). Mehmet Yilmaz, Mustafa Karaaslan, HCA, MFB, ST, and TT declare to have no conflicts of interest.\n",
      "\n",
      "Cagri Aybal, Halil\n",
      "A. Miernik receives research funds of the German 10.13039/501100002347Federal Ministry of Education and Research, Berlin (D). He receives support for his travel activities from the European Society of Urology, Arnhem (NL), and the 10.13039/501100006186German Society of Urology, Dusseldorf (D). Furthermore, A. Miernik is consulted for: KLS Martin, Tuttlingen (D), Avateramedical, Jena (D), LISA LaserProducts GmbH, Katlenburg-Lindau (D), Schoellyfiberoptics GmbH, Denzlingen (D), Dornier MedTech Laser GmbH (D), Medi-Tate Ltd. (IL, USA) and B. BraunNewventures GmbH, Freiburg (D). A. Miernik is speaker for the companies Richard Wolf GmbH (D) and Boston Scientific (USA). Additionally, he performed expert activities for the Ludwig Boltzmann Gesellschaft, Wien (A). A. Miernik is  involved in numerous patents and inventions in the field of medical technology. C. Gratzke is advisor for Astellas Pharma GmbH, Munich (D), Ipsen Pharma GmbH, Munich (D), Steba Biotech S.A., Luxembourg (LUX), Bayer Pharma, Leverkusen (D), Olympus Winter &Ibe GmbH, Hamburg (D), Medi-Tate Ltd., Or Akiva (IL), MSD, Haar (D), Astra-Zeneca, Cambridge (UK) and Roche, Basel (CH). C. Gratzke receives speaker fees from 10.13039/100002429Amgen, California (10.13039/100011408USA), 10.13039/501100004948Astellas Pharma GmbH, Munich (D), 10.13039/501100014382Ipsen Pharma GmbH, Munich (D), 10.13039/100015756Janssen-Cilag GmbH, Neuss (D), 10.13039/100004326Bayer Pharma, Leverkusen (D), Takeda Pharmaceuticals, Tokio (JPN) and 10.13039/501100014841medac GmbH, Wedel (D). Mehmet Yilmaz, Mustafa Karaaslan, Halil Cagri Aybal, MFB, ST, and TT declare to have no conflicts of interest.\n",
      "\n",
      "Ferry von Bargen, Maximilian\n",
      "A. Miernik receives research funds of the German 10.13039/501100002347Federal Ministry of Education and Research, Berlin (D). He receives support for his travel activities from the European Society of Urology, Arnhem (NL), and the 10.13039/501100006186German Society of Urology, Dusseldorf (D). Furthermore, A. Miernik is consulted for: KLS Martin, Tuttlingen (D), Avateramedical, Jena (D), LISA LaserProducts GmbH, Katlenburg-Lindau (D), Schoellyfiberoptics GmbH, Denzlingen (D), Dornier MedTech Laser GmbH (D), Medi-Tate Ltd. (IL, USA) and B. BraunNewventures GmbH, Freiburg (D). A. Miernik is speaker for the companies Richard Wolf GmbH (D) and Boston Scientific (USA). Additionally, he performed expert activities for the Ludwig Boltzmann Gesellschaft, Wien (A). A. Miernik is  involved in numerous patents and inventions in the field of medical technology. C. Gratzke is advisor for Astellas Pharma GmbH, Munich (D), Ipsen Pharma GmbH, Munich (D), Steba Biotech S.A., Luxembourg (LUX), Bayer Pharma, Leverkusen (D), Olympus Winter &Ibe GmbH, Hamburg (D), Medi-Tate Ltd., Or Akiva (IL), MSD, Haar (D), Astra-Zeneca, Cambridge (UK) and Roche, Basel (CH). C. Gratzke receives speaker fees from 10.13039/100002429Amgen, California (10.13039/100011408USA), 10.13039/501100004948Astellas Pharma GmbH, Munich (D), 10.13039/501100014382Ipsen Pharma GmbH, Munich (D), 10.13039/100015756Janssen-Cilag GmbH, Neuss (D), 10.13039/100004326Bayer Pharma, Leverkusen (D), Takeda Pharmaceuticals, Tokio (JPN) and 10.13039/501100014841medac GmbH, Wedel (D). Mehmet Yilmaz, Mustafa Karaaslan, Halil Cagri Aybal, Maximilian Ferry von Bargen, ST, and TT declare to have no conflicts of interest.\n",
      "\n",
      "Tonyali, Senol\n",
      "A. Miernik receives research funds of the German 10.13039/501100002347Federal Ministry of Education and Research, Berlin (D). He receives support for his travel activities from the European Society of Urology, Arnhem (NL), and the 10.13039/501100006186German Society of Urology, Dusseldorf (D). Furthermore, A. Miernik is consulted for: KLS Martin, Tuttlingen (D), Avateramedical, Jena (D), LISA LaserProducts GmbH, Katlenburg-Lindau (D), Schoellyfiberoptics GmbH, Denzlingen (D), Dornier MedTech Laser GmbH (D), Medi-Tate Ltd. (IL, USA) and B. BraunNewventures GmbH, Freiburg (D). A. Miernik is speaker for the companies Richard Wolf GmbH (D) and Boston Scientific (USA). Additionally, he performed expert activities for the Ludwig Boltzmann Gesellschaft, Wien (A). A. Miernik is  involved in numerous patents and inventions in the field of medical technology. C. Gratzke is advisor for Astellas Pharma GmbH, Munich (D), Ipsen Pharma GmbH, Munich (D), Steba Biotech S.A., Luxembourg (LUX), Bayer Pharma, Leverkusen (D), Olympus Winter &Ibe GmbH, Hamburg (D), Medi-Tate Ltd., Or Akiva (IL), MSD, Haar (D), Astra-Zeneca, Cambridge (UK) and Roche, Basel (CH). C. Gratzke receives speaker fees from 10.13039/100002429Amgen, California (10.13039/100011408USA), 10.13039/501100004948Astellas Pharma GmbH, Munich (D), 10.13039/501100014382Ipsen Pharma GmbH, Munich (D), 10.13039/100015756Janssen-Cilag GmbH, Neuss (D), 10.13039/100004326Bayer Pharma, Leverkusen (D), Takeda Pharmaceuticals, Tokio (JPN) and 10.13039/501100014841medac GmbH, Wedel (D). Mehmet Yilmaz, Mustafa Karaaslan, Halil Cagri Aybal, Maximilian Ferry von Bargen, Senol Tonyali, and TT declare to have no conflicts of interest.\n",
      "\n",
      "Toprak, Tuncay\n",
      "A. Miernik receives research funds of the German 10.13039/501100002347Federal Ministry of Education and Research, Berlin (D). He receives support for his travel activities from the European Society of Urology, Arnhem (NL), and the 10.13039/501100006186German Society of Urology, Dusseldorf (D). Furthermore, A. Miernik is consulted for: KLS Martin, Tuttlingen (D), Avateramedical, Jena (D), LISA LaserProducts GmbH, Katlenburg-Lindau (D), Schoellyfiberoptics GmbH, Denzlingen (D), Dornier MedTech Laser GmbH (D), Medi-Tate Ltd. (IL, USA) and B. BraunNewventures GmbH, Freiburg (D). A. Miernik is speaker for the companies Richard Wolf GmbH (D) and Boston Scientific (USA). Additionally, he performed expert activities for the Ludwig Boltzmann Gesellschaft, Wien (A). A. Miernik is  involved in numerous patents and inventions in the field of medical technology. C. Gratzke is advisor for Astellas Pharma GmbH, Munich (D), Ipsen Pharma GmbH, Munich (D), Steba Biotech S.A., Luxembourg (LUX), Bayer Pharma, Leverkusen (D), Olympus Winter &Ibe GmbH, Hamburg (D), Medi-Tate Ltd., Or Akiva (IL), MSD, Haar (D), Astra-Zeneca, Cambridge (UK) and Roche, Basel (CH). C. Gratzke receives speaker fees from 10.13039/100002429Amgen, California (10.13039/100011408USA), 10.13039/501100004948Astellas Pharma GmbH, Munich (D), 10.13039/501100014382Ipsen Pharma GmbH, Munich (D), 10.13039/100015756Janssen-Cilag GmbH, Neuss (D), 10.13039/100004326Bayer Pharma, Leverkusen (D), Takeda Pharmaceuticals, Tokio (JPN) and 10.13039/501100014841medac GmbH, Wedel (D). Mehmet Yilmaz, Mustafa Karaaslan, Halil Cagri Aybal, Maximilian Ferry von Bargen, Senol Tonyali, and Tuncay Toprak declare to have no conflicts of interest.\n",
      "\n",
      "Gratzke, Christian\n",
      "A. Miernik receives research funds of the German 10.13039/501100002347Federal Ministry of Education and Research, Berlin (D). He receives support for his travel activities from the European Society of Urology, Arnhem (NL), and the 10.13039/501100006186German Society of Urology, Dusseldorf (D). Furthermore, A. Miernik is consulted for: KLS Martin, Tuttlingen (D), Avateramedical, Jena (D), LISA LaserProducts GmbH, Katlenburg-Lindau (D), Schoellyfiberoptics GmbH, Denzlingen (D), Dornier MedTech Laser GmbH (D), Medi-Tate Ltd. (IL, USA) and B. BraunNewventures GmbH, Freiburg (D). A. Miernik is speaker for the companies Richard Wolf GmbH (D) and Boston Scientific (USA). Additionally, he performed expert activities for the Ludwig Boltzmann Gesellschaft, Wien (A). A. Miernik is  involved in numerous patents and inventions in the field of medical technology. Christian Gratzke is advisor for Astellas Pharma GmbH, Munich (D), Ipsen Pharma GmbH, Munich (D), Steba Biotech S.A., Luxembourg (LUX), Bayer Pharma, Leverkusen (D), Olympus Winter &Ibe GmbH, Hamburg (D), Medi-Tate Ltd., Or Akiva (IL), MSD, Haar (D), Astra-Zeneca, Cambridge (UK) and Roche, Basel (CH). Christian Gratzke receives speaker fees from 10.13039/100002429Amgen, California (10.13039/100011408USA), 10.13039/501100004948Astellas Pharma GmbH, Munich (D), 10.13039/501100014382Ipsen Pharma GmbH, Munich (D), 10.13039/100015756Janssen-Cilag GmbH, Neuss (D), 10.13039/100004326Bayer Pharma, Leverkusen (D), Takeda Pharmaceuticals, Tokio (JPN) and 10.13039/501100014841medac GmbH, Wedel (D). Mehmet Yilmaz, Mustafa Karaaslan, Halil Cagri Aybal, Maximilian Ferry von Bargen, Senol Tonyali, and Tuncay Toprak declare to have no conflicts of interest.\n",
      "\n",
      "Miernik, Arkadiusz\n",
      "Arkadiusz Miernik receives research funds of the German 10.13039/501100002347Federal Ministry of Education and Research, Berlin (D). He receives support for his travel activities from the European Society of Urology, Arnhem (NL), and the 10.13039/501100006186German Society of Urology, Dusseldorf (D). Furthermore, Arkadiusz Miernik is consulted for: KLS Martin, Tuttlingen (D), Avateramedical, Jena (D), LISA LaserProducts GmbH, Katlenburg-Lindau (D), Schoellyfiberoptics GmbH, Denzlingen (D), Dornier MedTech Laser GmbH (D), Medi-Tate Ltd. (IL, USA) and B. BraunNewventures GmbH, Freiburg (D). Arkadiusz Miernik is speaker for the companies Richard Wolf GmbH (D) and Boston Scientific (USA). Additionally, he performed expert activities for the Ludwig Boltzmann Gesellschaft, Wien (A). Arkadiusz Miernik is  involved in numerous patents and inventions in the field of medical technology. Christian Gratzke is advisor for Astellas Pharma GmbH, Munich (D), Ipsen Pharma GmbH, Munich (D), Steba Biotech S.A., Luxembourg (LUX), Bayer Pharma, Leverkusen (D), Olympus Winter &Ibe GmbH, Hamburg (D), Medi-Tate Ltd., Or Akiva (IL), MSD, Haar (D), Astra-Zeneca, Cambridge (UK) and Roche, Basel (CH). Christian Gratzke receives speaker fees from 10.13039/100002429Amgen, California (10.13039/100011408USA), 10.13039/501100004948Astellas Pharma GmbH, Munich (D), 10.13039/501100014382Ipsen Pharma GmbH, Munich (D), 10.13039/100015756Janssen-Cilag GmbH, Neuss (D), 10.13039/100004326Bayer Pharma, Leverkusen (D), Takeda Pharmaceuticals, Tokio (JPN) and 10.13039/501100014841medac GmbH, Wedel (D). Mehmet Yilmaz, Mustafa Karaaslan, Halil Cagri Aybal, Maximilian Ferry von Bargen, Senol Tonyali, and Tuncay Toprak declare to have no conflicts of interest.\n",
      "\n",
      "NA.\n",
      "\n",
      "NA.\n",
      "\n",
      "NA.\n",
      "\n",
      "The author(s) declared no potential Computing of interest to the research, authorship, and/or publication of this article.\n",
      "\n",
      "The author(s) declared no potential Computing of interest to the research, authorship, and/or publication of this article.\n",
      "\n",
      "The author(s) declared no potential Computing of interest to the research, authorship, and/or publication of this article.\n",
      "\n",
      "The authors declared no potential conflicts of interest with respect to the research, authorship and/or publication of this article. (All contributing authors must complete the ICMJE form individually and the completed forms should  be submitted to the online system by the corresponding author. The form is available at http://www.icmje.org/conflicts-of-interest/After that the information which were stated at the end of the forms must be combined and declared in this section).\n",
      "\n",
      "The authors declared no potential conflicts of interest with respect to the research, authorship and/or publication of this article. (All contributing authors must complete the ICMJE form individually and the completed forms should  be submitted to the online system by the corresponding author. The form is available at http://www.icmje.org/conflicts-of-interest/After that the information which were stated at the end of the forms must be combined and declared in this section).\n",
      "\n",
      "The authors declared no potential conflicts of interest with respect to the research, authorship and/or publication of this article. (All contributing authors must complete the ICMJE form individually and the completed forms should  be submitted to the online system by the corresponding author. The form is available at http://www.icmje.org/conflicts-of-interest/After that the information which were stated at the end of the forms must be combined and declared in this section).\n",
      "\n",
      "The authors declared no potential conflicts of interest with respect to the research, authorship and/or publication of this article. (All contributing authors must complete the ICMJE form individually and the completed forms should  be submitted to the online system by the corresponding author. The form is available at http://www.icmje.org/conflicts-of-interest/After that the information which were stated at the end of the forms must be combined and declared in this section).\n",
      "\n",
      "The authors declared no potential conflicts of interest with respect to the research, authorship and/or publication of this article. (All contributing authors must complete the ICMJE form individually and the completed forms should  be submitted to the online system by the corresponding author. The form is available at http://www.icmje.org/conflicts-of-interest/After that the information which were stated at the end of the forms must be combined and declared in this section).\n",
      "\n",
      "The authors declared no potential conflicts of interest with respect to the research, authorship and/or publication of this article. (All contributing authors must complete the ICMJE form individually and the completed forms should  be submitted to the online system by the corresponding author. The form is available at http://www.icmje.org/conflicts-of-interest/After that the information which were stated at the end of the forms must be combined and declared in this section).\n",
      "\n",
      "NA.\n",
      "\n",
      "NA.\n",
      "\n",
      "NA.\n",
      "\n",
      "NA.\n",
      "\n",
      "NA.\n",
      "\n",
      "NA.\n",
      "\n",
      "NA.\n",
      "\n",
      "NA.\n",
      "\n",
      "NA.\n",
      "\n",
      "NA.\n",
      "\n",
      "NA.\n",
      "\n",
      "Bagus Aprinda, Devani\n",
      "Devani Bagus Aprinda and Satriyo Dwi Suryantoro declare that they have no conflict of interest.\n",
      "\n",
      "Dwi Suryantoro, Satriyo\n",
      "Devani Bagus Aprinda and Satriyo Dwi Suryantoro declare that they have no conflict of interest.\n",
      "\n",
      "Declaration of interests K.D.M. has filed a patent application for the DART-seq technology through Duke University.\n",
      "\n",
      "Declaration of interests K.D.M. has filed a patent application for the DART-seq technology through Duke University.\n",
      "\n",
      "Declaration of interests K.D.M. has filed a patent application for the DART-seq technology through Duke University.\n",
      "\n",
      "Declaration of interests K.D.M. has filed a patent application for the DART-seq technology through Duke University.\n",
      "\n",
      "Declaration of interests K.D.M. has filed a patent application for the DART-seq technology through Duke University.\n",
      "\n",
      "Declaration of interests K.D.M. has filed a patent application for the DART-seq technology through Duke University.\n",
      "\n",
      "Declaration of interests K.D.M. has filed a patent application for the DART-seq technology through Duke University.\n",
      "\n",
      "Declaration of interests K.D.M. has filed a patent application for the DART-seq technology through Duke University.\n",
      "\n",
      "Declaration of interests K.D.M. has filed a patent application for the DART-seq technology through Duke University.\n",
      "\n",
      "Meyer, Kate D.\n",
      "Declaration of interests Kate D. Meyer has filed a patent application for the DART-seq technology through Duke University.\n",
      "\n",
      "Declaration of interests N.A.M. currently serves on the Medical Advisory Board for TearSolutions. All other authors declare no competing interests.\n",
      "\n",
      "Declaration of interests N.A.M. currently serves on the Medical Advisory Board for TearSolutions. All other authors declare no competing interests.\n",
      "\n",
      "Declaration of interests N.A.M. currently serves on the Medical Advisory Board for TearSolutions. All other authors declare no competing interests.\n",
      "\n",
      "Declaration of interests N.A.M. currently serves on the Medical Advisory Board for TearSolutions. All other authors declare no competing interests.\n",
      "\n",
      "McNamara, Nancy A.\n",
      "Declaration of interests Nancy A. McNamara currently serves on the Medical Advisory Board for TearSolutions. All other authors declare no competing interests.\n",
      "\n",
      "Declaration of interests Nancy A. McNamara currently serves on the Medical Advisory Board for TearSolutions. All other authors declare no competing interests.\n",
      "\n",
      "Declaration of interests S.A.G. is a part-time employee and stockholder of Sana Biotechnology, a cell therapy company, and his lab receives sponsored research support from Sana. S.A.G. is also a co-founder and adviser to CNS2 Therapeutics,  another cell therapy company. None of the work described in this paper overlaps with his work with those companies. D.C.-M. is also a consultant to Sana.\n",
      "\n",
      "Declaration of interests S.A.G. is a part-time employee and stockholder of Sana Biotechnology, a cell therapy company, and his lab receives sponsored research support from Sana. S.A.G. is also a co-founder and adviser to CNS2 Therapeutics,  another cell therapy company. None of the work described in this paper overlaps with his work with those companies. D.C.-M. is also a consultant to Sana.\n",
      "\n",
      "Declaration of interests S.A.G. is a part-time employee and stockholder of Sana Biotechnology, a cell therapy company, and his lab receives sponsored research support from Sana. S.A.G. is also a co-founder and adviser to CNS2 Therapeutics,  another cell therapy company. None of the work described in this paper overlaps with his work with those companies. D.C.-M. is also a consultant to Sana.\n",
      "\n",
      "Declaration of interests S.A.G. is a part-time employee and stockholder of Sana Biotechnology, a cell therapy company, and his lab receives sponsored research support from Sana. S.A.G. is also a co-founder and adviser to CNS2 Therapeutics,  another cell therapy company. None of the work described in this paper overlaps with his work with those companies. D.C.-M. is also a consultant to Sana.\n",
      "\n",
      "Declaration of interests S.A.G. is a part-time employee and stockholder of Sana Biotechnology, a cell therapy company, and his lab receives sponsored research support from Sana. S.A.G. is also a co-founder and adviser to CNS2 Therapeutics,  another cell therapy company. None of the work described in this paper overlaps with his work with those companies. D.C.-M. is also a consultant to Sana.\n",
      "\n",
      "Declaration of interests S.A.G. is a part-time employee and stockholder of Sana Biotechnology, a cell therapy company, and his lab receives sponsored research support from Sana. S.A.G. is also a co-founder and adviser to CNS2 Therapeutics,  another cell therapy company. None of the work described in this paper overlaps with his work with those companies. D.C.-M. is also a consultant to Sana.\n",
      "\n",
      "Declaration of interests S.A.G. is a part-time employee and stockholder of Sana Biotechnology, a cell therapy company, and his lab receives sponsored research support from Sana. S.A.G. is also a co-founder and adviser to CNS2 Therapeutics,  another cell therapy company. None of the work described in this paper overlaps with his work with those companies. D.C.-M. is also a consultant to Sana.\n",
      "\n",
      "Declaration of interests S.A.G. is a part-time employee and stockholder of Sana Biotechnology, a cell therapy company, and his lab receives sponsored research support from Sana. S.A.G. is also a co-founder and adviser to CNS2 Therapeutics,  another cell therapy company. None of the work described in this paper overlaps with his work with those companies. D.C.-M. is also a consultant to Sana.\n",
      "\n",
      "Declaration of interests S.A.G. is a part-time employee and stockholder of Sana Biotechnology, a cell therapy company, and his lab receives sponsored research support from Sana. S.A.G. is also a co-founder and adviser to CNS2 Therapeutics,  another cell therapy company. None of the work described in this paper overlaps with his work with those companies. D.C.-M. is also a consultant to Sana.\n",
      "\n",
      "Chandler-Militello, Devin\n",
      "Declaration of interests S.A.G. is a part-time employee and stockholder of Sana Biotechnology, a cell therapy company, and his lab receives sponsored research support from Sana. S.A.G. is also a co-founder and adviser to CNS2 Therapeutics,  another cell therapy company. None of the work described in this paper overlaps with his work with those companies. Devin Chandler-Militello-M. is also a consultant to Sana.\n",
      "\n",
      "Goldman, Steven A.\n",
      "Declaration of interests Steven A. Goldman is a part-time employee and stockholder of Sana Biotechnology, a cell therapy company, and his lab receives sponsored research support from Sana. Steven A. Goldman is also a co-founder and adviser to CNS2 Therapeutics,  another cell therapy company. None of the work described in this paper overlaps with his work with those companies. Devin Chandler-Militello-M. is also a consultant to Sana.\n",
      "\n",
      "Declaration of interests A.D.D. is a consultant/advisory board member for Merck-EMD Serono, Cyteir Therapeutics, Third Rock Ventures, AstraZeneca, and Cedilla Therapeutics Inc. He is also a stockholder in Cedilla Therapeutics Inc.,  Oncolinea Pharmaceuticals Inc, Impact Therapeutics Inc, and Cyteir Therapeutics Inc, and reports receiving commercial research grants from Merck-EMD Serono, Bristol Meyers Squibb, Moderna Inc, and Tango Therapeutics Inc.\n",
      "\n",
      "Declaration of interests A.D.D. is a consultant/advisory board member for Merck-EMD Serono, Cyteir Therapeutics, Third Rock Ventures, AstraZeneca, and Cedilla Therapeutics Inc. He is also a stockholder in Cedilla Therapeutics Inc.,  Oncolinea Pharmaceuticals Inc, Impact Therapeutics Inc, and Cyteir Therapeutics Inc, and reports receiving commercial research grants from Merck-EMD Serono, Bristol Meyers Squibb, Moderna Inc, and Tango Therapeutics Inc.\n",
      "\n",
      "Declaration of interests A.D.D. is a consultant/advisory board member for Merck-EMD Serono, Cyteir Therapeutics, Third Rock Ventures, AstraZeneca, and Cedilla Therapeutics Inc. He is also a stockholder in Cedilla Therapeutics Inc.,  Oncolinea Pharmaceuticals Inc, Impact Therapeutics Inc, and Cyteir Therapeutics Inc, and reports receiving commercial research grants from Merck-EMD Serono, Bristol Meyers Squibb, Moderna Inc, and Tango Therapeutics Inc.\n",
      "\n",
      "Declaration of interests A.D.D. is a consultant/advisory board member for Merck-EMD Serono, Cyteir Therapeutics, Third Rock Ventures, AstraZeneca, and Cedilla Therapeutics Inc. He is also a stockholder in Cedilla Therapeutics Inc.,  Oncolinea Pharmaceuticals Inc, Impact Therapeutics Inc, and Cyteir Therapeutics Inc, and reports receiving commercial research grants from Merck-EMD Serono, Bristol Meyers Squibb, Moderna Inc, and Tango Therapeutics Inc.\n",
      "\n",
      "Declaration of interests A.D.D. is a consultant/advisory board member for Merck-EMD Serono, Cyteir Therapeutics, Third Rock Ventures, AstraZeneca, and Cedilla Therapeutics Inc. He is also a stockholder in Cedilla Therapeutics Inc.,  Oncolinea Pharmaceuticals Inc, Impact Therapeutics Inc, and Cyteir Therapeutics Inc, and reports receiving commercial research grants from Merck-EMD Serono, Bristol Meyers Squibb, Moderna Inc, and Tango Therapeutics Inc.\n",
      "\n",
      "Declaration of interests A.D.D. is a consultant/advisory board member for Merck-EMD Serono, Cyteir Therapeutics, Third Rock Ventures, AstraZeneca, and Cedilla Therapeutics Inc. He is also a stockholder in Cedilla Therapeutics Inc.,  Oncolinea Pharmaceuticals Inc, Impact Therapeutics Inc, and Cyteir Therapeutics Inc, and reports receiving commercial research grants from Merck-EMD Serono, Bristol Meyers Squibb, Moderna Inc, and Tango Therapeutics Inc.\n",
      "\n",
      "Declaration of interests A.D.D. is a consultant/advisory board member for Merck-EMD Serono, Cyteir Therapeutics, Third Rock Ventures, AstraZeneca, and Cedilla Therapeutics Inc. He is also a stockholder in Cedilla Therapeutics Inc.,  Oncolinea Pharmaceuticals Inc, Impact Therapeutics Inc, and Cyteir Therapeutics Inc, and reports receiving commercial research grants from Merck-EMD Serono, Bristol Meyers Squibb, Moderna Inc, and Tango Therapeutics Inc.\n",
      "\n",
      "D'Andrea, Alan D.\n",
      "Declaration of interests Alan D. D'Andrea is a consultant/advisory board member for Merck-EMD Serono, Cyteir Therapeutics, Third Rock Ventures, AstraZeneca, and Cedilla Therapeutics Inc. He is also a stockholder in Cedilla Therapeutics Inc.,  Oncolinea Pharmaceuticals Inc, Impact Therapeutics Inc, and Cyteir Therapeutics Inc, and reports receiving commercial research grants from Merck-EMD Serono, Bristol Meyers Squibb, Moderna Inc, and Tango Therapeutics Inc.\n",
      "\n",
      "McKernan, Courtney M.\n",
      "Declaration of interests A.M.P. is a consultant and advisory board member for the Pew Charitable Trusts. Courtney M. McKernan is an employee of Altavant Sciences. M.H. is an employee of Torque Bio, Inc.\n",
      "\n",
      "Declaration of interests A.M.P. is a consultant and advisory board member for the Pew Charitable Trusts. Courtney M. McKernan is an employee of Altavant Sciences. M.H. is an employee of Torque Bio, Inc.\n",
      "\n",
      "Hannigan, Molly\n",
      "Declaration of interests A.M.P. is a consultant and advisory board member for the Pew Charitable Trusts. Courtney M. McKernan is an employee of Altavant Sciences. Molly Hannigan is an employee of Torque Bio, Inc.\n",
      "\n",
      "Declaration of interests A.M.P. is a consultant and advisory board member for the Pew Charitable Trusts. Courtney M. McKernan is an employee of Altavant Sciences. Molly Hannigan is an employee of Torque Bio, Inc.\n",
      "\n",
      "Declaration of interests A.M.P. is a consultant and advisory board member for the Pew Charitable Trusts. Courtney M. McKernan is an employee of Altavant Sciences. Molly Hannigan is an employee of Torque Bio, Inc.\n",
      "\n",
      "Declaration of interests A.M.P. is a consultant and advisory board member for the Pew Charitable Trusts. Courtney M. McKernan is an employee of Altavant Sciences. Molly Hannigan is an employee of Torque Bio, Inc.\n",
      "\n",
      "Declaration of interests A.M.P. is a consultant and advisory board member for the Pew Charitable Trusts. Courtney M. McKernan is an employee of Altavant Sciences. Molly Hannigan is an employee of Torque Bio, Inc.\n",
      "\n",
      "Declaration of interests A.M.P. is a consultant and advisory board member for the Pew Charitable Trusts. Courtney M. McKernan is an employee of Altavant Sciences. Molly Hannigan is an employee of Torque Bio, Inc.\n",
      "\n",
      "Marie Pendergast, Ann\n",
      "Declaration of interests Ann Marie Pendergast is a consultant and advisory board member for the Pew Charitable Trusts. Courtney M. McKernan is an employee of Altavant Sciences. Molly Hannigan is an employee of Torque Bio, Inc.\n",
      "\n",
      "Declaration of Competing Interest The authors declare no conflict of interest. We declare that we have no financial and personal relationships with other people or organizations that can inappropriately influence our work, there is no professional or other personal interest of any nature or kind in any product, service and/or company that could be construed as influencing the position presented in, or the review of, the manuscript entitled \"Efficient and selective  solid-phase microextraction of polychlorinated biphenyls by using a three-dimensional covalent organic framework as functional coating\".\n",
      "\n",
      "Declaration of Competing Interest The authors declare no conflict of interest. We declare that we have no financial and personal relationships with other people or organizations that can inappropriately influence our work, there is no professional or other personal interest of any nature or kind in any product, service and/or company that could be construed as influencing the position presented in, or the review of, the manuscript entitled \"Efficient and selective  solid-phase microextraction of polychlorinated biphenyls by using a three-dimensional covalent organic framework as functional coating\".\n",
      "\n",
      "Declaration of Competing Interest The authors declare no conflict of interest. We declare that we have no financial and personal relationships with other people or organizations that can inappropriately influence our work, there is no professional or other personal interest of any nature or kind in any product, service and/or company that could be construed as influencing the position presented in, or the review of, the manuscript entitled \"Efficient and selective  solid-phase microextraction of polychlorinated biphenyls by using a three-dimensional covalent organic framework as functional coating\".\n",
      "\n",
      "Declaration of Competing Interest The authors declare no conflict of interest. We declare that we have no financial and personal relationships with other people or organizations that can inappropriately influence our work, there is no professional or other personal interest of any nature or kind in any product, service and/or company that could be construed as influencing the position presented in, or the review of, the manuscript entitled \"Efficient and selective  solid-phase microextraction of polychlorinated biphenyls by using a three-dimensional covalent organic framework as functional coating\".\n",
      "\n",
      "Declaration of Competing Interest The authors declare no conflict of interest. We declare that we have no financial and personal relationships with other people or organizations that can inappropriately influence our work, there is no professional or other personal interest of any nature or kind in any product, service and/or company that could be construed as influencing the position presented in, or the review of, the manuscript entitled \"Efficient and selective  solid-phase microextraction of polychlorinated biphenyls by using a three-dimensional covalent organic framework as functional coating\".\n",
      "\n",
      "Dowlati, Afshin\n",
      "Afshin DowlatiConsulting or Advisory Role: AbbVie/Stemcentrx, AstraZeneca, Bristol Myers Squibb, Takeda, Bayer, G1 Therapeutics, Ipsen, MerckResearch Funding: Lilly/ImClone (Inst), Amgen (Inst), Bristol Myers Squibb (Inst), EMD Serono (Inst), Tesaro (Inst), Takeda (Inst), Mirati Therapeutics (Inst), AbbVie/Stemcentrx (Inst), United Therapeutics (Inst), Regeneron (Inst), Bayer (Inst), Seattle Genetics (Inst), Symphogen (Inst), Ipsen (Inst) Timothy ChanLeadership: Cancer Genetics, Illumina, Bristol Myers SquibbStock and Other Ownership Interests: Gritstone BioHonoraria: IlluminaConsulting or Advisory Role: Bristol Myers Squibb/Celgene, Illumina, LG Chem, PfizerResearch Funding: Bristol  Myers Squibb (Inst), AstraZeneca/MedImmune (Inst), Pfizer (Inst), Nysnobio (Inst)Patents, Royalties, Other Intellectual Property: Neoantigen discovery and genomic biomarkers for immunotherapy response Brian HenickThis author is a member of the JCO Precision Oncology Editorial Board. Journal policy recused the author  from having any role in the peer review of this manuscript.Consulting or Advisory Role: AstraZeneca, IDEAYA Biosciences, Jazz PharmaceuticalsResearch Funding: NexImmune Xuya WangEmployment: Bristol Myers SquibbStock and Other Ownership Interests: Bristol Myers Squibb Parul DoshiEmployment: Bristol Myers Squibb, Gilead SciencesStock and Other Ownership Interests: Bristol Myers SquibbTravel, Accommodations, Expenses: Bristol Myers Squibb, Gilead Sciences Jyoti PatelConsulting or Advisory Role: AbbVie, AstraZeneca, Takeda Science Foundation, Lilly, GenentechResearch Funding: Bristol Myers Squibb (Inst) Fengshen KuoStock and Other Ownership Interests: Sanofi, General Electric, 10x Genomics, Merck, Cigna, Cigna, Viatris, Pfizer Han ChangEmployment: Bristol Myers SquibbStock and  Other Ownership Interests: Bristol Myers SquibbResearch Funding: Bristol Myers SquibbPatents, Royalties, Other Intellectual Property: I am an employee of BMS, and an inventor on one or more pending pa tent applications, including applications for TMB as a predictive biomarker of immunotherapyTravel, Accommodations, Expenses: Bristol Myers Squibb David BalliEmployment: Bristol Myers SquibbStock and Other Ownership Interests: Bristol Myers SquibbNo other potential conflicts of interest were reported.\n",
      "\n",
      "Afshin DowlatiConsulting or Advisory Role: AbbVie/Stemcentrx, AstraZeneca, Bristol Myers Squibb, Takeda, Bayer, G1 Therapeutics, Ipsen, MerckResearch Funding: Lilly/ImClone (Inst), Amgen (Inst), Bristol Myers Squibb (Inst), EMD Serono (Inst), Tesaro (Inst), Takeda (Inst), Mirati Therapeutics (Inst), AbbVie/Stemcentrx (Inst), United Therapeutics (Inst), Regeneron (Inst), Bayer (Inst), Seattle Genetics (Inst), Symphogen (Inst), Ipsen (Inst) Timothy ChanLeadership: Cancer Genetics, Illumina, Bristol Myers SquibbStock and Other Ownership Interests: Gritstone BioHonoraria: IlluminaConsulting or Advisory Role: Bristol Myers Squibb/Celgene, Illumina, LG Chem, PfizerResearch Funding: Bristol  Myers Squibb (Inst), AstraZeneca/MedImmune (Inst), Pfizer (Inst), Nysnobio (Inst)Patents, Royalties, Other Intellectual Property: Neoantigen discovery and genomic biomarkers for immunotherapy response Brian HenickThis author is a member of the JCO Precision Oncology Editorial Board. Journal policy recused the author  from having any role in the peer review of this manuscript.Consulting or Advisory Role: AstraZeneca, IDEAYA Biosciences, Jazz PharmaceuticalsResearch Funding: NexImmune Xuya WangEmployment: Bristol Myers SquibbStock and Other Ownership Interests: Bristol Myers Squibb Parul DoshiEmployment: Bristol Myers Squibb, Gilead SciencesStock and Other Ownership Interests: Bristol Myers SquibbTravel, Accommodations, Expenses: Bristol Myers Squibb, Gilead Sciences Jyoti PatelConsulting or Advisory Role: AbbVie, AstraZeneca, Takeda Science Foundation, Lilly, GenentechResearch Funding: Bristol Myers Squibb (Inst) Fengshen KuoStock and Other Ownership Interests: Sanofi, General Electric, 10x Genomics, Merck, Cigna, Cigna, Viatris, Pfizer Han ChangEmployment: Bristol Myers SquibbStock and  Other Ownership Interests: Bristol Myers SquibbResearch Funding: Bristol Myers SquibbPatents, Royalties, Other Intellectual Property: I am an employee of BMS, and an inventor on one or more pending pa tent applications, including applications for TMB as a predictive biomarker of immunotherapyTravel, Accommodations, Expenses: Bristol Myers Squibb David BalliEmployment: Bristol Myers SquibbStock and Other Ownership Interests: Bristol Myers SquibbNo other potential conflicts of interest were reported.\n",
      "\n",
      "Chan, Timothy\n",
      "Afshin DowlatiConsulting or Advisory Role: AbbVie/Stemcentrx, AstraZeneca, Bristol Myers Squibb, Takeda, Bayer, G1 Therapeutics, Ipsen, MerckResearch Funding: Lilly/ImClone (Inst), Amgen (Inst), Bristol Myers Squibb (Inst), EMD Serono (Inst), Tesaro (Inst), Takeda (Inst), Mirati Therapeutics (Inst), AbbVie/Stemcentrx (Inst), United Therapeutics (Inst), Regeneron (Inst), Bayer (Inst), Seattle Genetics (Inst), Symphogen (Inst), Ipsen (Inst) Timothy ChanLeadership: Cancer Genetics, Illumina, Bristol Myers SquibbStock and Other Ownership Interests: Gritstone BioHonoraria: IlluminaConsulting or Advisory Role: Bristol Myers Squibb/Celgene, Illumina, LG Chem, PfizerResearch Funding: Bristol  Myers Squibb (Inst), AstraZeneca/MedImmune (Inst), Pfizer (Inst), Nysnobio (Inst)Patents, Royalties, Other Intellectual Property: Neoantigen discovery and genomic biomarkers for immunotherapy response Brian HenickThis author is a member of the JCO Precision Oncology Editorial Board. Journal policy recused the author  from having any role in the peer review of this manuscript.Consulting or Advisory Role: AstraZeneca, IDEAYA Biosciences, Jazz PharmaceuticalsResearch Funding: NexImmune Xuya WangEmployment: Bristol Myers SquibbStock and Other Ownership Interests: Bristol Myers Squibb Parul DoshiEmployment: Bristol Myers Squibb, Gilead SciencesStock and Other Ownership Interests: Bristol Myers SquibbTravel, Accommodations, Expenses: Bristol Myers Squibb, Gilead Sciences Jyoti PatelConsulting or Advisory Role: AbbVie, AstraZeneca, Takeda Science Foundation, Lilly, GenentechResearch Funding: Bristol Myers Squibb (Inst) Fengshen KuoStock and Other Ownership Interests: Sanofi, General Electric, 10x Genomics, Merck, Cigna, Cigna, Viatris, Pfizer Han ChangEmployment: Bristol Myers SquibbStock and  Other Ownership Interests: Bristol Myers SquibbResearch Funding: Bristol Myers SquibbPatents, Royalties, Other Intellectual Property: I am an employee of BMS, and an inventor on one or more pending pa tent applications, including applications for TMB as a predictive biomarker of immunotherapyTravel, Accommodations, Expenses: Bristol Myers Squibb David BalliEmployment: Bristol Myers SquibbStock and Other Ownership Interests: Bristol Myers SquibbNo other potential conflicts of interest were reported.\n",
      "\n",
      "Henick, Brian\n",
      "Afshin DowlatiConsulting or Advisory Role: AbbVie/Stemcentrx, AstraZeneca, Bristol Myers Squibb, Takeda, Bayer, G1 Therapeutics, Ipsen, MerckResearch Funding: Lilly/ImClone (Inst), Amgen (Inst), Bristol Myers Squibb (Inst), EMD Serono (Inst), Tesaro (Inst), Takeda (Inst), Mirati Therapeutics (Inst), AbbVie/Stemcentrx (Inst), United Therapeutics (Inst), Regeneron (Inst), Bayer (Inst), Seattle Genetics (Inst), Symphogen (Inst), Ipsen (Inst) Timothy ChanLeadership: Cancer Genetics, Illumina, Bristol Myers SquibbStock and Other Ownership Interests: Gritstone BioHonoraria: IlluminaConsulting or Advisory Role: Bristol Myers Squibb/Celgene, Illumina, LG Chem, PfizerResearch Funding: Bristol  Myers Squibb (Inst), AstraZeneca/MedImmune (Inst), Pfizer (Inst), Nysnobio (Inst)Patents, Royalties, Other Intellectual Property: Neoantigen discovery and genomic biomarkers for immunotherapy response Brian HenickThis author is a member of the JCO Precision Oncology Editorial Board. Journal policy recused the author  from having any role in the peer review of this manuscript.Consulting or Advisory Role: AstraZeneca, IDEAYA Biosciences, Jazz PharmaceuticalsResearch Funding: NexImmune Xuya WangEmployment: Bristol Myers SquibbStock and Other Ownership Interests: Bristol Myers Squibb Parul DoshiEmployment: Bristol Myers Squibb, Gilead SciencesStock and Other Ownership Interests: Bristol Myers SquibbTravel, Accommodations, Expenses: Bristol Myers Squibb, Gilead Sciences Jyoti PatelConsulting or Advisory Role: AbbVie, AstraZeneca, Takeda Science Foundation, Lilly, GenentechResearch Funding: Bristol Myers Squibb (Inst) Fengshen KuoStock and Other Ownership Interests: Sanofi, General Electric, 10x Genomics, Merck, Cigna, Cigna, Viatris, Pfizer Han ChangEmployment: Bristol Myers SquibbStock and  Other Ownership Interests: Bristol Myers SquibbResearch Funding: Bristol Myers SquibbPatents, Royalties, Other Intellectual Property: I am an employee of BMS, and an inventor on one or more pending pa tent applications, including applications for TMB as a predictive biomarker of immunotherapyTravel, Accommodations, Expenses: Bristol Myers Squibb David BalliEmployment: Bristol Myers SquibbStock and Other Ownership Interests: Bristol Myers SquibbNo other potential conflicts of interest were reported.\n",
      "\n",
      "Wang, Xuya\n",
      "Afshin DowlatiConsulting or Advisory Role: AbbVie/Stemcentrx, AstraZeneca, Bristol Myers Squibb, Takeda, Bayer, G1 Therapeutics, Ipsen, MerckResearch Funding: Lilly/ImClone (Inst), Amgen (Inst), Bristol Myers Squibb (Inst), EMD Serono (Inst), Tesaro (Inst), Takeda (Inst), Mirati Therapeutics (Inst), AbbVie/Stemcentrx (Inst), United Therapeutics (Inst), Regeneron (Inst), Bayer (Inst), Seattle Genetics (Inst), Symphogen (Inst), Ipsen (Inst) Timothy ChanLeadership: Cancer Genetics, Illumina, Bristol Myers SquibbStock and Other Ownership Interests: Gritstone BioHonoraria: IlluminaConsulting or Advisory Role: Bristol Myers Squibb/Celgene, Illumina, LG Chem, PfizerResearch Funding: Bristol  Myers Squibb (Inst), AstraZeneca/MedImmune (Inst), Pfizer (Inst), Nysnobio (Inst)Patents, Royalties, Other Intellectual Property: Neoantigen discovery and genomic biomarkers for immunotherapy response Brian HenickThis author is a member of the JCO Precision Oncology Editorial Board. Journal policy recused the author  from having any role in the peer review of this manuscript.Consulting or Advisory Role: AstraZeneca, IDEAYA Biosciences, Jazz PharmaceuticalsResearch Funding: NexImmune Xuya WangEmployment: Bristol Myers SquibbStock and Other Ownership Interests: Bristol Myers Squibb Parul DoshiEmployment: Bristol Myers Squibb, Gilead SciencesStock and Other Ownership Interests: Bristol Myers SquibbTravel, Accommodations, Expenses: Bristol Myers Squibb, Gilead Sciences Jyoti PatelConsulting or Advisory Role: AbbVie, AstraZeneca, Takeda Science Foundation, Lilly, GenentechResearch Funding: Bristol Myers Squibb (Inst) Fengshen KuoStock and Other Ownership Interests: Sanofi, General Electric, 10x Genomics, Merck, Cigna, Cigna, Viatris, Pfizer Han ChangEmployment: Bristol Myers SquibbStock and  Other Ownership Interests: Bristol Myers SquibbResearch Funding: Bristol Myers SquibbPatents, Royalties, Other Intellectual Property: I am an employee of BMS, and an inventor on one or more pending pa tent applications, including applications for TMB as a predictive biomarker of immunotherapyTravel, Accommodations, Expenses: Bristol Myers Squibb David BalliEmployment: Bristol Myers SquibbStock and Other Ownership Interests: Bristol Myers SquibbNo other potential conflicts of interest were reported.\n",
      "\n",
      "Doshi, Parul\n",
      "Afshin DowlatiConsulting or Advisory Role: AbbVie/Stemcentrx, AstraZeneca, Bristol Myers Squibb, Takeda, Bayer, G1 Therapeutics, Ipsen, MerckResearch Funding: Lilly/ImClone (Inst), Amgen (Inst), Bristol Myers Squibb (Inst), EMD Serono (Inst), Tesaro (Inst), Takeda (Inst), Mirati Therapeutics (Inst), AbbVie/Stemcentrx (Inst), United Therapeutics (Inst), Regeneron (Inst), Bayer (Inst), Seattle Genetics (Inst), Symphogen (Inst), Ipsen (Inst) Timothy ChanLeadership: Cancer Genetics, Illumina, Bristol Myers SquibbStock and Other Ownership Interests: Gritstone BioHonoraria: IlluminaConsulting or Advisory Role: Bristol Myers Squibb/Celgene, Illumina, LG Chem, PfizerResearch Funding: Bristol  Myers Squibb (Inst), AstraZeneca/MedImmune (Inst), Pfizer (Inst), Nysnobio (Inst)Patents, Royalties, Other Intellectual Property: Neoantigen discovery and genomic biomarkers for immunotherapy response Brian HenickThis author is a member of the JCO Precision Oncology Editorial Board. Journal policy recused the author  from having any role in the peer review of this manuscript.Consulting or Advisory Role: AstraZeneca, IDEAYA Biosciences, Jazz PharmaceuticalsResearch Funding: NexImmune Xuya WangEmployment: Bristol Myers SquibbStock and Other Ownership Interests: Bristol Myers Squibb Parul DoshiEmployment: Bristol Myers Squibb, Gilead SciencesStock and Other Ownership Interests: Bristol Myers SquibbTravel, Accommodations, Expenses: Bristol Myers Squibb, Gilead Sciences Jyoti PatelConsulting or Advisory Role: AbbVie, AstraZeneca, Takeda Science Foundation, Lilly, GenentechResearch Funding: Bristol Myers Squibb (Inst) Fengshen KuoStock and Other Ownership Interests: Sanofi, General Electric, 10x Genomics, Merck, Cigna, Cigna, Viatris, Pfizer Han ChangEmployment: Bristol Myers SquibbStock and  Other Ownership Interests: Bristol Myers SquibbResearch Funding: Bristol Myers SquibbPatents, Royalties, Other Intellectual Property: I am an employee of BMS, and an inventor on one or more pending pa tent applications, including applications for TMB as a predictive biomarker of immunotherapyTravel, Accommodations, Expenses: Bristol Myers Squibb David BalliEmployment: Bristol Myers SquibbStock and Other Ownership Interests: Bristol Myers SquibbNo other potential conflicts of interest were reported.\n",
      "\n",
      "Fu, Pingfu\n",
      "Afshin DowlatiConsulting or Advisory Role: AbbVie/Stemcentrx, AstraZeneca, Bristol Myers Squibb, Takeda, Bayer, G1 Therapeutics, Ipsen, MerckResearch Pingfu Funding: Lilly/ImClone (Inst), Amgen (Inst), Bristol Myers Squibb (Inst), EMD Serono (Inst), Tesaro (Inst), Takeda (Inst), Mirati Therapeutics (Inst), AbbVie/Stemcentrx (Inst), United Therapeutics (Inst), Regeneron (Inst), Bayer (Inst), Seattle Genetics (Inst), Symphogen (Inst), Ipsen (Inst) Timothy ChanLeadership: Cancer Genetics, Illumina, Bristol Myers SquibbStock and Other Ownership Interests: Gritstone BioHonoraria: IlluminaConsulting or Advisory Role: Bristol Myers Squibb/Celgene, Illumina, LG Chem, PfizerResearch Pingfu Funding: Bristol  Myers Squibb (Inst), AstraZeneca/MedImmune (Inst), Pfizer (Inst), Nysnobio (Inst)Patents, Royalties, Other Intellectual Property: Neoantigen discovery and genomic biomarkers for immunotherapy response Brian HenickThis author is a member of the JCO Precision Oncology Editorial Board. Journal policy recused the author  from having any role in the peer review of this manuscript.Consulting or Advisory Role: AstraZeneca, IDEAYA Biosciences, Jazz PharmaceuticalsResearch Pingfu Funding: NexImmune Xuya WangEmployment: Bristol Myers SquibbStock and Other Ownership Interests: Bristol Myers Squibb Parul DoshiEmployment: Bristol Myers Squibb, Gilead SciencesStock and Other Ownership Interests: Bristol Myers SquibbTravel, Accommodations, Expenses: Bristol Myers Squibb, Gilead Sciences Jyoti PatelConsulting or Advisory Role: AbbVie, AstraZeneca, Takeda Science Foundation, Lilly, GenentechResearch Pingfu Funding: Bristol Myers Squibb (Inst) Fengshen KuoStock and Other Ownership Interests: Sanofi, General Electric, 10x Genomics, Merck, Cigna, Cigna, Viatris, Pfizer Han ChangEmployment: Bristol Myers SquibbStock and  Other Ownership Interests: Bristol Myers SquibbResearch Pingfu Funding: Bristol Myers SquibbPatents, Royalties, Other Intellectual Property: I am an employee of BMS, and an inventor on one or more pending pa tent applications, including applications for TMB as a predictive biomarker of immunotherapyTravel, Accommodations, Expenses: Bristol Myers Squibb David BalliEmployment: Bristol Myers SquibbStock and Other Ownership Interests: Bristol Myers SquibbNo other potential conflicts of interest were reported.\n",
      "\n",
      "Patel, Jyoti\n",
      "Afshin DowlatiConsulting or Advisory Role: AbbVie/Stemcentrx, AstraZeneca, Bristol Myers Squibb, Takeda, Bayer, G1 Therapeutics, Ipsen, MerckResearch Pingfu Funding: Lilly/ImClone (Inst), Amgen (Inst), Bristol Myers Squibb (Inst), EMD Serono (Inst), Tesaro (Inst), Takeda (Inst), Mirati Therapeutics (Inst), AbbVie/Stemcentrx (Inst), United Therapeutics (Inst), Regeneron (Inst), Bayer (Inst), Seattle Genetics (Inst), Symphogen (Inst), Ipsen (Inst) Timothy ChanLeadership: Cancer Genetics, Illumina, Bristol Myers SquibbStock and Other Ownership Interests: Gritstone BioHonoraria: IlluminaConsulting or Advisory Role: Bristol Myers Squibb/Celgene, Illumina, LG Chem, PfizerResearch Pingfu Funding: Bristol  Myers Squibb (Inst), AstraZeneca/MedImmune (Inst), Pfizer (Inst), Nysnobio (Inst)Patents, Royalties, Other Intellectual Property: Neoantigen discovery and genomic biomarkers for immunotherapy response Brian HenickThis author is a member of the JCO Precision Oncology Editorial Board. Journal policy recused the author  from having any role in the peer review of this manuscript.Consulting or Advisory Role: AstraZeneca, IDEAYA Biosciences, Jazz PharmaceuticalsResearch Pingfu Funding: NexImmune Xuya WangEmployment: Bristol Myers SquibbStock and Other Ownership Interests: Bristol Myers Squibb Parul DoshiEmployment: Bristol Myers Squibb, Gilead SciencesStock and Other Ownership Interests: Bristol Myers SquibbTravel, Accommodations, Expenses: Bristol Myers Squibb, Gilead Sciences Jyoti PatelConsulting or Advisory Role: AbbVie, AstraZeneca, Takeda Science Foundation, Lilly, GenentechResearch Pingfu Funding: Bristol Myers Squibb (Inst) Fengshen KuoStock and Other Ownership Interests: Sanofi, General Electric, 10x Genomics, Merck, Cigna, Cigna, Viatris, Pfizer Han ChangEmployment: Bristol Myers SquibbStock and  Other Ownership Interests: Bristol Myers SquibbResearch Pingfu Funding: Bristol Myers SquibbPatents, Royalties, Other Intellectual Property: I am an employee of BMS, and an inventor on one or more pending pa tent applications, including applications for TMB as a predictive biomarker of immunotherapyTravel, Accommodations, Expenses: Bristol Myers Squibb David BalliEmployment: Bristol Myers SquibbStock and Other Ownership Interests: Bristol Myers SquibbNo other potential conflicts of interest were reported.\n",
      "\n",
      "Kuo, Fengshen\n",
      "Afshin DowlatiConsulting or Advisory Role: AbbVie/Stemcentrx, AstraZeneca, Bristol Myers Squibb, Takeda, Bayer, G1 Therapeutics, Ipsen, MerckResearch Pingfu Funding: Lilly/ImClone (Inst), Amgen (Inst), Bristol Myers Squibb (Inst), EMD Serono (Inst), Tesaro (Inst), Takeda (Inst), Mirati Therapeutics (Inst), AbbVie/Stemcentrx (Inst), United Therapeutics (Inst), Regeneron (Inst), Bayer (Inst), Seattle Genetics (Inst), Symphogen (Inst), Ipsen (Inst) Timothy ChanLeadership: Cancer Genetics, Illumina, Bristol Myers SquibbStock and Other Ownership Interests: Gritstone BioHonoraria: IlluminaConsulting or Advisory Role: Bristol Myers Squibb/Celgene, Illumina, LG Chem, PfizerResearch Pingfu Funding: Bristol  Myers Squibb (Inst), AstraZeneca/MedImmune (Inst), Pfizer (Inst), Nysnobio (Inst)Patents, Royalties, Other Intellectual Property: Neoantigen discovery and genomic biomarkers for immunotherapy response Brian HenickThis author is a member of the JCO Precision Oncology Editorial Board. Journal policy recused the author  from having any role in the peer review of this manuscript.Consulting or Advisory Role: AstraZeneca, IDEAYA Biosciences, Jazz PharmaceuticalsResearch Pingfu Funding: NexImmune Xuya WangEmployment: Bristol Myers SquibbStock and Other Ownership Interests: Bristol Myers Squibb Parul DoshiEmployment: Bristol Myers Squibb, Gilead SciencesStock and Other Ownership Interests: Bristol Myers SquibbTravel, Accommodations, Expenses: Bristol Myers Squibb, Gilead Sciences Jyoti PatelConsulting or Advisory Role: AbbVie, AstraZeneca, Takeda Science Foundation, Lilly, GenentechResearch Pingfu Funding: Bristol Myers Squibb (Inst) Fengshen KuoStock and Other Ownership Interests: Sanofi, General Electric, 10x Genomics, Merck, Cigna, Cigna, Viatris, Pfizer Han ChangEmployment: Bristol Myers SquibbStock and  Other Ownership Interests: Bristol Myers SquibbResearch Pingfu Funding: Bristol Myers SquibbPatents, Royalties, Other Intellectual Property: I am an employee of BMS, and an inventor on one or more pending pa tent applications, including applications for TMB as a predictive biomarker of immunotherapyTravel, Accommodations, Expenses: Bristol Myers Squibb David BalliEmployment: Bristol Myers SquibbStock and Other Ownership Interests: Bristol Myers SquibbNo other potential conflicts of interest were reported.\n",
      "\n",
      "Chang, Han\n",
      "Afshin DowlatiConsulting or Advisory Role: AbbVie/Stemcentrx, AstraZeneca, Bristol Myers Squibb, Takeda, Bayer, G1 Therapeutics, Ipsen, MerckResearch Pingfu Funding: Lilly/ImClone (Inst), Amgen (Inst), Bristol Myers Squibb (Inst), EMD Serono (Inst), Tesaro (Inst), Takeda (Inst), Mirati Therapeutics (Inst), AbbVie/Stemcentrx (Inst), United Therapeutics (Inst), Regeneron (Inst), Bayer (Inst), Seattle Genetics (Inst), Symphogen (Inst), Ipsen (Inst) Timothy ChanLeadership: Cancer Genetics, Illumina, Bristol Myers SquibbStock and Other Ownership Interests: Gritstone BioHonoraria: IlluminaConsulting or Advisory Role: Bristol Myers Squibb/Celgene, Illumina, LG Chem, PfizerResearch Pingfu Funding: Bristol  Myers Squibb (Inst), AstraZeneca/MedImmune (Inst), Pfizer (Inst), Nysnobio (Inst)Patents, Royalties, Other Intellectual Property: Neoantigen discovery and genomic biomarkers for immunotherapy response Brian HenickThis author is a member of the JCO Precision Oncology Editorial Board. Journal policy recused the author  from having any role in the peer review of this manuscript.Consulting or Advisory Role: AstraZeneca, IDEAYA Biosciences, Jazz PharmaceuticalsResearch Pingfu Funding: NexImmune Xuya WangEmployment: Bristol Myers SquibbStock and Other Ownership Interests: Bristol Myers Squibb Parul DoshiEmployment: Bristol Myers Squibb, Gilead SciencesStock and Other Ownership Interests: Bristol Myers SquibbTravel, Accommodations, Expenses: Bristol Myers Squibb, Gilead Sciences Jyoti PatelConsulting or Advisory Role: AbbVie, AstraZeneca, Takeda Science Foundation, Lilly, GenentechResearch Pingfu Funding: Bristol Myers Squibb (Inst) Fengshen KuoStock and Other Ownership Interests: Sanofi, General Electric, 10x Genomics, Merck, Cigna, Cigna, Viatris, Pfizer Han ChangEmployment: Bristol Myers SquibbStock and  Other Ownership Interests: Bristol Myers SquibbResearch Pingfu Funding: Bristol Myers SquibbPatents, Royalties, Other Intellectual Property: I am an employee of BMS, and an inventor on one or more pending pa tent applications, including applications for TMB as a predictive biomarker of immunotherapyTravel, Accommodations, Expenses: Bristol Myers Squibb David BalliEmployment: Bristol Myers SquibbStock and Other Ownership Interests: Bristol Myers SquibbNo other potential conflicts of interest were reported.\n",
      "\n",
      "Balli, David\n",
      "Afshin DowlatiConsulting or Advisory Role: AbbVie/Stemcentrx, AstraZeneca, Bristol Myers Squibb, Takeda, Bayer, G1 Therapeutics, Ipsen, MerckResearch Pingfu Funding: Lilly/ImClone (Inst), Amgen (Inst), Bristol Myers Squibb (Inst), EMD Serono (Inst), Tesaro (Inst), Takeda (Inst), Mirati Therapeutics (Inst), AbbVie/Stemcentrx (Inst), United Therapeutics (Inst), Regeneron (Inst), Bayer (Inst), Seattle Genetics (Inst), Symphogen (Inst), Ipsen (Inst) Timothy ChanLeadership: Cancer Genetics, Illumina, Bristol Myers SquibbStock and Other Ownership Interests: Gritstone BioHonoraria: IlluminaConsulting or Advisory Role: Bristol Myers Squibb/Celgene, Illumina, LG Chem, PfizerResearch Pingfu Funding: Bristol  Myers Squibb (Inst), AstraZeneca/MedImmune (Inst), Pfizer (Inst), Nysnobio (Inst)Patents, Royalties, Other Intellectual Property: Neoantigen discovery and genomic biomarkers for immunotherapy response Brian HenickThis author is a member of the JCO Precision Oncology Editorial Board. Journal policy recused the author  from having any role in the peer review of this manuscript.Consulting or Advisory Role: AstraZeneca, IDEAYA Biosciences, Jazz PharmaceuticalsResearch Pingfu Funding: NexImmune Xuya WangEmployment: Bristol Myers SquibbStock and Other Ownership Interests: Bristol Myers Squibb Parul DoshiEmployment: Bristol Myers Squibb, Gilead SciencesStock and Other Ownership Interests: Bristol Myers SquibbTravel, Accommodations, Expenses: Bristol Myers Squibb, Gilead Sciences Jyoti PatelConsulting or Advisory Role: AbbVie, AstraZeneca, Takeda Science Foundation, Lilly, GenentechResearch Pingfu Funding: Bristol Myers Squibb (Inst) Fengshen KuoStock and Other Ownership Interests: Sanofi, General Electric, 10x Genomics, Merck, Cigna, Cigna, Viatris, Pfizer Han ChangEmployment: Bristol Myers SquibbStock and  Other Ownership Interests: Bristol Myers SquibbResearch Pingfu Funding: Bristol Myers SquibbPatents, Royalties, Other Intellectual Property: I am an employee of BMS, and an inventor on one or more pending pa tent applications, including applications for TMB as a predictive biomarker of immunotherapyTravel, Accommodations, Expenses: Bristol Myers Squibb David BalliEmployment: Bristol Myers SquibbStock and Other Ownership Interests: Bristol Myers SquibbNo other potential conflicts of interest were reported.\n",
      "\n",
      "Moller, Mathias B.\n",
      "Mathias B. Moller has received grants from The Research Council of Rigshopitalet  anm The Research Council of the Heart Center, Rigshospitalet. Joanne D. Schuijf is an employee of Canon Medical Systems Europe. Noriko Oyama-Manabe has received  grants from, Canon Medical Systems Corporation, and from the Japan Society for the Promotion of Science (JSPS) KAKENHI # 26461780, has activities as a consultant for Canon Medical Systems, and received payment for lectures from Daiichi-Sankyo, Philips Medical Systems, Eisai, Bayer Healthcare, GE Healthcare,  Nihon Medi-Physics Co. Ltd and Canon Medical Systems. Jorgen T. Kuhl has received funding from the Research Council of Rigshospitalet. Jesper J. Linde has received grants from The Danish Research Foundation and The Research Council of Rigshospitalet. Klaus F. Kofoed AP Moller og hustru Chastine McKinney Mollers Fond, The John and Birthe Meyer Foundation, The Danish Agency for Science, Technology and Innovation, The Lundbeck Foundation, GE Healthcare, Canon Medical  Systems, The Danish Heart Foundation, The University of Copenhagen, and is on the Speakers Bureau of Canon Medical Systems Corporation. The remaining authors declare no conflicts of interest.\n",
      "\n",
      "Schuijf, Joanne D.\n",
      "Mathias B. Moller has received grants from The Research Council of Rigshopitalet  anm The Research Council of the Heart Center, Rigshospitalet. Joanne D. Schuijf is an employee of Canon Medical Systems Europe. Noriko Oyama-Manabe has received  grants from, Canon Medical Systems Corporation, and from the Japan Society for the Promotion of Science (JSPS) KAKENHI # 26461780, has activities as a consultant for Canon Medical Systems, and received payment for lectures from Daiichi-Sankyo, Philips Medical Systems, Eisai, Bayer Healthcare, GE Healthcare,  Nihon Medi-Physics Co. Ltd and Canon Medical Systems. Jorgen T. Kuhl has received funding from the Research Council of Rigshospitalet. Jesper J. Linde has received grants from The Danish Research Foundation and The Research Council of Rigshospitalet. Klaus F. Kofoed AP Moller og hustru Chastine McKinney Mollers Fond, The John and Birthe Meyer Foundation, The Danish Agency for Science, Technology and Innovation, The Lundbeck Foundation, GE Healthcare, Canon Medical  Systems, The Danish Heart Foundation, The University of Copenhagen, and is on the Speakers Bureau of Canon Medical Systems Corporation. The remaining authors declare no conflicts of interest.\n",
      "\n",
      "Oyama-Manabe, Noriko\n",
      "Mathias B. Moller has received grants from The Research Council of Rigshopitalet  anm The Research Council of the Heart Center, Rigshospitalet. Joanne D. Schuijf is an employee of Canon Medical Systems Europe. Noriko Oyama-Manabe has received  grants from, Canon Medical Systems Corporation, and from the Japan Society for the Promotion of Science (JSPS) KAKENHI # 26461780, has activities as a consultant for Canon Medical Systems, and received payment for lectures from Daiichi-Sankyo, Philips Medical Systems, Eisai, Bayer Healthcare, GE Healthcare,  Nihon Medi-Physics Co. Ltd and Canon Medical Systems. Jorgen T. Kuhl has received funding from the Research Council of Rigshospitalet. Jesper J. Linde has received grants from The Danish Research Foundation and The Research Council of Rigshospitalet. Klaus F. Kofoed AP Moller og hustru Chastine McKinney Mollers Fond, The John and Birthe Meyer Foundation, The Danish Agency for Science, Technology and Innovation, The Lundbeck Foundation, GE Healthcare, Canon Medical  Systems, The Danish Heart Foundation, The University of Copenhagen, and is on the Speakers Bureau of Canon Medical Systems Corporation. The remaining authors declare no conflicts of interest.\n",
      "\n",
      "Linde, Jesper J.\n",
      "Mathias B. Moller has received grants from The Research Council of Rigshopitalet  anm The Research Council of the Heart Center, Rigshospitalet. Joanne D. Schuijf is an employee of Canon Medical Systems Europe. Noriko Oyama-Manabe has received  grants from, Canon Medical Systems Corporation, and from the Japan Society for the Promotion of Science (JSPS) KAKENHI # 26461780, has activities as a consultant for Canon Medical Systems, and received payment for lectures from Daiichi-Sankyo, Philips Medical Systems, Eisai, Bayer Healthcare, GE Healthcare,  Nihon Medi-Physics Co. Ltd and Canon Medical Systems. Jorgen T. Kuhl has received funding from the Research Council of Rigshospitalet. Jesper J. Linde has received grants from The Danish Research Foundation and The Research Council of Rigshospitalet. Klaus F. Kofoed AP Moller og hustru Chastine McKinney Mollers Fond, The John and Birthe Meyer Foundation, The Danish Agency for Science, Technology and Innovation, The Lundbeck Foundation, GE Healthcare, Canon Medical  Systems, The Danish Heart Foundation, The University of Copenhagen, and is on the Speakers Bureau of Canon Medical Systems Corporation. The remaining authors declare no conflicts of interest.\n",
      "\n",
      "Kuhl, Jorgen T.\n",
      "Mathias B. Moller has received grants from The Research Council of Rigshopitalet  anm The Research Council of the Heart Center, Rigshospitalet. Joanne D. Schuijf is an employee of Canon Medical Systems Europe. Noriko Oyama-Manabe has received  grants from, Canon Medical Systems Corporation, and from the Japan Society for the Promotion of Science (JSPS) KAKENHI # 26461780, has activities as a consultant for Canon Medical Systems, and received payment for lectures from Daiichi-Sankyo, Philips Medical Systems, Eisai, Bayer Healthcare, GE Healthcare,  Nihon Medi-Physics Co. Ltd and Canon Medical Systems. Jorgen T. Kuhl has received funding from the Research Council of Rigshospitalet. Jesper J. Linde has received grants from The Danish Research Foundation and The Research Council of Rigshospitalet. Klaus F. Kofoed AP Moller og hustru Chastine McKinney Mollers Fond, The John and Birthe Meyer Foundation, The Danish Agency for Science, Technology and Innovation, The Lundbeck Foundation, GE Healthcare, Canon Medical  Systems, The Danish Heart Foundation, The University of Copenhagen, and is on the Speakers Bureau of Canon Medical Systems Corporation. The remaining authors declare no conflicts of interest.\n",
      "\n",
      "Mathias B. Moller has received grants from The Research Council of Rigshopitalet  anm The Research Council of the Heart Center, Rigshospitalet. Joanne D. Schuijf is an employee of Canon Medical Systems Europe. Noriko Oyama-Manabe has received  grants from, Canon Medical Systems Corporation, and from the Japan Society for the Promotion of Science (JSPS) KAKENHI # 26461780, has activities as a consultant for Canon Medical Systems, and received payment for lectures from Daiichi-Sankyo, Philips Medical Systems, Eisai, Bayer Healthcare, GE Healthcare,  Nihon Medi-Physics Co. Ltd and Canon Medical Systems. Jorgen T. Kuhl has received funding from the Research Council of Rigshospitalet. Jesper J. Linde has received grants from The Danish Research Foundation and The Research Council of Rigshospitalet. Klaus F. Kofoed AP Moller og hustru Chastine McKinney Mollers Fond, The John and Birthe Meyer Foundation, The Danish Agency for Science, Technology and Innovation, The Lundbeck Foundation, GE Healthcare, Canon Medical  Systems, The Danish Heart Foundation, The University of Copenhagen, and is on the Speakers Bureau of Canon Medical Systems Corporation. The remaining authors declare no conflicts of interest.\n",
      "\n",
      "Kofoed, Klaus F.\n",
      "Mathias B. Moller has received grants from The Research Council of Rigshopitalet  anm The Research Council of the Heart Center, Rigshospitalet. Joanne D. Schuijf is an employee of Canon Medical Systems Europe. Noriko Oyama-Manabe has received  grants from, Canon Medical Systems Corporation, and from the Japan Society for the Promotion of Science (JSPS) KAKENHI # 26461780, has activities as a consultant for Canon Medical Systems, and received payment for lectures from Daiichi-Sankyo, Philips Medical Systems, Eisai, Bayer Healthcare, GE Healthcare,  Nihon Medi-Physics Co. Ltd and Canon Medical Systems. Jorgen T. Kuhl has received funding from the Research Council of Rigshospitalet. Jesper J. Linde has received grants from The Danish Research Foundation and The Research Council of Rigshospitalet. Klaus F. Kofoed AP Moller og hustru Chastine McKinney Mollers Fond, The John and Birthe Meyer Foundation, The Danish Agency for Science, Technology and Innovation, The Lundbeck Foundation, GE Healthcare, Canon Medical  Systems, The Danish Heart Foundation, The University of Copenhagen, and is on the Speakers Bureau of Canon Medical Systems Corporation. The remaining authors declare no conflicts of interest.\n",
      "\n",
      "Conflicts of Interest and Sources of Funding: All authors declare that they have  no conflicts of interest. This work was supported by the National Institute on Aging grant (R01-046116) and Center for Clinical and Translational Science, University of Kentucky (UL1TR001998)\n",
      "\n",
      "Conflicts of Interest and Sources of Funding: All authors declare that they have  no conflicts of interest. This work was supported by the National Institute on Aging grant (R01-046116) and Center for Clinical and Translational Science, University of Kentucky (UL1TR001998)\n",
      "\n",
      "Conflicts of Interest and Sources of Funding: All authors declare that they have  no conflicts of interest. This work was supported by the National Institute on Aging grant (R01-046116) and Center for Clinical and Translational Science, University of Kentucky (UL1TR001998)\n",
      "\n",
      "Conflicts of Interest and Sources of Funding: All authors declare that they have  no conflicts of interest. This work was supported by the National Institute on Aging grant (R01-046116) and Center for Clinical and Translational Science, University of Kentucky (UL1TR001998)\n",
      "\n",
      "Conflicts of Interest and Sources of Funding: All authors declare that they have  no conflicts of interest. This work was supported by the National Institute on Aging grant (R01-046116) and Center for Clinical and Translational Science, University of Kentucky (UL1TR001998)\n",
      "\n",
      "Conflict of Interest: The authors report no conflicts of interest.\n",
      "\n",
      "Conflict of Interest: The authors report no conflicts of interest.\n",
      "\n",
      "Conflict of Interest: The authors report no conflicts of interest.\n",
      "\n",
      "Conflict of Interest: The authors report no conflicts of interest.\n",
      "\n",
      "Conflict of Interest: The authors report no conflicts of interest.\n",
      "\n",
      "Conflict of Interest: The authors report no conflicts of interest.\n",
      "\n",
      "Conflict of Interest: The authors report no conflicts of interest.\n",
      "\n",
      "Conflict of Interest: The authors report no conflicts of interest.\n",
      "\n",
      "Conflict of Interest: The authors report no conflicts of interest.\n",
      "\n",
      "Conflict of Interest: The authors report no conflicts of interest.\n",
      "\n",
      "Conflict of Interest: The authors report no conflicts of interest.\n",
      "\n",
      "Conflict of Interest: The authors report no conflicts of interest.\n",
      "\n",
      "A.J. Kroll is employed by Weyerhaeuser, which provided funding to support this research. Jake Verschuyl is employed by NCASI, which provided funding for this research. This does not alter our adherence to PLOS ONE policies on sharing data  and materials.\n",
      "\n",
      "Kroll, Andrew J.\n",
      "A.J. Andrew J. Kroll is employed by Weyerhaeuser, which provided funding to support this research. Jake Verschuyl is employed by NCASI, which provided funding for this research. This does not alter our adherence to PLOS ONE policies on sharing data  and materials.\n",
      "\n",
      "Verschuyl, Jake\n",
      "A.J. Andrew J. Kroll is employed by Weyerhaeuser, which provided funding to support this research. Jake Verschuyl is employed by NCASI, which provided funding for this research. This does not alter our adherence to PLOS ONE policies on sharing data  and materials.\n",
      "\n",
      "A.J. Andrew J. Kroll is employed by Weyerhaeuser, which provided funding to support this research. Jake Verschuyl is employed by NCASI, which provided funding for this research. This does not alter our adherence to PLOS ONE policies on sharing data  and materials.\n",
      "\n",
      "Mossberg, Karin\n",
      "Karin Mossberg, EF, JO, PAJ, HB have declared that no competing interests exist. SJ has read  the journal's policy and the authors of this manuscript have the following competing interests: Cereno Scientific AB: Dr. Jern was one of the founders and owns shares in the start-up company \"Cereno Scientific AB\" which will manage the  IP of possible future patents to improve endogenous fibrinolysis. At present, Dr. Jern acts as a member of the Board of directors of \"Cereno Scientific AB\". And following patents: 1. European application 2012: WO 212120262 A1. Methods for improving impaired endogenous fibrinolysis using histone deacetylase inhibitors.  2. US application 2014: 20140051716. Methods for improving impaired endogenous fibrinolysis using histone deacetylase inhibitors. 3. PCT application 2016:WO2016055797. Compounds and compositions for the treatment or prevention of  pathological conditions associated with excess fibrin deposition and/or thrombus  formation.\n",
      "\n",
      "Olausson, Josefin\n",
      "Karin Mossberg, EF, Josefin Olausson, PAJ, HB have declared that no competing interests exist. SJ has read  the journal's policy and the authors of this manuscript have the following competing interests: Cereno Scientific AB: Dr. Jern was one of the founders and owns shares in the start-up company \"Cereno Scientific AB\" which will manage the  IP of possible future patents to improve endogenous fibrinolysis. At present, Dr. Jern acts as a member of the Board of directors of \"Cereno Scientific AB\". And following patents: 1. European application 2012: WO 212120262 A1. Methods for improving impaired endogenous fibrinolysis using histone deacetylase inhibitors.  2. US application 2014: 20140051716. Methods for improving impaired endogenous fibrinolysis using histone deacetylase inhibitors. 3. PCT application 2016:WO2016055797. Compounds and compositions for the treatment or prevention of  pathological conditions associated with excess fibrin deposition and/or thrombus  formation.\n",
      "\n",
      "Fryk, Emanuel\n",
      "Karin Mossberg, Emanuel Fryk, Josefin Olausson, PAJ, HB have declared that no competing interests exist. SJ has read  the journal's policy and the authors of this manuscript have the following competing interests: Cereno Scientific AB: Dr. Jern was one of the founders and owns shares in the start-up company \"Cereno Scientific AB\" which will manage the  IP of possible future patents to improve endogenous fibrinolysis. At present, Dr. Jern acts as a member of the Board of directors of \"Cereno Scientific AB\". And following patents: 1. European application 2012: WO 212120262 A1. Methods for improving impaired endogenous fibrinolysis using histone deacetylase inhibitors.  2. US application 2014: 20140051716. Methods for improving impaired endogenous fibrinolysis using histone deacetylase inhibitors. 3. PCT application 2016:WO2016055797. Compounds and compositions for the treatment or prevention of  pathological conditions associated with excess fibrin deposition and/or thrombus  formation.\n",
      "\n",
      "Jern, Sverker\n",
      "Karin Mossberg, Emanuel Fryk, Josefin Olausson, PAJ, HB have declared that no competing interests exist. SJ has read  the journal's policy and the authors of this manuscript have the following competing interests: Cereno Scientific AB: Dr. Sverker Jern was one of the founders and owns shares in the start-up company \"Cereno Scientific AB\" which will manage the  IP of possible future patents to improve endogenous fibrinolysis. At present, Dr. Sverker Jern acts as a member of the Board of directors of \"Cereno Scientific AB\". And following patents: 1. European application 2012: WO 212120262 A1. Methods for improving impaired endogenous fibrinolysis using histone deacetylase inhibitors.  2. US application 2014: 20140051716. Methods for improving impaired endogenous fibrinolysis using histone deacetylase inhibitors. 3. PCT application 2016:WO2016055797. Compounds and compositions for the treatment or prevention of  pathological conditions associated with excess fibrin deposition and/or thrombus  formation.\n",
      "\n",
      "Karin Mossberg, Emanuel Fryk, Josefin Olausson, PAJ, HB have declared that no competing interests exist. SJ has read  the journal's policy and the authors of this manuscript have the following competing interests: Cereno Scientific AB: Dr. Sverker Jern was one of the founders and owns shares in the start-up company \"Cereno Scientific AB\" which will manage the  IP of possible future patents to improve endogenous fibrinolysis. At present, Dr. Sverker Jern acts as a member of the Board of directors of \"Cereno Scientific AB\". And following patents: 1. European application 2012: WO 212120262 A1. Methods for improving impaired endogenous fibrinolysis using histone deacetylase inhibitors.  2. US application 2014: 20140051716. Methods for improving impaired endogenous fibrinolysis using histone deacetylase inhibitors. 3. PCT application 2016:WO2016055797. Compounds and compositions for the treatment or prevention of  pathological conditions associated with excess fibrin deposition and/or thrombus  formation.\n",
      "\n",
      "Brogren, Helen\n",
      "Karin Mossberg, Emanuel Fryk, Josefin Olausson, PAJ, Helen Brogren have declared that no competing interests exist. SJ has read  the journal's policy and the authors of this manuscript have the following competing interests: Cereno Scientific AB: Dr. Sverker Jern was one of the founders and owns shares in the start-up company \"Cereno Scientific AB\" which will manage the  IP of possible future patents to improve endogenous fibrinolysis. At present, Dr. Sverker Jern acts as a member of the Board of directors of \"Cereno Scientific AB\". And following patents: 1. European application 2012: WO 212120262 A1. Methods for improving impaired endogenous fibrinolysis using histone deacetylase inhibitors.  2. US application 2014: 20140051716. Methods for improving impaired endogenous fibrinolysis using histone deacetylase inhibitors. 3. PCT application 2016:WO2016055797. Compounds and compositions for the treatment or prevention of  pathological conditions associated with excess fibrin deposition and/or thrombus  formation.\n",
      "\n",
      "Conflict of Interest Statement None of the authors included in this study have any financial conflicts of interest pertaining to this manuscript.\n",
      "\n",
      "Conflict of Interest Statement None of the authors included in this study have any financial conflicts of interest pertaining to this manuscript.\n",
      "\n",
      "Conflict of Interest Statement None of the authors included in this study have any financial conflicts of interest pertaining to this manuscript.\n",
      "\n",
      "Conflict of Interest Statement None of the authors included in this study have any financial conflicts of interest pertaining to this manuscript.\n",
      "\n",
      "Conflict of Interest Statement None of the authors included in this study have any financial conflicts of interest pertaining to this manuscript.\n",
      "\n",
      "Conflict of Interest Statement None of the authors included in this study have any financial conflicts of interest pertaining to this manuscript.\n",
      "\n",
      "Conflict of Interest Statement None of the authors included in this study have any financial conflicts of interest pertaining to this manuscript.\n",
      "\n",
      "Conflict of Interest Statement None of the authors included in this study have any financial conflicts of interest pertaining to this manuscript.\n",
      "\n",
      "Conflict of Interest Statement None of the authors included in this study have any financial conflicts of interest pertaining to this manuscript.\n",
      "\n",
      "Conflict of Interest Statement None of the authors included in this study have any financial conflicts of interest pertaining to this manuscript.\n",
      "\n",
      "Conflict of Interest Statement None of the authors included in this study have any financial conflicts of interest pertaining to this manuscript.\n",
      "\n",
      "Conflict of Interest Statement None of the authors included in this study have any financial conflicts of interest pertaining to this manuscript.\n",
      "\n",
      "Conflict of Interest Statement None of the authors included in this study have any financial conflicts of interest pertaining to this manuscript.\n",
      "\n",
      "Conflict of Interest Statement None of the authors included in this study have any financial conflicts of interest pertaining to this manuscript.\n",
      "\n",
      "Conflict of Interest Statement None of the authors included in this study have any financial conflicts of interest pertaining to this manuscript.\n",
      "\n",
      "The authors have read the journal's policy and have the following competing interests: Tianjin Hong Bin He Sheng Agricultural Technology Development Co. Ltd. provided the researchers with experimental sites, materials, and personnel. Hongying Zhang was a paid employee at Tianjin Hong Bin He Sheng Agricultural Technology Development Co. Ltd. at the time the study was conducted. After the study was completed, Hongying Zhang became an employee at Tianjin Bin Hai De Sheng Agricultural Technology Co. Ltd. There are no patents, products in development or marketed products associated with this research to declare. This does not alter our adherence to PLOS ONE policies on sharing data and materials.\n",
      "\n",
      "The authors have read the journal's policy and have the following competing interests: Tianjin Hong Bin He Sheng Agricultural Technology Development Co. Ltd. provided the researchers with experimental sites, materials, and personnel. Hongying Zhang was a paid employee at Tianjin Hong Bin He Sheng Agricultural Technology Development Co. Ltd. at the time the study was conducted. After the study was completed, Hongying Zhang became an employee at Tianjin Bin Hai De Sheng Agricultural Technology Co. Ltd. There are no patents, products in development or marketed products associated with this research to declare. This does not alter our adherence to PLOS ONE policies on sharing data and materials.\n",
      "\n",
      "The authors have read the journal's policy and have the following competing interests: Tianjin Hong Bin He Sheng Agricultural Technology Development Co. Ltd. provided the researchers with experimental sites, materials, and personnel. Hongying Zhang was a paid employee at Tianjin Hong Bin He Sheng Agricultural Technology Development Co. Ltd. at the time the study was conducted. After the study was completed, Hongying Zhang became an employee at Tianjin Bin Hai De Sheng Agricultural Technology Co. Ltd. There are no patents, products in development or marketed products associated with this research to declare. This does not alter our adherence to PLOS ONE policies on sharing data and materials.\n",
      "\n",
      "The authors have read the journal's policy and have the following competing interests: Tianjin Hong Bin He Sheng Agricultural Technology Development Co. Ltd. provided the researchers with experimental sites, materials, and personnel. Hongying Zhang was a paid employee at Tianjin Hong Bin He Sheng Agricultural Technology Development Co. Ltd. at the time the study was conducted. After the study was completed, Hongying Zhang became an employee at Tianjin Bin Hai De Sheng Agricultural Technology Co. Ltd. There are no patents, products in development or marketed products associated with this research to declare. This does not alter our adherence to PLOS ONE policies on sharing data and materials.\n",
      "\n",
      "The authors have read the journal's policy and have the following competing interests: Tianjin Hong Bin He Sheng Agricultural Technology Development Co. Ltd. provided the researchers with experimental sites, materials, and personnel. Hongying Zhang was a paid employee at Tianjin Hong Bin He Sheng Agricultural Technology Development Co. Ltd. at the time the study was conducted. After the study was completed, Hongying Zhang became an employee at Tianjin Bin Hai De Sheng Agricultural Technology Co. Ltd. There are no patents, products in development or marketed products associated with this research to declare. This does not alter our adherence to PLOS ONE policies on sharing data and materials.\n",
      "\n",
      "The authors have read the journal's policy and have the following competing interests: Tianjin Hong Bin He Sheng Agricultural Technology Development Co. Ltd. provided the researchers with experimental sites, materials, and personnel. Hongying Zhang was a paid employee at Tianjin Hong Bin He Sheng Agricultural Technology Development Co. Ltd. at the time the study was conducted. After the study was completed, Hongying Zhang became an employee at Tianjin Bin Hai De Sheng Agricultural Technology Co. Ltd. There are no patents, products in development or marketed products associated with this research to declare. This does not alter our adherence to PLOS ONE policies on sharing data and materials.\n",
      "\n",
      "The authors have read the journal's policy and have the following competing interests: Tianjin Hong Bin He Sheng Agricultural Technology Development Co. Ltd. provided the researchers with experimental sites, materials, and personnel. Hongying Zhang was a paid employee at Tianjin Hong Bin He Sheng Agricultural Technology Development Co. Ltd. at the time the study was conducted. After the study was completed, Hongying Zhang became an employee at Tianjin Bin Hai De Sheng Agricultural Technology Co. Ltd. There are no patents, products in development or marketed products associated with this research to declare. This does not alter our adherence to PLOS ONE policies on sharing data and materials.\n",
      "\n",
      "Zhang, Hongyang\n",
      "The authors have read the journal's policy and have the following competing interests: Tianjin Hong Bin He Sheng Agricultural Technology Development Co. Ltd. provided the researchers with experimental sites, materials, and personnel. Hongying Hongyang Zhang was a paid employee at Tianjin Hong Bin He Sheng Agricultural Technology Development Co. Ltd. at the time the study was conducted. After the study was completed, Hongying Hongyang Zhang became an employee at Tianjin Bin Hai De Sheng Agricultural Technology Co. Ltd. There are no patents, products in development or marketed products associated with this research to declare. This does not alter our adherence to PLOS ONE policies on sharing data and materials.\n",
      "\n",
      "The authors have read the journal's policy and have the following conflicts: The  study is affiliated with Southern Queensland Centre of Excellence in Aboriginal and Torres Strait Islander Primary Health Care, Wuchopperen Health Service Pty Ltd and Yerin Eleanor Duncan Aboriginal Health Centre. These commercial affiliations provided support in the form of salaries for authors CM, JM, and EW, respectively. This does not alter our adherence to all the PLOS ONE policies on sharing data and materials.\n",
      "\n",
      "The authors have read the journal's policy and have the following conflicts: The  study is affiliated with Southern Queensland Centre of Excellence in Aboriginal and Torres Strait Islander Primary Health Care, Wuchopperen Health Service Pty Ltd and Yerin Eleanor Duncan Aboriginal Health Centre. These commercial affiliations provided support in the form of salaries for authors CM, JM, and EW, respectively. This does not alter our adherence to all the PLOS ONE policies on sharing data and materials.\n",
      "\n",
      "The authors have read the journal's policy and have the following conflicts: The  study is affiliated with Southern Queensland Centre of Excellence in Aboriginal and Torres Strait Islander Primary Health Care, Wuchopperen Health Service Pty Ltd and Yerin Eleanor Duncan Aboriginal Health Centre. These commercial affiliations provided support in the form of salaries for authors CM, JM, and EW, respectively. This does not alter our adherence to all the PLOS ONE policies on sharing data and materials.\n",
      "\n",
      "The authors have read the journal's policy and have the following conflicts: The  study is affiliated with Southern Queensland Centre of Excellence in Aboriginal and Torres Strait Islander Primary Health Care, Wuchopperen Health Service Pty Ltd and Yerin Eleanor Duncan Aboriginal Health Centre. These commercial affiliations provided support in the form of salaries for authors CM, JM, and EW, respectively. This does not alter our adherence to all the PLOS ONE policies on sharing data and materials.\n",
      "\n",
      "The authors have read the journal's policy and have the following conflicts: The  study is affiliated with Southern Queensland Centre of Excellence in Aboriginal and Torres Strait Islander Primary Health Care, Wuchopperen Health Service Pty Ltd and Yerin Eleanor Duncan Aboriginal Health Centre. These commercial affiliations provided support in the form of salaries for authors CM, JM, and EW, respectively. This does not alter our adherence to all the PLOS ONE policies on sharing data and materials.\n",
      "\n",
      "The authors have read the journal's policy and have the following conflicts: The  study is affiliated with Southern Queensland Centre of Excellence in Aboriginal and Torres Strait Islander Primary Health Care, Wuchopperen Health Service Pty Ltd and Yerin Eleanor Duncan Aboriginal Health Centre. These commercial affiliations provided support in the form of salaries for authors CM, JM, and EW, respectively. This does not alter our adherence to all the PLOS ONE policies on sharing data and materials.\n",
      "\n",
      "The authors have read the journal's policy and have the following conflicts: The  study is affiliated with Southern Queensland Centre of Excellence in Aboriginal and Torres Strait Islander Primary Health Care, Wuchopperen Health Service Pty Ltd and Yerin Eleanor Duncan Aboriginal Health Centre. These commercial affiliations provided support in the form of salaries for authors CM, JM, and EW, respectively. This does not alter our adherence to all the PLOS ONE policies on sharing data and materials.\n",
      "\n",
      "The authors have read the journal's policy and have the following conflicts: The  study is affiliated with Southern Queensland Centre of Excellence in Aboriginal and Torres Strait Islander Primary Health Care, Wuchopperen Health Service Pty Ltd and Yerin Eleanor Duncan Aboriginal Health Centre. These commercial affiliations provided support in the form of salaries for authors CM, JM, and EW, respectively. This does not alter our adherence to all the PLOS ONE policies on sharing data and materials.\n",
      "\n",
      "The authors have read the journal's policy and have the following conflicts: The  study is affiliated with Southern Queensland Centre of Excellence in Aboriginal and Torres Strait Islander Primary Health Care, Wuchopperen Health Service Pty Ltd and Yerin Eleanor Duncan Aboriginal Health Centre. These commercial affiliations provided support in the form of salaries for authors CM, JM, and EW, respectively. This does not alter our adherence to all the PLOS ONE policies on sharing data and materials.\n",
      "\n",
      "Maher, Clare M.\n",
      "The authors have read the journal's policy and have the following conflicts: The  study is affiliated with Southern Queensland Centre of Excellence in Aboriginal and Torres Strait Islander Primary Health Care, Wuchopperen Health Service Pty Ltd and Yerin Eleanor Duncan Aboriginal Health Centre. These commercial affiliations provided support in the form of salaries for authors Clare M. Maher, JM, and EW, respectively. This does not alter our adherence to all the PLOS ONE policies on sharing data and materials.\n",
      "\n",
      "Mein, Jacqueline K.\n",
      "The authors have read the journal's policy and have the following conflicts: The  study is affiliated with Southern Queensland Centre of Excellence in Aboriginal and Torres Strait Islander Primary Health Care, Wuchopperen Health Service Pty Ltd and Yerin Eleanor Duncan Aboriginal Health Centre. These commercial affiliations provided support in the form of salaries for authors Clare M. Maher, Jacqueline K. Mein, and EW, respectively. This does not alter our adherence to all the PLOS ONE policies on sharing data and materials.\n",
      "\n",
      "Warren, Eloise F.\n",
      "The authors have read the journal's policy and have the following conflicts: The  study is affiliated with Southern Queensland Centre of Excellence in Aboriginal and Torres Strait Islander Primary Health Care, Wuchopperen Health Service Pty Ltd and Yerin Eleanor Duncan Aboriginal Health Centre. These commercial affiliations provided support in the form of salaries for authors Clare M. Maher, Jacqueline K. Mein, and Eloise F. Warren, respectively. This does not alter our adherence to all the PLOS ONE policies on sharing data and materials.\n",
      "\n",
      "The authors have read the journal's policy and have the following conflicts: The  study is affiliated with Southern Queensland Centre of Excellence in Aboriginal and Torres Strait Islander Primary Health Care, Wuchopperen Health Service Pty Ltd and Yerin Eleanor Duncan Aboriginal Health Centre. These commercial affiliations provided support in the form of salaries for authors Clare M. Maher, Jacqueline K. Mein, and Eloise F. Warren, respectively. This does not alter our adherence to all the PLOS ONE policies on sharing data and materials.\n",
      "\n",
      "One of the authors is director of Faubertlab at the University of Montreal and he is the Chief Science Officer of Cognisens Athletics Inc. who produces the commercial version of the NeuroTracker used in this study. In this capacity, he holds shares in the company. This does not alter our adherence to your journal policies on sharing data and materials.\n",
      "\n",
      "One of the authors is director of Faubertlab at the University of Montreal and he is the Chief Science Officer of Cognisens Athletics Inc. who produces the commercial version of the NeuroTracker used in this study. In this capacity, he holds shares in the company. This does not alter our adherence to your journal policies on sharing data and materials.\n",
      "\n",
      "Faubert, Jocelyn\n",
      "One of the authors is director of Jocelyn Faubertlab at the University of Montreal and he is the Chief Science Officer of Cognisens Athletics Inc. who produces the commercial version of the NeuroTracker used in this study. In this capacity, he holds shares in the company. This does not alter our adherence to your journal policies on sharing data and materials.\n",
      "\n",
      "I have read the journal's policy and the authors of this manuscript have the following competing interests: JWM is a consultant to Gilead Sciences and owns share options of Co-Crystal Pharmaceuticals and Infectious Disease Connect, and shares of Abound Bio, unrelated to the current work. All other authors declare they have no competing interests.\n",
      "\n",
      "I have read the journal's policy and the authors of this manuscript have the following competing interests: JWM is a consultant to Gilead Sciences and owns share options of Co-Crystal Pharmaceuticals and Infectious Disease Connect, and shares of Abound Bio, unrelated to the current work. All other authors declare they have no competing interests.\n",
      "\n",
      "I have read the journal's policy and the authors of this manuscript have the following competing interests: JWM is a consultant to Gilead Sciences and owns share options of Co-Crystal Pharmaceuticals and Infectious Disease Connect, and shares of Abound Bio, unrelated to the current work. All other authors declare they have no competing interests.\n",
      "\n",
      "I have read the journal's policy and the authors of this manuscript have the following competing interests: JWM is a consultant to Gilead Sciences and owns share options of Co-Crystal Pharmaceuticals and Infectious Disease Connect, and shares of Abound Bio, unrelated to the current work. All other authors declare they have no competing interests.\n",
      "\n",
      "I have read the journal's policy and the authors of this manuscript have the following competing interests: JWM is a consultant to Gilead Sciences and owns share options of Co-Crystal Pharmaceuticals and Infectious Disease Connect, and shares of Abound Bio, unrelated to the current work. All other authors declare they have no competing interests.\n",
      "\n",
      "I have read the journal's policy and the authors of this manuscript have the following competing interests: JWM is a consultant to Gilead Sciences and owns share options of Co-Crystal Pharmaceuticals and Infectious Disease Connect, and shares of Abound Bio, unrelated to the current work. All other authors declare they have no competing interests.\n",
      "\n",
      "I have read the journal's policy and the authors of this manuscript have the following competing interests: JWM is a consultant to Gilead Sciences and owns share options of Co-Crystal Pharmaceuticals and Infectious Disease Connect, and shares of Abound Bio, unrelated to the current work. All other authors declare they have no competing interests.\n",
      "\n",
      "I have read the journal's policy and the authors of this manuscript have the following competing interests: JWM is a consultant to Gilead Sciences and owns share options of Co-Crystal Pharmaceuticals and Infectious Disease Connect, and shares of Abound Bio, unrelated to the current work. All other authors declare they have no competing interests.\n",
      "\n",
      "I have read the journal's policy and the authors of this manuscript have the following competing interests: JWM is a consultant to Gilead Sciences and owns share options of Co-Crystal Pharmaceuticals and Infectious Disease Connect, and shares of Abound Bio, unrelated to the current work. All other authors declare they have no competing interests.\n",
      "\n",
      "I have read the journal's policy and the authors of this manuscript have the following competing interests: JWM is a consultant to Gilead Sciences and owns share options of Co-Crystal Pharmaceuticals and Infectious Disease Connect, and shares of Abound Bio, unrelated to the current work. All other authors declare they have no competing interests.\n",
      "\n",
      "I have read the journal's policy and the authors of this manuscript have the following competing interests: JWM is a consultant to Gilead Sciences and owns share options of Co-Crystal Pharmaceuticals and Infectious Disease Connect, and shares of Abound Bio, unrelated to the current work. All other authors declare they have no competing interests.\n",
      "\n",
      "I have read the journal's policy and the authors of this manuscript have the following competing interests: JWM is a consultant to Gilead Sciences and owns share options of Co-Crystal Pharmaceuticals and Infectious Disease Connect, and shares of Abound Bio, unrelated to the current work. All other authors declare they have no competing interests.\n",
      "\n",
      "I have read the journal's policy and the authors of this manuscript have the following competing interests: JWM is a consultant to Gilead Sciences and owns share options of Co-Crystal Pharmaceuticals and Infectious Disease Connect, and shares of Abound Bio, unrelated to the current work. All other authors declare they have no competing interests.\n",
      "\n",
      "Mellors, John W.\n",
      "I have read the journal's policy and the authors of this manuscript have the following competing interests: John W. Mellors is a consultant to Gilead Sciences and owns share options of Co-Crystal Pharmaceuticals and Infectious Disease Connect, and shares of Abound Bio, unrelated to the current work. All other authors declare they have no competing interests.\n",
      "\n",
      "I have read the journal's policy and the authors of this manuscript have the following competing interests: John W. Mellors is a consultant to Gilead Sciences and owns share options of Co-Crystal Pharmaceuticals and Infectious Disease Connect, and shares of Abound Bio, unrelated to the current work. All other authors declare they have no competing interests.\n",
      "\n",
      "Schrurs, Charlotte\n",
      "The authors received no specific funding for this work. Charlotte Schrurs is self-funding her PhD. All data were collected by Arioneo Ltd. David S Gardner is  funded by The School of Veterinary Medicine and Science, University of Nottingham. Guillaume Dubois is an employee of Arioneo Ltd and had no influence on the reporting of results as presented. Emmanuelle Van Erck-Westergren is an Equine Sports Medicine specialist and consultant for Arioneo Ltd. This does not alter our adherence to PLOS ONE policies on sharing data and materials.\n",
      "\n",
      "Dubois, Guillaume\n",
      "The authors received no specific funding for this work. Charlotte Schrurs is self-funding her PhD. All data were collected by Arioneo Ltd. David S Gardner is  funded by The School of Veterinary Medicine and Science, University of Nottingham. Guillaume Dubois is an employee of Arioneo Ltd and had no influence on the reporting of results as presented. Emmanuelle Van Erck-Westergren is an Equine Sports Medicine specialist and consultant for Arioneo Ltd. This does not alter our adherence to PLOS ONE policies on sharing data and materials.\n",
      "\n",
      "Van Erck-Westergren, Emmanuelle\n",
      "The authors received no specific funding for this work. Charlotte Schrurs is self-funding her PhD. All data were collected by Arioneo Ltd. David S Gardner is  funded by The School of Veterinary Medicine and Science, University of Nottingham. Guillaume Dubois is an employee of Arioneo Ltd and had no influence on the reporting of results as presented. Emmanuelle Van Erck-Westergren is an Equine Sports Medicine specialist and consultant for Arioneo Ltd. This does not alter our adherence to PLOS ONE policies on sharing data and materials.\n",
      "\n",
      "Gardner, David S.\n",
      "The authors received no specific funding for this work. Charlotte Schrurs is self-funding her PhD. All data were collected by Arioneo Ltd. David S. Gardner is  funded by The School of Veterinary Medicine and Science, University of Nottingham. Guillaume Dubois is an employee of Arioneo Ltd and had no influence on the reporting of results as presented. Emmanuelle Van Erck-Westergren is an Equine Sports Medicine specialist and consultant for Arioneo Ltd. This does not alter our adherence to PLOS ONE policies on sharing data and materials.\n",
      "\n",
      "Basso, Jessica\n",
      "Authors Jessica Basso, JZ, DL, SR, KJC, and DC were salaried employees of Insmed Incorporated during the course of the study. The authors would like to declare that a patent application associated with this research has been filed by Insmed  Incorporated and has been published as WO 2022/020245 with Jessica Basso, JZ and DC as inventors. This does not alter our adherence to PLOS ONE policies on sharing data and materials.\n",
      "\n",
      "Zhang, Jimin\n",
      "Authors Jessica Basso, Jimin Zhang, DL, SR, KJC, and DC were salaried employees of Insmed Incorporated during the course of the study. The authors would like to declare that a patent application associated with this research has been filed by Insmed  Incorporated and has been published as WO 2022/020245 with Jessica Basso, Jimin Zhang and DC as inventors. This does not alter our adherence to PLOS ONE policies on sharing data and materials.\n",
      "\n",
      "Lasala, Daniel\n",
      "Authors Jessica Basso, Jimin Zhang, Daniel Lasala, SR, KJC, and DC were salaried employees of Insmed Incorporated during the course of the study. The authors would like to declare that a patent application associated with this research has been filed by Insmed  Incorporated and has been published as WO 2022/020245 with Jessica Basso, Jimin Zhang and DC as inventors. This does not alter our adherence to PLOS ONE policies on sharing data and materials.\n",
      "\n",
      "Rose, Sasha J.\n",
      "Authors Jessica Basso, Jimin Zhang, Daniel Lasala, Sasha J. Rose, KJC, and DC were salaried employees of Insmed Incorporated during the course of the study. The authors would like to declare that a patent application associated with this research has been filed by Insmed  Incorporated and has been published as WO 2022/020245 with Jessica Basso, Jimin Zhang and DC as inventors. This does not alter our adherence to PLOS ONE policies on sharing data and materials.\n",
      "\n",
      "Authors Jessica Basso, Jimin Zhang, Daniel Lasala, Sasha J. Rose, KJC, and DC were salaried employees of Insmed Incorporated during the course of the study. The authors would like to declare that a patent application associated with this research has been filed by Insmed  Incorporated and has been published as WO 2022/020245 with Jessica Basso, Jimin Zhang and DC as inventors. This does not alter our adherence to PLOS ONE policies on sharing data and materials.\n",
      "\n",
      "Cipolla, David\n",
      "Authors Jessica Basso, Jimin Zhang, Daniel Lasala, Sasha J. Rose, KJC, and David Cipolla were salaried employees of Insmed Incorporated during the course of the study. The authors would like to declare that a patent application associated with this research has been filed by Insmed  Incorporated and has been published as WO 2022/020245 with Jessica Basso, Jimin Zhang and David Cipolla as inventors. This does not alter our adherence to PLOS ONE policies on sharing data and materials.\n",
      "\n",
      "The study was part-funded by the Canal and River Trust, which is a registered charity in the United Kingdom. Jenny Shepherd and Graham Reeves are both employed by The Canal and River Trust. This does not alter our adherence to PLOS ONE policies on sharing data and materials.\n",
      "\n",
      "The study was part-funded by the Canal and River Trust, which is a registered charity in the United Kingdom. Jenny Shepherd and Graham Reeves are both employed by The Canal and River Trust. This does not alter our adherence to PLOS ONE policies on sharing data and materials.\n",
      "\n",
      "The study was part-funded by the Canal and River Trust, which is a registered charity in the United Kingdom. Jenny Shepherd and Graham Reeves are both employed by The Canal and River Trust. This does not alter our adherence to PLOS ONE policies on sharing data and materials.\n",
      "\n",
      "The study was part-funded by the Canal and River Trust, which is a registered charity in the United Kingdom. Jenny Shepherd and Graham Reeves are both employed by The Canal and River Trust. This does not alter our adherence to PLOS ONE policies on sharing data and materials.\n",
      "\n",
      "The study was part-funded by the Canal and River Trust, which is a registered charity in the United Kingdom. Jenny Shepherd and Graham Reeves are both employed by The Canal and River Trust. This does not alter our adherence to PLOS ONE policies on sharing data and materials.\n",
      "\n",
      "The study was part-funded by the Canal and River Trust, which is a registered charity in the United Kingdom. Jenny Shepherd and Graham Reeves are both employed by The Canal and River Trust. This does not alter our adherence to PLOS ONE policies on sharing data and materials.\n",
      "\n",
      "Reeves, Graeme\n",
      "The study was part-funded by the Canal and River Trust, which is a registered charity in the United Kingdom. Jenny Shepherd and Graham Graeme Reeves are both employed by The Canal and River Trust. This does not alter our adherence to PLOS ONE policies on sharing data and materials.\n",
      "\n",
      "Shepherd, Jenny\n",
      "The study was part-funded by the Canal and River Trust, which is a registered charity in the United Kingdom. Jenny Shepherd and Graham Graeme Reeves are both employed by The Canal and River Trust. This does not alter our adherence to PLOS ONE policies on sharing data and materials.\n",
      "\n",
      "The study was part-funded by the Canal and River Trust, which is a registered charity in the United Kingdom. Jenny Shepherd and Graham Graeme Reeves are both employed by The Canal and River Trust. This does not alter our adherence to PLOS ONE policies on sharing data and materials.\n",
      "\n",
      "Li, Ying\n",
      "Ying Li is currently receiving a grant from the Scoliosis Research Society, has received consulting fees from Medtronic, has received support for travel from Zimmer Biomet, is the Chair of the Scoliosis Research Society's Morbidity and Mortality Committee, and is the Chair of the Pediatric Orthopaedic Society of North America's Membership Committee. Denning has received a speaker honorarium from OrthoPediatrics. Goldstein is a Member At Large of the Board of Directors of the Pediatric Orthopaedic Society of North America. Johnson is currently receiving grants from the Scoliosis Research Society and the Pediatric Orthopaedic Society of North America. Truong is currently receiving grants from the National Institutes of Health and the Gillette Foundation. Shore is on the Board of Directors of the American Academy of Cerebral Palsy and Developmental Medicine and the Advisory Board of the International Pediatric Orthopaedic Symposium. The remaining authors have no conflicts of interest or source of funding to report.\n",
      "\n",
      "Ying Li is currently receiving a grant from the Scoliosis Research Society, has received consulting fees from Medtronic, has received support for travel from Zimmer Biomet, is the Chair of the Scoliosis Research Society's Morbidity and Mortality Committee, and is the Chair of the Pediatric Orthopaedic Society of North America's Membership Committee. Denning has received a speaker honorarium from OrthoPediatrics. Goldstein is a Member At Large of the Board of Directors of the Pediatric Orthopaedic Society of North America. Johnson is currently receiving grants from the Scoliosis Research Society and the Pediatric Orthopaedic Society of North America. Truong is currently receiving grants from the National Institutes of Health and the Gillette Foundation. Shore is on the Board of Directors of the American Academy of Cerebral Palsy and Developmental Medicine and the Advisory Board of the International Pediatric Orthopaedic Symposium. The remaining authors have no conflicts of interest or source of funding to report.\n",
      "\n",
      "Ying Li is currently receiving a grant from the Scoliosis Research Society, has received consulting fees from Medtronic, has received support for travel from Zimmer Biomet, is the Chair of the Scoliosis Research Society's Morbidity and Mortality Committee, and is the Chair of the Pediatric Orthopaedic Society of North America's Membership Committee. Denning has received a speaker honorarium from OrthoPediatrics. Goldstein is a Member At Large of the Board of Directors of the Pediatric Orthopaedic Society of North America. Johnson is currently receiving grants from the Scoliosis Research Society and the Pediatric Orthopaedic Society of North America. Truong is currently receiving grants from the National Institutes of Health and the Gillette Foundation. Shore is on the Board of Directors of the American Academy of Cerebral Palsy and Developmental Medicine and the Advisory Board of the International Pediatric Orthopaedic Symposium. The remaining authors have no conflicts of interest or source of funding to report.\n",
      "\n",
      "Ying Li is currently receiving a grant from the Scoliosis Research Society, has received consulting fees from Medtronic, has received support for travel from Zimmer Biomet, is the Chair of the Scoliosis Research Society's Morbidity and Mortality Committee, and is the Chair of the Pediatric Orthopaedic Society of North America's Membership Committee. Denning has received a speaker honorarium from OrthoPediatrics. Goldstein is a Member At Large of the Board of Directors of the Pediatric Orthopaedic Society of North America. Johnson is currently receiving grants from the Scoliosis Research Society and the Pediatric Orthopaedic Society of North America. Truong is currently receiving grants from the National Institutes of Health and the Gillette Foundation. Shore is on the Board of Directors of the American Academy of Cerebral Palsy and Developmental Medicine and the Advisory Board of the International Pediatric Orthopaedic Symposium. The remaining authors have no conflicts of interest or source of funding to report.\n",
      "\n",
      "Ying Li is currently receiving a grant from the Scoliosis Research Society, has received consulting fees from Medtronic, has received support for travel from Zimmer Biomet, is the Chair of the Scoliosis Research Society's Morbidity and Mortality Committee, and is the Chair of the Pediatric Orthopaedic Society of North America's Membership Committee. Denning has received a speaker honorarium from OrthoPediatrics. Goldstein is a Member At Large of the Board of Directors of the Pediatric Orthopaedic Society of North America. Johnson is currently receiving grants from the Scoliosis Research Society and the Pediatric Orthopaedic Society of North America. Truong is currently receiving grants from the National Institutes of Health and the Gillette Foundation. Shore is on the Board of Directors of the American Academy of Cerebral Palsy and Developmental Medicine and the Advisory Board of the International Pediatric Orthopaedic Symposium. The remaining authors have no conflicts of interest or source of funding to report.\n",
      "\n",
      "Denning, Jaime R.\n",
      "Ying Li is currently receiving a grant from the Scoliosis Research Society, has received consulting fees from Medtronic, has received support for travel from Zimmer Biomet, is the Chair of the Scoliosis Research Society's Morbidity and Mortality Committee, and is the Chair of the Pediatric Orthopaedic Society of North America's Membership Committee. Jaime R. Denning has received a speaker honorarium from OrthoPediatrics. Goldstein is a Member At Large of the Board of Directors of the Pediatric Orthopaedic Society of North America. Johnson is currently receiving grants from the Scoliosis Research Society and the Pediatric Orthopaedic Society of North America. Truong is currently receiving grants from the National Institutes of Health and the Gillette Foundation. Shore is on the Board of Directors of the American Academy of Cerebral Palsy and Developmental Medicine and the Advisory Board of the International Pediatric Orthopaedic Symposium. The remaining authors have no conflicts of interest or source of funding to report.\n",
      "\n",
      "Goldstein, Rachel Y.\n",
      "Ying Li is currently receiving a grant from the Scoliosis Research Society, has received consulting fees from Medtronic, has received support for travel from Zimmer Biomet, is the Chair of the Scoliosis Research Society's Morbidity and Mortality Committee, and is the Chair of the Pediatric Orthopaedic Society of North America's Membership Committee. Jaime R. Denning has received a speaker honorarium from OrthoPediatrics. Rachel Y. Goldstein is a Member At Large of the Board of Directors of the Pediatric Orthopaedic Society of North America. Johnson is currently receiving grants from the Scoliosis Research Society and the Pediatric Orthopaedic Society of North America. Truong is currently receiving grants from the National Institutes of Health and the Gillette Foundation. Shore is on the Board of Directors of the American Academy of Cerebral Palsy and Developmental Medicine and the Advisory Board of the International Pediatric Orthopaedic Symposium. The remaining authors have no conflicts of interest or source of funding to report.\n",
      "\n",
      "Ying Li is currently receiving a grant from the Scoliosis Research Society, has received consulting fees from Medtronic, has received support for travel from Zimmer Biomet, is the Chair of the Scoliosis Research Society's Morbidity and Mortality Committee, and is the Chair of the Pediatric Orthopaedic Society of North America's Membership Committee. Jaime R. Denning has received a speaker honorarium from OrthoPediatrics. Rachel Y. Goldstein is a Member At Large of the Board of Directors of the Pediatric Orthopaedic Society of North America. Johnson is currently receiving grants from the Scoliosis Research Society and the Pediatric Orthopaedic Society of North America. Truong is currently receiving grants from the National Institutes of Health and the Gillette Foundation. Shore is on the Board of Directors of the American Academy of Cerebral Palsy and Developmental Medicine and the Advisory Board of the International Pediatric Orthopaedic Symposium. The remaining authors have no conflicts of interest or source of funding to report.\n",
      "\n",
      "Johnson, Megan E.\n",
      "Ying Li is currently receiving a grant from the Scoliosis Research Society, has received consulting fees from Medtronic, has received support for travel from Zimmer Biomet, is the Chair of the Scoliosis Research Society's Morbidity and Mortality Committee, and is the Chair of the Pediatric Orthopaedic Society of North America's Membership Committee. Jaime R. Denning has received a speaker honorarium from OrthoPediatrics. Rachel Y. Goldstein is a Member At Large of the Board of Directors of the Pediatric Orthopaedic Society of North America. Megan E. Johnson is currently receiving grants from the Scoliosis Research Society and the Pediatric Orthopaedic Society of North America. Truong is currently receiving grants from the National Institutes of Health and the Gillette Foundation. Shore is on the Board of Directors of the American Academy of Cerebral Palsy and Developmental Medicine and the Advisory Board of the International Pediatric Orthopaedic Symposium. The remaining authors have no conflicts of interest or source of funding to report.\n",
      "\n",
      "Truong, Walter H.\n",
      "Ying Li is currently receiving a grant from the Scoliosis Research Society, has received consulting fees from Medtronic, has received support for travel from Zimmer Biomet, is the Chair of the Scoliosis Research Society's Morbidity and Mortality Committee, and is the Chair of the Pediatric Orthopaedic Society of North America's Membership Committee. Jaime R. Denning has received a speaker honorarium from OrthoPediatrics. Rachel Y. Goldstein is a Member At Large of the Board of Directors of the Pediatric Orthopaedic Society of North America. Megan E. Johnson is currently receiving grants from the Scoliosis Research Society and the Pediatric Orthopaedic Society of North America. Walter H. Truong is currently receiving grants from the National Institutes of Health and the Gillette Foundation. Shore is on the Board of Directors of the American Academy of Cerebral Palsy and Developmental Medicine and the Advisory Board of the International Pediatric Orthopaedic Symposium. The remaining authors have no conflicts of interest or source of funding to report.\n",
      "\n",
      "Shore, Benjamin J.\n",
      "Ying Li is currently receiving a grant from the Scoliosis Research Society, has received consulting fees from Medtronic, has received support for travel from Zimmer Biomet, is the Chair of the Scoliosis Research Society's Morbidity and Mortality Committee, and is the Chair of the Pediatric Orthopaedic Society of North America's Membership Committee. Jaime R. Denning has received a speaker honorarium from OrthoPediatrics. Rachel Y. Goldstein is a Member At Large of the Board of Directors of the Pediatric Orthopaedic Society of North America. Megan E. Johnson is currently receiving grants from the Scoliosis Research Society and the Pediatric Orthopaedic Society of North America. Walter H. Truong is currently receiving grants from the National Institutes of Health and the Gillette Foundation. Benjamin J. Shore is on the Board of Directors of the American Academy of Cerebral Palsy and Developmental Medicine and the Advisory Board of the International Pediatric Orthopaedic Symposium. The remaining authors have no conflicts of interest or source of funding to report.\n",
      "\n",
      "Watson, Christopher J.E.\n",
      "Christopher J.E. Watson participated in advisory boards with Nefro Health and Jazz Pharmaceuticals and has received speaker fees from OrganOx. A.J.B. is co-holder of a patent on the circuit used in the OrganOx metra. C.D.L.C. has received income from OrganOx Ltd for teaching and training and for carrying out normothermic preservations after normal working hours. The other authors declare  no conflicts of interest.\n",
      "\n",
      "Christopher J.E. Watson participated in advisory boards with Nefro Health and Jazz Pharmaceuticals and has received speaker fees from OrganOx. A.J.B. is co-holder of a patent on the circuit used in the OrganOx metra. C.D.L.C. has received income from OrganOx Ltd for teaching and training and for carrying out normothermic preservations after normal working hours. The other authors declare  no conflicts of interest.\n",
      "\n",
      "Christopher J.E. Watson participated in advisory boards with Nefro Health and Jazz Pharmaceuticals and has received speaker fees from OrganOx. A.J.B. is co-holder of a patent on the circuit used in the OrganOx metra. C.D.L.C. has received income from OrganOx Ltd for teaching and training and for carrying out normothermic preservations after normal working hours. The other authors declare  no conflicts of interest.\n",
      "\n",
      "Christopher J.E. Watson participated in advisory boards with Nefro Health and Jazz Pharmaceuticals and has received speaker fees from OrganOx. A.J.B. is co-holder of a patent on the circuit used in the OrganOx metra. C.D.L.C. has received income from OrganOx Ltd for teaching and training and for carrying out normothermic preservations after normal working hours. The other authors declare  no conflicts of interest.\n",
      "\n",
      "Christopher J.E. Watson participated in advisory boards with Nefro Health and Jazz Pharmaceuticals and has received speaker fees from OrganOx. A.J.B. is co-holder of a patent on the circuit used in the OrganOx metra. C.D.L.C. has received income from OrganOx Ltd for teaching and training and for carrying out normothermic preservations after normal working hours. The other authors declare  no conflicts of interest.\n",
      "\n",
      "Ceresa, Carlo D.L.\n",
      "Christopher J.E. Watson participated in advisory boards with Nefro Health and Jazz Pharmaceuticals and has received speaker fees from OrganOx. A.J.B. is co-holder of a patent on the circuit used in the OrganOx metra. Carlo D.L. Ceresa has received income from OrganOx Ltd for teaching and training and for carrying out normothermic preservations after normal working hours. The other authors declare  no conflicts of interest.\n",
      "\n",
      "Christopher J.E. Watson participated in advisory boards with Nefro Health and Jazz Pharmaceuticals and has received speaker fees from OrganOx. A.J.B. is co-holder of a patent on the circuit used in the OrganOx metra. Carlo D.L. Ceresa has received income from OrganOx Ltd for teaching and training and for carrying out normothermic preservations after normal working hours. The other authors declare  no conflicts of interest.\n",
      "\n",
      "Christopher J.E. Watson participated in advisory boards with Nefro Health and Jazz Pharmaceuticals and has received speaker fees from OrganOx. A.J.B. is co-holder of a patent on the circuit used in the OrganOx metra. Carlo D.L. Ceresa has received income from OrganOx Ltd for teaching and training and for carrying out normothermic preservations after normal working hours. The other authors declare  no conflicts of interest.\n",
      "\n",
      "Christopher J.E. Watson participated in advisory boards with Nefro Health and Jazz Pharmaceuticals and has received speaker fees from OrganOx. A.J.B. is co-holder of a patent on the circuit used in the OrganOx metra. Carlo D.L. Ceresa has received income from OrganOx Ltd for teaching and training and for carrying out normothermic preservations after normal working hours. The other authors declare  no conflicts of interest.\n",
      "\n",
      "Christopher J.E. Watson participated in advisory boards with Nefro Health and Jazz Pharmaceuticals and has received speaker fees from OrganOx. A.J.B. is co-holder of a patent on the circuit used in the OrganOx metra. Carlo D.L. Ceresa has received income from OrganOx Ltd for teaching and training and for carrying out normothermic preservations after normal working hours. The other authors declare  no conflicts of interest.\n",
      "\n",
      "Christopher J.E. Watson participated in advisory boards with Nefro Health and Jazz Pharmaceuticals and has received speaker fees from OrganOx. A.J.B. is co-holder of a patent on the circuit used in the OrganOx metra. Carlo D.L. Ceresa has received income from OrganOx Ltd for teaching and training and for carrying out normothermic preservations after normal working hours. The other authors declare  no conflicts of interest.\n",
      "\n",
      "Butler, Andrew J.\n",
      "Christopher J.E. Watson participated in advisory boards with Nefro Health and Jazz Pharmaceuticals and has received speaker fees from OrganOx. Andrew J. Butler is co-holder of a patent on the circuit used in the OrganOx metra. Carlo D.L. Ceresa has received income from OrganOx Ltd for teaching and training and for carrying out normothermic preservations after normal working hours. The other authors declare  no conflicts of interest.\n",
      "\n",
      "Conflict of Interest and Funding Source: The results of the study are presented clearly, honestly, and without fabrication, falsification, or inappropriate data  manipulation. The results of the present study do not constitute endorsement by the American College of Sports Medicine. The authors have no conflicts of interest to declare. This study was not funded.\n",
      "\n",
      "Conflict of Interest and Funding Source: The results of the study are presented clearly, honestly, and without fabrication, falsification, or inappropriate data  manipulation. The results of the present study do not constitute endorsement by the American College of Sports Medicine. The authors have no conflicts of interest to declare. This study was not funded.\n",
      "\n",
      "Conflict of Interest and Funding Source: The results of the study are presented clearly, honestly, and without fabrication, falsification, or inappropriate data  manipulation. The results of the present study do not constitute endorsement by the American College of Sports Medicine. The authors have no conflicts of interest to declare. This study was not funded.\n",
      "\n",
      "Conflict of Interest and Funding Source: The results of the study are presented clearly, honestly, and without fabrication, falsification, or inappropriate data  manipulation. The results of the present study do not constitute endorsement by the American College of Sports Medicine. The authors have no conflicts of interest to declare. This study was not funded.\n",
      "\n",
      "Conflict of Interest and Funding Source: The results of the study are presented clearly, honestly, and without fabrication, falsification, or inappropriate data  manipulation. The results of the present study do not constitute endorsement by the American College of Sports Medicine. The authors have no conflicts of interest to declare. This study was not funded.\n",
      "\n",
      "Conflict of Interest and Funding Source: The results of the study are presented clearly, honestly, and without fabrication, falsification, or inappropriate data  manipulation. The results of the present study do not constitute endorsement by the American College of Sports Medicine. The authors have no conflicts of interest to declare. This study was not funded.\n",
      "\n",
      "Conflict of Interest and Funding Source: The results of the study are presented clearly, honestly, and without fabrication, falsification, or inappropriate data  manipulation. The results of the present study do not constitute endorsement by the American College of Sports Medicine. The authors have no conflicts of interest to declare. This study was not funded.\n",
      "\n",
      "Conflict of Interest and Funding Source: The results of the study are presented clearly, honestly, and without fabrication, falsification, or inappropriate data  manipulation. The results of the present study do not constitute endorsement by the American College of Sports Medicine. The authors have no conflicts of interest to declare. This study was not funded.\n",
      "\n",
      "Conflict of Interest and Funding Source: The results of the study are presented clearly, honestly, and without fabrication, falsification, or inappropriate data  manipulation. The results of the present study do not constitute endorsement by the American College of Sports Medicine. The authors have no conflicts of interest to declare. This study was not funded.\n",
      "\n",
      "Conflict of Interest and Funding Source: The results of the study are presented clearly, honestly, and without fabrication, falsification, or inappropriate data  manipulation. The results of the present study do not constitute endorsement by the American College of Sports Medicine. The authors have no conflicts of interest to declare. This study was not funded.\n",
      "\n",
      "Conflict of Interest and Funding Source: The results of the study are presented clearly, honestly, and without fabrication, falsification, or inappropriate data  manipulation. The results of the present study do not constitute endorsement by the American College of Sports Medicine. The authors have no conflicts of interest to declare. This study was not funded.\n",
      "\n",
      "Conflict of Interest and Funding Source: The results of the study are presented clearly, honestly, and without fabrication, falsification, or inappropriate data  manipulation. The results of the present study do not constitute endorsement by the American College of Sports Medicine. The authors have no conflicts of interest to declare. This study was not funded.\n",
      "\n",
      "Conflict of Interest and Funding Source: The results of the study are presented clearly, honestly, and without fabrication, falsification, or inappropriate data  manipulation. The results of the present study do not constitute endorsement by the American College of Sports Medicine. The authors have no conflicts of interest to declare. This study was not funded.\n",
      "\n",
      "Conflict of Interest and Funding Source: The results of the study are presented clearly, honestly, and without fabrication, falsification, or inappropriate data  manipulation. The results of the present study do not constitute endorsement by the American College of Sports Medicine. The authors have no conflicts of interest to declare. This study was not funded.\n",
      "\n",
      "Conflict of Interest and Funding Source: The results of the study are presented clearly, honestly, and without fabrication, falsification, or inappropriate data  manipulation. The results of the present study do not constitute endorsement by the American College of Sports Medicine. The authors have no conflicts of interest to declare. This study was not funded.\n",
      "\n",
      "Conflict of Interest and Funding Source: The results of the study are presented clearly, honestly, and without fabrication, falsification, or inappropriate data  manipulation. The results of the present study do not constitute endorsement by the American College of Sports Medicine. The authors have no conflicts of interest to declare. This study was not funded.\n",
      "\n",
      "Conflict of Interest and Funding Source: The results of the study are presented clearly, honestly, and without fabrication, falsification, or inappropriate data  manipulation. The results of the present study do not constitute endorsement by the American College of Sports Medicine. The authors have no conflicts of interest to declare. This study was not funded.\n",
      "\n",
      "Conflict of Interest and Funding Source: The results of the study are presented clearly, honestly, and without fabrication, falsification, or inappropriate data  manipulation. The results of the present study do not constitute endorsement by the American College of Sports Medicine. The authors have no conflicts of interest to declare. This study was not funded.\n",
      "\n",
      "Conflict of Interest and Funding Source: The results of the study are presented clearly, honestly, and without fabrication, falsification, or inappropriate data  manipulation. The results of the present study do not constitute endorsement by the American College of Sports Medicine. The authors have no conflicts of interest to declare. This study was not funded.\n",
      "\n",
      "Conflict of Interest and Funding Source: The results of the study are presented clearly, honestly, and without fabrication, falsification, or inappropriate data  manipulation. The results of the present study do not constitute endorsement by the American College of Sports Medicine. The authors have no conflicts of interest to declare. This study was not funded.\n",
      "\n",
      "Conflict of Interest and Funding Source: The results of the study are presented clearly, honestly, and without fabrication, falsification, or inappropriate data  manipulation. The results of the present study do not constitute endorsement by the American College of Sports Medicine. The authors have no conflicts of interest to declare. This study was not funded.\n",
      "\n",
      "Conflict of Interest and Funding Source: The results of the study are presented clearly, honestly, and without fabrication, falsification, or inappropriate data  manipulation. The results of the present study do not constitute endorsement by the American College of Sports Medicine. The authors have no conflicts of interest to declare. This study was not funded.\n",
      "\n",
      "D.L. is consultant for Olympus. E.G. is consultant for Olympus, DiLumen, and Boston Scientific and receives honorarium from OpClear. The remaining authors declare no conflicts of interest.\n",
      "\n",
      "Liska, David\n",
      "David Liska is consultant for Olympus. E.G. is consultant for Olympus, DiLumen, and Boston Scientific and receives honorarium from OpClear. The remaining authors declare no conflicts of interest.\n",
      "\n",
      "David Liska is consultant for Olympus. E.G. is consultant for Olympus, DiLumen, and Boston Scientific and receives honorarium from OpClear. The remaining authors declare no conflicts of interest.\n",
      "\n",
      "David Liska is consultant for Olympus. E.G. is consultant for Olympus, DiLumen, and Boston Scientific and receives honorarium from OpClear. The remaining authors declare no conflicts of interest.\n",
      "\n",
      "Gorgun, Emre\n",
      "David Liska is consultant for Olympus. Emre Gorgun is consultant for Olympus, DiLumen, and Boston Scientific and receives honorarium from OpClear. The remaining authors declare no conflicts of interest.\n",
      "\n",
      "Hagedoorn, Nienke N.\n",
      "Drs. Nienke N. Hagedoorn's and Zenz's institutions received funding from the European Union (EU). Dr. Boeddha received funding from GlaxoSmithKline. Drs. Kohlfuerst's, Hazelzet's, and Emonts' institutions received funding from EU Project European Union Childhood Life-threatening Infectious Disease study (EUCLIDS). Dr. Kohlfuerst received support for article research from EU Project EUCLIDS. Drs. Carrol, van der Flier, and Herberg received support for article research from EU  Horizon 2020. Dr. Hazelzet's institution received funding from Erasmus Medical Centre. Dr. Zenz received support for article research from the EU. Dr. Driessen's institution received funding from Merck and the Elizabeth von Freyburg Foundation. Dr. Emonts' institution received funding from the EU, FP7, EU H2020 Personalized Risk assessment in Febrile illness to Optimize Real-life Management  across the European Union (PERFORM), and EU H2020 Diagnosis and Management of Febrile Illness using RNA Personalised Molecular Signature Diagnosis (DIAMONDS).  The remaining authors have disclosed that they do not have any potential conflicts of interest.\n",
      "\n",
      "Boeddha, Navin P.\n",
      "Drs. Nienke N. Hagedoorn's and Zenz's institutions received funding from the European Union (EU). Dr. Navin P. Boeddha received funding from GlaxoSmithKline. Drs. Kohlfuerst's, Hazelzet's, and Emonts' institutions received funding from EU Project European Union Childhood Life-threatening Infectious Disease study (EUCLIDS). Dr. Kohlfuerst received support for article research from EU Project EUCLIDS. Drs. Carrol, van der Flier, and Herberg received support for article research from EU  Horizon 2020. Dr. Hazelzet's institution received funding from Erasmus Medical Centre. Dr. Zenz received support for article research from the EU. Dr. Driessen's institution received funding from Merck and the Elizabeth von Freyburg Foundation. Dr. Emonts' institution received funding from the EU, FP7, EU H2020 Personalized Risk assessment in Febrile illness to Optimize Real-life Management  across the European Union (PERFORM), and EU H2020 Diagnosis and Management of Febrile Illness using RNA Personalised Molecular Signature Diagnosis (DIAMONDS).  The remaining authors have disclosed that they do not have any potential conflicts of interest.\n",
      "\n",
      "Kohlfuerst, Daniela S.\n",
      "Drs. Nienke N. Hagedoorn's and Zenz's institutions received funding from the European Union (EU). Dr. Navin P. Boeddha received funding from GlaxoSmithKline. Drs. Daniela S. Kohlfuerst's, Hazelzet's, and Emonts' institutions received funding from EU Project European Union Childhood Life-threatening Infectious Disease study (EUCLIDS). Dr. Daniela S. Kohlfuerst received support for article research from EU Project EUCLIDS. Drs. Carrol, van der Flier, and Herberg received support for article research from EU  Horizon 2020. Dr. Hazelzet's institution received funding from Erasmus Medical Centre. Dr. Zenz received support for article research from the EU. Dr. Driessen's institution received funding from Merck and the Elizabeth von Freyburg Foundation. Dr. Emonts' institution received funding from the EU, FP7, EU H2020 Personalized Risk assessment in Febrile illness to Optimize Real-life Management  across the European Union (PERFORM), and EU H2020 Diagnosis and Management of Febrile Illness using RNA Personalised Molecular Signature Diagnosis (DIAMONDS).  The remaining authors have disclosed that they do not have any potential conflicts of interest.\n",
      "\n",
      "Drs. Nienke N. Hagedoorn's and Zenz's institutions received funding from the European Union (EU). Dr. Navin P. Boeddha received funding from GlaxoSmithKline. Drs. Daniela S. Kohlfuerst's, Hazelzet's, and Emonts' institutions received funding from EU Project European Union Childhood Life-threatening Infectious Disease study (EUCLIDS). Dr. Daniela S. Kohlfuerst received support for article research from EU Project EUCLIDS. Drs. Carrol, van der Flier, and Herberg received support for article research from EU  Horizon 2020. Dr. Hazelzet's institution received funding from Erasmus Medical Centre. Dr. Zenz received support for article research from the EU. Dr. Driessen's institution received funding from Merck and the Elizabeth von Freyburg Foundation. Dr. Emonts' institution received funding from the EU, FP7, EU H2020 Personalized Risk assessment in Febrile illness to Optimize Real-life Management  across the European Union (PERFORM), and EU H2020 Diagnosis and Management of Febrile Illness using RNA Personalised Molecular Signature Diagnosis (DIAMONDS).  The remaining authors have disclosed that they do not have any potential conflicts of interest.\n",
      "\n",
      "Carrol, Enitan D.\n",
      "Drs. Nienke N. Hagedoorn's and Zenz's institutions received funding from the European Union (EU). Dr. Navin P. Boeddha received funding from GlaxoSmithKline. Drs. Daniela S. Kohlfuerst's, Hazelzet's, and Emonts' institutions received funding from EU Project European Union Childhood Life-threatening Infectious Disease study (EUCLIDS). Dr. Daniela S. Kohlfuerst received support for article research from EU Project EUCLIDS. Drs. Enitan D. Carrol, van der Flier, and Herberg received support for article research from EU  Horizon 2020. Dr. Hazelzet's institution received funding from Erasmus Medical Centre. Dr. Zenz received support for article research from the EU. Dr. Driessen's institution received funding from Merck and the Elizabeth von Freyburg Foundation. Dr. Emonts' institution received funding from the EU, FP7, EU H2020 Personalized Risk assessment in Febrile illness to Optimize Real-life Management  across the European Union (PERFORM), and EU H2020 Diagnosis and Management of Febrile Illness using RNA Personalised Molecular Signature Diagnosis (DIAMONDS).  The remaining authors have disclosed that they do not have any potential conflicts of interest.\n",
      "\n",
      "Drs. Nienke N. Hagedoorn's and Zenz's institutions received funding from the European Union (EU). Dr. Navin P. Boeddha received funding from GlaxoSmithKline. Drs. Daniela S. Kohlfuerst's, Hazelzet's, and Emonts' institutions received funding from EU Project European Union Childhood Life-threatening Infectious Disease study (EUCLIDS). Dr. Daniela S. Kohlfuerst received support for article research from EU Project EUCLIDS. Drs. Enitan D. Carrol, van der Flier, and Herberg received support for article research from EU  Horizon 2020. Dr. Hazelzet's institution received funding from Erasmus Medical Centre. Dr. Zenz received support for article research from the EU. Dr. Driessen's institution received funding from Merck and the Elizabeth von Freyburg Foundation. Dr. Emonts' institution received funding from the EU, FP7, EU H2020 Personalized Risk assessment in Febrile illness to Optimize Real-life Management  across the European Union (PERFORM), and EU H2020 Diagnosis and Management of Febrile Illness using RNA Personalised Molecular Signature Diagnosis (DIAMONDS).  The remaining authors have disclosed that they do not have any potential conflicts of interest.\n",
      "\n",
      "van der Flier, Michiel\n",
      "Drs. Nienke N. Hagedoorn's and Zenz's institutions received funding from the European Union (EU). Dr. Navin P. Boeddha received funding from GlaxoSmithKline. Drs. Daniela S. Kohlfuerst's, Hazelzet's, and Emonts' institutions received funding from EU Project European Union Childhood Life-threatening Infectious Disease study (EUCLIDS). Dr. Daniela S. Kohlfuerst received support for article research from EU Project EUCLIDS. Drs. Enitan D. Carrol, van der Michiel van der Flier, and Herberg received support for article research from EU  Horizon 2020. Dr. Hazelzet's institution received funding from Erasmus Medical Centre. Dr. Zenz received support for article research from the EU. Dr. Driessen's institution received funding from Merck and the Elizabeth von Freyburg Foundation. Dr. Emonts' institution received funding from the EU, FP7, EU H2020 Personalized Risk assessment in Febrile illness to Optimize Real-life Management  across the European Union (PERFORM), and EU H2020 Diagnosis and Management of Febrile Illness using RNA Personalised Molecular Signature Diagnosis (DIAMONDS).  The remaining authors have disclosed that they do not have any potential conflicts of interest.\n",
      "\n",
      "Hazelzet, Jan\n",
      "Drs. Nienke N. Hagedoorn's and Zenz's institutions received funding from the European Union (EU). Dr. Navin P. Boeddha received funding from GlaxoSmithKline. Drs. Daniela S. Kohlfuerst's, Jan Hazelzet's, and Emonts' institutions received funding from EU Project European Union Childhood Life-threatening Infectious Disease study (EUCLIDS). Dr. Daniela S. Kohlfuerst received support for article research from EU Project EUCLIDS. Drs. Enitan D. Carrol, van der Michiel van der Flier, and Herberg received support for article research from EU  Horizon 2020. Dr. Jan Hazelzet's institution received funding from Erasmus Medical Centre. Dr. Zenz received support for article research from the EU. Dr. Driessen's institution received funding from Merck and the Elizabeth von Freyburg Foundation. Dr. Emonts' institution received funding from the EU, FP7, EU H2020 Personalized Risk assessment in Febrile illness to Optimize Real-life Management  across the European Union (PERFORM), and EU H2020 Diagnosis and Management of Febrile Illness using RNA Personalised Molecular Signature Diagnosis (DIAMONDS).  The remaining authors have disclosed that they do not have any potential conflicts of interest.\n",
      "\n",
      "Herberg, Jethro\n",
      "Drs. Nienke N. Hagedoorn's and Zenz's institutions received funding from the European Union (EU). Dr. Navin P. Boeddha received funding from GlaxoSmithKline. Drs. Daniela S. Kohlfuerst's, Jan Hazelzet's, and Emonts' institutions received funding from EU Project European Union Childhood Life-threatening Infectious Disease study (EUCLIDS). Dr. Daniela S. Kohlfuerst received support for article research from EU Project EUCLIDS. Drs. Enitan D. Carrol, van der Michiel van der Flier, and Jethro Herberg received support for article research from EU  Horizon 2020. Dr. Jan Hazelzet's institution received funding from Erasmus Medical Centre. Dr. Zenz received support for article research from the EU. Dr. Driessen's institution received funding from Merck and the Elizabeth von Freyburg Foundation. Dr. Emonts' institution received funding from the EU, FP7, EU H2020 Personalized Risk assessment in Febrile illness to Optimize Real-life Management  across the European Union (PERFORM), and EU H2020 Diagnosis and Management of Febrile Illness using RNA Personalised Molecular Signature Diagnosis (DIAMONDS).  The remaining authors have disclosed that they do not have any potential conflicts of interest.\n",
      "\n",
      "Drs. Nienke N. Hagedoorn's and Zenz's institutions received funding from the European Union (EU). Dr. Navin P. Boeddha received funding from GlaxoSmithKline. Drs. Daniela S. Kohlfuerst's, Jan Hazelzet's, and Emonts' institutions received funding from EU Project European Union Childhood Life-threatening Infectious Disease study (EUCLIDS). Dr. Daniela S. Kohlfuerst received support for article research from EU Project EUCLIDS. Drs. Enitan D. Carrol, van der Michiel van der Flier, and Jethro Herberg received support for article research from EU  Horizon 2020. Dr. Jan Hazelzet's institution received funding from Erasmus Medical Centre. Dr. Zenz received support for article research from the EU. Dr. Driessen's institution received funding from Merck and the Elizabeth von Freyburg Foundation. Dr. Emonts' institution received funding from the EU, FP7, EU H2020 Personalized Risk assessment in Febrile illness to Optimize Real-life Management  across the European Union (PERFORM), and EU H2020 Diagnosis and Management of Febrile Illness using RNA Personalised Molecular Signature Diagnosis (DIAMONDS).  The remaining authors have disclosed that they do not have any potential conflicts of interest.\n",
      "\n",
      "Drs. Nienke N. Hagedoorn's and Zenz's institutions received funding from the European Union (EU). Dr. Navin P. Boeddha received funding from GlaxoSmithKline. Drs. Daniela S. Kohlfuerst's, Jan Hazelzet's, and Emonts' institutions received funding from EU Project European Union Childhood Life-threatening Infectious Disease study (EUCLIDS). Dr. Daniela S. Kohlfuerst received support for article research from EU Project EUCLIDS. Drs. Enitan D. Carrol, van der Michiel van der Flier, and Jethro Herberg received support for article research from EU  Horizon 2020. Dr. Jan Hazelzet's institution received funding from Erasmus Medical Centre. Dr. Zenz received support for article research from the EU. Dr. Driessen's institution received funding from Merck and the Elizabeth von Freyburg Foundation. Dr. Emonts' institution received funding from the EU, FP7, EU H2020 Personalized Risk assessment in Febrile illness to Optimize Real-life Management  across the European Union (PERFORM), and EU H2020 Diagnosis and Management of Febrile Illness using RNA Personalised Molecular Signature Diagnosis (DIAMONDS).  The remaining authors have disclosed that they do not have any potential conflicts of interest.\n",
      "\n",
      "Drs. Nienke N. Hagedoorn's and Zenz's institutions received funding from the European Union (EU). Dr. Navin P. Boeddha received funding from GlaxoSmithKline. Drs. Daniela S. Kohlfuerst's, Jan Hazelzet's, and Emonts' institutions received funding from EU Project European Union Childhood Life-threatening Infectious Disease study (EUCLIDS). Dr. Daniela S. Kohlfuerst received support for article research from EU Project EUCLIDS. Drs. Enitan D. Carrol, van der Michiel van der Flier, and Jethro Herberg received support for article research from EU  Horizon 2020. Dr. Jan Hazelzet's institution received funding from Erasmus Medical Centre. Dr. Zenz received support for article research from the EU. Dr. Driessen's institution received funding from Merck and the Elizabeth von Freyburg Foundation. Dr. Emonts' institution received funding from the EU, FP7, EU H2020 Personalized Risk assessment in Febrile illness to Optimize Real-life Management  across the European Union (PERFORM), and EU H2020 Diagnosis and Management of Febrile Illness using RNA Personalised Molecular Signature Diagnosis (DIAMONDS).  The remaining authors have disclosed that they do not have any potential conflicts of interest.\n",
      "\n",
      "Drs. Nienke N. Hagedoorn's and Zenz's institutions received funding from the European Union (EU). Dr. Navin P. Boeddha received funding from GlaxoSmithKline. Drs. Daniela S. Kohlfuerst's, Jan Hazelzet's, and Emonts' institutions received funding from EU Project European Union Childhood Life-threatening Infectious Disease study (EUCLIDS). Dr. Daniela S. Kohlfuerst received support for article research from EU Project EUCLIDS. Drs. Enitan D. Carrol, van der Michiel van der Flier, and Jethro Herberg received support for article research from EU  Horizon 2020. Dr. Jan Hazelzet's institution received funding from Erasmus Medical Centre. Dr. Zenz received support for article research from the EU. Dr. Driessen's institution received funding from Merck and the Elizabeth von Freyburg Foundation. Dr. Emonts' institution received funding from the EU, FP7, EU H2020 Personalized Risk assessment in Febrile illness to Optimize Real-life Management  across the European Union (PERFORM), and EU H2020 Diagnosis and Management of Febrile Illness using RNA Personalised Molecular Signature Diagnosis (DIAMONDS).  The remaining authors have disclosed that they do not have any potential conflicts of interest.\n",
      "\n",
      "Drs. Nienke N. Hagedoorn's and Zenz's institutions received funding from the European Union (EU). Dr. Navin P. Boeddha received funding from GlaxoSmithKline. Drs. Daniela S. Kohlfuerst's, Jan Hazelzet's, and Emonts' institutions received funding from EU Project European Union Childhood Life-threatening Infectious Disease study (EUCLIDS). Dr. Daniela S. Kohlfuerst received support for article research from EU Project EUCLIDS. Drs. Enitan D. Carrol, van der Michiel van der Flier, and Jethro Herberg received support for article research from EU  Horizon 2020. Dr. Jan Hazelzet's institution received funding from Erasmus Medical Centre. Dr. Zenz received support for article research from the EU. Dr. Driessen's institution received funding from Merck and the Elizabeth von Freyburg Foundation. Dr. Emonts' institution received funding from the EU, FP7, EU H2020 Personalized Risk assessment in Febrile illness to Optimize Real-life Management  across the European Union (PERFORM), and EU H2020 Diagnosis and Management of Febrile Illness using RNA Personalised Molecular Signature Diagnosis (DIAMONDS).  The remaining authors have disclosed that they do not have any potential conflicts of interest.\n",
      "\n",
      "Drs. Nienke N. Hagedoorn's and Zenz's institutions received funding from the European Union (EU). Dr. Navin P. Boeddha received funding from GlaxoSmithKline. Drs. Daniela S. Kohlfuerst's, Jan Hazelzet's, and Emonts' institutions received funding from EU Project European Union Childhood Life-threatening Infectious Disease study (EUCLIDS). Dr. Daniela S. Kohlfuerst received support for article research from EU Project EUCLIDS. Drs. Enitan D. Carrol, van der Michiel van der Flier, and Jethro Herberg received support for article research from EU  Horizon 2020. Dr. Jan Hazelzet's institution received funding from Erasmus Medical Centre. Dr. Zenz received support for article research from the EU. Dr. Driessen's institution received funding from Merck and the Elizabeth von Freyburg Foundation. Dr. Emonts' institution received funding from the EU, FP7, EU H2020 Personalized Risk assessment in Febrile illness to Optimize Real-life Management  across the European Union (PERFORM), and EU H2020 Diagnosis and Management of Febrile Illness using RNA Personalised Molecular Signature Diagnosis (DIAMONDS).  The remaining authors have disclosed that they do not have any potential conflicts of interest.\n",
      "\n",
      "Zenz, Werner\n",
      "Drs. Nienke N. Hagedoorn's and Werner Zenz's institutions received funding from the European Union (EU). Dr. Navin P. Boeddha received funding from GlaxoSmithKline. Drs. Daniela S. Kohlfuerst's, Jan Hazelzet's, and Emonts' institutions received funding from EU Project European Union Childhood Life-threatening Infectious Disease study (EUCLIDS). Dr. Daniela S. Kohlfuerst received support for article research from EU Project EUCLIDS. Drs. Enitan D. Carrol, van der Michiel van der Flier, and Jethro Herberg received support for article research from EU  Horizon 2020. Dr. Jan Hazelzet's institution received funding from Erasmus Medical Centre. Dr. Werner Zenz received support for article research from the EU. Dr. Driessen's institution received funding from Merck and the Elizabeth von Freyburg Foundation. Dr. Emonts' institution received funding from the EU, FP7, EU H2020 Personalized Risk assessment in Febrile illness to Optimize Real-life Management  across the European Union (PERFORM), and EU H2020 Diagnosis and Management of Febrile Illness using RNA Personalised Molecular Signature Diagnosis (DIAMONDS).  The remaining authors have disclosed that they do not have any potential conflicts of interest.\n",
      "\n",
      "Drs. Nienke N. Hagedoorn's and Werner Zenz's institutions received funding from the European Union (EU). Dr. Navin P. Boeddha received funding from GlaxoSmithKline. Drs. Daniela S. Kohlfuerst's, Jan Hazelzet's, and Emonts' institutions received funding from EU Project European Union Childhood Life-threatening Infectious Disease study (EUCLIDS). Dr. Daniela S. Kohlfuerst received support for article research from EU Project EUCLIDS. Drs. Enitan D. Carrol, van der Michiel van der Flier, and Jethro Herberg received support for article research from EU  Horizon 2020. Dr. Jan Hazelzet's institution received funding from Erasmus Medical Centre. Dr. Werner Zenz received support for article research from the EU. Dr. Driessen's institution received funding from Merck and the Elizabeth von Freyburg Foundation. Dr. Emonts' institution received funding from the EU, FP7, EU H2020 Personalized Risk assessment in Febrile illness to Optimize Real-life Management  across the European Union (PERFORM), and EU H2020 Diagnosis and Management of Febrile Illness using RNA Personalised Molecular Signature Diagnosis (DIAMONDS).  The remaining authors have disclosed that they do not have any potential conflicts of interest.\n",
      "\n",
      "Driessen, Gertjan\n",
      "Drs. Nienke N. Hagedoorn's and Werner Zenz's institutions received funding from the European Union (EU). Dr. Navin P. Boeddha received funding from GlaxoSmithKline. Drs. Daniela S. Kohlfuerst's, Jan Hazelzet's, and Emonts' institutions received funding from EU Project European Union Childhood Life-threatening Infectious Disease study (EUCLIDS). Dr. Daniela S. Kohlfuerst received support for article research from EU Project EUCLIDS. Drs. Enitan D. Carrol, van der Michiel van der Flier, and Jethro Herberg received support for article research from EU  Horizon 2020. Dr. Jan Hazelzet's institution received funding from Erasmus Medical Centre. Dr. Werner Zenz received support for article research from the EU. Dr. Gertjan Driessen's institution received funding from Merck and the Elizabeth von Freyburg Foundation. Dr. Emonts' institution received funding from the EU, FP7, EU H2020 Personalized Risk assessment in Febrile illness to Optimize Real-life Management  across the European Union (PERFORM), and EU H2020 Diagnosis and Management of Febrile Illness using RNA Personalised Molecular Signature Diagnosis (DIAMONDS).  The remaining authors have disclosed that they do not have any potential conflicts of interest.\n",
      "\n",
      "Emonts, Marieke\n",
      "Drs. Nienke N. Hagedoorn's and Werner Zenz's institutions received funding from the European Union (EU). Dr. Navin P. Boeddha received funding from GlaxoSmithKline. Drs. Daniela S. Kohlfuerst's, Jan Hazelzet's, and Marieke Emonts' institutions received funding from EU Project European Union Childhood Life-threatening Infectious Disease study (EUCLIDS). Dr. Daniela S. Kohlfuerst received support for article research from EU Project EUCLIDS. Drs. Enitan D. Carrol, van der Michiel van der Flier, and Jethro Herberg received support for article research from EU  Horizon 2020. Dr. Jan Hazelzet's institution received funding from Erasmus Medical Centre. Dr. Werner Zenz received support for article research from the EU. Dr. Gertjan Driessen's institution received funding from Merck and the Elizabeth von Freyburg Foundation. Dr. Marieke Emonts' institution received funding from the EU, FP7, EU H2020 Personalized Risk assessment in Febrile illness to Optimize Real-life Management  across the European Union (PERFORM), and EU H2020 Diagnosis and Management of Febrile Illness using RNA Personalised Molecular Signature Diagnosis (DIAMONDS).  The remaining authors have disclosed that they do not have any potential conflicts of interest.\n",
      "\n",
      "McLachlan, Ian G.\n",
      "Ian G. McLachlan, TK, MD, ED, MG, UD, JS, SF No competing interests declared\n",
      "\n",
      "Kramer, Talya S.\n",
      "Ian G. McLachlan, Talya S. Kramer, MD, ED, MG, UD, JS, SF No competing interests declared\n",
      "\n",
      "Dua, Malvika\n",
      "Ian G. McLachlan, Talya S. Kramer, Malvika Dua, ED, MG, UD, JS, SF No competing interests declared\n",
      "\n",
      "DiLoreto, Elizabeth M.\n",
      "Ian G. McLachlan, Talya S. Kramer, Malvika Dua, Elizabeth M. DiLoreto, MG, UD, JS, SF No competing interests declared\n",
      "\n",
      "Gomes, Matthew A.\n",
      "Ian G. McLachlan, Talya S. Kramer, Malvika Dua, Elizabeth M. DiLoreto, Matthew A. Gomes, UD, JS, SF No competing interests declared\n",
      "\n",
      "Dag, Ugur\n",
      "Ian G. McLachlan, Talya S. Kramer, Malvika Dua, Elizabeth M. DiLoreto, Matthew A. Gomes, Ugur Dag, JS, SF No competing interests declared\n",
      "\n",
      "Srinivasan, Jagan\n",
      "Ian G. McLachlan, Talya S. Kramer, Malvika Dua, Elizabeth M. DiLoreto, Matthew A. Gomes, Ugur Dag, Jagan Srinivasan, SF No competing interests declared\n",
      "\n",
      "Flavell, Steven W.\n",
      "Ian G. McLachlan, Talya S. Kramer, Malvika Dua, Elizabeth M. DiLoreto, Matthew A. Gomes, Ugur Dag, Jagan Srinivasan, Steven W. Flavell No competing interests declared\n",
      "\n",
      "Lebecq, Alexis\n",
      "Alexis Lebecq, MD, AF, VB, JL, FR, MM, LA, RB, MS, MF, BM, SU, YJ, MC No competing interests declared\n",
      "\n",
      "Doumane, Mehdi\n",
      "Alexis Lebecq, Mehdi Doumane, AF, VB, JL, FR, MM, LA, RB, MS, MF, BM, SU, YJ, MC No competing interests declared\n",
      "\n",
      "Fangain, Aurelie\n",
      "Alexis Lebecq, Mehdi Doumane, Aurelie Fangain, VB, JL, FR, MM, LA, RB, MS, MF, BM, SU, YJ, MC No competing interests declared\n",
      "\n",
      "Bayle, Vincent\n",
      "Alexis Lebecq, Mehdi Doumane, Aurelie Fangain, Vincent Bayle, JL, FR, MM, LA, RB, MS, MF, BM, SU, YJ, MC No competing interests declared\n",
      "\n",
      "Xuan Leong, Jia\n",
      "Alexis Lebecq, Mehdi Doumane, Aurelie Fangain, Vincent Bayle, Jia Xuan Leong, FR, MM, LA, RB, MS, MF, BM, SU, YJ, MC No competing interests declared\n",
      "\n",
      "Rozier, Frederique\n",
      "Alexis Lebecq, Mehdi Doumane, Aurelie Fangain, Vincent Bayle, Jia Xuan Leong, Frederique Rozier, MM, LA, RB, MS, MF, BM, SU, YJ, MC No competing interests declared\n",
      "\n",
      "Del Marques-Bueno, Maria\n",
      "Alexis Lebecq, Mehdi Doumane, Aurelie Fangain, Vincent Bayle, Jia Xuan Leong, Frederique Rozier, Maria Del Marques-Bueno, LA, RB, MS, MF, BM, SU, YJ, MC No competing interests declared\n",
      "\n",
      "Armengot, Laia\n",
      "Alexis Lebecq, Mehdi Doumane, Aurelie Fangain, Vincent Bayle, Jia Xuan Leong, Frederique Rozier, Maria Del Marques-Bueno, Laia Armengot, RB, MS, MF, BM, SU, YJ, MC No competing interests declared\n",
      "\n",
      "Boisseau, Romain\n",
      "Alexis Lebecq, Mehdi Doumane, Aurelie Fangain, Vincent Bayle, Jia Xuan Leong, Frederique Rozier, Maria Del Marques-Bueno, Laia Armengot, Romain Boisseau, MS, MF, BM, SU, YJ, MC No competing interests declared\n",
      "\n",
      "Laetitia Simon, Mathilde\n",
      "Alexis Lebecq, Mehdi Doumane, Aurelie Fangain, Vincent Bayle, Jia Xuan Leong, Frederique Rozier, Maria Del Marques-Bueno, Laia Armengot, Romain Boisseau, Mathilde Laetitia Simon, MF, BM, SU, YJ, MC No competing interests declared\n",
      "\n",
      "Franz-Wachtel, Mirita\n",
      "Alexis Lebecq, Mehdi Doumane, Aurelie Fangain, Vincent Bayle, Jia Xuan Leong, Frederique Rozier, Maria Del Marques-Bueno, Laia Armengot, Romain Boisseau, Mathilde Laetitia Simon, Mirita Franz-Wachtel, BM, SU, YJ, MC No competing interests declared\n",
      "\n",
      "Macek, Boris\n",
      "Alexis Lebecq, Mehdi Doumane, Aurelie Fangain, Vincent Bayle, Jia Xuan Leong, Frederique Rozier, Maria Del Marques-Bueno, Laia Armengot, Romain Boisseau, Mathilde Laetitia Simon, Mirita Franz-Wachtel, Boris Macek, SU, YJ, MC No competing interests declared\n",
      "\n",
      "Ustun, Suayib\n",
      "Alexis Lebecq, Mehdi Doumane, Aurelie Fangain, Vincent Bayle, Jia Xuan Leong, Frederique Rozier, Maria Del Marques-Bueno, Laia Armengot, Romain Boisseau, Mathilde Laetitia Simon, Mirita Franz-Wachtel, Boris Macek, Suayib Ustun, YJ, MC No competing interests declared\n",
      "\n",
      "Jaillais, Yvon\n",
      "Alexis Lebecq, Mehdi Doumane, Aurelie Fangain, Vincent Bayle, Jia Xuan Leong, Frederique Rozier, Maria Del Marques-Bueno, Laia Armengot, Romain Boisseau, Mathilde Laetitia Simon, Mirita Franz-Wachtel, Boris Macek, Suayib Ustun, Yvon Jaillais, MC No competing interests declared\n",
      "\n",
      "Caillaud, Marie-Cecile\n",
      "Alexis Lebecq, Mehdi Doumane, Aurelie Fangain, Vincent Bayle, Jia Xuan Leong, Frederique Rozier, Maria Del Marques-Bueno, Laia Armengot, Romain Boisseau, Mathilde Laetitia Simon, Mirita Franz-Wachtel, Boris Macek, Suayib Ustun, Yvon Jaillais, Marie-Cecile Caillaud No competing interests declared\n",
      "\n",
      "Yang, Marty G.\n",
      "Marty G. Yang, EL, CC, MG, TV The authors declare that no competing interests exist.\n",
      "\n",
      "Ling, Emi\n",
      "Marty G. Yang, Emi Ling, CC, MG, TV The authors declare that no competing interests exist.\n",
      "\n",
      "Cowley, Christopher J.\n",
      "Marty G. Yang, Emi Ling, Christopher J. Cowley, MG, TV The authors declare that no competing interests exist.\n",
      "\n",
      "Greenberg, Michael E.\n",
      "Marty G. Yang, Emi Ling, Christopher J. Cowley, Michael E. Greenberg, TV The authors declare that no competing interests exist.\n",
      "\n",
      "Vierbuchen, Thomas\n",
      "Marty G. Yang, Emi Ling, Christopher J. Cowley, Michael E. Greenberg, Thomas Vierbuchen The authors declare that no competing interests exist.\n",
      "\n",
      "Cai, Wesley L.\n",
      "Wesley L. Cai, JC, HC, EW, SK, LC, MZ, AA, MZ, AB, WL, XY, EK, YD, YL, TW, QY The other authors declare that no competing interests exist. JJ Jian Jin, . The Jin laboratory received research funds un-related to this study from Celgene Corporation, Levo Therapeutics, Inc., Cullgen, Inc. and Cullinan Oncology, Inc. J.J. is a cofounder, scientific advisory board member and equity shareholder in Cullgen, Inc. and a consultant for Cullgen, Inc., EpiCypher, Inc. and Accent Therapeutics, Inc.. DN Don X Nguyen, has received research funding un-related to  this study from AstraZeneca Inc..\n",
      "\n",
      "Fang-Yi Chen, Jocelyn\n",
      "Wesley L. Cai, Jocelyn Fang-Yi Chen, HC, EW, SK, LC, MZ, AA, MZ, AB, WL, XY, EK, YD, YL, TW, QY The other authors declare that no competing interests exist. JJ Jian Jin, . The Jin laboratory received research funds un-related to this study from Celgene Corporation, Levo Therapeutics, Inc., Cullgen, Inc. and Cullinan Oncology, Inc. J.J. is a cofounder, scientific advisory board member and equity shareholder in Cullgen, Inc. and a consultant for Cullgen, Inc., EpiCypher, Inc. and Accent Therapeutics, Inc.. DN Don X Nguyen, has received research funding un-related to  this study from AstraZeneca Inc..\n",
      "\n",
      "Chen, Huacui\n",
      "Wesley L. Cai, Jocelyn Fang-Yi Huacui Chen, HC, EW, SK, LC, MZ, AA, MZ, AB, WL, XY, EK, YD, YL, TW, QY The other authors declare that no competing interests exist. JJ Jian Jin, . The Jin laboratory received research funds un-related to this study from Celgene Corporation, Levo Therapeutics, Inc., Cullgen, Inc. and Cullinan Oncology, Inc. J.J. is a cofounder, scientific advisory board member and equity shareholder in Cullgen, Inc. and a consultant for Cullgen, Inc., EpiCypher, Inc. and Accent Therapeutics, Inc.. DN Don X Nguyen, has received research funding un-related to  this study from AstraZeneca Inc..\n",
      "\n",
      "Wingrove, Emily\n",
      "Wesley L. Cai, Jocelyn Fang-Yi Huacui Chen, HC, Emily Wingrove, SK, LC, MZ, AA, MZ, AB, WL, XY, EK, YD, YL, TW, QY The other authors declare that no competing interests exist. JJ Jian Jin, . The Jin laboratory received research funds un-related to this study from Celgene Corporation, Levo Therapeutics, Inc., Cullgen, Inc. and Cullinan Oncology, Inc. J.J. is a cofounder, scientific advisory board member and equity shareholder in Cullgen, Inc. and a consultant for Cullgen, Inc., EpiCypher, Inc. and Accent Therapeutics, Inc.. DN Don X Nguyen, has received research funding un-related to  this study from AstraZeneca Inc..\n",
      "\n",
      "Kurley, Sarah J.\n",
      "Wesley L. Cai, Jocelyn Fang-Yi Huacui Chen, HC, Emily Wingrove, Sarah J. Kurley, LC, MZ, AA, MZ, AB, WL, XY, EK, YD, YL, TW, QY The other authors declare that no competing interests exist. JJ Jian Jin, . The Jin laboratory received research funds un-related to this study from Celgene Corporation, Levo Therapeutics, Inc., Cullgen, Inc. and Cullinan Oncology, Inc. J.J. is a cofounder, scientific advisory board member and equity shareholder in Cullgen, Inc. and a consultant for Cullgen, Inc., EpiCypher, Inc. and Accent Therapeutics, Inc.. DN Don X Nguyen, has received research funding un-related to  this study from AstraZeneca Inc..\n",
      "\n",
      "Hei Chan, Lok\n",
      "Wesley L. Cai, Jocelyn Fang-Yi Huacui Chen, HC, Emily Wingrove, Sarah J. Kurley, Lok Hei Chan, MZ, AA, MZ, AB, WL, XY, EK, YD, YL, TW, QY The other authors declare that no competing interests exist. JJ Jian Jin, . The Jin laboratory received research funds un-related to this study from Celgene Corporation, Levo Therapeutics, Inc., Cullgen, Inc. and Cullinan Oncology, Inc. J.J. is a cofounder, scientific advisory board member and equity shareholder in Cullgen, Inc. and a consultant for Cullgen, Inc., EpiCypher, Inc. and Accent Therapeutics, Inc.. DN Don X Nguyen, has received research funding un-related to  this study from AstraZeneca Inc..\n",
      "\n",
      "Zhang, Meiling\n",
      "Wesley L. Cai, Jocelyn Fang-Yi Huacui Chen, HC, Emily Wingrove, Sarah J. Kurley, Lok Hei Chan, Meiling Zhang, AA, Meiling Zhang, AB, WL, XY, EK, YD, YL, TW, QY The other authors declare that no competing interests exist. JJ Jian Jin, . The Jin laboratory received research funds un-related to this study from Celgene Corporation, Levo Therapeutics, Inc., Cullgen, Inc. and Cullinan Oncology, Inc. J.J. is a cofounder, scientific advisory board member and equity shareholder in Cullgen, Inc. and a consultant for Cullgen, Inc., EpiCypher, Inc. and Accent Therapeutics, Inc.. DN Don X Nguyen, has received research funding un-related to  this study from AstraZeneca Inc..\n",
      "\n",
      "Arnal-Estape, Anna\n",
      "Wesley L. Cai, Jocelyn Fang-Yi Huacui Chen, HC, Emily Wingrove, Sarah J. Kurley, Lok Hei Chan, Meiling Zhang, Anna Arnal-Estape, Meiling Zhang, AB, WL, XY, EK, YD, YL, TW, QY The other authors declare that no competing interests exist. JJ Jian Jin, . The Jin laboratory received research funds un-related to this study from Celgene Corporation, Levo Therapeutics, Inc., Cullgen, Inc. and Cullinan Oncology, Inc. J.J. is a cofounder, scientific advisory board member and equity shareholder in Cullgen, Inc. and a consultant for Cullgen, Inc., EpiCypher, Inc. and Accent Therapeutics, Inc.. DN Don X Nguyen, has received research funding un-related to  this study from AstraZeneca Inc..\n",
      "\n",
      "Wesley L. Cai, Jocelyn Fang-Yi Huacui Chen, HC, Emily Wingrove, Sarah J. Kurley, Lok Hei Chan, Meiling Zhang, Anna Arnal-Estape, Meiling Zhang, AB, WL, XY, EK, YD, YL, TW, QY The other authors declare that no competing interests exist. JJ Jian Jin, . The Jin laboratory received research funds un-related to this study from Celgene Corporation, Levo Therapeutics, Inc., Cullgen, Inc. and Cullinan Oncology, Inc. J.J. is a cofounder, scientific advisory board member and equity shareholder in Cullgen, Inc. and a consultant for Cullgen, Inc., EpiCypher, Inc. and Accent Therapeutics, Inc.. DN Don X Nguyen, has received research funding un-related to  this study from AstraZeneca Inc..\n",
      "\n",
      "Balabaki, Amer\n",
      "Wesley L. Cai, Jocelyn Fang-Yi Huacui Chen, HC, Emily Wingrove, Sarah J. Kurley, Lok Hei Chan, Meiling Zhang, Anna Arnal-Estape, Meiling Zhang, Amer Balabaki, WL, XY, EK, YD, YL, TW, QY The other authors declare that no competing interests exist. JJ Jian Jin, . The Jin laboratory received research funds un-related to this study from Celgene Corporation, Levo Therapeutics, Inc., Cullgen, Inc. and Cullinan Oncology, Inc. J.J. is a cofounder, scientific advisory board member and equity shareholder in Cullgen, Inc. and a consultant for Cullgen, Inc., EpiCypher, Inc. and Accent Therapeutics, Inc.. DN Don X Nguyen, has received research funding un-related to  this study from AstraZeneca Inc..\n",
      "\n",
      "Li, Wenxue\n",
      "Wesley L. Cai, Jocelyn Fang-Yi Huacui Chen, HC, Emily Wingrove, Sarah J. Kurley, Lok Hei Chan, Meiling Zhang, Anna Arnal-Estape, Meiling Zhang, Amer Balabaki, Wenxue Li, XY, EK, YD, YL, TW, QY The other authors declare that no competing interests exist. JJ Jian Jin, . The Jin laboratory received research funds un-related to this study from Celgene Corporation, Levo Therapeutics, Inc., Cullgen, Inc. and Cullinan Oncology, Inc. J.J. is a cofounder, scientific advisory board member and equity shareholder in Cullgen, Inc. and a consultant for Cullgen, Inc., EpiCypher, Inc. and Accent Therapeutics, Inc.. DN Don X Nguyen, has received research funding un-related to  this study from AstraZeneca Inc..\n",
      "\n",
      "Yu, Xufen\n",
      "Wesley L. Cai, Jocelyn Fang-Yi Huacui Chen, HC, Emily Wingrove, Sarah J. Kurley, Lok Hei Chan, Meiling Zhang, Anna Arnal-Estape, Meiling Zhang, Amer Balabaki, Wenxue Li, Xufen Yu, EK, YD, YL, TW, QY The other authors declare that no competing interests exist. JJ Jian Jin, . The Jin laboratory received research funds un-related to this study from Celgene Corporation, Levo Therapeutics, Inc., Cullgen, Inc. and Cullinan Oncology, Inc. J.J. is a cofounder, scientific advisory board member and equity shareholder in Cullgen, Inc. and a consultant for Cullgen, Inc., EpiCypher, Inc. and Accent Therapeutics, Inc.. DN Don X Nguyen, has received research funding un-related to  this study from AstraZeneca Inc..\n",
      "\n",
      "Krop, Ethan D.\n",
      "Wesley L. Cai, Jocelyn Fang-Yi Huacui Chen, HC, Emily Wingrove, Sarah J. Kurley, Lok Hei Chan, Meiling Zhang, Anna Arnal-Estape, Meiling Zhang, Amer Balabaki, Wenxue Li, Xufen Yu, Ethan D. Krop, YD, YL, TW, QY The other authors declare that no competing interests exist. JJ Jian Jin, . The Jin laboratory received research funds un-related to this study from Celgene Corporation, Levo Therapeutics, Inc., Cullgen, Inc. and Cullinan Oncology, Inc. J.J. is a cofounder, scientific advisory board member and equity shareholder in Cullgen, Inc. and a consultant for Cullgen, Inc., EpiCypher, Inc. and Accent Therapeutics, Inc.. DN Don X Nguyen, has received research funding un-related to  this study from AstraZeneca Inc..\n",
      "\n",
      "Dou, Yali\n",
      "Wesley L. Cai, Jocelyn Fang-Yi Huacui Chen, HC, Emily Wingrove, Sarah J. Kurley, Lok Hei Chan, Meiling Zhang, Anna Arnal-Estape, Meiling Zhang, Amer Balabaki, Wenxue Li, Xufen Yu, Ethan D. Krop, Yali Dou, YL, TW, QY The other authors declare that no competing interests exist. JJ Jian Jin, . The Jin laboratory received research funds un-related to this study from Celgene Corporation, Levo Therapeutics, Inc., Cullgen, Inc. and Cullinan Oncology, Inc. J.J. is a cofounder, scientific advisory board member and equity shareholder in Cullgen, Inc. and a consultant for Cullgen, Inc., EpiCypher, Inc. and Accent Therapeutics, Inc.. DN Don X Nguyen, has received research funding un-related to  this study from AstraZeneca Inc..\n",
      "\n",
      "Liu, Yansheng\n",
      "Wesley L. Cai, Jocelyn Fang-Yi Huacui Chen, HC, Emily Wingrove, Sarah J. Kurley, Lok Hei Chan, Meiling Zhang, Anna Arnal-Estape, Meiling Zhang, Amer Balabaki, Wenxue Li, Xufen Yu, Ethan D. Krop, Yali Dou, Yansheng Liu, TW, QY The other authors declare that no competing interests exist. JJ Jian Jin, . The Jin laboratory received research funds un-related to this study from Celgene Corporation, Levo Therapeutics, Inc., Cullgen, Inc. and Cullinan Oncology, Inc. J.J. is a cofounder, scientific advisory board member and equity shareholder in Cullgen, Inc. and a consultant for Cullgen, Inc., EpiCypher, Inc. and Accent Therapeutics, Inc.. DN Don X Nguyen, has received research funding un-related to  this study from AstraZeneca Inc..\n",
      "\n",
      "Jin, Jian\n",
      "Wesley L. Cai, Jocelyn Fang-Yi Huacui Chen, HC, Emily Wingrove, Sarah J. Kurley, Lok Hei Chan, Meiling Zhang, Anna Arnal-Estape, Meiling Zhang, Amer Balabaki, Wenxue Li, Xufen Yu, Ethan D. Krop, Yali Dou, Yansheng Liu, TW, QY The other authors declare that no competing interests exist. JJ Jian Jin, . The Jin laboratory received research funds un-related to this study from Celgene Corporation, Levo Therapeutics, Inc., Cullgen, Inc. and Cullinan Oncology, Inc. J.J. is a cofounder, scientific advisory board member and equity shareholder in Cullgen, Inc. and a consultant for Cullgen, Inc., EpiCypher, Inc. and Accent Therapeutics, Inc.. DN Don X Nguyen, has received research funding un-related to  this study from AstraZeneca Inc..\n",
      "\n",
      "Westbrook, Thomas F.\n",
      "Wesley L. Cai, Jocelyn Fang-Yi Huacui Chen, HC, Emily Wingrove, Sarah J. Kurley, Lok Hei Chan, Meiling Zhang, Anna Arnal-Estape, Meiling Zhang, Amer Balabaki, Wenxue Li, Xufen Yu, Ethan D. Krop, Yali Dou, Yansheng Liu, Thomas F. Westbrook, QY The other authors declare that no competing interests exist. JJ Jian Jin, . The Jin laboratory received research funds un-related to this study from Celgene Corporation, Levo Therapeutics, Inc., Cullgen, Inc. and Cullinan Oncology, Inc. J.J. is a cofounder, scientific advisory board member and equity shareholder in Cullgen, Inc. and a consultant for Cullgen, Inc., EpiCypher, Inc. and Accent Therapeutics, Inc.. DN Don X Nguyen, has received research funding un-related to  this study from AstraZeneca Inc..\n",
      "\n",
      "Nguyen, Don X.\n",
      "Wesley L. Cai, Jocelyn Fang-Yi Huacui Chen, HC, Emily Wingrove, Sarah J. Kurley, Lok Hei Chan, Meiling Zhang, Anna Arnal-Estape, Meiling Zhang, Amer Balabaki, Wenxue Li, Xufen Yu, Ethan D. Krop, Yali Dou, Yansheng Liu, Thomas F. Westbrook, QY The other authors declare that no competing interests exist. JJ Jian Jin, . The Jin laboratory received research funds un-related to this study from Celgene Corporation, Levo Therapeutics, Inc., Cullgen, Inc. and Cullinan Oncology, Inc. J.J. is a cofounder, scientific advisory board member and equity shareholder in Cullgen, Inc. and a consultant for Cullgen, Inc., EpiCypher, Inc. and Accent Therapeutics, Inc.. DN Don X. Nguyen, has received research funding un-related to  this study from AstraZeneca Inc..\n",
      "\n",
      "Yan, Qin\n",
      "Wesley L. Cai, Jocelyn Fang-Yi Huacui Chen, HC, Emily Wingrove, Sarah J. Kurley, Lok Hei Chan, Meiling Zhang, Anna Arnal-Estape, Meiling Zhang, Amer Balabaki, Wenxue Li, Xufen Yu, Ethan D. Krop, Yali Dou, Qin Yansheng Liu, Thomas F. Westbrook, QY The other authors declare that no competing interests exist. JJ Jian Jin, . The Jin laboratory received research funds un-related to this study from Celgene Corporation, Levo Therapeutics, Inc., Cullgen, Inc. and Cullinan Oncology, Inc. J.J. is a cofounder, scientific advisory board member and equity shareholder in Cullgen, Inc. and a consultant for Cullgen, Inc., EpiCypher, Inc. and Accent Therapeutics, Inc.. DN Don X. Nguyen, has received research funding un-related to  this study from AstraZeneca Inc..\n",
      "\n",
      "Jeganathan, Jayson\n",
      "Jayson Jeganathan, MC, MH, GP, MB No competing interests declared\n",
      "\n",
      "Campbell, Megan\n",
      "Jayson Jeganathan, Megan Campbell, MH, GP, MB No competing interests declared\n",
      "\n",
      "Hyett, Matthew\n",
      "Jayson Jeganathan, Megan Campbell, Matthew Hyett, GP, MB No competing interests declared\n",
      "\n",
      "Parker, Gordon\n",
      "Jayson Jeganathan, Megan Campbell, Matthew Hyett, Gordon Parker, MB No competing interests declared\n",
      "\n",
      "Breakspear, Michael\n",
      "Jayson Jeganathan, Megan Campbell, Matthew Hyett, Gordon Parker, Michael Breakspear No competing interests declared\n",
      "\n",
      "Carraro, Caterina\n",
      "Caterina Carraro, LB, JS, AH, MO, SW, TH, MD, KH, SM, TU, VG, RG, AA, JS, BG No competing interests declared\n",
      "\n",
      "Bonaguro, Lorenzo\n",
      "Caterina Carraro, Lorenzo Bonaguro, JS, AH, MO, SW, TH, MD, KH, SM, TU, VG, RG, AA, JS, BG No competing interests declared\n",
      "\n",
      "Schulte-Schrepping, Jonas\n",
      "Caterina Carraro, Lorenzo Bonaguro, Jonas Schulte-Schrepping, AH, MO, SW, TH, MD, KH, SM, TU, VG, RG, AA, Jonas Schulte-Schrepping, BG No competing interests declared\n",
      "\n",
      "Horne, Arik\n",
      "Caterina Carraro, Lorenzo Bonaguro, Jonas Schulte-Schrepping, Arik Horne, MO, SW, TH, MD, KH, SM, TU, VG, RG, AA, Jonas Schulte-Schrepping, BG No competing interests declared\n",
      "\n",
      "Oestreich, Marie\n",
      "Caterina Carraro, Lorenzo Bonaguro, Jonas Schulte-Schrepping, Arik Horne, Marie Oestreich, SW, TH, MD, KH, SM, TU, VG, RG, AA, Jonas Schulte-Schrepping, BG No competing interests declared\n",
      "\n",
      "Warnat-Herresthal, Stefanie\n",
      "Caterina Carraro, Lorenzo Bonaguro, Jonas Schulte-Schrepping, Arik Horne, Marie Oestreich, Stefanie Warnat-Herresthal, TH, MD, KH, SM, TU, VG, RG, AA, Jonas Schulte-Schrepping, BG No competing interests declared\n",
      "\n",
      "Helbing, Tim\n",
      "Caterina Carraro, Lorenzo Bonaguro, Jonas Schulte-Schrepping, Arik Horne, Marie Oestreich, Stefanie Warnat-Herresthal, Tim Helbing, MD, KH, SM, TU, VG, RG, AA, Jonas Schulte-Schrepping, BG No competing interests declared\n",
      "\n",
      "Caterina Carraro, Lorenzo Bonaguro, Jonas Schulte-Schrepping, Arik Horne, Marie Oestreich, Stefanie Warnat-Herresthal, Tim Helbing, MD, KH, SM, TU, VG, RG, AA, Jonas Schulte-Schrepping, BG No competing interests declared\n",
      "\n",
      "Haendler, Kristian\n",
      "Caterina Carraro, Lorenzo Bonaguro, Jonas Schulte-Schrepping, Arik Horne, Marie Oestreich, Stefanie Warnat-Herresthal, Tim Helbing, MD, Kristian Haendler, SM, TU, VG, RG, AA, Jonas Schulte-Schrepping, BG No competing interests declared\n",
      "\n",
      "Mukherjee, Sach\n",
      "Caterina Carraro, Lorenzo Bonaguro, Jonas Schulte-Schrepping, Arik Horne, Marie Oestreich, Stefanie Warnat-Herresthal, Tim Helbing, MD, Kristian Haendler, Sach Mukherjee, TU, VG, RG, AA, Jonas Schulte-Schrepping, BG No competing interests declared\n",
      "\n",
      "Ulas, Thomas\n",
      "Caterina Carraro, Lorenzo Bonaguro, Jonas Schulte-Schrepping, Arik Horne, Marie Oestreich, Stefanie Warnat-Herresthal, Tim Helbing, MD, Kristian Haendler, Sach Mukherjee, Thomas Ulas, VG, RG, AA, Jonas Schulte-Schrepping, BG No competing interests declared\n",
      "\n",
      "Gandin, Valentina\n",
      "Caterina Carraro, Lorenzo Bonaguro, Jonas Schulte-Schrepping, Arik Horne, Marie Oestreich, Stefanie Warnat-Herresthal, Tim Helbing, MD, Kristian Haendler, Sach Mukherjee, Thomas Ulas, Valentina Gandin, RG, AA, Jonas Schulte-Schrepping, BG No competing interests declared\n",
      "\n",
      "Goettlich, Richard\n",
      "Caterina Carraro, Lorenzo Bonaguro, Jonas Schulte-Schrepping, Arik Horne, Marie Oestreich, Stefanie Warnat-Herresthal, Tim Helbing, MD, Kristian Haendler, Sach Mukherjee, Thomas Ulas, Valentina Gandin, Richard Goettlich, AA, Jonas Schulte-Schrepping, BG No competing interests declared\n",
      "\n",
      "Aschenbrenner, Anna C.\n",
      "Caterina Carraro, Lorenzo Bonaguro, Jonas Schulte-Schrepping, Arik Horne, Marie Oestreich, Stefanie Warnat-Herresthal, Tim Helbing, MD, Kristian Haendler, Sach Mukherjee, Thomas Ulas, Valentina Gandin, Richard Goettlich, Anna C. Aschenbrenner, Jonas Schulte-Schrepping, BG No competing interests declared\n",
      "\n",
      "Caterina Carraro, Lorenzo Bonaguro, Jonas Schulte-Schrepping, Arik Horne, Marie Oestreich, Stefanie Warnat-Herresthal, Tim Helbing, MD, Kristian Haendler, Sach Mukherjee, Thomas Ulas, Valentina Gandin, Richard Goettlich, Anna C. Aschenbrenner, Jonas Schulte-Schrepping, BG No competing interests declared\n",
      "\n",
      "Gatto, Barbara\n",
      "Caterina Carraro, Lorenzo Bonaguro, Jonas Schulte-Schrepping, Arik Horne, Marie Oestreich, Stefanie Warnat-Herresthal, Tim Helbing, MD, Kristian Haendler, Sach Mukherjee, Thomas Ulas, Valentina Gandin, Richard Goettlich, Anna C. Aschenbrenner, Jonas Schulte-Schrepping, Barbara Gatto No competing interests declared\n",
      "\n",
      "The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Hannah S Mumby reports  financial support was provided by Branco Weiss-Society In Science Fellowship. Hannah S Mumby reports financial support was provided by Association for the Study of Animal Behaviour.\n",
      "\n",
      "The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Hannah S Mumby reports  financial support was provided by Branco Weiss-Society In Science Fellowship. Hannah S Mumby reports financial support was provided by Association for the Study of Animal Behaviour.\n",
      "\n",
      "The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Hannah S Mumby reports  financial support was provided by Branco Weiss-Society In Science Fellowship. Hannah S Mumby reports financial support was provided by Association for the Study of Animal Behaviour.\n",
      "\n",
      "The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Hannah S Mumby reports  financial support was provided by Branco Weiss-Society In Science Fellowship. Hannah S Mumby reports financial support was provided by Association for the Study of Animal Behaviour.\n",
      "\n",
      "The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Hannah S Mumby reports  financial support was provided by Branco Weiss-Society In Science Fellowship. Hannah S Mumby reports financial support was provided by Association for the Study of Animal Behaviour.\n",
      "\n",
      "The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Hannah S Mumby reports  financial support was provided by Branco Weiss-Society In Science Fellowship. Hannah S Mumby reports financial support was provided by Association for the Study of Animal Behaviour.\n",
      "\n",
      "The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Hannah S Mumby reports  financial support was provided by Branco Weiss-Society In Science Fellowship. Hannah S Mumby reports financial support was provided by Association for the Study of Animal Behaviour.\n",
      "\n",
      "The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Hannah S Mumby reports  financial support was provided by Branco Weiss-Society In Science Fellowship. Hannah S Mumby reports financial support was provided by Association for the Study of Animal Behaviour.\n",
      "\n",
      "The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Hannah S Mumby reports  financial support was provided by Branco Weiss-Society In Science Fellowship. Hannah S Mumby reports financial support was provided by Association for the Study of Animal Behaviour.\n",
      "\n",
      "Mumby, Hannah S.\n",
      "The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Hannah S. Mumby reports  financial support was provided by Branco Weiss-Society In Science Fellowship. Hannah S. Mumby reports financial support was provided by Association for the Study of Animal Behaviour.\n",
      "\n",
      "Conflict of Interest: The authors stated that they have no conflicts of interest  regarding the publication of this article.\n",
      "\n",
      "Conflict of Interest: The authors stated that they have no conflicts of interest  regarding the publication of this article.\n",
      "\n",
      "Conflict of Interest: The authors stated that they have no conflicts of interest  regarding the publication of this article.\n",
      "\n",
      "Conflict of Interest: The authors stated that they have no conflicts of interest  regarding the publication of this article.\n",
      "\n",
      "Conflict of Interest: The authors stated that they have no conflicts of interest  regarding the publication of this article.\n",
      "\n",
      "Conflict of Interest: The authors stated that they have no conflicts of interest  regarding the publication of this article.\n",
      "\n",
      "Conflict of Interest: The authors stated that they have no conflicts of interest  regarding the publication of this article.\n",
      "\n",
      "Conflict of Interest: The authors stated that they have no conflicts of interest  regarding the publication of this article.\n",
      "\n",
      "Conflict of Interest: The authors stated that they have no conflicts of interest  regarding the publication of this article.\n",
      "\n",
      "Conflict of Interest: The authors stated that they have no conflicts of interest  regarding the publication of this article.\n",
      "\n",
      "Conflict of Interest: The authors stated that they have no conflicts of interest  regarding the publication of this article.\n",
      "\n",
      "Conflict of Interest: The authors stated that they have no conflicts of interest  regarding the publication of this article.\n",
      "\n",
      "Conflict of Interest: The authors stated that they have no conflicts of interest  regarding the publication of this article.\n",
      "\n",
      "Conflict of Interest: The authors stated that they have no conflicts of interest  regarding the publication of this article.\n",
      "\n",
      "Conflict of Interest: The authors stated that they have no conflicts of interest  regarding the publication of this article.\n",
      "\n",
      "Conflict of Interest: The authors stated that they have no conflicts of interest  regarding the publication of this article.\n",
      "\n",
      "Conflict of Interest: The authors stated that they have no conflicts of interest  regarding the publication of this article.\n",
      "\n",
      "Conflict of Interest: The authors stated that they have no conflicts of interest  regarding the publication of this article.\n",
      "\n",
      "Conflict of Interest: The authors stated that they have no conflicts of interest  regarding the publication of this article.\n",
      "\n",
      "Conflict of Interest: The authors stated that they have no conflicts of interest  regarding the publication of this article.\n",
      "\n",
      "Conflict of Interest: The authors stated that they have no conflicts of interest  regarding the publication of this article.\n",
      "\n",
      "Conflict of Interest: The authors stated that they have no conflicts of interest  regarding the publication of this article.\n",
      "\n",
      "Conflict of Interest: The authors stated that they have no conflicts of interest  regarding the publication of this article.\n",
      "\n",
      "Conflict of Interest: The authors stated that they have no conflicts of interest  regarding the publication of this article.\n",
      "\n",
      "Conflict of Interest: The authors stated that they have no conflicts of interest  regarding the publication of this article.\n",
      "\n",
      "Conflict of Interest: The authors stated that they have no conflicts of interest  regarding the publication of this article.\n",
      "\n",
      "Conflict of Interest: The authors stated that they have no conflicts of interest  regarding the publication of this article.\n",
      "\n",
      "Conflict of Interest: The authors stated that they have no conflicts of interest  regarding the publication of this article.\n",
      "\n",
      "Conflict of Interest: The authors stated that they have no conflicts of interest  regarding the publication of this article.\n",
      "\n",
      "Conflict of Interest: The authors stated that they have no conflicts of interest  regarding the publication of this article.\n",
      "\n",
      "Conflict of Interest: The authors stated that they have no conflicts of interest  regarding the publication of this article.\n",
      "\n",
      "Conflict of Interest: The authors stated that they have no conflicts of interest  regarding the publication of this article.\n",
      "\n",
      "Conflict of Interest: The authors stated that they have no conflicts of interest  regarding the publication of this article.\n",
      "\n",
      "Conflict of Interest: The authors stated that they have no conflicts of interest  regarding the publication of this article.\n",
      "\n",
      "Conflict of Interest: The authors stated that they have no conflicts of interest  regarding the publication of this article.\n",
      "\n",
      "Conflict of Interest: The authors stated that they have no conflicts of interest  regarding the publication of this article.\n",
      "\n",
      "Conflict of Interest: The authors stated that they have no conflicts of interest  regarding the publication of this article.\n",
      "\n",
      "Conflict of Interest: The authors stated that they have no conflicts of interest  regarding the publication of this article.\n",
      "\n",
      "Conflict of Interest: The authors stated that they have no conflicts of interest  regarding the publication of this article.\n",
      "\n",
      "Conflict of Interest: The authors stated that they have no conflicts of interest  regarding the publication of this article.\n",
      "\n",
      "Conflict of Interest: The authors stated that they have no conflicts of interest  regarding the publication of this article.\n",
      "\n",
      "Conflict of Interest: The authors stated that they have no conflicts of interest  regarding the publication of this article.\n",
      "\n",
      "Conflict of Interest: The authors stated that they have no conflicts of interest  regarding the publication of this article.\n",
      "\n",
      "Conflict of Interest: The authors stated that they have no conflicts of interest  regarding the publication of this article.\n",
      "\n",
      "Conflict of Interest: The authors stated that they have no conflicts of interest  regarding the publication of this article.\n",
      "\n",
      "Conflict of Interest: The authors stated that they have no conflicts of interest  regarding the publication of this article.\n",
      "\n",
      "Conflict of Interest: The authors stated that they have no conflicts of interest  regarding the publication of this article.\n",
      "\n",
      "Conflict of Interest: The authors stated that they have no conflicts of interest  regarding the publication of this article.\n",
      "\n",
      "Conflict of Interest: The authors stated that they have no conflicts of interest  regarding the publication of this article.\n",
      "\n",
      "Conflict of Interest: The authors stated that they have no conflicts of interest  regarding the publication of this article.\n",
      "\n",
      "Conflict of Interest: The authors stated that they have no conflicts of interest  regarding the publication of this article.\n",
      "\n",
      "Conflict of Interest: The authors stated that they have no conflicts of interest  regarding the publication of this article.\n",
      "\n",
      "Conflict of Interest: The authors stated that they have no conflicts of interest  regarding the publication of this article.\n",
      "\n",
      "Conflict of Interest: The authors stated that they have no conflicts of interest  regarding the publication of this article.\n",
      "\n",
      "Conflict of Interest: The authors stated that they have no conflicts of interest  regarding the publication of this article.\n",
      "\n",
      "Conflict of Interest: The authors stated that they have no conflicts of interest  regarding the publication of this article.\n",
      "\n",
      "Conflict of Interest: The authors stated that they have no conflicts of interest  regarding the publication of this article.\n",
      "\n",
      "Conflict of Interest: The authors stated that they have no conflicts of interest  regarding the publication of this article.\n",
      "\n",
      "Conflict of Interest: The authors stated that they have no conflicts of interest  regarding the publication of this article.\n",
      "\n",
      "Conflict of Interest: The authors stated that they have no conflicts of interest  regarding the publication of this article.\n",
      "\n",
      "Conflict of Interest: The authors stated that they have no conflicts of interest  regarding the publication of this article.\n",
      "\n",
      "Conflict of Interest: The authors stated that they have no conflicts of interest  regarding the publication of this article.\n",
      "\n",
      "Conflict of Interest: The authors stated that they have no conflicts of interest  regarding the publication of this article.\n",
      "\n",
      "Conflict of Interest: The authors stated that they have no conflicts of interest  regarding the publication of this article.\n",
      "\n",
      "Conflict of Interest: The authors stated that they have no conflicts of interest  regarding the publication of this article.\n",
      "\n",
      "Conflict of Interest: The authors stated that they have no conflicts of interest  regarding the publication of this article.\n",
      "\n",
      "Conflict of Interest: The authors stated that they have no conflicts of interest  regarding the publication of this article.\n",
      "\n",
      "Conflict of Interest: The authors stated that they have no conflicts of interest  regarding the publication of this article.\n",
      "\n",
      "Conflict of Interest: The authors stated that they have no conflicts of interest  regarding the publication of this article.\n",
      "\n",
      "Conflict of Interest: The authors stated that they have no conflicts of interest  regarding the publication of this article.\n",
      "\n",
      "Conflict of Interest: The authors stated that they have no conflicts of interest  regarding the publication of this article.\n",
      "\n",
      "Conflict of Interest: The authors stated that they have no conflicts of interest  regarding the publication of this article.\n",
      "\n",
      "Conflict of Interest: The authors stated that they have no conflicts of interest  regarding the publication of this article.\n",
      "\n",
      "Conflict of Interest: The authors stated that they have no conflicts of interest  regarding the publication of this article.\n",
      "\n",
      "Conflict of Interest: The authors stated that they have no conflicts of interest  regarding the publication of this article.\n",
      "\n",
      "Conflict of Interest: The authors stated that they have no conflicts of interest  regarding the publication of this article.\n",
      "\n",
      "Conflict of Interest: The authors stated that they have no conflicts of interest  regarding the publication of this article.\n",
      "\n",
      "Conflict of Interest: The authors stated that they have no conflicts of interest  regarding the publication of this article.\n",
      "\n",
      "Conflict of Interest: The authors stated that they have no conflicts of interest  regarding the publication of this article.\n",
      "\n",
      "Conflict of Interest: The authors stated that they have no conflicts of interest  regarding the publication of this article.\n",
      "\n",
      "Conflict of Interest: The authors stated that they have no conflicts of interest  regarding the publication of this article.\n",
      "\n",
      "Conflict of Interest: The authors stated that they have no conflicts of interest  regarding the publication of this article.\n",
      "\n",
      "Conflict of Interest: The authors stated that they have no conflicts of interest  regarding the publication of this article.\n",
      "\n",
      "Conflict of Interest: The authors stated that they have no conflicts of interest  regarding the publication of this article.\n",
      "\n",
      "All authors reports grants from the Health Research Council of New Zealand, during the conduct of this study. No other conflicts of interest are declared by  the authors.\n",
      "\n",
      "All authors reports grants from the Health Research Council of New Zealand, during the conduct of this study. No other conflicts of interest are declared by  the authors.\n",
      "\n",
      "All authors reports grants from the Health Research Council of New Zealand, during the conduct of this study. No other conflicts of interest are declared by  the authors.\n",
      "\n",
      "All authors reports grants from the Health Research Council of New Zealand, during the conduct of this study. No other conflicts of interest are declared by  the authors.\n",
      "\n",
      "All authors reports grants from the Health Research Council of New Zealand, during the conduct of this study. No other conflicts of interest are declared by  the authors.\n",
      "\n",
      "All authors reports grants from the Health Research Council of New Zealand, during the conduct of this study. No other conflicts of interest are declared by  the authors.\n",
      "\n",
      "K.D.M. has filed a pending patent application for the use of DART-seq technology  with Duke University.\n",
      "\n",
      "Meyer, Kate D.\n",
      "Kate D. Meyer has filed a pending patent application for the use of DART-seq technology  with Duke University.\n",
      "\n",
      "Methods and results presented here are part of a patent application (J.R. and A.P.).\n",
      "\n",
      "Paquet, Agnes\n",
      "Methods and results presented here are part of a patent application (J.R. and Agnes Paquet).\n",
      "\n",
      "Methods and results presented here are part of a patent application (J.R. and Agnes Paquet).\n",
      "\n",
      "Methods and results presented here are part of a patent application (J.R. and Agnes Paquet).\n",
      "\n",
      "Methods and results presented here are part of a patent application (J.R. and Agnes Paquet).\n",
      "\n",
      "Methods and results presented here are part of a patent application (J.R. and Agnes Paquet).\n",
      "\n",
      "Methods and results presented here are part of a patent application (J.R. and Agnes Paquet).\n",
      "\n",
      "Methods and results presented here are part of a patent application (J.R. and Agnes Paquet).\n",
      "\n",
      "Methods and results presented here are part of a patent application (J.R. and Agnes Paquet).\n",
      "\n",
      "Methods and results presented here are part of a patent application (J.R. and Agnes Paquet).\n",
      "\n",
      "Methods and results presented here are part of a patent application (J.R. and Agnes Paquet).\n",
      "\n",
      "Roux, Jeremie\n",
      "Methods and results presented here are part of a patent application (Jeremie Roux and Agnes Paquet).\n",
      "\n",
      "Elman, Tamar\n",
      "The method described in this MS appears in a PCT Patent Application No. PCT/IL2021/051282 ''PHOTOSYNTHETIC MICROALGAE AND USE THEREOF FOR HYDROGEN PRODUCTION\" as a mean to produce algal- hydrogen under ambient, continuous growth conditions at cost-effective amounts. The patent was jointly submitted by the Tel Aviv University and the University of Munster. List of inventors: Iftach Yacoby,  Tamar Elman, Oren Bez-zvi, Chris Philip Schwier, Thi Thu Hoai Ho, and Michael Hippler. Submitted on 28 Oct 2021.\n",
      "\n",
      "Yacoby, Iftach\n",
      "The method described in this MS appears in a PCT Patent Application No. PCT/IL2021/051282 ''PHOTOSYNTHETIC MICROALGAE AND USE THEREOF FOR HYDROGEN PRODUCTION\" as a mean to produce algal- hydrogen under ambient, continuous growth conditions at cost-effective amounts. The patent was jointly submitted by the Tel Aviv University and the University of Munster. List of inventors: Iftach Yacoby,  Tamar Elman, Oren Bez-zvi, Chris Philip Schwier, Thi Thu Hoai Ho, and Michael Hippler. Submitted on 28 Oct 2021.\n",
      "\n",
      "H.C. is head of Roche's Pharma Research and Early Development in Basel, Switzerland since March 2022. J.B. and H.C. are inventors on several patents related to organoid technology. H.C.'s full disclosure is given at https://www.uu.nl/staff/JCClevers/.\n",
      "\n",
      "H.C. is head of Roche's Pharma Research and Early Development in Basel, Switzerland since March 2022. J.B. and H.C. are inventors on several patents related to organoid technology. H.C.'s full disclosure is given at https://www.uu.nl/staff/JCClevers/.\n",
      "\n",
      "H.C. is head of Roche's Pharma Research and Early Development in Basel, Switzerland since March 2022. J.B. and H.C. are inventors on several patents related to organoid technology. H.C.'s full disclosure is given at https://www.uu.nl/staff/JCClevers/.\n",
      "\n",
      "H.C. is head of Roche's Pharma Research and Early Development in Basel, Switzerland since March 2022. J.B. and H.C. are inventors on several patents related to organoid technology. H.C.'s full disclosure is given at https://www.uu.nl/staff/JCClevers/.\n",
      "\n",
      "H.C. is head of Roche's Pharma Research and Early Development in Basel, Switzerland since March 2022. J.B. and H.C. are inventors on several patents related to organoid technology. H.C.'s full disclosure is given at https://www.uu.nl/staff/JCClevers/.\n",
      "\n",
      "H.C. is head of Roche's Pharma Research and Early Development in Basel, Switzerland since March 2022. J.B. and H.C. are inventors on several patents related to organoid technology. H.C.'s full disclosure is given at https://www.uu.nl/staff/JCClevers/.\n",
      "\n",
      "H.C. is head of Roche's Pharma Research and Early Development in Basel, Switzerland since March 2022. J.B. and H.C. are inventors on several patents related to organoid technology. H.C.'s full disclosure is given at https://www.uu.nl/staff/JCClevers/.\n",
      "\n",
      "H.C. is head of Roche's Pharma Research and Early Development in Basel, Switzerland since March 2022. J.B. and H.C. are inventors on several patents related to organoid technology. H.C.'s full disclosure is given at https://www.uu.nl/staff/JCClevers/.\n",
      "\n",
      "Beumer, Joep\n",
      "H.C. is head of Roche's Pharma Research and Early Development in Basel, Switzerland since March 2022. Joep Beumer and H.C. are inventors on several patents related to organoid technology. H.C.'s full disclosure is given at https://www.uu.nl/staff/JCClevers/.\n",
      "\n",
      "Clevers, Hans\n",
      "H.C. is head of Roche's Pharma Research and Early Development in Basel, Switzerland since March 2022. Joep Beumer and H.C. are inventors on several patents related to organoid technology. H.C.'s full disclosure is given at https://www.uu.nl/staff/JCHans Clevers/.\n",
      "\n",
      "Erik R. Seiffert is an Academic Editor for PeerJ.\n",
      "\n",
      "Seiffert, Erik R.\n",
      "Erik R. Seiffert is an Academic Editor for PeerJ.\n",
      "\n",
      "Irie, Shun\n",
      "Shun Irie and Yoshiteru Watanabe received a grant donated through Dokkyo Medical  University as research funding provided for studies conducted regarding the application of wearable e-textiles in the healthcare fields from Xenoma Inc. on July 31, 2021.\n",
      "\n",
      "Watanabe, Yoshiteru\n",
      "Shun Irie and Yoshiteru Watanabe received a grant donated through Dokkyo Medical  University as research funding provided for studies conducted regarding the application of wearable e-textiles in the healthcare fields from Xenoma Inc. on July 31, 2021.\n",
      "\n",
      "Shun Irie and Yoshiteru Watanabe received a grant donated through Dokkyo Medical  University as research funding provided for studies conducted regarding the application of wearable e-textiles in the healthcare fields from Xenoma Inc. on July 31, 2021.\n",
      "\n",
      "Shun Irie and Yoshiteru Watanabe received a grant donated through Dokkyo Medical  University as research funding provided for studies conducted regarding the application of wearable e-textiles in the healthcare fields from Xenoma Inc. on July 31, 2021.\n",
      "\n",
      "Sebastian Springer has patent pending to Assignee.\n",
      "\n",
      "Sebastian Springer has patent pending to Assignee.\n",
      "\n",
      "Sebastian Springer has patent pending to Assignee.\n",
      "\n",
      "Springer, Sebastian\n",
      "Sebastian Springer has patent pending to Assignee.\n",
      "\n",
      "Source of support: Nil Conflict of interest: None\n",
      "\n",
      "Source of support: Nil Conflict of interest: None\n",
      "\n",
      "Source of support: Nil Conflict of interest: None\n",
      "\n",
      "Source of support: Nil Conflict of interest: None\n",
      "\n",
      "Source of support: Nil Conflict of interest: None\n",
      "\n",
      "Source of support: Nil Conflict of interest: None\n",
      "\n",
      "Source of support: Nil Conflict of interest: None\n",
      "\n",
      "Source of support: Nil Conflict of interest: None\n",
      "\n",
      "Source of support: Nil Conflict of interest: None\n",
      "\n",
      "Source of support: Nil Conflict of interest: None\n",
      "\n",
      "Source of support: Nil Conflict of interest: None\n",
      "\n",
      "Source of support: Nil Conflict of interest: None\n",
      "\n",
      "Source of support: Nil Conflict of interest: None\n",
      "\n",
      "Source of support: Nil Conflict of interest: None\n",
      "\n",
      "Source of support: Nil Conflict of interest: None\n",
      "\n",
      "Source of support: Nil Conflict of interest: None\n",
      "\n",
      "Source of support: Nil Conflict of interest: None\n",
      "\n",
      "Source of support: Nil Conflict of interest: None\n",
      "\n",
      "Source of support: Nil Conflict of interest: None\n",
      "\n",
      "Source of support: Nil Conflict of interest: None\n",
      "\n",
      "Source of support: Nil Conflict of interest: None\n",
      "\n",
      "Source of support: Nil Conflict of interest: None\n",
      "\n",
      "Source of support: Nil Conflict of interest: None\n",
      "\n",
      "Source of support: Nil Conflict of interest: None\n",
      "\n",
      "Source of support: Nil Conflict of interest: None\n",
      "\n",
      "Source of support: Nil Conflict of interest: None\n",
      "\n",
      "Source of support: Nil Conflict of interest: None\n",
      "\n",
      "Source of support: Nil Conflict of interest: None\n",
      "\n",
      "Source of support: Nil Conflict of interest: None\n",
      "\n",
      "Source of support: Nil Conflict of interest: None\n",
      "\n",
      "Source of support: Nil Conflict of interest: None\n",
      "\n",
      "Source of support: Nil Conflict of interest: None\n",
      "\n",
      "Source of support: Nil Conflict of interest: None\n",
      "\n",
      "Source of support: Nil Conflict of interest: None\n",
      "\n",
      "Source of support: Nil Conflict of interest: None\n",
      "\n",
      "Source of support: Nil Conflict of interest: None\n",
      "\n",
      "Source of support: Nil Conflict of interest: None\n",
      "\n",
      "Source of support: Nil Conflict of interest: None\n",
      "\n",
      "Source of support: Nil Conflict of interest: None\n",
      "\n",
      "Source of support: Nil Conflict of interest: None\n",
      "\n",
      "Source of support: Nil Conflict of interest: None\n",
      "\n",
      "Source of support: Nil Conflict of interest: None\n",
      "\n",
      "Source of support: Nil Conflict of interest: None\n",
      "\n",
      "Source of support: Nil Conflict of interest: None\n",
      "\n",
      "Source of support: Nil Conflict of interest: None\n",
      "\n",
      "Source of support: Nil Conflict of interest: None\n",
      "\n",
      "Source of support: Nil Conflict of interest: None\n",
      "\n",
      "Source of support: Nil Conflict of interest: None\n",
      "\n",
      "Source of support: Nil Conflict of interest: None\n",
      "\n",
      "Source of support: Nil Conflict of interest: None\n",
      "\n",
      "Source of support: Nil Conflict of interest: None\n",
      "\n",
      "Source of support: Nil Conflict of interest: None\n",
      "\n",
      "Source of support: Nil Conflict of interest: None\n",
      "\n",
      "Source of support: Nil Conflict of interest: None\n",
      "\n",
      "Source of support: Nil Conflict of interest: None\n",
      "\n",
      "Source of support: Nil Conflict of interest: None\n",
      "\n",
      "Source of support: Nil Conflict of interest: None\n",
      "\n",
      "Source of support: Nil Conflict of interest: None\n",
      "\n",
      "Source of support: Nil Conflict of interest: None\n",
      "\n",
      "Source of support: Nil Conflict of interest: None\n",
      "\n",
      "Source of support: Nil Conflict of interest: None\n",
      "\n",
      "Source of support: Nil Conflict of interest: None\n",
      "\n",
      "Source of support: Nil Conflict of interest: None\n",
      "\n",
      "Source of support: Nil Conflict of interest: None\n",
      "\n",
      "Source of support: Nil Conflict of interest: None\n",
      "\n",
      "Source of support: Nil Conflict of interest: None\n",
      "\n",
      "Source of support: Nil Conflict of interest: None\n",
      "\n",
      "Source of support: Nil Conflict of interest: None\n",
      "\n",
      "Source of support: Nil Conflict of interest: None\n",
      "\n",
      "Source of support: Nil Conflict of interest: None\n",
      "\n",
      "Source of support: Nil Conflict of interest: None\n",
      "\n",
      "Source of support: Nil Conflict of interest: None\n",
      "\n",
      "Source of support: Nil Conflict of interest: None\n",
      "\n",
      "Source of support: Nil Conflict of interest: None\n",
      "\n",
      "Source of support: Nil Conflict of interest: None\n",
      "\n",
      "Source of support: Nil Conflict of interest: None\n",
      "\n",
      "Source of support: Nil Conflict of interest: None\n",
      "\n",
      "Source of support: Nil Conflict of interest: None\n",
      "\n",
      "Source of support: Nil Conflict of interest: None\n",
      "\n",
      "Source of support: Nil Conflict of interest: None\n",
      "\n",
      "Source of support: Nil Conflict of interest: None\n",
      "\n",
      "Source of support: Nil Conflict of interest: None\n",
      "\n",
      "Source of support: Nil Conflict of interest: None\n",
      "\n",
      "Source of support: Nil Conflict of interest: None\n",
      "\n",
      "Source of support: Nil Conflict of interest: None\n",
      "\n",
      "Source of support: Nil Conflict of interest: None\n",
      "\n",
      "Source of support: Nil Conflict of interest: None\n",
      "\n",
      "Source of support: Nil Conflict of interest: None\n",
      "\n",
      "Source of support: Nil Conflict of interest: None\n",
      "\n",
      "Source of support: Nil Conflict of interest: None\n",
      "\n",
      "Source of support: Nil Conflict of interest: None\n",
      "\n",
      "Source of support: Nil Conflict of interest: None\n",
      "\n",
      "Source of support: Nil Conflict of interest: None\n",
      "\n",
      "Source of support: Nil Conflict of interest: None\n",
      "\n",
      "Source of support: Nil Conflict of interest: None\n",
      "\n",
      "Source of support: Nil Conflict of interest: None\n",
      "\n",
      "The corresponding author Prof Frederic Coulon is one of the Section Editor of the Environment Section.\n",
      "\n",
      "The corresponding author Prof Frederic Coulon is one of the Section Editor of the Environment Section.\n",
      "\n",
      "The corresponding author Prof Frederic Coulon is one of the Section Editor of the Environment Section.\n",
      "\n",
      "The corresponding author Prof Frederic Coulon is one of the Section Editor of the Environment Section.\n",
      "\n",
      "The corresponding author Prof Frederic Coulon is one of the Section Editor of the Environment Section.\n",
      "\n",
      "Coulon, Frederic\n",
      "The corresponding author Prof Frederic Coulon is one of the Section Editor of the Environment Section.\n",
      "\n",
      "Wong, Nikita A.\n",
      "The authors declare the following conflict of interests: Nikita A. Wong is supported by Dopavision GmbH. Hamed Bahmani is supported by and has financial interest in Dopavision GmbH.\n",
      "\n",
      "Bahmani, Hamed\n",
      "The authors declare the following conflict of interests: Nikita A. Wong is supported by Dopavision GmbH. Hamed Bahmani is supported by and has financial interest in Dopavision GmbH.\n",
      "\n",
      "Conflict of Interest Statement: All named authors have no conflicts of interest to declare.\n",
      "\n",
      "Conflict of Interest Statement: All named authors have no conflicts of interest to declare.\n",
      "\n",
      "Conflict of Interest Statement: All named authors have no conflicts of interest to declare.\n",
      "\n",
      "Conflict of Interest Statement: All named authors have no conflicts of interest to declare.\n",
      "\n",
      "Declaration of interests The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. KLC is co-founder, consultant, board member, and holds equity interest in Ventrix, Inc.\n",
      "\n",
      "Declaration of interests The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. KLC is co-founder, consultant, board member, and holds equity interest in Ventrix, Inc.\n",
      "\n",
      "Declaration of interests The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. KLC is co-founder, consultant, board member, and holds equity interest in Ventrix, Inc.\n",
      "\n",
      "Declaration of interests The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. KLC is co-founder, consultant, board member, and holds equity interest in Ventrix, Inc.\n",
      "\n",
      "Declaration of interests The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. KLC is co-founder, consultant, board member, and holds equity interest in Ventrix, Inc.\n",
      "\n",
      "Declaration of interests The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. KLC is co-founder, consultant, board member, and holds equity interest in Ventrix, Inc.\n",
      "\n",
      "Declaration of interests The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. KLC is co-founder, consultant, board member, and holds equity interest in Ventrix, Inc.\n",
      "\n",
      "Declaration of interests The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. KLC is co-founder, consultant, board member, and holds equity interest in Ventrix, Inc.\n",
      "\n",
      "Declaration of interests The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. KLC is co-founder, consultant, board member, and holds equity interest in Ventrix, Inc.\n",
      "\n",
      "Declaration of interests The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. KLC is co-founder, consultant, board member, and holds equity interest in Ventrix, Inc.\n",
      "\n",
      "Declaration of interests The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. KLC is co-founder, consultant, board member, and holds equity interest in Ventrix, Inc.\n",
      "\n",
      "Christman, Karen L.\n",
      "Declaration of interests The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. Karen L. Christman is co-founder, consultant, board member, and holds equity interest in Ventrix, Inc.\n",
      "\n",
      "Competing interests statement: DJT is a member of the SAB at Dewpoint Therapeutics.\n",
      "\n",
      "Competing interests statement: DJT is a member of the SAB at Dewpoint Therapeutics.\n",
      "\n",
      "Competing interests statement: DJT is a member of the SAB at Dewpoint Therapeutics.\n",
      "\n",
      "Competing interests statement: DJT is a member of the SAB at Dewpoint Therapeutics.\n",
      "\n",
      "Competing interests statement: DJT is a member of the SAB at Dewpoint Therapeutics.\n",
      "\n",
      "Competing interests statement: DJT is a member of the SAB at Dewpoint Therapeutics.\n",
      "\n",
      "Competing interests statement: DJT is a member of the SAB at Dewpoint Therapeutics.\n",
      "\n",
      "Competing interests statement: DJT is a member of the SAB at Dewpoint Therapeutics.\n",
      "\n",
      "Competing interests statement: DJT is a member of the SAB at Dewpoint Therapeutics.\n",
      "\n",
      "Competing interests statement: DJT is a member of the SAB at Dewpoint Therapeutics.\n",
      "\n",
      "Taatjes, Dylan J.\n",
      "Competing interests statement: Dylan J. Taatjes is a member of the SAB at Dewpoint Therapeutics.\n",
      "\n",
      "Competing interests statement: Dylan J. Taatjes is a member of the SAB at Dewpoint Therapeutics.\n",
      "\n",
      "Conflict of interest statement The authors are engaged in directed evolution efforts to produce thermostable cytochrome P450 enzymes for biocatalysis and synthetic biology applications, some of which have been licensed for application  in pharmaceutical and fine chemical production under the tradename \"CYPerior\".\n",
      "\n",
      "Conflict of interest statement The authors are engaged in directed evolution efforts to produce thermostable cytochrome P450 enzymes for biocatalysis and synthetic biology applications, some of which have been licensed for application  in pharmaceutical and fine chemical production under the tradename \"CYPerior\".\n",
      "\n",
      "Conflict of interest statement The authors are engaged in directed evolution efforts to produce thermostable cytochrome P450 enzymes for biocatalysis and synthetic biology applications, some of which have been licensed for application  in pharmaceutical and fine chemical production under the tradename \"CYPerior\".\n",
      "\n",
      "Ivanov, Iliyan\n",
      "Conflict of Interest Dr. Arnold reported holding the Alberta Innovates Translational Health Chair in Child and Youth Mental Health outside the submitted work. Prof. Mataix-Cols receives royalties for contributing articles to UpToDate, Wolters Kluwer Health and fees from Elsevier for editorial tasks (all unrelated to the submitted work). Dr. Narayanaswamy reported Government of India grants DST INSPIRE faculty grant IFA12-LSBM-26 and BT/06/IYBA/2012 outside the submitted work. Dr. Reddy reported Government of India grants SR/S0/HS/0016/2011 and BT/PR13334/Med/30/259/2009 outside the submitted work. Dr. Venkatasubramanian reported Wellcome-DBT India Alliance grant 500236/Z/11/Z outside the submitted work. Dr. Simpson reported Biohaven Research support for a clinical trial and royalties from UpToDate, Inc. and Cambridge University Press outside the submitted work. Dr. Soreni reported support from Lundbeck-Iliyan IvanovT outside the submitted work. Dr. Walitza has received in the last 3years royalties from Thieme Hogrefe, Kohlhammer, Springer, Beltz; Her work was supported in the last 3years by the Swiss National Science Foundation (SNF), diff. EU FP7s, HSM Hochspezialisierte Medizin of the Kanton Zurich, Switzerland, Bfarm Germany, ZInEP, Hartmann Muller Stiftung, Olga Mayenfisch, Gertrud Thalmann Fonds (all unrelated to the submitted work). Dr. Thompson has received a research grant from Biogen, Inc., unrelated to the topic of this paper.\n",
      "\n",
      "Conflict of Interest Dr. Arnold reported holding the Alberta Innovates Translational Health Chair in Child and Youth Mental Health outside the submitted work. Prof. Mataix-Cols receives royalties for contributing articles to UpToDate, Wolters Kluwer Health and fees from Elsevier for editorial tasks (all unrelated to the submitted work). Dr. Narayanaswamy reported Government of India grants DST INSPIRE faculty grant IFA12-LSBM-26 and BT/06/IYBA/2012 outside the submitted work. Dr. Reddy reported Government of India grants SR/S0/HS/0016/2011 and BT/PR13334/Med/30/259/2009 outside the submitted work. Dr. Venkatasubramanian reported Wellcome-DBT India Alliance grant 500236/Z/11/Z outside the submitted work. Dr. Simpson reported Biohaven Research support for a clinical trial and royalties from UpToDate, Inc. and Cambridge University Press outside the submitted work. Dr. Soreni reported support from Lundbeck-Iliyan IvanovT outside the submitted work. Dr. Walitza has received in the last 3years royalties from Thieme Hogrefe, Kohlhammer, Springer, Beltz; Her work was supported in the last 3years by the Swiss National Science Foundation (SNF), diff. EU FP7s, HSM Hochspezialisierte Medizin of the Kanton Zurich, Switzerland, Bfarm Germany, ZInEP, Hartmann Muller Stiftung, Olga Mayenfisch, Gertrud Thalmann Fonds (all unrelated to the submitted work). Dr. Thompson has received a research grant from Biogen, Inc., unrelated to the topic of this paper.\n",
      "\n",
      "Conflict of Interest Dr. Arnold reported holding the Alberta Innovates Translational Health Chair in Child and Youth Mental Health outside the submitted work. Prof. Mataix-Cols receives royalties for contributing articles to UpToDate, Wolters Kluwer Health and fees from Elsevier for editorial tasks (all unrelated to the submitted work). Dr. Narayanaswamy reported Government of India grants DST INSPIRE faculty grant IFA12-LSBM-26 and BT/06/IYBA/2012 outside the submitted work. Dr. Reddy reported Government of India grants SR/S0/HS/0016/2011 and BT/PR13334/Med/30/259/2009 outside the submitted work. Dr. Venkatasubramanian reported Wellcome-DBT India Alliance grant 500236/Z/11/Z outside the submitted work. Dr. Simpson reported Biohaven Research support for a clinical trial and royalties from UpToDate, Inc. and Cambridge University Press outside the submitted work. Dr. Soreni reported support from Lundbeck-Iliyan IvanovT outside the submitted work. Dr. Walitza has received in the last 3years royalties from Thieme Hogrefe, Kohlhammer, Springer, Beltz; Her work was supported in the last 3years by the Swiss National Science Foundation (SNF), diff. EU FP7s, HSM Hochspezialisierte Medizin of the Kanton Zurich, Switzerland, Bfarm Germany, ZInEP, Hartmann Muller Stiftung, Olga Mayenfisch, Gertrud Thalmann Fonds (all unrelated to the submitted work). Dr. Thompson has received a research grant from Biogen, Inc., unrelated to the topic of this paper.\n",
      "\n",
      "Conflict of Interest Dr. Arnold reported holding the Alberta Innovates Translational Health Chair in Child and Youth Mental Health outside the submitted work. Prof. Mataix-Cols receives royalties for contributing articles to UpToDate, Wolters Kluwer Health and fees from Elsevier for editorial tasks (all unrelated to the submitted work). Dr. Narayanaswamy reported Government of India grants DST INSPIRE faculty grant IFA12-LSBM-26 and BT/06/IYBA/2012 outside the submitted work. Dr. Reddy reported Government of India grants SR/S0/HS/0016/2011 and BT/PR13334/Med/30/259/2009 outside the submitted work. Dr. Venkatasubramanian reported Wellcome-DBT India Alliance grant 500236/Z/11/Z outside the submitted work. Dr. Simpson reported Biohaven Research support for a clinical trial and royalties from UpToDate, Inc. and Cambridge University Press outside the submitted work. Dr. Soreni reported support from Lundbeck-Iliyan IvanovT outside the submitted work. Dr. Walitza has received in the last 3years royalties from Thieme Hogrefe, Kohlhammer, Springer, Beltz; Her work was supported in the last 3years by the Swiss National Science Foundation (SNF), diff. EU FP7s, HSM Hochspezialisierte Medizin of the Kanton Zurich, Switzerland, Bfarm Germany, ZInEP, Hartmann Muller Stiftung, Olga Mayenfisch, Gertrud Thalmann Fonds (all unrelated to the submitted work). Dr. Thompson has received a research grant from Biogen, Inc., unrelated to the topic of this paper.\n",
      "\n",
      "Conflict of Interest Dr. Arnold reported holding the Alberta Innovates Translational Health Chair in Child and Youth Mental Health outside the submitted work. Prof. Mataix-Cols receives royalties for contributing articles to UpToDate, Wolters Kluwer Health and fees from Elsevier for editorial tasks (all unrelated to the submitted work). Dr. Narayanaswamy reported Government of India grants DST INSPIRE faculty grant IFA12-LSBM-26 and BT/06/IYBA/2012 outside the submitted work. Dr. Reddy reported Government of India grants SR/S0/HS/0016/2011 and BT/PR13334/Med/30/259/2009 outside the submitted work. Dr. Venkatasubramanian reported Wellcome-DBT India Alliance grant 500236/Z/11/Z outside the submitted work. Dr. Simpson reported Biohaven Research support for a clinical trial and royalties from UpToDate, Inc. and Cambridge University Press outside the submitted work. Dr. Soreni reported support from Lundbeck-Iliyan IvanovT outside the submitted work. Dr. Walitza has received in the last 3years royalties from Thieme Hogrefe, Kohlhammer, Springer, Beltz; Her work was supported in the last 3years by the Swiss National Science Foundation (SNF), diff. EU FP7s, HSM Hochspezialisierte Medizin of the Kanton Zurich, Switzerland, Bfarm Germany, ZInEP, Hartmann Muller Stiftung, Olga Mayenfisch, Gertrud Thalmann Fonds (all unrelated to the submitted work). Dr. Thompson has received a research grant from Biogen, Inc., unrelated to the topic of this paper.\n",
      "\n",
      "Arnold, Paul D.\n",
      "Conflict of Interest Dr. Paul D. Arnold reported holding the Alberta Innovates Translational Health Chair in Child and Youth Mental Health outside the submitted work. Prof. Mataix-Cols receives royalties for contributing articles to UpToDate, Wolters Kluwer Health and fees from Elsevier for editorial tasks (all unrelated to the submitted work). Dr. Narayanaswamy reported Government of India grants DST INSPIRE faculty grant IFA12-LSBM-26 and BT/06/IYBA/2012 outside the submitted work. Dr. Reddy reported Government of India grants SR/S0/HS/0016/2011 and BT/PR13334/Med/30/259/2009 outside the submitted work. Dr. Venkatasubramanian reported Wellcome-DBT India Alliance grant 500236/Z/11/Z outside the submitted work. Dr. Simpson reported Biohaven Research support for a clinical trial and royalties from UpToDate, Inc. and Cambridge University Press outside the submitted work. Dr. Soreni reported support from Lundbeck-Iliyan IvanovT outside the submitted work. Dr. Walitza has received in the last 3years royalties from Thieme Hogrefe, Kohlhammer, Springer, Beltz; Her work was supported in the last 3years by the Swiss National Science Foundation (SNF), diff. EU FP7s, HSM Hochspezialisierte Medizin of the Kanton Zurich, Switzerland, Bfarm Germany, ZInEP, Hartmann Muller Stiftung, Olga Mayenfisch, Gertrud Thalmann Fonds (all unrelated to the submitted work). Dr. Thompson has received a research grant from Biogen, Inc., unrelated to the topic of this paper.\n",
      "\n",
      "Balachander, Srinivas\n",
      "Conflict of Interest Dr. Paul D. Arnold reported holding the Alberta Innovates Translational Health Chair in Child and Youth Mental Health outside the submitted work. Prof. Mataix-Cols receives royalties for contributing articles to UpToDate, Wolters Kluwer Health and fees from Elsevier for editorial tasks (all unrelated to the submitted work). Dr. Narayanaswamy reported Government of India grants DST INSPIRE faculty grant IFA12-LSrinivas BalachanderM-26 and BT/06/IYBA/2012 outside the submitted work. Dr. Reddy reported Government of India grants SR/S0/HS/0016/2011 and BT/PR13334/Med/30/259/2009 outside the submitted work. Dr. Venkatasubramanian reported Wellcome-DBT India Alliance grant 500236/Z/11/Z outside the submitted work. Dr. Simpson reported Biohaven Research support for a clinical trial and royalties from UpToDate, Inc. and Cambridge University Press outside the submitted work. Dr. Soreni reported support from Lundbeck-Iliyan IvanovT outside the submitted work. Dr. Walitza has received in the last 3years royalties from Thieme Hogrefe, Kohlhammer, Springer, Beltz; Her work was supported in the last 3years by the Swiss National Science Foundation (SNF), diff. EU FP7s, HSM Hochspezialisierte Medizin of the Kanton Zurich, Switzerland, Bfarm Germany, ZInEP, Hartmann Muller Stiftung, Olga Mayenfisch, Gertrud Thalmann Fonds (all unrelated to the submitted work). Dr. Thompson has received a research grant from Biogen, Inc., unrelated to the topic of this paper.\n",
      "\n",
      "Conflict of Interest Dr. Paul D. Arnold reported holding the Alberta Innovates Translational Health Chair in Child and Youth Mental Health outside the submitted work. Prof. Mataix-Cols receives royalties for contributing articles to UpToDate, Wolters Kluwer Health and fees from Elsevier for editorial tasks (all unrelated to the submitted work). Dr. Narayanaswamy reported Government of India grants DST INSPIRE faculty grant IFA12-LSrinivas BalachanderM-26 and BT/06/IYBA/2012 outside the submitted work. Dr. Reddy reported Government of India grants SR/S0/HS/0016/2011 and BT/PR13334/Med/30/259/2009 outside the submitted work. Dr. Venkatasubramanian reported Wellcome-DBT India Alliance grant 500236/Z/11/Z outside the submitted work. Dr. Simpson reported Biohaven Research support for a clinical trial and royalties from UpToDate, Inc. and Cambridge University Press outside the submitted work. Dr. Soreni reported support from Lundbeck-Iliyan IvanovT outside the submitted work. Dr. Walitza has received in the last 3years royalties from Thieme Hogrefe, Kohlhammer, Springer, Beltz; Her work was supported in the last 3years by the Swiss National Science Foundation (SNF), diff. EU FP7s, HSM Hochspezialisierte Medizin of the Kanton Zurich, Switzerland, Bfarm Germany, ZInEP, Hartmann Muller Stiftung, Olga Mayenfisch, Gertrud Thalmann Fonds (all unrelated to the submitted work). Dr. Thompson has received a research grant from Biogen, Inc., unrelated to the topic of this paper.\n",
      "\n",
      "Conflict of Interest Dr. Paul D. Arnold reported holding the Alberta Innovates Translational Health Chair in Child and Youth Mental Health outside the submitted work. Prof. Mataix-Cols receives royalties for contributing articles to UpToDate, Wolters Kluwer Health and fees from Elsevier for editorial tasks (all unrelated to the submitted work). Dr. Narayanaswamy reported Government of India grants DST INSPIRE faculty grant IFA12-LSrinivas BalachanderM-26 and BT/06/IYBA/2012 outside the submitted work. Dr. Reddy reported Government of India grants SR/S0/HS/0016/2011 and BT/PR13334/Med/30/259/2009 outside the submitted work. Dr. Venkatasubramanian reported Wellcome-DBT India Alliance grant 500236/Z/11/Z outside the submitted work. Dr. Simpson reported Biohaven Research support for a clinical trial and royalties from UpToDate, Inc. and Cambridge University Press outside the submitted work. Dr. Soreni reported support from Lundbeck-Iliyan IvanovT outside the submitted work. Dr. Walitza has received in the last 3years royalties from Thieme Hogrefe, Kohlhammer, Springer, Beltz; Her work was supported in the last 3years by the Swiss National Science Foundation (SNF), diff. EU FP7s, HSM Hochspezialisierte Medizin of the Kanton Zurich, Switzerland, Bfarm Germany, ZInEP, Hartmann Muller Stiftung, Olga Mayenfisch, Gertrud Thalmann Fonds (all unrelated to the submitted work). Dr. Thompson has received a research grant from Biogen, Inc., unrelated to the topic of this paper.\n",
      "\n",
      "Conflict of Interest Dr. Paul D. Arnold reported holding the Alberta Innovates Translational Health Chair in Child and Youth Mental Health outside the submitted work. Prof. Mataix-Cols receives royalties for contributing articles to UpToDate, Wolters Kluwer Health and fees from Elsevier for editorial tasks (all unrelated to the submitted work). Dr. Narayanaswamy reported Government of India grants DST INSPIRE faculty grant IFA12-LSrinivas BalachanderM-26 and BT/06/IYBA/2012 outside the submitted work. Dr. Reddy reported Government of India grants SR/S0/HS/0016/2011 and BT/PR13334/Med/30/259/2009 outside the submitted work. Dr. Venkatasubramanian reported Wellcome-DBT India Alliance grant 500236/Z/11/Z outside the submitted work. Dr. Simpson reported Biohaven Research support for a clinical trial and royalties from UpToDate, Inc. and Cambridge University Press outside the submitted work. Dr. Soreni reported support from Lundbeck-Iliyan IvanovT outside the submitted work. Dr. Walitza has received in the last 3years royalties from Thieme Hogrefe, Kohlhammer, Springer, Beltz; Her work was supported in the last 3years by the Swiss National Science Foundation (SNF), diff. EU FP7s, HSM Hochspezialisierte Medizin of the Kanton Zurich, Switzerland, Bfarm Germany, ZInEP, Hartmann Muller Stiftung, Olga Mayenfisch, Gertrud Thalmann Fonds (all unrelated to the submitted work). Dr. Thompson has received a research grant from Biogen, Inc., unrelated to the topic of this paper.\n",
      "\n",
      "Conflict of Interest Dr. Paul D. Arnold reported holding the Alberta Innovates Translational Health Chair in Child and Youth Mental Health outside the submitted work. Prof. Mataix-Cols receives royalties for contributing articles to UpToDate, Wolters Kluwer Health and fees from Elsevier for editorial tasks (all unrelated to the submitted work). Dr. Narayanaswamy reported Government of India grants DST INSPIRE faculty grant IFA12-LSrinivas BalachanderM-26 and BT/06/IYBA/2012 outside the submitted work. Dr. Reddy reported Government of India grants SR/S0/HS/0016/2011 and BT/PR13334/Med/30/259/2009 outside the submitted work. Dr. Venkatasubramanian reported Wellcome-DBT India Alliance grant 500236/Z/11/Z outside the submitted work. Dr. Simpson reported Biohaven Research support for a clinical trial and royalties from UpToDate, Inc. and Cambridge University Press outside the submitted work. Dr. Soreni reported support from Lundbeck-Iliyan IvanovT outside the submitted work. Dr. Walitza has received in the last 3years royalties from Thieme Hogrefe, Kohlhammer, Springer, Beltz; Her work was supported in the last 3years by the Swiss National Science Foundation (SNF), diff. EU FP7s, HSM Hochspezialisierte Medizin of the Kanton Zurich, Switzerland, Bfarm Germany, ZInEP, Hartmann Muller Stiftung, Olga Mayenfisch, Gertrud Thalmann Fonds (all unrelated to the submitted work). Dr. Thompson has received a research grant from Biogen, Inc., unrelated to the topic of this paper.\n",
      "\n",
      "Conflict of Interest Dr. Paul D. Arnold reported holding the Alberta Innovates Translational Health Chair in Child and Youth Mental Health outside the submitted work. Prof. Mataix-Cols receives royalties for contributing articles to UpToDate, Wolters Kluwer Health and fees from Elsevier for editorial tasks (all unrelated to the submitted work). Dr. Narayanaswamy reported Government of India grants DST INSPIRE faculty grant IFA12-LSrinivas BalachanderM-26 and BT/06/IYBA/2012 outside the submitted work. Dr. Reddy reported Government of India grants SR/S0/HS/0016/2011 and BT/PR13334/Med/30/259/2009 outside the submitted work. Dr. Venkatasubramanian reported Wellcome-DBT India Alliance grant 500236/Z/11/Z outside the submitted work. Dr. Simpson reported Biohaven Research support for a clinical trial and royalties from UpToDate, Inc. and Cambridge University Press outside the submitted work. Dr. Soreni reported support from Lundbeck-Iliyan IvanovT outside the submitted work. Dr. Walitza has received in the last 3years royalties from Thieme Hogrefe, Kohlhammer, Springer, Beltz; Her work was supported in the last 3years by the Swiss National Science Foundation (SNF), diff. EU FP7s, HSM Hochspezialisierte Medizin of the Kanton Zurich, Switzerland, Bfarm Germany, ZInEP, Hartmann Muller Stiftung, Olga Mayenfisch, Gertrud Thalmann Fonds (all unrelated to the submitted work). Dr. Thompson has received a research grant from Biogen, Inc., unrelated to the topic of this paper.\n",
      "\n",
      "Conflict of Interest Dr. Paul D. Arnold reported holding the Alberta Innovates Translational Health Chair in Child and Youth Mental Health outside the submitted work. Prof. Mataix-Cols receives royalties for contributing articles to UpToDate, Wolters Kluwer Health and fees from Elsevier for editorial tasks (all unrelated to the submitted work). Dr. Narayanaswamy reported Government of India grants DST INSPIRE faculty grant IFA12-LSrinivas BalachanderM-26 and BT/06/IYBA/2012 outside the submitted work. Dr. Reddy reported Government of India grants SR/S0/HS/0016/2011 and BT/PR13334/Med/30/259/2009 outside the submitted work. Dr. Venkatasubramanian reported Wellcome-DBT India Alliance grant 500236/Z/11/Z outside the submitted work. Dr. Simpson reported Biohaven Research support for a clinical trial and royalties from UpToDate, Inc. and Cambridge University Press outside the submitted work. Dr. Soreni reported support from Lundbeck-Iliyan IvanovT outside the submitted work. Dr. Walitza has received in the last 3years royalties from Thieme Hogrefe, Kohlhammer, Springer, Beltz; Her work was supported in the last 3years by the Swiss National Science Foundation (SNF), diff. EU FP7s, HSM Hochspezialisierte Medizin of the Kanton Zurich, Switzerland, Bfarm Germany, ZInEP, Hartmann Muller Stiftung, Olga Mayenfisch, Gertrud Thalmann Fonds (all unrelated to the submitted work). Dr. Thompson has received a research grant from Biogen, Inc., unrelated to the topic of this paper.\n",
      "\n",
      "Conflict of Interest Dr. Paul D. Arnold reported holding the Alberta Innovates Translational Health Chair in Child and Youth Mental Health outside the submitted work. Prof. Mataix-Cols receives royalties for contributing articles to UpToDate, Wolters Kluwer Health and fees from Elsevier for editorial tasks (all unrelated to the submitted work). Dr. Narayanaswamy reported Government of India grants DST INSPIRE faculty grant IFA12-LSrinivas BalachanderM-26 and BT/06/IYBA/2012 outside the submitted work. Dr. Reddy reported Government of India grants SR/S0/HS/0016/2011 and BT/PR13334/Med/30/259/2009 outside the submitted work. Dr. Venkatasubramanian reported Wellcome-DBT India Alliance grant 500236/Z/11/Z outside the submitted work. Dr. Simpson reported Biohaven Research support for a clinical trial and royalties from UpToDate, Inc. and Cambridge University Press outside the submitted work. Dr. Soreni reported support from Lundbeck-Iliyan IvanovT outside the submitted work. Dr. Walitza has received in the last 3years royalties from Thieme Hogrefe, Kohlhammer, Springer, Beltz; Her work was supported in the last 3years by the Swiss National Science Foundation (SNF), diff. EU FP7s, HSM Hochspezialisierte Medizin of the Kanton Zurich, Switzerland, Bfarm Germany, ZInEP, Hartmann Muller Stiftung, Olga Mayenfisch, Gertrud Thalmann Fonds (all unrelated to the submitted work). Dr. Thompson has received a research grant from Biogen, Inc., unrelated to the topic of this paper.\n",
      "\n",
      "Conflict of Interest Dr. Paul D. Arnold reported holding the Alberta Innovates Translational Health Chair in Child and Youth Mental Health outside the submitted work. Prof. Mataix-Cols receives royalties for contributing articles to UpToDate, Wolters Kluwer Health and fees from Elsevier for editorial tasks (all unrelated to the submitted work). Dr. Narayanaswamy reported Government of India grants DST INSPIRE faculty grant IFA12-LSrinivas BalachanderM-26 and BT/06/IYBA/2012 outside the submitted work. Dr. Reddy reported Government of India grants SR/S0/HS/0016/2011 and BT/PR13334/Med/30/259/2009 outside the submitted work. Dr. Venkatasubramanian reported Wellcome-DBT India Alliance grant 500236/Z/11/Z outside the submitted work. Dr. Simpson reported Biohaven Research support for a clinical trial and royalties from UpToDate, Inc. and Cambridge University Press outside the submitted work. Dr. Soreni reported support from Lundbeck-Iliyan IvanovT outside the submitted work. Dr. Walitza has received in the last 3years royalties from Thieme Hogrefe, Kohlhammer, Springer, Beltz; Her work was supported in the last 3years by the Swiss National Science Foundation (SNF), diff. EU FP7s, HSM Hochspezialisierte Medizin of the Kanton Zurich, Switzerland, Bfarm Germany, ZInEP, Hartmann Muller Stiftung, Olga Mayenfisch, Gertrud Thalmann Fonds (all unrelated to the submitted work). Dr. Thompson has received a research grant from Biogen, Inc., unrelated to the topic of this paper.\n",
      "\n",
      "Conflict of Interest Dr. Paul D. Arnold reported holding the Alberta Innovates Translational Health Chair in Child and Youth Mental Health outside the submitted work. Prof. Mataix-Cols receives royalties for contributing articles to UpToDate, Wolters Kluwer Health and fees from Elsevier for editorial tasks (all unrelated to the submitted work). Dr. Narayanaswamy reported Government of India grants DST INSPIRE faculty grant IFA12-LSrinivas BalachanderM-26 and BT/06/IYBA/2012 outside the submitted work. Dr. Reddy reported Government of India grants SR/S0/HS/0016/2011 and BT/PR13334/Med/30/259/2009 outside the submitted work. Dr. Venkatasubramanian reported Wellcome-DBT India Alliance grant 500236/Z/11/Z outside the submitted work. Dr. Simpson reported Biohaven Research support for a clinical trial and royalties from UpToDate, Inc. and Cambridge University Press outside the submitted work. Dr. Soreni reported support from Lundbeck-Iliyan IvanovT outside the submitted work. Dr. Walitza has received in the last 3years royalties from Thieme Hogrefe, Kohlhammer, Springer, Beltz; Her work was supported in the last 3years by the Swiss National Science Foundation (SNF), diff. EU FP7s, HSM Hochspezialisierte Medizin of the Kanton Zurich, Switzerland, Bfarm Germany, ZInEP, Hartmann Muller Stiftung, Olga Mayenfisch, Gertrud Thalmann Fonds (all unrelated to the submitted work). Dr. Thompson has received a research grant from Biogen, Inc., unrelated to the topic of this paper.\n",
      "\n",
      "Conflict of Interest Dr. Paul D. Arnold reported holding the Alberta Innovates Translational Health Chair in Child and Youth Mental Health outside the submitted work. Prof. Mataix-Cols receives royalties for contributing articles to UpToDate, Wolters Kluwer Health and fees from Elsevier for editorial tasks (all unrelated to the submitted work). Dr. Narayanaswamy reported Government of India grants DST INSPIRE faculty grant IFA12-LSrinivas BalachanderM-26 and BT/06/IYBA/2012 outside the submitted work. Dr. Reddy reported Government of India grants SR/S0/HS/0016/2011 and BT/PR13334/Med/30/259/2009 outside the submitted work. Dr. Venkatasubramanian reported Wellcome-DBT India Alliance grant 500236/Z/11/Z outside the submitted work. Dr. Simpson reported Biohaven Research support for a clinical trial and royalties from UpToDate, Inc. and Cambridge University Press outside the submitted work. Dr. Soreni reported support from Lundbeck-Iliyan IvanovT outside the submitted work. Dr. Walitza has received in the last 3years royalties from Thieme Hogrefe, Kohlhammer, Springer, Beltz; Her work was supported in the last 3years by the Swiss National Science Foundation (SNF), diff. EU FP7s, HSM Hochspezialisierte Medizin of the Kanton Zurich, Switzerland, Bfarm Germany, ZInEP, Hartmann Muller Stiftung, Olga Mayenfisch, Gertrud Thalmann Fonds (all unrelated to the submitted work). Dr. Thompson has received a research grant from Biogen, Inc., unrelated to the topic of this paper.\n",
      "\n",
      "Conflict of Interest Dr. Paul D. Arnold reported holding the Alberta Innovates Translational Health Chair in Child and Youth Mental Health outside the submitted work. Prof. Mataix-Cols receives royalties for contributing articles to UpToDate, Wolters Kluwer Health and fees from Elsevier for editorial tasks (all unrelated to the submitted work). Dr. Narayanaswamy reported Government of India grants DST INSPIRE faculty grant IFA12-LSrinivas BalachanderM-26 and BT/06/IYBA/2012 outside the submitted work. Dr. Reddy reported Government of India grants SR/S0/HS/0016/2011 and BT/PR13334/Med/30/259/2009 outside the submitted work. Dr. Venkatasubramanian reported Wellcome-DBT India Alliance grant 500236/Z/11/Z outside the submitted work. Dr. Simpson reported Biohaven Research support for a clinical trial and royalties from UpToDate, Inc. and Cambridge University Press outside the submitted work. Dr. Soreni reported support from Lundbeck-Iliyan IvanovT outside the submitted work. Dr. Walitza has received in the last 3years royalties from Thieme Hogrefe, Kohlhammer, Springer, Beltz; Her work was supported in the last 3years by the Swiss National Science Foundation (SNF), diff. EU FP7s, HSM Hochspezialisierte Medizin of the Kanton Zurich, Switzerland, Bfarm Germany, ZInEP, Hartmann Muller Stiftung, Olga Mayenfisch, Gertrud Thalmann Fonds (all unrelated to the submitted work). Dr. Thompson has received a research grant from Biogen, Inc., unrelated to the topic of this paper.\n",
      "\n",
      "Conflict of Interest Dr. Paul D. Arnold reported holding the Alberta Innovates Translational Health Chair in Child and Youth Mental Health outside the submitted work. Prof. Mataix-Cols receives royalties for contributing articles to UpToDate, Wolters Kluwer Health and fees from Elsevier for editorial tasks (all unrelated to the submitted work). Dr. Narayanaswamy reported Government of India grants DST INSPIRE faculty grant IFA12-LSrinivas BalachanderM-26 and BT/06/IYBA/2012 outside the submitted work. Dr. Reddy reported Government of India grants SR/S0/HS/0016/2011 and BT/PR13334/Med/30/259/2009 outside the submitted work. Dr. Venkatasubramanian reported Wellcome-DBT India Alliance grant 500236/Z/11/Z outside the submitted work. Dr. Simpson reported Biohaven Research support for a clinical trial and royalties from UpToDate, Inc. and Cambridge University Press outside the submitted work. Dr. Soreni reported support from Lundbeck-Iliyan IvanovT outside the submitted work. Dr. Walitza has received in the last 3years royalties from Thieme Hogrefe, Kohlhammer, Springer, Beltz; Her work was supported in the last 3years by the Swiss National Science Foundation (SNF), diff. EU FP7s, HSM Hochspezialisierte Medizin of the Kanton Zurich, Switzerland, Bfarm Germany, ZInEP, Hartmann Muller Stiftung, Olga Mayenfisch, Gertrud Thalmann Fonds (all unrelated to the submitted work). Dr. Thompson has received a research grant from Biogen, Inc., unrelated to the topic of this paper.\n",
      "\n",
      "Conflict of Interest Dr. Paul D. Arnold reported holding the Alberta Innovates Translational Health Chair in Child and Youth Mental Health outside the submitted work. Prof. Mataix-Cols receives royalties for contributing articles to UpToDate, Wolters Kluwer Health and fees from Elsevier for editorial tasks (all unrelated to the submitted work). Dr. Narayanaswamy reported Government of India grants DST INSPIRE faculty grant IFA12-LSrinivas BalachanderM-26 and BT/06/IYBA/2012 outside the submitted work. Dr. Reddy reported Government of India grants SR/S0/HS/0016/2011 and BT/PR13334/Med/30/259/2009 outside the submitted work. Dr. Venkatasubramanian reported Wellcome-DBT India Alliance grant 500236/Z/11/Z outside the submitted work. Dr. Simpson reported Biohaven Research support for a clinical trial and royalties from UpToDate, Inc. and Cambridge University Press outside the submitted work. Dr. Soreni reported support from Lundbeck-Iliyan IvanovT outside the submitted work. Dr. Walitza has received in the last 3years royalties from Thieme Hogrefe, Kohlhammer, Springer, Beltz; Her work was supported in the last 3years by the Swiss National Science Foundation (SNF), diff. EU FP7s, HSM Hochspezialisierte Medizin of the Kanton Zurich, Switzerland, Bfarm Germany, ZInEP, Hartmann Muller Stiftung, Olga Mayenfisch, Gertrud Thalmann Fonds (all unrelated to the submitted work). Dr. Thompson has received a research grant from Biogen, Inc., unrelated to the topic of this paper.\n",
      "\n",
      "Conflict of Interest Dr. Paul D. Arnold reported holding the Alberta Innovates Translational Health Chair in Child and Youth Mental Health outside the submitted work. Prof. Mataix-Cols receives royalties for contributing articles to UpToDate, Wolters Kluwer Health and fees from Elsevier for editorial tasks (all unrelated to the submitted work). Dr. Narayanaswamy reported Government of India grants DST INSPIRE faculty grant IFA12-LSrinivas BalachanderM-26 and BT/06/IYBA/2012 outside the submitted work. Dr. Reddy reported Government of India grants SR/S0/HS/0016/2011 and BT/PR13334/Med/30/259/2009 outside the submitted work. Dr. Venkatasubramanian reported Wellcome-DBT India Alliance grant 500236/Z/11/Z outside the submitted work. Dr. Simpson reported Biohaven Research support for a clinical trial and royalties from UpToDate, Inc. and Cambridge University Press outside the submitted work. Dr. Soreni reported support from Lundbeck-Iliyan IvanovT outside the submitted work. Dr. Walitza has received in the last 3years royalties from Thieme Hogrefe, Kohlhammer, Springer, Beltz; Her work was supported in the last 3years by the Swiss National Science Foundation (SNF), diff. EU FP7s, HSM Hochspezialisierte Medizin of the Kanton Zurich, Switzerland, Bfarm Germany, ZInEP, Hartmann Muller Stiftung, Olga Mayenfisch, Gertrud Thalmann Fonds (all unrelated to the submitted work). Dr. Thompson has received a research grant from Biogen, Inc., unrelated to the topic of this paper.\n",
      "\n",
      "Conflict of Interest Dr. Paul D. Arnold reported holding the Alberta Innovates Translational Health Chair in Child and Youth Mental Health outside the submitted work. Prof. Mataix-Cols receives royalties for contributing articles to UpToDate, Wolters Kluwer Health and fees from Elsevier for editorial tasks (all unrelated to the submitted work). Dr. Narayanaswamy reported Government of India grants DST INSPIRE faculty grant IFA12-LSrinivas BalachanderM-26 and BT/06/IYBA/2012 outside the submitted work. Dr. Reddy reported Government of India grants SR/S0/HS/0016/2011 and BT/PR13334/Med/30/259/2009 outside the submitted work. Dr. Venkatasubramanian reported Wellcome-DBT India Alliance grant 500236/Z/11/Z outside the submitted work. Dr. Simpson reported Biohaven Research support for a clinical trial and royalties from UpToDate, Inc. and Cambridge University Press outside the submitted work. Dr. Soreni reported support from Lundbeck-Iliyan IvanovT outside the submitted work. Dr. Walitza has received in the last 3years royalties from Thieme Hogrefe, Kohlhammer, Springer, Beltz; Her work was supported in the last 3years by the Swiss National Science Foundation (SNF), diff. EU FP7s, HSM Hochspezialisierte Medizin of the Kanton Zurich, Switzerland, Bfarm Germany, ZInEP, Hartmann Muller Stiftung, Olga Mayenfisch, Gertrud Thalmann Fonds (all unrelated to the submitted work). Dr. Thompson has received a research grant from Biogen, Inc., unrelated to the topic of this paper.\n",
      "\n",
      "Conflict of Interest Dr. Paul D. Arnold reported holding the Alberta Innovates Translational Health Chair in Child and Youth Mental Health outside the submitted work. Prof. Mataix-Cols receives royalties for contributing articles to UpToDate, Wolters Kluwer Health and fees from Elsevier for editorial tasks (all unrelated to the submitted work). Dr. Narayanaswamy reported Government of India grants DST INSPIRE faculty grant IFA12-LSrinivas BalachanderM-26 and BT/06/IYBA/2012 outside the submitted work. Dr. Reddy reported Government of India grants SR/S0/HS/0016/2011 and BT/PR13334/Med/30/259/2009 outside the submitted work. Dr. Venkatasubramanian reported Wellcome-DBT India Alliance grant 500236/Z/11/Z outside the submitted work. Dr. Simpson reported Biohaven Research support for a clinical trial and royalties from UpToDate, Inc. and Cambridge University Press outside the submitted work. Dr. Soreni reported support from Lundbeck-Iliyan IvanovT outside the submitted work. Dr. Walitza has received in the last 3years royalties from Thieme Hogrefe, Kohlhammer, Springer, Beltz; Her work was supported in the last 3years by the Swiss National Science Foundation (SNF), diff. EU FP7s, HSM Hochspezialisierte Medizin of the Kanton Zurich, Switzerland, Bfarm Germany, ZInEP, Hartmann Muller Stiftung, Olga Mayenfisch, Gertrud Thalmann Fonds (all unrelated to the submitted work). Dr. Thompson has received a research grant from Biogen, Inc., unrelated to the topic of this paper.\n",
      "\n",
      "Conflict of Interest Dr. Paul D. Arnold reported holding the Alberta Innovates Translational Health Chair in Child and Youth Mental Health outside the submitted work. Prof. Mataix-Cols receives royalties for contributing articles to UpToDate, Wolters Kluwer Health and fees from Elsevier for editorial tasks (all unrelated to the submitted work). Dr. Narayanaswamy reported Government of India grants DST INSPIRE faculty grant IFA12-LSrinivas BalachanderM-26 and BT/06/IYBA/2012 outside the submitted work. Dr. Reddy reported Government of India grants SR/S0/HS/0016/2011 and BT/PR13334/Med/30/259/2009 outside the submitted work. Dr. Venkatasubramanian reported Wellcome-DBT India Alliance grant 500236/Z/11/Z outside the submitted work. Dr. Simpson reported Biohaven Research support for a clinical trial and royalties from UpToDate, Inc. and Cambridge University Press outside the submitted work. Dr. Soreni reported support from Lundbeck-Iliyan IvanovT outside the submitted work. Dr. Walitza has received in the last 3years royalties from Thieme Hogrefe, Kohlhammer, Springer, Beltz; Her work was supported in the last 3years by the Swiss National Science Foundation (SNF), diff. EU FP7s, HSM Hochspezialisierte Medizin of the Kanton Zurich, Switzerland, Bfarm Germany, ZInEP, Hartmann Muller Stiftung, Olga Mayenfisch, Gertrud Thalmann Fonds (all unrelated to the submitted work). Dr. Thompson has received a research grant from Biogen, Inc., unrelated to the topic of this paper.\n",
      "\n",
      "Conflict of Interest Dr. Paul D. Arnold reported holding the Alberta Innovates Translational Health Chair in Child and Youth Mental Health outside the submitted work. Prof. Mataix-Cols receives royalties for contributing articles to UpToDate, Wolters Kluwer Health and fees from Elsevier for editorial tasks (all unrelated to the submitted work). Dr. Narayanaswamy reported Government of India grants DST INSPIRE faculty grant IFA12-LSrinivas BalachanderM-26 and BT/06/IYBA/2012 outside the submitted work. Dr. Reddy reported Government of India grants SR/S0/HS/0016/2011 and BT/PR13334/Med/30/259/2009 outside the submitted work. Dr. Venkatasubramanian reported Wellcome-DBT India Alliance grant 500236/Z/11/Z outside the submitted work. Dr. Simpson reported Biohaven Research support for a clinical trial and royalties from UpToDate, Inc. and Cambridge University Press outside the submitted work. Dr. Soreni reported support from Lundbeck-Iliyan IvanovT outside the submitted work. Dr. Walitza has received in the last 3years royalties from Thieme Hogrefe, Kohlhammer, Springer, Beltz; Her work was supported in the last 3years by the Swiss National Science Foundation (SNF), diff. EU FP7s, HSM Hochspezialisierte Medizin of the Kanton Zurich, Switzerland, Bfarm Germany, ZInEP, Hartmann Muller Stiftung, Olga Mayenfisch, Gertrud Thalmann Fonds (all unrelated to the submitted work). Dr. Thompson has received a research grant from Biogen, Inc., unrelated to the topic of this paper.\n",
      "\n",
      "Conflict of Interest Dr. Paul D. Arnold reported holding the Alberta Innovates Translational Health Chair in Child and Youth Mental Health outside the submitted work. Prof. Mataix-Cols receives royalties for contributing articles to UpToDate, Wolters Kluwer Health and fees from Elsevier for editorial tasks (all unrelated to the submitted work). Dr. Narayanaswamy reported Government of India grants DST INSPIRE faculty grant IFA12-LSrinivas BalachanderM-26 and BT/06/IYBA/2012 outside the submitted work. Dr. Reddy reported Government of India grants SR/S0/HS/0016/2011 and BT/PR13334/Med/30/259/2009 outside the submitted work. Dr. Venkatasubramanian reported Wellcome-DBT India Alliance grant 500236/Z/11/Z outside the submitted work. Dr. Simpson reported Biohaven Research support for a clinical trial and royalties from UpToDate, Inc. and Cambridge University Press outside the submitted work. Dr. Soreni reported support from Lundbeck-Iliyan IvanovT outside the submitted work. Dr. Walitza has received in the last 3years royalties from Thieme Hogrefe, Kohlhammer, Springer, Beltz; Her work was supported in the last 3years by the Swiss National Science Foundation (SNF), diff. EU FP7s, HSM Hochspezialisierte Medizin of the Kanton Zurich, Switzerland, Bfarm Germany, ZInEP, Hartmann Muller Stiftung, Olga Mayenfisch, Gertrud Thalmann Fonds (all unrelated to the submitted work). Dr. Thompson has received a research grant from Biogen, Inc., unrelated to the topic of this paper.\n",
      "\n",
      "Conflict of Interest Dr. Paul D. Arnold reported holding the Alberta Innovates Translational Health Chair in Child and Youth Mental Health outside the submitted work. Prof. Mataix-Cols receives royalties for contributing articles to UpToDate, Wolters Kluwer Health and fees from Elsevier for editorial tasks (all unrelated to the submitted work). Dr. Narayanaswamy reported Government of India grants DST INSPIRE faculty grant IFA12-LSrinivas BalachanderM-26 and BT/06/IYBA/2012 outside the submitted work. Dr. Reddy reported Government of India grants SR/S0/HS/0016/2011 and BT/PR13334/Med/30/259/2009 outside the submitted work. Dr. Venkatasubramanian reported Wellcome-DBT India Alliance grant 500236/Z/11/Z outside the submitted work. Dr. Simpson reported Biohaven Research support for a clinical trial and royalties from UpToDate, Inc. and Cambridge University Press outside the submitted work. Dr. Soreni reported support from Lundbeck-Iliyan IvanovT outside the submitted work. Dr. Walitza has received in the last 3years royalties from Thieme Hogrefe, Kohlhammer, Springer, Beltz; Her work was supported in the last 3years by the Swiss National Science Foundation (SNF), diff. EU FP7s, HSM Hochspezialisierte Medizin of the Kanton Zurich, Switzerland, Bfarm Germany, ZInEP, Hartmann Muller Stiftung, Olga Mayenfisch, Gertrud Thalmann Fonds (all unrelated to the submitted work). Dr. Thompson has received a research grant from Biogen, Inc., unrelated to the topic of this paper.\n",
      "\n",
      "Conflict of Interest Dr. Paul D. Arnold reported holding the Alberta Innovates Translational Health Chair in Child and Youth Mental Health outside the submitted work. Prof. Mataix-Cols receives royalties for contributing articles to UpToDate, Wolters Kluwer Health and fees from Elsevier for editorial tasks (all unrelated to the submitted work). Dr. Narayanaswamy reported Government of India grants DST INSPIRE faculty grant IFA12-LSrinivas BalachanderM-26 and BT/06/IYBA/2012 outside the submitted work. Dr. Reddy reported Government of India grants SR/S0/HS/0016/2011 and BT/PR13334/Med/30/259/2009 outside the submitted work. Dr. Venkatasubramanian reported Wellcome-DBT India Alliance grant 500236/Z/11/Z outside the submitted work. Dr. Simpson reported Biohaven Research support for a clinical trial and royalties from UpToDate, Inc. and Cambridge University Press outside the submitted work. Dr. Soreni reported support from Lundbeck-Iliyan IvanovT outside the submitted work. Dr. Walitza has received in the last 3years royalties from Thieme Hogrefe, Kohlhammer, Springer, Beltz; Her work was supported in the last 3years by the Swiss National Science Foundation (SNF), diff. EU FP7s, HSM Hochspezialisierte Medizin of the Kanton Zurich, Switzerland, Bfarm Germany, ZInEP, Hartmann Muller Stiftung, Olga Mayenfisch, Gertrud Thalmann Fonds (all unrelated to the submitted work). Dr. Thompson has received a research grant from Biogen, Inc., unrelated to the topic of this paper.\n",
      "\n",
      "Conflict of Interest Dr. Paul D. Arnold reported holding the Alberta Innovates Translational Health Chair in Child and Youth Mental Health outside the submitted work. Prof. Mataix-Cols receives royalties for contributing articles to UpToDate, Wolters Kluwer Health and fees from Elsevier for editorial tasks (all unrelated to the submitted work). Dr. Narayanaswamy reported Government of India grants DST INSPIRE faculty grant IFA12-LSrinivas BalachanderM-26 and BT/06/IYBA/2012 outside the submitted work. Dr. Reddy reported Government of India grants SR/S0/HS/0016/2011 and BT/PR13334/Med/30/259/2009 outside the submitted work. Dr. Venkatasubramanian reported Wellcome-DBT India Alliance grant 500236/Z/11/Z outside the submitted work. Dr. Simpson reported Biohaven Research support for a clinical trial and royalties from UpToDate, Inc. and Cambridge University Press outside the submitted work. Dr. Soreni reported support from Lundbeck-Iliyan IvanovT outside the submitted work. Dr. Walitza has received in the last 3years royalties from Thieme Hogrefe, Kohlhammer, Springer, Beltz; Her work was supported in the last 3years by the Swiss National Science Foundation (SNF), diff. EU FP7s, HSM Hochspezialisierte Medizin of the Kanton Zurich, Switzerland, Bfarm Germany, ZInEP, Hartmann Muller Stiftung, Olga Mayenfisch, Gertrud Thalmann Fonds (all unrelated to the submitted work). Dr. Thompson has received a research grant from Biogen, Inc., unrelated to the topic of this paper.\n",
      "\n",
      "Conflict of Interest Dr. Paul D. Arnold reported holding the Alberta Innovates Translational Health Chair in Child and Youth Mental Health outside the submitted work. Prof. Mataix-Cols receives royalties for contributing articles to UpToDate, Wolters Kluwer Health and fees from Elsevier for editorial tasks (all unrelated to the submitted work). Dr. Narayanaswamy reported Government of India grants DST INSPIRE faculty grant IFA12-LSrinivas BalachanderM-26 and BT/06/IYBA/2012 outside the submitted work. Dr. Reddy reported Government of India grants SR/S0/HS/0016/2011 and BT/PR13334/Med/30/259/2009 outside the submitted work. Dr. Venkatasubramanian reported Wellcome-DBT India Alliance grant 500236/Z/11/Z outside the submitted work. Dr. Simpson reported Biohaven Research support for a clinical trial and royalties from UpToDate, Inc. and Cambridge University Press outside the submitted work. Dr. Soreni reported support from Lundbeck-Iliyan IvanovT outside the submitted work. Dr. Walitza has received in the last 3years royalties from Thieme Hogrefe, Kohlhammer, Springer, Beltz; Her work was supported in the last 3years by the Swiss National Science Foundation (SNF), diff. EU FP7s, HSM Hochspezialisierte Medizin of the Kanton Zurich, Switzerland, Bfarm Germany, ZInEP, Hartmann Muller Stiftung, Olga Mayenfisch, Gertrud Thalmann Fonds (all unrelated to the submitted work). Dr. Thompson has received a research grant from Biogen, Inc., unrelated to the topic of this paper.\n",
      "\n",
      "Conflict of Interest Dr. Paul D. Arnold reported holding the Alberta Innovates Translational Health Chair in Child and Youth Mental Health outside the submitted work. Prof. Mataix-Cols receives royalties for contributing articles to UpToDate, Wolters Kluwer Health and fees from Elsevier for editorial tasks (all unrelated to the submitted work). Dr. Narayanaswamy reported Government of India grants DST INSPIRE faculty grant IFA12-LSrinivas BalachanderM-26 and BT/06/IYBA/2012 outside the submitted work. Dr. Reddy reported Government of India grants SR/S0/HS/0016/2011 and BT/PR13334/Med/30/259/2009 outside the submitted work. Dr. Venkatasubramanian reported Wellcome-DBT India Alliance grant 500236/Z/11/Z outside the submitted work. Dr. Simpson reported Biohaven Research support for a clinical trial and royalties from UpToDate, Inc. and Cambridge University Press outside the submitted work. Dr. Soreni reported support from Lundbeck-Iliyan IvanovT outside the submitted work. Dr. Walitza has received in the last 3years royalties from Thieme Hogrefe, Kohlhammer, Springer, Beltz; Her work was supported in the last 3years by the Swiss National Science Foundation (SNF), diff. EU FP7s, HSM Hochspezialisierte Medizin of the Kanton Zurich, Switzerland, Bfarm Germany, ZInEP, Hartmann Muller Stiftung, Olga Mayenfisch, Gertrud Thalmann Fonds (all unrelated to the submitted work). Dr. Thompson has received a research grant from Biogen, Inc., unrelated to the topic of this paper.\n",
      "\n",
      "Conflict of Interest Dr. Paul D. Arnold reported holding the Alberta Innovates Translational Health Chair in Child and Youth Mental Health outside the submitted work. Prof. Mataix-Cols receives royalties for contributing articles to UpToDate, Wolters Kluwer Health and fees from Elsevier for editorial tasks (all unrelated to the submitted work). Dr. Narayanaswamy reported Government of India grants DST INSPIRE faculty grant IFA12-LSrinivas BalachanderM-26 and BT/06/IYBA/2012 outside the submitted work. Dr. Reddy reported Government of India grants SR/S0/HS/0016/2011 and BT/PR13334/Med/30/259/2009 outside the submitted work. Dr. Venkatasubramanian reported Wellcome-DBT India Alliance grant 500236/Z/11/Z outside the submitted work. Dr. Simpson reported Biohaven Research support for a clinical trial and royalties from UpToDate, Inc. and Cambridge University Press outside the submitted work. Dr. Soreni reported support from Lundbeck-Iliyan IvanovT outside the submitted work. Dr. Walitza has received in the last 3years royalties from Thieme Hogrefe, Kohlhammer, Springer, Beltz; Her work was supported in the last 3years by the Swiss National Science Foundation (SNF), diff. EU FP7s, HSM Hochspezialisierte Medizin of the Kanton Zurich, Switzerland, Bfarm Germany, ZInEP, Hartmann Muller Stiftung, Olga Mayenfisch, Gertrud Thalmann Fonds (all unrelated to the submitted work). Dr. Thompson has received a research grant from Biogen, Inc., unrelated to the topic of this paper.\n",
      "\n",
      "Conflict of Interest Dr. Paul D. Arnold reported holding the Alberta Innovates Translational Health Chair in Child and Youth Mental Health outside the submitted work. Prof. Mataix-Cols receives royalties for contributing articles to UpToDate, Wolters Kluwer Health and fees from Elsevier for editorial tasks (all unrelated to the submitted work). Dr. Narayanaswamy reported Government of India grants DST INSPIRE faculty grant IFA12-LSrinivas BalachanderM-26 and BT/06/IYBA/2012 outside the submitted work. Dr. Reddy reported Government of India grants SR/S0/HS/0016/2011 and BT/PR13334/Med/30/259/2009 outside the submitted work. Dr. Venkatasubramanian reported Wellcome-DBT India Alliance grant 500236/Z/11/Z outside the submitted work. Dr. Simpson reported Biohaven Research support for a clinical trial and royalties from UpToDate, Inc. and Cambridge University Press outside the submitted work. Dr. Soreni reported support from Lundbeck-Iliyan IvanovT outside the submitted work. Dr. Walitza has received in the last 3years royalties from Thieme Hogrefe, Kohlhammer, Springer, Beltz; Her work was supported in the last 3years by the Swiss National Science Foundation (SNF), diff. EU FP7s, HSM Hochspezialisierte Medizin of the Kanton Zurich, Switzerland, Bfarm Germany, ZInEP, Hartmann Muller Stiftung, Olga Mayenfisch, Gertrud Thalmann Fonds (all unrelated to the submitted work). Dr. Thompson has received a research grant from Biogen, Inc., unrelated to the topic of this paper.\n",
      "\n",
      "Conflict of Interest Dr. Paul D. Arnold reported holding the Alberta Innovates Translational Health Chair in Child and Youth Mental Health outside the submitted work. Prof. Mataix-Cols receives royalties for contributing articles to UpToDate, Wolters Kluwer Health and fees from Elsevier for editorial tasks (all unrelated to the submitted work). Dr. Narayanaswamy reported Government of India grants DST INSPIRE faculty grant IFA12-LSrinivas BalachanderM-26 and BT/06/IYBA/2012 outside the submitted work. Dr. Reddy reported Government of India grants SR/S0/HS/0016/2011 and BT/PR13334/Med/30/259/2009 outside the submitted work. Dr. Venkatasubramanian reported Wellcome-DBT India Alliance grant 500236/Z/11/Z outside the submitted work. Dr. Simpson reported Biohaven Research support for a clinical trial and royalties from UpToDate, Inc. and Cambridge University Press outside the submitted work. Dr. Soreni reported support from Lundbeck-Iliyan IvanovT outside the submitted work. Dr. Walitza has received in the last 3years royalties from Thieme Hogrefe, Kohlhammer, Springer, Beltz; Her work was supported in the last 3years by the Swiss National Science Foundation (SNF), diff. EU FP7s, HSM Hochspezialisierte Medizin of the Kanton Zurich, Switzerland, Bfarm Germany, ZInEP, Hartmann Muller Stiftung, Olga Mayenfisch, Gertrud Thalmann Fonds (all unrelated to the submitted work). Dr. Thompson has received a research grant from Biogen, Inc., unrelated to the topic of this paper.\n",
      "\n",
      "Conflict of Interest Dr. Paul D. Arnold reported holding the Alberta Innovates Translational Health Chair in Child and Youth Mental Health outside the submitted work. Prof. Mataix-Cols receives royalties for contributing articles to UpToDate, Wolters Kluwer Health and fees from Elsevier for editorial tasks (all unrelated to the submitted work). Dr. Narayanaswamy reported Government of India grants DST INSPIRE faculty grant IFA12-LSrinivas BalachanderM-26 and BT/06/IYBA/2012 outside the submitted work. Dr. Reddy reported Government of India grants SR/S0/HS/0016/2011 and BT/PR13334/Med/30/259/2009 outside the submitted work. Dr. Venkatasubramanian reported Wellcome-DBT India Alliance grant 500236/Z/11/Z outside the submitted work. Dr. Simpson reported Biohaven Research support for a clinical trial and royalties from UpToDate, Inc. and Cambridge University Press outside the submitted work. Dr. Soreni reported support from Lundbeck-Iliyan IvanovT outside the submitted work. Dr. Walitza has received in the last 3years royalties from Thieme Hogrefe, Kohlhammer, Springer, Beltz; Her work was supported in the last 3years by the Swiss National Science Foundation (SNF), diff. EU FP7s, HSM Hochspezialisierte Medizin of the Kanton Zurich, Switzerland, Bfarm Germany, ZInEP, Hartmann Muller Stiftung, Olga Mayenfisch, Gertrud Thalmann Fonds (all unrelated to the submitted work). Dr. Thompson has received a research grant from Biogen, Inc., unrelated to the topic of this paper.\n",
      "\n",
      "Conflict of Interest Dr. Paul D. Arnold reported holding the Alberta Innovates Translational Health Chair in Child and Youth Mental Health outside the submitted work. Prof. Mataix-Cols receives royalties for contributing articles to UpToDate, Wolters Kluwer Health and fees from Elsevier for editorial tasks (all unrelated to the submitted work). Dr. Narayanaswamy reported Government of India grants DST INSPIRE faculty grant IFA12-LSrinivas BalachanderM-26 and BT/06/IYBA/2012 outside the submitted work. Dr. Reddy reported Government of India grants SR/S0/HS/0016/2011 and BT/PR13334/Med/30/259/2009 outside the submitted work. Dr. Venkatasubramanian reported Wellcome-DBT India Alliance grant 500236/Z/11/Z outside the submitted work. Dr. Simpson reported Biohaven Research support for a clinical trial and royalties from UpToDate, Inc. and Cambridge University Press outside the submitted work. Dr. Soreni reported support from Lundbeck-Iliyan IvanovT outside the submitted work. Dr. Walitza has received in the last 3years royalties from Thieme Hogrefe, Kohlhammer, Springer, Beltz; Her work was supported in the last 3years by the Swiss National Science Foundation (SNF), diff. EU FP7s, HSM Hochspezialisierte Medizin of the Kanton Zurich, Switzerland, Bfarm Germany, ZInEP, Hartmann Muller Stiftung, Olga Mayenfisch, Gertrud Thalmann Fonds (all unrelated to the submitted work). Dr. Thompson has received a research grant from Biogen, Inc., unrelated to the topic of this paper.\n",
      "\n",
      "Conflict of Interest Dr. Paul D. Arnold reported holding the Alberta Innovates Translational Health Chair in Child and Youth Mental Health outside the submitted work. Prof. Mataix-Cols receives royalties for contributing articles to UpToDate, Wolters Kluwer Health and fees from Elsevier for editorial tasks (all unrelated to the submitted work). Dr. Narayanaswamy reported Government of India grants DST INSPIRE faculty grant IFA12-LSrinivas BalachanderM-26 and BT/06/IYBA/2012 outside the submitted work. Dr. Reddy reported Government of India grants SR/S0/HS/0016/2011 and BT/PR13334/Med/30/259/2009 outside the submitted work. Dr. Venkatasubramanian reported Wellcome-DBT India Alliance grant 500236/Z/11/Z outside the submitted work. Dr. Simpson reported Biohaven Research support for a clinical trial and royalties from UpToDate, Inc. and Cambridge University Press outside the submitted work. Dr. Soreni reported support from Lundbeck-Iliyan IvanovT outside the submitted work. Dr. Walitza has received in the last 3years royalties from Thieme Hogrefe, Kohlhammer, Springer, Beltz; Her work was supported in the last 3years by the Swiss National Science Foundation (SNF), diff. EU FP7s, HSM Hochspezialisierte Medizin of the Kanton Zurich, Switzerland, Bfarm Germany, ZInEP, Hartmann Muller Stiftung, Olga Mayenfisch, Gertrud Thalmann Fonds (all unrelated to the submitted work). Dr. Thompson has received a research grant from Biogen, Inc., unrelated to the topic of this paper.\n",
      "\n",
      "Conflict of Interest Dr. Paul D. Arnold reported holding the Alberta Innovates Translational Health Chair in Child and Youth Mental Health outside the submitted work. Prof. Mataix-Cols receives royalties for contributing articles to UpToDate, Wolters Kluwer Health and fees from Elsevier for editorial tasks (all unrelated to the submitted work). Dr. Narayanaswamy reported Government of India grants DST INSPIRE faculty grant IFA12-LSrinivas BalachanderM-26 and BT/06/IYBA/2012 outside the submitted work. Dr. Reddy reported Government of India grants SR/S0/HS/0016/2011 and BT/PR13334/Med/30/259/2009 outside the submitted work. Dr. Venkatasubramanian reported Wellcome-DBT India Alliance grant 500236/Z/11/Z outside the submitted work. Dr. Simpson reported Biohaven Research support for a clinical trial and royalties from UpToDate, Inc. and Cambridge University Press outside the submitted work. Dr. Soreni reported support from Lundbeck-Iliyan IvanovT outside the submitted work. Dr. Walitza has received in the last 3years royalties from Thieme Hogrefe, Kohlhammer, Springer, Beltz; Her work was supported in the last 3years by the Swiss National Science Foundation (SNF), diff. EU FP7s, HSM Hochspezialisierte Medizin of the Kanton Zurich, Switzerland, Bfarm Germany, ZInEP, Hartmann Muller Stiftung, Olga Mayenfisch, Gertrud Thalmann Fonds (all unrelated to the submitted work). Dr. Thompson has received a research grant from Biogen, Inc., unrelated to the topic of this paper.\n",
      "\n",
      "Conflict of Interest Dr. Paul D. Arnold reported holding the Alberta Innovates Translational Health Chair in Child and Youth Mental Health outside the submitted work. Prof. Mataix-Cols receives royalties for contributing articles to UpToDate, Wolters Kluwer Health and fees from Elsevier for editorial tasks (all unrelated to the submitted work). Dr. Narayanaswamy reported Government of India grants DST INSPIRE faculty grant IFA12-LSrinivas BalachanderM-26 and BT/06/IYBA/2012 outside the submitted work. Dr. Reddy reported Government of India grants SR/S0/HS/0016/2011 and BT/PR13334/Med/30/259/2009 outside the submitted work. Dr. Venkatasubramanian reported Wellcome-DBT India Alliance grant 500236/Z/11/Z outside the submitted work. Dr. Simpson reported Biohaven Research support for a clinical trial and royalties from UpToDate, Inc. and Cambridge University Press outside the submitted work. Dr. Soreni reported support from Lundbeck-Iliyan IvanovT outside the submitted work. Dr. Walitza has received in the last 3years royalties from Thieme Hogrefe, Kohlhammer, Springer, Beltz; Her work was supported in the last 3years by the Swiss National Science Foundation (SNF), diff. EU FP7s, HSM Hochspezialisierte Medizin of the Kanton Zurich, Switzerland, Bfarm Germany, ZInEP, Hartmann Muller Stiftung, Olga Mayenfisch, Gertrud Thalmann Fonds (all unrelated to the submitted work). Dr. Thompson has received a research grant from Biogen, Inc., unrelated to the topic of this paper.\n",
      "\n",
      "Conflict of Interest Dr. Paul D. Arnold reported holding the Alberta Innovates Translational Health Chair in Child and Youth Mental Health outside the submitted work. Prof. Mataix-Cols receives royalties for contributing articles to UpToDate, Wolters Kluwer Health and fees from Elsevier for editorial tasks (all unrelated to the submitted work). Dr. Narayanaswamy reported Government of India grants DST INSPIRE faculty grant IFA12-LSrinivas BalachanderM-26 and BT/06/IYBA/2012 outside the submitted work. Dr. Reddy reported Government of India grants SR/S0/HS/0016/2011 and BT/PR13334/Med/30/259/2009 outside the submitted work. Dr. Venkatasubramanian reported Wellcome-DBT India Alliance grant 500236/Z/11/Z outside the submitted work. Dr. Simpson reported Biohaven Research support for a clinical trial and royalties from UpToDate, Inc. and Cambridge University Press outside the submitted work. Dr. Soreni reported support from Lundbeck-Iliyan IvanovT outside the submitted work. Dr. Walitza has received in the last 3years royalties from Thieme Hogrefe, Kohlhammer, Springer, Beltz; Her work was supported in the last 3years by the Swiss National Science Foundation (SNF), diff. EU FP7s, HSM Hochspezialisierte Medizin of the Kanton Zurich, Switzerland, Bfarm Germany, ZInEP, Hartmann Muller Stiftung, Olga Mayenfisch, Gertrud Thalmann Fonds (all unrelated to the submitted work). Dr. Thompson has received a research grant from Biogen, Inc., unrelated to the topic of this paper.\n",
      "\n",
      "Conflict of Interest Dr. Paul D. Arnold reported holding the Alberta Innovates Translational Health Chair in Child and Youth Mental Health outside the submitted work. Prof. Mataix-Cols receives royalties for contributing articles to UpToDate, Wolters Kluwer Health and fees from Elsevier for editorial tasks (all unrelated to the submitted work). Dr. Narayanaswamy reported Government of India grants DST INSPIRE faculty grant IFA12-LSrinivas BalachanderM-26 and BT/06/IYBA/2012 outside the submitted work. Dr. Reddy reported Government of India grants SR/S0/HS/0016/2011 and BT/PR13334/Med/30/259/2009 outside the submitted work. Dr. Venkatasubramanian reported Wellcome-DBT India Alliance grant 500236/Z/11/Z outside the submitted work. Dr. Simpson reported Biohaven Research support for a clinical trial and royalties from UpToDate, Inc. and Cambridge University Press outside the submitted work. Dr. Soreni reported support from Lundbeck-Iliyan IvanovT outside the submitted work. Dr. Walitza has received in the last 3years royalties from Thieme Hogrefe, Kohlhammer, Springer, Beltz; Her work was supported in the last 3years by the Swiss National Science Foundation (SNF), diff. EU FP7s, HSM Hochspezialisierte Medizin of the Kanton Zurich, Switzerland, Bfarm Germany, ZInEP, Hartmann Muller Stiftung, Olga Mayenfisch, Gertrud Thalmann Fonds (all unrelated to the submitted work). Dr. Thompson has received a research grant from Biogen, Inc., unrelated to the topic of this paper.\n",
      "\n",
      "Conflict of Interest Dr. Paul D. Arnold reported holding the Alberta Innovates Translational Health Chair in Child and Youth Mental Health outside the submitted work. Prof. Mataix-Cols receives royalties for contributing articles to UpToDate, Wolters Kluwer Health and fees from Elsevier for editorial tasks (all unrelated to the submitted work). Dr. Narayanaswamy reported Government of India grants DST INSPIRE faculty grant IFA12-LSrinivas BalachanderM-26 and BT/06/IYBA/2012 outside the submitted work. Dr. Reddy reported Government of India grants SR/S0/HS/0016/2011 and BT/PR13334/Med/30/259/2009 outside the submitted work. Dr. Venkatasubramanian reported Wellcome-DBT India Alliance grant 500236/Z/11/Z outside the submitted work. Dr. Simpson reported Biohaven Research support for a clinical trial and royalties from UpToDate, Inc. and Cambridge University Press outside the submitted work. Dr. Soreni reported support from Lundbeck-Iliyan IvanovT outside the submitted work. Dr. Walitza has received in the last 3years royalties from Thieme Hogrefe, Kohlhammer, Springer, Beltz; Her work was supported in the last 3years by the Swiss National Science Foundation (SNF), diff. EU FP7s, HSM Hochspezialisierte Medizin of the Kanton Zurich, Switzerland, Bfarm Germany, ZInEP, Hartmann Muller Stiftung, Olga Mayenfisch, Gertrud Thalmann Fonds (all unrelated to the submitted work). Dr. Thompson has received a research grant from Biogen, Inc., unrelated to the topic of this paper.\n",
      "\n",
      "Conflict of Interest Dr. Paul D. Arnold reported holding the Alberta Innovates Translational Health Chair in Child and Youth Mental Health outside the submitted work. Prof. Mataix-Cols receives royalties for contributing articles to UpToDate, Wolters Kluwer Health and fees from Elsevier for editorial tasks (all unrelated to the submitted work). Dr. Narayanaswamy reported Government of India grants DST INSPIRE faculty grant IFA12-LSrinivas BalachanderM-26 and BT/06/IYBA/2012 outside the submitted work. Dr. Reddy reported Government of India grants SR/S0/HS/0016/2011 and BT/PR13334/Med/30/259/2009 outside the submitted work. Dr. Venkatasubramanian reported Wellcome-DBT India Alliance grant 500236/Z/11/Z outside the submitted work. Dr. Simpson reported Biohaven Research support for a clinical trial and royalties from UpToDate, Inc. and Cambridge University Press outside the submitted work. Dr. Soreni reported support from Lundbeck-Iliyan IvanovT outside the submitted work. Dr. Walitza has received in the last 3years royalties from Thieme Hogrefe, Kohlhammer, Springer, Beltz; Her work was supported in the last 3years by the Swiss National Science Foundation (SNF), diff. EU FP7s, HSM Hochspezialisierte Medizin of the Kanton Zurich, Switzerland, Bfarm Germany, ZInEP, Hartmann Muller Stiftung, Olga Mayenfisch, Gertrud Thalmann Fonds (all unrelated to the submitted work). Dr. Thompson has received a research grant from Biogen, Inc., unrelated to the topic of this paper.\n",
      "\n",
      "Conflict of Interest Dr. Paul D. Arnold reported holding the Alberta Innovates Translational Health Chair in Child and Youth Mental Health outside the submitted work. Prof. Mataix-Cols receives royalties for contributing articles to UpToDate, Wolters Kluwer Health and fees from Elsevier for editorial tasks (all unrelated to the submitted work). Dr. Narayanaswamy reported Government of India grants DST INSPIRE faculty grant IFA12-LSrinivas BalachanderM-26 and BT/06/IYBA/2012 outside the submitted work. Dr. Reddy reported Government of India grants SR/S0/HS/0016/2011 and BT/PR13334/Med/30/259/2009 outside the submitted work. Dr. Venkatasubramanian reported Wellcome-DBT India Alliance grant 500236/Z/11/Z outside the submitted work. Dr. Simpson reported Biohaven Research support for a clinical trial and royalties from UpToDate, Inc. and Cambridge University Press outside the submitted work. Dr. Soreni reported support from Lundbeck-Iliyan IvanovT outside the submitted work. Dr. Walitza has received in the last 3years royalties from Thieme Hogrefe, Kohlhammer, Springer, Beltz; Her work was supported in the last 3years by the Swiss National Science Foundation (SNF), diff. EU FP7s, HSM Hochspezialisierte Medizin of the Kanton Zurich, Switzerland, Bfarm Germany, ZInEP, Hartmann Muller Stiftung, Olga Mayenfisch, Gertrud Thalmann Fonds (all unrelated to the submitted work). Dr. Thompson has received a research grant from Biogen, Inc., unrelated to the topic of this paper.\n",
      "\n",
      "Conflict of Interest Dr. Paul D. Arnold reported holding the Alberta Innovates Translational Health Chair in Child and Youth Mental Health outside the submitted work. Prof. Mataix-Cols receives royalties for contributing articles to UpToDate, Wolters Kluwer Health and fees from Elsevier for editorial tasks (all unrelated to the submitted work). Dr. Narayanaswamy reported Government of India grants DST INSPIRE faculty grant IFA12-LSrinivas BalachanderM-26 and BT/06/IYBA/2012 outside the submitted work. Dr. Reddy reported Government of India grants SR/S0/HS/0016/2011 and BT/PR13334/Med/30/259/2009 outside the submitted work. Dr. Venkatasubramanian reported Wellcome-DBT India Alliance grant 500236/Z/11/Z outside the submitted work. Dr. Simpson reported Biohaven Research support for a clinical trial and royalties from UpToDate, Inc. and Cambridge University Press outside the submitted work. Dr. Soreni reported support from Lundbeck-Iliyan IvanovT outside the submitted work. Dr. Walitza has received in the last 3years royalties from Thieme Hogrefe, Kohlhammer, Springer, Beltz; Her work was supported in the last 3years by the Swiss National Science Foundation (SNF), diff. EU FP7s, HSM Hochspezialisierte Medizin of the Kanton Zurich, Switzerland, Bfarm Germany, ZInEP, Hartmann Muller Stiftung, Olga Mayenfisch, Gertrud Thalmann Fonds (all unrelated to the submitted work). Dr. Thompson has received a research grant from Biogen, Inc., unrelated to the topic of this paper.\n",
      "\n",
      "Conflict of Interest Dr. Paul D. Arnold reported holding the Alberta Innovates Translational Health Chair in Child and Youth Mental Health outside the submitted work. Prof. Mataix-Cols receives royalties for contributing articles to UpToDate, Wolters Kluwer Health and fees from Elsevier for editorial tasks (all unrelated to the submitted work). Dr. Narayanaswamy reported Government of India grants DST INSPIRE faculty grant IFA12-LSrinivas BalachanderM-26 and BT/06/IYBA/2012 outside the submitted work. Dr. Reddy reported Government of India grants SR/S0/HS/0016/2011 and BT/PR13334/Med/30/259/2009 outside the submitted work. Dr. Venkatasubramanian reported Wellcome-DBT India Alliance grant 500236/Z/11/Z outside the submitted work. Dr. Simpson reported Biohaven Research support for a clinical trial and royalties from UpToDate, Inc. and Cambridge University Press outside the submitted work. Dr. Soreni reported support from Lundbeck-Iliyan IvanovT outside the submitted work. Dr. Walitza has received in the last 3years royalties from Thieme Hogrefe, Kohlhammer, Springer, Beltz; Her work was supported in the last 3years by the Swiss National Science Foundation (SNF), diff. EU FP7s, HSM Hochspezialisierte Medizin of the Kanton Zurich, Switzerland, Bfarm Germany, ZInEP, Hartmann Muller Stiftung, Olga Mayenfisch, Gertrud Thalmann Fonds (all unrelated to the submitted work). Dr. Thompson has received a research grant from Biogen, Inc., unrelated to the topic of this paper.\n",
      "\n",
      "Mataix-Cols, David\n",
      "Conflict of Interest Dr. Paul D. Arnold reported holding the Alberta Innovates Translational Health Chair in Child and Youth Mental Health outside the submitted work. Prof. David Mataix-Cols receives royalties for contributing articles to UpToDate, Wolters Kluwer Health and fees from Elsevier for editorial tasks (all unrelated to the submitted work). Dr. Narayanaswamy reported Government of India grants DST INSPIRE faculty grant IFA12-LSrinivas BalachanderM-26 and BT/06/IYBA/2012 outside the submitted work. Dr. Reddy reported Government of India grants SR/S0/HS/0016/2011 and BT/PR13334/Med/30/259/2009 outside the submitted work. Dr. Venkatasubramanian reported Wellcome-DBT India Alliance grant 500236/Z/11/Z outside the submitted work. Dr. Simpson reported Biohaven Research support for a clinical trial and royalties from UpToDate, Inc. and Cambridge University Press outside the submitted work. Dr. Soreni reported support from Lundbeck-Iliyan IvanovT outside the submitted work. Dr. Walitza has received in the last 3years royalties from Thieme Hogrefe, Kohlhammer, Springer, Beltz; Her work was supported in the last 3years by the Swiss National Science Foundation (SNF), diff. EU FP7s, HSM Hochspezialisierte Medizin of the Kanton Zurich, Switzerland, Bfarm Germany, ZInEP, Hartmann Muller Stiftung, Olga Mayenfisch, Gertrud Thalmann Fonds (all unrelated to the submitted work). Dr. Thompson has received a research grant from Biogen, Inc., unrelated to the topic of this paper.\n",
      "\n",
      "Conflict of Interest Dr. Paul D. Arnold reported holding the Alberta Innovates Translational Health Chair in Child and Youth Mental Health outside the submitted work. Prof. David Mataix-Cols receives royalties for contributing articles to UpToDate, Wolters Kluwer Health and fees from Elsevier for editorial tasks (all unrelated to the submitted work). Dr. Narayanaswamy reported Government of India grants DST INSPIRE faculty grant IFA12-LSrinivas BalachanderM-26 and BT/06/IYBA/2012 outside the submitted work. Dr. Reddy reported Government of India grants SR/S0/HS/0016/2011 and BT/PR13334/Med/30/259/2009 outside the submitted work. Dr. Venkatasubramanian reported Wellcome-DBT India Alliance grant 500236/Z/11/Z outside the submitted work. Dr. Simpson reported Biohaven Research support for a clinical trial and royalties from UpToDate, Inc. and Cambridge University Press outside the submitted work. Dr. Soreni reported support from Lundbeck-Iliyan IvanovT outside the submitted work. Dr. Walitza has received in the last 3years royalties from Thieme Hogrefe, Kohlhammer, Springer, Beltz; Her work was supported in the last 3years by the Swiss National Science Foundation (SNF), diff. EU FP7s, HSM Hochspezialisierte Medizin of the Kanton Zurich, Switzerland, Bfarm Germany, ZInEP, Hartmann Muller Stiftung, Olga Mayenfisch, Gertrud Thalmann Fonds (all unrelated to the submitted work). Dr. Thompson has received a research grant from Biogen, Inc., unrelated to the topic of this paper.\n",
      "\n",
      "Conflict of Interest Dr. Paul D. Arnold reported holding the Alberta Innovates Translational Health Chair in Child and Youth Mental Health outside the submitted work. Prof. David Mataix-Cols receives royalties for contributing articles to UpToDate, Wolters Kluwer Health and fees from Elsevier for editorial tasks (all unrelated to the submitted work). Dr. Narayanaswamy reported Government of India grants DST INSPIRE faculty grant IFA12-LSrinivas BalachanderM-26 and BT/06/IYBA/2012 outside the submitted work. Dr. Reddy reported Government of India grants SR/S0/HS/0016/2011 and BT/PR13334/Med/30/259/2009 outside the submitted work. Dr. Venkatasubramanian reported Wellcome-DBT India Alliance grant 500236/Z/11/Z outside the submitted work. Dr. Simpson reported Biohaven Research support for a clinical trial and royalties from UpToDate, Inc. and Cambridge University Press outside the submitted work. Dr. Soreni reported support from Lundbeck-Iliyan IvanovT outside the submitted work. Dr. Walitza has received in the last 3years royalties from Thieme Hogrefe, Kohlhammer, Springer, Beltz; Her work was supported in the last 3years by the Swiss National Science Foundation (SNF), diff. EU FP7s, HSM Hochspezialisierte Medizin of the Kanton Zurich, Switzerland, Bfarm Germany, ZInEP, Hartmann Muller Stiftung, Olga Mayenfisch, Gertrud Thalmann Fonds (all unrelated to the submitted work). Dr. Thompson has received a research grant from Biogen, Inc., unrelated to the topic of this paper.\n",
      "\n",
      "Conflict of Interest Dr. Paul D. Arnold reported holding the Alberta Innovates Translational Health Chair in Child and Youth Mental Health outside the submitted work. Prof. David Mataix-Cols receives royalties for contributing articles to UpToDate, Wolters Kluwer Health and fees from Elsevier for editorial tasks (all unrelated to the submitted work). Dr. Narayanaswamy reported Government of India grants DST INSPIRE faculty grant IFA12-LSrinivas BalachanderM-26 and BT/06/IYBA/2012 outside the submitted work. Dr. Reddy reported Government of India grants SR/S0/HS/0016/2011 and BT/PR13334/Med/30/259/2009 outside the submitted work. Dr. Venkatasubramanian reported Wellcome-DBT India Alliance grant 500236/Z/11/Z outside the submitted work. Dr. Simpson reported Biohaven Research support for a clinical trial and royalties from UpToDate, Inc. and Cambridge University Press outside the submitted work. Dr. Soreni reported support from Lundbeck-Iliyan IvanovT outside the submitted work. Dr. Walitza has received in the last 3years royalties from Thieme Hogrefe, Kohlhammer, Springer, Beltz; Her work was supported in the last 3years by the Swiss National Science Foundation (SNF), diff. EU FP7s, HSM Hochspezialisierte Medizin of the Kanton Zurich, Switzerland, Bfarm Germany, ZInEP, Hartmann Muller Stiftung, Olga Mayenfisch, Gertrud Thalmann Fonds (all unrelated to the submitted work). Dr. Thompson has received a research grant from Biogen, Inc., unrelated to the topic of this paper.\n",
      "\n",
      "Conflict of Interest Dr. Paul D. Arnold reported holding the Alberta Innovates Translational Health Chair in Child and Youth Mental Health outside the submitted work. Prof. David Mataix-Cols receives royalties for contributing articles to UpToDate, Wolters Kluwer Health and fees from Elsevier for editorial tasks (all unrelated to the submitted work). Dr. Narayanaswamy reported Government of India grants DST INSPIRE faculty grant IFA12-LSrinivas BalachanderM-26 and BT/06/IYBA/2012 outside the submitted work. Dr. Reddy reported Government of India grants SR/S0/HS/0016/2011 and BT/PR13334/Med/30/259/2009 outside the submitted work. Dr. Venkatasubramanian reported Wellcome-DBT India Alliance grant 500236/Z/11/Z outside the submitted work. Dr. Simpson reported Biohaven Research support for a clinical trial and royalties from UpToDate, Inc. and Cambridge University Press outside the submitted work. Dr. Soreni reported support from Lundbeck-Iliyan IvanovT outside the submitted work. Dr. Walitza has received in the last 3years royalties from Thieme Hogrefe, Kohlhammer, Springer, Beltz; Her work was supported in the last 3years by the Swiss National Science Foundation (SNF), diff. EU FP7s, HSM Hochspezialisierte Medizin of the Kanton Zurich, Switzerland, Bfarm Germany, ZInEP, Hartmann Muller Stiftung, Olga Mayenfisch, Gertrud Thalmann Fonds (all unrelated to the submitted work). Dr. Thompson has received a research grant from Biogen, Inc., unrelated to the topic of this paper.\n",
      "\n",
      "Conflict of Interest Dr. Paul D. Arnold reported holding the Alberta Innovates Translational Health Chair in Child and Youth Mental Health outside the submitted work. Prof. David Mataix-Cols receives royalties for contributing articles to UpToDate, Wolters Kluwer Health and fees from Elsevier for editorial tasks (all unrelated to the submitted work). Dr. Narayanaswamy reported Government of India grants DST INSPIRE faculty grant IFA12-LSrinivas BalachanderM-26 and BT/06/IYBA/2012 outside the submitted work. Dr. Reddy reported Government of India grants SR/S0/HS/0016/2011 and BT/PR13334/Med/30/259/2009 outside the submitted work. Dr. Venkatasubramanian reported Wellcome-DBT India Alliance grant 500236/Z/11/Z outside the submitted work. Dr. Simpson reported Biohaven Research support for a clinical trial and royalties from UpToDate, Inc. and Cambridge University Press outside the submitted work. Dr. Soreni reported support from Lundbeck-Iliyan IvanovT outside the submitted work. Dr. Walitza has received in the last 3years royalties from Thieme Hogrefe, Kohlhammer, Springer, Beltz; Her work was supported in the last 3years by the Swiss National Science Foundation (SNF), diff. EU FP7s, HSM Hochspezialisierte Medizin of the Kanton Zurich, Switzerland, Bfarm Germany, ZInEP, Hartmann Muller Stiftung, Olga Mayenfisch, Gertrud Thalmann Fonds (all unrelated to the submitted work). Dr. Thompson has received a research grant from Biogen, Inc., unrelated to the topic of this paper.\n",
      "\n",
      "Conflict of Interest Dr. Paul D. Arnold reported holding the Alberta Innovates Translational Health Chair in Child and Youth Mental Health outside the submitted work. Prof. David Mataix-Cols receives royalties for contributing articles to UpToDate, Wolters Kluwer Health and fees from Elsevier for editorial tasks (all unrelated to the submitted work). Dr. Narayanaswamy reported Government of India grants DST INSPIRE faculty grant IFA12-LSrinivas BalachanderM-26 and BT/06/IYBA/2012 outside the submitted work. Dr. Reddy reported Government of India grants SR/S0/HS/0016/2011 and BT/PR13334/Med/30/259/2009 outside the submitted work. Dr. Venkatasubramanian reported Wellcome-DBT India Alliance grant 500236/Z/11/Z outside the submitted work. Dr. Simpson reported Biohaven Research support for a clinical trial and royalties from UpToDate, Inc. and Cambridge University Press outside the submitted work. Dr. Soreni reported support from Lundbeck-Iliyan IvanovT outside the submitted work. Dr. Walitza has received in the last 3years royalties from Thieme Hogrefe, Kohlhammer, Springer, Beltz; Her work was supported in the last 3years by the Swiss National Science Foundation (SNF), diff. EU FP7s, HSM Hochspezialisierte Medizin of the Kanton Zurich, Switzerland, Bfarm Germany, ZInEP, Hartmann Muller Stiftung, Olga Mayenfisch, Gertrud Thalmann Fonds (all unrelated to the submitted work). Dr. Thompson has received a research grant from Biogen, Inc., unrelated to the topic of this paper.\n",
      "\n",
      "Conflict of Interest Dr. Paul D. Arnold reported holding the Alberta Innovates Translational Health Chair in Child and Youth Mental Health outside the submitted work. Prof. David Mataix-Cols receives royalties for contributing articles to UpToDate, Wolters Kluwer Health and fees from Elsevier for editorial tasks (all unrelated to the submitted work). Dr. Narayanaswamy reported Government of India grants DST INSPIRE faculty grant IFA12-LSrinivas BalachanderM-26 and BT/06/IYBA/2012 outside the submitted work. Dr. Reddy reported Government of India grants SR/S0/HS/0016/2011 and BT/PR13334/Med/30/259/2009 outside the submitted work. Dr. Venkatasubramanian reported Wellcome-DBT India Alliance grant 500236/Z/11/Z outside the submitted work. Dr. Simpson reported Biohaven Research support for a clinical trial and royalties from UpToDate, Inc. and Cambridge University Press outside the submitted work. Dr. Soreni reported support from Lundbeck-Iliyan IvanovT outside the submitted work. Dr. Walitza has received in the last 3years royalties from Thieme Hogrefe, Kohlhammer, Springer, Beltz; Her work was supported in the last 3years by the Swiss National Science Foundation (SNF), diff. EU FP7s, HSM Hochspezialisierte Medizin of the Kanton Zurich, Switzerland, Bfarm Germany, ZInEP, Hartmann Muller Stiftung, Olga Mayenfisch, Gertrud Thalmann Fonds (all unrelated to the submitted work). Dr. Thompson has received a research grant from Biogen, Inc., unrelated to the topic of this paper.\n",
      "\n",
      "Narayanaswamy, Janardhanan C.\n",
      "Conflict of Interest Dr. Paul D. Arnold reported holding the Alberta Innovates Translational Health Chair in Child and Youth Mental Health outside the submitted work. Prof. David Mataix-Cols receives royalties for contributing articles to UpToDate, Wolters Kluwer Health and fees from Elsevier for editorial tasks (all unrelated to the submitted work). Dr. Janardhanan C. Narayanaswamy reported Government of India grants DST INSPIRE faculty grant IFA12-LSrinivas BalachanderM-26 and BT/06/IYBA/2012 outside the submitted work. Dr. Reddy reported Government of India grants SR/S0/HS/0016/2011 and BT/PR13334/Med/30/259/2009 outside the submitted work. Dr. Venkatasubramanian reported Wellcome-DBT India Alliance grant 500236/Z/11/Z outside the submitted work. Dr. Simpson reported Biohaven Research support for a clinical trial and royalties from UpToDate, Inc. and Cambridge University Press outside the submitted work. Dr. Soreni reported support from Lundbeck-Iliyan IvanovT outside the submitted work. Dr. Walitza has received in the last 3years royalties from Thieme Hogrefe, Kohlhammer, Springer, Beltz; Her work was supported in the last 3years by the Swiss National Science Foundation (SNF), diff. EU FP7s, HSM Hochspezialisierte Medizin of the Kanton Zurich, Switzerland, Bfarm Germany, ZInEP, Hartmann Muller Stiftung, Olga Mayenfisch, Gertrud Thalmann Fonds (all unrelated to the submitted work). Dr. Thompson has received a research grant from Biogen, Inc., unrelated to the topic of this paper.\n",
      "\n",
      "Conflict of Interest Dr. Paul D. Arnold reported holding the Alberta Innovates Translational Health Chair in Child and Youth Mental Health outside the submitted work. Prof. David Mataix-Cols receives royalties for contributing articles to UpToDate, Wolters Kluwer Health and fees from Elsevier for editorial tasks (all unrelated to the submitted work). Dr. Janardhanan C. Narayanaswamy reported Government of India grants DST INSPIRE faculty grant IFA12-LSrinivas BalachanderM-26 and BT/06/IYBA/2012 outside the submitted work. Dr. Reddy reported Government of India grants SR/S0/HS/0016/2011 and BT/PR13334/Med/30/259/2009 outside the submitted work. Dr. Venkatasubramanian reported Wellcome-DBT India Alliance grant 500236/Z/11/Z outside the submitted work. Dr. Simpson reported Biohaven Research support for a clinical trial and royalties from UpToDate, Inc. and Cambridge University Press outside the submitted work. Dr. Soreni reported support from Lundbeck-Iliyan IvanovT outside the submitted work. Dr. Walitza has received in the last 3years royalties from Thieme Hogrefe, Kohlhammer, Springer, Beltz; Her work was supported in the last 3years by the Swiss National Science Foundation (SNF), diff. EU FP7s, HSM Hochspezialisierte Medizin of the Kanton Zurich, Switzerland, Bfarm Germany, ZInEP, Hartmann Muller Stiftung, Olga Mayenfisch, Gertrud Thalmann Fonds (all unrelated to the submitted work). Dr. Thompson has received a research grant from Biogen, Inc., unrelated to the topic of this paper.\n",
      "\n",
      "Conflict of Interest Dr. Paul D. Arnold reported holding the Alberta Innovates Translational Health Chair in Child and Youth Mental Health outside the submitted work. Prof. David Mataix-Cols receives royalties for contributing articles to UpToDate, Wolters Kluwer Health and fees from Elsevier for editorial tasks (all unrelated to the submitted work). Dr. Janardhanan C. Narayanaswamy reported Government of India grants DST INSPIRE faculty grant IFA12-LSrinivas BalachanderM-26 and BT/06/IYBA/2012 outside the submitted work. Dr. Reddy reported Government of India grants SR/S0/HS/0016/2011 and BT/PR13334/Med/30/259/2009 outside the submitted work. Dr. Venkatasubramanian reported Wellcome-DBT India Alliance grant 500236/Z/11/Z outside the submitted work. Dr. Simpson reported Biohaven Research support for a clinical trial and royalties from UpToDate, Inc. and Cambridge University Press outside the submitted work. Dr. Soreni reported support from Lundbeck-Iliyan IvanovT outside the submitted work. Dr. Walitza has received in the last 3years royalties from Thieme Hogrefe, Kohlhammer, Springer, Beltz; Her work was supported in the last 3years by the Swiss National Science Foundation (SNF), diff. EU FP7s, HSM Hochspezialisierte Medizin of the Kanton Zurich, Switzerland, Bfarm Germany, ZInEP, Hartmann Muller Stiftung, Olga Mayenfisch, Gertrud Thalmann Fonds (all unrelated to the submitted work). Dr. Thompson has received a research grant from Biogen, Inc., unrelated to the topic of this paper.\n",
      "\n",
      "Conflict of Interest Dr. Paul D. Arnold reported holding the Alberta Innovates Translational Health Chair in Child and Youth Mental Health outside the submitted work. Prof. David Mataix-Cols receives royalties for contributing articles to UpToDate, Wolters Kluwer Health and fees from Elsevier for editorial tasks (all unrelated to the submitted work). Dr. Janardhanan C. Narayanaswamy reported Government of India grants DST INSPIRE faculty grant IFA12-LSrinivas BalachanderM-26 and BT/06/IYBA/2012 outside the submitted work. Dr. Reddy reported Government of India grants SR/S0/HS/0016/2011 and BT/PR13334/Med/30/259/2009 outside the submitted work. Dr. Venkatasubramanian reported Wellcome-DBT India Alliance grant 500236/Z/11/Z outside the submitted work. Dr. Simpson reported Biohaven Research support for a clinical trial and royalties from UpToDate, Inc. and Cambridge University Press outside the submitted work. Dr. Soreni reported support from Lundbeck-Iliyan IvanovT outside the submitted work. Dr. Walitza has received in the last 3years royalties from Thieme Hogrefe, Kohlhammer, Springer, Beltz; Her work was supported in the last 3years by the Swiss National Science Foundation (SNF), diff. EU FP7s, HSM Hochspezialisierte Medizin of the Kanton Zurich, Switzerland, Bfarm Germany, ZInEP, Hartmann Muller Stiftung, Olga Mayenfisch, Gertrud Thalmann Fonds (all unrelated to the submitted work). Dr. Thompson has received a research grant from Biogen, Inc., unrelated to the topic of this paper.\n",
      "\n",
      "Conflict of Interest Dr. Paul D. Arnold reported holding the Alberta Innovates Translational Health Chair in Child and Youth Mental Health outside the submitted work. Prof. David Mataix-Cols receives royalties for contributing articles to UpToDate, Wolters Kluwer Health and fees from Elsevier for editorial tasks (all unrelated to the submitted work). Dr. Janardhanan C. Narayanaswamy reported Government of India grants DST INSPIRE faculty grant IFA12-LSrinivas BalachanderM-26 and BT/06/IYBA/2012 outside the submitted work. Dr. Reddy reported Government of India grants SR/S0/HS/0016/2011 and BT/PR13334/Med/30/259/2009 outside the submitted work. Dr. Venkatasubramanian reported Wellcome-DBT India Alliance grant 500236/Z/11/Z outside the submitted work. Dr. Simpson reported Biohaven Research support for a clinical trial and royalties from UpToDate, Inc. and Cambridge University Press outside the submitted work. Dr. Soreni reported support from Lundbeck-Iliyan IvanovT outside the submitted work. Dr. Walitza has received in the last 3years royalties from Thieme Hogrefe, Kohlhammer, Springer, Beltz; Her work was supported in the last 3years by the Swiss National Science Foundation (SNF), diff. EU FP7s, HSM Hochspezialisierte Medizin of the Kanton Zurich, Switzerland, Bfarm Germany, ZInEP, Hartmann Muller Stiftung, Olga Mayenfisch, Gertrud Thalmann Fonds (all unrelated to the submitted work). Dr. Thompson has received a research grant from Biogen, Inc., unrelated to the topic of this paper.\n",
      "\n",
      "Conflict of Interest Dr. Paul D. Arnold reported holding the Alberta Innovates Translational Health Chair in Child and Youth Mental Health outside the submitted work. Prof. David Mataix-Cols receives royalties for contributing articles to UpToDate, Wolters Kluwer Health and fees from Elsevier for editorial tasks (all unrelated to the submitted work). Dr. Janardhanan C. Narayanaswamy reported Government of India grants DST INSPIRE faculty grant IFA12-LSrinivas BalachanderM-26 and BT/06/IYBA/2012 outside the submitted work. Dr. Reddy reported Government of India grants SR/S0/HS/0016/2011 and BT/PR13334/Med/30/259/2009 outside the submitted work. Dr. Venkatasubramanian reported Wellcome-DBT India Alliance grant 500236/Z/11/Z outside the submitted work. Dr. Simpson reported Biohaven Research support for a clinical trial and royalties from UpToDate, Inc. and Cambridge University Press outside the submitted work. Dr. Soreni reported support from Lundbeck-Iliyan IvanovT outside the submitted work. Dr. Walitza has received in the last 3years royalties from Thieme Hogrefe, Kohlhammer, Springer, Beltz; Her work was supported in the last 3years by the Swiss National Science Foundation (SNF), diff. EU FP7s, HSM Hochspezialisierte Medizin of the Kanton Zurich, Switzerland, Bfarm Germany, ZInEP, Hartmann Muller Stiftung, Olga Mayenfisch, Gertrud Thalmann Fonds (all unrelated to the submitted work). Dr. Thompson has received a research grant from Biogen, Inc., unrelated to the topic of this paper.\n",
      "\n",
      "Piras, Fabrizio\n",
      "Conflict of Interest Dr. Paul D. Arnold reported holding the Alberta Innovates Translational Health Chair in Child and Youth Mental Health outside the submitted work. Prof. David Mataix-Cols receives royalties for contributing articles to UpToDate, Wolters Kluwer Health and fees from Elsevier for editorial tasks (all unrelated to the submitted work). Dr. Janardhanan C. Narayanaswamy reported Government of India grants DST INSPIRE faculty grant IFA12-LSrinivas BalachanderM-26 and BT/06/IYBA/2012 outside the submitted work. Dr. Reddy reported Government of India grants SR/S0/HS/0016/2011 and BT/PR13334/Med/30/259/2009 outside the submitted work. Dr. Venkatasubramanian reported Wellcome-DBT India Alliance grant 500236/Z/11/Z outside the submitted work. Dr. Simpson reported Biohaven Research support for a clinical trial and royalties from UpToDate, Inc. and Cambridge University Press outside the submitted work. Dr. Soreni reported support from Lundbeck-Iliyan IvanovT outside the submitted work. Dr. Walitza has received in the last 3years royalties from Thieme Hogrefe, Kohlhammer, Springer, Beltz; Her work was supported in the last 3years by the Swiss National Science Foundation (SNF), diff. EU Fabrizio Piras7s, HSM Hochspezialisierte Medizin of the Kanton Zurich, Switzerland, Bfarm Germany, ZInEP, Hartmann Muller Stiftung, Olga Mayenfisch, Gertrud Thalmann Fonds (all unrelated to the submitted work). Dr. Thompson has received a research grant from Biogen, Inc., unrelated to the topic of this paper.\n",
      "\n",
      "Piras, Federica\n",
      "Conflict of Interest Dr. Paul D. Arnold reported holding the Alberta Innovates Translational Health Chair in Child and Youth Mental Health outside the submitted work. Prof. David Mataix-Cols receives royalties for contributing articles to UpToDate, Wolters Kluwer Health and fees from Elsevier for editorial tasks (all unrelated to the submitted work). Dr. Janardhanan C. Narayanaswamy reported Government of India grants DST INSPIRE faculty grant IFA12-LSrinivas BalachanderM-26 and BT/06/IYBA/2012 outside the submitted work. Dr. Reddy reported Government of India grants SR/S0/HS/0016/2011 and BT/PR13334/Med/30/259/2009 outside the submitted work. Dr. Venkatasubramanian reported Wellcome-DBT India Alliance grant 500236/Z/11/Z outside the submitted work. Dr. Simpson reported Biohaven Research support for a clinical trial and royalties from UpToDate, Inc. and Cambridge University Press outside the submitted work. Dr. Soreni reported support from Lundbeck-Iliyan IvanovT outside the submitted work. Dr. Walitza has received in the last 3years royalties from Thieme Hogrefe, Kohlhammer, Springer, Beltz; Her work was supported in the last 3years by the Swiss National Science Foundation (SNF), diff. EU Fabrizio Federica Piras7s, HSM Hochspezialisierte Medizin of the Kanton Zurich, Switzerland, Bfarm Germany, ZInEP, Hartmann Muller Stiftung, Olga Mayenfisch, Gertrud Thalmann Fonds (all unrelated to the submitted work). Dr. Thompson has received a research grant from Biogen, Inc., unrelated to the topic of this paper.\n",
      "\n",
      "C Janardhan Reddy, Y.\n",
      "Conflict of Interest Dr. Paul D. Arnold reported holding the Alberta Innovates Translational Health Chair in Child and Youth Mental Health outside the submitted work. Prof. David Mataix-Cols receives royalties for contributing articles to UpToDate, Wolters Kluwer Health and fees from Elsevier for editorial tasks (all unrelated to the submitted work). Dr. Janardhanan C. Narayanaswamy reported Government of India grants DST INSPIRE faculty grant IFA12-LSrinivas BalachanderM-26 and BT/06/IYBA/2012 outside the submitted work. Dr. Y. C Janardhan Reddy reported Government of India grants SR/S0/HS/0016/2011 and BT/PR13334/Med/30/259/2009 outside the submitted work. Dr. Venkatasubramanian reported Wellcome-DBT India Alliance grant 500236/Z/11/Z outside the submitted work. Dr. Simpson reported Biohaven Research support for a clinical trial and royalties from UpToDate, Inc. and Cambridge University Press outside the submitted work. Dr. Soreni reported support from Lundbeck-Iliyan IvanovT outside the submitted work. Dr. Walitza has received in the last 3years royalties from Thieme Hogrefe, Kohlhammer, Springer, Beltz; Her work was supported in the last 3years by the Swiss National Science Foundation (SNF), diff. EU Fabrizio Federica Piras7s, HSM Hochspezialisierte Medizin of the Kanton Zurich, Switzerland, Bfarm Germany, ZInEP, Hartmann Muller Stiftung, Olga Mayenfisch, Gertrud Thalmann Fonds (all unrelated to the submitted work). Dr. Thompson has received a research grant from Biogen, Inc., unrelated to the topic of this paper.\n",
      "\n",
      "Conflict of Interest Dr. Paul D. Arnold reported holding the Alberta Innovates Translational Health Chair in Child and Youth Mental Health outside the submitted work. Prof. David Mataix-Cols receives royalties for contributing articles to UpToDate, Wolters Kluwer Health and fees from Elsevier for editorial tasks (all unrelated to the submitted work). Dr. Janardhanan C. Narayanaswamy reported Government of India grants DST INSPIRE faculty grant IFA12-LSrinivas BalachanderM-26 and BT/06/IYBA/2012 outside the submitted work. Dr. Y. C Janardhan Reddy reported Government of India grants SR/S0/HS/0016/2011 and BT/PR13334/Med/30/259/2009 outside the submitted work. Dr. Venkatasubramanian reported Wellcome-DBT India Alliance grant 500236/Z/11/Z outside the submitted work. Dr. Simpson reported Biohaven Research support for a clinical trial and royalties from UpToDate, Inc. and Cambridge University Press outside the submitted work. Dr. Soreni reported support from Lundbeck-Iliyan IvanovT outside the submitted work. Dr. Walitza has received in the last 3years royalties from Thieme Hogrefe, Kohlhammer, Springer, Beltz; Her work was supported in the last 3years by the Swiss National Science Foundation (SNF), diff. EU Fabrizio Federica Piras7s, HSM Hochspezialisierte Medizin of the Kanton Zurich, Switzerland, Bfarm Germany, ZInEP, Hartmann Muller Stiftung, Olga Mayenfisch, Gertrud Thalmann Fonds (all unrelated to the submitted work). Dr. Thompson has received a research grant from Biogen, Inc., unrelated to the topic of this paper.\n",
      "\n",
      "Conflict of Interest Dr. Paul D. Arnold reported holding the Alberta Innovates Translational Health Chair in Child and Youth Mental Health outside the submitted work. Prof. David Mataix-Cols receives royalties for contributing articles to UpToDate, Wolters Kluwer Health and fees from Elsevier for editorial tasks (all unrelated to the submitted work). Dr. Janardhanan C. Narayanaswamy reported Government of India grants DST INSPIRE faculty grant IFA12-LSrinivas BalachanderM-26 and BT/06/IYBA/2012 outside the submitted work. Dr. Y. C Janardhan Reddy reported Government of India grants SR/S0/HS/0016/2011 and BT/PR13334/Med/30/259/2009 outside the submitted work. Dr. Venkatasubramanian reported Wellcome-DBT India Alliance grant 500236/Z/11/Z outside the submitted work. Dr. Simpson reported Biohaven Research support for a clinical trial and royalties from UpToDate, Inc. and Cambridge University Press outside the submitted work. Dr. Soreni reported support from Lundbeck-Iliyan IvanovT outside the submitted work. Dr. Walitza has received in the last 3years royalties from Thieme Hogrefe, Kohlhammer, Springer, Beltz; Her work was supported in the last 3years by the Swiss National Science Foundation (SNF), diff. EU Fabrizio Federica Piras7s, HSM Hochspezialisierte Medizin of the Kanton Zurich, Switzerland, Bfarm Germany, ZInEP, Hartmann Muller Stiftung, Olga Mayenfisch, Gertrud Thalmann Fonds (all unrelated to the submitted work). Dr. Thompson has received a research grant from Biogen, Inc., unrelated to the topic of this paper.\n",
      "\n",
      "Conflict of Interest Dr. Paul D. Arnold reported holding the Alberta Innovates Translational Health Chair in Child and Youth Mental Health outside the submitted work. Prof. David Mataix-Cols receives royalties for contributing articles to UpToDate, Wolters Kluwer Health and fees from Elsevier for editorial tasks (all unrelated to the submitted work). Dr. Janardhanan C. Narayanaswamy reported Government of India grants DST INSPIRE faculty grant IFA12-LSrinivas BalachanderM-26 and BT/06/IYBA/2012 outside the submitted work. Dr. Y. C Janardhan Reddy reported Government of India grants SR/S0/HS/0016/2011 and BT/PR13334/Med/30/259/2009 outside the submitted work. Dr. Venkatasubramanian reported Wellcome-DBT India Alliance grant 500236/Z/11/Z outside the submitted work. Dr. Simpson reported Biohaven Research support for a clinical trial and royalties from UpToDate, Inc. and Cambridge University Press outside the submitted work. Dr. Soreni reported support from Lundbeck-Iliyan IvanovT outside the submitted work. Dr. Walitza has received in the last 3years royalties from Thieme Hogrefe, Kohlhammer, Springer, Beltz; Her work was supported in the last 3years by the Swiss National Science Foundation (SNF), diff. EU Fabrizio Federica Piras7s, HSM Hochspezialisierte Medizin of the Kanton Zurich, Switzerland, Bfarm Germany, ZInEP, Hartmann Muller Stiftung, Olga Mayenfisch, Gertrud Thalmann Fonds (all unrelated to the submitted work). Dr. Thompson has received a research grant from Biogen, Inc., unrelated to the topic of this paper.\n",
      "\n",
      "Blair Simpson, H.\n",
      "Conflict of Interest Dr. Paul D. Arnold reported holding the Alberta Innovates Translational Health Chair in Child and Youth Mental Health outside the submitted work. Prof. David Mataix-Cols receives royalties for contributing articles to UpToDate, Wolters Kluwer Health and fees from Elsevier for editorial tasks (all unrelated to the submitted work). Dr. Janardhanan C. Narayanaswamy reported Government of India grants DST INSPIRE faculty grant IFA12-LSrinivas BalachanderM-26 and BT/06/IYBA/2012 outside the submitted work. Dr. Y. C Janardhan Reddy reported Government of India grants SR/S0/HS/0016/2011 and BT/PR13334/Med/30/259/2009 outside the submitted work. Dr. Venkatasubramanian reported Wellcome-DBT India Alliance grant 500236/Z/11/Z outside the submitted work. Dr. H. Blair Simpson reported Biohaven Research support for a clinical trial and royalties from UpToDate, Inc. and Cambridge University Press outside the submitted work. Dr. Soreni reported support from Lundbeck-Iliyan IvanovT outside the submitted work. Dr. Walitza has received in the last 3years royalties from Thieme Hogrefe, Kohlhammer, Springer, Beltz; Her work was supported in the last 3years by the Swiss National Science Foundation (SNF), diff. EU Fabrizio Federica Piras7s, HSM Hochspezialisierte Medizin of the Kanton Zurich, Switzerland, Bfarm Germany, ZInEP, Hartmann Muller Stiftung, Olga Mayenfisch, Gertrud Thalmann Fonds (all unrelated to the submitted work). Dr. Thompson has received a research grant from Biogen, Inc., unrelated to the topic of this paper.\n",
      "\n",
      "Soreni, Noam\n",
      "Conflict of Interest Dr. Paul D. Arnold reported holding the Alberta Innovates Translational Health Chair in Child and Youth Mental Health outside the submitted work. Prof. David Mataix-Cols receives royalties for contributing articles to UpToDate, Wolters Kluwer Health and fees from Elsevier for editorial tasks (all unrelated to the submitted work). Dr. Janardhanan C. Narayanaswamy reported Government of India grants DST INSPIRE faculty grant IFA12-LSrinivas BalachanderM-26 and BT/06/IYBA/2012 outside the submitted work. Dr. Y. C Janardhan Reddy reported Government of India grants SR/S0/HS/0016/2011 and BT/PR13334/Med/30/259/2009 outside the submitted work. Dr. Venkatasubramanian reported Wellcome-DBT India Alliance grant 500236/Z/11/Z outside the submitted work. Dr. H. Blair Simpson reported Biohaven Research support for a clinical trial and royalties from UpToDate, Inc. and Cambridge University Press outside the submitted work. Dr. Noam Soreni reported support from Lundbeck-Iliyan IvanovT outside the submitted work. Dr. Walitza has received in the last 3years royalties from Thieme Hogrefe, Kohlhammer, Springer, Beltz; Her work was supported in the last 3years by the Swiss National Science Foundation (SNF), diff. EU Fabrizio Federica Piras7s, HSM Hochspezialisierte Medizin of the Kanton Zurich, Switzerland, Bfarm Germany, ZInEP, Hartmann Muller Stiftung, Olga Mayenfisch, Gertrud Thalmann Fonds (all unrelated to the submitted work). Dr. Thompson has received a research grant from Biogen, Inc., unrelated to the topic of this paper.\n",
      "\n",
      "Conflict of Interest Dr. Paul D. Arnold reported holding the Alberta Innovates Translational Health Chair in Child and Youth Mental Health outside the submitted work. Prof. David Mataix-Cols receives royalties for contributing articles to UpToDate, Wolters Kluwer Health and fees from Elsevier for editorial tasks (all unrelated to the submitted work). Dr. Janardhanan C. Narayanaswamy reported Government of India grants DST INSPIRE faculty grant IFA12-LSrinivas BalachanderM-26 and BT/06/IYBA/2012 outside the submitted work. Dr. Y. C Janardhan Reddy reported Government of India grants SR/S0/HS/0016/2011 and BT/PR13334/Med/30/259/2009 outside the submitted work. Dr. Venkatasubramanian reported Wellcome-DBT India Alliance grant 500236/Z/11/Z outside the submitted work. Dr. H. Blair Simpson reported Biohaven Research support for a clinical trial and royalties from UpToDate, Inc. and Cambridge University Press outside the submitted work. Dr. Noam Soreni reported support from Lundbeck-Iliyan IvanovT outside the submitted work. Dr. Walitza has received in the last 3years royalties from Thieme Hogrefe, Kohlhammer, Springer, Beltz; Her work was supported in the last 3years by the Swiss National Science Foundation (SNF), diff. EU Fabrizio Federica Piras7s, HSM Hochspezialisierte Medizin of the Kanton Zurich, Switzerland, Bfarm Germany, ZInEP, Hartmann Muller Stiftung, Olga Mayenfisch, Gertrud Thalmann Fonds (all unrelated to the submitted work). Dr. Thompson has received a research grant from Biogen, Inc., unrelated to the topic of this paper.\n",
      "\n",
      "Conflict of Interest Dr. Paul D. Arnold reported holding the Alberta Innovates Translational Health Chair in Child and Youth Mental Health outside the submitted work. Prof. David Mataix-Cols receives royalties for contributing articles to UpToDate, Wolters Kluwer Health and fees from Elsevier for editorial tasks (all unrelated to the submitted work). Dr. Janardhanan C. Narayanaswamy reported Government of India grants DST INSPIRE faculty grant IFA12-LSrinivas BalachanderM-26 and BT/06/IYBA/2012 outside the submitted work. Dr. Y. C Janardhan Reddy reported Government of India grants SR/S0/HS/0016/2011 and BT/PR13334/Med/30/259/2009 outside the submitted work. Dr. Venkatasubramanian reported Wellcome-DBT India Alliance grant 500236/Z/11/Z outside the submitted work. Dr. H. Blair Simpson reported Biohaven Research support for a clinical trial and royalties from UpToDate, Inc. and Cambridge University Press outside the submitted work. Dr. Noam Soreni reported support from Lundbeck-Iliyan IvanovT outside the submitted work. Dr. Walitza has received in the last 3years royalties from Thieme Hogrefe, Kohlhammer, Springer, Beltz; Her work was supported in the last 3years by the Swiss National Science Foundation (SNF), diff. EU Fabrizio Federica Piras7s, HSM Hochspezialisierte Medizin of the Kanton Zurich, Switzerland, Bfarm Germany, ZInEP, Hartmann Muller Stiftung, Olga Mayenfisch, Gertrud Thalmann Fonds (all unrelated to the submitted work). Dr. Thompson has received a research grant from Biogen, Inc., unrelated to the topic of this paper.\n",
      "\n",
      "Conflict of Interest Dr. Paul D. Arnold reported holding the Alberta Innovates Translational Health Chair in Child and Youth Mental Health outside the submitted work. Prof. David Mataix-Cols receives royalties for contributing articles to UpToDate, Wolters Kluwer Health and fees from Elsevier for editorial tasks (all unrelated to the submitted work). Dr. Janardhanan C. Narayanaswamy reported Government of India grants DST INSPIRE faculty grant IFA12-LSrinivas BalachanderM-26 and BT/06/IYBA/2012 outside the submitted work. Dr. Y. C Janardhan Reddy reported Government of India grants SR/S0/HS/0016/2011 and BT/PR13334/Med/30/259/2009 outside the submitted work. Dr. Venkatasubramanian reported Wellcome-DBT India Alliance grant 500236/Z/11/Z outside the submitted work. Dr. H. Blair Simpson reported Biohaven Research support for a clinical trial and royalties from UpToDate, Inc. and Cambridge University Press outside the submitted work. Dr. Noam Soreni reported support from Lundbeck-Iliyan IvanovT outside the submitted work. Dr. Walitza has received in the last 3years royalties from Thieme Hogrefe, Kohlhammer, Springer, Beltz; Her work was supported in the last 3years by the Swiss National Science Foundation (SNF), diff. EU Fabrizio Federica Piras7s, HSM Hochspezialisierte Medizin of the Kanton Zurich, Switzerland, Bfarm Germany, ZInEP, Hartmann Muller Stiftung, Olga Mayenfisch, Gertrud Thalmann Fonds (all unrelated to the submitted work). Dr. Thompson has received a research grant from Biogen, Inc., unrelated to the topic of this paper.\n",
      "\n",
      "Conflict of Interest Dr. Paul D. Arnold reported holding the Alberta Innovates Translational Health Chair in Child and Youth Mental Health outside the submitted work. Prof. David Mataix-Cols receives royalties for contributing articles to UpToDate, Wolters Kluwer Health and fees from Elsevier for editorial tasks (all unrelated to the submitted work). Dr. Janardhanan C. Narayanaswamy reported Government of India grants DST INSPIRE faculty grant IFA12-LSrinivas BalachanderM-26 and BT/06/IYBA/2012 outside the submitted work. Dr. Y. C Janardhan Reddy reported Government of India grants SR/S0/HS/0016/2011 and BT/PR13334/Med/30/259/2009 outside the submitted work. Dr. Venkatasubramanian reported Wellcome-DBT India Alliance grant 500236/Z/11/Z outside the submitted work. Dr. H. Blair Simpson reported Biohaven Research support for a clinical trial and royalties from UpToDate, Inc. and Cambridge University Press outside the submitted work. Dr. Noam Soreni reported support from Lundbeck-Iliyan IvanovT outside the submitted work. Dr. Walitza has received in the last 3years royalties from Thieme Hogrefe, Kohlhammer, Springer, Beltz; Her work was supported in the last 3years by the Swiss National Science Foundation (SNF), diff. EU Fabrizio Federica Piras7s, HSM Hochspezialisierte Medizin of the Kanton Zurich, Switzerland, Bfarm Germany, ZInEP, Hartmann Muller Stiftung, Olga Mayenfisch, Gertrud Thalmann Fonds (all unrelated to the submitted work). Dr. Thompson has received a research grant from Biogen, Inc., unrelated to the topic of this paper.\n",
      "\n",
      "Conflict of Interest Dr. Paul D. Arnold reported holding the Alberta Innovates Translational Health Chair in Child and Youth Mental Health outside the submitted work. Prof. David Mataix-Cols receives royalties for contributing articles to UpToDate, Wolters Kluwer Health and fees from Elsevier for editorial tasks (all unrelated to the submitted work). Dr. Janardhanan C. Narayanaswamy reported Government of India grants DST INSPIRE faculty grant IFA12-LSrinivas BalachanderM-26 and BT/06/IYBA/2012 outside the submitted work. Dr. Y. C Janardhan Reddy reported Government of India grants SR/S0/HS/0016/2011 and BT/PR13334/Med/30/259/2009 outside the submitted work. Dr. Venkatasubramanian reported Wellcome-DBT India Alliance grant 500236/Z/11/Z outside the submitted work. Dr. H. Blair Simpson reported Biohaven Research support for a clinical trial and royalties from UpToDate, Inc. and Cambridge University Press outside the submitted work. Dr. Noam Soreni reported support from Lundbeck-Iliyan IvanovT outside the submitted work. Dr. Walitza has received in the last 3years royalties from Thieme Hogrefe, Kohlhammer, Springer, Beltz; Her work was supported in the last 3years by the Swiss National Science Foundation (SNF), diff. EU Fabrizio Federica Piras7s, HSM Hochspezialisierte Medizin of the Kanton Zurich, Switzerland, Bfarm Germany, ZInEP, Hartmann Muller Stiftung, Olga Mayenfisch, Gertrud Thalmann Fonds (all unrelated to the submitted work). Dr. Thompson has received a research grant from Biogen, Inc., unrelated to the topic of this paper.\n",
      "\n",
      "Conflict of Interest Dr. Paul D. Arnold reported holding the Alberta Innovates Translational Health Chair in Child and Youth Mental Health outside the submitted work. Prof. David Mataix-Cols receives royalties for contributing articles to UpToDate, Wolters Kluwer Health and fees from Elsevier for editorial tasks (all unrelated to the submitted work). Dr. Janardhanan C. Narayanaswamy reported Government of India grants DST INSPIRE faculty grant IFA12-LSrinivas BalachanderM-26 and BT/06/IYBA/2012 outside the submitted work. Dr. Y. C Janardhan Reddy reported Government of India grants SR/S0/HS/0016/2011 and BT/PR13334/Med/30/259/2009 outside the submitted work. Dr. Venkatasubramanian reported Wellcome-DBT India Alliance grant 500236/Z/11/Z outside the submitted work. Dr. H. Blair Simpson reported Biohaven Research support for a clinical trial and royalties from UpToDate, Inc. and Cambridge University Press outside the submitted work. Dr. Noam Soreni reported support from Lundbeck-Iliyan IvanovT outside the submitted work. Dr. Walitza has received in the last 3years royalties from Thieme Hogrefe, Kohlhammer, Springer, Beltz; Her work was supported in the last 3years by the Swiss National Science Foundation (SNF), diff. EU Fabrizio Federica Piras7s, HSM Hochspezialisierte Medizin of the Kanton Zurich, Switzerland, Bfarm Germany, ZInEP, Hartmann Muller Stiftung, Olga Mayenfisch, Gertrud Thalmann Fonds (all unrelated to the submitted work). Dr. Thompson has received a research grant from Biogen, Inc., unrelated to the topic of this paper.\n",
      "\n",
      "Conflict of Interest Dr. Paul D. Arnold reported holding the Alberta Innovates Translational Health Chair in Child and Youth Mental Health outside the submitted work. Prof. David Mataix-Cols receives royalties for contributing articles to UpToDate, Wolters Kluwer Health and fees from Elsevier for editorial tasks (all unrelated to the submitted work). Dr. Janardhanan C. Narayanaswamy reported Government of India grants DST INSPIRE faculty grant IFA12-LSrinivas BalachanderM-26 and BT/06/IYBA/2012 outside the submitted work. Dr. Y. C Janardhan Reddy reported Government of India grants SR/S0/HS/0016/2011 and BT/PR13334/Med/30/259/2009 outside the submitted work. Dr. Venkatasubramanian reported Wellcome-DBT India Alliance grant 500236/Z/11/Z outside the submitted work. Dr. H. Blair Simpson reported Biohaven Research support for a clinical trial and royalties from UpToDate, Inc. and Cambridge University Press outside the submitted work. Dr. Noam Soreni reported support from Lundbeck-Iliyan IvanovT outside the submitted work. Dr. Walitza has received in the last 3years royalties from Thieme Hogrefe, Kohlhammer, Springer, Beltz; Her work was supported in the last 3years by the Swiss National Science Foundation (SNF), diff. EU Fabrizio Federica Piras7s, HSM Hochspezialisierte Medizin of the Kanton Zurich, Switzerland, Bfarm Germany, ZInEP, Hartmann Muller Stiftung, Olga Mayenfisch, Gertrud Thalmann Fonds (all unrelated to the submitted work). Dr. Thompson has received a research grant from Biogen, Inc., unrelated to the topic of this paper.\n",
      "\n",
      "Conflict of Interest Dr. Paul D. Arnold reported holding the Alberta Innovates Translational Health Chair in Child and Youth Mental Health outside the submitted work. Prof. David Mataix-Cols receives royalties for contributing articles to UpToDate, Wolters Kluwer Health and fees from Elsevier for editorial tasks (all unrelated to the submitted work). Dr. Janardhanan C. Narayanaswamy reported Government of India grants DST INSPIRE faculty grant IFA12-LSrinivas BalachanderM-26 and BT/06/IYBA/2012 outside the submitted work. Dr. Y. C Janardhan Reddy reported Government of India grants SR/S0/HS/0016/2011 and BT/PR13334/Med/30/259/2009 outside the submitted work. Dr. Venkatasubramanian reported Wellcome-DBT India Alliance grant 500236/Z/11/Z outside the submitted work. Dr. H. Blair Simpson reported Biohaven Research support for a clinical trial and royalties from UpToDate, Inc. and Cambridge University Press outside the submitted work. Dr. Noam Soreni reported support from Lundbeck-Iliyan IvanovT outside the submitted work. Dr. Walitza has received in the last 3years royalties from Thieme Hogrefe, Kohlhammer, Springer, Beltz; Her work was supported in the last 3years by the Swiss National Science Foundation (SNF), diff. EU Fabrizio Federica Piras7s, HSM Hochspezialisierte Medizin of the Kanton Zurich, Switzerland, Bfarm Germany, ZInEP, Hartmann Muller Stiftung, Olga Mayenfisch, Gertrud Thalmann Fonds (all unrelated to the submitted work). Dr. Thompson has received a research grant from Biogen, Inc., unrelated to the topic of this paper.\n",
      "\n",
      "Conflict of Interest Dr. Paul D. Arnold reported holding the Alberta Innovates Translational Health Chair in Child and Youth Mental Health outside the submitted work. Prof. David Mataix-Cols receives royalties for contributing articles to UpToDate, Wolters Kluwer Health and fees from Elsevier for editorial tasks (all unrelated to the submitted work). Dr. Janardhanan C. Narayanaswamy reported Government of India grants DST INSPIRE faculty grant IFA12-LSrinivas BalachanderM-26 and BT/06/IYBA/2012 outside the submitted work. Dr. Y. C Janardhan Reddy reported Government of India grants SR/S0/HS/0016/2011 and BT/PR13334/Med/30/259/2009 outside the submitted work. Dr. Venkatasubramanian reported Wellcome-DBT India Alliance grant 500236/Z/11/Z outside the submitted work. Dr. H. Blair Simpson reported Biohaven Research support for a clinical trial and royalties from UpToDate, Inc. and Cambridge University Press outside the submitted work. Dr. Noam Soreni reported support from Lundbeck-Iliyan IvanovT outside the submitted work. Dr. Walitza has received in the last 3years royalties from Thieme Hogrefe, Kohlhammer, Springer, Beltz; Her work was supported in the last 3years by the Swiss National Science Foundation (SNF), diff. EU Fabrizio Federica Piras7s, HSM Hochspezialisierte Medizin of the Kanton Zurich, Switzerland, Bfarm Germany, ZInEP, Hartmann Muller Stiftung, Olga Mayenfisch, Gertrud Thalmann Fonds (all unrelated to the submitted work). Dr. Thompson has received a research grant from Biogen, Inc., unrelated to the topic of this paper.\n",
      "\n",
      "Conflict of Interest Dr. Paul D. Arnold reported holding the Alberta Innovates Translational Health Chair in Child and Youth Mental Health outside the submitted work. Prof. David Mataix-Cols receives royalties for contributing articles to UpToDate, Wolters Kluwer Health and fees from Elsevier for editorial tasks (all unrelated to the submitted work). Dr. Janardhanan C. Narayanaswamy reported Government of India grants DST INSPIRE faculty grant IFA12-LSrinivas BalachanderM-26 and BT/06/IYBA/2012 outside the submitted work. Dr. Y. C Janardhan Reddy reported Government of India grants SR/S0/HS/0016/2011 and BT/PR13334/Med/30/259/2009 outside the submitted work. Dr. Venkatasubramanian reported Wellcome-DBT India Alliance grant 500236/Z/11/Z outside the submitted work. Dr. H. Blair Simpson reported Biohaven Research support for a clinical trial and royalties from UpToDate, Inc. and Cambridge University Press outside the submitted work. Dr. Noam Soreni reported support from Lundbeck-Iliyan IvanovT outside the submitted work. Dr. Walitza has received in the last 3years royalties from Thieme Hogrefe, Kohlhammer, Springer, Beltz; Her work was supported in the last 3years by the Swiss National Science Foundation (SNF), diff. EU Fabrizio Federica Piras7s, HSM Hochspezialisierte Medizin of the Kanton Zurich, Switzerland, Bfarm Germany, ZInEP, Hartmann Muller Stiftung, Olga Mayenfisch, Gertrud Thalmann Fonds (all unrelated to the submitted work). Dr. Thompson has received a research grant from Biogen, Inc., unrelated to the topic of this paper.\n",
      "\n",
      "Conflict of Interest Dr. Paul D. Arnold reported holding the Alberta Innovates Translational Health Chair in Child and Youth Mental Health outside the submitted work. Prof. David Mataix-Cols receives royalties for contributing articles to UpToDate, Wolters Kluwer Health and fees from Elsevier for editorial tasks (all unrelated to the submitted work). Dr. Janardhanan C. Narayanaswamy reported Government of India grants DST INSPIRE faculty grant IFA12-LSrinivas BalachanderM-26 and BT/06/IYBA/2012 outside the submitted work. Dr. Y. C Janardhan Reddy reported Government of India grants SR/S0/HS/0016/2011 and BT/PR13334/Med/30/259/2009 outside the submitted work. Dr. Venkatasubramanian reported Wellcome-DBT India Alliance grant 500236/Z/11/Z outside the submitted work. Dr. H. Blair Simpson reported Biohaven Research support for a clinical trial and royalties from UpToDate, Inc. and Cambridge University Press outside the submitted work. Dr. Noam Soreni reported support from Lundbeck-Iliyan IvanovT outside the submitted work. Dr. Walitza has received in the last 3years royalties from Thieme Hogrefe, Kohlhammer, Springer, Beltz; Her work was supported in the last 3years by the Swiss National Science Foundation (SNF), diff. EU Fabrizio Federica Piras7s, HSM Hochspezialisierte Medizin of the Kanton Zurich, Switzerland, Bfarm Germany, ZInEP, Hartmann Muller Stiftung, Olga Mayenfisch, Gertrud Thalmann Fonds (all unrelated to the submitted work). Dr. Thompson has received a research grant from Biogen, Inc., unrelated to the topic of this paper.\n",
      "\n",
      "Venkatasubramanian, Ganesan\n",
      "Conflict of Interest Dr. Paul D. Arnold reported holding the Alberta Innovates Translational Health Chair in Child and Youth Mental Health outside the submitted work. Prof. David Mataix-Cols receives royalties for contributing articles to UpToDate, Wolters Kluwer Health and fees from Elsevier for editorial tasks (all unrelated to the submitted work). Dr. Janardhanan C. Narayanaswamy reported Government of India grants DST INSPIRE faculty grant IFA12-LSrinivas BalachanderM-26 and BT/06/IYBA/2012 outside the submitted work. Dr. Y. C Janardhan Reddy reported Government of India grants SR/S0/HS/0016/2011 and BT/PR13334/Med/30/259/2009 outside the submitted work. Dr. Ganesan Venkatasubramanian reported Wellcome-DBT India Alliance grant 500236/Z/11/Z outside the submitted work. Dr. H. Blair Simpson reported Biohaven Research support for a clinical trial and royalties from UpToDate, Inc. and Cambridge University Press outside the submitted work. Dr. Noam Soreni reported support from Lundbeck-Iliyan IvanovT outside the submitted work. Dr. Walitza has received in the last 3years royalties from Thieme Hogrefe, Kohlhammer, Springer, Beltz; Her work was supported in the last 3years by the Swiss National Science Foundation (SNF), diff. EU Fabrizio Federica Piras7s, HSM Hochspezialisierte Medizin of the Kanton Zurich, Switzerland, Bfarm Germany, ZInEP, Hartmann Muller Stiftung, Olga Mayenfisch, Gertrud Thalmann Fonds (all unrelated to the submitted work). Dr. Thompson has received a research grant from Biogen, Inc., unrelated to the topic of this paper.\n",
      "\n",
      "Walitza, Susanne\n",
      "Conflict of Interest Dr. Paul D. Arnold reported holding the Alberta Innovates Translational Health Chair in Child and Youth Mental Health outside the submitted work. Prof. David Mataix-Cols receives royalties for contributing articles to UpToDate, Wolters Kluwer Health and fees from Elsevier for editorial tasks (all unrelated to the submitted work). Dr. Janardhanan C. Narayanaswamy reported Government of India grants DST INSPIRE faculty grant IFA12-LSrinivas BalachanderM-26 and BT/06/IYBA/2012 outside the submitted work. Dr. Y. C Janardhan Reddy reported Government of India grants SR/S0/HS/0016/2011 and BT/PR13334/Med/30/259/2009 outside the submitted work. Dr. Ganesan Venkatasubramanian reported Wellcome-DBT India Alliance grant 500236/Z/11/Z outside the submitted work. Dr. H. Blair Simpson reported Biohaven Research support for a clinical trial and royalties from UpToDate, Inc. and Cambridge University Press outside the submitted work. Dr. Noam Soreni reported support from Lundbeck-Iliyan IvanovT outside the submitted work. Dr. Susanne Walitza has received in the last 3years royalties from Thieme Hogrefe, Kohlhammer, Springer, Beltz; Her work was supported in the last 3years by the Swiss National Science Foundation (SNF), diff. EU Fabrizio Federica Piras7s, HSM Hochspezialisierte Medizin of the Kanton Zurich, Switzerland, Bfarm Germany, ZInEP, Hartmann Muller Stiftung, Olga Mayenfisch, Gertrud Thalmann Fonds (all unrelated to the submitted work). Dr. Thompson has received a research grant from Biogen, Inc., unrelated to the topic of this paper.\n",
      "\n",
      "Conflict of Interest Dr. Paul D. Arnold reported holding the Alberta Innovates Translational Health Chair in Child and Youth Mental Health outside the submitted work. Prof. David Mataix-Cols receives royalties for contributing articles to UpToDate, Wolters Kluwer Health and fees from Elsevier for editorial tasks (all unrelated to the submitted work). Dr. Janardhanan C. Narayanaswamy reported Government of India grants DST INSPIRE faculty grant IFA12-LSrinivas BalachanderM-26 and BT/06/IYBA/2012 outside the submitted work. Dr. Y. C Janardhan Reddy reported Government of India grants SR/S0/HS/0016/2011 and BT/PR13334/Med/30/259/2009 outside the submitted work. Dr. Ganesan Venkatasubramanian reported Wellcome-DBT India Alliance grant 500236/Z/11/Z outside the submitted work. Dr. H. Blair Simpson reported Biohaven Research support for a clinical trial and royalties from UpToDate, Inc. and Cambridge University Press outside the submitted work. Dr. Noam Soreni reported support from Lundbeck-Iliyan IvanovT outside the submitted work. Dr. Susanne Walitza has received in the last 3years royalties from Thieme Hogrefe, Kohlhammer, Springer, Beltz; Her work was supported in the last 3years by the Swiss National Science Foundation (SNF), diff. EU Fabrizio Federica Piras7s, HSM Hochspezialisierte Medizin of the Kanton Zurich, Switzerland, Bfarm Germany, ZInEP, Hartmann Muller Stiftung, Olga Mayenfisch, Gertrud Thalmann Fonds (all unrelated to the submitted work). Dr. Thompson has received a research grant from Biogen, Inc., unrelated to the topic of this paper.\n",
      "\n",
      "Conflict of Interest Dr. Paul D. Arnold reported holding the Alberta Innovates Translational Health Chair in Child and Youth Mental Health outside the submitted work. Prof. David Mataix-Cols receives royalties for contributing articles to UpToDate, Wolters Kluwer Health and fees from Elsevier for editorial tasks (all unrelated to the submitted work). Dr. Janardhanan C. Narayanaswamy reported Government of India grants DST INSPIRE faculty grant IFA12-LSrinivas BalachanderM-26 and BT/06/IYBA/2012 outside the submitted work. Dr. Y. C Janardhan Reddy reported Government of India grants SR/S0/HS/0016/2011 and BT/PR13334/Med/30/259/2009 outside the submitted work. Dr. Ganesan Venkatasubramanian reported Wellcome-DBT India Alliance grant 500236/Z/11/Z outside the submitted work. Dr. H. Blair Simpson reported Biohaven Research support for a clinical trial and royalties from UpToDate, Inc. and Cambridge University Press outside the submitted work. Dr. Noam Soreni reported support from Lundbeck-Iliyan IvanovT outside the submitted work. Dr. Susanne Walitza has received in the last 3years royalties from Thieme Hogrefe, Kohlhammer, Springer, Beltz; Her work was supported in the last 3years by the Swiss National Science Foundation (SNF), diff. EU Fabrizio Federica Piras7s, HSM Hochspezialisierte Medizin of the Kanton Zurich, Switzerland, Bfarm Germany, ZInEP, Hartmann Muller Stiftung, Olga Mayenfisch, Gertrud Thalmann Fonds (all unrelated to the submitted work). Dr. Thompson has received a research grant from Biogen, Inc., unrelated to the topic of this paper.\n",
      "\n",
      "Wolters, Lidewij H.\n",
      "Conflict of Interest Dr. Paul D. Arnold reported holding the Alberta Innovates Translational Health Chair in Child and Youth Mental Health outside the submitted work. Prof. David Mataix-Cols receives royalties for contributing articles to UpToDate, Lidewij H. Wolters Kluwer Health and fees from Elsevier for editorial tasks (all unrelated to the submitted work). Dr. Janardhanan C. Narayanaswamy reported Government of India grants DST INSPIRE faculty grant IFA12-LSrinivas BalachanderM-26 and BT/06/IYBA/2012 outside the submitted work. Dr. Y. C Janardhan Reddy reported Government of India grants SR/S0/HS/0016/2011 and BT/PR13334/Med/30/259/2009 outside the submitted work. Dr. Ganesan Venkatasubramanian reported Wellcome-DBT India Alliance grant 500236/Z/11/Z outside the submitted work. Dr. H. Blair Simpson reported Biohaven Research support for a clinical trial and royalties from UpToDate, Inc. and Cambridge University Press outside the submitted work. Dr. Noam Soreni reported support from Lundbeck-Iliyan IvanovT outside the submitted work. Dr. Susanne Walitza has received in the last 3years royalties from Thieme Hogrefe, Kohlhammer, Springer, Beltz; Her work was supported in the last 3years by the Swiss National Science Foundation (SNF), diff. EU Fabrizio Federica Piras7s, HSM Hochspezialisierte Medizin of the Kanton Zurich, Switzerland, Bfarm Germany, ZInEP, Hartmann Muller Stiftung, Olga Mayenfisch, Gertrud Thalmann Fonds (all unrelated to the submitted work). Dr. Thompson has received a research grant from Biogen, Inc., unrelated to the topic of this paper.\n",
      "\n",
      "Conflict of Interest Dr. Paul D. Arnold reported holding the Alberta Innovates Translational Health Chair in Child and Youth Mental Health outside the submitted work. Prof. David Mataix-Cols receives royalties for contributing articles to UpToDate, Lidewij H. Wolters Kluwer Health and fees from Elsevier for editorial tasks (all unrelated to the submitted work). Dr. Janardhanan C. Narayanaswamy reported Government of India grants DST INSPIRE faculty grant IFA12-LSrinivas BalachanderM-26 and BT/06/IYBA/2012 outside the submitted work. Dr. Y. C Janardhan Reddy reported Government of India grants SR/S0/HS/0016/2011 and BT/PR13334/Med/30/259/2009 outside the submitted work. Dr. Ganesan Venkatasubramanian reported Wellcome-DBT India Alliance grant 500236/Z/11/Z outside the submitted work. Dr. H. Blair Simpson reported Biohaven Research support for a clinical trial and royalties from UpToDate, Inc. and Cambridge University Press outside the submitted work. Dr. Noam Soreni reported support from Lundbeck-Iliyan IvanovT outside the submitted work. Dr. Susanne Walitza has received in the last 3years royalties from Thieme Hogrefe, Kohlhammer, Springer, Beltz; Her work was supported in the last 3years by the Swiss National Science Foundation (SNF), diff. EU Fabrizio Federica Piras7s, HSM Hochspezialisierte Medizin of the Kanton Zurich, Switzerland, Bfarm Germany, ZInEP, Hartmann Muller Stiftung, Olga Mayenfisch, Gertrud Thalmann Fonds (all unrelated to the submitted work). Dr. Thompson has received a research grant from Biogen, Inc., unrelated to the topic of this paper.\n",
      "\n",
      "Conflict of Interest Dr. Paul D. Arnold reported holding the Alberta Innovates Translational Health Chair in Child and Youth Mental Health outside the submitted work. Prof. David Mataix-Cols receives royalties for contributing articles to UpToDate, Lidewij H. Wolters Kluwer Health and fees from Elsevier for editorial tasks (all unrelated to the submitted work). Dr. Janardhanan C. Narayanaswamy reported Government of India grants DST INSPIRE faculty grant IFA12-LSrinivas BalachanderM-26 and BT/06/IYBA/2012 outside the submitted work. Dr. Y. C Janardhan Reddy reported Government of India grants SR/S0/HS/0016/2011 and BT/PR13334/Med/30/259/2009 outside the submitted work. Dr. Ganesan Venkatasubramanian reported Wellcome-DBT India Alliance grant 500236/Z/11/Z outside the submitted work. Dr. H. Blair Simpson reported Biohaven Research support for a clinical trial and royalties from UpToDate, Inc. and Cambridge University Press outside the submitted work. Dr. Noam Soreni reported support from Lundbeck-Iliyan IvanovT outside the submitted work. Dr. Susanne Walitza has received in the last 3years royalties from Thieme Hogrefe, Kohlhammer, Springer, Beltz; Her work was supported in the last 3years by the Swiss National Science Foundation (SNF), diff. EU Fabrizio Federica Piras7s, HSM Hochspezialisierte Medizin of the Kanton Zurich, Switzerland, Bfarm Germany, ZInEP, Hartmann Muller Stiftung, Olga Mayenfisch, Gertrud Thalmann Fonds (all unrelated to the submitted work). Dr. Thompson has received a research grant from Biogen, Inc., unrelated to the topic of this paper.\n",
      "\n",
      "Conflict of Interest Dr. Paul D. Arnold reported holding the Alberta Innovates Translational Health Chair in Child and Youth Mental Health outside the submitted work. Prof. David Mataix-Cols receives royalties for contributing articles to UpToDate, Lidewij H. Wolters Kluwer Health and fees from Elsevier for editorial tasks (all unrelated to the submitted work). Dr. Janardhanan C. Narayanaswamy reported Government of India grants DST INSPIRE faculty grant IFA12-LSrinivas BalachanderM-26 and BT/06/IYBA/2012 outside the submitted work. Dr. Y. C Janardhan Reddy reported Government of India grants SR/S0/HS/0016/2011 and BT/PR13334/Med/30/259/2009 outside the submitted work. Dr. Ganesan Venkatasubramanian reported Wellcome-DBT India Alliance grant 500236/Z/11/Z outside the submitted work. Dr. H. Blair Simpson reported Biohaven Research support for a clinical trial and royalties from UpToDate, Inc. and Cambridge University Press outside the submitted work. Dr. Noam Soreni reported support from Lundbeck-Iliyan IvanovT outside the submitted work. Dr. Susanne Walitza has received in the last 3years royalties from Thieme Hogrefe, Kohlhammer, Springer, Beltz; Her work was supported in the last 3years by the Swiss National Science Foundation (SNF), diff. EU Fabrizio Federica Piras7s, HSM Hochspezialisierte Medizin of the Kanton Zurich, Switzerland, Bfarm Germany, ZInEP, Hartmann Muller Stiftung, Olga Mayenfisch, Gertrud Thalmann Fonds (all unrelated to the submitted work). Dr. Thompson has received a research grant from Biogen, Inc., unrelated to the topic of this paper.\n",
      "\n",
      "Conflict of Interest Dr. Paul D. Arnold reported holding the Alberta Innovates Translational Health Chair in Child and Youth Mental Health outside the submitted work. Prof. David Mataix-Cols receives royalties for contributing articles to UpToDate, Lidewij H. Wolters Kluwer Health and fees from Elsevier for editorial tasks (all unrelated to the submitted work). Dr. Janardhanan C. Narayanaswamy reported Government of India grants DST INSPIRE faculty grant IFA12-LSrinivas BalachanderM-26 and BT/06/IYBA/2012 outside the submitted work. Dr. Y. C Janardhan Reddy reported Government of India grants SR/S0/HS/0016/2011 and BT/PR13334/Med/30/259/2009 outside the submitted work. Dr. Ganesan Venkatasubramanian reported Wellcome-DBT India Alliance grant 500236/Z/11/Z outside the submitted work. Dr. H. Blair Simpson reported Biohaven Research support for a clinical trial and royalties from UpToDate, Inc. and Cambridge University Press outside the submitted work. Dr. Noam Soreni reported support from Lundbeck-Iliyan IvanovT outside the submitted work. Dr. Susanne Walitza has received in the last 3years royalties from Thieme Hogrefe, Kohlhammer, Springer, Beltz; Her work was supported in the last 3years by the Swiss National Science Foundation (SNF), diff. EU Fabrizio Federica Piras7s, HSM Hochspezialisierte Medizin of the Kanton Zurich, Switzerland, Bfarm Germany, ZInEP, Hartmann Muller Stiftung, Olga Mayenfisch, Gertrud Thalmann Fonds (all unrelated to the submitted work). Dr. Thompson has received a research grant from Biogen, Inc., unrelated to the topic of this paper.\n",
      "\n",
      "Conflict of Interest Dr. Paul D. Arnold reported holding the Alberta Innovates Translational Health Chair in Child and Youth Mental Health outside the submitted work. Prof. David Mataix-Cols receives royalties for contributing articles to UpToDate, Lidewij H. Wolters Kluwer Health and fees from Elsevier for editorial tasks (all unrelated to the submitted work). Dr. Janardhanan C. Narayanaswamy reported Government of India grants DST INSPIRE faculty grant IFA12-LSrinivas BalachanderM-26 and BT/06/IYBA/2012 outside the submitted work. Dr. Y. C Janardhan Reddy reported Government of India grants SR/S0/HS/0016/2011 and BT/PR13334/Med/30/259/2009 outside the submitted work. Dr. Ganesan Venkatasubramanian reported Wellcome-DBT India Alliance grant 500236/Z/11/Z outside the submitted work. Dr. H. Blair Simpson reported Biohaven Research support for a clinical trial and royalties from UpToDate, Inc. and Cambridge University Press outside the submitted work. Dr. Noam Soreni reported support from Lundbeck-Iliyan IvanovT outside the submitted work. Dr. Susanne Walitza has received in the last 3years royalties from Thieme Hogrefe, Kohlhammer, Springer, Beltz; Her work was supported in the last 3years by the Swiss National Science Foundation (SNF), diff. EU Fabrizio Federica Piras7s, HSM Hochspezialisierte Medizin of the Kanton Zurich, Switzerland, Bfarm Germany, ZInEP, Hartmann Muller Stiftung, Olga Mayenfisch, Gertrud Thalmann Fonds (all unrelated to the submitted work). Dr. Thompson has received a research grant from Biogen, Inc., unrelated to the topic of this paper.\n",
      "\n",
      "Thompson, Paul M.\n",
      "Conflict of Interest Dr. Paul D. Arnold reported holding the Alberta Innovates Translational Health Chair in Child and Youth Mental Health outside the submitted work. Prof. David Mataix-Cols receives royalties for contributing articles to UpToDate, Lidewij H. Wolters Kluwer Health and fees from Elsevier for editorial tasks (all unrelated to the submitted work). Dr. Janardhanan C. Narayanaswamy reported Government of India grants DST INSPIRE faculty grant IFA12-LSrinivas BalachanderM-26 and BT/06/IYBA/2012 outside the submitted work. Dr. Y. C Janardhan Reddy reported Government of India grants SR/S0/HS/0016/2011 and BT/PR13334/Med/30/259/2009 outside the submitted work. Dr. Ganesan Venkatasubramanian reported Wellcome-DBT India Alliance grant 500236/Z/11/Z outside the submitted work. Dr. H. Blair Simpson reported Biohaven Research support for a clinical trial and royalties from UpToDate, Inc. and Cambridge University Press outside the submitted work. Dr. Noam Soreni reported support from Lundbeck-Iliyan IvanovT outside the submitted work. Dr. Susanne Walitza has received in the last 3years royalties from Thieme Hogrefe, Kohlhammer, Springer, Beltz; Her work was supported in the last 3years by the Swiss National Science Foundation (SNF), diff. EU Fabrizio Federica Piras7s, HSM Hochspezialisierte Medizin of the Kanton Zurich, Switzerland, Bfarm Germany, ZInEP, Hartmann Muller Stiftung, Olga Mayenfisch, Gertrud Thalmann Fonds (all unrelated to the submitted work). Dr. Paul M. Thompson has received a research grant from Biogen, Inc., unrelated to the topic of this paper.\n",
      "\n",
      "Stein, Dan J.\n",
      "Conflict of Interest Dr. Paul D. Arnold reported holding the Alberta Innovates Translational Health Chair in Child and Youth Mental Health outside the submitted work. Prof. David Mataix-Cols receives royalties for contributing articles to UpToDate, Lidewij H. Wolters Kluwer Health and fees from Elsevier for editorial tasks (all unrelated to the submitted work). Dr. Janardhanan C. Narayanaswamy reported Government of India grants Dan J. SteinT INSPIRE faculty grant IFA12-LSrinivas BalachanderM-26 and BT/06/IYBA/2012 outside the submitted work. Dr. Y. C Janardhan Reddy reported Government of India grants SR/S0/HS/0016/2011 and BT/PR13334/Med/30/259/2009 outside the submitted work. Dr. Ganesan Venkatasubramanian reported Wellcome-DBT India Alliance grant 500236/Z/11/Z outside the submitted work. Dr. H. Blair Simpson reported Biohaven Research support for a clinical trial and royalties from UpToDate, Inc. and Cambridge University Press outside the submitted work. Dr. Noam Soreni reported support from Lundbeck-Iliyan IvanovT outside the submitted work. Dr. Susanne Walitza has received in the last 3years royalties from Thieme Hogrefe, Kohlhammer, Springer, Beltz; Her work was supported in the last 3years by the Swiss National Science Foundation (SNF), diff. EU Fabrizio Federica Piras7s, HSM Hochspezialisierte Medizin of the Kanton Zurich, Switzerland, Bfarm Germany, ZInEP, Hartmann Muller Stiftung, Olga Mayenfisch, Gertrud Thalmann Fonds (all unrelated to the submitted work). Dr. Paul M. Thompson has received a research grant from Biogen, Inc., unrelated to the topic of this paper.\n",
      "\n",
      "Conflict of Interest Dr. Paul D. Arnold reported holding the Alberta Innovates Translational Health Chair in Child and Youth Mental Health outside the submitted work. Prof. David Mataix-Cols receives royalties for contributing articles to UpToDate, Lidewij H. Wolters Kluwer Health and fees from Elsevier for editorial tasks (all unrelated to the submitted work). Dr. Janardhanan C. Narayanaswamy reported Government of India grants Dan J. SteinT INSPIRE faculty grant IFA12-LSrinivas BalachanderM-26 and BT/06/IYBA/2012 outside the submitted work. Dr. Y. C Janardhan Reddy reported Government of India grants SR/S0/HS/0016/2011 and BT/PR13334/Med/30/259/2009 outside the submitted work. Dr. Ganesan Venkatasubramanian reported Wellcome-DBT India Alliance grant 500236/Z/11/Z outside the submitted work. Dr. H. Blair Simpson reported Biohaven Research support for a clinical trial and royalties from UpToDate, Inc. and Cambridge University Press outside the submitted work. Dr. Noam Soreni reported support from Lundbeck-Iliyan IvanovT outside the submitted work. Dr. Susanne Walitza has received in the last 3years royalties from Thieme Hogrefe, Kohlhammer, Springer, Beltz; Her work was supported in the last 3years by the Swiss National Science Foundation (SNF), diff. EU Fabrizio Federica Piras7s, HSM Hochspezialisierte Medizin of the Kanton Zurich, Switzerland, Bfarm Germany, ZInEP, Hartmann Muller Stiftung, Olga Mayenfisch, Gertrud Thalmann Fonds (all unrelated to the submitted work). Dr. Paul M. Thompson has received a research grant from Biogen, Inc., unrelated to the topic of this paper.\n",
      "\n",
      "Conflict of Interest Dr. Paul D. Arnold reported holding the Alberta Innovates Translational Health Chair in Child and Youth Mental Health outside the submitted work. Prof. David Mataix-Cols receives royalties for contributing articles to UpToDate, Lidewij H. Wolters Kluwer Health and fees from Elsevier for editorial tasks (all unrelated to the submitted work). Dr. Janardhanan C. Narayanaswamy reported Government of India grants Dan J. SteinT INSPIRE faculty grant IFA12-LSrinivas BalachanderM-26 and BT/06/IYBA/2012 outside the submitted work. Dr. Y. C Janardhan Reddy reported Government of India grants SR/S0/HS/0016/2011 and BT/PR13334/Med/30/259/2009 outside the submitted work. Dr. Ganesan Venkatasubramanian reported Wellcome-DBT India Alliance grant 500236/Z/11/Z outside the submitted work. Dr. H. Blair Simpson reported Biohaven Research support for a clinical trial and royalties from UpToDate, Inc. and Cambridge University Press outside the submitted work. Dr. Noam Soreni reported support from Lundbeck-Iliyan IvanovT outside the submitted work. Dr. Susanne Walitza has received in the last 3years royalties from Thieme Hogrefe, Kohlhammer, Springer, Beltz; Her work was supported in the last 3years by the Swiss National Science Foundation (SNF), diff. EU Fabrizio Federica Piras7s, HSM Hochspezialisierte Medizin of the Kanton Zurich, Switzerland, Bfarm Germany, ZInEP, Hartmann Muller Stiftung, Olga Mayenfisch, Gertrud Thalmann Fonds (all unrelated to the submitted work). Dr. Paul M. Thompson has received a research grant from Biogen, Inc., unrelated to the topic of this paper.\n",
      "\n",
      "Declarations of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared  to influence the work reported in this paper.\n",
      "\n",
      "Declarations of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared  to influence the work reported in this paper.\n",
      "\n",
      "Declarations of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared  to influence the work reported in this paper.\n",
      "\n",
      "Declarations of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared  to influence the work reported in this paper.\n",
      "\n",
      "Declarations of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared  to influence the work reported in this paper.\n",
      "\n",
      "Declarations of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared  to influence the work reported in this paper.\n",
      "\n",
      "Declarations of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared  to influence the work reported in this paper.\n",
      "\n",
      "Declarations of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared  to influence the work reported in this paper.\n",
      "\n",
      "Declarations of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared  to influence the work reported in this paper.\n",
      "\n",
      "Declarations of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared  to influence the work reported in this paper.\n",
      "\n",
      "Declarations of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared  to influence the work reported in this paper.\n",
      "\n",
      "Mexhitaj, Ina\n",
      "Declaration of Competing Interest LAC, NL, TZ, JIF-V: None. Ina Mexhitaj: Currently employed by Sanofi. LMV: Served on scientific advisory boards, participated in meetings sponsored by, received speaking honoraria, travel funding, or research grants from Roche, Sanofi, Merck, Biogen, Bristol Myers, and Novartis. PAM: Received travel support and speaker honoraria from unrestricted educational activities organized by Novartis, Bayer HealthCare, Bayer Pharma, Biogen Idec, Merck-Serono and Sanofi Aventis. Consulted for Magenta Therapeutics and Jasper Therapeutics. KMH: Currently employed by and holds equity in Rubius Therapeutics. AB-O: Participated as a speaker in meetings sponsored by and received consulting  fees from Accure, Atara Biotherapeutics, Biogen, BMS/Celgene/Receptos, GlaxoSmithKline, Gossamer, Janssen/Actelion, Medimmune, Merck/EMD Serono, Novartis, Roche/Genentech, Sanofi-Genzyme; and has received grant support to the  University of Pennsylvania from Biogen Idec, Roche/Genentech, Merck/EMD Serono and Novartis.\n",
      "\n",
      "Lim, Noha\n",
      "Declaration of Competing Interest LAC, Noha Lim, TZ, JIF-V: None. Ina Mexhitaj: Currently employed by Sanofi. LMV: Served on scientific advisory boards, participated in meetings sponsored by, received speaking honoraria, travel funding, or research grants from Roche, Sanofi, Merck, Biogen, Bristol Myers, and Novartis. PAM: Received travel support and speaker honoraria from unrestricted educational activities organized by Novartis, Bayer HealthCare, Bayer Pharma, Biogen Idec, Merck-Serono and Sanofi Aventis. Consulted for Magenta Therapeutics and Jasper Therapeutics. KMH: Currently employed by and holds equity in Rubius Therapeutics. AB-O: Participated as a speaker in meetings sponsored by and received consulting  fees from Accure, Atara Biotherapeutics, Biogen, BMS/Celgene/Receptos, GlaxoSmithKline, Gossamer, Janssen/Actelion, Medimmune, Merck/EMD Serono, Novartis, Roche/Genentech, Sanofi-Genzyme; and has received grant support to the  University of Pennsylvania from Biogen Idec, Roche/Genentech, Merck/EMD Serono and Novartis.\n",
      "\n",
      "Fernandez-Velasco, Jose I.\n",
      "Declaration of Competing Interest LAC, Noha Lim, TZ, Jose I. Fernandez-Velasco-V: None. Ina Mexhitaj: Currently employed by Sanofi. LMV: Served on scientific advisory boards, participated in meetings sponsored by, received speaking honoraria, travel funding, or research grants from Roche, Sanofi, Merck, Biogen, Bristol Myers, and Novartis. PAM: Received travel support and speaker honoraria from unrestricted educational activities organized by Novartis, Bayer HealthCare, Bayer Pharma, Biogen Idec, Merck-Serono and Sanofi Aventis. Consulted for Magenta Therapeutics and Jasper Therapeutics. KMH: Currently employed by and holds equity in Rubius Therapeutics. AB-O: Participated as a speaker in meetings sponsored by and received consulting  fees from Accure, Atara Biotherapeutics, Biogen, BMS/Celgene/Receptos, GlaxoSmithKline, Gossamer, Janssen/Actelion, Medimmune, Merck/EMD Serono, Novartis, Roche/Genentech, Sanofi-Genzyme; and has received grant support to the  University of Pennsylvania from Biogen Idec, Roche/Genentech, Merck/EMD Serono and Novartis.\n",
      "\n",
      "Zrzavy, Tobias\n",
      "Declaration of Competing Interest LAC, Noha Lim, Tobias Zrzavy, Jose I. Fernandez-Velasco-V: None. Ina Mexhitaj: Currently employed by Sanofi. LMV: Served on scientific advisory boards, participated in meetings sponsored by, received speaking honoraria, travel funding, or research grants from Roche, Sanofi, Merck, Biogen, Bristol Myers, and Novartis. PAM: Received travel support and speaker honoraria from unrestricted educational activities organized by Novartis, Bayer HealthCare, Bayer Pharma, Biogen Idec, Merck-Serono and Sanofi Aventis. Consulted for Magenta Therapeutics and Jasper Therapeutics. KMH: Currently employed by and holds equity in Rubius Therapeutics. AB-O: Participated as a speaker in meetings sponsored by and received consulting  fees from Accure, Atara Biotherapeutics, Biogen, BMS/Celgene/Receptos, GlaxoSmithKline, Gossamer, Janssen/Actelion, Medimmune, Merck/EMD Serono, Novartis, Roche/Genentech, Sanofi-Genzyme; and has received grant support to the  University of Pennsylvania from Biogen Idec, Roche/Genentech, Merck/EMD Serono and Novartis.\n",
      "\n",
      "Harris, Kristina M.\n",
      "Declaration of Competing Interest LAC, Noha Lim, Tobias Zrzavy, Jose I. Fernandez-Velasco-V: None. Ina Mexhitaj: Currently employed by Sanofi. LMV: Served on scientific advisory boards, participated in meetings sponsored by, received speaking honoraria, travel funding, or research grants from Roche, Sanofi, Merck, Biogen, Bristol Myers, and Novartis. PAM: Received travel support and speaker honoraria from unrestricted educational activities organized by Novartis, Bayer HealthCare, Bayer Pharma, Biogen Idec, Merck-Serono and Sanofi Aventis. Consulted for Magenta Therapeutics and Jasper Therapeutics. Kristina M. Harris: Currently employed by and holds equity in Rubius Therapeutics. AB-O: Participated as a speaker in meetings sponsored by and received consulting  fees from Accure, Atara Biotherapeutics, Biogen, BMS/Celgene/Receptos, GlaxoSmithKline, Gossamer, Janssen/Actelion, Medimmune, Merck/EMD Serono, Novartis, Roche/Genentech, Sanofi-Genzyme; and has received grant support to the  University of Pennsylvania from Biogen Idec, Roche/Genentech, Merck/EMD Serono and Novartis.\n",
      "\n",
      "Muraro, Paolo A.\n",
      "Declaration of Competing Interest LAC, Noha Lim, Tobias Zrzavy, Jose I. Fernandez-Velasco-V: None. Ina Mexhitaj: Currently employed by Sanofi. LMV: Served on scientific advisory boards, participated in meetings sponsored by, received speaking honoraria, travel funding, or research grants from Roche, Sanofi, Merck, Biogen, Bristol Myers, and Novartis. Paolo A. Muraro: Received travel support and speaker honoraria from unrestricted educational activities organized by Novartis, Bayer HealthCare, Bayer Pharma, Biogen Idec, Merck-Serono and Sanofi Aventis. Consulted for Magenta Therapeutics and Jasper Therapeutics. Kristina M. Harris: Currently employed by and holds equity in Rubius Therapeutics. AB-O: Participated as a speaker in meetings sponsored by and received consulting  fees from Accure, Atara Biotherapeutics, Biogen, BMS/Celgene/Receptos, GlaxoSmithKline, Gossamer, Janssen/Actelion, Medimmune, Merck/EMD Serono, Novartis, Roche/Genentech, Sanofi-Genzyme; and has received grant support to the  University of Pennsylvania from Biogen Idec, Roche/Genentech, Merck/EMD Serono and Novartis.\n",
      "\n",
      "Villar, Luisa M.\n",
      "Declaration of Competing Interest LAC, Noha Lim, Tobias Zrzavy, Jose I. Fernandez-Velasco-V: None. Ina Mexhitaj: Currently employed by Sanofi. Luisa M. Villar: Served on scientific advisory boards, participated in meetings sponsored by, received speaking honoraria, travel funding, or research grants from Roche, Sanofi, Merck, Biogen, Bristol Myers, and Novartis. Paolo A. Muraro: Received travel support and speaker honoraria from unrestricted educational activities organized by Novartis, Bayer HealthCare, Bayer Pharma, Biogen Idec, Merck-Serono and Sanofi Aventis. Consulted for Magenta Therapeutics and Jasper Therapeutics. Kristina M. Harris: Currently employed by and holds equity in Rubius Therapeutics. AB-O: Participated as a speaker in meetings sponsored by and received consulting  fees from Accure, Atara Biotherapeutics, Biogen, BMS/Celgene/Receptos, GlaxoSmithKline, Gossamer, Janssen/Actelion, Medimmune, Merck/EMD Serono, Novartis, Roche/Genentech, Sanofi-Genzyme; and has received grant support to the  University of Pennsylvania from Biogen Idec, Roche/Genentech, Merck/EMD Serono and Novartis.\n",
      "\n",
      "Bar-Or, Amit\n",
      "Declaration of Competing Interest LAC, Noha Lim, Tobias Zrzavy, Jose I. Fernandez-Velasco-V: None. Ina Mexhitaj: Currently employed by Sanofi. Luisa M. Villar: Served on scientific advisory boards, participated in meetings sponsored by, received speaking honoraria, travel funding, or research grants from Roche, Sanofi, Merck, Biogen, Bristol Myers, and Novartis. Paolo A. Muraro: Received travel support and speaker honoraria from unrestricted educational activities organized by Novartis, Bayer HealthCare, Bayer Pharma, Biogen Idec, Merck-Serono and Sanofi Aventis. Consulted for Magenta Therapeutics and Jasper Therapeutics. Kristina M. Harris: Currently employed by and holds equity in Rubius Therapeutics. Amit Bar-Or-O: Participated as a speaker in meetings sponsored by and received consulting  fees from Accure, Atara Biotherapeutics, Biogen, BMS/Celgene/Receptos, GlaxoSmithKline, Gossamer, Janssen/Actelion, Medimmune, Merck/EMD Serono, Novartis, Roche/Genentech, Sanofi-Genzyme; and has received grant support to the  University of Pennsylvania from Biogen Idec, Roche/Genentech, Merck/EMD Serono and Novartis.\n",
      "\n",
      "Cooney, Laura A.\n",
      "Declaration of Competing Interest Laura A. Cooney, Noha Lim, Tobias Zrzavy, Jose I. Fernandez-Velasco-V: None. Ina Mexhitaj: Currently employed by Sanofi. Luisa M. Villar: Served on scientific advisory boards, participated in meetings sponsored by, received speaking honoraria, travel funding, or research grants from Roche, Sanofi, Merck, Biogen, Bristol Myers, and Novartis. Paolo A. Muraro: Received travel support and speaker honoraria from unrestricted educational activities organized by Novartis, Bayer HealthCare, Bayer Pharma, Biogen Idec, Merck-Serono and Sanofi Aventis. Consulted for Magenta Therapeutics and Jasper Therapeutics. Kristina M. Harris: Currently employed by and holds equity in Rubius Therapeutics. Amit Bar-Or-O: Participated as a speaker in meetings sponsored by and received consulting  fees from Accure, Atara Biotherapeutics, Biogen, BMS/Celgene/Receptos, GlaxoSmithKline, Gossamer, Janssen/Actelion, Medimmune, Merck/EMD Serono, Novartis, Roche/Genentech, Sanofi-Genzyme; and has received grant support to the  University of Pennsylvania from Biogen Idec, Roche/Genentech, Merck/EMD Serono and Novartis.\n",
      "\n",
      "Bolik, Stephanie\n",
      "Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Juliette Jouhet reports financial support was provided by French National Research Agency. Stephanie Bolik reports financial support was provided  by Institut Laue-Langevin. Stephanie Bolik reports financial support was provided by French National Research Agency.\n",
      "\n",
      "Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Juliette Jouhet reports financial support was provided by French National Research Agency. Stephanie Bolik reports financial support was provided  by Institut Laue-Langevin. Stephanie Bolik reports financial support was provided by French National Research Agency.\n",
      "\n",
      "Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Juliette Jouhet reports financial support was provided by French National Research Agency. Stephanie Bolik reports financial support was provided  by Institut Laue-Langevin. Stephanie Bolik reports financial support was provided by French National Research Agency.\n",
      "\n",
      "Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Juliette Jouhet reports financial support was provided by French National Research Agency. Stephanie Bolik reports financial support was provided  by Institut Laue-Langevin. Stephanie Bolik reports financial support was provided by French National Research Agency.\n",
      "\n",
      "Jouhet, Juliette\n",
      "Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Juliette Jouhet reports financial support was provided by French National Research Agency. Stephanie Bolik reports financial support was provided  by Institut Laue-Langevin. Stephanie Bolik reports financial support was provided by French National Research Agency.\n",
      "\n",
      "Marie Todd, Candice\n",
      "Dr. Candice Marie Todd: No conflicts Dr. Chrsitine lay: H. Lundbeck A/S Advisory Board  Teva Pharmaceuticals Eli Lilly Novartis All fees were paid to Women's College Hospital's Department of Medicine Dr. Claire Sandoe: Lundbeck, Eli Lilly, Abbvie, Aralez, and Novartis. All fees were paid to Women's College Hospital's Department of Medicine\n",
      "\n",
      "Sandoe, Claire H.\n",
      "Dr. Candice Marie Todd: No conflicts Dr. Chrsitine lay: H. Lundbeck A/S Advisory Board  Teva Pharmaceuticals Eli Lilly Novartis All fees were paid to Women's College Hospital's Department of Medicine Dr. Claire H. Sandoe: Lundbeck, Eli Lilly, Abbvie, Aralez, and Novartis. All fees were paid to Women's College Hospital's Department of Medicine\n",
      "\n",
      "Dr. Candice Marie Todd: No conflicts Dr. Chrsitine lay: H. Lundbeck A/S Advisory Board  Teva Pharmaceuticals Eli Lilly Novartis All fees were paid to Women's College Hospital's Department of Medicine Dr. Claire H. Sandoe: Lundbeck, Eli Lilly, Abbvie, Aralez, and Novartis. All fees were paid to Women's College Hospital's Department of Medicine\n",
      "\n",
      "Dr. Bert Vargas is employed by Eli Lilly and Co.\n",
      "\n",
      "Dr. Bert Vargas is employed by Eli Lilly and Co.\n",
      "\n",
      "Vargas, Bert B.\n",
      "Dr. Bert B. Vargas is employed by Eli Lilly and Co.\n",
      "\n",
      "Dr. Bert B. Vargas is employed by Eli Lilly and Co.\n",
      "\n",
      "I have served as the principal investigator of the completed JUPITER trial, which was funded by AstraZeneca and evaluated the role of statin therapy among individuals with residual inflammatory risk. I have served as principal investigator of the completed CANTOS trial, which was funded by Novartis and evaluated IL-1b inhibition in cardiovascular disease. I have served as principal  investigator of the completed CIRT trial, which was funded by the US National Heart Lung and Blood Institute (NHLBI) and evaluated low-dose methotrexate in cardiovascular disease. I am serving as principal investigator of studies of inflammatory biomarkers associated with eicosapent ethyl, supported by Amarin, and bempedoic acid, supported by Esperion, and am currently serving as the co-chair of the ongoing ZEUS trial, which is funded by Novo Nordisk and evaluating the role of IL-6 inhibition in cardiovascular disease. I am also a consultant for Flame, Agepha, Jannsen, and Montai Health, entities involved at least partially in the development of novel anti-inflammatory therapies that might be applied to either cardiovascular disease or cancer. I also report research grants from Kowa, Pfizer, and the NHLBI outside the area of work commented on here, and personal fees from AstraZeneca, Civi Biopharm, GSK, SOCAR, Health Outlook, New Amsterdam, Boehringer Ingelheim, Angiowave, RTI, Horizon Therapeutics, Cardio Therapeutics, the Peter Munk Advisory Bord (University of Toronto), the Leducq Foundation, Paris FR, and the Baim Institute (Boston, MA, USA), outside the area of work commented on here.\n",
      "\n",
      "Declaration of interests JJVM reports personal fees for lectures from Abbott, Alkem Metabolics, Eris Lifesciences, Hikma, Lupin, Sun Pharmaceuticals, Medscape/Heart.Org, ProAdWise Communications, Radcliffe Cardiology, Servier, and  the Corpus; and fees paid to their university for steering committees and advisory board membership, trial planning, being principal investigator or co-principal investigator for trials, consulting and advising, and travel expenses from Cytokinetics, Amgen, AstraZeneca, Theracos, Ionis Pharmaceuticals,  DalCor, Cardurion, Novartis, GSK, Bayer, KBP Biosciences, Boehringer Ingelheim, and Bristol-Myers Squibb. All other authors declare no competing interests.\n",
      "\n",
      "Declaration of interests JJVM reports personal fees for lectures from Abbott, Alkem Metabolics, Eris Lifesciences, Hikma, Lupin, Sun Pharmaceuticals, Medscape/Heart.Org, ProAdWise Communications, Radcliffe Cardiology, Servier, and  the Corpus; and fees paid to their university for steering committees and advisory board membership, trial planning, being principal investigator or co-principal investigator for trials, consulting and advising, and travel expenses from Cytokinetics, Amgen, AstraZeneca, Theracos, Ionis Pharmaceuticals,  DalCor, Cardurion, Novartis, GSK, Bayer, KBP Biosciences, Boehringer Ingelheim, and Bristol-Myers Squibb. All other authors declare no competing interests.\n",
      "\n",
      "Declaration of interests JJVM reports personal fees for lectures from Abbott, Alkem Metabolics, Eris Lifesciences, Hikma, Lupin, Sun Pharmaceuticals, Medscape/Heart.Org, ProAdWise Communications, Radcliffe Cardiology, Servier, and  the Corpus; and fees paid to their university for steering committees and advisory board membership, trial planning, being principal investigator or co-principal investigator for trials, consulting and advising, and travel expenses from Cytokinetics, Amgen, AstraZeneca, Theracos, Ionis Pharmaceuticals,  DalCor, Cardurion, Novartis, GSK, Bayer, KBP Biosciences, Boehringer Ingelheim, and Bristol-Myers Squibb. All other authors declare no competing interests.\n",
      "\n",
      "Declaration of interests JJVM reports personal fees for lectures from Abbott, Alkem Metabolics, Eris Lifesciences, Hikma, Lupin, Sun Pharmaceuticals, Medscape/Heart.Org, ProAdWise Communications, Radcliffe Cardiology, Servier, and  the Corpus; and fees paid to their university for steering committees and advisory board membership, trial planning, being principal investigator or co-principal investigator for trials, consulting and advising, and travel expenses from Cytokinetics, Amgen, AstraZeneca, Theracos, Ionis Pharmaceuticals,  DalCor, Cardurion, Novartis, GSK, Bayer, KBP Biosciences, Boehringer Ingelheim, and Bristol-Myers Squibb. All other authors declare no competing interests.\n",
      "\n",
      "Declaration of interests JJVM reports personal fees for lectures from Abbott, Alkem Metabolics, Eris Lifesciences, Hikma, Lupin, Sun Pharmaceuticals, Medscape/Heart.Org, ProAdWise Communications, Radcliffe Cardiology, Servier, and  the Corpus; and fees paid to their university for steering committees and advisory board membership, trial planning, being principal investigator or co-principal investigator for trials, consulting and advising, and travel expenses from Cytokinetics, Amgen, AstraZeneca, Theracos, Ionis Pharmaceuticals,  DalCor, Cardurion, Novartis, GSK, Bayer, KBP Biosciences, Boehringer Ingelheim, and Bristol-Myers Squibb. All other authors declare no competing interests.\n",
      "\n",
      "Declaration of interests JJVM reports personal fees for lectures from Abbott, Alkem Metabolics, Eris Lifesciences, Hikma, Lupin, Sun Pharmaceuticals, Medscape/Heart.Org, ProAdWise Communications, Radcliffe Cardiology, Servier, and  the Corpus; and fees paid to their university for steering committees and advisory board membership, trial planning, being principal investigator or co-principal investigator for trials, consulting and advising, and travel expenses from Cytokinetics, Amgen, AstraZeneca, Theracos, Ionis Pharmaceuticals,  DalCor, Cardurion, Novartis, GSK, Bayer, KBP Biosciences, Boehringer Ingelheim, and Bristol-Myers Squibb. All other authors declare no competing interests.\n",
      "\n",
      "Declaration of interests JJVM reports personal fees for lectures from Abbott, Alkem Metabolics, Eris Lifesciences, Hikma, Lupin, Sun Pharmaceuticals, Medscape/Heart.Org, ProAdWise Communications, Radcliffe Cardiology, Servier, and  the Corpus; and fees paid to their university for steering committees and advisory board membership, trial planning, being principal investigator or co-principal investigator for trials, consulting and advising, and travel expenses from Cytokinetics, Amgen, AstraZeneca, Theracos, Ionis Pharmaceuticals,  DalCor, Cardurion, Novartis, GSK, Bayer, KBP Biosciences, Boehringer Ingelheim, and Bristol-Myers Squibb. All other authors declare no competing interests.\n",
      "\n",
      "Declaration of interests JJVM reports personal fees for lectures from Abbott, Alkem Metabolics, Eris Lifesciences, Hikma, Lupin, Sun Pharmaceuticals, Medscape/Heart.Org, ProAdWise Communications, Radcliffe Cardiology, Servier, and  the Corpus; and fees paid to their university for steering committees and advisory board membership, trial planning, being principal investigator or co-principal investigator for trials, consulting and advising, and travel expenses from Cytokinetics, Amgen, AstraZeneca, Theracos, Ionis Pharmaceuticals,  DalCor, Cardurion, Novartis, GSK, Bayer, KBP Biosciences, Boehringer Ingelheim, and Bristol-Myers Squibb. All other authors declare no competing interests.\n",
      "\n",
      "McMurray, John J.V.\n",
      "Declaration of interests John J.V. McMurray reports personal fees for lectures from Abbott, Alkem Metabolics, Eris Lifesciences, Hikma, Lupin, Sun Pharmaceuticals, Medscape/Heart.Org, ProAdWise Communications, Radcliffe Cardiology, Servier, and  the Corpus; and fees paid to their university for steering committees and advisory board membership, trial planning, being principal investigator or co-principal investigator for trials, consulting and advising, and travel expenses from Cytokinetics, Amgen, AstraZeneca, Theracos, Ionis Pharmaceuticals,  DalCor, Cardurion, Novartis, GSK, Bayer, KBP Biosciences, Boehringer Ingelheim, and Bristol-Myers Squibb. All other authors declare no competing interests.\n",
      "\n",
      "Verbakel, Jan Y.\n",
      "Declaration of interests John Jan Y. Verbakel McMurray reports personal fees for lectures from Abbott, Alkem Metabolics, Eris Lifesciences, Hikma, Lupin, Sun Pharmaceuticals, Medscape/Heart.Org, ProAdWise Communications, Radcliffe Cardiology, Servier, and  the Corpus; and fees paid to their university for steering committees and advisory board membership, trial planning, being principal investigator or co-principal investigator for trials, consulting and advising, and travel expenses from Cytokinetics, Amgen, AstraZeneca, Theracos, Ionis Pharmaceuticals,  DalCor, Cardurion, Novartis, GSK, Bayer, KBP Biosciences, Boehringer Ingelheim, and Bristol-Myers Squibb. All other authors declare no competing interests.\n",
      "\n",
      "Vaduganathan, Muthiah\n",
      "Declaration of interests Muthiah Vaduganathan has received research grant support or served on advisory boards for American Regent, Amgen, AstraZeneca, Bayer, Baxter Healthcare, Boehringer Ingelheim, Cytokinetics, Lexicon Pharmaceuticals, Novartis, Pharmacosmos, Relypsa, Roche Diagnostics, and Sanofi; received speaker  fees from AstraZeneca, Novartis, and Roche Diagnostics; and participates on clinical trial committees for studies sponsored by Galmed, Novartis, Bayer, Occlutech, and Impulse Dynamics. KFD's employer has been remunerated by AstraZeneca for clinical trial work. KFD also reports speakers' fees from AstraZeneca and research funding from Boehringer Ingelheim. KFD, PSJ, and JJVM are funded by a British Heart Foundation Centre of Research Excellence Grant. BLC has received consulting fees from Boehringer Ingelheim. PSJ's employer has been remunerated by AstraZeneca, Bayer, and Novo Nordisk for clinical trial work. PSJ  also reports consulting and speakers' fees from Novartis, AstraZeneca, and Boehringer Ingelheim; and research funding Boehringer Ingelheim. RadB has received research grant support from AstraZeneca, Abbott, Boehringer Ingelheim, Cardior Pharmaceuticals, Ionis Pharmaceuticals, Novo Nordisk, and Roche; and received speaker fees from Abbott, AstraZeneca, Bayer, Novartis, and Roche. AFH reports research grant support from American Regent, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Merck, Novartis, Somologic, and Verily; and consulting Fees from Amgen, AstraZeneca, Bayer, Biofourmis, Boston Scientific, Cytokinetics, Merck, Novartis and NovoNordisk. SEI has served on clinical trial committees or as a consultant to AstraZeneca, Boehringer Ingelheim, Novo Nordisk, Lexicon, Merck, Pfizer, vTv Therapeutics, Abbott, and Esperion; and has given lectures sponsored by AstraZeneca and Boehringer Ingelheim. MNK reports research grant support from AstraZeneca and Boehringer Ingelheim; and consulting fees from Alnylam, AstraZeneca, Amgen, Bayer, Boehringer Ingelheim, Cytokinetics, Esperion, Eli Lilly, Janssen, Lexicon, Merck (Diabetes and Cardiovascular), Pharmacosmos, Novo Nordisk, Sanofi, and Vifor. CSPL is supported by a Clinician Scientist Award from the National Medical Research Council of Singapore; has received research support from Bayer and Roche Diagnostics; has served as consultant or on the advisory board, steering committee, or executive committee for Abbott, Actelion,  Alleviant Medical, Allysta Pharma, Amgen, AnaCardio, Applied Therapeutics, AstraZeneca, Bayer, Boehringer Ingelheim, Boston Scientific, Cytokinetics, Darma, EchoNous, Impulse Dynamics, Ionis Pharmaceutical, Janssen Research & Development, Medscape/WebMD Global, Merck, Novartis, Novo Nordisk, Prosciento, Radcliffe Group, Roche Diagnostics, Sanofi, Siemens Healthcare Diagnostics, and Us2.ai; and serves as co-founder and non-executive director of Us2.ai. FM has received personal fees from AstraZeneca. SJS reports research grants from the US National  Institutes of Health, Actelion, AstraZeneca, Corvia, Novartis, and Pfizer; and consulting fees from Abbott, Actelion, AstraZeneca, Amgen, Aria CV, Axon Therapies, Bayer, Boehringer Ingelheim, Boston Scientific, Bristol Myers Squibb,  Cardiora, Coridea, CVRx, Cyclerion, Cytokinetics, Edwards Lifesciences, Eidos, Eisai, Imara, Impulse Dynamics, Intellia, Ionis, Ironwood, Lilly, Merck, MyoKardia, Novartis, Novo Nordisk, Pfizer, Prothena, Regeneron, Rivus, Sanofi, Shifamed, Tenax, Tenaya, and United Therapeutics. ASD reports institutional grant support from Abbott, Alnylam, AstraZeneca, Bayer, Novartis; and consulting fees from Abbott, Alnylam, AstraZeneca, Avidity, Axon Therapeutics, Bayer, Biofourmis, Boston Scientific, Cytokinetics, GlaxoSmithKline, Merck, Novartis, Parel, Regeneron, Roche, and Verily. JJVM has received funding to his institution, Glasgow University, for his work on clinical trials, consulting, and other activities from Alnylam, Amgen, AstraZeneca, Bayer, Bristol Myers Squibb, Cardurion, Cytokinetics, GlaxoSmithKline, Novartis, Pfizer, and Theracos; and has received personal lecture fees from the Corpus, Abbott, Hickma, Sun Pharmaceuticals, and Medsca. SDS has received research grants from Actelion, Alnylam, Amgen, AstraZeneca, Bellerophon, Bayer, Bristol Myers Squibb, Celladon,  Cytokinetics, Eidos, Gilead, GlaxoSmithKline, Ionis, Lilly, Mesoblast, MyoKardia, National Institutes of Health/National Heart Lung and Blood Institute, Neurotronik, Novartis, NovoNordisk, Respicardia, Sanofi Pasteur, Theracos, and US2.AI; and has consulted for Abbott, Action, Akros, Alnylam, Amgen, Arena, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Cardior, Cardurion, Corvia, Cytokinetics, Daiichi-Sankyo, GlaxoSmithKline, Lilly, Merck, Myokardia, Novartis, Roche, Theracos, Quantum Genomics, Cardurion, Janssen, Cardiac Dimensions, Tenaya, Sanofi-Pasteur, Dinaqor, Tremeau, CellProThera, Moderna, American Regent, and Sarepta.\n",
      "\n",
      "Docherty, Kieran F.\n",
      "Declaration of interests Muthiah Vaduganathan has received research grant support or served on advisory boards for American Regent, Amgen, AstraZeneca, Bayer, Baxter Healthcare, Boehringer Ingelheim, Cytokinetics, Lexicon Pharmaceuticals, Novartis, Pharmacosmos, Relypsa, Roche Diagnostics, and Sanofi; received speaker  fees from AstraZeneca, Novartis, and Roche Diagnostics; and participates on clinical trial committees for studies sponsored by Galmed, Novartis, Bayer, Occlutech, and Impulse Dynamics. Kieran F. Docherty's employer has been remunerated by AstraZeneca for clinical trial work. Kieran F. Docherty also reports speakers' fees from AstraZeneca and research funding from Boehringer Ingelheim. Kieran F. Docherty, PSJ, and JJVM are funded by a British Heart Foundation Centre of Research Excellence Grant. BLC has received consulting fees from Boehringer Ingelheim. PSJ's employer has been remunerated by AstraZeneca, Bayer, and Novo Nordisk for clinical trial work. PSJ  also reports consulting and speakers' fees from Novartis, AstraZeneca, and Boehringer Ingelheim; and research funding Boehringer Ingelheim. RadB has received research grant support from AstraZeneca, Abbott, Boehringer Ingelheim, Cardior Pharmaceuticals, Ionis Pharmaceuticals, Novo Nordisk, and Roche; and received speaker fees from Abbott, AstraZeneca, Bayer, Novartis, and Roche. AFH reports research grant support from American Regent, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Merck, Novartis, Somologic, and Verily; and consulting Fees from Amgen, AstraZeneca, Bayer, Biofourmis, Boston Scientific, Cytokinetics, Merck, Novartis and NovoNordisk. SEI has served on clinical trial committees or as a consultant to AstraZeneca, Boehringer Ingelheim, Novo Nordisk, Lexicon, Merck, Pfizer, vTv Therapeutics, Abbott, and Esperion; and has given lectures sponsored by AstraZeneca and Boehringer Ingelheim. MNK reports research grant support from AstraZeneca and Boehringer Ingelheim; and consulting fees from Alnylam, AstraZeneca, Amgen, Bayer, Boehringer Ingelheim, Cytokinetics, Esperion, Eli Lilly, Janssen, Lexicon, Merck (Diabetes and Cardiovascular), Pharmacosmos, Novo Nordisk, Sanofi, and Vifor. CSPL is supported by a Clinician Scientist Award from the National Medical Research Council of Singapore; has received research support from Bayer and Roche Diagnostics; has served as consultant or on the advisory board, steering committee, or executive committee for Abbott, Actelion,  Alleviant Medical, Allysta Pharma, Amgen, AnaCardio, Applied Therapeutics, AstraZeneca, Bayer, Boehringer Ingelheim, Boston Scientific, Cytokinetics, Darma, EchoNous, Impulse Dynamics, Ionis Pharmaceutical, Janssen Research & Development, Medscape/WebMD Global, Merck, Novartis, Novo Nordisk, Prosciento, Radcliffe Group, Roche Diagnostics, Sanofi, Siemens Healthcare Diagnostics, and Us2.ai; and serves as co-founder and non-executive director of Us2.ai. FM has received personal fees from AstraZeneca. SJS reports research grants from the US National  Institutes of Health, Actelion, AstraZeneca, Corvia, Novartis, and Pfizer; and consulting fees from Abbott, Actelion, AstraZeneca, Amgen, Aria CV, Axon Therapies, Bayer, Boehringer Ingelheim, Boston Scientific, Bristol Myers Squibb,  Cardiora, Coridea, CVRx, Cyclerion, Cytokinetics, Edwards Lifesciences, Eidos, Eisai, Imara, Impulse Dynamics, Intellia, Ionis, Ironwood, Lilly, Merck, MyoKardia, Novartis, Novo Nordisk, Pfizer, Prothena, Regeneron, Rivus, Sanofi, Shifamed, Tenax, Tenaya, and United Therapeutics. ASD reports institutional grant support from Abbott, Alnylam, AstraZeneca, Bayer, Novartis; and consulting fees from Abbott, Alnylam, AstraZeneca, Avidity, Axon Therapeutics, Bayer, Biofourmis, Boston Scientific, Cytokinetics, GlaxoSmithKline, Merck, Novartis, Parel, Regeneron, Roche, and Verily. JJVM has received funding to his institution, Glasgow University, for his work on clinical trials, consulting, and other activities from Alnylam, Amgen, AstraZeneca, Bayer, Bristol Myers Squibb, Cardurion, Cytokinetics, GlaxoSmithKline, Novartis, Pfizer, and Theracos; and has received personal lecture fees from the Corpus, Abbott, Hickma, Sun Pharmaceuticals, and Medsca. SDS has received research grants from Actelion, Alnylam, Amgen, AstraZeneca, Bellerophon, Bayer, Bristol Myers Squibb, Celladon,  Cytokinetics, Eidos, Gilead, GlaxoSmithKline, Ionis, Lilly, Mesoblast, MyoKardia, National Institutes of Health/National Heart Lung and Blood Institute, Neurotronik, Novartis, NovoNordisk, Respicardia, Sanofi Pasteur, Theracos, and US2.AI; and has consulted for Abbott, Action, Akros, Alnylam, Amgen, Arena, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Cardior, Cardurion, Corvia, Cytokinetics, Daiichi-Sankyo, GlaxoSmithKline, Lilly, Merck, Myokardia, Novartis, Roche, Theracos, Quantum Genomics, Cardurion, Janssen, Cardiac Dimensions, Tenaya, Sanofi-Pasteur, Dinaqor, Tremeau, CellProThera, Moderna, American Regent, and Sarepta.\n",
      "\n",
      "Claggett, Brian L.\n",
      "Declaration of interests Muthiah Vaduganathan has received research grant support or served on advisory boards for American Regent, Amgen, AstraZeneca, Bayer, Baxter Healthcare, Boehringer Ingelheim, Cytokinetics, Lexicon Pharmaceuticals, Novartis, Pharmacosmos, Relypsa, Roche Diagnostics, and Sanofi; received speaker  fees from AstraZeneca, Novartis, and Roche Diagnostics; and participates on clinical trial committees for studies sponsored by Galmed, Novartis, Bayer, Occlutech, and Impulse Dynamics. Kieran F. Docherty's employer has been remunerated by AstraZeneca for clinical trial work. Kieran F. Docherty also reports speakers' fees from AstraZeneca and research funding from Boehringer Ingelheim. Kieran F. Docherty, PSJ, and JJVM are funded by a British Heart Foundation Centre of Research Excellence Grant. Brian L. Claggett has received consulting fees from Boehringer Ingelheim. PSJ's employer has been remunerated by AstraZeneca, Bayer, and Novo Nordisk for clinical trial work. PSJ  also reports consulting and speakers' fees from Novartis, AstraZeneca, and Boehringer Ingelheim; and research funding Boehringer Ingelheim. RadB has received research grant support from AstraZeneca, Abbott, Boehringer Ingelheim, Cardior Pharmaceuticals, Ionis Pharmaceuticals, Novo Nordisk, and Roche; and received speaker fees from Abbott, AstraZeneca, Bayer, Novartis, and Roche. AFH reports research grant support from American Regent, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Merck, Novartis, Somologic, and Verily; and consulting Fees from Amgen, AstraZeneca, Bayer, Biofourmis, Boston Scientific, Cytokinetics, Merck, Novartis and NovoNordisk. SEI has served on clinical trial committees or as a consultant to AstraZeneca, Boehringer Ingelheim, Novo Nordisk, Lexicon, Merck, Pfizer, vTv Therapeutics, Abbott, and Esperion; and has given lectures sponsored by AstraZeneca and Boehringer Ingelheim. MNK reports research grant support from AstraZeneca and Boehringer Ingelheim; and consulting fees from Alnylam, AstraZeneca, Amgen, Bayer, Boehringer Ingelheim, Cytokinetics, Esperion, Eli Lilly, Janssen, Lexicon, Merck (Diabetes and Cardiovascular), Pharmacosmos, Novo Nordisk, Sanofi, and Vifor. CSPL is supported by a Clinician Scientist Award from the National Medical Research Council of Singapore; has received research support from Bayer and Roche Diagnostics; has served as consultant or on the advisory board, steering committee, or executive committee for Abbott, Actelion,  Alleviant Medical, Allysta Pharma, Amgen, AnaCardio, Applied Therapeutics, AstraZeneca, Bayer, Boehringer Ingelheim, Boston Scientific, Cytokinetics, Darma, EchoNous, Impulse Dynamics, Ionis Pharmaceutical, Janssen Research & Development, Medscape/WebMD Global, Merck, Novartis, Novo Nordisk, Prosciento, Radcliffe Group, Roche Diagnostics, Sanofi, Siemens Healthcare Diagnostics, and Us2.ai; and serves as co-founder and non-executive director of Us2.ai. FM has received personal fees from AstraZeneca. SJS reports research grants from the US National  Institutes of Health, Actelion, AstraZeneca, Corvia, Novartis, and Pfizer; and consulting fees from Abbott, Actelion, AstraZeneca, Amgen, Aria CV, Axon Therapies, Bayer, Boehringer Ingelheim, Boston Scientific, Bristol Myers Squibb,  Cardiora, Coridea, CVRx, Cyclerion, Cytokinetics, Edwards Lifesciences, Eidos, Eisai, Imara, Impulse Dynamics, Intellia, Ionis, Ironwood, Lilly, Merck, MyoKardia, Novartis, Novo Nordisk, Pfizer, Prothena, Regeneron, Rivus, Sanofi, Shifamed, Tenax, Tenaya, and United Therapeutics. ASD reports institutional grant support from Abbott, Alnylam, AstraZeneca, Bayer, Novartis; and consulting fees from Abbott, Alnylam, AstraZeneca, Avidity, Axon Therapeutics, Bayer, Biofourmis, Boston Scientific, Cytokinetics, GlaxoSmithKline, Merck, Novartis, Parel, Regeneron, Roche, and Verily. JJVM has received funding to his institution, Glasgow University, for his work on clinical trials, consulting, and other activities from Alnylam, Amgen, AstraZeneca, Bayer, Bristol Myers Squibb, Cardurion, Cytokinetics, GlaxoSmithKline, Novartis, Pfizer, and Theracos; and has received personal lecture fees from the Corpus, Abbott, Hickma, Sun Pharmaceuticals, and Medsca. SDS has received research grants from Actelion, Alnylam, Amgen, AstraZeneca, Bellerophon, Bayer, Bristol Myers Squibb, Celladon,  Cytokinetics, Eidos, Gilead, GlaxoSmithKline, Ionis, Lilly, Mesoblast, MyoKardia, National Institutes of Health/National Heart Lung and Blood Institute, Neurotronik, Novartis, NovoNordisk, Respicardia, Sanofi Pasteur, Theracos, and US2.AI; and has consulted for Abbott, Action, Akros, Alnylam, Amgen, Arena, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Cardior, Cardurion, Corvia, Cytokinetics, Daiichi-Sankyo, GlaxoSmithKline, Lilly, Merck, Myokardia, Novartis, Roche, Theracos, Quantum Genomics, Cardurion, Janssen, Cardiac Dimensions, Tenaya, Sanofi-Pasteur, Dinaqor, Tremeau, CellProThera, Moderna, American Regent, and Sarepta.\n",
      "\n",
      "Jhund, Pardeep S.\n",
      "Declaration of interests Muthiah Vaduganathan has received research grant support or served on advisory boards for American Regent, Amgen, AstraZeneca, Bayer, Baxter Healthcare, Boehringer Ingelheim, Cytokinetics, Lexicon Pharmaceuticals, Novartis, Pharmacosmos, Relypsa, Roche Diagnostics, and Sanofi; received speaker  fees from AstraZeneca, Novartis, and Roche Diagnostics; and participates on clinical trial committees for studies sponsored by Galmed, Novartis, Bayer, Occlutech, and Impulse Dynamics. Kieran F. Docherty's employer has been remunerated by AstraZeneca for clinical trial work. Kieran F. Docherty also reports speakers' fees from AstraZeneca and research funding from Boehringer Ingelheim. Kieran F. Docherty, Pardeep S. Jhund, and JJVM are funded by a British Heart Foundation Centre of Research Excellence Grant. Brian L. Claggett has received consulting fees from Boehringer Ingelheim. Pardeep S. Jhund's employer has been remunerated by AstraZeneca, Bayer, and Novo Nordisk for clinical trial work. Pardeep S. Jhund  also reports consulting and speakers' fees from Novartis, AstraZeneca, and Boehringer Ingelheim; and research funding Boehringer Ingelheim. RadB has received research grant support from AstraZeneca, Abbott, Boehringer Ingelheim, Cardior Pharmaceuticals, Ionis Pharmaceuticals, Novo Nordisk, and Roche; and received speaker fees from Abbott, AstraZeneca, Bayer, Novartis, and Roche. AFH reports research grant support from American Regent, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Merck, Novartis, Somologic, and Verily; and consulting Fees from Amgen, AstraZeneca, Bayer, Biofourmis, Boston Scientific, Cytokinetics, Merck, Novartis and NovoNordisk. SEI has served on clinical trial committees or as a consultant to AstraZeneca, Boehringer Ingelheim, Novo Nordisk, Lexicon, Merck, Pfizer, vTv Therapeutics, Abbott, and Esperion; and has given lectures sponsored by AstraZeneca and Boehringer Ingelheim. MNK reports research grant support from AstraZeneca and Boehringer Ingelheim; and consulting fees from Alnylam, AstraZeneca, Amgen, Bayer, Boehringer Ingelheim, Cytokinetics, Esperion, Eli Lilly, Janssen, Lexicon, Merck (Diabetes and Cardiovascular), Pharmacosmos, Novo Nordisk, Sanofi, and Vifor. CSPL is supported by a Clinician Scientist Award from the National Medical Research Council of Singapore; has received research support from Bayer and Roche Diagnostics; has served as consultant or on the advisory board, steering committee, or executive committee for Abbott, Actelion,  Alleviant Medical, Allysta Pharma, Amgen, AnaCardio, Applied Therapeutics, AstraZeneca, Bayer, Boehringer Ingelheim, Boston Scientific, Cytokinetics, Darma, EchoNous, Impulse Dynamics, Ionis Pharmaceutical, Janssen Research & Development, Medscape/WebMD Global, Merck, Novartis, Novo Nordisk, Prosciento, Radcliffe Group, Roche Diagnostics, Sanofi, Siemens Healthcare Diagnostics, and Us2.ai; and serves as co-founder and non-executive director of Us2.ai. FM has received personal fees from AstraZeneca. SJS reports research grants from the US National  Institutes of Health, Actelion, AstraZeneca, Corvia, Novartis, and Pfizer; and consulting fees from Abbott, Actelion, AstraZeneca, Amgen, Aria CV, Axon Therapies, Bayer, Boehringer Ingelheim, Boston Scientific, Bristol Myers Squibb,  Cardiora, Coridea, CVRx, Cyclerion, Cytokinetics, Edwards Lifesciences, Eidos, Eisai, Imara, Impulse Dynamics, Intellia, Ionis, Ironwood, Lilly, Merck, MyoKardia, Novartis, Novo Nordisk, Pfizer, Prothena, Regeneron, Rivus, Sanofi, Shifamed, Tenax, Tenaya, and United Therapeutics. ASD reports institutional grant support from Abbott, Alnylam, AstraZeneca, Bayer, Novartis; and consulting fees from Abbott, Alnylam, AstraZeneca, Avidity, Axon Therapeutics, Bayer, Biofourmis, Boston Scientific, Cytokinetics, GlaxoSmithKline, Merck, Novartis, Parel, Regeneron, Roche, and Verily. JJVM has received funding to his institution, Glasgow University, for his work on clinical trials, consulting, and other activities from Alnylam, Amgen, AstraZeneca, Bayer, Bristol Myers Squibb, Cardurion, Cytokinetics, GlaxoSmithKline, Novartis, Pfizer, and Theracos; and has received personal lecture fees from the Corpus, Abbott, Hickma, Sun Pharmaceuticals, and Medsca. SDS has received research grants from Actelion, Alnylam, Amgen, AstraZeneca, Bellerophon, Bayer, Bristol Myers Squibb, Celladon,  Cytokinetics, Eidos, Gilead, GlaxoSmithKline, Ionis, Lilly, Mesoblast, MyoKardia, National Institutes of Health/National Heart Lung and Blood Institute, Neurotronik, Novartis, NovoNordisk, Respicardia, Sanofi Pasteur, Theracos, and US2.AI; and has consulted for Abbott, Action, Akros, Alnylam, Amgen, Arena, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Cardior, Cardurion, Corvia, Cytokinetics, Daiichi-Sankyo, GlaxoSmithKline, Lilly, Merck, Myokardia, Novartis, Roche, Theracos, Quantum Genomics, Cardurion, Janssen, Cardiac Dimensions, Tenaya, Sanofi-Pasteur, Dinaqor, Tremeau, CellProThera, Moderna, American Regent, and Sarepta.\n",
      "\n",
      "Declaration of interests Muthiah Vaduganathan has received research grant support or served on advisory boards for American Regent, Amgen, AstraZeneca, Bayer, Baxter Healthcare, Boehringer Ingelheim, Cytokinetics, Lexicon Pharmaceuticals, Novartis, Pharmacosmos, Relypsa, Roche Diagnostics, and Sanofi; received speaker  fees from AstraZeneca, Novartis, and Roche Diagnostics; and participates on clinical trial committees for studies sponsored by Galmed, Novartis, Bayer, Occlutech, and Impulse Dynamics. Kieran F. Docherty's employer has been remunerated by AstraZeneca for clinical trial work. Kieran F. Docherty also reports speakers' fees from AstraZeneca and research funding from Boehringer Ingelheim. Kieran F. Docherty, Pardeep S. Jhund, and JJVM are funded by a British Heart Foundation Centre of Research Excellence Grant. Brian L. Claggett has received consulting fees from Boehringer Ingelheim. Pardeep S. Jhund's employer has been remunerated by AstraZeneca, Bayer, and Novo Nordisk for clinical trial work. Pardeep S. Jhund  also reports consulting and speakers' fees from Novartis, AstraZeneca, and Boehringer Ingelheim; and research funding Boehringer Ingelheim. RadB has received research grant support from AstraZeneca, Abbott, Boehringer Ingelheim, Cardior Pharmaceuticals, Ionis Pharmaceuticals, Novo Nordisk, and Roche; and received speaker fees from Abbott, AstraZeneca, Bayer, Novartis, and Roche. AFH reports research grant support from American Regent, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Merck, Novartis, Somologic, and Verily; and consulting Fees from Amgen, AstraZeneca, Bayer, Biofourmis, Boston Scientific, Cytokinetics, Merck, Novartis and NovoNordisk. SEI has served on clinical trial committees or as a consultant to AstraZeneca, Boehringer Ingelheim, Novo Nordisk, Lexicon, Merck, Pfizer, vTv Therapeutics, Abbott, and Esperion; and has given lectures sponsored by AstraZeneca and Boehringer Ingelheim. MNK reports research grant support from AstraZeneca and Boehringer Ingelheim; and consulting fees from Alnylam, AstraZeneca, Amgen, Bayer, Boehringer Ingelheim, Cytokinetics, Esperion, Eli Lilly, Janssen, Lexicon, Merck (Diabetes and Cardiovascular), Pharmacosmos, Novo Nordisk, Sanofi, and Vifor. CSPL is supported by a Clinician Scientist Award from the National Medical Research Council of Singapore; has received research support from Bayer and Roche Diagnostics; has served as consultant or on the advisory board, steering committee, or executive committee for Abbott, Actelion,  Alleviant Medical, Allysta Pharma, Amgen, AnaCardio, Applied Therapeutics, AstraZeneca, Bayer, Boehringer Ingelheim, Boston Scientific, Cytokinetics, Darma, EchoNous, Impulse Dynamics, Ionis Pharmaceutical, Janssen Research & Development, Medscape/WebMD Global, Merck, Novartis, Novo Nordisk, Prosciento, Radcliffe Group, Roche Diagnostics, Sanofi, Siemens Healthcare Diagnostics, and Us2.ai; and serves as co-founder and non-executive director of Us2.ai. FM has received personal fees from AstraZeneca. SJS reports research grants from the US National  Institutes of Health, Actelion, AstraZeneca, Corvia, Novartis, and Pfizer; and consulting fees from Abbott, Actelion, AstraZeneca, Amgen, Aria CV, Axon Therapies, Bayer, Boehringer Ingelheim, Boston Scientific, Bristol Myers Squibb,  Cardiora, Coridea, CVRx, Cyclerion, Cytokinetics, Edwards Lifesciences, Eidos, Eisai, Imara, Impulse Dynamics, Intellia, Ionis, Ironwood, Lilly, Merck, MyoKardia, Novartis, Novo Nordisk, Pfizer, Prothena, Regeneron, Rivus, Sanofi, Shifamed, Tenax, Tenaya, and United Therapeutics. ASD reports institutional grant support from Abbott, Alnylam, AstraZeneca, Bayer, Novartis; and consulting fees from Abbott, Alnylam, AstraZeneca, Avidity, Axon Therapeutics, Bayer, Biofourmis, Boston Scientific, Cytokinetics, GlaxoSmithKline, Merck, Novartis, Parel, Regeneron, Roche, and Verily. JJVM has received funding to his institution, Glasgow University, for his work on clinical trials, consulting, and other activities from Alnylam, Amgen, AstraZeneca, Bayer, Bristol Myers Squibb, Cardurion, Cytokinetics, GlaxoSmithKline, Novartis, Pfizer, and Theracos; and has received personal lecture fees from the Corpus, Abbott, Hickma, Sun Pharmaceuticals, and Medsca. SDS has received research grants from Actelion, Alnylam, Amgen, AstraZeneca, Bellerophon, Bayer, Bristol Myers Squibb, Celladon,  Cytokinetics, Eidos, Gilead, GlaxoSmithKline, Ionis, Lilly, Mesoblast, MyoKardia, National Institutes of Health/National Heart Lung and Blood Institute, Neurotronik, Novartis, NovoNordisk, Respicardia, Sanofi Pasteur, Theracos, and US2.AI; and has consulted for Abbott, Action, Akros, Alnylam, Amgen, Arena, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Cardior, Cardurion, Corvia, Cytokinetics, Daiichi-Sankyo, GlaxoSmithKline, Lilly, Merck, Myokardia, Novartis, Roche, Theracos, Quantum Genomics, Cardurion, Janssen, Cardiac Dimensions, Tenaya, Sanofi-Pasteur, Dinaqor, Tremeau, CellProThera, Moderna, American Regent, and Sarepta.\n",
      "\n",
      "Hernandez, Adrian F.\n",
      "Declaration of interests Muthiah Vaduganathan has received research grant support or served on advisory boards for American Regent, Amgen, AstraZeneca, Bayer, Baxter Healthcare, Boehringer Ingelheim, Cytokinetics, Lexicon Pharmaceuticals, Novartis, Pharmacosmos, Relypsa, Roche Diagnostics, and Sanofi; received speaker  fees from AstraZeneca, Novartis, and Roche Diagnostics; and participates on clinical trial committees for studies sponsored by Galmed, Novartis, Bayer, Occlutech, and Impulse Dynamics. Kieran F. Docherty's employer has been remunerated by AstraZeneca for clinical trial work. Kieran F. Docherty also reports speakers' fees from AstraZeneca and research funding from Boehringer Ingelheim. Kieran F. Docherty, Pardeep S. Jhund, and JJVM are funded by a British Heart Foundation Centre of Research Excellence Grant. Brian L. Claggett has received consulting fees from Boehringer Ingelheim. Pardeep S. Jhund's employer has been remunerated by AstraZeneca, Bayer, and Novo Nordisk for clinical trial work. Pardeep S. Jhund  also reports consulting and speakers' fees from Novartis, AstraZeneca, and Boehringer Ingelheim; and research funding Boehringer Ingelheim. RadB has received research grant support from AstraZeneca, Abbott, Boehringer Ingelheim, Cardior Pharmaceuticals, Ionis Pharmaceuticals, Novo Nordisk, and Roche; and received speaker fees from Abbott, AstraZeneca, Bayer, Novartis, and Roche. Adrian F. Hernandez reports research grant support from American Regent, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Merck, Novartis, Somologic, and Verily; and consulting Fees from Amgen, AstraZeneca, Bayer, Biofourmis, Boston Scientific, Cytokinetics, Merck, Novartis and NovoNordisk. SEI has served on clinical trial committees or as a consultant to AstraZeneca, Boehringer Ingelheim, Novo Nordisk, Lexicon, Merck, Pfizer, vTv Therapeutics, Abbott, and Esperion; and has given lectures sponsored by AstraZeneca and Boehringer Ingelheim. MNK reports research grant support from AstraZeneca and Boehringer Ingelheim; and consulting fees from Alnylam, AstraZeneca, Amgen, Bayer, Boehringer Ingelheim, Cytokinetics, Esperion, Eli Lilly, Janssen, Lexicon, Merck (Diabetes and Cardiovascular), Pharmacosmos, Novo Nordisk, Sanofi, and Vifor. CSPL is supported by a Clinician Scientist Award from the National Medical Research Council of Singapore; has received research support from Bayer and Roche Diagnostics; has served as consultant or on the advisory board, steering committee, or executive committee for Abbott, Actelion,  Alleviant Medical, Allysta Pharma, Amgen, AnaCardio, Applied Therapeutics, AstraZeneca, Bayer, Boehringer Ingelheim, Boston Scientific, Cytokinetics, Darma, EchoNous, Impulse Dynamics, Ionis Pharmaceutical, Janssen Research & Development, Medscape/WebMD Global, Merck, Novartis, Novo Nordisk, Prosciento, Radcliffe Group, Roche Diagnostics, Sanofi, Siemens Healthcare Diagnostics, and Us2.ai; and serves as co-founder and non-executive director of Us2.ai. FM has received personal fees from AstraZeneca. SJS reports research grants from the US National  Institutes of Health, Actelion, AstraZeneca, Corvia, Novartis, and Pfizer; and consulting fees from Abbott, Actelion, AstraZeneca, Amgen, Aria CV, Axon Therapies, Bayer, Boehringer Ingelheim, Boston Scientific, Bristol Myers Squibb,  Cardiora, Coridea, CVRx, Cyclerion, Cytokinetics, Edwards Lifesciences, Eidos, Eisai, Imara, Impulse Dynamics, Intellia, Ionis, Ironwood, Lilly, Merck, MyoKardia, Novartis, Novo Nordisk, Pfizer, Prothena, Regeneron, Rivus, Sanofi, Shifamed, Tenax, Tenaya, and United Therapeutics. ASD reports institutional grant support from Abbott, Alnylam, AstraZeneca, Bayer, Novartis; and consulting fees from Abbott, Alnylam, AstraZeneca, Avidity, Axon Therapeutics, Bayer, Biofourmis, Boston Scientific, Cytokinetics, GlaxoSmithKline, Merck, Novartis, Parel, Regeneron, Roche, and Verily. JJVM has received funding to his institution, Glasgow University, for his work on clinical trials, consulting, and other activities from Alnylam, Amgen, AstraZeneca, Bayer, Bristol Myers Squibb, Cardurion, Cytokinetics, GlaxoSmithKline, Novartis, Pfizer, and Theracos; and has received personal lecture fees from the Corpus, Abbott, Hickma, Sun Pharmaceuticals, and Medsca. SDS has received research grants from Actelion, Alnylam, Amgen, AstraZeneca, Bellerophon, Bayer, Bristol Myers Squibb, Celladon,  Cytokinetics, Eidos, Gilead, GlaxoSmithKline, Ionis, Lilly, Mesoblast, MyoKardia, National Institutes of Health/National Heart Lung and Blood Institute, Neurotronik, Novartis, NovoNordisk, Respicardia, Sanofi Pasteur, Theracos, and US2.AI; and has consulted for Abbott, Action, Akros, Alnylam, Amgen, Arena, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Cardior, Cardurion, Corvia, Cytokinetics, Daiichi-Sankyo, GlaxoSmithKline, Lilly, Merck, Myokardia, Novartis, Roche, Theracos, Quantum Genomics, Cardurion, Janssen, Cardiac Dimensions, Tenaya, Sanofi-Pasteur, Dinaqor, Tremeau, CellProThera, Moderna, American Regent, and Sarepta.\n",
      "\n",
      "Inzucchi, Silvio E.\n",
      "Declaration of interests Muthiah Vaduganathan has received research grant support or served on advisory boards for American Regent, Amgen, AstraZeneca, Bayer, Baxter Healthcare, Boehringer Ingelheim, Cytokinetics, Lexicon Pharmaceuticals, Novartis, Pharmacosmos, Relypsa, Roche Diagnostics, and Sanofi; received speaker  fees from AstraZeneca, Novartis, and Roche Diagnostics; and participates on clinical trial committees for studies sponsored by Galmed, Novartis, Bayer, Occlutech, and Impulse Dynamics. Kieran F. Docherty's employer has been remunerated by AstraZeneca for clinical trial work. Kieran F. Docherty also reports speakers' fees from AstraZeneca and research funding from Boehringer Ingelheim. Kieran F. Docherty, Pardeep S. Jhund, and JJVM are funded by a British Heart Foundation Centre of Research Excellence Grant. Brian L. Claggett has received consulting fees from Boehringer Ingelheim. Pardeep S. Jhund's employer has been remunerated by AstraZeneca, Bayer, and Novo Nordisk for clinical trial work. Pardeep S. Jhund  also reports consulting and speakers' fees from Novartis, AstraZeneca, and Boehringer Ingelheim; and research funding Boehringer Ingelheim. RadB has received research grant support from AstraZeneca, Abbott, Boehringer Ingelheim, Cardior Pharmaceuticals, Ionis Pharmaceuticals, Novo Nordisk, and Roche; and received speaker fees from Abbott, AstraZeneca, Bayer, Novartis, and Roche. Adrian F. Hernandez reports research grant support from American Regent, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Merck, Novartis, Somologic, and Verily; and consulting Fees from Amgen, AstraZeneca, Bayer, Biofourmis, Boston Scientific, Cytokinetics, Merck, Novartis and NovoNordisk. Silvio E. Inzucchi has served on clinical trial committees or as a consultant to AstraZeneca, Boehringer Ingelheim, Novo Nordisk, Lexicon, Merck, Pfizer, vTv Therapeutics, Abbott, and Esperion; and has given lectures sponsored by AstraZeneca and Boehringer Ingelheim. MNK reports research grant support from AstraZeneca and Boehringer Ingelheim; and consulting fees from Alnylam, AstraZeneca, Amgen, Bayer, Boehringer Ingelheim, Cytokinetics, Esperion, Eli Lilly, Janssen, Lexicon, Merck (Diabetes and Cardiovascular), Pharmacosmos, Novo Nordisk, Sanofi, and Vifor. CSPL is supported by a Clinician Scientist Award from the National Medical Research Council of Singapore; has received research support from Bayer and Roche Diagnostics; has served as consultant or on the advisory board, steering committee, or executive committee for Abbott, Actelion,  Alleviant Medical, Allysta Pharma, Amgen, AnaCardio, Applied Therapeutics, AstraZeneca, Bayer, Boehringer Ingelheim, Boston Scientific, Cytokinetics, Darma, EchoNous, Impulse Dynamics, Ionis Pharmaceutical, Janssen Research & Development, Medscape/WebMD Global, Merck, Novartis, Novo Nordisk, Prosciento, Radcliffe Group, Roche Diagnostics, Sanofi, Siemens Healthcare Diagnostics, and Us2.ai; and serves as co-founder and non-executive director of Us2.ai. FM has received personal fees from AstraZeneca. SJS reports research grants from the US National  Institutes of Health, Actelion, AstraZeneca, Corvia, Novartis, and Pfizer; and consulting fees from Abbott, Actelion, AstraZeneca, Amgen, Aria CV, Axon Therapies, Bayer, Boehringer Ingelheim, Boston Scientific, Bristol Myers Squibb,  Cardiora, Coridea, CVRx, Cyclerion, Cytokinetics, Edwards Lifesciences, Eidos, Eisai, Imara, Impulse Dynamics, Intellia, Ionis, Ironwood, Lilly, Merck, MyoKardia, Novartis, Novo Nordisk, Pfizer, Prothena, Regeneron, Rivus, Sanofi, Shifamed, Tenax, Tenaya, and United Therapeutics. ASD reports institutional grant support from Abbott, Alnylam, AstraZeneca, Bayer, Novartis; and consulting fees from Abbott, Alnylam, AstraZeneca, Avidity, Axon Therapeutics, Bayer, Biofourmis, Boston Scientific, Cytokinetics, GlaxoSmithKline, Merck, Novartis, Parel, Regeneron, Roche, and Verily. JJVM has received funding to his institution, Glasgow University, for his work on clinical trials, consulting, and other activities from Alnylam, Amgen, AstraZeneca, Bayer, Bristol Myers Squibb, Cardurion, Cytokinetics, GlaxoSmithKline, Novartis, Pfizer, and Theracos; and has received personal lecture fees from the Corpus, Abbott, Hickma, Sun Pharmaceuticals, and Medsca. SDS has received research grants from Actelion, Alnylam, Amgen, AstraZeneca, Bellerophon, Bayer, Bristol Myers Squibb, Celladon,  Cytokinetics, Eidos, Gilead, GlaxoSmithKline, Ionis, Lilly, Mesoblast, MyoKardia, National Institutes of Health/National Heart Lung and Blood Institute, Neurotronik, Novartis, NovoNordisk, Respicardia, Sanofi Pasteur, Theracos, and US2.AI; and has consulted for Abbott, Action, Akros, Alnylam, Amgen, Arena, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Cardior, Cardurion, Corvia, Cytokinetics, Daiichi-Sankyo, GlaxoSmithKline, Lilly, Merck, Myokardia, Novartis, Roche, Theracos, Quantum Genomics, Cardurion, Janssen, Cardiac Dimensions, Tenaya, Sanofi-Pasteur, Dinaqor, Tremeau, CellProThera, Moderna, American Regent, and Sarepta.\n",
      "\n",
      "Kosiborod, Mikhail N.\n",
      "Declaration of interests Muthiah Vaduganathan has received research grant support or served on advisory boards for American Regent, Amgen, AstraZeneca, Bayer, Baxter Healthcare, Boehringer Ingelheim, Cytokinetics, Lexicon Pharmaceuticals, Novartis, Pharmacosmos, Relypsa, Roche Diagnostics, and Sanofi; received speaker  fees from AstraZeneca, Novartis, and Roche Diagnostics; and participates on clinical trial committees for studies sponsored by Galmed, Novartis, Bayer, Occlutech, and Impulse Dynamics. Kieran F. Docherty's employer has been remunerated by AstraZeneca for clinical trial work. Kieran F. Docherty also reports speakers' fees from AstraZeneca and research funding from Boehringer Ingelheim. Kieran F. Docherty, Pardeep S. Jhund, and JJVM are funded by a British Heart Foundation Centre of Research Excellence Grant. Brian L. Claggett has received consulting fees from Boehringer Ingelheim. Pardeep S. Jhund's employer has been remunerated by AstraZeneca, Bayer, and Novo Nordisk for clinical trial work. Pardeep S. Jhund  also reports consulting and speakers' fees from Novartis, AstraZeneca, and Boehringer Ingelheim; and research funding Boehringer Ingelheim. RadB has received research grant support from AstraZeneca, Abbott, Boehringer Ingelheim, Cardior Pharmaceuticals, Ionis Pharmaceuticals, Novo Nordisk, and Roche; and received speaker fees from Abbott, AstraZeneca, Bayer, Novartis, and Roche. Adrian F. Hernandez reports research grant support from American Regent, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Merck, Novartis, Somologic, and Verily; and consulting Fees from Amgen, AstraZeneca, Bayer, Biofourmis, Boston Scientific, Cytokinetics, Merck, Novartis and NovoNordisk. Silvio E. Inzucchi has served on clinical trial committees or as a consultant to AstraZeneca, Boehringer Ingelheim, Novo Nordisk, Lexicon, Merck, Pfizer, vTv Therapeutics, Abbott, and Esperion; and has given lectures sponsored by AstraZeneca and Boehringer Ingelheim. Mikhail N. Kosiborod reports research grant support from AstraZeneca and Boehringer Ingelheim; and consulting fees from Alnylam, AstraZeneca, Amgen, Bayer, Boehringer Ingelheim, Cytokinetics, Esperion, Eli Lilly, Janssen, Lexicon, Merck (Diabetes and Cardiovascular), Pharmacosmos, Novo Nordisk, Sanofi, and Vifor. CSPL is supported by a Clinician Scientist Award from the National Medical Research Council of Singapore; has received research support from Bayer and Roche Diagnostics; has served as consultant or on the advisory board, steering committee, or executive committee for Abbott, Actelion,  Alleviant Medical, Allysta Pharma, Amgen, AnaCardio, Applied Therapeutics, AstraZeneca, Bayer, Boehringer Ingelheim, Boston Scientific, Cytokinetics, Darma, EchoNous, Impulse Dynamics, Ionis Pharmaceutical, Janssen Research & Development, Medscape/WebMD Global, Merck, Novartis, Novo Nordisk, Prosciento, Radcliffe Group, Roche Diagnostics, Sanofi, Siemens Healthcare Diagnostics, and Us2.ai; and serves as co-founder and non-executive director of Us2.ai. FM has received personal fees from AstraZeneca. SJS reports research grants from the US National  Institutes of Health, Actelion, AstraZeneca, Corvia, Novartis, and Pfizer; and consulting fees from Abbott, Actelion, AstraZeneca, Amgen, Aria CV, Axon Therapies, Bayer, Boehringer Ingelheim, Boston Scientific, Bristol Myers Squibb,  Cardiora, Coridea, CVRx, Cyclerion, Cytokinetics, Edwards Lifesciences, Eidos, Eisai, Imara, Impulse Dynamics, Intellia, Ionis, Ironwood, Lilly, Merck, MyoKardia, Novartis, Novo Nordisk, Pfizer, Prothena, Regeneron, Rivus, Sanofi, Shifamed, Tenax, Tenaya, and United Therapeutics. ASD reports institutional grant support from Abbott, Alnylam, AstraZeneca, Bayer, Novartis; and consulting fees from Abbott, Alnylam, AstraZeneca, Avidity, Axon Therapeutics, Bayer, Biofourmis, Boston Scientific, Cytokinetics, GlaxoSmithKline, Merck, Novartis, Parel, Regeneron, Roche, and Verily. JJVM has received funding to his institution, Glasgow University, for his work on clinical trials, consulting, and other activities from Alnylam, Amgen, AstraZeneca, Bayer, Bristol Myers Squibb, Cardurion, Cytokinetics, GlaxoSmithKline, Novartis, Pfizer, and Theracos; and has received personal lecture fees from the Corpus, Abbott, Hickma, Sun Pharmaceuticals, and Medsca. SDS has received research grants from Actelion, Alnylam, Amgen, AstraZeneca, Bellerophon, Bayer, Bristol Myers Squibb, Celladon,  Cytokinetics, Eidos, Gilead, GlaxoSmithKline, Ionis, Lilly, Mesoblast, MyoKardia, National Institutes of Health/National Heart Lung and Blood Institute, Neurotronik, Novartis, NovoNordisk, Respicardia, Sanofi Pasteur, Theracos, and US2.AI; and has consulted for Abbott, Action, Akros, Alnylam, Amgen, Arena, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Cardior, Cardurion, Corvia, Cytokinetics, Daiichi-Sankyo, GlaxoSmithKline, Lilly, Merck, Myokardia, Novartis, Roche, Theracos, Quantum Genomics, Cardurion, Janssen, Cardiac Dimensions, Tenaya, Sanofi-Pasteur, Dinaqor, Tremeau, CellProThera, Moderna, American Regent, and Sarepta.\n",
      "\n",
      "Lam, Carolyn S.P.\n",
      "Declaration of interests Muthiah Vaduganathan has received research grant support or served on advisory boards for American Regent, Amgen, AstraZeneca, Bayer, Baxter Healthcare, Boehringer Ingelheim, Cytokinetics, Lexicon Pharmaceuticals, Novartis, Pharmacosmos, Relypsa, Roche Diagnostics, and Sanofi; received speaker  fees from AstraZeneca, Novartis, and Roche Diagnostics; and participates on clinical trial committees for studies sponsored by Galmed, Novartis, Bayer, Occlutech, and Impulse Dynamics. Kieran F. Docherty's employer has been remunerated by AstraZeneca for clinical trial work. Kieran F. Docherty also reports speakers' fees from AstraZeneca and research funding from Boehringer Ingelheim. Kieran F. Docherty, Pardeep S. Jhund, and JJVM are funded by a British Heart Foundation Centre of Research Excellence Grant. Brian L. Claggett has received consulting fees from Boehringer Ingelheim. Pardeep S. Jhund's employer has been remunerated by AstraZeneca, Bayer, and Novo Nordisk for clinical trial work. Pardeep S. Jhund  also reports consulting and speakers' fees from Novartis, AstraZeneca, and Boehringer Ingelheim; and research funding Boehringer Ingelheim. RadB has received research grant support from AstraZeneca, Abbott, Boehringer Ingelheim, Cardior Pharmaceuticals, Ionis Pharmaceuticals, Novo Nordisk, and Roche; and received speaker fees from Abbott, AstraZeneca, Bayer, Novartis, and Roche. Adrian F. Hernandez reports research grant support from American Regent, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Merck, Novartis, Somologic, and Verily; and consulting Fees from Amgen, AstraZeneca, Bayer, Biofourmis, Boston Scientific, Cytokinetics, Merck, Novartis and NovoNordisk. Silvio E. Inzucchi has served on clinical trial committees or as a consultant to AstraZeneca, Boehringer Ingelheim, Novo Nordisk, Lexicon, Merck, Pfizer, vTv Therapeutics, Abbott, and Esperion; and has given lectures sponsored by AstraZeneca and Boehringer Ingelheim. Mikhail N. Kosiborod reports research grant support from AstraZeneca and Boehringer Ingelheim; and consulting fees from Alnylam, AstraZeneca, Amgen, Bayer, Boehringer Ingelheim, Cytokinetics, Esperion, Eli Lilly, Janssen, Lexicon, Merck (Diabetes and Cardiovascular), Pharmacosmos, Novo Nordisk, Sanofi, and Vifor. Carolyn S.P. Lam is supported by a Clinician Scientist Award from the National Medical Research Council of Singapore; has received research support from Bayer and Roche Diagnostics; has served as consultant or on the advisory board, steering committee, or executive committee for Abbott, Actelion,  Alleviant Medical, Allysta Pharma, Amgen, AnaCardio, Applied Therapeutics, AstraZeneca, Bayer, Boehringer Ingelheim, Boston Scientific, Cytokinetics, Darma, EchoNous, Impulse Dynamics, Ionis Pharmaceutical, Janssen Research & Development, Medscape/WebMD Global, Merck, Novartis, Novo Nordisk, Prosciento, Radcliffe Group, Roche Diagnostics, Sanofi, Siemens Healthcare Diagnostics, and Us2.ai; and serves as co-founder and non-executive director of Us2.ai. FM has received personal fees from AstraZeneca. SJS reports research grants from the US National  Institutes of Health, Actelion, AstraZeneca, Corvia, Novartis, and Pfizer; and consulting fees from Abbott, Actelion, AstraZeneca, Amgen, Aria CV, Axon Therapies, Bayer, Boehringer Ingelheim, Boston Scientific, Bristol Myers Squibb,  Cardiora, Coridea, CVRx, Cyclerion, Cytokinetics, Edwards Lifesciences, Eidos, Eisai, Imara, Impulse Dynamics, Intellia, Ionis, Ironwood, Lilly, Merck, MyoKardia, Novartis, Novo Nordisk, Pfizer, Prothena, Regeneron, Rivus, Sanofi, Shifamed, Tenax, Tenaya, and United Therapeutics. ASD reports institutional grant support from Abbott, Alnylam, AstraZeneca, Bayer, Novartis; and consulting fees from Abbott, Alnylam, AstraZeneca, Avidity, Axon Therapeutics, Bayer, Biofourmis, Boston Scientific, Cytokinetics, GlaxoSmithKline, Merck, Novartis, Parel, Regeneron, Roche, and Verily. JJVM has received funding to his institution, Glasgow University, for his work on clinical trials, consulting, and other activities from Alnylam, Amgen, AstraZeneca, Bayer, Bristol Myers Squibb, Cardurion, Cytokinetics, GlaxoSmithKline, Novartis, Pfizer, and Theracos; and has received personal lecture fees from the Corpus, Abbott, Hickma, Sun Pharmaceuticals, and Medsca. SDS has received research grants from Actelion, Alnylam, Amgen, AstraZeneca, Bellerophon, Bayer, Bristol Myers Squibb, Celladon,  Cytokinetics, Eidos, Gilead, GlaxoSmithKline, Ionis, Lilly, Mesoblast, MyoKardia, National Institutes of Health/National Heart Lung and Blood Institute, Neurotronik, Novartis, NovoNordisk, Respicardia, Sanofi Pasteur, Theracos, and US2.AI; and has consulted for Abbott, Action, Akros, Alnylam, Amgen, Arena, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Cardior, Cardurion, Corvia, Cytokinetics, Daiichi-Sankyo, GlaxoSmithKline, Lilly, Merck, Myokardia, Novartis, Roche, Theracos, Quantum Genomics, Cardurion, Janssen, Cardiac Dimensions, Tenaya, Sanofi-Pasteur, Dinaqor, Tremeau, CellProThera, Moderna, American Regent, and Sarepta.\n",
      "\n",
      "Martinez, Felipe\n",
      "Declaration of interests Muthiah Vaduganathan has received research grant support or served on advisory boards for American Regent, Amgen, AstraZeneca, Bayer, Baxter Healthcare, Boehringer Ingelheim, Cytokinetics, Lexicon Pharmaceuticals, Novartis, Pharmacosmos, Relypsa, Roche Diagnostics, and Sanofi; received speaker  fees from AstraZeneca, Novartis, and Roche Diagnostics; and participates on clinical trial committees for studies sponsored by Galmed, Novartis, Bayer, Occlutech, and Impulse Dynamics. Kieran F. Docherty's employer has been remunerated by AstraZeneca for clinical trial work. Kieran F. Docherty also reports speakers' fees from AstraZeneca and research funding from Boehringer Ingelheim. Kieran F. Docherty, Pardeep S. Jhund, and JJVM are funded by a British Heart Foundation Centre of Research Excellence Grant. Brian L. Claggett has received consulting fees from Boehringer Ingelheim. Pardeep S. Jhund's employer has been remunerated by AstraZeneca, Bayer, and Novo Nordisk for clinical trial work. Pardeep S. Jhund  also reports consulting and speakers' fees from Novartis, AstraZeneca, and Boehringer Ingelheim; and research funding Boehringer Ingelheim. RadB has received research grant support from AstraZeneca, Abbott, Boehringer Ingelheim, Cardior Pharmaceuticals, Ionis Pharmaceuticals, Novo Nordisk, and Roche; and received speaker fees from Abbott, AstraZeneca, Bayer, Novartis, and Roche. Adrian F. Hernandez reports research grant support from American Regent, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Merck, Novartis, Somologic, and Verily; and consulting Fees from Amgen, AstraZeneca, Bayer, Biofourmis, Boston Scientific, Cytokinetics, Merck, Novartis and NovoNordisk. Silvio E. Inzucchi has served on clinical trial committees or as a consultant to AstraZeneca, Boehringer Ingelheim, Novo Nordisk, Lexicon, Merck, Pfizer, vTv Therapeutics, Abbott, and Esperion; and has given lectures sponsored by AstraZeneca and Boehringer Ingelheim. Mikhail N. Kosiborod reports research grant support from AstraZeneca and Boehringer Ingelheim; and consulting fees from Alnylam, AstraZeneca, Amgen, Bayer, Boehringer Ingelheim, Cytokinetics, Esperion, Eli Lilly, Janssen, Lexicon, Merck (Diabetes and Cardiovascular), Pharmacosmos, Novo Nordisk, Sanofi, and Vifor. Carolyn S.P. Lam is supported by a Clinician Scientist Award from the National Medical Research Council of Singapore; has received research support from Bayer and Roche Diagnostics; has served as consultant or on the advisory board, steering committee, or executive committee for Abbott, Actelion,  Alleviant Medical, Allysta Pharma, Amgen, AnaCardio, Applied Therapeutics, AstraZeneca, Bayer, Boehringer Ingelheim, Boston Scientific, Cytokinetics, Darma, EchoNous, Impulse Dynamics, Ionis Pharmaceutical, Janssen Research & Development, Medscape/WebMD Global, Merck, Novartis, Novo Nordisk, Prosciento, Radcliffe Group, Roche Diagnostics, Sanofi, Siemens Healthcare Diagnostics, and Us2.ai; and serves as co-founder and non-executive director of Us2.ai. Felipe Martinez has received personal fees from AstraZeneca. SJS reports research grants from the US National  Institutes of Health, Actelion, AstraZeneca, Corvia, Novartis, and Pfizer; and consulting fees from Abbott, Actelion, AstraZeneca, Amgen, Aria CV, Axon Therapies, Bayer, Boehringer Ingelheim, Boston Scientific, Bristol Myers Squibb,  Cardiora, Coridea, CVRx, Cyclerion, Cytokinetics, Edwards Lifesciences, Eidos, Eisai, Imara, Impulse Dynamics, Intellia, Ionis, Ironwood, Lilly, Merck, MyoKardia, Novartis, Novo Nordisk, Pfizer, Prothena, Regeneron, Rivus, Sanofi, Shifamed, Tenax, Tenaya, and United Therapeutics. ASD reports institutional grant support from Abbott, Alnylam, AstraZeneca, Bayer, Novartis; and consulting fees from Abbott, Alnylam, AstraZeneca, Avidity, Axon Therapeutics, Bayer, Biofourmis, Boston Scientific, Cytokinetics, GlaxoSmithKline, Merck, Novartis, Parel, Regeneron, Roche, and Verily. JJVM has received funding to his institution, Glasgow University, for his work on clinical trials, consulting, and other activities from Alnylam, Amgen, AstraZeneca, Bayer, Bristol Myers Squibb, Cardurion, Cytokinetics, GlaxoSmithKline, Novartis, Pfizer, and Theracos; and has received personal lecture fees from the Corpus, Abbott, Hickma, Sun Pharmaceuticals, and Medsca. SDS has received research grants from Actelion, Alnylam, Amgen, AstraZeneca, Bellerophon, Bayer, Bristol Myers Squibb, Celladon,  Cytokinetics, Eidos, Gilead, GlaxoSmithKline, Ionis, Lilly, Mesoblast, MyoKardia, National Institutes of Health/National Heart Lung and Blood Institute, Neurotronik, Novartis, NovoNordisk, Respicardia, Sanofi Pasteur, Theracos, and US2.AI; and has consulted for Abbott, Action, Akros, Alnylam, Amgen, Arena, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Cardior, Cardurion, Corvia, Cytokinetics, Daiichi-Sankyo, GlaxoSmithKline, Lilly, Merck, Myokardia, Novartis, Roche, Theracos, Quantum Genomics, Cardurion, Janssen, Cardiac Dimensions, Tenaya, Sanofi-Pasteur, Dinaqor, Tremeau, CellProThera, Moderna, American Regent, and Sarepta.\n",
      "\n",
      "Shah, Sanjiv J.\n",
      "Declaration of interests Muthiah Vaduganathan has received research grant support or served on advisory boards for American Regent, Amgen, AstraZeneca, Bayer, Baxter Healthcare, Boehringer Ingelheim, Cytokinetics, Lexicon Pharmaceuticals, Novartis, Pharmacosmos, Relypsa, Roche Diagnostics, and Sanofi; received speaker  fees from AstraZeneca, Novartis, and Roche Diagnostics; and participates on clinical trial committees for studies sponsored by Galmed, Novartis, Bayer, Occlutech, and Impulse Dynamics. Kieran F. Docherty's employer has been remunerated by AstraZeneca for clinical trial work. Kieran F. Docherty also reports speakers' fees from AstraZeneca and research funding from Boehringer Ingelheim. Kieran F. Docherty, Pardeep S. Jhund, and JJVM are funded by a British Heart Foundation Centre of Research Excellence Grant. Brian L. Claggett has received consulting fees from Boehringer Ingelheim. Pardeep S. Jhund's employer has been remunerated by AstraZeneca, Bayer, and Novo Nordisk for clinical trial work. Pardeep S. Jhund  also reports consulting and speakers' fees from Novartis, AstraZeneca, and Boehringer Ingelheim; and research funding Boehringer Ingelheim. RadB has received research grant support from AstraZeneca, Abbott, Boehringer Ingelheim, Cardior Pharmaceuticals, Ionis Pharmaceuticals, Novo Nordisk, and Roche; and received speaker fees from Abbott, AstraZeneca, Bayer, Novartis, and Roche. Adrian F. Hernandez reports research grant support from American Regent, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Merck, Novartis, Somologic, and Verily; and consulting Fees from Amgen, AstraZeneca, Bayer, Biofourmis, Boston Scientific, Cytokinetics, Merck, Novartis and NovoNordisk. Silvio E. Inzucchi has served on clinical trial committees or as a consultant to AstraZeneca, Boehringer Ingelheim, Novo Nordisk, Lexicon, Merck, Pfizer, vTv Therapeutics, Abbott, and Esperion; and has given lectures sponsored by AstraZeneca and Boehringer Ingelheim. Mikhail N. Kosiborod reports research grant support from AstraZeneca and Boehringer Ingelheim; and consulting fees from Alnylam, AstraZeneca, Amgen, Bayer, Boehringer Ingelheim, Cytokinetics, Esperion, Eli Lilly, Janssen, Lexicon, Merck (Diabetes and Cardiovascular), Pharmacosmos, Novo Nordisk, Sanofi, and Vifor. Carolyn S.P. Lam is supported by a Clinician Scientist Award from the National Medical Research Council of Singapore; has received research support from Bayer and Roche Diagnostics; has served as consultant or on the advisory board, steering committee, or executive committee for Abbott, Actelion,  Alleviant Medical, Allysta Pharma, Amgen, AnaCardio, Applied Therapeutics, AstraZeneca, Bayer, Boehringer Ingelheim, Boston Scientific, Cytokinetics, Darma, EchoNous, Impulse Dynamics, Ionis Pharmaceutical, Janssen Research & Development, Medscape/WebMD Global, Merck, Novartis, Novo Nordisk, Prosciento, Radcliffe Group, Roche Diagnostics, Sanofi, Siemens Healthcare Diagnostics, and Us2.ai; and serves as co-founder and non-executive director of Us2.ai. Felipe Martinez has received personal fees from AstraZeneca. Sanjiv J. Shah reports research grants from the US National  Institutes of Health, Actelion, AstraZeneca, Corvia, Novartis, and Pfizer; and consulting fees from Abbott, Actelion, AstraZeneca, Amgen, Aria CV, Axon Therapies, Bayer, Boehringer Ingelheim, Boston Scientific, Bristol Myers Squibb,  Cardiora, Coridea, CVRx, Cyclerion, Cytokinetics, Edwards Lifesciences, Eidos, Eisai, Imara, Impulse Dynamics, Intellia, Ionis, Ironwood, Lilly, Merck, MyoKardia, Novartis, Novo Nordisk, Pfizer, Prothena, Regeneron, Rivus, Sanofi, Shifamed, Tenax, Tenaya, and United Therapeutics. ASD reports institutional grant support from Abbott, Alnylam, AstraZeneca, Bayer, Novartis; and consulting fees from Abbott, Alnylam, AstraZeneca, Avidity, Axon Therapeutics, Bayer, Biofourmis, Boston Scientific, Cytokinetics, GlaxoSmithKline, Merck, Novartis, Parel, Regeneron, Roche, and Verily. JJVM has received funding to his institution, Glasgow University, for his work on clinical trials, consulting, and other activities from Alnylam, Amgen, AstraZeneca, Bayer, Bristol Myers Squibb, Cardurion, Cytokinetics, GlaxoSmithKline, Novartis, Pfizer, and Theracos; and has received personal lecture fees from the Corpus, Abbott, Hickma, Sun Pharmaceuticals, and Medsca. SDS has received research grants from Actelion, Alnylam, Amgen, AstraZeneca, Bellerophon, Bayer, Bristol Myers Squibb, Celladon,  Cytokinetics, Eidos, Gilead, GlaxoSmithKline, Ionis, Lilly, Mesoblast, MyoKardia, National Institutes of Health/National Heart Lung and Blood Institute, Neurotronik, Novartis, NovoNordisk, Respicardia, Sanofi Pasteur, Theracos, and US2.AI; and has consulted for Abbott, Action, Akros, Alnylam, Amgen, Arena, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Cardior, Cardurion, Corvia, Cytokinetics, Daiichi-Sankyo, GlaxoSmithKline, Lilly, Merck, Myokardia, Novartis, Roche, Theracos, Quantum Genomics, Cardurion, Janssen, Cardiac Dimensions, Tenaya, Sanofi-Pasteur, Dinaqor, Tremeau, CellProThera, Moderna, American Regent, and Sarepta.\n",
      "\n",
      "Desai, Akshay S.\n",
      "Declaration of interests Muthiah Vaduganathan has received research grant support or served on advisory boards for American Regent, Amgen, AstraZeneca, Bayer, Baxter Healthcare, Boehringer Ingelheim, Cytokinetics, Lexicon Pharmaceuticals, Novartis, Pharmacosmos, Relypsa, Roche Diagnostics, and Sanofi; received speaker  fees from AstraZeneca, Novartis, and Roche Diagnostics; and participates on clinical trial committees for studies sponsored by Galmed, Novartis, Bayer, Occlutech, and Impulse Dynamics. Kieran F. Docherty's employer has been remunerated by AstraZeneca for clinical trial work. Kieran F. Docherty also reports speakers' fees from AstraZeneca and research funding from Boehringer Ingelheim. Kieran F. Docherty, Pardeep S. Jhund, and JJVM are funded by a British Heart Foundation Centre of Research Excellence Grant. Brian L. Claggett has received consulting fees from Boehringer Ingelheim. Pardeep S. Jhund's employer has been remunerated by AstraZeneca, Bayer, and Novo Nordisk for clinical trial work. Pardeep S. Jhund  also reports consulting and speakers' fees from Novartis, AstraZeneca, and Boehringer Ingelheim; and research funding Boehringer Ingelheim. RadB has received research grant support from AstraZeneca, Abbott, Boehringer Ingelheim, Cardior Pharmaceuticals, Ionis Pharmaceuticals, Novo Nordisk, and Roche; and received speaker fees from Abbott, AstraZeneca, Bayer, Novartis, and Roche. Adrian F. Hernandez reports research grant support from American Regent, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Merck, Novartis, Somologic, and Verily; and consulting Fees from Amgen, AstraZeneca, Bayer, Biofourmis, Boston Scientific, Cytokinetics, Merck, Novartis and NovoNordisk. Silvio E. Inzucchi has served on clinical trial committees or as a consultant to AstraZeneca, Boehringer Ingelheim, Novo Nordisk, Lexicon, Merck, Pfizer, vTv Therapeutics, Abbott, and Esperion; and has given lectures sponsored by AstraZeneca and Boehringer Ingelheim. Mikhail N. Kosiborod reports research grant support from AstraZeneca and Boehringer Ingelheim; and consulting fees from Alnylam, AstraZeneca, Amgen, Bayer, Boehringer Ingelheim, Cytokinetics, Esperion, Eli Lilly, Janssen, Lexicon, Merck (Diabetes and Cardiovascular), Pharmacosmos, Novo Nordisk, Sanofi, and Vifor. Carolyn S.P. Lam is supported by a Clinician Scientist Award from the National Medical Research Council of Singapore; has received research support from Bayer and Roche Diagnostics; has served as consultant or on the advisory board, steering committee, or executive committee for Abbott, Actelion,  Alleviant Medical, Allysta Pharma, Amgen, AnaCardio, Applied Therapeutics, AstraZeneca, Bayer, Boehringer Ingelheim, Boston Scientific, Cytokinetics, Darma, EchoNous, Impulse Dynamics, Ionis Pharmaceutical, Janssen Research & Development, Medscape/WebMD Global, Merck, Novartis, Novo Nordisk, Prosciento, Radcliffe Group, Roche Diagnostics, Sanofi, Siemens Healthcare Diagnostics, and Us2.ai; and serves as co-founder and non-executive director of Us2.ai. Felipe Martinez has received personal fees from AstraZeneca. Sanjiv J. Shah reports research grants from the US National  Institutes of Health, Actelion, AstraZeneca, Corvia, Novartis, and Pfizer; and consulting fees from Abbott, Actelion, AstraZeneca, Amgen, Aria CV, Axon Therapies, Bayer, Boehringer Ingelheim, Boston Scientific, Bristol Myers Squibb,  Cardiora, Coridea, CVRx, Cyclerion, Cytokinetics, Edwards Lifesciences, Eidos, Eisai, Imara, Impulse Dynamics, Intellia, Ionis, Ironwood, Lilly, Merck, MyoKardia, Novartis, Novo Nordisk, Pfizer, Prothena, Regeneron, Rivus, Sanofi, Shifamed, Tenax, Tenaya, and United Therapeutics. Akshay S. Desai reports institutional grant support from Abbott, Alnylam, AstraZeneca, Bayer, Novartis; and consulting fees from Abbott, Alnylam, AstraZeneca, Avidity, Axon Therapeutics, Bayer, Biofourmis, Boston Scientific, Cytokinetics, GlaxoSmithKline, Merck, Novartis, Parel, Regeneron, Roche, and Verily. JJVM has received funding to his institution, Glasgow University, for his work on clinical trials, consulting, and other activities from Alnylam, Amgen, AstraZeneca, Bayer, Bristol Myers Squibb, Cardurion, Cytokinetics, GlaxoSmithKline, Novartis, Pfizer, and Theracos; and has received personal lecture fees from the Corpus, Abbott, Hickma, Sun Pharmaceuticals, and Medsca. SDS has received research grants from Actelion, Alnylam, Amgen, AstraZeneca, Bellerophon, Bayer, Bristol Myers Squibb, Celladon,  Cytokinetics, Eidos, Gilead, GlaxoSmithKline, Ionis, Lilly, Mesoblast, MyoKardia, National Institutes of Health/National Heart Lung and Blood Institute, Neurotronik, Novartis, NovoNordisk, Respicardia, Sanofi Pasteur, Theracos, and US2.AI; and has consulted for Abbott, Action, Akros, Alnylam, Amgen, Arena, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Cardior, Cardurion, Corvia, Cytokinetics, Daiichi-Sankyo, GlaxoSmithKline, Lilly, Merck, Myokardia, Novartis, Roche, Theracos, Quantum Genomics, Cardurion, Janssen, Cardiac Dimensions, Tenaya, Sanofi-Pasteur, Dinaqor, Tremeau, CellProThera, Moderna, American Regent, and Sarepta.\n",
      "\n",
      "McMurray, John J.V.\n",
      "Declaration of interests Muthiah Vaduganathan has received research grant support or served on advisory boards for American Regent, Amgen, AstraZeneca, Bayer, Baxter Healthcare, Boehringer Ingelheim, Cytokinetics, Lexicon Pharmaceuticals, Novartis, Pharmacosmos, Relypsa, Roche Diagnostics, and Sanofi; received speaker  fees from AstraZeneca, Novartis, and Roche Diagnostics; and participates on clinical trial committees for studies sponsored by Galmed, Novartis, Bayer, Occlutech, and Impulse Dynamics. Kieran F. Docherty's employer has been remunerated by AstraZeneca for clinical trial work. Kieran F. Docherty also reports speakers' fees from AstraZeneca and research funding from Boehringer Ingelheim. Kieran F. Docherty, Pardeep S. Jhund, and John J.V. McMurray are funded by a British Heart Foundation Centre of Research Excellence Grant. Brian L. Claggett has received consulting fees from Boehringer Ingelheim. Pardeep S. Jhund's employer has been remunerated by AstraZeneca, Bayer, and Novo Nordisk for clinical trial work. Pardeep S. Jhund  also reports consulting and speakers' fees from Novartis, AstraZeneca, and Boehringer Ingelheim; and research funding Boehringer Ingelheim. RadB has received research grant support from AstraZeneca, Abbott, Boehringer Ingelheim, Cardior Pharmaceuticals, Ionis Pharmaceuticals, Novo Nordisk, and Roche; and received speaker fees from Abbott, AstraZeneca, Bayer, Novartis, and Roche. Adrian F. Hernandez reports research grant support from American Regent, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Merck, Novartis, Somologic, and Verily; and consulting Fees from Amgen, AstraZeneca, Bayer, Biofourmis, Boston Scientific, Cytokinetics, Merck, Novartis and NovoNordisk. Silvio E. Inzucchi has served on clinical trial committees or as a consultant to AstraZeneca, Boehringer Ingelheim, Novo Nordisk, Lexicon, Merck, Pfizer, vTv Therapeutics, Abbott, and Esperion; and has given lectures sponsored by AstraZeneca and Boehringer Ingelheim. Mikhail N. Kosiborod reports research grant support from AstraZeneca and Boehringer Ingelheim; and consulting fees from Alnylam, AstraZeneca, Amgen, Bayer, Boehringer Ingelheim, Cytokinetics, Esperion, Eli Lilly, Janssen, Lexicon, Merck (Diabetes and Cardiovascular), Pharmacosmos, Novo Nordisk, Sanofi, and Vifor. Carolyn S.P. Lam is supported by a Clinician Scientist Award from the National Medical Research Council of Singapore; has received research support from Bayer and Roche Diagnostics; has served as consultant or on the advisory board, steering committee, or executive committee for Abbott, Actelion,  Alleviant Medical, Allysta Pharma, Amgen, AnaCardio, Applied Therapeutics, AstraZeneca, Bayer, Boehringer Ingelheim, Boston Scientific, Cytokinetics, Darma, EchoNous, Impulse Dynamics, Ionis Pharmaceutical, Janssen Research & Development, Medscape/WebMD Global, Merck, Novartis, Novo Nordisk, Prosciento, Radcliffe Group, Roche Diagnostics, Sanofi, Siemens Healthcare Diagnostics, and Us2.ai; and serves as co-founder and non-executive director of Us2.ai. Felipe Martinez has received personal fees from AstraZeneca. Sanjiv J. Shah reports research grants from the US National  Institutes of Health, Actelion, AstraZeneca, Corvia, Novartis, and Pfizer; and consulting fees from Abbott, Actelion, AstraZeneca, Amgen, Aria CV, Axon Therapies, Bayer, Boehringer Ingelheim, Boston Scientific, Bristol Myers Squibb,  Cardiora, Coridea, CVRx, Cyclerion, Cytokinetics, Edwards Lifesciences, Eidos, Eisai, Imara, Impulse Dynamics, Intellia, Ionis, Ironwood, Lilly, Merck, MyoKardia, Novartis, Novo Nordisk, Pfizer, Prothena, Regeneron, Rivus, Sanofi, Shifamed, Tenax, Tenaya, and United Therapeutics. Akshay S. Desai reports institutional grant support from Abbott, Alnylam, AstraZeneca, Bayer, Novartis; and consulting fees from Abbott, Alnylam, AstraZeneca, Avidity, Axon Therapeutics, Bayer, Biofourmis, Boston Scientific, Cytokinetics, GlaxoSmithKline, Merck, Novartis, Parel, Regeneron, Roche, and Verily. John J.V. McMurray has received funding to his institution, Glasgow University, for his work on clinical trials, consulting, and other activities from Alnylam, Amgen, AstraZeneca, Bayer, Bristol Myers Squibb, Cardurion, Cytokinetics, GlaxoSmithKline, Novartis, Pfizer, and Theracos; and has received personal lecture fees from the Corpus, Abbott, Hickma, Sun Pharmaceuticals, and Medsca. SDS has received research grants from Actelion, Alnylam, Amgen, AstraZeneca, Bellerophon, Bayer, Bristol Myers Squibb, Celladon,  Cytokinetics, Eidos, Gilead, GlaxoSmithKline, Ionis, Lilly, Mesoblast, MyoKardia, National Institutes of Health/National Heart Lung and Blood Institute, Neurotronik, Novartis, NovoNordisk, Respicardia, Sanofi Pasteur, Theracos, and US2.AI; and has consulted for Abbott, Action, Akros, Alnylam, Amgen, Arena, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Cardior, Cardurion, Corvia, Cytokinetics, Daiichi-Sankyo, GlaxoSmithKline, Lilly, Merck, Myokardia, Novartis, Roche, Theracos, Quantum Genomics, Cardurion, Janssen, Cardiac Dimensions, Tenaya, Sanofi-Pasteur, Dinaqor, Tremeau, CellProThera, Moderna, American Regent, and Sarepta.\n",
      "\n",
      "Solomon, Scott D.\n",
      "Declaration of interests Muthiah Vaduganathan has received research grant support or served on advisory boards for American Regent, Amgen, AstraZeneca, Bayer, Baxter Healthcare, Boehringer Ingelheim, Cytokinetics, Lexicon Pharmaceuticals, Novartis, Pharmacosmos, Relypsa, Roche Diagnostics, and Sanofi; received speaker  fees from AstraZeneca, Novartis, and Roche Diagnostics; and participates on clinical trial committees for studies sponsored by Galmed, Novartis, Bayer, Occlutech, and Impulse Dynamics. Kieran F. Docherty's employer has been remunerated by AstraZeneca for clinical trial work. Kieran F. Docherty also reports speakers' fees from AstraZeneca and research funding from Boehringer Ingelheim. Kieran F. Docherty, Pardeep S. Jhund, and John J.V. McMurray are funded by a British Heart Foundation Centre of Research Excellence Grant. Brian L. Claggett has received consulting fees from Boehringer Ingelheim. Pardeep S. Jhund's employer has been remunerated by AstraZeneca, Bayer, and Novo Nordisk for clinical trial work. Pardeep S. Jhund  also reports consulting and speakers' fees from Novartis, AstraZeneca, and Boehringer Ingelheim; and research funding Boehringer Ingelheim. RadB has received research grant support from AstraZeneca, Abbott, Boehringer Ingelheim, Cardior Pharmaceuticals, Ionis Pharmaceuticals, Novo Nordisk, and Roche; and received speaker fees from Abbott, AstraZeneca, Bayer, Novartis, and Roche. Adrian F. Hernandez reports research grant support from American Regent, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Merck, Novartis, Somologic, and Verily; and consulting Fees from Amgen, AstraZeneca, Bayer, Biofourmis, Boston Scientific, Cytokinetics, Merck, Novartis and NovoNordisk. Silvio E. Inzucchi has served on clinical trial committees or as a consultant to AstraZeneca, Boehringer Ingelheim, Novo Nordisk, Lexicon, Merck, Pfizer, vTv Therapeutics, Abbott, and Esperion; and has given lectures sponsored by AstraZeneca and Boehringer Ingelheim. Mikhail N. Kosiborod reports research grant support from AstraZeneca and Boehringer Ingelheim; and consulting fees from Alnylam, AstraZeneca, Amgen, Bayer, Boehringer Ingelheim, Cytokinetics, Esperion, Eli Lilly, Janssen, Lexicon, Merck (Diabetes and Cardiovascular), Pharmacosmos, Novo Nordisk, Sanofi, and Vifor. Carolyn S.P. Lam is supported by a Clinician Scientist Award from the National Medical Research Council of Singapore; has received research support from Bayer and Roche Diagnostics; has served as consultant or on the advisory board, steering committee, or executive committee for Abbott, Actelion,  Alleviant Medical, Allysta Pharma, Amgen, AnaCardio, Applied Therapeutics, AstraZeneca, Bayer, Boehringer Ingelheim, Boston Scientific, Cytokinetics, Darma, EchoNous, Impulse Dynamics, Ionis Pharmaceutical, Janssen Research & Development, Medscape/WebMD Global, Merck, Novartis, Novo Nordisk, Prosciento, Radcliffe Group, Roche Diagnostics, Sanofi, Siemens Healthcare Diagnostics, and Us2.ai; and serves as co-founder and non-executive director of Us2.ai. Felipe Martinez has received personal fees from AstraZeneca. Sanjiv J. Shah reports research grants from the US National  Institutes of Health, Actelion, AstraZeneca, Corvia, Novartis, and Pfizer; and consulting fees from Abbott, Actelion, AstraZeneca, Amgen, Aria CV, Axon Therapies, Bayer, Boehringer Ingelheim, Boston Scientific, Bristol Myers Squibb,  Cardiora, Coridea, CVRx, Cyclerion, Cytokinetics, Edwards Lifesciences, Eidos, Eisai, Imara, Impulse Dynamics, Intellia, Ionis, Ironwood, Lilly, Merck, MyoKardia, Novartis, Novo Nordisk, Pfizer, Prothena, Regeneron, Rivus, Sanofi, Shifamed, Tenax, Tenaya, and United Therapeutics. Akshay S. Desai reports institutional grant support from Abbott, Alnylam, AstraZeneca, Bayer, Novartis; and consulting fees from Abbott, Alnylam, AstraZeneca, Avidity, Axon Therapeutics, Bayer, Biofourmis, Boston Scientific, Cytokinetics, GlaxoSmithKline, Merck, Novartis, Parel, Regeneron, Roche, and Verily. John J.V. McMurray has received funding to his institution, Glasgow University, for his work on clinical trials, consulting, and other activities from Alnylam, Amgen, AstraZeneca, Bayer, Bristol Myers Squibb, Cardurion, Cytokinetics, GlaxoSmithKline, Novartis, Pfizer, and Theracos; and has received personal lecture fees from the Corpus, Abbott, Hickma, Sun Pharmaceuticals, and Medsca. Scott D. Solomon has received research grants from Actelion, Alnylam, Amgen, AstraZeneca, Bellerophon, Bayer, Bristol Myers Squibb, Celladon,  Cytokinetics, Eidos, Gilead, GlaxoSmithKline, Ionis, Lilly, Mesoblast, MyoKardia, National Institutes of Health/National Heart Lung and Blood Institute, Neurotronik, Novartis, NovoNordisk, Respicardia, Sanofi Pasteur, Theracos, and US2.AI; and has consulted for Abbott, Action, Akros, Alnylam, Amgen, Arena, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Cardior, Cardurion, Corvia, Cytokinetics, Daiichi-Sankyo, GlaxoSmithKline, Lilly, Merck, Myokardia, Novartis, Roche, Theracos, Quantum Genomics, Cardurion, Janssen, Cardiac Dimensions, Tenaya, Sanofi-Pasteur, Dinaqor, Tremeau, CellProThera, Moderna, American Regent, and Sarepta.\n",
      "\n",
      "Die Autorinnen/Autoren geben an, dass kein Interessenkonflikt besteht.\n",
      "\n",
      "Die Autorinnen/Autoren geben an, dass kein Interessenkonflikt besteht.\n",
      "\n",
      "Declaration of interests F.M. is an employee and shareholder of MGI Tech Co., Ltd. We have a patent related to this work with the patent application number 202110807148.6 in China.\n",
      "\n",
      "Declaration of interests F.M. is an employee and shareholder of MGI Tech Co., Ltd. We have a patent related to this work with the patent application number 202110807148.6 in China.\n",
      "\n",
      "Declaration of interests F.M. is an employee and shareholder of MGI Tech Co., Ltd. We have a patent related to this work with the patent application number 202110807148.6 in China.\n",
      "\n",
      "Declaration of interests F.M. is an employee and shareholder of MGI Tech Co., Ltd. We have a patent related to this work with the patent application number 202110807148.6 in China.\n",
      "\n",
      "Declaration of interests F.M. is an employee and shareholder of MGI Tech Co., Ltd. We have a patent related to this work with the patent application number 202110807148.6 in China.\n",
      "\n",
      "Declaration of interests F.M. is an employee and shareholder of MGI Tech Co., Ltd. We have a patent related to this work with the patent application number 202110807148.6 in China.\n",
      "\n",
      "Declaration of interests F.M. is an employee and shareholder of MGI Tech Co., Ltd. We have a patent related to this work with the patent application number 202110807148.6 in China.\n",
      "\n",
      "Declaration of interests F.M. is an employee and shareholder of MGI Tech Co., Ltd. We have a patent related to this work with the patent application number 202110807148.6 in China.\n",
      "\n",
      "Declaration of interests F.M. is an employee and shareholder of MGI Tech Co., Ltd. We have a patent related to this work with the patent application number 202110807148.6 in China.\n",
      "\n",
      "Declaration of interests F.M. is an employee and shareholder of MGI Tech Co., Ltd. We have a patent related to this work with the patent application number 202110807148.6 in China.\n",
      "\n",
      "Declaration of interests F.M. is an employee and shareholder of MGI Tech Co., Ltd. We have a patent related to this work with the patent application number 202110807148.6 in China.\n",
      "\n",
      "Declaration of interests F.M. is an employee and shareholder of MGI Tech Co., Ltd. We have a patent related to this work with the patent application number 202110807148.6 in China.\n",
      "\n",
      "Declaration of interests F.M. is an employee and shareholder of MGI Tech Co., Ltd. We have a patent related to this work with the patent application number 202110807148.6 in China.\n",
      "\n",
      "Mu, Feng\n",
      "Declaration of interests Feng Mu is an employee and shareholder of MGI Tech Co., Ltd. We have a patent related to this work with the patent application number 202110807148.6 in China.\n",
      "\n",
      "Youn Kim, Ju\n",
      "Declaration of interests M.K. is the founder and scientific advisory board member of Elgia Therapeutics and receives research support from Merck, Jenssen, and Gossamer. Ju Youn Kim and M.K. are authors/inventors of patent titled Method for inhibition nonalcoholic steatohepatitis, nonalcoholic fatty liver disease, and/or de novo lipogenesis (2017-152-2) (patent is pending approval).\n",
      "\n",
      "Declaration of interests M.K. is the founder and scientific advisory board member of Elgia Therapeutics and receives research support from Merck, Jenssen, and Gossamer. Ju Youn Kim and M.K. are authors/inventors of patent titled Method for inhibition nonalcoholic steatohepatitis, nonalcoholic fatty liver disease, and/or de novo lipogenesis (2017-152-2) (patent is pending approval).\n",
      "\n",
      "Declaration of interests M.K. is the founder and scientific advisory board member of Elgia Therapeutics and receives research support from Merck, Jenssen, and Gossamer. Ju Youn Kim and M.K. are authors/inventors of patent titled Method for inhibition nonalcoholic steatohepatitis, nonalcoholic fatty liver disease, and/or de novo lipogenesis (2017-152-2) (patent is pending approval).\n",
      "\n",
      "Declaration of interests M.K. is the founder and scientific advisory board member of Elgia Therapeutics and receives research support from Merck, Jenssen, and Gossamer. Ju Youn Kim and M.K. are authors/inventors of patent titled Method for inhibition nonalcoholic steatohepatitis, nonalcoholic fatty liver disease, and/or de novo lipogenesis (2017-152-2) (patent is pending approval).\n",
      "\n",
      "Declaration of interests M.K. is the founder and scientific advisory board member of Elgia Therapeutics and receives research support from Merck, Jenssen, and Gossamer. Ju Youn Kim and M.K. are authors/inventors of patent titled Method for inhibition nonalcoholic steatohepatitis, nonalcoholic fatty liver disease, and/or de novo lipogenesis (2017-152-2) (patent is pending approval).\n",
      "\n",
      "Declaration of interests M.K. is the founder and scientific advisory board member of Elgia Therapeutics and receives research support from Merck, Jenssen, and Gossamer. Ju Youn Kim and M.K. are authors/inventors of patent titled Method for inhibition nonalcoholic steatohepatitis, nonalcoholic fatty liver disease, and/or de novo lipogenesis (2017-152-2) (patent is pending approval).\n",
      "\n",
      "Declaration of interests M.K. is the founder and scientific advisory board member of Elgia Therapeutics and receives research support from Merck, Jenssen, and Gossamer. Ju Youn Kim and M.K. are authors/inventors of patent titled Method for inhibition nonalcoholic steatohepatitis, nonalcoholic fatty liver disease, and/or de novo lipogenesis (2017-152-2) (patent is pending approval).\n",
      "\n",
      "Declaration of interests M.K. is the founder and scientific advisory board member of Elgia Therapeutics and receives research support from Merck, Jenssen, and Gossamer. Ju Youn Kim and M.K. are authors/inventors of patent titled Method for inhibition nonalcoholic steatohepatitis, nonalcoholic fatty liver disease, and/or de novo lipogenesis (2017-152-2) (patent is pending approval).\n",
      "\n",
      "Declaration of interests M.K. is the founder and scientific advisory board member of Elgia Therapeutics and receives research support from Merck, Jenssen, and Gossamer. Ju Youn Kim and M.K. are authors/inventors of patent titled Method for inhibition nonalcoholic steatohepatitis, nonalcoholic fatty liver disease, and/or de novo lipogenesis (2017-152-2) (patent is pending approval).\n",
      "\n",
      "Declaration of interests M.K. is the founder and scientific advisory board member of Elgia Therapeutics and receives research support from Merck, Jenssen, and Gossamer. Ju Youn Kim and M.K. are authors/inventors of patent titled Method for inhibition nonalcoholic steatohepatitis, nonalcoholic fatty liver disease, and/or de novo lipogenesis (2017-152-2) (patent is pending approval).\n",
      "\n",
      "Declaration of interests M.K. is the founder and scientific advisory board member of Elgia Therapeutics and receives research support from Merck, Jenssen, and Gossamer. Ju Youn Kim and M.K. are authors/inventors of patent titled Method for inhibition nonalcoholic steatohepatitis, nonalcoholic fatty liver disease, and/or de novo lipogenesis (2017-152-2) (patent is pending approval).\n",
      "\n",
      "Declaration of interests M.K. is the founder and scientific advisory board member of Elgia Therapeutics and receives research support from Merck, Jenssen, and Gossamer. Ju Youn Kim and M.K. are authors/inventors of patent titled Method for inhibition nonalcoholic steatohepatitis, nonalcoholic fatty liver disease, and/or de novo lipogenesis (2017-152-2) (patent is pending approval).\n",
      "\n",
      "Karin, Michael\n",
      "Declaration of interests Michael Karin is the founder and scientific advisory board member of Elgia Therapeutics and receives research support from Merck, Jenssen, and Gossamer. Ju Youn Kim and Michael Karin are authors/inventors of patent titled Method for inhibition nonalcoholic steatohepatitis, nonalcoholic fatty liver disease, and/or de novo lipogenesis (2017-152-2) (patent is pending approval).\n",
      "\n",
      "Erklarung zu finanziellen Interessen Forschungsforderung erhalten: nein; Honorar/geldwerten Vorteil fur Referententatigkeit erhalten: nein; Bezahlter Berater/interner Schulungsreferent/Gehaltsempfanger: nein; Patent/Geschaftsanteile/Aktien (Autor/Partner, Ehepartner, Kinder) an im Bereich  der Medizin aktiven Firma: nein; Patent/Geschaftsanteile/Aktien (Autor/Partner, Ehepartner, Kinder) an zu Sponsoren dieser Fortbildung bzw. durch die Fortbildung in ihren Geschaftsinteressen beruhrten Firma: nein Erklarung zu nichtfinanziellen Interessen Die Autorinnen/Autoren geben an, dass kein Interessenkonflikt besteht.\n",
      "\n",
      "Erklarung zu finanziellen Interessen Forschungsforderung erhalten: nein; Honorar/geldwerten Vorteil fur Referententatigkeit erhalten: nein; Bezahlter Berater/interner Schulungsreferent/Gehaltsempfanger: nein; Patent/Geschaftsanteile/Aktien (Autor/Partner, Ehepartner, Kinder) an im Bereich  der Medizin aktiven Firma: nein; Patent/Geschaftsanteile/Aktien (Autor/Partner, Ehepartner, Kinder) an zu Sponsoren dieser Fortbildung bzw. durch die Fortbildung in ihren Geschaftsinteressen beruhrten Firma: nein Erklarung zu nichtfinanziellen Interessen Die Autorinnen/Autoren geben an, dass kein Interessenkonflikt besteht.\n",
      "\n",
      "Erklarung zu finanziellen Interessen Forschungsforderung erhalten: nein; Honorar/geldwerten Vorteil fur Referententatigkeit erhalten: nein; Bezahlter Berater/interner Schulungsreferent/Gehaltsempfanger: nein; Patent/Geschaftsanteile/Aktien (Autor/Partner, Ehepartner, Kinder) an im Bereich  der Medizin aktiven Firma: nein; Patent/Geschaftsanteile/Aktien (Autor/Partner, Ehepartner, Kinder) an zu Sponsoren dieser Fortbildung bzw. durch die Fortbildung in ihren Geschaftsinteressen beruhrten Firma: nein Erklarung zu nichtfinanziellen Interessen Die Autorinnen/Autoren geben an, dass kein Interessenkonflikt besteht.\n",
      "\n",
      "Erklarung zu finanziellen Interessen Forschungsforderung erhalten: nein; Honorar/geldwerten Vorteil fur Referententatigkeit erhalten: nein; Bezahlter Berater/interner Schulungsreferent/Gehaltsempfanger: nein; Patent/Geschaftsanteile/Aktien (Autor/Partner, Ehepartner, Kinder) an im Bereich  der Medizin aktiven Firma: nein; Patent/Geschaftsanteile/Aktien (Autor/Partner, Ehepartner, Kinder) an zu Sponsoren dieser Fortbildung bzw. durch die Fortbildung in ihren Geschaftsinteressen beruhrten Firma: nein Erklarung zu nichtfinanziellen Interessen Die Autorinnen/Autoren geben an, dass kein Interessenkonflikt besteht.\n",
      "\n",
      "Erklarung zu finanziellen Interessen Forschungsforderung erhalten: nein; Honorar/geldwerten Vorteil fur Referententatigkeit erhalten: nein; Bezahlter Berater/interner Schulungsreferent/Gehaltsempfanger: nein; Patent/Geschaftsanteile/Aktien (Autor/Partner, Ehepartner, Kinder) an im Bereich  der Medizin aktiven Firma: nein; Patent/Geschaftsanteile/Aktien (Autor/Partner, Ehepartner, Kinder) an zu Sponsoren dieser Fortbildung bzw. durch die Fortbildung in ihren Geschaftsinteressen beruhrten Firma: nein Erklarung zu nichtfinanziellen Interessen Die Autorinnen/Autoren geben an, dass kein Interessenkonflikt besteht.\n",
      "\n",
      "Erklarung zu finanziellen Interessen Forschungsforderung erhalten: nein; Honorar/geldwerten Vorteil fur Referententatigkeit erhalten: nein; Bezahlter Berater/interner Schulungsreferent/Gehaltsempfanger: nein; Patent/Geschaftsanteile/Aktien (Autor/Partner, Ehepartner, Kinder) an im Bereich  der Medizin aktiven Firma: nein; Patent/Geschaftsanteile/Aktien (Autor/Partner, Ehepartner, Kinder) an zu Sponsoren dieser Fortbildung bzw. durch die Fortbildung in ihren Geschaftsinteressen beruhrten Firma: nein Erklarung zu nichtfinanziellen Interessen Die Autorinnen/Autoren geben an, dass kein Interessenkonflikt besteht.\n",
      "\n",
      "Erklarung zu finanziellen Interessen Forschungsforderung erhalten: nein; Honorar/geldwerten Vorteil fur Referententatigkeit erhalten: nein; Bezahlter Berater/interner Schulungsreferent/Gehaltsempfanger: nein; Patent/Geschaftsanteile/Aktien (Autor/Partner, Ehepartner, Kinder) an im Bereich  der Medizin aktiven Firma: nein; Patent/Geschaftsanteile/Aktien (Autor/Partner, Ehepartner, Kinder) an zu Sponsoren dieser Fortbildung bzw. durch die Fortbildung in ihren Geschaftsinteressen beruhrten Firma: nein Erklarung zu nichtfinanziellen Interessen Die Autorinnen/Autoren geben an, dass kein Interessenkonflikt besteht.\n",
      "\n",
      "Erklarung zu finanziellen Interessen Forschungsforderung erhalten: nein; Honorar/geldwerten Vorteil fur Referententatigkeit erhalten: nein; Bezahlter Berater/interner Schulungsreferent/Gehaltsempfanger: nein; Patent/Geschaftsanteile/Aktien (Autor/Partner, Ehepartner, Kinder) an im Bereich  der Medizin aktiven Firma: nein; Patent/Geschaftsanteile/Aktien (Autor/Partner, Ehepartner, Kinder) an zu Sponsoren dieser Fortbildung bzw. durch die Fortbildung in ihren Geschaftsinteressen beruhrten Firma: nein Erklarung zu nichtfinanziellen Interessen Die Autorinnen/Autoren geben an, dass kein Interessenkonflikt besteht.\n",
      "\n",
      "Die Autorinnen/Autoren geben an, dass kein Interessenkonflikt besteht.\n",
      "\n",
      "Die Autorinnen/Autoren geben an, dass kein Interessenkonflikt besteht.\n",
      "\n",
      "Die Autorinnen/Autoren geben an, dass kein Interessenkonflikt besteht.\n",
      "\n",
      "Die Autorinnen/Autoren geben an, dass kein Interessenkonflikt besteht.\n",
      "\n",
      "Declaration of interests H.H.W. is a scientific advisor of SNIPR Biome, Kingdom Supercultures, and Fitbiomics, who were not involved in the study. K.H. is a scientific advisory board member of Vedanta Biosciences and 4BIO CAPITAL, who were not involved in the study.\n",
      "\n",
      "Declaration of interests H.H.W. is a scientific advisor of SNIPR Biome, Kingdom Supercultures, and Fitbiomics, who were not involved in the study. K.H. is a scientific advisory board member of Vedanta Biosciences and 4BIO CAPITAL, who were not involved in the study.\n",
      "\n",
      "Declaration of interests H.H.W. is a scientific advisor of SNIPR Biome, Kingdom Supercultures, and Fitbiomics, who were not involved in the study. K.H. is a scientific advisory board member of Vedanta Biosciences and 4BIO CAPITAL, who were not involved in the study.\n",
      "\n",
      "Declaration of interests H.H.W. is a scientific advisor of SNIPR Biome, Kingdom Supercultures, and Fitbiomics, who were not involved in the study. K.H. is a scientific advisory board member of Vedanta Biosciences and 4BIO CAPITAL, who were not involved in the study.\n",
      "\n",
      "Declaration of interests H.H.W. is a scientific advisor of SNIPR Biome, Kingdom Supercultures, and Fitbiomics, who were not involved in the study. K.H. is a scientific advisory board member of Vedanta Biosciences and 4BIO CAPITAL, who were not involved in the study.\n",
      "\n",
      "Declaration of interests H.H.W. is a scientific advisor of SNIPR Biome, Kingdom Supercultures, and Fitbiomics, who were not involved in the study. K.H. is a scientific advisory board member of Vedanta Biosciences and 4BIO CAPITAL, who were not involved in the study.\n",
      "\n",
      "Declaration of interests H.H.W. is a scientific advisor of SNIPR Biome, Kingdom Supercultures, and Fitbiomics, who were not involved in the study. K.H. is a scientific advisory board member of Vedanta Biosciences and 4BIO CAPITAL, who were not involved in the study.\n",
      "\n",
      "Declaration of interests H.H.W. is a scientific advisor of SNIPR Biome, Kingdom Supercultures, and Fitbiomics, who were not involved in the study. K.H. is a scientific advisory board member of Vedanta Biosciences and 4BIO CAPITAL, who were not involved in the study.\n",
      "\n",
      "Declaration of interests H.H.W. is a scientific advisor of SNIPR Biome, Kingdom Supercultures, and Fitbiomics, who were not involved in the study. K.H. is a scientific advisory board member of Vedanta Biosciences and 4BIO CAPITAL, who were not involved in the study.\n",
      "\n",
      "Wang, Harris H.\n",
      "Declaration of interests Harris H. Wang is a scientific advisor of SNIPR Biome, Kingdom Supercultures, and Fitbiomics, who were not involved in the study. K.H. is a scientific advisory board member of Vedanta Biosciences and 4BIO CAPITAL, who were not involved in the study.\n",
      "\n",
      "Declaration of interests Harris H. Wang is a scientific advisor of SNIPR Biome, Kingdom Supercultures, and Fitbiomics, who were not involved in the study. K.H. is a scientific advisory board member of Vedanta Biosciences and 4BIO CAPITAL, who were not involved in the study.\n",
      "\n",
      "Honda, Kenya\n",
      "Declaration of interests Harris H. Wang is a scientific advisor of SNIPR Biome, Kingdom Supercultures, and Fitbiomics, who were not involved in the study. Kenya Honda is a scientific advisory board member of Vedanta Biosciences and 4BIO CAPITAL, who were not involved in the study.\n",
      "\n",
      "Declaration of interests Harris H. Wang is a scientific advisor of SNIPR Biome, Kingdom Supercultures, and Fitbiomics, who were not involved in the study. Kenya Honda is a scientific advisory board member of Vedanta Biosciences and 4BIO CAPITAL, who were not involved in the study.\n",
      "\n",
      "Bhardwaj, Gaurav\n",
      "Declaration of interests V.K.M. is a cofounder and shareholder of Menten AI, a biotechnology company. G.T.M. is a cofounder of Nexomics Biosciences, Inc., a structural biology contract research organization. A provisional patent covering  the membrane-permeable peptides described in this paper has been filed by the University of Washington, Seattle. Gaurav Bhardwaj, L.S., and D.B. are cofounders and shareholders of an early-stage biotechnology company that has licensed the provisional patent.\n",
      "\n",
      "Declaration of interests V.K.M. is a cofounder and shareholder of Menten AI, a biotechnology company. G.T.M. is a cofounder of Nexomics Biosciences, Inc., a structural biology contract research organization. A provisional patent covering  the membrane-permeable peptides described in this paper has been filed by the University of Washington, Seattle. Gaurav Bhardwaj, L.S., and D.B. are cofounders and shareholders of an early-stage biotechnology company that has licensed the provisional patent.\n",
      "\n",
      "Declaration of interests V.K.M. is a cofounder and shareholder of Menten AI, a biotechnology company. G.T.M. is a cofounder of Nexomics Biosciences, Inc., a structural biology contract research organization. A provisional patent covering  the membrane-permeable peptides described in this paper has been filed by the University of Washington, Seattle. Gaurav Bhardwaj, L.S., and D.B. are cofounders and shareholders of an early-stage biotechnology company that has licensed the provisional patent.\n",
      "\n",
      "Declaration of interests V.K.M. is a cofounder and shareholder of Menten AI, a biotechnology company. G.T.M. is a cofounder of Nexomics Biosciences, Inc., a structural biology contract research organization. A provisional patent covering  the membrane-permeable peptides described in this paper has been filed by the University of Washington, Seattle. Gaurav Bhardwaj, L.S., and D.B. are cofounders and shareholders of an early-stage biotechnology company that has licensed the provisional patent.\n",
      "\n",
      "Declaration of interests V.K.M. is a cofounder and shareholder of Menten AI, a biotechnology company. G.T.M. is a cofounder of Nexomics Biosciences, Inc., a structural biology contract research organization. A provisional patent covering  the membrane-permeable peptides described in this paper has been filed by the University of Washington, Seattle. Gaurav Bhardwaj, L.S., and D.B. are cofounders and shareholders of an early-stage biotechnology company that has licensed the provisional patent.\n",
      "\n",
      "Khipple Mulligan, Vikram\n",
      "Declaration of interests Vikram Khipple Mulligan is a cofounder and shareholder of Menten AI, a biotechnology company. G.T.M. is a cofounder of Nexomics Biosciences, Inc., a structural biology contract research organization. A provisional patent covering  the membrane-permeable peptides described in this paper has been filed by the University of Washington, Seattle. Gaurav Bhardwaj, L.S., and D.B. are cofounders and shareholders of an early-stage biotechnology company that has licensed the provisional patent.\n",
      "\n",
      "Declaration of interests Vikram Khipple Mulligan is a cofounder and shareholder of Menten AI, a biotechnology company. G.T.M. is a cofounder of Nexomics Biosciences, Inc., a structural biology contract research organization. A provisional patent covering  the membrane-permeable peptides described in this paper has been filed by the University of Washington, Seattle. Gaurav Bhardwaj, L.S., and D.B. are cofounders and shareholders of an early-stage biotechnology company that has licensed the provisional patent.\n",
      "\n",
      "Declaration of interests Vikram Khipple Mulligan is a cofounder and shareholder of Menten AI, a biotechnology company. G.T.M. is a cofounder of Nexomics Biosciences, Inc., a structural biology contract research organization. A provisional patent covering  the membrane-permeable peptides described in this paper has been filed by the University of Washington, Seattle. Gaurav Bhardwaj, L.S., and D.B. are cofounders and shareholders of an early-stage biotechnology company that has licensed the provisional patent.\n",
      "\n",
      "Declaration of interests Vikram Khipple Mulligan is a cofounder and shareholder of Menten AI, a biotechnology company. G.T.M. is a cofounder of Nexomics Biosciences, Inc., a structural biology contract research organization. A provisional patent covering  the membrane-permeable peptides described in this paper has been filed by the University of Washington, Seattle. Gaurav Bhardwaj, L.S., and D.B. are cofounders and shareholders of an early-stage biotechnology company that has licensed the provisional patent.\n",
      "\n",
      "Declaration of interests Vikram Khipple Mulligan is a cofounder and shareholder of Menten AI, a biotechnology company. G.T.M. is a cofounder of Nexomics Biosciences, Inc., a structural biology contract research organization. A provisional patent covering  the membrane-permeable peptides described in this paper has been filed by the University of Washington, Seattle. Gaurav Bhardwaj, L.S., and D.B. are cofounders and shareholders of an early-stage biotechnology company that has licensed the provisional patent.\n",
      "\n",
      "Declaration of interests Vikram Khipple Mulligan is a cofounder and shareholder of Menten AI, a biotechnology company. G.T.M. is a cofounder of Nexomics Biosciences, Inc., a structural biology contract research organization. A provisional patent covering  the membrane-permeable peptides described in this paper has been filed by the University of Washington, Seattle. Gaurav Bhardwaj, L.S., and D.B. are cofounders and shareholders of an early-stage biotechnology company that has licensed the provisional patent.\n",
      "\n",
      "Declaration of interests Vikram Khipple Mulligan is a cofounder and shareholder of Menten AI, a biotechnology company. G.T.M. is a cofounder of Nexomics Biosciences, Inc., a structural biology contract research organization. A provisional patent covering  the membrane-permeable peptides described in this paper has been filed by the University of Washington, Seattle. Gaurav Bhardwaj, L.S., and D.B. are cofounders and shareholders of an early-stage biotechnology company that has licensed the provisional patent.\n",
      "\n",
      "Declaration of interests Vikram Khipple Mulligan is a cofounder and shareholder of Menten AI, a biotechnology company. G.T.M. is a cofounder of Nexomics Biosciences, Inc., a structural biology contract research organization. A provisional patent covering  the membrane-permeable peptides described in this paper has been filed by the University of Washington, Seattle. Gaurav Bhardwaj, L.S., and D.B. are cofounders and shareholders of an early-stage biotechnology company that has licensed the provisional patent.\n",
      "\n",
      "Declaration of interests Vikram Khipple Mulligan is a cofounder and shareholder of Menten AI, a biotechnology company. G.T.M. is a cofounder of Nexomics Biosciences, Inc., a structural biology contract research organization. A provisional patent covering  the membrane-permeable peptides described in this paper has been filed by the University of Washington, Seattle. Gaurav Bhardwaj, L.S., and D.B. are cofounders and shareholders of an early-stage biotechnology company that has licensed the provisional patent.\n",
      "\n",
      "Declaration of interests Vikram Khipple Mulligan is a cofounder and shareholder of Menten AI, a biotechnology company. G.T.M. is a cofounder of Nexomics Biosciences, Inc., a structural biology contract research organization. A provisional patent covering  the membrane-permeable peptides described in this paper has been filed by the University of Washington, Seattle. Gaurav Bhardwaj, L.S., and D.B. are cofounders and shareholders of an early-stage biotechnology company that has licensed the provisional patent.\n",
      "\n",
      "Declaration of interests Vikram Khipple Mulligan is a cofounder and shareholder of Menten AI, a biotechnology company. G.T.M. is a cofounder of Nexomics Biosciences, Inc., a structural biology contract research organization. A provisional patent covering  the membrane-permeable peptides described in this paper has been filed by the University of Washington, Seattle. Gaurav Bhardwaj, L.S., and D.B. are cofounders and shareholders of an early-stage biotechnology company that has licensed the provisional patent.\n",
      "\n",
      "Declaration of interests Vikram Khipple Mulligan is a cofounder and shareholder of Menten AI, a biotechnology company. G.T.M. is a cofounder of Nexomics Biosciences, Inc., a structural biology contract research organization. A provisional patent covering  the membrane-permeable peptides described in this paper has been filed by the University of Washington, Seattle. Gaurav Bhardwaj, L.S., and D.B. are cofounders and shareholders of an early-stage biotechnology company that has licensed the provisional patent.\n",
      "\n",
      "Declaration of interests Vikram Khipple Mulligan is a cofounder and shareholder of Menten AI, a biotechnology company. G.T.M. is a cofounder of Nexomics Biosciences, Inc., a structural biology contract research organization. A provisional patent covering  the membrane-permeable peptides described in this paper has been filed by the University of Washington, Seattle. Gaurav Bhardwaj, L.S., and D.B. are cofounders and shareholders of an early-stage biotechnology company that has licensed the provisional patent.\n",
      "\n",
      "Declaration of interests Vikram Khipple Mulligan is a cofounder and shareholder of Menten AI, a biotechnology company. G.T.M. is a cofounder of Nexomics Biosciences, Inc., a structural biology contract research organization. A provisional patent covering  the membrane-permeable peptides described in this paper has been filed by the University of Washington, Seattle. Gaurav Bhardwaj, L.S., and D.B. are cofounders and shareholders of an early-stage biotechnology company that has licensed the provisional patent.\n",
      "\n",
      "Declaration of interests Vikram Khipple Mulligan is a cofounder and shareholder of Menten AI, a biotechnology company. G.T.M. is a cofounder of Nexomics Biosciences, Inc., a structural biology contract research organization. A provisional patent covering  the membrane-permeable peptides described in this paper has been filed by the University of Washington, Seattle. Gaurav Bhardwaj, L.S., and D.B. are cofounders and shareholders of an early-stage biotechnology company that has licensed the provisional patent.\n",
      "\n",
      "Declaration of interests Vikram Khipple Mulligan is a cofounder and shareholder of Menten AI, a biotechnology company. G.T.M. is a cofounder of Nexomics Biosciences, Inc., a structural biology contract research organization. A provisional patent covering  the membrane-permeable peptides described in this paper has been filed by the University of Washington, Seattle. Gaurav Bhardwaj, L.S., and D.B. are cofounders and shareholders of an early-stage biotechnology company that has licensed the provisional patent.\n",
      "\n",
      "Declaration of interests Vikram Khipple Mulligan is a cofounder and shareholder of Menten AI, a biotechnology company. G.T.M. is a cofounder of Nexomics Biosciences, Inc., a structural biology contract research organization. A provisional patent covering  the membrane-permeable peptides described in this paper has been filed by the University of Washington, Seattle. Gaurav Bhardwaj, L.S., and D.B. are cofounders and shareholders of an early-stage biotechnology company that has licensed the provisional patent.\n",
      "\n",
      "Stewart, Lance\n",
      "Declaration of interests Vikram Khipple Mulligan is a cofounder and shareholder of Menten AI, a biotechnology company. G.T.M. is a cofounder of Nexomics Biosciences, Inc., a structural biology contract research organization. A provisional patent covering  the membrane-permeable peptides described in this paper has been filed by the University of Washington, Seattle. Gaurav Bhardwaj, Lance Stewart, and D.B. are cofounders and shareholders of an early-stage biotechnology company that has licensed the provisional patent.\n",
      "\n",
      "Montelione, Gaetano T.\n",
      "Declaration of interests Vikram Khipple Mulligan is a cofounder and shareholder of Menten AI, a biotechnology company. Gaetano T. Montelione is a cofounder of Nexomics Biosciences, Inc., a structural biology contract research organization. A provisional patent covering  the membrane-permeable peptides described in this paper has been filed by the University of Washington, Seattle. Gaurav Bhardwaj, Lance Stewart, and D.B. are cofounders and shareholders of an early-stage biotechnology company that has licensed the provisional patent.\n",
      "\n",
      "Declaration of interests Vikram Khipple Mulligan is a cofounder and shareholder of Menten AI, a biotechnology company. Gaetano T. Montelione is a cofounder of Nexomics Biosciences, Inc., a structural biology contract research organization. A provisional patent covering  the membrane-permeable peptides described in this paper has been filed by the University of Washington, Seattle. Gaurav Bhardwaj, Lance Stewart, and D.B. are cofounders and shareholders of an early-stage biotechnology company that has licensed the provisional patent.\n",
      "\n",
      "Baker, David\n",
      "Declaration of interests Vikram Khipple Mulligan is a cofounder and shareholder of Menten AI, a biotechnology company. Gaetano T. Montelione is a cofounder of Nexomics Biosciences, Inc., a structural biology contract research organization. A provisional patent covering  the membrane-permeable peptides described in this paper has been filed by the University of Washington, Seattle. Gaurav Bhardwaj, Lance Stewart, and David Baker are cofounders and shareholders of an early-stage biotechnology company that has licensed the provisional patent.\n",
      "\n",
      "DISCLOSURES I hereby declare, on behalf of all authors, that we do not have any conflict of interest in relation to the study described in the manuscript \"Eggshell temperature during early and late incubation affects embryo and hatchling development in broiler chicks\". The study described in this manuscript  is executed according to the code of conduct of Uludag University and Wageningen  University.\n",
      "\n",
      "DISCLOSURES I hereby declare, on behalf of all authors, that we do not have any conflict of interest in relation to the study described in the manuscript \"Eggshell temperature during early and late incubation affects embryo and hatchling development in broiler chicks\". The study described in this manuscript  is executed according to the code of conduct of Uludag University and Wageningen  University.\n",
      "\n",
      "DISCLOSURES I hereby declare, on behalf of all authors, that we do not have any conflict of interest in relation to the study described in the manuscript \"Eggshell temperature during early and late incubation affects embryo and hatchling development in broiler chicks\". The study described in this manuscript  is executed according to the code of conduct of Uludag University and Wageningen  University.\n",
      "\n",
      "Corley, Amanda\n",
      "Declaration of Competing Interest Amanda Corley's employer on her behalf has received investigator-initiated research grant from Cardinal Health (unrelated to the current project). AJU's employer on her behalf has received investigator-initiated research grants and speaker fees from 3 M, Becton Dickinson-Bard, Cardinal Health (unrelated to the current project). NM's employer has received on her behalf investigator-initiated research grants unrestricted educational grants and from Becton Dickinson-Bard, and Cardinal Health; and a consultancy payment from Becton Dickinson-Bard for expert advice (unrelated to the current project). ENL's employer has received on her behalf, an investigator-initiated research grant from Cardinal Health and a conference scholarship attendance supported by Angiodynamics (unrelated to the current project). CR's employer has received on her behalf investigator-initiated research or educational grants from Becton Dickinson-Bard; and consultancy payments for educational lectures/expert advice from 3 M, Becton Dickinson-Bard,  BBraun (unrelated to the current project). JG, EM, CB, PNAH - no conflicts of interest to declare\n",
      "\n",
      "Ullman, Amanda J.\n",
      "Declaration of Competing Interest Amanda Corley's employer on her behalf has received investigator-initiated research grant from Cardinal Health (unrelated to the current project). Amanda J. Ullman's employer on her behalf has received investigator-initiated research grants and speaker fees from 3 M, Becton Dickinson-Bard, Cardinal Health (unrelated to the current project). NM's employer has received on her behalf investigator-initiated research grants unrestricted educational grants and from Becton Dickinson-Bard, and Cardinal Health; and a consultancy payment from Becton Dickinson-Bard for expert advice (unrelated to the current project). ENL's employer has received on her behalf, an investigator-initiated research grant from Cardinal Health and a conference scholarship attendance supported by Angiodynamics (unrelated to the current project). CR's employer has received on her behalf investigator-initiated research or educational grants from Becton Dickinson-Bard; and consultancy payments for educational lectures/expert advice from 3 M, Becton Dickinson-Bard,  BBraun (unrelated to the current project). JG, EM, CB, PNAH - no conflicts of interest to declare\n",
      "\n",
      "Marsh, Nicole\n",
      "Declaration of Competing Interest Amanda Corley's employer on her behalf has received investigator-initiated research grant from Cardinal Health (unrelated to the current project). Amanda J. Ullman's employer on her behalf has received investigator-initiated research grants and speaker fees from 3 M, Becton Dickinson-Bard, Cardinal Health (unrelated to the current project). Nicole Marsh's employer has received on her behalf investigator-initiated research grants unrestricted educational grants and from Becton Dickinson-Bard, and Cardinal Health; and a consultancy payment from Becton Dickinson-Bard for expert advice (unrelated to the current project). ENL's employer has received on her behalf, an investigator-initiated research grant from Cardinal Health and a conference scholarship attendance supported by Angiodynamics (unrelated to the current project). CR's employer has received on her behalf investigator-initiated research or educational grants from Becton Dickinson-Bard; and consultancy payments for educational lectures/expert advice from 3 M, Becton Dickinson-Bard,  BBraun (unrelated to the current project). JG, EM, CB, PNAH - no conflicts of interest to declare\n",
      "\n",
      "Genzel, Jodie\n",
      "Declaration of Competing Interest Amanda Corley's employer on her behalf has received investigator-initiated research grant from Cardinal Health (unrelated to the current project). Amanda J. Ullman's employer on her behalf has received investigator-initiated research grants and speaker fees from 3 M, Becton Dickinson-Bard, Cardinal Health (unrelated to the current project). Nicole Marsh's employer has received on her behalf investigator-initiated research grants unrestricted educational grants and from Becton Dickinson-Bard, and Cardinal Health; and a consultancy payment from Becton Dickinson-Bard for expert advice (unrelated to the current project). ENL's employer has received on her behalf, an investigator-initiated research grant from Cardinal Health and a conference scholarship attendance supported by Angiodynamics (unrelated to the current project). CR's employer has received on her behalf investigator-initiated research or educational grants from Becton Dickinson-Bard; and consultancy payments for educational lectures/expert advice from 3 M, Becton Dickinson-Bard,  BBraun (unrelated to the current project). Jodie Genzel, EM, CB, PNAH - no conflicts of interest to declare\n",
      "\n",
      "Larsen, Emily N.\n",
      "Declaration of Competing Interest Amanda Corley's employer on her behalf has received investigator-initiated research grant from Cardinal Health (unrelated to the current project). Amanda J. Ullman's employer on her behalf has received investigator-initiated research grants and speaker fees from 3 M, Becton Dickinson-Bard, Cardinal Health (unrelated to the current project). Nicole Marsh's employer has received on her behalf investigator-initiated research grants unrestricted educational grants and from Becton Dickinson-Bard, and Cardinal Health; and a consultancy payment from Becton Dickinson-Bard for expert advice (unrelated to the current project). Emily N. Larsen's employer has received on her behalf, an investigator-initiated research grant from Cardinal Health and a conference scholarship attendance supported by Angiodynamics (unrelated to the current project). CR's employer has received on her behalf investigator-initiated research or educational grants from Becton Dickinson-Bard; and consultancy payments for educational lectures/expert advice from 3 M, Becton Dickinson-Bard,  BBraun (unrelated to the current project). Jodie Genzel, EM, CB, PNAH - no conflicts of interest to declare\n",
      "\n",
      "Young, Emily\n",
      "Declaration of Competing Interest Amanda Corley's employer on her behalf has received investigator-initiated research grant from Cardinal Health (unrelated to the current project). Amanda J. Ullman's employer on her behalf has received investigator-initiated research grants and speaker fees from 3 M, Becton Dickinson-Bard, Cardinal Health (unrelated to the current project). Nicole Marsh's employer has received on her behalf investigator-initiated research grants unrestricted educational grants and from Becton Dickinson-Bard, and Cardinal Health; and a consultancy payment from Becton Dickinson-Bard for expert advice (unrelated to the current project). Emily Young N. Larsen's employer has received on her behalf, an investigator-initiated research grant from Cardinal Health and a conference scholarship attendance supported by Angiodynamics (unrelated to the current project). CR's employer has received on her behalf investigator-initiated research or educational grants from Becton Dickinson-Bard; and consultancy payments for educational lectures/expert advice from 3 M, Becton Dickinson-Bard,  BBraun (unrelated to the current project). Jodie Genzel, EM, CB, PNAH - no conflicts of interest to declare\n",
      "\n",
      "Booker, Catriona\n",
      "Declaration of Competing Interest Amanda Corley's employer on her behalf has received investigator-initiated research grant from Cardinal Health (unrelated to the current project). Amanda J. Ullman's employer on her behalf has received investigator-initiated research grants and speaker fees from 3 M, Becton Dickinson-Bard, Cardinal Health (unrelated to the current project). Nicole Marsh's employer has received on her behalf investigator-initiated research grants unrestricted educational grants and from Becton Dickinson-Bard, and Cardinal Health; and a consultancy payment from Becton Dickinson-Bard for expert advice (unrelated to the current project). Emily Young N. Larsen's employer has received on her behalf, an investigator-initiated research grant from Cardinal Health and a conference scholarship attendance supported by Angiodynamics (unrelated to the current project). CR's employer has received on her behalf investigator-initiated research or educational grants from Becton Dickinson-Bard; and consultancy payments for educational lectures/expert advice from 3 M, Becton Dickinson-Bard,  BBraun (unrelated to the current project). Jodie Genzel, EM, Catriona Booker, PNAH - no conflicts of interest to declare\n",
      "\n",
      "Harris, Patrick N.A.\n",
      "Declaration of Competing Interest Amanda Corley's employer on her behalf has received investigator-initiated research grant from Cardinal Health (unrelated to the current project). Amanda J. Ullman's employer on her behalf has received investigator-initiated research grants and speaker fees from 3 M, Becton Dickinson-Bard, Cardinal Health (unrelated to the current project). Nicole Marsh's employer has received on her behalf investigator-initiated research grants unrestricted educational grants and from Becton Dickinson-Bard, and Cardinal Health; and a consultancy payment from Becton Dickinson-Bard for expert advice (unrelated to the current project). Emily Young N. Larsen's employer has received on her behalf, an investigator-initiated research grant from Cardinal Health and a conference scholarship attendance supported by Angiodynamics (unrelated to the current project). CR's employer has received on her behalf investigator-initiated research or educational grants from Becton Dickinson-Bard; and consultancy payments for educational lectures/expert advice from 3 M, Becton Dickinson-Bard,  BBraun (unrelated to the current project). Jodie Genzel, EM, Catriona Booker, Patrick N.A. Harris - no conflicts of interest to declare\n",
      "\n",
      "Rickard, Claire M.\n",
      "Declaration of Competing Interest Amanda Corley's employer on her behalf has received investigator-initiated research grant from Cardinal Health (unrelated to the current project). Amanda J. Ullman's employer on her behalf has received investigator-initiated research grants and speaker fees from 3 M, Becton Dickinson-Bard, Cardinal Health (unrelated to the current project). Nicole Marsh's employer has received on her behalf investigator-initiated research grants unrestricted educational grants and from Becton Dickinson-Bard, and Cardinal Health; and a consultancy payment from Becton Dickinson-Bard for expert advice (unrelated to the current project). Emily Young N. Larsen's employer has received on her behalf, an investigator-initiated research grant from Cardinal Health and a conference scholarship attendance supported by Angiodynamics (unrelated to the current project). Claire M. Rickard's employer has received on her behalf investigator-initiated research or educational grants from Becton Dickinson-Bard; and consultancy payments for educational lectures/expert advice from 3 M, Becton Dickinson-Bard,  BBraun (unrelated to the current project). Jodie Genzel, EM, Catriona Booker, Patrick N.A. Harris - no conflicts of interest to declare\n",
      "\n",
      "Saunders, Tyler S.\n",
      "Declaration of interests KB has served as a consultant, at advisory boards, or at data monitoring committees for Abcam, Axon, BioArctic, Biogen, JOMDD/Shimadzu. Julius Clinical, Lilly, MagQu, Novartis, Ono Pharma, Pharmatrophix, Prothena, Roche Diagnostics, and Siemens Healthineers, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program. KB has received payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from GEECD, Rochie Diagnostics, and IFCC/SNIBE. CR has served as a consultant for Roche, Eli Lilly, Merck, Biogen, Eisai, Roche Diagnostics, and Actinogen. CR has  participanted on a data safety monitory board/advisory board for the DESPIAD study (an NIHR funded project), and is the director for Brain Health Scotland, and the chair for the Scottish Dementia Research Consortium. Tyler S. Saunders, GM, NJ have no conflicts of interest to report.\n",
      "\n",
      "Jenkins, Natalie\n",
      "Declaration of interests KB has served as a consultant, at advisory boards, or at data monitoring committees for Abcam, Axon, BioArctic, Biogen, JOMDD/Shimadzu. Julius Clinical, Lilly, MagQu, Novartis, Ono Pharma, Pharmatrophix, Prothena, Roche Diagnostics, and Siemens Healthineers, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program. KB has received payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from GEECD, Rochie Diagnostics, and IFCC/SNIBE. CR has served as a consultant for Roche, Eli Lilly, Merck, Biogen, Eisai, Roche Diagnostics, and Actinogen. CR has  participanted on a data safety monitory board/advisory board for the DESPIAD study (an NIHR funded project), and is the director for Brain Health Scotland, and the chair for the Scottish Dementia Research Consortium. Tyler S. Saunders, GM, Natalie Jenkins have no conflicts of interest to report.\n",
      "\n",
      "Blennow, Kaj\n",
      "Declaration of interests Kaj Blennow has served as a consultant, at advisory boards, or at data monitoring committees for Abcam, Axon, BioArctic, Biogen, JOMDD/Shimadzu. Julius Clinical, Lilly, MagQu, Novartis, Ono Pharma, Pharmatrophix, Prothena, Roche Diagnostics, and Siemens Healthineers, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program. Kaj Blennow has received payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from GEECD, Rochie Diagnostics, and IFCC/SNIBE. CR has served as a consultant for Roche, Eli Lilly, Merck, Biogen, Eisai, Roche Diagnostics, and Actinogen. CR has  participanted on a data safety monitory board/advisory board for the DESPIAD study (an NIHR funded project), and is the director for Brain Health Scotland, and the chair for the Scottish Dementia Research Consortium. Tyler S. Saunders, GM, Natalie Jenkins have no conflicts of interest to report.\n",
      "\n",
      "Ritchie, Craig\n",
      "Declaration of interests Kaj Blennow has served as a consultant, at advisory boards, or at data monitoring committees for Abcam, Axon, BioArctic, Biogen, JOMDD/Shimadzu. Julius Clinical, Lilly, MagQu, Novartis, Ono Pharma, Pharmatrophix, Prothena, Roche Diagnostics, and Siemens Healthineers, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program. Kaj Blennow has received payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from GEECD, Rochie Diagnostics, and IFCC/SNIBE. Craig Ritchie has served as a consultant for Roche, Eli Lilly, Merck, Biogen, Eisai, Roche Diagnostics, and Actinogen. Craig Ritchie has  participanted on a data safety monitory board/advisory board for the DESPIAD study (an NIHR funded project), and is the director for Brain Health Scotland, and the chair for the Scottish Dementia Research Consortium. Tyler S. Saunders, GM, Natalie Jenkins have no conflicts of interest to report.\n",
      "\n",
      "Muniz-Terrera, Graciela\n",
      "Declaration of interests Kaj Blennow has served as a consultant, at advisory boards, or at data monitoring committees for Abcam, Axon, BioArctic, Biogen, JOMDD/Shimadzu. Julius Clinical, Lilly, MagQu, Novartis, Ono Pharma, Pharmatrophix, Prothena, Roche Diagnostics, and Siemens Healthineers, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program. Kaj Blennow has received payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from GEECD, Rochie Diagnostics, and IFCC/SNIBE. Craig Ritchie has served as a consultant for Roche, Eli Lilly, Merck, Biogen, Eisai, Roche Diagnostics, and Actinogen. Craig Ritchie has  participanted on a data safety monitory board/advisory board for the DESPIAD study (an NIHR funded project), and is the director for Brain Health Scotland, and the chair for the Scottish Dementia Research Consortium. Tyler S. Saunders, Graciela Muniz-Terrera, Natalie Jenkins have no conflicts of interest to report.\n",
      "\n",
      "Kitazawa, Koji\n",
      "C.S. receives grants and personal fees from San contact lens; grants from Hirosaki Lifescience Innovation Inc.; grants from CorneaGen Inc. S.K. receives grants and personal fees from Senju Pharmaceutical Co. Ltd; personal fees from Kowa Co. Ltd; grants, personal fees, and other from CorneaGen. Koji Kitazawa has no conflicts of interest to declare.\n",
      "\n",
      "Sotozono, Chie\n",
      "Chie Sotozono receives grants and personal fees from San contact lens; grants from Hirosaki Lifescience Innovation Inc.; grants from CorneaGen Inc. S.K. receives grants and personal fees from Senju Pharmaceutical Co. Ltd; personal fees from Kowa Co. Ltd; grants, personal fees, and other from CorneaGen. Koji Kitazawa has no conflicts of interest to declare.\n",
      "\n",
      "Kinoshita, Shigeru\n",
      "Chie Sotozono receives grants and personal fees from San contact lens; grants from Hirosaki Lifescience Innovation Inc.; grants from CorneaGen Inc. Shigeru Kinoshita receives grants and personal fees from Senju Pharmaceutical Co. Ltd; personal fees from Kowa Co. Ltd; grants, personal fees, and other from CorneaGen. Koji Kitazawa has no conflicts of interest to declare.\n",
      "\n",
      "Buller, David\n",
      "Conflicts of Interest: David Buller receives a salary from Klein Buendel, Inc., and his spouse is an owner of Klein Buendel. AK, BW, WGW, and JB receive a salary from Klein Buendel, Inc. SP, KH, KB, JD, and JH have no conflicts to declare.\n",
      "\n",
      "Walkosz, Barbara\n",
      "Conflicts of Interest: David Buller receives a salary from Klein Buendel, Inc., and his spouse is an owner of Klein Buendel. AK, Barbara Walkosz, WGW, and JB receive a salary from Klein Buendel, Inc. SP, KH, KB, JD, and JH have no conflicts to declare.\n",
      "\n",
      "Henry, Kimberly\n",
      "Conflicts of Interest: David Buller receives a salary from Klein Buendel, Inc., and his spouse is an owner of Klein Buendel. AK, Barbara Walkosz, WGW, and JB receive a salary from Klein Buendel, Inc. SP, Kimberly Henry, KB, JD, and JH have no conflicts to declare.\n",
      "\n",
      "Gill Woodall, W.\n",
      "Conflicts of Interest: David Buller receives a salary from Klein Buendel, Inc., and his spouse is an owner of Klein Buendel. AK, Barbara Walkosz, W. Gill Woodall, and JB receive a salary from Klein Buendel, Inc. SP, Kimberly Henry, KB, JD, and JH have no conflicts to declare.\n",
      "\n",
      "Pagoto, Sherry\n",
      "Conflicts of Interest: David Buller receives a salary from Klein Buendel, Inc., and his spouse is an owner of Klein Buendel. AK, Barbara Walkosz, W. Gill Woodall, and JB receive a salary from Klein Buendel, Inc. Sherry Pagoto, Kimberly Henry, KB, JD, and JH have no conflicts to declare.\n",
      "\n",
      "Berteletti, Julia\n",
      "Conflicts of Interest: David Buller receives a salary from Klein Buendel, Inc., and his spouse is an owner of Klein Buendel. AK, Barbara Walkosz, W. Gill Woodall, and Julia Berteletti receive a salary from Klein Buendel, Inc. Sherry Pagoto, Kimberly Henry, KB, JD, and JH have no conflicts to declare.\n",
      "\n",
      "Kinsey, Alishia\n",
      "Conflicts of Interest: David Buller receives a salary from Klein Buendel, Inc., and his spouse is an owner of Klein Buendel. Alishia Kinsey, Barbara Walkosz, W. Gill Woodall, and Julia Berteletti receive a salary from Klein Buendel, Inc. Sherry Pagoto, Kimberly Henry, KB, JD, and JH have no conflicts to declare.\n",
      "\n",
      "Divito, Joseph\n",
      "Conflicts of Interest: David Buller receives a salary from Klein Buendel, Inc., and his spouse is an owner of Klein Buendel. Alishia Kinsey, Barbara Walkosz, W. Gill Woodall, and Julia Berteletti receive a salary from Klein Buendel, Inc. Sherry Pagoto, Kimberly Henry, KB, Joseph Divito, and JH have no conflicts to declare.\n",
      "\n",
      "Baker, Katie\n",
      "Conflicts of Interest: David Buller receives a salary from Klein Buendel, Inc., and his spouse is an owner of Klein Buendel. Alishia Kinsey, Barbara Walkosz, W. Gill Woodall, and Julia Berteletti receive a salary from Klein Buendel, Inc. Sherry Pagoto, Kimberly Henry, Katie Baker, Joseph Divito, and JH have no conflicts to declare.\n",
      "\n",
      "Hillhouse, Joel\n",
      "Conflicts of Interest: David Buller receives a salary from Klein Buendel, Inc., and his spouse is an owner of Klein Buendel. Alishia Kinsey, Barbara Walkosz, W. Gill Woodall, and Julia Berteletti receive a salary from Klein Buendel, Inc. Sherry Pagoto, Kimberly Henry, Katie Baker, Joseph Divito, and Joel Hillhouse have no conflicts to declare.\n",
      "\n",
      "Ceolini, Enea\n",
      "A.G. is a cofounder of QuantActions AG, Zurich, Switzerland, and Enea Ceolini is a founding team member. This company focuses on converting smartphone taps to mental health indicators. Software and data collection services from QuantActions were used to monitor smartphone activity. R.D.T. reports personal fees from Union Chimique Belge (UCB), Theravarance, Novartis, Zogenix, and Arvelle and grants from the Dutch National Epilepsy Fund, Christelijke Vereniging voor de Verpleging van Lijders aan Epilepsie, Medtronic, NewLife Wearables, and The Netherlands Organisation for Health Research and Development. H.J.M. receives travel reimbursements and other compensation from Eisai and UCB for organizing clinical  education. Authors I.B. and J.B. have no competing interests to report.\n",
      "\n",
      "Brunner, Iris\n",
      "A.G. is a cofounder of QuantActions AG, Zurich, Switzerland, and Enea Ceolini is a founding team member. This company focuses on converting smartphone taps to mental health indicators. Software and data collection services from QuantActions were used to monitor smartphone activity. R.D.T. reports personal fees from Union Chimique Belge (UCB), Theravarance, Novartis, Zogenix, and Arvelle and grants from the Dutch National Epilepsy Fund, Christelijke Vereniging voor de Verpleging van Lijders aan Epilepsie, Medtronic, NewLife Wearables, and The Netherlands Organisation for Health Research and Development. H.J.M. receives travel reimbursements and other compensation from Eisai and UCB for organizing clinical  education. Authors Iris Brunner and J.B. have no competing interests to report.\n",
      "\n",
      "Bunschoten, Johanna\n",
      "A.G. is a cofounder of QuantActions AG, Zurich, Switzerland, and Enea Ceolini is a founding team member. This company focuses on converting smartphone taps to mental health indicators. Software and data collection services from QuantActions were used to monitor smartphone activity. R.D.T. reports personal fees from Union Chimique Belge (UCB), Theravarance, Novartis, Zogenix, and Arvelle and grants from the Dutch National Epilepsy Fund, Christelijke Vereniging voor de Verpleging van Lijders aan Epilepsie, Medtronic, NewLife Wearables, and The Netherlands Organisation for Health Research and Development. H.J.M. receives travel reimbursements and other compensation from Eisai and UCB for organizing clinical  education. Authors Iris Brunner and Johanna Bunschoten have no competing interests to report.\n",
      "\n",
      "A.G. is a cofounder of QuantActions AG, Zurich, Switzerland, and Enea Ceolini is a founding team member. This company focuses on converting smartphone taps to mental health indicators. Software and data collection services from QuantActions were used to monitor smartphone activity. R.D.T. reports personal fees from Union Chimique Belge (UCB), Theravarance, Novartis, Zogenix, and Arvelle and grants from the Dutch National Epilepsy Fund, Christelijke Vereniging voor de Verpleging van Lijders aan Epilepsie, Medtronic, NewLife Wearables, and The Netherlands Organisation for Health Research and Development. H.J.M. receives travel reimbursements and other compensation from Eisai and UCB for organizing clinical  education. Authors Iris Brunner and Johanna Bunschoten have no competing interests to report.\n",
      "\n",
      "Thijs, Roland D.\n",
      "A.G. is a cofounder of QuantActions AG, Zurich, Switzerland, and Enea Ceolini is a founding team member. This company focuses on converting smartphone taps to mental health indicators. Software and data collection services from QuantActions were used to monitor smartphone activity. Roland D. Thijs reports personal fees from Union Chimique Belge (UCB), Theravarance, Novartis, Zogenix, and Arvelle and grants from the Dutch National Epilepsy Fund, Christelijke Vereniging voor de Verpleging van Lijders aan Epilepsie, Medtronic, NewLife Wearables, and The Netherlands Organisation for Health Research and Development. H.J.M. receives travel reimbursements and other compensation from Eisai and UCB for organizing clinical  education. Authors Iris Brunner and Johanna Bunschoten have no competing interests to report.\n",
      "\n",
      "Ghosh, Arko\n",
      "Arko Ghosh is a cofounder of QuantActions AG, Zurich, Switzerland, and Enea Ceolini is a founding team member. This company focuses on converting smartphone taps to mental health indicators. Software and data collection services from QuantActions were used to monitor smartphone activity. Roland D. Thijs reports personal fees from Union Chimique Belge (UCB), Theravarance, Novartis, Zogenix, and Arvelle and grants from the Dutch National Epilepsy Fund, Christelijke Vereniging voor de Verpleging van Lijders aan Epilepsie, Medtronic, NewLife Wearables, and The Netherlands Organisation for Health Research and Development. H.J.M. receives travel reimbursements and other compensation from Eisai and UCB for organizing clinical  education. Authors Iris Brunner and Johanna Bunschoten have no competing interests to report.\n",
      "\n",
      "Tsudome, Mikiko\n",
      "JAMSTEC has patents relating to the production and uses of the nanofibrous cellulose plate, of which SD and Mikiko Tsudome are named inventors. SD and Mikiko Tsudome have received  research support and may profit from the sale of the nanofibrous cellulose plate, which has been developed by Kyokuto Pharmaceutical Industrial Co., Ltd., Japan, through a joint research agreement with JAMSTEC. All other authors declare no competing interests.\n",
      "\n",
      "JAMSTEC has patents relating to the production and uses of the nanofibrous cellulose plate, of which SD and Mikiko Tsudome are named inventors. SD and Mikiko Tsudome have received  research support and may profit from the sale of the nanofibrous cellulose plate, which has been developed by Kyokuto Pharmaceutical Industrial Co., Ltd., Japan, through a joint research agreement with JAMSTEC. All other authors declare no competing interests.\n",
      "\n",
      "JAMSTEC has patents relating to the production and uses of the nanofibrous cellulose plate, of which SD and Mikiko Tsudome are named inventors. SD and Mikiko Tsudome have received  research support and may profit from the sale of the nanofibrous cellulose plate, which has been developed by Kyokuto Pharmaceutical Industrial Co., Ltd., Japan, through a joint research agreement with JAMSTEC. All other authors declare no competing interests.\n",
      "\n",
      "JAMSTEC has patents relating to the production and uses of the nanofibrous cellulose plate, of which SD and Mikiko Tsudome are named inventors. SD and Mikiko Tsudome have received  research support and may profit from the sale of the nanofibrous cellulose plate, which has been developed by Kyokuto Pharmaceutical Industrial Co., Ltd., Japan, through a joint research agreement with JAMSTEC. All other authors declare no competing interests.\n",
      "\n",
      "JAMSTEC has patents relating to the production and uses of the nanofibrous cellulose plate, of which SD and Mikiko Tsudome are named inventors. SD and Mikiko Tsudome have received  research support and may profit from the sale of the nanofibrous cellulose plate, which has been developed by Kyokuto Pharmaceutical Industrial Co., Ltd., Japan, through a joint research agreement with JAMSTEC. All other authors declare no competing interests.\n",
      "\n",
      "JAMSTEC has patents relating to the production and uses of the nanofibrous cellulose plate, of which SD and Mikiko Tsudome are named inventors. SD and Mikiko Tsudome have received  research support and may profit from the sale of the nanofibrous cellulose plate, which has been developed by Kyokuto Pharmaceutical Industrial Co., Ltd., Japan, through a joint research agreement with JAMSTEC. All other authors declare no competing interests.\n",
      "\n",
      "Deguchi, Shigeru\n",
      "JAMSTEC has patents relating to the production and uses of the nanofibrous cellulose plate, of which Shigeru Deguchi and Mikiko Tsudome are named inventors. Shigeru Deguchi and Mikiko Tsudome have received  research support and may profit from the sale of the nanofibrous cellulose plate, which has been developed by Kyokuto Pharmaceutical Industrial Co., Ltd., Japan, through a joint research agreement with JAMSTEC. All other authors declare no competing interests.\n",
      "\n",
      "Ceolini, Enea\n",
      "A.G. is a co-founder of QuantActions Ltd., Lausanne, Switzerland, and Enea Ceolini is a founding team member. This company focuses on converting smartphone taps to mental health indicators. Software and data collection services from QuantActions were used to monitor smartphone activity. Authors R.K., G.B., and G.S. have no competing interests to report.\n",
      "\n",
      "Kock, Ruchella\n",
      "A.G. is a co-founder of QuantActions Ltd., Lausanne, Switzerland, and Enea Ceolini is a founding team member. This company focuses on converting smartphone taps to mental health indicators. Software and data collection services from QuantActions were used to monitor smartphone activity. Authors Ruchella Kock, G.B., and G.S. have no competing interests to report.\n",
      "\n",
      "Band, Guido P.H.\n",
      "A.G. is a co-founder of QuantActions Ltd., Lausanne, Switzerland, and Enea Ceolini is a founding team member. This company focuses on converting smartphone taps to mental health indicators. Software and data collection services from QuantActions were used to monitor smartphone activity. Authors Ruchella Kock, Guido P.H. Band, and G.S. have no competing interests to report.\n",
      "\n",
      "Stoet, Gijsbert\n",
      "A.G. is a co-founder of QuantActions Ltd., Lausanne, Switzerland, and Enea Ceolini is a founding team member. This company focuses on converting smartphone taps to mental health indicators. Software and data collection services from QuantActions were used to monitor smartphone activity. Authors Ruchella Kock, Guido P.H. Band, and Gijsbert Stoet have no competing interests to report.\n",
      "\n",
      "Ghosh, Arko\n",
      "Arko Ghosh is a co-founder of QuantActions Ltd., Lausanne, Switzerland, and Enea Ceolini is a founding team member. This company focuses on converting smartphone taps to mental health indicators. Software and data collection services from QuantActions were used to monitor smartphone activity. Authors Ruchella Kock, Guido P.H. Band, and Gijsbert Stoet have no competing interests to report.\n",
      "\n",
      "Conflict of interestNone declared. No author has received funding or other support from a sponsor/commercial entity/third party. The authors have no financial relationship with any of the device mentioned in the manuscript, which  are solely for educational purpose.\n",
      "\n",
      "Conflict of interestNone declared. No author has received funding or other support from a sponsor/commercial entity/third party. The authors have no financial relationship with any of the device mentioned in the manuscript, which  are solely for educational purpose.\n",
      "\n",
      "Conflict of interestNone declared. No author has received funding or other support from a sponsor/commercial entity/third party. The authors have no financial relationship with any of the device mentioned in the manuscript, which  are solely for educational purpose.\n",
      "\n",
      "Kotlinski, Mateusz\n",
      "Competing InterestsAuthors confirms that there is no indication of competing interest and potential bias judgements impacting results of the study. For information purposes - Author Mateusz Kotlinski was employed by the Polish Air Navigation Services Agency when engaged in the study and directly involved in the subject of the study.\n",
      "\n",
      "Competing InterestsAuthors confirms that there is no indication of competing interest and potential bias judgements impacting results of the study. For information purposes - Author Mateusz Kotlinski was employed by the Polish Air Navigation Services Agency when engaged in the study and directly involved in the subject of the study.\n",
      "\n",
      "Barber, Cara\n",
      "Dr Lear is the cofounder of and chief technical officer for SUTUREGARD Medical, Inc, the manufacturer of the adhesive retention suture device used in this study. Drs Cara Barber, Roybal, and Young have no conflicts of interest to declare.\n",
      "\n",
      "Roybal, Lacey\n",
      "Dr Lear is the cofounder of and chief technical officer for SUTUREGARD Medical, Inc, the manufacturer of the adhesive retention suture device used in this study. Drs Cara Barber, Lacey Roybal, and Young have no conflicts of interest to declare.\n",
      "\n",
      "Young, John\n",
      "Dr Lear is the cofounder of and chief technical officer for SUTUREGARD Medical, Inc, the manufacturer of the adhesive retention suture device used in this study. Drs Cara Barber, Lacey Roybal, and John Young have no conflicts of interest to declare.\n",
      "\n",
      "Lear, William\n",
      "Dr William Lear is the cofounder of and chief technical officer for SUTUREGARD Medical, Inc, the manufacturer of the adhesive retention suture device used in this study. Drs Cara Barber, Lacey Roybal, and John Young have no conflicts of interest to declare.\n",
      "\n",
      "The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Iridium Netwerk is involved in an on-going scientific collaboration with RaySearch Laboratories, C-RAD, Sun Nuclear Corporation and Sordina IORT Technologies.\n",
      "\n",
      "The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Iridium Netwerk is involved in an on-going scientific collaboration with RaySearch Laboratories, C-RAD, Sun Nuclear Corporation and Sordina IORT Technologies.\n",
      "\n",
      "The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Iridium Netwerk is involved in an on-going scientific collaboration with RaySearch Laboratories, C-RAD, Sun Nuclear Corporation and Sordina IORT Technologies.\n",
      "\n",
      "The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Iridium Netwerk is involved in an on-going scientific collaboration with RaySearch Laboratories, C-RAD, Sun Nuclear Corporation and Sordina IORT Technologies.\n",
      "\n",
      "The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Iridium Netwerk is involved in an on-going scientific collaboration with RaySearch Laboratories, C-RAD, Sun Nuclear Corporation and Sordina IORT Technologies.\n",
      "\n",
      "The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Dana Spence reports a relationship with LifeBlood that includes: equity or stocks.\n",
      "\n",
      "The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Dana Spence reports a relationship with LifeBlood that includes: equity or stocks.\n",
      "\n",
      "The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Dana Spence reports a relationship with LifeBlood that includes: equity or stocks.\n",
      "\n",
      "D. Spence\n",
      "The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Dana D .   S p e n c e reports a relationship with LifeBlood that includes: equity or stocks.\n",
      "\n",
      "Bikila, Demiraw\n",
      "A thesis of this paper by Demiraw Bikila et al has previously been published.25 The abstract of this paper was presented at the International Conference on Clinical  Pathology, Diagnostic Techniques and Testing as a poster presentation with interim findings. The poster's abstract was published in \"Poster Abstracts\" in International Journal of Medical and Health Sciences.26 All authors declare that  they have no conflicts of interest in relation to this work.\n",
      "\n",
      "A thesis of this paper by Demiraw Bikila et al has previously been published.25 The abstract of this paper was presented at the International Conference on Clinical  Pathology, Diagnostic Techniques and Testing as a poster presentation with interim findings. The poster's abstract was published in \"Poster Abstracts\" in International Journal of Medical and Health Sciences.26 All authors declare that  they have no conflicts of interest in relation to this work.\n",
      "\n",
      "A thesis of this paper by Demiraw Bikila et al has previously been published.25 The abstract of this paper was presented at the International Conference on Clinical  Pathology, Diagnostic Techniques and Testing as a poster presentation with interim findings. The poster's abstract was published in \"Poster Abstracts\" in International Journal of Medical and Health Sciences.26 All authors declare that  they have no conflicts of interest in relation to this work.\n",
      "\n",
      "A thesis of this paper by Demiraw Bikila et al has previously been published.25 The abstract of this paper was presented at the International Conference on Clinical  Pathology, Diagnostic Techniques and Testing as a poster presentation with interim findings. The poster's abstract was published in \"Poster Abstracts\" in International Journal of Medical and Health Sciences.26 All authors declare that  they have no conflicts of interest in relation to this work.\n",
      "\n",
      "A thesis of this paper by Demiraw Bikila et al has previously been published.25 The abstract of this paper was presented at the International Conference on Clinical  Pathology, Diagnostic Techniques and Testing as a poster presentation with interim findings. The poster's abstract was published in \"Poster Abstracts\" in International Journal of Medical and Health Sciences.26 All authors declare that  they have no conflicts of interest in relation to this work.\n",
      "\n",
      "A thesis of this paper by Demiraw Bikila et al has previously been published.25 The abstract of this paper was presented at the International Conference on Clinical  Pathology, Diagnostic Techniques and Testing as a poster presentation with interim findings. The poster's abstract was published in \"Poster Abstracts\" in International Journal of Medical and Health Sciences.26 All authors declare that  they have no conflicts of interest in relation to this work.\n",
      "\n",
      "A thesis of this paper by Demiraw Bikila et al has previously been published.25 The abstract of this paper was presented at the International Conference on Clinical  Pathology, Diagnostic Techniques and Testing as a poster presentation with interim findings. The poster's abstract was published in \"Poster Abstracts\" in International Journal of Medical and Health Sciences.26 All authors declare that  they have no conflicts of interest in relation to this work.\n",
      "\n",
      "A thesis of this paper by Demiraw Bikila et al has previously been published.25 The abstract of this paper was presented at the International Conference on Clinical  Pathology, Diagnostic Techniques and Testing as a poster presentation with interim findings. The poster's abstract was published in \"Poster Abstracts\" in International Journal of Medical and Health Sciences.26 All authors declare that  they have no conflicts of interest in relation to this work.\n",
      "\n",
      "A thesis of this paper by Demiraw Bikila et al has previously been published.25 The abstract of this paper was presented at the International Conference on Clinical  Pathology, Diagnostic Techniques and Testing as a poster presentation with interim findings. The poster's abstract was published in \"Poster Abstracts\" in International Journal of Medical and Health Sciences.26 All authors declare that  they have no conflicts of interest in relation to this work.\n",
      "\n",
      "A thesis of this paper by Demiraw Bikila et al has previously been published.25 The abstract of this paper was presented at the International Conference on Clinical  Pathology, Diagnostic Techniques and Testing as a poster presentation with interim findings. The poster's abstract was published in \"Poster Abstracts\" in International Journal of Medical and Health Sciences.26 All authors declare that  they have no conflicts of interest in relation to this work.\n",
      "\n",
      "A thesis of this paper by Demiraw Bikila et al has previously been published.25 The abstract of this paper was presented at the International Conference on Clinical  Pathology, Diagnostic Techniques and Testing as a poster presentation with interim findings. The poster's abstract was published in \"Poster Abstracts\" in International Journal of Medical and Health Sciences.26 All authors declare that  they have no conflicts of interest in relation to this work.\n",
      "\n",
      "A thesis of this paper by Demiraw Bikila et al has previously been published.25 The abstract of this paper was presented at the International Conference on Clinical  Pathology, Diagnostic Techniques and Testing as a poster presentation with interim findings. The poster's abstract was published in \"Poster Abstracts\" in International Journal of Medical and Health Sciences.26 All authors declare that  they have no conflicts of interest in relation to this work.\n",
      "\n",
      "A thesis of this paper by Demiraw Bikila et al has previously been published.25 The abstract of this paper was presented at the International Conference on Clinical  Pathology, Diagnostic Techniques and Testing as a poster presentation with interim findings. The poster's abstract was published in \"Poster Abstracts\" in International Journal of Medical and Health Sciences.26 All authors declare that  they have no conflicts of interest in relation to this work.\n",
      "\n",
      "A thesis of this paper by Demiraw Bikila et al has previously been published.25 The abstract of this paper was presented at the International Conference on Clinical  Pathology, Diagnostic Techniques and Testing as a poster presentation with interim findings. The poster's abstract was published in \"Poster Abstracts\" in International Journal of Medical and Health Sciences.26 All authors declare that  they have no conflicts of interest in relation to this work.\n",
      "\n",
      "A thesis of this paper by Demiraw Bikila et al has previously been published.25 The abstract of this paper was presented at the International Conference on Clinical  Pathology, Diagnostic Techniques and Testing as a poster presentation with interim findings. The poster's abstract was published in \"Poster Abstracts\" in International Journal of Medical and Health Sciences.26 All authors declare that  they have no conflicts of interest in relation to this work.\n",
      "\n",
      "A thesis of this paper by Demiraw Bikila et al has previously been published.25 The abstract of this paper was presented at the International Conference on Clinical  Pathology, Diagnostic Techniques and Testing as a poster presentation with interim findings. The poster's abstract was published in \"Poster Abstracts\" in International Journal of Medical and Health Sciences.26 All authors declare that  they have no conflicts of interest in relation to this work.\n",
      "\n",
      "Li, Yupeng\n",
      "BR is an employee of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc.,  Rahway, NJ, USA and stockholders in Merck & Co., Inc., Rahway, NJ, USA. Yupeng Li and AB were employees of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA when they worked on this study. YG serves as scientific advisor to Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA. YG serves as editor and receives payment from Elsevier (iScience).\n",
      "\n",
      "BR is an employee of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc.,  Rahway, NJ, USA and stockholders in Merck & Co., Inc., Rahway, NJ, USA. Yupeng Li and AB were employees of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA when they worked on this study. YG serves as scientific advisor to Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA. YG serves as editor and receives payment from Elsevier (iScience).\n",
      "\n",
      "Ru, Boshu\n",
      "Boshu Ru is an employee of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc.,  Rahway, NJ, USA and stockholders in Merck & Co., Inc., Rahway, NJ, USA. Yupeng Li and AB were employees of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA when they worked on this study. YG serves as scientific advisor to Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA. YG serves as editor and receives payment from Elsevier (iScience).\n",
      "\n",
      "Black, Adam\n",
      "Boshu Ru is an employee of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc.,  Rahway, NJ, USA and stockholders in Merck & Co., Inc., Rahway, NJ, USA. Yupeng Li and Adam Black were employees of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA when they worked on this study. YG serves as scientific advisor to Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA. YG serves as editor and receives payment from Elsevier (iScience).\n",
      "\n",
      "Boshu Ru is an employee of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc.,  Rahway, NJ, USA and stockholders in Merck & Co., Inc., Rahway, NJ, USA. Yupeng Li and Adam Black were employees of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA when they worked on this study. YG serves as scientific advisor to Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA. YG serves as editor and receives payment from Elsevier (iScience).\n",
      "\n",
      "Guan, Yuanfang\n",
      "Boshu Ru is an employee of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc.,  Rahway, NJ, USA and stockholders in Merck & Co., Inc., Rahway, NJ, USA. Yupeng Li and Adam Black were employees of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA when they worked on this study. Yuanfang Guan serves as scientific advisor to Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA. Yuanfang Guan serves as editor and receives payment from Elsevier (iScience).\n",
      "\n",
      "IWD manages a fee-for-service nanopore sequencing facility at the Garvan Institute of Medical Research that is a customer of Oxford Nanopore Technologies  but has no further financial relationship. The authors declare no other competing financial or nonfinancial interests.\n",
      "\n",
      "IWD manages a fee-for-service nanopore sequencing facility at the Garvan Institute of Medical Research that is a customer of Oxford Nanopore Technologies  but has no further financial relationship. The authors declare no other competing financial or nonfinancial interests.\n",
      "\n",
      "IWD manages a fee-for-service nanopore sequencing facility at the Garvan Institute of Medical Research that is a customer of Oxford Nanopore Technologies  but has no further financial relationship. The authors declare no other competing financial or nonfinancial interests.\n",
      "\n",
      "IWD manages a fee-for-service nanopore sequencing facility at the Garvan Institute of Medical Research that is a customer of Oxford Nanopore Technologies  but has no further financial relationship. The authors declare no other competing financial or nonfinancial interests.\n",
      "\n",
      "IWD manages a fee-for-service nanopore sequencing facility at the Garvan Institute of Medical Research that is a customer of Oxford Nanopore Technologies  but has no further financial relationship. The authors declare no other competing financial or nonfinancial interests.\n",
      "\n",
      "Deveson, Ira W.\n",
      "Ira W. Deveson manages a fee-for-service nanopore sequencing facility at the Garvan Institute of Medical Research that is a customer of Oxford Nanopore Technologies  but has no further financial relationship. The authors declare no other competing financial or nonfinancial interests.\n",
      "\n",
      "Ira W. Deveson manages a fee-for-service nanopore sequencing facility at the Garvan Institute of Medical Research that is a customer of Oxford Nanopore Technologies  but has no further financial relationship. The authors declare no other competing financial or nonfinancial interests.\n",
      "\n",
      "PV has received unrestricted research grants from Gilead not related to the submitted work. This research was funded in whole, or in part, by the National Institute for Health Research Health Protection Research Unit for Behavioural Science and Evaluation and the Wellcome Trust [WT 220866/Z/20/Z].\n",
      "\n",
      "PV has received unrestricted research grants from Gilead not related to the submitted work. This research was funded in whole, or in part, by the National Institute for Health Research Health Protection Research Unit for Behavioural Science and Evaluation and the Wellcome Trust [WT 220866/Z/20/Z].\n",
      "\n",
      "PV has received unrestricted research grants from Gilead not related to the submitted work. This research was funded in whole, or in part, by the National Institute for Health Research Health Protection Research Unit for Behavioural Science and Evaluation and the Wellcome Trust [WT 220866/Z/20/Z].\n",
      "\n",
      "PV has received unrestricted research grants from Gilead not related to the submitted work. This research was funded in whole, or in part, by the National Institute for Health Research Health Protection Research Unit for Behavioural Science and Evaluation and the Wellcome Trust [WT 220866/Z/20/Z].\n",
      "\n",
      "PV has received unrestricted research grants from Gilead not related to the submitted work. This research was funded in whole, or in part, by the National Institute for Health Research Health Protection Research Unit for Behavioural Science and Evaluation and the Wellcome Trust [WT 220866/Z/20/Z].\n",
      "\n",
      "PV has received unrestricted research grants from Gilead not related to the submitted work. This research was funded in whole, or in part, by the National Institute for Health Research Health Protection Research Unit for Behavioural Science and Evaluation and the Wellcome Trust [WT 220866/Z/20/Z].\n",
      "\n",
      "PV has received unrestricted research grants from Gilead not related to the submitted work. This research was funded in whole, or in part, by the National Institute for Health Research Health Protection Research Unit for Behavioural Science and Evaluation and the Wellcome Trust [WT 220866/Z/20/Z].\n",
      "\n",
      "PV has received unrestricted research grants from Gilead not related to the submitted work. This research was funded in whole, or in part, by the National Institute for Health Research Health Protection Research Unit for Behavioural Science and Evaluation and the Wellcome Trust [WT 220866/Z/20/Z].\n",
      "\n",
      "PV has received unrestricted research grants from Gilead not related to the submitted work. This research was funded in whole, or in part, by the National Institute for Health Research Health Protection Research Unit for Behavioural Science and Evaluation and the Wellcome Trust [WT 220866/Z/20/Z].\n",
      "\n",
      "PV has received unrestricted research grants from Gilead not related to the submitted work. This research was funded in whole, or in part, by the National Institute for Health Research Health Protection Research Unit for Behavioural Science and Evaluation and the Wellcome Trust [WT 220866/Z/20/Z].\n",
      "\n",
      "Vickerman, Peter\n",
      "Peter Vickerman has received unrestricted research grants from Gilead not related to the submitted work. This research was funded in whole, or in part, by the National Institute for Health Research Health Protection Research Unit for Behavioural Science and Evaluation and the Wellcome Trust [WT 220866/Z/20/Z].\n",
      "\n",
      "A small token was paid to Dr. Ibrahim Sange, one of the co-authors, who contributed to the writing of the abstract and helped in proofreading and editing the article.\n",
      "\n",
      "A small token was paid to Dr. Ibrahim Sange, one of the co-authors, who contributed to the writing of the abstract and helped in proofreading and editing the article.\n",
      "\n",
      "A small token was paid to Dr. Ibrahim Sange, one of the co-authors, who contributed to the writing of the abstract and helped in proofreading and editing the article.\n",
      "\n",
      "A small token was paid to Dr. Ibrahim Sange, one of the co-authors, who contributed to the writing of the abstract and helped in proofreading and editing the article.\n",
      "\n",
      "A small token was paid to Dr. Ibrahim Sange, one of the co-authors, who contributed to the writing of the abstract and helped in proofreading and editing the article.\n",
      "\n",
      "A small token was paid to Dr. Ibrahim Sange, one of the co-authors, who contributed to the writing of the abstract and helped in proofreading and editing the article.\n",
      "\n",
      "Sange, Ibrahim\n",
      "A small token was paid to Dr. Ibrahim Sange, one of the co-authors, who contributed to the writing of the abstract and helped in proofreading and editing the article.\n",
      "\n",
      "Horiuchi, Hiroshi\n",
      "All authors meet the ICMJE authorship criteria; Hiroshi Horiuchi was responsible  for the conception of the work, interpretation of data, and drafting of the work. Shusuke Utada, Yoshie Shinomiya, Azusa Sogo, Takao Miyagawa, Shoko Niida, Hiromu  Okano, Naoya Suzuki, Tsuyoshi Otsuka, Hiroshi Miyazaki, and Ryosuke Furuya were responsible for the design of the work and the analysis of data. All authors revised this work critically and contributed to the writing of the final manuscript. All authors agreed to be accountable for all aspects of the work.\n",
      "\n",
      "Utada, Syusuke\n",
      "All authors meet the ICMJE authorship criteria; Hiroshi Horiuchi was responsible  for the conception of the work, interpretation of data, and drafting of the work. Shusuke Syusuke Utada, Yoshie Shinomiya, Azusa Sogo, Takao Miyagawa, Shoko Niida, Hiromu  Okano, Naoya Suzuki, Tsuyoshi Otsuka, Hiroshi Miyazaki, and Ryosuke Furuya were responsible for the design of the work and the analysis of data. All authors revised this work critically and contributed to the writing of the final manuscript. All authors agreed to be accountable for all aspects of the work.\n",
      "\n",
      "Shinomiya, Yoshie\n",
      "All authors meet the ICMJE authorship criteria; Hiroshi Horiuchi was responsible  for the conception of the work, interpretation of data, and drafting of the work. Shusuke Syusuke Utada, Yoshie Shinomiya, Azusa Sogo, Takao Miyagawa, Shoko Niida, Hiromu  Okano, Naoya Suzuki, Tsuyoshi Otsuka, Hiroshi Miyazaki, and Ryosuke Furuya were responsible for the design of the work and the analysis of data. All authors revised this work critically and contributed to the writing of the final manuscript. All authors agreed to be accountable for all aspects of the work.\n",
      "\n",
      "Miyagawa, Takao\n",
      "All authors meet the ICMJE authorship criteria; Hiroshi Horiuchi was responsible  for the conception of the work, interpretation of data, and drafting of the work. Shusuke Syusuke Utada, Yoshie Shinomiya, Azusa Sogo, Takao Miyagawa, Shoko Niida, Hiromu  Okano, Naoya Suzuki, Tsuyoshi Otsuka, Hiroshi Miyazaki, and Ryosuke Furuya were responsible for the design of the work and the analysis of data. All authors revised this work critically and contributed to the writing of the final manuscript. All authors agreed to be accountable for all aspects of the work.\n",
      "\n",
      "Sogo, Azusa\n",
      "All authors meet the ICMJE authorship criteria; Hiroshi Horiuchi was responsible  for the conception of the work, interpretation of data, and drafting of the work. Shusuke Syusuke Utada, Yoshie Shinomiya, Azusa Sogo, Takao Miyagawa, Shoko Niida, Hiromu  Okano, Naoya Suzuki, Tsuyoshi Otsuka, Hiroshi Miyazaki, and Ryosuke Furuya were responsible for the design of the work and the analysis of data. All authors revised this work critically and contributed to the writing of the final manuscript. All authors agreed to be accountable for all aspects of the work.\n",
      "\n",
      "Niida, Shoko\n",
      "All authors meet the ICMJE authorship criteria; Hiroshi Horiuchi was responsible  for the conception of the work, interpretation of data, and drafting of the work. Shusuke Syusuke Utada, Yoshie Shinomiya, Azusa Sogo, Takao Miyagawa, Shoko Niida, Hiromu  Okano, Naoya Suzuki, Tsuyoshi Otsuka, Hiroshi Miyazaki, and Ryosuke Furuya were responsible for the design of the work and the analysis of data. All authors revised this work critically and contributed to the writing of the final manuscript. All authors agreed to be accountable for all aspects of the work.\n",
      "\n",
      "Okano, Hiromu\n",
      "All authors meet the ICMJE authorship criteria; Hiroshi Horiuchi was responsible  for the conception of the work, interpretation of data, and drafting of the work. Shusuke Syusuke Utada, Yoshie Shinomiya, Azusa Sogo, Takao Miyagawa, Shoko Niida, Hiromu  Hiromu Okano, Naoya Suzuki, Tsuyoshi Otsuka, Hiroshi Miyazaki, and Ryosuke Furuya were responsible for the design of the work and the analysis of data. All authors revised this work critically and contributed to the writing of the final manuscript. All authors agreed to be accountable for all aspects of the work.\n",
      "\n",
      "Suzuki, Naoya\n",
      "All authors meet the ICMJE authorship criteria; Hiroshi Horiuchi was responsible  for the conception of the work, interpretation of data, and drafting of the work. Shusuke Syusuke Utada, Yoshie Shinomiya, Azusa Sogo, Takao Miyagawa, Shoko Niida, Hiromu  Hiromu Okano, Naoya Suzuki, Tsuyoshi Otsuka, Hiroshi Miyazaki, and Ryosuke Furuya were responsible for the design of the work and the analysis of data. All authors revised this work critically and contributed to the writing of the final manuscript. All authors agreed to be accountable for all aspects of the work.\n",
      "\n",
      "Otsuka, Tsuyoshi\n",
      "All authors meet the ICMJE authorship criteria; Hiroshi Horiuchi was responsible  for the conception of the work, interpretation of data, and drafting of the work. Shusuke Syusuke Utada, Yoshie Shinomiya, Azusa Sogo, Takao Miyagawa, Shoko Niida, Hiromu  Hiromu Okano, Naoya Suzuki, Tsuyoshi Otsuka, Hiroshi Miyazaki, and Ryosuke Furuya were responsible for the design of the work and the analysis of data. All authors revised this work critically and contributed to the writing of the final manuscript. All authors agreed to be accountable for all aspects of the work.\n",
      "\n",
      "Miyazaki, Hiroshi\n",
      "All authors meet the ICMJE authorship criteria; Hiroshi Horiuchi was responsible  for the conception of the work, interpretation of data, and drafting of the work. Shusuke Syusuke Utada, Yoshie Shinomiya, Azusa Sogo, Takao Miyagawa, Shoko Niida, Hiromu  Hiromu Okano, Naoya Suzuki, Tsuyoshi Otsuka, Hiroshi Miyazaki, and Ryosuke Furuya were responsible for the design of the work and the analysis of data. All authors revised this work critically and contributed to the writing of the final manuscript. All authors agreed to be accountable for all aspects of the work.\n",
      "\n",
      "Furuya, Ryosuke\n",
      "All authors meet the ICMJE authorship criteria; Hiroshi Horiuchi was responsible  for the conception of the work, interpretation of data, and drafting of the work. Shusuke Syusuke Utada, Yoshie Shinomiya, Azusa Sogo, Takao Miyagawa, Shoko Niida, Hiromu  Hiromu Okano, Naoya Suzuki, Tsuyoshi Otsuka, Hiroshi Miyazaki, and Ryosuke Furuya were responsible for the design of the work and the analysis of data. All authors revised this work critically and contributed to the writing of the final manuscript. All authors agreed to be accountable for all aspects of the work.\n",
      "\n",
      "Toth, Peter P.\n",
      "GGS has received research support to the University of Colorado from AstraZeneca, Resverlogix, Roche, Sanofi, and The Medicines Company. He is coinventor of pending US patent 62/806,313 (\"Methods for Reducing Cardiovascular Risk\") assigned in full to the University of Colorado. SJN reports research grants from  AstraZeneca, Amgen, Anthera, Eli Lilly, Esperion, Novartis, Cerenis, The Medicines Company, Resverlogix, InfraReDx, Roche, Sanofi-Regeneron and LipoScience and honoraria from AstraZeneca, Akcea, Eli Lilly, Anthera, Omthera, Merck, Takeda, Resverlogix, Sanofi-Regeneron, CSL Behring, Esperion, Boehringer Ingelheim. Peter P. Toth reports speaker bureau compensation from Amgen, Esperion, Novo-Nordisk; consultant compensation from Amarin, Amgen, Kowa, and Novartis. AK, JJ, EK, MS, and NCWW are employees of Resverlogix Corporation. KKZ has received honoraria from Abbott, Abbvie, ACI Clinical, Akebia, Alexion, Amgen, Ardelyx, Astra-Zeneca, Aveo, Braun, Cara Therapeutics, Chugai, Cytokinetics, Daiichi, DaVita, Fresenius, Genentech, Haymarket Media, Hospira, Kabi, Keryx, Kissei, Novartis, Pfizer, Regulus, Relypsa, Resverlogix, Dr. Schaer, Sandoz, Sanofi, Shire, Vifor, UpToDate, and ZS-Pharma. HNG has received research support from AstraZeneca, Amgen, Pfizer and honoraria from Astrazeneca, Amgen, Pfizer, Merck,  Kowa, Resverlogix, Regeneron, Sanofi. KKR reports honoraria from Resverlogix, Aegerion, Amgen, Pfizer, AstraZeneca, Cerenis, Akcea, The Medicines Company, Kowa, Novartis, Cipla, Eli Lilly, Algorithm, Takeda, Boehringer Ingelheim, Abbvie, Silence Therapeutics, Dr. Reddys, Bayer, Daiichi Sankyo, Esperion, Zuelling Pharma, Sanofi-Regeneron and Merck and grants from Sanofi-Regeneron and  Merck.\n",
      "\n",
      "Schwartz, Gregory G.\n",
      "Gregory G. Schwartz has received research support to the University of Colorado from AstraZeneca, Resverlogix, Roche, Sanofi, and The Medicines Company. He is coinventor of pending US patent 62/806,313 (\"Methods for Reducing Cardiovascular Risk\") assigned in full to the University of Colorado. SJN reports research grants from  AstraZeneca, Amgen, Anthera, Eli Lilly, Esperion, Novartis, Cerenis, The Medicines Company, Resverlogix, InfraReDx, Roche, Sanofi-Regeneron and LipoScience and honoraria from AstraZeneca, Akcea, Eli Lilly, Anthera, Omthera, Merck, Takeda, Resverlogix, Sanofi-Regeneron, CSL Behring, Esperion, Boehringer Ingelheim. Peter P. Toth reports speaker bureau compensation from Amgen, Esperion, Novo-Nordisk; consultant compensation from Amarin, Amgen, Kowa, and Novartis. AK, JJ, EK, MS, and NCWW are employees of Resverlogix Corporation. KKZ has received honoraria from Abbott, Abbvie, ACI Clinical, Akebia, Alexion, Amgen, Ardelyx, Astra-Zeneca, Aveo, Braun, Cara Therapeutics, Chugai, Cytokinetics, Daiichi, DaVita, Fresenius, Genentech, Haymarket Media, Hospira, Kabi, Keryx, Kissei, Novartis, Pfizer, Regulus, Relypsa, Resverlogix, Dr. Schaer, Sandoz, Sanofi, Shire, Vifor, UpToDate, and ZS-Pharma. HNG has received research support from AstraZeneca, Amgen, Pfizer and honoraria from Astrazeneca, Amgen, Pfizer, Merck,  Kowa, Resverlogix, Regeneron, Sanofi. KKR reports honoraria from Resverlogix, Aegerion, Amgen, Pfizer, AstraZeneca, Cerenis, Akcea, The Medicines Company, Kowa, Novartis, Cipla, Eli Lilly, Algorithm, Takeda, Boehringer Ingelheim, Abbvie, Silence Therapeutics, Dr. Reddys, Bayer, Daiichi Sankyo, Esperion, Zuelling Pharma, Sanofi-Regeneron and Merck and grants from Sanofi-Regeneron and  Merck.\n",
      "\n",
      "Nicholls, Stephen J.\n",
      "Gregory G. Schwartz has received research support to the University of Colorado from AstraZeneca, Resverlogix, Roche, Sanofi, and The Medicines Company. He is coinventor of pending US patent 62/806,313 (\"Methods for Reducing Cardiovascular Risk\") assigned in full to the University of Colorado. Stephen J. Nicholls reports research grants from  AstraZeneca, Amgen, Anthera, Eli Lilly, Esperion, Novartis, Cerenis, The Medicines Company, Resverlogix, InfraReDx, Roche, Sanofi-Regeneron and LipoScience and honoraria from AstraZeneca, Akcea, Eli Lilly, Anthera, Omthera, Merck, Takeda, Resverlogix, Sanofi-Regeneron, CSL Behring, Esperion, Boehringer Ingelheim. Peter P. Toth reports speaker bureau compensation from Amgen, Esperion, Novo-Nordisk; consultant compensation from Amarin, Amgen, Kowa, and Novartis. AK, JJ, EK, MS, and NCWW are employees of Resverlogix Corporation. KKZ has received honoraria from Abbott, Abbvie, ACI Clinical, Akebia, Alexion, Amgen, Ardelyx, Astra-Zeneca, Aveo, Braun, Cara Therapeutics, Chugai, Cytokinetics, Daiichi, DaVita, Fresenius, Genentech, Haymarket Media, Hospira, Kabi, Keryx, Kissei, Novartis, Pfizer, Regulus, Relypsa, Resverlogix, Dr. Schaer, Sandoz, Sanofi, Shire, Vifor, UpToDate, and ZS-Pharma. HNG has received research support from AstraZeneca, Amgen, Pfizer and honoraria from Astrazeneca, Amgen, Pfizer, Merck,  Kowa, Resverlogix, Regeneron, Sanofi. KKR reports honoraria from Resverlogix, Aegerion, Amgen, Pfizer, AstraZeneca, Cerenis, Akcea, The Medicines Company, Kowa, Novartis, Cipla, Eli Lilly, Algorithm, Takeda, Boehringer Ingelheim, Abbvie, Silence Therapeutics, Dr. Reddys, Bayer, Daiichi Sankyo, Esperion, Zuelling Pharma, Sanofi-Regeneron and Merck and grants from Sanofi-Regeneron and  Merck.\n",
      "\n",
      "Khan, Aziz\n",
      "Gregory G. Schwartz has received research support to the University of Colorado from AstraZeneca, Resverlogix, Roche, Sanofi, and The Medicines Company. He is coinventor of pending US patent 62/806,313 (\"Methods for Reducing Cardiovascular Risk\") assigned in full to the University of Colorado. Stephen J. Nicholls reports research grants from  AstraZeneca, Amgen, Anthera, Eli Lilly, Esperion, Novartis, Cerenis, The Medicines Company, Resverlogix, InfraReDx, Roche, Sanofi-Regeneron and LipoScience and honoraria from AstraZeneca, Akcea, Eli Lilly, Anthera, Omthera, Merck, Takeda, Resverlogix, Sanofi-Regeneron, CSL Behring, Esperion, Boehringer Ingelheim. Peter P. Toth reports speaker bureau compensation from Amgen, Esperion, Novo-Nordisk; consultant compensation from Amarin, Amgen, Kowa, and Novartis. Aziz Khan, JJ, EK, MS, and NCWW are employees of Resverlogix Corporation. KKZ has received honoraria from Abbott, Abbvie, ACI Clinical, Akebia, Alexion, Amgen, Ardelyx, Astra-Zeneca, Aveo, Braun, Cara Therapeutics, Chugai, Cytokinetics, Daiichi, DaVita, Fresenius, Genentech, Haymarket Media, Hospira, Kabi, Keryx, Kissei, Novartis, Pfizer, Regulus, Relypsa, Resverlogix, Dr. Schaer, Sandoz, Sanofi, Shire, Vifor, UpToDate, and ZS-Pharma. HNG has received research support from AstraZeneca, Amgen, Pfizer and honoraria from Astrazeneca, Amgen, Pfizer, Merck,  Kowa, Resverlogix, Regeneron, Sanofi. KKR reports honoraria from Resverlogix, Aegerion, Amgen, Pfizer, AstraZeneca, Cerenis, Akcea, The Medicines Company, Kowa, Novartis, Cipla, Eli Lilly, Algorithm, Takeda, Boehringer Ingelheim, Abbvie, Silence Therapeutics, Dr. Reddys, Bayer, Daiichi Sankyo, Esperion, Zuelling Pharma, Sanofi-Regeneron and Merck and grants from Sanofi-Regeneron and  Merck.\n",
      "\n",
      "Szarek, Michael\n",
      "Gregory G. Schwartz has received research support to the University of Colorado from AstraZeneca, Resverlogix, Roche, Sanofi, and The Medicines Company. He is coinventor of pending US patent 62/806,313 (\"Methods for Reducing Cardiovascular Risk\") assigned in full to the University of Colorado. Stephen J. Nicholls reports research grants from  AstraZeneca, Amgen, Anthera, Eli Lilly, Esperion, Novartis, Cerenis, The Medicines Company, Resverlogix, InfraReDx, Roche, Sanofi-Regeneron and LipoScience and honoraria from AstraZeneca, Akcea, Eli Lilly, Anthera, Omthera, Merck, Takeda, Resverlogix, Sanofi-Regeneron, CSL Behring, Esperion, Boehringer Ingelheim. Peter P. Toth reports speaker bureau compensation from Amgen, Esperion, Novo-Nordisk; consultant compensation from Amarin, Amgen, Kowa, and Novartis. Aziz Khan, JJ, EK, Michael Szarek, and NCWW are employees of Resverlogix Corporation. KKZ has received honoraria from Abbott, Abbvie, ACI Clinical, Akebia, Alexion, Amgen, Ardelyx, Astra-Zeneca, Aveo, Braun, Cara Therapeutics, Chugai, Cytokinetics, Daiichi, DaVita, Fresenius, Genentech, Haymarket Media, Hospira, Kabi, Keryx, Kissei, Novartis, Pfizer, Regulus, Relypsa, Resverlogix, Dr. Schaer, Sandoz, Sanofi, Shire, Vifor, UpToDate, and ZS-Pharma. HNG has received research support from AstraZeneca, Amgen, Pfizer and honoraria from Astrazeneca, Amgen, Pfizer, Merck,  Kowa, Resverlogix, Regeneron, Sanofi. KKR reports honoraria from Resverlogix, Aegerion, Amgen, Pfizer, AstraZeneca, Cerenis, Akcea, The Medicines Company, Kowa, Novartis, Cipla, Eli Lilly, Algorithm, Takeda, Boehringer Ingelheim, Abbvie, Silence Therapeutics, Dr. Reddys, Bayer, Daiichi Sankyo, Esperion, Zuelling Pharma, Sanofi-Regeneron and Merck and grants from Sanofi-Regeneron and  Merck.\n",
      "\n",
      "Ginsberg, Henry N.\n",
      "Gregory G. Schwartz has received research support to the University of Colorado from AstraZeneca, Resverlogix, Roche, Sanofi, and The Medicines Company. He is coinventor of pending US patent 62/806,313 (\"Methods for Reducing Cardiovascular Risk\") assigned in full to the University of Colorado. Stephen J. Nicholls reports research grants from  AstraZeneca, Amgen, Anthera, Eli Lilly, Esperion, Novartis, Cerenis, The Medicines Company, Resverlogix, InfraReDx, Roche, Sanofi-Regeneron and LipoScience and honoraria from AstraZeneca, Akcea, Eli Lilly, Anthera, Omthera, Merck, Takeda, Resverlogix, Sanofi-Regeneron, CSL Behring, Esperion, Boehringer Ingelheim. Peter P. Toth reports speaker bureau compensation from Amgen, Esperion, Novo-Nordisk; consultant compensation from Amarin, Amgen, Kowa, and Novartis. Aziz Khan, JJ, EK, Michael Szarek, and NCWW are employees of Resverlogix Corporation. KKZ has received honoraria from Abbott, Abbvie, ACI Clinical, Akebia, Alexion, Amgen, Ardelyx, Astra-Zeneca, Aveo, Braun, Cara Therapeutics, Chugai, Cytokinetics, Daiichi, DaVita, Fresenius, Genentech, Haymarket Media, Hospira, Kabi, Keryx, Kissei, Novartis, Pfizer, Regulus, Relypsa, Resverlogix, Dr. Schaer, Sandoz, Sanofi, Shire, Vifor, UpToDate, and ZS-Pharma. Henry N. Ginsberg has received research support from AstraZeneca, Amgen, Pfizer and honoraria from Astrazeneca, Amgen, Pfizer, Merck,  Kowa, Resverlogix, Regeneron, Sanofi. KKR reports honoraria from Resverlogix, Aegerion, Amgen, Pfizer, AstraZeneca, Cerenis, Akcea, The Medicines Company, Kowa, Novartis, Cipla, Eli Lilly, Algorithm, Takeda, Boehringer Ingelheim, Abbvie, Silence Therapeutics, Dr. Reddys, Bayer, Daiichi Sankyo, Esperion, Zuelling Pharma, Sanofi-Regeneron and Merck and grants from Sanofi-Regeneron and  Merck.\n",
      "\n",
      "Johansson, Jan O.\n",
      "Gregory G. Schwartz has received research support to the University of Colorado from AstraZeneca, Resverlogix, Roche, Sanofi, and The Medicines Company. He is coinventor of pending US patent 62/806,313 (\"Methods for Reducing Cardiovascular Risk\") assigned in full to the University of Colorado. Stephen J. Nicholls reports research grants from  AstraZeneca, Amgen, Anthera, Eli Lilly, Esperion, Novartis, Cerenis, The Medicines Company, Resverlogix, InfraReDx, Roche, Sanofi-Regeneron and LipoScience and honoraria from AstraZeneca, Akcea, Eli Lilly, Anthera, Omthera, Merck, Takeda, Resverlogix, Sanofi-Regeneron, CSL Behring, Esperion, Boehringer Ingelheim. Peter P. Toth reports speaker bureau compensation from Amgen, Esperion, Novo-Nordisk; consultant compensation from Amarin, Amgen, Kowa, and Novartis. Aziz Khan, Jan O. Johansson, EK, Michael Szarek, and NCWW are employees of Resverlogix Corporation. KKZ has received honoraria from Abbott, Abbvie, ACI Clinical, Akebia, Alexion, Amgen, Ardelyx, Astra-Zeneca, Aveo, Braun, Cara Therapeutics, Chugai, Cytokinetics, Daiichi, DaVita, Fresenius, Genentech, Haymarket Media, Hospira, Kabi, Keryx, Kissei, Novartis, Pfizer, Regulus, Relypsa, Resverlogix, Dr. Schaer, Sandoz, Sanofi, Shire, Vifor, UpToDate, and ZS-Pharma. Henry N. Ginsberg has received research support from AstraZeneca, Amgen, Pfizer and honoraria from Astrazeneca, Amgen, Pfizer, Merck,  Kowa, Resverlogix, Regeneron, Sanofi. KKR reports honoraria from Resverlogix, Aegerion, Amgen, Pfizer, AstraZeneca, Cerenis, Akcea, The Medicines Company, Kowa, Novartis, Cipla, Eli Lilly, Algorithm, Takeda, Boehringer Ingelheim, Abbvie, Silence Therapeutics, Dr. Reddys, Bayer, Daiichi Sankyo, Esperion, Zuelling Pharma, Sanofi-Regeneron and Merck and grants from Sanofi-Regeneron and  Merck.\n",
      "\n",
      "Kalantar-Zadeh, Kamyar\n",
      "Gregory G. Schwartz has received research support to the University of Colorado from AstraZeneca, Resverlogix, Roche, Sanofi, and The Medicines Company. He is coinventor of pending US patent 62/806,313 (\"Methods for Reducing Cardiovascular Risk\") assigned in full to the University of Colorado. Stephen J. Nicholls reports research grants from  AstraZeneca, Amgen, Anthera, Eli Lilly, Esperion, Novartis, Cerenis, The Medicines Company, Resverlogix, InfraReDx, Roche, Sanofi-Regeneron and LipoScience and honoraria from AstraZeneca, Akcea, Eli Lilly, Anthera, Omthera, Merck, Takeda, Resverlogix, Sanofi-Regeneron, CSL Behring, Esperion, Boehringer Ingelheim. Peter P. Toth reports speaker bureau compensation from Amgen, Esperion, Novo-Nordisk; consultant compensation from Amarin, Amgen, Kowa, and Novartis. Aziz Khan, Jan O. Johansson, EK, Michael Szarek, and NCWW are employees of Resverlogix Corporation. Kamyar Kalantar-ZadehZ has received honoraria from Abbott, Abbvie, ACI Clinical, Akebia, Alexion, Amgen, Ardelyx, Astra-Zeneca, Aveo, Braun, Cara Therapeutics, Chugai, Cytokinetics, Daiichi, DaVita, Fresenius, Genentech, Haymarket Media, Hospira, Kabi, Keryx, Kissei, Novartis, Pfizer, Regulus, Relypsa, Resverlogix, Dr. Schaer, Sandoz, Sanofi, Shire, Vifor, UpToDate, and ZS-Pharma. Henry N. Ginsberg has received research support from AstraZeneca, Amgen, Pfizer and honoraria from Astrazeneca, Amgen, Pfizer, Merck,  Kowa, Resverlogix, Regeneron, Sanofi. Kamyar Kalantar-ZadehR reports honoraria from Resverlogix, Aegerion, Amgen, Pfizer, AstraZeneca, Cerenis, Akcea, The Medicines Company, Kowa, Novartis, Cipla, Eli Lilly, Algorithm, Takeda, Boehringer Ingelheim, Abbvie, Silence Therapeutics, Dr. Reddys, Bayer, Daiichi Sankyo, Esperion, Zuelling Pharma, Sanofi-Regeneron and Merck and grants from Sanofi-Regeneron and  Merck.\n",
      "\n",
      "Kulikowski, Ewelina\n",
      "Gregory G. Schwartz has received research support to the University of Colorado from AstraZeneca, Resverlogix, Roche, Sanofi, and The Medicines Company. He is coinventor of pending US patent 62/806,313 (\"Methods for Reducing Cardiovascular Risk\") assigned in full to the University of Colorado. Stephen J. Nicholls reports research grants from  AstraZeneca, Amgen, Anthera, Eli Lilly, Esperion, Novartis, Cerenis, The Medicines Company, Resverlogix, InfraReDx, Roche, Sanofi-Regeneron and LipoScience and honoraria from AstraZeneca, Akcea, Eli Lilly, Anthera, Omthera, Merck, Takeda, Resverlogix, Sanofi-Regeneron, CSL Behring, Esperion, Boehringer Ingelheim. Peter P. Toth reports speaker bureau compensation from Amgen, Esperion, Novo-Nordisk; consultant compensation from Amarin, Amgen, Kowa, and Novartis. Aziz Khan, Jan O. Johansson, Ewelina Kulikowski, Michael Szarek, and NCWW are employees of Resverlogix Corporation. Kamyar Kalantar-ZadehZ has received honoraria from Abbott, Abbvie, ACI Clinical, Akebia, Alexion, Amgen, Ardelyx, Astra-Zeneca, Aveo, Braun, Cara Therapeutics, Chugai, Cytokinetics, Daiichi, DaVita, Fresenius, Genentech, Haymarket Media, Hospira, Kabi, Keryx, Kissei, Novartis, Pfizer, Regulus, Relypsa, Resverlogix, Dr. Schaer, Sandoz, Sanofi, Shire, Vifor, UpToDate, and ZS-Pharma. Henry N. Ginsberg has received research support from AstraZeneca, Amgen, Pfizer and honoraria from Astrazeneca, Amgen, Pfizer, Merck,  Kowa, Resverlogix, Regeneron, Sanofi. Kamyar Kalantar-ZadehR reports honoraria from Resverlogix, Aegerion, Amgen, Pfizer, AstraZeneca, Cerenis, Akcea, The Medicines Company, Kowa, Novartis, Cipla, Eli Lilly, Algorithm, Takeda, Boehringer Ingelheim, Abbvie, Silence Therapeutics, Dr. Reddys, Bayer, Daiichi Sankyo, Esperion, Zuelling Pharma, Sanofi-Regeneron and Merck and grants from Sanofi-Regeneron and  Merck.\n",
      "\n",
      "Gregory G. Schwartz has received research support to the University of Colorado from AstraZeneca, Resverlogix, Roche, Sanofi, and The Medicines Company. He is coinventor of pending US patent 62/806,313 (\"Methods for Reducing Cardiovascular Risk\") assigned in full to the University of Colorado. Stephen J. Nicholls reports research grants from  AstraZeneca, Amgen, Anthera, Eli Lilly, Esperion, Novartis, Cerenis, The Medicines Company, Resverlogix, InfraReDx, Roche, Sanofi-Regeneron and LipoScience and honoraria from AstraZeneca, Akcea, Eli Lilly, Anthera, Omthera, Merck, Takeda, Resverlogix, Sanofi-Regeneron, CSL Behring, Esperion, Boehringer Ingelheim. Peter P. Toth reports speaker bureau compensation from Amgen, Esperion, Novo-Nordisk; consultant compensation from Amarin, Amgen, Kowa, and Novartis. Aziz Khan, Jan O. Johansson, Ewelina Kulikowski, Michael Szarek, and NCWW are employees of Resverlogix Corporation. Kamyar Kalantar-ZadehZ has received honoraria from Abbott, Abbvie, ACI Clinical, Akebia, Alexion, Amgen, Ardelyx, Astra-Zeneca, Aveo, Braun, Cara Therapeutics, Chugai, Cytokinetics, Daiichi, DaVita, Fresenius, Genentech, Haymarket Media, Hospira, Kabi, Keryx, Kissei, Novartis, Pfizer, Regulus, Relypsa, Resverlogix, Dr. Schaer, Sandoz, Sanofi, Shire, Vifor, UpToDate, and ZS-Pharma. Henry N. Ginsberg has received research support from AstraZeneca, Amgen, Pfizer and honoraria from Astrazeneca, Amgen, Pfizer, Merck,  Kowa, Resverlogix, Regeneron, Sanofi. Kamyar Kalantar-ZadehR reports honoraria from Resverlogix, Aegerion, Amgen, Pfizer, AstraZeneca, Cerenis, Akcea, The Medicines Company, Kowa, Novartis, Cipla, Eli Lilly, Algorithm, Takeda, Boehringer Ingelheim, Abbvie, Silence Therapeutics, Dr. Reddys, Bayer, Daiichi Sankyo, Esperion, Zuelling Pharma, Sanofi-Regeneron and Merck and grants from Sanofi-Regeneron and  Merck.\n",
      "\n",
      "Wong, Norman C.W.\n",
      "Gregory G. Schwartz has received research support to the University of Colorado from AstraZeneca, Resverlogix, Roche, Sanofi, and The Medicines Company. He is coinventor of pending US patent 62/806,313 (\"Methods for Reducing Cardiovascular Risk\") assigned in full to the University of Colorado. Stephen J. Nicholls reports research grants from  AstraZeneca, Amgen, Anthera, Eli Lilly, Esperion, Novartis, Cerenis, The Medicines Company, Resverlogix, InfraReDx, Roche, Sanofi-Regeneron and LipoScience and honoraria from AstraZeneca, Akcea, Eli Lilly, Anthera, Omthera, Merck, Takeda, Resverlogix, Sanofi-Regeneron, CSL Behring, Esperion, Boehringer Ingelheim. Peter P. Toth reports speaker bureau compensation from Amgen, Esperion, Novo-Nordisk; consultant compensation from Amarin, Amgen, Kowa, and Novartis. Aziz Khan, Jan O. Johansson, Ewelina Kulikowski, Michael Szarek, and Norman C.W. Wong are employees of Resverlogix Corporation. Kamyar Kalantar-ZadehZ has received honoraria from Abbott, Abbvie, ACI Clinical, Akebia, Alexion, Amgen, Ardelyx, Astra-Zeneca, Aveo, Braun, Cara Therapeutics, Chugai, Cytokinetics, Daiichi, DaVita, Fresenius, Genentech, Haymarket Media, Hospira, Kabi, Keryx, Kissei, Novartis, Pfizer, Regulus, Relypsa, Resverlogix, Dr. Schaer, Sandoz, Sanofi, Shire, Vifor, UpToDate, and ZS-Pharma. Henry N. Ginsberg has received research support from AstraZeneca, Amgen, Pfizer and honoraria from Astrazeneca, Amgen, Pfizer, Merck,  Kowa, Resverlogix, Regeneron, Sanofi. Kamyar Kalantar-ZadehR reports honoraria from Resverlogix, Aegerion, Amgen, Pfizer, AstraZeneca, Cerenis, Akcea, The Medicines Company, Kowa, Novartis, Cipla, Eli Lilly, Algorithm, Takeda, Boehringer Ingelheim, Abbvie, Silence Therapeutics, Dr. Reddys, Bayer, Daiichi Sankyo, Esperion, Zuelling Pharma, Sanofi-Regeneron and Merck and grants from Sanofi-Regeneron and  Merck.\n",
      "\n",
      "Sweeney, Michael\n",
      "Gregory G. Schwartz has received research support to the University of Colorado from AstraZeneca, Resverlogix, Roche, Sanofi, and The Medicines Company. He is coinventor of pending US patent 62/806,313 (\"Methods for Reducing Cardiovascular Risk\") assigned in full to the University of Colorado. Stephen J. Nicholls reports research grants from  AstraZeneca, Amgen, Anthera, Eli Lilly, Esperion, Novartis, Cerenis, The Medicines Company, Resverlogix, InfraReDx, Roche, Sanofi-Regeneron and LipoScience and honoraria from AstraZeneca, Akcea, Eli Lilly, Anthera, Omthera, Merck, Takeda, Resverlogix, Sanofi-Regeneron, CSL Behring, Esperion, Boehringer Ingelheim. Peter P. Toth reports speaker bureau compensation from Amgen, Esperion, Novo-Nordisk; consultant compensation from Amarin, Amgen, Kowa, and Novartis. Aziz Khan, Jan O. Johansson, Ewelina Kulikowski, Michael Sweeneyzarek, and Norman C.W. Wong are employees of Resverlogix Corporation. Kamyar Kalantar-ZadehZ has received honoraria from Abbott, Abbvie, ACI Clinical, Akebia, Alexion, Amgen, Ardelyx, Astra-Zeneca, Aveo, Braun, Cara Therapeutics, Chugai, Cytokinetics, Daiichi, DaVita, Fresenius, Genentech, Haymarket Media, Hospira, Kabi, Keryx, Kissei, Novartis, Pfizer, Regulus, Relypsa, Resverlogix, Dr. Schaer, Sandoz, Sanofi, Shire, Vifor, UpToDate, and ZS-Pharma. Henry N. Ginsberg has received research support from AstraZeneca, Amgen, Pfizer and honoraria from Astrazeneca, Amgen, Pfizer, Merck,  Kowa, Resverlogix, Regeneron, Sanofi. Kamyar Kalantar-ZadehR reports honoraria from Resverlogix, Aegerion, Amgen, Pfizer, AstraZeneca, Cerenis, Akcea, The Medicines Company, Kowa, Novartis, Cipla, Eli Lilly, Algorithm, Takeda, Boehringer Ingelheim, Abbvie, Silence Therapeutics, Dr. Reddys, Bayer, Daiichi Sankyo, Esperion, Zuelling Pharma, Sanofi-Regeneron and Merck and grants from Sanofi-Regeneron and  Merck.\n",
      "\n",
      "Gregory G. Schwartz has received research support to the University of Colorado from AstraZeneca, Resverlogix, Roche, Sanofi, and The Medicines Company. He is coinventor of pending US patent 62/806,313 (\"Methods for Reducing Cardiovascular Risk\") assigned in full to the University of Colorado. Stephen J. Nicholls reports research grants from  AstraZeneca, Amgen, Anthera, Eli Lilly, Esperion, Novartis, Cerenis, The Medicines Company, Resverlogix, InfraReDx, Roche, Sanofi-Regeneron and LipoScience and honoraria from AstraZeneca, Akcea, Eli Lilly, Anthera, Omthera, Merck, Takeda, Resverlogix, Sanofi-Regeneron, CSL Behring, Esperion, Boehringer Ingelheim. Peter P. Toth reports speaker bureau compensation from Amgen, Esperion, Novo-Nordisk; consultant compensation from Amarin, Amgen, Kowa, and Novartis. Aziz Khan, Jan O. Johansson, Ewelina Kulikowski, Michael Sweeneyzarek, and Norman C.W. Wong are employees of Resverlogix Corporation. Kamyar Kalantar-ZadehZ has received honoraria from Abbott, Abbvie, ACI Clinical, Akebia, Alexion, Amgen, Ardelyx, Astra-Zeneca, Aveo, Braun, Cara Therapeutics, Chugai, Cytokinetics, Daiichi, DaVita, Fresenius, Genentech, Haymarket Media, Hospira, Kabi, Keryx, Kissei, Novartis, Pfizer, Regulus, Relypsa, Resverlogix, Dr. Schaer, Sandoz, Sanofi, Shire, Vifor, UpToDate, and ZS-Pharma. Henry N. Ginsberg has received research support from AstraZeneca, Amgen, Pfizer and honoraria from Astrazeneca, Amgen, Pfizer, Merck,  Kowa, Resverlogix, Regeneron, Sanofi. Kamyar Kalantar-ZadehR reports honoraria from Resverlogix, Aegerion, Amgen, Pfizer, AstraZeneca, Cerenis, Akcea, The Medicines Company, Kowa, Novartis, Cipla, Eli Lilly, Algorithm, Takeda, Boehringer Ingelheim, Abbvie, Silence Therapeutics, Dr. Reddys, Bayer, Daiichi Sankyo, Esperion, Zuelling Pharma, Sanofi-Regeneron and Merck and grants from Sanofi-Regeneron and  Merck.\n",
      "\n",
      "Joo Leow, Liang\n",
      "Nicolas Zubrzycki has nothing to disclose. Liang Joo Leow has received education, writing, and travel support from Sun Pharmaceutical Industries, Inc.\n",
      "\n",
      "Zubrzycki, Nicolas\n",
      "Nicolas Zubrzycki has nothing to disclose. Liang Joo Leow has received education, writing, and travel support from Sun Pharmaceutical Industries, Inc.\n",
      "\n",
      "Dr Jonathan M Hagedorn reports personal fees from Abbott, Boston Scientific, Medtronic, Nevro, and Saluda, outside the submitted work. Dr Scott Pritzlaff reports personal fees from EBT Medical, SPR Therapeutics, and Nalu Medical, during the conduct of the study. Dr Dawood Sayed reports grants from Spr, during  the conduct of the study; personal fees from Spr, Nevro, Medtronic, and Abbott, outside the submitted work. Dr Alexander Escobar reports personal fees from Abbott, personal fees from Boston Scientific, personal fees from Medtronic, personal fees from Nevro, outside the submitted work. Dr Mark Huntoon reports fees from SPR for consulting and teaching, outside the submitted work; and Saluda- Membership on Clinical Events Committee for national study. Dr Timothy R  Deer reports personal fees, from Abbott, personal fees, from Vertos, grants from  Flowonix, personal fees, from SpineThera, personal fees, from Saluda, from Mainstay, personal fees, from Nalu, personal fees, from Cornerloc, personal fees, from Ethos, personal fees, from SPR Therapuetics, personal fees from SI Bone, personal fees from Nevro, personal fees from Medtronic, personal fees, from Boston Scientific, personal fees, from PainTeq, personal fees from Tissue Tech, personal fees, from Spinal Simplicity, from Avanos, outside the submitted work; in addition, Dr Timothy R Deer has a patent Abbott pending to DRG Leads pending.  The authors report no other conflicts of interest in this work.\n",
      "\n",
      "Dr Jonathan M Hagedorn reports personal fees from Abbott, Boston Scientific, Medtronic, Nevro, and Saluda, outside the submitted work. Dr Scott Pritzlaff reports personal fees from EBT Medical, SPR Therapeutics, and Nalu Medical, during the conduct of the study. Dr Dawood Sayed reports grants from Spr, during  the conduct of the study; personal fees from Spr, Nevro, Medtronic, and Abbott, outside the submitted work. Dr Alexander Escobar reports personal fees from Abbott, personal fees from Boston Scientific, personal fees from Medtronic, personal fees from Nevro, outside the submitted work. Dr Mark Huntoon reports fees from SPR for consulting and teaching, outside the submitted work; and Saluda- Membership on Clinical Events Committee for national study. Dr Timothy R  Deer reports personal fees, from Abbott, personal fees, from Vertos, grants from  Flowonix, personal fees, from SpineThera, personal fees, from Saluda, from Mainstay, personal fees, from Nalu, personal fees, from Cornerloc, personal fees, from Ethos, personal fees, from SPR Therapuetics, personal fees from SI Bone, personal fees from Nevro, personal fees from Medtronic, personal fees, from Boston Scientific, personal fees, from PainTeq, personal fees from Tissue Tech, personal fees, from Spinal Simplicity, from Avanos, outside the submitted work; in addition, Dr Timothy R Deer has a patent Abbott pending to DRG Leads pending.  The authors report no other conflicts of interest in this work.\n",
      "\n",
      "Hagedorn, Jonathan M.\n",
      "Dr Jonathan M. Hagedorn reports personal fees from Abbott, Boston Scientific, Medtronic, Nevro, and Saluda, outside the submitted work. Dr Scott Pritzlaff reports personal fees from EBT Medical, SPR Therapeutics, and Nalu Medical, during the conduct of the study. Dr Dawood Sayed reports grants from Spr, during  the conduct of the study; personal fees from Spr, Nevro, Medtronic, and Abbott, outside the submitted work. Dr Alexander Escobar reports personal fees from Abbott, personal fees from Boston Scientific, personal fees from Medtronic, personal fees from Nevro, outside the submitted work. Dr Mark Huntoon reports fees from SPR for consulting and teaching, outside the submitted work; and Saluda- Membership on Clinical Events Committee for national study. Dr Timothy R  Deer reports personal fees, from Abbott, personal fees, from Vertos, grants from  Flowonix, personal fees, from SpineThera, personal fees, from Saluda, from Mainstay, personal fees, from Nalu, personal fees, from Cornerloc, personal fees, from Ethos, personal fees, from SPR Therapuetics, personal fees from SI Bone, personal fees from Nevro, personal fees from Medtronic, personal fees, from Boston Scientific, personal fees, from PainTeq, personal fees from Tissue Tech, personal fees, from Spinal Simplicity, from Avanos, outside the submitted work; in addition, Dr Timothy R Deer has a patent Abbott pending to DRG Leads pending.  The authors report no other conflicts of interest in this work.\n",
      "\n",
      "Pritzlaff, Scott\n",
      "Dr Jonathan M. Hagedorn reports personal fees from Abbott, Boston Scientific, Medtronic, Nevro, and Saluda, outside the submitted work. Dr Scott Pritzlaff reports personal fees from EBT Medical, SPR Therapeutics, and Nalu Medical, during the conduct of the study. Dr Dawood Sayed reports grants from Spr, during  the conduct of the study; personal fees from Spr, Nevro, Medtronic, and Abbott, outside the submitted work. Dr Alexander Escobar reports personal fees from Abbott, personal fees from Boston Scientific, personal fees from Medtronic, personal fees from Nevro, outside the submitted work. Dr Mark Huntoon reports fees from SPR for consulting and teaching, outside the submitted work; and Saluda- Membership on Clinical Events Committee for national study. Dr Timothy R  Deer reports personal fees, from Abbott, personal fees, from Vertos, grants from  Flowonix, personal fees, from SpineThera, personal fees, from Saluda, from Mainstay, personal fees, from Nalu, personal fees, from Cornerloc, personal fees, from Ethos, personal fees, from SPR Therapuetics, personal fees from SI Bone, personal fees from Nevro, personal fees from Medtronic, personal fees, from Boston Scientific, personal fees, from PainTeq, personal fees from Tissue Tech, personal fees, from Spinal Simplicity, from Avanos, outside the submitted work; in addition, Dr Timothy R Deer has a patent Abbott pending to DRG Leads pending.  The authors report no other conflicts of interest in this work.\n",
      "\n",
      "Sayed, Dawood\n",
      "Dr Jonathan M. Hagedorn reports personal fees from Abbott, Boston Scientific, Medtronic, Nevro, and Saluda, outside the submitted work. Dr Scott Pritzlaff reports personal fees from EBT Medical, SPR Therapeutics, and Nalu Medical, during the conduct of the study. Dr Dawood Sayed reports grants from Spr, during  the conduct of the study; personal fees from Spr, Nevro, Medtronic, and Abbott, outside the submitted work. Dr Alexander Escobar reports personal fees from Abbott, personal fees from Boston Scientific, personal fees from Medtronic, personal fees from Nevro, outside the submitted work. Dr Mark Huntoon reports fees from SPR for consulting and teaching, outside the submitted work; and Saluda- Membership on Clinical Events Committee for national study. Dr Timothy R  Deer reports personal fees, from Abbott, personal fees, from Vertos, grants from  Flowonix, personal fees, from SpineThera, personal fees, from Saluda, from Mainstay, personal fees, from Nalu, personal fees, from Cornerloc, personal fees, from Ethos, personal fees, from SPR Therapuetics, personal fees from SI Bone, personal fees from Nevro, personal fees from Medtronic, personal fees, from Boston Scientific, personal fees, from PainTeq, personal fees from Tissue Tech, personal fees, from Spinal Simplicity, from Avanos, outside the submitted work; in addition, Dr Timothy R Deer has a patent Abbott pending to DRG Leads pending.  The authors report no other conflicts of interest in this work.\n",
      "\n",
      "Dr Jonathan M. Hagedorn reports personal fees from Abbott, Boston Scientific, Medtronic, Nevro, and Saluda, outside the submitted work. Dr Scott Pritzlaff reports personal fees from EBT Medical, SPR Therapeutics, and Nalu Medical, during the conduct of the study. Dr Dawood Sayed reports grants from Spr, during  the conduct of the study; personal fees from Spr, Nevro, Medtronic, and Abbott, outside the submitted work. Dr Alexander Escobar reports personal fees from Abbott, personal fees from Boston Scientific, personal fees from Medtronic, personal fees from Nevro, outside the submitted work. Dr Mark Huntoon reports fees from SPR for consulting and teaching, outside the submitted work; and Saluda- Membership on Clinical Events Committee for national study. Dr Timothy R  Deer reports personal fees, from Abbott, personal fees, from Vertos, grants from  Flowonix, personal fees, from SpineThera, personal fees, from Saluda, from Mainstay, personal fees, from Nalu, personal fees, from Cornerloc, personal fees, from Ethos, personal fees, from SPR Therapuetics, personal fees from SI Bone, personal fees from Nevro, personal fees from Medtronic, personal fees, from Boston Scientific, personal fees, from PainTeq, personal fees from Tissue Tech, personal fees, from Spinal Simplicity, from Avanos, outside the submitted work; in addition, Dr Timothy R Deer has a patent Abbott pending to DRG Leads pending.  The authors report no other conflicts of interest in this work.\n",
      "\n",
      "Dr Jonathan M. Hagedorn reports personal fees from Abbott, Boston Scientific, Medtronic, Nevro, and Saluda, outside the submitted work. Dr Scott Pritzlaff reports personal fees from EBT Medical, SPR Therapeutics, and Nalu Medical, during the conduct of the study. Dr Dawood Sayed reports grants from Spr, during  the conduct of the study; personal fees from Spr, Nevro, Medtronic, and Abbott, outside the submitted work. Dr Alexander Escobar reports personal fees from Abbott, personal fees from Boston Scientific, personal fees from Medtronic, personal fees from Nevro, outside the submitted work. Dr Mark Huntoon reports fees from SPR for consulting and teaching, outside the submitted work; and Saluda- Membership on Clinical Events Committee for national study. Dr Timothy R  Deer reports personal fees, from Abbott, personal fees, from Vertos, grants from  Flowonix, personal fees, from SpineThera, personal fees, from Saluda, from Mainstay, personal fees, from Nalu, personal fees, from Cornerloc, personal fees, from Ethos, personal fees, from SPR Therapuetics, personal fees from SI Bone, personal fees from Nevro, personal fees from Medtronic, personal fees, from Boston Scientific, personal fees, from PainTeq, personal fees from Tissue Tech, personal fees, from Spinal Simplicity, from Avanos, outside the submitted work; in addition, Dr Timothy R Deer has a patent Abbott pending to DRG Leads pending.  The authors report no other conflicts of interest in this work.\n",
      "\n",
      "Escobar, Alexander\n",
      "Dr Jonathan M. Hagedorn reports personal fees from Abbott, Boston Scientific, Medtronic, Nevro, and Saluda, outside the submitted work. Dr Scott Pritzlaff reports personal fees from EBT Medical, SPR Therapeutics, and Nalu Medical, during the conduct of the study. Dr Dawood Sayed reports grants from Spr, during  the conduct of the study; personal fees from Spr, Nevro, Medtronic, and Abbott, outside the submitted work. Dr Alexander Escobar reports personal fees from Abbott, personal fees from Boston Scientific, personal fees from Medtronic, personal fees from Nevro, outside the submitted work. Dr Mark Huntoon reports fees from SPR for consulting and teaching, outside the submitted work; and Saluda- Membership on Clinical Events Committee for national study. Dr Timothy R  Deer reports personal fees, from Abbott, personal fees, from Vertos, grants from  Flowonix, personal fees, from SpineThera, personal fees, from Saluda, from Mainstay, personal fees, from Nalu, personal fees, from Cornerloc, personal fees, from Ethos, personal fees, from SPR Therapuetics, personal fees from SI Bone, personal fees from Nevro, personal fees from Medtronic, personal fees, from Boston Scientific, personal fees, from PainTeq, personal fees from Tissue Tech, personal fees, from Spinal Simplicity, from Avanos, outside the submitted work; in addition, Dr Timothy R Deer has a patent Abbott pending to DRG Leads pending.  The authors report no other conflicts of interest in this work.\n",
      "\n",
      "Huntoon, Mark A.\n",
      "Dr Jonathan M. Hagedorn reports personal fees from Abbott, Boston Scientific, Medtronic, Nevro, and Saluda, outside the submitted work. Dr Scott Pritzlaff reports personal fees from EBT Medical, SPR Therapeutics, and Nalu Medical, during the conduct of the study. Dr Dawood Sayed reports grants from Spr, during  the conduct of the study; personal fees from Spr, Nevro, Medtronic, and Abbott, outside the submitted work. Dr Alexander Escobar reports personal fees from Abbott, personal fees from Boston Scientific, personal fees from Medtronic, personal fees from Nevro, outside the submitted work. Dr Mark A. Huntoon reports fees from SPR for consulting and teaching, outside the submitted work; and Saluda- Membership on Clinical Events Committee for national study. Dr Timothy R  Deer reports personal fees, from Abbott, personal fees, from Vertos, grants from  Flowonix, personal fees, from SpineThera, personal fees, from Saluda, from Mainstay, personal fees, from Nalu, personal fees, from Cornerloc, personal fees, from Ethos, personal fees, from SPR Therapuetics, personal fees from SI Bone, personal fees from Nevro, personal fees from Medtronic, personal fees, from Boston Scientific, personal fees, from PainTeq, personal fees from Tissue Tech, personal fees, from Spinal Simplicity, from Avanos, outside the submitted work; in addition, Dr Timothy R Deer has a patent Abbott pending to DRG Leads pending.  The authors report no other conflicts of interest in this work.\n",
      "\n",
      "Dr Jonathan M. Hagedorn reports personal fees from Abbott, Boston Scientific, Medtronic, Nevro, and Saluda, outside the submitted work. Dr Scott Pritzlaff reports personal fees from EBT Medical, SPR Therapeutics, and Nalu Medical, during the conduct of the study. Dr Dawood Sayed reports grants from Spr, during  the conduct of the study; personal fees from Spr, Nevro, Medtronic, and Abbott, outside the submitted work. Dr Alexander Escobar reports personal fees from Abbott, personal fees from Boston Scientific, personal fees from Medtronic, personal fees from Nevro, outside the submitted work. Dr Mark A. Huntoon reports fees from SPR for consulting and teaching, outside the submitted work; and Saluda- Membership on Clinical Events Committee for national study. Dr Timothy R  Deer reports personal fees, from Abbott, personal fees, from Vertos, grants from  Flowonix, personal fees, from SpineThera, personal fees, from Saluda, from Mainstay, personal fees, from Nalu, personal fees, from Cornerloc, personal fees, from Ethos, personal fees, from SPR Therapuetics, personal fees from SI Bone, personal fees from Nevro, personal fees from Medtronic, personal fees, from Boston Scientific, personal fees, from PainTeq, personal fees from Tissue Tech, personal fees, from Spinal Simplicity, from Avanos, outside the submitted work; in addition, Dr Timothy R Deer has a patent Abbott pending to DRG Leads pending.  The authors report no other conflicts of interest in this work.\n",
      "\n",
      "Deer, Timothy R.\n",
      "Dr Jonathan M. Hagedorn reports personal fees from Abbott, Boston Scientific, Medtronic, Nevro, and Saluda, outside the submitted work. Dr Scott Pritzlaff reports personal fees from EBT Medical, SPR Therapeutics, and Nalu Medical, during the conduct of the study. Dr Dawood Sayed reports grants from Spr, during  the conduct of the study; personal fees from Spr, Nevro, Medtronic, and Abbott, outside the submitted work. Dr Alexander Escobar reports personal fees from Abbott, personal fees from Boston Scientific, personal fees from Medtronic, personal fees from Nevro, outside the submitted work. Dr Mark A. Huntoon reports fees from SPR for consulting and teaching, outside the submitted work; and Saluda- Membership on Clinical Events Committee for national study. Dr Timothy R  Deer reports personal fees, from Abbott, personal fees, from Vertos, grants from  Flowonix, personal fees, from SpineThera, personal fees, from Saluda, from Mainstay, personal fees, from Nalu, personal fees, from Cornerloc, personal fees, from Ethos, personal fees, from SPR Therapuetics, personal fees from SI Bone, personal fees from Nevro, personal fees from Medtronic, personal fees, from Boston Scientific, personal fees, from PainTeq, personal fees from Tissue Tech, personal fees, from Spinal Simplicity, from Avanos, outside the submitted work; in addition, Dr Timothy R. Deer has a patent Abbott pending to DRG Leads pending.  The authors report no other conflicts of interest in this work.\n",
      "\n",
      "Sav, Adem\n",
      "Adem Sav reports grants from Gold Coast Health Collaborative Research Grant Scheme, during the conduct of the study; and grants from the Gold Coast Health Collaborative Research Grant Scheme, outside the submitted work. Claudia C Dobler reports grants from Gold Coast Health and Australian National Health and Medical  Research Council (NHMRC), during the conduct of the study. The authors report no  other potential conflicts of interest in this work.\n",
      "\n",
      "Adem Sav reports grants from Gold Coast Health Collaborative Research Grant Scheme, during the conduct of the study; and grants from the Gold Coast Health Collaborative Research Grant Scheme, outside the submitted work. Claudia C Dobler reports grants from Gold Coast Health and Australian National Health and Medical  Research Council (NHMRC), during the conduct of the study. The authors report no  other potential conflicts of interest in this work.\n",
      "\n",
      "Adem Sav reports grants from Gold Coast Health Collaborative Research Grant Scheme, during the conduct of the study; and grants from the Gold Coast Health Collaborative Research Grant Scheme, outside the submitted work. Claudia C Dobler reports grants from Gold Coast Health and Australian National Health and Medical  Research Council (NHMRC), during the conduct of the study. The authors report no  other potential conflicts of interest in this work.\n",
      "\n",
      "Adem Sav reports grants from Gold Coast Health Collaborative Research Grant Scheme, during the conduct of the study; and grants from the Gold Coast Health Collaborative Research Grant Scheme, outside the submitted work. Claudia C Dobler reports grants from Gold Coast Health and Australian National Health and Medical  Research Council (NHMRC), during the conduct of the study. The authors report no  other potential conflicts of interest in this work.\n",
      "\n",
      "Dobler, Claudia C.\n",
      "Adem Sav reports grants from Gold Coast Health Collaborative Research Grant Scheme, during the conduct of the study; and grants from the Gold Coast Health Collaborative Research Grant Scheme, outside the submitted work. Claudia C. Dobler reports grants from Gold Coast Health and Australian National Health and Medical  Research Council (NHMRC), during the conduct of the study. The authors report no  other potential conflicts of interest in this work.\n",
      "\n",
      "Zhang, Peiming\n",
      "Peiming Zhang and Jie Zhan are co-first authors. Professor Liming Lu reports grants from National Natural Science Foundation of China, grants from The special project of \"Lingnan modernization of traditional Chinese medicine\" in 2019 Guangdong Provincial R & D Program, grants from The Chinese Medicine Innovation Team Project of the State Administration of Traditional Chinese Medicine, during  the conduct of the study. The authors declare that they have no other competing interests.\n",
      "\n",
      "Zhan, Jie\n",
      "Peiming Zhang and Jie Zhan are co-first authors. Professor Liming Lu reports grants from National Natural Science Foundation of China, grants from The special project of \"Lingnan modernization of traditional Chinese medicine\" in 2019 Guangdong Provincial R & D Program, grants from The Chinese Medicine Innovation Team Project of the State Administration of Traditional Chinese Medicine, during  the conduct of the study. The authors declare that they have no other competing interests.\n",
      "\n",
      "Peiming Zhang and Jie Zhan are co-first authors. Professor Liming Lu reports grants from National Natural Science Foundation of China, grants from The special project of \"Lingnan modernization of traditional Chinese medicine\" in 2019 Guangdong Provincial R & D Program, grants from The Chinese Medicine Innovation Team Project of the State Administration of Traditional Chinese Medicine, during  the conduct of the study. The authors declare that they have no other competing interests.\n",
      "\n",
      "Peiming Zhang and Jie Zhan are co-first authors. Professor Liming Lu reports grants from National Natural Science Foundation of China, grants from The special project of \"Lingnan modernization of traditional Chinese medicine\" in 2019 Guangdong Provincial R & D Program, grants from The Chinese Medicine Innovation Team Project of the State Administration of Traditional Chinese Medicine, during  the conduct of the study. The authors declare that they have no other competing interests.\n",
      "\n",
      "Peiming Zhang and Jie Zhan are co-first authors. Professor Liming Lu reports grants from National Natural Science Foundation of China, grants from The special project of \"Lingnan modernization of traditional Chinese medicine\" in 2019 Guangdong Provincial R & D Program, grants from The Chinese Medicine Innovation Team Project of the State Administration of Traditional Chinese Medicine, during  the conduct of the study. The authors declare that they have no other competing interests.\n",
      "\n",
      "Peiming Zhang and Jie Zhan are co-first authors. Professor Liming Lu reports grants from National Natural Science Foundation of China, grants from The special project of \"Lingnan modernization of traditional Chinese medicine\" in 2019 Guangdong Provincial R & D Program, grants from The Chinese Medicine Innovation Team Project of the State Administration of Traditional Chinese Medicine, during  the conduct of the study. The authors declare that they have no other competing interests.\n",
      "\n",
      "Peiming Zhang and Jie Zhan are co-first authors. Professor Liming Lu reports grants from National Natural Science Foundation of China, grants from The special project of \"Lingnan modernization of traditional Chinese medicine\" in 2019 Guangdong Provincial R & D Program, grants from The Chinese Medicine Innovation Team Project of the State Administration of Traditional Chinese Medicine, during  the conduct of the study. The authors declare that they have no other competing interests.\n",
      "\n",
      "Peiming Zhang and Jie Zhan are co-first authors. Professor Liming Lu reports grants from National Natural Science Foundation of China, grants from The special project of \"Lingnan modernization of traditional Chinese medicine\" in 2019 Guangdong Provincial R & D Program, grants from The Chinese Medicine Innovation Team Project of the State Administration of Traditional Chinese Medicine, during  the conduct of the study. The authors declare that they have no other competing interests.\n",
      "\n",
      "Peiming Zhang and Jie Zhan are co-first authors. Professor Liming Lu reports grants from National Natural Science Foundation of China, grants from The special project of \"Lingnan modernization of traditional Chinese medicine\" in 2019 Guangdong Provincial R & D Program, grants from The Chinese Medicine Innovation Team Project of the State Administration of Traditional Chinese Medicine, during  the conduct of the study. The authors declare that they have no other competing interests.\n",
      "\n",
      "Peiming Zhang and Jie Zhan are co-first authors. Professor Liming Lu reports grants from National Natural Science Foundation of China, grants from The special project of \"Lingnan modernization of traditional Chinese medicine\" in 2019 Guangdong Provincial R & D Program, grants from The Chinese Medicine Innovation Team Project of the State Administration of Traditional Chinese Medicine, during  the conduct of the study. The authors declare that they have no other competing interests.\n",
      "\n",
      "Peiming Zhang and Jie Zhan are co-first authors. Professor Liming Lu reports grants from National Natural Science Foundation of China, grants from The special project of \"Lingnan modernization of traditional Chinese medicine\" in 2019 Guangdong Provincial R & D Program, grants from The Chinese Medicine Innovation Team Project of the State Administration of Traditional Chinese Medicine, during  the conduct of the study. The authors declare that they have no other competing interests.\n",
      "\n",
      "Peiming Zhang and Jie Zhan are co-first authors. Professor Liming Lu reports grants from National Natural Science Foundation of China, grants from The special project of \"Lingnan modernization of traditional Chinese medicine\" in 2019 Guangdong Provincial R & D Program, grants from The Chinese Medicine Innovation Team Project of the State Administration of Traditional Chinese Medicine, during  the conduct of the study. The authors declare that they have no other competing interests.\n",
      "\n",
      "Lu, Liming\n",
      "Peiming Zhang and Jie Zhan are co-first authors. Professor Liming Lu reports grants from National Natural Science Foundation of China, grants from The special project of \"Lingnan modernization of traditional Chinese medicine\" in 2019 Guangdong Provincial R & D Program, grants from The Chinese Medicine Innovation Team Project of the State Administration of Traditional Chinese Medicine, during  the conduct of the study. The authors declare that they have no other competing interests.\n",
      "\n",
      "All authors have completed the ICMJE uniform disclosure form and declare the following: no support from any organisation for the submitted work; no financial  relationships with any organisations that might have an interest in the submitted work in the previous three years; no other relationships or activities that could appear to have influenced the submitted work.\n",
      "\n",
      "All authors have completed the ICMJE uniform disclosure form and declare the following: no support from any organisation for the submitted work; no financial  relationships with any organisations that might have an interest in the submitted work in the previous three years; no other relationships or activities that could appear to have influenced the submitted work.\n",
      "\n",
      "All authors have completed the ICMJE uniform disclosure form and declare the following: no support from any organisation for the submitted work; no financial  relationships with any organisations that might have an interest in the submitted work in the previous three years; no other relationships or activities that could appear to have influenced the submitted work.\n",
      "\n",
      "All authors have completed the ICMJE uniform disclosure form and declare the following: no support from any organisation for the submitted work; no financial  relationships with any organisations that might have an interest in the submitted work in the previous three years; no other relationships or activities that could appear to have influenced the submitted work.\n",
      "\n",
      "RU has in the past 3 years received honoraria for speaking events from Oktuska, Synovion and Vyalife; has participated as a Chair TSC for an NIHR-funded clinical trial on antipsychotic medication for treatment resistant depression, and as an Expert Member for an NIHR-funded clinical trial on psychological therapies for common mental disorders; is honorary general secretary for the British Association of Psychopharmacology and a Deputy Editor for British Journal of Psychiatry. PBJ is Chair of the MQ Mental Health Sciences Council and has participated in an advisory board for MSD on an unrelated mental health topic. FV received in the past 3 years honoraria for conferences or teaching CME courses from Forum fur MedizinischeFortbildung and Sysmex Suisse AG. NA received in the past 3 years honoraria for a conference from Sysmex Suisse AG. SC received in the past 3 years honoraria for teaching CME courses from Forum pour la formation medicale, Barr Switzerland and for consultancy from the Swiss Health Observatory  (Obsan) of the Swiss Federal Office of Public Health. CBE received in the past 3  years honoraria for conferences or teaching CME courses from Janssen-Cilag, Lundbeck, Otsuka, Sandoz, Servier, Sunovion, Sysmex Suisse AG, Takeda, Vifor-Pharma and Zeller. All other authors declare no potential conflicts of interest.\n",
      "\n",
      "Vandenberghe, Frederik\n",
      "RU has in the past 3 years received honoraria for speaking events from Oktuska, Synovion and Vyalife; has participated as a Chair TSC for an NIHR-funded clinical trial on antipsychotic medication for treatment resistant depression, and as an Expert Member for an NIHR-funded clinical trial on psychological therapies for common mental disorders; is honorary general secretary for the British Association of Psychopharmacology and a Deputy Editor for British Journal of Psychiatry. PBJ is Chair of the MQ Mental Health Sciences Council and has participated in an advisory board for MSD on an unrelated mental health topic. Frederik Vandenberghe received in the past 3 years honoraria for conferences or teaching CME courses from Forum fur MedizinischeFortbildung and Sysmex Suisse AG. NA received in the past 3 years honoraria for a conference from Sysmex Suisse AG. SC received in the past 3 years honoraria for teaching CME courses from Forum pour la formation medicale, Barr Switzerland and for consultancy from the Swiss Health Observatory  (Obsan) of the Swiss Federal Office of Public Health. CBE received in the past 3  years honoraria for conferences or teaching CME courses from Janssen-Cilag, Lundbeck, Otsuka, Sandoz, Servier, Sunovion, Sysmex Suisse AG, Takeda, Vifor-Pharma and Zeller. All other authors declare no potential conflicts of interest.\n",
      "\n",
      "RU has in the past 3 years received honoraria for speaking events from Oktuska, Synovion and Vyalife; has participated as a Chair TSC for an NIHR-funded clinical trial on antipsychotic medication for treatment resistant depression, and as an Expert Member for an NIHR-funded clinical trial on psychological therapies for common mental disorders; is honorary general secretary for the British Association of Psychopharmacology and a Deputy Editor for British Journal of Psychiatry. PBJ is Chair of the MQ Mental Health Sciences Council and has participated in an advisory board for MSD on an unrelated mental health topic. Frederik Vandenberghe received in the past 3 years honoraria for conferences or teaching CME courses from Forum fur MedizinischeFortbildung and Sysmex Suisse AG. NA received in the past 3 years honoraria for a conference from Sysmex Suisse AG. SC received in the past 3 years honoraria for teaching CME courses from Forum pour la formation medicale, Barr Switzerland and for consultancy from the Swiss Health Observatory  (Obsan) of the Swiss Federal Office of Public Health. CBE received in the past 3  years honoraria for conferences or teaching CME courses from Janssen-Cilag, Lundbeck, Otsuka, Sandoz, Servier, Sunovion, Sysmex Suisse AG, Takeda, Vifor-Pharma and Zeller. All other authors declare no potential conflicts of interest.\n",
      "\n",
      "RU has in the past 3 years received honoraria for speaking events from Oktuska, Synovion and Vyalife; has participated as a Chair TSC for an NIHR-funded clinical trial on antipsychotic medication for treatment resistant depression, and as an Expert Member for an NIHR-funded clinical trial on psychological therapies for common mental disorders; is honorary general secretary for the British Association of Psychopharmacology and a Deputy Editor for British Journal of Psychiatry. PBJ is Chair of the MQ Mental Health Sciences Council and has participated in an advisory board for MSD on an unrelated mental health topic. Frederik Vandenberghe received in the past 3 years honoraria for conferences or teaching CME courses from Forum fur MedizinischeFortbildung and Sysmex Suisse AG. NA received in the past 3 years honoraria for a conference from Sysmex Suisse AG. SC received in the past 3 years honoraria for teaching CME courses from Forum pour la formation medicale, Barr Switzerland and for consultancy from the Swiss Health Observatory  (Obsan) of the Swiss Federal Office of Public Health. CBE received in the past 3  years honoraria for conferences or teaching CME courses from Janssen-Cilag, Lundbeck, Otsuka, Sandoz, Servier, Sunovion, Sysmex Suisse AG, Takeda, Vifor-Pharma and Zeller. All other authors declare no potential conflicts of interest.\n",
      "\n",
      "RU has in the past 3 years received honoraria for speaking events from Oktuska, Synovion and Vyalife; has participated as a Chair TSC for an NIHR-funded clinical trial on antipsychotic medication for treatment resistant depression, and as an Expert Member for an NIHR-funded clinical trial on psychological therapies for common mental disorders; is honorary general secretary for the British Association of Psychopharmacology and a Deputy Editor for British Journal of Psychiatry. PBJ is Chair of the MQ Mental Health Sciences Council and has participated in an advisory board for MSD on an unrelated mental health topic. Frederik Vandenberghe received in the past 3 years honoraria for conferences or teaching CME courses from Forum fur MedizinischeFortbildung and Sysmex Suisse AG. NA received in the past 3 years honoraria for a conference from Sysmex Suisse AG. SC received in the past 3 years honoraria for teaching CME courses from Forum pour la formation medicale, Barr Switzerland and for consultancy from the Swiss Health Observatory  (Obsan) of the Swiss Federal Office of Public Health. CBE received in the past 3  years honoraria for conferences or teaching CME courses from Janssen-Cilag, Lundbeck, Otsuka, Sandoz, Servier, Sunovion, Sysmex Suisse AG, Takeda, Vifor-Pharma and Zeller. All other authors declare no potential conflicts of interest.\n",
      "\n",
      "RU has in the past 3 years received honoraria for speaking events from Oktuska, Synovion and Vyalife; has participated as a Chair TSC for an NIHR-funded clinical trial on antipsychotic medication for treatment resistant depression, and as an Expert Member for an NIHR-funded clinical trial on psychological therapies for common mental disorders; is honorary general secretary for the British Association of Psychopharmacology and a Deputy Editor for British Journal of Psychiatry. PBJ is Chair of the MQ Mental Health Sciences Council and has participated in an advisory board for MSD on an unrelated mental health topic. Frederik Vandenberghe received in the past 3 years honoraria for conferences or teaching CME courses from Forum fur MedizinischeFortbildung and Sysmex Suisse AG. NA received in the past 3 years honoraria for a conference from Sysmex Suisse AG. SC received in the past 3 years honoraria for teaching CME courses from Forum pour la formation medicale, Barr Switzerland and for consultancy from the Swiss Health Observatory  (Obsan) of the Swiss Federal Office of Public Health. CBE received in the past 3  years honoraria for conferences or teaching CME courses from Janssen-Cilag, Lundbeck, Otsuka, Sandoz, Servier, Sunovion, Sysmex Suisse AG, Takeda, Vifor-Pharma and Zeller. All other authors declare no potential conflicts of interest.\n",
      "\n",
      "Upthegrove, Rachel\n",
      "Rachel Upthegrove has in the past 3 years received honoraria for speaking events from Oktuska, Synovion and Vyalife; has participated as a Chair TSC for an NIHR-funded clinical trial on antipsychotic medication for treatment resistant depression, and as an Expert Member for an NIHR-funded clinical trial on psychological therapies for common mental disorders; is honorary general secretary for the British Association of Psychopharmacology and a Deputy Editor for British Journal of Psychiatry. PBJ is Chair of the MQ Mental Health Sciences Council and has participated in an advisory board for MSD on an unrelated mental health topic. Frederik Vandenberghe received in the past 3 years honoraria for conferences or teaching CME courses from Forum fur MedizinischeFortbildung and Sysmex Suisse AG. NA received in the past 3 years honoraria for a conference from Sysmex Suisse AG. SC received in the past 3 years honoraria for teaching CME courses from Forum pour la formation medicale, Barr Switzerland and for consultancy from the Swiss Health Observatory  (Obsan) of the Swiss Federal Office of Public Health. CBE received in the past 3  years honoraria for conferences or teaching CME courses from Janssen-Cilag, Lundbeck, Otsuka, Sandoz, Servier, Sunovion, Sysmex Suisse AG, Takeda, Vifor-Pharma and Zeller. All other authors declare no potential conflicts of interest.\n",
      "\n",
      "Rachel Upthegrove has in the past 3 years received honoraria for speaking events from Oktuska, Synovion and Vyalife; has participated as a Chair TSC for an NIHR-funded clinical trial on antipsychotic medication for treatment resistant depression, and as an Expert Member for an NIHR-funded clinical trial on psychological therapies for common mental disorders; is honorary general secretary for the British Association of Psychopharmacology and a Deputy Editor for British Journal of Psychiatry. PBJ is Chair of the MQ Mental Health Sciences Council and has participated in an advisory board for MSD on an unrelated mental health topic. Frederik Vandenberghe received in the past 3 years honoraria for conferences or teaching CME courses from Forum fur MedizinischeFortbildung and Sysmex Suisse AG. NA received in the past 3 years honoraria for a conference from Sysmex Suisse AG. SC received in the past 3 years honoraria for teaching CME courses from Forum pour la formation medicale, Barr Switzerland and for consultancy from the Swiss Health Observatory  (Obsan) of the Swiss Federal Office of Public Health. CBE received in the past 3  years honoraria for conferences or teaching CME courses from Janssen-Cilag, Lundbeck, Otsuka, Sandoz, Servier, Sunovion, Sysmex Suisse AG, Takeda, Vifor-Pharma and Zeller. All other authors declare no potential conflicts of interest.\n",
      "\n",
      "Rachel Upthegrove has in the past 3 years received honoraria for speaking events from Oktuska, Synovion and Vyalife; has participated as a Chair TSC for an NIHR-funded clinical trial on antipsychotic medication for treatment resistant depression, and as an Expert Member for an NIHR-funded clinical trial on psychological therapies for common mental disorders; is honorary general secretary for the British Association of Psychopharmacology and a Deputy Editor for British Journal of Psychiatry. PBJ is Chair of the MQ Mental Health Sciences Council and has participated in an advisory board for MSD on an unrelated mental health topic. Frederik Vandenberghe received in the past 3 years honoraria for conferences or teaching CME courses from Forum fur MedizinischeFortbildung and Sysmex Suisse AG. NA received in the past 3 years honoraria for a conference from Sysmex Suisse AG. SC received in the past 3 years honoraria for teaching CME courses from Forum pour la formation medicale, Barr Switzerland and for consultancy from the Swiss Health Observatory  (Obsan) of the Swiss Federal Office of Public Health. CBE received in the past 3  years honoraria for conferences or teaching CME courses from Janssen-Cilag, Lundbeck, Otsuka, Sandoz, Servier, Sunovion, Sysmex Suisse AG, Takeda, Vifor-Pharma and Zeller. All other authors declare no potential conflicts of interest.\n",
      "\n",
      "Jones, Peter B.\n",
      "Rachel Upthegrove has in the past 3 years received honoraria for speaking events from Oktuska, Synovion and Vyalife; has participated as a Chair TSC for an NIHR-funded clinical trial on antipsychotic medication for treatment resistant depression, and as an Expert Member for an NIHR-funded clinical trial on psychological therapies for common mental disorders; is honorary general secretary for the British Association of Psychopharmacology and a Deputy Editor for British Journal of Psychiatry. Peter B. Jones is Chair of the MQ Mental Health Sciences Council and has participated in an advisory board for MSD on an unrelated mental health topic. Frederik Vandenberghe received in the past 3 years honoraria for conferences or teaching CME courses from Forum fur MedizinischeFortbildung and Sysmex Suisse AG. NA received in the past 3 years honoraria for a conference from Sysmex Suisse AG. SC received in the past 3 years honoraria for teaching CME courses from Forum pour la formation medicale, Barr Switzerland and for consultancy from the Swiss Health Observatory  (Obsan) of the Swiss Federal Office of Public Health. CBE received in the past 3  years honoraria for conferences or teaching CME courses from Janssen-Cilag, Lundbeck, Otsuka, Sandoz, Servier, Sunovion, Sysmex Suisse AG, Takeda, Vifor-Pharma and Zeller. All other authors declare no potential conflicts of interest.\n",
      "\n",
      "Rachel Upthegrove has in the past 3 years received honoraria for speaking events from Oktuska, Synovion and Vyalife; has participated as a Chair TSC for an NIHR-funded clinical trial on antipsychotic medication for treatment resistant depression, and as an Expert Member for an NIHR-funded clinical trial on psychological therapies for common mental disorders; is honorary general secretary for the British Association of Psychopharmacology and a Deputy Editor for British Journal of Psychiatry. Peter B. Jones is Chair of the MQ Mental Health Sciences Council and has participated in an advisory board for MSD on an unrelated mental health topic. Frederik Vandenberghe received in the past 3 years honoraria for conferences or teaching CME courses from Forum fur MedizinischeFortbildung and Sysmex Suisse AG. NA received in the past 3 years honoraria for a conference from Sysmex Suisse AG. SC received in the past 3 years honoraria for teaching CME courses from Forum pour la formation medicale, Barr Switzerland and for consultancy from the Swiss Health Observatory  (Obsan) of the Swiss Federal Office of Public Health. CBE received in the past 3  years honoraria for conferences or teaching CME courses from Janssen-Cilag, Lundbeck, Otsuka, Sandoz, Servier, Sunovion, Sysmex Suisse AG, Takeda, Vifor-Pharma and Zeller. All other authors declare no potential conflicts of interest.\n",
      "\n",
      "Rachel Upthegrove has in the past 3 years received honoraria for speaking events from Oktuska, Synovion and Vyalife; has participated as a Chair TSC for an NIHR-funded clinical trial on antipsychotic medication for treatment resistant depression, and as an Expert Member for an NIHR-funded clinical trial on psychological therapies for common mental disorders; is honorary general secretary for the British Association of Psychopharmacology and a Deputy Editor for British Journal of Psychiatry. Peter B. Jones is Chair of the MQ Mental Health Sciences Council and has participated in an advisory board for MSD on an unrelated mental health topic. Frederik Vandenberghe received in the past 3 years honoraria for conferences or teaching CME courses from Forum fur MedizinischeFortbildung and Sysmex Suisse AG. NA received in the past 3 years honoraria for a conference from Sysmex Suisse AG. SC received in the past 3 years honoraria for teaching CME courses from Forum pour la formation medicale, Barr Switzerland and for consultancy from the Swiss Health Observatory  (Obsan) of the Swiss Federal Office of Public Health. CBE received in the past 3  years honoraria for conferences or teaching CME courses from Janssen-Cilag, Lundbeck, Otsuka, Sandoz, Servier, Sunovion, Sysmex Suisse AG, Takeda, Vifor-Pharma and Zeller. All other authors declare no potential conflicts of interest.\n",
      "\n",
      "Stochl, Jan\n",
      "Rachel Upthegrove has in the past 3 years received honoraria for speaking events from Oktuska, Synovion and Vyalife; has participated as a Chair TSC for an NIHR-funded clinical trial on antipsychotic medication for treatment resistant depression, and as an Expert Member for an NIHR-funded clinical trial on psychological therapies for common mental disorders; is honorary general secretary for the British Association of Psychopharmacology and a Deputy Editor for British Journal of Psychiatry. Peter B. Jones is Chair of the MQ Mental Health Sciences Council and has participated in an advisory board for MSD on an unrelated mental health topic. Frederik Vandenberghe received in the past 3 years honoraria for conferences or teaching CME courses from Forum fur MedizinischeFortbildung and Sysmex Suisse AG. NA received in the past 3 years honoraria for a conference from Sysmex Suisse AG. SC received in the past 3 years honoraria for teaching CME courses from Forum pour la formation medicale, Barr Switzerland and for consultancy from the Swiss Health Observatory  (Obsan) of the Swiss Federal Office of Public Health. CBE received in the past 3  years honoraria for conferences or teaching CME courses from Jan Stochlssen-Cilag, Lundbeck, Otsuka, Sandoz, Servier, Sunovion, Sysmex Suisse AG, Takeda, Vifor-Pharma and Zeller. All other authors declare no potential conflicts of interest.\n",
      "\n",
      "Rachel Upthegrove has in the past 3 years received honoraria for speaking events from Oktuska, Synovion and Vyalife; has participated as a Chair TSC for an NIHR-funded clinical trial on antipsychotic medication for treatment resistant depression, and as an Expert Member for an NIHR-funded clinical trial on psychological therapies for common mental disorders; is honorary general secretary for the British Association of Psychopharmacology and a Deputy Editor for British Journal of Psychiatry. Peter B. Jones is Chair of the MQ Mental Health Sciences Council and has participated in an advisory board for MSD on an unrelated mental health topic. Frederik Vandenberghe received in the past 3 years honoraria for conferences or teaching CME courses from Forum fur MedizinischeFortbildung and Sysmex Suisse AG. NA received in the past 3 years honoraria for a conference from Sysmex Suisse AG. SC received in the past 3 years honoraria for teaching CME courses from Forum pour la formation medicale, Barr Switzerland and for consultancy from the Swiss Health Observatory  (Obsan) of the Swiss Federal Office of Public Health. CBE received in the past 3  years honoraria for conferences or teaching CME courses from Jan Stochlssen-Cilag, Lundbeck, Otsuka, Sandoz, Servier, Sunovion, Sysmex Suisse AG, Takeda, Vifor-Pharma and Zeller. All other authors declare no potential conflicts of interest.\n",
      "\n",
      "Rachel Upthegrove has in the past 3 years received honoraria for speaking events from Oktuska, Synovion and Vyalife; has participated as a Chair TSC for an NIHR-funded clinical trial on antipsychotic medication for treatment resistant depression, and as an Expert Member for an NIHR-funded clinical trial on psychological therapies for common mental disorders; is honorary general secretary for the British Association of Psychopharmacology and a Deputy Editor for British Journal of Psychiatry. Peter B. Jones is Chair of the MQ Mental Health Sciences Council and has participated in an advisory board for MSD on an unrelated mental health topic. Frederik Vandenberghe received in the past 3 years honoraria for conferences or teaching CME courses from Forum fur MedizinischeFortbildung and Sysmex Suisse AG. NA received in the past 3 years honoraria for a conference from Sysmex Suisse AG. SC received in the past 3 years honoraria for teaching CME courses from Forum pour la formation medicale, Barr Switzerland and for consultancy from the Swiss Health Observatory  (Obsan) of the Swiss Federal Office of Public Health. CBE received in the past 3  years honoraria for conferences or teaching CME courses from Jan Stochlssen-Cilag, Lundbeck, Otsuka, Sandoz, Servier, Sunovion, Sysmex Suisse AG, Takeda, Vifor-Pharma and Zeller. All other authors declare no potential conflicts of interest.\n",
      "\n",
      "Rachel Upthegrove has in the past 3 years received honoraria for speaking events from Oktuska, Synovion and Vyalife; has participated as a Chair TSC for an NIHR-funded clinical trial on antipsychotic medication for treatment resistant depression, and as an Expert Member for an NIHR-funded clinical trial on psychological therapies for common mental disorders; is honorary general secretary for the British Association of Psychopharmacology and a Deputy Editor for British Journal of Psychiatry. Peter B. Jones is Chair of the MQ Mental Health Sciences Council and has participated in an advisory board for MSD on an unrelated mental health topic. Frederik Vandenberghe received in the past 3 years honoraria for conferences or teaching CME courses from Forum fur MedizinischeFortbildung and Sysmex Suisse AG. NA received in the past 3 years honoraria for a conference from Sysmex Suisse AG. SC received in the past 3 years honoraria for teaching CME courses from Forum pour la formation medicale, Barr Switzerland and for consultancy from the Swiss Health Observatory  (Obsan) of the Swiss Federal Office of Public Health. CBE received in the past 3  years honoraria for conferences or teaching CME courses from Jan Stochlssen-Cilag, Lundbeck, Otsuka, Sandoz, Servier, Sunovion, Sysmex Suisse AG, Takeda, Vifor-Pharma and Zeller. All other authors declare no potential conflicts of interest.\n",
      "\n",
      "Rachel Upthegrove has in the past 3 years received honoraria for speaking events from Oktuska, Synovion and Vyalife; has participated as a Chair TSC for an NIHR-funded clinical trial on antipsychotic medication for treatment resistant depression, and as an Expert Member for an NIHR-funded clinical trial on psychological therapies for common mental disorders; is honorary general secretary for the British Association of Psychopharmacology and a Deputy Editor for British Journal of Psychiatry. Peter B. Jones is Chair of the MQ Mental Health Sciences Council and has participated in an advisory board for MSD on an unrelated mental health topic. Frederik Vandenberghe received in the past 3 years honoraria for conferences or teaching CME courses from Forum fur MedizinischeFortbildung and Sysmex Suisse AG. NA received in the past 3 years honoraria for a conference from Sysmex Suisse AG. SC received in the past 3 years honoraria for teaching CME courses from Forum pour la formation medicale, Barr Switzerland and for consultancy from the Swiss Health Observatory  (Obsan) of the Swiss Federal Office of Public Health. CBE received in the past 3  years honoraria for conferences or teaching CME courses from Jan Stochlssen-Cilag, Lundbeck, Otsuka, Sandoz, Servier, Sunovion, Sysmex Suisse AG, Takeda, Vifor-Pharma and Zeller. All other authors declare no potential conflicts of interest.\n",
      "\n",
      "Ansermot, Nicolas\n",
      "Rachel Upthegrove has in the past 3 years received honoraria for speaking events from Oktuska, Synovion and Vyalife; has participated as a Chair TSC for an NIHR-funded clinical trial on antipsychotic medication for treatment resistant depression, and as an Expert Member for an NIHR-funded clinical trial on psychological therapies for common mental disorders; is honorary general secretary for the British Association of Psychopharmacology and a Deputy Editor for British Journal of Psychiatry. Peter B. Jones is Chair of the MQ Mental Health Sciences Council and has participated in an advisory board for MSD on an unrelated mental health topic. Frederik Vandenberghe received in the past 3 years honoraria for conferences or teaching CME courses from Forum fur MedizinischeFortbildung and Sysmex Suisse AG. Nicolas Ansermot received in the past 3 years honoraria for a conference from Sysmex Suisse AG. SC received in the past 3 years honoraria for teaching CME courses from Forum pour la formation medicale, Barr Switzerland and for consultancy from the Swiss Health Observatory  (Obsan) of the Swiss Federal Office of Public Health. CBE received in the past 3  years honoraria for conferences or teaching CME courses from Jan Stochlssen-Cilag, Lundbeck, Otsuka, Sandoz, Servier, Sunovion, Sysmex Suisse AG, Takeda, Vifor-Pharma and Zeller. All other authors declare no potential conflicts of interest.\n",
      "\n",
      "Rachel Upthegrove has in the past 3 years received honoraria for speaking events from Oktuska, Synovion and Vyalife; has participated as a Chair TSC for an NIHR-funded clinical trial on antipsychotic medication for treatment resistant depression, and as an Expert Member for an NIHR-funded clinical trial on psychological therapies for common mental disorders; is honorary general secretary for the British Association of Psychopharmacology and a Deputy Editor for British Journal of Psychiatry. Peter B. Jones is Chair of the MQ Mental Health Sciences Council and has participated in an advisory board for MSD on an unrelated mental health topic. Frederik Vandenberghe received in the past 3 years honoraria for conferences or teaching CME courses from Forum fur MedizinischeFortbildung and Sysmex Suisse AG. Nicolas Ansermot received in the past 3 years honoraria for a conference from Sysmex Suisse AG. SC received in the past 3 years honoraria for teaching CME courses from Forum pour la formation medicale, Barr Switzerland and for consultancy from the Swiss Health Observatory  (Obsan) of the Swiss Federal Office of Public Health. CBE received in the past 3  years honoraria for conferences or teaching CME courses from Jan Stochlssen-Cilag, Lundbeck, Otsuka, Sandoz, Servier, Sunovion, Sysmex Suisse AG, Takeda, Vifor-Pharma and Zeller. All other authors declare no potential conflicts of interest.\n",
      "\n",
      "Crettol, Severine\n",
      "Rachel Upthegrove has in the past 3 years received honoraria for speaking events from Oktuska, Synovion and Vyalife; has participated as a Chair TSeverine Crettol for an NIHR-funded clinical trial on antipsychotic medication for treatment resistant depression, and as an Expert Member for an NIHR-funded clinical trial on psychological therapies for common mental disorders; is honorary general secretary for the British Association of Psychopharmacology and a Deputy Editor for British Journal of Psychiatry. Peter B. Jones is Chair of the MQ Mental Health Sciences Council and has participated in an advisory board for MSD on an unrelated mental health topic. Frederik Vandenberghe received in the past 3 years honoraria for conferences or teaching CME courses from Forum fur MedizinischeFortbildung and Sysmex Suisse AG. Nicolas Ansermot received in the past 3 years honoraria for a conference from Sysmex Suisse AG. Severine Crettol received in the past 3 years honoraria for teaching CME courses from Forum pour la formation medicale, Barr Switzerland and for consultancy from the Swiss Health Observatory  (Obsan) of the Swiss Federal Office of Public Health. CBE received in the past 3  years honoraria for conferences or teaching CME courses from Jan Stochlssen-Cilag, Lundbeck, Otsuka, Sandoz, Servier, Sunovion, Sysmex Suisse AG, Takeda, Vifor-Pharma and Zeller. All other authors declare no potential conflicts of interest.\n",
      "\n",
      "Rachel Upthegrove has in the past 3 years received honoraria for speaking events from Oktuska, Synovion and Vyalife; has participated as a Chair TSeverine Crettol for an NIHR-funded clinical trial on antipsychotic medication for treatment resistant depression, and as an Expert Member for an NIHR-funded clinical trial on psychological therapies for common mental disorders; is honorary general secretary for the British Association of Psychopharmacology and a Deputy Editor for British Journal of Psychiatry. Peter B. Jones is Chair of the MQ Mental Health Sciences Council and has participated in an advisory board for MSD on an unrelated mental health topic. Frederik Vandenberghe received in the past 3 years honoraria for conferences or teaching CME courses from Forum fur MedizinischeFortbildung and Sysmex Suisse AG. Nicolas Ansermot received in the past 3 years honoraria for a conference from Sysmex Suisse AG. Severine Crettol received in the past 3 years honoraria for teaching CME courses from Forum pour la formation medicale, Barr Switzerland and for consultancy from the Swiss Health Observatory  (Obsan) of the Swiss Federal Office of Public Health. CBE received in the past 3  years honoraria for conferences or teaching CME courses from Jan Stochlssen-Cilag, Lundbeck, Otsuka, Sandoz, Servier, Sunovion, Sysmex Suisse AG, Takeda, Vifor-Pharma and Zeller. All other authors declare no potential conflicts of interest.\n",
      "\n",
      "Rachel Upthegrove has in the past 3 years received honoraria for speaking events from Oktuska, Synovion and Vyalife; has participated as a Chair TSeverine Crettol for an NIHR-funded clinical trial on antipsychotic medication for treatment resistant depression, and as an Expert Member for an NIHR-funded clinical trial on psychological therapies for common mental disorders; is honorary general secretary for the British Association of Psychopharmacology and a Deputy Editor for British Journal of Psychiatry. Peter B. Jones is Chair of the MQ Mental Health Sciences Council and has participated in an advisory board for MSD on an unrelated mental health topic. Frederik Vandenberghe received in the past 3 years honoraria for conferences or teaching CME courses from Forum fur MedizinischeFortbildung and Sysmex Suisse AG. Nicolas Ansermot received in the past 3 years honoraria for a conference from Sysmex Suisse AG. Severine Crettol received in the past 3 years honoraria for teaching CME courses from Forum pour la formation medicale, Barr Switzerland and for consultancy from the Swiss Health Observatory  (Obsan) of the Swiss Federal Office of Public Health. CBE received in the past 3  years honoraria for conferences or teaching CME courses from Jan Stochlssen-Cilag, Lundbeck, Otsuka, Sandoz, Servier, Sunovion, Sysmex Suisse AG, Takeda, Vifor-Pharma and Zeller. All other authors declare no potential conflicts of interest.\n",
      "\n",
      "Rachel Upthegrove has in the past 3 years received honoraria for speaking events from Oktuska, Synovion and Vyalife; has participated as a Chair TSeverine Crettol for an NIHR-funded clinical trial on antipsychotic medication for treatment resistant depression, and as an Expert Member for an NIHR-funded clinical trial on psychological therapies for common mental disorders; is honorary general secretary for the British Association of Psychopharmacology and a Deputy Editor for British Journal of Psychiatry. Peter B. Jones is Chair of the MQ Mental Health Sciences Council and has participated in an advisory board for MSD on an unrelated mental health topic. Frederik Vandenberghe received in the past 3 years honoraria for conferences or teaching CME courses from Forum fur MedizinischeFortbildung and Sysmex Suisse AG. Nicolas Ansermot received in the past 3 years honoraria for a conference from Sysmex Suisse AG. Severine Crettol received in the past 3 years honoraria for teaching CME courses from Forum pour la formation medicale, Barr Switzerland and for consultancy from the Swiss Health Observatory  (Obsan) of the Swiss Federal Office of Public Health. CBE received in the past 3  years honoraria for conferences or teaching CME courses from Jan Stochlssen-Cilag, Lundbeck, Otsuka, Sandoz, Servier, Sunovion, Sysmex Suisse AG, Takeda, Vifor-Pharma and Zeller. All other authors declare no potential conflicts of interest.\n",
      "\n",
      "Rachel Upthegrove has in the past 3 years received honoraria for speaking events from Oktuska, Synovion and Vyalife; has participated as a Chair TSeverine Crettol for an NIHR-funded clinical trial on antipsychotic medication for treatment resistant depression, and as an Expert Member for an NIHR-funded clinical trial on psychological therapies for common mental disorders; is honorary general secretary for the British Association of Psychopharmacology and a Deputy Editor for British Journal of Psychiatry. Peter B. Jones is Chair of the MQ Mental Health Sciences Council and has participated in an advisory board for MSD on an unrelated mental health topic. Frederik Vandenberghe received in the past 3 years honoraria for conferences or teaching CME courses from Forum fur MedizinischeFortbildung and Sysmex Suisse AG. Nicolas Ansermot received in the past 3 years honoraria for a conference from Sysmex Suisse AG. Severine Crettol received in the past 3 years honoraria for teaching CME courses from Forum pour la formation medicale, Barr Switzerland and for consultancy from the Swiss Health Observatory  (Obsan) of the Swiss Federal Office of Public Health. CBE received in the past 3  years honoraria for conferences or teaching CME courses from Jan Stochlssen-Cilag, Lundbeck, Otsuka, Sandoz, Servier, Sunovion, Sysmex Suisse AG, Takeda, Vifor-Pharma and Zeller. All other authors declare no potential conflicts of interest.\n",
      "\n",
      "Rachel Upthegrove has in the past 3 years received honoraria for speaking events from Oktuska, Synovion and Vyalife; has participated as a Chair TSeverine Crettol for an NIHR-funded clinical trial on antipsychotic medication for treatment resistant depression, and as an Expert Member for an NIHR-funded clinical trial on psychological therapies for common mental disorders; is honorary general secretary for the British Association of Psychopharmacology and a Deputy Editor for British Journal of Psychiatry. Peter B. Jones is Chair of the MQ Mental Health Sciences Council and has participated in an advisory board for MSD on an unrelated mental health topic. Frederik Vandenberghe received in the past 3 years honoraria for conferences or teaching CME courses from Forum fur MedizinischeFortbildung and Sysmex Suisse AG. Nicolas Ansermot received in the past 3 years honoraria for a conference from Sysmex Suisse AG. Severine Crettol received in the past 3 years honoraria for teaching CME courses from Forum pour la formation medicale, Barr Switzerland and for consultancy from the Swiss Health Observatory  (Obsan) of the Swiss Federal Office of Public Health. CBE received in the past 3  years honoraria for conferences or teaching CME courses from Jan Stochlssen-Cilag, Lundbeck, Otsuka, Sandoz, Servier, Sunovion, Sysmex Suisse AG, Takeda, Vifor-Pharma and Zeller. All other authors declare no potential conflicts of interest.\n",
      "\n",
      "Eap, Chin B.\n",
      "Rachel Upthegrove has in the past 3 years received honoraria for speaking events from Oktuska, Synovion and Vyalife; has participated as a Chair TSeverine Crettol for an NIHR-funded clinical trial on antipsychotic medication for treatment resistant depression, and as an Expert Member for an NIHR-funded clinical trial on psychological therapies for common mental disorders; is honorary general secretary for the British Association of Psychopharmacology and a Deputy Editor for British Journal of Psychiatry. Peter B. Jones is Chair of the MQ Mental Health Sciences Council and has participated in an advisory board for MSD on an unrelated mental health topic. Frederik Vandenberghe received in the past 3 years honoraria for conferences or teaching CME courses from Forum fur MedizinischeFortbildung and Sysmex Suisse AG. Nicolas Ansermot received in the past 3 years honoraria for a conference from Sysmex Suisse AG. Severine Crettol received in the past 3 years honoraria for teaching CME courses from Forum pour la formation medicale, Barr Switzerland and for consultancy from the Swiss Health Observatory  (Obsan) of the Swiss Federal Office of Public Health. Chin B. Eap received in the past 3  years honoraria for conferences or teaching CME courses from Jan Stochlssen-Cilag, Lundbeck, Otsuka, Sandoz, Servier, Sunovion, Sysmex Suisse AG, Takeda, Vifor-Pharma and Zeller. All other authors declare no potential conflicts of interest.\n",
      "\n",
      "Rachel Upthegrove has in the past 3 years received honoraria for speaking events from Oktuska, Synovion and Vyalife; has participated as a Chair TSeverine Crettol for an NIHR-funded clinical trial on antipsychotic medication for treatment resistant depression, and as an Expert Member for an NIHR-funded clinical trial on psychological therapies for common mental disorders; is honorary general secretary for the British Association of Psychopharmacology and a Deputy Editor for British Journal of Psychiatry. Peter B. Jones is Chair of the MQ Mental Health Sciences Council and has participated in an advisory board for MSD on an unrelated mental health topic. Frederik Vandenberghe received in the past 3 years honoraria for conferences or teaching CME courses from Forum fur MedizinischeFortbildung and Sysmex Suisse AG. Nicolas Ansermot received in the past 3 years honoraria for a conference from Sysmex Suisse AG. Severine Crettol received in the past 3 years honoraria for teaching CME courses from Forum pour la formation medicale, Barr Switzerland and for consultancy from the Swiss Health Observatory  (Obsan) of the Swiss Federal Office of Public Health. Chin B. Eap received in the past 3  years honoraria for conferences or teaching CME courses from Jan Stochlssen-Cilag, Lundbeck, Otsuka, Sandoz, Servier, Sunovion, Sysmex Suisse AG, Takeda, Vifor-Pharma and Zeller. All other authors declare no potential conflicts of interest.\n",
      "\n",
      "Younossi, Zobair\n",
      "IS, JF, PJ, and MA are employees of Novo Nordisk A/S or Novo Nordisk Denmark A/S. PJ, IS, and JF are also shareholders of Novo Nordisk A/S. Zobair Younossi has received research funding and/or serves as a consultant to Abbott, AbbVie, Bristol Myers Squibb, Gilead Sciences, Intercept, Madrigal, Merck, Novartis, Novo Nordisk, Quest, Siemens, Terns, and Viking. The SLR was commissioned to DRG Abacus (Clarivate) by Novo Nordisk, and PA and SN are employees of DRG Abacus (Clarivate). Please refer to the accompanying ICMJE disclosure forms for further  details.\n",
      "\n",
      "Aggarwal, Priya\n",
      "IS, JF, PJ, and MA are employees of Novo Nordisk A/S or Novo Nordisk Denmark A/S. PJ, IS, and JF are also shareholders of Novo Nordisk A/S. Zobair Younossi has received research funding and/or serves as a consultant to Abbott, AbbVie, Bristol Myers Squibb, Gilead Sciences, Intercept, Madrigal, Merck, Novartis, Novo Nordisk, Quest, Siemens, Terns, and Viking. The SLR was commissioned to DRG Abacus (Clarivate) by Novo Nordisk, and Priya Aggarwal and SN are employees of DRG Abacus (Clarivate). Please refer to the accompanying ICMJE disclosure forms for further  details.\n",
      "\n",
      "Shrestha, Ichhya\n",
      "Ichhya Shrestha, JF, PJ, and MA are employees of Novo Nordisk A/S or Novo Nordisk Denmark A/S. PJ, Ichhya Shrestha, and JF are also shareholders of Novo Nordisk A/S. Zobair Younossi has received research funding and/or serves as a consultant to Abbott, AbbVie, Bristol Myers Squibb, Gilead Sciences, Intercept, Madrigal, Merck, Novartis, Novo Nordisk, Quest, Siemens, Terns, and Viking. The SLR was commissioned to DRG Abacus (Clarivate) by Novo Nordisk, and Priya Aggarwal and SN are employees of DRG Abacus (Clarivate). Please refer to the accompanying ICMJE disclosure forms for further  details.\n",
      "\n",
      "Fernandes, Joao\n",
      "Ichhya Shrestha, Joao Fernandes, PJ, and MA are employees of Novo Nordisk A/S or Novo Nordisk Denmark A/S. PJ, Ichhya Shrestha, and Joao Fernandes are also shareholders of Novo Nordisk A/S. Zobair Younossi has received research funding and/or serves as a consultant to Abbott, AbbVie, Bristol Myers Squibb, Gilead Sciences, Intercept, Madrigal, Merck, Novartis, Novo Nordisk, Quest, Siemens, Terns, and Viking. The SLR was commissioned to DRG Abacus (Clarivate) by Novo Nordisk, and Priya Aggarwal and SN are employees of DRG Abacus (Clarivate). Please refer to the accompanying ICMJE disclosure forms for further  details.\n",
      "\n",
      "Johansen, Pierre\n",
      "Ichhya Shrestha, Joao Fernandes, Pierre Johansen, and MA are employees of Novo Nordisk A/S or Novo Nordisk Denmark A/S. Pierre Johansen, Ichhya Shrestha, and Joao Fernandes are also shareholders of Novo Nordisk A/S. Zobair Younossi has received research funding and/or serves as a consultant to Abbott, AbbVie, Bristol Myers Squibb, Gilead Sciences, Intercept, Madrigal, Merck, Novartis, Novo Nordisk, Quest, Siemens, Terns, and Viking. The SLR was commissioned to DRG Abacus (Clarivate) by Novo Nordisk, and Priya Aggarwal and SN are employees of DRG Abacus (Clarivate). Please refer to the accompanying ICMJE disclosure forms for further  details.\n",
      "\n",
      "Augusto, Margarida\n",
      "Ichhya Shrestha, Joao Fernandes, Pierre Johansen, and Margarida Augusto are employees of Novo Nordisk A/S or Novo Nordisk Denmark A/S. Pierre Johansen, Ichhya Shrestha, and Joao Fernandes are also shareholders of Novo Nordisk A/S. Zobair Younossi has received research funding and/or serves as a consultant to Abbott, AbbVie, Bristol Myers Squibb, Gilead Sciences, Intercept, Madrigal, Merck, Novartis, Novo Nordisk, Quest, Siemens, Terns, and Viking. The SLR was commissioned to DRG Abacus (Clarivate) by Novo Nordisk, and Priya Aggarwal and SN are employees of DRG Abacus (Clarivate). Please refer to the accompanying ICMJE disclosure forms for further  details.\n",
      "\n",
      "Nair, Sunita\n",
      "Ichhya Shrestha, Joao Fernandes, Pierre Johansen, and Margarida Augusto are employees of Novo Nordisk A/S or Novo Nordisk Denmark A/S. Pierre Johansen, Ichhya Shrestha, and Joao Fernandes are also shareholders of Novo Nordisk A/S. Zobair Younossi has received research funding and/or serves as a consultant to Abbott, AbbVie, Bristol Myers Squibb, Gilead Sciences, Intercept, Madrigal, Merck, Novartis, Novo Nordisk, Quest, Siemens, Terns, and Viking. The SLR was commissioned to DRG Abacus (Clarivate) by Novo Nordisk, and Priya Aggarwal and Sunita Nair are employees of DRG Abacus (Clarivate). Please refer to the accompanying ICMJE disclosure forms for further  details.\n",
      "\n",
      "Conflict of Interest Statement The authors of the manuscript submitted for consideration for publication in Cardiovascular Pathology declare no conflicts of interest.\n",
      "\n",
      "Conflict of Interest Statement The authors of the manuscript submitted for consideration for publication in Cardiovascular Pathology declare no conflicts of interest.\n",
      "\n",
      "Conflict of Interest Statement The authors of the manuscript submitted for consideration for publication in Cardiovascular Pathology declare no conflicts of interest.\n",
      "\n",
      "Conflict of Interest Statement The authors of the manuscript submitted for consideration for publication in Cardiovascular Pathology declare no conflicts of interest.\n",
      "\n",
      "Conflict of Interest Statement The authors of the manuscript submitted for consideration for publication in Cardiovascular Pathology declare no conflicts of interest.\n",
      "\n",
      "Conflict of Interest Statement The authors of the manuscript submitted for consideration for publication in Cardiovascular Pathology declare no conflicts of interest.\n",
      "\n",
      "Conflict of Interest Statement The authors of the manuscript submitted for consideration for publication in Cardiovascular Pathology declare no conflicts of interest.\n",
      "\n",
      "Conflict of Interest Statement The authors of the manuscript submitted for consideration for publication in Cardiovascular Pathology declare no conflicts of interest.\n",
      "\n",
      "Conflict of Interest Statement The authors of the manuscript submitted for consideration for publication in Cardiovascular Pathology declare no conflicts of interest.\n",
      "\n",
      "Conflict of Interest Statement The authors of the manuscript submitted for consideration for publication in Cardiovascular Pathology declare no conflicts of interest.\n",
      "\n",
      "Conflict of Interest Statement The authors of the manuscript submitted for consideration for publication in Cardiovascular Pathology declare no conflicts of interest.\n",
      "\n",
      "Conflict of Interest Statement The authors of the manuscript submitted for consideration for publication in Cardiovascular Pathology declare no conflicts of interest.\n",
      "\n",
      "Declarations of Competing Interest none.\n",
      "\n",
      "Declarations of Competing Interest none.\n",
      "\n",
      "Declarations of Competing Interest none.\n",
      "\n",
      "Declarations of Competing Interest none.\n",
      "\n",
      "Declaration of Competing Interest The authors report no declarations of interest. Conflict of Interest Statement The authors declare no competing interest.\n",
      "\n",
      "Declaration of Competing Interest The authors report no declarations of interest. Conflict of Interest Statement The authors declare no competing interest.\n",
      "\n",
      "Declaration of Competing Interest The authors report no declarations of interest. Conflict of Interest Statement The authors declare no competing interest.\n",
      "\n",
      "Conflicts of interest Jonathan Foulds has completed paid consulting for pharmaceutical companies involved in producing smoking cessation medications, including GSK, Pfizer, Novartis, J&J, and Cypress Bioscience, and received a research grant from Pfizer (not related to reduced nicotine cigarettes). The other authors declare that they have no conflict of interest. Dr. Hayes has received speaking and/or consulting fees from nonprofit organizations, corporate  entities in the food and beverage industries, and federal agencies, including the US Food and Drug Administration Center for Tobacco Products. The FDA CTP was not  involved in this project and the views shown here belong solely to the authors.\n",
      "\n",
      "Conflicts of interest Jonathan Foulds has completed paid consulting for pharmaceutical companies involved in producing smoking cessation medications, including GSK, Pfizer, Novartis, J&J, and Cypress Bioscience, and received a research grant from Pfizer (not related to reduced nicotine cigarettes). The other authors declare that they have no conflict of interest. Dr. Hayes has received speaking and/or consulting fees from nonprofit organizations, corporate  entities in the food and beverage industries, and federal agencies, including the US Food and Drug Administration Center for Tobacco Products. The FDA CTP was not  involved in this project and the views shown here belong solely to the authors.\n",
      "\n",
      "Conflicts of interest Jonathan Foulds has completed paid consulting for pharmaceutical companies involved in producing smoking cessation medications, including GSK, Pfizer, Novartis, J&J, and Cypress Bioscience, and received a research grant from Pfizer (not related to reduced nicotine cigarettes). The other authors declare that they have no conflict of interest. Dr. Hayes has received speaking and/or consulting fees from nonprofit organizations, corporate  entities in the food and beverage industries, and federal agencies, including the US Food and Drug Administration Center for Tobacco Products. The FDA CTP was not  involved in this project and the views shown here belong solely to the authors.\n",
      "\n",
      "Conflicts of interest Jonathan Foulds has completed paid consulting for pharmaceutical companies involved in producing smoking cessation medications, including GSK, Pfizer, Novartis, J&J, and Cypress Bioscience, and received a research grant from Pfizer (not related to reduced nicotine cigarettes). The other authors declare that they have no conflict of interest. Dr. Hayes has received speaking and/or consulting fees from nonprofit organizations, corporate  entities in the food and beverage industries, and federal agencies, including the US Food and Drug Administration Center for Tobacco Products. The FDA CTP was not  involved in this project and the views shown here belong solely to the authors.\n",
      "\n",
      "Hayes, John E.\n",
      "Conflicts of interest Jonathan Foulds has completed paid consulting for pharmaceutical companies involved in producing smoking cessation medications, including GSK, Pfizer, Novartis, J&J, and Cypress Bioscience, and received a research grant from Pfizer (not related to reduced nicotine cigarettes). The other authors declare that they have no conflict of interest. Dr. John E. Hayes has received speaking and/or consulting fees from nonprofit organizations, corporate  entities in the food and beverage industries, and federal agencies, including the US Food and Drug Administration Center for Tobacco Products. The FDA CTP was not  involved in this project and the views shown here belong solely to the authors.\n",
      "\n",
      "P Jr Richie, John\n",
      "Conflicts of interest Jonathan Foulds has completed paid consulting for pharmaceutical companies involved in producing smoking cessation medications, including GSK, Pfizer, Novartis, J&J, and Cypress Bioscience, and received a research grant from Pfizer (not related to reduced nicotine cigarettes). The other authors declare that they have no conflict of interest. Dr. John P Jr Richie E. Hayes has received speaking and/or consulting fees from nonprofit organizations, corporate  entities in the food and beverage industries, and federal agencies, including the US Food and Drug Administration Center for Tobacco Products. The FDA CTP was not  involved in this project and the views shown here belong solely to the authors.\n",
      "\n",
      "Conflicts of interest Jonathan Foulds has completed paid consulting for pharmaceutical companies involved in producing smoking cessation medications, including GSK, Pfizer, Novartis, J&J, and Cypress Bioscience, and received a research grant from Pfizer (not related to reduced nicotine cigarettes). The other authors declare that they have no conflict of interest. Dr. John P Jr Richie E. Hayes has received speaking and/or consulting fees from nonprofit organizations, corporate  entities in the food and beverage industries, and federal agencies, including the US Food and Drug Administration Center for Tobacco Products. The FDA CTP was not  involved in this project and the views shown here belong solely to the authors.\n",
      "\n",
      "Conflicts of interest Jonathan Foulds has completed paid consulting for pharmaceutical companies involved in producing smoking cessation medications, including GSK, Pfizer, Novartis, J&J, and Cypress Bioscience, and received a research grant from Pfizer (not related to reduced nicotine cigarettes). The other authors declare that they have no conflict of interest. Dr. John P Jr Richie E. Hayes has received speaking and/or consulting fees from nonprofit organizations, corporate  entities in the food and beverage industries, and federal agencies, including the US Food and Drug Administration Center for Tobacco Products. The FDA CTP was not  involved in this project and the views shown here belong solely to the authors.\n",
      "\n",
      "Foulds, Jonathan\n",
      "Conflicts of interest Jonathan Foulds has completed paid consulting for pharmaceutical companies involved in producing smoking cessation medications, including GSK, Pfizer, Novartis, J&J, and Cypress Bioscience, and received a research grant from Pfizer (not related to reduced nicotine cigarettes). The other authors declare that they have no conflict of interest. Dr. John P Jr Richie E. Hayes has received speaking and/or consulting fees from nonprofit organizations, corporate  entities in the food and beverage industries, and federal agencies, including the US Food and Drug Administration Center for Tobacco Products. The FDA CTP was not  involved in this project and the views shown here belong solely to the authors.\n",
      "\n",
      "Conflicts of interest Jonathan Foulds has completed paid consulting for pharmaceutical companies involved in producing smoking cessation medications, including GSK, Pfizer, Novartis, J&J, and Cypress Bioscience, and received a research grant from Pfizer (not related to reduced nicotine cigarettes). The other authors declare that they have no conflict of interest. Dr. John P Jr Richie E. Hayes has received speaking and/or consulting fees from nonprofit organizations, corporate  entities in the food and beverage industries, and federal agencies, including the US Food and Drug Administration Center for Tobacco Products. The FDA CTP was not  involved in this project and the views shown here belong solely to the authors.\n",
      "\n",
      "Conflicts of interest Yolanda R. Smith, MD, MS is a peer reviewer for UpToDate and receives royalties. The other authors have no disclosures or conflicts of interest.\n",
      "\n",
      "Conflicts of interest Yolanda R. Smith, MD, MS is a peer reviewer for UpToDate and receives royalties. The other authors have no disclosures or conflicts of interest.\n",
      "\n",
      "Dendrinos, Melina L.\n",
      "Conflicts of interest Yolanda R. Smith, Melina L. Dendrinos, MS is a peer reviewer for UpToDate and receives royalties. The other authors have no disclosures or conflicts of interest.\n",
      "\n",
      "Conflicts of interest Yolanda R. Smith, Melina L. Dendrinos, MS is a peer reviewer for UpToDate and receives royalties. The other authors have no disclosures or conflicts of interest.\n",
      "\n",
      "Smith, Yolanda R.\n",
      "Conflicts of interest Yolanda R. Smith, Melina L. Dendrinos, MS is a peer reviewer for UpToDate and receives royalties. The other authors have no disclosures or conflicts of interest.\n",
      "\n",
      "Conflicts of interest Yolanda R. Smith, Melina L. Dendrinos, MS is a peer reviewer for UpToDate and receives royalties. The other authors have no disclosures or conflicts of interest.\n",
      "\n",
      "Declaration of Competing Interest VB: Through contracts between UAB and the sponsor, VB was national coordinator for the STRENGTH Trial (Astra Zeneca) and the Dalgene trial (DalCor); is national coordinator for the CLEAR Outcomes trial  (Esperion) and Steering Committee member for the ODYSSEY OUTCOMES trial (Sanofi/Regeneron) and serves as site PI for the ORION trial (Novartis). She was  a consultant for Pfizer and currently serves on a Data Safety and Monitoring Board for Verve Therapeutics. LS: consulting honoraria from Amgen and Regeneron.  NJS: honorarium for an educational presentation from Knowledge to Practice. This  company has no ties to industry. CJL: Consultant and Speaker for Amgen and Sanofi on their PCSK9Is and for Novartis on their new injectable and speaker and consultant for DSM and GOED on omega-3, speaker and Consultant for Esperion.\n",
      "\n",
      "Declaration of Competing Interest VB: Through contracts between UAB and the sponsor, VB was national coordinator for the STRENGTH Trial (Astra Zeneca) and the Dalgene trial (DalCor); is national coordinator for the CLEAR Outcomes trial  (Esperion) and Steering Committee member for the ODYSSEY OUTCOMES trial (Sanofi/Regeneron) and serves as site PI for the ORION trial (Novartis). She was  a consultant for Pfizer and currently serves on a Data Safety and Monitoring Board for Verve Therapeutics. LS: consulting honoraria from Amgen and Regeneron.  NJS: honorarium for an educational presentation from Knowledge to Practice. This  company has no ties to industry. CJL: Consultant and Speaker for Amgen and Sanofi on their PCSK9Is and for Novartis on their new injectable and speaker and consultant for DSM and GOED on omega-3, speaker and Consultant for Esperion.\n",
      "\n",
      "Declaration of Competing Interest VB: Through contracts between UAB and the sponsor, VB was national coordinator for the STRENGTH Trial (Astra Zeneca) and the Dalgene trial (DalCor); is national coordinator for the CLEAR Outcomes trial  (Esperion) and Steering Committee member for the ODYSSEY OUTCOMES trial (Sanofi/Regeneron) and serves as site PI for the ORION trial (Novartis). She was  a consultant for Pfizer and currently serves on a Data Safety and Monitoring Board for Verve Therapeutics. LS: consulting honoraria from Amgen and Regeneron.  NJS: honorarium for an educational presentation from Knowledge to Practice. This  company has no ties to industry. CJL: Consultant and Speaker for Amgen and Sanofi on their PCSK9Is and for Novartis on their new injectable and speaker and consultant for DSM and GOED on omega-3, speaker and Consultant for Esperion.\n",
      "\n",
      "Declaration of Competing Interest VB: Through contracts between UAB and the sponsor, VB was national coordinator for the STRENGTH Trial (Astra Zeneca) and the Dalgene trial (DalCor); is national coordinator for the CLEAR Outcomes trial  (Esperion) and Steering Committee member for the ODYSSEY OUTCOMES trial (Sanofi/Regeneron) and serves as site PI for the ORION trial (Novartis). She was  a consultant for Pfizer and currently serves on a Data Safety and Monitoring Board for Verve Therapeutics. LS: consulting honoraria from Amgen and Regeneron.  NJS: honorarium for an educational presentation from Knowledge to Practice. This  company has no ties to industry. CJL: Consultant and Speaker for Amgen and Sanofi on their PCSK9Is and for Novartis on their new injectable and speaker and consultant for DSM and GOED on omega-3, speaker and Consultant for Esperion.\n",
      "\n",
      "Declaration of Competing Interest VB: Through contracts between UAB and the sponsor, VB was national coordinator for the STRENGTH Trial (Astra Zeneca) and the Dalgene trial (DalCor); is national coordinator for the CLEAR Outcomes trial  (Esperion) and Steering Committee member for the ODYSSEY OUTCOMES trial (Sanofi/Regeneron) and serves as site PI for the ORION trial (Novartis). She was  a consultant for Pfizer and currently serves on a Data Safety and Monitoring Board for Verve Therapeutics. LS: consulting honoraria from Amgen and Regeneron.  NJS: honorarium for an educational presentation from Knowledge to Practice. This  company has no ties to industry. CJL: Consultant and Speaker for Amgen and Sanofi on their PCSK9Is and for Novartis on their new injectable and speaker and consultant for DSM and GOED on omega-3, speaker and Consultant for Esperion.\n",
      "\n",
      "Slipczuk, Leandro\n",
      "Declaration of Competing Interest VB: Through contracts between UAB and the sponsor, VB was national coordinator for the STRENGTH Trial (Astra Zeneca) and the Dalgene trial (DalCor); is national coordinator for the CLEAR Outcomes trial  (Esperion) and Steering Committee member for the ODYSSEY OUTCOMES trial (Sanofi/Regeneron) and serves as site PI for the ORION trial (Novartis). She was  a consultant for Pfizer and currently serves on a Data Safety and Monitoring Board for Verve Therapeutics. Leandro Slipczuk: consulting honoraria from Amgen and Regeneron.  NJS: honorarium for an educational presentation from Knowledge to Practice. This  company has no ties to industry. CJL: Consultant and Speaker for Amgen and Sanofi on their PCSK9Is and for Novartis on their new injectable and speaker and consultant for DSM and GOED on omega-3, speaker and Consultant for Esperion.\n",
      "\n",
      "Declaration of Competing Interest VB: Through contracts between UAB and the sponsor, VB was national coordinator for the STRENGTH Trial (Astra Zeneca) and the Dalgene trial (DalCor); is national coordinator for the CLEAR Outcomes trial  (Esperion) and Steering Committee member for the ODYSSEY OUTCOMES trial (Sanofi/Regeneron) and serves as site PI for the ORION trial (Novartis). She was  a consultant for Pfizer and currently serves on a Data Safety and Monitoring Board for Verve Therapeutics. Leandro Slipczuk: consulting honoraria from Amgen and Regeneron.  NJS: honorarium for an educational presentation from Knowledge to Practice. This  company has no ties to industry. CJL: Consultant and Speaker for Amgen and Sanofi on their PCSK9Is and for Novartis on their new injectable and speaker and consultant for DSM and GOED on omega-3, speaker and Consultant for Esperion.\n",
      "\n",
      "Bittner, Vera\n",
      "Declaration of Competing Interest Vera Bittner: Through contracts between UAB and the sponsor, Vera Bittner was national coordinator for the STRENGTH Trial (Astra Zeneca) and the Dalgene trial (DalCor); is national coordinator for the CLEAR Outcomes trial  (Esperion) and Steering Committee member for the ODYSSEY OUTCOMES trial (Sanofi/Regeneron) and serves as site PI for the ORION trial (Novartis). She was  a consultant for Pfizer and currently serves on a Data Safety and Monitoring Board for Verve Therapeutics. Leandro Slipczuk: consulting honoraria from Amgen and Regeneron.  NJS: honorarium for an educational presentation from Knowledge to Practice. This  company has no ties to industry. CJL: Consultant and Speaker for Amgen and Sanofi on their PCSK9Is and for Novartis on their new injectable and speaker and consultant for DSM and GOED on omega-3, speaker and Consultant for Esperion.\n",
      "\n",
      "Declaration of Competing Interest Vera Bittner: Through contracts between UAB and the sponsor, Vera Bittner was national coordinator for the STRENGTH Trial (Astra Zeneca) and the Dalgene trial (DalCor); is national coordinator for the CLEAR Outcomes trial  (Esperion) and Steering Committee member for the ODYSSEY OUTCOMES trial (Sanofi/Regeneron) and serves as site PI for the ORION trial (Novartis). She was  a consultant for Pfizer and currently serves on a Data Safety and Monitoring Board for Verve Therapeutics. Leandro Slipczuk: consulting honoraria from Amgen and Regeneron.  NJS: honorarium for an educational presentation from Knowledge to Practice. This  company has no ties to industry. CJL: Consultant and Speaker for Amgen and Sanofi on their PCSK9Is and for Novartis on their new injectable and speaker and consultant for DSM and GOED on omega-3, speaker and Consultant for Esperion.\n",
      "\n",
      "Stone, Neil J.\n",
      "Declaration of Competing Interest Vera Bittner: Through contracts between UAB and the sponsor, Vera Bittner was national coordinator for the STRENGTH Trial (Astra Zeneca) and the Dalgene trial (DalCor); is national coordinator for the CLEAR Outcomes trial  (Esperion) and Steering Committee member for the ODYSSEY OUTCOMES trial (Sanofi/Regeneron) and serves as site PI for the ORION trial (Novartis). She was  a consultant for Pfizer and currently serves on a Data Safety and Monitoring Board for Verve Therapeutics. Leandro Slipczuk: consulting honoraria from Amgen and Regeneron.  Neil J. Stone: honorarium for an educational presentation from Knowledge to Practice. This  company has no ties to industry. CJL: Consultant and Speaker for Amgen and Sanofi on their PCSK9Is and for Novartis on their new injectable and speaker and consultant for DSM and GOED on omega-3, speaker and Consultant for Esperion.\n",
      "\n",
      "Lavie, Carl J.\n",
      "Declaration of Competing Interest Vera Bittner: Through contracts between UAB and the sponsor, Vera Bittner was national coordinator for the STRENGTH Trial (Astra Zeneca) and the Dalgene trial (DalCor); is national coordinator for the CLEAR Outcomes trial  (Esperion) and Steering Committee member for the ODYSSEY OUTCOMES trial (Sanofi/Regeneron) and serves as site PI for the ORION trial (Novartis). She was  a consultant for Pfizer and currently serves on a Data Safety and Monitoring Board for Verve Therapeutics. Leandro Slipczuk: consulting honoraria from Amgen and Regeneron.  Neil J. Stone: honorarium for an educational presentation from Knowledge to Practice. This  company has no ties to industry. Carl J. Lavie: Consultant and Speaker for Amgen and Sanofi on their PCSK9Is and for Novartis on their new injectable and speaker and consultant for DSM and GOED on omega-3, speaker and Consultant for Esperion.\n",
      "\n",
      "Declaration of Competing Interest Vera Bittner: Through contracts between UAB and the sponsor, Vera Bittner was national coordinator for the STRENGTH Trial (Astra Zeneca) and the Dalgene trial (DalCor); is national coordinator for the CLEAR Outcomes trial  (Esperion) and Steering Committee member for the ODYSSEY OUTCOMES trial (Sanofi/Regeneron) and serves as site PI for the ORION trial (Novartis). She was  a consultant for Pfizer and currently serves on a Data Safety and Monitoring Board for Verve Therapeutics. Leandro Slipczuk: consulting honoraria from Amgen and Regeneron.  Neil J. Stone: honorarium for an educational presentation from Knowledge to Practice. This  company has no ties to industry. Carl J. Lavie: Consultant and Speaker for Amgen and Sanofi on their PCSK9Is and for Novartis on their new injectable and speaker and consultant for DSM and GOED on omega-3, speaker and Consultant for Esperion.\n",
      "\n",
      "Declaration of Competing Interest Wei Li is a scientific consultant for Veru, Inc. who licensed the patent portfolio covering tubulin inhibitors, including CH-2-102 and QW-296 discussed in this paper, for commercial development. Wei Li also reports receiving sponsored research agreement grants from Veru, Inc. However, Veru, Inc. did not have any input or influence in the experimental design, data collection, and data analyses in this paper.\n",
      "\n",
      "Declaration of Competing Interest Wei Li is a scientific consultant for Veru, Inc. who licensed the patent portfolio covering tubulin inhibitors, including CH-2-102 and QW-296 discussed in this paper, for commercial development. Wei Li also reports receiving sponsored research agreement grants from Veru, Inc. However, Veru, Inc. did not have any input or influence in the experimental design, data collection, and data analyses in this paper.\n",
      "\n",
      "Declaration of Competing Interest Wei Li is a scientific consultant for Veru, Inc. who licensed the patent portfolio covering tubulin inhibitors, including CH-2-102 and QW-296 discussed in this paper, for commercial development. Wei Li also reports receiving sponsored research agreement grants from Veru, Inc. However, Veru, Inc. did not have any input or influence in the experimental design, data collection, and data analyses in this paper.\n",
      "\n",
      "Hao, Chen\n",
      "Declaration of Competing Interest Wei Li is a scientific consultant for Veru, Inc. who licensed the patent portfolio covering tubulin inhibitors, including Chen Hao-2-102 and QW-296 discussed in this paper, for commercial development. Wei Li also reports receiving sponsored research agreement grants from Veru, Inc. However, Veru, Inc. did not have any input or influence in the experimental design, data collection, and data analyses in this paper.\n",
      "\n",
      "Declaration of Competing Interest Wei Li is a scientific consultant for Veru, Inc. who licensed the patent portfolio covering tubulin inhibitors, including Chen Hao-2-102 and QW-296 discussed in this paper, for commercial development. Wei Li also reports receiving sponsored research agreement grants from Veru, Inc. However, Veru, Inc. did not have any input or influence in the experimental design, data collection, and data analyses in this paper.\n",
      "\n",
      "Li, Wei\n",
      "Declaration of Competing Interest Wei Li is a scientific consultant for Veru, Inc. who licensed the patent portfolio covering tubulin inhibitors, including Chen Hao-2-102 and QW-296 discussed in this paper, for commercial development. Wei Li also reports receiving sponsored research agreement grants from Veru, Inc. However, Veru, Inc. did not have any input or influence in the experimental design, data collection, and data analyses in this paper.\n",
      "\n",
      "Declaration of Competing Interest Wei Li is a scientific consultant for Veru, Inc. who licensed the patent portfolio covering tubulin inhibitors, including Chen Hao-2-102 and QW-296 discussed in this paper, for commercial development. Wei Li also reports receiving sponsored research agreement grants from Veru, Inc. However, Veru, Inc. did not have any input or influence in the experimental design, data collection, and data analyses in this paper.\n",
      "\n",
      "Declaration of Competing Interest The authors declare the following competing financial interest(s): J.Y. and J.K. are co-inventors on a pending US patent application (PCT/US2014/023784; assigned to the University of Utah) related to this work. J.K. is Chief Scientific Advisor and J.Y. Scientific Advisor, and P.S. Chief Medical Advisor for Bastion Biologics. Otherwise, the authors declare no competing financial interests."
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "IOPub data rate exceeded.\n",
      "The notebook server will temporarily stop sending output\n",
      "to the client in order to avoid crashing it.\n",
      "To change this limit, set the config variable\n",
      "`--NotebookApp.iopub_data_rate_limit`.\n",
      "\n",
      "Current values:\n",
      "NotebookApp.iopub_data_rate_limit=1000000.0 (bytes/sec)\n",
      "NotebookApp.rate_limit_window=3.0 (secs)\n",
      "\n"
     ]
    }
   ],
   "source": [
    "for index, row in data2.iterrows():\n",
    "    names = row['FAU'].split(';')\n",
    "    string = row['COIS']\n",
    "    res = row.LAU\n",
    "    for r in res:\n",
    "        if r is None:\n",
    "            continue\n",
    "        \n",
    "        r = [i for i in r if i is not None]\n",
    "        sort(r)\n",
    "        string = check_all(index, r, string)\n",
    "        print(string)\n",
    "        print(\"\")\n",
    "    '''for name in names:\n",
    "        string = replacementFunction(string,name,res)'''\n",
    "    '''\n",
    "    #---- Printing the String before the Modification and After ----#\n",
    "    print(\"\")\n",
    "    print(row['COIS'])\n",
    "    print(\"\")\n",
    "    print(string)\n",
    "    \n",
    "    print(\"\")\n",
    "    print(row['COIS']==string) #Whether any changes were made\n",
    "    print(\"\")\n",
    "    print(names) #Names used\n",
    "    print(\"----------------------------------------------------------------------------------\")\n",
    "    '''\n",
    "    #---- Updating ----#\n",
    "    row['COIS'] = string"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "072a5fa7",
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3 (ipykernel)",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.9.12"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 5
}
